<SEC-DOCUMENT>0001564590-22-009634.txt : 20220310
<SEC-HEADER>0001564590-22-009634.hdr.sgml : 20220310
<ACCEPTANCE-DATETIME>20220310160617
ACCESSION NUMBER:		0001564590-22-009634
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220310
DATE AS OF CHANGE:		20220310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Stoke Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001623526
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				471144582
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38938
		FILM NUMBER:		22729088

	BUSINESS ADDRESS:	
		STREET 1:		3 PRESTON COURT
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		781-430-8200

	MAIL ADDRESS:	
		STREET 1:		3 PRESTON COURT
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ASOthera Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20141028
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>stok-10k_20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T16:43:57.8420131+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 8d9d5b43144d4c21a62f9c029c9e37fb -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stok="http://www.stoketherapeutics.com/20211231" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
stok-10k_20211231.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001623526_20210101_20211231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001623526_20210101_20211231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000006" name="dei:EntityCentralIndexKey" contextRef="C_0001623526_20210101_20211231">0001623526</ix:nonNumeric>
			<ix:nonNumeric id="F_000010" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001623526_20210101_20211231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000271" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000281" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201711Member_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000283" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201711Member_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000284" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000286" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000287" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000289" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000391" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630">true</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001623526_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001623526_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000403" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001623526_20211231">http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000404" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001623526_20201231">http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000407" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001623526_20211231">http://fasb.org/us-gaap/2021-01-31#LiabilitiesNoncurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000408" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001623526_20201231">http://fasb.org/us-gaap/2021-01-31#LiabilitiesNoncurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000411" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001623526_20211231">P3Y1M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_000454" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001623526_20200101_20201231">P8Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000455" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001623526_20210101_20211231">P8Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000456" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001623526_20210101_20211231">P6Y10M24D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000478" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001623526_20210101_20211231" decimals="INF">0.0151</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000479" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001623526_20200101_20201231" decimals="INF">0.0148</ix:nonFraction>
			<ix:nonNumeric id="F_000482" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001623526_srtRangeAxis_srtMinimumMember_20210101_20211231">P5Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000483" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_20210101_20211231">P6Y3M</ix:nonNumeric>
			<ix:nonNumeric id="F_000484" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001623526_srtRangeAxis_srtMinimumMember_20200101_20201231">P5Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000485" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_20200101_20201231">P6Y3M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000476" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001623526_20210101_20211231" decimals="INF">0.0078</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000477" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001623526_20200101_20201231" decimals="INF">0.0038</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000486" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001623526_20210101_20211231" decimals="2">0.70</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000488" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001623526_20210101_20211231" decimals="2">0.73</ix:nonFraction>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="stok-20211231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001623526_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001623526_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001623526_20220301">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001623526_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:FollowOnOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:FollowOnOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:FollowOnOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:FollowOnOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:FollowOnOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokBaseProspectusMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:BaseProspectusMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokSalesAgreementProspectusMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:SalesAgreementProspectusMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_stokUnderwrittenPublicOfferingMember_20201123_20201124">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-23</xbrli:startDate>
					<xbrli:endDate>2020-11-24</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_stokUnderwrittenPublicOfferingMember_20201124">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-24</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20201123_20201124">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-23</xbrli:startDate>
					<xbrli:endDate>2020-11-24</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201123_20201124">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-23</xbrli:startDate>
					<xbrli:endDate>2020-11-24</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokComputerAndOfficeEquipmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">stok:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokComputerAndOfficeEquipmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">stok:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokLaboratoryEquipmentAndFurnitureAndFixturesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">stok:LaboratoryEquipmentAndFurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokLaboratoryEquipmentAndFurnitureAndFixturesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">stok:LaboratoryEquipmentAndFurnitureAndFixturesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001623526_20170101_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-01-01</xbrli:startDate>
					<xbrli:endDate>2017-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_stokSegment">
				<xbrli:measure>stok:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201711Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201711Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201813Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_srtRangeAxis_srtMinimumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_srtRangeAxis_srtMaximumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001623526_20180801_20180831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-08-01</xbrli:startDate>
					<xbrli:endDate>2018-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_20180831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210901_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">stok:LeaseCommencementTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">stok:LeaseCommencementTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyTwoMember_20210901_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">stok:LeaseCommencementTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyTwoMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">stok:LeaseCommencementTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_20181201_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_stokOption">
				<xbrli:measure>stok:Option</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">stok:LeaseExtensionEndDateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-06-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">stok:LeaseExtensionEndDateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20150701_20150731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:ColdSpringHarborLaboratoryAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-07-01</xbrli:startDate>
					<xbrli:endDate>2015-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:ColdSpringHarborLaboratoryAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:ColdSpringHarborLaboratoryAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:ColdSpringHarborLaboratoryAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217GBP">
				<xbrli:measure>iso4217:GBP</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:SouthamptonAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:SouthamptonAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:SouthamptonAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:SouthamptonAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEquityIncentivePlanMember_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEquityIncentivePlanMember_20190601_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-01</xbrli:startDate>
					<xbrli:endDate>2019-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndFourteenEquityIncentivePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEquityIncentivePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_srtRangeAxis_srtMinimumMember_srtTitleOfIndividualAxis_srtDirectorMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_srtRangeAxis_srtMaximumMember_srtTitleOfIndividualAxis_srtDirectorMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_srtRangeAxis_srtMinimumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_srtRangeAxis_srtMaximumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20190601_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-01</xbrli:startDate>
					<xbrli:endDate>2019-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_srtCounterpartyNameAxis_stokAcadiaPharmaceuticalsIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">stok:AcadiaPharmaceuticalsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokSalesAgreementProspectusMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001623526</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:SalesAgreementProspectusMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000000" fromRefs="F_000457 F_000458 F_000459"></ix:relationship>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001623526_20210101_20211231">10-K</ix:nonNumeric><span style="font-weight:normal;"> </span></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:DocumentAnnualReport" contextRef="C_0001623526_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001623526_20210101_20211231" format="ixt:datemonthdayyearen">December 31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001623526_20210101_20211231">2021</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:DocumentTransitionReport" contextRef="C_0001623526_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number&#160;<ix:nonNumeric id="F_000019" name="dei:EntityFileNumber" contextRef="C_0001623526_20210101_20211231">001-38938</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000005" name="dei:EntityRegistrantName" contextRef="C_0001623526_20210101_20211231">Stoke Therapeutics, Inc.</ix:nonNumeric></span><span style="color:#000000;"> </span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000020" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001623526_20210101_20211231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000021" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001623526_20210101_20211231">47-1144582</ix:nonNumeric></span></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityAddressAddressLine1" contextRef="C_0001623526_20210101_20211231">45 Wiggins Ave</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityAddressCityOrTown" contextRef="C_0001623526_20210101_20211231">Bedford</ix:nonNumeric>, <ix:nonNumeric id="F_000024" name="dei:EntityAddressStateOrProvince" contextRef="C_0001623526_20210101_20211231" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:EntityAddressPostalZipCode" contextRef="C_0001623526_20210101_20211231">01730</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <span style="Background-color:#FFFFFF;color:#000000;">(<ix:nonNumeric id="F_000026" name="dei:CityAreaCode" contextRef="C_0001623526_20210101_20211231">781</ix:nonNumeric>)&#160;<ix:nonNumeric id="F_000027" name="dei:LocalPhoneNumber" contextRef="C_0001623526_20210101_20211231">430-8200</ix:nonNumeric></span></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000034" name="dei:Security12bTitle" contextRef="C_0001623526_20210101_20211231">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000035" name="dei:TradingSymbol" contextRef="C_0001623526_20210101_20211231">STOK</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000036" name="dei:SecurityExchangeName" contextRef="C_0001623526_20210101_20211231" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></span></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <span style="font-weight:bold;">None </span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> <span style="text-transform:uppercase;"><ix:nonNumeric id="F_000012" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001623526_20210101_20211231">No</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. <span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> <span style="text-transform:uppercase;"><ix:nonNumeric id="F_000008" name="dei:EntityVoluntaryFilers" contextRef="C_0001623526_20210101_20211231">No</ix:nonNumeric></span> <span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <span style="text-transform:uppercase;"><ix:nonNumeric id="F_000007" name="dei:EntityCurrentReportingStatus" contextRef="C_0001623526_20210101_20211231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). <span style="text-transform:uppercase;"><ix:nonNumeric id="F_000009" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001623526_20210101_20211231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityFilerCategory" contextRef="C_0001623526_20210101_20211231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:EntitySmallBusiness" contextRef="C_0001623526_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001623526_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000018" name="dei:EntityExTransitionPeriod" contextRef="C_0001623526_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000030" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001623526_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). <span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000015" name="dei:EntityShellCompany" contextRef="C_0001623526_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span><span style="font-size:10pt;">&#160;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;<span style="font-size:8pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The NASDAQ Stock Market as</span><span style="color:#000000;font-size:8pt;">&#160;of the last business day of the registrant&#8217;s most recently completed second fiscal quarter</span><span style="font-size:8pt;">, was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000013" name="dei:EntityPublicFloat" contextRef="C_0001623526_20210630" decimals="-6" scale="6">665</ix:nonFraction> million. The number of shares of Registrant&#8217;s Common Stock outstanding as of March 1, 2022 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000014" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001623526_20220301" decimals="INF" format="ixt:numdotdecimal">37,359,218</ix:nonFraction>.  </span></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p><ix:nonNumeric id="F_000201" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K to the extent stated herein. The Definitive Proxy Statement will be filed within 120 days of the Registrant&#8217;s fiscal year ended December 31, 2021.&#160;Except with respect to information specifically incorporated by reference in this Form 10-K, the Definitive Proxy Statement is not deemed to be filed as part of this Form 10-K.</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Auditor Firm Id:</span><span style="Background-color:#FFFFFF;margin-left:36pt;"></span><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000031" name="dei:AuditorFirmId" contextRef="C_0001623526_20210101_20211231">185</ix:nonNumeric></span><span style="Background-color:#FFFFFF;margin-left:36pt;"></span><span style="Background-color:#FFFFFF;">Auditor Name:</span><span style="Background-color:#FFFFFF;margin-left:36pt;"></span><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000032" name="dei:AuditorName" contextRef="C_0001623526_20210101_20211231">KPMG LLP</ix:nonNumeric></span><span style="Background-color:#FFFFFF;margin-left:36pt;"></span><span style="Background-color:#FFFFFF;">Auditor Location:</span><span style="Background-color:#FFFFFF;margin-left:36pt;"></span><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000033" name="dei:AuditorLocation" contextRef="C_0001623526_20210101_20211231">Boston, MA USA</ix:nonNumeric></span></p></ix:nonNumeric>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:1pt;">
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:83%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#FORWARDLOOKING_STATEMENTS"><span style="text-decoration:underline;">Special Note Regarding Forward-Looking statements</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">Business</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:underline;">Unresolved Staff Comments</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:underline;">Properties</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
</tr>
<tr style="height:2.4pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_RESERVED"><span style="text-decoration:underline;">[Reserved]</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
</tr>
<tr style="height:2.4pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
</tr>
<tr style="height:2.4pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 7A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:underline;">Financial Statements and Supplementary Data</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9C.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9C_DISCLOSURE_REGARDING_FOREIGN_JUR"><span style="text-decoration:underline;">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:underline;">Executive Compensation</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:underline;">Principal Accounting Fees and Services</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:underline;">Exhibits, Financial Statement Schedules</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:underline;">Form 10-K Summary</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="FORWARDLOOKING_STATEMENTS">FORWARD-LOOKING STATEMENTS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements within the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of present and historical facts contained in this Annual Report on Form 10-K, including statements regarding our future results of operations and financial position, business strategy, prospective products, planned preclinical studies and clinical or field trials, regulatory approvals, research and development costs, and timing and likelihood of success, as well as plans and objectives of management for future operations, may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified in Part II. Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and Part I. Item 1A &#8220;Risk Factors.&#8221; These risks and uncertainties include, but are not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the direct and indirect impact of COVID-19 on our business, financial condition and operations, including on our expenses, supply chain, strategic partners, research and development costs, clinical trials and employees&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to become profitable&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to procure sufficient funding&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our limited operating history&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to develop, obtain regulatory approval for and commercialize&#160;STK-001, STK-002&#160;and our future product candidates, including any impact from COVID-19&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our success in early preclinical studies or clinical trials, which may not be indicative of results obtained in later studies or trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to obtain regulatory approval to commercialize&#160;STK-001, STK-002&#160;or any other future product candidate&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to identify patients with the diseases treated by&#160;STK-001, STK-002&#160;or our future product candidates, and to enroll patients in trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the success of our efforts to use TANGO to expand our pipeline of product candidates and develop marketable products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to obtain, maintain and protect our intellectual property&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our reliance upon intellectual property licensed from third parties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to identify, recruit and retain key personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our financial performance&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">developments or projections relating to our competitors or our industry.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read this Annual Report on Form 10-K and the documents that we reference herein completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I">PART I</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">Item 1. Business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. <span style="Background-color:#FFFFFF;">Using our proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, we are developing antisense oligonucleotides (&#8220;ASOs&#8221;) to selectively restore protein levels. Our first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is characterized by frequent, prolonged and refractory seizures beginning within the first year of life. The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with it.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of approximately 50% of normal protein levels leads to disease. We are also pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (&#8220;ADOA&#8221;), the most common inherited optic nerve disorder. Our initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting our belief in the broad potential for our proprietary approach.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TANGO is based on the pioneering work conducted on pre-mRNA splicing and ASOs in the laboratory of one of our co-founders, Adrian R. Krainer, Ph.D., of Cold Spring Harbor Laboratory in New York (&#8220;CSHL&#8221;). Inspired by the clinical success of SPINRAZA (nusinersen), an ASO medicine for the treatment of spinal muscular atrophy that was co-invented by Professor Krainer, our company was founded to develop a general antisense approach to upregulate protein expression. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our executive management team has extensive collective expertise in human genetics and modulation of RNA processes using ASOs, as well as a track record of success in rare disease drug development. Our executive team and co-founders have been previously involved with other companies in the discovery, development and commercialization of many treatments for rare diseases, including Sarepta&#8217;s Exondys 51 (eteplirsen) and Biogen&#8217;s SPINRAZA. Our scientific and clinical advisory boards are comprised of leading experts in the fields of human genetics, pre-mRNA splicing and ASOs, and neurodevelopmental and neurodegenerative diseases. Their involvement in both academic research and clinical practice allows us to gain proprietary and early insight into emerging biology and clinical practice that informs our business strategy. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our strategy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are using our proprietary RNA therapeutics platform to create ASOs for the treatment of severe diseases. The critical components of our strategy include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Rapidly advance our lead program, STK-001, to clinical proof-of-concept, approval and commercialization.&#160;&#160;</span><span style="font-size:10pt;color:#000000;">Phase 1/2a trials of STK-001 are ongoing in the United States (MONARCH) evaluating children and adolescents ages 2 to 18 with Dravet syndrome and in the United Kingdom (ADMIRAL) evaluating children and adolescents ages 2 to up to 18 with Dravet syndrome. We are leveraging previously-validated ASO chemistry, a modality that has been successfully utilized for other diseases, a well-defined patient population based on routine genetic testing and learnings from approved drugs for the treatment of Dravet syndrome to inform the clinical and regulatory pathways for STK-001 and minimize potential safety concerns and development risk. We believe STK-001 has the potential to significantly reduce both the occurrence and frequency of seizures and also non-seizure comorbidities. If we see evidence of efficacy following clinical data, then we would plan to meet with regulatory authorities to discuss expedited regulatory pathways. If approved, we intend to leverage a lean, targeted internal commercial organization to bring STK-001 to patients. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Advance STK-002 to the clinic, for the potential treatment of ADOA.</span><span style="font-size:10pt;color:#000000;"> STK-002 is a proprietary ASO in preclinical development for the treatment of ADOA, the most common inherited optic nerve disorder. ADOA represents a second haploinsufficiency disease addressed by TANGO and our first treatment for diseases of the eye. STK-002 is designed to upregulate OPA1 protein expression by leveraging the non-mutant (wild-type) copy of the </span><span style="font-style:italic;font-size:10pt;color:#000000;">OPA1</span><span style="font-size:10pt;color:#000000;"> gene. Preclinical toxicology studies are currently ongoing to support future clinical trials for STK-002.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Expand our pipeline through internal discovery and collaboration to fully exploit the potential of our proprietary platform (TANGO). </span><span style="font-size:10pt;color:#000000;">We have built a target discovery process utilizing proprietary bioinformatics algorithms and extensive in-house expertise in whole transcriptome RNA sequencing to rapidly and systematically identify diseases that we believe can be addressed using our platform. We are also advancing additional early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system (the &#8220;CNS&#8221;) and eye. In January 2022, we announced a collaboration with Acadia Pharmaceuticals to pursue RNA-based </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;color:#000000;">treatments for severe and rare genetic neurodevelopmental diseases of the CNS. The collaboration combines our TANGO research platform with Acadia&#8217;s expertise in neurology drug development and commercialization. Longer-term, we believe that our ASOs may have the potential to upregulate non-mutated genes in biological pathways to treat diseases or conditions that are caused by multiple genes or are multifactorial, such as autoimmune diseases, aging and cancer. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Maintain broad commercial rights to our product candidates where we believe we can realize maximum value.&#160;&#160;</span><span style="font-size:10pt;color:#000000;">We intend to build a fully integrated biotechnology company and independently pursue the development and commercialization of our key product candidates, if approved. We own commercial rights to our technologies and our lead product candidates, STK-001 and STK-002. As we continue to advance our programs, we may pursue strategic collaborations to share risk and upside in programs with higher inherent biology risk, larger clinical trial sizes or longer or more complex clinical, regulatory or commercial paths. Our current collaboration with Acadia is an example of where we believe that the development of treatments for severe and rare genetic neurodevelopmental diseases of the CNS is well served by a strategic collaboration. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Continue to strengthen and expand our intellectual property portfolio.&#160;&#160;</span><span style="font-size:10pt;color:#000000;">We have an intellectual property estate that includes multi-national allowed and pending claims for the TANGO mechanisms, as well as multi-national pending claims relating to compositions of matter of oligonucleotides designed to target specific TANGO elements in genes for many genetic diseases that we believe are amenable to upregulation of target protein expression using TANGO. Our proprietary position is reinforced by additional technical know-how and trade secrets. We continually assess and refine our intellectual property strategy as we identify new targets amenable to TANGO, and we will file additional patent applications as appropriate. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary RNA therapeutics platform (TANGO) </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;">TANGO (Targeted Augmentation of Nuclear Gene Output) is our proprietary research platform. Our initial applications for this technology are diseases in which one copy of a gene functions normally and the other is mutated, also called haploinsufficiencies. In these cases, the mutated gene does not produce its share of protein, so the body does not function normally. Using the TANGO approach and a deep understanding of RNA science, Stoke researchers design ASOs that bind to pre-mRNA and help the target genes produce more protein. TANGO aims to restore missing proteins by increasing &#8211; or stoking &#8211; protein output from healthy genes, thus compensating for the non-functioning copy of the gene.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;">TANGO exploits unique mechanisms for modulation of splicing to prevent the synthesis of naturally occurring non-productive mRNA and increase the synthesis of productive mRNA, resulting in increased production of functional protein. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human cells naturally regulate protein production to maintain health. Pre-mRNA splicing, including alternative splicing, is an important mechanism used to regulate how much protein and which protein variant is produced. During splicing, introns are removed and exons are joined together to generate the mRNA template that carries the code to synthesize proteins. More than one third of alternative splicing events in mammals do not produce functional proteins and lead to mRNA degradation through nonsense-mediated mRNA decay (&#8220;NMD&#8221;). TANGO ASOs act at the pre-mRNA level and prevent non-productive alternative splicing so that the body produces more protein-coding mRNA and thus more protein. This approach is particularly applicable to diseases that are caused by insufficient protein production.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we published data in the Journal Nature Communications that support our proprietary approach to precisely upregulate protein expression using TANGO ASOs. To evaluate the approach broadly, Stoke researchers selected four gene targets that vary in type and abundance of non-productive splicing events, gene size and protein function:&#160;<span style="font-style:italic;">PCCA</span>&#160;(propionic acidemia)&#59;&#160;<span style="font-style:italic;">SYNGAP1</span>&#160;(autosomal dominant mental retardation 5)&#59;&#160;<span style="font-style:italic;">CD274&#160;</span>(autoimmune diseases, including uveitis)&#59; and&#160;<span style="font-style:italic;">SCN1A</span>&#160;(Dravet syndrome). Stoke researchers designed TANGO ASOs to target the non-productive splicing events in these genes and their activity was evaluated. Dose-dependent reductions of non-productive mRNA were observed to lead to increases in both productive mRNA and protein levels for each of the target genes. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Treatment of autosomal dominant haploinsufficiency diseases with TANGO ASOs</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are initially focused on applying the transformative potential of our platform to developing precision medicines for autosomal dominant haploinsufficiencies, or disorders in which only one allele of a gene is mutated, resulting in approximately 50% of normal protein expression. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibits 1 and 2 shown below illustrate the TANGO mechanism for increasing protein synthesis in a prospective patient with a haploinsufficiency. To date, we have demonstrated this TANGO mechanism in preclinical models of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">haploinsufficiencies</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 1 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">illustrates the prospective patient with a haploinsufficiency possessing one wild-type allele and one mutant allele. The mutant allele is translated into non-functional protein and results in approximately 50% of normal protein expression. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2 illustrates</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> treatment with our ASO would prevent the synthesis of naturally occurring non-productive mRNA and would increase the synthesis of productive mRNA, thereby restoring the target protein to near normal levels. Our preclinical studies show that any increase in mutant mRNA would have no effect on the net protein level. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibit 1: Haploinsufficiency without TANGO-ASO<span style="margin-left:36pt;"> Exhibit 2: Haploinsufficiency with TANGO-ASO</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000001.jpg" title="" alt="" style="width:616px;height:243px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">TANGO mechanisms of action </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ASOs are specifically designed to bind to a desired RNA sequence inside the nuclei of patients&#8217; cells to prevent the occurrence of non-productive splicing. By doing so, our ASOs decrease the amount of non-productive mRNA and increase the level of productive mRNA, leading to the generation of more protein. TANGO operates in a mutation-independent manner, given it utilizes one wild-type allele, and does not alter protein coding splicing isoforms. The net effect is increased expression of functional protein from the wild-type allele. The two categories of non-productive splicing events amenable to TANGO are retained introns and nonsense-mediated mRNA decay of the resulting mRNA. While we benefit from leveraging previously-validated ASO chemistries, both of these TANGO mechanisms are novel. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first category of non-productive splicing events amenable to TANGO is retained introns. Retained introns are found in approximately 60% of gene transcripts and are part of the wild-type sequence of the gene. In some cases, retained introns are part of normal gene regulation. The non-productive mRNA, which contains these retained introns, remain in the nucleus of the cell and are not translated into protein, and offer a reservoir of non-productive mRNA that can be converted into productive mRNA. Our ASOs bind to the pre-mRNA and redirect the splicing machinery to remove the retained intron. This splice-switching decreases non-productive mRNA and increases productive mRNA, which is translated into increased protein expression from the wild-type allele. This is shown in the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibits 3 and 4 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">below, with the left panel illustrating non-productive mRNA, which includes retained introns, and the right panel illustrating our ASOs binding to the pre-mRNA and redirecting the splicing machinery. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibit 3: Retained introns without TANGO-ASO<span style="font-weight:normal;margin-left:36pt;"> </span>Exhibit 4: Retained introns with TANGO-ASO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000002.jpg" title="" alt="" style="width:616px;height:243px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Stoke data</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The second category of non-productive splicing events amenable to TANGO is alternative splicing that leads to nonsense-mediated mRNA decay, or NMD, of the resulting mRNA. An example of a NMD event is a NMD exon, which is found in over 25% of gene transcripts. Like retained introns, NMD exons are part of the wild-type sequence of the genes. In some cases, NMD exons are part of normal gene regulation. Non-productive mRNA, which includes these NMD exons, is degraded in the cytoplasm of the cell by nonsense-mediated mRNA decay and is not translated into protein. Our ASOs bind to the pre-mRNA and redirect the splicing machinery to prevent inclusion of the NMD exon. As with retained introns, this splice-switching decreases non-productive mRNA and increases productive mRNA, which is translated into increased protein expression from the wild-type allele. In contrast to current exon skipping therapies, which remove a coding exon and result in a truncated protein, our TANGO mechanism skips out a non-coding NMD exon and yields a full-length functional protein. Our lead product candidates, STK-001 and STK-002, target an NMD exon and the general mechanism is shown in exhibits 5 and 6 below, with the left panel showing the non-productive mRNA failing to be translated into protein and the right panel showing our ASOs binding to the pre-mRNA and redirecting the splicing machinery. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibit 5: NMD exon without TANGO-ASO<span style="margin-left:36pt;"> Exhibit 6: NMD exon with TANGO-ASO</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000003.jpg" title="" alt="" style="width:616px;height:243px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Stoke data</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advantages of TANGO </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe TANGO may have several key advantages, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Ability to address the underlying genetic cause of the disease.&#160;&#160;</span><span style="font-size:10pt;color:#000000;">We utilize TANGO to design ASOs to precisely upregulate protein expression, thereby addressing the underlying cause of the disease in addition to the symptoms of the disease. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Applicability is mutation-independent.&#160;&#160;</span><span style="font-size:10pt;color:#000000;">Our ASOs upregulate expression of the wild-type allele, meaning the TANGO mechanism does not rely on targeting a specific mutation. Given this, we believe our therapies are well-suited for diseases caused by multiple mutations in a single gene, such as many haploinsufficiencies, and provide a single-drug approach that can address the full spectrum of loss-of-function mutations. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Utility across small and large gene targets encoding intracellular and extracellular proteins.&#160;&#160;</span><span style="font-size:10pt;color:#000000;">Our ASOs upregulate protein expression regardless of gene size and are not constrained to smaller gene targets. We believe our therapies also have the flexibility to address genes encoding intracellular as well as extracellular proteins. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">No observed unwanted off-target effects.&#160;&#160;</span><span style="font-size:10pt;color:#000000;">Our ASOs do not create detectable changes at the DNA level and make no detectable irreversible modifications to a patient&#8217;s genome. The activities of our ASOs are inherently tissue-specific. TANGO-mediated upregulation of protein expression only occurs where the gene is being naturally transcribed, limiting the likelihood of expression in non-native tissues. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Ability to control dose level and duration.&#160;&#160;</span><span style="font-size:10pt;color:#000000;">Our ASOs provide the ability for dose titration, thereby allowing for dose-dependent and reversible control of level and duration of protein expression. The ability to titrate dosage provides us with flexibility to address a variety of tissue types, and potentially enables us to deliver the right dose, at the right location, for each indication. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Utility across wide array of diseases and tissue types.&#160;&#160;</span><span style="font-size:10pt;color:#000000;">We believe that</span><span style="font-style:italic;font-size:10pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">ASO</span><span style="font-style:italic;font-size:10pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">delivery to the CNS, eye, kidney and liver is well-established, providing us the potential to address a broad range of severe diseases. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Fixed dose, rather than weight-based dosing</span><span style="font-size:10pt;color:#000000;">.&#160;&#160;We have observed that while the quantity of non-productive mRNA can vary across tissue types for a gene, it remains constant across individuals. As a result, for CNS and eye targets, the dose of our ASOs should not require adjustment between patients to be effective. We believe that a fixed dose across all ages in these targets may lessen reimbursement hurdles associated with a weight-adjusted dose pricing model. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Favorable dosing regimen.&#160;&#160;</span><span style="font-size:10pt;color:#000000;">We believe our ASOs may require as few as two to three administrations per year for the CNS and as infrequent as once per year for the eye and will generally involve relatively low doses, which would translate to simplified use and an improved safety profile due to reduced systemic exposure. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Simple and scalable manufacturing</span><span style="font-size:10pt;color:#000000;">.&#160;&#160;Our novel ASOs are synthesized by highly scalable, solid-phase chemical synthesis and we leverage a well-established contract manufacturing base. We believe the manufacturing requirements for our ASOs are much simpler, more scalable and more cost-effective than gene therapy and gene editing. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our approach </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ a systematic and capital-efficient approach to develop ASOs for genetically defined patient populations. We rely on our proprietary database to identify novel drug targets and corroborate these findings with existing knowledge to improve our probability of success in the clinic. We believe that leveraging our proprietary database and focusing on our core competencies of target identification and clinical and regulatory execution will allow us to reduce the time, cost and risks of drug development. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Target identification </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to make significant investments in our infrastructure to accelerate the pace and scale of target identification. We have built a significant bioinformatics capability, which includes proprietary bioinformatics algorithms and extensive in-house expertise in whole transcriptome RNA sequencing, also referred to as RNAseq. RNAseq uses next-generation sequencing to determine the quantity and sequences of RNA in a sample. We leverage large internal datasets of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNAseq</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> from key tissues known to be addressable with antisense, such as the CNS, eye, liver and kidney, that are purpose-built to enhance the capture of non-productive events. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ machine learning to iteratively refine our search and scoring criteria for the most addressable non-productive mRNA elements based on internal target validation and Hit identification data. Our technology is amenable to a large number of mutations and can thereby potentially provide a single-drug approach for diseases that are caused by many loss-of-function mutations in a single gene. We have identified approximately 1,200 monogenic, or single gene, diseases containing at least one NMD-inducing nonproductive event,<span style="font-size:12pt;"> </span>which we believe may be amenable to TANGO. We believe our approach is highly predictive and enables rapid and systematic identification of those targets that are most likely to have clinical relevance, thereby increasing the probability for clinical success and accelerating the expansion of our emerging pipeline. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Hit identification </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a TANGO target is validated in cells and tissues that are relevant to the disease, we employ cell lines to rapidly screen for Hit ASOs that can increase the target protein expression by specifically preventing the occurrence of the non-productive event in the target mRNA. ASO arrays utilize clinically translatable previously-validated ASO chemistries, such as 2&#8217; methoxyethyl phosphorothioate and PMO. Hit compounds are evaluated in vivo to identify Lead ASOs that possess suitable efficacy and safety to merit preclinical development. Lead ASOs are subsequently evaluated in animal disease models or <span style="font-style:italic;">ex vivo</span> disease model systems. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Lead evaluation and prioritization </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After we have identified lead compounds, we evaluate and prioritize the advancement of new development candidates based on both program-specific and portfolio-wide considerations. Program-specific criteria include, among other relevant factors, the severity of the unmet medical need, the likelihood of therapeutic utility, the feasibility of clinical development, the costs of development and the commercial opportunity. Portfolio-wide considerations include the ability to demonstrate technical success for our platform, thereby increasing the probability of success and learnings for subsequent programs. We believe that the learnings from our lead Dravet syndrome program will significantly reduce the uncertainty of development of subsequent programs in our pipeline, particularly those targeting the CNS. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical trial and regulatory execution </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ a multi-pronged approach to bring new product candidates forward as rapidly as possible. Our approach leverages previously-validated ASO chemistry and a modality that has been successfully utilized for other diseases, to minimize potential safety concerns and development risk. We have two ongoing Phase 1/2a open-label studies of STK-001 for Dravet syndrome, MONARCH in the United States and ADMIRAL in the United Kingdom, each&#160;&#160;with a design and endpoints common to the trials for approved anti-seizure medications (&#8220;ASMs&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Commercialization </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to retain broad commercial rights and independently bring our therapies to patients through a lean, targeted internal commercial organization where we believe we can realize maximum value. To do this, we are focused on ensuring that we can effectively identify and access those patients who may benefit from our product candidates. We target diseases in which genetic testing is routinely performed, thereby shortening the diagnostic odyssey and enabling rapid identification of patients who harbor the relevant genetic mutations. We have partnered with Invitae, a leading genetic information company, to provide genetic testing for pediatric epilepsy at no cost to patient. Lastly, to maximize patient access, we aim to leverage an established network of academic and tertiary centers with extensive experience with analogous drug administration. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Therapeutic focus and product candidates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our ASOs can be applied to treat a wide range of severe diseases, and we have carefully designed and prioritized our pipeline strategy to maximize this opportunity. We are focused on applying the transformative potential of our TANGO platform to developing medicines for patients with diseases where the genetic abnormality is known and is found in a single gene. We therefore know for a given disease precisely which gene will need to be upregulated, thus mitigating against the uncertainty of the disease biology. We are currently focused on developing product candidates to treat autosomal dominant haploinsufficiency diseases, or disorders in which one copy of a gene is mutated and results in approximately 50% of normal protein expression. Within haploinsufficiencies, we are prioritizing genetic diseases of the CNS and the eye for our near-term development efforts. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Development Programs</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our technology, development experience and scientific knowledge in the field of biologics, RNA splicing, and antisense oligonucleotide chemistry has enabled us to build a pipeline of programs targeting the underlying cause of severe diseases. Exhibit 7 below represents a summary of our programs, which are focused on genetic diseases of the CNS and eye. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 7: Pipeline</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000004.jpg" title="" alt="" style="width:610px;height:255px;" /></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Stoke corporate presentation, March 2022</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">STK-001 for the treatment of Dravet syndrome </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;">STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials. We believe that STK-001 has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. STK-001 is designed to upregulate Na<sub style="font-size:85%; vertical-align:bottom">v</sub>1.1 protein expression by leveraging the non-mutant (wild-type) copy of the <span style="font-style:italic;">SCN1A</span> gene to restore physiological Na<sub style="font-size:85%; vertical-align:bottom">v</sub>1.1 protein levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Disease Overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dravet syndrome is one of the most severe genetic epilepsies and affects approximately 6.4 in 100,000 people worldwide, including 5-5.5 in 100,000 people who possess a mutation in the <span style="font-style:italic;">SCN1A</span> gene, according to a 2018 market research report commissioned by us and prepared by Health Advances, LLC, or the Health Advances Report. The disease is caused by a pathogenic mutation or deletion of the <span style="font-style:italic;">SCN1A</span> gene in approximately 85% of patients. At least 1,700 different <span style="font-style:italic;">de novo </span>mutations in the <span style="font-style:italic;">SCN1A </span>gene have been identified to date in Dravet syndrome patients, including single nucleotide substitutions, small insertions or deletions and even whole gene deletions. <span style="font-style:italic;">SCN1A</span> codes for the alpha subunit of the voltage-gated sodium channel, or Na<sub style="font-size:85%; vertical-align:bottom">v</sub>1.1 protein, an ion channel that is essential for the generation and propagation of action potentials. More than 95% of the disease-causing mutations of <span style="font-style:italic;">SCN1A</span> cause loss-of-function, resulting in haploinsufficiency (approximately 50% reduction) of the Na<sub style="font-size:85%; vertical-align:bottom">v</sub>1.1 protein in select neurons in the brain. This loss of Na<sub style="font-size:85%; vertical-align:bottom">v</sub>1.1 channels in inhibitory interneurons and other nerve cells results in Dravet syndrome. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dravet syndrome is characterized by multiple seizure types and may progress to status epilepticus or prolonged seizures lasting more than five minutes that require immediate intervention. Patients typically experience their first seizure before 12 months of age. More than 90% of patients suffer from at least one non-seizure comorbidity, including severe intellectual and developmental disabilities, motor and speech impairment, autism, attention deficit hyperactivity disorder and behavioral difficulties. Neurologic function and cognition are usually normal in children with Dravet syndrome up to two years of age. However, nearly all Dravet syndrome patients exhibit intellectual impairment by the age of four, ranging from minor learning difficulty to global developmental delay. The time between one year and eight years of age is a critical period for intervention. After eight years of age, nearly all Dravet syndrome patients exhibit evidence of substantial developmental delay. The symptoms of the disease result in remarkably low quality of life and shortened life expectancy, and as a result impose an immense burden on individuals and families. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cognitive impairment in Dravet syndrome is not purely a consequence of seizures. Patients with few seizures have been observed to possess severe encephalopathy, and conversely patients with frequent seizures have been observed to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exhibit relatively minimal cognitive decline. In addition, there does not appear to be a correlation between cognitive outcome and </span><span style="font-style:italic;">SCN1A </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mutation type, whether a missense or truncating mutation. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Importantly, patients with Dravet syndrome have an increased risk of premature death, primarily due to SUDEP, or Sudden Unexpected Death in Epilepsy. Dravet syndrome patients have the highest SUDEP rate of any epilepsy. An analysis of mortality in the Epilepsy Genetics Research Program demonstrated a Dravet syndrome-specific mortality rate of 15.84 per 1,000 patient years. SUDEP was the most common cause of premature death among Dravet syndrome patients (59%), equating to a Dravet syndrome-specific SUDEP rate of 9.32 per 1,000 patient-years. This is nearly twice the rate for adults with refractory epilepsy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with Dravet syndrome are often diagnosed by three years of age, and neither patient gender nor family history of seizures is associated with risk of Dravet syndrome. Dravet syndrome occurs worldwide and is not concentrated in any particular geographic area or ethnic group. Early diagnosis is driven by heightened awareness of Dravet syndrome and other genetic epilepsy disorders as well as an emerging consensus amongst epilepsy specialists that early diagnosis is cost-effective and beneficial for prognosis. Among pediatric Dravet syndrome patients, approximately 90% in North America and Europe undergo genetic testing as part of their diagnostic work-up, according to a 2021 market research report commissioned by Stoke and prepared by Recon Strategy, or the Recon Strategy report. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The incidence of Dravet syndrome is approximately 64 per million births, which translates to an overall prevalence of approximately 35,000 patients across the United States, Canada, Japan, Germany, France and the United Kingdom, with approximately 16,000 patients in the United States. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Current treatments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current treatments for Dravet syndrome only address the occurrence of seizures, not the underlying cause, and according to a 2017 study as published in the <span style="font-style:italic;">Developmental Medicine &#38; Child Neurology</span> Journal, more than 90% of Dravet syndrome patients still report suffering from incomplete seizure control with existing ASM regimens. As a result, the current treatment strategy involves the use of multiple ASMs, including combinations of cannabidiol, stiripentol, clobazam, valproate, topiramate and others. Patients are typically treated with two to four drugs administered concomitantly, and in most cases the relief provided by polytherapy is insufficient. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cannabidiol (Epidiolex), fenfluramine (Fintepla) and stiripentol (Diacomit) are currently the only FDA-approved ASMs for the treatment of Dravet syndrome. None of these approved ASMs address the significant non-seizure comorbidities. Moreover, patients are still likely to be affected by non-seizure comorbidities and may develop tolerance to these ASMs over time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with Dravet syndrome need a novel therapeutic that addresses the genetic basis of the disease and treats the large number of seizures and multiple seizure types that persist despite treatment with existing therapy. Importantly, additional therapy options are needed to address the disabling comorbidities that occur with Dravet syndrome. If STK-001 is approved by the FDA, we believe our precision medicine approach may have a profound impact on individuals and families. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical data </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have generated compelling preclinical data that demonstrate proof-of-mechanism for STK-001. Our initial target engagement, pharmacology and efficacy studies were performed in mice, including both wild-type and a Dravet syndrome mouse model. The targeted non-productive splicing event in <span style="font-style:italic;">SCN1A </span>is highly conserved across multiple species, including mouse, non-human primates and humans. The target sequence for STK-001 is also identical across species. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We evaluated STK-001 pharmacology and efficacy in transgenic mice with a heterozygous deletion of <span style="font-style:italic;">Scn1a</span>. This model was created by introducing a targeted deletion in the first coding exon of the <span style="font-style:italic;">Scn1a</span> gene&#59; these mice exhibit many aspects of the Dravet syndrome phenotype including seizures and premature lethality. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neonate (postnatal day two) Dravet syndrome mice and wild-type littermate controls were administered a single dose of either placebo (consisting of a phosphate-buffered solution), or 20 &#181;g of STK-001 (n&#61;~50/group) by intracerebroventricular injection. Animals from each group were monitored through day 90. Brains were collected from cohorts of these animals at approximately 7 weeks after dosing (placebo: n&#61;11 wild-type mice, n&#61;4 Dravet syndrome mice&#59; STK-001: n&#61;9 wild-type mice, n&#61;10 Dravet syndrome mice) and 14 weeks after dosing (placebo: n&#61;10 wild-type mice, n&#61;10 Dravet syndrome mice&#59; STK-001: n&#61;10 wild-type mice, n&#61;10 Dravet syndrome mice). Notably, a single injection of STK-001 restored Na</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">v</sub></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1 protein in Dravet syndrome mice to levels that are near those of the wild-type mice at both 7 and 14 weeks</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as shown in exhibit 8</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. These data demonstrate that STK-001 has an impact on Na</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">v</sub></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1 protein expression and we believe this may translate to a favorable dosing regimen in humans. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 8.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000005.jpg" title="" alt="" style="width:575px;height:314px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Han <span style="font-style:italic;">et al</span>., Science Trans Med, 2020</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to an increase in the Na<sub style="font-size:85%; vertical-align:bottom">v</sub>1.1 protein, the administration of a single dose of 20 &#181;g of STK-001 in neonate Dravet syndrome mice (postnatal day two) resulted in a significant reduction in premature mortality. Treatment with STK-001 resulted in 97% survival of Dravet syndrome mice for the 90-day post-natal observation period (survival of 33 out of 34 mice was observed in the STK-001 Dravet syndrome mouse group) compared with 23% survival of placebo-treated mice (survival of 14 out of 62 mice). This is illustrated in exhibit 9. </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 9.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000006.jpg" title="" alt="" style="width:553px;height:293px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Han <span style="font-style:italic;">et al</span>., Science Trans Med, 2020</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further preclinical studies of STK-001 have shown significant reductions in seizure frequency in a mouse model of Dravet syndrome (DS). Data from electroencephalography (EEG) recordings showed 76% (16/21) of DS mice treated with STK-001 were seizure free compared to 48% (10/21) that were treated with a placebo. An 80% reduction in the average number of spontaneous seizures (3 seizures vs 16 seizures) was also observed among treated DS mice compared to placebo. EEG is a highly sensitive measure of seizure activity, which enables the detection of seizures that may not be otherwise visible. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These data are published in Han et al., Science Trans. Med, 2020.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Analyses were also performed <span style="font-style:italic;">in silico</span> to understand the specificity of STK-001. We evaluated STK-001 via bioinformatic analysis against all annotated protein-coding genes to predict potential off-target activities. Results showed no perfect 18- to 16-nucleotide match for STK-001 anywhere in the transcriptome other than <span style="font-style:italic;">SCN1A</span> pre-mRNA, indicating that STK-001 recognizes a unique sequence in the human transcriptome and should possess minimal off-target bindings. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further supporting our specificity analysis, we also evaluated brain samples of wild-type neonate mice to ensure that STK-001 does not alter levels of other channels in the highly homologous <span style="font-style:italic;">SCN</span> family. Importantly, the mRNA levels of closely related ion channels were not altered in the mouse brain five days after administration of 10 &#181;g of STK-001 (n&#61;2/group placebo, n&#61;4/group STK-001), as shown in the figure below. Similar analysis was performed in wild-type and Dravet syndrome mice treated with 20 &#181;g of STK-001 at 7 and 14 weeks after dosing. As illustrated in exhibit 10, STK-001 treated samples showed an increase in expression of the <span style="font-style:italic;">SCN1A</span> gene, but not any of the other <span style="font-style:italic;">SCN</span> family members. These biological studies demonstrate that STK-001 is highly specific for <span style="font-style:italic;">SCN1A</span> among the highly homologous family of sodium channel genes, limiting the likelihood of off-target activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000007.jpg" title="" alt="" style="width:618px;height:212px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source:&#160;&#160;Stoke data.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also investigated the pharmacology, distribution and tolerability of STK-001 in a study with cynomolgus monkeys. As a pilot experiment, this study was not required to be performed under Good Laboratory Practices, or GLP. Pre-pubescent monkeys (age 2-2.5 years old) were administered a single dose of STK-001 (n&#61;3/group&#59; 4&#160;groups dosed) or control solution (n&#61;2/group&#59; 2 groups dosed) by intrathecal injection at a dose range that we believe coincides with the estimated therapeutic dose range and stays below the maximum tolerated dose based on tolerability in mice and published data for molecules of similar chemistry. The animals were sacrificed at 3 days (n&#61;8) and 29 days (n&#61;8) after dosing. An increase in Na<sub style="font-size:85%; vertical-align:bottom">V</sub>1.1 levels was observed ranging from 1.1-fold to 2.0-fold, compared to the control group, varying by the anatomical region, dose and day of necropsy, with the greatest changes observed in the cerebral cortex. The increase in Na<sub style="font-size:85%; vertical-align:bottom">v</sub>1.1 was also correlated with the presence of STK-001 in brain tissue. Additionally, all doses tested showed no drug-related toxicities, including no changes in platelet counts or hepatic function, no clinical signs or symptoms over the 28-day period after administration and no abnormal histopathology. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Single dose GLP toxicology studies in rats and cynomolgus monkeys, that characterized the pharmacology, exposure and tolerability of STK-001 were included in the investigational new drug application (the &#8220;IND&#8221;) that was submitted to the FDA in late 2019. Additional multiple dose GLP toxicology data have subsequently been submitted to the FDA and the MHRA (UK regulatory agency) to support multiple dosing in the clinic.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical program and data </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We designed our lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. This program draws on a well-defined patient population based on routine genetic testing and learnings from drugs approved for the treatment of Dravet syndrome to inform the clinical and regulatory pathways for STK-001. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have two ongoing Phase 1/2a open-label studies of STK-001, MONARCH in the United States and ADMIRAL in the United Kingdom. The MONARCH Study is designed to evaluate single and multiple ascending dose levels of STK-001 administered intrathecally in children and adolescents with Dravet syndrome. Patients are eligible for the trial if they are between the ages of 2 to 18, have an established diagnosis of Dravet syndrome and have evidence of a pathogenic genetic mutation in the SCN1A gene. Requiring an SCN1A </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mutation&#160;&#160;for</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> trial enrollment allows for a clear and definitive etiologic diagnosis, a more homogeneous patient population and tailored treatment based on a precision medicine approach. Eligible patients will also have failed at least two epilepsy treatments in the past and currently be taking at least one ASM. All medications and interventions will remain unchanged throughout the trials, which will allow for assessment of STK-001 with a variety of ASMs. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary objectives are the assessment of the safety and tolerability of STK-001, as well as to characterize blood pharmacokinetics (&#8220;PK&#8221;) and cerebrospinal fluid (&#8220;CSF&#8221;) exposure levels. A secondary objective is to assess the efficacy of STK-001 as an adjunctive ASM treatment with respect to the percent change from baseline in convulsive seizure frequency over a 12-week treatment period. We are measuring non-seizure aspects of the disease, such as quality of life as secondary endpoints. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These endpoints as well as other exploratory endpoints will be informed based on our two-year observational study (BUTTERFLY). Enrollment in BUTTERFLY is complete and the study is ongoing. BUTTERFLY is designed to evaluate seizure frequency and non-seizure comorbidities associated with the disease, including motor and speech impairment, intellectual and developmental disabilities, behavioral deficits and abnormal sleep patterns. Data from the study will support clinical development plans for STK-001.&#160;&#160;Initial data from BUTTERFLY suggest that commonly used cognition assessments, BSID-III (Bayley Scales of Infant Development, Third Edition), and WPPSI-IV (Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition) may be useful for clinical studies assessing neurodevelopment and adaptive behavior in patients with Dravet syndrome. All three assessments showed relatively low intra-patient variability and no significant change from baseline three months after baseline assessments for all 36 patients enrolled.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, we announced the FDA had placed a partial clinical hold on doses of STK-001 above 20mg in the MONARCH Study, pending additional preclinical testing to determine the safety profile of doses higher than the current no observed adverse effect level (&#8220;NOAEL&#8221;). When intrathecal doses above the NOAEL were administered to non-human primates (&#8220;NHPs&#8221;) adverse hind limb paresis was observed. This finding is known to occur following intrathecal delivery of ASOs to NHPs and is not known to translate to the human experience. When extremely high dose levels were administered, acute convulsions were observed immediately following STK-001 administration. The dose levels were well above the range of corresponding human doses that would ever be administered in the clinic and were delivered in a formulation that was at a higher concentration than would be administered in the clinic. There is no apparent correlation of these acute adverse events with the mechanism of action of STK-001. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since March 2020, the FDA has agreed to allow us to add additional higher dose levels to the MONARCH study. The study is currently permitted to evaluate single doses (10mg, 20mg, 30mg or 45mg) and multiple doses administered monthly for three months (20mg, 30mg or 45mg). Dosing above 45mg in this study remains on FDA partial clinical hold. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ADMIRAL study is a Phase 1/2a open-label study of children and adolescents ages 2 to &#60;18 who have an established diagnosis of Dravet syndrome and have evidence of a genetic mutation in the&#160;<span style="font-style:italic;">SCN1A</span>&#160;gene. The primary objectives for the study are to assess the safety and tolerability of multiple doses of STK-001 up to 70mg, as well as to determine the pharmacokinetics in plasma and exposure in cerebrospinal fluid. A secondary objective is to assess the effect of multiple doses of STK-001 as an adjunctive antiepileptic treatment with respect to the percentage change from baseline in convulsive seizure frequency over a 24-week treatment period. We are measuring non-seizure aspects of the disease, such as overall clinical status and quality of life, as secondary endpoints.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second half of 2021, we announced positive interim safety, PK, CSF exposure, and efficacy data from the MONARCH study. The interim analysis was based on data from 22 patients who were treated in the single 10mg (n&#61;5), 20mg (n&#61;4), or 30mg (n&#61;7) dose cohorts of STK-001 and who were followed for at least three months after their last dose.&#160;&#160;Also included in this analysis were six patients from the 20mg MAD dose cohort, most of whom had received three monthly doses of STK-001.&#160;&#160;Key findings from the interim analysis include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Single doses of STK-001 up to 30mg, and three 20mg doses of STK-001 given every four weeks were found to be well tolerated with no safety concerns related to the study drug.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The most common treatment-emergent adverse events (&#8220;TEAEs&#8221;) were headache, vomiting, seizure, irritability, and back pain.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">18.2% (4/22) of patients experienced a TEAE that was related to study drug, none of which were severe.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">22.7% (5/22) patients had a serious treatment-emergent adverse event (&#8220;SAE&#8221;), none of which were related to study drug.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">70.6% (12/17) patients treated with single doses (10mg, 20mg, 30mg) or multiple doses (20mg) of STK-001 experienced a reduction from baseline in convulsive seizure frequency measured from Day 29 to Day 84 after receiving their first dose of STK-001.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">All patients ages 2-12 (n&#61;7) experienced a reduction from baseline in convulsive seizure frequency measured from Day 29 to Day 84. Reductions in seizure frequency were also observed among patients ages 13-18 in the higher dose cohorts.&#160;&#160;This is illustrated in exhibits 11 and 12 below</span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 11.<span style="margin-left:36pt;">Exhibit 12.</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000008.jpg" title="" alt="" style="width:577px;height:228px;" /></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Interim Safety, PK, and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001, an Antisense Oligonucleotide (AS0), in Children and Adolescents with Dravet Syndrome (DS) (AES 2021)</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:12.95%;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Across all cohorts median reductions of 17% to 37% from baseline in convulsive seizure frequency from Day 29 to Day 84 were observed. This is illustrated in exhibit 13 shown below.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 13.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000009.jpg" title="" alt="" style="width:262px;height:250px;" /></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Interim Safety, PK, and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001, an Antisense Oligonucleotide (AS0), in Children and Adolescents with Dravet Syndrome (DS) (AES 2021)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2021, a population PK model for intrathecal STK-001 was developed using non-human primate data and was scaled and adjusted using clinical data to predict STK-001 concentrations in plasma, CSF, and brain in pediatric patients with Dravet syndrome.&#160;&#160;STK-001 levels in plasma and CSF in patients treated with STK-001 correlated very well with model predictions, indicating that plasma and CSF levels observed in patients are good predictors of STK-001 brain levels in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients.&#160;&#160;Modeling of clinical data also suggest that more than 95% of patients are predicted to have pharmacologically active STK-001 brain levels following three doses of 30mg administered one month apart and half of all patients are anticipated to maintain greater than minimum pharmacologically active levels of STK-001 for approximately three months after their last dose as shown in </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as shown in exhibit 14.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 14.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000010.jpg" title="" alt="" style="width:522px;height:300px;" /></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: A Pharmacokinetic (PK) Model for STK-001, an Antisense Oligonucleotide (AS), Based on Data from Non-human Primates (NHP) Enables Dose Selection in Patients with Dravet Syndrome (DS) (AES 2021)<span style="font-size:12pt;">&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MONARCH and ADMIRAL continue to progress with enrollment and dosing of patients ongoing. We expect to announce preliminary clinical data on 30mg MAD doses of STK-001 in the second half of 2022.&#160;&#160;Enrollment and dosing of patients is ongoing in the 45mg SAD cohort of MONARCH. The first patients have also been dosed with STK-001 at 45mg in the ADMIRAL study, which is a multiple ascending dose study.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, we initiated enrollment and dosing in our SWALLOWTAIL Open Label Extension (OLE) study of STK-001 for children and adolescents with Dravet syndrome. Patients who participated in the MONARCH study and meet study entry criteria are eligible to continue treatment in SWALLOWTAIL which is designed to evaluate the long-term safety and tolerability of repeated doses of STK-001. SWALLOWTAIL will also provide valuable information on the preliminary effects of STK-001 on seizures along with non-seizure aspects of the disease, such as quality of life and cognition. In this study, patients will initially be administered the same dose level they received in the previous study and will receive a maximum of three doses. One dose will be administered every four months. In December 2021 we presented initial data from the SWALLOWTAIL study that demonstrated that multiple doses up to 30mg of STK-001 intrathecally every four months appears to be well tolerated. Enrollment and dosing in SWALLOWTAIL are underway. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we continue working to minimize any potential delay to continued clinical testing of STK-001, we expect that the COVID-19 pandemic may directly or indirectly impact the timeline. Our ability to continue the clinical trials may be adversely affected, directly or indirectly, by the COVID-19 pandemic. For example, although MONARCH and ADMIRAL have not been delayed, we plan to have clinical trial sites in various parts of the United States and the United Kingdom, some of which have had high incident rates of COVID-19 patients. Restrictions on travel and/or transport of clinical materials, as well as diversion of hospital staff and resources to COVID-19 infected patients, could disrupt trial operations as well as recruitment, possibly resulting in a slowdown in enrollment and/or deviations from or disruptions in key clinical trial activities, such as clinical trial site monitoring. These challenges may lead to difficulties in meeting protocol-specified procedures. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet discussed with regulatory authorities the evidence necessary for approval of STK-001. However, if we see evidence of clinical efficacy as we dose escalate, then we would plan to meet with regulatory authorities to discuss expedited regulatory pathways. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">STK-002 for the treatment of Autosomal Dominant Optic Atrophy </span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(ADOA)</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STK-002 is our lead clinical candidate for the treatment of ADOA. STK-002 is designed to upregulate OPA1 protein expression by leveraging the non-mutant (wild-type) copy of the <span style="font-style:italic;">OPA1</span> gene to restore OPA1 protein expression with the aim to stop or slow vision loss in patients with ADOA. To date, we have generated preclinical data demonstrating proof-of-mechanism and proof-of-concept for STK-002. Based on preclinical data generated to date, we believe that STK-002 has the potential to be the first disease-modifying therapy for people living with ADOA. Preclinical toxicology studies are underway to support future clinical trials for STK-002.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Disease Overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADOA is the most common inherited optic nerve disorder seen in clinical practice. ADOA causes progressive and irreversible vision loss in both eyes starting in the first decade of life. Many children progress to blindness. Roughly half of people with ADOA fail driving standards and up to 46% are registered as legally blind. The disease affects one in 30,000 people globally with a higher incidence of approximately one in 10,000 in Denmark due to a founder effect. 65% to 90% of ADOA is caused by mutations in one allele of the <span style="font-style:italic;">OPA1</span> gene, most of which lead to haploinsufficiency and disease manifestation. More than 400 different <span style="font-style:italic;">OPA1</span> mutations have been reported in people diagnosed with ADOA. Most mutations result in a severe decrease &#8211; up to 50% &#8211; of the normal amount of the OPA1 protein. There is no strong genotype-phenotype correlation. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OPA1 is a dynamin-related GTPase that plays a key role in maintaining mitochondria structure and dynamics. The OPA1 protein is imported into the mitochondria and is the crucial molecule that mediates inner mitochondria membrane fusion and cristae morphogenesis and is critical for oxidative phosphorylation and Adenosine triphosphate (&#8220;ATP&#8221;) synthesis. Insufficient OPA1 activity causes mitochondria dysfunction with consequent insufficient ATP production, excess reactive oxygen species production and eventual cell death. High energy demanding cells such as neurons and cardiomyocytes are particularly susceptible to mitochondria dysfunction, and retinal ganglion cells (&#8220;RGCs&#8221;) are a neuronal cell type most susceptible to loss of OPA1 protein as evidenced by RGC death in ADOA caused by <span style="font-style:italic;">OPA1</span> haploinsufficiency. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A clinical diagnosis of ADOA is made when a patient meets some or all of the following criteria: pathogenic variant of the <span style="font-style:italic;">OPA1</span> gene identified in the patient or a family member&#59; reduced visual acuity&#59; temporal disc pallor&#59; visual field defect&#59; color vision defect (acquired blue-yellow loss)&#59; thinning of retinal nerve fiber layer and abnormal visual evoked potentials. Clinical findings are based on: intraocular pressure measurement&#59; visual field assessment&#59; color discrimination&#59; dilated slit lamp biomicroscopy&#59; optical coherence tomography&#59; or visual electrophysiology. Patients suspected of ADOA are recommended to receive genetic testing to confirm the clinical diagnosis, help identify other family members who are affected and ensure patients avoid stressors that could increase disease progression (e.g. smoking, alcohol). The prognosis for many patients with ADOA is poor and the rate of visual loss can be difficult to predict given significant inter- and intra-familial variability. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Current Treatments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently no available treatments for ADOA. Because ADOA causes deterioration of the optic nerves, corrective aids such as glasses or contacts do not help to improve vision lost to the disease. Supportive services and low-vision aids are offered for patients with severely decreased visual acuity. Our ASOs are designed to target the underlying cause of ADOA, which is <span style="font-style:italic;">OPA1</span> haploinsufficiency, by decreasing a non-productive mRNA splicing event in the <span style="font-style:italic;">OPA1</span> gene to increase productive <span style="font-style:italic;">OPA1</span> mRNA and OPA1 protein in the retinal ganglion cells. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical data<span style="font-weight:bold;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:7.14%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We previously identified a novel exon inclusion event (&#8220;Exon X&#8221;) in OPA1 that leads to non-productive mRNA due to introduction of a premature termination codon (&#8220;PTC&#8221;) (exhibit 15 below). Our preclinical studies showed that our ASOs blocked the incorporation of Exon X with consequent dose-dependent increase in productive OPA1 mRNA and protein due to reduction of Exon X-directed non-sense mediated decay (&#8220;NMD&#8221;) of OPA1 mRNA (exhibit 16 below). We have now demonstrated that a single injection of ASO-14 surrogate in the rabbit eye leads to a dose-dependent increase in ASO accumulation in the retina that correlated with an increase in target engagement (removal of Exon X) and an increase in OPA1 protein (exhibit 17 below). The study was conducted using female New Zealand white rabbits that were injected with a single dose of vehicle alone or vehicle containing ASO (n&#61;3/group). On Days 15 and 29, the retinal tissue was collected and analyzed. Retinal exposure of ASO-14 surrogate (ST-1102) was elevated with increased dosing, dose-dependent target engagement was seen at all three time-points examined, and protein increase of OPA1 protein was observed at both Day 15 and Day 29 of the study. We further showed that in OPA1 haploinsufficient human cells, ASO-14-mediated increase in OPA1 protein </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">translates to improved mitochondrial function as measured by the substantial restoration of ATP levels in the treated cells (exhibit 18 below). ATP is produced by the mitochondria and is the key energy carrying molecule in cells. We observed a 20% ATP deficit in OPA1 +/- HEK293. Treatment with ASO-14 restored ATP levels to ~90% of control cells. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 15: A representation of the non-productive mRNA splicing event in <span style="font-style:italic;">OPA1</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000011.jpg" title="" alt="" style="width:524px;height:213px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 16: Inhibition of NMD with cycloheximide allows for evaluation of the abundance of this event in vitro</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000012.jpg" title="" alt="" style="width:492px;height:278px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 17: Rabbit ASO demonstrates dose-dependent OPA1 protein increase in rabbit retina<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000013.jpg" title="" alt="" style="width:624px;height:246px;" /></p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Venkatesh A, et al. Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for treatment of autosomal dominant optic atrophy. Presented at The Association for Research in Vision and Ophthalmology&#59; May 3-7, 2020&#59; Baltimore, MD.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 18: <span style="color:#000000;">Human ASO demonstrates ATP upregulation in </span><span style="font-style:italic;color:#000000;">OPA1 </span><span style="color:#000000;">haploinsufficient HEK293 cells</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000014.jpg" title="" alt="" style="width:488px;height:298px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Stoke data</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, we presented new preclinical efficacy data at The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting demonstrating that our TANGO ASOs can increase OPA1 protein levels and improve mitochondrial function in human cells derived from ADOA patients with different OPA1 mutations. Exhibit 19 below demonstrates that our TANGO ASO increases OPA1 protein and ATP linked mitochondrial respiration in ADOA patient cells.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 19: TANGO ASO increases OPA1 protein and ATP linked mitochondrial respiration in ADOA patient cells</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gu0gjnulhgsv000015.jpg" title="" alt="" style="width:575px;height:236px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source (left graph): Stoke data Source (right graph): Venkatesh A, et al. Antisense oligonucleotide mediated increase in OPA1 improves mitochondrial function in fibroblasts derived from patients with autosomal dominant optic atrophy (ADOA). Presented at The Association for Research in Vision and Ophthalmology&#59; May 1-7, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with STK-001 for Dravet syndrome, our study and development of STK-002 and the use of our TANGO technology to treat ADOA is subject to the risks and uncertainties<span style="color:#000000;"> stemming from the COVID-19 pandemic, which may directly or indirectly impact our ability to pursue this new target, and the timing in which we do so.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Additional product opportunities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also advancing additional programs focused on multiple targets, including haploinsufficiency diseases of the CNS and eye. These tissues are affected in many severe genetic diseases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Longer-term, we believe that ASOs designed using TANGO may have the potential to upregulate non-mutated genes in biological pathways to treat diseases or conditions caused by multiple genes or are multifactorial, such as autoimmune diseases, aging and cancer. For these diseases, we intend to opportunistically secure partnerships with biopharmaceutical partners whose scientific, development or commercial capabilities complement our own. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Acadia License and Collaboration Agreement</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, we entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. (&#8220;Acadia&#8221;) for the discovery, development and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The agreement focuses on the targets SYNGAP1, MECP2 (Rett syndrome), and an undisclosed neurodevelopmental target of mutual interest. In connection with each target, we will collaborate with Acadia to identify potential treatments for further development and commercialization as licensed products. With respect to SYNGAP1, we have agreed with Acadia to co-develop and co-commercialize licensed products for such target globally, and in connection therewith we granted to Acadia worldwide, co-exclusive (with us) licenses for such licensed products. With respect to MECP2 and the neurodevelopmental target, we granted to Acadia worldwide, exclusive licenses to develop and commercialize licensed products for such targets. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the agreement, we received an upfront payment of $60 million from Acadia. Acadia agreed to fund the research to identify potential licensed products for MECP2 and the neurodevelopmental target, and we will equally fund with Acadia the research to identify potential licensed products for SYNGAP1. We are e<span style="Background-color:#FFFFFF;color:#000000;">ligible to receive up to $907,500,000 in potential total milestone payments based upon the achievement of certain development, regulatory, first commercial sales and sales milestone events across the programs for the three targets, assuming each milestone were achieved at least once.</span> With respect to licensed products for MECP2 and the neurodevelopmental target, we are also eligible to receive tiered royalties at percentages ranging from the mid-single digits to the mid-teens on future net sales by Acadia of licensed products worldwide. Royalties payable under the agreement are subject to standard royalty reductions. For SYNGAP1 licensed products that we are co-developing and co-commercializing, we will be responsible for 50% of the development and commercialization costs and will receive 50% of the profits from global commercialization.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to each SYNGAP1 licensed product being co-developed or co-commercialized, the agreement will remain in effect, unless earlier terminated, until the parties have agreed to permanently abandon the further development and commercialization of such licensed product. With respect to licensed products for MECP2 and the neurodevelopmental target, the agreement will remain in effect, unless earlier terminated, until the expiration, on a country-by-country and licensed product-by-licensed product basis, of the applicable royalty term, at which point the license for such licensed product shall become fully paid-up, royalty-free, perpetual and irrevocable in such country.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement also contains customary provisions for termination by Acadia for convenience and by either party for cause, including for material breach (subject to cure). We have standard reversion rights in connection with certain early termination events.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SYNGAP1 syndrome is a rare neurological disorder characterized by moderate to severe intellectual disability that is evident in early childhood. Mutations in the SYNGAP1 gene (which produces the SynGAP protein) were first identified in 2009 and since then, an increasing number of children with SYNGAP1 syndrome have been identified. Normal levels of SynGAP protein are essential for proper brain function and development. Mutations in the SYNGAP1 gene also play an important role in the development of epileptic encephalopathies (DEEs). The severity and onset of symptoms can vary from patient to patient. SYNGAP1 syndrome is characterized by developmental delay or intellectual disability, generalized epilepsy, and autism spectrum disorder (ASD) and other behavioral abnormalities. More than 80% of cases of SYNGAP1 syndrome are caused by a haploinsufficiency of the SYNGAP1 gene. SYNGAP1 syndrome is estimated to account for 1% to 2% of all intellectual disability cases. There are currently no approved treatments for SYNGAP1 syndrome.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rett syndrome is a rare, debilitating neurological disorder that occurs primarily in females following apparently normal development for the first six months of life. Rett syndrome is often misdiagnosed as autism, cerebral palsy, or non-specific developmental delay. Rett syndrome is caused by mutations on the X chromosome on a gene called MECP2. There are more than 200 different mutations found on the MECP2 gene that interfere with its ability to generate a normal gene product. Rett syndrome occurs worldwide in approximately one of every 10,000 to 15,000 female births and in the United States impacts 6,000 to 9,000 patients. Rett syndrome causes problems in brain function that are responsible for cognitive, sensory, emotional, motor and autonomic function. Typically, with symptoms presenting between 6 to 18 months of age, patients experience a period of rapid decline with loss of purposeful hand use (fine motor skills), development of hand stereotypies, absent or impaired mobility (gross motor skills), loss of communication skills (including eye contact) and inability to independently conduct activities of daily living. Symptoms also include seizures, disorganized breathing patterns, an abnormal side-to-side curvature of the spine (scoliosis), and sleep disturbances. Currently, there are no FDA-approved medicines for the treatment of Rett syndrome.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Business Update Regarding COVID-19</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current COVID-19 pandemic continues to present a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as the U.S. economy and financial markets. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, liquidity and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including the timing and effectiveness of global efforts to roll out vaccines, new information that may emerge concerning COVID-19 and COVID-19 variants, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, our third party contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations (&#8220;CMOs&#8221;), and other third-party vendors have been able to continue to provide services and supply reagents, materials, and products and currently do not anticipate any significant disruption in services or interruptions in supply. We have pursued mitigation strategies to keep key research activities on track. Our third-party CMOs continue to operate their manufacturing facilities at or near normal levels. While we currently do not anticipate any significant interruptions in our manufacturing processes, it is possible that the COVID-19 pandemic and response efforts may have an impact in the future on our third-party suppliers and CMO&#8217;s ability to manufacture reagents, materials, or products that we need to use in our research and clinical trial. However, we are continuing to assess the potential impact of the COVID-19 pandemic on our business and operations, including our expenses, our observational study, our clinical trials, and our ability to hire and retain employees.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to continue our clinical trials and our observational study may be adversely affected, directly or indirectly, by the COVID-19 pandemic. Currently we are monitoring patient enrollment and participation in our clinical trials and our observational study, including the duration and degree to which we may see declines in enrollment, delays in conducting in-person follow-ups, and disruptions in our ability to monitor patients due to hospitals closing sites or diverting the resources that are necessary to conduct our clinical trials and our observational study. While we continue to enroll and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dose patients in our clinical trials at sites across the United States and the United Kingdom, we take into consideration that COVID-19 precautions may directly or indirectly impact the timeline for some of our clinical trial activities due to hospitals closing sites and/or diverting the resources that are necessary to conduct clinical trials. We are pursuing approaches to help mitigate the impact to our clinical trials. Currently we have not experienced any </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significant </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays in our clinical trials due to COVID-19.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has caused us to modify our business practices including but not limited to curtailing or modifying employee travel, moving to partial remote work, and minimizing some physical participation in meetings, events and conferences. We continue to monitor our operations and applicable governmental recommendations, and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees, patients and business partners. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our office-based employees had been primarily working from home from early March 2020 through early September 2021. Since then, our office-based staff have been working in a hybrid-model fluctuating between work from home and work from the office. Throughout the pandemic, we continue to ensure that essential staffing levels in our operations remain in place, including maintaining key personnel in our laboratories</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional information on the various risks posed by the COVID-19 pandemic, please read Item 1A. Risk Factors included in this annual report.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently contract with third parties to manufacture our products undergoing late-preclinical testing and anticipate using third parties for all clinical and commercial manufacturing. We do not own or operate facilities for product manufacturing, packaging, storage and distribution, or testing. We have personnel with extensive technical, manufacturing, analytical and quality experience and good project management to oversee contract manufacturing and testing activities. We will continue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the future if there is a technical need, or a strategic or financial benefit. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing is subject to extensive regulations that impose procedural and documentation requirements. At a minimum these regulations govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance. Our systems, procedures and contractors are required to be in compliance with these regulations and are assessed through regular monitoring and formal audits. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Drug substance </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oligonucleotide drug substance requirements for our most advanced programs can be readily met by a variety of domestic and international contractors. Many of these contractors are also able to source all the required raw materials, which allows us to consolidate raw material procurement and drug substance manufacturing activities with a single supplier. To ensure supply chain continuity, we plan to establish supply agreements with alternative suppliers as appropriate. As part of each development program, efforts will be made to invest in process changes to improve purity and yield as warranted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future drug substance compositions may require different manufacturing capabilities, which will be addressed through either expanded capability with existing contractors or establishing manufacturing supply relationships with new contractors. These changes in composition may also require new supply chain agreements with contractors that specialize in raw material manufacturing. Our internal personnel will work to identify and establish relationships with contractors that may be ideally suited to meeting these new manufacturing requirements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Drug product </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the near future, we expect all our oligonucleotide drug products to consist of drug substance formulated in either saline, buffered saline, or some other diluent appropriate for intrathecal, intraocular, subcutaneous, or intravenous injection. These types of formulations can be manufactured using common processes and readily available materials. We are establishing agreements with a variety of contractors that are suitably equipped to manufacture, package, and test these types of oligonucleotide drug product formulations for subsequent shipment to clinical sites. Several of these manufacturers would also be capable of formulation and packaging for commercial use. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and biopharmaceutical industries, and the genetic medicines fields, are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. Any product candidates that we successfully develop and commercialize will have to compete with existing therapies and new therapies that may become available in the future. While we believe that our technology, development experience and scientific knowledge in the field of biologics, RNA splicing, and antisense oligonucleotide chemistry provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing and commercialization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While therapeutic modalities, including gene therapy, gene editing, modified RNA and protein-based drugs, are currently being developed to address monogenic diseases, most of these approaches are focused on autosomal recessive or autosomal dominant gain-of-function diseases. The nature and fundamental limitations of these approaches make them less suited for addressing the underlying cause of autosomal dominant haploinsufficiencies. Other next generation antisense oligonucleotides have also generally had limited success in upregulating gene expression of haploinsufficiencies, due to a focus on indirectly and weakly validated mechanisms of action such as targeting microRNAs or long non-coding RNAs that are associated with a gene transcript. We are pioneers in developing disease-modifying therapies to treat haploinsufficiencies and are uniquely positioned to exploit this significant opportunity with our TANGO platform. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our current product candidate, STK-001, is approved for the treatment of Dravet syndrome, it may compete with other products currently marketed or in development. Currently marketed anti-seizure medicines (ASMs) range from cannabidiols, such as Jazz Pharmaceuticals&#8217; Epidiolex, Fintepla&#174; (fenfluramine) from Zogenix, to GABA receptor agonists, such as clobazam and stiripentol, to glutamate blockers, such as topiramate. Companies such as Ovid Therapeutics/Takeda, Xenon Pharmaceuticals, Eisai Pharmaceuticals, Longboard Pharmaceuticals and Encoded Therapeutics are also developing treatments for Dravet syndrome. Many of the currently marketed ASMs are available as generics. In addition, numerous compounds are in clinical development for treatment of epilepsy. To our knowledge, the clinical development pipeline includes cannabinoids, 5-HT release stimulants, cholesterol 24-hydroxylase inhibitors, and sodium channel antagonists from a variety of companies. Importantly, we believe none of the drugs in clinical development address the underlying genetic cause of Dravet syndrome. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our second product candidate, STK-002, is in development for treatment of Autosomal Dominant Optic Atrophy (ADOA).&#160;There are no products currently marketed or in clinical development for treatment of ADOA.&#160;To our knowledge, there are also very limited preclinical development efforts beyond our product candidate.&#160;PYC Therapeutics is developing a cell penetrating peptide PMO conjugated to ASO for treatment of ADOA.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical, and human resources than we do. Accordingly, our competitors may be more successful than us in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive. Merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our commercial opportunity could be substantially limited if our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than our comparable products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of the entry of our products. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of other drugs. The key competitive factors affecting the success of all of our programs are likely to be their efficacy, safety, convenience and availability of reimbursement. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern pricing and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription biopharmaceutical pricing remains subject </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to continuing governmental control even after initial approval is granted. As a result, a drug company can obtain regulatory approval for a product in a country, but then be subject to price regulations that delay commercial launch of that product. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A drug company&#8217;s ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government authorities, private health insurers and other organizations. Even if one or more products are successfully brought to the market, these products may not be considered cost effective, and the amount reimbursed for such products may be insufficient to allow them to be sold on a competitive basis. Third-party payors who reimburse patients or healthcare providers, such as government plans, are requiring that drug companies provide them with predetermined discounts from list prices and are seeking to reduce the prices charged or the amounts reimbursed for biopharmaceutical products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant delays can occur in obtaining reimbursement for newly-approved drugs or therapeutic biologics, and coverage may be more limited than the purposes for which the drug or therapeutic biologic is approved by the FDA or similar foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be reimbursed in all cases or at a rate that covers a drug company&#8217;s costs, including research, development, manufacture, sale and distribution. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim reimbursement levels for new drugs, if applicable, may also be insufficient to cover a drug company&#8217;s costs and may not be made permanent. Reimbursement rates may be based on payments allowed for lower cost drugs or therapeutic biologics that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs or therapeutic biologics may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs or therapeutic biologics from countries where they may be sold at lower prices than in the United States. Further, no uniform policy for coverage and reimbursement exists in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement can differ significantly from payor to payor. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to our business, including obtaining, maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among, other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms and product candidates that are important to the development and implementation of our business. Our patent portfolio, including in-licensed patents and patent applications, is intended to cover, but is not limited to, our technology platforms, product candidates and components thereof, their methods of use and processes for their manufacture, and any other inventions that are commercially important to our business. We also rely on trade secret protection of our confidential information and know-how relating to our proprietary technology, platforms and product candidates, continuing innovation, and in-licensing opportunities to develop, strengthen, and maintain our position in our TANGO platform and product candidates. Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions and improvements&#59; to preserve the confidentiality of our trade secrets&#59; to maintain our licenses to use intellectual property owned or controlled by third parties&#59; to defend and enforce our proprietary rights, including our patents&#59; to defend against challenges and assertions by third parties of their purported intellectual property rights&#59; and to operate without infringement of valid and enforceable patents and other proprietary rights of third parties. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our TANGO platform, we have exclusively licensed intellectual property for our TANGO technology from the University of Southampton and Cold Spring Harbor Laboratory, which includes issued U.S. and foreign patents and pending U.S. and foreign patent applications that cover the TANGO mechanisms. As of December 31, 2021, the issued U.S. patents, issued foreign patents, pending U.S. patent applications and pending foreign patent applications that we have licensed from the University of Southampton are anticipated to expire between 2035 and 2036, absent any patent term adjustments or extensions. As of December 31, 2021, the issued U.S. patents, pending U.S. patent applications and pending foreign patent applications that we have licensed from Cold Spring Harbor Laboratory are anticipated to expire in 2035, absent any patent term adjustments or extensions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, we have filed patent applications with claims that are intended to cover compositions of matter of oligonucleotides designed to target specific elements in genes for many genetic diseases that we believe are amenable to upregulation of target protein expression using our TANGO platform. As of December 31, 2021, any patents that may issue </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from these currently pending patent applications, including PCT international applications, U.S. patent applications, and foreign patent applications, are expected to expire between 2036 and 2042, absent any patent term adjustments or extensions.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to STK-001, as of December 31, 2021, we have exclusively licensed U.S. patents that cover the mechanism of action of STK-001, as well as foreign patents and pending foreign patent applications. The issued patents and any patents that may issue from these pending patent applications are expected to expire between 2035 and 2036, absent any patent term adjustments or extensions. As of December 31, 2021, we also own U.S. patents, a pending U.S. patent application, a PCT international application, foreign patents and pending foreign patent applications relating to STK-001, and the U.S. patent any patents that may issue from these pending patent applications are expected to expire between 2038 and 2040, absent any patent term adjustments or extensions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to STK-002, as of December 31, 2021, we have exclusively licensed U.S. patents that cover the mechanism of action of STK-002, as well as foreign patents and pending foreign patent applications. The issued patents and any patents that may issue from these pending patent applications are expected to expire between 2035 and 2036, absent any patent term adjustments or extensions. As of December 31, 2021, we also own a pending U.S. patent application, a PCT international application, and pending foreign patent applications relating to STK-002, and any patents that may issue from these pending patent applications are expected to expire between 2038 and 2041, absent any patent term adjustments or extensions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of individual patents depends upon the laws of the countries in which they are obtained. In most countries in which we file, the patent term is 20&#160;years from the earliest date of filing of a non-provisional patent application. However, the term of United States patents may be extended for delays incurred due to compliance with the FDA requirements or by delays encountered during prosecution that are caused by the United States Patent and Trademark Office, or the USPTO. For example, for drugs that are regulated by the FDA under the Hatch-Waxman Act, it is permitted to extend the term of a patent that covers such drug for up to five years beyond the normal expiration date of the patent. For more information on patent term extensions, see &#8220;Business&#8212;Government regulation: The Hatch-Waxman Act&#8212;Patent term extension&#8221;. In the future, if and when our biopharmaceutical product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates. We intend to seek patent term extensions to any of our issued patents in any jurisdiction where these are available&#59; however, there is no guarantee that the applicable authorities, including the USPTO and FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. Our currently issued patents will likely expire on dates ranging from 2035 to 2038, unless we receive patent term extension or patent term adjustment, or both. If patents are issued on our pending patent applications, the resulting patents are projected to expire on dates ranging from 2036 to 2041, unless we receive patent term extension or patent term adjustment, or both. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of genetic therapy has emerged in the United States. The patent situation outside of the United States is even more uncertain. Changes in the patent laws and rules, either by legislation, judicial decisions, or regulatory interpretation in the United States and other countries may diminish our ability to protect our inventions and enforce our intellectual property rights, and more generally could affect the value of our intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, importing or otherwise commercializing any of our patented inventions, either directly or indirectly, will depend in part on our success in obtaining, defending and enforcing patent claims that cover our technology, inventions, and improvements. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our platform and product candidates and the methods used to manufacture them. Moreover, our issued patents and those that may issue in the future may not guarantee us the right to practice our technology in relation to the commercialization of our platform&#8217;s product candidates. The area of patent and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties, and third parties may have blocking patents that could be used to prevent us from commercializing our TANGO platform and product candidates and practicing our proprietary technology. Our issued patents and those that may issue in the future may be challenged, narrowed, circumvented or invalidated, which could limit our ability to stop competitors from marketing related platforms or product candidates or limit the length of the term of patent protection that we may have for our TANGO platform and product candidates. In addition, the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies. For these reasons, we may have competition for our TANGO platform and product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before any product candidate can be commercialized, any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent. For this and other risks related to our proprietary technology, inventions, improvements, platforms and product candidates, please see the section entitled &#8220;Risk factors&#8212;Risks related to our intellectual property.&#8221; </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have filed for trademark protection of the &#8220;Stoke Therapeutics&#8221; mark with the United States Patent and Trademark Office and foreign trademark organizations. We have registered, and intend to maintain, the trademark &#8220;Stoke Therapeutics&#8221; in the United States Patent and Trademark Office and in numerous other jurisdictions, including but not limited to the European Union, China, India, and Canada.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our confidential and proprietary information as trade secrets, including through contractual means with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements under the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result of the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. Although we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. To the extent that our employees, contractors, consultants, collaborators and advisors use intellectual property owned by others in their work for us, disputes may arise as to the rights in relation to the resulting know-how or inventions. For more information, please see the section entitled &#8220;Risk factors &#8211; Risks related to our intellectual property.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License and research agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, we entered into a worldwide license agreement (the &#8220;CSHL Agreement&#8221;), with CSHL, with respect to TANGO patents. The CSHL Agreement was subsequently amended in May 2019 and in July 2020. Under the CSHL Agreement, we receive an exclusive (except with respect to certain government rights and non-exclusive licenses), worldwide license under certain patents and applications relating to TANGO. As part of the CSHL Agreement, we granted CSHL 164,927&#160;shares of common stock valued based on an independent appraisal at approximately $0.07 million. The CSHL Agreement obligates us to make additional payments that are contingent upon certain milestones being achieved. We are also required to pay royalties, tiered based on the scope of patent coverage for each licensed product, ranging from a low-single digit percentage to a mid-single digit percentage on annual net sales. These royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until the latest of (i)&#160;the expiration of the last valid claim of a CSHL patent covering the applicable licensed product or (ii)&#160;the expiration of any regulatory exclusivity for the applicable licensed product. In addition, if we sublicense the rights under the CSHL Agreement, we are required to pay a maximum of twenty percent of the sublicense revenue to CSHL, which may be reduced to a mid-teens or a mid-single digit percentage upon achievement of certain clinical milestones for the applicable licensed product. Finally, we are required to pay an annual license maintenance fee of $0.01 million, which amount is creditable against any owed royalty or milestone payments. The maximum aggregate potential milestone payments payable total approximately $0.9 million. Additionally, certain licenses under the CSHL Agreement require us to reimburse CSHL for certain past and ongoing patent related expenses, however there were no expenses related to these reimbursable patent costs during the years ended December 31, 2021 and 2020.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, we entered into an exclusive, worldwide license agreement with the University of Southampton, (the &#8220;Southampton Agreement&#8221;), whereby we acquired rights to foundational technologies related to our TANGO technology. Under the Southampton Agreement, we received an exclusive, worldwide license under certain licensed patents and applications relating to TANGO. As part of the Southampton Agreement, we paid 0.06 million pounds sterling (approximately $0.07 million as of the date thereof) as an up-front license fee. Under the Southampton Agreement, we may </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be obligated to make additional payments that are contingent upon certain milestones being achieved, as well as royalties on future product sales. These royalty obligations survive until the latest of (</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;the expiration of the last valid claim of a licensed patent covering a subject product or (ii)&#160;the expiration of any regulatory exclusivity for the subject product in a country. In addition, if </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> sublicense </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> rights under the Southampton Agreement, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we are</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> required to pay a mid-single digit percentage of the sublicense revenue to the University of Southampton. The maximum aggregate potential milestone payments payable by </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> totaled approximately 0.4 million pounds sterling (approximately $0.5 million as of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 202</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">). As of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 202</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> had recorded no liabilities under the Southampton Agreement. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, certain licenses under the Southampton Agreement require the Company to reimburse the University of Southampton for certain past and ongoing patent related expenses. For the three months ended </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021 these expenses were $0.03 million compared to $0.0</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million for three months ended </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020 and for the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year ended</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021 these expenses were $0.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million compared to $0.0</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million for the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ended </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FDA approval process </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, pharmaceutical products are subject to extensive regulation by FDA. The Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;) and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling and import and export of pharmaceutical products. Failure to comply with applicable U.S. regulations may subject a company to a variety of administrative or judicial sanctions, such as a clinical hold, FDA refusal to approve pending new drug applications, or NDAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical product development for a new product or certain changes to an approved product in the U.S. typically involves preclinical laboratory and animal testing followed by submission to the FDA of an IND which must become effective before clinical testing may commence. Data from adequate and well-controlled clinical trials are required to demonstrate the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical requirements include laboratory evaluation of product chemistry, formulation, pharmacology and toxicity studies in animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including GLP. The results of preclinical testing are submitted to FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. The clinical trial proposed in the IND may begin after a safe to proceed communication is received from the FDA.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&#160;in compliance with federal regulations&#59; (ii)&#160;in compliance with good clinical practice (&#8220;GCP&#8221;), an international standard designed to protect the rights and health of patients and to define the roles, qualifications and responsibilities of clinical trial sponsors, administrators and monitors&#59; as well as (iii)&#160;under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may order a clinical hold, which is the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. If FDA imposes a clinical hold, clinical trials cannot commence or recommence without FDA authorization and then only under terms authorized by the FDA. The study protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board (&#8220;IRB&#8221;), for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase 1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence of effectiveness. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generally for a specific </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indication, dosage tolerance and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 trial with other confirmatory evidence may be sufficient in rare instances, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including (1) </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">where the study is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or (2) when in conjunction with other confirmatory evidence. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After completion of the required clinical testing, an NDA is prepared and submitted to FDA. FDA approval of the NDA is required before marketing of the product may begin in the U.S. The NDA must include the results of all preclinical, clinical and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture and controls. The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee, currently $3,117,218 for fiscal year 2022, and the applicant under an approved NDA is also subject to an annual program fee, currently $369,413 for each prescription drug product. These fees are typically increased annually. Sponsors of applications for drugs granted Orphan Drug Designation are exempt from these user fees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. FDA may request additional information rather than file an NDA. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before FDA files it. Once the submission is accepted for filing, FDA begins an in-depth review. FDA has agreed to certain performance goals in the review of new drug applications to encourage timeliness. Most applications for standard review drug products are reviewed within ten to twelve months of the date of submission of the new drug application to FDA&#59; the target review period for priority review drugs is six months from the date of filing (accepted for review by the FDA) of the new drug application. Priority review can be applied to an application for a drug that treats a serious condition and if approved would provide a significant improvement in safety or effectiveness over existing treatments or provide a treatment where no adequate therapy exists. The review process for both standard and priority review may be extended by FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an external drug advisory committee&#8212;typically a panel that includes clinicians, statisticians, patient representatives and other experts&#8212;for review, evaluation and a recommendation as to whether the application should be approved. FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA, FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, FDA will inspect the facility or the facilities at which the drug substance and drug product are manufactured. FDA will not approve the product unless compliance with current good manufacturing practices (&#8220;cGMPs&#8221;) is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for FDA to reconsider the application. Even after an applicant submits additional information, FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If, or when, those deficiencies have been addressed to FDA&#8217;s satisfaction in a resubmission of the NDA, FDA will issue an approval letter. FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use (&#8220;ETASU&#8221;). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drug. FDA may also require a REMS for a drug that is already on the market if it determines, based on new safety information, that a REMS plan is necessary to ensure that the products benefits outweigh its risks.&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fast Track Designation, Breakthrough Designation, Accelerated Approval, and Priority Review </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following four FDA programs are intended to facilitate and expedite development and review of new drugs to address unmet medical need in the treatment of a serious or life-threatening condition: fast track designation, breakthrough therapy designation, accelerated approval, and priority review. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Fast Track program, the sponsor of a new drug candidate may request that FDA designate the drug candidate for a specific indication as a Fast Track drug concurrent with, or after, the filing of the IND for the drug candidate. FDA must determine if the drug candidate qualifies for Fast Track Designation within 60 days of receipt of the sponsor&#8217;s request. Fast Track Designation is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions so that an approved product can reach the market expeditiously. If a submission is granted Fast Track Designation, the sponsor may engage in more frequent interactions with FDA, and FDA may review sections of the NDA before the full application is complete. This rolling review is available if, in agreement with the FDA, the applicant provides, a schedule for the submission of the remaining information. However, the FDA does not start the review clock for the application until the last section of the NDA is submitted. Fast Track Designation may be withdrawn by FDA if they believe that the designation is no longer supported by data emerging data in the development process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breakthrough Therapy Designation may be granted by the FDA to the development of a new drug and also for a new use or indication of an approved drug. This designation requires preliminary clinical evidence of a treatment effect that may represent substantial improvement over available therapies for the treatment of a serious condition. FDA expects that such evidence generally would be derived from early phase trials such as phase 1 or 2 trials. For purposes of Breakthrough Therapy Designation, preliminary clinical evidence refers to evidence that is sufficient to indicate that the drug may demonstrate substantial improvement in effectiveness or safety over available therapies. A Breakthrough Therapy Designation conveys more intensive FDA guidance on an efficient drug development program. FDA also has an organizational commitment to involve senior management in such guidance. Such guidance may include holding meetings with the sponsor and review team throughout the development of the drug, providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the non-clinical and clinical data necessary for approval is as efficient as possible, and taking steps to ensure that the design of the clinical trials is as efficient as practicable, when scientifically appropriate, such as by minimizing the number of patients exposed to a potentially less efficacious treatment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s accelerated approval pathway is available under FDA&#8217;s accelerated approval regulations and under the FDCA for drugs that have been granted Fast Track designation. FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug candidate approved on this basis is subject to rigorous and mandatory post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to priority review by FDA. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A drug candidate is eligible for priority review, or review within a six-month time frame from the time an NDA is filed by FDA, if the drug candidate is intended for the treatment, diagnosis or prevention of a serious or life-threatening condition, demonstrates the potential to address an unmet medical need, or provides a significant improvement compared to marketed drugs.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orphan Drugs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition&#8212;generally a disease or condition that affects fewer than 200,000 individuals in the U.S. Orphan Drug designation must be requested before submitting an NDA. After FDA grants Orphan Drug Designation, the generic identity of the drug and its potential orphan use are disclosed publicly by FDA. Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA Orphan Drug Designation is entitled to a seven-year exclusive marketing period in the U.S. for that product, for that indication. During the seven-year exclusivity period, FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of Orphan Drug Designation are tax credits for certain research and an exemption from the NDA application user fee. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Rare Pediatric Disease Priority Review Voucher Program </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Rare Pediatric Disease Priority Review Voucher program, FDA may award a priority review voucher to the sponsor of an approved marketing application for a product that treats or prevents a rare pediatric disease. The voucher entitles the sponsor to priority review of one subsequent marketing application. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A voucher may be awarded only for an approved rare pediatric disease product application. A rare pediatric disease product application is an NDA or a Biologics License Application (&#8220;BLA&#8221;) for a product that treats or prevents a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years&#59; in general, the disease must affect fewer than 200,000 such individuals in the U.S.&#59; the NDA must be deemed eligible for priority review&#59; the NDA must not seek approval for a different adult indication (i.e., for a different disease/condition)&#59; the product must not contain an active ingredient that has been previously approved by FDA&#59; and the NDA must rely on clinical data derived from studies examining a pediatric population such that the approved product can be adequately labeled for the pediatric population. Before NDA approval, FDA may designate a product in development as a product for a rare pediatric disease, but such designation is not required to receive a voucher. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To receive a rare pediatric disease priority review voucher, a sponsor must notify FDA, upon submission of the NDA, of its intent to request a voucher. If FDA determines that the NDA is a rare pediatric disease product application, and if the NDA is approved, FDA will award the sponsor of the NDA a voucher upon approval of the NDA. FDA may revoke a rare pediatric disease priority review voucher if the product for which it was awarded is not marketed in the U.S. within 365 days of the product&#8217;s approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The voucher, which is transferable to another sponsor, may be submitted with a subsequent NDA or biologics license application, or BLA, and entitles the holder to priority review of the accompanying NDA or BLA. The sponsor submitting the priority review voucher must notify FDA of is intent to submit the voucher with the NDA or BLA at least 90 days prior to submission of the NDA or BLA and must pay a priority review user fee in addition to any other required user fee ($1,226,651 in fiscal year 2022). FDA must take action on an NDA or BLA under priority review within six months of filing the NDA or BLA by FDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher Program was extended. Under the current statutory sunset provisions, after September 30, 2024, FDA may only award a voucher for an approved rare pediatric disease product application if the sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2024. Without further statutory amendments, after September 30, 2026, the FDA may not award any rare pediatric disease priority review vouchers.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-approval requirements </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an NDA is approved, a product will be subject to certain post-approval requirements. For instance, FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adverse event reporting and submission of periodic reports are required following FDA approval of an NDA. FDA also may require post-marketing testing or studies, known as Phase 4 commitments, risk evaluation and mitigation strategies, or REMS, and surveillance to monitor the effects of an approved product, or FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with FDA and certain state agencies. Registration with FDA subjects entities to periodic unannounced inspections by FDA, during which the Agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Pediatric information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pediatric Research Equity Act, or PREA, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. FDA may grant full or partial waivers, or deferrals, for submission of data. With certain exceptions, PREA does not apply to any drug for an indication for which orphan designation has been granted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Best Pharmaceuticals for Children Act, or BPCA, provides NDA holders a six-month extension of any exclusivity&#8212;patent or nonpatent&#8212;for a drug if certain conditions are met. Conditions for exclusivity include FDA&#8217;s determination that information relating to the use of a new drug in the pediatric population may produce health benefits in that population, FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disclosure of clinical trial information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sponsors of clinical trials of FDA regulated products, including drugs, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. The government recently released a regulation and policy to expand and enhance the requirements related to registering and reporting the results of clinical trials, which may result in greater enforcement of these requirements in the future.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Hatch-Waxman Act </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Orange Book listing </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&#8217;s product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book. Specifically, the applicant must certify that (i)&#160;the required patent information has not been filed&#59; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)&#160;the listed patent has expired&#59; (iii)&#160;the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration&#59; or (iv)&#160;the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section viii statement certifying that its proposed ANDA label does not contain (or carve out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. A certification that the new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ANDA application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon NDA approval of a new chemical entity, or NCE, which is a drug that contains no active moiety that has been approved by FDA in any other NDA, that drug receives five years of marketing exclusivity during which FDA cannot receive any ANDA seeking approval of a generic version of that drug. An ANDA may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. If there is no listed patent in the Orange Book, there may not be a Paragraph IV certification, and, thus, no ANDA may be filed before the expiration of the exclusivity period. Certain changes to a drug, such as the addition of a new indication to the package insert, can be the subject of a three-year period if the application contains reports of new clinical investigations (other than bioavailability studies) conducted or sponsored by the sponsor that were essential to the approval of the application. FDA cannot approve an ANDA for a generic drug that includes the change during the exclusivity period.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Patent term extension </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After NDA approval, owners of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term extension is calculated as half of the drug&#8217;s testing phase (the time between IND application and NDA submission) and all of the review phase (the time between NDA submission and approval up to a maximum of five years). The time can be shortened if FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed 14 years from the date of product approval. Only one patent applicable to an approved drug is eligible for extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended and the application for the extension must be submitted prior to the expiration of the patent. For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the United States Patent and Trademark Office must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other healthcare laws </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain general business and marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes, false claims statutes and other healthcare laws and regulations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. The Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act, collectively, the ACA, amended the intent element of the federal statute so that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to commit a violation. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal civil and criminal false claims laws, including the federal civil False Claims Act, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. This includes claims made to programs where the federal government reimburses, such as Medicaid, as well as programs where the federal government is a direct purchaser, such as when it purchases off the Federal Supply Schedule. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Additionally, the ACA amended the federal Anti-Kickback Statute such that a violation of that statute can serve as a basis for liability under the federal False Claims Act. Most states also have statutes or regulations similar to the federal Anti-Kickback Statute and False Claims Act, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other federal statutes pertaining to healthcare fraud and abuse include the civil monetary penalties statute, which prohibits, among other things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offeror or payor knows or should know is likely to influence the beneficiary to order a receive a reimbursable item or service from a particular supplier, and the additional federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, including the Final Omnibus Rule published on January&#160;25, 2013, impose obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their business associates that perform certain services involving the storage, use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information. HITECH increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, pursuant to the ACA, the Centers for Medicare&#160;&#38; Medicaid Services (the &#8220;CMS&#8221;) has issued a final rule that requires manufacturers of prescription drugs to collect and report annually information on certain payments or transfers of value to physicians, physician assistants, certain types of advance practice nurses and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, such providers, and to report annually certain ownership and investment interests held by physicians and their immediate family members. The reported data is made available in searchable form on a public website on an annual basis. Failure to submit required information may result in civil monetary penalties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, several states now require prescription drug companies to report certain expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual healthcare practitioners in these states. Other states prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals. Still other states require the posting of information relating to clinical studies and their outcomes. Some states require the reporting of certain pricing information, including information pertaining to and justifying price increases, or prohibit prescription drug price gouging. In addition, certain states require pharmaceutical companies to implement compliance programs and/or marketing codes. Certain states and local jurisdictions also require the registration of pharmaceutical sales representatives. Compliance with these laws is difficult and time consuming, and companies that do not comply with these state laws face civil penalties. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that business arrangements with third parties comply with applicable healthcare laws and regulations involve substantial costs. If a drug company&#8217;s operations are found to be in violation of any such requirements, it may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">imprisonment, the curtailment or restructuring of its operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other federal or state government healthcare programs, including Medicare and Medicaid, integrity oversight and reporting obligations, imprisonment, and reputational harm. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action for an alleged or suspected violation can cause a drug company to incur significant legal expenses and divert management&#8217;s attention from the operation of the business, even if such action is successfully defended. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Possible Change in Law or Policy</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare reforms that have been adopted, and that may be adopted in the future, could result in further reductions in coverage and levels of reimbursement for pharmaceutical products, increases in rebates payable under U.S. government rebate programs and additional downward pressure on pharmaceutical product prices.&#160;&#160; On September 9, 2021, the Biden administration published a wide-ranging list of policy proposals, most of which would need to be carried out by Congress, to reduce drug prices and drug payment. The HHS plan includes, among other reform measures, proposals to lower prescription drug prices, including by allowing Medicare to negotiate prices and disincentivizing price increases, and to support market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase price transparency. Many similar proposals, including the plans to give Medicare Part D authority to negotiate drug prices, require drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation, and cap out-of-pocket costs, have already been included in policy statements and legislation currently being considered by Congress. It is unclear to what extent these and other statutory, regulatory, and administrative initiatives will be enacted and implemented. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign regulation </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our product candidates to the extent we choose to sell any products outside of the United States. For clinical trials, many countries outside of the United States have a similar process that requires the submission of a clinical study application similar to the process in the United States. However, the specific requirements governing the conduct of clinical trials vary greatly from country to country. In the European Union, for example, clinical trials are governed by the new EU Regulation on Clinical Trials (Reg. EU No. 536/2014) (the &#8220;CTR&#8221;) that has become applicable on January 31, 2022. The CTR stipulates the process of obtaining competent authority approval for clinical trials. Under the CTR, trial sponsors submit their application for approval via an EU Portal. While the procedure for approval is conducted in a coordinated manner among the concerned EU Member States as provided under the CTR, the approvals will still have to be granted by the competent authorities of the EU Member States where a trial takes place. The CTR has streamlined the process for the application and granting of the approvals in comparison with the predecessor legislation, Directive 2001/20/EC on clinical trials (the &#8220;CTD&#8221;). However, the process of obtaining clinical trial approval in the EU is still complex and can significantly delay the start of a multinational clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the United Kingdom&#8217;s exit from the European Union on December 31, 2020, different rules apply in the United Kingdom from the European Union. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Approval and Reimbursement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whether or not we obtain FDA approval for a product, we must obtain approval or licensing of a product by regulatory authorities of foreign countries before we can commence marketing of the product in those countries. The approval processes for both approval and marketing of commercial drugs vary from country to country and the time may be longer or shorter than that required for FDA approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The requirements governing the product licensing, pricing and reimbursement vary greatly from country to country. As in the United States, post-approval regulatory requirements, such as those regarding product manufacture, marketing, or distribution would apply to any product that is approved outside the United States. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain regulatory approval of a medicinal product under EU regulatory systems, a sponsor must submit a marketing authorization application. The grant of marketing authorization in the EU is governed by Directive 2001/83/EC of the European Parliament and of the Council, commonly known as the Community Code and Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing the European Medicines Agency (the &#8220;EMA&#8221;), commonly referred to as the EMA Regulation. In addition, Regulation 1394/2007/EC on advanced therapy </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">medicinal products (&#8220;ATMP&#8221;) lays down specific rules concerning the authorization, supervision and pharmacovigilance of gene therapy medicinal products, somatic cell therapy medicinal products and tissue engineered products. The EMA&#8217;s Committee for Advanced Therapies (&#8220;CAT&#8221;) is responsible for assessing the quality, safety and efficacy of ATMP. The role of CAT is to prepare a draft opinion on an application for marketing authorization for an ATMP candidate. EMA then provides a final opinion regarding the application for marketing authorization. The European Commission grants or refuses marketing authorization after the EMA has delivered its opinion.</span></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Innovative medicinal products are authorized in the EU on the basis of a full marketing authorization application (as opposed to an application for marketing authorization that relies, in whole or in part, on data in the marketing authorization dossier for another, previously approved medicinal product). Applications for marketing authorization for innovative medicinal products must contain the results of pharmaceutical tests, preclinical tests and clinical trials conducted with the medicinal product for which marketing authorization is sought. </p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EU legislation provides for a system of regulatory data and market exclusivity. According to Article&#160;14(11) of the EMA Regulation, and Article&#160;10(1) of the Community Code, upon receiving marketing authorization, new chemical entities approved on the basis of complete independent data package benefit from eight years of data exclusivity and an additional two years of market exclusivity. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic (abbreviated) application. During the additional two-year period of market exclusivity, a generic marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder, or MAH, obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity and the innovator is able to gain the period of data exclusivity, another company nevertheless could also market another version of the drug if such company obtained marketing authorization based on an application with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials. Depending upon the timing and duration of the EU marketing authorization process, products may be eligible for up to five years&#8217; supplementary protection certificates, or SPC, pursuant to Regulation (EC) No 469/2009. Such SPC extend the rights under the basic patent for the drug.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products authorized as &#8220;orphan medicinal products&#8221; in the EU are entitled to benefits additional to those granted in relation to innovative medicinal products. In accordance with Article 3 of Regulation (EC) No.&#160;141/2000 of the European Parliament and of the Council of 16&#160;December 1999 on orphan medicinal products, a medicinal product may be designated as an orphan medicinal product if (1)&#160;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition&#59; (2)&#160;either (a)&#160;such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b)&#160;the product, without the incentives derived from orphan medicinal product status, would not generate sufficient return in the EU to justify investment&#59; and (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. Further guidance on such criteria is provided in European Commission Regulation (EC) No.&#160;847/2000 of 27&#160;April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts &#8220;similar medicinal product&#8221; and &#8220;clinical superiority&#8221;. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and following grant of a marketing authorization, EMA and the EU Member States&#8217; competent authorities are not permitted to accept another application for a marketing authorization, or grant a marketing authorization or accept an application to extend an existing marketing authorization, for the same therapeutic indication of a similar medicinal product for ten years following grant or authorization. The application for orphan drug designation must be submitted before the application for marketing authorization. The applicant may receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 10-year market exclusivity that an orphan drug enjoys may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product during the 10-year period of market exclusivity for the same therapeutic indication at any time if:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The second applicant can establish in its application that its product, although similar to the orphan medicinal product already authorized, is safer, more effective or otherwise clinically superior&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application&#59; or</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">The holder of the marketing authorization for the original orphan medicinal product cannot supply enough orphan medicinal product.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to obligations imposed in the United States, medicinal products authorized in the EU may be subject to post-authorization obligations, including the obligation to conduct Post Marketing Safety Studies (&#8220;PASS&#8221;) or Post Marketing Efficacy Studies (&#8220;PAES&#8221;).</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement for medicinal products is still an area that is not harmonized in the EU, but largely governed by EU Member States&#8217; laws. At EU level, Council Directive 89/105/EEC (the &#8220;Price Transparency Directive&#8221;) aims to ensure that pricing and reimbursement mechanisms established in EU Member States are transparent and objective, do not hinder the free movement and trade of medicinal products in the EU and do not hinder, prevent or distort competition on the market. The Price Transparency Directive does not, however, provide any guidance concerning the specific criteria based on which pricing and reimbursement decisions are to be made in individual EU Member States. Neither does it have any direct consequence for pricing or levels of reimbursement in individual EU Member States. The national authorities of the individual EU Member States are free to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices and/or reimbursement of medicinal products for human use. Individual EU Member States adopt policies according to which a specific price or level of reimbursement is approved for the medicinal product. Other EU Member States adopt a system of reference pricing, basing the price or reimbursement level in their territory either, on the pricing and reimbursement levels in other countries, or on the pricing and reimbursement levels of medicinal products intended for the same therapeutic indication. Furthermore, some EU Member States impose direct or indirect controls on the profitability of the company placing the medicinal product on the market.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.84%;letter-spacing:-0.2pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Health Technology Assessment (&#8220;HTA&#8221;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in EU Member States. HTA is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of the use of a given medicinal product in the national healthcare systems of the individual country is conducted. HTA generally focuses on the clinical efficacy and effectiveness, safety, cost, and cost-effectiveness of individual medicinal products as well as their potential implications for the national healthcare system. Those elements of medicinal products are compared with other treatment options available on the market.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outcome of HTA may influence the pricing and reimbursement status for specific medicinal products within individual EU member states. The extent to which pricing and imbursement decisions are influenced by the HTA of a specific medicinal product vary between the EU Member States.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A new EU Regulation on HTA was adopted on December 13, 2021, Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15&#160;December 2021 on health technology assessment and amending Directive 2011/24/EU (&#8220;HTA Regulation&#8221;). It will become applicable on January12, 2025. The HTA Regulation covers new medicines and certain new medical devices, &#8220;providing the basis for permanent and sustainable cooperation at the EU level for joint clinical assessments in these areas.&#8221; Member states will be able to use common HTA tools, methodologies and procedures across the EU, working together in four main areas: 1) joint clinical assessments focusing on the most innovative health technologies with the most potential impact for patients&#59; 2) joint scientific consultations whereby developers can seek advice from HTA authorities&#59; 3) identification of emerging health technologies to identify promising technologies early&#59; and 4) continuing voluntary cooperation in other areas. Individual member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United Kingdom and following the United Kingdom&#8217;s exit from the European Union, EU medicines regulation has been adopted as standalone United Kingdom legislation with some amendments to reflect procedural and other requirements with respect to marketing authorizations and other regulatory provisions.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market a medicinal product in the United Kingdom, a license or marketing authorization must be obtained from the United Kingdom Medicines and Healthcare Products Regulatory Agency (the &#8220;MHRA&#8221;). The United Kingdom legislation includes multiple assessment routes for applications for medicinal products, including a 150-day national assessment or a rolling review application. Further, and for a transitional period until December 31, 2022, the MHRA may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure. In addition, the MHRA has the power to have regard to marketing authorizations approved in EU member states.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The MHRA reviews applications for orphan designation at the time of a marketing authorization application or as part of a subsequent variation to that authorization. To qualify for orphan designation, a medicine must meet certain criteria in the United Kingdom including that the medicine for the treatment, prevention or diagnosis of a disease that is life-threatening or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">chronically debilitating, the prevalence of the condition must not be more than 5 in 10,000 or it must be unlikely that the marketing would generate sufficient returns to justify investment and no satisfactory method of diagnosis, prevention or treatment must exist in Great Britain or, if such a method exists the medicine must be of significant benefit to those affected by the condition. On grant of a marketing authorization with orphan status, the medicinal product will benefit from up to 10&#160;years of market exclusivity from similar products in the approved orphan indication starting from the date of first approval of the product in Great Britain.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United Kingdom has adopted new legislation, the Medicines and Medical Devices Act 2021 and may make changes to the licensing or authorization of medicines in the future.<span style="font-size:12pt;"> </span>The separate UK authorization system, albeit with transitional recognition procedures in the UK, may lead to additional regulatory costs. In addition, further regulatory costs will be incurred with respect to the lack of mutual recognition of batch testing and related regulatory measures between the European Union and the United Kingdom.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement in the United Kingdom for use by public payors (National Health Service) organizations may depend on a positive technology assessment by the National Institute for Health and Care Excellence (&#8220;NICE&#8221;). A positive recommendation by NICE would lead to an obligation to fund, subject to terms of that approval, by NHS organizations. In assessing any new medicinal product, NICE will take into account clinical as well as the economic value of the product.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to obtain positive reimbursement recommendations or failure to obtain government and third-party payor reimbursement coverage in foreign countries may affect the marketability and commercial sales of any product candidates for which regulatory approval is received.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees and Human Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we had 102 employees, 37 of whom have an M.D. or Ph.D. We have not experienced any work stoppages. None of our employees is represented by a labor union or covered by collective bargaining agreements, and we consider our relationship with our employees to be good.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We seek to attract, hire and retain individuals of diverse backgrounds and of all ages, genders, ethnicities, religions, home countries and sexual orientation. As of December 31, 2021, approximately 57% of our employees are female, and approximately 38% of our management team (which we define as at the vice president level and above) are female. More than one-third of our employees self-identify as racially or ethnically diverse as of December 31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive and cash-based performance bonus plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stoke Therapeutics, Inc. was founded in June 2014 and was incorporated under the laws of the State of Delaware. <span style="color:#000000;">Our principal executive offices are located at 45 Wiggins Ave, Bedford, Massachusetts 01730, and our telephone number is (781) 430-8200. Our website address is www.stoketherapeutics.com. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated by reference into, this Annual Report. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file annual, quarterly and current reports, proxy statements and other documents with the Securities and Exchange Commission, or SEC, under the Securities Exchange Act of 1934, as amended, or Exchange Act. The SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC. The public can obtain any documents that we file with the SEC at www.sec.gov. Copies of each of our filings with the SEC can also be viewed and downloaded free of charge at our website, www. stoketherapeutics.com, after the reports and amendments are electronically filed with or furnished to the SEC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item 1A. Risk Factors. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you should carefully consider the risks described below, together with the other information contained in this annual report, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. We cannot assure you that any of the events discussed below will not occur. These events could have a material and adverse impact on our business, financial condition, results of operations and prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Summary of Risk Factors</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An investment in our common stock involves various risks, and prospective investors are urged to carefully consider the matters discussed in the section titled &#8220;Risk Factors&#8221; prior to making an investment in our common stock. These risks include, but are not limited to, the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We are early in our development efforts. If we or our collaborators are unable to develop, obtain regulatory approval for and commercialize STK-001, STK-002 and our future product candidates, or if we experience significant delays in doing so, our business will be materially harmed.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Success in early preclinical studies or clinical trials may not be indicative of results obtained in later preclinical studies and clinical trials, including in our Dravet syndrome program or our ADOA program. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Certain of the diseases we seek to treat have low prevalence, and it may be difficult to identify patients with these diseases, which may lead to delays in enrollment for our trials or slower commercial revenue growth if STK-001, STK-002 or our future product candidates are approved.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If clinical trials of STK-001, STK-002 or any other product candidate that we develop fail to demonstrate safety and efficacy to the satisfaction of FDA or foreign regulatory authorities or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately may be unable to complete, the development and commercialization of such product candidate.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We may not be successful in our efforts to use TANGO to expand our pipeline of product candidates and develop marketable products.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the United States.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">STK-001, STK-002 or our future product candidates may cause undesirable and unforeseen side effects or be perceived by the public as unsafe, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">A Fast Track Designation by the FDA, even if granted for any of our future product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">A Breakthrough Therapy Designation by the FDA for STK-001, STK-002 or our future product candidates may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the product candidate will receive marketing approval.  </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:'Times New Roman';"></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The commercial success of our product candidates, including STK-001 and STK-002 will depend upon their degree of market acceptance by providers, patients, patient advocacy groups, third-party payors and the general medical community.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The pricing, insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue.&#160;&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Current and potential future healthcare reforms may adversely impact pricing, insurance coverage and reimbursement status of newly approved products.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have a history of operating losses, and we may not achieve or sustain profitability. We anticipate that we will continue to incur losses for the foreseeable future. If we fail to obtain additional funding to conduct our planned research and development effort, we could be forced to delay, reduce or eliminate our product development programs or commercial development efforts.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We expect that we will need to raise additional funding before we can expect to become profitable from any potential future sales of STK-001, STK-002 or our future product candidates. This additional financing may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our success depends in part on our ability to obtain, maintain and protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The market price of our stock may be volatile, and you could lose all or part of your investment.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to product development and regulatory approval </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are early in our development efforts. If we are unable to develop, obtain regulatory approval for and commercialize STK-001, STK-002 and our future product candidates, or if we experience significant delays in doing so, our business will be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have invested substantially all of our efforts and financial resources in the development of our Targeted Augmentation of Nuclear Gene Output (&#8220;TANGO&#8221;) technology and our current lead product candidate, STK-001, for the treatment of Dravet syndrome. We submitted an investigational new drug application (&#8220;IND&#8221;) for STK-001 to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in late 2019. In August 2020, we dosed the first patient with STK-001 in the single ascending dose portion of the MONARCH Phase 1/2a Study at the 10mg dose level. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in November 2020, we announced the nomination of OPA1 as our next target for preclinical development to treat Autosomal Dominant Optic Atrophy (&#8220;ADOA&#8221;). In November 2021, we announced the nomination of STK-002 as the lead product candidate for the treatment of ADOA and intend to invest significant efforts and financial resources in its development.&#160;&#160;Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of TANGO and our product candidates, which may never occur. We currently generate no revenue from sales of any product and we may never be able to develop or commercialize a marketable product.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of our programs and product candidates will require preclinical and clinical development, regulatory approval in multiple jurisdictions, obtaining preclinical, clinical and commercial manufacturing supply, capacity and expertise, building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenue from product sales. STK-001, STK-002 and our future product candidates must be authorized for marketing by the FDA or certain other foreign regulatory agencies, such as the European Medicines Agency (the &#8220;EMA&#8221;) or the United Kingdom Medicines and Healthcare products Regulatory Agency (the &#8220;MHRA&#8221;), before we may commercialize any of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of STK-001, STK-002 and our future product candidates depends on multiple factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">effective INDs and Clinical Trial Authorizations (&#8220;CTAs&#8221;) that allow commencement of our planned clinical trials or future clinical trials for our product candidates in relevant territories&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to obtain approval from institutional review boards (&#8220;IRBs&#8221;) or ethics committees to conduct clinical trials at their respective sites&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">potential delays in enrollment, site visits, evaluations, or dosing of patients participating in clinical trials as hospitals prioritize the treatment of COVID-19 patients or patients decide not to enroll in the study as a result of the COVID-19 pandemic&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">government regulations that may be imposed in response to the COVID-19 pandemic may restrict the movement of our global supply chain and divert hospital resources that are necessary to administer STK-001, STK-002 or delay the review of future product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the direct and indirect impact of COVID-19 on our business and operations, third party vendors, supply chain, and regulatory approvals&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">successful completion of preclinical studies, including those compliant with Good Laboratory Practices (&#8220;GLP&#8221;) or GLP toxicology studies, biodistribution studies and minimum effective dose studies in animals&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to reach agreements on acceptable terms with prospective third-party contract research organizations (&#8220;CROs&#8221;) and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among CROs and trial sites&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">successful enrollment and completion of clinical trials compliant with current Good Clinical Practices (&#8220;GCPs&#8221;)&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">positive results from our clinical programs that are supportive of safety and efficacy and provide an acceptable risk-benefit profile for our product candidates in the intended patient populations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">receipt of regulatory approvals from applicable regulatory authorities&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establishment of arrangements with third-party contract manufacturing organizations (&#8220;CMOs&#8221;) for key materials used in our manufacturing processes and to establish backup sources for clinical and large-scale commercial supply&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establishment and maintenance of patent and trade secret protection and regulatory exclusivity for our product candidates&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">commercial launch of our product candidates, if and when approved, whether alone or in collaboration with others&#59;&#160;&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">acceptance of our product candidates, if and when approved, by patients, patient advocacy groups, third-party payors and the general medical community&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our effective competition against other therapies available in the market&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establishment and maintenance of adequate reimbursement from third-party payors for our product candidates&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to acquire or in-license additional product candidates&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">prosecution, maintenance, enforcement and defense of intellectual property rights and claims&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">maintenance of a continued acceptable safety profile of our product candidates following approval.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Success in early preclinical studies or clinical trials may not be indicative of results obtained in later preclinical studies and clinical trials, including in our Dravet syndrome program or our ADOA program.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STK-001 is currently being evaluated in human clinical trials, and we may experience unexpected or negative results in the future. We will be required to demonstrate through adequate and well-controlled clinical trials that our product candidates are safe and effective, with a favorable benefit-risk profile, for use in their target indications before we can seek regulatory approvals for their commercial sale. The positive results we have observed for our product candidates in preclinical animal models may not be predictive of our future clinical trials in humans, as mouse models carry inherent </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limitations relevant to all preclinical studies. In particular, the Dravet syndrome mouse model is more severe than the human disease and provides a shorter post-symptomatic observation period. Trial designs and results from early-phase trials are not necessarily predictive of future clinical trial designs or results, and initial positive results we may observe may not be confirmed in later-phase clinical trials. Our product candidates may also fail to show the desired safety and efficacy in later stages of clinical development even if they successfully advance through initial clinical trials. We may not be able to demonstrate a disease-modifying effect of STK-001 in our clinical trials in Dravet syndrome patients, even if we are able to demonstrate efficacy on seizure reduction, and we may be similarly unable to demonstrate the efficacy of STK-002 in our ADOA program or other future programs. In addition, our clinical trials to date have necessarily involved relatively small numbers of participants. Therefore, conclusions we draw based upon trial results to date may not be repeatable across larger cohorts of participants or patients with different characteristics. Moreover, even if our clinical trials demonstrate acceptable safety and efficacy of STK-001, STK-002 or our future product candidates, the labeling we obtain through negotiations with the FDA or foreign regulatory authorities may not include data on secondary endpoints and may not provide us with a competitive advantage over other products approved for the same or similar indications. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies in the biotechnology industry have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development and there is a high failure rate for product candidates proceeding through clinical trials. In addition, different methodologies, assumptions and applications we utilize to assess particular safety or efficacy parameters may yield different statistical results. Even if we believe the data collected from clinical trials of our product candidates are promising, these data may not be sufficient to support approval by the FDA or foreign regulatory authorities. Preclinical and clinical data can be interpreted in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us or our partners, which could delay, limit or prevent regulatory approval. If our study data do not consistently or sufficiently demonstrate the safety or efficacy of any of our product candidates, including STK-001 for Dravet syndrome or STK-002 for ADOA, then the regulatory approvals for such product candidates could be significantly delayed as we work to meet approval requirements, or, if we are not able to meet these requirements, such approvals could be withheld or withdrawn. Regulatory delays or rejections may be encountered as a result of many factors, including changes in regulatory policy during the period of product development. We cannot be certain that we will not face similar setbacks. While currently we are not experiencing any significant delays or disruptions to our clinical trial a result of the global COVID-19 pandemic, we take into consideration that the COVID-19 pandemic may directly or indirectly impact our clinical trial enrollment, dosing, and regulatory approval timelines. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If clinical trials of STK-001, STK-002 or any other product candidate that we develop fail to demonstrate safety and efficacy to the satisfaction of FDA or foreign regulatory authorities or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately may be unable to complete, the development and commercialization of such product candidate.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, including STK-001 and STK-002, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials may be placed on a full or partial clinical hold by the FDA, foreign regulatory authorities, or us for various reasons, including but not limited to: deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements or clinical protocols&#59; deficiencies in the clinical trial operations or trial sites&#59; deficiencies in the trial designs necessary to demonstrate efficacy&#59; fatalities or other adverse effects arising during a clinical trial due to medical problems that may or may not be related to clinical trial treatments&#59; the product candidates may not appear to be more effective than current therapies&#59; the quality or stability of the product candidates may fall below acceptable standards&#59; or the data from animal studies are not sufficient to support the anticipated exposure (dose, route of administration, and duration) for the proposed clinical trial.&#160;&#160;For example, in March 2020, we announced that the FDA had placed a partial clinical hold on doses of STK-001 above 20 mg in our Phase 1/2a clinical trial (the &#8220;MONARCH Study&#8221;) based on observations of adverse hind limb paresis in non-human primates, pending additional preclinical testing to determine the safety profile of doses higher than the current no observed adverse effect level. The partial clinical hold remains in place in the MONARCH Study for dosing above 45 mg.&#160;&#160;If the partial clinical hold is not lifted, our ability to successfully conclude the MONARCH Study or other studies related to STK-001, and our business, results of operations and financial condition, may be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to commercialization, STK-001, STK-002, and our other future product candidates must be approved by the FDA pursuant to a new drug application (&#8220;NDA&#8221;) in the United States and pursuant to similar marketing applications by the EMA and similar regulatory authorities outside the United States. The process of obtaining marketing approvals, both in the United States and abroad, is expensive and takes many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not received approval to market STK-001, STK-002 or any of our other future product candidates from regulatory authorities in any jurisdiction. We have no experience in submitting and supporting the applications necessary to gain marketing approvals, and, in the event regulatory authorities indicate that we may submit such applications, we may be unable to do so as quickly and efficiently as desired. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. Regulatory authorities have substantial discretion in the approval process and may refuse to accept or file any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval of STK-001, STK-002 and our other future product candidates may be delayed or refused for many reasons, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may be unable to demonstrate, to the satisfaction of the FDA or comparable foreign regulatory authorities, that our product candidates are safe and effective for any of their proposed indications&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical programs or clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the facilities of third-party manufacturers with which we contract or procure certain service or raw materials, may not be adequate to support approval of our product candidates&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">potential delays in enrollment, site visits, evaluations, or dosing of patients participating in the clinical trial as hospitals prioritize the treatment of COVID-19 patients or patients decide to not enroll in the study as a result of the COVID-19 pandemic&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">government regulations that may be imposed in response to the COVID-19 pandemic may restrict the movement of our global supply chain, divert hospital resources that are necessary to administer STK-001, STK-002 or our future product candidates.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our product candidates meet their safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or Risk Evaluation and Mitigation Strategies. These regulatory authorities may require precautions or contra-indications with respect to conditions of use or they may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates and adversely affect our business, financial condition, results of operations and prospects. While currently we are not experiencing any significant delays or disruptions to our clinical trial a result of the global COVID-19 pandemic, we take into consideration that the COVID-19 pandemic may directly or indirectly impact our clinical trial enrollment, dosing, and regulatory approval timelines. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business could be materially adversely affected, directly or indirectly, by the widespread outbreak of contagious disease, including the ongoing COVID-19 pandemic and variants of COVID-19, which has spread to many of the countries in which we and our suppliers do business. National, state and local governments in affected regions have implemented and may continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter in place orders and shutdowns, business closures, cancellations of public gatherings and other measures. Organizations and individuals are taking additional steps to avoid or reduce infection, including limiting travel and staying home from work. These measures are disrupting normal business operations both in and outside of affected areas and have had significant negative impacts on businesses and financial markets worldwide. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has caused us to modify our business practices including, but not limited to, curtailing or modifying employee travel, moving to partial remote work, and minimizing some physical participation in meetings, events and conferences. Our office-based employees had been working from home from early March 2020 through early September 2021. Since then, our office-based staff have been working in a hybrid-model fluctuating between work from home and work from the office. Throughout the pandemic, we continue to ensure that ensuring essential staffing levels in our operations remain in place, including maintaining key personnel in our laboratories.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding these measures, the COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third parties we rely on taking similar measures. If members of our management and other key personnel in critical functions across our organization are unable to perform their duties or have limited availability due to COVID-19, we may not be able to execute on our business strategy and/or our operations may be negatively impacted. We may also experience limitations in employee resources, including because of sickness of employees or their families or the desire of employees to avoid contact with individuals or large groups of people. In addition, we have experienced and will continue to experience disruptions to our business operations resulting from quarantines, self-isolations and other restrictions on the ability of our employees to perform their jobs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has disrupted business operations. The extent and severity of the impact on our business and clinical trial will be determined largely by the extent of disruptions in the supply chains for STK-001, STK-002 and our future product candidates in other indications, and delays in the conduct of current and future clinical trials. Our ability to continue our observational study may be adversely affected, directly or indirectly, by the COVID-19 pandemic. Currently we are monitoring patient participation in our observational study, including delays in conducting in-person follow-ups and disruptions in our ability to monitor patients due to hospitals closing sites or diverting the resources that are necessary to conduct our observational study to care for COVID-19 patients. For these reasons we expect that COVID-19 precautions may directly or indirectly impact the timeline for some of our clinical trial activities. In addition, the impact of the COVID-19 pandemic on the operations of the FDA and other health authorities may delay potential approvals of STK-001, STK-002 and our future product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While it is not possible at this time to estimate the entirety of the impact that the COVID-19 pandemic will have on our business, operations, employees, customers, or our suppliers, continued spread of COVID-19, measures taken by governments, actions taken to protect employees and the broad impact of the pandemic on all business activities may materially and adversely affect our business, results of operations and financial condition.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certain of the diseases we seek to treat have low prevalence, and it may be difficult to identify patients with these diseases, which may lead to delays in enrollment for our trials or slower commercial revenue growth if STK-001, STK-002 or our future product candidates are approved. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genetically defined diseases generally, and especially those for which our product candidates are targeted, have low incidence and prevalence. We estimate that the worldwide incidence of Dravet syndrome is approximately one in 16,000 births, and the incidence of ADOA is approximately one in 30,000 births. This could pose obstacles to the timely recruitment and enrollment of a sufficient number of eligible patients into our trials or limit a product candidate&#8217;s commercial potential. Patient enrollment may be affected by other factors including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the ability to identify and enroll patients that meet study eligibility criteria in a timely manner for clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the severity of the disease under investigation&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">design of the study protocol&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the perceived risks, benefits and convenience of administration of the product candidate being studied&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the patient referral practices of providers&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the proximity and availability of clinical trial sites to prospective patients. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any inability to enroll a sufficient number of patients with these diseases for our planned clinical trials would result in significant delays and could cause us to not initiate or abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidate, which would cause the value of our company to decline and limit our ability to obtain additional financing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, our projections of both the number of people who have Dravet syndrome or ADOA, as well as the people with this disease who have the potential to benefit from treatment with our product candidate, are based on estimates derived from a market research study that we commissioned, which may not accurately identify the size of the market for our product candidates. The total addressable market opportunity for STK-001, STK-002 and our future product candidates will ultimately depend upon, among other things, the final labeling for our product candidates, if our product candidates are approved for sale in our target indications, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients globally may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, in light of the limited number of potential patients impacted by Dravet syndrome and ADOA, our per-patient therapy pricing of STK-001, STK-002 and our future product candidates, if approved, must be high in order to recover our development and manufacturing costs, fund additional research and achieve profitability. We may also need to fund patient support programs upon the marketing of a product candidate, which would negatively affect our product revenue. We may be unable to maintain or obtain sufficient therapy sales volumes at a price high enough to justify our development efforts and our sales, marketing and manufacturing expenses. While currently we are not experiencing any significant delays or disruptions to our clinical trial as a result of the global COVID-19 pandemic, we take into consideration that the COVID-19 pandemic may directly or indirectly impact our clinical trial enrollment, dosing, and regulatory approval timelines. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in our efforts to use TANGO to expand our pipeline of product candidates and develop marketable products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. Our business depends on our successful development and commercialization of the limited number of internal product candidates we are researching or have in preclinical development. Even if we are successful in continuing to build our pipeline, development of the potential product candidates that we identify will require substantial investment in additional clinical development, management of clinical, preclinical and manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply capability, building a commercial organization, and significant marketing efforts before we generate any revenue from product sales. Furthermore, such product candidates may not be suitable for clinical development, including as a result of their harmful side effects, limited efficacy or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we cannot validate TANGO by successfully developing and commercializing product candidates based upon our technological approach, we may not be able to obtain product revenue in future periods, which would adversely affect our business, prospects, financial condition and results of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, we announced the nomination of STK-002 as our lead product candidate for in the treatment of ADOA&#59; however, we are primarily focused on our lead product candidate for Dravet syndrome, STK-001, and we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. Our understanding and evaluation of biological targets for the discovery and development of new product candidates may fail to identify challenges encountered in subsequent preclinical and clinical development. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Any product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved. <span style="font-weight:normal;font-style:normal;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and the activities associated with their development and potential commercialization, including their testing, manufacturing, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other U.S. and international regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, including current Good Manufacturing Practices (&#8220;GMPs&#8221;), quality control, quality assurance and corresponding maintenance of records and documents, including periodic inspections by the FDA and other regulatory authorities and requirements regarding the distribution of samples to providers and recordkeeping. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of any approved product. The FDA closely regulates the post-approval marketing and promotion of drugs and biologics to ensure they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding use of their products. If we promote our product candidates in a manner inconsistent with FDA-approved labeling or otherwise not in compliance with FDA regulations, we may be subject to enforcement action. Moreover, while we believe our product candidates may provide improved safety profiles over existing products, unless we conduct head-to-head studies, we will not be able to make comparative claims for products, if approved. Violations of the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;) relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws and similar laws in international jurisdictions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, later discovery of previously unknown adverse events or other problems with our product candidates, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">restrictions on such product candidates, manufacturers or manufacturing processes&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">restrictions on the labeling or marketing of a product&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">restrictions on product distribution or use&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">requirements to conduct post-marketing studies or clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">warning or untitled letters&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">withdrawal of any approved product from the market&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refusal to approve pending applications or supplements to approved applications that we submit&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">recall of product candidates&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">fines, restitution or disgorgement of profits or revenues&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">suspension or withdrawal of marketing approvals&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refusal to permit the import or export of our product candidates&#59; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">product seizure&#59; or </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-compliance with European requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with Europe&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the United States. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To market and sell STK-001, STK-002 and our future product candidates, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, we must secure product reimbursement approvals before regulatory authorities will approve the product for sale in that country. Failure to obtain foreign regulatory approvals or non-compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. The United Kingdom&#8217;s exit from the European Union (the &#8220;EU&#8221;), which is referred to as &#8220;Brexit,&#8221; became fully effective on December 31, 2020. Brexit continues to create political and economic uncertainty, particularly in the United Kingdom and the EU. Prior to Brexit, a significant proportion of the regulatory framework in the United Kingdom was derived from EU directives and regulations. Following Brexit, the United Kingdom retained the EU regulatory regime with certain modifications as standalone UK legislation. Therefore, the UK regulatory regime is currently similar to EU regulations, but the United Kingdom has enacted new legislation, the Medicines and Medical Devices Act. Under this legislation, the UK may adopt changed regulations that may diverge from the EU legislative regime for medicines, including their research, development and commercialization and has issued a consultation document with respect to future changes. Brexit may lead to additional regulatory costs and could materially impact the regulatory regime with respect to the approval of our product candidates in the United Kingdom or the EU.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with the regulatory requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be adversely affected. We may not obtain foreign regulatory approvals on a timely basis, if at all. Our failure to obtain approval of any of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and our business prospects could decline. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">STK-001, STK-002 or our future product candidates may cause undesirable and unforeseen side effects or be perceived by the public as unsafe, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although other ASOs have received regulatory approval, our method of seeking to upregulate protein expression by targeting the underlying genetic causes of haploinsufficiencies presents a new approach to disease treatment, which means there is uncertainty associated with the safety profile of STK-001, STK-002 or our future product candidates and drugs in the antisense oligonucleotide class. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to side effects caused by our product candidates, the intrathecal or intravitreal administration process or related procedures also can cause adverse side effects. If any such adverse events occur, our clinical trials could be suspended or terminated. If we are unable to demonstrate that any adverse events were caused by the administration process or related procedures, the FDA, the European Commission, the EMA, the UK MHRA or other regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. Even if we can demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may adversely affect our business, financial condition, results of operations and prospects significantly. Finally, SPINRAZA, which is produced by Biogen Inc., is an ASO therapy utilizing intrathecal delivery, and if SPINRAZA is found to cause undesirable side effects or to be unsafe due to a potential class effect, it may adversely affect demand for STK-001 and our other future product candidates. Other </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASOs in clinical development utilizing intrathecal delivery could also generate data that could adversely affect the clinical, regulatory or commercial perception of STK-001 and our other future product candidates. &#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if any of our product candidates receives marketing approval, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy to ensure that the benefits of the product outweigh its risks, which may include, for example, a Medication Guide outlining the risks of the product for distribution to patients and a communication plan to health care practitioners, or other elements to assure safe use of the product. Furthermore, if we or others later identify undesirable side effects caused by our product candidate, several potentially significant negative consequences could result, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory authorities may suspend or withdraw approvals of such product candidate&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory authorities may require additional warnings in the labeling&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may be required to change the way a product candidate is administered or conduct additional clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we could be sued and held liable for harm caused to patients&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our reputation may suffer. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these occurrences may harm our business, financial condition, results of operations and prospects significantly. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A Fast Track Designation by the FDA, even if granted for any of our future product candidates, or any use of the accelerated approval pathway, may not lead to a faster development or regulatory review or approval process, and would not increase the likelihood that our product candidates will receive marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply to the FDA for Fast Track Designation. The FDA has broad discretion whether to grant this designation. Even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it.&#160;&#160;Even if we do receive Fast Track Designation for any of our product candidates, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Many drugs that have received Fast Track Designation have failed to obtain approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also seek accelerated approval for our product candidates. Under the FDA&#8217;s accelerated approval program, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Full approval of another product for the same indication as any of our product candidates for which we are seeking accelerated approval may make accelerated approval of our product candidates more difficult. For drugs granted accelerated approval, post-marketing confirmatory trials are required to describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence and in general the FDA may require that the trial be designed and/or initiated prior to approval. All promotional materials for product candidates approved via accelerated approval are subject to prior review by the FDA. Moreover, the FDA may withdraw approval of any product candidate or indication approved under the accelerated approval pathway if, for example:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the trial or trials required to verify the predicted clinical benefit of the product candidate fail to verify such benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with the drug&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">other evidence demonstrates that the product candidate is not shown to be safe or effective under the conditions of use&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we fail to conduct any required post-approval trial of the product candidate with due diligence&#59; or </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we disseminate false or misleading promotional materials relating to the product candidate. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A Breakthrough Therapy Designation by the FDA for STK-001, STK-002 or our future product candidates may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the product candidate will receive marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek a Breakthrough Therapy Designation for STK-001, STK-002 or one or more of our future product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the NDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a drug may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;ACA&#8221;) was enacted, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The ACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form at this time. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021, and closed on August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is uncertain how any such challenges and the healthcare measures of the Biden administration will impact the ACA and our business.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect on April 1, 2013, and will remain in effect through 2030 with the exception of a temporary suspension from May 1, 2020, through March 31, 2022, due to the COVID-19 pandemic, unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations. Additionally, on May&#160;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Act of 2017 was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA authorization under an FDA expanded access program&#59; however, manufacturers are not obligated to provide investigational new drug products under the current federal right to try law. We may choose to seek an expanded access program for our product candidates, or to utilize comparable rules in other countries that allow the use of a drug, on a named patient basis or under a compassionate use program. &#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be unsuccessful in obtaining Orphan Drug Designation or transfer of designations obtained by others for future product candidates. And, even if we obtain such designation, we may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity, for STK-001, STK-002 or our future product candidates. <span style="font-weight:normal;font-style:normal;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our business strategy, we applied for and, in August 2019, received Orphan Drug Designation for STK-001 in the United States, and we may seek such designation in Europe and other countries. However, Orphan Drug Designation does not guarantee future orphan drug marketing exclusivity, and there is no guarantee that we will be successful in obtaining such designation for our future product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs intended to treat relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is defined as a patient population of fewer than 200,000 individuals in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for tax credits for qualified clinical research costs and exemption from prescription drug user fees. Similarly, in the EU, the European Commission grants Orphan Drug Designation after receiving the opinion of the EMA&#8217;s Committee for Orphan Medicinal Products on an Orphan Drug Designation application. In the EU, Orphan Drug Designation is intended to promote the development of drug that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than five in 10,000 persons in the EU and for which no satisfactory method of diagnosis, prevention or treatment has been authorized (or the product would be a significant benefit to those affected). In the EU, Orphan Drug Designation entitles a party to financial incentives such as reduction of fees or fee waivers. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, if a drug with an Orphan Drug Designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes EMA or the FDA from approving another marketing application for the same drug and indication for that time period, except in limited circumstances. If a competitor is able to obtain orphan drug exclusivity prior to us for a product that constitutes the same active moiety and treats the same indications as our product candidates, we may not be able to obtain approval of our drug by the applicable regulatory authority for a significant period of time unless we are able to show that our drug is clinically superior to the approved drug. The applicable period is seven years in the United States and ten years in the EU. The EU exclusivity period can be reduced to six years if a drug no longer meets the criteria for Orphan Drug Designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even after an orphan drug is approved, the FDA can also subsequently approve a later application for the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer in a substantial portion of the target populations, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Orphan Drug Designation </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The orphan drug exclusivity contained in the Orphan Drug Act has been the subject of recent scrutiny from the press, from some members of Congress and from some in the medical community. Furthermore, the FDA&#8217;s interpretations of the Orphan Drug Act have not been successfully challenged in court and future court decisions could continue that trend. There can be no assurances that the exclusivity granted to orphan drugs approved by the FDA will not be modified in the future, or as to how any such changes might affect our products, if approved.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A Rare Pediatric Disease designation by the FDA does not guarantee that the NDA for the product will qualify for a priority review voucher upon approval, and it does not lead to a faster development or regulatory review process, or increase the likelihood that STK-001, STK-002 or our future product candidates will receive marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Rare Pediatric Disease Priority Review Voucher program, upon the approval of a qualifying NDA for the treatment of a rare pediatric disease, the sponsor of such an application would be eligible for a rare pediatric disease priority review voucher that can be used to obtain priority review for a subsequent Biologics License Application or NDA. We may seek Rare Pediatric Disease designations for STK-001 or any future product candidates. If a product candidate is designated before September 30, 2024, it is eligible to receive a voucher if it is approved before September 30, 2026. However, there is no expectation that STK-001, STK-002 or our future product candidates will be designated or approved by those dates, or at all, or that the program will be further extended, and, therefore, we may not be in a position to obtain any priority review vouchers. Additionally, designation of a drug for a rare pediatric disease does not guarantee that an NDA will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Finally, a Rare Pediatric Disease Designation does not lead to faster development or regulatory review of the product or increase the likelihood that it will receive marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The FDA&#8217;s ability to review and approve new products may be hindered by a variety of factors, including budget and funding levels, ability to hire and retain key personnel, and statutory, regulatory and policy changes. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including budget and funding levels, ability to hire and retain key personnel, and statutory, regulatory, and policy changes. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA and other government agencies to properly administer their functions is highly dependent on the levels of government funding and the ability to fill key leadership appointments, among various factors. Delays in filling or replacing key positions could significantly impact the ability of the FDA and other agencies to fulfill their functions, and could greatly impact healthcare and the pharmaceutical industry. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, the 21<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup>&#160;Century Cures Act was signed into law, and was designed to advance medical innovation and empower the FDA with the authority to directly hire positions related to drug and device development and review. In the past, the FDA was often unable to offer key leadership candidates (including scientists) competitive compensation packages as compared to those offered by private industry. The 21<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup>&#160;Century Cures Act is designed to streamline the agency&#8217;s hiring process and enable the FDA to compete for leadership talent by expanding the narrow ranges that are provided in the existing compensation structures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions at the FDA and other governmental agencies may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would adversely affect our operating results and business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our operations and relationships with future customers, providers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to penalties including criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with providers, third-party payors and customers will subject us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we obtain marketing approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restrictions under applicable U.S. federal and state healthcare laws and regulations include the following: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">federal false claims laws, including the federal False Claims Act, imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, also imposes obligations, including mandatory contractual terms, on certain types of people and entities with respect to safeguarding the privacy, security and transmission of individually identifiable health information&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the federal Physician Payment Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually payments and other transfers of value to physicians, physician assistants, certain types of advance practice nurses and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, such providers, and to report annually certain ownership and investment interests held by physicians and their immediate family, which includes annual data collection and reporting obligations&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or pricing. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of product candidates from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to commercialization and manufacturing </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The commercial success of our product candidates, including STK-001 and STK-002, will depend upon their degree of market acceptance by providers, patients, patient advocacy groups, third-party payors and the general medical community. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ethical, social and legal concerns about genetic treatments generally could result in additional regulations restricting or prohibiting our product candidates. Even with the requisite approvals from the FDA, the EMA and other regulatory authorities internationally, the commercial success of our product candidates will depend, in part, on the acceptance of providers, patients and third-party payors of drugs designed to increase protein expression in general, and our product candidates in particular, as medically necessary, cost-effective and safe. In addition, we may face challenges in seeking to establish and grow sales of STK-001, STK-002 and any future product candidates, including acceptance of intravitreal injection, the lumbar puncture and intrathecal administration, which carries risks of infection or other complications. Any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product that we commercialize may not gain acceptance by providers, patients, patient advocacy groups, third-party payors and the general medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of genetic medicines and, in particular, STK-001, STK-002 and our future product candidates, if approved for commercial sale, will depend on several factors, including: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the efficacy, durability and safety of such product candidates as demonstrated in clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the potential and perceived advantages of product candidates over alternative treatments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the cost of treatment relative to alternative treatments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the clinical indications for which the product candidate is approved by the FDA or the European Commission&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the willingness of providers to prescribe new therapies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the willingness of the target patient population to try new therapies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the prevalence and severity of any side effects&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">product labeling or product insert requirements of the FDA, EMA or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the willingness of providers to prescribe, and of patients to receive, intrathecal injections&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the strength of marketing and distribution support&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the timing of market introduction of competitive products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the quality of our relationships with patient advocacy groups&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">publicity concerning our product candidates or competing products and treatments&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">sufficient third-party payor coverage and adequate reimbursement. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after it is launched. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The pricing, insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our target indications, including Dravet syndrome and ADOA, are indications with small patient populations. For product candidates that are designed to treat smaller patient populations to be commercially viable, the reimbursement for such product candidates must be higher, on a relative basis, to account for the lack of volume. Accordingly, we will need to implement a coverage and reimbursement strategy for any approved product candidate that accounts for the smaller potential market size. If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those product candidates and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that coverage and reimbursement by third-party payors will be essential for most patients to be able to afford these treatments. Accordingly, sales of STK-001, STK-002 and our future product candidates will depend substantially, both domestically and internationally, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement by government authorities for new products are typically made by the Centers for Medicare&#160;&#38; Medicaid Services (&#8220;CMS&#8221;) since CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. However, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Further, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement in certain European countries </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the EU, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, the prices of products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payors, in the United States and internationally, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of certain third-party payors, such as health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the healthcare market. Recently there have been instances in which third-party payors have refused to reimburse treatments for patients for whom the treatment is indicated in the FDA-approved product label. Even if we are successful in obtaining FDA approvals to commercialize our product candidates, we cannot guarantee that we will be able to secure reimbursement for all patients for whom treatment with our product candidates is indicated. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to CMS and private payors, professional organizations such as the American Medical Association, or the AMA, can influence decisions about reimbursement for new products by determining standards for care. In addition, many private payors contract with commercial vendors who sell software that provide guidelines that attempt to limit utilization of, and therefore reimbursement for, certain products deemed to provide limited benefit to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of our product candidates. Even if favorable coverage and reimbursement status is attained for one or more product candidates for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The CARES Act, and other potential future healthcare reforms may adversely impact pricing, insurance coverage and reimbursement status of newly approved products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act") was signed into law in March 2020. The CARES Act is aimed at providing emergency assistance and health care for individuals, families and businesses affected by the COVID-19 pandemic and generally supporting the U.S. economy. Due to the recent enactment of the CARES Act, there is a high degree of uncertainty around its implementation. We expect that additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our future products or additional pricing pressures. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If third parties on which we depend to conduct our planned preclinical studies, any future clinical trials, or manufacturing of our product candidates do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with adverse effects on our business, financial condition, results of operations and prospects. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third parties for genetic testing, and on third party CROs, CMOs, consultants and others to design, conduct, supervise and monitor key activities relating to, discovery, manufacturing, preclinical studies and clinical trials of our product candidates, and we intend to do the same for future activities relating to existing and future programs. Because we rely on third parties and do not have the ability to conduct all required testing, discovery, manufacturing, preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of discovery, manufacturing, preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs, CMOs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties we contract with might not be diligent, careful or timely in conducting our discovery, manufacturing, preclinical studies or clinical trials, resulting in testing, discovery, manufacturing, preclinical studies or clinical trials being delayed or unsuccessful, in whole or in part. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Any such event could have an adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face significant competition in an environment of rapid technological change and it is possible that our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours, which may harm our business, financial condition and our ability to successfully market or commercialize STK-001, STK-002 and our future product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries, including the genetic medicine and antisense oligonucleotide fields, are characterized by rapidly changing technologies, competition and a strong emphasis on intellectual property. We are aware of several companies focused on developing RNA-based treatments in various indications as well as several companies addressing other methods for modifying genes and regulating protein expression. We may also face competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerous treatments for epilepsy exist, including 5-HT agonists, such as Zogenix&#8217;s Fintepla, cannabidiols, such as Jazz Pharmaceuticals&#8217; Epidiolex, GABA receptor agonists, such as clobazam and stiripentol, and glutamate blockers, such as topiramate. In addition, numerous compounds are in clinical development for treatment of epilepsy. We believe the clinical development pipeline includes cannabinoids, 5-HT release stimulants, cholesterol 24-hydroxylase inhibitors, and sodium channel agonists from a variety of companies. In addition to competition from these small molecule drugs, any products we may develop may also face competition from other types of therapies, such as gene therapy, gene editing, modified mRNA therapies or other ASO approaches. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources than we do, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market, if ever. Additionally, new or advanced technologies developed by our competitors may render our current or future product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we must develop and eventually commercialize product candidates with significant market potential, which will require us to be successful in a range of challenging activities. These activities include, among other things, completing preclinical studies and initiating and completing clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that are approved and satisfying any post marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of STK-001, STK-002 or our future product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our product candidates for patients, if approved, could be delayed or stopped. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established manufacturing relationships with a limited number of suppliers to manufacture raw materials and the drug substance of any product candidate for which we are responsible for preclinical or clinical development. Each supplier may require licenses to manufacture such components if such processes are not owned by the supplier or in the public domain. As part of any marketing approval, a manufacturer and its processes are required to be qualified by the FDA prior to commercialization. If supply from the approved vendor is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified through an NDA supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of manufacturing drugs is complex, highly-regulated and subject to multiple risks. Manufacturing drugs is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered at the facilities of our manufacturers, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. Moreover, if the FDA determines that our manufacturers are not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may deny NDA approval until the deficiencies are corrected or we replace the manufacturer in our NDA with a manufacturer that is in compliance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. Even if we or our collaborators obtain regulatory approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, research and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on a limited number of manufacturers, the complexity of drug manufacturing and the difficulty of scaling up a manufacturing process could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our product candidates successfully. Furthermore, if our suppliers fail to deliver the required commercial quantities of materials on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement suppliers capable of production in a timely manner at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell STK-001, STK-002 and our future product candidates, we may be unable to generate any revenues. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently do not have an organization for the sales, marketing and distribution of STK-001, STK-002 and our future product candidates and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. To market any products that may be approved, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. With respect to certain of our current programs as well as future programs, we may rely completely on an alliance partner for sales and marketing. In </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition, although we intend to establish a sales organization if we are able to obtain approval to market any product candidates, we may enter into strategic alliances with third parties to develop and commercialize STK-001, STK-002 and other future product candidates, including in markets outside of the United States or for other large markets that are beyond our resources. This will reduce the revenue generated from the sales of these products. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any future strategic alliance partners may not dedicate sufficient resources to the commercialization of our product candidates or may otherwise fail in their commercialization due to factors beyond our control. If we are unable to establish effective alliances to enable the sale of our product candidates to healthcare professionals and in geographical regions, including the United States, that will not be covered by our own marketing and sales force, or if our potential future strategic alliance partners do not successfully commercialize the product candidates, our ability to generate revenues from product sales will be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have entered into a collaboration with Acadia Pharmaceuticals and may, in the future, seek to enter into collaborations with other third parties for the discovery, development and commercialization of our product candidates. If our collaborators cease development efforts under our collaboration agreements, or if any of those agreements are terminated, these collaborations may fail to lead to commercial products and we may never receive milestone payments or future royalties under these agreements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into a collaborations with Acadia Pharmaceuticals to discover or develop certain novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS). The collaboration includes SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of mutual interest, and such collaboration could represent a significant portion of our product pipeline. We may derive a significant portion of our future revenue from these agreements or other similar agreements into which we may enter in the future. Revenue from research and development collaborations depends upon continuation of the collaborations, payments for research and development services and resulting options to acquire any licenses of successful product candidates, and the achievement of milestones, contingent payments and royalties, if any, derived from future products developed from our research</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.57%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations involving our product candidates currently pose, and will continue to pose, the following risks to us:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on preclinical studies or clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:5pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:5pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the foregoing, our current and any future collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. Any failure to successfully develop or commercialize our product candidates pursuant to our current or any future collaboration agreements could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, to the extent that any of our existing or future collaborators were to terminate a collaboration agreement, we may be forced to independently develop these product candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and defending intellectual property rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in finding strategic collaborators for continuing development of certain of our future product candidates or successfully commercializing or competing in the market for certain indications. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may decide to collaborate with non-profit organizations, universities, pharmaceutical and biotechnology companies for the development and potential commercialization of existing and new product candidates. We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of any potential collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of such collaboration arrangements. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our financial position </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have a history of operating losses, and we may not achieve or sustain profitability. We anticipate that we will continue to incur losses for the foreseeable future. If we fail to obtain additional funding to conduct our planned research and development effort, we could be forced to delay, reduce or eliminate our product development programs or commercial development efforts. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an early-stage biotechnology company with a limited operating history on which to base your investment decision. Biotechnology product development is a highly speculative undertaking and involves a substantial degree of risk. Our operations to date have been limited primarily to organizing and staffing our company, business planning, raising capital, acquiring and developing product and technology rights, manufacturing, and conducting research and development activities for our product candidates. We have never generated any revenue from product sales. We have not obtained regulatory approvals for any of our product candidates, and have funded our operations to date through proceeds from sales of our preferred stock and common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred net losses in each year since our inception. We incurred net losses of $85.8&#160;million and $52.2&#160;million, for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021 and 2020, we had accumulated deficits of $196.1 million and $110.3 million, respectively. Substantially all of our operating losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to continue to incur significant expenses and operating losses over the next several years and for the foreseeable future as we intend to continue to conduct research and development, clinical testing, regulatory compliance activities, manufacturing activities, and, if any of our product candidates is approved, sales and marketing activities that, together with anticipated general and administrative expenses, will likely result in us incurring significant losses for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, we entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. (&#8220;Acadia&#8221;) for the discovery, development and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The agreement focuses on the targets SYNGAP1, MECP2 (Rett syndrome), and an undisclosed neurodevelopmental target of mutual interest. In connection with each target, we will collaborate with Acadia to identify potential treatments for further development and commercialization as licensed products. With respect to SYNGAP1, we have agreed with Acadia to co-develop and co-commercialize licensed products for such target globally, and in connection therewith we granted to Acadia worldwide, co-exclusive (with us) licenses for such licensed products. With respect to MECP2 and the neurodevelopmental target, we granted to Acadia worldwide, exclusive licenses to develop and commercialize licensed products for such targets. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the agreement, we received an upfront payment of $60 million from Acadia. Acadia agreed to fund the research to identify potential licensed products for MECP2 and the neurodevelopmental target, and we will equally fund with Acadia the research to identify potential licensed products for SYNGAP1. We are e<span style="Background-color:#FFFFFF;color:#000000;">ligible to receive up to $907,500,000 in potential total milestone payments based upon the achievement of certain development, regulatory, first commercial sales and sales milestone events across the programs for the three targets, assuming each milestone were achieved at least once.</span> With respect to licensed products for MECP2 and the neurodevelopmental target, we are also eligible to receive tiered royalties at percentages ranging from the mid-single digits to the mid-teens on future net sales by Acadia of licensed products worldwide. Royalties payable under the agreement are subject to standard royalty reductions. For SYNGAP1 licensed products that we are co-developing and co-commercializing, we will be responsible for 50% of the development and commercialization costs and will receive 50% of the profits from global commercialization.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company filed a universal Shelf Registration statement on Form S-3 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission (the &#8220;SEC&#8221;). The Registration Statement was declared effective by the SEC on July 20, 2020,&#160;&#160;and contains two prospectuses: a base prospectus, which covers the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $400,000,000 of our common stock, preferred stock, debt </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">securities, warrants to purchase our common stock, preferred stock or debt securities, subscription rights to purchase our common stock, preferred stock or debt securities and/or units consisting of some or all of these securities&#59; and a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $150,000,000 of our common stock that may be issued and sold under a Controlled Equity Offering Sales Agreement (&#8220;Sales Agreement&#8221;). The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The $150,000,000 of common stock that may be offered, issued and sold under the sales agreement prospectus is included in the $400,000,000 of securities that may be offered, issued and sold by the Company under the base prospectus. As of December 31, 2021, the Company had not issued any securities in connection with the Sales Agreement. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since December 31, 2021, we sold </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403,000 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shares of our common stock and received </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.5</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million after deducting commissions related to the Sales Agreement.&#160;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may terminate this at-the-market program at any time, pursuant to its terms.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect that we will need to raise additional funding before we can expect to become profitable from any potential future sales of STK-001, STK-002 or our future product candidates. This additional financing may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will require substantial future capital in order to complete planned and future preclinical and clinical development for STK-001, STK-002and other future product candidates, if any, and potentially commercialize these product candidates. Based upon our current operating plan, we believe that our <span style="font-family:Calibri;">cash, cash equivalents, marketable securities, and restricted cash </span>of $220.4 million as of December 31, 2021, <span style="color:#000000;">together with the proceeds from the $60 million upfront from Acadia and the proceeds since December 31, 2021 from the Sales Agreement of $7.5 million, </span>will enable us to fund our operating expenses and capital expenditure requirements into the second half 2024. We expect our spending levels to increase in connection with our preclinical studies and clinical trials of our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant expenses related to commercial launch, product sales, medical affairs, marketing, manufacturing and distribution. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate certain of our licensing activities, our research and development programs or other operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional capital might not be available when we need it and our actual cash requirements might be greater than anticipated. If we require additional capital at a time when investment in our industry or in the marketplace in general is limited, we might not be able to raise funding on favorable terms if at all. If we are not able to obtain financing on terms favorable to us, we may need to cease or reduce development or commercialization activities, sell some or all of our assets or merge with another entity, which could result in a loss of all or part of your investment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements will depend on many factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs associated with the scope, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs associated with the development of our internal manufacturing facility and processes&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs related to the extent to which we enter into partnerships or other arrangements with third parties to further develop our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs and fees associated with the discovery, acquisition or in-license of product candidates or technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to establish collaborations on favorable terms, if at all&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs of future commercialization activities, if any, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of product candidates that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives, which may not be available to us on acceptable terms, or at all. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biotechnology company formed in June 2014. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, acquiring our technology, identifying potential product candidates, undertaking research, preclinical and clinical development of our product candidates, manufacturing, and establishing licensing arrangements. We have not yet demonstrated the ability to complete clinical trials of our product candidates, obtain marketing approvals, manufacture a commercial scale product or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition from a company with a licensing and research focus to a company that is also capable of supporting clinical development and commercial activities. We may not be successful in such a transition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to utilize our net operating loss carryforwards may be subject to limitations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. As of December&#160;31, 2021, we had federal and state net operating loss carryforwards, or NOLs, of approximately $191.1 million and $191.4 million, respectively, and as of December&#160;31, 2020, we had federal and state NOLs of approximately $116.9 million and $118.8 million, respectively. Our NOLs expire at various dates beginning in 2034, for those net operating loss carryforwards generated prior to 2018. Net operating losses generated in 2018 and beyond have no expiration. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. We may have experienced one or more ownership changes in prior years, and we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. federal income tax reform and changes in other tax laws could adversely affect us. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act, or the TCJA, was signed into law, significantly reforming the Code. The TCJA, among other things, includes changes to U.S. federal tax rates, imposes significant additional limitations on the deductibility of business interest, allows for the expensing of capital expenditures, puts into effect the migration from a &#8220;worldwide&#8221; system of taxation to a partial &#8220;territorial&#8221; system, and modifies or repeals many business deductions and credits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to examine the impact the TCJA may have on our business. The TCJA is a&#160;far-reaching&#160;and complex revision to the U.S. federal income tax laws with disparate and, in some cases, countervailing impacts on different categories of taxpayers and industries, and will require subsequent rulemaking and interpretation in a number of areas. The long-term impact of the TCJA on the overall economy, the industries in which we operate and our and our partners&#8217; businesses cannot be reliably predicted at this early stage of the new law&#8217;s implementation. There can be no assurance that the TCJA will not negatively impact our operating results, financial condition, and future business operations. The estimated impact of the TCJA is based on our management&#8217;s current knowledge and assumptions, following consultation with our tax advisors. Because of our valuation allowance in the U.S., ongoing tax effects of the Act are not expected to materially change our effective tax rate in future periods. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the CARES Act temporarily repealed the 80% taxable income limitation for tax years beginning before January 1, 2021. Federal NOL carry forwards generated from 2018 or later and Federal NOL carryforwards to taxable years beginning after December 31, 2020 will be subject to the 80% limitation. Also, under the CARES Act, federal NOLs arising in 2018, 2019 and 2020 can be carried back 5 years. New legislation or regulation which could affect our tax burden could be enacted by any governmental authority. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cannot predict the timing or extent of such tax related developments which could have a negative impact on our financial results. Additionally, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> use</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> our</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> best judgment in attempting to quantify and reserve for these tax obligations. However, a challenge by a taxing authority, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ability to utilize tax benefits such as carryforwards or tax credits, or a deviation from other tax-related assumptions could have a material adverse effect on our business, results of operations, or financial condition.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our intellectual property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our success depends in part on our ability to obtain, maintain and protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success will depend in large part on obtaining and maintaining patent, trademark, trade secret and other intellectual property protection of our proprietary technologies and product candidates, which include TANGO, STK-001, STK-002 and the additional gene targets identified by TANGO, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending our patents and other intellectual property rights against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, importing or otherwise commercializing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected. The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees to do so. Our pending and future patent applications may not result in issued patents. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we hold or in-license may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether any of our platform advances and product candidates will be protectable or remain protected by valid and enforceable patents. In addition, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technologies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We depend on intellectual property licensed from third parties, and our licensors may not always act in our best interest. If we fail to comply with our obligations under our intellectual property licenses, if the licenses are terminated, or if disputes regarding these licenses arise, we could lose significant rights that are important to our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dependent on patents, know-how and proprietary technology licensed from others. Our licenses to such patents, know-how and proprietary technology may not provide exclusive rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our products in the future. The agreements under which we license patents, know-how and proprietary technology from others are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we are a party to license agreements with Cold Spring Harbor Laboratory and the University of Southampton, pursuant to which we in-license key patent and patent applications for our TANGO platform, STK-001, STK-002 and future product candidates. For more information regarding these agreements, please see &#8220;Business&#8212;License and research agreements.&#8221; These agreements impose various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, our licensors may have the right to terminate our license, in which event we would not be able to develop or market our TANGO platform, STK-001, STK-002 or any other technology or product candidates covered by the intellectual property licensed under these agreements. In addition, we may need to obtain additional licenses from our existing licensors and others to advance our research or allow commercialization of product candidates we may develop. It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on reasonable terms, if at all. In either event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology or product candidates. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our licensors fail to adequately protect our licensed intellectual property, our ability to commercialize product candidates could suffer. We do not have complete control over the maintenance, prosecution and litigation of our in-licensed patents and patent applications and may have limited control over future intellectual property that may be in-licensed. For example, we cannot be certain that activities such as the maintenance and prosecution by our licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. It is possible that our licensors&#8217; infringement proceedings or defense activities may be less vigorous than had we conducted them ourselves, or may not be conducted in accordance with our best interests. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, inventions contained within some of our in-licensed patents and patent applications were made using U.S. government funding or other non-governmental funding. We rely on our licensors to ensure compliance with applicable obligations arising from such funding, such as timely reporting, an obligation associated with in-licensed patents and patent applications. The failure of our licensors to meet their obligations may lead to a loss of rights or the unenforceability of relevant patents. For example, the government could have certain rights in such in-licensed patents, including a non-exclusive license authorizing the government to use the invention or to have others use the invention on its behalf for non-commercial purposes. If the U.S. government then decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. These rights may also permit the government to exercise march-in rights to use or allow third parties to use the technology covered by such in-licensed patents. The government may also exercise its march-in rights if it determines that action is necessary because we or our licensors failed to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such in-licensed government-funded inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any of the foregoing could harm our business, financial condition, results of operations, and prospects significantly. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant patents, know-how and proprietary technology, or increase what we believe to be our financial or other obligations under the relevant agreement. Disputes that may arise between us and our licensors regarding intellectual property subject to a license agreement could include disputes regarding: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the scope of rights granted under the license agreement and other interpretation-related issues&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our right to sublicense patent and other rights to third parties under collaborative development relationships&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates and what activities satisfy those diligence obligations&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected technology or product candidates. As a result, any termination of or disputes over our intellectual property licenses could result in the loss of our ability to develop and commercialize our TANGO platform, STK-001, or STK-002, or we could lose other significant rights, any of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, our agreements with certain of our third-party research partners provide that improvements developed in the course of our relationship may be owned solely by either us or our third-party research partner, or jointly between us and the third party. If we determine that rights to such improvements owned solely by a research partner or other third party with whom we collaborate are necessary to commercialize our drug candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to use the improvements and continue developing, manufacturing or marketing our drug candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from commercializing our drug candidates or allow our competitors or others the chance to access technology that is important to our business. We also may need the cooperation of any co-owners of our intellectual property in order to enforce such intellectual property against third parties, and such cooperation may not be provided to us. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our owned and in-licensed patents and patent applications may not provide sufficient protection of our TANGO platform, our STK-001 and STK-002 product candidates, and our future product candidates or result in any competitive advantage. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own an issued U.S. patent covering STK-001 and related compositions, an issued U.S. patent covering the mechanism of action of STK-001 and use of STK-001 for treating diseases, and our U.S. patent application and PCT international application covering the mechanism of action of STK-001 and use of STK-001 for treating diseases are currently pending. We have also in-licensed two issued U.S. patents and at least three issued foreign patents that cover the mechanism of action of STK-001, use of the mechanism for treating diseases, and related compositions. We have obtained at least six issued foreign patents covering STK-001, related compositions and its uses and are currently pursuing patent protection for STK-001, related compositions, and its uses in several economically significant countries. With respect to STK-002, we have applied for and are currently pursuing patent protection for the mechanism of action and methods of treatment in several economically significant countries. We have also filed a PCT international application and foreign patent applications that specifically disclose compositions related to STK-002 and uses of those compositions. Furthermore, our in-licensed issued U.S. patents (mentioned above) cover the mechanism of action of STK-002.We cannot be certain that any of these patent applications will issue as patents, and if they do, that such patents will cover or adequately protect STK-001, STK-002 and other programs or that such patents will not be challenged, narrowed, circumvented, invalidated or held unenforceable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to claims directed toward the technology underlying our TANGO platform, our owned and in-licensed patents and patent applications contain claims directed to compositions of matter on the active pharmaceutical ingredients (&#8220;APIs&#8221;) in our product candidates, as well as methods-of-use directed to the use of an API for a specified treatment. Composition-of-matter patents on the active pharmaceutical ingredient in prescription drug products provide protection without regard to any particular method of use of the API used. Method-of-use patents do not prevent a competitor or other third party from developing or marketing an identical product for an indication that is outside the scope of the patented method. Moreover, with respect to method-of-use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, providers may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method-of-use patents, the practice is common and this type of infringement is difficult to prevent or prosecute. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. For example, while our patent applications are pending, we may be subject to a third party preissuance submission of prior art to the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) or become involved in interference or derivation proceedings, or equivalent proceedings in foreign jurisdictions. Even if patents do successfully issue, third parties may challenge their inventorship, validity, enforceability or scope, including through opposition, revocation, reexamination, post-grant and <span style="font-style:italic;">inter partes</span> review proceedings. An adverse determination in any such submission, proceeding or litigation may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. Moreover, some of our owned and in-licensed patents and patent applications may be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in development, testing, and regulatory review of new product candidates, the period of time during which we could market our product candidates under patent protection would be reduced. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since patent applications in the United States and other countries are confidential for a period of time after filing, at any moment in time, we cannot be certain that we were in the past or will be in the future the first to file any patent application related to our product candidates. In addition, some patent applications in the United States may be maintained in secrecy until the patents are issued. As a result, there may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim, and we may be subject to priority disputes. We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that, if challenged, our patents would be declared by a court, patent office or other governmental authority to be valid or enforceable or that even if found valid and enforceable, a competitor&#8217;s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, that block our efforts or potentially result in our product candidates or our activities infringing such claims. It is possible that our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Those patent applications may have priority over our owned and in-licensed patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. The possibility also exists that others will develop products that have the same effect as our product candidates on an independent basis that do not infringe our patents or other intellectual property rights, or will design around the claims of patents that we have had issued that cover our product candidates.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Likewise, our currently owned and in-licensed patents and patent applications, if issued as patents, directed to our proprietary technologies and our product candidates are expected to expire from 2035 through 2042, without taking into account any possible patent term adjustments or extensions. Our earliest in-licensed patents may expire before, or soon after, our first product achieves marketing approval in the United States or foreign jurisdictions. Additionally, we cannot be assured that the USPTO or relevant foreign patent offices will grant any of the pending patent applications we own or in-license currently or in the future. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">others may be able to make or use compounds that are similar to the active compositions of our product candidates but that are not covered by the claims of our patents&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the active pharmaceutical ingredients in our current product candidates will eventually become commercially available in generic drug products, and no patent protection may be available with regard to formulation or method of use&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government regarding any in-licensed patents and patent applications funded by U.S. government grants, leading to the loss or unenforceability of patent rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we or our licensors, as the case may be, might not have been the first to file patent applications for certain inventions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">others may independently develop similar or alternative technologies or duplicate any of our technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">it is possible that our pending patent applications will not result in issued patents&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">it is possible that there are prior public disclosures that could invalidate our owned or in-licensed patents, as the case may be, or parts of our owned or in-licensed patents&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">it is possible that others may circumvent our owned or in-licensed patents&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our product candidates or technology similar to ours&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the laws of foreign countries may not protect our or our licensors&#8217;, as the case may be, proprietary rights to the same extent as the laws of the United States&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our owned or in-licensed issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes that design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we have engaged in scientific collaborations in the past and will continue to do so in the future and our collaborators may develop adjacent or competing products that are outside the scope of our patents&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we may not develop additional proprietary technologies for which we can obtain patent protection&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">it is possible that product candidates or diagnostic tests we develop may be covered by third parties&#8217; patents or other exclusive rights&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the patents of others may have an adverse effect on our business. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the foregoing could have a material adverse effect on our business, financial conditions, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our strategy of obtaining rights to key technologies through in-licenses may not be successful. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We seek to expand our product candidate pipeline in part by in-licensing the rights to key technologies, including those related to specific gene targets which may be upregulated by TANGO. The future growth of our business will depend in part on our ability to in-license or otherwise acquire the rights to additional product candidates and technologies. Although we have succeeded in licensing technologies from Cold Spring Harbor Laboratory and the University of Southampton in the past, we cannot assure you that we will be able to in-license or acquire the rights to any product candidates or technologies from third parties on acceptable terms or at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, our agreements with certain of our third-party research partners provide that improvements developed in the course of our relationship may be owned solely by either us or our third-party research partner, or jointly between us and the third party. If we determine that exclusive rights to such improvements owned solely by a research partner or other third party with whom we collaborate are necessary to commercialize our drug candidates or maintain our competitive advantage, we may need to obtain an exclusive license from such third party in order to use the improvements and continue developing, manufacturing or marketing our drug candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from commercializing our drug candidates or allow our competitors or others the opportunity to access technology that is important to our business. We also may need the cooperation of any co-owners of our intellectual property in order to enforce such intellectual property against third parties, and such cooperation may not be provided to us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the in-licensing and acquisition of these technologies is a highly competitive area, and a number of more established companies are also pursuing strategies to license or acquire product candidates or technologies that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to license rights to us. Furthermore, we may be unable to identify suitable product candidates or technologies within our area of focus. If we are unable to successfully obtain rights to suitable product candidates or technologies, our business and prospects could be materially and adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patent protection, we rely upon know-how and trade secret protection, as well as non-disclosure agreements and invention assignment agreements with our employees, consultants and third-parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties, except in certain specified circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and that are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In the case of consultants and other third parties, the agreements provide that all inventions conceived in connection with the services provided are our exclusive property. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We have also adopted policies and conduct training that provides guidance on our expectations, and our advice for best practices, in protecting our trade secrets. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information through other appropriate precautions, such as physical and technological security measures. However, trade secrets and know-how can be difficult to protect. These measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and any recourse we might take against this type of misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent us from receiving legal recourse. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any of that information was independently developed by a competitor, our competitive position could be harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. Even if we are successful, these types of lawsuits may consume our time and other resources. Although we take steps to protect our proprietary information and trade secrets, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. As a result, we may not be able to meaningfully protect our trade secrets. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third-party claims of intellectual property infringement may prevent, delay or otherwise interfere with our product discovery and development efforts. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property or proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, <span style="font-style:italic;">inter partes</span> review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our field, third parties may allege they have patent rights encompassing our product candidates, technologies or methods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a third party claims that we infringe, misappropriate or otherwise violate its intellectual property rights, we may face a number of issues, including, but not limited to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">infringement and other intellectual property claims that, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages plus the patent owner&#8217;s attorneys&#8217; fees&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third party licenses its product rights to us, which it is not required to do, on commercially reasonable terms or at all&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the requirement that we redesign our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that we are employing their proprietary technology without authorization, including by enforcing its patents against us by filing a patent infringement lawsuit against us. In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, or materials used in or formed during the manufacturing process, or any final product itself, the holders of those patents may be able to block our ability to commercialize our product candidate unless we obtain a license under the applicable patents, or until those patents were to expire or those patents are finally determined to be invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of that patent may be able to block our ability to develop and commercialize the product candidate unless we obtain a license or until such patent expires or is finally determined to be invalid or unenforceable. In either case, a license may not be available on commercially reasonable terms, or at all, particularly if such patent is owned or controlled by one of our primary competitors. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee time and resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any license of this nature would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates and we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could significantly harm our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful and could result in a finding that such patents are unenforceable or invalid. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. These types of mechanisms include re-examination, post-grant review,<span style="font-style:italic;">&#160;inter partes</span>&#160;review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g.,&#160;opposition proceedings). These types of proceedings could result in revocation or amendment to our patents such that they no longer cover our product candidates. The outcome for any particular patent following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Defense of these types of claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversely, we may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in re-examination, post-grant review, <span style="font-style:italic;">inter partes</span> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings), or we may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the European Patent Office (the &#8220;EPO&#8221;) or another foreign patent office. Even if successful, the costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, the EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common stock. Any of the foregoing could have a material adverse effect on our business financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our product candidates in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our use of open source software could impose limitations on our ability to commercialize our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our use of open source software could impose limitations on our ability to commercialize our product candidates. Our technology utilizes open source software that contains modules licensed for use from third-party authors under open source licenses. In particular, some of the software that powers TANGO may be provided under license arrangements that allow use of the software for research or other non-commercial purposes. As a result, in the future, as we seek to use our platform in connection with commercially available products, we may be required to license that software under different license terms, which may not be possible on commercially reasonable terms, if at all. If we are unable to license software components on terms that permit its use for commercial purposes, we may be required to replace those software components, which could result in delays, additional cost and additional regulatory approvals. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the software code. Some open source licenses contain requirements that we make available source code for modifications or derivative works we create based upon the type of open source software we use. If we combine our proprietary software with open source software in a certain manner, we could, under certain of the open source licenses, be required to release the source code of our proprietary software to the public. This could allow our competitors to create similar products with lower development effort and time, and ultimately could result in a loss of product sales for us. Although we monitor our use of open source software, the terms of many open source licenses have not been interpreted by U.S. courts, and there is a risk that those licenses could be construed in a manner that could impose unanticipated conditions or restrictions on our ability to commercialize our product candidates. We could be required to seek licenses from third parties in order to continue offering our product candidates, to re-engineer our product candidates or to discontinue the sale of our product candidates in the event re-engineering cannot be accomplished on a timely basis, any of which could materially and adversely affect our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at universities or other biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. Although no misappropriation or improper disclosure claims against us are currently pending, and although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. We may then have to pursue litigation to defend against these claims. If we fail in defending any claims of this nature in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against these types of claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities, and we may not have sufficient financial or other resources to adequately conduct this type of litigation or proceedings. For example, some of our competitors may be able to sustain the costs of this type of litigation or proceedings more effectively than we can because of their substantially greater financial resources. In any case, uncertainties resulting from the initiation and continuation of intellectual property litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The growth of our business may depend in part on our ability to acquire, in-license or use third-party proprietary rights. For example, our product candidates may require specific formulations to work effectively and efficiently, we may develop product candidates containing our compounds and pre-existing pharmaceutical compounds, or we may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our product candidates, any of which could require us to obtain rights to use intellectual property held by third parties. In addition, with respect to any patents we may co-own with third parties, we may require licenses to such co-owners interest to such patents. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. In addition, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. Were that to happen, we may need to cease use of the compositions or methods covered by those third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on those intellectual property rights, which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, which means that our competitors may also receive access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Even if we hold such an option, we may be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. There can be no assurance that we will be able to successfully complete these types of negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to develop or market. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of certain programs and our business financial condition, results of operations and prospects could suffer. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign patent agencies also require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Were a noncompliance event to occur, our competitors might be able to enter the market, which would have a material adverse effect on our business financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Past or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. For example, in March&#160;2013, under the Leahy-Smith America Invents Act (the &#8220;America Invents Act&#8221;) the United States moved from a &#8220;first to invent&#8221; to a &#8220;first-to-file&#8221; patent system. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file&#160;a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO continues to promulgate new regulations and procedures in connection with the America Invents Act and many of the substantive changes to patent law, including the &#8220;first-to-file&#8221; provisions, only became effective in March 2013. In addition, the courts have yet to address many of these provisions and the applicability of the act and new regulations on the specific patents discussed in this filing have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the case, <span style="font-style:italic;">Assoc. for Molecular Pathology v. Myriad Genetics,&#160;Inc.,</span> the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of our owned or in-licensed patents will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Any similar adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after we or our partners commercialize those candidates. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we do not obtain patent term extension for any product candidates we may develop, our business may be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (the &#8220;Hatch-Waxman Amendments&#8221;). The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent per product may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, even if we were to seek a patent term extension, it may not be granted because of, for example, the failure to exercise due diligence during the testing phase or regulatory review process, the failure to apply within applicable deadlines, the failure to apply prior to expiration of relevant patents, or any other failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to a variety of privacy and data security laws, and our failure to comply with them could harm our business. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain a large quantity of sensitive information, including confidential business and patient health information in connection with our preclinical studies, and are subject to laws and regulations governing the privacy and security of such information. In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws, and federal and state consumer protection laws. Each of these laws is subject to varying interpretations and constantly evolving. In May 2018, a new privacy regime, the General Data Protection Regulation (the &#8220;GDPR&#8221;) took effect in the European Economic Area (the &#8220;EEA&#8221;) and the United Kingdom. The GDPR governs the collection, use, disclosure, transfer or other processing of personal data of European and United Kingdom persons. The GDPR continues to form part of law in the United Kingdom with some amendments following Brexit (&#8220;UK GDPR&#8221;), although there is a risk of divergence in the future which may increase our overall data protection compliance cost. Among other things, the GDPR and UK GDPR impose new requirements regarding the security of personal data and notification of data processing obligations to the competent national data processing authorities, changes the lawful bases on which personal data can be processed, expands the definition of personal data and requires changes to informed consent practices, as well as more detailed notices for clinical trial subjects and investigators. In addition, the GDPR and UK GDPR increase the scrutiny of transfers of personal data from clinical trial sites located in the EEA and the United Kingdom to the United States and other jurisdictions that the European Commission or the United Kingdom do not recognize as having &#8220;adequate&#8221; data protection laws, and imposes substantial fines for breaches and violations (up to the greater of &#8364;20&#160;million or 4% of our consolidated annual worldwide gross revenue). The GDPR and UK GDPR also confer a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR or UK GDPR. Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to employee matters, managing growth and other risks related to our business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of product candidate development and growing our capability to conduct clinical trials. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We must attract and retain highly skilled employees to succeed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan, harm our results of operations and increase our capabilities to successfully commercialize STK-001, STK-002 and our future product candidates. In particular, we believe that our future success is highly dependent upon the contributions of our senior management, including Edward M. Kaye, our Chief Executive Officer, as well as our senior scientists and other members of our senior management team. The loss of services of one or more of these individuals, who all have at-will employment arrangements with us, could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of our product candidates, if approved. The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover and develop product candidates and our business will be limited. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If members of our management and other key personnel in critical functions across our organization are unable to perform their duties or have limited availability due to the COVID-19 pandemic, we may not be able to execute on our business strategy and/or our operations may be negatively impacted. Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes, the underperformance or discontinuation of our clinical stage program, recruitment by competitors or delays in the recruiting and hiring process as a result of the COVID-19 pandemic. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any such personnel will not have a material impact on our financial condition and results of operations.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future acquisitions or strategic alliances could disrupt our business and harm our financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may acquire additional businesses or drugs, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new drugs resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction. The risks we face in connection with acquisitions, include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">diversion of management time and focus from operating our business to addressing acquisition integration challenges&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">coordination of research and development efforts&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">retention of key employees from the acquired company&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">changes in relationships with strategic partners as a result of product acquisitions or strategic positioning resulting from the acquisition&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">cultural challenges associated with integrating employees from the acquired company into our organization&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the need to implement or improve controls, procedures, and policies at a business that prior to the acquisition may have lacked sufficiently effective controls, procedures and policies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">liability for activities of the acquired company before the acquisition, including intellectual property infringement claims, violation of laws, commercial disputes, tax liabilities, and other known liabilities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">unanticipated write-offs or charges&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">litigation or other claims in connection with the acquired company, including claims from terminated employees, customers, former stockholders or other third parties. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our failure to address these risks or other problems encountered in connection with our past or future acquisitions or strategic alliances could cause us to fail to realize the anticipated benefits of these transactions, cause us to incur unanticipated liabilities and harm the business generally. There is also a risk that future acquisitions will result in the incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm our financial condition or results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will become subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. Our operations will involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also may produce hazardous waste products. We generally anticipate contracting with third parties for the disposal of these materials and wastes. We will not be able to eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development, or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unfavorable global economic conditions could adversely affect our business, financial condition, stock price and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the 2008 global financial crisis, could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. As another example, our financial results may be negatively impacted by the recent COVID-19 outbreak. The extent and duration of such impacts remain largely uncertain and dependent on future developments that cannot be accurately predicted at this time, such as the severity and transmission rate of COVID-19, the extent and effectiveness of containment actions taken and the impact of these and other factors on our operations and the global economy in general. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive such difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. Furthermore, our stock price may decline due in part to the volatility of the stock market and any general economic downturn. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We, or our third party service providers, face risks related to health epidemics and other outbreaks, which could significantly disrupt our operations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business could be adversely impacted by the effects of COVID-19 or other epidemics. A public health epidemic, including COVID-19, poses the risk that we or our employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested or mandated by governmental authorities. We currently rely, and may continue to rely, on third-party service providers that are located in locals significantly impacted by COVID-19 and/or who source raw materials, samples, components, or other materials and reports from countries significantly impacted by COVID-19. Consequently, supply of research materials and early research activities are susceptible to factors adversely affecting one or more of our third-party service providers who are located in and/or who source from locations significantly impacted by COVID-19. We may also experience impacts to certain of our suppliers as a result of COVID-19 or other health epidemic or outbreak occurring in one or more of these locations, which may materially and adversely affect our business, financial condition and results of operations. In addition, <span style="color:#000000;">hospitals or other clinical trial sites could also become overwhelmed by COVID-19 and shift resources or attention away from our clinical trials or limit key clinical trial activities, such as clinical trial site monitoring and in-person follow-ups, which may cause delays in our trials or negatively affect enrollment. COVID-19 and mitigation measures may also have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition. The extent to which COVID-19 impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Natural disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, fire, hurricane, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suppliers&#8217; manufacturing facilities, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our internal computer and information systems, or those used by our CROs, CMOs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our development programs. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of appropriate security measures, our internal computer and information systems and those of our current and any future CROs, CMOs and other contractors or consultants may become vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system failure, or accident, and are unaware of any security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of data from completed or future preclinical studies or clinical trials could result in significant delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be significantly delayed. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are increasingly dependent upon technology systems and data to operate our business. In particular, the COVID-19 pandemic has caused us to modify our business practices, including our office-based employees having been primarily working in a hybrid-model fluctuating between work from home and work from office since early September 2021. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). A breakdown, invasion, corruption, destruction or breach of our technology systems, including the cloud technologies that we utilize, and/or unauthorized access to our data and information could subject us to liability or negatively impact the operation of our business. Our technology systems, including the cloud technologies that we utilize, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack. Likewise, data privacy or security breaches by individuals authorized to access our technology systems, including the cloud technologies that we utilize, may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients or other business partners, may be exposed to unauthorized persons or to the public. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks could also include supply chain attacks, which could cause a delay in the manufacturing of our products or products produced for contract manufacturing. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial-of-service, social engineering fraud or other means to threaten data confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. To date, we have not experienced a material compromise of our data or information systems. However, although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the computer systems of various third parties on which we rely, including our CROs, CMOs and other contractors, consultants and law and accounting firms, may sustain damage from computer viruses, unauthorized access, data breaches, phishing attacks, cybercriminals, natural disasters (including hurricanes and earthquakes), terrorism, war and telecommunication and electrical failures. We rely on our third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches. &#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, our increased use of cloud technologies and remote working arrangements could heighten these and other operational risks, and any failure by cloud technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information. Despite the implementation of appropriate security measures, our internal computer and information systems and those of our current and any future CROs, CMOs and other contractors or consultants may become vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system failure, or accident, and are unaware of any security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of data from completed or future preclinical studies or clinical trials could result in significant delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be significantly delayed. While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business, operational or reputational harm to us, or loss of competitive advantage. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees, principal investigators, CROs, CMOs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will face an inherent risk of product liability exposure related to the testing of STK-001, STK-002 and our future product candidates in clinical trials and will face an even greater risk if we commercialize any of our product candidates. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">decreased demand for any product candidates that we may develop&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">injury to our reputation and significant negative media attention&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">withdrawal of clinical trial participants&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">significant time and costs to defend the related litigation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">substantial monetary awards to trial participants or patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">loss of revenue&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the inability to commercialize any product candidates that we may develop. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we currently have product liability insurance that we believe is appropriate for our stage of development, we may need to obtain higher levels prior to clinical development or marketing STK-001, STK-002 or any of our future product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks related to ownership of our common stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The market price of our stock may be volatile, and you could lose all or part of your investment. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading price of our common stock may be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The market price for our common stock may be influenced by many factors, including the other risks described in this section and elsewhere in this report and the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">results of preclinical studies and clinical trials of our product candidates, or those of our competitors or our existing or future collaborators&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the impact of the COVID-19 pandemic on our employees, trials, collaboration partners, suppliers, our results of operations, liquidity and financial condition&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the success of competitive products or technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">introductions and announcements of new products by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing terms&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the success of our efforts to acquire or in-license additional technologies, products or product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">developments concerning any future collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">market conditions in the pharmaceutical and biotechnology sectors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital commitments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our product candidates and products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability or inability to raise additional capital and the terms on which we raise it&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the recruitment or departure of key personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">changes in the structure of healthcare payment systems&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">fluctuations in the valuation of companies perceived by investors to be comparable to us&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">announcement and expectation of additional financing efforts&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">speculation in the press or investment community&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">trading volume of our common stock&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">sales of our common stock by us or our stockholders&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the concentrated ownership of our common stock&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">changes in accounting principles&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">terrorist acts, acts of war or periods of widespread civil unrest&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">natural disasters and other calamities&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">general economic, industry and market conditions. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the stock market in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme price and volume fluctuations that have been often unrelated or disproportionate to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk factors&#8221; section, could have a dramatic and adverse impact on the market price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 entities affiliated with Skorpios Trust beneficially owned 39.14% of the voting power of all outstanding shares of our common stock. As a result, these entities will have considerable influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of such entities may not be the same as or may even conflict with your interests. For example, these entities could potentially delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, Skorpios Trust received its shares from Apple Tree Partners, which previously controlled a majority of the voting power of our common stock. Seth L. Harrison, the chairman of our board of directors, serves as Managing Partner of Apple Tree Partners. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not have any control over the analysts, or the content and opinions included in their reports. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our preclinical studies and clinical trials and results of operations fail to meet the expectations of analysts, our stock price would likely decline. If one or more of such analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause a decline in our stock price or trading volume. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies or smaller reporting companies will make our common stock less attractive to investors. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (i)&#160;not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;), (ii)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (iii)&#160;exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not approved previously. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an emerging growth company until the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">earliest</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of (</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) the last day of the fiscal year (a) in which we have total annual gross revenue of at least $1.07 billion or (b) in which we are deemed to be a large accelerated filer, which </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">means</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the market value of our common stock that is held by non-affiliates exceed</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $700 million as of the prior June 30th, (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period and (iii) December 31, 2024. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our consolidated financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards. Until the date that we are no longer an &#8220;emerging growth company&#8221; or affirmatively and irrevocably opt out of the exemption provided by Section&#160;7(a)(2)(B) of the Securities Act, upon issuance of a new or revised accounting standard that applies to our consolidated financial statements and that has a different effective date for public and private companies, we will disclose the date on which adoption is required for non-emerging growth companies and the date on which we will adopt the recently issued accounting standard. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates was less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company as long as either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation and our restated bylaws contain provisions that could delay or prevent a change in control of our company. These provisions could also make it difficult for stockholders to elect directors who are not nominated by current members of our board of directors or take other corporate actions, including effecting changes in our management. These provisions: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">establish a classified board of directors so that not all members of our board are elected at one time&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">permit only the board of directors to establish the number of directors and fill vacancies on the board&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">eliminate the ability of our stockholders to call special meetings of stockholders&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">prohibit cumulative voting&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The exclusive forum provision in our restated certificate of incorporation may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation, to the fullest extent permitted by law, provides that the Court of Chancery of the State of Delaware is the exclusive forum for: any derivative action or proceeding brought on our behalf&#59; any action asserting a breach of fiduciary duty&#59; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law (the &#8220;DGCL&#8221;), our restated certificate of incorporation, or our restated bylaws&#59; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act, inasmuch as Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rule and regulations thereunder. There is uncertainty as to whether a court would enforce such provision with respect to claims under the Securities Act, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, Section&#160;203 of the DGCL may discourage, delay or prevent a change in control of our company. Section&#160;203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. In April 2020, we amended and restated our restated bylaws to provide that the federal district courts of the United States will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (such provision, a &#8220;Federal Forum Provision&#8221;). Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. In addition, neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability created by the Exchange Act. Accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder must be brought in federal court. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum Provision. These provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market, or Nasdaq, and other applicable securities rules and regulations impose various requirements on public companies, including </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. Moreover, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors&#8217; views of us and, as a result, the value of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <span style="color:#000000;font-family:Calibri;">previously were not required to independently comply with Section&#160;404(a) of the Sarbanes-Oxley Act. Section&#160;404(a) of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting, starting with the second annual report that we file with the SEC. We were required to meet these standards in the course of preparing our financial statements as of and for the year ended December 31, 2021, and our management is required to report on the effectiveness of our internal control over financial reporting for such year and annually thereafter. Additionally, once we are no longer an &#8220;emerging growth company,&#8221; our independent registered public accounting firm will be required pursuant to Section 404(b) of the Sarbanes-Oxley Act to attest to the effectiveness of our internal control over financial reporting on an annual basis. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing, and possible remediation.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To achieve compliance with Section&#160;404(b) within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&#160;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on Nasdaq. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we grow, we expect to hire additional personnel and may utilize external temporary resources to implement, document and modify policies and procedures to maintain effective internal controls. However, it is possible that we may identify deficiencies and weaknesses in our internal controls. If material weaknesses or deficiencies in our internal controls exist and go undetected or unremediated, our consolidated financial statements could contain material misstatements that, when discovered in the future, could cause us to fail to meet our future reporting obligations and cause the price of our common stock to decline. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to securities litigation, which is expensive and could divert management attention. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 1B. Unresolve</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">d Staff Comments. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_PROPERTIES">Item 2. Properties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently occupy approximately 23,000 square feet of office and laboratory space in Bedford, Massachusetts, under a lease that expires December 31, 2024. In addition, this lease provides for the lease of an additional 15,000 square feet of rentable space beginning in April 2022 and ending on December 31, 2024. We also occupy 4,842 square feet of office space in Cambridge, Massachusetts under a lease that expires on April 30, 2025. We believe that our facilities suffice to meet our current and near-term needs and that suitable additional space will be available as and when needed.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_LEGAL_PROCEEDINGS">Item 3. Legal Proceedings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputation harm, and other factors. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_MINE_SAFETY_DISCLOSURES">Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART II</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_MARKET_FOR_REGISTRANTS_COMMON_EQU">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unregistered Sales of Equity Securities and Use of Proceeds.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Unregistered Sales of Equity Securities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Proceeds</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 24, 2020, we completed an underwritten public offering, of our common stock and issued and sold 2,875,000 shares of common stock at a public offering price of $39.00 per share, which included 375,000 shares sold upon full exercise of the underwriters&#8217; option to purchase additional shares of common stock resulting in net proceeds of $104.9 million after deducting underwriting discounts and commissions and estimated offering expenses.&#160;&#160; <span style="color:#000000;">J.P. Morgan Securities LLC, Cowen and Company, LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers of the offering and as representatives of the underwriters. None of the expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to their associates, or to our affiliates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders of Record</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, there were 9 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividends</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not declared or paid any cash dividends on our common stock since our inception. We do not plan to pay dividends in the foreseeable future. We currently intend to retain all available funds and any future earnings, if any, for use in the operation of our business. Any future determination to declare cash dividends will be made at the discretion of our board of directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors may deem relevant, and subject to the restrictions contained in future financing instruments. Consequently, stockholders will need to sell shares of our common stock to realize a return on their investment, if any.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_RESERVED">Item 6. [Reserved]</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and consolidated results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should carefully read the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. <span style="Background-color:#FFFFFF;">Using our proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, we are developing antisense oligonucleotides (&#8220;ASOs&#8221;) to selectively restore protein levels. Our first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is characterized by frequent, prolonged and refractory seizures beginning within the first year of life. The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with it.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of approximately 50% of normal protein levels leads to disease. We are also pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (&#8220;ADOA&#8221;), the most common inherited optic nerve disorder. Our initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting our belief in the broad potential for our proprietary approach.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TANGO is based on the pioneering work conducted on pre-mRNA splicing and ASOs in the laboratory of one of our co-founders, Adrian R. Krainer, Ph.D., of Cold Spring Harbor Laboratory (&#8220;CSHL&#8221;) in New York. Inspired by the clinical success of SPINRAZA (nusinersen), an ASO medicine for the treatment of spinal muscular atrophy that was co-invented by Professor Krainer, our company was founded to develop a general antisense approach to upregulate protein expression. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in June 2014. In July 2015 and April 2016, we entered into worldwide license agreements with Cold Spring Harbor Laboratory (&#8220;CSHL&#8221;), and the University of Southampton, respectively, with respect to certain licensed patents and applications relating to TANGO. TANGO exploits non-productive splicing events to effect targeted enhancement of protein expression. Since our inception through June 21, 2019, our operations had been financed primarily from the sale of convertible notes payable and our convertible preferred stock. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 21, 2019, we completed an initial public offering (&#8220;IPO&#8221;), of our common stock and issued and sold 9,074,776 shares of common stock at a public offering price of $18.00 per share, which included 1,183,666 shares sold upon full exercise of the underwriters&#8217; option to purchase additional shares of common stock resulting in net proceeds of $151.9 million after deducting underwriting discounts and commissions but before deducting offering costs of approximately $2.5 million.&#160;&#160; </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company filed a universal Shelf Registration statement on Form S-3 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission (the &#8220;SEC&#8221;). The Registration Statement was declared effective by the SEC on July 20, 2020,&#160;&#160;and contains two prospectuses: a base prospectus, which covers the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $400,000,000 of our common stock, preferred stock, debt securities, warrants to purchase our common stock, preferred stock or debt securities, subscription rights to purchase our common stock, preferred stock or debt securities and/or units consisting of some or all of these securities&#59; and a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $150,000,000 of our common stock that may be issued and sold under a Controlled Equity Offering Sales Agreement (&#8220;Sales Agreement&#8221;). The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The $150,000,000 of common stock that may be offered, issued and sold under the sales agreement prospectus is included in the $400,000,000 of securities that may be offered, issued and sold by the Company under the base prospectus. As of December 31, 2021, the Company had not issued any securities in connection with the Sales Agreement. We may terminate this at-the-market program at any time, pursuant to its terms.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 24, 2020, we completed an underwritten public offering, of our common stock and issued and sold 2,875,000 shares of common stock at a public offering price of $39.00 per share, which included 375,000 shares sold upon full exercise of the underwriters&#8217; option to purchase additional shares of common stock resulting in net proceeds of $104.9 million after deducting underwriting discounts and commissions and estimated offering expenses.&#160;&#160; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and December 31, 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we had $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220.4</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million and $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287.5</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, respectively, in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cash, cash equivalents, marketable securities, and restricted cash.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, we have had operating losses, the majority of which are attributable to research and development activities. Our net losses were $85.8 million and $52.2 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $196.1 million and as of December 31, 2020, we had an accumulated deficit of $110.3 million.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. In particular, we expect our expenses and losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products, as well as hire additional personnel, develop commercial infrastructure, pay fees to outside consultants, lawyers and accountants, and incur increased costs associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC requirements, insurance and investor relations costs. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. &#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon our current operating plan, we believe that our existing cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2021, <span style="color:#000000;">together with the proceeds from the $60 million upfront from Acadia, discussed further below, and the proceeds since December 31, 2021 from the Sales Agreement of $7.5 million, </span>will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2024. To date, we have not had any products approved for sale and have not generated any product sales. We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License and Collaboration Agreement with Acadia Pharmaceuticals Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, we entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. (&#8220;Acadia&#8221;) for the discovery, development and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The agreement focuses on the targets SYNGAP1, MECP2 (Rett syndrome), and an undisclosed neurodevelopmental target of mutual interest. In connection with each target, we will collaborate with Acadia to identify potential treatments for further development and commercialization as licensed products. With respect to SYNGAP1, we have agreed with Acadia to co-develop and co-commercialize licensed products for such target globally, and in connection therewith we granted to Acadia worldwide, co-exclusive (with us) licenses for such licensed products. With respect to MECP2 and the neurodevelopmental target, we granted to Acadia worldwide, exclusive licenses to develop and commercialize licensed products for such targets. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the agreement, we received an upfront payment of $60 million from Acadia. Acadia agreed to fund the research to identify potential licensed products for MECP2 and the neurodevelopmental target, and we will equally fund with Acadia the research to identify potential licensed products for SYNGAP1. We are eligible to receive up to $907,500,000 in potential total milestone payments based upon the achievement of certain development, regulatory, first commercial sales and sales milestone events across the programs for the three targets, assuming each milestone were achieved at least once. With respect to licensed products for MECP2 and the neurodevelopmental target, we are also eligible to receive tiered royalties at percentages ranging from the mid-single digits to the mid-teens on future net sales by Acadia of licensed products worldwide. Royalties payable under the agreement are subject to standard royalty reductions. For SYNGAP1 licensed products that we are co-developing and co-commercializing, we will be responsible for 50% of the development and commercialization costs and will receive 50% of the profits from global commercialization.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Business Update Regarding COVID-19</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current COVID-19 pandemic, including variants thereof, continues to present a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as the U.S. economy and financial markets. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, liquidity and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including the timing and effectiveness of global efforts to roll out vaccines, new information that may emerge concerning COVID-19 and COVID-19 variants, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, our third party contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations (&#8220;CMOs&#8221;), and other third party vendors have been able to continue to provide services and supply reagents, materials, and products and currently do not anticipate any significant disruption in services or interruptions in supply. We have pursued mitigation strategies to keep key research activities on track. Our third-party CMOs continue to operate their manufacturing facilities at or near normal levels. While we currently do not anticipate any significant interruptions in our manufacturing processes, it is possible that the COVID-19 pandemic and response efforts may have an impact in the future on our third-party suppliers and CMO&#8217;s ability to manufacture reagents, materials, or products that we need to use in our research and clinical trial. However, we are continuing to assess the potential impact of the COVID-19 pandemic on our business and operations, including our expenses, our observational study, our clinical trials, and our ability to hire and retain employees.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to continue our clinical trials and our observational study may be adversely affected, directly or indirectly, by the COVID-19 pandemic. Currently we are monitoring patient enrollment and participation in our clinical trials and our observational study, including the duration and degree to which we may see declines in enrollment, delays in conducting in-person follow-ups, and disruptions in our ability to monitor patients due to hospitals closing sites or diverting the resources that are necessary to conduct our clinical trials and our observational study. While we continue to enroll and dose patients in our clinical trials at sites across the United States and the United Kingdom, we take into consideration that COVID-19 precautions may directly or indirectly impact the timeline for some of our clinical trial activities due to hospitals closing sites and/or diverting the resources that are necessary to conduct clinical trials. We are pursuing approaches to help mitigate the impact to our clinical trials. Currently we have not experienced any significant delays in our clinical trials due to COVID-19.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has caused us to modify our business practices including but not limited to curtailing or modifying employee travel, moving to partial remote work, and minimizing some physical participation in meetings, events and conferences. We continue to monitor our operations and applicable governmental recommendations, and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees, patients and business partners. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our office-based employees had been primarily working from home from early March 2020 through early September 2021. Since then, our office-based staff have been working in a hybrid-model fluctuating between work from home and work from the office. Throughout the pandemic, we continue to ensure that essential staffing levels in our operations remain in place, including maintaining key personnel in our laboratories</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional information on the various risks posed by the COVID-19 pandemic, please read Item 1A. Risk Factors included in this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial operations overview </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently do not have any products approved for sale and have not generated any revenue since inception. If we are able to successfully develop, receive regulatory approval for and commercialize any of our current or future product candidates alone or in collaboration with third parties, we may generate revenue from the sales of these product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain operating expenses related to the prior period have been restated to conform to current period presentation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and development </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for the development of our discovery work and preclinical programs, which include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">personnel costs, which include salaries, benefits and stock-based compensation expense&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenses incurred under agreements with consultants, third-party contract organizations that conduct research and development activities on our behalf, costs related to production of preclinical material and laboratory and vendor expenses related to the execution of preclinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">scientific consulting, collaboration and licensing fees&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">laboratory supplies&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">facilities costs, depreciation and other expenses related to internal research and development activities. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use our personnel and infrastructure resources across multiple research and development programs directed toward identifying and developing product candidates. Our direct research and development expenses are tracked on a program-by-program basis from the point a program becomes a clinical candidate for us and consists primarily of external costs, such as fees paid to consultants, central laboratories and contractors in connection with our preclinical activities. We do not allocate employee costs, costs associated with our technology or facility expenses, including depreciation or other indirect costs, to specific programs because these costs are currently deployed across multiple product development programs and, as such, are not separately classified. We use internal resources to manage our development activities and our employees work across multiple development programs and, therefore, we do not track their costs by program. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes our research and development expenses incurred by development program: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STK-001</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,778</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,055</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STK-002</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,436</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">414</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-program specific and unallocated research</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,954</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,728</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,168</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,197</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our expenses will increase substantially in connection with our planned discovery work, preclinical and clinical development activities in the near term and our planned clinical trials in the future. At this time, we cannot reasonably estimate the costs for completing the preclinical and clinical development of any of our other product candidates. We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in manufacturing, as our programs advance into later stages of development and we conduct clinical trials. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration and completion costs of the current or future preclinical studies and clinical trials or if, when, or to what extent we will generate revenues from the commercialization and sale of our product candidates. We may never succeed in achieving regulatory approval for our product candidates. The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">successful completion of preclinical studies and investigational new drug-enabling studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">successful enrollment in, and completion of, clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">receipt of regulatory approvals from applicable regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">furthering our commercial manufacturing capabilities and arrangements with third-party manufacturers&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining and maintaining patent and trade secret protection and&#160;non-patent&#160;exclusivity&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">effectively competing with other therapies and treatment options&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a continued acceptable safety profile following approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">enforcing and defending intellectual property and proprietary rights and claims&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">achieving desirable medicinal properties for the intended indications. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these factors could mean a significant change in the costs and timing associated with the development of our current and future preclinical and clinical product candidates. For example, if the FDA, or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or clinical trials, we could be required to expend significant additional financial resources and time on the completion of preclinical and clinical development. We expect our research and development expenses to increase for the foreseeable future as we continue the development of product candidates. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and administrative expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of personnel costs, costs related to maintenance and filing of intellectual property, expenses for outside professional services, including legal, human resources, information technology, audit and accounting services, and facilities and other expenses. Personnel costs consist of salaries, benefits and stock-based compensation expense. We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, increased costs of operating as a public company and the potential commercialization of our product candidates. These increases are anticipated to include increased costs related to the hiring of additional personnel, developing commercial infrastructure, fees to outside consultants, lawyers and accountants, and increased costs associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC requirements, insurance and investor relations costs. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other income (expense) </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The decrease in our other income (expense) for the year ended December 31, 2021 as compared to the year ended December&#160;31, 2020 reflects decreased interest income due to overall decreased market interest rates as well as a decreased cash and cash equivalents balance.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of operations for the years ended </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">and 2020</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth our results of operations: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated statements of operations and</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; comprehensive loss:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,168</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,197</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,897</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,847</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,065</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,044</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86,065</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,044</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income (expense), net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">260</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,805</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,243</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share&#8212;basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.34</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.56</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding&#8212;basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,739,269</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,488,456</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,805</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,243</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(168</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(168</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,973</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,243</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and development expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $54.2&#160;million for the year ended December 31, 2021 as compared to $32.2&#160;million for the year ended December&#160;31, 2020, an increase of $22.0&#160;million. The table below summarizes our research and development expenses: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STK-001</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,778</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,055</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STK-002</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,436</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">414</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel-related expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,603</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,140</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party services</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,675</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,273</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scientific consulting</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">539</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities and other research and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,137</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,421</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,168</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,197</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increases in research and development expenses were primarily attributable to the increase of $11.2 million in personnel-related expenses, stock compensation expense and facilities costs resulting primarily from increased growth in our research and development personnel.&#160;&#160;Increases of $10.8 million in our STK-001 and STK-002 programs were comprised primarily of third party services and scientific consulting fees.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and administrative expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $31.9&#160;million for the year ended December 31, 2021 as compared to $20.8&#160;million for the year ended December&#160;31, 2020, an increase of $11.1&#160;million. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increases in general and administrative expenses were primarily attributable to an increase of </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million in personnel costs </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resulting from an increase in headcount </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compensation expense resulting from a higher stock price at the time that the annual </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">options </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were granted</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an increase of $</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D&#38;O </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nsurance</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> expense </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">due to increased premiums</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an increase of $0.</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consulting fees,</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and an increase of $</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6 </span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million in</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> third-party services to support our in-house personnel in various aspects of developing and supporting the business including human resources, information technology, audit, tax, public relations, communications and other general and administrative activities</span><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other income (expense) </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The decrease in our other income (expense) for the year ended December 31, 2021 as compared to the year ended December&#160;31, 2020 reflects decreased interest income due to overall decreased market interest rates as well as a decreased cash and cash equivalents balance.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and capital resources</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception through December 31, 2021, our operations have been financed by net proceeds of $385.3&#160;million from the sale of convertible notes payable and our convertible preferred stock as well as our IPO and follow-on offering. As of December 31, 2021, we had $220.4&#160;million in cash, cash equivalents, marketable securities, and restricted cash. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred losses since our inception in June 2014 and, as of December 31, 2021 and 2020, we had accumulated deficits of $196.1&#160;million and $110.3 million, respectively. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, costs relating to the&#160;build-out&#160;of our headquarters and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon our current operating plan, we believe that our existing cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2021, <span style="color:#000000;">together with the $60 million upfront from Acadia and the proceeds since December 31, 2021 from the Sales Agreement of $7.5 million, </span>will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or&#160;in-license&#160;other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope, progress, results and costs of researching and developing our lead product candidates or any future product candidates, and conducting nonclinical studies and clinical trials&#59; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:'Times New Roman';"></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the timing of, and the costs involved in, obtaining regulatory approvals or clearances for our lead product candidates or any future product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the number and characteristics of any additional product candidates we develop or acquire&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the timing of any cash milestone payments if we successfully achieve certain predetermined milestones&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the cost of manufacturing our lead product candidates or any future product candidates and any products we successfully commercialize, including costs associated with&#160;building-out&#160;our manufacturing capabilities&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the expenses needed to attract and retain skilled personnel&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs associated with being a public company&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the timing, receipt and amount of sales of any future approved or cleared products, if any. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development activities. We currently have no credit facility or committed sources of capital. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash flows </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,907</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,221</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76,426</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,050</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,284</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,108</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(142,049</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,837</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating activities </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, cash used in operating activities was $66.9&#160;million and was attributable to a net loss of $85.8&#160;million partially offset by a net change of $1.3 million in our operating assets and liabilities, $0.1 million due to amortization and accretion of marketable securities, and by&#160;non-cash&#160;charges of $17.4&#160;million for share-based compensation and depreciation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, cash used in operating activities was $42.2&#160;million and was attributable to a net loss of $52.2&#160;million partially offset by a net change of $3.4 million in our operating assets and liabilities, and by&#160;non-cash&#160;charges of $6.7&#160;million for share-based compensation and depreciation.  </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investing activities </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our investing activities during the year ended December 31, 2021 have consisted of purchases of property and equipment and net purchases of marketable securities. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our investing activities during the year ended December 31, 2020 consisted principally of purchases of property and equipment.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financing activities </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financing activities during the year ended December 31, 2021 included $0.8 million in proceeds from the issuance of common stock upon exercise of stock options and $0.5 million in proceeds from our Employee Stock Purchase Plan. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financing activities during the year ended December 31, 2020 primarily included net proceeds of $104.9 million attributed to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an underwritten public offering of our common stock, $2.8 million in proceeds from the issuance of common stock upon exercise of stock options, and $0.4 million in proceeds from our Employee Stock Purchase Plan. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual obligations and commitments </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our contractual obligations as of December 31, 2021 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments Due by Period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less Than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 Year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 to 3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4 to 5</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5 Years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,437</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,124</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,140</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,437</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,124</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,140</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, we entered into an agreement to lease approximately 23,000 square feet of space for a term of three years. Lease terms are triple net lease commencing at $0.9&#160;million per year, then with 3% annual base rent increases plus operating expenses, real estate taxes, utilities and janitorial fees. The lease commencement date was December&#160;10, 2018. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, we entered into an agreement to extend the initial term of the 23,000 square foot lease for a period of three years ending December 31, 2024.&#160;&#160;In addition, this agreement provides for the lease of an additional 15,000 square feet of rentable space beginning in April 2022 and ending on December 31, 2024. Initial monthly lease payments are approximately $0.1 million with respect to the 23,000 square feet space, and $0.1 million with respect to the 15,000 square feet space, and in each case subject to annual rent escalations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, we entered into an agreement to lease 2,485 square feet of space for a term of three years. The lease includes one renewal option for an additional two years. Lease terms commence at $0.2&#160;million per year, with 2.5% annual base rent increases plus operating expenses, real estate taxes, utilities and janitorial fees. We occupied this space in May 2019.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2021, we amended the agreement to extend the initial term of the 2,485 square foot lease for a period of three years ending April 30, 2025. In addition, the amendment provided for the lease of an additional 2,357 square feet of rentable space beginning on July 6, 2021 and ending on April 30, 2025. The amended lease provides us with the option to extend the term of the lease for an additional two years with a base annual rent increase of 3%.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Commitments </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commitments primarily consist of obligations under our agreements with CSHL and the University of Southampton. As of December 31, 2021, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales. For additional information regarding our agreements, see &#8220;Business License and research agreements.&#8221; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we have entered into agreements with third-party contract manufacturers for the manufacture and processing of certain of our product candidates for preclinical testing purposes, and we have entered and will enter into other contracts in the normal course of business with contract research organizations for clinical trials and other vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-balance&#160;sheet arrangements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the periods presented, we did not have, nor do we currently have, any&#160;off-balance&#160;sheet arrangements as defined under SEC rules. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical accounting policies and significant judgments and estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are the most critical in order to fully understand and evaluate our financial condition and results of operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued research and development expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing financial statements, we are required to estimate and accrue research and development expenses. This process involves the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">estimating and accruing expenses in our consolidated financial statements as of each balance sheet date based on facts and circumstances known to us at the time&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">periodically confirming the accuracy of our estimates with selected service providers and making adjustments, if necessary. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Examples of estimated research and development expenses that we accrue include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fees paid to investigative sites in connection with clinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fees paid to contract manufacturing organizations in connection with non-clinical development, preclinical research, and the production of clinical study materials&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">professional service fees for consulting and related services. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We base our expense accruals related to non-clinical development, preclinical studies, and clinical trials on our estimates of the services received and efforts expended pursuant to contracts with organizations/consultants that conduct and manage clinical studies on our behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts may depend on many factors, such as the successful enrollment of patients, site initiation, and the completion of clinical study milestones.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our service providers invoice us monthly in arrears for services performed. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If we do not identify costs that we have begun to incur, or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates. To date, we have not experienced significant changes in our estimates of accrued research and development expenses after a reporting period. However, due to the nature of estimates, we cannot assure you that we will not make changes to our estimates in the future as we become aware of additional information about the status or conduct of our clinical trials and other research activities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-based compensation </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Options</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize compensation costs related to share-based awards granted to employees and directors, including stock options, based on the estimated fair value of the awards on the date of grant. We estimate the grant date fair value, and the resulting stock-based compensation, using the Black-Scholes option-pricing model. The grant date fair value of the stock-based awards is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option-pricing model requires the use of subjective assumptions to determine the fair value of stock-based awards. These assumptions include: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Fair value of common stock</span><span style="color:#000000;">&#8212;Historically, for all periods prior to our initial public offering, the fair value of the shares of common stock underlying our share-based awards was estimated on each grant date by our board of directors. To determine the fair value of our common stock underlying option grants, our board of directors considered, among other things, valuations of our common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide, </span><span style="font-style:italic;color:#000000;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="color:#000000;">, or the </span><span style="font-style:italic;color:#000000;">Practice Aid</span><span style="color:#000000;">. Since becoming a public company we have used our stock price to determine fair value of our common stock.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Expected term</span><span style="color:#000000;">&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the expected term to be the midpoint between the vesting date and the contractual life of the stock-based awards. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Expected volatility</span><span style="color:#000000;">&#8212; We completed our IPO in June 2019 and accordingly, we lack sufficient company-specific historical and implied volatility information for our shares traded in the public markets. Therefore, we estimate our expected share price volatility based on a blend of our historical volatility and the historical volatility of publicly traded peer companies and expect to continue to do so until such time as we have adequate historical data regarding the volatility of our own traded share price. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Expected term</span><span style="color:#000000;">&#8212; The expected term of our stock options has been determined utilizing the "simplified" method for awards.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Risk-free interest rate</span><span style="color:#000000;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Expected dividend</span><span style="color:#000000;">&#8212;We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the weighted-average assumptions used to estimate the fair value of share-based awards granted: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.78-1.51%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.58%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.38-1.48%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5-6.25 years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5-6.25 years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70-73%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will continue to use judgment in evaluating the assumptions utilized for our share-based compensation expense calculations on a prospective basis. In addition to the assumptions used in the Black-Scholes option-pricing model, the amount of stock-based compensation expense we recognize in our consolidated financial statements includes actual stock option forfeitures. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Information </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Operating Loss Carryforwards </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, we had federal net operating loss carryforwards of $191.1 million and $116.9 million, respectively, which may be available to reduce future taxable income, and expire at various dates beginning in 2034, for those net operating loss carryforwards generated prior to 2018. Net operating losses generated in 2018 and beyond have no expiration. As of December 31, 2021 and 2020, we had state net operating loss carry forwards of $191.4 million and $118.8 million, respectively, which may be available to reduce future taxable income and expire at various dates beginning in 2034. In addition, at December 31, 2021 and 2020, we had federal research and development tax credit carryforwards of $5.4 million and $2.0 million, respectively, and state research and development tax credit carry forwards of $3.0 million and $1.0 million, respectively. Both federal and state research and development tax credit carry forwards may be available to reduce future tax liabilities and expire at various dates beginning in 2030. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CARES Act temporarily repealed the 80% taxable income limitation for tax years beginning before January 1, 2021. Federal NOL carry forwards generated from 2018 or later and Federal NOL carryforwards to taxable years beginning after December 31, 2020 will be subject to the 80% limitation. Also, under the CARES Act, federal NOLs arising in 2018, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 and 2020 can be carried back 5 years. New legislation or regulation which could affect our tax burden could be enacted by any governmental authority. The Company cannot predict the timing or extent of such tax related developments which could have a negative impact on our financial results. Additionally, the Company uses its best judgment in attempting to quantify and reserve for these tax obligations.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Statement of Accounting Standards Codification (ASC) 740, <span style="font-style:italic;">Accounting for Income Taxes</span>, our management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards. Management has determined that it is more likely than not that we will not recognize the benefits of federal and state deferred tax assets and, as a result, a full valuation allowance of $68.2 million and $37.2 million was established at December 31, 2021 and 2020, respectively. The change in the valuation allowance was an increase of $31.0 million and $19.3 million in 2021 and 2020, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (&#8220;the Code&#8221;) due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. We have not conducted a formal study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If we have experienced a change of control, as defined for purposes of Section 382 and 383 of the Code, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards may be subject to an annual limitation under Section 382 and 383 of the Code, which is determined by first multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We apply ASC 740 related to accounting for uncertainty in income taxes. Our reserves related to income taxes are based on a determination of whether, and how much of, a tax benefit taken by us in our tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. At December 31, 2021, and 2020 we had no unrecognized tax benefits. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as income tax expense in the consolidated statements of operations and comprehensive loss. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company and smaller reporting company status </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart our Business Startups&#160;Act of 2012, or the JOBS Act. Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act until such time as those standards apply to private companies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an emerging growth company until the earliest of (i)&#160;the last day of our first fiscal year (a)&#160;following the fifth anniversary of the completion of our IPO, (b)&#160;in which we have total annual gross revenues of at least $1.07&#160;billion, or (c)&#160;when we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of the prior June 30<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> and (ii)&#160;the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates was less than $700&#160;million and our annual revenue is less than $100&#160;million during the most recently completed fiscal year. We will continue to be a smaller reporting company for so long as either (i)&#160;the market value of our stock held by non-affiliates is less than $250&#160;million or (ii)&#160;our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently issued accounting pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.46%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02, <span style="font-style:italic;">Leases </span>(Topic 842). This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements. The Company adopted Topic 842 on January 1, 2020 using the modified retrospective approach and elected to apply the transition method that allows companies to continue applying guidance under the lease standard in effect at that time in the comparative period financial statements and recognize a cumulative-effect adjustment to the balance sheet on the date of adoption. The Company elected the package of practical expedients to not reassess its prior conclusions about lease identification, lease classification and indirect costs and to not separate lease and non-lease components.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features&#59; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this update do not have an accounting effect. For public business entities, the amendments in Part I of ASU-2017-11 are effective for fiscal years and interim periods within those years beginning after December 15, 2018. For all other entities, the amendments in Part I of this update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. We adopted Part I of this update on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13, &#8220;Fair Value Measurement (Topic 820), Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement&#8221;. This ASU removed the following disclosure requirements: (1) the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy&#59; (2) the policy for timing of transfers between levels&#59; and (3) the valuation processes for Level 3 fair value measurements. Additionally, this update added the following disclosure requirements: (1) the changes in unrealized gains and losses for the period included in other comprehensive income and loss for recurring Level 3 fair value measurements held at the end of the reporting period&#59; (2) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 will be effective for all entities, for fiscal years beginning after December 15, 2019 with early adoption permitted. We adopted this standard on January 1, 2020 and the adoption did not have a material impact on our consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.36%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12,&#160;<span style="font-style:italic;">Income Taxes</span>&#160;<span style="font-style:italic;">(Topic 740): Simplifying the Accounting for Income Taxes.</span>&#160;This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for interim and annual periods beginning after December 15, 2020, and early adoption is permitted. <span style="Background-color:#FFFFFF;">The Company adopted this standard on January 1, 2021 and the adoption of this update did not have a material impact on its consolidated financial statements.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest rate risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risks in the ordinary course, primarily including interest sensitivities. As of December 31, 2021, we had cash, cash equivalents, marketable securities, and restricted cash of $220.4 million and $287.5 million as of December 31, 2021. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. A hypothetical 100 basis point change in interest rates would affect the fair market value of our cash equivalents and marketable securities by approximately $2.2 million. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inflation Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inflation generally affects us by increasing our clinical trial costs. We do not believe that inflation has had a material effect on our business, financial condition or results of operations during the years ended December&#160;31, 2021 or 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">Item 8. Financial Statements and Supplementary Data. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements required to be filed pursuant to this Item 8 are appended to this report. An index of those financial statements is found in Item 15 of Part IV of this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9A_CONTROLS_PROCEDURES">Item 9A. Controls and Procedures. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Evaluation of Disclosure Controls and Procedures </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the supervision and with the participation of our management, including our Chief Financial Officer (Our principal accounting officer) and Chief Executive Officer (Our principal executive officer), we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)) as of December 31, 2021. <span style="color:#000000;">The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </span>Based on our management&#8217;s evaluation (with the participation of our Chief Executive Officer and our Chief Financial Officer), as of the end of the period covered by this report, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.25%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.25%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) of the Exchange Act. Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&#8212;Integrated Framework issued in 2013. Based upon the assessments, management has concluded that as of December 31, 2021 our internal control over financial reporting was effective to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K does not include an attestation report from our independent registered public accounting firm due to a transition period established by the rules of the Securities and Exchange Commission for newly public companies. Additionally, for so long as we remain an &#8220;emerging growth company&#8221; under the JOBS Act or a &#8220;smaller reporting company,&#8221; our independent registered public accounting firm is not required to attest to the effectiveness of our internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inherent Limitations on Effectiveness of Controls</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:6.25%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal control over financial reporting may not prevent or detect all errors and all fraud.&#160;Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9B_OR_INFORMATION">Item 9B. Other Information. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9C_DISCLOSURE_REGARDING_FOREIGN_JUR">Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.46%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART III </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 10 will be included in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission, or SEC, with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a Code of Conduct that applies to all of our officers, directors, and employees, including our principal executive officer, principal financial officer, principal accounting officer, and controller, or persons performing similar functions, which is posted on our website. Our Code of Conduct is a &#8220;code of ethics,&#8221; as defined in Item 406(b) of Regulation S-K. We will make any legally required disclosures regarding amendments to, or waivers of, provisions of our Code of Conduct on our website. The information contained on, or accessible from, our website is not part of this Annual Report on Form 10-K by reference or otherwise.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_11_EXECUTIVE_COMPENSATION">Item 11. Executive Compensation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 11 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 12 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.<span style="color:#000000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 13 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC">Item 14. Principal Accounting Fees and Services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 14 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference<span style="color:#000000;">. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV">PART IV </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">Item 15. Exhibits, Financial Statement Schedules. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The following documents are filed as a part of this Form 10-K:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our consolidated financial statements are listed in the &#8220;Index to Consolidated Financial Statements&#8221; under Part II, Item 8 of this Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financial Statement Schedules</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial statement schedules not listed have been omitted because they are not applicable, or the required information is shown in the consolidated financial statements or notes thereto.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.72%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Exhibits</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:41.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="top" style="width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:5.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:9.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:6.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed/Furnished</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="middle" style="width:9.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;3.1</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1623526/000156459019032126/stok-ex31_114.htm"><span style="text-decoration:underline;">Restated Certificate of Incorporation.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38938</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 14, 2019</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;3.2</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1623526/000156459019032126/stok-ex32_115.htm"><span style="text-decoration:underline;">Restated Bylaws, as amended</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-3</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239801</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 10, 2020</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;4.1</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1623526/000119312519167576/d675029dex41.htm"><span style="text-decoration:underline;">Form of Common Stock Certificate</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231700</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 7, 2019</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;4.2</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1623526/000119312519155301/d675029dex42.htm"><span style="text-decoration:underline;">Amended and Restated Investors&#8217; Rights Agreement, dated October 22, 2018, by and among the Registrant and certain of its stockholders.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231700</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 23, 2019</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;4.3</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001623526/000156459021011760/stok-ex43_1204.htm"><span style="text-decoration:underline;">Description of Common Stock Registered Under Section 12 of the Securities Exchange Act of 1934.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38938</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;10.1</span><span style="font-size:7.5pt;">*</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1623526/000119312519167576/d675029dex101.htm"><span style="text-decoration:underline;">Form of Indemnification Agreement with directors and officers.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231700</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 7, 2019</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;10.2</span><span style="font-size:7.5pt;">*</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1623526/000119312519155301/d675029dex102.htm"><span style="text-decoration:underline;">2014 Equity Incentive Plan, as amended, and forms of award agreements.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231700</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 23, 2019</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;10.3</span><span style="font-size:7.5pt;">*</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1623526/000119312519167576/d675029dex104.htm"><span style="text-decoration:underline;">2019 Equity Incentive Plan, and forms of award agreements.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231700</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 7, 2019</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;10.4</span><span style="font-size:7.5pt;">*</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1623526/000119312519167576/d675029dex105.htm"><span style="text-decoration:underline;">2019 Employee Stock Purchase Plan, and forms of award agreements.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231700</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 7, 2019</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.5*</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001623526/000156459020053586/stok-ex101_200.htm"><span style="text-decoration:underline;">Amended and Restated Executive Employment Agreement, by and between the Registrant and Edward M. Kaye, effective as of October 21, 2020</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38938</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 12, 2020</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.6*</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001623526/000156459020053586/stok-ex102_199.htm"><span style="text-decoration:underline;">Amended and Restated Executive Employment Agreement, by and between the Registrant and Stephen J. Tulipano, effective as of October 21, 2020.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38938</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 12, 2020</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.7*</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1623526/000156459021011760/stok-ex1010_829.htm"><span style="text-decoration:underline;">Amended and Restated Executive Employment Agreement, by and between the Registrant and Barry Ticho, effective as of October 21, 2020.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38938</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.8*</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001623526/000156459020053586/stok-ex104_394.htm"><span style="text-decoration:underline;">Change of Control and Severance Agreement, by and between the Registrant and Edward M. Kaye, effective as of October 21, 2020.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38938</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 12, 2020</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.9*</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001623526/000156459020053586/stok-ex105_196.htm"><span style="text-decoration:underline;">Change of Control and Severance Agreement, by and between the Registrant and Stephen J. Tulipano, effective as of October 21, 2020.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38938</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 12, 2020</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;10.10*</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1623526/000156459021011760/stok-ex107_828.htm"><span style="text-decoration:underline;">Change of Control and Severance Agreement, by and between the Registrant and Barry Ticho, effective as of October 21, 2020.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38938</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:41.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="top" style="width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:5.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:9.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:12.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="top" style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:6.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed/Furnished</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.11</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1623526/000156459021055240/stok-ex101_235.htm"><span style="text-decoration:underline;">Lease Agreement, dated as of September 8, 2021, by and between ARE-MA Region No. 24, LLC and the Registrant.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38938</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 8, 2021</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.12</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1623526/000156459021043072/stok-ex101_165.htm"><span style="text-decoration:underline;">Lease Agreement, by and between MIT 139 Main Street Leasehold LLC, and the Registrant., as amended to date</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38938</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 10, 2021</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:25.65pt;">
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.13</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="stok-ex1013_176.htm"><span style="text-decoration:underline;">Scientific Advisory Board Agreement by and between the Registrant and Adrian Krainer, Ph.D., dated June 1, 2021</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:38.25pt;">
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.14</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001623526/000119312520191098/d13608dex12.htm"><span style="text-decoration:underline;">Controlled Equity Offering Sales Agreement, dated as of July 10, 2020, between the Registrant, Cantor Fitzgerald &#38; Co. and Stifel, Nicolaus &#38; Company, Incorporated.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-3</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239801</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 10, 2020</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">21.1</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1623526/000119312519155301/d675029dex211.htm"><span style="text-decoration:underline;">Subsidiary</span><span style="text-decoration:underline;"> of the Registrant.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231700</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 23, 2019</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">23.1</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="stok-ex231_6.htm"><span style="text-decoration:underline;">Consent of independent registered public accounting firm.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">31.1</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="stok-ex311_13.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">31.2</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="stok-ex312_10.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;&#160;&#160;32.1**</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="stok-ex321_9.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:4.35pt;">
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;&#160;&#160;32.2**</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="stok-ex322_8.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;&#160;&#160;101.INS</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document.</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;&#160;&#160;101.SCH</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document.</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;&#160;&#160;101.CAL</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;&#160;&#160;101.DEF</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;&#160;&#160;101.LAB</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;&#160;&#160;&#160;101.PRE</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">104</span></p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</p></td>
<td valign="top" style="width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:9.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:6.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-size:2pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Registrant has omitted certain portions of the exhibit pursuant to Item 601(b)(10) of Regulation S-K.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates a management contract or compensatory plan or arrangement in which directors or executive officers are eligible to participate.&#160;&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;color:#000000;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-K and are not deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_16_FORM_10K_SUMMARY">Item 16. Form 10-K Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized<span style="font-weight:bold;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STOKE THERAPEUTICS, INC. </p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Edward M. Kaye, M.D.</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Edward M. Kaye, M.D.</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">POWER OF ATTORNEY</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.36%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Each person whose individual signature appears below hereby authorizes and appoints Edward M. Kaye and Stephen J. Tulipano, and each of them, with full power of substitution and re-substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span><span style="Background-color:#FFFFFF;margin-left:36pt;"></span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.36%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:12.3pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr style="height:5.45pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:15.05pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Edward M. Kaye</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edward M. Kaye, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:6.15pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:15.05pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Stephen J. Tulipano</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stephen J. Tulipano</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:6.15pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:15.05pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Julie A. Smith</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Julie A. Smith</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:6.15pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:15.05pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Seth L. Harrison</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seth L. Harrison, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:6.15pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:15.05pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Adrian R. Krainer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adrian R. Krainer, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:6.15pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:15.05pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Arthur A. Levin</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arthur A. Levin, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:6.15pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:15.05pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Arthur O. Tzianabos</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arthur O. Tzianabos, Ph.D. </p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:6.15pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:15.05pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jennifer C. Burstein</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:17.65pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jennifer C. Burstein</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:5.5pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4pt;">&#160;</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Garry E. Menzel</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:15.05pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Garry E. Menzel</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">STOKE THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="middle" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:7%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Report of independent registered public accounting firm</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
</tr>
<tr>
<td valign="middle" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Consolidated balance sheets</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="middle" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><span style="text-decoration:underline;">Consolidated statements of operations and comprehensive loss</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="middle" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"><span style="text-decoration:underline;">Consolidated statements of stockholders&#8217; equity </span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="middle" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Consolidated statements of cash flows</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="middle" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:underline;">Notes to consolidated financial statements</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">Report of independent registered public accounting firm </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and Board of Directors </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stoke Therapeutics, Inc.: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Opinion on the Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Stoke Therapeutics, Inc. and subsidiary (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years then ended, in conformity with U.S. generally accepted accounting principles.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stoke Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS">Consolidated balance sheets </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">144,895</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">287,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">74,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred financing costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="C_0001623526_20211231" decimals="-3" scale="3">117</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="C_0001623526_20201231" decimals="-3" scale="3">181</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:InterestReceivableCurrent" contextRef="C_0001623526_20211231" decimals="-3" scale="3">132</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:InterestReceivableCurrent" contextRef="C_0001623526_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:AssetsCurrent" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">229,218</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:AssetsCurrent" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">293,930</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001623526_20211231" decimals="-3" scale="3">569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001623526_20201231" decimals="-3" scale="3">205</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,939</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,675</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:Assets" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">238,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:Assets" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">297,925</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,495</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="stok:AccruedAndOtherCurrentLiabilities" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,754</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="stok:AccruedAndOtherCurrentLiabilities" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,930</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,425</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long term liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,949</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_0001623526_20201231" decimals="-3" scale="3">422</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:Liabilities" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,088</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:Liabilities" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,847</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 7)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000066">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000067">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000079" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001623526_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000080" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001623526_20201231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> per share&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000081" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001623526_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000082" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001623526_20201231" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="U_xbrlishares" id="F_000083" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001623526_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000085" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001623526_20211231" decimals="INF" format="ixt:numdotdecimal">36,902,499</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000084" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001623526_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000086" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001623526_20201231" decimals="INF" format="ixt:numdotdecimal">36,577,149</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2021 and 2020, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:CommonStockValue" contextRef="C_0001623526_20211231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:CommonStockValue" contextRef="C_0001623526_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">414,024</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">396,352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001623526_20211231" decimals="-3" sign="-" scale="3">168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001623526_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">196,083</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001623526_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">110,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">217,777</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">286,078</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">238,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">297,925</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stoke Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS">Consolidated statements of operations and comprehensive loss </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,847</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:OperatingExpenses" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">86,065</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:OperatingExpenses" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">86,065</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001623526_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">53,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income (expense), net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0001623526_20210101_20211231" decimals="-3" scale="3">120</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0001623526_20200101_20201231" decimals="-3" scale="3">700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001623526_20210101_20211231" decimals="-3" scale="3">140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001623526_20200101_20201231" decimals="-3" scale="3">101</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001623526_20210101_20211231" decimals="-3" scale="3">260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001623526_20200101_20201231" decimals="-3" scale="3">801</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:NetIncomeLoss" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,805</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:NetIncomeLoss" contextRef="C_0001623526_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share&#8212;basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000103" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001623526_20210101_20211231" decimals="2" sign="-">2.34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000104" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001623526_20200101_20201231" decimals="2" sign="-">1.56</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding&#8212;basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000105" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001623526_20210101_20211231" decimals="0" format="ixt:numdotdecimal">36,739,269</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000106" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001623526_20200101_20201231" decimals="0" format="ixt:numdotdecimal">33,488,456</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:NetIncomeLoss" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,805</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:NetIncomeLoss" contextRef="C_0001623526_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" scale="3">168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" scale="3">168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001623526_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stoke Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU">Consolidated statements of stockholders&#8217; equity </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Other Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000113" name="us-gaap:SharesOutstanding" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">32,861,842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">282,460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">58,035</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">224,428</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000120" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">822,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,843</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,843</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock related to employee stock purchase plan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000123" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">17,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001623526_20200101_20201231" decimals="-3" scale="3">352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon follow-on offering, net of underwriting discounts, commissions, and offering costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000126" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,875,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20200101_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">104,929</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">104,930</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:NetIncomeLoss" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:NetIncomeLoss" contextRef="C_0001623526_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000132" name="us-gaap:SharesOutstanding" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">36,577,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">396,352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">110,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">286,078</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231" decimals="-3" sign="-" scale="3">168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" scale="3">168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,450</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,450</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000141" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">304,857</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" scale="3">777</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001623526_20210101_20211231" decimals="-3" scale="3">777</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock related to employee stock purchase plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000144" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">20,493</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" scale="3">509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001623526_20210101_20211231" decimals="-3" scale="3">509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon follow-on offering, net of underwriting discounts, commissions, and offering costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20210101_20211231" decimals="-3" sign="-" scale="3">64</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20210101_20211231" decimals="-3" sign="-" scale="3">64</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:NetIncomeLoss" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,805</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:NetIncomeLoss" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,805</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000151" name="us-gaap:SharesOutstanding" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">36,902,499</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">414,024</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231" decimals="-3" sign="-" scale="3">168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">196,083</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">217,777</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stoke Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">Consolidated statements of cash flows </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:ProfitLoss" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,805</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:ProfitLoss" contextRef="C_0001623526_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:Depreciation" contextRef="C_0001623526_20210101_20211231" decimals="-3" scale="3">974</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:Depreciation" contextRef="C_0001623526_20200101_20201231" decimals="-3" scale="3">888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization and accretion of marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="stok:AmortizationAndAccretionOfMarketableSecurities" contextRef="C_0001623526_20210101_20211231" decimals="-3" scale="3">143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:ShareBasedCompensation" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,450</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:ShareBasedCompensation" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on disposal of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_0001623526_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reduction in the carrying amount of right of use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="stok:ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,256</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="stok:ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,038</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">66,907</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001623526_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">42,221</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,050</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">87,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">76,426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001623526_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,050</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon public offerings</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,398</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of offering costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001623526_20200101_20201231" decimals="-3" scale="3">306</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001623526_20210101_20211231" decimals="-3" scale="3">777</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,843</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from Employee Stock Purchase Plan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001623526_20210101_20211231" decimals="-3" scale="3">509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001623526_20200101_20201231" decimals="-3" scale="3">352</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred financing costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:PaymentsOfFinancingCosts" contextRef="C_0001623526_20200101_20201231" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,284</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">108,108</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">142,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">64,837</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash&#8212;beginning of year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">287,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001623526_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">222,676</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash&#8212;end of year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">145,464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">287,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental Disclosure of Non-Cash Investing and Financing Activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets recognized in exchange for operating leases under Topic 842</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,081</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment included in accrued expense and accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,267</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001623526_20200101_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs not yet paid</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="stok:DeferredOfferingCostsNotYetPaid" contextRef="C_0001623526_20200101_20201231" decimals="-3" scale="3">162</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stoke Therapeutics, Inc. and subsidiary </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">Notes to consolidated financial statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts) </p><ix:nonNumeric id="F_000202" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true" continuedAt="F_000202_dcnt_a478dbc0-b9da-4544-b55b-71ca00fde891">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the business and basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Organization </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stoke Therapeutics, Inc. (the Company) was founded in June 2014 and was incorporated under the laws of the State of <ix:nonNumeric id="F_000248" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001623526_20210101_20211231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric>. The Company is an early-stage biopharmaceutical company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Shelf Registration</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company filed a universal Shelf Registration statement on Form S-3 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission (the &#8220;SEC&#8221;). The Registration Statement was declared effective by the SEC on July 20, 2020,&#160;&#160;and contains two prospectuses: a base prospectus, which covers the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="stok:MaximumAggregateOfferingPrice" contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokBaseProspectusMember_20200701_20200731" decimals="INF" format="ixt:numdotdecimal">400,000,000</ix:nonFraction> of our common stock, preferred stock, debt securities, warrants to purchase our common stock, preferred stock or debt securities, subscription rights to purchase our common stock, preferred stock or debt securities and/or units consisting of some or all of these securities&#59; and a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="stok:MaximumAggregateOfferingPrice" contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokSalesAgreementProspectusMember_20200701_20200731" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction> of our common stock that may be issued and sold under a Controlled Equity Offering Sales Agreement (&#8220;Sales Agreement&#8221;). The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="stok:MaximumAggregateOfferingPrice" contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokSalesAgreementProspectusMember_20200701_20200731" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction> of common stock that may be offered, issued and sold under the sales agreement prospectus is included in the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="stok:MaximumAggregateOfferingPrice" contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokBaseProspectusMember_20200701_20200731" decimals="INF" format="ixt:numdotdecimal">400,000,000</ix:nonFraction> of securities that may be offered, issued and sold by the Company under the base prospectus. As of December 31, 2021, the Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="stok:SecuritiesIssuedInConnectionWithShelfRegistration" contextRef="C_0001623526_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t issued any securities in connection with the Sales Agreement. (see note 12 for sales of common stock subsequent to year end)</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Follow-on public offering</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 24, 2020, pursuant to a prospectus supplement to the Registration Statement, we completed an underwritten public offering, of our common stock and issued and sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000254" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_stokUnderwrittenPublicOfferingMember_20201123_20201124" decimals="INF" format="ixt:numdotdecimal">2,875,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000255" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_stokUnderwrittenPublicOfferingMember_20201124" decimals="INF">39.00</ix:nonFraction> per share, which included <ix:nonFraction unitRef="U_xbrlishares" id="F_000256" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20201123_20201124" decimals="INF" format="ixt:numdotdecimal">375,000</ix:nonFraction> shares sold upon full exercise of the underwriters&#8217; option to purchase additional shares of common stock resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="stok:ProceedsFromIssuanceUnderwrittenPublicOfferingNet" contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201123_20201124" decimals="-5" scale="6">104.9</ix:nonFraction> million after deducting underwriting discounts and commissions and estimated offering expenses.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Uncertainties </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects that its operating losses and negative cash flows will continue for the foreseeable future. As of the issuance date of its consolidated financial statements for the year ended December 31, 2021, the Company expects that its cash and cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into 2024. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000202_dcnt_a478dbc0-b9da-4544-b55b-71ca00fde891">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company plans to seek additional funding through public or private equity offerings, debt financings, other collaborations, strategic </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alliances</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and licensing arrangements</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (see note 12 for license and collaboration agreement entered</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> January 2022)</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </span></p></ix:continuation><ix:nonNumeric id="F_000203" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true" continuedAt="F_000203_dcnt_2970c540-d26d-469a-b1c2-3879ce73aa38">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of significant accounting policies and recent accounting pronouncements </p><ix:nonNumeric id="F_000214" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of presentation and consolidation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP), and include the accounts of Stoke Therapeutics, Inc. and its wholly-owned subsidiary. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). All intercompany transactions between and among the Company and its&#8217; consolidated subsidiary have been eliminated. </p></ix:nonNumeric><ix:nonNumeric id="F_000215" name="us-gaap:UseOfEstimates" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, expenses and disclosure of contingent assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates. </p></ix:nonNumeric><ix:nonNumeric id="F_000216" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and cash equivalents </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash in checking, sweep and money market accounts. </p></ix:nonNumeric><ix:nonNumeric id="F_000217" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted cash </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2021, restricted cash consisted of money market accounts collateralizing letters of credit issued as security deposits in connection with the Company&#8217;s leases of its corporate facilities. </p><ix:nonNumeric id="F_000232" name="stok:ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reconciles cash and cash equivalents and restricted cash per the consolidated balance sheets to the statement of cash flows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">144,895</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">287,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_0001623526_20211231" decimals="-3" scale="3">569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_0001623526_20201231" decimals="-3" scale="3">205</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">145,464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">287,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000218" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities consist of government securities and obligations, corporate bonds and commercial paper with original maturities of more than 90 days. Investments are classified as available-for-sale and are recorded on the balance sheet at fair value with unrealized gains or losses reported as a separate component of other comprehensive income/(loss). Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date.</p></ix:nonNumeric><ix:nonNumeric id="F_000219" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at an accredited financial institution in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000203_dcnt_2970c540-d26d-469a-b1c2-3879ce73aa38" continuedAt="F_000203_dcnt_818a809e-2b85-41e9-8c01-1751ecc9650d"><ix:nonNumeric id="F_000220" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair value of financial instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC Topic 820, <span style="font-style:italic;">Fair Value Measurement</span> (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC&#160;820 establishes a three-tier value hierarchy that distinguishes between the following: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;Quoted market prices in active markets for identical assets or liabilities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p></ix:nonNumeric><ix:nonNumeric id="F_000221" name="stok:DeferredOfferingCostsPolicyTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred offering costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with&#160;in-process&#160;equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in the consolidated statement of stockholders&#8217; equity as a reduction of additional&#160;paid-in&#160;capital. </p></ix:nonNumeric><ix:nonNumeric id="F_000222" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying consolidated statements of operations and comprehensive loss. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits. </p><ix:nonNumeric id="F_000233" name="stok:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful lives for property and equipment are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer and office equipment</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000264" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001623526_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokComputerAndOfficeEquipmentMember_20210101_20211231" format="ixt-sec:durwordsen" continuedAt="C_247f58a8-9bb2-448f-a5f8-513369fdea42">3</ix:nonNumeric>-<ix:nonNumeric id="F_000265" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokComputerAndOfficeEquipmentMember_20210101_20211231" format="ixt-sec:durwordsen">5<ix:continuation id="C_247f58a8-9bb2-448f-a5f8-513369fdea42"> years</ix:continuation></ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment and Furniture and fixtures</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000266" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001623526_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokLaboratoryEquipmentAndFurnitureAndFixturesMember_20210101_20211231" format="ixt-sec:durwordsen" continuedAt="C_2c5a6a5b-1235-41a0-bb24-3359ccbe7e06">5</ix:nonNumeric>-<ix:nonNumeric id="F_000267" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokLaboratoryEquipmentAndFurnitureAndFixturesMember_20210101_20211231" format="ixt-sec:durwordsen">7<ix:continuation id="C_2c5a6a5b-1235-41a0-bb24-3359ccbe7e06"> years</ix:continuation></ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000268" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231">Lesser of estimated useful life or remaining lease term</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000223" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of long-lived assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the assets may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the assets from the expected future cash flows (undiscounted and without interest expense) of the related operations. If these cash flows are less than the carrying value of such assets, an impairment loss for the difference between the estimated fair value and carrying value is recorded. There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="C_0001623526_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="C_0001623526_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> impairment losses recognized during the years ended December 31, 2021 and 2020. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000203_dcnt_818a809e-2b85-41e9-8c01-1751ecc9650d" continuedAt="F_000203_dcnt_e15f6d24-a2b5-45db-80b5-08004ebf0f7b"><ix:nonNumeric id="F_000224" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, depreciation, third-party license fees, and costs related to third parties engaged to conduct preclinical research development activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions and other companies to conduct research on its behalf. These agreements are generally cancellable. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs. </p></ix:nonNumeric><ix:nonNumeric id="F_000225" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock options </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its stock-based awards granted based on the estimated fair values of the awards and recognizes the compensation for employees and nonemployees over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock-based awards. The Company has elected the practical expedient to use the midpoint between vesting date and the contractual term as the expected term for certain awards with service or performance conditions. Stock-based compensation is recognized using the straight-line method. Forfeitures of unvested stock-based awards are accounted for when they occur. </p></ix:nonNumeric><ix:nonNumeric id="F_000226" name="stok:PatentCostsPolicyTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent costs </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. </p></ix:nonNumeric><ix:nonNumeric id="F_000227" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements. The Company adopted Topic 842 on <ix:nonNumeric id="F_000272" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231" format="ixt:datemonthdayyearen">January 1, 2020</ix:nonNumeric> using the modified retrospective approach and elected to apply the transition method that allows companies to continue applying guidance under the lease standard in effect at that time in the comparative period financial statements and recognize a cumulative-effect adjustment to the balance sheet on the date of adoption. The Company has also elected the package of practical expedients to not reassess its prior conclusions about lease identification, lease classification and indirect costs and to not separate lease and non-lease components.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon adoption of Topic 842 on January 1, 2020, the Company recorded right-of-use assets of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101" decimals="-5" scale="6">2.2</ix:nonFraction> million, operating lease liabilities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101" decimals="-5" scale="6">2.2</ix:nonFraction> million and the elimination of deferred rent of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:DeferredRentCredit" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101" decimals="-4" scale="6">0.03</ix:nonFraction> million. Adoption of the standard did <ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:StockholdersEquity" contextRef="C_0001623526_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t result in the Company recording a cumulative effect adjustment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines whether an arrangement is a lease at inception. The Company accounts for a lease when it has the right to control the leased asset for a period of time while obtaining substantially all of the assets&#8217; economic benefits. The Company determined that it held operating leases for office and laboratory space as of January 1, 2020. Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. The discount rate used to determine the present value of the lease payments is the Company&#8217;s incremental borrowing rate based on the information available at lease inception, as the Company does not have information to determine the rate implicit in the leases. Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments (which include initial direct costs and lease incentives). The expense is included in operating expenses in the consolidated statements of operations and comprehensive loss. The Company&#8217;s lease agreements also contain variable payments, primarily maintenance-related costs, which are expensed as incurred and not included in the measurement of the right-of-use assets and lease liabilities.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000203_dcnt_e15f6d24-a2b5-45db-80b5-08004ebf0f7b" continuedAt="F_000203_dcnt_d6c6707c-a715-4cf6-b61f-ba7935dfdb17"><ix:nonNumeric id="F_000228" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be settled or recovered. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December 31, 2021 and 2020, the Company has recorded a full valuation allowance. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes&#59; however, the Company currently has <ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="C_0001623526_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> interest or penalties related to uncertain income tax benefits. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Tax Cuts and Jobs Act (the TCJA) was enacted on December&#160;22, 2017. The TCJA reduced the U.S. federal corporate tax rate from a top rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000278" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001623526_20170101_20171231" decimals="2" scale="-2">35</ix:nonFraction>% to a flat rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000279" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001623526_20210101_20211231" decimals="2" scale="-2">21</ix:nonFraction>%. The Company continues to monitor for legislative developments, issuance of regulations and technical memorandum to provide further clarification and/or interpretations of the TCJA and will adjust its consolidated financial statements as needed. </p></ix:nonNumeric><ix:nonNumeric id="F_000229" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment and geographic information </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in <ix:nonFraction unitRef="U_stokSegment" id="F_000280" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001623526_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> segment in the United States. The Company&#8217;s chief executive officer, as the chief operating decision-maker, manages and allocates resources to the operations of the Company on a total company basis using consolidated financial information. </p></ix:nonNumeric><ix:nonNumeric id="F_000230" name="stok:EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true" continuedAt="F_000230_dcnt_bc6d1faf-8bb8-47c3-a418-ac2749534f74">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging growth company and smaller reporting company status </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&#160;Act). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act, until such time as those standards apply to private companies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS&#160;Act. As a result, the Company&#8217;s consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will remain an emerging growth company until the earliest of (i)&#160;the last day of its first fiscal year (a)&#160;&#160;in which the Company has total annual gross revenues of at least $1.07&#160;billion or (b)&#160;in which the Company is deemed to be a large accelerated filer, which means the market value of the Company&#8217;s common stock that is held by non-affiliates exceeds $700.0&#160;million as of the prior June 30<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>, (ii)&#160;the date on which the Company has issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period, and (iii) December 31, 2024</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also a &#8220;smaller reporting company,&#8221; meaning that in the event of an initial public offering the market value of its stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to the Company as a result of such offering is less than $700&#160;million and its annual revenue is less than $100&#160;million during the most recently completed fiscal year. The Company may continue to be a smaller reporting company as long as either (i)&#160;the market value of its stock held by non-affiliates is less than $250&#160;million or (ii)&#160;its annual revenue is less than $100 million during the most recently </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000203_dcnt_d6c6707c-a715-4cf6-b61f-ba7935dfdb17" continuedAt="F_000203_dcnt_9764e3b6-cc96-40bc-b041-42f9aa35a01a"><ix:continuation id="F_000230_dcnt_bc6d1faf-8bb8-47c3-a418-ac2749534f74">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">completed fiscal year and the market value of its stock held by non-affiliates is less than $700&#160;million. If the Company is a smaller reporting company at the time it ceases to be an emerging growth company, the Company may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, the Company may choose to present only the two most recent fiscal years of audited financial statements in its Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </span></p></ix:continuation><ix:nonNumeric id="F_000231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true" continuedAt="F_000231_dcnt_b7f65423-f9c9-4e5c-a91f-9a09cb95dc6b">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently issued accounting pronouncements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.46%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, the FASB issued ASU 2017-11, <span style="font-style:italic;">Earnings Per Share</span> (Topic 260), <span style="font-style:italic;">Distinguishing Liabilities from Equity</span> (Topic 480) and <span style="font-style:italic;">Derivatives and Hedging</span> (Topic 815): <span style="font-style:italic;">I. Accounting for Certain Financial Instruments with Down Round Features&#59; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</span>. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, <span style="font-style:italic;">Distinguishing Liabilities from Equity</span>, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this update do not have an accounting effect. For public business entities, the amendments in Part I of ASU-2017-11 are effective for fiscal years and interim periods within those years beginning after December&#160;15, 2018. For all other entities, the amendments in Part I of this update are effective for fiscal years beginning after December&#160;15, 2019, and interim periods within fiscal years beginning after December&#160;15, 2020. We adopted this update on <ix:nonNumeric id="F_000282" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201711Member_20211231" format="ixt:datemonthdayyearen">January 1, 2020</ix:nonNumeric>, and the adoption did not have a material impact on our consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.46%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13,<span style="font-style:italic;">&#160;&#8220;Fair Value Measurement (Topic 820), Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement&#8221;.</span>&#160;This ASU removed the following disclosure requirements: (1)&#160;the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy&#59; (2)&#160;the policy for timing of transfers between levels&#59; and (3)&#160;the valuation processes for Level&#160;3 fair value measurements. Additionally, this update added the following disclosure requirements: (1)&#160;the changes in unrealized gains and losses for the period included in other comprehensive income and loss for recurring Level&#160;3 fair value measurements held at the end of the reporting period&#59; (2)&#160;the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level&#160;3 fair value measurements. ASU&#160;2018-13 is effective for all entities, for fiscal years beginning after December&#160;15, 2019 with early adoption permitted. We adopted this update on <ix:nonNumeric id="F_000285" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20211231" format="ixt:datemonthdayyearen">January 1, 2020</ix:nonNumeric>, and the adoption did not have a material impact on our consolidated financial statements.  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.36%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.36%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12,&#160;<span style="font-style:italic;">Income Taxes</span>&#160;<span style="font-style:italic;">(Topic 740): Simplifying the Accounting for Income Taxes.</span>&#160;This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for interim and annual periods beginning after December 15, 2020, and early adoption is permitted. <span style="Background-color:#FFFFFF;">The Company adopted this standard on <ix:nonNumeric id="F_000288" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231" format="ixt:datemonthdayyearen">January 1, 2021</ix:nonNumeric> and the adoption of this update did not have a material impact on its consolidated financial statements.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000203_dcnt_9764e3b6-cc96-40bc-b041-42f9aa35a01a"><ix:continuation id="F_000231_dcnt_b7f65423-f9c9-4e5c-a91f-9a09cb95dc6b">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000204" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true" continuedAt="F_000204_dcnt_df1dc4af-0d6f-4e7b-b5ff-c22ff5b39807">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Fair value measurements </p><ix:nonNumeric id="F_000234" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">144,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">144,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">144,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">144,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,524</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,524</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US Government debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">74,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">74,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">287,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">287,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">287,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">287,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US Government debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above and in Note 2. The carrying value of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s assets with fair value categorized as Level 1 within the fair value hierarchy include money market funds. Money market funds are publicly traded mutual funds and are presented as cash equivalents on the consolidated balance sheets as of December 30, 2021 and December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its marketable securities at fair value on a recurring basis and classifies those instruments within Level 2 of the fair value hierarchy.<span style="font-size:12pt;"> </span>Marketable securities are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" contextRef="C_0001623526_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" contextRef="C_0001623526_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> transfers to Level&#160;3 in the periods presented. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000204_dcnt_df1dc4af-0d6f-4e7b-b5ff-c22ff5b39807">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000205" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Marketable Securities</p><ix:nonNumeric id="F_000235" name="us-gaap:MarketableSecuritiesTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s marketable securities as of December 31, 2021 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,598</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" scale="3">74</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,524</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US Government debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,998</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" scale="3">94</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">75,083</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001623526_20211231" decimals="-3" scale="3">168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">74,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001623526_20201231" decimals="-3" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> marketable securities as of December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average maturity of the Company&#8217;s marketable securities as of December 31, 2021 ranges from approximately <ix:nonNumeric id="F_000320" name="stok:DebtSecuritiesAvailableForSaleMaturityPeriod" contextRef="C_0001623526_srtRangeAxis_srtMinimumMember_20210101_20211231" format="ixt-sec:duryear">0.2</ix:nonNumeric> years to <ix:nonNumeric id="F_000321" name="stok:DebtSecuritiesAvailableForSaleMaturityPeriod" contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_20210101_20211231" format="ixt-sec:duryear">1.1</ix:nonNumeric> years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" contextRef="C_0001623526_20211231" decimals="-3" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction>t record an allowance for credit losses as of December&#160;31, 2021 related to our marketable securities. Further, given the lack of significant change in the credit risk of these investments, the Company did&#160;not recognize any other-than-temporary impairment losses. </p></ix:nonNumeric><ix:nonNumeric id="F_000206" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Property and equipment, net </p><ix:nonNumeric id="F_000236" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,670</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,936</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231" decimals="-3" scale="3">153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" scale="3">108</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231" decimals="-3" scale="3">263</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" scale="3">210</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20211231" decimals="-3" scale="3">108</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231" decimals="-3" scale="3">108</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,661</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,692</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,675</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="us-gaap:Depreciation" contextRef="C_0001623526_20210101_20211231" decimals="-5" scale="6">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:Depreciation" contextRef="C_0001623526_20200101_20201231" decimals="-5" scale="6">0.9</ix:nonFraction> million&#160;for the years ended December 31, 2021 and 2020, respectively. </p></ix:nonNumeric><ix:nonNumeric id="F_000207" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true" continuedAt="F_000207_dcnt_cedc8c97-6d03-40bc-8493-365e0df08a8e">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Accrued and other current liabilities </p><ix:nonNumeric id="F_000237" name="stok:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued employee compensation costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,383</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,123</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001623526_20211231" decimals="-3" scale="3">523</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001623526_20201231" decimals="-3" scale="3">593</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="stok:AccruedResearchAndDevelopmentCostsCurrent" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,801</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="stok:AccruedResearchAndDevelopmentCostsCurrent" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,689</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,507</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,066</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0001623526_20211231" decimals="-3" scale="3">540</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0001623526_20201231" decimals="-3" scale="3">459</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="stok:AccruedAndOtherCurrentLiabilities" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,754</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="stok:AccruedAndOtherCurrentLiabilities" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,930</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000207_dcnt_cedc8c97-6d03-40bc-8493-365e0df08a8e">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000208" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true" continuedAt="F_000208_dcnt_b343c260-9759-45f3-9118-7870a9040dc8">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.<span style="font-weight:normal;"> </span>Commitments and contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Company entered into an agreement to lease approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000353" name="stok:AreaOfSpaceSubjectToOperatingLease" contextRef="C_0001623526_20180801_20180831" decimals="INF" format="ixt:numdotdecimal">23,000</ix:nonFraction> square feet of space for a term of <ix:nonNumeric id="F_000354" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001623526_20180831" format="ixt-sec:durwordsen">three years</ix:nonNumeric>. Lease terms are triple net lease commencing at $<ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="stok:OperatingLeaseCostPerYear" contextRef="C_0001623526_20180801_20180831" decimals="-5" scale="6">0.9</ix:nonFraction> million per year, then with <ix:nonFraction unitRef="U_xbrlipure" id="F_000356" name="stok:AnnualBaseRentIncreasePercentageForOperatingLease" contextRef="C_0001623526_20180801_20180831" decimals="2" scale="-2">3</ix:nonFraction>% annual base rent increases plus operating expenses, real estate taxes, utilities and janitorial fees. The lease commencement date was <ix:nonNumeric id="F_000357" name="stok:OperatingLeaseCommencementDate" contextRef="C_0001623526_20180801_20180831" format="ixt:datemonthdayyearen">December&#160;10, 2018</ix:nonNumeric>. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, the Company entered into an agreement to extend the initial term of the <ix:nonFraction unitRef="U_utrsqft" id="F_000358" name="stok:AreaOfSpaceSubjectToOperatingLease" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210901_20210930" decimals="INF" format="ixt:numdotdecimal">23,000</ix:nonFraction> square foot lease for a period of <ix:nonNumeric id="F_000359" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210930" format="ixt-sec:durwordsen">three years</ix:nonNumeric> commencing on <ix:nonNumeric id="F_000362" name="stok:OperatingLeaseCommencementDate" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210901_20210930" format="ixt:datemonthdayyearen">December 15, 2021</ix:nonNumeric> and ending <ix:nonNumeric id="F_000363" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210901_20210930" format="ixt:datemonthdayyearen">December 31, 2024</ix:nonNumeric>.&#160;&#160;In addition, this lease provides for the lease of an additional <ix:nonFraction unitRef="U_utrsqft" id="F_000364" name="stok:AreaOfSpaceSubjectToOperatingLease" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyTwoMember_20210901_20210930" decimals="INF" format="ixt:numdotdecimal">15,000</ix:nonFraction> square feet of rentable space beginning in <ix:nonNumeric id="F_000365" name="stok:OperatingLeaseCommencementMonthAndYear" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyTwoMember_20210901_20210930" format="ixt:datemonthyearen">April 2022</ix:nonNumeric> and ending on <ix:nonNumeric id="F_000366" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyTwoMember_20210901_20210930" format="ixt:datemonthdayyearen">December 31, 2024</ix:nonNumeric>. The Company recognized a right-of-use asset and operating lease liability of <span>$<ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210930" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210930" decimals="-5" scale="6">3.5</ix:nonFraction></ix:nonFraction></span> million for the 23,000 square feet.&#160;&#160;As the Company did not have access to the additional 15,000 square feet of space, a right of use asset was <ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyTwoMember_20210930" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyTwoMember_20210930" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t recognized as of December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, the Company entered into an agreement to lease <ix:nonFraction unitRef="U_utrsqft" id="F_000369" name="stok:AreaOfSpaceSubjectToOperatingLease" contextRef="C_0001623526_20181201_20181231" decimals="INF" format="ixt:numdotdecimal">2,485</ix:nonFraction> square feet of space for an initial term of <ix:nonNumeric id="F_000370" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001623526_20181231" format="ixt-sec:durwordsen">three years</ix:nonNumeric>. The lease includes <ix:nonFraction unitRef="U_stokOption" id="F_000371" name="stok:NumberOfRenewalOptionToExtendOperatingLeaseTerms" contextRef="C_0001623526_20181201_20181231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> renewal option for an additional <ix:nonNumeric id="F_000372" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001623526_20181231" format="ixt-sec:durwordsen">two years</ix:nonNumeric>, however, any time after the initial term the landlord may relocate the Company from the premises to a space reasonably comparable in size and utility. As the Company does not have the right to control the use of the identified asset after the initial term, the renewal option was excluded from the lease liability calculation. Lease terms commence at $<ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="stok:OperatingLeaseCostPerYear" contextRef="C_0001623526_20181201_20181231" decimals="-5" scale="6">0.2</ix:nonFraction> million per annum, with <ix:nonFraction unitRef="U_xbrlipure" id="F_000374" name="stok:AnnualBaseRentIncreasePercentageForOperatingLease" contextRef="C_0001623526_20181201_20181231" decimals="3" scale="-2">2.5</ix:nonFraction>% annual base rent increases plus operating expenses, real estate taxes, utilities and janitorial fees. The lease commencement date was <ix:nonNumeric id="F_000375" name="stok:OperatingLeaseCommencementDate" contextRef="C_0001623526_20181201_20181231" format="ixt:datemonthdayyearen">May 1, 2019</ix:nonNumeric>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-size:10pt;">In June 2021, the Company amended the agreement to extend the initial term of the <ix:nonFraction unitRef="U_utrsqft" id="F_000376" name="stok:AreaOfSpaceSubjectToOperatingLease" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630" decimals="INF" format="ixt:numdotdecimal">2,485</ix:nonFraction> square foot lease for a period of <ix:nonNumeric id="F_000377" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210630" format="ixt-sec:durwordsen">three years</ix:nonNumeric> commencing <ix:nonNumeric id="F_000378" name="stok:OperatingLeaseCommencementDate" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630" format="ixt:datemonthdayyearen">May 1, 2022</ix:nonNumeric> and ending <ix:nonNumeric id="F_000379" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630" format="ixt:datemonthdayyearen">April 30, 2025</ix:nonNumeric>. In addition, the amendment provided for the lease of an additional <ix:nonFraction unitRef="U_utrsqft" id="F_000380" name="stok:AreaOfAdditionalRentableSpaceSubjectToOperatingLease" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630" decimals="INF" format="ixt:numdotdecimal">2,357</ix:nonFraction> square feet of rentable space beginning on <ix:nonNumeric id="F_000381" name="stok:AdditionalOperatingLeaseCommencementDate" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630" format="ixt:datemonthdayyearen">July 6, 2021</ix:nonNumeric> and ending on <ix:nonNumeric id="F_000382" name="stok:AdditionalLeaseExpirationDate" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630" format="ixt:datemonthdayyearen">April 30, 2025</ix:nonNumeric>. <ix:nonNumeric id="F_000390" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630">The amended lease provides the Company with the option to extend the term of the lease for an additional <ix:nonNumeric id="F_000383" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210630" format="ixt-sec:durwordsen">two years</ix:nonNumeric>.</ix:nonNumeric> The Company recognized a right-of-use asset and operating lease liabilities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210630" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210630" decimals="-5" scale="6">0.7</ix:nonFraction></ix:nonFraction> million for the extension of the lease to <ix:nonNumeric id="F_000386" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630" format="ixt:datemonthdayyearen">April 30, 2025</ix:nonNumeric> and a right-of-use asset and operating lease liabilities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="stok:AdditionalOperatingLeaseRightOfUseAsset" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210630" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="stok:AdditionalOperatingLeaseLiabilities" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210630" decimals="-5" scale="6">0.8</ix:nonFraction></ix:nonFraction> million for the additional <ix:nonFraction unitRef="U_utrsqft" id="F_000387" name="stok:AreaOfAdditionalRentableSpaceSubjectToOperatingLease" contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630" decimals="INF" format="ixt:numdotdecimal">2,357</ix:nonFraction> square feet of rentable space. </span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000238" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments under non-cancellable leases as of December 31, 2021, including leases entered into where access has yet to be granted, are as follows (in thousands): <span style="font-family:Calibri;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,124</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,532</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,608</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001623526_20211231" decimals="-3" scale="3">173</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,437</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001623526_20211231" decimals="-3" scale="3">462</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000239" name="stok:SummaryOfLeaseBalancesTableTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease balances as of December 31, 2021 and December 31, 2020 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating right-of-use assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,939</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Portion of operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,507</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,066</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current portion of operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,532</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001623526_20201231" decimals="-3" scale="3">80</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="stok:OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,039</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="stok:OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000240" name="stok:SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average remaining lease term and weighted average discount rate of our operating leases as of December 31, 2021 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease term in years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000411">3.1</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average discount rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000412" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001623526_20211231" decimals="4" scale="-2">4.14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Topic 842, lease expense incurred under operating leases was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210101_20211231" decimals="-5" scale="6">1.4</ix:nonFraction> million for the year ended December 31, 2021, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101_20201231" decimals="-5" scale="6">1.1</ix:nonFraction> million for the year ended December 31, 2020.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000208_dcnt_b343c260-9759-45f3-9118-7870a9040dc8" continuedAt="F_000208_dcnt_ecb79f7d-11ce-40c6-ba29-d0b74760e229">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Consulting Agreement </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2014, the Company entered into a consulting agreement with a member of the Company&#8217;s board of directors, who is also an employee of Cold Spring Harbor Laboratory (&#8220;CSHL&#8221;), to provide consulting services related to scientific research related to the development of antisense-based drugs, therapies, diagnostic and research tools, products, services and intellectual property. The Company recognized expenses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="stok:ConsultingServicesExpenses" contextRef="C_0001623526_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20200101_20201231" decimals="-4" scale="6">0.02</ix:nonFraction> million for the year ended December 31, 2020. The initial term of this agreement was <ix:nonNumeric id="F_000416" name="stok:ConsultingServicesAgreementTerm" contextRef="C_0001623526_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20210101_20211231" format="ixt-sec:durwordsen">five years</ix:nonNumeric> and the parties mutually agreed not to extend the consulting agreement in April 2020. &#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Scientific Advisory Board Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, the Company entered into a scientific advisory board agreement with a member of the Company&#8217;s board of directors, who is also an employee of CSHL, to provide scientific advisory services related to the Company&#8217;s Targeted Augmentation of Nuclear Gene Output (&#8220;TANGO&#8221;) antisense oligonucleotide technology and other antisense oligonucleotide technologies, as well as current and future therapeutic targets and programs. Following the expiration of the initial scientific agreement in June 2021, the parties entered into a subsequent scientific board agreement. The Company recognized expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="stok:ScientificAdvisoryServicesExpenses" contextRef="C_0001623526_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20200101_20201231" decimals="-4" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="stok:ScientificAdvisoryServicesExpenses" contextRef="C_0001623526_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20210101_20211231" decimals="-4" scale="6">0.05</ix:nonFraction></ix:nonFraction> million each for the years ended December 31, 2021 and 2020 for such scientific advisory services. The term of this agreement is <ix:nonNumeric id="F_000419" name="stok:ScientificAdvisoryServicesAgreementTerm" contextRef="C_0001623526_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20210101_20211231" format="ixt-sec:durmonth">12</ix:nonNumeric> months.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License and research agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, the Company entered into a worldwide license agreement, or the CSHL Agreement, with CSHL, with respect to TANGO patents. Under the CSHL Agreement, the Company receives an exclusive (except with respect to certain government rights and non-exclusive licenses), worldwide license under certain patents and applications relating to TANGO. The CSHL Agreement obligates the Company to make payments that are contingent upon certain milestones being achieved. The Company is also required to pay royalties, tiered based on the scope of patent coverage for each licensed product, ranging from a low-single digit percentage to a mid-single digit percentage on annual net sales. These royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until the latest of (i)&#160;the expiration of the last valid claim of a CSHL patent covering the applicable licensed product or (ii)&#160;the expiration of any regulatory exclusivity for the applicable licensed product. In addition, if the Company sublicenses the rights under the CSHL Agreement, the Company is required to pay a maximum of <ix:nonFraction unitRef="U_xbrlipure" id="F_000420" name="stok:PercentageOfMaximumRequiredPaymentOfSublicenseRevenue" contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20150701_20150731" decimals="INF" format="ixt-sec:numwordsen" scale="-2">twenty</ix:nonFraction> percent of the sublicense revenue to CSHL, which may be reduced to a mid-teens or a mid-single digit percentage upon achievement of certain clinical milestones for the applicable licensed product. Finally, the Company is required to pay an annual license maintenance fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="stok:AnnualLicenseMaintenanceFee" contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20210101_20211231" decimals="-4" scale="6">0.01</ix:nonFraction> million, which amount is creditable against any owed royalty or milestone payments. The maximum aggregate potential milestone payments payable total approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="stok:MaximumAggregatePotentialMilestonePaymentsPayable" contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20211231" decimals="INF" scale="6">0.9</ix:nonFraction> million. Additionally, certain licenses under the CSHL Agreement require the Company to reimburse CSHL for certain past and ongoing patent related expenses, however there were <ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="stok:ExpensesRelatedToReimbursablePatentCosts" contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="stok:ExpensesRelatedToReimbursablePatentCosts" contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> expenses related to these reimbursable patent costs during the years ended December 31, 2021 and 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, the Company entered into an exclusive, worldwide license agreement with the University of Southampton, or the Southampton Agreement, whereby the Company acquired rights to foundational technologies related to the Company&#8217;s TANGO technology. Under the Southampton Agreement, the Company receives an exclusive, worldwide license under certain licensed patents and applications relating to TANGO. Under the Southampton Agreement, the Company may be obligated to make additional payments that are contingent upon certain milestones being achieved, as well as royalties on future product sales. These royalty obligations survive until the latest of (i)&#160;the expiration of the last valid claim of a licensed patent covering a subject product or (ii)&#160;the expiration of any regulatory exclusivity for the subject product in a country. In addition, if the Company sublicenses its rights under the Southampton Agreement, the Company is required to pay a mid-single digit percentage of the sublicense revenue to the University of Southampton. The maximum aggregate potential milestone payments payable by the Company total approximately <ix:nonFraction unitRef="U_iso4217GBP" id="F_000425" name="stok:MaximumAggregatePotentialMilestonePaymentsPayable" contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20211231" decimals="INF" scale="6">0.4</ix:nonFraction> million pounds sterling (approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="stok:MaximumAggregatePotentialMilestonePaymentsPayable" contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20211231" decimals="INF" scale="6">0.5</ix:nonFraction> million as of December 31, 2021). As of December 31, 2021, and 2020, the Company has recorded <ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="us-gaap:Liabilities" contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:Liabilities" contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> liabilities under the Southampton Agreement. For the year ended December 31, 2021 these expenses were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="stok:ExpensesRelatedToReimbursablePatentCosts" contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20210101_20211231" decimals="-4" scale="6">0.12</ix:nonFraction> million compared to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="stok:ExpensesRelatedToReimbursablePatentCosts" contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20200101_20201231" decimals="-4" scale="6">0.09</ix:nonFraction> million for the year ended December 31, 2020. Additionally, certain licenses under the Southampton Agreement require the Company to reimburse the University of Southampton for certain past and ongoing patent related expenses. (see note 12 for payments to University of Southampton)</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000208_dcnt_ecb79f7d-11ce-40c6-ba29-d0b74760e229">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Litigation </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which it is focused. As of December 31, 2021, the Company had no legal proceedings to which it was a party or to which its property was subject. </p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000209" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true" continuedAt="F_000209_dcnt_a1a17ddf-b812-4f39-835d-4ecbdb10d59d">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Share-Based Compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company&#8217;s board of directors and stockholders approved the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which became effective on June 17, 2019 and replaced the Company&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;). In addition to the shares of common stock reserved for future issuance under the 2014 Plan that were added to the 2019 Plan upon its effective date, the Company initially reserved <ix:nonFraction unitRef="U_xbrlishares" id="F_000431" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEquityIncentivePlanMember_20190630" decimals="INF" format="ixt:numdotdecimal">2,200,000</ix:nonFraction> shares of common stock for issuance under the 2019 Plan. The number of shares reserved for issuance under the Company&#8217;s 2019 Plan will increase automatically on January 1 of each of 2020 through 2029 by the number of shares equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000432" name="stok:PercentageOfIncreaseInReservedCommonShares" contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEquityIncentivePlanMember_20190601_20190630" decimals="2" scale="-2">4</ix:nonFraction>% of the aggregate number of outstanding shares of the Company&#8217;s common stock as of the immediately preceding December 31, or a lesser number as may be determined by the Company&#8217;s board of directors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000433" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndFourteenEquityIncentivePlanMember_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> shares available for future issuance under the 2014 Plan and <ix:nonFraction unitRef="U_xbrlishares" id="F_000434" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEquityIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">2,372,006</ix:nonFraction> shares were available under the 2019 Plan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2021 and December 31, 2020, the Company granted options to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000435" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001623526_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,311,897</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000436" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001623526_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,231,532</ix:nonFraction> shares of common stock to certain of its employees, and directors, respectively. The options vest up to <ix:nonNumeric id="F_000437" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_20210101_20211231" format="ixt-sec:durwordsen">four years</ix:nonNumeric> except for certain options granted to members of our board of directors which vest over <ix:nonNumeric id="F_000438" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001623526_srtRangeAxis_srtMinimumMember_srtTitleOfIndividualAxis_srtDirectorMember_20210101_20211231" format="ixt-sec:durwordsen" continuedAt="C_d1020fe4-ab21-4a85-ac2b-42a542b9f43b">one</ix:nonNumeric> or <ix:nonNumeric id="F_000439" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_srtTitleOfIndividualAxis_srtDirectorMember_20210101_20211231" format="ixt-sec:durwordsen">three<ix:continuation id="C_d1020fe4-ab21-4a85-ac2b-42a542b9f43b"> years</ix:continuation></ix:nonNumeric> and are exercisable at a per share price equal to the fair value of the common stock on the grant date. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000241" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of stock option activity for awards is presented below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:94.36%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">life (years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000440" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001623526_20201231" decimals="INF" format="ixt:numdotdecimal">4,454,422</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000447" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001623526_20201231" decimals="2">8.80</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000454">8.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">236,685</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000441" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001623526_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,311,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000448" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001623526_20210101_20211231" decimals="2">53.93</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000442" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001623526_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">287,566</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000449" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001623526_20210101_20211231" decimals="2">2.70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000443" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001623526_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">41,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000450" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001623526_20210101_20211231" decimals="2">40.12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000444" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_0001623526_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000451" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001623526_20210101_20211231" decimals="2">28.73</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000445" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001623526_20211231" decimals="INF" format="ixt:numdotdecimal">5,435,304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000452" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001623526_20211231" decimals="2">19.77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000455">8.0</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">64,981</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000446" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001623526_20211231" decimals="INF" format="ixt:numdotdecimal">3,103,635</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000453" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001623526_20211231" decimals="2">9.74</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000456">6.9</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,003</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><ix:footnote id="FNT_000000" xml:lang="en-US">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at December 31, 2021 and 2020.</ix:footnote> </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value per share of stock options granted during the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000460" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001623526_20210101_20211231" decimals="2">34.07</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000461" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001623526_20200101_20201231" decimals="2">14.75</ix:nonFraction>, respectively. The aggregate grant date fair value of stock options granted during the years ended December 31, 2021 and 2020 was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="stok:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" contextRef="C_0001623526_20210101_20211231" decimals="-5" scale="6">44.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="stok:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" contextRef="C_0001623526_20200101_20201231" decimals="-5" scale="6">18.2</ix:nonFraction> million, respectively. The aggregate intrinsic value of stock options exercised during the year ended December 31, 2021 and 2020 was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001623526_20210101_20211231" decimals="-5" scale="6">9.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001623526_20200101_20201231" decimals="-5" scale="6">27.3</ix:nonFraction> million, respectively.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000209_dcnt_a1a17ddf-b812-4f39-835d-4ecbdb10d59d">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based compensation and stock options </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001623526_20210101_20211231" decimals="-5" scale="6">16.5</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001623526_20200101_20201231" decimals="-5" scale="6">5.8</ix:nonFraction> million during the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_0001623526_20211231" decimals="-5" scale="6">45.0</ix:nonFraction> million of unrecognized compensation cost related to unvested stock-based compensation arrangements granted under the 2014 and the 2019 Plans. The compensation is expected to be recognized over a weighted average period of <ix:nonNumeric id="F_000469" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_0001623526_20210101_20211231" format="ixt-sec:duryear">2.8</ix:nonNumeric> years as of December 31, 2021. </p><ix:nonNumeric id="F_000242" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense recorded as research and development and general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,215</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,235</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,893</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001623526_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,450</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001623526_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000243" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option pricing model to calculate the grant-date fair value of an award. The fair values of the options granted to employees and directors were calculated using the following assumptions for the years ended December 31, 2021 and 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000478">0.78-1.51%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000479">0.38-1.48%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000480" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001623526_20210101_20211231" decimals="2" scale="-2">0</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000481" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001623526_20200101_20201231" decimals="2" scale="-2">0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000482">5.5-6.25 years</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000484">5.5-6.25 years</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70-73%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000487" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001623526_20200101_20201231" decimals="2" scale="-2">70</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2019 Employee stock purchase plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company adopted the 2019 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), which became effective on June 18, 2019. The Company initially reserved <ix:nonFraction unitRef="U_xbrlishares" id="F_000489" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20190630" decimals="INF" format="ixt:numdotdecimal">315,000</ix:nonFraction> shares of common stock for sale under the ESPP. At December 31, 2021, the Company had <ix:nonFraction unitRef="U_xbrlishares" id="F_000490" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">634,580</ix:nonFraction> shares available for issuance under the plan. The average grant date fair value per share under the plan was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000491" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20210101_20211231" decimals="2">46.08</ix:nonFraction> for 2021. The total ESPP stock-based compensation expense for the year ended December 31, 2021 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20210101_20211231" decimals="-5" scale="6">0.3</ix:nonFraction> million and for the year ended December 31, 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="-5" scale="6">0.3</ix:nonFraction> million. The number of shares reserved for issuance under the ESPP will increase automatically on January 1st of each of the first ten calendar years following the first offering date by the number of shares equal to the lesser of <ix:nonFraction unitRef="U_xbrlipure" id="F_000494" name="stok:PercentageOfIncreaseInReservedCommonShares" contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20190601_20190630" decimals="2" scale="-2">1</ix:nonFraction>% of the total outstanding shares of the Company&#8217;s common stock as of the immediately preceding December 31 or a lower amount determined by the Company&#8217;s board of directors. The aggregate number of shares issued over the term of the ESPP will not exceed <ix:nonFraction unitRef="U_xbrlishares" id="F_000495" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20190630" decimals="INF" format="ixt:numdotdecimal">3,150,000</ix:nonFraction> shares of the Company&#8217;s common stock.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000210" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true" continuedAt="F_000210_dcnt_6c796002-ea73-4e19-ad56-b1c9472ee747">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">9. <span style="font-family:Times New Roman;">Net loss per share attributable to common stockholders </span></p><ix:nonNumeric id="F_000244" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:NetIncomeLoss" contextRef="C_0001623526_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,805</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:NetIncomeLoss" contextRef="C_0001623526_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of common shares, basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000498" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001623526_20210101_20211231" decimals="0" format="ixt:numdotdecimal">36,739,269</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000499" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001623526_20200101_20201231" decimals="0" format="ixt:numdotdecimal">33,488,456</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000500" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001623526_20210101_20211231" decimals="2" sign="-">2.34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000501" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001623526_20200101_20201231" decimals="2" sign="-">1.56</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000210_dcnt_6c796002-ea73-4e19-ad56-b1c9472ee747">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potential dilutive securities, which include common stock options and ESPP purchase rights, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. </p><ix:nonNumeric id="F_000245" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options to purchase common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000502" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001623526_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">5,435,304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000503" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001623526_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">4,454,424</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000211" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true" continuedAt="F_000211_dcnt_f69f2e66-25cf-4718-80b8-30267afea098">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Income taxes </p><ix:nonNumeric id="F_000246" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the expected income tax expense (benefit) computed using the federal statutory income tax rate the Company&#8217;s effective income tax rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected income tax benefit at the federal statutory rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000506" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001623526_20210101_20211231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000507" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001623526_20200101_20201231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000508" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001623526_20210101_20211231" decimals="3" scale="-2">7.9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000509" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001623526_20200101_20201231" decimals="3" scale="-2">8.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible items</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000510" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="C_0001623526_20210101_20211231" decimals="3" scale="-2">0.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000511" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="C_0001623526_20200101_20201231" decimals="3" scale="-2">6.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000512" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001623526_20210101_20211231" decimals="3" scale="-2">4.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000513" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001623526_20200101_20201231" decimals="3" scale="-2">1.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000514" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001623526_20210101_20211231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000515" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001623526_20200101_20201231" decimals="3" scale="-2">0.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000516" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001623526_20210101_20211231" decimals="3" sign="-" scale="-2">33.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000517" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001623526_20200101_20201231" decimals="3" sign="-" scale="-2">36.9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000518" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001623526_20210101_20211231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000519" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001623526_20200101_20201231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000247" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The principal components of the Company&#8217;s deferred tax assets and liabilities consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state net operating loss carryforwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,231</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,726</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000524" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,075</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,293</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001623526_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001623526_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> As of December 31, 2021 and 2020, the Company had federal net operating loss carryforwards of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-5" scale="6">191.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">116.9</ix:nonFraction> million, respectively, which may be available to reduce future taxable income, and expire at various dates beginning in <ix:nonNumeric id="F_000532" name="stok:OperatingLossCarryforwardsExpirationBeginningYear" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231"><ix:nonNumeric id="F_000533" name="stok:OperatingLossCarryforwardsExpirationBeginningYear" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2034</ix:nonNumeric></ix:nonNumeric>, for those net operating loss carryforwards generated prior to 2018. Net operating losses generated in 2018 and beyond have no expiration. As of December 31, 2021 and 2020, the Company had state net operating loss carry forwards of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231" decimals="-5" scale="6">191.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" scale="6">118.8</ix:nonFraction> million, respectively, which may be available to reduce future taxable income and expire at various dates beginning in <ix:nonNumeric id="F_000536" name="stok:OperatingLossCarryforwardsExpirationBeginningYear" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231"><ix:nonNumeric id="F_000537" name="stok:OperatingLossCarryforwardsExpirationBeginningYear" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2034</ix:nonNumeric></ix:nonNumeric>. In addition, at December 31, 2021 and 2020, the Company had federal research and development tax credit carryforwards of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231" decimals="-5" scale="6">5.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-5" scale="6">2.0</ix:nonFraction> million, respectively, and state research and development tax credit carry forwards of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231" decimals="-5" scale="6">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-5" scale="6">1.0</ix:nonFraction> million, respectively.&#160;&#160;Both federal and state research and development tax credit carry forwards may be available to reduce future tax liabilities and expire at various dates beginning in <ix:nonNumeric id="F_000542" name="stok:TaxCreditCarryforwardsExpirationBeginningYear" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231"><ix:nonNumeric id="F_000543" name="stok:TaxCreditCarryforwardsExpirationBeginningYear" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231"><ix:nonNumeric id="F_000544" name="stok:TaxCreditCarryforwardsExpirationBeginningYear" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231"><ix:nonNumeric id="F_000545" name="stok:TaxCreditCarryforwardsExpirationBeginningYear" contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">2030</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>. In accordance with ASC 740, <span style="font-style:italic;">Accounting for Income Taxes</span>, management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards. Management has determined that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets and, as a result, a full valuation allowance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001623526_20211231" decimals="-5" scale="6">66.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001623526_20201231" decimals="-5" scale="6">37.2</ix:nonFraction> million was established at December 31, 2021 and 2020, respectively. The change in the valuation allowance was an increase of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000548" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001623526_20210101_20211231" decimals="-5" scale="6">28.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001623526_20200101_20201231" decimals="-5" scale="6">19.3</ix:nonFraction> million in 2021 and 2020, respectively.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000211_dcnt_f69f2e66-25cf-4718-80b8-30267afea098">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CARES Act temporarily repealed the <ix:nonFraction unitRef="U_xbrlipure" id="F_000550" name="stok:PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct" contextRef="C_0001623526_20210101_20211231" decimals="2" scale="-2">80</ix:nonFraction>% taxable income limitation for tax years beginning before January 1, 2021. Federal NOL carry forwards generated from 2018 or later and Federal NOL carryforwards to taxable years beginning after December 31, 2021 will be subject to the <ix:nonFraction unitRef="U_xbrlipure" id="F_000551" name="stok:PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct" contextRef="C_0001623526_20210101_20211231" decimals="2" scale="-2">80</ix:nonFraction>% limitation. Also, under the CARES Act, federal NOLs arising in 2018, 2019 and 2020 can be carried back <ix:nonNumeric id="F_000552" name="stok:FederalNOLCarryForwardsPeriodUnderCARESAct" contextRef="C_0001623526_20210101_20211231" format="ixt-sec:duryear">5</ix:nonNumeric> years. New legislation or regulation which could affect our tax burden could be enacted by any governmental authority. The Company cannot predict the timing or extent of such&#160;tax-related&#160;developments which could have a negative impact on our financial results. Additionally, the Company uses its best judgment in attempting to quantify and reserve for these tax obligations. </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended (the Code) due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. The Company has not conducted a formal study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined for purposes of Section&#160;382 and 383 of the Code, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards may be subject to an annual limitation under Section&#160;382 and 383 of the Code, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term&#160;tax-exempt&#160;rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies ASC 740 related to accounting for uncertainty in income taxes. The Company&#8217;s reserves related to income taxes are based on a determination of whether, and how much of, a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. At December 31, 2021, and 2020 the Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001623526_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001623526_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as income tax expense in the accompanying consolidated statements of operations and comprehensive loss.</p></ix:continuation><ix:nonNumeric id="F_000212" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Employee benefits </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-size:10pt;">In 2016, the Company established a defined-contribution savings plan under Section&#160;401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. On January 1, 2020, the Company began to make matching contributions up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000553" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_20210101_20211231" decimals="INF" scale="-2">4</ix:nonFraction>% of annual salary for those employees who are participating in the 401(k) Plan. For the year ended December 31, 2021, the Company made matching contributions of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000554" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0001623526_20210101_20211231" decimals="-5" scale="6">0.5</ix:nonFraction> million and for the year ended December 31, 2020, the Company made matching contributions of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0001623526_20200101_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million. </span>&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000213" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001623526_20210101_20211231" escape="true" continuedAt="F_000213_dcnt_009c9477-dfdd-4cae-bf64-9e73e88ff41e">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. Subsequent events </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, the Company entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. (&#8220;Acadia&#8221;) for the discovery, development and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (the &#8220;CNS&#8221;). The agreement focuses on the targets SYNGAP1, MECP2 (Rett syndrome), and an undisclosed neurodevelopmental target of mutual interest. In connection with each target, the Company will collaborate with Acadia to identify potential treatments for further development and commercialization as licensed products. With respect to SYNGAP1, the Company has agreed with Acadia to co-develop and co-commercialize licensed products for such target globally, and in connection therewith the Company granted to Acadia worldwide, co-exclusive (with the Company) licenses for such licensed products. With respect to MECP2 and the neurodevelopmental target, the Company granted to Acadia worldwide, exclusive licenses to develop and commercialize licensed products for such targets. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="stok:UpfrontPaymentReceived" contextRef="C_0001623526_srtCounterpartyNameAxis_stokAcadiaPharmaceuticalsIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220131" decimals="-6" scale="6">60</ix:nonFraction> million from Acadia. Acadia agreed to fund the research to identify potential licensed products for MECP2 and the neurodevelopmental target, and the Company will equally fund with Acadia the research to identify potential licensed products for SYNGAP1. The Company is eligible to receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000557" name="stok:MilestonePaymentsReceivable" contextRef="C_0001623526_srtCounterpartyNameAxis_stokAcadiaPharmaceuticalsIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220131" decimals="-5" scale="6">907.5</ix:nonFraction> million in potential total milestone payments based upon the achievement of certain development, regulatory, first commercial sales and sales milestone events across the programs for the three targets, assuming each milestone were achieved at least once. With respect to licensed products for MECP2 and the neurodevelopmental target, the Company is also eligible to receive tiered royalties at percentages ranging from the mid-single digits to the mid-teens on future net sales by Acadia of licensed products worldwide. Royalties payable under the agreement are subject to standard royalty reductions. For SYNGAP1 licensed products that the Company is co-developing and co-commercializing, the Company will be responsible for 50% of the development and commercialization costs and will receive 50% of the profits from global commercialization.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000213_dcnt_009c9477-dfdd-4cae-bf64-9e73e88ff41e">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of and related to the out-license of SYNGAP1, the Company is obligated to make payments to the University of Southampton under certain licensed patents and applications relating to TANGO.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since December 31, 2021, the Company sold approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_000558" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokSalesAgreementProspectusMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">403,000</ix:nonFraction> shares of our common stock and received $<ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="stok:ProceedsFromIssuanceUnderwrittenPublicOfferingNet" contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokSalesAgreementProspectusMember_20210101_20211231" decimals="-5" scale="6">7.5</ix:nonFraction> million after deducting commissions related to the Sales Agreement. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated subsequent events through the issuance date of these consolidated financial statements.&#160;&#160;The Company has concluded that no events or transactions other than those described above have occurred that require disclosure in the accompanying consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>2
<FILENAME>stok-ex1013_176.htm
<DESCRIPTION>EX-10.13
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
stok-ex1013_176.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Exhibit 10.13</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STOKE THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCIENTIFIC ADVISORY BOARD AGREEMENT</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;text-transform:uppercase;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">This SCIENTIFIC ADVISORY BOARD Agreement<font style="text-transform:none;"> (this &#8220;</font><font style="font-weight:bold;text-transform:none;">Agreement</font><font style="text-transform:none;">&#8221;) is entered into as of </font><font style="font-weight:bold;text-transform:none;">June 1, 2021</font><font style="text-transform:none;"> (the &#8220;</font><font style="font-weight:bold;text-transform:none;">Effective Date</font><font style="text-transform:none;">&#8221;) between Stoke Therapeutics, Inc., a Delaware corporation having offices at 45 Wiggins Avenue, Bedford, MA 01730  (&#8220;</font><font style="font-weight:bold;text-transform:none;">Stoke</font><font style="text-transform:none;">&#8221;) and </font><font style="font-weight:bold;text-transform:none;">Adrian Krainer, Ph.D. </font><font style="text-transform:none;">(</font><font style="color:#000000;text-transform:none;">&#8220;</font><font style="font-weight:bold;color:#000000;text-transform:none;">Advisor</font><font style="color:#000000;text-transform:none;">&#8221;)</font><font style="text-transform:none;">.&nbsp;&nbsp;Advisor has unique skills and knowledge pertinent to Stoke&#8217;s business and Stoke desires to retain Advisor as a member of Stoke&#8217;s Scientific Advisory Board (&#8220;</font><font style="font-weight:bold;text-transform:none;">SAB</font><font style="text-transform:none;">&#8221;) under the terms of this Agreement.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advisor is a full-time employee at <font style="font-weight:bold;">Cold Spring Harbor Laboratory</font> (&#8220;<font style="font-weight:bold;">Organization</font>&#8221;).&nbsp;&nbsp;Nothing in this Agreement shall be construed to conflict with Advisor&#8217;s obligations and duties as such, including Advisor&#8217;s duties to protect information that is confidential and/or the property of Organization, to not disclose such protected information to Stoke or any third party, and to fully comply with Organization&#8217;s patent policy and other applicable regulations.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk41410926"></a>NOW, THEREFORE, in consideration of the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, Advisor and Stoke agree as follows:</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529894469"></a><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">SERVICES AND COMPENSATION</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk529894412"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Services.</font><font style="color:#000000;"> Advisor agrees to serve as a member of Stoke&#8217;s SAB and serve as the Chairperson of the SAB with respect to such matters and projects as are mutually agreed from time to time by and between Advisor and Stoke, and perform the services described on </font><font style="font-weight:bold;text-decoration:underline;color:#000000;">Exhibit A</font><font style="color:#000000;"> (collectively, &#8220;</font><font style="font-weight:bold;color:#000000;">Services</font><font style="color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk529894421"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Compensation.</font><font style="color:#000000;"> Stoke agrees to pay Advisor the compensation set forth in </font><font style="font-weight:bold;text-decoration:underline;color:#000000;">Exhibit&#160;A</font><font style="color:#000000;"> for the performance of the Services. Advisor acknowledges and agrees that Stoke&#8217;s payment obligations are in each instance subject to Advisor&#8217;s completion to Stoke&#8217;s reasonable satisfaction of the Services.&nbsp;&nbsp;In addition, Stoke will reimburse Advisor for all properly documented and reasonable travel and out-of-pocket expenses that are pre-approved by Stoke and incurred by Advisor in performing Services pursuant to this Agreement, and that otherwise comply with the requirements set forth in </font><font style="font-weight:bold;text-decoration:underline;color:#000000;">Exhibit A</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">To the extent that Advisor is required to attend meetings at or otherwise use any Stoke facilities or resources, Advisor will first obtain from Stoke, and comply with, Stoke&#8217;s workplace, computer and security policies and procedures.</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529894475"></a><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">CONFIDENTIALITY</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk529888731"></a><a name="_Hlk529888768"></a><a name="_Hlk529888793"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Confidential Information</font><font style="color:#000000;">&#8221; means any proprietary data, information,<a name="_Hlk529888731"></a> technical data, trade secrets or know-how, including, but not limited to, research and product plans, software, algorithms, products, product candidates, services, markets, developments, inventions, processes, formulas, databases, compositions of matter, formulations, <a name="_Hlk529888768"></a>technology, marketing, finances or other business information, including any filings with any governmental agency (including patent and regulatory filings), disclosed to Advisor by Stoke either directly or indirectly in writing, orally or otherwise (including all tangible embodiments of any of the foregoing, including electronic materials)<a name="_Hlk529888793"></a>.&nbsp;&nbsp;Confidential Information also includes all Inventions (as defined below) and any other information or materials generated in connection with the Services and any Personal Data (as defined below) which Advisor receives, accesses, uses or otherwise processes in connection with the Services provided hereunder.&nbsp;&nbsp; </font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-1</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529895196"></a><a name="_Hlk529889462"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Advisor shall not, during or subsequent to the term of this Agreement, use any Confidential Information for any purpose whatsoever, other than for the performance of the Services on behalf of Stoke, nor shall Advisor disclose Confidential Information to any third party.&nbsp;&nbsp;Advisor agrees to maintain the Confidential Information in strict confidence and that Confidential Information shall remain the sole property of Stoke.&nbsp;&nbsp;Advisor further agrees to take all reasonable precautions to prevent any unauthorized access, <a name="_Hlk529889462"></a>disclosure or use of Confidential Information, to immediately notify Stoke of any unauthorized access, disclosure or use of Confidential Information (and to provide to Stoke all information required by applicable laws with respect thereto), and to take such actions as may reasonably be required to mitigate or remediate the effects of any unauthorized access, disclosure or use of Confidential Information (including at Stoke&#8217;s direction).&nbsp;&nbsp;Notwithstanding the above, Advisor&#8217;s obligation under this Section 2(b) relating to Confidential Information shall not apply to information (other than Personal Data) which (i)&#160;is rightfully known to Advisor before the time of disclosure to Advisor by Stoke as evidenced by written records of Advisor, (ii)&#160;has become publicly known and made generally available through no act or omission of Advisor, or (iii)&#160;has been rightfully received by Advisor from a third party authorized to make such disclosure.&nbsp;&nbsp;Nothing in this Section&#160;2 or otherwise in this Agreement shall limit or restrict in any way Advisor&#8217;s immunity from liability for disclosing Stoke&#8217;s trade secrets as specifically permitted by 18 U.S. Code Section&#160;1833, the pertinent provisions of which are attached as </font><font style="text-decoration:underline;color:#000000;">Exhibit C</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Advisor agrees that Advisor will not, during the term of this Agreement, improperly use or disclose to Stoke any proprietary information or trade secrets of any former or current employer or other person or entity to which Advisor has a duty to keep in confidence such information and that Advisor will not bring onto the premises of Stoke any proprietary information or trade secrets belonging to such employer, person or entity unless consented to in writing by the same.&nbsp;&nbsp;Advisor will indemnify Stoke and hold it harmless from and against all claims, liabilities, damages and expenses, including reasonable attorneys&#8217; fees and costs of suit, arising out of or in connection with any violation or claimed violation of such third party&#8217;s rights resulting in whole or in part from the use of the work product of Advisor under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529895325"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Advisor recognizes that Stoke has received and in the future will receive from third parties their confidential or proprietary information subject to a duty on Stoke&#8217;s part to maintain the confidentiality of such information and to use it only for certain limited purposes.&nbsp;&nbsp;Advisor agrees that Advisor owes Stoke and such third parties, during the term of this Agreement and thereafter, a duty with respect to all such confidential or proprietary information: (i) to hold it in the strictest confidence, (ii) not to disclose it to any third party, and (iii) not to use it except as necessary to perform the Services for Stoke; in each case, consistent with Stoke&#8217;s agreement with such third party.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529894701"></a><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Advisor agrees that Advisor will not disclose or use material nonpublic information acquired from Stoke during the term of this Agreement to make investment decisions concerning Stoke&#8217;s or another company&#8217;s securities.&nbsp;&nbsp;Information is &#8220;material&#8221; if it would be expected to affect the investment or voting decisions of a reasonable stockholder or investor, or if the disclosure of the information would be expected to alter significantly the total mix of the information in the marketplace about Stoke.&nbsp;&nbsp;Advisor acknowledges and agrees that Advisor is aware that federal and state securities laws and Stoke&#8217;s Insider Trading Policy prohibit trading while in possession of material nonpublic information and prohibit sharing this information with others to enable them to trade.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upon the termination of this Agreement, or upon Stoke&#8217;s earlier request, Advisor will deliver to Stoke or, at Stoke&#8217;s option, destroy all Confidential Information and Stoke property, in Advisor&#8217;s possession or control.&nbsp;&nbsp;This includes the confidential or proprietary information of the third parties mentioned in Section 2(d) above.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-2</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529894480"></a><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">OWNERSHIP</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk529897367"></a><a name="_Hlk529897238"></a><a name="_Hlk529897264"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Advisor agrees to assign and does hereby irrevocably assign to Stoke all right, title and interest in and to any information (including, without limitation, business plans and/or business information), technology, know-how, materials, deliverables, works of authorship, documents, notes, records, drawings, flowcharts, reports, data, databases, designs, algorithms, <a name="_Hlk529897367"></a>ideas, inventions, improvements, devices, developments, discoveries, compositions, trade secrets, processes, methods and/or techniques, whether or not patentable or copyrightable, that are conceived, reduced to practice, developed, created or made by Advisor<a name="_Hlk529897238"></a> alone or jointly with others in the course of performing the Services or through the use of Confidential Information (collectively, &#8220;</font><font style="font-weight:bold;color:#000000;">Inventions</font><font style="color:#000000;">&#8221;), including all worldwide patent rights (including patent applications and disclosures), copyright rights, mask work rights, trade secret rights, know-how, and any and all other intellectual property or proprietary rights (collectively, &#8220;</font><font style="font-weight:bold;color:#000000;">Intellectual Property Rights</font><font style="color:#000000;">&#8221;) therein.<a name="_Hlk529897264"></a> Advisor will, as an integral part of the performance of Services, promptly disclose and describe in writing to Stoke any and all Inventions.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529894709"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upon the termination of this Agreement, or upon Stoke&#8217;s earlier requests, Advisor will deliver to Stoke all property relating to, and all tangible embodiments of, Inventions, including all work in progress on any Inventions not previously delivered to Stoke, if any, in Advisor&#8217;s possession or control.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk529897445"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Advisor agrees that, in the course of performing the Services, Advisor will not <a name="_Hlk529897445"></a>incorporate into any Invention developed hereunder any invention, work of authorship, trade secret, improvement, development concept, discovery or other proprietary subject matter owned by Advisor or in which Advisor has an interest (&#8220;</font><font style="font-weight:bold;color:#000000;">Item</font><font style="color:#000000;">&#8221;), without prior written agreement between Advisor, Stoke and Organization.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk529889794"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Advisor agrees to sign, execute and acknowledge or cause to be signed, executed and acknowledged without cost, but at the expense of Stoke, any and all documents and to perform such acts as may be necessary, useful or convenient for the purposes of perfecting the foregoing assignments and obtaining, enforcing and defending Intellectual Property Rights in any and all countries with respect to Inventions.&nbsp;&nbsp;It is understood and agreed that Stoke or Stoke&#8217;s designee shall have the sole right, but not the obligation, to prepare, file, prosecute and maintain patent applications and patents worldwide with respect to Inventions. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">REPORTS</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Advisor agrees, from time to time during the term of this Agreement, to keep Stoke advised as to Advisor&#8217;s progress in performing the Services and, as reasonably requested by Stoke, prepare written reports with respect thereto.&nbsp;&nbsp;It is understood that the time required in the preparation of such written reports shall be considered time devoted to the performance of the Services by Advisor.&nbsp;&nbsp;All such reports prepared by Advisor shall be the sole property of Stoke.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529894533"></a><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">TERM AND TERMINATION</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Term.</font><font style="color:#000000;"> This Agreement will commence on the Effective Date and will continue for a period of twelve (12) months ending on </font><font style="font-weight:bold;color:#000000;">June 1, 2022</font><font style="color:#000000;">, unless terminated earlier as provided below (the &#8220;</font><font style="font-weight:bold;color:#000000;">Term</font><font style="color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk529894057"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination.</font><font style="color:#000000;"> Either Advisor or Stoke may terminate this Agreement at any time, for any reason or for no reason, by giving written notice of termination to the other party; provided that Advisor shall give Stoke at least ten (10) days prior notice of termination.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529894538"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Effect of Termination.</font><font style="color:#000000;"> Upon termination of this Agreement, all rights and duties of the parties hereunder shall cease except: (i) Advisor will promptly comply with Sections 2(f) and 3(b); (ii) </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-3-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Stoke</font><font style="color:#000000;"> </font><font style="color:#000000;">will</font><font style="color:#000000;"> pay, within thirty (30) days after receipt of </font><font style="color:#000000;">Advisor</font><font style="color:#000000;">&#8217;s final statement, all amounts owing to </font><font style="color:#000000;">Advisor</font><font style="color:#000000;"> for unpaid Services completed by </font><font style="color:#000000;">Advisor</font><font style="color:#000000;"> and related expenses, if any, in accordance with </font><font style="color:#000000;">Section</font><font style="color:#000000;"> </font><font style="color:#000000;">1</font><font style="color:#000000;">;</font><font style="color:#000000;"> and</font><font style="color:#000000;"> (i</font><font style="color:#000000;">ii</font><font style="color:#000000;">) </font><font style="color:#000000;">Sections&#160;2, 3, </font><font style="color:#000000;">5</font><font style="color:#000000;">(c), </font><font style="color:#000000;">6, </font><font style="color:#000000;">7, </font><font style="color:#000000;">8</font><font style="color:#000000;"> and 1</font><font style="color:#000000;">0</font><font style="color:#000000;"> shall survive termination of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529894584"></a><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">RELATIONSHIP OF THE PARTIES</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Independent Contractor</font><font style="color:#000000;">.&nbsp;&nbsp;Advisor is an independent contractor and nothing in this Agreement will be construed as establishing an employment or agency relationship between Stoke and Advisor.&nbsp;&nbsp;Advisor has no authority to bind Stoke by contract or otherwise. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Taxes and Employee Benefits</font><font style="color:#000000;">.&nbsp;&nbsp;Advisor acknowledges and agrees that Advisor is obligated to report as income, and pay all applicable taxes with respect to, all compensation received by Advisor pursuant to this Agreement.&nbsp;&nbsp;Advisor will not be entitled to any benefits paid or made available by Stoke to its employees, including, without limitation, any vacation or illness payments, or to participate in any plans, arrangements or distributions made by Stoke pertaining to any bonus, stock option, profit sharing, insurance or similar benefits.&nbsp;&nbsp;Advisor acknowledges that Stoke will not carry any liability insurance on behalf of Advisor.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">WARRANTIES.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Performance Standard</font><font style="color:#000000;">.&nbsp;&nbsp;Advisor represents and warrants that Advisor has the requisite training, background, experience, technical knowledge and skills to perform the Services and that Advisor will perform the Services in a thorough and professional manner, consistent with high professional and industry standards and in compliance with all applicable laws and regulations.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Non-infringement</font><font style="color:#000000;">.&nbsp;&nbsp;Advisor represents and warrants that the performance of the Services, the Inventions, or their use, will not infringe, misappropriate or violate the rights of any third party, including, without limitation, any Intellectual Property Rights or any rights of privacy or rights of publicity.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Exclusion and Debarment</font><font style="color:#000000;">.&nbsp;&nbsp;Advisor represents and warrants that Advisor is not currently: (i) excluded, debarred, suspended or otherwise ineligible to participate in any governmental healthcare program, including any Federal health care programs as defined in 42 U.S.C. &#167; 1320a-7b(f), or from federal procurement or nonprocurement activities as defined in Executive Order 12689 (collectively &#8220;</font><font style="font-weight:bold;color:#000000;">Ineligible</font><font style="color:#000000;">&#8221;); or (ii) debarred pursuant to the Generic Drug Enforcement Act of 1992, 21 U.S.C. &#167; 335(a), as amended, or subject to any similar sanction pursuant to any similar state or foreign law or regulation (collectively &#8220;</font><font style="font-weight:bold;color:#000000;">Debarred</font><font style="color:#000000;">&#8221;) or (iii) convicted of a criminal offense that falls within the ambit of 42 U.S.C. &#167; 1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible (&#8220;</font><font style="font-weight:bold;color:#000000;">Convicted</font><font style="color:#000000;">&#8221;). If Advisor becomes Ineligible, Debarred or Convicted, or subject to any investigation or proceeding with respect thereto, during the term of this Agreement, Advisor will notify Stoke promptly, and in any event no later than two (2) business days after receiving notification of the Ineligibility, Debarment, Conviction or related investigation or proceeding. Upon receipt of such notice, or if Stoke becomes aware of any existing or threatened Ineligibility, Debarment or Conviction, Stoke shall have the right to terminate this Agreement immediately, without liability or indemnity.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Privacy</font><font style="color:#000000;">. Stoke has a responsibility to protect and secure personal information, personal data, and/or protected health information as defined by applicable laws (collectively &#8220;</font><font style="font-weight:bold;color:#000000;">Personal Data</font><font style="color:#000000;">&#8221;), including to safeguard Personal Data against unauthorized use, access, and disclosure, and to ensure that Advisor adheres to such responsibilities. If and when Advisor receives, accesses, uses or otherwise processes Personal Data in connection with the Services provided hereunder, Advisor acknowledges and agrees that such Personal Data will be Stoke&#8217;s Confidential Information for purposes of this Agreement </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-4</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">and </font><font style="color:#000000;">Advisor</font><font style="color:#000000;"> represents and warrants that it will: (i) </font><font style="color:#000000;">only use Personal Data at </font><font style="color:#000000;">Stoke</font><font style="color:#000000;">&#8217;s documented instruction and only to the extent related to and necessary for the performance of Services; (ii) </font><font style="color:#000000;">o</font><font style="color:#000000;">nly use Personal Data in accordance with all applicable laws; (iii) ensure persons permitted to process Personal Data are committed to confidentiality; (iv) implement and maintain appropriate organizational and technical security measures to protect Personal Data; (v) immediately notify </font><font style="color:#000000;">Stoke</font><font style="color:#000000;"> with all information required by applicable law of any unauthorized use, access, or disclosure of Personal Data or any security incident involving Personal Data; (vi) </font><font style="color:#000000;">mitigate any harmful effects resulting from and otherwise remediate (including at </font><font style="color:#000000;">Stoke</font><font style="color:#000000;">&#8217;s instruction) any unauthorized use, access, or disclosure of Personal Data or any security incident involving Personal Data; </font><font style="color:#000000;">(vii) </font><font style="color:#000000;">only engage or share Personal Data with a third party (including </font><font style="color:#000000;">Advisor</font><font style="color:#000000;">&#8217;s agents, subcontractors, and service providers) after receiving </font><font style="color:#000000;">Stoke</font><font style="color:#000000;">&#8217;s prior written authorization. If </font><font style="color:#000000;">Stoke</font><font style="color:#000000;"> does so authorize </font><font style="color:#000000;">Advisor</font><font style="color:#000000;">&#8217;s third party, </font><font style="color:#000000;">Advisor</font><font style="color:#000000;"> and such third party must sign a written contract containing equivalent obligations applicable to Personal Data as contained in this Agreement and as otherwise required by applicable law. </font><font style="color:#000000;">Advisor</font><font style="color:#000000;"> shall remain fully liable to </font><font style="color:#000000;">Stoke</font><font style="color:#000000;"> for the performance of any such third party under the Agreement; (viii) only transfer Personal Data from any jurisdiction to any other jurisdiction (the European Economic Area constituting a single jurisdiction for this purpose), with the prior written authorization of </font><font style="color:#000000;">Stoke</font><font style="color:#000000;"> and, if applicable, put into place an appropriate data transfer agreement (with </font><font style="color:#000000;">Stoke</font><font style="color:#000000;"> and/or any relevant agents, subcontractors, and service providers) or other mechanism appropriate to comply with applicable law; (ix) assist </font><font style="color:#000000;">Stoke</font><font style="color:#000000;"> with any individual rights requests (including amendments) or other compliance obligations it may have under applicable law (including making available all information necessary to demonstrate compliance and allowing for and contributing to audits, including at the request of any applicable oversight agency); and (x) delete or return all Personal Data upon termination or </font><font style="color:#000000;">Stoke</font><font style="color:#000000;">&#8217;s request. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529894594"></a><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">ARBITRATION AND EQUITABLE RELIEF</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk529897817"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Arbitration.</font><font style="color:#000000;"> Stoke and Advisor hereby agree that any dispute arising under this Agreement, or in connection with any breach thereof, shall be finally resolved through binding arbitration administered by JAMS pursuant to its Streamlined Arbitration Rules and Procedures by one (1) arbitrator appointed in accordance with said rules.&nbsp;&nbsp;Any such arbitration shall be held in Boston, MA.&nbsp;&nbsp;The arbitrator shall determine what discovery will be permitted; provided the arbitrator shall permit such discovery as the arbitrator deems necessary to permit an equitable resolution of the dispute.&nbsp;&nbsp;Any written evidence originally in a language other than English shall be submitted in English translation accompanied by the original or a true copy thereof.&nbsp;&nbsp;The costs of the arbitration, including administrative and arbitrators&#8217; fees, shall be shared equally by the parties, and each party shall bear its own costs and attorneys&#8217; and witness&#8217; fees incurred in connection with the arbitration.&nbsp;&nbsp;Any award may be entered in a court of competent jurisdiction for a judicial recognition of the decision and applicable orders of enforcement.&nbsp;&nbsp;The parties agree that, any provision of applicable law notwithstanding, they will not request and the arbitrator shall have no authority to award, punitive or exemplary damages against either party.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk529898051"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Equitable Remedies</font><font style="color:#000000;">. Because the Services are personal and unique and because Advisor will have access to Confidential Information of Stoke, Stoke will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without having to post a bond or other consideration, in addition to all other remedies that Stoke may have for a breach of this Agreement at law or otherwise.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk529895743"></a><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">CONFLICTING OBLIGATIONS</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Advisor hereby represents, warrants and certifies that Advisor has no outstanding agreement, commitment or obligation that is in conflict with any of the provisions of this Agreement, or that would preclude Advisor from complying with the provisions hereof, and further represents, warrants and certifies that Advisor will not enter into any such conflicting agreement<a name="_Hlk529895743"></a>, commitment or obligation during the term of this Agreement.&nbsp;&nbsp;Subject to written waivers that </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-5-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">may be provided by </font><font style="font-weight:normal;color:#000000;">Stoke</font><font style="font-weight:normal;color:#000000;"> upon request, which shall not be unreasonably withheld, </font><font style="font-weight:normal;color:#000000;">Advisor</font><font style="font-weight:normal;color:#000000;"> agrees that, during the term of this Agreement, </font><font style="font-weight:normal;color:#000000;">Advisor</font><font style="font-weight:normal;color:#000000;"> will not directly or indirectly (i) provide any services in the Field of Interest (as defined </font><font style="font-weight:normal;color:#000000;">i</font><font style="font-weight:normal;color:#000000;">n </font><font style="text-decoration:underline;color:#000000;">Exhibit A</font><font style="font-weight:normal;color:#000000;">) to any business or commercial entity, (ii) provide any services for any </font><font style="font-weight:normal;color:#000000;">third party</font><font style="font-weight:normal;color:#000000;"> that is competitive with </font><font style="font-weight:normal;color:#000000;">Stoke, and shall list in </font><font style="text-decoration:underline;color:#000000;">Exhibit B</font><font style="font-weight:normal;color:#000000;"> hereto any other companies for whom Advisor is providing services</font><font style="font-weight:normal;color:#000000;"> (&#8220;</font><font style="color:#000000;">Outside Companies</font><font style="font-weight:normal;color:#000000;">&#8221;)</font><font style="font-weight:normal;color:#000000;">, or (iii) participate in the formation of any business or commercial entity in the Field of Interest or otherwise competitive with </font><font style="font-weight:normal;color:#000000;">Stoke</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">The Services performed hereunder will not be conducted on time that is required to be devoted to any other third party.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Advisor</font><font style="font-weight:normal;color:#000000;"> shall not use the funding, resources </font><font style="font-weight:normal;color:#000000;">or </font><font style="font-weight:normal;color:#000000;">facilities of any other third party, without the prior written consent of </font><font style="font-weight:normal;color:#000000;">Stoke</font><font style="font-weight:normal;color:#000000;">, to perform Services hereunder and shall not perform the Services hereunder in any manner that would give any </font><font style="font-weight:normal;color:#000000;">third party</font><font style="font-weight:normal;color:#000000;"> rights or access to the product of such Services.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Without limiting the foregoing, </font><font style="font-weight:normal;color:#000000;">Advisor</font><font style="font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">agrees</font><font style="font-weight:normal;color:#000000;"> to</font><font style="font-weight:normal;color:#000000;"> (</font><font style="font-weight:normal;color:#000000;">A) segregate </font><font style="font-weight:normal;color:#000000;">Advisor</font><font style="font-weight:normal;color:#000000;">&#8217;s Services performed under this Agreement from</font><font style="font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Advisor</font><font style="font-weight:normal;color:#000000;">&#8217;s work done for </font><font style="font-weight:normal;color:#000000;">Organization, Outside Companies, or </font><font style="font-weight:normal;color:#000000;">any other third party </font><font style="font-weight:normal;color:#000000;">so as to minimize any questions of disclosure of, or rights under, any inventions, (B) notify </font><font style="font-weight:normal;color:#000000;">the CEO of Stoke</font><font style="font-weight:normal;color:#000000;"> if at any time </font><font style="font-weight:normal;color:#000000;">Advisor</font><font style="font-weight:normal;color:#000000;"> believes that such questions may result from </font><font style="font-weight:normal;color:#000000;">Advisor</font><font style="font-weight:normal;color:#000000;">&#8217;s</font><font style="font-weight:normal;color:#000000;"> performance under this Agreement and (C) assist </font><font style="font-weight:normal;color:#000000;">Stoke</font><font style="font-weight:normal;color:#000000;"> in fairly resolving any questions in this regard which may arise.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Notwithstanding anything to the contrary in this Agreement, Stoke </font><font style="font-weight:normal;color:#000000;">and Advisor </font><font style="font-weight:normal;color:#000000;">acknowledge that Advisor is an employee of Organization and </font><font style="font-weight:normal;color:#000000;">subject to Organization&#8217;s policies, including policies concerning consulting, conflicts of interest, and intellectual property.&nbsp;&nbsp;To ensure compliance with these policies, this Agreement incorporates the terms of Organization&#8217;s Uniform Consulting Agreement Provisions, which are attached hereto as </font><font style="text-decoration:underline;color:#000000;">Exhibit D</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Stoke and Advisor agree that if anything in this Agreement is inconsistent with the Organization&#8217;s Uniform Consulting Agreement Provisions, the Organization&#8217;s Uniform Consulting Agreement Provisions will </font><font style="font-weight:normal;color:#000000;">govern</font><font style="font-weight:normal;color:#000000;"> and Advisor&#8217;s compliance therewith shall not be deemed to be a breach of this Agreement.&nbsp;&nbsp;Without limiting the foregoing, </font><font style="font-weight:normal;color:#000000;">Advisor shall use reasonable efforts to notify Stoke of any such conflict or any material changes to the policies of Organization.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529894606"></a><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">NON-SOLICITATION</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;During the term of this Agreement and for a period of one (1) year thereafter, Advisor shall not, either alone or in association with others, solicit or attempt to solicit any employee, independent contractor, or consultant of Stoke to terminate their employment or relationship with Stoke.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">GENERAL</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;This Agreement, including the Exhibits hereto, is the sole agreement and understanding between Stoke and Advisor concerning the subject matter hereof, and it supersedes all prior agreements and understandings with respect to such matter.&nbsp;&nbsp;Any required notice shall be given in writing by customary means with receipt confirmed at the address of each party set forth below, or to such other address as either party may substitute by written notice to the other.&nbsp;&nbsp;Advisor shall not subcontract any portion of Advisor&#8217;s duties under this Agreement without the prior written consent of Stoke.&nbsp;&nbsp;Neither this Agreement nor any right or obligation hereunder or interest herein may be assigned or transferred, in whole or in part, by Advisor without the prior written consent of Stoke and any attempted transfer or assignment without such consent will be void.&nbsp;&nbsp;Stoke may freely assign this Agreement to any entity without restriction.&nbsp;&nbsp;This Agreement will be interpreted and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to conflict of law principles.&nbsp;&nbsp;This Agreement may only be amended or modified by a writing signed by both parties. Waiver of any term or provision of this Agreement or forbearance to enforce any term or provision by either party shall not constitute a waiver as to any subsequent breach or failure of the same term or provision or a waiver of any other term or provision of this Agreement.&nbsp;&nbsp;</font><font style="color:#000000;font-weight:normal;">Except as expressly set forth in this Agreement, the exercise by either party of any remedy under this Agreement will be without prejudice to its other remedies under this Agreement or otherwise.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision, provided that no such severability shall be effective if it materially changes the economic benefit of this Agreement to either Stoke or Advisor.&nbsp;&nbsp;This Agreement </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-6</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">may be executed in two or more counterparts, each of which will be deemed an original, but all of which together shall constitute one and the same instrument. Once signed, any reproduction of this Agreement </font><font style="font-weight:normal;color:#000000;">or any amendment hereto </font><font style="font-weight:normal;color:#000000;">made by reliable means (e.g., photocopy, facsimile) is considered an original.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.&nbsp;&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:53.85%;text-indent:-53.85%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:8.37%;"></td>
<td style="width:36.51%;"></td>
<td style="width:5.13%;"></td>
<td style="width:8.97%;"></td>
<td style="width:41.03%;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STOKE THERAPEUTICS, INC.</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ADVISOR</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ed Kaye</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adrian Krainer, Ph.D.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Address:</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45 Wiggins Avenue</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bedford, MA 01730</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Address:</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256 Daly Road</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">East Northport, NY 11731</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:53.85%;text-indent:-53.85%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:53.85%;text-indent:-53.85%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-7</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT A</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SERVICES AND COMPENSATION</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Services</font><font style="font-weight:normal;">. Advisor will render to Stoke the following Services:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;color:#000000;">Provide expert advisory services to Stoke regarding matters relating to: Stoke&#8217;s TANGO (targeted gene up-regulation) antisense oligonucleotide technology and other antisense oligonucleotide technologies, current and future therapeutic targets and programs</font><font style="font-weight:bold;font-size:11pt;color:#000000;"> </font><font style="font-size:11pt;color:#000000;">(the &#8220;</font><font style="font-weight:bold;font-size:11pt;color:#000000;">Field of Interest</font><font style="font-size:11pt;color:#000000;">&#8221;); and, </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;color:#000000;">Attend a minimum of four (4) Stoke SAB meetings per year at such times and locations as Stoke may request.&nbsp;&nbsp;SAB meetings may be attended by Advisor either in-person or by telephone or by videoconference, as may be mutually agreed by Stoke and Advisor; and,</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;color:#000000;">Perform the duties of an SAB member, as established from time to time by mutual agreement of Stoke and SAB, including, but not limited to, meeting with Stoke employees, other SAB members, reviewing goals of Stoke and assisting in developing strategies for achieving such goals, and providing advice, support, theories, techniques and improvements in Stoke&#8217;s business model; and,</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;color:#000000;">Provide occasional consultation by e-mail or phone, and at Stoke&#8217;s request, facilitate introductions to potential partners, prospects and relevant experts; and,</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;color:#000000;">Collaborate and provide other advice and assistance to Stoke as is mutually agreed by the parties.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Compensation and Expenses</font>.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;color:#000000;">Stoke anticipates having four (4) SAB meetings during the Term and shall pay Advisor </font><font style="font-weight:bold;font-size:11pt;color:#000000;">$11,250</font><font style="font-size:11pt;color:#000000;"> quarterly for a total of </font><font style="font-weight:bold;font-size:11pt;color:#000000;">$45,000</font><font style="font-size:11pt;color:#000000;"> for the Term of this Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;color:#000000;">Stoke shall reimburse Advisor for all reasonable travel and out-of-pocket expenses incurred by Advisor in performing Services pursuant to this Agreement that are pre-approved in writing by Stoke.&nbsp;&nbsp;Advisor shall submit all statements for such expenses on a monthly basis in a form prescribed by Stoke.</font></p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-8</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT </font><font style="text-decoration:underline;">B</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OUTSIDE COMPANIES</p>
<p style="margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Skyhawk Therapeutics (SAB)</p>
<p style="margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Envisagenics, Inc. (SAB)</p>
<p style="margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biogen (Speaker)</p>
<p style="margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Autoimmunity BioSolutions (SAB)</p>
<p style="margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Silagene (SAB)</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-9</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT </font><font style="text-decoration:underline;">C</font></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DEFEND TRADE SECRETS ACT, 18 U.S. CODE &#167; 1833 NOTICE:</p>
<p style="margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18 U.S. Code Section 1833 provides as follows:</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Immunity From Liability For Confidential Disclosure Of A Trade Secret To The Government Or In A Court Filing.<font style="font-weight:normal;">&nbsp;&nbsp;An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made, (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii)&#160;solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk529899365"></a>Use of Trade Secret Information in Anti-Retaliation Lawsuit.<font style="font-weight:normal;"><a name="_Hlk529899365"></a>&nbsp;&nbsp;An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-10</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:12pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;color:#000000;">EXHIBIT </font><font style="font-weight:bold;text-decoration:underline;color:#000000;">D</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:16.61%;margin-right:16.67%;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CSHL<font style="letter-spacing:-0.05pt;"> </font>UNIFORM<font style="letter-spacing:-0.05pt;"> </font>CONSULTING<font style="letter-spacing:-0.15pt;"> </font>AGREEMENT<font style="letter-spacing:-0.1pt;"> </font>PROVISIONS</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-size:12pt;margin-left:41pt;color:#000000;"></font><font style="color:#000000;">These Uniform Consulting Agreement Provisions (the &#8220;Uniform Provisions&#8221;) are attached as</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Exhibit D</font><font style="color:#000000;"> to a Scientific Advisory Board Agreement (the &#8220;Agreement&#8221;) under which Adrian Krainer,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">PhD,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">a</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Cold</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Spring</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Harbor</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Laboratory</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">(CSHL)</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">scientist</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">(the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">&#8220;Consultant&#8221;)</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">has</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">agreed</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">provide</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">consulting</font><font style="letter-spacing:0.95pt;color:#000000;"> </font><font style="color:#000000;">services</font><font style="letter-spacing:1.1pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:1.2pt;color:#000000;"> </font><font style="color:#000000;">Stoke</font><font style="letter-spacing:1.05pt;color:#000000;"> </font><font style="color:#000000;">Therapeutics,</font><font style="letter-spacing:1.1pt;color:#000000;"> </font><font style="color:#000000;">Inc.</font><font style="letter-spacing:1.05pt;color:#000000;"> </font><font style="color:#000000;">(the</font><font style="letter-spacing:1.1pt;color:#000000;"> </font><font style="color:#000000;">&#8220;Company&#8221;).</font><font style="letter-spacing:0.55pt;color:#000000;"> </font><font style="color:#000000;">By</font><font style="letter-spacing:0.95pt;color:#000000;"> </font><font style="color:#000000;">signing</font><font style="letter-spacing:1pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.95pt;color:#000000;"> </font><font style="color:#000000;">Uniform</font><font style="letter-spacing:0.8pt;color:#000000;"> </font><font style="color:#000000;">Provisions,</font><font style="letter-spacing:-2.65pt;color:#000000;"> </font><font style="color:#000000;">the Consultant and the Company agree to abide by these Uniform Provisions, and also agree that if</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">anything in the Agreement is inconsistent with the Uniform Provisions, the Uniform Provisions will</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">govern.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-size:12pt;margin-left:41pt;color:#000000;"></font><font style="color:#000000;">The Agreement will disclose all compensation of whatever kind that is to be provided to the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">in connection with the consulting</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">services.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-size:12pt;margin-left:41pt;color:#000000;"></font><font style="color:#000000;">The Consultant&#8217;s services for the Company will</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">consist</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">only of the exchange of ideas and</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">provision of</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">advice;</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">will</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">not</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">direct</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">conduct</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">research</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">for</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">on</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">behalf</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Company.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-size:12pt;margin-left:41pt;color:#000000;"></font><font style="color:#000000;">The Company acknowledges that the Consultant is a CSHL employee and is subject to CSHL&#8217;s</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">policies, including policies concerning consulting, conflicts of</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">interest, and intellectual property.</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">In</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">accordance with CSHL policy, the Consultant may disclose to the Company any information that the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">would</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">normally</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">freely</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">disclose</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">other</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">members</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">scientific</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">community</font><font style="letter-spacing:2.75pt;color:#000000;"> </font><font style="color:#000000;">at</font><font style="letter-spacing:2.75pt;color:#000000;"> </font><font style="color:#000000;">large,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">whether by publication, by presentation at seminars, or in informal scientific discussions.</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">However, the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant will not disclose to the Company information that (i) is proprietary to CSHL and (ii) is not</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">generally</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">available</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">to the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">public, except</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">through formal</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">technology</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">transfer</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">procedures.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-size:12pt;margin-left:41pt;color:#000000;"></font><font style="color:#000000;">This</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Agreement</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">any</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">information</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">materials</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">covered</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">hereunder</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">will</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">be</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">subject</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">all</font><font style="letter-spacing:-2.6pt;color:#000000;"> </font><font style="color:#000000;">applicable</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">government</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">export</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">import</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">laws</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">regulations.</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">The</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">parties</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">agree</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">comply</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">reasonably assist the other party, upon request by that party, in complying with all applicable government</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">export and import laws and regulations. The parties acknowledge that they may not directly or indirectly</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">export, re-export, distribute or transfer any technology, information or materials of any value to any</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">nation, individual or entity that is prohibited or restricted by the International Traffic in Arms Regulation</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">(ITAR),</font><font style="letter-spacing:0.95pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.95pt;color:#000000;"> </font><font style="color:#000000;">Export</font><font style="letter-spacing:1pt;color:#000000;"> </font><font style="color:#000000;">Administration</font><font style="letter-spacing:0.95pt;color:#000000;"> </font><font style="color:#000000;">Regulations</font><font style="letter-spacing:1pt;color:#000000;"> </font><font style="color:#000000;">(EAR),</font><font style="letter-spacing:0.95pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.95pt;color:#000000;"> </font><font style="color:#000000;">Office</font><font style="letter-spacing:0.95pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:1pt;color:#000000;"> </font><font style="color:#000000;">Foreign</font><font style="letter-spacing:0.95pt;color:#000000;"> </font><font style="color:#000000;">Assets</font><font style="letter-spacing:0.95pt;color:#000000;"> </font><font style="color:#000000;">Controls</font><font style="letter-spacing:0.95pt;color:#000000;"> </font><font style="color:#000000;">(OFAC),</font><font style="letter-spacing:-2.6pt;color:#000000;"> </font><font style="color:#000000;">the United States Department of State&#8217;s State Sponsors of Terrorism, or by any other United States</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">government</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">agency</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">without</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">first</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">obtaining</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">appropriate license.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-size:12pt;margin-left:41pt;color:#000000;"></font><font style="color:#000000;">Subject to the terms of paragraph 7, below, the Consultant may assign to the Company any right,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">title and interest the Consultant may have in any invention, discovery, improvement, or other intellectual</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">property which the Consultant (whether alone or with others) develops (i) in the course of performing</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">consulting services for the Company under the Agreement and (ii) outside the course of the Consultant&#8217;s</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">activities</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">as a CSHL employee.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-size:12pt;margin-left:41pt;color:#000000;"></font><font style="color:#000000;">The Company will have no rights by reason of the Agreement in any publication, invention,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">discovery,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">improvement,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">other</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">intellectual</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">property</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">whatsoever,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">whether</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">not</font><font style="letter-spacing:2.75pt;color:#000000;"> </font><font style="color:#000000;">publishable,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">patentable,</font><font style="letter-spacing:0.75pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.8pt;color:#000000;"> </font><font style="color:#000000;">copyrightable,</font><font style="letter-spacing:0.75pt;color:#000000;"> </font><font style="color:#000000;">which</font><font style="letter-spacing:0.65pt;color:#000000;"> </font><font style="color:#000000;">is</font><font style="letter-spacing:0.7pt;color:#000000;"> </font><font style="color:#000000;">developed</font><font style="letter-spacing:0.65pt;color:#000000;"> </font><font style="color:#000000;">as</font><font style="letter-spacing:0.65pt;color:#000000;"> </font><font style="color:#000000;">a</font><font style="letter-spacing:0.65pt;color:#000000;"> </font><font style="color:#000000;">result</font><font style="letter-spacing:0.65pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:0.65pt;color:#000000;"> </font><font style="color:#000000;">a</font><font style="letter-spacing:0.7pt;color:#000000;"> </font><font style="color:#000000;">program</font><font style="letter-spacing:0.45pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:0.65pt;color:#000000;"> </font><font style="color:#000000;">research</font><font style="letter-spacing:0.65pt;color:#000000;"> </font><font style="color:#000000;">financed,</font><font style="letter-spacing:0.65pt;color:#000000;"> </font><font style="color:#000000;">in</font><font style="letter-spacing:0.65pt;color:#000000;"> </font><font style="color:#000000;">whole</font><font style="letter-spacing:-2.65pt;color:#000000;">  </font><font style="color:#000000;">or in part, by funds provided by or under the control of CSHL.</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">The Company also acknowledges and</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">agrees</font><font style="letter-spacing:0.55pt;color:#000000;"> </font><font style="color:#000000;">that</font><font style="letter-spacing:0.55pt;color:#000000;"> </font><font style="color:#000000;">it</font><font style="letter-spacing:0.6pt;color:#000000;"> </font><font style="color:#000000;">will</font><font style="letter-spacing:0.55pt;color:#000000;"> </font><font style="color:#000000;">enjoy</font><font style="letter-spacing:0.45pt;color:#000000;"> </font><font style="color:#000000;">no</font><font style="letter-spacing:0.5pt;color:#000000;"> </font><font style="color:#000000;">priority</font><font style="letter-spacing:0.4pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.45pt;color:#000000;"> </font><font style="color:#000000;">advantage</font><font style="letter-spacing:0.4pt;color:#000000;"> </font><font style="color:#000000;">as</font><font style="letter-spacing:0.4pt;color:#000000;"> </font><font style="color:#000000;">a</font><font style="letter-spacing:0.45pt;color:#000000;"> </font><font style="color:#000000;">result</font><font style="letter-spacing:0.45pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:0.45pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.4pt;color:#000000;"> </font><font style="color:#000000;">consultancy</font><font style="letter-spacing:0.25pt;color:#000000;"> </font><font style="color:#000000;">created</font><font style="letter-spacing:0.45pt;color:#000000;"> </font><font style="color:#000000;">by</font><font style="letter-spacing:0.25pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.4pt;color:#000000;"> </font><font style="color:#000000;">Agreement</font><font style="letter-spacing:-2.6pt;color:#000000;"> </font><font style="color:#000000;">in</font><font style="letter-spacing:0.25pt;color:#000000;"> </font><font style="color:#000000;">gaining</font><font style="letter-spacing:0.2pt;color:#000000;"> </font><font style="color:#000000;">access,</font><font style="letter-spacing:0.3pt;color:#000000;"> </font><font style="color:#000000;">whether</font><font style="letter-spacing:0.35pt;color:#000000;"> </font><font style="color:#000000;">by</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">license</font><font style="letter-spacing:0.25pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.25pt;color:#000000;"> </font><font style="color:#000000;">otherwise,</font><font style="letter-spacing:0.5pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:0.2pt;color:#000000;"> </font><font style="color:#000000;">any</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">proprietary information</font><font style="letter-spacing:0.2pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.25pt;color:#000000;"> </font><font style="color:#000000;">intellectual</font><font style="letter-spacing:0.25pt;color:#000000;"> </font><font style="color:#000000;">property that</font><font style="letter-spacing:1.9pt;color:#000000;"> </font><font style="color:#000000;">arises</font><font style="letter-spacing:1.85pt;color:#000000;"> </font><font style="color:#000000;">from</font><font style="letter-spacing:1.65pt;color:#000000;"> </font><font style="color:#000000;">any</font><font style="letter-spacing:1.75pt;color:#000000;"> </font><font style="color:#000000;">research</font><font style="letter-spacing:1.9pt;color:#000000;"> </font><font style="color:#000000;">undertaken</font><font style="letter-spacing:1.85pt;color:#000000;"> </font><font style="color:#000000;">by</font><font style="letter-spacing:1.7pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:1.85pt;color:#000000;"> </font><font style="color:#000000;">Consultant</font><font style="letter-spacing:1.95pt;color:#000000;"> </font><font style="color:#000000;">in</font><font style="letter-spacing:1.8pt;color:#000000;"> </font><font style="color:#000000;">his</font><font style="letter-spacing:1.85pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:1.75pt;color:#000000;"> </font><font style="color:#000000;">her</font><font style="letter-spacing:1.75pt;color:#000000;"> </font><font style="color:#000000;">capacity</font><font style="letter-spacing:1.65pt;color:#000000;"> </font><font style="color:#000000;">as</font><font style="letter-spacing:1.75pt;color:#000000;"> </font><font style="color:#000000;">an</font><font style="letter-spacing:1.75pt;color:#000000;"> </font><font style="color:#000000;">employee</font><font style="letter-spacing:1.75pt;color:#000000;"> </font><font style="color:#000000;">of </font><font style="letter-spacing:-2.6pt;color:#000000;"> </font><font style="color:#000000;">CSHL.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-size:12pt;margin-left:41pt;color:#000000;"></font><font style="color:#000000;">Nothing in the Agreement will affect the Consultant&#8217;s right to use, disseminate, or publish any</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">information that (i) is or becomes available to the public through no breach of the Agreement by the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant; (ii) is obtained by the Consultant from a third party who had the legal right to disclose the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">information</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant;</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">(iii)</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">is</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">already in the possession of the Consultant on the date the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Agreement becomes effective; or (iv) is required to be disclosed by law, government regulation, or court</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">order, provided that the Consultant takes reasonable steps to provide the Company with sufficient prior</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">notice to allow the Company to consent to the disclosure or seek a protective order.</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">In addition, the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Company&#8217;s confidential information does not include information generated by the Consultant (whether</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">alone or with others) unless the Consultant generated the information (i) during the course of performing</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">consulting services for the Company under the Agreement and (ii) outside the course of the Consultant&#8217;s</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">activities</font><font style="letter-spacing:-0.05pt;color:#000000;"> </font><font style="color:#000000;">as a CSHL employee.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-11</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-size:12pt;margin-left:41pt;color:#000000;"></font><font style="color:#000000;">The</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Company</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">acknowledges</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">agrees</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">that</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">nothing</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">in</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Agreement</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">will</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">affect</font><font style="letter-spacing:2.75pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant&#8217;s</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">obligations</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">CSHL,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant&#8217;s</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">research</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">on</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">behalf</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">CSHL,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">research</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">collaborations in which the Consultant is a participant, and that the Agreement will have no effect upon</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">transfers</font><font style="letter-spacing:0.65pt;color:#000000;"> </font><font style="color:#000000;">(by</font><font style="letter-spacing:0.55pt;color:#000000;"> </font><font style="color:#000000;">way</font><font style="letter-spacing:0.55pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:0.7pt;color:#000000;"> </font><font style="color:#000000;">license</font><font style="letter-spacing:0.7pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.95pt;color:#000000;"> </font><font style="color:#000000;">otherwise)</font><font style="letter-spacing:0.7pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:0.6pt;color:#000000;"> </font><font style="color:#000000;">third</font><font style="letter-spacing:0.65pt;color:#000000;"> </font><font style="color:#000000;">parties</font><font style="letter-spacing:0.7pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:0.7pt;color:#000000;"> </font><font style="color:#000000;">materials</font><font style="letter-spacing:0.7pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.7pt;color:#000000;"> </font><font style="color:#000000;">intellectual</font><font style="letter-spacing:0.6pt;color:#000000;"> </font><font style="color:#000000;">property</font><font style="letter-spacing:0.4pt;color:#000000;"> </font><font style="color:#000000;">developed </font><font style="letter-spacing:-2.6pt;color:#000000;"> </font><font style="color:#000000;">in whole or</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">in part</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">by</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">the Consultant</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">as a CSHL employee.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-size:12pt;margin-left:41pt;color:#000000;"></font><font style="color:#000000;">Paragraphs 5, 6, 7, 8, 9, 10 and 11 of these Uniform Provisions will survive termination of the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Agreement.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-size:12pt;margin-left:41pt;color:#000000;"></font><font style="color:#000000;">The</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Company</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">may</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">use</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant&#8217;s</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">name,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">in</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">doing</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">so</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">may</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">cite</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant&#8217;s</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">relationship</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">with</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">CSHL,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">so</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">long</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">as</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">any</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">such</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">usage</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">(i)</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">is</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">limited</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">to</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">reporting</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">factual</font><font style="letter-spacing:2.75pt;color:#000000;"> </font><font style="color:#000000;">events</font><font style="letter-spacing:2.75pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">occurrences only, and (ii) is made in a manner that could not reasonably constitute an endorsement of the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Company or of any Company program, product or service.</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">However, the Company will not use the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant&#8217;s name or CSHL&#8217;s</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">name in</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">any press release, or quote the Consultant in any company</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">materials,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">otherwise</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">use</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant&#8217;s</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">name</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">CSHL&#8217;s</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">name</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">in</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">a</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">manner</font><font style="letter-spacing:2.75pt;color:#000000;"> </font><font style="color:#000000;">not</font><font style="letter-spacing:2.75pt;color:#000000;"> </font><font style="color:#000000;">specifically</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">permitted</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">by the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">preceding sentence,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">unless</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">in</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">each</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">case</font><font style="letter-spacing:2.75pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:2.75pt;color:#000000;"> </font><font style="color:#000000;">Company obtains in advance CSHL&#8217;s</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">written</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">consent,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">and,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">in</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">case</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">use</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant&#8217;s</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">name,</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant&#8217;s</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">consent</font><font style="letter-spacing:0.1pt;color:#000000;"> </font><font style="color:#000000;">as</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">well.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-size:12pt;margin-left:41pt;color:#000000;"></font><font style="color:#000000;">The</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">and</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Company</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">acknowledge</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">that</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">(i)</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Consultant</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">is</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">entering</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">into</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">Agreement and these Uniform Provisions in the Consultant&#8217;s individual capacity and not as an employee</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">or agent of CSHL, (ii) CSHL is not a party to the Agreement or the Uniform Provisions and has no</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">liability or obligation under them and (iii) CSHL is an intended third-party beneficiary of this Agreement</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">and certain provisions of this Agreement are for CSHL&#8217;s benefit and are enforceable by CSHL in its own</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">name.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-size:12pt;margin-left:41pt;color:#000000;"></font><font style="color:#000000;">These</font><font style="letter-spacing:1.2pt;color:#000000;"> </font><font style="color:#000000;">Uniform</font><font style="letter-spacing:1.05pt;color:#000000;"> </font><font style="color:#000000;">Provisions</font><font style="letter-spacing:1.25pt;color:#000000;"> </font><font style="color:#000000;">will</font><font style="letter-spacing:1.25pt;color:#000000;"> </font><font style="color:#000000;">be</font><font style="letter-spacing:1.25pt;color:#000000;"> </font><font style="color:#000000;">in</font><font style="letter-spacing:1.2pt;color:#000000;"> </font><font style="color:#000000;">effect</font><font style="letter-spacing:1.25pt;color:#000000;"> </font><font style="color:#000000;">for</font><font style="letter-spacing:1.25pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:1.25pt;color:#000000;"> </font><font style="color:#000000;">full</font><font style="letter-spacing:1.25pt;color:#000000;"> </font><font style="color:#000000;">term</font><font style="letter-spacing:1.05pt;color:#000000;"> </font><font style="color:#000000;">of</font><font style="letter-spacing:1.1pt;color:#000000;"> </font><font style="color:#000000;">the</font><font style="letter-spacing:1.1pt;color:#000000;"> </font><font style="color:#000000;">Agreement.</font><font style="letter-spacing:2.3pt;color:#000000;"> </font><font style="color:#000000;">The</font><font style="letter-spacing:1.1pt;color:#000000;"> </font><font style="color:#000000;">Company</font><font style="letter-spacing:-2.65pt;color:#000000;"> </font><font style="color:#000000;">and the Consultant</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">agree that any amendment of the Agreement (including, without limitation, any</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">extension of the Agreement&#8217;s term or any change in the consideration to be provided to the Consultant</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">under the Agreement) or any other departure from the terms or conditions of the Agreement must be</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">signed by the Consultant and an authorized representative of the Company, and also is subject to CSHL&#8217;s</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">prior written approval.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.</font><font style="font-size:12pt;margin-left:41pt;color:#000000;"></font><font style="color:#000000;">If any of these Uniform Provisions is adjudicated to be invalid, unenforceable, contrary to, or</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">prohibited</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">under</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">applicable</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">laws</font><font style="letter-spacing:2.75pt;color:#000000;"> </font><font style="color:#000000;">or</font><font style="letter-spacing:2.75pt;color:#000000;"> </font><font style="color:#000000;">regulations of any jurisdiction, the Agreement will terminate as of</font><font style="letter-spacing:0.05pt;color:#000000;"> </font><font style="color:#000000;">the date such adjudication is effective.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-12</a>-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:6.27%;"></td>
<td style="width:43.78%;"></td>
<td style="width:6.27%;"></td>
<td style="width:43.68%;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR COMPANY:</p></td>
<td colspan="2" valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CONSULTANT:</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STOKE<font style="letter-spacing:-0.1pt;"> </font>THERAPEUTICS,<font style="letter-spacing:-0.05pt;"> </font>INC.</p></td>
<td colspan="2" valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ADRIAN<font style="letter-spacing:-0.35pt;"> </font>KRAINER</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edward M. Kaye</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adrian<font style="letter-spacing:0.05pt;"> </font>Krainer, PhD</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief<font style="letter-spacing:0.05pt;"> </font>Executive Officer</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-13</a>-</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>stok-ex231_6.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
stok-ex231_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-top:63pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the registration statements (No. 333-232191,No. 333-237345 and No. 333-254499) on Form S-8 and (No. 333-239801) on Form S-3, of our report dated March 10, 2022, with respect to the consolidated financial statements of Stoke Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts</p>
<p style="margin-top:10pt;margin-bottom:10pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>stok-ex311_13.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
stok-ex311_13.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF<br />THE SECURITIES EXCHANGE ACT OF 1934, <br />AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Edward M. Kaye, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Form 10-K of Stoke Therapeutics, Inc.; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) <font style="color:#000000;">and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) f</font>or the registrant and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:59.62%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Edward M. Kaye, M.D.</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:59.62%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edward M. Kaye, M.D.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:59.62%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:59.62%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>stok-ex312_10.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
stok-ex312_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF<br />THE SECURITIES EXCHANGE ACT OF 1934, <br />AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Stephen J. Tulipano, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Form 10-K of Stoke Therapeutics, Inc.; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:3.85%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:59.62%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Stephen J. Tulipano, CPA</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:59.62%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stephen J. Tulipano, CPA</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:59.62%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:59.62%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting Officer)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>stok-ex321_9.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
stok-ex321_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Edward M. Kaye, Chief Executive Officer of Stoke Therapeutics, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Annual Report on Form&#160;10-K&#160;of the Company for the year ended December 31, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2022</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Edward M. Kaye, M.D.&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.5%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Edward M. Kaye, M.D. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>stok-ex322_8.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
stok-ex322_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Stephen J. Tulipano, Chief Financial Officer of Stoke Therapeutics, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Annual Report on Form&#160;10-K&#160;of the Company for the year ended December 31, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2022</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Stephen J. Tulipano, CPA</p></td>
</tr>
<tr>
<td rowspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.5%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stephen J. Tulipano</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gu0gjnulhgsv000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (5 VD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M K6$6FY2ZG+B*].<%"":LV]7?<6BBBM#D"BBB@ HHHH **** "BBB@ HHHH
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M#-K^F3I=^'X7CE'R:<S;G'<$8/.,]<=:A5I.=O0Z5@:3I<[;5[V\K=S3L/\
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MIIR:70YYX><(*H]GYZ_<:-%%%4<X4444 %%%% !1110 4444 %%%% !1110
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M^VWW&=I_A_2M*E,MG9I'(1C>6+$?0DG%:=%%-))61,YRF[S=V%%%%,D****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBN4L_'EG=31%],U*VLYKQ[&*]F6(Q/,KE-ORR%QEE(!90* Z7.KHHHH **
MR8-:\[Q5>:)]GQ]FM(KGSM_WM[.NW;CC&SKGO6M0'D%%%1S3PVT+S3RI%$@R
M[R,%51ZDGI0!)17-7WC:PL9KK_1+VXL[-U2\OH%1H;<L ?FRP8X#*255@ >:
MV-4U6UT?39+^[8B%-H&P99RQ 55'<DD ?6@/(NT5S0\:V,45]_:%G>Z=<V:Q
MN]K<JAD82':A3RV96W-\O!SGKB@>-;&**^_M"SO=.N;-8W>UN50R,)#M0IY;
M,K;F^7@YSUQ18#I:*Y^W\7V+"^74+:[TN>QC6::"\5"WEMD*RF-G5@2", DY
M&,5:\.>(;3Q/I U*RBN(H3+)%LN8]C@HQ4Y7)QR._/J!18#6HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** ,?5M>.F:C:6$&E7VHW5U%+,J6A
MA&U(S&&),DB#K*O3/>J__"0ZI_T)FN?]_K+_ .2*+S_DH>C?]@J__P#1MI70
M4 <__P )#JG_ $)FN?\ ?ZR_^2*/^$AU3_H3-<_[_67_ ,D5T%% '/\ _"0Z
MI_T)FN?]_K+_ .2*/^$AU3_H3-<_[_67_P D5T%% '/_ /"0ZI_T)FN?]_K+
M_P"2*/\ A(=4_P"A,US_ +_67_R17044 9>BZT-9%ZK6%W8SV5Q]GF@NC&6#
M>6D@(,;LI!61>_K6I7/^'O\ D.>+/^PJG_I%:UT% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?^#_"<DU@L^KSZ
MCL@U2YN8-.F58XD;SW*28"!VZ[AN8CG('2O0**:=@>JL<9XX&I:5=V'B/1M/
MGO[N!9+.6V@0LSQR#Y3@=ED5"3V!:N=UW09[+2['0CI,5V$L2_VR;39K]7N6
M+%]J(RB)RQW>8Q[X[5ZK14VTM_7]:W'?6_\ 7]=#R-]%US4-%U5'LKM[NX\+
M6469D8&293(63+?Q\\@\\C-:6L/JVO7.K3Z%8ZG;2MH)A@FN+5[<M+YF2J[]
MI#8SUQZ@]Z]*HJY/F=_7\;_YDI67W?A;_(\_\#:7]EUN:XA<6T?V;9+9P^'[
MC3XW?<,2,TK,LCCD97D@]36O?:%>KKKZLRIK,((:*SNFVFV('6'^#/\ O -_
MMXXKJ:*5]@2M<\QOK:_BTCQ=X>_LR_EO-8N99+-UMV:)EF11EI0-B;3G(8@\
M<9R*V?%4=WJ&CMIUGI]\\VD7-E<EO*PERJ.KL(C_ !$!3D>N!7:T4)VM;I;\
M-A_\'\=SR[Q%I]_XCU:?7]/TZ]^S6B67EQSV[0RW!BN/-D"QN W"],@9/3-'
MB+3[_P 1ZM/K^GZ=>_9K1++RXY[=H9;@Q7'FR!8W ;A>F0,GIFO4:*$^6UNC
MNO4'K>_73[CC;&X-SXMU#Q,;*_BTZ+3H[5#+92K+*P=F;;"5\P@9 ^[SGC-+
M\.[@G2KZWDM+^WE&H74X%U930 I),[(074 Y!!P.1WQ78T4+33^M[@]?Z\K!
M1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JAKFI_V-H&H:IY/G?8[>2?R]VW?M4G&<'&<=<5?K(\565QJ7A'6+&TC\
MRYN+*6*)-P&YF0@#)X'/K2E>VA4+.2OL4-)\3WMSJ]KIFJZ9#:37EHUW;/;7
M9G1D4KN#$HA5AO'8CWK=;4K%8[J1KVW"6A(N6,JXAP WSG/R\$'GL:R_#_AF
MPT:"&=8)3?&W6*2:XN9+AU&!E SLQ"Y'0'%8'B/PUJUYXI$=A"IT75Q$-6<N
MHV>2V1\IY;S%^0X["K=N:R_K^D1&_+=G6OKFDQW\-A)JEDEY.H:&W:X022 ]
MU7.2/I6=H/B+^T!>B_DM8)$U2>QMU#;3*$/  )Y; )./3I7*^(M#\3:EJ4T,
M5I.+5=2MKB(6WV5+>2))$)9RW[XR@ ],# '7H9_^$=UFU\N^6P:>2U\17&H"
MVCEC#S0NKJ"I9@H/S9PQ'2IC;=_UK'_-_<-[:?UH_P!;'<2ZKIT$%S/-?VL<
M-JVVXD>90L)P#AR3A3@@\^HJ2SOK34;5+JQNH+JW?[DL$@=&^A'!KSF[\->(
MK]+F^^S7%E*NN_VBMM!- \LD0@5!M+@Q[P1G#<9'7H:ZGPCI3V-KJ$TZ:M'/
M>W)FF&I/;;RVU5W+]G^0 @#WR":=M/E_E_7R%U_KS_KYFO/JUA;7L=E)<I]J
MDY6!<L^/[Q49(7_:/ ]:YVV\:SS-I][)I:1Z)J-S]FMKP769"Q)",T>P!58C
M@AR>1D#/%S3/#<V@.\&FS1S6-PY:9+H'SAGJPE'+X]'!/^T,5SVG>'];_L?0
MO#5QIIBM])O(YI-0,R&.:.)BR;%#%]Q^7.Y5 YY/&2.ZOY?\'[@>S_KT.KUK
M6YM/N['3[&T2[U&^+^5%+,8D54&69F"L0!D#A3R161#XVFNQ!8VNEHVN27,U
MM)9RW6V.)H@"[&0(3MPRX.S)W#@<X9?0:W/K&C^(O[#<S6375M+8174;2-$Y
M 6168JF?D4[21@,1U%9EMX=UK3=;M_%']FM<7,EW=27&GPS)YB1RJBKAF94+
M#RES\V.3@G'(O/\ KL-^7];FM#XVFNQ!8VNEHVN27,UM)9RW6V.)H@"[&0(3
MMPRX.S)W#@<X2Y\=R6WAB]U(:'=3W]E++!<64#AEC>,;F)DP $VX(8@$@CC/
M%95MX=UK3=;M_%']FM<7,EW=27&GPS)YB1RJBKAF94+#RES\V.3@G'-J32]8
MMO"/B!?[(GN=0UR:XD^RV\T7^C[X]B;V=U4X"KG:3R>,]:F5^6_6WXZ:?F.-
MN9)[7_#7_@'9Z?=_;]-M;S9L\^%)=F<[=P!QGOUJS65X;-T/#UE%>6$]E/!"
MD+13-&QRJ@9!C9A@]N<^PK5JY6YG8B#;BK[E.3389=9MM49I//M[>:W101M*
MR-&S$\9SF)<<]S^%RBBI*"BBB@ HHHH **** .?\/?\ (<\6?]A5/_2*UKH*
MY_P]_P ASQ9_V%4_](K6N@H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+(A8 XMP<9'J*[2N?\=_\D\\3?\ 8*NO_134 =!1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA#;ECZ*)&!/UZ>] &<5#2-Y2N4!)&1SCKS^%='X<^('B;PO=6KV&KW?V:W(
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M"WL+/P_JLMS<2+%&@,?+$X'>O8%R5!(P<<C/2@!:*** "BBB@ HHHH ****
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M&['7M6A\./C!_P + \0W&D_V%]@\FT:Y\W[7YN<.B[<;%_OYSGM0!ZA1110
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M>H^'/AQJVK:3<?9[Z#R?+EV*^W=,BGA@0>"1R*^</^%V_$/_ *&'_P DK?\
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M &"K_P#]&VE=!0 5Y]\4]%L-=LM/M;^'S(P9&4@X93\O(/:O0:X[QY_S#_\
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M\Q_PK\V?0Y3_  7Z_H@HHHKPSTPKU?2/^0+8_P#7O'_Z"*\HKU?2/^0+8_\
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M?FSZ'*?X+]?T04445X9Z85ZOI'_(%L?^O>/_ -!%>45ZOI'_ "!;'_KWC_\
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M*_1CXX*\<KV.O'*^:XB_Y=_/]#VLG^W\OU"BBBOF3V@KOO!'_(%F_P"OAO\
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M ,C+:?\  _\ T!JZL%_O-/\ Q+\S'$_P9^C_ "/2J***_03Y$QO%7_(M7?\
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MRWDNK< S0)*"\8/3<H.1GMFK- '/WG_)0]&_[!5__P"C;2N@KG[S_DH>C?\
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M?FSZ'*?X+]?T04445X9Z85ZOI'_(%L?^O>/_ -!%>45ZOI'_ "!;'_KWC_\
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MDN1NB4]>#UQSCD8R..*YWF<.2+3CS/=<RT^?6QLL%+F:=[=^5Z_(][\,^/\
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M:R?[?R_4****^9/:"N^\$?\ (%F_Z^&_]!6N!KOO!'_(%F_Z^&_]!6O8R/\
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MV)))[BYMQ<2K9W%R#YDT ;Y&;/)X[GD@ ]Z([!+?^NQTM%%% !1110 4444
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MK[S/LEPDNS,MIC.TG&<'KZ&NPKG[S_DH>C?]@J__ /1MI704@"N.\>?\P_\
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M%%%%?2GBGCE%%%?FA]H%%%% '?>"/^0+-_U\-_Z"M=+7->"/^0+-_P!?#?\
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M_P"@FO**]7U?_D"WW_7O)_Z":\HKY7B'^+#T/>RCX)>H4445\\>L%>E>%?\
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MAK?V?_B5Z'#Y.[_F+3-G./\ IV'I7#F5&=;"RITU=NWYHZL%4C3KQG-V2O\
MD<K16E_PA_C#_GTT/_P93?\ R/5.30?%46LVVEM9:-Y]Q;S7",-1EVA8VC5@
M?W&<YE7''8_C\K_8^-_D_%?YGN_VCAOYOP?^1#5S2/\ D-6/_7Q'_P"A"IO^
M$/\ &'_/IH?_ (,IO_D>IK3PMXPM;V"X^Q:&WE2*^W^TYAG!SC_CWK2EE.,C
M.+<.O=?YDSS##.+2E^#_ ,CTNBN?^V>,/^@%H?\ X.9O_D6C[9XP_P"@%H?_
M (.9O_D6OM#YHZ"O'*]#^V>,/^@%H?\ X.9O_D6N._X0_P 8?\^FA_\ @RF_
M^1Z\/.<'7Q/)[*-[7[>7<]3+<12H\WM':]OU,VBM+_A#_&'_ #Z:'_X,IO\
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M.DER6&.O D3\_8UL44 %%%16UU;WMNMQ:SQ3PMG;)$X93@X."..HH EHHHH
M**** ,?Q98W&I^#=<L+./S+JZT^>&%-P&YVC8*,G@9)'6MBBB@ HHHH ****
M "BBB@#'\2V-QJ&E00VL?F2+J%E,1N PD=U%(YY]%5C[XXYK8HHH **A2[MI
M+J2U2XB:XB57DA#@NBMG!(Z@'!Q]#4U !1110 4444 8_A.QN-,\&Z'87D?E
MW5KI\$,R;@=KK&H89'!P0>E;%%% !1110 4444 %%%% !1110 4444 %%%%
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M-7T>WUF&VBN7E5;>ZBND\L@$M&P8 Y!XR.:H6_@_2K7Q#JVMQ+*+S4XA%/\
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M6:_NC=2[R" Q55PN .,*.N:T<ESR??\ S1"7NI=O^":%%%%04%%%% !1110
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M]F=2R,H8J2,;AU%8L?A;3D\(OX:;S9+%X&@=W8>8^[.YB<8W$DG..M):._\
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MVO?Z* / /^&9?^IN_P#*;_\ ;:/^&9?^IN_\IO\ ]MKW^B@#P#_AF7_J;O\
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M +;7O]% '@'_  S+_P!3=_Y3?_MM'_#,O_4W?^4W_P"VU[_10!X!_P ,R_\
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M*F*ORKOK^#:_"Q;ZOM_FD_QN>VT4V/?Y:^9M\S W;>F>^*=2$%%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_3;[^IZ)13(F9XD9T,;,H+(2"5/IQQ3Z0!1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M34KH7<5XCIL3]VBE&4MOW97LI&#U%=3112Z)#ZA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gu0gjnulhgsv000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &; LP# 2(  A$! Q$!_\0
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MHH **** "BBLA]9E$LBQVJ,J.R9:8@G!(Z;3Z4 :]%8W]LW'_/G%_P!_S_\
M$T?VS<?\^<7_ '_/_P 30!LT5C?VS<?\^<7_ '_/_P 31_;-Q_SYQ?\ ?\__
M !- &S16-_;-Q_SYQ?\ ?\__ !-']LW'_/G%_P!_S_\ $T ;-%8W]LW'_/G%
M_P!_S_\ $T?VS<?\^<7_ '_/_P 30!LT5C?VS<?\^<7_ '_/_P 31_;-Q_SY
MQ?\ ?\__ !- &S16-_;-Q_SYQ?\ ?\__ !-']LW'_/G%_P!_S_\ $T ;-%8W
M]LW'_/G%_P!_S_\ $T?VS<?\^<7_ '_/_P 30!LT5C?VS<?\^<7_ '_/_P 3
M1_;-Q_SYQ?\ ?\__ !- &S16-_;-Q_SYQ?\ ?\__ !-']LW'_/G%_P!_S_\
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M0!LT5C?VS<?\^<7_ '_/_P 31_;-Q_SYQ?\ ?\__ !- &S16-_;-Q_SYQ?\
M?\__ !-']LW'_/G%_P!_S_\ $T ;-%8W]LW'_/G%_P!_S_\ $T?VS<?\^<7_
M '_/_P 30!LT5C?VS<?\^<7_ '_/_P 31_;-Q_SYQ?\ ?\__ !- &S16-_;-
MQ_SYQ?\ ?\__ !-']LW'_/G%_P!_S_\ $T ;-%8W]LW'_/G%_P!_S_\ $T?V
MS<?\^<7_ '_/_P 30!LT5C?VS<?\^<7_ '_/_P 31_;-Q_SYQ?\ ?\__ !-
M&S16-_;-Q_SYQ?\ ?\__ !-']LW'_/G%_P!_S_\ $T ;-%8W]LW'_/G%_P!_
MS_\ $T?VS<?\^<7_ '_/_P 30!LT5C?VS<?\^<7_ '_/_P 31_;-Q_SYQ?\
M?\__ !- &S16-_;-Q_SYQ?\ ?\__ !-']LW'_/G%_P!_S_\ $T ;-%8W]LW'
M_/G%_P!_S_\ $T?VS<?\^<7_ '_/_P 30!LT5C?VS<?\^<7_ '_/_P 31_;-
MQ_SYQ?\ ?\__ !- &S16-_;-Q_SYQ?\ ?\__ !-']LW'_/G%_P!_S_\ $T ;
M-%8W]LW'_/G%_P!_S_\ $T?VS<?\^<7_ '_/_P 30!LT54TV^&I:?%=JA029
M^4G.,$C^E6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_=JQ_:EM_<NO_ 27_P")H NT52_M6V_N77_@)+_\31_:EM_<NO\ P$E_^)H
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M3]:12=HX[>M.I%^Z/I0 9/I^M&3Z?K2T4 ,8G<G'?U]J=D^GZTC?>3Z_TIU
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M2?\ H;5J5E^'?^0'!_O2?^AM6I0 4444 %%%% !1110 4444 %%%% !1110
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M-?H/J/YT .HHHH *3^(_2EI/XC]* %HHHH :_P#JV^AIPZ4U_P#5M]#3ATH
M**** $_B'TI:3^(?2EH **** &Q_ZM?I3J;'_JU^E.H *0]1]:6D/4?6@!:*
M** "FK_%]:=35_B^M #J*** ,KP[_P @.#_>D_\ 0VK5K*\._P#(#@_WI/\
MT-JU: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$\CQ)IXN#M! R2TJ!>3C'.?PI@:/A:1YO#-C))<I<ED)$J3B8%<G \P??(&
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M&)).2,$')&"*7J#\OZW_ . 07=WKEO>:=H:W]LUY=>;(UZ;;&V) /X-V"Q+
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M#XW9P.O Z<=:@C\'0C3Y=.N-5U&XL# 8(K=W4")3[A06(QP6SBJ?7^NK_P"
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M/YBGRWV!5(O0O"BF1RQR#*.K?0T^D6%(?ZTM(?ZT@%HHHH *.]%'>@ HHHH
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M^N\W_HQJ +=(?NGZ4M(?NGZ4 "_<7Z4M(OW%^E+0 4AZCZTM(>H^M "T444
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M49' Z^E.I#U'UH -H]!^5&T>@_*EHH 3:/0?E344;>@ZGM[T^FI]W\3_ #H
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M%% !1110 54T[_CV?_KO-_Z,:K=5-._X]G_Z[S?^C&H MTA^Z?I2TA^Z?I0
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M[OXG^=+D>_Y4U"-O?J>WO0 ^BDR/?\J,CW_*@ /3\12TTD8[]1VI<CW_ "H
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M40I\LKDQ@XLL4445J:&5X<_Y 4'^])_Z&U:M97AS_D!0?[TG_H;5JT %%%%
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M2JS6RL#O)DVAMN.AX7.=H% '1>=%_P ]4_[Z%'G1?\]4_P"^A5'_ (1_1?\
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M5>#G!&5Y!P<$<'!H V/.B_YZI_WT*/.B_P">J?\ ?0JC_P (_HO_ $!]/_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMNB@#-TK37LI;^YF96N+VY,SE>@  1%'T55S[YK2HHH **** "BBB@ HHHH
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MTV64ETTLL6_=B0@+C(P!U)]Q1!XGU;5+JUCM-L,DB6SM$+8NN'&Z0E\X7 Z
M]??/ M?Z_KL#T.YHKCK'4KZXNQI]I-!9[I;R5I7C,F1'-M  +>^3S],5I:_J
ME]:2Z;:6*,\MVS@R1HK$!5S\H9@,GW/0&CI<.MC>) (!(&>GO0"&&00?I7"7
M,6JW^KVDU\8+>ZBTN>7RW@#^6X<#<OS'!/!X/'2J^D7VL66GVNGZ3:)*T-A!
M<D101J)6D!X8LXQPN-PR2>?:A:_UZ_Y _P"OP_S/1**YC[=JE_'JLT=[#:QV
M[RVZ0>3N?*IG=NW#G//3I^=0737+_"^26ZN?M$TE@KF3;@G*@\\G)]^]"_R_
M$#KJ*X#6-5EL;_[7%;B1K;5)U &<8^S#YFZG SDX[#@5?76]<GU.2"RB6[CM
M6@5VC1 DH=59GR9,J,-Q@'IWH6H/0["BN$@UV?0[:=V17@GN;Y81CDW F8HN
M?1AG\JV];\U8-#^T,IF%_#YA48!;:V<>V:%T^7X@^OE?\#H**XJW\0ZQ=3SQ
M66VY\ZS:YM'D@6(,0ZK\HWDD$-QNQR!4MEJ%_?>(-,\O4G\K[/<">&2WV$ND
MB AANP&&<9&>^.M']?U]P/0["BL/P_J%Y=/<V^IMMOHMK/!Y054#9P58$AE.
M#@]>.:YW2]6O]*LK>7SH;BUFN;Q/LRQX==AE?.[/)RN#QW'XC=AV.^HKB[?7
M/$(TN349K4-;+;I=%VC09&075 KL2-A)!//'O4L.NZEJVHBWL[FWM;:;SY8)
MVBWEXXRJ<<@<L6.?3'UH>F@O,Z^BN&/B;6;K3Y;R![6 6^F)?.AB+>8V9 0#
MGA2$^O-'B+4;V]@U)%N((+6TGM8S"T>6D+%&SNSQUP..Q_ ZV [FBL#57OAX
MJT:*WO?)@D28R1;,A]NT\\CL>/2L>'5M3-K'#8R6UN%M[RY8M$9,F.8J ,MW
MSS^E*]AI7.WHKB9?$VK6=I+++Y$[S6<%S"J1;1$9) F#EOF R#R1T/3M8;5=
M?B6UMYU2V>XOA;QSW$:99#&S9VHY&X,N!SSQQ56_K\!7_KY7.NHKC[36]5U"
MYCTU+JV@F0W.^Z\G<)1$X0;5S@9SD\GIQ55/$E[):7&HQPP)='3K:0$ABI9I
M74\9^[QD=^>M+?4#NJ*XG4+[6O,>R.HQI+;ZE;1^?'"5WI)@X*[N@)/?D5J^
M(M;NM"%M)B.2.:.2(97&9]N8QUZ'##'THZ7_ *V#J=#17 7>MW^M:+*N(8WM
MI+2*8[20+KSU##K]T8''O5V?7M7MY6TW(N+K[?\ 9A/%"H)3R1+PK,%W<XZT
M?U^7^8'945R+:IXAD,%LY@LKG['/<2>9"')*. O ? R"">3BKM\EWKWA:QEM
MWCCFG6&X:%I&191@,8RPY /X]*.E_P"OZT Z&BN$N(;#4-/TF:*VN+9AJ*V<
MT1N7.W#,&7(;!&>_\NE"R/'XON--FFFATD7,2JPD8YD$2%(B<Y53R?\ :(QW
MY%K_ %Z?Y@SNZ*YG6[J6\NM.L)[6ZMK2:^$4K.ZJ)E".0 48G!95ZXSTK'L(
MUO-7CTBZEE?3(YKSR5,S8;88PJ[LY(7<^.>WM0M0>G]>O^1WU%<-:-<RZ=X5
MO)+VZ9C=B':9#MD3$F&;^\2 O)S6MXD$[:MH"6UQ';RM<R 2.FX#]T_;(R?2
M@#HZ*Y*RUK5=0ETRW6>VB,@NO/F$18/Y,BH"HSQNS[]:S;GQ'>36M^K$7%K)
MI[W4#O!Y0;# < .6VD'O@\4+4#OZ*Y236=474I9!-;_8XM4CL?)\H[F5POS;
ML]06].U7[N]OI?$#6%M=06L4%LEP[21;S)N9ACJ, ;>3[BA:V_KI<'I_7G8W
M**Y*#7=2>:TO&E@:VNKZ2S%H(L-&%+@-NSR?DR1C&#5./Q/J]MID-_=-;3BY
MTR2\2-(B@C9-F,G)R#OY^E"U_KYAUM_78[FBN5U#4=8L&L;)+E+RXNY&/F06
MZ!D4)NP%9P"3ZD],\'K4%QK'B'RV1OL]G<0:<UW*CQ;RS*S #AL $ 'J<9H>
M@+4[&BN(EU?58)-=U&.[1HX;&">*V="55F5CUS[<\<_A4^N:UJ>CP$)=K<W-
MO +B=$M0$VEB!N8N,#@@8R>,T[6=@W5SL**XF:YOT?6GGNEN(8]3MHXX64C8
M&,/0AN@#'CUY]JLP:[J3S6EXTL#6UU?268M!%AHPI<!MV>3\F2,8P:F^E_ZZ
M?Y@=;29&[;D9QG%<MH&L:I=7.F&^FMY(]1L6N0D<13RF4IQG)SD/^E49GFL_
M$NM79N8_/:6"VM]MH))/F4$*I+#'?KQW-/\ K] .XHKSZYU&YU.RM)[H 3I#
MJ4+8 &=BE<D D \=B16QI>HWL-_86MTWE6<T$:VNV(,LI\K<P+9RK#!.",$#
MUH7]?B#_ ,_P.IHKBM6O;[3]=UZ]L[F",6ME!,T4D>XRX,GRYR, ],^I%6K7
M6M:OM:D%O9L;.&\^SR*50!4 &6+%]V[)SC;C'YT+4'H=717!:1J6H#28K6SN
M;>U6UL&NV::+?YA,CC'484;>3UY%27/C._M_+!MXQ(XANRA!RMJ4W2'ZJ0PS
M[B@'_7]?,[FBN?&LW3^$;_65$>Y8YYK8;>"BYV$^N0 ?QK*NM8UZS^WLUW:.
M+*WANR!;$;PY.4^]P!M//7D4 =K17(_VC??VG)9V3P0-<:I)"TCQE\*(%?.-
MW7/X>U5'\0WRVGVXI ;R/3;EB^UMI:.94Z9Z'&?ZT=OZZ7';^OG8[FBN-N=7
MUVRFOQ)=VDJ6,ENS 6Q4RK*0"OWN,<X//;\;HU^Y\R-"80SZNUEC'/E@$^O7
M@4+5V_KI_F+I?^NYTM%<;;:MKMY/9!;RTC2]EN8E'V8DQ")C@_>Y)"_3FIKR
M_FU+P18WDX432W%J7V# R)T!Q^5" ZRBN2MM8UZ_U*;[+;?Z*MU+;$LB;(PN
M0'SOW$[@#C;T/XU3;Q?J-Q;Q-:P)O_<VTX" E+AV(8#+ ?*%/!/5A0M0>AW-
M%<E;3:C-KFB_VG 8IE>Z5=P4%TVKAB%9@#^/:NMH **** "BBB@ HHHH ***
M* "BBB@ HHHH *9'#%$TC1Q(C2-N<JH!8X R?4X 'X4^B@" 6-H%11:P!4+,
M@\L?*6SN(],Y.?7)J"#1=+M8GB@TVTCC? =5A4!L'(SQS@]*O44 0R6=M,9#
M+;PR&5/+D+(#O7GY3ZCD\>YJ.XTRPNUD6XL[>42;=^^,'=M^[GZ9X]*M44 9
M\NAZ3-;QV\FF6;0Q,6CC,"[5)ZD#'&:>ND::E_\ ;EL+9;O&/.$0W],=>O3B
MKM% %&XT72KN&**XTVTECASY:/"I"9ZX&.,UEWWA&VOM2DNGFVK(T;,ODH67
M9C 1R,H..@]3C&:Z*B@"E<:-IEW&L=QIUK*BN9%5X5(#$Y)Z=3W]:DN]/L[^
M 07=K#/$I!"2(& (Z$>E6:* *\5A9PJBQ6D"*D9B4+&!A#U4>WM4,^BZ7=>3
MY^G6LGDKLBWPJ=B^@XX'M5ZB@"I_96G_ &\W_P!AM_M9&TS^4-Y&,=>O3BEA
MTRPM[)K*&SMTM6SF%8QL.>O'2K5% $'V*U\SS/LT._>9-WEC.XC:6SZD<9]*
MK'0M),L,O]F6>^$ 1-Y*_( <C''8]*T** ,Z\T:VO#:#:L<=O=?:C&B !WY.
M3_P(YSW-7I(8IMGFQ(^Q@Z;E!VL.A'H:?10!G+H.CHDJKI=FJR@B0"!?F!.<
M'CID _A3QHVF*ENBZ?;!;9BT $0_=D]2OH:O44 5;+3;'3@XLK."V#G+^5&%
MW?7%,AT?3+:[:[@T^UBN&!#2I"JL<]>0.]7:* ,Y=#T^W@NDL;2WM)+B-D:2
M*%0>?_UYQ35\/Z6=+M-/GLH+B"U0)$)HPV,#&>?6M.B@" V-HRNIM8"KQB%P
M8QAD&<*?5>3QTY-0S:/IES=+<SZ?:RSJH59'A5F '3DCM5VB@"O<V-I>-"US
M;13-"_F1&1 2C>H]#0MC9I]VT@7Y63B,?=8Y8?0GD^M6** *[6%DZ%&M(&4Q
M>25,8P8_[O\ N^W2LZX\+Z5/%;0+9P16\,_GM"L2[9#L9?F'T;]!6S10!0ET
M/29[2&TETVT>WA_U430J53Z#'%3M86; AK2 @HJ$&,<JIRH^@/(':K%% %6X
MTVQNXYH[BS@E68@RAXP=Y'3/KCM4DEI;31QQRV\4D<3*T:N@(4KT(ST([5-1
M0!7%A9A)$%I %DD\UQY8PSY!W'U;(!SUX%-N-,L+N.2.XLK>5)6#R!XP=S
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M.G7TR2W=A;3R(NU6EB5B!Z<CI5RB@"HVEZ>]U)<O96[3R!0\AC!9MI!7)]B
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MPQR>!R:M44 5;;3;&S6-;:S@B$1)39&!M)ZX^O>K5%% !1110 4444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gu0gjnulhgsv000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000002.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +Z!X@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Y,_9%_8L^
M'WB[X(S?%/XBZGK&H6]G+<H7EU"\9Y4MYGCWL%F"AW"AF"A5R3M SBOTD_9Z
M_P""9'[,W[1?@'Q/XUT&ZO[*/PRLIFB>_O%:0QAB< SC(^4_IZUP/[$,$>J?
MLG:5H5U\UKJ^M7%E(O8+-?2H<_\ ?5?H!\3=!UK]BCX=Z!=>$O.A\(^,[>WE
MUN:W1A$BW 7S-Y7@'#G.2*#1RDF]?ETZ/^OR1YG\%_\ @B1\!/BI;37!U>[T
MY$GD@1[C4+Q%D9&*@*3. 23V[_2OH&7_ (-V/@K;E3/KUU!%(1Y3R:E=JL@)
MX*YN,$$=.M:_BCXSWFG_  2^&OB?X<:W-:Q:IK6GB\N+1V&]I9D\Q79".I8@
MY_&ONG]IKXH^-M#\#?!>ZL_$$]M/JND6,URT4YWS,8$9BX4YR<G.?I0+GEW_
M *T_R/S[N/\ @WA^ EA&D^H>*WLX&*XDGU6X1"">S-< =J^6/VE?^"(?P:^&
M7AJ76?#/B.XU,(5'F66J74BC)/=+@XQ^-?8_PT^,OQ0_:Y^.4_[/_P#PE^H^
M'[?3!AM1$LT0*H.6!!&_C) 7<Q/"@GBOLCXX? #6O@5\*KO3]8\8W/BP7$#L
MMQ/)+(04']V<!P 01DJ <<<4!SR[]OP_K\%8_*[]GS_@@U\&_B%\,;3QGXCU
M^ZT_[5N(EO-2NT4;5W'YFG&>#Z_E7M%O_P &\7P#O8VN++Q6]Q;+]^>+5;AH
MUP.["X(_45Q'AG]ICXL_%C1I/V?_ (?W=]I,FG3RPQW4!DB'=?OC'IZXR*];
MDUC]KOX"?##4[76KK5K[3Y2J/JQ:>4PJQ(9M^6(P#SR,XZT!SR[_ -:?Y?UH
M<_\ \0[/P3*^<NO7+6W/^D#4KKRSC_:^T8IO_$/%\ UB:9_%3!%R"S:K<@#
M'7_2*_0/P[\5O&!_9+LO%$WB"<ZBT.Z2Y:<^<'*$D$$[^#Q7QUH'B?\ :1^)
M7AO6+CP?K&I7=I [F6=993L0,VXAL\8 SU[4!SR[_P!:?Y?UH>?6_P#P;N_
M_4%+:=X@GO@.OD:G=/MP<<[;@FK7_$.;\)/^?_4/_!A>?_'J_4S]@KQ/$RW/
MA[Q!XUEUCQG LBWVE37'FM$P!$@*%B05(/T(S7Z@4!SR_F?]?\,ON/Y<_P#B
M'-^$G_/_ *A_X,+S_P"/4?\ $.;\)/\ G_U#_P &%Y_\>K^HRB@.>7\S_K_A
ME]Q_+G_Q#F_"3_G_ -0_\&%Y_P#'J/\ B'-^$G_/_J'_ (,+S_X]7]1E% <\
MOYG_ %_PR^X_ES_XAS?A)_S_ .H?^#"\_P#CU'_$.;\)/^?_ %#_ ,&%Y_\
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MQ \(2ZW>7VI>:TKQ1E[^\R3R1UGYZ?AGCW_I1_:<U"6R\#S649\NWDA^95X
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M^(<WX2?\_P#J'_@PO/\ X]1_Q#F_"3_G_P!0_P#!A>?_ !ZOZC** YY?S/\
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MZ+[C\'?$'_!"K]G;PQ;W5Q/K5Q=+!#*Q\O4KE@&0'@@7!Z<U\*^"_P#@D-X
M^)OQ;F\*^'+O5GTV"[:)_*O[XJJ+)@YQ/V R?UK^E[XV^!]-^%'A?4;75?&S
M7^O7YE6"U-QODS,"$783O[\@@'GD4[]@+X,:KX<UC5O'>L6S&/5!=264\J')
M\S.T@L.N'S]:!<\N_P#2/Q3^+?\ P07^&'@:QTTQ7NIBYN/+$@^WWV[+ ;N/
M/'<_Y.*],\&_\&\OPN\0^$;'59+W4%NKR+>NZ_O >W/,X/7.#S7[@?M0Z\UI
MXITVWO)S'I\3P$DG"J!MW'T['\<Y[UZCX8_:+^%NB^&]#TL:Y'+>I"EOY *\
M-G/4'W/&.,9SS@ <TM==_P"OZ_S/YT];_P"#<'PU)!*-,U?44D.[85U.['T_
MY>..]?"G[2O_  0]/P$TB+4[S4M:G2[&Z(IJ-\R_>*G!%P0?ND'\<U_7_P"+
M_P!IQM/OH['PWIRZC),H:/$;/G(!'KZU^9?[67[0?B_Q[KN@>!M>T$VT-_<1
MP0)Y.%7?(%S@+U)8DDT!SR/S#_9!_P""$_P]^,/PZ;Q/X@OM4,[.L:&34+TX
M+@LO+3]0 >.N.M?5'_$.=\)2,?VAJ&!_U$+O_P".U^^O[*O@*;P!\+=+TZ5=
MGVR."\$>,8WQ9!_$-7TM0/GEW^?7I_D?RY_\0YOPD_Y_]0_\&%Y_\>H_XAS?
MA)_S_P"H?^#"\_\ CU?U&44!SR_F?]?\,ON/Y<_^(<WX2?\ /_J'_@PO/_CU
M'_$.;\)/^?\ U#_P87G_ ,>K^HRB@.>7\S_K_AE]Q_+G_P 0YOPD_P"?_4/_
M  87G_QZC_B'-^$G_/\ ZA_X,+S_ ./5_4910'/+^9_U_P ,ON/Y<_\ B'-^
M$G_/_J'_ (,+S_X]1_Q#F_"3_G_U#_P87G_QZOZC** YY?S/^O\ AE]Q_+G_
M ,0YOPD_Y_\ 4/\ P87G_P >H_XAS?A)_P _^H?^#"\_^/5_4910'/+^9_U_
MPR^X_ES_ .(<WX2?\_\ J'_@PO/_ (]1_P 0YOPD_P"?_4/_  87G_QZOZC*
M* YY?S/^O^&7W'\N?_$.;\)/^?\ U#_P87G_ ,>H_P"(<WX2?\_^H?\ @PO/
M_CU?U&44!SR_F?\ 7_#+[C^7/_B'-^$G_/\ ZA_X,+S_ ./4?\0YOPD_Y_\
M4/\ P87G_P >K^HRB@.>7\S_ *_X9?<?RY_\0YOPD_Y_]0_\&%Y_\>H_XAS?
MA)_S_P"H?^#"\_\ CU?U&44!SR_F?]?\,ON/Y<_^(<WX2?\ /_J'_@PO/_CU
M'_$.;\)/^?\ U#_P87G_ ,>K^HRB@.>7\S_K_AE]Q_+G_P 0YOPD_P"?_4/_
M  87G_QZC_B'-^$G_/\ ZA_X,+S_ ./5_4910'/+^9_U_P ,ON/Y<_\ B'-^
M$G_/_J'_ (,+S_X]1_Q#F_"3_G_U#_P87G_QZOZC** YY?S/^O\ AE]Q_+G_
M ,0YOPD_Y_\ 4/\ P87G_P >H_XAS?A)_P _^H?^#"\_^/5_4910'/+^9_U_
MPR^X_ES_ .(<WX2?\_\ J'_@PO/_ (]1_P 0YOPD_P"?_4/_  87G_QZOZC*
M* YY?S/^O^&7W'\N?_$.;\)/^?\ U#_P87G_ ,>H_P"(<WX2?\_^H?\ @PO/
M_CU?U&44!SR_F?\ 7_#+[C^7/_B'-^$G_/\ ZA_X,+S_ ./4?\0YOPD_Y_\
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MDL3H?^!*10!^=WPNN-*\._$?4+S5+NTM8A=NY%RR#.U]V!N^I]_3K72?'_\
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MJ(#D ^H!_.@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOYYO^#D;_DQH?]C"/Y6]?T,U_/-_P<C?\F-#_L81_*WH%3^./J=__P $"_\
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MQ];"S/YV\=,"_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5/4/^/"]_Z]9_\ T4U7*IZA_P >%[_UZS_^BFH _D#E
M_P"4X_@;_L3?%'_I\\,442_\IQ_ W_8F^*/_ $^>&**"I;K_  P_](B>S?\
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M329;B>&SB$A9 ^\JFU>GH,?_ *J_HZ_:*N+BU^$7BV:UW><MDVT("6/R29
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M2YNUFW>^W<_D[$8:=+&U\)%>TG#$U,/!4TY<[55TX**UNY:)6W;T.CK\9_\
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M1/7Z_GF_X.1O^3&A_P!C"/Y6]?T,U_/-_P '(W_)C0_[&$?RMZ!4_CCZG?\
M_! O_DS/P;_UXQ_^@K7[M5^$O_! O_DS/P;_ ->,?_H*U^[5!+W?J_S"BBB@
M04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %(&R2.>*6D) !)X ZF@#DO&OB_3_!6A76MZBZK% C;0S!=S[6*
M]>V0/K7XP_%/X?\ Q4^,GC8?$OPS-<C0=%NWO5A4N8I4BD#D  X/RCL.,^@K
MZH_;"^*UO#J%GX.%PRV<\L*W#1$L,YPV=N<=*^DO@#JO@<_#W2=$T^XMG>2
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M_L;P9M+RUNA_T[W$4W3_ *YLQH MT444 %%%% !1110 4444 %%%% !1110
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MC]+^*UC%I>L,EAXNCQ]HL&"QDG:"0%^7!!Z  DDU]4$G( ''&>#ZT .HHHH
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M%% !1110 452N-2T^T.+N^M+8^D]S#$?R=U/Z5/#<V]RN^WGAN$_O0RI*O\
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M6PB*X"KN5MN 3QD]LG.>_->L5\U_'3]H'1OAAIMU8:?*EYXL*D6NGX5CN"Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*IZA_P >%[_UZS_^BFJY5/4/^/"]_P"O6?\ ]%-0!_('+_RG'\#?]B;XH_\
M3YX8HHE_Y3C^!O\ L3?%'_I\\,44%2W7^&'_ *1$]F_X-R?^2::A_P!?U_\
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M*@?TKUJL'POIAT;0-*TPC!L[2.$CT*YK>H **** $P"<XY%+12,2!P,\^AH
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MX/-O%*T:W$,B2!3C<"6&#ZU^;=_;FR^'+VEO^Y%Q?(7D3@N&8;@2,$YR<^M
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MP!^E '04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 53U#_ (\+W_KUG_\ 135<JGJ'_'A>_P#7K/\ ^BFH _D#E_Y3
MC^!O^Q-\4?\ I\\,442_\IQ_ W_8F^*/_3YX8HH*ENO\,/\ TB)[-_P;D_\
M)--0_P"OZ_\ _2R:OZHJ_E=_X-R?^2::A_U_7_\ Z635_5%0$_B?R_)!1110
M2%-5MV>.E.HH ***0$'IS0 M%%% '(>/[*74O!'BNPA!,MWH.I01@=2\EM(J
M@>^>E?Q4_!K5X_V?/^"D$\7C;&EVNJ>)M\5S>?(I#WC;<,^!W%?W!LJNK(X#
M*P*LI&05(P01Z$5_/;_P5;_X)NZO\6[A/C#\([=K7QCI ^W*;*(B9IH<R?\
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M"Y12$@8SWZ4M !1110 4444 %-=$E1XY%#QR*R.C#*LC JRL#P002"/2G44
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M=TQ\W]X8QZ8KS+]N[]K"XBT?PS8_#*[N?M&IND9D7='DRL.I&.F_;U[9QVH
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M,UI&P]QM% 'L-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS:/?ZCIW@JX6#S(-\R1B' 7;C('"8'0X_.OU.^#?[,EAX*EBU/Q&5U'455)
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M$PDL9"5$9Z@8(]/<U\_?L1_MZ^+/V>[N7PMX@O;B^T>*,PL;AV9(W' "[R0
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MBP!_ UE:_JJZ?I=S<PW%LDXC+6XDE0>8W8)S\Q/;&:"3=Y[?Y_0T5\*?%_\
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MWHTXJ6GDTS^;L7.-7%XBI'X*E>K.+W]V4VUZZ/YCAV'M_+'^-?DM^W=XYL_
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M?Q$8KVL[U?WCPW-JI-<O+=G0V'_!+O\ :"W 2^/;E<XY;4'&/7)\WCMW^M>
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MBIB.)Y99.3J^T@\'E]'#58I?#&5:'OS\[[[L_.?]O&\DMU\%1H2!+. WH?\
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MIIUD/RMHA0!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 53U#_CPO?^O6?_T4U7*IZA_QX7O_ %ZS_P#HIJ /Y Y?
M^4X_@;_L3?%'_I\\,442_P#*<?P-_P!B;XH_]/GABB@J6Z_PP_\ 2(GM/_!N
M01_PK/4!CG[=J/./^GJX_&OW7_;>U#Q?X;^"/BCQ?X0NY+?4-!LS<!8F978
M.Q(V\G&T9/H<5^$?_!N23_PK74..#?:A_P"ED^/TK^FOXD>#K7Q]X,USPI>H
MLEOJ]I);R(PRI#*R\@]>O2@)_$_E^2/Y,/$W_!0?XU^-?A_X3T3PSJ]U'XCT
MSQ'#'KIBEE$JV<-RHF,F#N"A0QYK[Y^+W[0WC_X@^'/A')\-/$K7UQIEA8+X
MQ6TG9]DZ1)Y_G[">=P;(8?IFO1/AK_P2WT[PKXY\>:K=6R/IVL6U^=.C:-2D
M5Q<*YC:,$8!!(P1SFNW_ &+/V#-=^$<_Q57QN9;Z#7KR]?0ENP6$$4DCF(0A
MQ@ *1@+P.,8H)/G/XL>/_$/BK2_#.GZW?-/")K5)%+'[^Y5?.??K^N:Y;QS\
M6OB%I/C_ .'?P<\!:[+I$?B6"W@81RM'D2HJG[I&>M??GB/]C/4M3:V*1MBV
MO?M"<9 4.7&/;@<"N0^+/[$&MW<^@_$KPJLC^-O"D:?V?$BY<R1+\F,#/510
M!^=^J?!GXB_"?]H>QU'QKXODUU6E@ODL7N3*Q+E9-NPL?7M7[&Z%^TYKNMI9
M>!K/P9>6[76CBRAU7RIU1/\ 1O*#@X\OIT(7_$_)'P[_ &5/C3XZ^(%E\0/B
MHETMW:W,8%O,'V>1$0%&&XY K]CM%\+:)IMAI\2:/I\<]K:PP^:+2'S040*Q
M\S9OY.3U[T ?RJ? ?X,^/=:_;\^+SZ%X@N(=<6WU&XMT%RX*RMN<!4#<;2?T
MZ5]M:/\ M&_$']GWX;_%3P[\5?$K_P#";2ZA=0>'8[N=O/D65V6 Q"0[SD$$
M;1WKW?3OV3OB+\-/VO=0^-W@^"6;3=?OG6_4*2@MIY/WF3Z!2<U\#?\ !3+X
M9ZS\1OVY?@QX=LH;ZVTG4Y]'?6HK2-_LLCEH _G;1L&>IW<]>F* +_QI\=_'
M^]^"7PX\6:=XSNM$O_%.LVT+L;J2(R17,RA>2RDY#?YXKK+F3X^_ WXK_"35
M=>\>W&HZ1KVE6MY=Z:UW(XN"\2R$[-Y!W;L<@UZ9_P %2_A-J?A'X0?"/POX
M M[HW>C36'V>.SC8YNK5TC)(C!ZNHQZUL? G]FGXU?&#6_A=XU^+L-W!8>'=
M%LUM8IU<*T(B7;N#CT]: /C;XC_MG?'KXC?'WQEX*\$PZC=PZ792BTLK;SB4
MF1"0VU>^X9!Q^-?=_P"Q[^T1\8O 'P6\=^,OCKI]_;OILES'IYU 3+L9-WE$
M&7' (SZ=1S73_$']D?QC\'/B_=_%KX->'+?6[_5U47<+6RRC#</D;3COG/X\
M5)\7[GXC?$'X7W'PK\6^%H]"UG77C=UL[7R@7?.=VU1R=WO^- '%_L__  ^U
MWQE=_$/]I_1)WMTO;;4;NT;)VN8U>1MA]@ 3CL2>W'Y^_$S_ (*!_%36O!?C
M[X?^&M:F7QQ9ZS-!:>5+)YXCCFQ\NT[NB]O>OZ%OV:?A$_P__9WT[X<7D6R6
M6PU&"<%<,WVZV2,;O7G./_KU^:?AW_@EQ#I?[0VH?$&:+S=$U*XN)YH'3,+/
M*S,"1C&?FZXZT ?-Z_M1_%3QA^S9X,\)Z%XDEG^)^FM$_B&&.9S=JJ[2_FX.
M\=3G/Z5TUU\5/'>L_#.UT?Q+J;S2JD45]&S,6$N '#9YSGK_ /7KZE^ G_!/
M2\\ ?M$^/O&^K*TWA76HIDTVSE4FVB+@[?+4C8,$C&/I[UZ7K_[%E[=W.L+;
M1%;:[OI)X55/E5"Y*@8'I^'ZT ?!7C_XP>*OA5X2^'&A^"-4?2[OQ7>VUF\D
M<C1EFG=8SRI_V_TKPO\ :.^!'Q2\+_%SX>^,O%WC*6\MM<BT_5#9O<LV_P P
M)+M"ECR<]*_5SXD?L+/XP\(:)* PUWP>T=YI"8^8W$&'C  '4NJ].G%?.<O[
M*W[0WQC\;:+J/Q)@N[;3?"CV]MIH99 KVUL55>#P?E'K0!]>?##]J;5M%T#P
MGX,M?!-Y<H;:*RCU-(IO+1F50),KA#AFSD@DYZ]!7Y>?&+X.>,_%G[?WA^_@
MUV>TOM2B%U;V_GNGE2299%V9 !#$#&/Z"OZ)_A_X T7PSX5T32I='T\W6GVR
M(\SVD#S&10/G\QD+ \ <$<C/>OSL_:,_9K^(^H?M'^'/C/X AE=M.GM&DCB4
M[%2-P7&%& ,#IT% 'RCX6^*OQ?\ V5OB5\6F^-GBF<Z%+8W8\*B^G;8[[&6$
M0^80I(;CY>1C\N/U;XS_ !G^(7[,OC'XB:5XFN-+N'UJ5-*O//= ;:27$>QL
MCC:1T/?-=1_P6#^'OB#XCZ7\$+)+:[L]9U*]L+?6VL8WW2![@&43[!R,L0<G
MM7JG[4'P*3X6?L ^'O"GA.&?^U)=+TV:?[-&WFR7<UI#.I8+EB1N .>=V10!
M\6^*C^TA\+/!/P/^)5[\1KF6#Q#J%D]_$U[(1=QO(I9<;SNW X]/Y5E_M'?M
MZ_&75/CUX(^%O@\WLGVW1[4S6MN9LW%P\ &_:O4L1]?Y5Z[^SS^SE\?/VA?A
MW\)[#XD6]]:>%/"=W#/8F=9%WPV\JD;PV/X0OY]^WUU\>/V#[G0_'_A;XU_#
M#2(-5\6^'+2W@6V,"OO:W51\R[><D=?KCO32OU2]0.1_X)P?$#]HO5_BEXMT
M;XMZ;JEIHBB?^SOMRSA "&\LKYF!QQC&:_4;X]?$V#X=^#;Z[MYE;4Y(Y([>
M!6_>;BA X'S9)/&/?\/+?V:;SXHW8U#4_BEX2M/#MTD+!98K58&81C +':O7
M'7/OQ7SY\6-?_P"$S^/%GHE_<;O#<=XJ,K-F#AL?-SM]^1Z],"O@?$/B">29
M+3PV%K1H9CG>)IY3@:S?^[5<4W3^LR7\M*][O3KT/N_#_(:>=9S.OBJ;JX#)
M\-4S3&4DK_6*>&M/ZLO.KMH<W^SAX\>U\:7GB?XAVC11:K/(;*XO%.R,R,VP
M@R  $$@\?RK](?%?A#P?\6M 2.X^SZA;% ]M<Q%6\LLNY5+#)!''0\8].:XK
MQ+\"O!?C'PO9:=8""T%O;H;:YM-G+[ 1ET/!SZYPWIS7@]QK_C7X"1C2U2YO
MM)691YC*\A$2D#/((&%/'X#Z_&9/A,?P)E57)>+:6'SOAJLI5:N<PI*I4J8C
M$-2JK%X=+^&I_#5^RK-,^JS;%X+C7-J6<<+U*V2\0T7&G2RF=1TZ4*&'2A2>
M%K/_ )>.&DJ2^)MW0NJZSXK^ FK6=I!;7%WX9ADYP'>**$^N,J!MZ8)_GGYU
MT+XD6'Q;_:KTRYLH(GBC:$2LJ@A'!7.XCN.F<Y_'./K'X@_'OX=>(/A'X@N-
M3DM?[6DTB9$MYEB$R7(QAHRW[P,.<*/QKY/_ &!?AD-8\0:S\27AD,0U.0PO
M,A!"%R4VEATQT _/D5YM?"5L9Q)PUDF49I',^&\3BJ?$-",6IO+%E[7)AHS5
MW[.=U92M[/:VU_<P56E@N&^)N(,YRRIEN?8;"5.'ZLI<U/\ M&KF"5\0Z;27
M/"SYG'F4]'?>W[ JJQHJCA44 >@ %?-GQT^.VD_#S1;ZWTRXCO==%O,8[6%@
M\@=5.  I)W;L#IU/XUD?M'_M#Z1\)O#EZ8)1/J)B9=L)W.A/&..A_P ]J^<?
MV;_ ^G?'B6Z^)?B.\>X5I_EL)FWDAF/'EL3P%!Y(P/Q%?9\2\68G&YO_ *E\
M+5:,\[KT93QV,<TZ>589JTJG:5=)WC#5]M=5\/P[PKA\'E2XPXGHUX9)1K1A
M@\+&+Y\SQ"M*%*^\*+VE.UN^A\W? WQYKG[0/QA^S?$>XETS3[>\<6UE=,T8
MG57(1520KG<, >QZ>GGWQZ^$&GZ/^UYH">'[';8K<0-A4!5@&3YO3D<Y]^_%
M??O[0?P'T+P2+;XI^%XSIK>'!]KN8;)/*,GDY?E4&#D+SGUQ7PU\ /C1:_M#
M?M-02S6[EM(G2T+3(<EH&5,DL">HSZY(K\DQ65XCA2OE'#]>G/%<1YAQ;@*M
M3/Y\U7$9G@:CYJTI-ZT:=*ZCR)VLK=K_ +)E^9T.):.=\181K"<-8+A#'X;^
MQ(<M.AEF/BHQI))65:I6UGSM)[^I^Y7@JW:U\*:';E=ABL85*XQC Y'Z5U51
M11I!$D2#;'&H51Z ?2I <C(K^J8KEC&._*DK^BL?RF]6W9VN_P 7U?<6BBBF
M(**** "BBB@ HS0>>/6D P,4 +7PY^VC^T,?A1X)71_#9&H^)O$4DNEK9VQW
MSP).IA+,JY92"S9XZ8/KCZ]\7^*M,\%^'=2\2ZO((K#38&GF<D*, $@9/KC\
MJ_*/X4>%KW]H;]H;4/B'J"/J/@*UNYGM(;@&6V5T<D&,-E,Y';% 'LG[$W[,
MA\&:=-\3O&<?VWQ%XN1-5MTNOWDEF9Y/-Z."RX&0!QZCO7Z.\Y[8_6J]I:V]
MC;0V=K&L5O;1I%%$HPJ1J,*H'0 #TJS0 A.!FFY &[')XZ_Y]/2GT4 -&!R.
M-W^?Z]J=4+&*+YI)40#G+LJ ?4L:RIO$6A02K!-JE@DC' 5KF'.>G]_UH_K\
ME^J!NUK]79:/<VCDCC@T#('/)ID<T4JAHI8Y%;E6C=75@>X*D@_A4E !1110
M 4444 %%%% !112$@=>* %HHHSCD\"@ SV[T$X!/I5&YU'3[0%[F\M8<#GS)
MXD('T9P?R&?PS63_ ,)?X9W;/[:T\L>WVF+^K 4?=]Z\O\T#^?W/_(Z-3D9Q
MWI&;;CCK56VU"PND#VMW;3(W(,4T;_\ H+'%7,T %%%% !1110 4444 -8J@
M:1N H+,?0 9)_ "O#/$'[1OPG\.75Y8:CXIT^*]LBPGMWN(E=64X((WYZU[1
MJ9*Z;J##.1979&.N1!(1CWK^9+P5\)9?C9^T7\7;77]?U:UM;&\U P1>9*L0
M"RR8"\X[=OUH _>M/VJ?@W-IOVZ#Q;ILLFX)]G6XB+@Y )/S@]_3\:R/C5\;
MM&LO@=XK\:^#=8M[RZL]-DFA^S2AI(9!$['=L)QM('<_G7XG?#O]E;39/B3K
M6C2^)M6>RLHKJ6)'FEV9C#$8!..P-;WP[O=8MO!7[0?@J:ZOK^PTFSU**S6<
MNZ@(LJKLSD=0.GUSZ ''>$/VMOB_X/\ "K?&S6?%<VK:3+XB%B-%^T.Y5&N
M@7R]QV\'IC]*^B_VX_\ @H)XO^#OP^^#WQ/T&TG6Q\5Q:=/?P(),!9Q$TFX
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MB@ HHHH **** "BBB@ HHHH **** /X@_P#@O]_R>7^S[_V-6E_^E\-?V._
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MTCI#Y0D._P#NXVCFN<^('CWX^Z_\$_ 5W9^+KK0]9\0ZO! \K7$D3RP7$P
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M*@?TH7]:6_ !]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M KG=2\*Z!JU_;ZGJ%A!<7MMM\F9U!9=OW>HYQCC\JZ*B@!%544*JA54 *H&
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M+WKR/)&H(W&3YCE?<Y]ZS_VJ_!?B/]GS0-=UKX?:A=2G7DE<P;F^3S<A@JY
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MZG+HD1=A&B.Z9&X[0 "./;I^%?+>M?&[]I35!;WVAZUJ.H3&0,JQ2W#[CG.
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M_E;T"I_''U.__P""!?\ R9GX-_Z\8_\ T%:_=JOPE_X(%_\ )F?@W_KQC_\
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M!_#1@MKJ\C^R6]M"R[H@_P"Z (4CYN.3CK@5Z1J$?A'X#?#^XN[*UM[6VT^
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M>'O$O+F.8TL=:GC<AY[5<5A(TMK*\XTV]%9-'UG^U9_P48^)_P 6OB?:Z?\
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MGVEG:G3A<?8C&T4DL$3/NCVD$DL><J.17=:G^SM\/-6U70=8N]/1[OP[Y?\
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MQQ\-_'.I?$NQT^XNM,EN)+A]H+H4\S><]NG/&:]_\,?\%*M+URXDTT^&U%]
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MUKJ5;O:>B['[145^3OA__@L)^S%KTR0 :S9NY49N"BJ-W'\4"]#[U]9_#_\
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M\2>'M*U&VNHWC9I[&W>5-XP660Q[L]>I(Y/?F@#\KOV6O^"N/PC^,TEOH_Q
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M4_3I^%/K^EUHDELDDO))))+R2T\K'\MMMMM[MMM]VW=M^;>K\P''J?K1110
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MR.X)H _$GPC:Z-XJ\.GP?J+H?%>G!TB9\"6VE0X5LM\RE6&1].M=_P"'=?\
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M7;\/Y_LU7SAI?[./A;2OC#=?&" #^W+IV:0XY^8Y)_I0!]'T4AW9&.F>:6@
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MO;I@D<@N(C&"QP,]_P!:]$\>?$_PK\/=&_MO6[Z$VIR4$,T99P!G((W#![4
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M,!+)'<#>5'R]&+=L>A/0$UK7.AZA^RCXT@U73X&N=-U618G 4LA61@C<@?Q
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MYXKZ=H 0@GH2*6D+8ZYI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD=\*_$.D_LG^-O"?Q*LKJ\AU'4+R&T&N1O+*VGS6U]C;YX+;!F)P1W5><<4
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M^7CKSW%?K50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '\0?\ P7^_Y/+_ &??^QJTO_TOAK^QWX ?
M\D3^%W_8E:%_Z11U_'%_P7^_Y/+_ &??^QJTO_TOAK^QWX ?\D3^%W_8E:%_
MZ11T&D_@A\_RB>OU_/-_P<C?\F-#_L81_*WK^AFOYY?^#D<X_8:'_8P_^RVY
M_I0*G\<?4] _X(%_\F9^#?\ KQC_ /05K]VJ_"3_ ((%'/[&7@T_].*?^@K7
M[MYZ^W_ZZ"7N_5_F%%%-^;=_L_AZ?GUH$.HKAO&_Q$\+^ --EU+Q!J5M:I&I
M80O-&DKXST4G/4>F:_*/XX?\%!]:&HR:1\.-/O"LCFVANT1S$7)VJV]>#R>Q
M^M '[(O-%$0))8XRWW0[JI/T!(S4@.>1R#R".]?@I!J_[:OB#P_=>/9+N[;2
M=AGMD5I/N<NHP.1@8X^E=9\./C9^T_%HUUK6L-=SV=AO,D(\QG98_O8')Z ]
MOTH _;^D)(Z#-?DU\+/^"BNGWVLS>'O&=C/:7EL[1/\ : T9=E.W*[B#UZ>M
M?:FF_M1?#2\CMY;G4$T^.XVXDN9XXT!;'=P/7/6@#Z1!S_GI02%!9B J@DD\
M  #))/8 <DURNE^./!VLVT=YIOB;0[J&5%<,FIV><$9^96F# C//&/?%?G3^
MW)^WAX5^#6A7/@;P3J5MKGC[60^GV\&F7"7,EO+,OEJ ("W(9CN;)!Q\IQR0
M#TS]JG]I;3_!NE77AWPO>)>:S(C12K;L'97;Y<?(21@G'Y^U?-G[&W@F]\;>
M+]5\5>-+)KA[LRO$DZEL!\L,;QQU_3O7CG[)?[.WQ+UCPUK_ ,:_V@+F>6UU
M>&75=*MKXL3%%([/&NV0\=5_EWK].?V<;71KJSFU/2#;QVD3O$HBVJ#M.%SC
M\._'.*_+<WX;AC/$3*,=B\9/%1H8*KB,/@9VY,+;]W)P@M);W<VFT]WT/U+)
M^(I8+P]SG!X; T\-.KC:6%KX^%_:8CGY9QA*?V7I913M;IVP=.L](\ ?$Q[5
MITLOMUS_ *- ,("'88  (X.?EQ7?_M!>#M/U;P\FN)IB7EY8@RJP0$A5 =7R
M!G)S_GMYI^T19Z)IWC?PWXINM3@MA:/#),AF51^[8$EN1UP/P.#7HGB+]HGX
M:V7@Z>[GU"TU%9-->,VL,L<I9_LY4 H-Q/SXP."#C'K7/AY9<L)QAPWC9X++
M\+EE>57"5I3A4FHUX?6/K+I3O:4:K2T5];]BZL,QEB>$<_P%+&8_%9A0A1Q=
M*$)PBY491H?5_:1W4J:E*\G;],K]GWXHZ=J^AW>GZG>0VC:4@B$4SA0BQ,5*
MX//&2:_-K]NB&/QGXSMK'X+79_X2JZNO)OKC3B2X+-ACNB^8#))7.<8YKRZV
M7XP?%#XAZHGPEMM2T[1[^\<R%4DCC,3R'=R %/!X[>U?JC^S]^RWIW@9(/%'
MC%6U'Q?+MDG-SB41R8RQ^8''/8>_3O\ (Y/B.(/$;(<%DM7!5,#A\'B)*KQ%
M4A*$Y4J%1PA5RZZ3]I5I63VT=[V1]IF>'R#PWSW'YTL=3QF-Q6&B\/P[2E&<
M(5J].%2=/,4KKV=*I[UM4WIU.*_8Z_9BOO 'AK2_$GQ G;5O%%S;Q3LUUNDD
MBE*AB3YF6!#?RQ7Z#CZ8J/,<:A,I&J@!5RJ@ <  <  =JB>\M(AF2ZMT'J\T
M2_S8"OW#),FR[A[+J&6Y?!4Z%&*YISE>K6J67/6K3>LIU)7DVWI>R/Q#/<[S
M+B3,\1FF8U'5Q&(E=1A'EI4::TA1HTXKEA3A%**26MKO4LTGOCG_ #WJJE_8
MR\QWMJX'79<0N/Q(8_SKR'XV_&OP?\&O FM^+/$&KV,'V.PNI+6%KF(/-,D3
M%  'S][  ZDGO@UZ%?$T</1J5ZE2"A3A*;]^*NHJ]E=[NUDN[L>;0PU?$5J=
M"E2G*I5G&$8J$F[R:2;LKV5[M]$>#?M>?%B[\/:))X3T+,VJZA$0(HLLY+*1
MC"YZ9Q_/%?+/["_Q,F'C[5/#7B2P&GZN[S@S3+L=]^1G+<\D\_\ UJX[]CWX
MPZ%^UCXX\5>//$]U#!I7AZXNOL:7KKY<L<;L5*;S@Y'3'7CV%<9\0_'FD>#_
M (_/X@\)*@LX;LB8V>!&R))SRG'(7'4^_6OYJS7,<SRWBG*_$;-,9'#9?B,R
M_LJEE565.;P>3_:Q56$7*4)2FKJ23=FE:Q_1^3Y;EV/X8S?P]R[ /$9G1RY9
MI5S.$9TUB,VO%QPE.3C&,XJ&CC*5KKR/U#_:-\!MJ6D_\)5HEF'UJR59%N(P
M-_R8(;<!G) !SGG\*Y;X*?M"Z+;:!_8WC_4X=+U'3MZ^==.%+JO&&W,">![G
M/;DUX7XJ_;<M->T:U\*^']$N[C5;RV2":40LZ"0H(P3@'')/I7S-I_[*WQF^
M+7B9-<O+B\T_1+N;S)HT+1KY$C9(. ,?*2/R[8KV\RXAKPXNP6<^'U&?$-#-
M(+#9QAL-"4,#3E)IQQM:=H/VJO[TK-K9NR/%ROA>E+A7%97Q_7AP[/+JCKY5
MB,3.,\;52TEA*-/FDO9MWLKI7LSOOVM?CS-\4O$$'@?X5::=:EEE6V.KVL3.
M4#8C+B2,$CJ3U]._->Z_L@?L;6_P]2+QWXX U+Q#J -PL-UEV@9U!!PP)&UB
M?0\=1BOI+X,_LQ> _A/:6EQ!:+?:P(D-Q<W:)+B;:,D%P3D'Z#/3I7TNI7A5
M& !P , #T ''TK]"R3@R-/.,1Q1G*I5<XQB3^K4E?"8+3:FG_$J):>UDG+S/
MA\]XVYLFP_"W#\9X;)L)>-3%5';&9@_YJDMZ5-W=J4&H]6NHJ(L:*B*%1%"J
MH& JJ,  >@ P*=117Z ?G04444 %%%% '\=/_!:73;WP=^V3X$\=WEN\FC#5
M-/D>=D8QH&DB8_-C: NX_3!K]X?#_P"U?X,^&7['OA?QQ9ZC;2WC:!#':0K(
MC,D\EN,.%!)W*W3C@\]>D7_!2/\ 8?L/VK?A?J']CVRCQIIT,UQI]PL8,I:&
M+?'L;!;(9/;'&#Z?RHZ9XW^,W[.6MK\'/VAM'\1:GX'T"]DBMCY5P\#6T4A"
M=1MQLXSTXH _H6_8YU3X7_M#?%";XQ>,_$5O)XVLM0633K"XD19=@EW+@/\
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M?CPOC_XQ?#CPA)X!\$>!;BPTC["MDD-O9NJ B+RF<%4')]>_!SQ7SYX%UO\
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MGXOB#+%J,EQ-"PSRLC,01T['Z?C7W;^VEJL<O@.WT6UE)OWO=QCC;Y]K!!C
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M7*K26B>C>^G1?DEX5_:;_:8^%FM7T/Q7M=5TKPW'(ZR:E<I<1I&FY@6WO\O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@84$\?D.*^J_%WQU^!'PUDFADN=%O;N$-F& VTLFY1RHW(V3V!"YSTKP^?\
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MQ225]1UXQRK'>#+YG^8##\Y&<?IP.*_3KX&:#9:+X2B?3[;[-;7:QR1@)L#
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M^R?KOB.^LO'7QJGN+[6U\NYBAF8N-PY52I;'7KD< >O7Y'(\[S[C7ABOPI#
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M5XE^*,\FKZU#%$\(O2TCHPY&-^XC  ].GTK]-XT2-%CC4(B *J@8"J.  /3
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MJCV "X ],8KSLV69RP%>.3RH0S"2M1GB>;V46_M/EUNCTLIEEL<?1EF\*]3
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M-5KV[@L;2XO+EUCAMH9)Y'8@!5C4L3D\#IC\:LYZ>XS_ "_QKX:_;P^+5_\
M#+X52+H]QY.I:P9K0;6P^R141<8YR6+#U_.N',\PH95@,7F.*ERT,)1E5J/R
M5DE\Y-+YG?EF78G-LPPF6X2/-B,97A1I1\Y.[^Z*;^1\'_M5_M-^,OB_X]7X
M0_"R:Y$9N18W=Q9;R%S+Y3DM'[[B>]?2O[./[ GAWPQ;6?B?XC"/Q!K5V$NI
M8+T&9E9P'PV_<%P>""<X[5RO_!/3X!62:?>?%/Q59_:]:UEOMEM+=)YA#2R!
M]P9\] 2>/ZYK]:P,  # '  &  .@ KXSAW))YM./%'$,?K./Q:<L#@ZGOX3
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M-?V._ #_ )(G\+O^Q*T+_P!(HZ_CB_X+_?\ )Y?[/O\ V-6E_P#I?#7]COP
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MJ6I_7:IR ?4 _F,TN:YGP?JIUGP[I>H,<M/:PLQSG)\M<]S72, /F8X QR>
M,'N37]?_ (II--;--737JF?Q<ONLVK/>Z=FOON.HH!R,CD'H1R** "BBB@ H
MHI!N[G/^?I0 M%%(6 (!(!/0$C)^@ZF@!:*** $R"<=Z6DP <XY-+0 44A;'
M7-+0 4A. 3Z GGVI:\E^-7C7_A!/ FIZXDHCFB&R/Y@"=R-G'?TH _/+XS>.
M8OB[\3Y?!TS8C\-W+=_E'E2 ]>@Y!KC_  ?X8U+7?COH.G%Y+C0+,PQR1\M#
M\FW.>J\8(Z?_ %LJRM[&2P\1?$>*14UC58[B2($_-(\F2 ON2>/RKZQ_8O\
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MRH4*5%U);S]E3C#F?F^4_-<56CB,5B<1&"IQQ&(K5U36T/:SE/E7E&]C\G_
MOPI^)7[3]]H%QX\\(MHFDV&B(;*^>W,6[RX/W;;BH] ?Y=Z^1OV5?@5XM^(/
M[:7C;P#-X]U.V\/^!KN[E@LOM$P@9+-F?:%#8( CQA0?:OZB_#NC0Z)H&G:/
M##%$MC8QV86-%1<1Q[,X '7J?4YKY#^#G[)FF?"_XV^+?BS;[/M/B5KMI-I&
M[-SO/.#G^+_]5;F!^%O[86K_ !JTC]L'1OA=X-U?4IK.W7[$MJCS""5E_=JQ
MP=I)]^:^H?V,/#_[5?PB^(7CC5O%=O?ZM87=O.=/L9Q)-"IE1BFU&W+QD$8
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M6T9[C\??K7Z_Z=86^EV5O86B!+>UC$42X  5?IQ[T_E_7D!XE^T3\0)/AYX
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MYKV,4T,CY."QZG)Z[CT)_&@1\V7?Q2_X6[\1[&W2^DM="TVY000Y*1F..0
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M1G'MTKNZ_E?^$OQV_:$_X)T>,)_!7Q1TW6/$G@2&<P6+$3S0Q6PD*K@X( "
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MK;!&>9865?\ QXCI6M10[/1JZ>C7=/<:;336C333[-.Z?JGJ?RF?M=?!:_\
MA%\1]5F9)8$UR_:Y@D56 "M(7'S#CH?\]OT9_8 _:NTZ+3[/X6^*+I($MP$L
M[F9@/GV8 !)Z$@9&>F/85]H_M;?LT:9\=/"MQ+# HU^RMV:UF"C?E%RN#U)!
M S7\X7B?P;X\^!OB^YL+BUOK.^LKN1H-0.^-/D8[#OP!C@$G/'\OY!XHP>=^
M"GB!BN.,IRZMF/!G$$E'-\+AH2F\#.4DZDX0BG:IS>_S-:I7NS^SN%,;D/CK
MX<X3@/.,PHY;QSPW"^38W%3C!8^$5:%-SDTW2<5RN*=[Z;G]@,<L=Q"DT+K)
M%*BR1NI!5T8!E((R#D4]<@ ?7^=?SU_L\_\ !1C7/ D,>G_$>[.K6T*+#$OF
M,Y$8X'.<C'Y]SQG/Z)_#_P#X*&_"3QQ>1VI/]EAV"^9<S;5YQW8<8S^-?OO#
MGBCP/Q12PTLKS[!/$8E*^"K58TL32J-+]U4C*R4EMH[73V/YVXF\)^/>$JV)
MAFW#V/6'PS=L=1HNKAJ]-.WMJ<H7?*WMH]+6;Z?H$1D8K'UW6]/\-Z3>:MJ=
MQ';VEE!+.[R,$!\M2VT$D<D@#\<U\P^//VR?A'X*TW[>-:L]3;9O$-O<(S],
MXPN3G/\ GO7Y<_&3]J'XG_M2:L/!'PKTW4M-TB[E:TEN(1*B&)\(26 YR,G)
M_/L/:SGBS*\I@Z<*JQ^8U%;!Y=@FJ]?%5791A%T^:$=^:3E)6BG;4\+).$<V
MSBHJDJ?]G9=3E?&9GCHNAA\+17O2G*,^6I)M74%&+]ZU]-#)^,WC?4_VJ_VD
M-(\.>'FFG\.Z9J$%O<&(,T&V&4(<E?DQA>OIZU^[7PX\'6O@3PAI'ANT4+'9
M6\88 8_>>6BOGIT*U\=_L=?LCV?P7T%-9\41"]\67ZQ7$MQ-AY8W?YV)9@6S
MS[9SD<5]^US\*9/C,''&YKFTN;-LXK?6:]'>.!IM>YA*3=VHQ5G-?SIG3Q;G
M."QDL#E.41<<IR:B\-0JO2>-J7O4Q=562YIROR=5!I,****^O/C0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^>/VE/B7)\-O %U
M?VK9N[LM;+&IRX1UVD[0<X);'2OS*L[>QTGPUJGB^VE\K7_$JR2J@.)"\^2
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M%%% !1110 4444 %%%% !5/4/^/"]_Z]9_\ T4U7*IZA_P >%[_UZS_^BFH
M_D#E_P"4X_@;_L3?%'_I\\,442_\IQ_ W_8F^*/_ $^>&**"I;K_  P_](B>
MS?\ !N3_ ,DTU#_K^O\ _P!+)J_JBK^5W_@W)_Y)IJ'_ %_7_P#Z635_5%0$
M_B?R_)!11102%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'(:&QA0@_@*[*B@"M;V=K9KMM;>*!<8Q%&J\#L,#]*L D]1CFEHH **** $
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MHJ$9+LIJ5@HHHKW#P0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **1@2.#CGWI1T% 'Y"_'J7?\ M+-;2J4CF)C$I&%^9B/O<=,_
MYS4WASQ);? [QY!J%\QN--U2XC,TI^=8D=LD@\@8#9X_^O7T5^UA\&+K6[)_
M''AF%O[>LR97:('S&$>7Z@9YQ^)[^GQYX.\3>'O&EBWA[XC1C3M1TT&-IKOY
M&=HQM)!;!.<9X_\ KT ?I/J/[2WPLAT6:^375+26CF"(*-QF>([(\ANH<@9
MR<<"OSBL-?UG7O%/B3QGXOC9_#T4LTVDS3YP8]Q\LJ6XZ8Z>W:I5T+X3R71L
M)-8@>"V_>Q+]HSN*G(&,\Y].WX52U74]0^(EY;_#KPQI<W]D%EMQ>01G84R$
M!9P,8QSDGW]<G]?._P#PX'K?[-GPZNO%GQ1;XE9:Z\/1S;88W!,(((VX!XZ+
MV'3IUK]3418P$10B* %51@#KP ./2O&_@5\-F^%W@>U\..0T@99I#U.YDR0Q
MY.06/7OFO9Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,:=/&BGRV2*2.)\ ] "".??Z4 ?4G['_ ,*#I)O/B/<$R'Q"LDD*R#[GF#/
M/3&X8_"OO<=_;I^0KE_!?AJW\(^&M+\/VRJL6GP+$-O0D  GZ\#\,5U- !2
M@]*6D  Z4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %4]0_X\+W_KUG_]%-5RJ>H?\>%[_P!>L_\
MZ*:@#^0.7_E./X&_[$WQ1_Z?/#%%$O\ RG'\#?\ 8F^*/_3YX8HH*ENO\,/_
M $B)[-_P;D_\DTU#_K^O_P#TLFK^J*OY7?\ @W)_Y)IJ'_7]?_\ I9-7]45
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M3U^OYYO^#D;_ ),:'_8PC^5O7]#-?SS?\'(W_)C0_P"QA'\K>@5/XX^IW_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0JYOPCHL.@>'],TZ%-@BM(-XQ_&8ER#[@\5TE, HHHH **** "BBB@ HHHH
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M*** "BBB@ HHHH *IZA_QX7O_7K/_P"BFJY5/4/^/"]_Z]9__134 ?R!R_\
M*<?P-_V)OBC_ -/GABBB7_E./X&_[$WQ1_Z?/#%%!4MU_AA_Z1$]F_X-R?\
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M"".N1Z"OT6HH _*O]N+]G#Q]\6/B_P#!OQ5X-L/-T[PC>V<U\8X_EA6&Y#G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !..M%%% "$@ DD
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M** "BBB@ HHHH ***,]N] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !0<X..O:C-&: $7=CYNN?\]*\A^,'Q7T?X7^'+F^O9E&H3VTO]
MFPAEW//]U,@G/7./<5W_ (G\16'A;1[O6-1E6*WMHV8LQ &X*2!R1Z5^2GC+
MQ+JWQM\97UQJ1D3POH\\CPSLQ\GRXY&;.3\I!_\ K8H P(IM0^('B.]^)7CB
M>0""226PM+ACY+J,F/",=O3'^<UT_P // 6K_'OQQ#/?12VOA[1)@\,2J5MY
M8XF'0#"D$#!["L"PTS5?BKXGLOA_X4A?^Q;6:.*XU*%3Y0",H8%UXZ<=?ZU^
MK?PS^'6E?#KPY8Z/90Q&ZAA"75TJC?,^>26ZD?XD4 =CHFC6.@:9::7IUO%;
M6UK!'$J1(J*2B!2Q"@9+$9Y]:^4?VH/C3;>#](/A739_-U'7(6LY/LS;I8?,
M8#HO((XS]:]6^-GQCTSX4^&[B_S'=ZNX,=K8*=TN]T.QR@.>&92.OO7YA6AN
M];O=2^*/CF1KA)VEGT_39V+&$[BZ 1MTQQC R.* *=I!!\-/#L^L:@YOM4UQ
MF>,O^\NU:XY& ?G&"WMCO7UA^RK\%&BN&^(>O0M<C50US9B[7<\9.&7 <$K@
MD=,8KQOX'_#;5/C+XYB\5:_!(?"-A<JL-C(#Y11&!7",-O0<<>W%?J]IVG6>
MDV5OI^GP);6=J@C@@C&$C0=@!0!= P  , < >PHIN[YMN/\ .,TZ@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH _B#_X+_?\GE_L^_\ 8U:7_P"E
M\-?V._ #_DB?PN_[$K0O_2*.OXXO^"_W_)Y?[/O_ &-6E_\ I?#7]COP _Y(
MG\+O^Q*T+_TBCH-)_!#Y_E$]?K^>;_@Y&_Y,:'_8PC^5O7]#-?SS?\'(W_)C
M0_[&$?RMZ!4_CCZG?_\ ! O_ ),S\&_]>,?_ *"M?NU7X2_\$"_^3,_!O_7C
M'_Z"M?NU02]WZO\ ,****!!1110 4444 %%%% !1110 4444 %%%% !1110
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M@Z'8>'M,M-+T^!(8;:&.+"*!N** 6. ,\YH T@MO9P$*D<%O"A.U%5$1%'.
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M?2D!R,T (N[G=^'3^E.HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\7,\S'BW-.!N/Z+RS&XF5?#Y9G.'I-2P=1WC0=736FDES-IK=KJ?L.<<!X#
M9%@.(N$ZBQF&H*E7QN75)J2Q--<KGR=I.]XVZ^6I^?/P@\&Z5H6F:K%H4\UI
MXQTX3,L1+(ZSH23QP1\_MQ^=?IS^S[^W!XB^#OPUU"V^)TLUS=6TCI9,[%V(
M0%8\9YZ<<8[<=:^5O'OA32(?B3K'CGP"T;:'K\C2P?9]IC43.6Z(=H'(./\
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MMDLLTB@NK%<MDL-PY/'T/X_4M%% !1110 4444 %%%% !1110 4444 %%%%
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M815.%.FOAIPA3C_AA%0C^"1_%\YRJ3G4EK*I.=27^*<G.7XMA1115$A1110
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MX#Q>+XKPE'(N)LMEB\KE!.CFE*')+#U8I*C4=:UG."25T[KL>9?$&QD_9O\
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M>8A1H4FXX++J%X8/"4MHJ%)>[SJ.CDDO)"T4BC:,=>:6ONS\_"BBB@ HHHH
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M':>%I=UDH8A'6W;Y<]CPN/S-?=7@C]L?X8^%-)M/#FOV,<T^CE!'(L8W;H,
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M(8_W3Z'M7UOX0\?>$O'=F+_PKK5IJUL5#;[=P3M/?;G./6@#L:*** "BBB@
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M0 4444 %%%% !1110 445SWB3Q5H'A*PDU/Q#J-OIMC$I:2>X8*JJ.23GVH
MZ&BO&/!?[0/PB^(.JR:)X1\9:9JVI1.4>V@D7>''!7KUSQ7L] !111G')X%
M#?FW?[/X>GY]:=30Z,<*RL1V# G]#3J "BN1\7>.O"W@6T@OO%.K6^DVMS+Y
M$,MP<+)+Q\H]_F'YUT&FZC9ZO86NI:?,MQ97L2SVTZ?=EB;.UE]C@T 7J***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%4*BA>G0<"J'A3P?X;\$:3#HGA?2;31]-@552VM(EC4[!A2VT#) ]@/05TM
M!111G'6@!"V"!SS2T8]OTI"2.@S0 M(6QUS0200,$^_^12XSU&?PH : 2"&]
M?;VI0,#%+10 4444 %%)CY@WIV_/_&E/((]: "D"X)//-"C:,=>:4\@CUH *
M*11M&.O-+0 4449H **** "BBB@ HHHH **** "BBB@ HHHH **** "@YP<=
M>U%% "#..>O^?2EHSCK3"X56=R$1069B> !R2>.!B@!]>"?&+X[^&OA?9M;S
M7"7.KW$1%M!#(KF-V!"[PI)#=".>,X/->>?'[]IG3/ &FG2_"+Q:YXENC+:M
M:P#S&MBX,8? .0RDELXXX(Y%?"=MH,VI3/XY^)6J-*+TFX2TN9"PMLD,L:HY
M.W'3  ],4 6=:E\1?%G7)_$OC:_EL_#5J[W,,,DI1)(P=ZIAC@@C Q[]NE5;
M0:Y\5=1B\&_#NREM-&LW2VN+J&,HLR*0K,7 YR!FM/PSX2\6?'CQ%%X:T6*;
M2?!5G*%.HQJ\<4\4?4%@ &!5>><8S7Z@_"[X2^&OAAHUM8:590?;4C5;F^5!
MYDS@ %LX!]3D_P Z .8^"GP1T;X9Z1;R26Z3:W(F;FXD1697(PV"03G.[Z9R
M*];\4>*=(\(Z3<ZQK%S'!;6R;]K2(CR8S\J!CD\ \@$<8[U3\9^-_#_@72)]
M6U^^BLXHX9GA61@&FDB0L(T!(R6; _'C)XK\J_'/Q,\7?'_Q!<01&72?#.G2
MB.,+NCBNX8R07Z@-O )S@YW4 :OQ7^*OB[XRZ])I6@RSVWA..=T9U9E4Q[B"
M20>F >O'M7FNJW\7AF*'P+X'CDOO%&I-'$]U;YDV-)A6+LF2""<G/UJ]J.HS
M:?';^#/A_:M?ZO?%;:\,";V@+G:\A91P0<GGZ^]?<_[/'[->G> ;2/Q+XG6/
M5_$FI11W>^Y4R/922_O"HW9P5!& #P3[8H M_LU_ .+X>Z7!XIU]"WC'4D,M
M[(1RHE4'#$X.>?TYKZW.[(P>._\ G%+2$$D')&.WK0 M(3@9I:3\!C_/;% "
M$D@%?7V]Z4C(Q6)KWB30_#%FU_KFHVVFVJ DR7$BH,#DD D$@>O_ ->OF'Q7
M^W/^S-X/:>#5?B3I(O(=RBTBD5I'D' 49<8R>,X/T- 'UC=7,5C:S74Q(AMX
MVED;T1>6)]@,D^@%<=X>^)/@OQ,9X],\0:6]Q;2-'-;/>VZ3(RD#[CR*3SQ@
M9/MBORW^,/\ P4AT:[\)^)XOAY9_VO%-IEY;17D,;.8_-B9!(&7/09.:_C\\
M?_M^?';X8_&+7=:LO%^K6MA-J\MPVG1SW&Q5\YG,>P-C&!C'2@#_ $@DD250
M\;I(AZ,C!U/T920?SI]?Q0?L^?\ !PUXVT!M/\.:[H%WKHD,<3R3VDDPR,+N
MW,K8//4$'TK^CS]D[]OW0?VA["QGOK%=(N;N-'$1C,9#. <8./7\/>@#](BV
M.N:6H8Y([F-)HG#1N-R,.0P/0BIJ &Y!)7&?7(XK\S?^"A'[&GA7X[_#?6=<
MT_38QXRLQYMI-%$HD<A';@JNXD,!GUR.]?ID>.0N3[#_ .M4<L,5S$T4\2R1
MOD-'(-RL",<@CW-<689=@LTPT\)C\/3Q%":=X5(J24K-*<;[2C>Z9UX+&XG
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M&Y/_ "334/\ K^O_ /TLFK^J*@)_$_E^2"BBB@D**** "BBB@ HHHH ****
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M$_BW0?!]@VI:_?Q6%J-V'D8#<5&2%!(R>E &_++'"IEFE2&)1\SR,J(/JSD
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M^@K7[M5^$O\ P0+_ .3,_!O_ %XQ_P#H*U^[5!+W?J_S"BBB@04444 %%%%
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M10 4444 %%&>W?THH ***\Y\??%#PG\.[-YM?U*&VN7A9[6V9@))GP=@P2,
MGGW' ]@#M]1U*QTJUFO=0NH;:WMXWF=YI$C&V-2S;=Q!9L X SUZ5^=/Q?\
MVI+_ ,63WWA#X9+.EU;NUO/=J3M<\JS*Z]O3&!@=SU\I^(GQ<\>_'37)- TP
MW&A^'+61]][&6A2:WYSEAM!RHY]<UQ4FHZ%X1@_LOP?:KJWBJ(^3-)$@DEFF
M;"EF8;F)W<YSGTZ T 0V]EIW@.%O%GC"<ZSXJOY"RV;/Y[([GCY"21\Q';K7
MH?@#X-^-OC3K%MJFLK/9>#YI(I9+<[XU$18'&W@8VXX[_P _3_@=^S7JGBRX
MM_'_ ,2&D+RS!XM&N0Y"J,.,1L-HZCJ /KS7Z)Z7I.GZ+9Q6&F6L5I:Q*%2*
M)0J@ 8&<=3B@#G_!'@;0/ &B6^A:!:QP6MN/O^6BRR' &791D\=LGJ:Y_P")
MGQ9\,?##1I]5UFYCD>-&*6D<J^<S8^4%1DX+8!'!QZ5P_P 8_C[X=^'5K<:?
M:W<5WXDVR(EDF&>-L8!(!SNW'CCC&1FOSCOY=;^(FIW7C+QW>R6_AV*0S?8Y
MW81LJMN5=C<'\J +GBGQ7XM^/6O2ZUK=U<:?X!MIV:UAD=H@R!MPX. 00*S;
MN^O]:EM_ OP[LV-T6CMTO8$^4JQV99D!]SR:GTB#Q)\5]4B\*>"--ELO",4@
M@:]AC9(V"D@MN4 '.,U^DOP:^!.@?#'38FE@@OM:98V>]D3=)$XPQVLW.X-W
MR1UXS0!RO[/O[/MC\.M/@USQ!"+OQ=<AFNI9E$@B+ <C=G#9)/3@@&OJFBC-
M !14<LL<$<DTSK'%$C222.=JHB LS,3P H!)-?D_^VK_ ,%0?AI^SO87?A[P
M=J%MXD\?,)+>'3K8+<,MPP*(JHA9LA_XL YZ 8S0!^DGCWXG^"?AMHUYK?BS
MQ!IFF6]G#)*T5Q>P13R>6NXJD;/NSCU7%?B5\>O^"T7@FWU*_P# /PAT/5-7
M\1F5K6#4+4-.AE;<D;*\0VA=^#P/<GBOSL\&_#;]LO\ X*5>,O[6\77NN>!/
M!-S>.RH[75I;RVDC9&02BX,9R>V/;BOW/_9E_P""8/P,^!EE:7.OZ#I?C#Q)
M#'&7U*]@\YC<+@M(S2)N8[L\@CGG- 'Y!Z=X&_X*3?M9:H-6DU+5M*\%7DC.
M(9)9XBMK(<J,'&/D..OZU]P_"C_@CUX/U06^M_&?5M7OM74))/"EP[EYOO'A
MG"X)'))_#L?W!TG1M*T&RCT_1["VTVQB $=M:QB*)0!@  >@'&2:TZ /@*3]
M@+X1^&/ .O\ AWP7ISK?WNGRP6DMVL<A\TH57GD@\Y_#%?C+IG_!"BZ\5^.]
M9U[Q^L,EC>ZE)<0*RJ0(7E9L8(QT/3\>E?U+X]OTHH _'3X<?\$5_P!DWPA:
MVLNH^'(KS4HEC)=+:#"NH&?F89)SZ+Z<\5]L_#[]C3X._#.2"3PMIDED;?;Y
M818T V\#[F.U?65% %>UMH[.WBMHL^7$H1<]< 8_I5BBB@ HIH7!)SUSV]3F
MEQ\P;T[?G_C0 !LDCGB@G S2X]OTHH 84C<?,B,"/XE4]?7(->+_ !%^ OP_
M^)8=M>TN$RLA >.*,#?CAB  .N":]KHKGQ6%PV.H5,+C,/1Q6'K1<*M"O3C4
MIU(/>,HR35FM/338UH5ZV&JPK8>K.C5@U*%2G)QE%K5--=C\1_C3_P $^O$<
MM[=WOA0!-&M_,D$<2X)C!) P!GI@?UZ5^7GQ=^$OQ/\ @Q,_B.70[R_\.VLF
M)DCMWD;Y,[B/DXZ9^E?U],H=2K ,K JRD9!!&""/0BN)\1_#CP1XLTVXTG7_
M  YINHV5RCI)%/ K#YQ@LN<@-Z$@CVK^>^*OHV<%YYF*S'*HO(Y3YHXC!X=/
MZC)2UYZ=%6Y*J>JE=H_6<B\8N(LLPZPN-?\ :-.'(Z=6HTL3[EERU*C^.#6C
M6A_';H'Q27QIK.C6=MIMU!)<2QHT+HP>-MVTX4_=P?I]<U^C=I\*_P!KVWTG
M3M1^%M[J$.BRP1R&%GE *%<D8Z;<?K7Z(P?\$X_A38>/$\8:9!:6D,=QY\5B
MD)")\^_:%";?;@U^@VB:+8Z!I=II-A"D5K:0I"J(H (5<$G@9S[CI75P/X.Y
MIPS+-,NQG$F85LKO%997P]>4,1&,EK&,KWIQA:W*[WT-N)O$K 9NL!C<+DN"
M6.<9?7:6)H*=!M6L^712E+HULKZ]#^=[Q7X3_;VU6P@L;*W,<S )<W"Q8E.1
MACY@7.>3C/TJ'X'_ /!,'XI>/OB':^.OCMJVH262SI.]M)-(8]V[<0$8\C';
M'0U_1N+:W4Y$$0)[^6O^%3=, 8 '&,?ECTQ7WV"\.\'1Y(9CFV;9S0IU55A0
MQ^)=2FVM;5%]N/D_FSX_%<:8NKSRP>7Y;EE6I3=.=7!X=4Y6?6#WB_/7=GS'
MI?[)7PATG3K/3K?1D*62(D,S1Q^:-@ !W<D$XS]ZO=_"_A32?"6G1Z;I,(2"
M/ 4L!O  P!NY./H?Y5TU%?<8?+\#A.7ZKA*%#DCR0]E2C#ECV2BEH?*5L9B\
M1S*OB*U;F?-+VDY3N^^K>H'.#CKVI%W8^;KG_/2EHKL.80;LG/3/%!..32TC
M#<,=.: %!SS3#M;Y&4,#U! (/&>A_P *=CC'MC],4BKCW/KB@#F/$7@WP[XG
ML)M/U33+22&<$,ZV\*R<]?G" G\37P%\;OV%]#U^TFG\"6Z6U_-O9AL56W'I
M]T<^QK])J*^?XAX5X?XKP4L!G^58/,J#BXP^L48RG1;^W1G;FA.+5XN[2['J
MY3G>:Y)B(XG+,;7PE1-.7LJDHPJ)?9G&]I1?5'\O?Q6_9:^(WPQ\^%[2]N+F
M3>5:))"H[]AQQTQC\#7Q;-97&@ZSCQC87MI+;R^8MQ,CI%E3P2S@#\>O>O[-
M=;\*>'_$2%-8TNUO25VAYHE9U'L2#^H-?'/Q^_87^&GQF\/S:7;6EKHE](K@
M7J1[7RP./FC0G.3UXQZBOY<S[Z*]"&:0Q/"&>U<LP,HRG5H8MRK8JEB+WB\-
M7VA2BDHJ-DUN?M^2^.-:.$5'B#+88W$1DH*I12A0J4'9256E?WIO5WV[G\]7
MA'Q2GC?QAHMEX>U.4W]D\2VB03]U(V@A6[X'Y^]?H//^T_\ 'CX>K!X0U+1K
M_4['[,L2M)%+,OEE0N[D$<COW['FO1?@=_P2GMOA!X_M/$YUK^T(+6X651YA
M<%5<-C#''3C!''0]*_7&3X7^ KI+?[?X6TF\F@ACB\Z>W#.=B!2200,G%?H/
MA]P-Q[E>5YE@,XSF6&K4<5&EEN,;=:>)PD86<ZZ3U?,E:_1_,^=XMXLX2QN/
MP6+R[+(XFA5PSGC,-R^RCA\2Y)\E*^RM?;2Z/YU/$GCS7_$6NH]QH>LVKWS9
M=;>*5$5Y",<*H Y/IZYXIWPP_8M^/?Q9^),.KZQJ6KP?#EIDE-M/-,%,!()#
M*QQC;Q@?_7K^B,_"/X:%UD_X0O0]Z$%6^R\@CD8^?M7<6&FV&E6ZVFG6D-G;
M)]V&! B#\!_4U]YA>"<7C*5'#\4X_#YQAZ%3VL:=*A.@ZTNBQ#O^\A;XH]?R
M^3K<54,-.I6R+!5,NKU8>SE.I4C65.-E=T5]B=UI+HCX"T_]@KP!H5SH\NF6
M=N3 (OMLS1*9&= -QW%23SSUK[@\*>$M(\&Z5!IFEP+''$BH6"@$D#GWQ]>3
M[=*ZJCKU%?9Y?DV5Y5!4\NP-#!TXJT*=&"C"G'JH+HF]7KJ]3YC&9GC\>[XW
M%5L1)OFE*I)RE.724N[2T6V@F>,CTXI1GO117IG %%%% !5/4/\ CPO?^O6?
M_P!%-5RJ>H?\>%[_ ->L_P#Z*:@#^0.7_E./X&_[$WQ1_P"GSPQ11+_RG'\#
M?]B;XH_]/GABB@J6Z_PP_P#2(GLW_!N3_P DTU#_ *_K_P#]+)J_JBK^5W_@
MW)_Y)IJ'_7]?_P#I9-7]45 3^)_+\D%%%%!(4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S/B
MKPCH7C/2;C1]>L8;RTN$9&$D:,Z[E*DHS*2#@_H*Z:BAI---)IZ--733W33T
M:?5/1C3<6I1;C)--.+:::U336J:9^4OQB_X)P^%-9GN=1\"P):W5P6<IM5<,
MQR>.G4GIGU/?/P;XU_X);?&W5!Y.E7;11*V5\L8XR/3'I^/4\5_2917YGG?A
M#P#GN+6.Q61X>CBN?VDZV$7U>52;WE4Y%[S>_KT/U'(O&7Q#R#!O 83B#%5\
M'R>SA0QK^LPIPT]R"GLE9>?F?S;^&?\ @EW\;K..WAOKUG6/;N\P@\#'K_45
M]L_"'_@F[H>G36\_C^*.Y^SLDFU51BS+@D8Z'D=\C]*_6^FY.[&./7!]/\:Q
MR/P:\/\ (<5]<PV1T<1B5/VD*F-_VATYWNI04E[K3U79^AOGOC=XD<083ZEB
MN(*^'PS@J<Z>!7U53A9)QGR-\R:5G?N^IQG@KX?^&/ &E0Z1X<TZ"SMH45%*
MQQB0A1@?,J@CWYKM:0C)!]#2U^HQC&$8PA%1C%*,8Q248Q2LDDM$DM$D?E$I
M2G*4YRE.<Y.4I2;E*4GJW)N[;?=A1113)"BBB@ HHHH **** "BBC..M !6/
MKV@:3XETN]T?6;*WOK&^MY+>>*>))1LD4J2N]6VL,Y!'\B:UBN2#GIC_ !I6
M) X&>?0T ?A%^TW^R7XX_9P\4S_'#X 27\6B6EQ%?:UI-LS $,YDE011G! V
ML,A<<CC'3[]_8\_:VT'X_P#A>UL+Z5;/QE8(8=1L9Y MPTD( <F-L/NW!N?P
MQ7VGJ6FV&L6-QINIVD-[8W<9BN+6X3?%+&>JNIZBOP:_:A^#?BG]C?XJV/QU
M^$<,TGA_6]2+ZMI-FDGDVD4DV^8M&@PNU2<G:!@YR1S0!^^0SSDY]*"0 22
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M_=?#+N( )SU[ ]<5\JKI5AX>#>*/B'>G4]3N=TVGVERWF%9GRR*JL6((9AP
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M'+.R0Q( ,X&=JC !X'8<"OB+XY_M36NAR2^#?! >[\1W3&*WNX&WHC<J""O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>H?\>%[_UZ
MS_\ HIJN53U#_CPO?^O6?_T4U '\@<O_ "G'\#?]B;XH_P#3YX8HHE_Y3C^!
MO^Q-\4?^GSPQ105+=?X8?^D1/9O^#<G_ ))IJ'_7]?\ _I9-7]45?RN_\&Y/
M_)--0_Z_K_\ ]+)J_JBH"?Q/Y?D@HHHH)"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!J
MAAG/^?\ ZW^<4ZBB@ I#GMQ2T4  SWHHHH **** "BBB@ HHHH **:K;L\=*
M=0 4A /6EHH ***\O\??%_P1\.(7;Q)JT-K.$W1V^Y2SMC(4_-D'UX)[=<X
M/4*X#XF> M)^(W@_6O#6K6L-RM]I]W#;F6-7\J>2%EC9<C@[L<CH>:^,-8_;
M%UV2YE;PUHBWVGA_W4WD!]T?9LE?3OS78^$/VN]+WQ?\)]$FAQ3L$20HL>"W
M?!"YQUQP#Z]Z /SF_9^\?W_[&'QZUGX1>*VG.E>++^1K!IV;R8DEEW0A WRA
M02,8]<BO8O$^J#6/C9KFLK.+O3(H6O4#$/$,YD^4'([<=.HK4_;X^&/A?Q_X
M5MOVB/"%S!=W/AN!9?M<)'F,+9 P8!26R0HSD]>>]?&W['?Q'/Q5EU$ZE<$W
M$QEL9'F;#;5/E]6Z\#_Z_6@#[*^'G@2\^/OCH&\F9?#&EW.VYMT/RD1-SQZ$
M?IUK]6_"WA31?!VCVVB:':1VUE:KA $4.W;+, "2  !GI^)K\D?#WB7Q9\!?
M'P_L6U>Y\,WUP'OKB,%HU5VR^2 1TSG/XU]0^,_VN/-TI(_ EJNIZK)#MFC5
M [0R, &(P"5*'..E 'U7X_\ B=X8^'NCW&JZM?6[O "19QSQF=R <@("6&#@
M=,\U^:7CWXV_$3XPZA<67A9[C2_"T[F&\W%XU%ODJQSP,;23S^-</>6.N^+-
M0E\<_$+6)K73(W,LNERR,$)SG;Y;'';T_2DL]5\0>,+TZ!\--$<:1?8M9KZ"
M%@(T(VM(6"\8!SG/OF@"LDOAKX:P_8/#D)US6=0.+R6/_2&2YDQNR1NQALCK
M7OGP@_9QUSXB7UIXL^) E.C!_/L+)\@C9AU&PX]EZ8ZYKW3X&?LKZ)X A&J^
M))$U[5+Y$N9([I3(()I/GVDN/X=V, Y['!%?7]O;P6D,=O;1)#!$NV.*-=J(
MOHH'04 9^C:'IF@V%MIVF6L5O;VL2Q1A(U5MJ@*-S  DX ]JUJ** "BBB@ H
MHHH **** "BBFL2,8&?P- #J*,T4 %%%% !1110 445Y]XZ^(6@^!+&2;4[I
M([N6-C:0-C,TASL R?7C !S4RDHIRDTDM;_UU[%1C*<E&*NY-)?/].[/0:AF
MN(+=0T\T4*GHTLB1@_0N1FOBIOCO\5;V2XN-)\*&YL%W&"5;8L&0#*D$)SN
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MU7X2_P#! O\ Y,S\&_\ 7C'_ .@K7[M4$O=^K_,****!!1110 4444 %%%%
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M QQSZ@C/L3:#F4YX&/TZU^MW_!.#49[OP)!',Y)6U7Y"<[?W0/3Z=_Y5\/\
M_!47P67^*>E:LEKOBW13,^S(_O$YZ=>?3GUKV3_@F=\4+"75;[PS=7"0F.)X
M849PHW;"@ R?7'\J_EOA?&4,I^D)Q9A<315"MG>$O@ZC:B\3L[):7\FNA_67
M%>!KYQ]&_@W&X:O+$TLBQEL93LYK")^[JU?D3?>WX6/VZSU]O_UTPN!QS3@0
M0".0<$$=P1P?RH('4@?E7]1G\G"T@.<CTH!!Z4@;G!&.N/?'X4 8_B#6[?P_
MI%YJUU_J;2%Y6SQ]U2W]*_+/Q!_P4W\':+\1O^$(:U)D^U&W#9PO$@3\?P'-
M?:G[57C*T\%_"'7]2N)DB8PO'&I8!FS&V<#OU ./7BOY=;+3[;Q[\9] U6UL
MUF:]U9=T@3<?FN!DD\XS_//L:_#_ !=\1,XX.Q?"F5\._5ZN99WF=*AB*-:"
MJ3^I2G&,JD([KK[WSZ'[UX,^&F2\;8+B[-^))8FCE>0Y95KX>O0FZ<'CHTW*
M%.<EH[NWN^>J/ZY/A]XTM?'?ARSU^T7;%=Q1R!?9UW5W%>7_  =\.+X8\ >'
MM/";&_LZU=UQC!,8(X[$@@G_ !KU"OVVDYNE2=2WM'2I.I967M'3BYI+RE='
MX15455K1A_#C5JQIWW=.,Y1@V^MXI._F%%%%60%%%% !1110 GS9Z\>GX?3U
MI:** $.<<=:!N[G/^?I2T@&"3ZF@!CPQ2\211R \'?&KY'3'S U\M?%S]D/X
M4?%Z];5];T^2VU:,%[:>TVQ(DH^9257;P6QDYX]#TKZI)QR> .23VKP'XC_M
M%?#[X?\ G6%WJT4NM ,L-FI4YDZ 'YCG)XQB@#\^?$7@[]H_]G'43JOA^[O=
M2^'5A,&%C#(TK>1#T!52V"4SUY]!7V-\ _VL_"7Q;@&FZD!X<UZV0126^I2"
MW-Q,F%.P2[3N8YYZ$^F:\@U']K'Q!JIEM)_"4>HZ+.V&1K<%9(<C!;*D$8/X
MYKY4^+^B>#/&ES#XQ\-ZF/ GBG3R+B#1[%OLWVR5"'VE$*D[F '(.<]* /V/
M^('B>T\->$]2U29@\,EG<11R(P*9EA958,.#D-E2#VK\<?"EU>:1J?C;QKN\
MV.6>YEMVF.[8"['Y&8<8SVKJO _[4.I^,/#=Y\,?B2K:>VGVIBMKV?*M<+$I
M56+MC=N'/4CGCC-<W\.5M?&T7BCPI:SI_9ZM*D,^\8=<M@YR <X'^<T ?0?[
M//P9M?BS>?\ "Q/%;-<VD5P3!#G*F0'*J,GC[OH>/RK],+&QLM)LH;.TBBMK
M6UB6-%55151!C+$ #W)-?E)\%?B_XB^"&JS>"]:M&_X1,3NT=ZZY08) 96((
M''<'I^5>G_%']JG7-7C?1/A]8F[MKY?)EOHDRT(8?,=X&1CZCIW(H ^H/BY\
M>_"GPOTQYIKB+4KYT=(K:UE61TEP53>$SSNYQ7YQ^(O%?Q"^,EY,^O:A-IW@
MR\9F"22-&$B))P<D8^3V_G6#%HUKH3R^*OB1J[:A]JS-;V,\AD43.2P0(Q/<
MXZ=?3MKZ#X>\??&"[_L'1=,FTGPK=R*(;^*-D586;;D, !C:?\XH RCJ5IHP
MB\"?#K3WO)I2(VU&)3(/.) W&10>C<GGM]*^O?@E^R\!<6OC+XD*U[K*"*>Q
MA?YE3D,NY6S@ #TST]>/<?@[^S[X7^%VC16DL-OK&J921]0GCW2*^,MAF&20
MW0Y(].V/H, * H      P !P !Z 4 1PPPP(D<,211HH1%1 H55& H"@<#%2
MT44 %%%>"_M'?&O2?@3\,-?\<:A-&)K"V8VL#,H>21D?:RJ>3M('0$YYH _/
M3_@IK^V9<?"SPLGPR^&]T+_QOXF:729K:QEW74 NQY RD>77:3W'!R?IPW_!
M-+]@A/!E@?CA\7+5M5\:^*#'JUDFI*)I;8SL)@3YNY@%!(Z#)X^GA'[&?[/>
ML?M2_'K4_P!ICXAK+J?A2?4)Y])L;U6:&,I*9$,:R_+D8 & "<X'45_199V=
MMI]I;V-G"D%K:0I!;PQ@*D<4:A450.  !0!8 "@*H"J   !@ #H !P .P%##
M((I:* $48 %+110 444A) X'- "T4Q0<[CU.>/J:=D X[T +1110 44A/('K
MG]*\3^)OQGT/P,_]C03)<>)IQ_HMA@%B>WR\DY)&.,#W[9U:L*,)5*CM&*;?
M=VZ)=7Y(NG3G5FH05Y2_#NV^B75GMOX'_/XU7FN[6!@L]S!"S?=665$8_0,P
M)KX@O_CU\8;/2K_5#X./E6L+SH?LO#1KR#RN.F/_ -=?DE\4/^"D%W+\01IW
MB;5)/#]U9WHA^Q+*8E;:^ H3*CH , >E?GW''B/EG!&12SW%8',<91C7I4?8
M87#3E6_>22<^5)NT+W?YGUG#?!V/XDS)9=AZV'HU/9SJ>TG4BX+E5TFT]V?T
MI!U90ZL&4C(92&!'J".#2@YY%?&O[(_[1.C?&SPQ''878NIK. ,\A.6<!03@
MGEO7Z5]E].@K['),VPV>Y3@,WPBG'#YAAJ6)I1JQ<*D8U8*7+.+U4HWLT^J/
MGLSR^OE>.Q.7XCE]MA:LZ4W%\T6XMJ\6MT[70444$XZUZG];,X0HHINWYMV?
MPQ[8H =1110 @.<CTI:/PHH 0'.1Z4$XY-(V1]T=^<#G^7ZT@7)W'\L?AW_.
M@!X.>:**\R\8_%OP9X)E:UUG4XXKX9"VV1N+#L><CGV_&HJ5(4H.I4DH0CJY
M2=DBX4YU9*%.,IR>T8J[/3:*^6=;_:D\%Z)H&H:[<W"K!9H[J6P 0JEAG/';
MG/KQZ5^>%K_P4QN-4^(B6=C'&WAYKX6@E# IC?MY'3O^')SUKXGBCQ&X4X/H
M8;$YYCY8>CBZL*-&=.E*JG4G)1C%\K]UMM6[]#Z/)>$<]X@J5J66X55)T(.=
M15)JG[L5=VYMVET/VT!ZC!&/6EKC/ /BVV\;>&-.\06K*R7L*2$*0<%E5NWU
MKLZ^RPV(I8O#T,50ES4<12IUZ4K6YJ=6*G"5NEXM.Q\[6I3H5:E"HK5*-2=.
M:WM.$G&2OULTT%%%%;F84444 %%%% !1110 4444 %%%% !1110 53U#_CPO
M?^O6?_T4U7*IZA_QX7O_ %ZS_P#HIJ /Y Y?^4X_@;_L3?%'_I\\,442_P#*
M<?P-_P!B;XH_]/GABB@J6Z_PP_\ 2(GLW_!N3_R334/^OZ__ /2R:OZHJ_E=
M_P"#<G_DFFH?]?U__P"EDU?U14!/XG\OR04444$A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 @ '04M%<;XN\>^&/ ]J;OQ%
MJ4=E'M+ $J7( )^Z6!&<9'MS0!V5<CXC\<>&?"]I=7.IZM8Q/;1N_P!F-S$)
MW91G8(]VX'Z@>G7BOAWXC?MAZJ+I[?X:Z<-7MN5-P(PY49(W;@I((ZYZ?E7R
MWXET#Q#XPNH_'?B_Q-<Z;&\GGSZ7Y[!=A)+(4W8Z<=/2@#Z1^)?[6^H>)A<^
M&?AU975KJ:NR1WOS89N1N#@ 8&#[=.M?.=SH%YXGC>\^+FMF>\A9IT@:?YWZ
ML%VEL\]._7!]*9+XHM9WM++X:Z&NIZI$%BDN(X-\CL>"V0N<YR?QS7N?@?\
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M^)Y]XP5.!O$3"X?.<UAC.'L\Q$,NIX54_9U<KQ+<$O:?RKFE:[Z=WH?IF6\
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M_D\O]GW_ +&K2_\ TOAK^QWX ?\ )$_A=_V)6A?^D4=?QQ?\%_O^3R_V??\
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M*B6>*W)(R0&.0OIS[5[UX;_93\1?%2UMM<\<:G=:)<J5=[4&09/7;M'..W3
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M?P5\._"C2VL=/6.ZN'V[[MT^?CK@L W)QSQ]*_-S_@I.3IOB'X?7@.TS:Q:
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M_@O]_P GE_L^_P#8U:7_ .E\-?V._ #_ )(G\+O^Q*T+_P!(HZ_CB_X+_?\
M)Y?[/O\ V-6E_P#I?#7]COP _P"2)_"[_L2M"_\ 2*.@TG\$/G^43U^OYYO^
M#D;_ ),:'_8PC^5O7]#-?SS?\'(W_)C0_P"QA'\K>@5/XX^IW_\ P0+_ .3,
M_!O_ %XQ_P#H*U^[5?A+_P $"_\ DS/P;_UXQ_\ H*U^[5!+W?J_S"BBB@04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !44\$5S%)!/&DL,JLDD;@,K*PP05((/]*EHH ^2/B5^QO\
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M/:;';K@#>RHSC&.5;:"O3Z^]=3JNNZ1HD+3ZKJ%K8QJA?-Q,D9*C^Z&(+$]
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MGAD4,KQLK###(SM)P?8U:H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGX*\+VI&#!HMC&1Z%85%=?0 44@&.!2T %%%% !1110 4444 %%%% !1110
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M:E*O*2Y%-QYHRF[:JR]W?0XKQQ<7'Q1^(/\ 9^BD75R=2!EAM^=D9DYRB@X
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M44 %%%% !1110 4444 %%%% '\0?_!?[_D\O]GW_ +&K2_\ TOAK^QWX ?\
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M>.^??MUK>^.ES^QS^U_I;>*_&^JZ;]JL+.0PRSR0EPR1' Y.1D_TK^U<OQF
MK4L7A7F^5RS"K6I8J.&3IQII6YJB4-ESN[?GOW/YWQ&%Q&'Q6%Q-?*\Q674Z
M=3#.LN?VKNU&F_:+5\JM9;'R'X'_ ."D?[-'BKQ]X>'A'P38V&H+=0#)LX@7
MD#+G'R8Z\?TK]'_C#^T_X7\7Z/9D:1:Z5+_93M%/)"D8):(L,%AD*N<(!@*.
M!BOPH^$WPP_92\/_ !=UC4/[4M4LO#UV\^F&#8RS&)\H,KG.<#MSW-=?^U'^
MT_X3\4:?;:%X-;[,UI(NGQO;\.T&1'NP@R?EY'_ZZ\K'<5O!X;&XJA*$Z-2H
MJ;PM"FIMU*'N.R7P*_P[IVYM3TH</X;$XO"TX1KP<(\[J5Y.-H5>5[OXVE\2
M>U]]1W@G1[[XP_&3Q!<Q1M?Z9I5U-)<31@R1)&KECZ@  9["OO\ ^'4FD1^)
MH]$F=KWPW&OV.XL[=\A7^XP95/48P1WZ>U> _L^>,_A;\$?@EJVH6+2ZEXY\
M96+H_F1,TL4UQ&1D9&X89NO]:^M_V5?@WK-O\--7^*>JQO=WU[J#W\%M*I?;
M$\GF8P02-JGL*\?A[+\3E[A4PF&G3S#-/:YGFEI.=*-&+4J49]*SY&KT_L[:
MV9VYOC:.+4HXBMSX3 NE@,O3M&3J22C4<5_R[2DK*=M?F?H1^S#\(M(\$:GJ
MWB+1+-K2PU:-C%'(F''F!CP?Q_GZU]H;AG'.>?TKR;X4>+=&UKPAINR2WM;J
MWMPMW;ED0HR]21G(^GMGJ:]2M;NVO(S+;2I,@8J61@P!'8X)_#UK]VR:CA\-
ME^'IT)1E"<75]VT;SJ>_.T>EI-KEZ;'Y+FE:MB,;6G6BU*#5+77W::Y87EUO
M%)I]5J<OX]NM$M/"VK2^(K2.]TC[-(+R&6-9$,6T[CM8$9 S@\$>O8_S0_MK
M_!3X9>(1>_$#X-1PZ'?0W<DET8@L67#Y;&TCG_\ 7ZU_2[\0-%?Q#X.U_2(U
MWS7FGS10C&<R,,#C\37\K?[3B^+_ (9>+-7\#^)5N=/TN[O)WBE(=(V5G; W
M' Z$=#[\<5^<>+V;/*>':U;%9-_;65U*=2GBL-'#.O.+DK1FFE>FENY]#[/P
M[P/UW-(QP^8O+<="<)4:GMO9QFDTW'ENO:/R_,Y_X8^,+N/P)+X4U2X\XWL+
MV^HSS-O0C:8R?F)'N/K7PK\5/@QXO\-ZO=:GX>2X/A#4)W::[3<;8&4Y.2/E
MXW9Z].:^E_ EK-K=E?:3:S!4F4I;W60&.3PP?)]>QS7Z\?"'X&>%OBC^S;J_
MPRODMI_%*V<UQ;WGR/<"01EDP>6Z@=_2OX\\,>%\\S;,L=ETL76HY%F6"QV9
MY'@JL?K5"EB*4KTZ4*CTPTH:+V:MS6T[']%\:9U@,JP.$Q[H4Y9EA<5A<%FF
M(IR]A4J4*JBI5916M9-;RO[JT/YL-)_9L\>13P^*_#6IN!(1+F%B /XCRO\
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M./O#!.?0'X2_;W_X)R?!CX]:[??&WP]\57T.65);H6]GJ C !#-]V.0=!_\
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MJ]>54790>RT.W/\ %PS&4L;B%#EP<J.&RZCR<WMXTZ:C7=*'67M8WYEKU/T
M_9/^%"^ =*U+5983'>ZX!-.S+@DNX=B.!U/]:^Q*R-!?3I-(L)=*V&QDMXVM
MV3'*8X)(ZFM9B0.!GGT-?OF6X2&"P6'PU-\T:<%:7\SE[S?G=N]^I^.X[$SQ
M>*K5ZBM*<M5V4?=2?FDK"XSU'^30!C@4U23G(Q^!IU=QR!1110 4444 %%%%
M !1110 53U#_ (\+W_KUG_\ 135<JGJ'_'A>_P#7K/\ ^BFH _D#E_Y3C^!O
M^Q-\4?\ I\\,442_\IQ_ W_8F^*/_3YX8HH*ENO\,/\ TB)YG_P1"^!'B3XB
M?#C4;_PK?-87HU#496D#E /],N&))!  ]2>GK7[WWWP/^+OP[=M5U:];6K91
MO:-/WP; )*@@D9[>M?EQ_P &X^L62_#S4[#[2D=P;W4E,;2!2Q^U3@J >26Z
M8[YQBOZII[>WNHS%<0QSQGJDB*ZG\""* G\3^7Y(_#3Q/XUMM0ODL-9\%WJ8
M<1O.L$B*,'#'(0>__P"KIV=AX?\  R:2M[IM^NDZDZ;HUEFV,CD<#&1SG_/%
M?K-K'PY\&ZU;RPW6@::'E4KYR6L:NI/?( '7GIFOF'Q1^Q=X2\17,EQ'K%S8
MAF++'$K*J'.0!M/04$GQ1X;\7?&GX>ZLFOSZ]-JOA.&7S!$LSR)Y"-D+C)'W
M>/I7Z=?!/XU:/\7-&:[LP(+JT1%N8V;!:085B >>I'0>O%?FE/#K'@3X@W_P
MMUM7NO#"EH8+N8%LC.WJ>V#[_C4_@GQF_P (_C%I/AO1)"-(URYB$J*<)B5U
MSTXXS^GK0!^S-(<D<<&HK>99[>&=3\DL22 ]L,H;KT[U\[?&+]HCPK\-X)]+
M@NTNO$TJLMG9Q[7_ 'F. 0"23G QCCGOT /HW.U?F(XZDGCKZFE!!&000>XY
M%?D2_P"U#\>M>U"2V71FM;+>[1/L,8://R'@ 9P?Y4R[_:<^/VA2+!::2+M"
M><KO'4CW''TH _7JBORS\-?M6?&J:93KN@+#;Y&YQ !\O7.=M?1.@?M9^$XH
MUC\52FSG. V%"X;&2<8_G^?>@#[! ())/'.!SZTZOG*+]J?X02C*ZZ?^^%/_
M +/6W8_M$_"_4"!;ZV&SC&54=3WR_% 'N5(IR,X[UQ.E_$3PGJX!L]5@?=C&
M70=?^!5UL5]9S@-#=6\@/]V5">F>F[/2@"U2*<C..] 8?W@?H?\ ZYI<YZ<T
M %%%% !1110 4444 %%%%  >AI%! Y.>?>FO+&@R\B(/5W51^9(K/GUG2[8$
MS7ULNWD_OHSCK_M>U &G3=WS;<?YQFO.]3^*O@K2=WVO5HEVYSM9&Z'!_CKA
M[O\ :7^%%DYCGUPJP/0(I_\ 9Z /?J*^:)_VL?A!"2!K3.0< !5&?_'C7G?B
MK]JZTFC?_A#(OMCX(3*ALGD#MUSB@#[;JK<WMI9C==7$4 QG,KA!@=^:_)[6
M_P!K#]H"&Y<67AT?9\_(WD 9&[']WZ?K5>+XL?%GX@+M\0%M-5QM;:^S ((.
M.1C'OQ0!^ILGC/PI"2LOB#2D(ZAKN('T]:\C^(7[1'@SP1&6ANH-8D .Y+67
M> 0,X!4_A]?;&?S=\1^"0$:[O?&%Y$S_ #LL=T_!)RPP&_E^%<;HMSX+TFZ*
M:AJMWJ[J1Q/OE!.,'KGM^.??J ?:TG[=FAY:.+PO=F0\(W[TCMSCOC/Z8KS3
MQ+\:/B5X^6>X\+R7&E)(#Y8W,FW(X/&/7_\ 57FMY+#KUOL\$>'(KJY4?)_H
MV26P<?P^N.GXXXK.T7PS^T8]XEL/"TEI82N%WI;LNV,X&00O3'U_3D YF[O?
MVATNYC)X\*R,?W4!NV#]>!C</7%>P^"/C=\4/A+';ZIX^N+C7+.5U1U+M)B,
M_*6[X&#G_.:]#G_9:\3:EH#^)IKZYC\0P0F2*RW,-T@4-@KD=_YUX/I7B&]N
M]>O?AIXYL5.KKYEI#'.O(&"BOAAP?RY[T ?JA\+?BKX>^*>AQZOHDR%MBO/;
M!PSPDX&&&=PY/>OE3]N&]:^\+V&A_,B?:ED+ XW,3Z_0 ?G7SA\)/%-S\ /B
MA'X86Z>:V\37*Q+;,<QQ"=P %4Y4!<@C'H.>E?5'[;7AG5=9^&MIK&@V[37]
MM,LLHC0LWDB-)-V!SW;M0!\67-[*FA^%O",T;+I=Y'!'<S@8 #;0<L/\?>OU
M ^!WPR\)>"?"MC-H<,,[WD22O<[5?YBH)"D@\@GKGCMZU^:7A#5M$\;^!;;1
M&98/$MA $D,A"2I-'D8&<'A@.G/X]-OPA\9_V@_ L;>%M)TAM4TRT=WAN9$,
MN$ QA2P/4 'TX%']?UW _7V\OK.PB,][<PVL(ZR3.$7CKRWI7CWQ"^.G@SP)
MI+:B-1L]6F7=BUM)UE?CUV$G).0![5^>4_Q9^,'Q1:?1?%,;Z';#*&1#Y( R
M02,8 /TZ\=:\S?1?"WA#52_B#Q#=:L'?=]GDD>9 Q))7!)'4_P!* /J'6_VP
M[WQQ!+HOA+1;K3KN3<J7)$F=WW0<GIUXZ?2OGFX_X63J>L.?B'XK/]A3.66V
MFN"H$;\XPS=.<?TZTM[)XHUB..;X4>&%N#@8D2V.X]!G(7MUKV?P+^S/XP^*
M-B+GXD7%UHLR#/EKO4G/0!1@GTQV/)[T ?/NK:MX1\!:I;R>&M$FUZ>=AOE@
M4SJ&8]?EW#KS[].]>HV'P?\ BM\7X[?6-%GDT#3WV-) ^8/W;8)!^[V/?T_"
MONSX:_LX^"?A];>2]M#KDHQLFOH1(5([_/DD]_KUZ<^^6EC9V$0@LK:&UA&,
M1P1K&G P.% Z#I0!\G_#W]E#P9I&GP3^+K,:KK8"&2?>I =3N+;B'SD]OQS7
MU-H^C:=H-C%IVEVR6UK" J1H .!P-Q &X@>M:E)D9QWH 6D8X&<=Z6B@!"<#
M- .1FEI,C..] "U^-]I>-\1/VM]5\,2'S%TN]E.P_-M"2^F>,"OUOU[Q1HOA
MRWDFU34+6U=8I)(XYI41W*H6 "L0>2 .G?.*_'G]E])]?_;5\=>(T4O8O)?M
M%( 2AR79=K#@X'/7WH _9RPM1965K:+TMX8XA]$4"K=%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 F!G..?\ (KS?XP06]W\,_&EK=1+-!<:'=Q21
ML,AE91G((/85Z367K6E0:WI=]I5T/]'OH'@E_P!UQ@UCB/;?5Z_L%%U_95/8
MJ?PNKR/D4O)RM?R-*+@JU)U&U352'M''=0YES->:C>WF?PJ^.]3TGPO\;O$O
MAO3HEMH9]5N6DC "Y)E;.!C^?U]*^@O@=\._'?B?Q%=>-/"=U<QZ=X;?[3>P
MH[?O$A(<@ 'VQ_C7L7_!2_\ 8SU3X.?$"Y^,&B6DTWAV>[>>:6")F^\Q<\J#
MTSWYY[54_8:\7>+M2FBTGPGI-S=:?XC80:@7MW"JCOL?=E<#@GKZ^AK^**V0
MX_*/%++I<18.M0K9O*=:?]FSDHNM>])QE35G!RY>=7MJTV?U)1S;"YEP#C7D
MU>C5IY?"%*+QJ7-[.T55C*,]5+EYN5[[,^[;[]IW3?'/PP_X0>W\%W4FOPQ'
M2Y]2:W=QY@4Q-)N*^O/!'?/H>T_9'_8E\+:3KD'Q&\4ZO:Q7-_+]I-A.R!@9
M&$FT(S#!R> >F.M?H9X/_9Z\'>&_AM?M)X;L/[=N-,N+YI#;IYB7/DF8'.W.
M[<#^'YU^17@/Q/\ $CQA\2_'?A^UU6YL&\.7%VNEV(F:.-S"Y\L!=P&"5  ]
M/;-?T'F>78+#8S*JW$.#IYWB\9&<<!@IT8JA1GAH1JQ<XO2=9122D]926S/Q
M_+\3BL5@\RIY'7J95A\)*$\9B%7;JU8UY^S?*UK&FFW>.RC^'Z;_ +>^LV/@
MC]FS59K!(H["&-H8_*VA/*6'((9, Y[D=_I7\LW@SXVZ'::1XDN7FBCED%SC
M<P#'.?4]?UK]BOB)\6/&/C[P+J'P@^+J-;6062""X<M\XPR*V3DDGCGO[<U\
M,?"C]@?PCXU\9-H\FIK#HE].5$C.$4I(WN1T!YQUZ?3\.\4,)@O%;,LLRO K
MZEB</["B\NQDUA,72K4*L7:-%V_V>R2A46CZ:*Q^F\#UJW N QF)QTGB:%2=
M2NL9A8NO0G2K0CJZB_Y?7NW!W:=_E\@?"VY\!_$?6)O[=U%4>[NS"N9\!3(V
M >6 XR"/3^7V'XD_9#@\$Z$FN^%/$3WUAK$8D<6URQ$ D'.[8QVX#?7(]ZP?
MVT/^"6GQ ^!=CIGB;X+W,VHV,LJ3S-9!I"@.&S^[R0!ZYY^E>@?"#PQ\6='^
M%5KI&O/J&HZE>VH21)A([6Y*@'"MDKMS]!CD5Q2RO,?#R%?*^*<FQ^:X+&^]
MEF+RW#3Q>+RZO",6H?6(>\Z$]DM5%,]"6/P/%ZHX_(<WPV!JX;3&87'8B.'P
M^+IMI7="?NQJQW<GJ]F^_EWPU_8J\-:%JEQ\4O&WB5-0TA"9Y+%[K>X PQ7:
M7//!_EGBOG_]H73OAUXP\76-I\,-*D:"RGC6ZB@&[S1&X#@A0<YVD$?@*_1[
MX;_"[3WM[K1_B'XDN["VO68""YF:*-3)GC#D+P#@8[CKS71^$?V4?"'A?XK:
M+=>&/)UW3-2N8FD90L\>V20'G!('4]?<\5CF.-XLQ/"WUC(N&Y95@*V886A6
M<JSQ6;XR6)K1INK*B_WF'ITD^::VY=-C'#_V%2SIT\QSB..QE+"UJM*,::H9
M;0C1IJ?LU47N59S^&,N[/3?V,++]F7Q5X '@CXF^&XO#NI:99-*VH:@HMDD=
M8""=\BC)W?-@\,P W*#N'V+^RWXQ\ ^$9_B"/!-W:7_A_P //=+!;6K(WVB.
M,/MV[#ELCIC/TQ7HWQ0_8<\!>/\ P2;6PE_X1;4?[%=I+K3X_)9I1:%UWM$5
MP-V Q.>,Y[U^$_[/<_C?]G3]I34O GVV[U?P*VIO;ZQ=7#.\+P^>4=I&<D?=
M]3[^U?U+EV'Q&49?D6&QE"E*MA\/"C5QL;03G[./OU.D;-V=WJ[ZW/Q'%3H9
MIB,VKX2M44*M656.#E=WCSW:IOKS):=K^1^F.G^*?&OQ4^+=[K/@>"YT:,WC
MP2P(&B!&\JS[0%!Z>G7]?>K>^^(_P[^(NA:9>ZI+?1:K/%]LC$C/M#LH8$9/
M;=GCIDCI7@7Q>_:&\'?"OQ-::G\*(+>[NM3MDC>&S"/B\F4!N(P3NWG_ .OZ
M_37[+7ASQY\16E^(7Q1LY8)KD)>:2EPC A&<%=H;T7],UE1P57'8JMB,/6JQ
MQ4,53YG3GRX6-*,DW4A%>[*5573:\UY%U\1#"X:E"K2A]5="7+&I'FQ$JDHI
M*$I_$HTY>]:_XGZ$P,7AA<]6BC8_5D!/ZFOB;_@H!X*T'Q5^SEXYGU*&#[=I
M^FR2V4[*OF!@KY56/S=<'(Z8K[<4!0$'\*@ >P  KQ+]H'X<2?%'X:Z_X7@=
MA->6<T:(N<2,R, I'?DBOK<V=6.5Y@Z6'^MU5@J_+AKV]O+V4K4[O^?IYV/E
M\NY?K^"YZOL(K$T6Z_\ SZM4C[_I'=^5S^)'X4ZE=VEIKFGV]P1>6VH70@!8
ME\+(X7')/I[\_A7VQ^Q7\3OB1IWQYT-?$AN;;P_#=QAKV4NMND8D )9CA<8Y
M/?UKY"^*/PC\=_L^_'76=*UNRN(-'.H7$L3&)TB=3(V.3P<@^_L>N?U"_9!M
M-*^,1'AB73Q87-TR)#J<<6V1=QQN#@ ]?1OPZ9_BO@K!8K+?$587&0Q.5U<0
MWC\+E#<N655R4O9-]%>WOZWOV1_4?$^+HXW@R>)PWL<=3H)87$9BN5N%-Q4?
M:1WN[/2.NI]9_MUQZ#\5;JQT_1)K6^N;VSB@@O+<*Q6X= !\ZY.0WO4O[#_[
M 7C#P==6_BOXA7@OM+N=ES96UR0Y\HL&7:CG)&..!C(/4@U[M\8/V7;?X6?#
M./6]&O)]8U71V%S(\NYW!AC\QL%NJ@@C([\^]?/GPX_;6^/.IV1M- T(W6A^
M&!]FO93$)"L<'RN"2I. ,G!P ?0$5^Z9YDG"TL^I9CQEEM7,,PC_ +?E^#HX
M>6*A0E17/.4>6WM)1LVTGU/R?*LSSZ.45<%PUC:6%P,TL)CL36J^PE453W8I
MMWY(S>B[_<>P?\%7=?T[PM\$=)T&U2VLK?S<*JHD92(;$10P .W"9(XR23UK
M\*-*\7:;I/@..YTS5;>+4&MLJRR(KAB/4$-U^N._O^DO[;OC%_VL?A9:Z)H\
MK1>++= D]KTV2J,. O& &ST [U^7WPY_X)W?M&^+H1;6WGO90QG(RQX7! P.
M_P"5?B'BMD3\2^+<NQO"]>K7I83"X24/JM/G=&IATFZ5:*M[&K2>CIM-Q?F?
MI? .9K@SAW$X7/(TZ$ZF)Q"E[>?*JU.K9*I3U?M:<T_B^U;1:C_AW\)_B3^T
M)<3P_P#";20)"[F");MU9N?E7&\=Q]>GN:]Q_P"%+?'+X1Z%J%K<>(+]-/C2
M2)9);F79(I# $'=@C SUYZU\6>/O"?[2'[%?C[36O;76%L)+R,+Y,,Y1SN
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MCGWH  Z4M(I)'(QSZ&OMSY 6BBB@ HHHH **** "BBB@ HHHH _B#_X+_?\
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MF,<'_P#70!]^50N]4TZQS]LO;:VQR?.E5,?7)XK\E[K]K#]HC[2T0\.K'$6
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M=U+I*W.KQ!))KEBN#,,,W!5L_-SG(^AKZ(MX(;6&.WMXUBAB14C1%"JJJ,#
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M../\@5^H/CGP+H?CS1;K2=9M8YUE@DCA=U!,3,#@C(]?<=37D7[-?PD/PO\
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MH<@CY&(ST/KQ@8H _)+5M.T^"^_M[X>>)X=-UJY&9UBG\LY<$E=JMU!.,?\
MZJZC1-1^,\7E3OXLENU3YF47#'('MN[X[^OK7M6M?L.Z7IDTVI^'=9NY)F=I
M%@9F7:S'< %SC /I^E>8:E\%_C1H,KQ:+!<7,*\+D,P(X_/./Z=<"@#K[#]I
MKQ9X$0C6K"XU3RUY(5G#8'/J><=>*L0_\%!+=Y?)?P->9#!2VVXP<\$\''Y5
MX[>?#[X] $WOAL3Q#.=]ONR <<Y'I@FHK.TUG0R!XC\*6Z,.6(M5SP!G^'US
M0!]B>%OVO]#UY(VNM&?3]V,^89%QD\_>/8?2O;M%^-O@/5$4S:U9V3L,[99E
M '3@Y.>_]*_+[6?&/@VVC87EA)9Y'/DP%=O&3C"CG\OQ[^2ZAXC^'=_,1'K&
MJ6Q))PGF+@DD=L?Y_&@#]Q5^(W@5_N^*=(;Z70_PJ9?'W@M_N^)=)/TNEK\4
MM T7PUJ;D6WB?5!O)"EYI!C.!W([CV]*]$@^&T&%DM_%5X2V" ;A_3/][T_S
MGH ?KJGB_P ,2_ZO7-.;Z7"U;C\0:++S'J=F_P#NS*:_(T^&=<L$*VGB"=R!
MQ_I!_JW7KCT[^V>VH_$G3&;[%J<DHY(S.3GD?[7H./\ Z]%_Z_S _9*.ZMIA
MNBGB<>JNI_K4V]#T=?\ OH?XU^.MO\6/C=IRB.!RZJ>"9.H QZG]*<WQR^.X
MX"9)Y&'/]3[>E%P/V)#*>C _0BN0\<Q>&;GPYJ%MXKDM8]*DMY?,^TE0,B-@
MI0-U<$_+TR>"1UK\IQ\>/CRN,1\KU^?T&/[Q[^U4]3\9?%GXH0C0?$]VVGZ<
M[#S)EEV?+QN&<CJ/_P!= ',>&9"/B!XOTZ+/_"%1O="TEZP&,.V-I^[C _QK
MWS]F>6YM?'UW;:$&.CO*XD:/_5Y'7./EZ]?Q]*\2\77FD>%/#:^"=*W7.LZA
M%Y$-W #)))+(,?,PR3\QYR>]?;G[''PPUKP1X.N+SQ-;D:CJ,B3V[RH?,$,N
M7R"WM@?C[T >"?M//'HGQ LKO7&"VL\T?V4R_=)+@<;N.O\ 3WKR]POAWQUH
M/C:]3[3H*^02A^:()E6!VG*XQ_GK7VY^UC\#IOBSX=MKO3<IJFBQO-"47YI&
M0O(HR.2<X_+ZU\!:!XKLK6T?X;?$&WG@U2 BVMI9$91A#L!RP]!Z^]']?D!^
MN'ACXI> M:T6POK/7M+MHI8$(MFF2-H2  5*#I@UMGX@^"5SGQ/I QU_TI:_
M*$?"S1K>!&TGQ3<HLA),*W!"H#R0%W8'?MQ_+(O/ .EVJLT_BN^+$;CMN'(S
MR?[WMWS_ %H _6V3XE^ X@2WBG2>.WVD9_D*\^\1_M ^"]%++:7D&HE5R/*D
MSDCG VGOQ^?M7Y$:M:^$[*5C<>)M6/EL<A99><$#L??BKWA_Q=\/;*51]MU"
M]D5L?O0[9Y'J#Q_G/% 'W/X@_;DTW1IGBB\)W%XJ$X=//((!Q_"?\CFN/C_X
M*!1W,GDQ>"+N-V^56*3G!Z G<2/7L1CK7D<'B/0-1C TS0ENF884R6VXG.,$
MDJ?3K6=<^&/'>I2*="\(P$,24(M%[],?*/6@#U?4_C7\0OB#OFT8W&D),"R@
MEDVYS@<X^M>5ZQJ?QFMF8R^-Y+=6.<-<L,#T/S#MQVK4L?A]^T$RA(] -K">
M5,<.WY>@Z#W)[?K7::/^S=\1?%DJCQ/)<VB,5WXW@ $\_I_DT:@>+VD=]J\I
M3Q=XPCO5D^^K7.[()&>K<^O^15C5/"_P_P!-MS<65H=6N "^V(ERSCYL#;DG
M)'&.>:^Q;+]A_P ("*)[S6KTW  W;2S 'Z[AS]!]#7J?A']F/P7X5G28/)?[
M#G9<H&!]CDFCHD!^7NC?$34M)O19:7\/[Y8RY5)3:R$8S@'.SZU[?IOPH^)W
MQ6C6[TYI="1U#[9%,>W=V.0,8'<]/Y?J/#X1\,0*BQ:!I*A!A3]AMV8?\"9"
MQ/U-;5O:6MHNRUMX;=.FV&)(UQ]$ % 'YM:-^Q_\2(ID36/%*W-H6'FQBY!#
M*2-PQO[C/H/K7U#X#_9G^'/@]H-1?2(KK6T"-)=MM(\Q<$GE3NR1UR*^C**
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MMO5ZMZMOJ)@ YQR:,#.<<_Y%+10 @.21CH:3=\VW'^<9IU% !1G'6BD(SP:
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M+=*]=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#^(/_@O]_R>7^S[_P!C5I?_ *7PU_8[\ /^2)_"[_L2M"_](HZ_CB_X
M+_?\GE_L^_\ 8U:7_P"E\-?V._ #_DB?PN_[$K0O_2*.@TG\$/G^43U^OYYO
M^#D;_DQH?]C"/Y6]?T,U_/-_P<C?\F-#_L81_*WH%3^./J=__P $"_\ DS/P
M;_UXQ_\ H*U^[5?A+_P0+_Y,S\&_]>,?_H*U^[5!+W?J_P PHHHH$%%%% "
MY)&.AI:CPP)P.I_SWIXSCGK0 M%%% #)(XY5*2HLBGJKJ&'ZUQNI?#WPEJQ9
MK[2()BV<DJ!G/_ :[6B@#Q.^_9Z^$VHDF[\+VLA;/4J.OI\G6N:NOV4_@Y-\
MT'AR*V?J"-K#/'^PI_GBOI $'IS2T ?'NL?LI:"5(T$I9?W?F"8_+Z_G7#S?
MLG>)06-OKP0=AYX''IU]/\YK[ZHH _.&Z_9"\?R.S0^*50$\8N5'_LWX?TK)
M/['7Q,#$CQ:I'8"Y7V_VOYU^FE% 'YA2?L=_%$$;/%:XZG_2$['(Z-FH#^Q_
M\5$Z>)]QZ<3?CZU^H8(/3FEH _+MOV1/BKD,/$AP!C'F^X[!J;!^Q[\5;FY4
M77BHK:YQ(AN-NY3C(^\,]/3'K7ZC44 ?-WPB_9Y\._#V*.]OX(M0UQ=I^UMM
M<JPY+;L'//3FOI&BB@"O=6T%Y;RVMU&LL$R&.6-P"K*W!!SG\^U?+?Q _9:\
M&^('EU+PW9Q:3K$Q8R3H54,QYW9 7J>H/?FOJRB@#\^K#]D;Q/;%Q+KX=&.<
M?: >,]/O>G%=KI?[*5I'@:G=)<@XWY<-GIGN:^T** /F&T_90^%F0^H:1'=-
MQD8'S=,Y)!_D:ZBS_9L^#U@P:V\)VJ,/XLC/U^X.:]U&>XI: //=/^%O@?3"
MIL]$MXBF-O"G&/\ @-=E9Z78Z>,6MO'$, #:B@C QU S6A10 <^G^?RHHHH
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M?^"2GP:^#O@W2-7_ &D_'E];:_JT(<+<W;+)YSE@<^8<_P"L4_YS7SG\<O\
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MB@!!D#GDTM%% !1110 4444 %%%% !1110 8]OTHHHH **** "BBB@ HHHH
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M<DX%?B;_ ,%-/VA/AY>64/P>T=+?Q#XTUP"RMX[39=^7+,3$ P3?C:6 _,T
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M62UU?5V2X,<L9CD"RH)#D$ ]_P#.:_8V@ HHHH **** "BBB@ HHHH ****
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M HHHH **** #&.@Q^%%%% !1110 T@D@@\<9'/K3J** "BBB@ HHHH ****
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MU_7_ /Z635_5%7\KO_!N3_R334/^OZ__ /2R:OZHJ G\3^7Y(****"0HHHH
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MO[/O5DCN@^S=C"YSCDD>OO7HT-Y:W"(\4\+AP" )$)Y[$9SFOT,_-BS1110
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MSP<9('MQ7[$111P1)#$@2.-0B(HP%51@ "D@@@MHEAMX8X(D 5(XD6-% &
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MHXE_NQHJ+^2@"@#P7]GK]GCP'^SOX(TSPCX,TJVL_LUK'#=W44:J]PZJH;+
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M+PDI)5:4FK.W+=I;-Z'\_G[%'[5=W\(]=M_#>N73-H]])$LTDKG9%N/(.XX
M'8=NHK^A[P9\1/"?CO3[>_\ #VKVE\L\2R&**56=,@$@@$CC..OU YK^:W]I
MC]D+QS\)M7U#4["SNGT0SO)#);1,76,-N&TH#V]__K^7_"_]I7XI?",1IX=E
MU0"%P"MVTB[=O)R'P!T].?Y?SMPGXIY[X4-<&>)^78V6"P4W0RG/,-2G6C5P
MZ:5-2:NI4^6SYG:SNE8_I;B_PFR#QBYN.?"K-,!''X^$:^<</8FM3H2HXAI.
MK*,='&;ES1C&*UT;OH?UM=.@J.66.&-Y9G6..-2SNYVJJCDDD] *_G%A_P""
MH/Q;L]D.H3()=H!_>8.0/]X<=>O^%<[XK_X*-?&WQ+8R6-K*WV6X4HWDR'=A
MAVPV<_K[GFOU7%>/GASA<&L;+,ZU6#CS1I4:$I5IZ7LH;\SO:VMGW/R'"?1X
M\3<;C9X"&54J52$U"=6O7C"A&]ES.;M>*^6VY^PW[3/[6_@[X3^&M0@TG5+6
M_P!=>&2-8H9%=HV*D8 !W;@>O Z8!K^<;Q'K^N_&GXC/?(LMQ<^(KMXFC 9_
M+$TN!QSC&[TXQ4%PWCWXP^)TB,.LW>I7TZDATF>$&0\]05 R??M7[/?L:_L-
MIX8%KXO\>6>;S"7%M%+$,[^''# =R"<8_05^/8W'<4_2&SK!X'!8#$9)X>99
MB88K$8K$1G2J9CR23VG9SG+EY?9VLEJK62/VO+\OX2^C;D6/S#'YCAL]\2LU
MP<\+A\)A90JTLL<X\K:G%ODC!OF]JG=O?0^IOV)_@7_PIWX:VT-Y%B_U*.&X
M;</F577?CD9ZXXZ#IVK[490ZE6&588(]0:9!!';0Q6\*!(H8TBC11@*B*%4
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MV=RMKXYT;7M7A63%G:W*N#(N<( KAV)(YX'45^-7QP_X*Q_'?X\2R>"/@/\
M#[4TMKES;QZM86MT5RY,8E\U 2>/F^]@=L5]*_"S_@AW\/[J:+Q%\4_$FM7N
MJM(D\UK+*\V7^\PV.P7&?[Q'\Q7ZY?!']DCX-? C38['PGX9TZ:6-%5;R]L+
M:2<;1@L-RN-Q]3G&>.>@!_/9\!/^"7O[0_[0^MVOQ!_:"\9:D^B3W$=W+H>H
M74X7RW8.T/E2MR<$@J%/!],FOZ'?@3^RM\'_ -G_ $:QL/ WA73[&^MX56?4
M5A0SRR[0&8-M!'/0DDYYSVKZ.BAB@01P11PQK]V.*-8T'T5 %'X"I"<<T %%
M,R2,KZ^U/&<#/7O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?Q!_\ !?[_ )/+_9]_
M[&K2_P#TOAK^QWX ?\D3^%W_ &)6A?\ I%'7\<7_  7^_P"3R_V??^QJTO\
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M= JJ % [   4I&1B@!<T4@&!BEH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /X@_P#@O]_R>7^S[_V-6E_^E\-?V._
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MO]KM?^?FW_[_ $?_ ,51]KM?^?FW_P"_T?\ \50!8HJO]KM?^?FW_P"_T?\
M\51]KM?^?FW_ ._T?_Q5 %BBJ_VNU_Y^;?\ [_1__%4?:[7_ )^;?_O]'_\
M%4 6**K_ &NU_P"?FW_[_1__ !5'VNU_Y^;?_O\ 1_\ Q5 %BBJ_VNU_Y^;?
M_O\ 1_\ Q5'VNU_Y^;?_ +_1_P#Q5 %BBJ_VNU_Y^;?_ +_1_P#Q5'VNU_Y^
M;?\ [_1__%4 6**K_:[7_GYM_P#O]'_\51]KM?\ GYM_^_T?_P 50!8HJO\
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M]'_\50!8HJO]KM?^?FW_ ._T?_Q5'VNU_P"?FW_[_1__ !5 %BBJ_P!KM?\
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MVTR66TQ]F=S S0[<8\LD_+C':K L/#ZW8O\ R]/%VHP+C=!Y@'8!LYXS@<T
M;E%5_M=K_P _-O\ ]_H__BJ/M=K_ ,_-O_W^C_\ BJ +%%5_M=K_ ,_-O_W^
MC_\ BJ/M=K_S\V__ '^C_P#BJ +%%5_M=K_S\V__ '^C_P#BJ/M=K_S\V_\
MW^C_ /BJ +%%5_M=K_S\V_\ W^C_ /BJ/M=K_P _-O\ ]_H__BJ +%%5_M=K
M_P _-O\ ]_H__BJ/M=K_ ,_-O_W^C_\ BJ +%%5_M=K_ ,_-O_W^C_\ BJ/M
M=K_S\V__ '^C_P#BJ +%%5_M=K_S\V__ '^C_P#BJ/M=K_S\V_\ W^C_ /BJ
M +%%5_M=K_S\V_\ W^C_ /BJ/M=K_P _-O\ ]_H__BJ +%%5_M=K_P _-O\
M]_H__BJ/M=K_ ,_-O_W^C_\ BJ +%%5_M=K_ ,_-O_W^C_\ BJ/M=K_S\V__
M '^C_P#BJ +%%5_M=K_S\V__ '^C_P#BJ/M=K_S\V_\ W^C_ /BJ +%%5_M=
MK_S\V_\ W^C_ /BJ/M=K_P _-O\ ]_H__BJ +%%5_M=K_P _-O\ ]_H__BJ/
MM=K_ ,_-O_W^C_\ BJ +%%5_M=K_ ,_-O_W^C_\ BJ/M=K_S\V__ '^C_P#B
MJ +%%5_M=K_S\V__ '^C_P#BJ/M=K_S\V_\ W^C_ /BJ +%%5_M=K_S\V_\
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M'_"/ZK:K:EW\HIMR%YQR/;W]Z^?&_P""9/QN?5TNCK:[%;!7=[\\<_GWKXO
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M:$5;2=#T^Q9/N&&!05^F<UO_ &NU_P"?FW_[_1__ !5'VNU_Y^;?_O\ 1_\
MQ5 %BBJ_VNU_Y^;?_O\ 1_\ Q5'VNU_Y^;?_ +_1_P#Q5 %BBJ_VNU_Y^;?_
M +_1_P#Q5'VNU_Y^;?\ [_1__%4 6**K_:[7_GYM_P#O]'_\51]KM?\ GYM_
M^_T?_P 50!8HJO\ :[7_ )^;?_O]'_\ %4?:[7_GYM_^_P!'_P#%4 6**K_:
M[7_GYM_^_P!'_P#%4?:[7_GYM_\ O]'_ /%4 6**K_:[7_GYM_\ O]'_ /%4
M?:[7_GYM_P#O]'_\50!8HJO]KM?^?FW_ ._T?_Q5'VNU_P"?FW_[_1__ !5
M%BBJ_P!KM?\ GYM_^_T?_P 51]KM?^?FW_[_ $?_ ,50!8HJO]KM?^?FW_[_
M $?_ ,51]KM?^?FW_P"_T?\ \50!8HJO]KM?^?FW_P"_T?\ \51]KM?^?FW_
M ._T?_Q5 %BBJ_VNU_Y^;?\ [_1__%4?:[7_ )^;?_O]'_\ %4 6**K_ &NU
M_P"?FW_[_1__ !5'VNU_Y^;?_O\ 1_\ Q5 %BBJ_VNU_Y^;?_O\ 1_\ Q5'V
MNU_Y^;?_ +_1_P#Q5 %BBJ_VNU_Y^;?_ +_1_P#Q5'VNU_Y^;?\ [_1__%4
M6**K_:[7_GYM_P#O]'_\51]KM?\ GYM_^_T?_P 50!8HJO\ :[7_ )^;?_O]
M'_\ %4?:[7_GYM_^_P!'_P#%4 6**K_:[7_GYM_^_P!'_P#%4?:[7_GYM_\
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MX+*'@_ V?_P>O_\ (E?V0T4!?R7X_P"?E_5V?QO#X]?\%E!P/@;/_P"#U_\
MY$I/^%]?\%EL_P#)#I\?]AUO_D,_S%?V144!?R7X_P"?E_5V?QO?\+Z_X+*_
M]$.G_P#!ZW_R)1_POK_@LK_T0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]79_&]_P +
MZ_X+*_\ 1#I__!ZW_P B4?\ "^O^"RO_ $0Z?_P>M_\ (E?V0T4!?R7X_P"?
ME_5V?QO?\+Z_X+*_]$.G_P#!ZW_R)1_POK_@LK_T0Z?_ ,'K?_(E?V0T4!?R
M7X_Y^7]79_&]_P +Z_X+*_\ 1#I__!ZW_P B4?\ "^O^"RO_ $0Z?_P>M_\
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M0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]79_&]_P +Z_X+*_\ 1#I__!ZW_P B4?\
M"^O^"RO_ $0Z?_P>M_\ (E?V0T4!?R7X_P"?E_5V?QO?\+Z_X+*_]$.G_P#!
MZW_R)1_POK_@LK_T0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]79_&]_P +Z_X+*_\
M1#I__!ZW_P B4?\ "^O^"RO_ $0Z?_P>M_\ (E?V0T4!?R7X_P"?E_5V?QO?
M\+Z_X+*_]$.G_P#!ZW_R)1_POK_@LK_T0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]7
M9_&]_P +Z_X+*_\ 1#I__!ZW_P B4?\ "^O^"RO_ $0Z?_P>M_\ (E?V0T4!
M?R7X_P"?E_5V?QO?\+Z_X+*_]$.G_P#!ZW_R)1_POK_@LK_T0Z?_ ,'K?_(E
M?V0T4!?R7X_Y^7]79_&]_P +Z_X+*_\ 1#I__!ZW_P B4?\ "^O^"RO_ $0Z
M?_P>M_\ (E?V0T4!?R7X_P"?E_5V?QO?\+Z_X+*_]$.G_P#!ZW_R)1_POK_@
MLK_T0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]79_&]_P +Z_X+*_\ 1#I__!ZW_P B
M4?\ "^O^"RO_ $0Z?_P>M_\ (E?V0T4!?R7X_P"?E_5V?QO?\+Z_X+*_]$.G
M_P#!ZW_R)1_POK_@LK_T0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]79_&]_P +Z_X+
M*_\ 1#I__!ZW_P B4?\ "^O^"RO_ $0Z?_P>M_\ (E?V0T4!?R7X_P"?E_5V
M?QO?\+Z_X+*_]$.G_P#!ZW_R)1_POK_@LK_T0Z?_ ,'K?_(E?V0T4!?R7X_Y
M^7]79_&]_P +Z_X+*_\ 1#I__!ZW_P B4?\ "^O^"RO_ $0Z?_P>M_\ (E?V
M0T4!?R7X_P"?E_5V?QO?\+Z_X+*_]$.G_P#!ZW_R)1_POK_@LK_T0Z?_ ,'K
M?_(E?V0T4!?R7X_Y^7]79_&]_P +Z_X+*_\ 1#I__!ZW_P B4?\ "^O^"RO_
M $0Z?_P>M_\ (E?V0T4!?R7X_P"?E_5V?QO?\+Z_X+*_]$.G_P#!ZW_R)1_P
MOK_@LK_T0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]79_&]_P +Z_X+*_\ 1#I__!ZW
M_P B4?\ "^O^"RO_ $0Z?_P>M_\ (E?V0T4!?R7X_P"?E_5V?QO?\+Z_X+*_
M]$.G_P#!ZW_R)1_POK_@LK_T0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]79_&]_P +
MZ_X+*_\ 1#I__!ZW_P B4?\ "^O^"RO_ $0Z?_P>M_\ (E?V0T4!?R7X_P"?
ME_5V?QO?\+Z_X+*_]$.G_P#!ZW_R)1_POK_@LK_T0Z?_ ,'K?_(E?V0T4!?R
M7X_Y^7]79_&]_P +Z_X+*_\ 1#I__!ZW_P B4?\ "^O^"RO_ $0Z?_P>M_\
M(E?V0T4!?R7X_P"?E_5V?QO?\+Z_X+*_]$.G_P#!ZW_R)1_POK_@LK_T0Z?_
M ,'K?_(E?V0T4!?R7X_Y^7]79_&]_P +Z_X+*_\ 1#I__!ZW_P B4?\ "^O^
M"RO_ $0Z?_P>M_\ (E?V0T4!?R7X_P"?E_5V?QO?\+Z_X+*_]$.G_P#!ZW_R
M)1_POK_@LK_T0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]79_&]_P +Z_X+*_\ 1#I_
M_!ZW_P B4?\ "^O^"RO_ $0Z?_P>M_\ (E?V0T4!?R7X_P"?E_5V?QO?\+Z_
MX+*_]$.G_P#!ZW_R)1_POK_@LK_T0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]79_&]
M_P +Z_X+*_\ 1#I__!ZW_P B4?\ "^O^"RO_ $0Z?_P>M_\ (E?V0T4!?R7X
M_P"?E_5V?QO?\+Z_X+*_]$.G_P#!ZW_R)1_POK_@LK_T0Z?_ ,'K?_(E?V0T
M4!?R7X_Y^7]79_&]_P +Z_X+*_\ 1#I__!ZW_P B4?\ "^O^"RO_ $0Z?_P>
MM_\ (E?V0T4!?R7X_P"?E_5V?QO?\+Z_X+*_]$.G_P#!ZW_R)1_POK_@LK_T
M0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]79_&]_P +Z_X+*_\ 1#I__!ZW_P B4?\
M"^O^"RO_ $0Z?_P>M_\ (E?V0T4!?R7X_P"?E_5V?QO?\+Z_X+*_]$.G_P#!
MZW_R)1_POK_@LK_T0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]79_&]_P +Z_X+*_\
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M&?Z5'_POK_@LK_T0Z?\ \'K?_(E?V0T4!S?W8_=_P3^-[_A?7_!97_HAT_\
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M7X_Y^7]79_&]_P +Z_X+*_\ 1#I__!ZW_P B4?\ "^O^"RO_ $0Z?_P>M_\
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M0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]79_&]_P +Z_X+*_\ 1#I__!ZW_P B4?\
M"^O^"RO_ $0Z?_P>M_\ (E?V0T4!?R7X_P"?E_5V?QO?\+Z_X+*_]$.G_P#!
MZW_R)1_POK_@LK_T0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]79_&]_P +Z_X+*_\
M1#I__!ZW_P B4?\ "^O^"RO_ $0Z?_P>M_\ (E?V0T4!?R7X_P"?E_5V?QO?
M\+Z_X+*_]$.G_P#!ZW_R)1_POK_@LK_T0Z?_ ,'K?_(E?V0T4!?R7X_Y^7]7
M9_&]_P +Z_X+*_\ 1#I__!ZW_P B4?\ "^O^"RO_ $0Z?_P>O_\ (E?V0T4!
M?R7X_P"?E_5V?QO?\+Z_X+*?]$.G_P#!Z_\ \B4J_'S_ (++*0R_ ^<$=#_;
MKC_VS/\ *O[(** YO[L?N?\ F?QU?\-#_P#!9S;M/P3N6[8_MUL8_&SJ,?M
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M5_9#10%_)?C_ )^7]79_&]_POK_@LK_T0Z?_ ,'K?_(E'_"^O^"RO_1#I_\
MP>M_\B5_9#10%_)?C_GY?U=G\;W_  OK_@LK_P!$.G_\'K?_ ")1_P +Z_X+
M*_\ 1#I__!ZW_P B5_9#10%_)?C_ )^7]79_&]_POK_@LK_T0Z?_ ,'K?_(E
M'_"^O^"RO_1#I_\ P>M_\B5_9#10%_)?C_GY?U=G\;W_  OK_@LK_P!$.G_\
M'K?_ ")1_P +Z_X+*_\ 1#I__!ZW_P B5_9#10%_)?C_ )^7]79_&]_POK_@
MLK_T0Z?_ ,'K?_(E'_"^O^"RO_1#I_\ P>M_\B5_9#10%_)?C_GY?U=G\;W_
M  OK_@LK_P!$.G_\'K?_ ")1_P +Z_X+*_\ 1#I__!ZW_P B5_9#10%_)?C_
M )^7]79_&]_POK_@LK_T0Z?_ ,'K?_(E'_"^O^"RO_1#I_\ P>M_\B5_9#10
M%_)?C_GY?U=G\;W_  OK_@LK_P!$.G_\'K?_ ")1_P +Z_X+*_\ 1#I__!ZW
M_P B5_9#10%_)?C_ )^7]79_&]_POK_@LK_T0Z?_ ,'K?_(E'_"^O^"RO_1#
MI_\ P>M_\B5_9#10%_)?C_GY?U=G\;W_  OK_@LK_P!$.G_\'K?_ ")1_P +
MZ_X+*_\ 1#I__!ZW_P B5_9#10%_)?C_ )^7]79_&]_POK_@LK_T0Z?_ ,'K
M?_(E'_"^O^"RO_1#I_\ P>M_\B5_9#10%_)?C_GY?U=G\;W_  OK_@LK_P!$
M.G_\'K?_ ")1_P +Z_X+*_\ 1#I__!ZW_P B5_9#10%_)?C_ )^7]79_&]_P
MOK_@LK_T0Z?_ ,'K?_(E'_"^O^"RO_1#I_\ P>M_\B5_9#10%_)?C_GY?U=G
M\;W_  OK_@LK_P!$.G_\'K?_ ")1_P +Z_X+*_\ 1#I__!ZW_P B5_9#10%_
M)?C_ )^7]79_&]_POK_@LK_T0Z?_ ,'K?_(E'_"^O^"RO_1#I_\ P>M_\B5_
M9#10%_)?C_GY?U=G\;W_  OK_@LK_P!$.G_\'K?_ ")1_P +Z_X+*_\ 1#I_
M_!ZW_P B5_9#10%_)?C_ )^7]79_&]_POK_@LK_T0Z?_ ,'K?_(E'_"^O^"R
MO_1#I_\ P>M_\B5_9#10%_)?C_GY?U=G\;W_  OK_@LK_P!$.G_\'K?_ ")1
M_P +Z_X+*_\ 1#I__!ZW_P B5_9#10%_)?C_ )^7]79_&]_POK_@LK_T0Z?_
M ,'K?_(E'_"^O^"RO_1#I_\ P>M_\B5_9#10%_)?C_GY?U=G\;W_  OK_@LK
M_P!$.G_\'K?_ ")1_P +Z_X+*_\ 1#I__!ZW_P B5_9#10%_)?C_ )^7]79_
M&]_POK_@LK_T0Z?_ ,'K?_(E'_"^O^"RO_1#I_\ P>M_\B5_9#10%_)?C_GY
M?U=G\;W_  OK_@LK_P!$.G_\'K?_ ")1_P +Z_X+*_\ 1#I__!ZW_P B5_9#
M10%_)?C_ )^7]79_&]_POK_@LI_T0Z<?]QU_Z69I)/CQ_P %DW@F@/P.G(F1
MD)&NO@;@0?\ ESSWK^R*B@.;^['[C^)K]A_]F7]O;7_^"CG@3]H/X[?#4^'/
M#MGH.N:9?W?]H2WKK+J&HZ'<PKY9M844 6,I,C294#8%/F,5*_MEHH!RO:Z6
(B2TTV^\__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gu0gjnulhgsv000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '6!&(# 2(  A$! Q$!_\0
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MO_B*^8:* /K73O&?A_5K'[;9:AYMOYC1;_)D7YE"DC!4'HR_G5G_ (2/2?\
MG[_\AO\ X5XW\._^1(_[B4__ *+AKIJ!V.^_X2/2?^?O_P AO_A1_P )'I/_
M #]_^0W_ ,*X&BD%COO^$CTG_G[_ /(;_P"%'_"1Z3_S]_\ D-_\*X&B@+'?
M?\)'I/\ S]_^0W_PH_X2/2?^?O\ \AO_ (5P-% 6.^_X2/2?^?O_ ,AO_A1_
MPD>D_P#/W_Y#?_"N!HH"QWW_  D>D_\ /W_Y#?\ PH_X2/2?^?O_ ,AO_A7
MT4!8[[_A(])_Y^__ "&_^%'_  D>D_\ /W_Y#?\ PK@:* L=]_PD>D_\_?\
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M.^_X2/2?^?O_ ,AO_A1_PD>D_P#/W_Y#?_"N!HH"QWW_  D>D_\ /W_Y#?\
MPH_X2/2?^?O_ ,AO_A7 T4!8[[_A(])_Y^__ "&_^%'_  D>D_\ /W_Y#?\
MPK@:* L=]_PD>D_\_?\ Y#?_  I\FOZ9$P5[G!*AO]6W0@$=O0BO/JM:A_Q\
MI_UPA_\ 1:T!8[3_ (2/2?\ G[_\AO\ X4?\)'I/_/W_ .0W_P *X&B@+'??
M\)'I/_/W_P"0W_PH_P"$CTG_ )^__(;_ .%<#10%COO^$CTG_G[_ /(;_P"%
M'_"1Z3_S]_\ D-_\*X&B@+'??\)'I/\ S]_^0W_PH_X2/2?^?O\ \AO_ (5P
M-% 6.^_X2/2?^?O_ ,AO_A1_PD>D_P#/W_Y#?_"N!HH"QWW_  D>D_\ /W_Y
M#?\ PH_X2/2?^?O_ ,AO_A7 T4!8[[_A(])_Y^__ "&_^%'_  D>D_\ /W_Y
M#?\ PK@:* L=]_PD>D_\_?\ Y#?_  H_X2/2?^?O_P AO_A7 T4!8[[_ (2/
M2?\ G[_\AO\ X4?\)'I/_/W_ .0W_P *X&B@+'??\)'I/_/W_P"0W_PH_P"$
MCTG_ )^__(;_ .%<#10%CT&+7],FE2*.YR[L%4>6W)/3M3/^$CTG_G[_ /(;
M_P"%<7IG_(6L_P#KNG_H0JK3"QWW_"1Z3_S]_P#D-_\ "C_A(])_Y^__ "&_
M^%<#12"QWW_"1Z3_ ,_?_D-_\*/^$CTG_G[_ /(;_P"%<#10%COO^$CTG_G[
M_P#(;_X4?\)'I/\ S]_^0W_PK@:* L=]_P )'I/_ #]_^0W_ ,*/^$CTG_G[
M_P#(;_X5P-% 6.^_X2/2?^?O_P AO_A1_P )'I/_ #]_^0W_ ,*X&B@+'??\
M)'I/_/W_ .0W_P */^$CTG_G[_\ (;_X5P-% 6.^_P"$CTG_ )^__(;_ .%'
M_"1Z3_S]_P#D-_\ "N!HH"QWW_"1Z3_S]_\ D-_\*/\ A(])_P"?O_R&_P#A
M7 T4!8[[_A(])_Y^_P#R&_\ A1_PD>D_\_?_ )#?_"N!HH"QWW_"1Z3_ ,_?
M_D-_\*/^$CTG_G[_ /(;_P"%<#10%CU.BBBF(\P^.W_(D67_ &$D_P#1<M?/
M=?0GQV_Y$BR_["2?^BY:^>Z .I\'^$;?Q/#JMQ=ZK_9UMIL GED^SF;Y><\
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MIL5[]A>[\]0?-SCB/J1[YKM*\.M[UK74X]6$;W7B1YI3<Z7):-\C$G;)'A2
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MC*P:"SD>TOX6NKU;$130['CD(!&X$],$<C/6M"^UNVT_5M-TV5)3-J!D$3(
M578 3NYSW[ UQ?BSQ'IVHV>@ZK"\HL+?6HBTSQ,H95&XLHQDC\.H-6=1U:QU
MOQ=X-O-.G\ZW,MVH?8R\A%SP0#0!OZ9XNTW5;G4K>%9TET_=YBR*!O"D@LN"
M<C(]NU$/BRPG;156*Y']L*[6^57Y=H!.[GCKVS7$P6TEOIM[KT 8M9ZE=P7*
MJ.7MG;#?]\D[A^-2Z=_KOAQ_URN/_0%H ZF\\<Z9:W\]LEMJ%TMLVVXN+6W,
MD4)[[FSV]@:M:[XKT[P]=6EO>+.S7)^]$H(C7(7<^2,#+#UKE/#7B&S\)6U[
MHVKQ7,6H+=R/&B0,YN0QX*D#DGW]J@U*PUKQ;J_B"?35T][,#^S0;HON&S#-
MLVC'W^<GVH [W4-:MM-U#3K*9)6DOY&CB* $ @9^;G^6:T:\KNO$4$MCX)U>
M_E,:P32)<N5)*LJA22 ,\XS^->DZ;J5IJ^GQ7]A-YUM+G8^TKG!(/! /4&@9
M;HHHH M2?\@FW_Z[R_\ H,=5:M2?\@FW_P"N\O\ Z#'56@ HHHH **** "BB
MB@#E=9\67UAX@?2;#0VU!X[474C+<B,A-V#@$<XX[]Z=;>-(+R3P]]GM':+6
M/. 9WVF$Q]1C'S<Y'4=*S-6\.3:W\1)3+)J-K9'3 IN+5C&';?\ ZLM@@@@Y
M(]A3?$/A2UGU7PII<>G2R:3;_:%F"!MJ JI&YATR1USR:!'2V.N_;?$NJZ/]
MFV?8%B/F[\^9O7=TQQCZFJ.C>,(]7\07.F?8FAC57:VN#)D7 1]C$#''/N:Y
MVVTN?PM?^+SI&EW2P?9X5LECC>3>Y7!VGDMAFR>>*A7POKGALZ!J*WCZBEC*
M(S:0685HHY,^9RI);D]_K0!TT/BVYO-<GL[+1)[BSMKO[)<7:S*#&^<$[.I4
M=SZ"HCXKU:XUR_T_3?#GVR.RE6.6;[<D>,C.=K#Z],U@ZI:W-SXD6?1]!U73
MM8%T/-NEXM98PW+,<X.1SC'YU"UA:6_CC5;S5/#.L7SF[22SN+6!RBX[DA@#
MSCUZ4 >DWUT;*RDN%MYKADQB*!=SL2<  ?CU[#FL_P ,ZZ?$6D?;S:_9CYKQ
MF,R;\;3CK@5>U*^_L[3Y;O[+<W7EX_<VL>^1LD#A>_7/T!KAO".KRZ%X1U'[
M=I>H6K6GFW(:Y@,:2;C\J@GJ<X'XT#-Z/Q'>37^N?9K W5KI[QP1)"/WDTQQ
MO&2< +D9].34GA_Q-+J^HWVF7NF/I]_9A3)$91(,,,@AA^'YU0TP7GAGX?K<
MQ6,U]J4J_:)(40LSRR')R!SQD9^E,\$3;KB[-SIFKQZE=#S[J\O;3RD<C "+
MR>!G@>@- CLZ***!A1110 4444 %%%% !5K4/^/E/^N$/_HM:JU:U#_CY3_K
MA#_Z+6@"K1110 4444 %%%% '-:OXULM'U633Y+#4KB2*(32O;0!U1#W/S9
M'TJU%XITVXO-)MH#++_:D;R6\BJ-H"#)W9.0?PZUR^HZ9?:K\2-2MK+5&T\-
MIR"9UA$A="<%1G[OU%1ZSX>@A\2^$=$MKJ\MH8X;A5GMY-DHPF20V.,GKQW-
M CM;'6[;4-6U+38DE$VGF,2LX 5MX)&WG/;N!570_%>G>(+R[M;-9U>V/WI%
M 61=Q7<A!.1D>U<-;SOX8E\<+%<W-S.@MH89;A]\KNZL%)/<C/Y"I;&QUGPE
MK_A^XU,:>MJR#2]UH7)(;++OW#&=W.1[T =='XSTZ;6&T^&VOI%6?[,UVD&8
M%EZ;2^>N?:HCXVMFU:XTZ#2-8N7MY_(EE@M@\:MG')W<#ZURC:A;V7BA/^$8
MN[];RYOO].TJ6%BF"?G?)&%^H/Z#%1:?>:3:>.-7.H:[J-C/_:>8K:W=Q%/S
M_& I!!/')'% 'I6J:G#I-DUU-'/*-P58X(R[NQZ  =ZJZ#XCM/$"7'V>&Y@E
MMGV307,>QT/;(R?2D\375M:Z)*;RXO;:W=@CW%D#YD/?=D D#C&<'K7-_#L_
MZ9K0M)9[K2VE1[>]N(RLDS$'=DD MCW_ *T#.\HHHH **** "BBB@"UIG_(6
ML_\ KNG_ *$*JU:TS_D+6?\ UW3_ -"%5: "BBB@ HHHH YSQ#XEN](U33]-
ML=)_M"YO5D9$^T"+&P9/)!'3/ITJLOC>.7PV^I1:=*;Q;L6/V%G 8SY'RAL>
MASG%5O%>BW.L>,/#ZQM?P6ZI<"6[LR5:+Y>/GP0N2,<]<FJ=YX5N5UC3-'T2
M2>PM;)'OFOI(/.#SL0HSNP&?&3[ T"-T^+HCX'/B6.U+@1[FMS)@AMVTKNQV
M.><56T_Q?J%S=M8W7AZ2UO9+1KJTC^U*ZSX'"[@,*3QUZ=ZYQ])U?3_#'BG0
M)(+F\^=)[:>.V(6;>5+!0,C@CH/>M/0-%N]!\76K3I>W\-W8A$N[C=(UJR\F
M,GHJGM^7K0!;TSQ?K>HZU-IO_"+>6UK)&EV_]H(?(#_Q8V_-P"< ]JFTGQO'
MJ8U59+%K>:QCDF1#+N\^-2RE@<#'S+COUIWAZTN8/&GBJ>6WECAG>V,4CH0L
MF$;.T]#CVKG%T+4(O#3:C#97'VZWNKE&@V$/-;R,0R@=^NX?3CK0!NW/C2[$
M>A+8:)]KN=6@:9(?M0CV84,1N*X/&?3I4VI>*=4TVVTE'\/[M1U"1XQ9_;%&
MPKT^?&#D8/:N3U327:U\'?VCH>I7UG;V3K=6]M Y=3L&T'!!!W8ZD=#6EJNE
M'5X?"<6G6.K:;9QRRJ<(R36JC@$GG;G'!)Y!H ZKP[K[:Y%=+/8R65W:3>3/
M [A]K8SPPZBMJN3\#V5SI2:IIEW;2B:&Z+_;'5O]+5N0^X]6XP<=.*ZR@844
M44 %%%% !1110!ZG1113)/,/CM_R)%E_V$D_]%RU\]U],?%CP[JOB;PM:V6D
M6OVFX2]25D\Q4PH1P3EB!U8?G7CG_"I?''_0$_\ )N'_ .+H XJBNU_X5+XX
M_P"@)_Y-P_\ Q='_  J7QQ_T!/\ R;A_^+H XJBNU_X5+XX_Z G_ )-P_P#Q
M='_"I?''_0$_\FX?_BZ .*HKM?\ A4OCC_H"?^3</_Q='_"I?''_ $!/_)N'
M_P"+H XJBNU_X5+XX_Z G_DW#_\ %T?\*E\<?] 3_P FX?\ XN@#BJ*[7_A4
MOCC_ * G_DW#_P#%T?\ "I?''_0$_P#)N'_XN@#BJ*[7_A4OCC_H"?\ DW#_
M /%T?\*E\<?] 3_R;A_^+H XJBNU_P"%2^./^@)_Y-P__%T?\*E\<?\ 0$_\
MFX?_ (N@#BJ*[7_A4OCC_H"?^3</_P 71_PJ7QQ_T!/_ ";A_P#BZ .*HKM?
M^%2^./\ H"?^3</_ ,71_P *E\<?] 3_ ,FX?_BZ ,2Z_P"1(TK_ +"5Y_Z+
MMJQ:]%F^&WBZ7P]9Z6FD9O+>[GN)8_M4/RI(D*H<[^YB?\JS_P#A4OCC_H"?
M^3</_P 70!Q5%=K_ ,*E\<?] 3_R;A_^+H_X5+XX_P"@)_Y-P_\ Q= '%45V
MO_"I?''_ $!/_)N'_P"+H_X5+XX_Z G_ )-P_P#Q= '%45VO_"I?''_0$_\
M)N'_ .+H_P"%2^./^@)_Y-P__%T <517:_\ "I?''_0$_P#)N'_XNC_A4OCC
M_H"?^3</_P 70!Q5%=K_ ,*E\<?] 3_R;A_^+H_X5+XX_P"@)_Y-P_\ Q= '
M%45VO_"I?''_ $!/_)N'_P"+H_X5+XX_Z G_ )-P_P#Q= '%45VO_"I?''_0
M$_\ )N'_ .+H_P"%2^./^@)_Y-P__%T <517:_\ "I?''_0$_P#)N'_XNC_A
M4OCC_H"?^3</_P 70!Q5%=K_ ,*E\<?] 3_R;A_^+H_X5+XX_P"@)_Y-P_\
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M5O\ GT_\B)_C0!E45J_\(YJW_/I_Y$3_ !H_X1S5O^?3_P B)_C0!E45J_\
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MT 7J*H_VK!_<D_(?XT?VK!_<D_(?XT 7J*H_VK!_<D_(?XT?VK!_<D_(?XT
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M$HK"T;Q%#<>$=-UK5KBTL_M-NDLC/((XPS#. 6/]:T/[7TS^SQJ']HVGV)B
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!TU%%% %'5?\ CU7_ 'Q_(UCUL:K_ ,>J_P"^/Y&L>@"AKE@V
MJ^']2TY&"M=VLL 8]BRE<_K7FW@KQYIGA?PO;^'M=AO+76+$O%]D%L[M-\Q(
M*8&._<CIZ5ZQ10!X#XKM0/B%K4NOZG_94-TD?V.2YT<7RR)MQM3(.QA[=\\\
M<Z"Z+:R:I\-]*O!-?6A2ZXO+<Q-(H.Y0R$G 'RX!/0#Z5[=10!XI!H]LW_"T
MM,MK"-H8!');6R1 B-]DI!1>Q],5GZE-HU[\&=+@TR&-98[VUBOC' 8RTVPY
MR<#<??FO>Z* /'?B+:Z=HFJZ)IL-EIVD:4T<A-^^EK=JC\?*(R""3M7)QGGK
MQ7)+Y@^#7B" L[)%K@"[HO+/1?X/X?\ =[5]'T4 <]X\!/@'7L?\^,O_ *":
M\TU>TETOX<Z-XCM(F99M";3+]5'WHY(CY;'_ '7(Y]#7ME% '@.OVLYT?P'=
M7ER;31H]-"O<O8B[CAD*]6B/!R-O7TR.E)>6-M:?"?Q+-8ZE-?VL]Y;NLIT_
M['$3N7)C3/3D#@#I7O\ 10!YCXV\+VFD^ K34="LH;6YT>:&^01( 7VX#%O4
MXP23S\M<W+;ZEXJ\(>,_%=A!/YVIS)#;Q)RYMHF4,!CU Y _NFO<J* /$(7\
M/:SXD\'IX+T\Q7EE<(^H216S1>5$,;UD; W$@,,\YZ9YJH^K0:3X?\>^'[J&
MZ&J75[//% L#-F(\[\@8"@ DDGIZU[U10!X1XD_LRVTCPI?W%PJ7\&@6XAM[
MZP-S:W0*?<&,[7SU/H5YKUKPQ<,G@G3KB737LBEH&-F@)* #A0#ST' //-;M
M% 'A4\N@S>*]*O/AZ]_!J\UZGVZRCAD2)8CRQ<,, >P..3TQ3=<L[[3/$>I_
M#^TC=;+Q!?PW4#IP(HF),OY%0/HAKW>N<?PKYWCZ/Q1<7ID$%H;:WM?*P(R>
MK;L\DY8=!U]J /*_&T6DZ5XNO39P1WM]((;<Z/?:>[^:H55!MY5Y7Y?0@\'K
MP*VIUT;2_C8L^KZ9#!%?V,9M@UIO#7;2(=PPI^?.[+?KS7KM% 'S)'I4;1ZA
M8:_K,MEK373LUHNA"XN)FSG='-PV"?<#\#7HT6BV.J_&F>UU6UCOHX=#1PMS
M'D%PR+N(/&<%OSKU6B@#YV@T'3%^">O:E]AA^W0Z@$BN&7,B*)8UP&/(&&/%
M>_Z;(TNE6<CG+O C,?<J*M44 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!TU%%% %:]MWN851"H(;//XU0_LJ?^_'^9_PK
M8HH Q_[*G_OQ_F?\*/[*G_OQ_F?\*V** ,?^RI_[\?YG_"C^RI_[\?YG_"MB
MB@#'_LJ?^_'^9_PH_LJ?^_'^9_PK8HH Q_[*G_OQ_F?\*/[*G_OQ_F?\*V**
M ,?^RI_[\?YG_"C^RI_[\?YG_"MBB@#'_LJ?^_'^9_PH_LJ?^_'^9_PK8HH
MQ_[*G_OQ_F?\*/[*G_OQ_F?\*V** ,?^RI_[\?YG_"C^RI_[\?YG_"MBB@#'
M_LJ?^_'^9_PH_LJ?^_'^9_PK8HH P5LY&O9;4,N^.-)"<\88L!_Z ?TJ;^RI
M_P"_'^9_PJQ#_P C#>_]>EO_ .AS5H4 8_\ 94_]^/\ ,_X4?V5/_?C_ #/^
M%;%% &/_ &5/_?C_ #/^%']E3_WX_P S_A6Q10!C_P!E3_WX_P S_A1_94_]
M^/\ ,_X5L44 8_\ 94_]^/\ ,_X4?V5/_?C_ #/^%;%% &/_ &5/_?C_ #/^
M%']E3_WX_P S_A6Q10!C_P!E3_WX_P S_A1_94_]^/\ ,_X5L44 8_\ 94_]
M^/\ ,_X4?V5/_?C_ #/^%;%% &/_ &5/_?C_ #/^%']E3_WX_P S_A6Q10!C
M_P!E3_WX_P S_A1_94_]^/\ ,_X5L44 8*V<C7LMJ&7?'&DA.>,,6 _] /Z5
M-_94_P#?C_,_X58A_P"1AO?^O2W_ /0YJT* ,?\ LJ?^_'^9_P */[*G_OQ_
MF?\ "MBB@#'_ +*G_OQ_F?\ "C^RI_[\?YG_  K8HH Q_P"RI_[\?YG_  H_
MLJ?^_'^9_P *V** ,?\ LJ?^_'^9_P */[*G_OQ_F?\ "MBB@#'_ +*G_OQ_
MF?\ "C^RI_[\?YG_  K8HH Q_P"RI_[\?YG_  H_LJ?^_'^9_P *V** ,?\
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M_P!^/\S_ (5L44 8_P#94_\ ?C_,_P"%']E3_P!^/\S_ (5L44 8_P#94_\
M?C_,_P"%']E3_P!^/\S_ (5L44 8_P#94_\ ?C_,_P"%']E3_P!^/\S_ (5L
M44 8_P#94_\ ?C_,_P"%']E3_P!^/\S_ (5L44 8_P#94_\ ?C_,_P"%']E3
M_P!^/\S_ (5L44 8_P#94_\ ?C_,_P"%']E3_P!^/\S_ (5L44 8_P#94_\
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M4 8-W9R6=E/=2,I2&-I&"GD@#)Q^53?V5/\ WX_S/^%6->_Y%[4_^O27_P!
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M[S_A;6O?\^FF_P#?M_\ XNC_ (6UKW_/IIO_ '[?_P"+K@Z*/;U.X?V5@_\
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M_P#Q=<'11[>IW#^RL'_S[1WG_"VM>_Y]--_[]O\ _%T?\+:U[_GTTW_OV_\
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M **** "BBB@ HHHH S]>_P"1>U/_ *])?_0#6A6?KW_(O:G_ ->DO_H!K0H
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M JV)E)-*R?=/O:ST?37IOY%+7_#]EI5AI]Q;ZE'*]Q:K,T9#Y<DD93Y  O\
MO$&K'A*RCO=/U1+2&UGUH*GV2*Y5&!7)+E5?Y2V!W' Z57UR\L=3T72)(;Q%
MN+.T%O);.CAR0QY! VD<YY(K+L[2SN8',VIQ6DRL,+-$Y1EQU#(&.<]B._7M
M2NE.Z+C&<\/:;=[]K[/LK73_ "ZEZXTO4-2&HW;V<%I-I\4;7%NL1A=@>-X3
M&!V)Q@<YQ18^%;[4!IOERVZ-J/FF!)&8'$8))/& #C KHH/$4%YXPTJW1I+Z
M!K1=,NIW0[KD,2"W/.,D'GG@U$VL66G_ !"MQ).4T[2X7LHW*D_=B92<#.<N
M3T]:KDANWU,/K&(2<(QL^5M?=:WWV?IH<Y=:!+;Z;)?PWEI>00RB&8V[,?*8
M],Y49![$9!]:Z?P?X>FTSQKIRW-[9B[13(]F';S4!0\'Y=N>0<!B<<XK"TO5
M+6U\):O9O*!=SS0/#&5)W;6R>>@_$UT%OJ^@GQ['XEDU41P/\YM_(D,D;E-I
M#8&W ZY!)Z#'<$%"Z?H+%2Q#A4IV=K25[;Z*WYO[CF+?PY--HB:O+>V=M9M(
M8@TS/G<.VU5).?;/0YQ3H/#4TB6?VB_LK.6] :WAG9]SJ?NM\JD*#VW$4^YU
M&TD\$6.G++F[BO))7CVGA2.#G&/UK0O;O1]<N=+OI]36S,%O'#<V[0R%OD[Q
M[05(/;)&*FT3=U*ZO>]KO97VV^_N9EOX7OI8=0EGEMK-=/D$=S]I<C:3GI@'
M/3MDG(QFK'_"'70FM4?4=.1;P*;21I&Q/N'8;=P[#Y@O)Q5S4?$EGJ>G>)&)
M,4U_<PR00E2254G.2. <8[U'<:S8/<>$V6?*V"1BY.QOD(DR>W/'IFGRT_Z]
M2/:XM[JWR_NI_GI_P3)AT"Z9;N2ZEALH;27R99;@G;YN<;!M#%FX)X!P!DU!
MJFE7&DW*0SM&ZRQK-%+$V4D0]&'?'!Z@=*ZAO$-E<1ZS9QW5M!YNJ27MO/=V
MGG12*QQM*E&*G&"#M]0<5SVNW\E]<P*]_'>+!"(U>*V$,:CD[5  R!GJ0/I4
MRC%+0UH5:\ZGOJR^?9>7?S_(RJ***R.\*V/"UM97GB:QM]1*BU=SOW-M!."5
M!/H3@?C6/6CI5EIMYYW]H:L-/*[?+W6[RA\YS]WICC\ZJ/Q(QK_PI*[6G1-O
M7T.BN[/4-6\06OAV[T73M,E><-YEO;!&V '.&'WEQD_45!=>(]*M+Q[.RT#3
M9]-C)C#S1YFE'3=YG4$]1CI5Y/%.FZ;J/AZ**>>_M],659;ED*EQ(,84'G"C
MIFL._L/#EK;W$EIK4U[(>+>%;9H]O/5V88.!Z=3Z5M)V5XL\VE'F:C5BTK:6
M3M>[3;[:6>NUV=#_ &182> TLQ;0#5ULO[3$H0;VC\PY!/4_+VK$U>"ST_2/
M#<<ELCS-"UU<;1L:5'?Y06Z_=4CVS5]_$ME;>.+&ZMI#)I=M!'9YVL-T6S:V
M01G@DG'M5;6Y](USQ*R+JBVFF6UM'#;3- [;@H QM R.2W;M3ERM:;[?\$5%
M58U%SI\KO/KHWIR]^M[?Y">+A9II^A);6-M:226AN'6%>JN?D#,>6("]2?7U
MK8T/0[*'09K*ZM8IM6U"PFNXO,0%H$4?N\>A8Y.1Z>U5]7G\-ZAXFL;M]723
M388TC:%;:0%4C487E>=QSZ8%/TWQY#/XKCO=0TZQMX7W1O<(DC2)'M( ^\1Z
M=%_"FN53NVNQG+V\L.HTXO1.3W3O=M+75Z_IW.#HIT@5965'WH"0K8QD>N*;
M7,>X%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %=QJMG):Z39W>C:99WNC&S FE-NDCB0@[R[#]XA'7@@#CZ5P]=9X>
MN]-\.ZJNIIK?G0+$<VB0R++*2N-C C9@$Y^\?N\5K3MLSBQBE92CJU?2S:?W
M;/LR?PY=_:]$UR6>TTZ22SM \#&PARK9QG[G/XYJ;PYI3^*M#U=/(LUO#-;J
MDRVZ1B)<DL0% QP.W6L?P_J=G9:1K\%Q*(Y+NU$<*A6.YL].^/QJ30]=32?#
M.J10W30:A)/!);[5.3M8D\XQT['K5QDM.;LSDK4:G[SV2L^:-M/\-_EW*.OW
MNGW%Q#;:5;+'96J>6DI0"2<]W<XR<]@>@]*N:5%!8>%+[67@AFN6N4M+<31"
M18R5+,VUL@G P,CBC6M4L)+Z/6-*$"3W:$W5G-;+(L,G<KO4J0W4=QSTSBGV
MFKVNHZ#?Z5J4T%G)),ES;S+;[8PZC:5*QKQD=POKFITYGJ;M3]A%*+M=7WOO
MKTU\[;KR-BSTK3M1CTK7+FUB5?L=S/=V\2;(Y3!@ [1@+G*D@<<=.360K1:W
MX5U:[N+6UANM/DBDBDMH$BRLC;2C!0 0."">?>K]GXCTS3Y--TO>T^GQ6DUM
M<W*H>3-@L54@':I '(!(!XZ5EM=6&E>'-0T^VODOKC4)8PSQ(ZI'&AW#.]0=
MQ/89&!UJVXV_K>W^9STX5>;5.]UR[Z1YG?T]WOTLBS?'3KGP MQ9Z9%:O'J*
M0^86WRN/)).YR!U/.  /:N4KJA_9H\'-I7]N67V@WPNL^5/MVB,KC/E]<GZ>
M]<K653H=V$T4EKN][_J%3V5T]E?V]W']^"59%^H.:@J_HNGOJNM6=C&N3-*J
MGV&>3^ S4*]]#HJ.*@W+8^DJ***]L_+@HHHH **** "L_1O^/&3_ *^[G_T<
M]:%9^C?\>,G_ %]W/_HYZ -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#/U[_D7M3_Z])?\ T UH5GZ]_P B]J?_ %Z2_P#H!K0H
M *1E5T9'4,K#!!&012U#=W,=E9SW4Q(B@C:1R/[JC)_E0!6MM#TBRG6>UTJQ
M@F7.V2*W16&>#@@9J2'2]/M[R2[AL;:*ZDSOF2%0[9.3E@,G)K-LY_$%[:Q7
MP_L^!)<.MI)&[.$..#(&P&Q_L''O2PZN8=:UQ;VY2.RLD@92X "!E);GJ<F@
M#2_LRP^W_;_L-M]L_P"?CRE\SIC[V,]./I4ZPQ)+)*D2+))C>X4 MCID]\5E
M/KUK<V=Z+261+J&V:94F@>)L8.&"NHR,CKR*AT#Q%::C9:=%)<L][/;*Y9HF
M197"C?M; 5B"3D*>,'T- &M:6%G8*ZV=I!;*[;F$,80,?4XZFHWTK3I+X7SZ
M?:M=@@B<PJ9,C@?-C-0Q:_ILU[':I._F2LRQL87"2%>H5R-K'@]">E0>&KZY
MU#3[B6ZD\QTO)XE.T#"JY ''L* -$V-FUZMZUI ;M5VK.8QO ] W7')_.F6V
MEZ?9W#W%K86L$\F0\D4*JS9.3D@9/-6Z* *PT^R"(@M+<)')YR+Y0PKY)W#C
MALD\]>:;#I>GV]Y)=PV-M%=29WS)"H=LG)RP&3DU;HH **** "BBB@ HHHH
M**** "BBB@#@_BU_R*MK_P!?J?\ H#UXU7T5XB\.VGB;3X[*]DGCC242@PL
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M?\*ET'_G[U+_ +^)_P#$4?5:@?V_@^[^X\:HKV7_ (5+H/\ S]ZE_P!_$_\
MB*/^%2Z#_P _>I?]_$_^(H^JU _M_!]W]QXU17LO_"I=!_Y^]2_[^)_\11_P
MJ70?^?O4O^_B?_$4?5:@?V_@^[^X\:HKV7_A4N@_\_>I?]_$_P#B*/\ A4N@
M_P#/WJ7_ '\3_P"(H^JU _M_!]W]QXU17LO_  J70?\ G[U+_OXG_P 11_PJ
M70?^?O4O^_B?_$4?5:@?V_@^[^X\:HKV7_A4N@_\_>I?]_$_^(H_X5+H/_/W
MJ7_?Q/\ XBCZK4#^W\'W?W'C5%>R_P#"I=!_Y^]2_P"_B?\ Q%'_  J70?\
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M^_B?_$4?5:@?V_@^[^X\:HKV7_A4N@_\_>I?]_$_^(H_X5+H/_/WJ7_?Q/\
MXBCZK4#^W\'W?W'C5%>R_P#"I=!_Y^]2_P"_B?\ Q%'_  J70?\ G[U+_OXG
M_P 11]5J!_;^#[O[CQJBO9?^%2Z#_P _>I?]_$_^(H_X5+H/_/WJ7_?Q/_B*
M/JM0/[?P?=_<>-45[+_PJ70?^?O4O^_B?_$4J_"?0%8$W.HL/0RIC]$H^JU
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MK$;1M[D<GI4%EI^J7,7AZTNM.^R#2]LDLYE1PY6,H%3:<\YR<@ 8ZGC/744
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M_"C_ (2K6O\ G]_\A)_A1_;^&_EE]R_S#^R:W=?C_D=UYVL?\^-C_P"!K_\
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MH_M_#?RR^Y?YA_9-;NOQ_P CNO.UC_GQL?\ P-?_ .-4>=K'_/C8_P#@:_\
M\:KB8O%VL1MEIHY1Z/&,?IBNET?Q7;:@ZP7*BWN#PO/RL?8]C[5TX?-\-7ER
MIV?F8ULOKTES-77D:/G:Q_SXV/\ X&O_ /&J/.UC_GQL?_ U_P#XU6A17IG"
M9_G:Q_SXV/\ X&O_ /&J/.UC_GQL?_ U_P#XU6A10!G^=K'_ #XV/_@:_P#\
M:H\[6/\ GQL?_ U__C5:%% &?YVL?\^-C_X&O_\ &J/.UC_GQL?_  -?_P"-
M5H44 9_G:Q_SXV/_ (&O_P#&J/.UC_GQL?\ P-?_ .-5H44 9_G:Q_SXV/\
MX&O_ /&J/.UC_GQL?_ U_P#XU6A10!G^=K'_ #XV/_@:_P#\:H\[6/\ GQL?
M_ U__C5:%% &?YVL?\^-C_X&O_\ &J/.UC_GQL?_  -?_P"-5H44 9_G:Q_S
MXV/_ (&O_P#&J/.UC_GQL?\ P-?_ .-5H44 8,4NJ_V[=D65GO\ LT&1]K;
M&Z7'/E_7MV'7/%[SM8_Y\;'_ ,#7_P#C5$/_ ",-[_UZ6_\ Z'-6A0!G^=K'
M_/C8_P#@:_\ \:H\[6/^?&Q_\#7_ /C5:%% &?YVL?\ /C8_^!K_ /QJCSM8
M_P"?&Q_\#7_^-5H44 9_G:Q_SXV/_@:__P :H\[6/^?&Q_\  U__ (U6A10!
MG^=K'_/C8_\ @:__ ,:H\[6/^?&Q_P# U_\ XU6A10!G^=K'_/C8_P#@:_\
M\:H\[6/^?&Q_\#7_ /C5:%% &?YVL?\ /C8_^!K_ /QJCSM8_P"?&Q_\#7_^
M-5H44 9_G:Q_SXV/_@:__P :H\[6/^?&Q_\  U__ (U6A10!G^=K'_/C8_\
M@:__ ,:H\[6/^?&Q_P# U_\ XU6A10!G^=K'_/C8_P#@:_\ \:H\[6/^?&Q_
M\#7_ /C5:%% &?YVL?\ /C8_^!K_ /QJCSM8_P"?&Q_\#7_^-5H44 9_G:Q_
MSXV/_@:__P :H\[6/^?&Q_\  U__ (U6A10!G^=K'_/C8_\ @:__ ,:H\[6/
M^?&Q_P# U_\ XU6A10!G^=K'_/C8_P#@:_\ \:JCI,NJBSD\NRLV'VFXR6NV
M'/G/G_EF>^?_ *W2MZL_1O\ CQD_Z^[G_P!'/0 >=K'_ #XV/_@:_P#\:H\[
M6/\ GQL?_ U__C5:%% &?YVL?\^-C_X&O_\ &J/.UC_GQL?_  -?_P"-5H44
M 9_G:Q_SXV/_ (&O_P#&J/.UC_GQL?\ P-?_ .-5H44 9_G:Q_SXV/\ X&O_
M /&J/.UC_GQL?_ U_P#XU6A10!G^=K'_ #XV/_@:_P#\:H\[6/\ GQL?_ U_
M_C5:%% &?YVL?\^-C_X&O_\ &J/.UC_GQL?_  -?_P"-5H44 9_G:Q_SXV/_
M (&O_P#&J/.UC_GQL?\ P-?_ .-5H44 9_G:Q_SXV/\ X&O_ /&J/.UC_GQL
M?_ U_P#XU6A10!G^=K'_ #XV/_@:_P#\:H\[6/\ GQL?_ U__C5:%% &?YVL
M?\^-C_X&O_\ &J/.UC_GQL?_  -?_P"-5H44 8.M2ZJ="U 265FJ&VDW%;MB
M0-IS@>6,_F*O>=K'_/C8_P#@:_\ \:HU[_D7M3_Z])?_ $ UH4 9_G:Q_P ^
M-C_X&O\ _&J/.UC_ )\;'_P-?_XU6A10!G^=K'_/C8_^!K__ !JCSM8_Y\;'
M_P #7_\ C5:%% &?YVL?\^-C_P"!K_\ QJCSM8_Y\;'_ ,#7_P#C57)IX;:(
MRSRI%&" 7=@HR3@<GU) _&I* ,_SM8_Y\;'_ ,#7_P#C5'G:Q_SXV/\ X&O_
M /&JT** ,_SM8_Y\;'_P-?\ ^-4>=K'_ #XV/_@:_P#\:K0HH S_ #M8_P"?
M&Q_\#7_^-4>=K'_/C8_^!K__ !JM"B@#/\[6/^?&Q_\  U__ (U1YVL?\^-C
M_P"!K_\ QJKD-Q!<JS031RJK%&,;!@&'!''<5)0!G^=K'_/C8_\ @:__ ,:H
M\[6/^?&Q_P# U_\ XU6A10!G^=K'_/C8_P#@:_\ \:H\[6/^?&Q_\#7_ /C5
M:%% &?YVL?\ /C8_^!K_ /QJI[9[YG875O;Q+C@Q3M(2?H46K-% !1110!S7
MC?\ Y L/_7PO_H+5P-=]XW_Y L/_ %\+_P"@M7 U\9GG^]OT1])EG^[_ #84
M5T6GM-<:/#;Z5=""^CD8RQ;]C3Y^Z0>^!GC_ .M3=/235(;G1KG$=R)#-#N&
MW:W\:X^F3@>AKD6$YN5)_$M--+]KWWZ>IT/$6O=;;][=_0Y^BNNLM24:S=M:
M_-;V-BZP#/!"XY_$]_3%0I:16]YJ$]M_QZ76G2RQ8[9QE?P/]*T^HIJ\97U:
MV_'TO^G<CZTT[2C8Y>BMZ7S-.L-/@LF6&XNH_-EGW!&()X7<3P./7FJ=[!J4
MSVBW3"9I24@D\Q9"W.,;@3GD]S7//#N*ZMZ=--;=?G]YK&LI/I;U[>1FT5U6
MK)'=:=>6D&&_LIT"'')3:%;_ ,>&34<?]J?V'H_]FFX!W2[S%G;G?QN[8Z]?
M>MG@;3<;WLKZ*]]>5]>YFL5>*=K7=M7Y7_(YFBN@^V6\'BMS8Q6[QR3(BOLR
M%Y&XIVZYY_*LO5_^0U??]?$G_H1K&K04(MJ5[.QK"JY22:M=7*=%=%I[37&C
MPV^E70@OHY&,L6_8T^?ND'O@9X_^M6=<:=+]A-\S'S?/:*:+R]IC;J/S^@IS
MPTE!2CKI?R\^NZZK]!1KIR<7IK;^O4SJ*VFT!(WNDDO0AM(XWE/ED@%NJCGG
M'ZGTJ$Z,TKV/V.7S4O"P0NNPJ5.#D9/'?K2>$K+=?BN]OST!8BF^O]6O^1G)
M#+*KM'&[J@W.54G:/4^E,KI=.@M8K'6?LUV9]MNRMNCV9YX(Y.1^59UQI,5O
M#:?Z4SW%U$KQQ)$.">@)+<?7GOTJYX2:@I+7OJN]A1Q$7)I_KVN9=%:XT:%[
MU]/CO2UZH(V^5^[9@,E0V<^O4=JC73;==/M;RYO3$MP64*L6YA@XSU''_P!;
M@UG]5JZZ;>:Z67?S17MX?TG_ %T,RBMMM 1;V>Q6\W7<2%PHB^4@<@;L\''/
M0CWJLFFP1VUM->W30?:3F-5BWX7.-S<C _.F\)63U7XKT[@J]-[/\&9M*JL[
M!5!9B<  <DU->6DMC>2VLV/,C;!P<@^XJWH=Y!8ZHDUP"$VLN]1DH2,;A]*S
MA3O55.;MK9^14I^YS1U*[:=?(Z(UE<*S\*#$P+?3CFH(X99BPBC=RJEB%4G
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MX'=AJMPG\)@)/U##_$UWE?=957E6PL92W6GW'R^/I*G7:CL%%%%>B<84444
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M7_"C^R--_P"@=:?]^%_PJ/\ LZZ_Z#-]_P!\0?\ QNC^SKK_ *#-]_WQ!_\
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M7_"C^R--_P"@=:?]^%_PJ/\ LZZ_Z#-]_P!\0?\ QNC^SKK_ *#-]_WQ!_\
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M^(/_ (W1_9UU_P!!F^_[X@_^-T :%%9_]G77_09OO^^(/_C=']G77_09OO\
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M?V==?]!F^_[X@_\ C= &A16?_9UU_P!!F^_[X@_^-T?V==?]!F^_[X@_^-T
M:%%9_P#9UU_T&;[_ +X@_P#C=']G77_09OO^^(/_ (W0!H45G_V==?\ 09OO
M^^(/_C=']G77_09OO^^(/_C= &A16?\ V==?]!F^_P"^(/\ XW1_9UU_T&;[
M_OB#_P"-T :%%9_]G77_ $&;[_OB#_XW1_9UU_T&;[_OB#_XW0!H45G_ -G7
M7_09OO\ OB#_ .-T?V==?]!F^_[X@_\ C= &A16?_9UU_P!!F^_[X@_^-T?V
M==?]!F^_[X@_^-T :%%9_P#9UU_T&;[_ +X@_P#C=']G77_09OO^^(/_ (W0
M!H45G_V==?\ 09OO^^(/_C=3VUK- [&2_N+D$8"RK& /?Y5% %FBBB@#G/&F
MJ7FDZ/#/8S>5*UP$+;0W&UCCD'T%<+_PFOB'_H(?^08__B:Z[XB_\B_;_P#7
MTO\ Z ]>95Y^)G)3LF?3970I3P]YQ3=WND;_ /PFOB'_ *"'_D&/_P")H_X3
M7Q#_ -!#_P @Q_\ Q-8%%8>UGW9Z/U3#_P B^Y&__P )KXA_Z"'_ )!C_P#B
M:/\ A-?$/_00_P#(,?\ \36!11[6?=A]4P_\B^Y&_P#\)KXA_P"@A_Y!C_\
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M_P#":^(?^@A_Y!C_ /B:/^$U\0_]!#_R#'_\36!11[6?=A]4P_\ (ON1O_\
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MT"K'_P !T_PH_L+2/^@58_\ @.G^%'U.7</[<I_R,\2HKVW^PM(_Z!5C_P"
MZ?X4?V%I'_0*L?\ P'3_  H^IR[A_;E/^1GB5%>V_P!A:1_T"K'_ ,!T_P *
M/["TC_H%6/\ X#I_A1]3EW#^W*?\C/$J*]M_L+2/^@58_P#@.G^%']A:1_T"
MK'_P'3_"CZG+N']N4_Y&>)45Z_%HVEG7;N,Z;9E%MH&"^0N 2TN3C'? _(5>
M_L+2/^@58_\ @.G^%'U.7</[<I_R,\2HKVW^PM(_Z!5C_P" Z?X4?V%I'_0*
ML?\ P'3_  H^IR[A_;E/^1GB5%>V_P!A:1_T"K'_ ,!T_P */["TC_H%6/\
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M#").\F85\ZE*-J4;>9%;6T5I;1V\"!(HU"JH["I:**[#PVVW=A1110(****
M"BBB@ HHHH **** "BBB@ HHHH **** ,^'_ )&&]_Z]+?\ ]#FK0K/A_P"1
MAO?^O2W_ /0YJT* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "L_1O^/&3_K[N?\ T<]:%9^C?\>,G_7W<_\ HYZ
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MFN()+R[B6WBDR=HB1 J!N,YZD\'K5Z32-3@U&\FLFM&BOH(XI3,S PLH*[E
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MFO\ V%H__0)L?_ =/\*/["T?_H$V/_@.G^%9'_"1WG_/.#_OD_XT?\)'>?\
M/.#_ +Y/^-'^L&"[O[@^I537_L+1_P#H$V/_ (#I_A1_86C_ /0)L?\ P'3_
M  K(_P"$CO/^><'_ 'R?\:/^$CO/^><'_?)_QH_U@P7=_<'U*J:_]A:/_P!
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M - FQ_\  =/\*PEUJY6]EN@D6^2-(R,'&%+$=_\ ;/Z5-_PD=Y_SS@_[Y/\
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M#I_A61_PD=Y_SS@_[Y/^-'_"1WG_ #S@_P"^3_C1_K!@N[^X/J54U_["T?\
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M_P !T_PK0HH S_["T?\ Z!-C_P" Z?X4?V%H_P#T";'_ ,!T_P *T** ,_\
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MI_A1_86C_P#0)L?_  '3_"M"B@#/_L+1_P#H$V/_ (#I_A1_86C_ /0)L?\
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M_H$V/_@.G^%&O?\ (O:G_P!>DO\ Z :T* ,_^PM'_P"@38_^ Z?X4?V%H_\
MT";'_P !T_PK0HH S_["T?\ Z!-C_P" Z?X4?V%H_P#T";'_ ,!T_P *M)=V
MTMS+;1W$3SPX\V)7!9,\C(ZC/O4U &?_ &%H_P#T";'_ ,!T_P */["T?_H$
MV/\ X#I_A6A5:^O[;3;;[1=R^7%O5-VTGEB !Q[D4 0?V%H__0)L?_ =/\*/
M["T?_H$V/_@.G^%6X[F":66**:-Y(2!(BL"4)&0".W%2T 9_]A:/_P! FQ_\
M!T_PH_L+1_\ H$V/_@.G^%:%% &?_86C_P#0)L?_  '3_"C^PM'_ .@38_\
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M* ,^'_D8;W_KTM__ $.:M"L^'_D8;W_KTM__ $.:M"@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/T;_CQD_P"O
MNY_]'/6A6?HW_'C)_P!?=S_Z.>@#0HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH S]>_Y%[4_^O27_ - -:%9^O?\ (O:G_P!>DO\
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M'S&=74GL,1#\#5A;+4M2\,W>HW.GR_:;N]BN)[-UVR201%1Y>T]R$)QWS[T
M=C;ZKIUW!+/;7]K/%$,R213*RIQGD@\<5GW_ (@A1K)=/N+6Y,M]';3!7#[
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M^W^-<_\ \+'T?_GVOO\ OVG_ ,51_P +'T?_ )]K[_OVG_Q5'U#"_P#/J/\
MX"O\@]M4_F?WG0?V)IW_ #[_ /C[?XT?V)IW_/O_ ./M_C7/_P#"Q]'_ .?:
M^_[]I_\ %4?\+'T?_GVOO^_:?_%4?4,+_P ^H_\ @*_R#VU3^9_>=!_8FG?\
M^_\ X^W^-']B:=_S[_\ C[?XUS__  L?1_\ GVOO^_:?_%4?\+'T?_GVOO\
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MQ^M6O^%CZ/\ \^U]_P!^T_\ BJ/J&%_Y]1_\!7^0>VJ?S/[SH/[$T[_GW_\
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M<?\ \+'T?_GVOO\ OVG_ ,51_P +'T?_ )]K[_OVG_Q5 '845Q__  L?1_\
MGVOO^_:?_%4?\+'T?_GVOO\ OVG_ ,50!V%%<?\ \+'T?_GVOO\ OVG_ ,51
M_P +'T?_ )]K[_OVG_Q5 '845Q__  L?1_\ GVOO^_:?_%4?\+'T?_GVOO\
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M^U]_W[3_ .*H ["BN/\ ^%CZ/_S[7W_?M/\ XJC_ (6/H_\ S[7W_?M/_BJ
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M ,]?_'3_ (4?VA:_\]?_ !T_X4 0?V%H_P#T";'_ ,!T_P */["T?_H$V/\
MX#I_A4_]H6O_ #U_\=/^%']H6O\ SU_\=/\ A0!!_86C_P#0)L?_  '3_"C^
MPM'_ .@38_\ @.G^%3_VA:_\]?\ QT_X4?VA:_\ /7_QT_X4 0?V%H__ $";
M'_P'3_"C^PM'_P"@38_^ Z?X5/\ VA:_\]?_ !T_X4?VA:_\]?\ QT_X4 0?
MV%H__0)L?_ =/\*/["T?_H$V/_@.G^%3_P!H6O\ SU_\=/\ A1_:%K_SU_\
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M3_VA:_\ /7_QT_X4?VA:_P#/7_QT_P"% $']A:/_ - FQ_\  =/\*/["T?\
MZ!-C_P" Z?X5/_:%K_SU_P#'3_A1_:%K_P ]?_'3_A0!!_86C_\ 0)L?_ =/
M\*/["T?_ *!-C_X#I_A4_P#:%K_SU_\ '3_A1_:%K_SU_P#'3_A0!E1:+I1U
MV[C.F691;:!@OD+@$M+DXQWP/R%7O["T?_H$V/\ X#I_A44=S"NLW-P7_=/;
MPHK8/)5I"1_X\/SJY_:%K_SU_P#'3_A0!!_86C_] FQ_\!T_PH_L+1_^@38_
M^ Z?X5/_ &A:_P#/7_QT_P"%']H6O_/7_P =/^% $']A:/\ ] FQ_P# =/\
M"C^PM'_Z!-C_ . Z?X5/_:%K_P ]?_'3_A1_:%K_ ,]?_'3_ (4 0?V%H_\
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M#^PM'_Z!-C_X#I_A1_86C_\ 0)L?_ =/\*G_ +0M?^>O_CI_PH_M"U_YZ_\
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M #U_\=/^%']H6O\ SU_\=/\ A0!!_86C_P#0)L?_  '3_"C^PM'_ .@38_\
M@.G^%3_VA:_\]?\ QT_X4?VA:_\ /7_QT_X4 0?V%H__ $";'_P'3_"K%M86
M=D6-I:06^_&[RHPN<=,XI/[0M?\ GK_XZ?\ "C^T+7_GK_XZ?\* +-%%% %'
M5?\ CU7_ 'Q_(UCUL:K_ ,>J_P"^/Y&L>@ HIKNL:,[L%51EB3P!7 I\1=2U
M**>^\/\ A&\U+28793=FY2(OMZE$()8?3]* /0**R?#?B*Q\4Z'#JNGEO)DR
M"CC#(PZJ?>KU].UKI]S<( 6BB9P#T) )H L45SO@77KKQ/X-L-8O8X8[BX\S
M>L((0;9&48!)/11WK137-.DU^30TN<ZE%!]H>'8W$>0,[L8ZD<9S0!HT5RW@
MKQ+>>)/[;^UQ01_8=2EM(O)4C*+C!;)//TQ]*ZF@ HKEO'OB6\\*Z%!?644$
MDLEW' 1,I(VMG/0CGBNIH **** "BN6\:^);SPW_ &)]DB@D^W:E%:2^<I.$
M;.2N".?KGZ5U- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"_L^Z_YY?^/#_&C^S[K_ )Y?^/#_ !K=HH PO[/NO^>7_CP_QH_L^Z_YY?\
MCP_QK=HH YX6TS7#VX3]ZB*[+D<!B0#_ ..G\JD_L^Z_YY?^/#_&KL/_ ",-
M[_UZ6_\ Z'-6A0!A?V?=?\\O_'A_C1_9]U_SR_\ 'A_C6[10!A?V?=?\\O\
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M_GE_X\/\:W:* ,+^S[K_ )Y?^/#_ !H_L^Z_YY?^/#_&MVB@#"_L^Z_YY?\
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M_P#)O_["M7XM?\BK:_\ 7ZG_ * ]>-5R8BM.$[19]3E&6X7$895*L;N[ZO\
M1GJ'_"X?^H%_Y-__ &%'_"X?^H%_Y-__ &%>7T5A]9J]SU/[$P'_ #[_ !?^
M9ZA_PN'_ *@7_DW_ /84?\+A_P"H%_Y-_P#V%>7T4?6:O</[$P'_ #[_ !?^
M9ZA_PN'_ *@7_DW_ /84?\+A_P"H%_Y-_P#V%>7T4?6:O</[$P'_ #[_ !?^
M9ZA_PN'_ *@7_DW_ /84?\+A_P"H%_Y-_P#V%>7T4?6:O</[$P'_ #[_ !?^
M9ZA_PN'_ *@7_DW_ /84?\+A_P"H%_Y-_P#V%>7T4?6:O</[$P'_ #[_ !?^
M9ZA_PN'_ *@7_DW_ /84?\+A_P"H%_Y-_P#V%>7T4?6:O</[$P'_ #[_ !?^
M9ZA_PN'_ *@7_DW_ /84?\+A_P"H%_Y-_P#V%>7T4?6:O</[$P'_ #[_ !?^
M9ZA_PN'_ *@7_DW_ /84?\+A_P"H%_Y-_P#V%>7T4?6:O</[$P'_ #[_ !?^
M9ZA_PN'_ *@7_DW_ /84?\+A_P"H%_Y-_P#V%>7T4?6:O</[$P'_ #[_ !?^
M9Z0GQ7V:C-=_V+GS8HX]OVKIM+G.=G??^E6/^%P_]0+_ ,F__L*\OHH^LU>X
M?V)@/^??XO\ S/4/^%P_]0+_ ,F__L*/^%P_]0+_ ,F__L*\OHH^LU>X?V)@
M/^??XO\ S/4/^%P_]0+_ ,F__L*/^%P_]0+_ ,F__L*\OHH^LU>X?V)@/^??
MXO\ S/4/^%P_]0+_ ,F__L*/^%P_]0+_ ,F__L*\OHH^LU>X?V)@/^??XO\
MS/4/^%P_]0+_ ,F__L*/^%P_]0+_ ,F__L*\OHH^LU>X?V)@/^??XO\ S/4/
M^%P_]0+_ ,F__L*/^%P_]0+_ ,F__L*\OHH^LU>X?V)@/^??XO\ S/4/^%P_
M]0+_ ,F__L*/^%P_]0+_ ,F__L*\OHH^LU>X?V)@/^??XO\ S/4/^%P_]0+_
M ,F__L*/^%P_]0+_ ,F__L*\OHH^LU>X?V)@/^??XO\ S/4/^%P_]0+_ ,F_
M_L*/^%P_]0+_ ,F__L*\OHH^LU>X?V)@/^??XO\ S/4/^%P_]0+_ ,F__L*/
M^%P_]0+_ ,F__L*\OHH^LU>X?V)@/^??XO\ S/2$^*^S49KO^Q<^;%''M^U=
M-I<YSL[[_P!*L?\ "X?^H%_Y-_\ V%>7T4?6:O</[$P'_/O\7_F>H?\ "X?^
MH%_Y-_\ V%'_  N'_J!?^3?_ -A7E]%'UFKW#^Q,!_S[_%_YGJ'_  N'_J!?
M^3?_ -A1_P +A_Z@7_DW_P#85Y?11]9J]P_L3 ?\^_Q?^9ZA_P +A_Z@7_DW
M_P#84?\ "X?^H%_Y-_\ V%>7T4?6:O</[$P'_/O\7_F>H?\ "X?^H%_Y-_\
MV%'_  N'_J!?^3?_ -A7E]%'UFKW#^Q,!_S[_%_YGJ'_  N'_J!?^3?_ -A1
M_P +A_Z@7_DW_P#85Y?11]9J]P_L3 ?\^_Q?^9ZA_P +A_Z@7_DW_P#84?\
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M -#FK0K/A_Y&&]_Z]+?_ -#FK0H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *S]&_P"/&3_K[N?_ $<]:%9^C?\
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M\CZ$HHHKV3\S"BBB@ HHHH SX?\ D8;W_KTM_P#T.:M"L^'_ )&&]_Z]+?\
M]#FK0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -_'_P#B*/85.P?VK@_^?B.#HKO/^%2Z]_S]Z;_W\?\ ^(H_X5+KW_/WIO\
MW\?_ .(H]A4[!_:N#_Y^(X.BN\_X5+KW_/WIO_?Q_P#XBC_A4NO?\_>F_P#?
MQ_\ XBCV%3L']JX/_GXC@Z*[S_A4NO?\_>F_]_'_ /B*/^%2Z]_S]Z;_ -_'
M_P#B*/85.P?VK@_^?B.#HKO/^%2Z]_S]Z;_W\?\ ^(H_X5+KW_/WIO\ W\?_
M .(H]A4[!_:N#_Y^(X.BN\_X5+KW_/WIO_?Q_P#XBC_A4NO?\_>F_P#?Q_\
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M1_PJ77O^?O3?^_C_ /Q%'L*G8/[5P?\ S\1P=%=Y_P *EU[_ )^]-_[^/_\
M$4?\*EU[_G[TW_OX_P#\11["IV#^U<'_ ,_$<'17>?\ "I=>_P"?O3?^_C__
M !%21?"362X$M]8*O<HSL?RVBCV%3L)YK@E_R\1Y_7KWPT\*2:= VL7T12XG
M7;"C#E$]3Z$_R^M:'A[X<:5HTJ7-RQOKI>5,B@(I]0OK]2:[.NJAAW%\TCP,
MUSF->#HT-GN_\@HHHKL/FPHHHH **** ,^'_ )&&]_Z]+?\ ]#FK0K/A_P"1
MAO?^O2W_ /0YJT* "BBB@ HHHH **** "BBB@ HHHH **** "BBD+*.K#\Z
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M$5\8?]![_P G)O\ "@#T"BO/_P#A%?&'_0>_\G)O\*/^$5\8?]![_P G)O\
M"@#T"BO/_P#A%?&'_0>_\G)O\*/^$5\8?]![_P G)O\ "@#T"BO/_P#A%?&'
M_0>_\G)O\*/^$5\8?]![_P G)O\ "@#T"BO/_P#A%?&'_0>_\G)O\*/^$5\8
M?]![_P G)O\ "@#T"BO/_P#A%?&'_0>_\G)O\*/^$5\8?]![_P G)O\ "@#T
M"BO/_P#A%?&'_0>_\G)O\*/^$5\8?]![_P G)O\ "@#T"BO/_P#A%?&'_0>_
M\G)O\*/^$5\8?]![_P G)O\ "@#L(?\ D8;W_KTM_P#T.:M"O/1X2\6B1I!K
MBAV 4M]KER0,X&=O;)_,T[_A%?&'_0>_\G)O\* /0**\_P#^$5\8?]![_P G
M)O\ "C_A%?&'_0>_\G)O\* /0**\_P#^$5\8?]![_P G)O\ "C_A%?&'_0>_
M\G)O\* /0**\_P#^$5\8?]![_P G)O\ "C_A%?&'_0>_\G)O\* /0**\_P#^
M$5\8?]![_P G)O\ "C_A%?&'_0>_\G)O\* /0**\_P#^$5\8?]![_P G)O\
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M /0YJT*\]'A+Q:)&D&N*'8!2WVN7) S@9V]LG\S3O^$5\8?]![_R<F_PH ]
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M_I[EX_2K/_"*^+P.->_\G)?\*4;2U0W=;GH%%>?_ /"*^,/^@]_Y.3?X4?\
M"*^,/^@]_P"3DW^%:$'H%%>?_P#"*^,/^@]_Y.3?X4?\(KXP_P"@]_Y.3?X4
M >@45Y__ ,(KXP_Z#W_DY-_A6_X9TG6=,:Y.JZA]K$@7R_WSR;<9S]X<=10!
MT-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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2BBM3,**** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gu0gjnulhgsv000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $6 >P# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHK'OO%GAO3+R2SO_$&E6EU'C?#/>QQNN0",J3D9!!_&@#(\1:!K%SXRT/Q!
MI4=C/_9\,\4D%U</#N\P  AEC?I@]JM6>@WUWXEA\0:VULMQ;0-#:6EJS.D(
M?&]B[!2S' 'W5P*E_P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^
M*H2M\K_C_P .)JYC1^!;A_#GB73+BXA$FI:A+>VDL9/[EB0T9.1P0R@\9J.7
MP/J,GP^&C-=6TFKSW<=Y>7#%@DDOFK(Y&%SC P..PZ5N_P#"=^#_ /H:]#_\
M&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 522M:W2WX?\,K^B!J^_G^/]/[R?4&
M\1I<2+I]OI-S;OPIN)Y(6BX&<@(XDYR>J>GO7/P_#S[+X3TK3K>_ U+3+K[=
M!=-'E/.+$L-N<[#N(QG.*V?^$[\'_P#0UZ'_ .#&'_XJC_A._!__ $->A_\
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MI_QI^&NDV_V?3;>2RASGR[;3Q&N?HN!4TG[0?@E& 7^TI..JVPX_-A3W6O\
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MAA3<3M10 HR>3@ =:Q_LGC#_ *#FA_\ @FF_^2J/LGC#_H.:'_X)IO\ Y*H
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MS0__  33?_)5 '045S_V3QA_T'-#_P#!--_\E4?9/&'_ $'-#_\ !--_\E4
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M_P#<TS\I/\:U^MP[/[C+ZG/NOO.JHKE?[7U_^YIGY2?XT?VOK_\ <TS\I/\
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M@32&@21(T@$>V1PY!4E3R.HR*T<$H<WI^*N9J;Y^7U_!G2UGZW_R")_^ _\
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M5-;_ .01/_P'_P!"%>65ZM>Z?KEY9R6_]D[-^/F^TH<8(/K[5RO_  KS7/\
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M45[!X@4444 <_:?\E#UG_L%6'_HV[K?K M/^2AZS_P!@JP_]&W=;] !1110
M4E+10 E+110 4E+24 %%%% "T444 )24M% "48I:* %I*7M24 %%%% !112T
M %-IU)0 E%+10 E.I*6@!#24ZDH 2BEHH !2T44 <_XA_P"0YX3_ .PK)_Z1
M75=#7/>(?^0YX3_["LG_ *175=#0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!S]I_P E#UG_ +!5A_Z-NZWZP+3_
M )*'K/\ V"K#_P!&W=;] !1110 4E%% "T4E+0 E+24M "4444 +1124 %%%
M% !1110 =J*#24 +112T )2T44 %%%% "44M% "4M%% !24M% "44M% !111
M0!S_ (A_Y#GA/_L*R?\ I%=5T-<]XA_Y#GA/_L*R?^D5U70T %%%% !1110
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M 4444 <_:?\ )0]9_P"P58?^C;NM^L"T_P"2AZS_ -@JP_\ 1MW6_0 4444
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M45H9A1110!XMKM]>OXH\1?Z3XW=K:<"W&CN6MH_W:G#CMSR0.U>J^&KR2_\
M#.F7<MS'<RRVR,\T8(5VQR0#CO[5AWWP]M;S5;V_CU[7[)KQQ)-#9W@BC8X"
M] OH.YKIM.T^VTK3K>PLX_+M[=!'&N<X ]^]:.47!+KI^6IE&,E-OIK^9:HH
MHK,U"C2/^1L;_KQ/_H8HHTC_ )&QO^O$_P#H8H7QQ]0?P2]#JJ***]0\D***
M* .?M/\ DH>L_P#8*L/_ $;=UOU@6G_)0]9_[!5A_P"C;NM^@ ICKD4_%&*
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M (+H?_B: .@HKG_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gu0gjnulhgsv000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000006.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" .7!L,# 2(  A$! Q$!_\0
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M3_:GMO%W_!.3XC_#[QAX#^-7B+QCJ&O>+K*VU+3)M0N+BW19;I%D3!E9<#+
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M>"_#NJ_M#_"+Q?\ M8^)_CCXCT/Q]I.NW&J:?X6@U&X5)8HYC*D2P"494C
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M=L_ASVK:U'7=#T=HTU75=-TYY?\ 5+>W=O;-)V^02NA;GTS7\5?B#PQ\;/\
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M_$Q^(GPD^ ?C>YC6.;5X],N60  *;EDG8 8& &D88QQCWKGOVU?B7XB^$?\
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M\Z-F3!'?/?/-?RA?M;?\%2OVC/BS^V3HO[/?[*GBOPKX>T6TUFWL-2U&YN4
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M]\0Z;I/A_P =7:I?PW-PK+;VU[@('63[I QCO[U_:A^SO\,[[X0?"#P=\/\
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M_@AU^R59:%%X>OIO$6MZ=!-YUO%J6R98&!R!&KW#A0O;% 1ERV?9WMT>V_\
MPW^9^57_  4&\3Z#XJ_X) _#.+PWJ$>JW=GH.D)?PP,7:VD6&(%6498$$8Y
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M=MK;_@!11102%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX6Z[\4+OQQX?;PY8:1=WMIJD6H0R6ES(D#O"L,H;8VYMIZ_KQ7Q;_P $_?\
M@H7\-OVMAXWMK;QGHSZSHNL-:V&E&]B^TW-H)9$\Z&/<6< JG"CHQ(X% 6=K
MVT/U,'045YWJWQ;^&6A37EMK'CKPSIUQIZ&2^@NM5MHIK5%&2TT9?>@ Y.15
M71?C1\*/$>E3ZWH?Q \,:GI%J6%QJ-KJ<+VL)7[P>7(4$=Z!'II)R,#J>>#1
MD[B,<>N#[5X%'^U1^SG+JJZ''\9O +ZLS^6M@NO6QN"Y.-NW.,YXZ]:[+X@_
M%+P9X$^'^N^/=7\1Z79:)IVAZAJD.HRW<0MY_LUI+/$L,F[:YE9550#SF@-=
MOZU/3*898U.#(@/H64'\B<U^3_[ O_!2WX5_M::C\0])'C+1+75?"VL26%E8
M3WL4<UW!'<O"9859LOT4@ 8P<YX&?GKXQ>"OVI;W]JC2]8\+_&NSL?A\=721
MO#PU,(TUJ9PWEK%O^;<G& O?@4#LT[6U/WHI"0,9[]*X74_&OA;P'X9TS4O'
M'B?2- MDTVR%QJ&K7L5I!)*EK$)I \K#<&<,V1GK7/\ @_X\?!GX@W?V'P5\
M2O"/B:\#8%MI.KV]S,6SC 16!;GTSF@1ZW29.X#''K@^]<UK_C/PGX6&?$?B
M+2=$!7<#J5[#:Y7KG]ZR]1R/6O.H?VC_ (#W&JQZ'!\6/!,NK3,$BL(];MFN
M'9C@*JAB"2> ,T >O7NGV>HV\UI?V\5W:3J5FMYDWQR*>H9>XJAHOAS0/#<#
MV^A:59Z5!(VYX[.'R5=CSD@=36K;75O>01W-I-'<6\JAHYH7$D;J>0RLI(((
M[BN;\5>./!_@BR;4?&'B/2/#E@@+-=:O>16< "C))>5@, 4 =717AOAK]ICX
M >,=231_"_Q<\#ZYJCL$CL=/UNVFG=L@;43(W') ^4FN3_:;_:@^'/[-W@*^
M\5^,/$6FZ<_V>1K-+BXC3>=A*N-S $$D8(SW/I0.S>ECZ=4;1CKS2U^?7[$?
M[:'P]_:<\/:MJ&G>-='OM32_6.UTQ+R(W#0-YGS1IN+-R%& .ASVK[]NKF"S
M@DNKJ:.WMH$:2>:5@D<<:]6=VX51W)(H$6*:J[<\YS[5Y-K/QZ^#'AZWDNM;
M^)G@_3;>)BDDMSK-JJ(ZYRK89B",'(Q70>"?B?\ #SXD6[W?@/QCH'BNVC&9
M)=%OX;Q4&<9;RSD<^HH [ND4DCD8Y]#7GGC7XN?#+X<1^;X[\<^'/"J'OK.I
M06?Z.=WZ5)X)^*WPW^)$1G\!^-?#WBN(#<7T748;P >I"'/Z4 >@'H:122.1
MCGT->6^-OC?\(OAQ((O'?Q$\*^%93C]WK&JP6K\G ^5B6'/J*BT_XY?"36M#
MN_$.A_$'POJVE6MK/=/>V.J030[(8FE)!##/RKP._2@->WD>L49STK\A/AC_
M ,%0/A#\2_CGJWPNB\<:+8MI.H/9,)+N%?.V3>4=OS\YQ^O%?J)=?$CP!I]F
MM]>>+] M;)E#+<SZE;Q1,I&0P=W ((YH [>BO%;7]H[X$7NK)H5I\5_!-QK$
MK!(]/BUNV>X=FZ*J!L$GMS7H.O\ C?PCX5TT:QXC\1Z3HNEL@D6_U"\BM[9D
M(W!A*Y"D$#/% '3MQR!D_2G#H*\)T/\ :=_9\\2ZH-$T'XP>!-5U8R>4+"SU
MRVDG,F<; N0"V>, UR/[6?[2?@O]FOX,>*/B7XA\0:;8'2K$7-A#/<QK)>LV
M2JPJ3EU*@G<N1T]: /J2BOS]_8<_;C^%_P"U?\,8?&.F>,]$DU5KF2"XTK[;
M$+F!59L,8]V[!Q@YQCWR<?2WBC]I#X#^"KD6?BOXL>"=!NRVP6^HZU;PS;O[
MOEY+9_"@=GM9_=\SVL$Y.1T/'!I<=\<^N*XWP?\ $/P-\0+/[?X)\5:)XGLP
M-QN-'OHKM N0,GRSD#)'4#K7\P$'[>7[21_X+,W7[-[^()_^%4QWLD0TOSWV
M!1*5 ,>2O Z#% )-W79?TC^K&F$%26'.3TP>_-/KSOQA\7/AE\/GCC\;>.O#
M7A=Y3B-=9U2WLBQ]/WK#'_ L>G6@1Z)17\EW[7O_  4G^+NG?\%4OAC\%O@A
M\1K+Q#\)=7DTM=9BT;4!<V@:81"=<PNR,H9F4'&&'/6OZ=-5^,OPU\":!I5]
M\0/'?AOPNT]A;32OK6IP699Y(E9B!(VXY)[ T%2BX\O]Y7/7::J[<\YKRGP3
M\=?@[\1YFMO OQ'\)^*;A/O0:1JL%S*/^V8(?]*Z6Z^(G@6QUF'P[>>+-"MM
M=G8)#I4^H6\=]*Y. J6[,'8D\  <T$G9TF/F#>G;\_\ &N9\2>-/"?@]+:3Q
M3XBTG0([R3RK5M4O8;,7$F0-D7FLN]LD# [\5N6]]:WEFE_93Q7=I-"9X)X'
M$D4T>TL&C=<AE8#@CK0!;_"BOP1_;<_X*:?%'X8^*[_P/\./AGX@O9M-F>)M
M0M;6Y=)C&P!8,B$-GMR!Z5Y7^PG_ ,%O]*^,/QI7]G'XL>'KGPQXX$HAC;4U
M>WF\PD+_ ,M=K')[$$=<4#L[7Z'](5%10RI/&DT3K)#*BO$ZG*LC#((/H:_G
MB_X*K?\ !0KX@> ?'GP]^!_[/>HR)XVU;74L=::TE;S(1)<K$=_EG< J]CT/
MUH!)O1'] 5_X4\-ZI>)J&H:-87E[&04N9X0\JD=,,>F*W(HHX(UBA18XT&U$
M0850.P K\@/BA^U;\8/V5?V<?"VI>+/#>J>-_'6O:#;7C2V<4UQ+%/<6Z-\Q
M4,0=S=2>E?E/X8_X+R>.OA;\2/"^B?&CP#K.DZ+XPOHK>WGU*">.*-)IQ&&+
M2!<8W=?4=105R-WMK;]%J?UMT5\#?''_ (*!?"+X*_LZ:7^T'JE[;76CZWID
M5YIUFDZ[GGGA\R.#AMS'>0H .3TS7X2WO_!<_P"*ME>S_%5_AEX@_P"%917*
M212_9;G[++9-*5$H(7RRA ;!Z';CB@2BW_F?UIT5\>_L9?MA^ OVQOA5I7Q&
M\(216LUW$IO-(,F;BVD" R;D)+#:V<YZ=N*^M=0U*PTJV>\U*[M[&UB!,EQ<
MR+%$@')+.Q '%!)=HKEM(\;^$/$$=Q+HGB31]4CM-QN7L;Z"X6#;][S2C$)C
MOFF:3X[\&:[?3:;HWB;1=3U"W)$]G9W\$]Q$5^\)(T8LN.^1Q0!U9&1CI2*N
MTYSG\*\D\5_'SX,>!KS^S_%_Q,\(>'KX-L-KJ6KV\$P?IM*$D@Y[&N:\2?&?
MX>^+O".LZ?\ #_XC^&=0\1:MIMQ:Z VFZI#<2F_E3%NR!&R,-W./H: /H*BO
MYAO@#_P4 ^.7P2_;J;]EG]HK5)KZV\1:F3HNH7,KM"MK-(?+4-(<8V],'^0%
M?TZ0S17$2302)+#(H:.2,AD=3T*D<$4#:M;S):***!!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4AZ'Z'^5+2'H?H?Y4  Z#Z#^5% Z
M#Z#^5%  .@^@_E2T@Z#Z#^5+0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5\G?MN_#+Q#\7_ -FGXD^ O"IE77-9TF1;+R=V\O'%,2!MYYST'7I7UC7
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MW;Q.\ +7$+<R(I08.>];'_!53PYXDO/V^OV.;FPTR>XM+:V\."XF2)V6/'D
M[B!@8YZ^GO03!KF][2T6MNWZ_P!;'RC_ ,%3?V,/$7[%WC#X#?$/P1\8/%-S
M?_%*]T2/5K(:C<^6@U!HQ)\OF 9&3]:[K_@HO^Q+X@_9F_9^^"G[7WA?XO\
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MI!&W/7C%1_\ !4SX:_L2ZSX.^)7C'X'W^F>&?CG;M)+;VUAY=O>W-^"6 58
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MD@9Q5CP%)XV_X)3_ /!1SPW^S+H?CC7/%_@#Q+IBW$,VJW4TC!+JW$T.1*Y
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M4:EXPM-1ETEDOM6D>:YCCN/(ECWF1F*N$D&\ G:<C/>OZ3O^"A'[$_PK^/\
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MEQHMSXT?4WA@N(GB9DNPVU@'4'D.#^/Y?LS_ ,%$E+?LQ^.,=197! ]2+>3
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&#SKY;:BSVAOA'QE!/('90V!NQAL?+G!(/EW_#CGX??]%&U#_OF\_P#BJ/\
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M_!)S38?'/C'QO\=;&\_M&TNY9]'M]AC2=FN@<L& 4@*2S9SD9]J_<[6OV3_
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MS_'[XP,FL>/+&Y+Z9/<[9W2)6!C 9MQ& .O%?M;TX P***!-MA1110(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/0_0_RI:0]#]#_
M "H !T'T'\J*!T'T'\J*  =!]!_*EI!T'T'\J6@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *3/S$8Z?_6_QI:* "BD7=CYNN?\]*6@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#Z^G/4BA3D9
MQWI:* "BD+8('/-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'H?H?Y4M(>A^A_
ME0 #H/H/Y44#H/H/Y44  Z#Z#^5+2#H/H/Y4M !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 8]OTHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ I#T/T/\ *EI#T/T/\J  =!]!_*B@=!]!_*B@
M '0?0?RI:0=!]!_*EH **** "BBB@ HHHH **** "BBB@ HHHH *3G)XX[4M
M% 'XZ_\ !=;_ )1W_%S_ *XI_P"DUU7X0?\ !IG_ ,@KXB?75/\ T:]?N_\
M\%UO^4=_Q<_ZXI_Z375?A!_P:9_\@KXB?75/_1KT%KX'Z_Y']M-%%%! 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %(>A^A_E2TAZ'Z'^5  .@^@_E10
M.@^@_E10 #H/H/Y4M(.@^@_E2T %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'XZ_\%UO^4=_Q<_ZXI_Z375?A!_P:9_\@KXB?75/_1KU^[__  76_P"4
M=_Q<_P"N*?\ I-=5^$'_  :9_P#(*^(GUU3_ -&O06O@?K_D?VTT444$!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1]NLO^?RU_\  B+_ .+H M455^W67_/Y:_\ @1%_\71]NLO^?RU_\"(O_BZ
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MU157[=9?\_EK_P"!$7_Q='VZR_Y_+7_P(B_^+H M455^W67_ #^6O_@1%_\
M%T?;K+_G\M?_  (B_P#BZ +5%5?MUE_S^6O_ ($1?_%T?;K+_G\M?_ B+_XN
M@"U157[=9?\ /Y:_^!$7_P 71]NLO^?RU_\  B+_ .+H M455^W67_/Y:_\
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M ($1?_%T?;K+_G\M?_ B+_XN@"U157[=9?\ /Y:_^!$7_P 71]NLO^?RU_\
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M,$C0S>)-'BE7[T;WT"N/JI?(J/\ X3OP;_T,^B_^!\'_ ,77^7'^UI_P5_\
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MK^1CPE^R+X9_:Q_X*L_&_0->\0ZAX<BM-&OKMY]*D:.=V2U::1<1LN6)!X+
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M*OA=\ ?#OPT\9_L]>+_'/B7XC>)M>T^36K%S?3Q1FZF0S*1RNP9/L.M?V(_
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M4.[EPO:ORV_9N_:]\9:)\?O''PL^,]Y);K>:E);^&%O)&4L#<[8O*\SD@IT
M[&ORI_9%^)NF^!_V^?!G@'X.ZQXM\0?#>_2PAU"XU-;N2T!D$:ON>3Y.=QSS
MTZUZY_P5KU6X^'W[>G[+LWA=?[/?Q-JVBC519#RO.)NXHW:4)@?.HR>._3%
M):V[JZ?X]TO^"?U%(P=%=>5=593ZA@"#^1IU9NCL7TC2G;EGTVQ8Y]6M8B?U
M-:)7)!YXH)%HHHH **** "BBB@ HHHH *0]#]#_*EI#T/T/\J  =!]!_*B@=
M!]!_*B@ '0?0?RI:0=!]!_*EH **** "BBB@!.!QP/;I2TF 3G'(I: ,_5K2
M2_TR_LHI#%)=6LT"2#@HTJ% P/;&<U_#%^UU\(O$WPK_ ."OWP8N[[Q#<:C:
M:YXFM)1;M<2LB!KX.%";B.X[=1^%?W0ZA>QZ=8W=_*"8[2WEN' ZE8D+G'X"
MOX7?^"A_[0UMK?\ P54^#6OZ;X6U.ZTOPKXBLDU&[BAD>%1'?(K%G *@ *<_
M@3D4%PW^3/T _P""W_Q8\5^-?'?P/^"&B:I/IFBW=SH[:Y!%*\:7T5W)"TR/
MM(#;HV"_-D8&.E4O^"E_[%GP:_9S_8%\(?M _!SPQ;^%/B7H.G^%[N_U^S;R
MKF^GOK%+J621D ;<)4?^)LC![UB?\%F?#&MRW?P'_:=\(Z%?ZMH0_P"$>FOK
M:RADE:"-!;F0R;%.T  YW<#'X5C?\%%?VY_#G[3O[#W@W]G+X=^&=4G\;:_8
M^%K:\ACC>3[,UA8QVC+Y:IN0EG<R!B<GD8Z4#@E>#OHW9Z_A\SYZ_:=_;F^)
M6J?L.?LI>%_[=N_[0^(D^E:3KUP)90UU#,\<+J[[LD;7;J>Y[5]Q_M(_\$[_
M ($>"O\ @GWX8^)OA?PM;:;\5KG2=/\ $EQXJB.VZDNYHOM#$R !\\!MQ8[M
MW08.?C;]JG]AGQUHG["7[+?B>'1KZYU7X:/I>L:S916\C3K';F.>0,@7<,;<
M=/6OHK]HC_@I5X2\=?L#>&?AIHWA+59_&,-CI_A>YL$BD:=9H(OLN\1!2ZG+
M'=V.!WZ@WJTEW;=M/O[>I^A'_!$_X\>)_B;\%=0\.^*-0FU"3P3:BS2>9V<^
M7;/&GWG/89Y_^O7GW[2O_!?3X ?LX?%O5/A1XD^RG5M+GFAFWE]VZ%RAX#CT
M_P ]*]8_X(O?L]^(/A;\!Y/%7B&UGL?^$_LA=+9W"&.:);@QS,I5@#G:>XXX
MKD_VB?\ @@=^RC^T=\5-4^*_C!;C^W=5GFGGVJQ&9G+'U]:->Q'NW=V[:V:Z
ML_'G_@I/_P %V?@1^TY^R9XZ^#_A.2V_MCQ3$(XHTR6WQQS11@;B2/\ 7D\>
MOTQ_+5^R%^T]^U'^R?:ZA<?"Y=4L;+5I[AVDM?M"B2.XD9QRF!R#T/K7]8'_
M  4W_P""%_[*G[,'[)/C'XO^!(;I?$GA=1+&TJXC=BLDB8.22!Y9!R%Z]Z_$
M3_@G?^RS\7?VW?"<FC_#.WMA)H<L\4\GD*S!()&3)(4G.%ZG^?%:TLJSK-92
MI9+B,BP]6DE4K2SO$3P]&4&TDJ,HJ[FGNGI;=GWO F'\,,1B,<O$W..*LGR^
M-&+R^KPQ@,/CJ]7%<R4H8F-=I4Z2CJI+5O3O;D6_X*\?\% 2Q/\ :GB#DD_Z
MRZ[G_?I/^'N__!0+_H*>(/\ OY=?_%U^J,G_  1&_:[C=T,,)*,5)%J,9!Q_
M<IG_  Y)_:Z_YX0_^ H_^(KH_P!4..O^AEP!T_YF=?\ N^77_P!N^_\ 1UEO
MT3-/^,X\7.G_ #3^ _N^?J?EC_P]W_X*!?\ 04\0?]_+K_XNC_A[O_P4"_Z"
MGB#_ +^77_Q=?J=_PY)_:Z_YX0_^ H_^(H_X<D_M=?\ /"'_ ,!1_P#$4?ZH
M<=?]#+@#I_S,Z_\ =\NO_MWWO^S?HF:?\9QXN=/^:?P']V_7U_IGY8_\/=_^
M"@7_ $%/$'_?RZ_^+H_X>[_\% O^@IX@_P"_EU_\77ZG?\.2?VNO^>$/_@*/
M_B*/^')/[77_ #PA_P# 4?\ Q%'^J''7_0RX Z?\S.O_ '?+K_[=]Y_9OT3-
M/^,X\7.G_-/X#^[?KZ_TS\L?^'N__!0+_H*>(/\ OY=?_%T?\/=_^"@7_04\
M0?\ ?RZ_^+K]3O\ AR3^UU_SPA_\!1_\11_PY)_:Z_YX0_\ @*/_ (BC_5#C
MK_H9< =/^9G7_N^77_V[[S^S?HF:?\9QXN=/^:?P']V_7U_IGY8_\/=_^"@7
M_04\0?\ ?RZ_^+H_X>[_ /!0+_H*>(/^_EU_\77ZG?\ #DG]KK_GA#_X"C_X
MBC_AR3^UU_SPA_\  4?_ !%'^J''7_0RX Z?\S.O_=\NO_MWWG]F_1,T_P",
MX\7.G_-/X#^[?KZ_TS\L?^'N_P#P4"_Z"GB#_OY=?_%T?\/=_P#@H%_T%/$'
M_?RZ_P#BZ_4[_AR3^UU_SPA_\!1_\11_PY)_:Z_YX0_^ H_^(H_U0XZ_Z&7
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M>+G3_FG\!_=OU]?Z9^6/_#W?_@H%_P!!3Q!_W\NO_BZ/^'N__!0+_H*>(/\
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M?,47_!5C_@H[<()X;CQ"\3@%6WWO(/.>&]__ *W%/_X>I_\ !2#_ )[>(?\
MOJ^_^*K[.\+?LQ?$[Q-X?LM=T;7_  U::9>(K002&V5T4@$ @CKT!X['/I6W
M_P ,D_%[./\ A)_"_P"=IU^NW^GXUZV"R7B3&X+!XV'$'AU2AC,-1Q4:5;-J
MD:U*-:$)JE6C]FI!.TUWOW=OX-XLR;Z1&0<6\49!E_A)',,NR/B'-,HR[,:E
M+'QGF&"P.+E0P^,FHTN13Q%*$:LE%N*<FD[6/A;_ (>I_P#!2#_GMXA_[ZOO
M_BJ/^'J?_!2#_GMXA_[ZOO\ XJONO_AD?XO_ /0S^%_^^K3_ .)IC_LD?& <
MCQ-X8.,DX:U]O1?YUTKASB;_ **3PV_\/%3^[_3]7W=O ]G])/1OP9I6T^QF
M/]S_ *=>?Y]SX7_X>I_\%(/^>WB'_OJ^_P#BJ/\ AZG_ ,%(/^>WB'_OJ^_^
M*K],?!W_  3I_::^(*[O#%UI&H+G@VT,,GZJA'/I]!Q7HK?\$COVT%./L=L?
MI9I_\;KII\'\9U8J=+.O#VI!VM*.:5VGMV7]:G@8OB?QLR_$3PN.\.,EP>)I
MNT\/B<3B:56+]WXH346OFNK773\B?^'J?_!2#_GMXA_[ZOO_ (JC_AZG_P %
M(/\ GMXA_P"^K[_XJOUT_P"'1_[:'_/E;?\ @&G_ ,;H_P"'1_[:'_/E;?\
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M (!I_P#&Z/\ AT?^VA_SY6W_ (!I_P#&Z/\ 4OC?_H;>'_3_ )F=?^[Y??\
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M]_\ V\'^N?C#_P!$%P]T_P"8ZM_=_KY^>GY%_P##U/\ X*0?\]O$/_?5]_\
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MC_4OC?\ Z&WA_P!/^9G7_N^7W_\ ;P?ZY^,/_1!</=/^8ZM_=_KY^>GY%_\
M#U/_ (*0?\]O$/\ WU??_%4?\/4_^"D'_/;Q#_WU??\ Q5?KI_PZ/_;0_P"?
M*V_\ T_^-T?\.C_VT/\ GRMO_ -/_C='^I?&_P#T-O#_ *?\S.O_ '?+[_\
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M0?\ /;Q#_P!]7W_Q5?KI_P .C_VT/^?*V_\  -/_ (W1_P .C_VT/^?*V_\
M -/_ (W1_J7QO_T-O#_I_P S.O\ W?+[_P#MX/\ 7/QA_P"B"X>Z?\QU;^[_
M %\_/3\B_P#AZG_P4@_Y[>(?^^K[_P"*H_X>I_\ !2#_ )[>(?\ OJ^_^*K]
M=/\ AT?^VA_SY6W_ (!I_P#&Z/\ AT?^VA_SY6W_ (!I_P#&Z/\ 4OC?_H;>
M'_3_ )F=?^[Y??\ ]O!_KGXP_P#1!</=/^8ZM_=_KY^>GY%_\/4_^"D'_/;Q
M#_WU??\ Q5'_  ]3_P""D'_/;Q#_ -]7W_Q5?KI_PZ/_ &T/^?*V_P# -/\
MXW1_PZ/_ &T/^?*V_P# -/\ XW1_J7QO_P!#;P_Z?\S.O_=\OO\ ^W@_US\8
M?^B"X>Z?\QU;^[_7S\]/R+_X>I_\%(/^>_B'_OJ^_P#BJKW/_!5W_@HW:KNE
MG\1 >QOSZ^A-?K!XK_X)7?MB^$/#NJ>);^SM#9Z3937L^;-0/+A3>W/ECL#6
M;_P34^'NC?'SXQWGPT^).BZ9<2Z1??8KT-:QMETE\ML@H?0]LFM:G 'B3_9F
M.S;!RX-S+"Y;!5,6L%CZ]2I3B[6NFDKNWXOHQ1XW\6O;T</4X)X:HU*[M#VN
M.KJ+?N]?S^?<_)\?\%<?^"B!Z77B3_OG4:7_ (>X?\%$?^?GQ)^6HU_>[+_P
M2;_9A;9Y?A;3%PB!LZ? <L!AB/D/4Y/;Z5#_ ,.F?V9O^A8TK_P70?\ Q%?G
M'UWC3_H59/\ /$5/[OEY/\>Y[2SSQA_Z)+@_YYEB-?A\NMNO=^9_!1_P]P_X
M*(_\_/B3\M1H_P"'N'_!1'_GY\2?EJ-?WK_\.F?V9O\ H6-*_P#!=!_\11_P
MZ9_9F_Z%C2O_  70?_$4?7>-?^A7DW3_ )B*G]WR]?Q[A_;?C#_T2?!W3_F9
M8G^[Y?U=]F?P4?\ #W#_ (*(_P#/SXD_+4:/^'N'_!1'_GY\2?EJ-?WK_P##
MIG]F;_H6-*_\%T'_ ,11_P .F?V9O^A8TK_P70?_ !%'UWC7_H5Y-T_YB*G]
MWR]?Q[A_;?C#_P!$GP=T_P"9EB?[OE_5WV9_!1_P]P_X*(_\_/B3\M1H_P"'
MN'_!1'_GY\2?EJ-?WK_\.F?V9O\ H6-*_P#!=!_\11_PZ9_9F_Z%C2O_  70
M?_$4?7>-?^A7DW3_ )B*G]WR]?Q[A_;?C#_T2?!W3_F98G^[Y?U=]F?P4?\
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MOVL/V@+S]FSQ5\*? GPIU'6+2]\026#ZG!8S.!'-,RE]RQG^')Z]@<]Z]_\
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M3[O79IS<+>RVD;S1R>9Y@97*[@0WO_*OOBC.>G- 'C=[\"_A[K?@"+X=>)=
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MSBOP@_X-,L?V3\1N.<ZISZ?OG_SQZU^[W_!=7/\ P[O^+F/^>*?^DUU7X/\
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M  LI>7][S_+N'^LN7=ZW_@N7EY>;^X_M(HK^+?\ X?._M5_]$[U[_P !;O\
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M)(JU7Y*[IV[77W'O!FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHIE*2Q1RH>"LB*ZD>A5@0?RJ2B@:;3NKIK9K1F--H>A"*9FT72F&QV<?V?:
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M\(SMMS13M]Y\Q?\ #'_P#_Z$'0O_  7V_P#\31_PQ_\  /\ Z$'0O_!?;_\
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M**** "BBB@ HHHH **** &C=DYZ<XZ>OYT?-N_V?P]/SZTZF[OFQC\?\_E0
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M/84 !S@XZ]J1=V/FZY_STI<T4 (#G(]*6C\*SM1U;3M)1)=1NX;1)&V(TSA
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MZ"U\#]?\C^VFBBB@@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P =H_X6+X#_ .AO\/?^#6T_^.U_"%_PMKXP?]#-XP_[ZO/\::?BW\7VRO\
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M_%S_ *XI_P"DUU7X0?\ !IG_ ,@KXB?75/\ T:]!:^!^O^1_;311100%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% $-Q_Q[S_ /7&7_T!J_C0_:J_Y2+^$/\ L9;7_P!+4K^R^X_X]Y_^N,O_
M * U?QH?M5?\I%_"'_8RVO\ Z6I7YKXE?[CD_P#V-L/_ .G*9_=WT$/^2N\2
M?^S;Y]_ZBUS^Q7PG_P BOX<_[ >E?^D,%=!7/^$_^17\.?\ 8#TK_P!(8*Z"
MOT>G_#I_X(_^DH_AK&?[YB_^PFO_ .G9!1115G,%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV\-Y>W&W&X?E7R?\6?V'/B%XA_8M^%?POM+.Y;6?#GC&SU6YB"/O6**Z64Y
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M %%%% !2'H?H?Y4M(>A^A_E0 #H/H/Y44#H/H/Y44  Z#Z#^5+2#H/H/Y4M
M!1110 4444 %%%% !1110 4444 %%%% !1110!^.O_!=;_E'?\7/^N*?^DUU
M7X0?\&F?_(*^(GUU3_T:]?N__P %UO\ E'?\7/\ KBG_ *375?A!_P &F?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?^DUU7X0?\&F?_(*^(GUU3_T:]?N_P#\%UO^4=_Q<_ZXI_Z375?A!_P:9_\
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M@)249N*ER[V=K]?Z^\_T1?\ AXG^SI_T-FG_ /@=!_C1_P /$_V=/^ALT_\
M\#H/\:_SNO\ A5'[5O\ S]^)_P#OS>4?\*H_:M_Y^_$__?F\KH_X@#PM_P!%
M-#I_R\C_ '?\U^/SC_6O'_\ 0OG_ . ^GE_5WVT_T1?^'B?[.?\ T-FG_P#@
M;!_C1_P\3_9T_P"ALT__ ,#H/\:_SNO^%4?M6_\ /WXG_P"_-Y2CX4_M6@C_
M $OQ/U'_ "PO*7_$ >%M&^)X)?\ 7R.ND7^">W],_P!:\?\ ]"^?_@+\O+[^
MQ_H^?#G]M3X)_%#7U\-^%O$5G>ZDS!1#%=12-DD#[J\]3CV_&OK8,KJL@Y!
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M<,(IA"D]\KRM'(0P16=0S_=&X9ZT UOHU:*>O=V/2/\ @GO^UC\;YOB?XZ^
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MI^/_ /@I;^RGKG@KQI\9O$UQJOP_OY;:?5E$[/&EO(4=PYS@80G(...U=/\
MMYNR_P#!2?X<;)TMV,^E[9))%C4']T#\S$#@_P J_0/_ (*B:WH]O^RC'I.H
MWUE?:W?:9"NGQQSQ23-.UM" T:*2[9X&X#YBIP<<T%?RV2^:UWZ^7Z'M.O\
M_!0_X1>$?@E8_&36)'GTN2Q@>6*"50\EWY*F6-/E;DR;@!R<UYY\'O\ @J/\
M//C'H=_K^@^!?$UO8V:/)&\\<A^TQKG#Q'R%#!L<$9'-?@CXQT35;7]ASX>Z
M=XD62/[5XLLPT%TK)Y]L]RGR;7ZJ0<$=\U_13X3N/@=^SO\ L;^$/B=J_@O0
M+#1],\":--?21V4"/<7,]LQWS2D?,9)$=LGG! />@+)/O=V[:W7KW/G#5_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2OZ Z3@9./<X'6@$[=%\T?D7^U#\!O"7PN_8HE^$6H0)J2&PEL+5F ES>"$
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M4 %%%% !C/49_"BBB@ HHI.<GT["@ !!Z<TM( !T% W9.3QV_P XH 6BBB@
MHHHH *,=\<^N**0Y[<4 +10,]Z3G)].PH ,@''>EI, G..12T %%%% !2'H?
MI_C2TAZ'Z?XT  Z#Z#^5% Z#Z#^5%  .@^@_E2T@Z#Z#^5+0 4444 %%%% !
M1110 4444 -95=61U#*P*LK#(92,$$'@@C@BOSB_X*/_ !1^%O[,_P"S3XZ^
M)VL^#/#5_JCVSZ?8B73K,74DUS%(&E5_+$KLGRC'()<GJ!7Z/^E?S0?\%>_
MWQ__ &B_CQX#^ /AOPOJ6H_"G5+O39=;U"&*=K2+/E"8R,JE.@.<GM0-;KU7
MYGC/_!++]D%_&7P/_: _:/LM"AM;_P",^F:Y_8=H+<(%:YCD*;  ,X,@Z?AZ
M5\Y_"V/]M3_@GY\/O&&O:G\$=+UWPI>^+;R^.K:AI".Z6#73N7626(X 0>O]
M:_I]^%_P]D_9%_9"T_PIX2T?^T;[P1X8DN+;2X8MSW-XT:LT6Q02[':!C!/8
M<\U_./\ M6_\%//VQ?VA?!VO_L^:5^RSKNFQ:QJQT>YUT:/>[9;='>"*XRT9
MCB5$D8YA$8(/.2!@*U=TK.[[].U]-/N_$_?[]@3]L'PK^U7\'6U[0-.L]*\3
MZ3I\AUC3;)(U2*[6+ 7;&HVXGPN.<_7K_,I^WU_P6X_X*'_ +]IGQ#\,OAI\
M-M8U7PEIUW=0VUY!IDLL;)%*ZKAUB8'*@8YK]X/^"/'[&WB3]F+X1W6M^+!-
M;:SXXMX[NZTV<OOM6E=+AE:-^4PPQC%?HMXF_97^ ?C#5Y=>\2?#;P]JNK3L
MSRWMS:(\SLQRQ+$<DD]Z NHR>G,MM3_.Y_;(_P""TO\ P4!_:(^!6N?"SXI_
M#?5=$\&:VICU._DTN2W1EVLJM-)Y*[BBR-M+L<;CC )K];O^#3^"*'2_'WE'
M(>VO96QTWR.[.._()]:_5[_@M1^R_P# +P?^P%\5]=T#X?:+HVLV,,1L+RRM
M(TD0F"Z,F6VY'*QXP1T.<U^2O_!IHS'2_B("20/[44>FT2R8H&VG!M*VOZH_
MMGHHHH,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "J>H_\@^^_Z\[G_P!$O5RJ>H_\@^^_Z\[G_P!$
MO2>S]'^1=/\ B4_\<?\ TI'\:EM_RDRU3_L89O\ TK-?V0Z#_P @/1_^P78?
M^DL5?QO6W_*3+5/^QAF_]*S7]D.@_P#(#T?_ +!=A_Z2Q5^9^'7\3B3_ +&]
M7_TJ1_=WTVOX'@C_ -FTRG_U&PYK4445^FG\'!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>A^A_E2TAZ'Z'^
M5  .@^@_E10.@^@_E10 #H/H/Y4M(.@^@_E020.!S0 M%("2.1S2T %%%% !
M1110 4444 %59+&QEF%Q+9VLDZ_=GDMX7F7'3$C(7'X-5JB@"%XUE5HY8HY(
MF&UHW570CT*L"&&.Q&*R1X9\-B3SAX>T,2YW>:-)L!)N_O;Q;[L^^<UN44 -
M1$C54C18T485$4(JCT55  'L!3J** /QU_X+K?\ *._XN?\ 7%/_ $FNJ_"#
M_@TS_P"05\1/KJG_ *->OW?_ ."ZW_*._P"+G_7%/_2:ZK\(/^#3/_D%?$3Z
MZI_Z->@M? _7_(_MIHHHH("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *IZC_R#[[_KSN?_ $2]7*IZ
MC_R#[[_KSN?_ $2])[/T?Y%T_P")3_QQ_P#2D?QJ6W_*3+5/^QAF_P#2LU_9
M#H/_ " ]'_[!=A_Z2Q5_&];?\I,M4_[&&;_TK-?V0Z#_ ,@/1_\ L%V'_I+%
M7YGX=?Q.)/\ L;U?_2I']W?3:_@>"/\ V;3*?_4;#FM1117Z:?P<%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/0_0_RI:0]#]#_
M "H !T'T'\J*!T'T'\J* /G/]J75?%&E_!SQ0WA3S4U*?3+N+SX0V^!/(^^"
MO(QN)R/2OY?= _9 \<^(OAG\2OC;XO\ 'E]?&QU2>:19KB9C:1I,S.H#,2-J
M^G85_65\4RR^!->;[+]LC&G7 FMPF]I8S$<JJ]22!7X-6'[>?P@^'J^,?@-X
MR^"?B2?PYKU[-;:IJ/\ 9EQ]EQ/(R2/YACV@ $L",= <X!%!4?2[TM\G=]CX
M(T2;X#:7JGP4N_ OBV/QYXZN=:LH=6TQ7,\VGNMPBR%ER2NP\<XK^P/PLY?P
MQX=<IY9?0M(8I_<)L+<E?^ ]*_&G]E;]F?\ X)QW'B:U^(/P\NM-L_%\]R;N
M/1=4U*"WGM[F5_,_=6]R&R5?C:I5O0=Z_:ZV2&*W@BM\>1'#%'!M.5\E$58]
MI'!&P+@C@CI0)N^W:UNWSZDU%%% @HHHH **** "BBB@ HHHH **** /QU_X
M+K?\H[_BY_UQ3_TFNJ_"#_@TS_Y!7Q$^NJ?^C7K]W_\ @NM_RCO^+G_7%/\
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M?W?]-I_N/!%?]6URA^=EAL/_ )FKC'08_"CWQS117Z:?P:%%(<XXZT#..>M
M"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %(>A^A_E2TAZ'Z'^5  .@^@_E10.@^@_E10!Q?CW78] \(ZUJGEPW,EG8R
MRI:R%")V5#A-A/S9[\5_-O\ %_XP?M5_%WQ1X@\+_#3]GCPI>Z'+=O;2:^^G
M6OVI$+,AE\PKD'#%@<]NV*_3KQAX5^+5O\;/$.H^(-?N(?AG/X<D98I)7^S1
M7#0\G:?D&..M?FAHNB?M!77CKQ=9_!/XA_;+2;4K@+:6L@=D4R-A>">0.W7K
M0/Y7Z[>FC_KKW.F_9-_X)2_$Z;Q_IGQ@^)/C>Z\,7=I>+?/X;L+N18F8R"8Q
M?9X7(V@@KDJ%' R*_I!L+46-C9V08N+.TM[4.W5Q;PI$&/NVS)]S7X<_!#X<
M_MO:?XZTJZ\>Z]J<NBK=*US&[RA&B# D$9QRO'M]>O[D60D6SM%ER95MH%E)
MZF01(')]]V: ;OKHO)%FBBB@04444 %%%% !1110 4444 %%%% 'XZ_\%UO^
M4=_Q<_ZXI_Z375?A!_P:9_\ (*^(GUU3_P!&O7[O_P#!=;_E'?\ %S_KBG_I
M-=5^$'_!IG_R"OB)]=4_]&O06O@?K_D?VTT444$!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]0_Y
M!]]_UYW/_HEZN4R5!+')&WW9$=&^CJ5/Z&D]4UW14'RSBWLI1;]$TS^&;XR?
M%RV^#?\ P4)\0^)M1M+PP6FLW$[.L#E-J7+,2& P>G?Z<]_VFTO_ (+5_#."
MRT:R=-DODVMH[S1!?F1$B&2R^W)SS7VM\3/^":OP/^*'C.^\9^(-&M9]2OW=
MYI&B4L3(=QYQGK[_ *5^-_\ P4\_8)^$OP(^&UKXD\)Z6EK=?:XW62+Y<$,#
MD8QTX/UXQVK\5JY9Q=PG3SK,<'7P;P=;$U<9*$HMU.5SNEUUL[/S^9_JME7'
MWT:?I&9CX6\$\4Y+Q.N*,#D.6\,8?$T*E.&#^L4,/&G.4D[2Y'.FFM=E=G]$
M?[.GQ]TCX]^%HO$FD,C021+*"F,8;&,8XZ$?X5]&U^/7_!'WGX#Z>V6)-E']
MXECP4 ZU^PM?J7#^-K9CD^!QE=IU:]&-2;6S<DF[>6MO0_SR\8>&,NX,\2>+
M>&,I4UEV3YMB,'A54=Y^SI2LN9J^H4445[)^:!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !NR<].<=/7\Z_#C_@M<3_PI>W&3C[1'QD^J_P")_.OW)K\-?^"UW_)&+?\
MZ^(__0DKY?C/_DF,W_[!9?FC^@OHL_\ )^?#K_L>4?U/1?\ @CY_R073O^O)
M/_0DK]A:_'[_ ((^1M_PH/3W^7 LT'49^^@Z=:_8&KX/37#F577_ #"T_P#T
ME'E_2/:?C;XB6U_XR'&?^EL**0D#J?YTH.>E?2GXB%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR,U^(?\ P6CTK5M1^"C_ -F6,U]-"?.6.*-G;Y%!  4<\XQ].:_;VO-/B/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#B/B.?\ BA_$OOIDX_0?X5_)5^SE_P I%=8[_P#$Z?\ #]^3^G2OZU?B0/\
MBAO$N/\ H&7!_,?XFOY*_P!G#_E(GK&>O]M2Y_\  CC]<_X5^:\=:9EPP[7_
M .%*GHO7^K?/R/[P^B%_R0GT@=_^2%Q/_I,=3^P"P_X\;3_KVA_]%K5NJ=B<
M6-H?^G:#_P!%K5L'(S7Z2MEZ+\C^$JG\2I_CE_Z4Q:***9 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AZ'Z'^5+2'H?H?Y4
M  Z#Z#^5% Z#Z#^5% $,T$-U;R6US$DT$\9BFBD7<DD;KAD93P58<$5X]9_L
MZ? W3_$1\66/PO\ "-KXC:7SFUB'3(TO6ESN\PR _>!YSCZU\A?\%$/VN_&O
M[+WP^-_X)\&7_B?4[W3Y)T>RAEE:%L.JI^[#8.5ST[\^E?C#^SW_ ,%Q_P!H
M>VTG5H/&O[-?BKQ-)]J:2TG2RU >2I8C&Z((Q!7'RDD#&<9H*2;U1_4_K?A3
MPMKQLVU[1M,U$V)4V1OH4D^SLG*^3OQM*]L=*Z&-$BCCCB4)'&BI&J_=5$4*
MBK[!0 /85_,A=?\ !1_]J;]K;X@_#OPG\/O@EXG^&.DV6L12>(;RXM[^*.>%
MK@;]\D^YL>2%&W<%&"< DD_TM^'Q=+H.B+>DF\&DZ<+LG))N?L</GY/KYN[-
M FFM&:]%%% @HHHH **** "BBB@ HHI,@=2* %HHHH _'7_@NM_RCO\ BY_U
MQ3_TFNJ_"#_@TS_Y!7Q$^NJ?^C7K]W_^"ZW_ "CO^+G_ %Q3_P!)KJOP@_X-
M,_\ D%?$3ZZI_P"C7H+7P/U_R/[::***" HHHH **** "BBB@ HHHH ****
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M*:<KM+3ST/;J*,T9KZ _& HHS10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%)D>HH 6BBB@ HHHH **** "BBB@ HHHSV[^E
M !1110 449STHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0-*OI(T2EQ^#$BOP._9W_P""B'[9_P 2_'^F^'O&/[-EQX:T>ZNUANM2?2C
ML,1<!G$C0J. 2>M?OA8RRS65G-,GES2VMO++'_<DDB1W3_@+$K^% 2Z:)>FW
M]>>S^3+5%%%!(4444 %%%("3U!'^?I0 C,J*6=E51R68A5'U)P!6:VNZ(C%'
MUC2T<'!5M0M%8'T*F8'/MBOG']KWQ[?_  ]^"GBS6M+F>WU%-,O#:2H2&258
M25((Y!W$8_\ K5_+5^S9H?[4?[4GB[Q1J$?Q9U;2S:Z^6M+!M0GB5H%N3\B@
MR@<KP>.GI0-*Z;OMT_KU^9_9FDT,D8FCECDB(W"5'5XR/4.I*D>^<5G#6-&E
MF\A-7TU[@<>0E_:--G/3RA*7S[;:_&?]MW]KK7?V!?V;_!/@G5[TZKX_\6:8
MNCV>H-(99VO)V6%G1\EBXD5ER#D\C/)K\<?%>F?MI?!KX7Z9^V3?>.->OM/U
M?4H=57PX]Q<M$MA*XDQY1<C9L)[=C0"5_+U^7^=S^SH=!CD8XI:^#OV /VL;
M3]JOX+:#XGF"QZ_:Z;;)K$.?G6X551RXZ@@D Y]*^K=4^+'P\T6\?3]3\4Z5
M9WD1*O;S7,:R*0<$%2V<B@1^7/\ P76_Y1W_ !<_ZXI_Z375?A#_ ,&F@QI?
MQ$^NJ_\ HZ0?TK]H_P#@N#\3_A]K7_!/?XKV.G^)-.O;VZA3[)#!=1,SE;>Z
M#_*&R>64#'3G-?BW_P &F:LNE?$0,#_S%3T[&:0@^V<T%KX'Z_Y']M-%%%!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'/5WMXF8_4E2:!J5GHEKW7EVVWN?YE?[8/[)W_!2_P "? _5O$?QD\3ZY>^
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MI=+._>ZC_G^:L?TV%P#CFCDX(/''%.HH("BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ;EV'R?B;/LJPJ:PV7YKC,)04FY-4J%:=.%V]6[+=A11174?/!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%%  3@$^E9^I0F\TO4;5>&N;&\
MMU^LUO)&/U:M"B@#\4_@7^P#XA^'_P"TCXD^*NH3&>QU759;U(Y5WJ%:X,@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 4444 %%%% !1110 4444 %%%% !1110 4AZ'Z'^5+2'H?H?Y4  Z#Z#^5%
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M=5^$'_!IG_R"OB)]=4_]&O06O@?K_D?VTT444$!1110 4444 %%%% !1110
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MW/ZD2,\&EHHK]./X)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYEQ%_P EMPUZ5_\ TFF?WGX+_P#*)GCG_P!AN6?^G)']25%%%?II_!@4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML,BRQ. R2(0RL",@@C@U^EQJ0G?DG&=M^62E;ULV?PC7PF+PO+]9PN(P_/\
M![>A5H\UM^7VD8\WRN244ASQC\:.<GT["J.<6BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ,,AACU__55JOOD[I-:IZI]T?QNTXMQDFI1;335FFG9IKHT]&@HHHH$%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1103CK0 4ASCCK_ )]:4'/2
MDR,X[T *,X&>O>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$_FO_@B?E_=\_P 5\S_B2W#?]'H\.O\ P[4?+S]?ZW_KY_X27P__ -!C3_\
MP)C_ ,:/^$E\/_\ 08T__P "8_\ &OY!O._X*2?\\=;_ .^;BCSO^"DG_/'6
M_P#OFXH_XB#/_HG\U_\ !$_+^[Y_BOF?\26X;_H]'AU_X=J/EY^O];_U\_\
M"2^'_P#H,:?_ .!,?^-'_"2^'_\ H,:?_P"!,?\ C7\@WG?\%)/^>.M_]\W%
M'G?\%)/^>.M_]\W%'_$09_\ 1/YK_P"")^7]WS_%?,_XDMPW_1Z/#K_P[4?+
MS]?ZW_KY_P"$E\/_ /08T_\ \"8_\:/^$E\/_P#08T__ ,"8_P#&OY!O._X*
M2?\ /'6_^^;BCSO^"DG_ #QUO_OFXH_XB#/_ *)_-?\ P1/R_N^?XKYG_$EN
M&_Z/1X=?^':CY>?K_6_]?/\ PDOA_P#Z#&G_ /@3'_C1_P )+X?_ .@QI_\
MX$Q_XU_(-YW_  4D_P">.M_]\W%'G?\ !23_ )XZW_WS<4?\1!G_ -$_FO\
MX(GY?W?/\5\S_B2W#?\ 1Z/#K_P[4?+S]?ZW_KY_X27P_P#]!C3_ /P)C_QH
M_P"$E\/_ /08T_\ \"8_\:_D&\[_ (*2?\\=;_[YN*/._P""DG_/'6_^^;BC
M_B(,_P#HG\U_\$3\O[OG^*^9_P 26X;_ */1X=?^':CY>?K_ %O_ %\_\)+X
M?_Z#&G_^!,?^-'_"2^'_ /H,:?\ ^!,?^-?R#>=_P4D_YXZW_P!\W%'G?\%)
M/^>.M_\ ?-Q1_P 1!G_T3^:_^")^7]WS_%?,_P")+<-_T>CPZ_\ #M1\O/U_
MK?\ KY_X27P__P!!C3__  )C_P :/^$E\/\ _08T_P#\"8_\:_D&\[_@I)_S
MQUO_ +YN*/._X*2?\\=;_P"^;BC_ (B#/_HG\U_\$3\O[OG^*^9_Q);AO^CT
M>'7_ (=J/EY^O];_ -?/_"2^'_\ H,:?_P"!,?\ C1_PDOA__H,:?_X$Q_XU
M_(-YW_!23_GCK?\ WS<4>=_P4D_YXZW_ -\W%'_$09_]$_FO_@B?E_=\_P 5
M\S_B2W#?]'H\.O\ P[4?+S]?ZW_KY_X27P__ -!C3_\ P)C_ ,:/^$E\/_\
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M#?\ 1Z/#K_P[4?+S]?ZW_KY_X27P_P#]!C3_ /P)C_QH_P"$E\/_ /08T_\
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M -?/_"2^'_\ H,:?_P"!,?\ C1_PDOA__H,:?_X$Q_XU_(-YW_!23_GCK?\
MWS<4>=_P4D_YXZW_ -\W%'_$09_]$_FO_@B?E_=\_P 5\S_B2W#?]'H\.O\
MP[4?+S]?ZW_KY_X27P__ -!C3_\ P)C_ ,:/^$E\/_\ 08T__P "8_\ &OY!
MO._X*2?\\=;_ .^;BCSO^"DG_/'6_P#OFXH_XB#/_HG\U_\ !$_+^[Y_BOF?
M\26X;_H]'AU_X=J/EY^O];_U\_\ "2^'_P#H,:?_ .!,?^-(?$OA['.L:?C_
M *^8_P#XJOY!_._X*2?\\=;_ .^;BI(Q_P %)[@E$BUO*J7/RS]$Y(_$"C_B
M(%1[</9JWV5"7E_=\_Q7S3^A=A4KOQH\.DEN_P"UZ/EY^O\ 6_\ 7O%XAT*5
MECBU:Q=F.%5+B-B3GL,Y/-; VMAA@Y'!!R"#Z=N]?Q5_"W]L?]IWPI^T!X4^
M&_C^]U&.[DUFWM;R&>20$(9U1\J6]R.>*_LV\)W,EYX8\/7<QW2W6C:=<2'U
M>:TBD;]6-?0<-<3T.(UC'1P]7#O!U(TJL*JM-3DF[-=&K:KIL?C'CQ]'[.?
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MT]?K7;0SPW$:36\L<T3@,DD;!T92,@AE)'2@"6BF/)'$I>5TC0=6=@BCZLQ
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M\/IZT?UZ@*?7%9EQHVDWDGG7.G6L\IZO+"K/^9'^>M:1.,#UI:32>Z3]5?\
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M $";'_OPG^%'_".:%_T";'_OPG^%;5%')'^6/_@*_P @^MXK_H)Q'_@ZI_\
M)>2^XQ?^$<T+_H$V/_?A/\*/^$<T+_H$V/\ WX3_  K:HHY(_P L?_ 5_D'U
MO%?]!.(_\'5/_DO)?<8O_".:%_T";'_OPG^%'_".:%_T";'_ +\)_A6U11R1
M_EC_ . K_(/K>*_Z"<1_X.J?_)>2^XQ?^$<T+_H$V/\ WX3_  H_X1S0O^@3
M8_\ ?A/\*VJ*.2/\L?\ P%?Y!];Q7_03B/\ P=4_^2\E]QB_\(YH7_0)L?\
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M_#E4\O\ IYY?AZ'\_O\ P^D^/W_1.=1_\ ;C_P"-T?\ #Z3X_?\ 1.=1_P#
M&X_^-U_0%_PQK\ _^A+L/_ >W_\ C-'_  QK\ _^A+L/_ >W_P#C-'^K?&O_
M $53_P#!*\O+R0?\1S^BA_TCT_\ PY5/+_IYY?AZ'\_O_#Z3X_?]$YU'_P
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MW_1.=1_\ ;C_ .-U_0%_PQK\ _\ H2[#_P ![?\ ^,T?\,:_ /\ Z$NP_P#
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MMPE'NT_PU/ZZJ*_(H_\ !8[]F0'']H)_X&)_\12?\/C_ -F3_G_7_P #$_\
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M@K+17WWTVT6FENOW???WW]J/]OKQKX4^.'@[X=> [.6^7QAH]I<A(-[^2]Y
MC ?+TVE^,U\@^+OVZ?VB/@9\6M)^%.N66HW=S\4)TBL'D68M9_:B @3(RN/,
M&/PJ7Q1X;UK0?VX_@M%J6GR7(?0M$9VFC\P0GR(,HV0<%??T]Z[#_@H!;7,O
M[='[-\EOHR/ E_I9=X[<!$^>$$L0I _'UH&U=QTTLON;_P""=K^SW^VC\7?A
M[^T=J_PT^*$5W)HHLFU$3W7F;$BE3S.LG  #'&.GM6W\</VZ/%WQK^*47PY^
M%=W+8Z7INXWM_:.P"FW!,FYT(ZG).3W'I7F'[2]C?:A^UCJEI9Z44DO/"<5O
M%);0[&,KV:J &5<YRWKGVKXC_9^^'OCCP3\=]<T/7;[_ (1H>(+V<0:AK#^2
MHAN'8?+)-@8*GCGM^% 6O?1;*W;6UW\OP\S]IO\ @GE^WI=_&WXJ^-/V=M8#
M7>K?#Z"[,FIR EY39HQ<>8>6!V=,D GC%?37_!1K]I;5/V6O@%<_$71XFFOC
MJ<=C$B@DEG"8QCOEJ^?_ -@[]D'P1\%?B[XS^(^D:W8Z[XA\2V]P^H7ME+',
MK&YC._YT)XP3_C6+_P %P(;F?]DBW2UMGNI/^$MLCY:*6.,P\X -!*7O):/5
M>:/A'QG^V?\ M(Z=\+O"'[1D-CJ*:));0WLEH%F$<ZMM;& ,$$'N/SZ5S_C?
M]OO]H'3_  I\._VB5LK^'0/$^LV6FW.G@2^4BR2)&[%<8'&3T_PKZ5^(\$O_
M  Z^\ VXT>'[2OA^TW1"W'F9,,?WOESGOS_2OF[XN6MT_P#P3N^$$*:.IN%\
M2V1:-;<>8H\]1G[N1P<B@J*UM;7L[;7CT^?4^W_CY^TUX:US3OA7K^M>&X=4
MU#7=-TZ\F=XPS0M)&C'JI(VYZGMUSC%<1^U#^W_XC\+^#/ GP]^"^DO/JWB+
M[+8W"V:,TECYI"-GRP2NW(Z]\^]?,_Q3MK]="^$2BPF?.AZ?&!M)V.T*J!C!
MQC(QTQCK7FTL=]\$?BW\._%/C;39'T+7-3L_*NK^,M:VB2RIALR#:@'X?4T#
MLK)]DVUW=E]W0_6;X%^,?BS\%_"]UXT^+-Y>3:=<Z-_:?^FM(5BGD@$PA_>$
MCG=C'O7YY>)OV]OBG\2KOXD?%?2;NZTKP]\-;N=[*RB9UCU"&UE. J+@,"%]
M#D8K]9/VN]?\.?%O]G.X\/\ P^UK3=9U2^T6#4(HM'GCFFAACT\9CVPDM&<D
MH4[;1VP:_ ?]C;X37_Q%L/B7\/?&'B"P\)V5K<7,%]::K+';2W@$K@_+*4+[
ML8&<GGK0**5KOO\ Y?+O\GY'[&^#?B)X5_X*$?L,^(/B#XLTF,ZMX6T76KR&
M.6/:\%]I6FR7,<X# $-(UN3NZDBO(O\ @AW\<_$?Q9\"?&+0-;O);FU\ ^)Q
MHNEI(S.(+:*YNX0B%N@VHO XX^E?3OPX^&O@/]F']C/XDZ19ZK9)I^L^&=;B
MM91+&L5S<W&G75O&L.#M;>TQQ@\\"OB/_@@3\/\ 7?!WA/\ :$U+5;.>WMO$
M?C9KZPDE1@D\+W=Y(K1,1AE*L#P: OI.R[?F?T1#H/H/Y44*?E'T_EQ100 Z
M#Z#^5+2#H/H/Y4M !1110 4444 %%%% !1110 4444 %%%%  >>/6F;![_Y_
M"GT4 ?CK_P %UO\ E'?\7/\ KBG_ *375?A!_P &F?\ R"OB)]=4_P#1KU^[
M_P#P76_Y1W_%S_KBG_I-=5^$'_!IG_R"OB)]=4_]&O06O@?K_D?VTT444$!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\#?^'"?P(_Z&K4/^_4G^-'_#A/X$?]#5J'_?J3_&OWRHI_ZC\*?]";"_=/\
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M?^DUU7X0?\&F?_(*^(GUU3_T:]?N_P#\%UO^4=_Q<_ZXI_Z375?A!_P:9_\
M(*^(GUU3_P!&O06O@?K_ )']M-%%%! 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3_TFNJ_"#_@TS_Y!7Q$^NJ?^C7H+7P/U_P C^VFBBB@@**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "D/0_0_RI:0]#]#_*@ '0?0?RHH'0?0?RHH !T'
MT'\J6D'0?0?RI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\=?^"ZW
M_*._XN?]<4_])KJOP@_X-,_^05\1/KJG_HUZ_=__ (+K?\H[_BY_UQ3_ -)K
MJOP@_P"#3/\ Y!7Q$^NJ?^C7H+7P/U_R/[::***" HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *0]#]#_*EI#T/T/\J  =!]!_*B@=!]!_*B@ '0?0?R
MI:0=!]!_*EH **** "BBB@ HHHH **** "BBB@ HHHH **** /QU_P""ZW_*
M._XN?]<4_P#2:ZK\(/\ @TS_ .05\1/KJG_HUZ_=_P#X+K?\H[_BY_UQ3_TF
MNJ_"#_@TS_Y!7Q$^NJ?^C7H+7P/U_P C^VFBBB@@**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "D/0_0_RI:0]#]#_*@ '0?0?RHH'0?0?RHH !T'T'\J
M6D'0?0?RI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\=?^"ZW_*._
MXN?]<4_])KJOP@_X-,_^05\1/KJG_HUZ_=__ (+K?\H[_BY_UQ3_ -)KJOP@
M_P"#3/\ Y!7Q$^NJ?^C7H+7P/U_R/[::***" HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *0]#]#_*EI#T/T/\J  =!]!_*B@=!]!_*B@ '0?0?RI:0=
M!]!_*EH **** "BBB@ HHHH **** "BBB@ HI <YZ\4OX?Y_"@ HHHH _'7_
M (+K?\H[_BY_UQ3_ -)KJOP@_P"#3/\ Y!7Q$^NJ?^C7K]W_ /@NM_RCO^+G
M_7%/_2:ZK\(/^#3/_D%?$3ZZI_Z->@M? _7_ "/[::***" HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0G
M S2@YYH **0G')I0<\T %%%% !1110 4444 %%%% !129Y([BEH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHI <\B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BD!SR*
M6@ HHHH **** "BBB@ HHHH **** "BBB@ HI"V.N:6@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/0_
M0_RI:0]#]#_*@ '0?0?RHH'0?0?RHH !T'T'\J6D'0?0?RI: "BBB@ HHHH
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M$JU;_P  KC_XFB_K]S_K^O)A[.7;\>]O_DD?VH45_%?_ ,12.H?]$JU;_P
MKC_XFE_XBD=0_P"B4ZOG_KRN/Y;/ZT?ULQ>SEVW_ %M_FC^T^BOXL/\ B*0U
M'_HE6K?^ =Q_\34$W_!TX]DAFU'X9:G9P+DO++:3*JJ.I)8 ?Y- >SG_ "O^
MOS^1_:K^6/3'^?Y4M?Q0VO\ P=7:9JA(T;P%>ZDR\.(;>5RI[@[5/3WQ5[_B
M*1U'O\*=6![C[%<?_$4![.?;M^-O\S^U"BOXK_\ B*1U#_HE.K?^ 5Q_\11_
MQ%(ZA_T2K5O_  "N/_B:/ZV?]?UZC]G+M^/>W_R2/[4**_BO_P"(I'4/^B5:
MM_X!7'_Q-'_$4CJ'_1*M6_\  *X_^)HOZ_<_Z_KR8>SEV_'O;_Y)']J%%?Q7
M_P#$4CJ'_1*M6_\  *X_^)H_XBD=0_Z)5JW_ (!7'_Q-%_7[G_7]>3#V<NWX
M][?_ "2/[4**_BO_ .(I'4/^B5:M_P" 5Q_\31_Q%(ZA_P!$JU;_ , KC_XF
MB_K]S_K^O)A[.7;\>]O_ ))']J%%?Q7_ /$4CJ'_ $2K5O\ P"N/_B:/^(I'
M4/\ HE6K?^ 5Q_\ $T7]?N?]?UY,/9R[?CWM_P#)(_M0]\<T5_%?_P 12.H?
M]$JU;_P"N/\ XFC_ (BD=2P<?"C5SCDXLKC@>OW:/ZV8>RF^GX^G^?YG]J%'
M/?\ E_\ 7-?Q.S_\'6FB6+B#4_ ]W97;D!+>6"179B<!0&&<D]L5?3_@Z6NI
MU$EO\+M5FA;E)%L[AE93R""%Q@@C\Z ]E/3W7KU^[\KG]J=%?Q7_ /$4CJ'_
M $2K5O\ P"N/_B:/^(I'4/\ HE6K?^ 5Q_\ $T7]?N?]?UY,/9R[?CWM_P#)
M(_M0HK^*_P#XBD=0_P"B5:M_X!7'_P 31_Q%(ZA_T2K5O_ *X_\ B:+^OW/^
MOZ\F'LY=OQ[V_P#DD?VH45_%?_Q%(ZA_T2K5O_ *X_\ B:/^(I'4/^B5:M_X
M!7'_ ,31?U^Y_P!?UY,/9R[?CWM_\DC^U"BOXK_^(I'4/^B5:M_X!7'_ ,31
M_P 12.H?]$JU;_P"N/\ XFB_K]S_ *_KR8>SEV_'O;_Y)']J%%?Q7_\ $4CJ
M'_1*M6_\ KC_ .)H_P"(I'4/^B5:M_X!7'_Q-%_7[G_7]>3#V<NWX][?_)(_
MM0HK^*__ (BD=0_Z)5JW_@%<?_$T?\12.H?]$JU;_P  KC_XFB_K]S_K^O)A
M[*;Z?CZ?Y_F?VH45_%7-_P '3%Q:1FXO_A?JEK:KG=<26<ZH .IR5QQ[G\JI
M6?\ P=7Z3J\C1:%X%O=5F3B2*"WDD*'/((0$@CI0+V<^W]:?E?H?VPT5_%?_
M ,12&I#@_"G5P1U!LKC@_P#?-'_$4CJ'_1*M6_\  *X_^)H_K9_U_7J/V<NW
MX][?_)(_M0HK^*__ (BD=0_Z)5JW_@%<?_$T?\12.H?]$JU;_P  KC_XFB_K
M]S_K^O)A[.7;\>]O_DD?VH45_%?_ ,12.H?]$JU;_P  KC_XFC_B*1U#_HE6
MK?\ @%<?_$T7]?N?]?UY,/9R[?CWM_\ )(_M0HK^*_\ XBD=0_Z)5JW_ (!7
M'_Q-'_$4CJ'_ $2K5O\ P"N/_B:+^OW/^OZ\F'LY=OQ[V_\ DD?VH45_%?\
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M'_Q-'_$4CJ'_ $2K5O\ P"N/_B:+^OW/^OZ\F'LY=OQ[V_\ DD?VH45_%?\
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MY>RR2S7$NFVLS,TC,S$N_P V<L:_1^&&*WBC@@C6*&%%CBC0;42- %55 X
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M^M3\H/\ ASE^QW_T)&F?^"JT_P :/^'.7['?_0D:9_X*K3_&OU?HH#FEW?\
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M_P#!5:?XT?\ #G+]CO\ Z$C3/_!5:?XU^K]% ^:7=_U_7]:GY0?\.<OV._\
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MIG_@JM/\:/\ ASE^QW_T)&F?^"JT_P :_5^B@.:7=_U_7]:GY0?\.<OV._\
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M08_"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX%H=7TS[4>EO]NMO.)Z8\OS=V[G[N,GTH NO:VLK!I+:"1AT9X8W8?0LI-3
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MC11109A1110 4444 %%%%  >AI%! Y.>?>EI@))X^[_];\^M 'Y*_P#!0_\
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MU^;/[2Z***#,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^"@7_!-KPG^VD=+\1KJ,>@>.?#\<8T?65!CN(9(?]64G4 IM(!R7&#TK\WO
MO_!#CQ[XB\6^%]3^.7Q:O_%VB>#-6AU#2['4KJ>ZC+6\BO&J1N\AYV*,A=H&
M.>17],]%!2DTK?TC\P?VR?\ @FQX"_:7^%?A_P 'Z%+;>$_$_A73X++2/$%L
MAAG MH42-O-C =6#ID'(&,9Z&OS,\ ?\$,?B#J7C'P9J/Q=^,&H>(] \!WT,
MUG87UY<W,=VEO*KQH(R[AD*H!G!4#OR*_IQHH#F>U_Z_KL<OX-\(:+X&\.:5
MX:T&SALM/TNRM;...% BO]GA6+S& Q\S[2QX[UU%%%!(4444 %%%% !1110
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M$NOAG^T%\%?"'POT9[;PU=^!;>V_L/488S&RW5JB*DB.B@H2Z[LL1VK]5Z*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "D/0_0_P J6D/0_0_RH !T
M'T'\J*!T'T'\J*  =!]!_*EI!T'T'\J6@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ I#T/T/\ *EI#T/T/\J  =!]!_*B@=!]!_*B@ '0?0?RI:0=!]!_*
MEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIC\Y?^#=S]FL6W@SXC_'76-(O+36I_$>H6NCS:C;/#=-(SS/%L,JJQ4!.<'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "D/0_0_RI:0]#]#0 #H/H/Y44#H/H/Y44 &#ZG]/\*,>Y_3_  HH
MH ,>Y_3_  HQ[G]/\*** #'N?T_PHQ[G]/\ "BB@ Q[G]/\ "C'N?T_PHHH
M,>Y_3_"C'N?T_P *** #'N?T_P *,>Y_3_"BB@ Q[G]/\*,>Y_3_  HHH ,>
MY_3_  HQ[G]/\*** #'N?T_PHQ[G]/\ "BB@ Q[G]/\ "C'N?T_PHHH ,>Y_
M3_"C'N?T_P *** #'N?T_P *,>Y_3_"BB@ Q[G]/\*,>Y_3_  HHH ,>Y_3_
M  HQ[G]/\*** #'N?T_PHQ[G]/\ "BB@ Q[G]/\ "C'N?T_PHHH ,>Y_3_"C
M'N?T_P *** #'N?T_P *,>Y_3_"BB@ Q[G]/\*,>Y_3_  HHH ,>Y_3_  HQ
M[G]/\*** #'N?T_PHQ[G]/\ "BB@ Q[G]/\ "C'N?T_PHHH ,>Y_3_"C'N?T
M_P *** #'N?T_P *,>Y_3_"BB@ Q[G]/\*,>Y_3_  HHH ,>Y_3_  HQ[G]/
M\*** #'N?T_PHQ[G]/\ "BB@ Q[G]/\ "C'N?T_PHHH ,>Y_3_"C'N?T_P *
M** #'N?T_P *,>Y_3_"BB@ Q[G]/\*,>Y_3_  HHH ,>Y_3_  HQ[G]/\***
M #'N?T_PHQ[G]/\ "BB@ Q[G]/\ "C'N?T_PHHH ,>Y_3_"C'N?T_P *** #
M'N?T_P *,>Y_3_"BB@ Q[G]/\*,>Y_3_  HHH ,>Y_3_  HQ[G]/\*** #'N
M?T_PHQ[G]/\ "BB@ (/9B/P!_I1CW/Z?X444 &/<_I_A1CW/Z?X444 &/<_I
M_A1CW/Z?X444 &/<_I_A1CW/Z?X444 &/<_I_A1CW/Z?X444 &/<_I_A1CW/
MZ?X444 <IXR\)V7C;0=0\-:L1)I&JP&VU"V>**1;B%CDHPDC<8.!QCJ!6/\
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E110 8]S^G^%&/<_I_A110 8]S^G^%&#ZG]/\*** %HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gu0gjnulhgsv000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /^!\D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&: .KHKC='^).BZIJ"6$\=SI]T_"K=(%5F] <]?KBNBUS5X-!T:YU.Y21XH
M"RQ@;CD@#&?<B@#0HKAM0^*>BV45L8H+JYEFA69HHP,Q*1GYCG&<=A723>(M
M-M?#\.MW<WV>SFB25/,^\=R[@N!U;'84 :M%<"?BKIZJ)WT;5EL3TN3"-O\
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M LQ] *SM$U_3O$5F]UIDQEA20QL2A7#8![CT(JW?_P#(-NO^N+_R-<#\&_\
MD5KW_K];_P! 2@#T:BBN;\0>-M*\/7*6D@FNKY^EM:KO<=^>>/YT =)17':5
M\1M+O]233KRUN],NI,!%NTVJQ/09]?J!6EXD\6V7A>6R6^@N&CNW*B6, JF,
M?>R1Z_H: -^BCJ,BL&Q\666H>*+S0;>&=IK1"TDVT>7D$ C.<YR<=.QH WJ*
MYOQ!XVTKP]<I:2":ZOGZ6UJN]QWYYX_G5+2OB-I=_J2:=>6MWIEU)@(MVFU6
M)Z#/K]0* -SQ+K)\/^'KO5!!YY@52(]VW.6"]<'UJ30=4.M:%9ZD8?)-Q&',
M>[=M_&L;XD?\B!JO^['_ .C%JQX%./ VD$]/LX_F: .BHKB;CXF:=]JEATW3
MM1U)86Q)-;0Y0?0__6KHM U^S\1Z;]NLA*J!S&Z2KM9&&,@_F* -2N+USQ[)
M9:^VAZ/I$NJ7T:YE"/M5.AQP#GKSTQFNDUK5H=#TF;4;B*>6*';N2!0SG) X
M!(]?6O(/#7C.QTSQEKNK7-G>RI>.WE+%$I=%+Y 8%ACC'<]* /7M#U&YU328
MKN\T^73YV+![>7.5P2/0<'KTK1K*D\1:=;Z!%K5W*;6TEC611,,/R,A<#.6]
MAFN4;XM:4/WJZ7JK6HZSB)<?^A?UH ] HK.T77-/\06"WFG3B6(G##HR'T8=
MC65?>.M(TW7+W2[SS8FLX!-),0-ASMPHYR3\P[4 =-17*>&/'ECXHU.:QMK.
MZ@9(C,K3 89 0.QZY(KJZ "BN&O/'EUX?UNXM/$.DRPV)F86U["I963/&1W.
M.N#GVKKM.U2QU:U%SI]U%<0G^*-LX]B.Q]C0!:9E12S,%51DDG  KD[SXE>%
MK.<PG4#,P.&,,;.H_'&#^&:Z6^LXM0L+BRGW>3<1M$^TX.UA@X/XU1LO"^AZ
M?:"UM]*M!%C!W1!BWU)R3^- $NCZ]IFOVQN-,O$N$4X8#(93[J>16C7DO@R"
M*S^+.KVVE?\ (/1) P4Y4<KQ^#9 KUJ@"EJNJV6BZ=)?W\WE6\>-S;23DG
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M#;X@S::NF8UA8=S7GE+R-H.-V<_=('Z5<U_Q39>';G3H;N.9C?2^6C(!A,$
MELD<?,/UH W**X6^^*FB6MRZ6]M>WL$38DN((QL'T)(S^E=3HFMV/B#34O\
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MX?\ $>G^)M/^V:>[%0VUXY!AT/H1_A2Z]XBTWPW8_:M1GV*>$C49>0^BCO\
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MV\7ZKH>FW.DIK&F?;7GF*VY\I7\LY7)^8^Z_E0!U%%,EECAB>65U2-%+,S'
M4#J2:X:Y^*VCI<21V5E?WL<9^>:&(;<>HR<_F!0!WE%9/A_Q%I_B73_MFG2,
M45MKHZX9&]"/\*R=:\?Z7I.H-IT$-SJ-\N=\-FF_8?0GU]AG% '645RV@^/=
M*UR_.GF.XL;\=+>Z3:6^GO['!KJ: "BLW7->T_P[I_VW49C'$6V*%4LS-R<
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MT [GVKCC\5=/51.^C:LMB>ER81M_GC]: .^HJKIVHVFK6,5[8SK/;RC*NO\
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M)MZYP1^1K;KE_!6JZ'JMO?/HFF_84CFVRCRE3><<'Y33[SQSH^G:_=Z3>M)
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MCNS\.Z5_8/B%+BTN;)F52T9;*DDX('((S],8H L?%X%I/#Z(<2-.^WU_@_\
MK4FMY7XX:.7Z&%=OY2#^=0)</\1O'MC=6]M*-#TL[C)(N [ Y_4A>/09]JN_
M$O3;ZTU32_%5A$938$"95'15;<"?]GE@?K0!Z37F/@D$_%/Q2Z'Y 9 <>OFC
M_ UHR_%KP^-+,\0N'NRORVIC(.[T+=,9[YIWPST.[L[*]UC4XF2^U*7S,.,,
M$R3DCMDDG\J .[KS'X,?\@C5/^NZ_P#H-='JWQ#\/Z+J<VGW<L_VB$@.$A)
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MXE\./&.D>&=/OH=1>97FE5T\N/=P!BO9[2ZBOK*"[@8M#/&LL9(QE6&1^AH
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M[0,+[31YJ,GWBG!8?48W#Z'UK/\ C-_R M._Z^3_ .@FO2(P# @(R"HR#]*
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MFMKAHRX52<C&,G[O&1TQBJGQ(\56WB73(4TN":6QMK@%[QD*H7*G"@'GIDT
M=Y\1"6^'FIL>I2,_^1%JWX$_Y$?2/^N _F:J?$/_ ))UJ7_7.+_T8E6_ G_(
MCZ1_UP'\S0!LW_\ R#;K_KB_\C7 _!O_ )%:]_Z_6_\ 0$KOK\$Z=<@#),3?
MR->.?#WQSI/AC1+BTU!;DRR7)E7RHPPQM4>H]#0![77B?@_Q,EKKFKZS<Z1J
M.I7=S+A9;>'?Y2Y.1[9X_ 5Z)X?\>Z-XDU$V-B+D3",R?O8P 0,9Y!/K7':3
M?GX;>*-3L]5@F&EWTGF072(2!C)'UX.#CD$"@"'QQKK>*M(B@M_#6L17<,H>
M.:2V/RCN,CGGC\JZCQCI4^N?#5'GC;[=;V\=T0P^8.J_.#[X+?C3[GXI>&8D
M'V6>XO9F.%B@MV#$_P# @!79$+)'AERK#!5AV]#0!R/ACQ/'+\.8]7G;<]E;
MLDP)Y+1C _$C:?QK.^%&G2#2;W7+KFYU*<MO/=03D_BQ;\A7G^H?;]$N-8\%
M6ZLR7E]$(@3_  YRO_?68_RKW;2["+2M*M;"'_5V\2Q@^N!U_'K0!X]X/\3)
M:ZYJ^LW.D:CJ5W<RX66WAW^4N3D>V>/P%7?'&NMXJTB*"W\-:Q%=PRAXYI+8
M_*.XR.>>/RJ;2;\_#;Q1J=GJL$PTN^D\R"Z1"0,9(^O!P<<@@5TMS\4O#,2#
M[+/<7LS'"Q06[!B?^! "@!/&3SR?"B=[I66X:U@,H8<AMR9S[YJYX2MS=_#>
MQME?89K-HPW]W.1FD^(QS\/M4.",K'P?^NBTGA>\_L[X:6-[Y+S>19F3RX_O
M-C)P* .0\+^(Y/A_')H7B+39X(_.9X[N--RMG'YCCJ,GMBO3]-OK'4K-;S3Y
MHIK>4[@\?<]\^_UYKCYOB3X-U'2I%O)'=70[K26V9F/MT*Y_&H/A+875KH=[
M<2QR16US/OMXW_N@8W?CP/PH ]"KS'P#_P E&\7?]=Y?_1S5Z=7F/@'_ )*-
MXN_Z[R_^CFH /'X_M?Q[X=T"9F^QOMED0<!LL0?T4C\:]*6"%+<6ZQ(L(78(
MPHVA>F,=,5Y]\2-,O[?4=*\4:="T[Z>P$T:C)V@[@?IU!],U;7XL>&C8>>7N
M!/MS]F\H[LXZ9^[^M &3X.C&B_%/7=&M\K9O&9%C7[JG*LOY!R*JWND6FM?&
M^>VO4\R!(TE,9Z.5B7 /MFMCX?:9?WFLZIXMU*!K=[_*P1,.=A(.?IPH'K@F
MJUM_R7B\_P"O8?\ HI* /2@JKC"@8&!@=!2T44 1SP0W4+0W$22Q.,,DBAE(
M]P:\A\6VWA_PU?FX\-:M<6>L;L?9+,^8C'T;GY?H2?\ =KI-3T?Q?XHU2ZMI
M[U=)T1)61!#_ *R= < \'//N0/8UT&@>#M%\-H#96H:XQ@W$OS2'\>WX8H =
MX1O-8OO#T$^N6_D7K$@J4V$KV)7L3Z5SVM>#O%.HSW9A\6RI;S2,R0;60*I/
M"Y4] .*ZW6]1ETG1KF_AM'NW@4-Y$9P6&1GL>@R?PKE[;XK^&)H-\TMS;2 <
MQR0$G/U7(H QO!%\?"GB ^%-4TRWMKJ?!2[@+'SS@XW$]0><8P >,5ZC7E.G
MR3^//B-::Y;6DL.DZ<H5995QO*DD#Z[FZ9X KU:@#BOBK_R(EQ_UVC_]"K#\
M2Z.=1^$FC7L(/VC3[6&92.NPH W]#_P&MSXJ_P#(B7'_ %VC_P#0JV/#,,=S
MX&TJ"50T<NGQHZGN"@!% &8GC)/^%;#Q"S*9Q!M*GO/]W&/][GZ5AZ!H[:;\
M)-7NYP?M6H6DUQ(S=2I0[?TY_P"!5Q5OI.I/XB'@9Y&^R+J)E?UV@<O^*<U[
M-XJC2+P5J\<:A42QE55'0 (<4 8OPJ_Y$2W_ .NTG_H58GPPACUG6-:\178\
MV[:;;&[C)0')./3C ^@Q6W\*O^1$M_\ KM)_Z%7,:5J#_#3Q3J5EJEO-_95Z
M^^"X1,CC)'UX.".Q% ':?$+3+?4O!FH&:-3);1&>)R.4*\G'U (_&LKP[>RW
MWP<F>9F:2.QN8MS=PH<+^F!^%9WBKQW:^(=,?0?#44]]=WH\LLL14*O?KCZ>
M@Y.:Z1-'_L#X97.F%@SPZ=-O8="Q5F;'MDF@#$^$>D647AYM5$(-[-*T;2MR
M0H[#T'\ZJ>.8TLOB5X7O84"332HLC+QN D Y_!B*V/A/_P B/%_UWD_G63\1
M/^1Z\)?]=U_]&I0!T7Q,_P"2>ZI_VR_]&I5WP3_R).C_ /7LM1^/;&;4? ^J
M6]NA>0QJX5>IVNK''X*:YWP-XZT?^Q=(T61Y5U ;;<1B,D$YP#GIC% &?X[T
M^WU7XHZ#8W2EH)H$5U!QD;WXS7H>IZ=:2>'+K3S;QBU^SL@B"@*H XP.V.U<
M-XJ_Y+#X;_ZXK_Z%)7H=_P#\@VZ_ZXO_ "- '#?!Z9Y/"-Q&Q)$5XX7V!5#_
M #)_.L72M1NOAKK6I0:QIT\MA>3;TO85SGDX]CUY&<CWS6I\'FV^$[]@I;%X
MQP.I^1*OP?$_PM=VCI?O+:R8*R6UQ;L_/<?*"/SQ0!T^CZQIFN6IO=,GCF1B
M%<J,,".S \@_6M&O,OAC:F37=<U6RMY+;1YWVVZ,,!OF)&![#^>*]-H \TMO
M^2\7G_7L/_125'\785N+GP[ ^0LD\B-CK@F,5);?\EXO/^O8?^BDH^*W_(2\
M,?\ 7R_\XZ ._LM*L=/TQ-.MK:-+14V>5C((/7/KGOGK7GOPG_T?4?$MBF?)
MAN$V#/3EQ_(#\J].KS'X7?\ (Q^*O^NZ_P#H<E 'IU>8_$3_ )'KPE_UW7_T
M:E>G5Y7\4+F.R\6^&;R;(AAD\QR!GA9%)_2@#U2O*_C%B:YT"VC&9V>7;CJ,
ME /U_E6O/\7/#L:X@BOKB0\!4B Y_$UF:)H^K^,?&$?B?6[-K.QML&UMY,Y.
M.5X/.,_,3CD]/8 T/C!_R)T'_7ZG_H#UTGA31;+1O#=I;6L0 DB625B.9&(!
M)/\ GI7-_&#_ )$Z#_K]3_T!Z[72_P#D$67_ %P3_P!!% &9KNN>'_#DZ7VI
MO#'>.FQ&$>Z5E!Z# SC)/M7G_CWQCIGB'PTUM#INI+(LB213S6X5%.<'G.>A
M(Z5-XBGAT+XN0ZMK<+-ILD2^1)LWA"$QG'J&R?7G-+X]\9V&O^';G3]%CFO(
MU*27%R(V6.)0PQU&22<"@#5UW2VUSX/V3XWW%M90W*'N2J#=^:[JTO#'B>.7
MX<QZO.VY[*W9)@3R6C&!^)&T_C6MX457\&:.K %6L8@01P1L%>,:A]OT2XUC
MP5;JS)>7T0B!/\.<K_WUF/\ *@#T#X4:=(-)O=<NN;G4IRV\]U!.3^+%OR%<
MIX/\3):ZYJ^LW.D:CJ5W<RX66WAW^4N3D>V>/P%>PZ781:5I5K80_P"KMXEC
M!]<#K^/6O,=)OS\-O%&IV>JP3#2[Z3S(+I$) QDCZ\'!QR"!0!#XXUUO%6D1
M06_AK6(KN&4/'-);'Y1W&1SSQ^5=[JCSR?#F]>Z5EN&TAS*&'(;R3G/OFLVY
M^*7AF)!]EGN+V9CA8H+=@Q/_  ( 5TFM6TFH>']1M(@?,N+62-0>.60@?SH
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MS:710>='=A%?'(5E;(_0?E77>&=)LM)\.VEM9P*B/$KOW+L0,DGN:Y?XP?\
M(G0?]?J?^@/7:Z7_ ,@BR_ZX)_Z"* ///AW&MGXY\564 V6Z2G:@Z +(P'Y
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M1\/M+BF4,&C<E6'!5G8_R-<=JEUJ_P 4+NUL["PGLM$B?S)+B<8W'U]"0"<
M9Z\GT[[6;QO"GAE)=/T]KJ*T"1^0A.1&, GH>@H Y+5_AE/:7K:GX3U![&X&
M6$!<@?16[#V.1[U=\#^,]0U'4I] UZ#RM4MP2'VXWXZ@@<9[Y'!'ZOB^+/AF
M2V\UVNXI,9\IH<MGTR#C]:R?!UM=^)/'UYXO>T>VL2I6#S!@N=H08]?E!R?4
MXH UOBVH;P22>JW,9'ZC^M=-X:9G\*Z.[?>:RA)^NP5QWQ@N2/#MC9)S+<78
M(4=2%4_U9:[S3[;[%IMK:#_EA"D?_?( _I0!9KRWX;01W6M>,+>90T4LH1U/
M=2T@(KU*O,?A=_R,?BK_ *[K_P"AR4 .^&MQ+HNN:SX3NF.Z"4RP$]P, _F-
MI_.G6)_X2WXL7%X?GL-$7RX^X,F2 ?\ OK<<_P"R*I?$V&Z\/^(]/\4:<=DD
MBF%VQQO"D#/U4D?\!KI_AKHITGPC#+*I%Q>G[1(3UP?NC\L'\30!@Z9_R775
M/^N'_M..G_%;_D)>&/\ KY?^<=,TS_DNNJ?]</\ VG'3_BM_R$O#'_7R_P#.
M.@#3^*]])9^"F2-ROVFX2%L=Q@L1_P".UT'A73;?2?#.GVUO&JCR$=R!]YR
M23^-9_Q T.;7_"=Q;6REKB)A/$@'WRN<CZD$USWAWXG:3::';V>L?:+:^M(Q
M"Z>43NVC&>.AXY!QS0!VM[';:)H^J7MG;QPN(I+AS&@&YPG4CUXKRWP#XDCT
M33KF=]#U2^O+J8M)=00[PP],_7)/UKT+0M;_ .$RTC4&-C-:V4FZ"%Y>LJE<
M%L?CZFN+\)>(D\!/=^'O$<4UNBS-)!<",LK@X!Z<D'&01GO0!4\6:O<^(=2T
MF]TWP[JUM?6DP/FR6Q!89! R/0C]37L=<@GQ)\/W.H6MEI\EQ>S7$JQCRH&
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MI7H?AWQ%:^)K&6\LX;B.!)3$K3)MWX .1STY_2N,\"_\E(\6_P#79_\ T8:
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M% %3^R]._P"?"U_[\K_A5GRT\KRMB^7C;MQQCTQ3J* &1Q1PQB.*-40=%48
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MS_)C\XC'F;1NQ]:DHH **** "BBB@ JG+I6G3S^=-86LDO\ ?>%2WYD5<HH
M:B+&@1%"J.  , 4ZBB@!DL,4\9CFC21#U5U!'Y&G*JH@1%"JHP !@ 4M% $?
MV>$3F<0Q^<1@R;1NQ]:>RJZ%'4,K#!!&012T4 ,BAB@C$<,:1H.BHH 'X4V>
MW@NHC%<0QS1GJDBAA^1J6B@""VLK6S7;:VT,"^D487^53,H92K %2,$$=:6B
M@!D4,4$?EPQI&@_A10!^E));PRNCR0QN\9RC,H)4^WI4E% !59-/LHKDW,=G
M;I.>LJQ*&_/&:LT4 1M;PO*LKPQM(GW7*@E?H:DHHH CA@AMTV011Q*3G:BA
M1G\*@GTS3[F837%C;2RCH\D*LWYD5;HH 155%"HH55&  , "EHHH C^SP^?Y
M_DQ^<1CS-HW8^M$MO#.5,T,<A0Y7>H.#[5)10 5'';PPL[10QHSG+E5 +'W]
M:DHH *BFMK>Y $\$<H7H)$#8_.I:* (8K.UMSF&VAC/JB ?RJ:BB@".:"*X3
M9-$DB9SM=01^M2    # '0"BB@".>WANHC%<0QRQGJDBA@?P-,2RM(K<V\=K
M"D)ZQK& I_#I4]% "*JH@1%"JHP !@ 5&UK;O.L[01-,O20H"P_&I:* "F2P
MQ3ILFC21#_"Z@BGT4 5;;3;"S??:V5M QZF*)5/Z"K5%% %9M/LGN1<M9V[3
M@Y$IB4L/QQFK-%% #)88IXS'-&DD;=5=00?P-06VFV-FVZULK>!O6*)5/Z"K
M5% !7F.D12>)_BU>:K+$_P!BTM3'"64@$C*K^I=ORKTZB@ J-+>&.1Y(X8UD
M?[[*H!;ZGO4E% #)8HYXS'-&DB'JKJ"#^%.551 B*%51@ #  I:* *L^FV-U
M*LMQ96\TB]'DB5B/Q(J9X(9&C9XHV:,Y0LH.T^WI4E% $<T$5PFR:))$SG:Z
M@C]:D    & .@%%% ",H92K %2,$$=:JP:7I]M(9+>QM8G/5HX54_F!5NB@
MJ-+>&.1Y(X8UD?[[*H!;ZGO4E% $<T$5PFR:))$SG:Z@C]:D    & .@%%%
M$:6\,<CR1PQK(_WV50"WU/>GD @@@$'@@TM% %,:1IBS><NG6@ESG>(%W?GB
MKE%% !7G>IV5QX?^*=CK%O!*]GJB^1<>6A(1C@<XZ#(0_@:]$HH ;)&DL9CD
M171NJL,@U FG6,;;DL[=3ZK$H_I5FB@ HHHH IOI.FR3&9]/M&E/)<PJ6_/%
M7    !@#H!110!YYJ5G<>)?BK:1/!*-.T>,2,[(0KR<-P3UYVC_@)KT.BB@
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MXS5FB@ JF^D:9)+YKZ=:-)_?:!2?SQ5RB@!      !P *8EO#'(\D<,:R/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/Y4 -HIVQO[I_*C8W]T_E0 VBG;&_NG\J-C?W3^5 #:*=L;^Z?RHV-_=/Y4
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M/Y4 -HIVQO[I_*C8W]T_E0 VBG;&_NG\J-C?W3^5 #:*=L;^Z?RHV-_=/Y4
M-HIVQO[I_*C8W]T_E0 VBG;&_NG\J-C?W3^5 #:*=L;^Z?RHV-_=/Y4 -HIV
MQO[I_*C8W]T_E0 VBG;&_NG\J-C?W3^5 #:*=L;^Z?RHV-_=/Y4 -HIVQO[I
M_*C8W]T_E0 VBG;&_NG\J-C?W3^5 #:*=L;^Z?RHV-_=/Y4 -HIVQO[I_*C8
MW]T_E0 VBG;&_NG\J-C?W3^5 #:*=L;^Z?RHV-_=/Y4 -HIVQO[I_*C8W]T_
ME0 VBG;&_NG\J-C?W3^5 #:*=L;^Z?RHV-_=/Y4 -HIVQO[I_*C8W]T_E0 V
MBG;&_NG\J-C?W3^5 #:*""#@C%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *LO^M:F4^7_ %K4R@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B8O\
MDX!?^Q4_]NZ]#KSR+_DX!?\ L5/_ &[KT.@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/U&WO9K[29+
M6;9#!=M)=KN(\R+R95"^_P [1G'^SGM6A69JEH+G4-%E-TD)M;UI1&QYGS;S
M)L'/7Y]W?A#]: -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH JR_P"M:F4^7_6M3* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** .)B_Y. 7_ +%3_P!NZ]#KSR+_ ). 7_L5/_;NO0Z "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "LO58;.74=#>ZN&BFBO6>U0#_6R?9YE*GC^XTC=ONUJ5EZJUBNHZ&+M)
M&G:]8697HLOV>8DMST\L2#OR10!J4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %67_6M3*?+
M_K6IE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '$Q?\ )P"_]BI_[=UZ'7GD7_)P"_\ 8J?^W=>A
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %9>JW5O;ZCH<4UJLTEQ>M% Y_Y8N+>9RX_X"K+_P #K4K.
MU*[GM[_1XH;<2QW-VT4SE2?*002ONXZ?,BKD_P!['>@#1HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** *LO\ K6IE/E_UK4R@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $)"@DD  9)/:N
M&N_C#X&M+F2!]9\QXV*L8H)'7(]&"X/X5U'B"%;GPYJ<#7*VRR6LB&=FVB/*
MD;B>V*\\^'WC+P18^#[.PGN]-L+NU7R;B-ROSR+P7#=&#=<CUH [7PSXUT'Q
M?]I_L6[:<VVWS0T+IC=G'W@,]#705DZ)KVA:UYW]BWUI=>5CS?L[ [<YQG'T
M-:U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <3%_R< O_ &*G
M_MW7H=>>1?\ )P"_]BI_[=UZ'0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5GZB^H+?:2+-<P-=L+TX'
M$7DRD=?^F@BZ<\^F:T*S]1M[V:^TF2UFV0P7;27:[B/,B\F50OO\[1G'^SGM
M0!H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% %67_6M3*?+_ *UJ90 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K,U2T%SJ&BRFZ2$VMZTHC8\SYMYDV#GK\^[OPA^M:=9>JPV<NHZ&
M]U<-%-%>L]J@'^MD^SS*5/']QI&[?=H U**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K+_K
M6IE/E_UK4R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5GZC;W
MLU]I,EK-LA@NVDNUW$>9%Y,JA??YVC./]G/:M"LS5+07.H:+*;I(3:WK2B-C
MS/FWF38.>OS[N_"'ZT :=%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5E_UK4RGR_P"M:F4
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M/H,G\* .+\::O<>)/!7P^TF:0_\ %07%N+M@3E@-@;\-SY_ 5Z+XK\,Z9?>
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M3/\ ]A7H%% '/^&/$_\ PD?VK_0_L_D;/^6N_=NS[#'2N@HHH \__P"%F_\
M4(_\F?\ ["C_ (6;_P!0C_R9_P#L*] HH *Y_P 3^)_^$<^R_P"A_://W_\
M+79MVX]CGK7044 >?_\ "S?^H1_Y,_\ V%=!X8\3_P#"1_:O]#^S^1L_Y:[]
MV[/L,=*Z"B@ KS__ (6;_P!0C_R9_P#L*] HH \__P"%F_\ 4(_\F?\ ["O0
M*** .?\ $_B?_A'/LO\ H?VCS]__ "UV;=N/8YZUS_\ PLW_ *A'_DS_ /85
MZ!10!S_ACQ/_ ,)']J_T/[/Y&S_EKOW;L^PQTKH*** //_\ A9O_ %"/_)G_
M .PH_P"%F_\ 4(_\F?\ ["O0** "N?\ $_B?_A'/LO\ H?VCS]__ "UV;=N/
M8YZUT%% 'G__  LW_J$?^3/_ -A70>&/$_\ PD?VK_0_L_D;/^6N_=NS[#'2
MN@HH *\__P"%F_\ 4(_\F?\ ["O0** //_\ A9O_ %"/_)G_ .PKT"BB@#G_
M !/XG_X1S[+_ *']H\_?_P M=FW;CV.>M<__ ,+-_P"H1_Y,_P#V%>@44 <_
MX8\3_P#"1_:O]#^S^1L_Y:[]V[/L,=*Z"BB@#S__ (6;_P!0C_R9_P#L*/\
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M3/\ ]A7H%% '/^&/$_\ PD?VK_0_L_D;/^6N_=NS[#'2N@HHH \__P"%F_\
M4(_\F?\ ["C_ (6;_P!0C_R9_P#L*] HH *Y_P 3^)_^$<^R_P"A_://W_\
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MS^1L_P"6N_=NS[#'2N@HHH \_P#^%F_]0C_R9_\ L*/^%F_]0C_R9_\ L*]
MHH *Y_Q/XG_X1S[+_H?VCS]__+79MVX]CGK7044 >?\ _"S?^H1_Y,__ &%=
M!X8\3_\ "1_:O]#^S^1L_P"6N_=NS[#'2N@HH *\_P#^%F_]0C_R9_\ L*]
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MO]#^S^1L_P"6N_=NS[#'2N@HHH \_P#^%F_]0C_R9_\ L*/^%F_]0C_R9_\
ML*] HH *Y_Q/XG_X1S[+_H?VCS]__+79MVX]CGK7044 >?\ _"S?^H1_Y,__
M &%=!X8\3_\ "1_:O]#^S^1L_P"6N_=NS[#'2N@HH *\_P#^%F_]0C_R9_\
ML*] HH \_P#^%F_]0C_R9_\ L*] HHH Y_Q/XG_X1S[+_H?VCS]__+79MVX]
MCGK7/_\ "S?^H1_Y,_\ V%>@44 <_P"&/$__  D?VK_0_L_D;/\ EKOW;L^P
MQTKH*** //\ _A9O_4(_\F?_ +"C_A9O_4(_\F?_ +"O0** "N?\3^)_^$<^
MR_Z']H\_?_RUV;=N/8YZUT%% &+I.I_VSID-_P"3Y/F[ODW;L8)'7 ]*NT^7
M_6M3* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *LO^M:F4^7_6M3*
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M1110 4444 %%%% !1110!Q,7_)P"_P#8J?\ MW7H=>>1?\G +_V*G_MW7H=
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M HHHH **** "BBB@ HHHH **** *&L:9_:VGFU\[RLL&W;=W3VR*YW_A _\
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MB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK>ZGY?VR;S/+SM^11C.,]!["N/'YO0Q&'E2@G=VWMW3[G1A,OJT:RJ2:LO\
M+T/2](_Y MC_ ->\?_H(JY7F4/B75X(8X8KO;'&H51Y:' ' [4__ (2K6O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN4_E^:.W+O\ >8_/\F<;1117PY].%%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<**** "BBB@ HHHH **** "BBB@ HHHH *]*\*_\BU:?\#_]#:O-:]*\*_\
M(M6G_ __ $-J]S(/]YE_A?YH\S-OX*]?T9LT445]>?/!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %9VI7<]O?Z/%#;B6.YNVBF<J3Y2""5]W'3
MYD5<G^]CO6C6?J+Z@M]I(LUS UVPO3@<1>3*1U_Z:"+ISSZ9H T**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@#B8O^3@%_P"Q4_\ ;NO0Z\\B_P"3@%_[%3_V[KT.@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%8WBK_D6KO\ X!_Z&M;-8WBK_D6KO_@'_H:US8W_ ':I_A?Y&^&_C0]5^9YK
M1117YZ?6A1110 4444 %%%% !1110 4444 %%%% !72^"/\ D-3?]>[?^A+7
M-5TO@C_D-3?]>[?^A+7=EO\ O=/U.;&_[O/T.^HHHK[T^4"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K+_K6IE/E_UK4R@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M )%M.?,P3QNW<>N* +WASXD>!(+;2_#^FZU+,T:16EN)+:7<^ %7)V 9/'/
MKT&O+/%FMZ)/XP\*GPY=VMSK?V]8I/L;*_\ HQ'[P/MXQT(S]:]3H **** "
MBBB@ HHHH **** "BBB@ HHHH XF+_DX!?\ L5/_ &[KT.O/(O\ DX!?^Q4_
M]NZ]#H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[QY_P P_P#[:?\
MLM=C7'>//^8?_P!M/_9:\S./]RG\OS1VY=_O,?G^3.-HHHKX<^G"BBB@ HHH
MH **** "BBB@ HHHH **** "O2O"O_(M6G_ _P#T-J\UKTKPK_R+5I_P/_T-
MJ]S(/]YE_A?YH\S-OX*]?T9LT445]>?/!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %9>JPV<NHZ&]U<-%-%>L]J@'^MD^SS*5/']QI&[?=K4K+
MU5K%=1T,7:2-.UZPLRO19?L\Q);GIY8D'?DB@#4HHHH **** "BBB@ HHHH
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MKHR.H96&"I&010!Y3_PNC_J ?^3G_P!A1_PNC_J ?^3G_P!A7H/_  B_A_\
MZ 6F?^ D?^%'_"+^'_\ H!:9_P" D?\ A6EX=B+2[GGW_"Z/^H!_Y.?_ &%'
M_"Z/^H!_Y.?_ &%;GQ!T'1[+P/J-Q:Z38P3)Y6V2*V167,B@X(&>AK,^%>C:
M7J/A>YFOM-L[F5;UE#SP*Y V(<9(Z<G\ZKW.6]A>]>URM_PNC_J ?^3G_P!A
M1_PNC_J ?^3G_P!A7H/_  B_A_\ Z 6F?^ D?^%'_"+^'_\ H!:9_P" D?\
MA4WAV':7<FT/5/[:T2TU+R?)^T1[_+W;MOMG S^5:%1P00VL"06\4<,*#"QQ
MJ%51[ =*DK,L**** "BBB@ HHHH **** "N.\>?\P_\ [:?^RUV-<=X\_P"8
M?_VT_P#9:\S./]RG\OS1VY=_O,?G^3.-HHHKX<^G"BBB@ HHHH **** "BBB
M@ HHHH **** "O2O"O\ R+5I_P #_P#0VKS6O2O"O_(M6G_ _P#T-J]S(/\
M>9?X7^:/,S;^"O7]&;-%%%?7GSP4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !67JMU;V^HZ'%-:K-)<7K10.?\ EBXMYG+C_@*LO_ ZU*SM2NY[
M>_T>*&W$L=S=M%,Y4GRD$$K[N.GS(JY/]['>@#1HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **\U\:_#W5O$GB)]0L[BR2%HE0+,
M[ALCZ*:YW_A3_B#_ )_-,_[^R?\ Q%6HQMN2Y/L>V45XG_PI_P 0?\_FF?\
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M6N:KI?!'_(:F_P"O=O\ T):[LM_WNGZG-C?]WGZ'?4445]Z?*!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5E_UK4RGR_P"M:F4
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MOAK_ ,D_TO\ [:_^C7K.I!15T5"3;U.KHHHK(T"BBB@ K&\5?\BU=_\  /\
MT-:V:QO%7_(M7?\ P#_T-:YL;_NU3_"_R-\-_&AZK\SS6BBBOST^M"BBB@ H
MHHH **** "BBB@ HHHH **** "NE\$?\AJ;_ *]V_P#0EKFJZ7P1_P AJ;_K
MW;_T):[LM_WNGZG-C?\ =Y^AWU%%%?>GR@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 59?\ 6M3*?+_K6IE !1110 4444 %%%%
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M8DNT+,?0<\GV% &W1110!Q,7_)P"_P#8J?\ MW7H=>>1?\G +_V*G_MW7H=
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MZ"@"Q_;VC_\ 05L?_ A/\:L6M_9WN[[)=P7&S&[RI ^W/3./H:Y?_A7&C_\
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MV8W>5('VYZ9Q]#5BL?0O#=GX?^T?9))W\_;N\U@<;<XQ@#U-;% &?_;VC_\
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MSLMOVN[@M]^=OFR!-V.N,_458K'UWPW9^(/L_P!KDG3R-VWRF SNQG.0?04
M6/[>T?\ Z"MC_P"!"?XU8M;^SO=WV2[@N-F-WE2!]N>F<?0UR_\ PKC1_P#G
MYOO^_B?_ !-;&A>&[/P_]H^R23OY^W=YK XVYQC 'J: -BL_^WM'_P"@K8_^
M!"?XUH5Q_P#PKC1_^?F^_P"_B?\ Q- '0?V]H_\ T%;'_P "$_QK0KC_ /A7
M&C_\_-]_W\3_ .)KL* *]U?V=EM^UW<%OOSM\V0)NQUQGZBJ_P#;VC_]!6Q_
M\"$_QJOKOANS\0?9_M<DZ>1NV^4P&=V,YR#Z"L?_ (5QH_\ S\WW_?Q/_B:
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MO_HUZSJ_"73W.KHHHKG-@HHHH *QO%7_ "+5W_P#_P!#6MFL;Q5_R+5W_P
M_P#0UKFQO^[5/\+_ "-\-_&AZK\SS6BBBOST^M"BBB@ HHHH **** "BBB@
MHHHH **** "NE\$?\AJ;_KW;_P!"6N:KI?!'_(:F_P"O=O\ T):[LM_WNGZG
M-C?]WGZ'?4445]Z?*!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!5E_UK4RGR_P"M:F4 %%%% !1110 4444 %%%% !1110 4444
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M_P!NZ]#KSR+_ ). 7_L5/_;NO0Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KYH\4?\C;K/_7]/_Z,:OI>OFCQ1_R-NL_]?T__ *,:M:6YG4V,FBBB
MMS(**** "BBB@ HHHH **** "BBB@ HHHH *^K:^4J^K:QK=#6GU"BBBL30*
M*** "N.\>?\ ,/\ ^VG_ ++78UQWCS_F'_\ ;3_V6O,SC_<I_+\T=N7?[S'Y
M_DSC:***^'/IPHHHH **** "BBB@ HHHH **** "BBB@ KTKPK_R+5I_P/\
M]#:O-:]*\*_\BU:?\#_]#:O<R#_>9?X7^:/,S;^"O7]&;-%%%?7GSP4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !6?J-O>S7VDR6LVR&"[:2[7<
M1YD7DRJ%]_G:,X_V<]JT*S-4M!<ZAHLINDA-K>M*(V/,^;>9-@YZ_/N[\(?K
M0!IT444 %%%% !1110 4444 %%%% !1110 4444 %>4?&C_F!_\ ;?\ ]IUZ
MO7E'QH_Y@?\ VW_]IU=/XD3/X3RFBBBNDP"BBB@ HHHH **** "BBB@ HHHH
M **** "OH+X:_P#)/]+_ .VO_HUZ^?:^@OAK_P D_P!+_P"VO_HUZSJ_"73W
M.KHHHKG-@HHHH *QO%7_ "+5W_P#_P!#6MFL;Q5_R+5W_P  _P#0UKFQO^[5
M/\+_ "-\-_&AZK\SS6BBBOST^M"BBB@ HHHH **** "BBB@ HHHH **** "N
ME\$?\AJ;_KW;_P!"6N:KI?!'_(:F_P"O=O\ T):[LM_WNGZG-C?]WGZ'?444
M5]Z?*!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5
ME_UK4RGR_P"M:F4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!3U9[R/1[Y].56OEMW-N'Z
M&3:=N?;.*YCPQJFB>*_#UC=ZL-.N-5AC$=XES"@DAF'#J5;E><_A767MM;WE
MC<6MVBO;31M'*K' *$8()^E>-Z9:?"76/$UOHFG^%[J?[0\D<-\!(+9V12S
M.9,G@=AZ4 >S0SP2KB"6-PN!B-@<>G2I:Y3P?I7A32+W5[3PY9"TN()4AO8_
MGSD#*'YB<@AC@CK75T %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!Q,7_)P"_\ 8J?^W=>AUYY%_P G +_V*G_MW7H= !1110 4444 %%%% !11
M10 4444 %%%% !1110 5\T>*/^1MUG_K^G_]&-7TO7S1XH_Y&W6?^OZ?_P!&
M-6M+<SJ;&31116YD%%%% !1110 4444 %%%% !1110 4444 %?5M?*5?5M8U
MNAK3ZA1116)H%%%% !7'>//^8?\ ]M/_ &6NQKCO'G_,/_[:?^RUYF<?[E/Y
M?FCMR[_>8_/\F<;1117PY].%%%% !1110 4444 %%%% !1110 4444 %>E>%
M?^1:M/\ @?\ Z&U>:UZ5X5_Y%JT_X'_Z&U>YD'^\R_PO\T>9FW\%>OZ,V:**
M*^O/G@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LO58;.74=#>
MZN&BFBO6>U0#_6R?9YE*GC^XTC=ONUJ5EZJUBNHZ&+M)&G:]8697HLOV>8DM
MST\L2#OR10!J4444 %%%% !1110 4444 %%%% !1110 4444 %>4?&C_ )@?
M_;?_ -IUZO7E'QH_Y@?_ &W_ /:=73^)$S^$\IHHHKI, HHHH **** "BBB@
M HHHH **** "BBB@ KZ"^&O_ "3_ $O_ +:_^C7KY]KZ"^&O_)/]+_[:_P#H
MUZSJ_"73W.KHHHKG-@HHHH *QO%7_(M7?_ /_0UK9K&\5?\ (M7?_ /_ $-:
MYL;_ +M4_P +_(WPW\:'JOS/-:***_/3ZT**** "BBB@ HHHH **** "BBB@
M HHHH *Z7P1_R&IO^O=O_0EKFJZ7P1_R&IO^O=O_ $):[LM_WNGZG-C?]WGZ
M'?4445]Z?*!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!5E_UK4RGR_ZUJ90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M444 %%%% !1110 4444 <3%_R< O_8J?^W=>AUYY%_R< O\ V*G_ +=UZ'0
M4444 %%%% !1110 4444 %%%% !1110 4444 %?-'BC_ )&W6?\ K^G_ /1C
M5]+U\T>*/^1MUG_K^G_]&-6M+<SJ;&31116YD%%%% !1110 4444 %%%% !1
M110 4444 %?5M?*5?5M8UNAK3ZA1116)H%%%% !7'>//^8?_ -M/_9:[&N.\
M>?\ ,/\ ^VG_ ++7F9Q_N4_E^:.W+O\ >8_/\F<;1117PY].%%%% !1110 4
M444 %%%% !1110 4444 %>E>%?\ D6K3_@?_ *&U>:UZ5X5_Y%JT_P"!_P#H
M;5[F0?[S+_"_S1YF;?P5Z_HS9HHHKZ\^>"BBB@ HHHH **** "BBB@ HHHH
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ME\$?\AJ;_KW;_P!"6N[+?][I^IS8W_=Y^AWU%%%?>GR@4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 59?]:U,I\O^M:F4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRUYF<?[E/Y?FCMR[_>8_/\F<;1117PY].%%%% !1110 4444 %%%% !1110
M4444 %>E>%?^1:M/^!_^AM7FM>E>%?\ D6K3_@?_ *&U>YD'^\R_PO\ -'F9
MM_!7K^C-FBBBOKSYX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK/U%]06^TD6:Y@:[87IP.(O)E(Z_]-!%TYY],UH5GZC;WLU]I,EK-LA@NVDN
MUW$>9%Y,JA??YVC./]G/:@#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *\H^-'_ # _^V__ +3KU>O*/C1_S _^V_\ [3JZ?Q(F?PGE-%%%=)@%%%%
M!1110 4444 %%%% !1110 4444 %?07PU_Y)_I?_ &U_]&O7S[7T%\-?^2?Z
M7_VU_P#1KUG5^$NGN=71117.;!1110 5C>*O^1:N_P#@'_H:ULUC>*O^1:N_
M^ ?^AK7-C?\ =JG^%_D;X;^-#U7YGFM%%%?GI]:%%%% !1110 4444 %%%%
M!1110 4444 %=+X(_P"0U-_U[M_Z$M<U72^"/^0U-_U[M_Z$M=V6_P"]T_4Y
ML;_N\_0[ZBBBOO3Y0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *LO^M:F4^7_6M3* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 4444 %%%% !1110 4444 %%%% !1110 5Y1\:/^8'_VW_\ :=>KUY1\:/\
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M1MUG_K^G_P#1C5K2W,ZFQDT445N9!1110 4444 %%%% !1110 4444 %%%%
M!7U;7RE7U;6-;H:T^H4445B:!1110 5QWCS_ )A__;3_ -EKL:X[QY_S#_\
MMI_[+7F9Q_N4_E^:.W+O]YC\_P F<;1117PY].%%%% !1110 4444 %%%% !
M1110 4444 %>E>%?^1:M/^!_^AM7FM>E>%?^1:M/^!_^AM7N9!_O,O\ "_S1
MYF;?P5Z_HS9HHHKZ\^>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *R]5:Q74=#%VDC3M>L+,KT67[/,26YZ>6)!WY(K4K+U6ZM[?4=#BFM5FDN
M+UHH'/\ RQ<6\SEQ_P !5E_X'0!J4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q,7_ "<
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M_:=>KUY1\:/^8'_VW_\ :=73^)$S^$\IHHHKI, HHHH **** "BBB@ HHHH
M**** "BBB@ KZ"^&O_)/]+_[:_\ HUZ^?:^@OAK_ ,D_TO\ [:_^C7K.K\)=
M/<ZNBBBN<V"BBB@ K&\5?\BU=_\  /\ T-:V:QO%7_(M7?\ P#_T-:YL;_NU
M3_"_R-\-_&AZK\SS6BBBOST^M"BBB@ HHHH **** "BBB@ HHHH **** "NE
M\$?\AJ;_ *]V_P#0EKFJZ7P1_P AJ;_KW;_T):[LM_WNGZG-C?\ =Y^AWU%%
M%?>GR@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5
M9?\ 6M3*?+_K6IE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '$Q?\G +_P!BI_[=UZ'7GD7_ "<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#B8O\ DX!?^Q4_]NZ]#KSR+_DX!?\ L5/_ &[KT.@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *^:/%'_ "-NL_\ 7]/_ .C&KZ7KYH\4?\C;
MK/\ U_3_ /HQJUI;F=38R:***W,@HHHH **** "BBB@ HHHH **** "BBB@
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M5&T$Y"D'\1ZUK_\ "[?AY_T,/_DE<?\ QN@#T"BO/_\ A=OP\_Z&'_R2N/\
MXW1_PNWX>?\ 0P_^25Q_\;H ] HKS_\ X7;\//\ H8?_ "2N/_C='_"[?AY_
MT,/_ ))7'_QN@#T"BO/_ /A=OP\_Z&'_ ,DKC_XW1_PNWX>?]##_ .25Q_\
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M]##_ .25Q_\ &Z/^%V_#S_H8?_)*X_\ C= 'H%%>?_\ "[?AY_T,/_DE<?\
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M^AA_\DKC_P"-T >@45Y__P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\
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M8G_GW+[F'UFC_.OO1T]%<Q_PL/PM_P!!3_R7E_\ B:/^%A^%O^@I_P"2\O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#D?B+X/?QEX;6VM9UM]1M9A<VDK=!(H/!] <_R/:N6U ?%
M3Q/H4F@76BZ;I:W">1=:B;I7WH>&*HI)&1GKV/:O5Z* ,W0-&M_#V@6.D6I)
MAM(5C#$8+$=6/N3D_C6E110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/TS0!]!4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7 ?%+Q&=,T==*MW*W-Z#O(/*Q#K^?3Z9KOZ^?OB)J+
M:AXUOLGY+<BW0>@7K_X\6/XT <M1113 **** "NN\<^(['Q =*^Q>9BVMMDF
M]<88XX_#%<C10 4444 %36BR/>P)$"9&D4(!ZYXJ&I()Y;:XCGA<I+$P='7J
MK Y!H ^IJ*YCP3XMB\4:5E\)?P +<1COZ,/8_I73T@"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,_BY86VJ7?@^
MPO(O-M;C6$BE3<5W*1@C(P1^%>F57N;"RO7@>[M()WMY!)"TL88QN/XER.#[
MB@#"T#X?>%?#%V;O2-&A@N<8$S.\CKV.TN25_"L'4_\ DO.A_P#8'F_]"->A
MU7:PLWOTOWM(&O(T,:7!C!D53U4-C('M0!Y?=ZW+K?CGQ!I.M^,)?#=CIC(M
MM!;SQVSS KDR&1P<CIP/4?C4^&4<-]?>/X=-U&ZOXIFC2&\NGW22Y1P&)P,\
M]#@<8KU/4-"T?5IHYM2TFQO)8AB-[FW20I]"P.*GMM.LK.>:>UL[>":?;YTD
M42JTFT8&X@<X' S0!YE\,?&7A[1/A]!IFK:E::;?Z8TL5U:W$@20,'8\*>6/
M/;//%4/'TD-_XF\&^)I[[4])T2XBDA:]@/DRV[."4+9!VAL]QT!KU2Y\/Z+>
M7ZW]UI%A/>+C;<2VR-(,=,,1GBKL\$-S \,\22Q.,.DBAE8>A!ZT >7IH'A"
M[UO1S<?$+4]7N8KI)[.UEU2*<-(.5.U4SCCKQ]:8GB+3/#WQQU]M5N/LMO<V
MEM"ES(,1*^W(5FZ+D XSQP:]%T_P]HND2-)INCZ?92,,%K:V2,D?50*DGT;2
M[IKEKC3;.5KI52X,D"L9E7H'R/F [9H \[CU.S\5_'#3;G1)DN[72-/D%W=P
MG=&2^0J!AP>N?S]#5?X<:_I7A67Q#X?U^]M],U"/5);C-Y((A-&^-K!F.#T_
M+%>H6&F:?I5O]GTZQMK.$G/EV\*QKGUPH J+4=#TC6-G]J:58WWE_<^U6Z2[
M?IN!Q0!P'A6XC\2?%_6_$FEDRZ/#8+8?:0,)-+N5CM/\0 '7Z>HKTZH[>W@M
M($@MH8X84&$CC4*JCV Z5)0 4444 %%%% !1110 4444 %9.L>)M$\/SVL.K
MZE!9-=[O),YVJVW&?FZ#[PZD5K56O=/LM3MS;W]G;W<)ZQSQ+(I_ C% 'C_B
M?_A';GQ_X9G\#3VCZ[+?!KM]+<,AM^LADV?+]>Y&<]JZOXT?\DKU;ZP_^C5K
ML-.T72M'#C3-,LK$/]\6UNL6[Z[0,U->V-GJ5H]K?VL%U;/C=#/&'1L'(R#P
M>: &Z9_R";/_ *X)_P"@BO%_#WA*;Q%X4U>]TJ;[+X@TW7KJ:PN5P#N^7*$_
MW6_G[9!]Q551%1%"JHP !@ 5!9V%EIZ2)96D%LDDAD=88P@9SU8X')/K0!R?
MAW7XOB'X1G@:YO-)U.)A!?QVK^7/;2J><9!P#@]NF1U!J:+P.UMIVJ6[>(M=
MU+[;9R6WEZC=+(B[AC< %&#[^YKI(-,L+6]N+VWL;:&ZN,>?/'$JO+CIN8#+
M?C5J@#RWX<>-M#TCP'!IFNZG;:;J.E;[>XMKIQ'(-K$C:IY;C'0'FL;3-#NO
M%'PY\=:I#:2J==NI+FRB(.Z2.,[DP/4D$>]>LWOAW1-2NUNK[1M/NKE<;9I[
M5'<8Z8)&:T0 H    X % 'GFA_$_PQ;^ +.]O-6M8[NVM%2:S:0"?S$7:5$?
MWN2.#C%3?"RS;0/AO%=:MLLC</+?3><VP1*QR"Q/0;0#S75OX<T.34?[1?1M
M.:^#;OM+6J&3/KNQG-7KFUM[VVDMKJ"*>WE7;)%*@97'H0>"* /)I_$_A\_'
M:VU$:YIAL5T4Q&Y%W'Y8?>3MW9QGVKUJ">&ZMX[BWE2:&50\<D;!E=3R""."
M#ZUB_P#"#^$O^A6T3_P7Q?\ Q-;4$$-K;QV]O$D,,2A(XXU"JBC@  < #TH
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M0/SKN]1T+1]89&U/2K&]9.$-S;I(5^FX'%78H8H(4AAC2.-!M5$4 */0 =*
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M#QR*'1AW!&0:^6*]\^&E^U]X*M0YRUL[0$^P.1^A H ZZBBBD 4444 %%%%
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M/_ZD;QM_X*?_ +.@#O**X/\ X6?_ -2-XV_\%/\ ]G1_PL__ *D;QM_X*?\
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MG_[.@#O**X/_ (6?_P!2-XV_\%/_ -G1_P +/_ZD;QM_X*?_ +.@#O**X/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'I,9T/3AC^[;(/Y"D7PCX=5@PT2PR/6!3_2@#YQAAEN)5BAC>21SA41223[
M5[_X T.XT#PM';W:[+B61II$_N9P /K@"M^UTZQL1BSLK>WR,?N8E3^0JS2
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\=P?S[5F_"S7I['Q"NE,Q:UO<_+V60#(8?4#!_#TH ]MHHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** $90RE6 *D8((X-8&E^"]!T;4VU
M"QL_+N""%)<L$SUV@],UT%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC867"C!.3GV!KLJ* //[CPWK'AKX@)KGAJU%SI>JMMU>Q$JIL;_GNFX@9YY
MYZ^O%J^USQ_I^H7,,/@ZSU6U\QOL\]OJ208CS\N]9.=V,9QQ7;44 <5X'\+Z
MIINJ:UXAUYK==5UB1&>"W.4@11A5W=SZ]N!7:T44 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ7NK&>XU*[C$KSF5@4+#(P <<9[YJ3PGK5Q:Z%K%OJ,C3RZ,[J7/5D4' _\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 9VL:+::Y#!%>!]L,PF78V/F&?TYK1
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gu0gjnulhgsv000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #5 @P# 2(  A$! Q$!_\0
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M_LZ] HH \_\ ^%I_]2%XY_\ !/\ _9T?\+3_ .I"\<_^"?\ ^SKT"B@#S_\
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MG_U(7CG_ ,$__P!G1_PM/_J0O'/_ ()__LZ] HH \_\ ^%I_]2%XY_\ !/\
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M3U&>[NXEABM[F??;VI,A&Z-,?+Z]\FAM*[?E;Y["6K2]?P/?JYK_ (274_\
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M\9^*M8O)[1[?5YQ) L+L74;F/S J #\PZ$UW=%4G;;S7WZL35T[^7X;'E[^
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MNZ_-KFKF/RHI7MU@6-<8X521G&?3J>*[VBE!<L;>OXBDN:5WY?@<CX&\#_\
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M:,>F>/U!K3T[P;H6FD-'8I+(/^6D_P"\/UYX'X"MZBFH(J&#HQ?,U=]WJ_Q
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M8VI8BE5^"29-1113-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \_P#BG_S)7_8UV/\ [/7H%>?_ !3_ .9*_P"QKL?_ &>O0* /
M/_%O_)7OAU_W$O\ T0M>@5Y_XM_Y*]\.O^XE_P"B%KT"@ HK'OO%GAO3+R2S
MO_$&E6EU'C?#/>QQNN0",J3D9!!_&J__  G?@_\ Z&O0_P#P8P__ !5 '045
MS_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"
M=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\
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M];!^NWC^1KHM/T33-*7%C90PG^\%RQ_X$>?UJ_1:3W8>QQ%3^).WE'_-_P#
M..'@R]U([M?UVYN@>3!"=D8/\OT%;NG>'=(TK!L["&-QTD(W/_WT>:U**:BD
M:4\)1IOF4=>[U?WL**CGGAM;>6XN)8X8(D+R22,%5% R22>  .]8?_"=^#_^
MAKT/_P &,/\ \55'0=!17/\ _"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\
M!C#_ /%4 =!17/\ _"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%4
M =!17/\ _"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%4 =!17/\
M_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%4 =!17/\ _"=^#_\
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MN:=! S!!)-<I&-Q!('S$<X!X]J:DGL:TL31JNT):]NOW;FQ17/\ _"=^#_\
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M[PO_ -"WH_\ X Q?_$UMTC,J(SNP55&22< "CF?<.5=C%_X0[PO_ -"WH_\
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M[4K;P_X2TK2HOMG]FW?G7,GF*F,D,Q&XCC.>!S5VI\R[77W=;D7J<OG9_P#
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MOX_H<M*+3CI^'ZG>4445R'8<_P" /^2G_$#_ +AW_HEJ]*KS7P!_R4_X@?\
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M5QHMW=1F6T9[E)A(O)&[:/E. >,GGBM&O>:7=K[B$_=4GVN>@T445)04444
M%%%% !1110 4444 %%%% 'G_ ,4_^9*_[&NQ_P#9Z] KS_XI_P#,E?\ 8UV/
M_L]>@4 >?^+?^2O?#K_N)?\ HA:] KS_ ,6_\E>^'7_<2_\ 1"UZ!0 4444
M%%%% 'DES&DW[2J12*&1]$*LI'!!W9%>:^)-'O\ PGX\TGPIY;OI8UF.^TY^
M3A'904'T( _#WKZEHHA[LHOM^.M_S_K4F2NI+O\ AI8\6\1W(\%_'5/%.MQ3
MKHEU9>2EXL+.D+8 P=H)ZC_QZD\-[O%GQ<UGQCIEO.NA+IY@2ZDB:,7#[0/E
M! )Z'\A7M5%3R^[;LFE\[_YE/>_I^%O\CP/X?J#^SMXHPO)%WGCK^[%=%\//
M#1\2?"#P]"VMZUI7DF5@^F77D,^7888X.17K5%6W=M][?A<E*R7JW]YX3\8-
M+_X1OP[X5M?MFIZOY6J^9OOIO/GEXSMS@9] ,4SQ#K-O\2OB9X1A\.P73?V7
M+YU]*]NT9M_F4E&R."-A'U/&:]+\<^!_^$T_LC_B8_8_[.NQ=?ZCS/,Q_#]X
M8^O-==2A=/F?1W_!()*]TNJM^+/'_ D$,GQU\<S/%&TL6SRW*@LF<9P>V:S=
M/U>V^''Q=\4WGBD3VUEJF'M+[R'=&&<[05!Y[?\  :]RHI13BHVZ*PVK\U^K
MO]QX)X>T#5/$MK\1M;L;*>VM=;B=-/25"C3\DY /8^O^U6-+XLTY_@1+X1CT
M^[.M6J;;FW^RL! %DWF5V(P!CWSFOI2BDXJW*MK)?=L-74N?K=O[_P#ACY]\
M613VW@+X8ZY]GEDL=-\F6ZDC7=Y:X0Y/M\IJW<>)+3Q3\??"FH:;%<G3Q \<
M-S- T:SX5R2FX D#<!7N]%:<WO\ -YM_>K$\ON<OE8\)\.ZW9_#3XD>+5\5>
M?;+J<_G6=T+=Y%F7<QVC:#_>'XBIOBW??:Y? OBK[+=PZ7!=^;.TT)#PJ70C
M<HR1D*<5[A141O'E[QM^!3U<G_-?\3P[XJZO9Z_=_#W4].=I;2XU$M$[(5+#
M>@S@@'G'>JGQ9N;SP#\0X_%.G1_+JNGRVLN.!Y@7 )]Q\A_X":]\HI.*M9=W
M]S5K#3UN^R_!W/GO7/ >I6_[/^D0V-M-+=K<+J-W%$N78.#V')*@K^52:+:^
M!_$>M:(J>)_&VM:E;SHZ6EP[2+:N""=Y:,!5&.2#T%?0%%7?WW+SO_7W$<ON
MJ/E;[S%\7_\ (EZY_P!>$_\ Z :\4@7/[*,N%_Y:$GC_ *>!7T+14.-TUWM^
M#N:*5G'R=SYZ^(8*_!#P)@$,)+?&.N?*:M3XF:59:Y\7O!6FZE#Y]I<0%)8]
M[+N&3W!!'X&O<:*N3YI\S_F;_"UC/E?+RI]+?C>YXCX4@C^&7Q@N/"XB4:1K
M2"2QE9 75N<)OZD9!&"?0]Z/!.@6OB>[^)VCW@_=7.HLH;'*-N?:P]P<&O;J
M*FUU:6NC7XIK[K%;.Z[I_<G^9\V?#B;5(?C+:V6MQE+K1].ELY'.>40-M;GM
M@C!],5K>"&\:^)?$WB+QKX<CT+RKV<VJ'5C-D1KC 39VQMSGO7OM%-;W>]G^
M+NW\Q<J5TMFU^"T1X=\)9-1\*?$?Q!X.U<6Z2W ^V1I;;O)W=3LW '&UN_\
M=KVR2UMYFW2P1.V,99 34M%.^B3Z!;5ON5_L%G_SZ0?]^Q1]@L_^?2#_ +]B
MK%%(97^P6?\ SZ0?]^Q5+6?#]EJ^AZAIABBA%Y;26YE2($IO4KN'N,YK5HH
MY+PC\-O#/@Q%;3; 27@&&O+C#S'Z'HOT4"NMHHH YKXA_P#).?$7_8/F_P#0
M37BVG:MXBU/X)VOA.Q\):G<37B[+>]BC#V[1>822S9^1N",''K7T!K.E0:YH
MM[I5R\B07<+0R-$0&"L,'&01G\*@\-Z!:^%_#]IHUE)-);6JE4:=@7.23R0
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M?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\
MBJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG
M_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!_
M_0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,
M8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_
M (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\
M]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@Q
MA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .
M@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A
M._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ
M'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\
MXJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3O
MP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H
M?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\
MBJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG
M_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!_
M_0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,
M8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_
M (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\
M]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@Q
MA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .
M@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A
M._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ
M'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\
MXJC_ (3OP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3O
MP?\ ]#7H?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H
M?_@QA_\ BJ .@HKG_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\
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M1_P@G@__ *%30_\ P70__$T44 '_  @G@_\ Z%30_P#P70__ !-'_"">#_\
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M_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-%% !_P ()X/_ .A4T/\
M\%T/_P 31_P@G@__ *%30_\ P70__$T44 '_  @G@_\ Z%30_P#P70__ !-'
M_"">#_\ H5-#_P#!=#_\3110 ?\ "">#_P#H5-#_ /!=#_\ $T?\()X/_P"A
M4T/_ ,%T/_Q-%% !_P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\ P70_
M_$T44 '_  @G@_\ Z%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\3110 ?\
M"">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-%% !_P ()X/_ .A4
MT/\ \%T/_P 31_P@G@__ *%30_\ P70__$T44 '_  @G@_\ Z%30_P#P70__
M !-'_"">#_\ H5-#_P#!=#_\3110 ?\ "">#_P#H5-#_ /!=#_\ $T?\()X/
M_P"A4T/_ ,%T/_Q-%% !_P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\
MP70__$T44 '_  @G@_\ Z%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\3110
M ?\ "">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-%% !_P ()X/_
M .A4T/\ \%T/_P 31_P@G@__ *%30_\ P70__$T44 '_  @G@_\ Z%30_P#P
M70__ !-'_"">#_\ H5-#_P#!=#_\3110!)!X,\*VMQ%<6_AG1H9XG#QR1V$2
/LC Y!!"Y!![UN444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gu0gjnulhgsv000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %1 U(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MKA?$GC#7[+QM!X:T'1[.^FDL?MA:XN3%@!RI'0^U'6P>9W5%<+H?Q.TNZ\,R
MZKKNS2);>]>PFA+F7,R]0FT9;CT'^-&L?%CPSIECI5[!=K=V^HW7D"1,J(@"
M-[,",C;D<8SR*/Z^\/Z^X[JBN3M?'-@B:[=:K=V5K8Z9=" 2K(S$@@$;AC[Q
MST&:M1^._"\FB#6%UFW_ +/,PMS,VX!9#_"P(RI^H% '145QE]\4?#%OX:U/
M6K.^6^CL"%DBC#*Q=ONCY@.OKTIP^*'A&+3K"[N]7A@-Y")E0*[E1G!SA> &
M!&3@<4 =C14 O+9K'[:LR-:F/S1*K94IC.[/ICFN)7QQKM_H&EW^C>&)+V?5
M9I?LX,A2*&!2=KRO@A2P&0/?K1UL'F=[17->#_%J^)_#4FJW%H;&2WEEAN8B
M^]4:,_,0P^\/>L_P[\4/#VO:)J.K/<I96MA,8Y3,W1<X1NG\6#@#)H_X<#M:
M*R-!\4:+XG@EFT;4([I8FVR!059#VRK $?E7/>+/B+;^'O$6EZ';6DEU>75W
M!#.Q5ECMTD. 2V,%CS@>QHZI=PZ-]CN**X+Q=XYUWP]>7[V7A9[K2]-A2:[O
M9Y_)5PW4197#D=^>O%;^L:U?P^#WUO1; 7<XMUN4M925+H0&(X_BQV]1BE=6
MYAVUL;U%<!9?$VVUO5-(MM$BAF@GM#?:E<32;5L8AV;_ &L@C!],]*WM)\=>
M&-<6[;3M9MYA:1F6<G*;$'5_F RON.*;T$M3H:*YG3OB%X4U9+QK+68I!9P&
MXGS&ZE8AU<!@-P]QFH/^%F^#39R7:Z[ T$<BQ%D1VRY&0% 7+''IG'>@#K:*
MY*]\=Z?'8Z/JUA)%>Z/?7@LYKE&(,+-D*2"/[V 0<$9K1\7>)K?PCX<N-7N(
MGG\LJD4*'#2R,<*H/;)[T/0%J[&Y17%:-XB\8?V[:6/B'PO';VMXC,EU8S&9
M;<@9VR\<9Z9Z9_32M/'OA:^US^QK;6K:2_WE!&,X9AU56QM8^P-%@N='17)O
M\3/!D5U]FD\06J2[F0A@P"LN<@G& >#U//:J.N?$W2K;PA-K^B3P:C%!=1VT
MH8M'L+, <@@$8!STH [JBN.N?B+HEQX=U;4=#U&SO)M.0-(DS/&JY( )^7.T
M^H!%6+WXA^&-("QZKJ]O;70BCEDB"NQ =<@C R1[_GB@#J:*Y_5O''AG1+:S
MN-0UB"**\3S+<C<_F)C.X!03M]^E&J^-_#6BP64U_K%O%'>KOMB"7\Q>NX;0
M?E]^E '045S7@7Q0_C#PRFKO!'!OFEC"QON!"L0#GWQ6+X>^*VB:E/-9:K=V
MUAJ OY;2*#<Q#!6PI+8PI;G@D46UM_7]:ATO_7]:'?T5B-XPT!-,NM2;4XA:
M6EP;6>0JWR2Y V$8SG)':D\6^)[;PGX;N-8N(GGV;4BA3AI78X51Z9)I7TN.
MVMC<HKBM&\1>,/[=M+'Q#X7CM[6\1F2ZL9C,MN0,[9>.,],],_II6GCWPM?:
MY_8UMK5M)?[R@C&<,PZJK8VL?8&G85SHZ*X'0/BKHE_<W%EJMU;V%\NHRV4,
M.6;>%;"DG&%+<]2.E;FJ^._"^AZHNF:EK-O;WAQF-LG9GIN(&%S_ +1%"U2?
M<'HVNQT5%<WJGC[PMHNH&PU#6(8;L;?W.UF8[AE3P#QCO3/!'C;3_'.DRWUB
MIC,4K1O"QRRC)VD\8Y S@9Q0M=@>AT]%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4450UR>2VT#4IX7*2Q6LKHP[$*2#2D[
M)L:5W8OT5\\>'?'.LR'PS)8^,KK6-6O;I([[1Y+4,J1DG<=X48P,<Y[^U>BZ
MC\4#I7BF'2;S1&BMIKU;))VO8O-9F. _D?>V9_B__556UM_7]:DWTN>A45XO
M/\0?$4^C>*)[^WN+&.PU9+6&6UEBW1_.J^5T.3@Y+=.>*Z75?BM;Z9J]_"FD
M33Z7IMPEM?7XN$4QNQ .V,_,X&1DBDM;>?\ P/\ ,;TO_7?_ "/0Z*\ZUCXI
M3:=>:[':^&[B]M]$>/[9<+<HBA& (8 C)//0>G6H)_B%JL/Q GMAIKR:##HW
M]HG8R>84(W>9C.3_ '-H[G/2E?\ KY7"W]?@>F45P_@GXA2>,+HQ_P!CBW@:
M'SDGAOH[@#G[L@7F-O8BK?B'6+S_ (3;PYX>LIFA%P9+R[=>IBC'"?1F(S["
MJL[I=Q7T;['6T5YM:^(?%$WQAMM,U&)+'2I+.=[>U20.90C8$CGL3U [#K5&
MYU;Q5HOQ,TFQO=?6>/4;E_,M#;+':Q0<[%60@$R\=!DFDM;>?_##>E_+_ASU
M>BN%^(WBG7/#D_A^+1[$7'V[4$@E^=%+#KY8W="W/S=L5%JGQ+FL[S5%L?#E
MU?V6C;1J=U'.B>2V,L%4\N5'7&.E).ZO_7]:A;6QW]%9TFIO/X>_M32K<WS2
MVPGM8=X3SLKE1D],Y')KSC0?$_BM_#GCRYU&YM5U;39G$"%@(;<B/.T$\$#W
MZFANU[]%<:5[6ZNQZQ17E7PM\4:IK.NWEI<:O=7]FMA#<'[? D,RS,?FV* "
MT?OTZ8-3^,O$^N> ?$DE^XN-2T;5(3%:0!03;W@'RJ.^U_\ 'TIR5OZ_KY"6
MIZ=17F$7C#6/"5K8Z)?V\VO^(Y;5M0O0;F.!($S]U21@XZ #KCWJ]JGQ02VT
M'3=8TW1S=V=Y;-<&6YO([5(P."F6SN?.1M%#T_K^NS!:GH-%>=2_%1IY-%@T
M?PY=ZC<:M8_;(HEF5"@#88,3QQ@\_3UIVF?%'^U?%#Z3;:(S0I>-:/*+V+SD
M9>"Y@^]LR/O4[.]OZTT%?2YZ'17)>$]8O)O$7B;0+^=IY=-NED@E;&3!*N]%
M/^[R,^F*P;F?7?&?CW7-&LM?N=%T_14B3_1$7S)I77=EB1]T=,=ZGM;JKC[W
MZ'I=%<))XDUOPEI&D:5J\2:]XDOIGAMDM&$0F5>=[LP 7 QGBJLOQ7CAL4\S
M0;L:HNIKIEQIPF0M'*P)4AONL#C@\4_3^OZN'K_7]6/1:*\OD^+UU;0WTMWX
M2NHDTR[6VU)A>1L("Q 4KW?KT &..:AN/'6O:3XW\81PZ7<ZQIVGQV\WEK,D
M2VT?E[G(R,L3UQ[&B_\ 7W?YA_7Z'JU%>9M\0X4UO4=3@>\N-/A\.IJ:6I95
M0@M],A^QY(J]I?Q,^TZI!;:IH=QIEO=:>VHVMQ).DGF1*,ME5^Z<<_X4>O\
M5K_Y,/Z_+_-'?45YYHGQ6M]2O;5+_29=.L[Z"6XLKEKA)/-2,;FW*O*':,@'
M-8L_Q$UO6=5\'S6VE7>E:7J>I!8YFF1Q=0X(PRCE#T.._K32U2_K>P=+GKM%
M<'\2-?U30;KPNVEB:1KG5%AEMH2H-PI4_)EN!DXYJ _%+[-87TNHZ#/:7.FW
MT-IJ$!G5Q DOW90P&&7\J2U_KT_S!Z?UZ_Y'H=%8.C^)X]:\1:UI=O;-Y.EM
M'&]UORLDC+DJ!CMWYKC_ #-?\<^,/$5E9^(KK1+#19$MH4M$4M+*1DNY/49'
M2C_AP/3J*X6;Q1K?AFQT71=1M(]=\4WN\+'9R"&-U3DNS, %XQVZYK!\1?$6
M\NM TN\TVWN[+4(/$$5A?V *M(2,[HP>A#<8/%'73^M;!TU_KJ>L45YZ/BG%
M:V&LMJVB7%GJ.F7$5L;%)EE,SR_ZL*PP.>_I[U)_PLJ2S@UJ+6?#\^GZGIEE
M]O-H;A9!-#G&5=1C.>",475K_P!=_P AI-NQWU%>2ZC\2O%,T_AJ2Q\+S6EK
MJ=X%19KB,O=1[ P S]S.<Y/I7K0Z<C%.SL3<****0PHHHH *\W\2^ #XI^*%
MM?ZE9RR:+'I1A:6.Y\H^=YA(7"L&Z'TQ7I%%%M4PZ6/-?%?A.^T?1M%T[P9I
MLL>G073/=Q6,R1W.".&227.#GJ<YZ5S%IX*\5:9X<LF.BS3W5GXG_M,V_P!L
MCDDDA*]=Y;!.>N<'OBNY;XF6/VW5K:*PEF:PG%L ES"6FE,@C50F_<H+'[S
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MUR.IZ8/%-C^%X&GVJ3:RTM^-:36;RZ:W'[^1<_(%##8/3DXKT*BB^M_ZWO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2-_Z_KN>]4444 <5\4/^19L?^PO9?^CEKM:XKXH?\BS8_P#87LO_ $<M=K0
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M<D=C26JN#T=BY\,_^29^'?\ KQC_ )5U=<I\,_\ DF?AW_KQC_E75T %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME_*_P_S#V<?YU^/^1T5%<XEGXLWQ[M4L=H:7?^Y/0_ZOMS[],>K5&;+QCY!
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MPPHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[E?Y24?\(=8#_5W^N)[#6+D_S<UT-%'UBM_,_O"R.>_X1-!]S7-=7_M_9O\
MT+-'_",7 ^YXGUU?^VL3?^A1FNAHH^L5._Y!9'/?\(]JB_ZOQAK(_P!^*T;_
M -HT?V)KR_=\671_ZZ64!_DHKH:*/;S[+[E_D%CGO[*\2K]WQ-"?^NFFJ?Y.
M*/L/BU?NZ_I+^TFDO_2<5T-%'MY=E]R_R"QSWD^,5_Y?]"D_[<ID_P#:IH_X
MK%>VA2?C,G^-=#11[9]8K[@L<]Y_C%?^8=H4G_;_ #)_[1-'V_Q8OWO#^F-_
MUSU9OZP"NAHH]K'^1?C_ )A8^)[)F&E:EAB/E3H?]H5])_!'_DF5G_UWF_\
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M "BBB@""ZL[>]C\NYA610<C(Y!]0>H/N*I_9]0L>;6;[7"/^6-PV''^Z_?\
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MA1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"686\RO;7)Z0S#!;_=/1OP)J]45Q;07<)BN(DEC/57&15'['>V/-C<>=$/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH PM6_Y&GP]_O7'_HNMVL+5O^1I\/?[UQ_Z+K=K*G\4_7]$;UO@
MI^G_ +=(****U, HHHH **** "BBJ.M1+/H6H0M>_85DMY%-UNQY&5/SYR,8
MZ]1TI-V5QI7=CPKQYJME)X\U"?4?[$M9[-WAAM[O3A)),%A+QRNQY8,V% 'M
M7NVCW,UYHEA=7$'V>::VCDDAQCRV*@E?P/%?,[V4T>K1Q6NJ:EXU:-L"32KN
MZ26/W+%73\FKZ9TH,NCV*O'-&PMXP4G?=(IVCACW;U/K515H?U_6HI/WB!O#
MFAN]Z[Z/8,U\,73&V3,X_P!OCYOQI]U:V]EH%Q;6L$<%O%;.L<42A50!3P .
M *T*JZG_ ,@F\_ZX/_Z":0'/?#/_ ))GX=_Z\8_Y5U=<I\,_^29^'?\ KQC_
M )5U= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%% !1110 4444 <5\4/^19L?^PO9?^CEKM:XKXH?\BS8_P#87LO_ $<M=K0
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M(G_0IZ1_X-C_ /&Z/[7^(G_0IZ1_X-C_ /&Z .UHKBO[7^(G_0IZ1_X-C_\
M&Z/[7^(G_0IZ1_X-C_\ &Z .UHKBO[7^(G_0IZ1_X-C_ /&Z/[7^(G_0IZ1_
MX-C_ /&Z .UHKBO[7^(G_0IZ1_X-C_\ &Z/[7^(G_0IZ1_X-C_\ &Z .UHKB
MO[7^(G_0IZ1_X-C_ /&Z/[7^(G_0IZ1_X-C_ /&Z .UHKBO[7^(G_0IZ1_X-
MC_\ &Z/[7^(G_0IZ1_X-C_\ &Z .UHKBO[7^(G_0IZ1_X-C_ /&Z/[7^(G_0
MIZ1_X-C_ /&Z .UHKBO[7^(G_0IZ1_X-C_\ &Z/[7^(G_0IZ1_X-C_\ &Z .
MUHKBO[7^(G_0IZ1_X-C_ /&Z/[7^(G_0IZ1_X-C_ /&Z .UHKBO[7^(G_0IZ
M1_X-C_\ &Z/[7^(G_0IZ1_X-C_\ &Z .UHKBO[7^(G_0IZ1_X-C_ /&Z/[7^
M(G_0IZ1_X-C_ /&Z .UHKBO[7^(G_0IZ1_X-C_\ &Z/[7^(G_0IZ1_X-C_\
M&Z .UJ&YL[:]B\JZMXIXP<A94# 'UY[UR']K_$3_ *%/2/\ P;'_ .-U5U+Q
M/X]TG2KS4KGPII7V>T@>>7;JA)VHI8X'E]<"DTFK,:;3NCN;:TMK*+RK6WB@
MC)R5B0*,^O'>IJHZ+?OJNA:=J,L/D27=M'.T0;=L+*&*Y[XSC-7J$DE9 VV[
ML****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"*YN(;.UEN;B18H(4+R2,<!5 R2?PK"'CWPH;#[=_PD%A]E\WR
M?-\X;=^,[<^N.:UKRVNY[BVDMM0>V2)BTL2QHPG']TD@D#Z8ZUPNJ>!M:N-
MTZ.VEM3K$<D\]Q="\F@*SRC_ %J,@RVWIM88( '%(9H?$Y@_A>P93E3JUB01
MW_?+7;5Y?XZ^&-CJ=A%>6MG=7>K/>V[SR"[D *[P)&"%]J_+N/ X[5M_\*H\
M)?\ /K?_ /@SN?\ XY5/<E;':T5P=Y\-/!5A:2W=U%>Q01+N=VU2YX'_ '\_
M2N=L=&^'-]>QVOV/68#*=JO-?W 4GL,B4XS[UC.M3IR49RLV;TZ%6I%RA%M+
M<]>HKBO^%4>$O^?6_P#_  9W/_QRHU^%W@UI6B6&\,BC+(-5N,CZCS*U,3N:
M*XD_"KP@" ;:^&3@9U2YY_\ (E+_ ,*H\)?\^M__ .#.Y_\ CE ':T5Q7_"J
M/"7_ #ZW_P#X,[G_ ..4G_"JO"&[;]GOMP&<?VI<Y_\ 1E ';45Q(^%/A$YQ
M;7QQU_XFES_\<I/^%5^#STM[WKC_ )"ESU]/]90!V]%<2/A5X0)(%O?$CJ/[
M4N>/_(E+_P *H\)?\^M__P"#.Y_^.4 =K17%?\*H\)?\^M__ .#.Y_\ CE-_
MX57X/PQ\B]PIP?\ B:7/'_D2@#MZ*XK_ (51X2_Y];__ ,&=S_\ '*:/A9X/
M;;B"].X97&J7//\ Y$H [>BN*_X51X2_Y];_ /\ !G<__'*/^%4>$O\ GUO_
M /P9W/\ \<H [6BN*_X51X2_Y];_ /\ !G<__'*/^%4>$O\ GUO_ /P9W/\
M\<H [6BN*_X51X2_Y];_ /\ !G<__'*/^%4>$O\ GUO_ /P9W/\ \<H [6BN
M*_X51X2_Y];_ /\ !G<__'*/^%4>$O\ GUO_ /P9W/\ \<H [6BN*_X51X2_
MY];_ /\ !G<__'*/^%4>$O\ GUO_ /P9W/\ \<H [6BN*_X51X2_Y];_ /\
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M$VES;X0[1;/'OE/7DJ4D7/\ M)5WQW9P7ZP65H9SK]P MD8IW7[. P+3$ X
M7U(YX7G-4TT[$IIG76]O%:6L-M @2&%!'&@Z*H& /RJ6O,_%5MJNGZI=:@UO
M<S3/>V@TZ\CN@JPKE%:(Q[@3N._("D$-STK5\7WUW?:=:VB:=>07$FHQQ16L
M\J(E\ &9E+QN2J;5+9/H.#TI=+_UT_S&=O17C.H:S<P^!+C2-^IVKQ"\>ZDB
MBED%NZ%BENLJ;OE!*_,2/E7MG ]9TBX6[T:RN%,A$D"-F1&5CQW# $?C3W5P
M>CMZ_@7:***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!@^+]*N=7\/S06C-YR$.L0;"RX/W3_3WQ7F%KH.
MJ:E=)9QV%Q&[,!(TT158AURQ/M7H/Q&\4W/A#PA/JEB+9KM9$2-+@$JV6 /
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M\/EF'&6(&X[OIP,&#0_!C0ZA<7=W =/C:T%I#;VFISRLB[@Q(D.TH/E4!5P
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MFE!XBBJTX1MP.\>:YS[<DCGTK.E^$7P]@U&WT^2WG6ZN4=XHS=/E@N,]_?\
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M0Z7I]MIQT^"RMX[(J5-NL0$9!Z@KT.<G/KFK2JJ*%50JJ,  8 %+10 4444
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M3:#P<X])JK?U]W^8KA1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gu0gjnulhgsv000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000003.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +Z!X@# 2(  A$! Q$!_\0
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M<_\ \0[/P3*^<NO7+6W/^D#4KKRSC_:^T8IO_$/%\ UB:9_%3!%R"S:K<@#
M'7_2*_0/P[\5O&!_9+LO%$WB"<ZBT.Z2Y:<^<'*$D$$[^#Q7QUH'B?\ :1^)
M7AO6+CP?K&I7=I [F6=993L0,VXAL\8 SU[4!SR[_P!:?Y?UH>?6_P#P;N_
M_4%+:=X@GO@.OD:G=/MP<<[;@FK7_$.;\)/^?_4/_!A>?_'J_4S]@KQ/$RW/
MA[Q!XUEUCQG LBWVE37'FM$P!$@*%B05(/T(S7Z@4!SR_F?]?\,ON/Y<_P#B
M'-^$G_/_ *A_X,+S_P"/4?\ $.;\)/\ G_U#_P &%Y_\>K^HRB@.>7\S_K_A
ME]Q_+G_Q#F_"3_G_ -0_\&%Y_P#'J/\ B'-^$G_/_J'_ (,+S_X]7]1E% <\
MOYG_ %_PR^X_ES_XAS?A)_S_ .H?^#"\_P#CU'_$.;\)/^?_ %#_ ,&%Y_\
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MQ \(2ZW>7VI>:TKQ1E[^\R3R1UGYZ?AGCW_I1_:<U"6R\#S649\NWDA^95X
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MY_\ 'J_J,HH#GE_,_P"O^&7W'\N?_$.;\)/^?_4/_!A>?_'J/^(<WX2?\_\
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MY_\ 'J_J,HH#GE_,_P"O^&7W'\N?_$.;\)/^?_4/_!A>?_'J/^(<WX2?\_\
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M,V[:1G.2>:]"\*_L<?$G7/&?_"<?$>^^V:M=1[+UG<.S!P/-&22><M7ZOT4
M?CK\2?V'/B)X!UZ7Q-^SQ)%8ZGJLHFU1@JKO9V#2;B.O.?7\Z]WU']F_Q_\
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M@ HHHH **** "BBB@ HHI"3D8'4\\&@!:*** "BD) ZTN?K^1_R/QH ****
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M*** "BBB@ HHHH **** "BBB@ HHHH **** /C3]ME2?AC;$#D:@<GOC$?\
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ME9^E:;:Z/IUEIEE$D5M96T-M$B*%&V&-8P<#N0N36A0 4444 %%%% !1110
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M@_3OA%_P4+N?!$2%)I;PM*K#GS"_/![Y/?G-?HO^PM\3(U\7>(K?XB0"SO\
M5GF.ERW<6"[-*-N/,QG<N0".F01DU\=2:'>>"_\ @J<WBBUB/]E7FH;XIE4^
M7Y;S K\P^7&#F@#^EBBH+>=;BWAG3E941Q]& )_+FIZ "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!5/4/^/"]_Z]9_\ T4U7*IZA_P >%[_UZS_^BFH _D#E_P"4X_@;_L3?%'_I
M\\,442_\IQ_ W_8F^*/_ $^>&**"I;K_  P_](B>S?\ !N3_ ,DTU#_K^O\
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MB@ HHHH **** "BBB@ HHHH **** /X@_P#@O]_R>7^S[_V-6E_^E\-?V._
M#_DB?PN_[$K0O_2*.OXXO^"_W_)Y?[/O_8U:7_Z7PU_8[\ /^2)_"[_L2M"_
M](HZ#2?P0^?Y1/7Z_GF_X.1O^3&A_P!C"/Y6]?T,U_/-_P '(W_)C0_[&$?R
MMZ!4_CCZG?\ _! O_DS/P;_UXQ_^@K7[M5^$O_! O_DS/P;_ ->,?_H*U^[5
M!+W?J_S"BBB@04444 %%%% !1110 4444 %%4KC4M/M#B[OK2V/I/<PQ'\G=
M3^E3PW-O<KOMYX;A/[T,J2K_ -]1LP_6@":BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH 0G S7->,=471_"^M:DT@C-KI\\J,3CY@O'\ZZ:OEG]J
MKQ6V@^!Y+".4QRZLCP !L%@V5 XYZ_T_  ^9?@YX T_X\^*==U[Q5&UY8Z?>
MRJA/SK\LAP 2< G( _GWKU7QW^S[XF\.ZA;ZO\.;V2STVPQ/):I)@LD>"1L!
M] 1T./7'-?-_P'\4?%#X665Z]CHLMUH>IS?:9+EH2P 9E;=RI&<?3K7VWX=_
M:*T9+8R>,@=-CD7"N8AC)!RK*=H8$<$$CKSGI3::T8'G=G^TA%86T_A;QEHD
MDB16,MK<W$\9*.XB*9^88///.?:OBO\ 98DT-?VF_%&L>'+40VM]>3L!$H"_
M/(>P '7^?2OO[QYK7P0\;^'-2GAFT^.[>VG:.Y$<4$C/M/7#G)+8Z8[]<U\3
M_L1^$KN+XW^++C[/YFC6TUW+:713*.$+LF''!SMX^M(#]4OB3XSM/!/A6_UF
MYF2)EB9(0Q .]D8COG.<#\:^'O@+\-Y?B1XPU[QIXPM9;_1KTW#V8F!:%BY.
MS:6!7C<O8],4G[8?BC4_$FLVWPV\/R2-?R%#Y,1)W2;1P0O^UQC^5<?\*OBS
M\6/@_967A3QAX<EMM(@90EV;<Y=?NY)*\\+G/_U\@'7_ !M^"=U\,M>G^)_@
MJ)XM,M;=Q<V%OD+M*9<,J8!XW $C!]*^*_V7OBAX0G^/.I:M D-CKVIWA2Z0
M[4E+&7# ]&)S7[(^'_B#X-^)VBRZ/=30,^H6S0SVDY0!O,0@'#$8(R.W7CCO
M^,/C7]G6#X2_M+V'B?3;I8;/4M561((&^0!YPP "G ZGM0!^_P!;R>;;P2CD
M20Q29'?>BM_6IJR=!?S-$TF3.=VG69SZG[/'DUK4 %%%% !1110 57NKJVLK
M>6ZNYX[:V@1I)IIF"1QHHRS,QX  %6*_#/\ X+%_MP:O^S]\/1X"\$3O_P )
M+XJMS:HULQ\]'N T2X"8;@-Z]\]Z /8_VG_^"MWP+_9XUN?PU#-;>)]8A9XF
MBM+D2$2KD;=D39R"",'-?$=I_P %_/",-^LFK^ +VVTEG ,\D,L:!"0 V_ (
M !R<-]37P[^QU_P3*U_XT^ ;[]H3XN7]UJNN:@SZI96.I!WW-+^\1 LI/&6Q
MQU]*^B?#W[./PBN/%5O\)OCGX7TCPS;^()?L7A^]%O%$\N]C'"P8J#R2IX_#
MKR ?MM^RS^WQ\&/VI-/BF\+ZQ8V6I2*O_$OENT,GF-CY-K'<#DX&3]?6ON<$
M, RD$$ @CD$'H0:_A\_:J_9F^*W_  3%^-'AWXB_"[5=2G^&^K:I;7G^C&;[
M*MI+(DG.T[ -C#\.U?UD_L7?M!Z5^T'\$O"/BJWNEFU5]+@&I1APS+(J+EFY
MW Y)'/IVH ^NZ*** /Q#_:Y_8$^)/QD^,A\<Z!?21Z<\Q)0$XPS=AGT..V>E
M?=?['W[/NL? OPW<Z?K,GF7-S&H8]R002:^T>O44A&<=>#FOC\LX%X=RC/\
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M<+7@?[0'QIL_@OX/O/$5P@D>")W5",Y 7/0Y_J:][R<]./7/3\*_'K_@I?\
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MIM9T;^T;^ &]CN)X1*&(^[AOFYW'GVQ7I6J>%_A!K8ECN[K2BTP)8I>PQG+
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M(Y2S2YC,KLJD@$ YQGC&<FOYL/VI?VAM;^.WBN^:2X=M&2:4:;9AR0<.0@5
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M?,!1110 4444 %%%% !1110 4444 %%%% !1110!5OKA;6RN[ER%6"VGF)/
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M!7PB\1^+]0F2(_V=?P6Y9@I\UK5@"N<<@N,8Y]*_F*_X)^_!_5?VM_VJ=?\
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MC%B=O0G/?]* /YX?#/[,GQ4MOA!\(/B+>R7=QX=L=3M+VYL<NRQ0B5)&#KV
M ] .:](^)FJ>'OBE^T'\/=,T_15EL+'3;2PN\0AT6X\M(R6&TC(;O_\ JK^A
M[3?A1X9T[X?Q_#H6\<NBQ0-#"CQK^[R  R+C VXZ>_3T\+\+_L9?#?PQXF;Q
M1!&LU_\ :!.A:$?NR&W *3Z<#B@#^:']L'P'\2OV/_CAX4\2S:??ZSX0\=7]
MK'8VD*RO!9I=NNW]VH*KMW>@K[%^-7QJ\4^./A=X4^ OAW2[M-1\4V=I<YC6
M0&/[1&GRL%';/0_7UK]Y_B_^SS\/OC5;Z'#XRTFUU ^'VC?3VG@27RFB(*%=
MP^7!';VKE]'_ &4_AKI7B_2?& TVVFO=&CBCLT:!=J+" $7IP!@=.PZ4 ?SA
M>,?#?QD_9\N_@_I2:=>^0NHV+ZA/%'(G[MIHR_F,JC.!D')[?C7]3_PP\0Q^
M)O ?A?5D(+SZ+IPG7NLJ6L2/GW+ UB_$#X.>!_B/;VT6N:/922V;9MYOL\9:
M,@Y&/EXVGH1ZX[5U?@_PG9^#M*CTFQ<M;0A5C7& JJ,  =!QZ4 1^/=?C\->
M$]<U9IEADM+":6$L<$R*. /?K7X[6&IK\1/$FK_$'Q,[D:;=S>296)B81N2
M 3C) Q@>M?H=^U5=S1>#S;Q2M&MQ#(D@4XW EA@^M?FW?VYLOAR]I;_N1<7R
M%Y$X+AF&X$C!.<G/K0!Z'I=[XL^+%Y-IO@S3)--M[([1>+"428)QE6"@'('/
MYU'9Z[<Z)X@?X?>-M(9IYE:$:G+#\N6RN0[+P?FXP<U^B_[/'A[1],^&'AF>
MTL+:.YGLPT]PL2>;*^ ,N^,]/YFO*OVP/#FCVG@1O$UM8V\&L07(5;R.,+,1
MA<?,!G(_SS0!\3^&=<N_@7\4M-M]*FD;3O$=W&C$.QCV3R'.!G;T;M7[-:?<
M?:K"RN<Y^T6EO/GU\V%'/ZM7X=7LPU>Y^'5W>_O+A;FV/F/RWRR*,Y]J_;'P
MH2?#>B9.?^)=;#/L(P!^E '04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 53U#_CPO?^O6?_T4U7*IZA_QX7O_ %ZS
M_P#HIJ /Y Y?^4X_@;_L3?%'_I\\,442_P#*<?P-_P!B;XH_]/GABB@J6Z_P
MP_\ 2(GLW_!N3_R334/^OZ__ /2R:OZHJ_E=_P"#<G_DFFH?]?U__P"EDU?U
M14!/XG\OR04444$A35;=GCI3J* "BBD!!Z<T +1110!R'C^REU+P1XKL(03+
M=Z#J4$8'4O);2*H'OGI7\5/P:U>/]GS_ (*03Q>-L:7:ZIXFWQ7-Y\BD/>-M
MPSX'<5_<&RJZLC@,K JRD9!4C!!'H17\]O\ P5;_ .";NK_%NX3XP_".W:U\
M8Z0/MRFRB(F::',G_+/DDLI^H.: /TL_:Z^+7A^V^$$M_I$]OK$.HV#W,+0%
M9AY=Q$AC'&<-@_,!WQUQ7CG_  3A\;6]_P"#O%$FIHNE1K+]H$ET1$A591N^
M9L 8#9Y[#Z5_,GX;_:\_:$^$E@/AG\?-)UJ;3]*8VJ37%M<.&A@PB\LIX(4?
MTKH=3_;]^+&MZ5)\/_@'H>K0SZN!;/-:VLZ$";*9RBCIU_#TH ]*_P""J7Q)
MTWXS?M@>#_ O@EXM7FTWQ+ LTUGB0@)=*#DQYQCZU_6[^SAH5SX<^"7PZTF[
M!%Q;^&]/\Q6SN5C @VG/0C;7\Z__  3)_P"";/C[5_'A^.O[0EM//JEU.VHV
MPU&)S('8^:H'FY.2VW';WK^HVQM(=/L[:QMU"06D$<$2 8"I&H50 ,#H* +5
M%%% !1110 4444 %%%% !1110 444F1G'?TH 6D)P,TG)R"..:/E16).%4%F
M9C@  9))X   R2>E #@<@'UK\H?V_P#Q]I7@1[;4+IDN9DD1UM1@MN!Z;>O;
M\>OT^TOB3^T)X6\)"XTG3;V*[\089(+='1CY@R  HW9.[BOP$_:VUGXE^/?B
M!IU[XAMYUTRXU.'RX9E81M"\@QPPP?E/7T^AK\TXE\2<ORFN\LR>G'.<WG+V
M/+2G_L>#JR:C'ZUB(WA3FGM!O_@?J'"'AIC,\MC\YK3R?)Z<77E*I!_7,72B
MN9_5</)*=2#6CG'17N>M0_%_]H/XW:=X9T3X9-?:7HN(K:Z\DRHOD;DW9VX'
M0=?3]?TC^"?[*.JZ>^G:Y\0;MM1NC'%/-%,^]O.P&8E6)/)X'^'->N_LH_"[
MPQX2^%'A6^M=,M!?:AIL-Q+)Y*91B,$#CD\=3T[<\U]6CC@# '  [5]?PZLZ
M_LJA+/\ $4<3F-7FJU)8>*A2IPJ6E"E&VDN2.G-]K1GQO$DLF_M7$4\AP];#
MY;0E[&DJ\G*I4=/W9UI7UBYM7Y?L[%*RLK73+6"RLH4@MH5"1QH H4# [#D^
M_L!7SS^U'K"Z+\.)KESA&G9'/3"[5R:^DZ_/3]NSQ7<IX4M?#-D"SW]RD+A>
MH\QMA/'/U_\ U5[AX)U?[-?C?X<Z'X9:YG\2:9;WMZNZ6&2:)9%)8,<\YSD$
M?3K7TDOQ1^&^H2/;2Z_I3'E29I(]I'3[W)%?GC\*OV$]*U#PAH7BO4/&-[8S
MZC:)>RP&618(D?J';>%3D'KV(SP17 _&#X4^%/#<#Z=X>\8W=QK)W0HMO<-(
M3*/E7[KD\G\Z=M+_ 'Z/3MJ'H>X?M4?%?X/VFA7_ (4TF"SUG7]8C\FWDL2K
ME)9 5RI0;CR1UQ_AF?L._LVS>#$;X@:G"\5QJ,YN(8IP=X1\NN W/ (_3/K7
MG/[+G['^JZAK4?C+XA7$^H6\$@GLDO0[[L-N4#?G.<K^'XU^N]C9VNG6L%C9
MQ)!;VT:1111KM5510!P.,X'-("Y12$@8SWZ4M !1110 4444 %-=$E1XY%#Q
MR*R.C#*LC JRL#P002"/2G44 ?E7^V)_P2[^$'[2:SZS9:5;:5XFEW,;J-(X
MB93R) XV=6YP>GOG-?DK=_\ !!WXKBZ:TL/&RPZ,TC*(EOD4B$G &1*, +_G
MT_J]) Y) 'J>*^4/CO\ MG? S]GNUNW\=>*[*WO+:%Y!:)<0;F=02$+>82.1
M@X7Z>M 'Y^_LC?\ !(+X2_L_74?BWQ^MKK6MV02<W5U-#/&CHV[<\TAD2, X
MR>>< #-?KSX;\4>")FB\.^&-2TV<6*+"EII\B,D*H NW"=QCGC'IQT_DI_:T
M_P""V?C_ .*_C$?"#]GVWN+JWUB[BM(;K3EW%DEE$2LQA +$*2<DG[QR>M?N
MU_P3J^"?C'PS\--&^(/Q%U.^G\6Z_&+JYM+LR9B$J"0Y#G(YD&..QH _30G
MS2<LHQQSZGWI3NR,#CO_ )S2T %%%% !1110 4444 %-8$XP<?F*=10!%-#%
M<1/!/&LL4BE'1U#*RL,$$'(KY5^)_P"R%\*/B*;F]GT.W@U28,1,(X\;SWSM
M4CG'^.>1]7T5S8O!8/'T98;'86AC,/+XJ.(IQJTY>L9)KYJS.K!8[&Y=76)R
M_%XC!8F/PU\-4E2JK6^DXM/IL[H_&SQ?_P $Q4ULRP6-[;PVC,2BEX\!<\#&
M>.@%4_#G_!,*?21'#<:C;R6Z')3?&> 1T&_TZ>P]\5^S_P"O^?:BOBI>&' D
MY<SX<RZWM?;>S5&*I^TT][DM;I;T/N8>*WB#"/*N)\SNJ7L?:.M)U/9]N?<^
M*OAC^Q+\*_!207>HZ/;WVI0[2)-L9&Y>0V[:W?T_.OLC3M.LM)LX;#3[>.VM
M;= D442JJJH&!PH )QWQ5VBOL<!EN7Y706&RW!8; X>*25'"T8TH:*RNHI7>
MF[;/BLPS/,<UQ$L5F>.Q688F3;E6Q=:=:H[^<F[?(****[3A"BDQR#W'^?ZT
M%=W7/% "T444 %%!..M% !12?-GIQZ_A]?6EH **** "BBB@ HHI!GG(^E "
MT'H:*0C.#Z4 >=?%27RO!VJG)&;:<<''_+,__7K\;4*G3_&SE>#)-CC_ &V'
M7Z5^O'QMO19^"-0;."\,XYX_Y9X'8^M?DBD$G]@^*Y]N1.9#T]6<^U 'Z._L
M<?\ ))+7_K[;^35Z=\>VQ\*/%AQUL&_D:\R_8Z1D^$MJ"/\ EZ;^35Z9\?7V
M?"CQ7GJUB5'U(8_CTH _(/1Y / T/!R=5(./>0?G^-?K7\ (RO@72V'1K6(_
M7*C/UYK\AH;I;3P/9J_!DUC;SQUD'KV]37[&_ RV,/PZT&0C!FM(V'N-HH ]
MAHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH _B#_X+_?\ )Y?[/O\ V-6E_P#I?#7]COP _P"2)_"[_L2M"_\
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M/DC'/F?W<=\U_-9!\$A\$/VH=/\ #^F>(9];,GAE)X)&G,Q$_P!G)0 [FYW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$0%&&XY K]CM%\+:)IMAI\2:/I\<]K:PP^:+2'S040*Q\S9OY.3U[T ?RJ?
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M \ <$<C/>OSL_:,_9K^(^H?M'^'/C/X AE=M.GM&DCB4[%2-P7&%& ,#IT%
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M5:I6UGSM)[^I^Y7@JW:U\*:';E=ABL85*XQC Y'Z5U5111I!$D2#;'&H51Z
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MQ*T+_P!(HZ_CB_X+_?\ )Y?[/O\ V-6E_P#I?#7]COP _P"2)_"[_L2M"_\
M2*.@TG\$/G^43U^OYYO^#D;_ ),:'_8PC^5O7]#-?SR_\'(^?^&&AC_H8?\
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M[(7Q1_:!\5_#/XH_'2&XM9?"6DVG]GQ7"L \:1 )D..X KT7X@_LD>./@_\
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M@ HHI!GG(^E 'RS#^RWX+A^.DGQR%I"?$<K[GFVKO;D9R<;CGOG]37-?&/\
M8F^$GQA^*'ACXL:YHUL?%'ARXBN(;ORD#M)$X96W;<Y.!W_I7V910!\IV7[*
MW@JQ^+*_%>&T@&M"P33_ #2JF3R$3RP,XS]WWZ4_3/V0?A%I?Q)F^*,&B6X\
M337#7+77DIO,C-NSNQG@^YKZIHH ^7(_V6O T?Q8U/XL_8X?[?U&R>Q>?8F_
MRG0H1G&<8/\ ]:OER_\ ^"=VDCQ[K_B32;R.TTSQ/=/<:S:I(J&?S7)D!4$9
MR">U?J-^)^G^1FB@#Q'X1_L__#KX-:?':^$=%AM+DJ#<785?,ED(^9LA<\MG
MG)S[5-\7/@EX1^+.FR+K.G02ZO!#C3;Z159K>10=GWAP,G.0>"!7M%% 'Q'\
M*/V;O&'@F\U2'6-=BO=%OHY8([02H^R%P55< G&%.!Z>U;NG?L<_#*STWQ3;
MR:7;RW?B.2:22=HT9HS(6/#D;EZ]C7U_10!^?VI_L'^!+3P@VF>%(8]-UYI&
MD-^NV-RS$G_6C:<C/]ZNC^%/[&WA7PY:/-XZAB\0:RI_T:ZD9)C#G/S!F#'C
MC@$$^M?;O.3QQVI: /"?#OP,\.>'+G5+BR@C0ZC;O;OM"C]VZE<=/0_Y%7?A
M3\&/#_PKN=<N=%ACB?7)VGN2@ +,\GF'.,=Z]IHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /SD_;L),_@Q5ZB=?\ T:3_ "->
M)>$[C[=\0?#FG'YF\JU^7KV4_@>/\FO7/VO+T^(_$OA_3K?Y_L-P@(')&'&<
MCG'^2<UX=\,)MW[1'AW2Y?NJELI';*[01C_/\Z /V)T6#[-I=G!C;Y<* CT.
MT5^:7[04['XZ6\!SLRK8SQT_R:_4  * H&   !["OR2_:*U@1_M$I:9&Y5./
MP!QW]O3K^5 &'J5B^K?$WPV(%+BVNX"<<X D3/KWSGO7Z^Z:I33K!3U6RM5/
MX01C^E?ES\"+9?%/Q)NO-7S/L4X(W<XVM]/7G _*OU0C3RXXXQT1%0?\!4#^
ME"_K2WX /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ JGJ'_'A>_\ 7K/_ .BFJY5/4/\ CPO?^O6?_P!%-0!_('+_
M ,IQ_ W_ &)OBC_T^>&**)?^4X_@;_L3?%'_ *?/#%%!4MU_AA_Z1$]I_P"#
M<O"_#._&,G[=J'./^GJXK^I^OY7?^#<G_DFFH?\ 7]?_ /I9-7]45 3^)_+\
MD'.?;]:***"1&.!G'>E!R ?6BB@ HHHH *\SU[X0?#_Q-XIL/&FM:!;7OB/3
M#&UGJ$BH983%C9M)0D8VCHPZ5Z910!Q?BWX?^$_'/V+_ (2?2H-3&GR"6U$R
MJPB<-O! 96'WN>U=;:VT%G;06EM&L5O;0QP0Q( JI%$H1%    "@#I4]% !7
M.ZEX5T#5K^WU/4+""XO;;;Y,SJ"R[?N]1SC''Y5T5% "*JHH55"JH 50,  =
M  *0M@@8ZX_G3J* "BBB@ HHHH **** .$\7?#;P;XZGT^Y\3Z/;ZI-I<BR6
M3S*K>2ZMO!&Y6Y#<]JT/$?@GPWXKT>'0-=TZ*]TJW$:Q6KA2B"%!'& "K#Y4
M4 <=JZH+@D\\T,< F@#,T71M-\/:9::/I%K'9Z?91^5;6\2A4C3). % &<GD
MXK4I%.0#2T >?_$W6DT7P=K,WFB.>2SE2 YP=Q'!!_#'_P!;FOA'P!\#M7^(
M^DZIXFDNS;ZBUW(;6=GVL6)9E"DGV&3GO@\UZA^V3XIOM*T+3]'TJ94U'4QY
M<"%L%W9F"C&1D<CU_"OD+P;^TMXV_9TL(;?XD(D>BW4D<L;$\%".#R?0G\?7
MO^ \7YOP]F''7]G<1T\1_963X..'J5Z=UAJ&*Q\8SI5:]5->QJ05^22U6EMS
M]WX/R+B*AP7+'\.3P[S3-<9[:GA9M/&8G#X)N%2EAJ3_ (L)_;B]'KWT^H=$
MUOXC_ Z^CM->@NM>TV4[-Q\R5(H^!G(X&!CD'WSZ^Z:[\3/A3X@\+2WWB>_T
MR&864KM97#KYZRF-L1HK9)(/'S8(.?0"OCOQQ^WM\.?%/A!UT/33J-[?0[87
M6-9BCLI7Y2 6 W8]?:ODGX;? GXK_'3QD?$-Y<ZG8>$YKL3>2?-CC$+OG;M(
MQC:<=,XQ7*^)JV6XR&0<'5:''V5XI*C]0JR]K3RI-J\J^+DFZT'I)*=^7:RW
M.ZGPC3Q^%J9YQI&MP#F&$;JK&QC[*KFDXVM##X5.U*I]F\=9/74Y#5_"/BKX
MX_&V+2O!EM=0^"H-0VW1AWBWE@$P#?=^0@K^>?R_9&[N/"/[-?PLM-/L4@M+
MAK2"$QY59)+PVX#.5&TY#L5!Y[GTQTWP]^%/@SX(>&;B\A@@,EI:"2]O9(T$
MAV@%\.P)W$]3Z XSUK\^_BYJ7BK]HOQS)I_A)KB31--G)<Q;GBS$<8RORYXQ
M_+I73C,,O#/(:[P%">8<7\15)_5L+AH>VG@U5;]HL)2^QA\,G:3C92DNQC#,
M)>)><X6GC*T,OX0X;I05;%5Y>RCC9T[>S>,J;3Q.):]U2NXQE96N>Q>$O@9-
M\;HK_P 3^+RT^FZIO>R65LKM<Y7:&R.C9P!V[BL72/A]XS^ 'C$0:))*?!_F
MB22)-WE",'() X^Z3SZ'IZ]C\&OC5=^ KRR^&OC"TDMA9[;6WG9&52<J@)8@
M<^_MT(XK[BU"QT;Q1ILEM,;:YAO;?"LIC>0)*F05().0#T['T-=_#W#G#N?Y
M7A,PR3%U\+Q)EM:-3,<1.<J>-GCVN>MAL?%OFE1G4O&*?,E%::,\C/.(^(,@
MS+%9=G.&HXKAS,*7)@L+&,:F#A@E:-#$X*234:U.E:4K6;D]3S";Q?X(^)W@
M76M.GO[2ZC>PDAU&UWH61PG.03CU!SCO7Y^_LV_!SP?X0^.M_JOA6RCCA>]>
M1Y(U!&XR?,<K[G/O6?\ M5^"_$?[/F@:[K7P^U"ZE.O)*Y@W-\GFY#!5R .<
M],]/QKUO_@GCH^LZMX"G\8>*DD_M>:Y!#2@[MTA+D@GGC;ZUEA\TS#B3C;*,
MFS?*X8+->'Z=;&8ZK#]Y0G&,U]7E0K_:]K#WI1Z-V.^IE6#X=X#SO/<IS:IB
M\ISZO0P.#PLU[.LI3A^_>(HWT]C-<L)/XE\S])Z0#' % SD^G&/ZTM?NI^$!
M1110 4444 %%%% !1156^N!:65Y='I;6MQ<'_MC$\G_LM 'PO^V3\0XELK7X
M21-MN_%R0P@*<-B;Y5''/1N/K7LO[,/PF3X1_#2PT%T'VJ=OM4SL/WA$@W %
MC\Q'S=_2OB.WM+S]HKX_0ZY'N>V\':@JL!\R!;63&.N!]WV]?3/ZS1((XHXP
M,!$1 /0*H4#\A0 ^BBB@!JMNSQTIU%% !1110!Y[\5/%'_"'>!=>\0;_ "S9
M6KLKDXVML<@Y_P" U_*1\9O%EY\0?B[+J4EPUQ_:^HRVB+O9@&>;:,#.,\_T
MK^FW]JZUO[[X&>-+;3$DDO)+,B%8P2Y/E3= .3VZ5_-M\%_@OXP\2^/]*DU3
M3;T?8]=,S&6!]NW[2#U(Z=#S]>O3^:?'[!YUQ'BN$.$L!A<94R_'YG2Q&8U\
M-"3IQIPJP3A7:TY'&+T:M:[ZG]2_1UQF0\,X3C+C+,<7@Z>9Y?E=;#97A\34
MC&K*M4IOEJ4(O7F4I+5:Z>I^ZG[#W[/6D?#KP-9^(=1T^-]9U***X@FEC!9$
M<!PRD@'/8#I]>:_0&N8\%V(TWPGX?L0@C^RZ5:0E0NW!2( \?7)KIZ_H7*,N
MPN497@,LP5&&'PV"PM&A2I0248\E.*DTE97E).3\V?S;G.:8O.LUS#-<=7GB
M<5CL56KU:U1N4I<\Y.*N[NT8VBO)!30""23QS@<^M1R316\9DN98H4!YDE=(
MT'U9BJC\Z(KBWN$\R">*>/\ OPR)*O\ WU&6'ZUZ)YASWC'PAH7COP]J/AGQ
M'8PW^E:G;R03P3(KC]XC('4."-R[C]>E?P??\%,_V:9/V>?CUJ_BCP_9OIVB
M6U[/=Z>$!CC5Q)O0KMPHP?\ ZU?WT5_,]_P< >!HG^'^F:QIMF#>W:?O'1 7
M8Y(;H,DG'^>M14JTZ,)5*U2-*E!7G4F^6,5W;>B-*5*K7J1I4:<ZM6;484Z<
M7*<I/912U;/IK_@BI^T-J/Q3^"IT7Q#?F>]L(HEM!++N81Q#: -QW<KQC'85
M^X]?R0_\$.+O7=#U&PTJ99H+>=(0Z-N4'+8.00.OX_G7];U31KT<1357#U:=
M:E+X:E.2G!^DEH.M0KX:HZ6)HU*%6/Q4JL7&<7V:84445J9"$X&:16R<8_S^
M5.I#GC'KS]* %HSV[U\Z?$K]I_X7?"K6(M#\5:JMM?2N$2/S(UR3C'#<]_\
M(KT3P%\4?"OQ(LA?>&+Q;J(KNR&4D+C/;_ZU<M/'8.KB*F$I8FA4Q-'6K0A4
MC*K37><$^:/S1U5,#C*6'IXNIA:\,+6=J6(E3DJ51]H3:Y9?)GH]%%(V<''7
MM74<HM%<#)X\TRS\2)X;O9%@NI2 CRL$4DC(&6('IW_#-=X#NY!#(1D$8(_
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MYK[?+H/W9/ 1I)^VJT_^7=3GBX.-M7KI<^GSDCC@T#('/)I:*_;3\0"BBB@
MHHHH *:P)Q@X_,4ZB@ HS17#?$O79?#/@3Q/KL!Q-INESW$?^\N  /?F@#\Y
M_P!I?6C\9?C%I_P&<F73?MD4TFPY4N"H/3CH.]?HQ\.O!UI\/?!FA^$K$+]F
MT>U6VCVX .,G/ Y/OZ8K\]?V3/#,GQ3\;:K\8M70F\L=2DBB=Q\WRL=N&/TX
MP17ZAT (P)'!QS[THZ"BB@!N[YMN/\XS2DX(&.II:* &[OFVX_SC-.HHH 1C
M@9QWI0<@'UHHH **** "FD$D$'CC(Y]:=10 4444 %- 8 Y/7IR>*=10 @R!
MSR:6BB@ HHHH ***8&)!]?\ .* 'T4WYMH]<\]/?\/2HKEI5A=HAEP,@ 9/%
M $]%<!H/C_2=8UFZ\/\ G(FI6F[?&SJI;;G(4'&3QP!S7?T %%%% !1110 4
M444 %%%% !1110 4R0[8W;T1C^2DT^HISB"8GH(I/_0#0!^5OC'45\1?%'5K
M9VW"PN)< \[=KL.A/'/Y_6N-^%FFFX_:4TV]5?D@EC4GL/F'X?\ ZO6L]]62
M/XN>.G5@?(EN2W.0/F;\<_+ZU[7^S?X>_MWQS)XG5=PAGY?&<%6!ZCZ^OZ=
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M4U '\@<O_*<?P-_V)OBC_P!/GABBB7_E./X&_P"Q-\4?^GSPQ105+=?X8?\
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M:UMK.&.WM((K:")52.*&-8XU5 %4!5 '  'K1V_K_AP)\U^/O_!6SP+%XO\
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M^IX+AK 8RE.I@L;7DJU>HU'FC3G"7NPJRV4>C>]S] R/@[@=4*M=XK&<1XG
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MC&<=>O.3WXKYY\!^ ]*_:!\6:QK&L79EMM.GD4)NWX(; P,GZ8X'L>:[>]^
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MV%P@<9 :/S Q_ =>O;/H88, RD,IY!!R#]".#0 N>W?THI-O.[G/_P!;%+0
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M:ZE6[VGHNQ^T5%?D[X?_ ."PG[,6O3) !K-F[E1FX**HW<?Q0+T/O7UG\/\
M]L[X&?$0PC2?%5C;&<J$%Y>6\9&XC&064CKSQ7WA\"?5]%9-AK^AZI&DNFZQ
MIE]'( R-:WUM/N!Z'$<C$?0@&M:@ HHHH **** "BBB@"&X8I;SN.J0RL/\
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M  KK&D?$+]O'7;'P-IXA>RU"9[F^L8P+:54D))$D8VG(SW.?6@#]X-9UW2M
MTV;5]7O8;'3H%#RW4S;8U4@L#D^H&17DFG?M%_"35+B:&V\6Z=MB8J)6GBVN
MP."% 8G.>G7/M7QA_P %+/$/C?1O@5<:-X7>YAGNK=(Y[BW+*T9\LH"64C'<
M\D=#[5^)_P )OV3OVDO&OAOP5XET#QI*EE+K44NM1-??O!:M*&E##?G&W.<]
MNO?(!_4P_P ;OAE% ]S/XIT^WA0XWRRHH;G V_-SGWQ46J?'3X7:+I2:UJ?B
MK3[339>8;F25 DOIL._DGMT^M?S$?\%&O$GB#X)ZW\-_"OAF^U:^M9(K"/Q'
M<:?)+)&+@[$E+M&<?>ZY_2N_\0ZC'XV^&WPET[6-7O[+2-3O--AGF:=T8+(T
M>XR,2#_$<YXQ0!_1%X3_ &C?A'XSU(:1HGBRPGU%\F*U\Y/,E4<[DPV><>GX
MU5\1?M.?!;POK4WA[5_&FFV^KVY_TBS,T?F0KW9P9 >._'XU^)GC?X8^&?@Q
M\>_A5-\.?$5UJS:KHUO)=):71GC5WB!)D",0#EN<\UQ?@[X!Z?\ %_XT_'?Q
M#XMUC58;W2M"OKFRA$\@C65('=-BYX.0.GUH _HQ\%_$'PA\0;!M2\(:U::U
M9H0));617"$] VTG!_&NSK\6/^"/#ZO;^&/BOH^HWEY=P:5XCFMK)KMV=A#'
M<E1M+$GIQ_GG]IZ &LJ2*58!U/!!&0?K5'^RM.R&^Q6X8'((B7/'X5? QP*6
MJ4Y1^&4H^C:_(EPC)WE&+?=Q3?XH15"@*H"J.  , ?2EHHJ2@SV[T4F.0>X_
MS_6EH **** "BBB@ HSCKQ12%=W7/% $<\$5S#+;SQK+#,C1RQNH9'1QAE8'
M@@@_UKXX^,?[#_P/^*EC?SGPEINF^)9U<P:Q!&J2)*V3N;"D[MQ!R",8QCN/
MLRD QD^M '\[_B+_ ()]?M)? W79O&7@/XD:EJ6A6LQN8=$MKR=T6.,[EA,2
MOQ\N0 5 /;.*ZGPW_P %(?CG\,KRV\(^._A;J%S:696&36)[*XQM4B-I/,QR
M#C=RV,DFOWV=$D4I(BR(>"KJ&4_56!!_$5YSXS^$W@/QWIT^GZYX=TN03J5-
MQ'8VR3J&!!.Y8UR><Y//O0!\Q?##]O7X)>,["W_X2#Q/IOAO5Y57=9W<HCP[
M 90AFW @^QKZT\,?$#P=XSC67PSK]AJZ,NY3:RA]PZ\=,G'..M?GCXR_X)8_
M [Q)?S:Q8W^KZ9J#,TL:PD10"3)*C]W)D#)QG;7S;XO_ &7OVK?@ZS0_ B_U
M&[M[8D6Q=Y'R$^[R#S\H'^>* /W1HK\%?"?Q@_;^^'MT)?BM9WT^G0N-^$D;
M,2GYO7MGW_I]-:9_P4Q\">&[6.T\>:+K*WZ!5E>")PV_&&R6C8'D>G\\T ?J
MAG/2O.?BQX??Q/X#U_1X4+SW5FZP@ D[\'I]?S]*^2_"?_!1+X(^+71+5-4M
M"Y _TK8F,],YB7U'YU]/^%OC9\//%L2O9:]I\/F#Y4N;N!,^WS,!^8H _)WP
MRFF^%[W5?AUXK@!N[BYG6U\T#Y&=F",-W3&0<_\ UJ[+PK_PL/X17=[/9:C<
M7^CWK$V=NLKND*/NV@ $@8!!Z5]@?&CX!^"_B ]WXL\-ZWI5KXK1&EMVBO;1
MXY9"%QM,<I8-D;L$=,\Y'/PS%\.OV@=(NKJRU;4[*ZM 66S)E5_EZ)CD]L>E
M '1M8:_JVM2^-_&NM22:7$3.FFSREE&TYQY;-Z>U9OAC1+SXQ_%G0M7\.0/'
MHV@74)E,:D1[8I%)Z#'/O3O"/[/OQV\7>((X_$VH)'X:>1?,2.3"F$D \ @=
M,\XQ]*_3WX3_  =\,?"K3?LNC1K)<W"+]IG95)9^"VP\DC(Z^E 'K-K&(;:W
M@&/W4$4>!_L(J_TJQ2!<$GGFEH **\X\7?%+PKX'D">([L:>C' FN&6*+Z[G
MP,8[YQ^'-9>F_'/X5ZHB/;^,]$&\ X>^@&,XZ_/[^E 'K=%<A;_$#P-= &#Q
M=X=?/3.KV2$_A),A_2MNTUO1K\XL=5TZ]/\ TZ7EO<9Z=/)D?/44 :E%%% !
M1110 4444 ,.5YR3D]/3O[THYY*X/N/_ *U*0#UI: "L/5/#FC:R<:E8Q77&
M,2*2.F/I6Y143A"K%PJ0C.$M'&<5*+]4[IETZE2E-3ISE3G'6,X2<9+TDFFC
MA](^'_AW0+N2[TFRBM&E!W!% &3@>F?6NLALX8]Q"?>))!'7.?\ ']*N44J=
M&E1BH4:5.E!7Y8TX1A&+=KM**23=M;;ZCJ5JM:3G5JU*LY6YIU)RG)VVO*3;
M=NEV1I%'&2415)ZD"GX.0<\>E+16AF( 02<DY[>E+110 4444 %%%% !1110
M!_$'_P %_O\ D\O]GW_L:M+_ /2^&O['?@!_R1/X7?\ 8E:%_P"D4=?QQ?\
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MK5.)>.\QI0A4HX9*I5HP2BHQ:N_8X>.BDXM.5N9]3P,;A,7QC1JU,JH4^'.
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M1']C:J3T_LV]/_DM+BORS_8FF63XZ_%51U%SJ'3VD?\ I0!^K]%%% !1110
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M7X!)WQ/ZG.#Z<=Z /U$KY@_:J\&W7BGX:WPTFV,NJ0.9(WC4L^T+D].>-O\
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MJRWMI"VV6>.,C^\<5.K=23P,>@]:^7_V@?%#:7X?U,:#=8UF*UG9!&_(<(P
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M%_;;F9NB\%<$YQG&/7% 'U?13(Y$E198I%EBD 9'1E=&4]&5UR&![$$_6GT
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M+4/$U]K?PX^(DOA&WU*Z:XN[:VGF@$JR.6D5A'@'*G'_ -:OLK]F?]DCPO\
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MU5O'O[17A>-8ET[4-0B11MQ',X8 ''0'KZ\^M9TG[6'[16@@A?A_J5WM.?\
MCTG;.,YY"^W^<U]R_LX?%?3_ (E>%[73=2M+;_A(=+@\K4%,,3[C&,%F#*6W
M9!!/0\#'K]*-IFFM][3K%OK:6Y_G'0!^.3?M[_M%VY93\'KZ7;D G39CG'?/
ME=_\^E9-U_P4-_:.MU.WX*7SD\ _V7-QSCIY7]*_9_\ L?2#UTK3OQL;4_\
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M)'?"OQ#I/[)_C;PG\2K*ZO(=1U"\AM!KD;RRMI\UM?8V^>"VP9B<$=U7G'%
M'$?\$G/^"C=U^T#HI^&'Q*?[!XQ\.1-9N;LE)Y9K?]WM(D(<[BN".V<XXK]W
M00P!!R" 01W!Y!_$5_#KX#$WP3_X*37VC^%I6M=-U+Q04DMK4^5%LDO\$%$(
M!';Z=>M?V\Z/*9M)TJ9L[IM.L9&_WI+6-SG\2: -*BBB@ _"BBB@!JKCW_#I
M7QM^W%9>,+SX*Z\G@^UEO[XV5V#:0HSLX$18G:N2>/8=.O!K[+J*>"&YB>&X
MACGAD5DDCE171T<;64JP(((.#0!_EY?M"?$'XN_#_P")7B.SU!]0\-*^I$7%
ML1/ L^;@Y!4[0<C(/^<?VW?\$4_BW;^-OV9=(T>XN%DU"W6&9MSY<MY9#9R2
M26R#Z]#TKYK_ ."NO_!*O1_C/X4U;XD_#/1X[?7+&$W]];V4"K)))&VXX"+D
MY(R,= <=<U\J?\$*/&7B/P+\2M2^"OBB&ZLKS3;EK-8;H-$3Y1*<*V/3TH _
MKCHHHH **** "CKU%%% !1110 8]OTHHHH **** "BBB@ HHHH *:R[L<XQ[
M4ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I",D'T-
M+10 4456O+J&RMIKJX8)# A=V)P HZ\F@#\_OVPO$5CXOAMOAQ;R WT=VLKQ
MJWS9. <CKT '3MZ9KY&UN+6+34_!'P[M=XL[MK>"ZVY("LZAMQ'MD<]JZSXE
MW%]KW[0VH^)K%WFT>V\UB5),/RD],94>IY']:]-^ ^C0?%#X@7>IRHK?V%.2
MC$;MGE-V/;D'^0H ^S_"?[/OPYTGPY;:?=^'K&]N9;93/<RQYD$DL(#%3QRI
M8GG(W>U? _Q6\/1?L_?$G3[+1V_XEWB:566- 2L*S.. N!@#=C\,>]?K3,WV
M6RE<?\NUK(P_[8Q$C_T&ORE^(>KP?%WXBW+W+J1X;G=02<[?)8XQS[8[=Z ,
MKX2*FF_M!PW]K^]>Z$4C./5MK=L^OUR.:_7="6521@D FOR7_9]LVO/C\P*&
M2SM\*LF,K\O'7GN*_6J@ HHHH *;M)()/0],?_7IU% !2$D$#!/O_D4M(3@9
MH 6BD!R,TM !1FC-5Y+FU0XEN8(_]EYHT_\ 0F!HO;5Z(-W9:OMU+&:*SFU?
M28R$?4].1CP%>]ME8_0-*":NQS12@-%+'*IY#1NK@CU!4D&B]]5JO+8"2BBD
M.<<=?\^M "YHIJC')ZGK^/Z4Z@ HHHH **** "BBB@ HHHH **** "BBB@#^
M(/\ X+_?\GE_L^_]C5I?_I?#7]COP _Y(G\+O^Q*T+_TBCK^.+_@O]_R>7^S
M[_V-6E_^E\-?V._ #_DB?PN_[$K0O_2*.@TG\$/G^43U^OYYO^#D;_DQK_N8
M1_*WK^AFOYY?^#D<X_8:'_8P_P#LMN?Z4"I_''U/0/\ @@7_ ,F9^#?^O&/_
M -!6OW:K\)/^"!1S^QEX-/\ TXI_Z"M?NWGK[?\ ZZ"7N_5_F%%%-^;=_L_A
MZ?GUH$.HKAO&_P 1/"_@#39=2\0:E;6J1J6$+S1I*^,]%)SU'IFORC^.'_!0
M?6AJ,FD?#C3[PK(YMH;M$<Q%R=JMO7@\GL?K0!^R+S11$"26.,M]T.ZJ3] 2
M,U(#GD<@\@CO7X*0:O\ MJ^(/#]UX]DN[MM)V&>V16D^YRZC Y&!CCZ5UGPX
M^-G[3\6C76M:PUW/9V&\R0CS&=EC^]@<GH#V_2@#]OZ0DCH,U^37PL_X**Z?
M?:S-X>\9V,]I>6SM$_V@-&793MRNX@]>GK7VIIO[47PTO([>6YU!-/CN-N)+
MF>.- 6QW<#USUH ^D0<_YZ4$A068@*H))/   R23V ')-<KI?CCP=K-M'>:;
MXFT.ZAE17#)J=GG!&?F5I@P(SSQCWQ7YT_MR?MX>%?@UH5SX&\$ZE;:YX^UD
M/I]O!IEPES);RS+Y:@" MR&8[FR0<?*<<D ],_:I_:6T_P &Z5=>'?"]XEYK
M,B-%*MNP=E=OEQ\A)&"<?G[5\V?L;>";WQMXOU7Q5XTLFN'NS*\23J6P'RPQ
MO''7].]>.?LE_L[?$O6/#6O_ !K_ &@+F>6UU>&75=*MKXL3%%([/&NV0\=5
M_EWK].?V<;71KJSFU/2#;QVD3O$HBVJ#M.%SC\._'.*_+<WX;AC/$3*,=B\9
M/%1H8*KB,/@9VY,+;]W)P@M);W<VFT]WT/U+)^(I8+P]SG!X; T\-.KC:6%K
MX^%_:8CGY9QA*?V7I913M;IVP=.L](\ ?$Q[5ITLOMUS_HT P@(=A@  C@Y^
M7%=_^T%X.T_5O#R:XFF)>7EB#*K! 2%4!U?(&<G/^>WFG[1%GHFG>-_#?BFZ
MU."V%H\,DR&95'[M@26Y'7 _ X->B>(OVB?AK9>#I[N?4+345DTUXS:PRQRE
MG^SE0"@W$_/C X(.,>M<^'EERPG&'#>-G@LOPN65Y5<)6E.%2:C7A]8^LNE.
M]I1JM+17UOV+JPS&6)X1S_ 4L9C\5F%"%'%TH0G"+E1E&A]7]I'=2IJ4KR=O
MTROV??BCIVKZ'=Z?J=Y#:-I2"(13.%"+$Q4K@\\9)K\VOVZ(8_&?C.VL?@M=
MG_A*KJZ\F^N-.)+@LV&.Z+Y@,DE<YQCFO+K9?C!\4/B'JB?"6VU+3M'O[QS(
M522.,Q/(=W( 4\'CM[5^J/[/W[+>G>!D@\4>,5;4?%\NV2<W.)1')C+'Y@<<
M]A[]._R.3XCB#Q&R'!9+5P53 X?!XB2J\15(2A.5*A4<(5<NND_:5:5D]M'>
M]D?:9GA\@\-\]Q^=+'4\9C<5AHO#\.TI1G"%:O3A4G3S%*Z]G2J>];5-Z=3B
MOV.OV8K[P!X:TOQ)\0)VU;Q1<V\4[-=;I)(I2H8D^9E@0W\L5^@X^F*CS'&H
M3*1JH 5<JH '  '  ':HGO+2(9DNK=!ZO-$O\V K]PR3)LNX>RZAEN7P5.A1
MBN:<Y7JUJEESUJTWK*=25Y-MZ7LC\0SW.\RXDS/$9IF-1U<1B)7481Y:5&FM
M(4:-.*Y84X12BDEK:[U+-)[XY_SWJJE_8R\QWMJX'79<0N/Q(8_SKR'XV_&O
MP?\ !KP)K?BSQ!J]C!]CL+J2UA:YB#S3)$Q0 !\_>P .I)[X->A7Q-'#T:E>
MI4@H4X2F_?BKJ*O97>[M9+N['FT,-7Q%:G0I4IRJ59QA&*A)N\FDF[*]E>[?
M1'@W[7GQ8N_#VB2>$]"S-JNH1$"*++.2RD8PN>F<?SQ7RS^PO\3)AX^U3PUX
MDL!I^KN\X,TR['??D9RW/)//_P!:N._8]^,.A?M8^./%7CSQ/=0P:5X>N+K[
M&EZZ^7+'&[%2F\X.1TQUX]A7&?$/QYI'@_X_/X@\)*@LX;LB8V>!&R))SRG'
M(7'4^_6OYJS7,<SRWBG*_$;-,9'#9?B,R_LJEE565.;P>3_:Q56$7*4)2FKJ
M23=FE:Q_1^3Y;EV/X8S?P]R[ /$9G1RY9I5S.$9TUB,VO%QPE.3C&,XJ&CC*
M5KKR/U#_ &C? ;:EI/\ PE6B68?6K)5D6XC W_)@AMP&<D '.>?PKEO@I^T+
MHMMH']C>/]3ATO4=.WKYUTX4NJ\8;<P)X'N<]N37A?BK]MRTU[1K7PKX?T2[
MN-5O+9()I1"SH)"@C!. <<D^E?,VG_LK?&;XM>)DUR\N+S3]$NYO,FC0M&OD
M2-D@X Q\I(_+MBO;S+B&O#B[!9SX?49\0T,T@L-G&&PT)0P-.4FG'&UIV@_:
MJ_O2LVMF[(\7*^%Z4N%<5E?']>'#L\NJ.OE6(Q,XSQM5+26$HT^:2]FW>RNE
M>S.^_:U^/,WQ2\00>!_A5IIUJ665;8ZO:Q,Y0-B,N)(P2.I/7T[\U[K^R!^Q
MM;_#U(O'?C@#4O$.H W"PW67:!G4$'# D;6)]#QU&*^DO@S^S%X#^$]I:7$%
MHM]K B0W%S=HDN)MHR07!.0?H,].E?2ZE>%48 '  P /0 <?2OT+).#(T\XQ
M'%&<JE5SC&)/ZM25\)@M-J:?\2HEI[62<O,^'SWC;FR;#\+</QGALFPEXU,5
M4=L9F#_FJ2WI4W=VI0:CU:ZBHBQHJ(H5$4*J@8"JHP !Z # IU%%?H!^=!11
M10 4444 ?QT_\%I=-O?!W[9/@3QW>6[R:,-4T^1YV1C&@:2)C\V-H"[C],&O
MWA\/_M7^#/AE^Q[X7\<6>HVTMXV@0QVD*R(S)/);C#A02=RMTXX//7I%_P %
M(_V'[#]JWX7ZA_8]LH\::=#-<:?<+&#*6ABWQ[&P6R&3VQQ@^G\J.F>-_C-^
MSEK:_!S]H;1_$6I^!] O9(K8^5</ UM%(0G4;<;.,].* /Z%OV.=4^%_[0WQ
M0F^,7C/Q%;R>-K+4%DTZPN)$678)=RX#_/P !QQ[5Q'_  7;^*_AG2?@SIGA
M.*]MKS6=5BFCCM8G6613-*R(-@);<>O'8BOS C_;?_9U^&UI%K_PK\.ZY%XM
M$!CBM[>.95,Y0[,HHQG>!SCVK@?A#\$OVF_^"DWQMT?Q=XXM-9M? >F:@DX@
MOXYA#]ECF5U&V0;2-@R?;- '[B?\$+O!VK>&/V:+FXU2"2 ZG<6T\*R*RY1U
M:0$!@.@/6OW"KR3X*_";P_\ !KP%H?@SP_;1V\&G:?9P3B- @>>*%4=L #^+
M/)YZUZR-V3GISCIZ_G0 ZOR _P""M?Q<U'X;_"&Y%I\.CXR\RTD,=\+-KEM-
M8HQ,BN$8IM+D\$<C/6OU_K@_B+\.O#'Q/\+:IX4\4Z;:ZAI^IVLMNPN((Y3&
M9$*AU+J2,9[&@#_.$T/]O[XO:;XDM]".NW]EHT_B&%#IAEFCCMHVG4&$(6 4
M*#@ #''I7]_'[#'CE/'W[-_P_P!9-P+BY?2X?M#;M[;FBB;)//.2:_CK_P""
MLG_!+#Q3\!?&K?%'X=Z7<3>#&U;^TIX[* E442M+_P LU   _+'Y?O=_P0_^
M-)\>?!N'PM+,1<:)9+&]K(W[R(P(%.Y"<C&WTH _>/;\V[/X8]L4ZB@YP<=>
MU !13%8YP>OX>GM3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1FVJ6/102?
MH!FEKD?''B6U\*>'-0U:[8)'%#(BL3@;V1@/ZG\* /S-^-.MV/Q4^)AT2:42
MKX?NN4W9"B)^>^.&'7W^E<+HWAS4?''QGT/PNQ>;PS;F&*>+&82J<,#_  \\
M]>!^5<_9:7?+XF\;>/HY&:WOOM,MN2<K\S.PVGCTXYYS7U]^QOH5OKFGZGXL
MU"(-?1792*1A\X)8XPW4< T>@'T3K'P!^&EQX:O=)A\-:?#,UA)%%>"("9)0
MI82;N@RX_N\ ]>,U^=.FV<GPX\3ZSX$EF-S9W)N/*8G<(U8' !Y QC'K^-?K
M#XUOVTOPIK^H(<-::=/,I]"H'^-?DII6MV/B6]\0>*M1<"6VGN8D9B.OS@ $
MGW'I0!ZM^QAOM_B1XQMT!\DFYP>W63_ZW;DU^GM?G)^QII,Z^*O$^LF-A;77
MG^3(1\K!MPR#CG(K]&Z "B@G'-(#GD4  !&><Y.?I2T44 &,]1G\**** "BB
MB@ HHHH **** #&.@Q^%<=XT\%:1XXTU-,UB!)H(Y?-0.N0'^7GH3_"*[&BI
MG"%2+A4A&<):2A.*E&2[2B[IKU*C*<)*<)2A.+3C.#<91:V<9+5/S1\>>,_@
MI>WVIZ586;,-(M"@$2G]V$4@] <=!W]ZP/B=XS\8?"C2+73/".B37B1(AFDB
MB=A\JC.2O?C\LU]PGN2!QGMGC\:SKK2M-OHW2ZM()UE!5O-B1\@@C^-2?6OD
MLTX1P^)IXRIE.*K9)F..<?;8_#I5)I1LDH4Y6C!):6CT[GUN4\75\+4P4,XP
ME+/LMP%_89=B7[.FW)W<IU8IRD[ZZ[M(^1OASXIU_P"+.AMJ%[<2Z9>VB_OK
M8ED)(^\""0<\>_(].*]0\+^%%T>=M91OM%\S$.N<G@XSCD^A_I7H^C^ ] T*
M6XDTZW^S_:6+2(@55Y[87%=%:Z5:VDC21*<G/!P0,G/2NW+LDK8;#82.-QU7
M&XO#4^26*GHZTU:U>4=E.RM;9G#F6=4,5B,4\%@:.!P>)J<\,)!<RH4WO0A/
M23A?6[UT^[F[CP]I/B6$KK&F1S>9DNLD8ZD=R0<?KQZ]MO1?#NC^'X/L^DV,
M-I'W$:@$_4@"MH #H /H,4-NQ\O7/^>M>W3PU&E+VL:5-5FN6=94XQJ33WYI
MI<S3[7L>)/$5JD?9RJU713YHT95)2IP?>,&[)Z;VN+10,X&>O>BMS$**** "
MBBB@ JGJ'_'A>_\ 7K/_ .BFJY5/4/\ CPO?^O6?_P!%-0!_('+_ ,IQ_ W_
M &)OBC_T^>&**)?^4X_@;_L3?%'_ *?/#%%!4MU_AA_Z1$]-_P"#='Q1X<L_
MA[J.GW>H0PWS7^H(L3R*I\S[9.,8)[-UK^KE'5U#HP=6&593D$'N"*_SJO\
M@EMXS^(7A.UNY_"LUW;*-;U ^:K.D/\ Q_S]QA>_\A7]*NF?MI?%'P-HJ7.M
MZW%-Y40/E-< N< <8+YY(H"7Q/Y?DC^@*OG7XX?M.?"SX$Z5=W7B_P 0V=MJ
M,<9^SZ<9%\V24KE%(SD<X! !.3@]Z_"#5_\ @JE\5?B'K$?@'X>6MY'KL\OV
M072>9M\QFV!MP.,<@_\ ZZ^AO 7[!OQ)_:$U33/&W[1^NWDFF3*M^(#.PC"C
M]X%(8[<G;CG'7DCJ DP?C%\>?BA^T;:)=>&A>:7X1N9C#;WD*RQQS1M]T@J
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M)&CBP"N>I Z5^]^L?M^?$'X<:0+C5]4CO9(8\R1)/O<[1DC ;.?6@4MWZG]
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M%H_A1PNG31Q!59;? 3D =0..>3WKWKXY7TNB>!UDLU4"&18E!'RJB(JJ/R%
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MO .<CK_7FO<[:UMK&%8+6&.WA3A8XU"J./\ #UJ9=W.[\.G]*4@'K7W>#R[
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MBC4L[N0JJHY))/ I)IH;>*2>XECAAB0R2RRL$CC11EF=V(55 ZDFOQT_;?\
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MH4,DDL\B1J%49.-Q&3[#-?GC\</^"@O@;P#-<Z'X:A?6]6#/"LEF_G;9!D#
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M<*([B\@V2PXVLGEI&%R.HSSV'2O?*=[ZJS7=:I^C6C)U6C33[--/YIA1110
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M.)K8?**F(JX2%><8JK/$M.:K.$MOO/QZ^)6L_M&_M :E;3MX7O=.M5DW12K
MZ!%R-I& ,8P,?I7M_P +_P!BSXC>)/L.I^,_&-_;6\*Q[K"6:;;@8RFS))&!
MC[N,>E?KC::9I]C"D-I9VT$2#:HCAC7@>I"Y)]S5T  8  'H!@?I7JY7X693
MA,;C,RS/'YAG6-S"<)XNIB:KI0JRIZPO3I22M%WT>ZTVT/&S+Q8S>O@,+E>4
M9=EV18'!QE##T\-25:I"$_B7M*T6U)_S)W3U1X]\/_@GX+\!V<"6VEV=S?Q
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M4&2.O<8Z5^E'A#]EOX7>%D@SH-C>2PJJAWA3YBO.3E,G//YU]) !0%4!0.
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MY7_@GK\ K--/O/BGXKL_M>M:PPO+:6Z3S"&E<.&#/GH#GC^N:_6L#   P!P
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M5<W,,PQ&\-I(1&&  ((7C:#GCTKRO_@WU^"?@7QQX%U+5/$-FMU.FH:C*BL
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MO\+.LFG:02ZXR92K9([X(/MW->TZ9HVFZ1 +?3[.&WC']R- Q^K!030!\/\
MAO\ 9"35KZWUWQQJ\NIEF6<V%P7D7);<5*G('T.*^S/#7@WPWX0LH;/0-)M-
M/CAC$8-O$$=\#!+$>O?VKJ** $!)'(YI>>./_K4A..32T %(<XX&>>0?2EI
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MD[PE(6V*1,2""%QWX_R:_J[9=P*G&U@58'N#P1T[CBO(-5^!/PWUG5_[<O\
M0H)M1+;S.53)8G)/W<]>>M?FGB;X<X;Q&R[*\%7QE3 3RK,Z.94:])>^Y4I0
ME[._1/E/U'PL\2\3X9YIFN84,%3S"&;976RVOAZTFH*%6,H^T2VYH\U_.QR?
M[,7]J+\-=*CU3S/-CMK=$$F05 3& #^'Z5\)?\%5M1N=(T3X=:E86QN]0M;\
M26L 0N7D%TV%"@<Y; K]:-)TBPT6SCLM.A6&WC 544# "@ =.^*\!^/WP)LO
MC.WAPWBQN-"N!.BR %21*9/XN#SVK]$PM&6'PV'P\INK*A0I474EO/V5.,.9
M^;Y3\UQ5:.(Q6)Q$8*G'$8BM75-;0]K.4^5>4;V/R?\  OPI^)7[3]]H%QX\
M\(MHFDV&B(;*^>W,6[RX/W;;BH] ?Y=Z^1OV5?@5XM^(/[:7C;P#-X]U.V\/
M^!KN[E@LOM$P@9+-F?:%#8( CQA0?:OZB_#NC0Z)H&G:/##%$MC8QV86-%1<
M1Q[,X '7J?4YKY#^#G[)FF?"_P"-OBWXLV^S[3XE:[:3:1NS<[SS@Y_B_P#U
M5N8'X6_MA:O\:M(_;!T;X7>#=7U*:SMU^Q+:H\P@E9?W:L<':2??FOJ']C#P
M_P#M5_"+XA>.-6\5V]_JUA=V\YT^QG$DT*F5&*;4;<O&01@#D>M??O[2_P"R
M'J'C_P ;VOQ3\ -!:>-;9UD6Y<(K;UP<[F.3EAGWKVO]G?P1\5/"]M<-\3KF
MVO;V2,HLD8C9N!A>5SU'!SSCK[@'Y\?ML?%[XRZS^S5KAU33[GPK=SZG';+=
MV\+V[JC,44@H%/W23G_Z]?F9\6?V8O'FC_!GX->.+3XHZPEYXHFLY+H)=S[O
MW[(6# /VW=Z_IK_:!^#]C\:O %QX+NXXO)GNH;DDJHP8LXP>,9]O05XGXK_9
M)TSQ'X \#^"I-OD>$6@,.2,#RL=.?8=* /R/L?@?XQ^#.FZ!\1!X^U/4IYM,
M@DDMVN)7#;HESD%CCUY_*O+O%?B/QOK_ /:6O>#M.GU/Q!<"1E58F>1Y,D=,
M$\FOWH\2_LT:=K_ARQT*3:8[2U2W7)& %  X_#\/?%8GPN_9/T7P#K$.H-!;
MSQ)*79)$212"<_=.1^'\J /RM_8+TS3[OQGX@U7XI0_V5\11IEX+>PG0QS.H
MB?C:P!(..WK7QGX=_9YM_$_[7?Q/^-7A^T.G7G@*^O-2O)((V5IOLSO*<E>6
MSY9[_P!<_P!#6K_LFZ3/\;5^*6G*EHAM7@>W@Q$A+JRG,:8!^\?IFK?PN_93
MT/P1XK^(6KW<$4]EXZ6Y2\CPI9DN P8=\<.>WZ<T ?AG^S3^U1X?^,7[8.JZ
MYK+M;7?A6PN]+2253&6N+1&C!!;ON3KW[9KQ'XD_$W7/%'Q(_:&GU?P[+XCF
MMEU ^%[RXMFG:W<%_):!R&P00N-M?L#>_P#!+?P?X7^)5[XY^'873SJE\]W>
M!66-F\YRS@C//WCD?SK[&\'_ +&OPET>QEDU;0H+[5-0CQJ,S)'F5CG(9BK%
MLY.?K[4 ?!W_  1E^+>L^(O@KJWACQU<SQ>)+?7&-G9W0=9$M5:9%C1'^8 !
MEQVPO%?MA7Q7X!_91TCX7_%(>*?!J+8:$[B1[.+;&F2<D&-< D9QTZC/2OM2
M@!,C.._I7Q]^UG\26\+^&U\+1G;)XDC^SY7&[;(60CCGDGU]_>OKNXD2WAFN
M'X$,4DK'_9C0L?;H*_)7XJ>-;;XW_$IM,B;RX?"=TRNQX7]PYZ_E^HH \KOM
M(U'P1X(MK6RD9[K6+E'D5#ERD[9.5&2!M;OTK]//V<_A_IWA/P1I>J00+%?Z
MS9I/=MM 9F8Y.XXSG(-?GY\/-*U?QU\;K'P]=QM<>&[%XTW $P@Q;1GN/Q]^
MM?K_ *=86^EV5O86B!+>UC$42X  5?IQ[T_E_7D!XE^T3\0)/AYX NM3BX>[
M9[(8^\!(@!([_P 5?E[9:3)IOAK6_%\%P?[0\0&29%#?/F8EA@=>_;\:^@?V
MF/B2GB_X@I\)F)-O!<AV<9V#& <]NW_Z\5X5JVA:W>^.O!_A70F:XT>WFMX[
M](OF4+O4-O5?09SG\:0'V_\ L?>$((/!Q\1ZC:#^V9I\?:)$Q(0V\Y!//8?G
M7VC7-^%/#]AX;T6RT[3X1#&EM;EU4  R")0YP.F6W'\:Z2@!&&X8Z<THX 'I
M110 4444 %%%% !1110 4444 %%%% !1110 8]OTKD_&OAI_%OAZ\T-+Q[$W
M>!]H3<&0 ,."O/\ %VKK*0G S43A&K"5.:O&I%QE&[5XR5FKJSUO;0NG4G2G
M"I!\LX24HNR=FG=.SNOO/SFO?#4VB:P_AK6K7RX-(F,MOK#(0]PT;%E^<C)S
MQW.>N37KWASX[RPS6_AU8/.>WV6\,A7=O11M4EMIXP/RY]Z^B_%7@W2/%-E-
M%=6Z?:&C<13  ,'(.,G&>O?W[CBO(/"WP2LM!-[J%\JS7N)/L;8W;3@[,]>0
M?\GK7PM3AG,LLQ\,;P_B*5.-5MYC#$*SK4(M>SITU'1SIK2$GJ[W9]S2XERW
M,\#/ \0X:M4=&,5EM3#OF]C7E95*E1RU4*F\HWY8V]U=3W+2];M[K3H[JXFB
MCE$>^:,NH9>-WW2<\#C\*P]4\>:+9V,UU!<"4Q-M8#'!&>.&.>F..E?!7C+0
M/C9X;\<QZDEQ=3^&+JXVM;QEV40%L#"@_P!WCTKZ;BCTDZ+8M+83$S1QM=JR
ML<R$#.?Q^OKFNG)^)<QS2>-HU<DQN6U,#5=&,\;'ECC+-15:AR[TV[R;[=CF
MSGAK+\KC@:M'/<%F=/'4E6FL#)N6#;5Y4:ZEM47PJVG>QV>IZOJ'C#PW=QZ=
MN@^U1,D<JY4@E3SGUY&/\BOS[\3_  7\<:/J\VIQ:;)K-[-=;DNW5I'A4N#D
M,<GC/KVZ\U^CMAI<LNDV9T5?L\&0=A&#A1Z$9Y_R.<UW-E RP1K<1HTBJ Q*
M*>0!Z@\^_MUIY]PU#BNG0H9A6Q.%C@YPJ6H\OLZTFU)JS>O*^O3H+A_B>IPI
M4KU\OH8?%5,7&=.3K\W/1C9)-..SDG>RTO;LSQOX)>$M9T+P_:WFM7,OVRYB
M(DM'+?NAM&T8/3!/3KQFO<Z0 #@  >@&*6OJ\)AJ>#PU'"TK^SH4XTX\S;;4
M4E=ON['RN+Q-3&8FMBJMO:5ZDJDN562<FW9)=%<****Z#G"BBB@ HHHH _B#
M_P""_P!_R>7^S[_V-6E_^E\-?V._ #_DB?PN_P"Q*T+_ -(HZ_CB_P""_P!_
MR>7^S[_V-6E_^E\-?V._ #_DB?PN_P"Q*T+_ -(HZ#2?P0^?Y1/7Z_GK_P"#
MD4_\8'ZBG]_5)E/L#%$,U_0I7\\W_!R,?^,&'7M)KK1M_NLD"G^9H%#XX^I^
M#W_!)#PQI>B_ _1M1M;#^T]0N5=D!B,A1CTQ@''..W-?J#K5_P#M+ZJMUHO@
M[P7>#3KA9(DO8K64>6C9 8,H&,!@:]P_X(,_L\?#G5OV2_"?B'5-.2ZOY+5'
MPRJ<D[><D'IDY&/K7]$&B^"_#.@6PM=-T>QBC VY:VA=B.F,LA_Q]303+=^K
M/Y ? 7_!/CXN^.?B##XT^+'Q)US1-.M[E9Y](EN;F*$H'\QD,9<#& 1C'/-?
MT(_!<_LP?"?PGI^GPV>E7NOZ7;)YVI26L<UW<3P)M!69B"A)')VMZ]L5]E>(
MOA)X)\3"47^E1J900Y@"Q]?0*O\ 6O&;_P#9$^'3^:]C%-#(^3@L>IR>NX]"
M?QH$?-EW\4O^%N_$>QMTOI+70M-N4$$.2D9CCD   X&"OZ5^A5MXP\*:386M
MJ=1@C2"VB7&5YVHH)/(R6/<]:^61^RJ-&E:XT"012 AE8, V1[YYZ"I9_@%X
MTNX]LNI2 XVC,W;@=F],?E0!Y'\8?B'HMS\4]$GMKKS+.&]C,SJ=RHJR GI7
MUG?_ +2?PGT&QM5O-?C\W[+$! %!.5B52I.X]^/N_@*\+C_9)N+F;[3J%P9)
MLYWF0%AZX.>#GT]<UU&G?L<>"+N1)_$0FN70Y"B0G.,<?>X'^?8@'R5\:/B"
M/&7C'3_%GPYM7EET^99E$,1/GE6##.T9.<?K7IVC^)_CG\98;72=4TV[T.Q$
M:0?:EC>+*[0I<L,=N3SS^M?:?AGX$?#OPHJ+IFD*-F,&7:^<'(SE3W%>N6MG
M:V42P6MO%!$@ "Q1J@XZ$[0,GW- 'QSX$_9!\.:-?Q:QXJNAK]UN65XKD-+A
MLAL$N"O!]#_A7U[I>CZ9HMLEII5E;V-LBJJQ6\81<*,#I6B3C ]:6@ I"0!Z
M"EI" >M "TW;\V[/X8]L4ZBB]OFOP *3(SCO2TF!G/>@!:*** "BBB@ HHHH
M **** "D.._3Z4M(0#UH %)(Y&.?0UY)\8?A/I_Q<\-R^'=1N/LT,J.GF88X
M#]3\H->MG=D8/'?_ #BEK*M1I8BE4H5HJI2K1<)P>TX26L7Y-=NAM0KU<-6I
MXBA-TZU&<:E.<=XS@U*,EYII,_+[X3_\$SO WPL^)\/Q+L]>:\OH+A9UMV6;
M&5;<!EE _,]?3K7Z?XW*!TY].PR!Q]*=17FY-D.4\/X>>$R? T<#AZE65:=.
MA&T959_%-W>[?XL]3/.(LYXDQ4,9G>/KYAB:=*-"%6NU*4:4$E&"LE[J25D-
M).0 ..,\'UH8D8P,_@:=2#=DY/';_.*]<\4,#I@8^E+12%L=<T ?E=_P4ZT6
MZG^&T&H0Q%DBNX2SA<XP5))/^>_ID?2'[#.IV][^SUX/ACD5I;:)UE0')7*Q
M@9';[IKJOVL? '_"POA!KNDQV_GW42&>!57+92-S@<'G*C'_ .JOSW_X)W_%
MS^Q/%&M_"3Q#>)9RZ;+<P6MO.X1FD5F6,*K$<[E Z=,U\#BIQR_Q PV*Q3]E
M0S?*(99@Y/:KC:-3VDH7V5XQ3U:/T+"4ZF9>'>)P>$2JULESF>:8R/6E@:])
M4HU+;VYY6TNK[I+?]H** <@$<@\@^HHK[X_/0]OTKY>_:7_:%M/@'H=EJMPL
M4K7>=L;[6;AF'W3D@<9Z5M?M!_'/3/@IX5NM;O4W.L,GEG.,-M)!X/&/?\Q7
M\[OQU_:"\8_M#ZE*\@N=0T6.606\4!9Q"@)QD#ICK[9Q[5^<\><=8+AK!5L'
MA:ZJ<05Z:6!P4(N=3FDTE4DK/W%?I<^+XLXIP^3X6KA<-74LWJ1MAZ$$Y3@W
M:TY*WPJ^MC]#_$__  4<U^[\*ZK>:/I,0!LI_+F2)$9<QMA@P7<#U(P>:_F9
MUW]J3QUXT_:\TB:ZNK@O=:XFR/<S %KK@=QC/0#^M?5/QHUG6?A]\+[R_LM7
MBA<P2*U@\B^<!L/RE#\V<''3V[5\+?L2?"WQ!\?/VC/"GB2TM);M;'6(I;YH
MU+A%2X4L6P#CH<_G73P?1Q^<9-AL7Q&J^(Q-3EFJ.)A"-&-31JKA[:N*V][K
MO:UCTN",?GM'!?7L3C<9'$XBDZ<XU(QA!PEO*BXZN,E[MWYZ=_[U?V?-0U+4
M_A5X4N]4W_:9=*LV)<'<085ZYYXZ5[5C@ C./:N;\'Z3%H7A7P_I,*"-;+2+
M"#: !B1+6/?D#_:!SUKI.<>^/UK[W:UNEDO))*Q]%W\VW\V[O\1::Q/0#.<Y
MX-*,]^:6@!BCCD8.>XYXQ7P'^WOKFKV'P[FL+"22.WO;:1+G9NPR$,"&QQ^9
M_#I7W_7SA^U#X$C\:?"KQ*B0^;>V>G3S6X RQ(4\#@GJ>W^%>1Q!0KXK(\WP
M^'DX8BKEV+A0:U?M'1ER)><OA7J>SP[B:&$S_)<3B8*>'HYI@9UXR^'V2Q%/
MG;\HKWGZ7/Y^OV!_%.K>$/CW+;F_D32KG4 7A+D1DO("?09YY_\ K8K^HRTN
M$N[:&YB8-'-&LBD="&&17\>?A76-7^%_C^2ZN$>UO(M>VD,"K"))\9R1R H_
M3\*_J=_9Z^)6C?$3X=>'[NPOH;F]@TZ%;V-) TBN ,E@,G.3@YZ<#M7X3]'3
MB;%X_(<VX;SG%3JY[D.9XF-2A5TJTL)*;5-*#=W%:/1:*]['] ?29X5PF7<1
MY1Q3D>&A3X?XBRK"U*5>BFZ=;&JE!U).:7+=ZK?70]UW'=CM_P#6S3J3 SG'
M/^12U_1I_,PC$@<#//H:4=!15/4+^WTRRN;^[D$5M:1---(QPJHO4DG@4+73
MN']:)O\ !'X[?\%2;T7VG^&-(@8/*-4@#1@@L#YBCH.>_3J/RK]$OV6]/_LW
MX&^ X"NUCI$+L,8(RJCZ]LU^/_QC\57'[1G[4MMX/T9OMFCZ?J:EC%EXP8Y?
M0<=J_=;P+H"^&/"&@Z"@"_V=I\5OC&,,H)_3//%? </2CF?%?$>>8>SPL:='
M)>9:\U? R3J6?6*5K-7[7/T/B*,LIX1X;X?Q"2Q3JXC/%'K&ACXI4^;JI/?6
MS\M3K:*09QSUI:^_/SP.O45& 5.!R#CG'3FI** .:\6>'+;Q7H6H:'=,%BOK
M>2!F(SM\Q<;NA/'7CVK\TM'_ ."7_@72?B3)\1(_$#-=/=_:OLNV;:#YGF8^
MYC.>.OO]?U0(/4<'N?;_ #BEZ#GL.:\3..'<ESZ>"J9OE]#'3RZM]8P4JT;O
M#UKI\]-W5G='NY+Q-GG#L,?3R;,<1@(9G0^KXZ-"5EB:+5G3J)IW36GH8WA_
M1X= TFSTF!MR6D2Q@\\A5"@_D!7Y*?MV?MB?$SX/?&_P)\(O &G/>/XK2S>1
MU'"F=49N>.F[GFOV#&#AAWZ_3I_/%?S4_P#!671_B3K/[7?P:L_A?-]F\12C
M24@FQ]UG2)>I'J?S'I7MQCHHQ6B2279))+?LE;<\-N[;ZN[?FWJW]^I]@? #
M]N_XDWOQRO/@Y\3-$-C9Z=;K-)?/%_JXL!F/FX[ DGYO4U]_6G[7GP)O_$Q\
M)67C"WN-:67RGMHPAV/G!#%96(P?4"OSY^$G[&_Q,\&P_$+XI_&*^BO_ !))
MX2O9(9(V0R1O!8M(>GS!@5 /0@CVKXM_X)]?"/1?'C_M"?$37_M][XF\/:IJ
MYT16EDD*&)Y?*" DD?-@=/3':@1^\7B']J_X)>&-5CT;5O%MM!?R$!8<QYYQ
MC/[SW]*]I\*^,?#OC33DU7PYJ4&I64@5A)"ZM@,,C(5FQ7\JUG\'K[XQ?$;Q
M*NO>+&T/6$DNX-,ANKTPNCJSK%A6<$$$+^5?H[^R9\'/VBO@]X'\2Z7=>*I=
M=CN)G_LB:.Y,XCA+ QX;)QP5Q^- 'ZW_ !%^*?@KX5Z4FL^-M7BTBQE8K'+)
MM^9EQD ,R^O'K7A,7[<7[.<LR0?\)Q;K+( T:,L8+@YY \X'M7YC?\%"++X@
MWG@/X5:-XOO+L_VGKMG#>E)71FCFF3S Q!!^HKYE^.?[.7@GPO\ &/X#:5HS
M7T=GX@TK3I-459G"N\L:;RP#<Y9CUZ_I0!^_/AS]JGX0^.H/$$'@SQ-!J>JZ
M+8W5P]IA58M%"SIC#M_$.F.WY?EEXL_;?^.>L>(?$4GA+1I)[3P_>R0\ A6C
MA<@^@Q@8_P#U5Q=]\,]!^!OB[Q%>^"6NHYK[2LW(:1RIWPJ6X)]R*^5[WP%^
MT-X\\)^+=2^#ERT-V]Y--=(B@N\>\M)VSTST[<F@#](?"_\ P42\8ZGX \3S
M7>C%?%V@Z?<31VXARTLT,9(4'&6)9<54_82_X*5:O\>H_&NC?$ZP&@^)-'N+
MN+2;:9/(>X$)<(5#!2V[;FOFWX'3^&++X;IX4\6VL;?%J)6CU]G4>9(1E90P
M(R<G/!KR+QW\'M2^#L]U^T;X>MI8_#^EN[ZC:VH*1R$9+[U3"MDYZ_K0!^U/
MP,_:;U;X@?$+Q;X<UN'[+I?AU+F5KA^%6*(.5<D\8 7/_P"JO@'XB_\ !3KQ
M]I_[7>G?#7PGI#W?PKM]533]8UM(RUO#^^\MS),!M4XZY;(KR']EG]IK1/$?
MAKXG>.946QG\0Z1>VEE YV3/,T4B 1]&+$^G4GW-?#%SXQU_1/A#\3GA\#ZG
M/XMU/Q%<7.EZL;.1YA"]P622.<H7"XY!! Q0!_8IX=U[3/%&D66N:3<)=6-]
M!'+#(A#+\RJY7(R"5W ?_KK<K\[?^":'Q#N?%O[-7A#3=?F8>)]-BD^WV\[D
MW"AUCVAU;YALV'([9K]$J "OS8_:[\<W6I>*K'X:H["TO&C\[;R!G:&W<X&,
M'K7Z ^,=;C\.^&M9UAY%0V%A/<)N."SHOR@#J23QQ7Y%67BJW^*'B77?&FM#
MRGTN:XBMY)> 60ML()QWQ_D<@&%K_AJ\CU#P?X6T*5IK>.ZMEOHHCN5D9EWA
M@I('!YSQZU^Q'@7PYI_AKPUI-C86L=M_H%HTX10I>4PJ6+8[AB17YP?LG>#]
M9U_XE:_KOB&)[C18C.^FO("T9V9,6PGY1G"X/X\U^HT\L-G:R2.RQ100LV6(
M4*L:$CT' ':@#XH_;+\>7WAS1M'T73I65M9)@N5C)SL>7;A@,G[N":^)M>\.
M16OA"ST71K@C6=5EAGEA0_.3*P9@5'/.[N/P.:[3QCXX?XE_%G6=/UE6?2?#
MUQ*T,KY,6(B<$?BHJ?X7>"]4\:?''3M;M"TWA?3I8XW4'="/+.#D=!ROX4M;
MJVW4#]$/V?\ PVOA[X;:!!/9I;ZCY'^E2;-LDC%4Y8]3_P#KKVZH;>WBM8D@
M@01Q( %11@   =OI4U, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "J>H?\>%[_ ->L_P#Z*:KE4]0_
MX\+W_KUG_P#134 ?R!R_\IQ_ W_8F^*/_3YX8HHE_P"4X_@;_L3?%'_I\\,4
M4%2W7^&'_I$3V;_@W)_Y)IJ'_7]?_P#I9-7]45?RN_\ !N3_ ,DTU#_K^O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN>XI<VBW;3?5G]2FO^(]&\,6$NIZW?0V-G"I9Y)75<@<G:&9=V/:OR-_:_\
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M$$9)[*D:+D^P  K\H_VB?%.L>-?B_9Z+8SO=>$;5E%XD9W1?)C=O'3L>OXT
M>4VUY86_@^?5IE6+7/$*R*'(Q*[RD*,Y^8DY'\Z^]/V/?!=YX<\$7%UJL&;N
M^G$T4LBG>8V+/P6&>XS@U\6P^&+3XE^.=#\/>&?^/70KF$W441P (V!?<H[<
M<YX_I^OV@:7!HVCZ=I\$:QK;6=O$P50,ND2*Q..^0>M &Q10>AI%! Y.>?>@
M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M .@K7[M5^$O_  0+_P"3,_!O_7C'_P"@K7[M4$O=^K_,****!!1110 4444
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MH.1F@#B="^'7@?PS%!#H_AO2;-H515EBLXA,Q4 ;FDVYR<>N*[8      #
M&  .@ '0"C )SCD4@;)(QTS_ #H =1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *IZA_QX7O\ UZS_ /HIJN53U#_CPO?^O6?_ -%-
M0!_('+_RG'\#?]B;XH_]/GABBB7_ )3C^!O^Q-\4?^GSPQ105+=?X8?^D1/9
MO^#<G_DFFH?]?U__ .EDU?U15_*[_P &Y/\ R334/^OZ_P#_ $LFK^J*@)_$
M_E^2"BBB@D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBD4$#DYY]Z
M%HHIDK;(Y'_NH[?]\J3_ $H _$#_ (*Z_$[5[%/AQ\._#=S([^);Z.QU6"!B
MV8Y[ORRLBH<X\MQU_D:_1+]CGX,:7\&_@YX=T^QMH[>ZUO3K'5-05%"YFG@$
MF6Q_%^\)_&OQ?\7:V_[1W[:LGA"X;[8G@_6RR0D^8(S;W..!SCD?G7]'.AVO
M]GZ'I%D%VBSTVRMMO3 AMHX@.G;:* -8D#KQ2TP@N 1QU_ST]J?0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110>
MAH **100.3GGWI: "OAC]K/XP3:-86W@C0I!++KO^BW[0G<\2.Q1@=N<<$?C
M7U9\1/'.F> /#=WKNJ2)%$B.D9<@ R%#MZ]<$BOR2@N;O7?$WB#XC^(Y6O=#
M5YI]/1SOC50S,FP'('&!Q0!0D6+X9^&X],\._P"G:]KT@:8K\TT9N,;CCEN"
MYZ]"*^U?@3^S3HEKH]GXN\2,VH:GK=O]IGM;E2ZQ>:!QAN 0<\8XKP;]GWX<
MR_%;Q\/']RA;PU87&V.W;F/*-P AXYP<#IWK]48H;73K18HPEO:V\> .%2.-
M?4\  4 ?F=^TM\#M+^&B)\4/#=V\$B70B?3DRB$D@C:@.TC&!D=#U'3/SIXH
ME.K77@CQ?>(%NB]O*N?O_*0>/\]J^@?VF/B+=^-O'\?PTTY_M.BQ7"O/<1Y:
M%&!^<DCC VCD\_2O&M?T2;4O%?@SPMHA_M*WL9[=+D6^7$0#J&W;<@8SSG@8
M^M+=\MM=P/UH^&&MR:[X/TJ[E!W+;0QY.<D",8Z\]*]"KF_".BPZ!X?TS3H4
MV"*T@WC'\9B7(/N#Q724P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _B#_ ."_
MW_)Y?[/O_8U:7_Z7PU_8[\ /^2)_"[_L2M"_](HZ_CB_X+_?\GE_L^_]C5I?
M_I?#7]COP _Y(G\+O^Q*T+_TBCH-)_!#Y_E$]?K^>;_@Y&_Y,:'_ &,(_E;U
M_0S7\\W_  <C?\F-#_L81_*WH%3^./J=_P#\$"_^3,_!O_7C'_Z"M?NU7X2_
M\$"_^3,_!O\ UXQ_^@K7[M4$O=^K_,****!!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %5[NZALK6XO+EQ%;VL,EQ-(W 2*)"[L3[*I-6*^.OV
MV/CA8?!?X.ZW<W$ZP7OB&RN])L'+;6$T\1CPO/!)< $?I0!^7W[9OQ?\4_M+
M_&_0_@;\+KRXN/")N[:S\0W=F6>(;9!',9&0E5S\Q()XSCWK]B?V=O@3X:^
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MG-S:6\[#!EB1R/0L,U8)(/\ L]S_ )_#M3$B$<:11_*J *HZ8 '3BI2,\&@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH _B#_P""_P!_R>7^S[_V-6E_^E\-?V._ #_DB?PN
M_P"Q*T+_ -(HZ_CB_P""_P!_R>7^S[_V-6E_^E\-?V._ #_DB?PN_P"Q*T+_
M -(HZ#2?P0^?Y1/7Z_GF_P"#D;_DQH?]C"/Y6]?T,U_/-_P<C?\ )C0_[&$?
MRMZ!4_CCZG?_ /! O_DS/P;_ ->,?_H*U^[5?A+_ ,$"_P#DS/P;_P!>,?\
MZ"M?NU02]WZO\PHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5_/S_P5<\:77Q,\2^!?A/H<S&73]?MWNHHCDL/M"EPP'L.X)[=J_H&K^9?
M6KP_$G_@I%JO@Z=O/CTS5I6$3'>%\N8]%.>E '] 7[/?AJW\*?!KX>Z/!;I
M]OX:T\7&U0K/,8LNS=\]!^%>S5EZ)8KIFD:;IZ#"VEG! !C& B 8Q[=*T2^#
MC'Z__6H ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)4UL7+F9&N(T_P"6V[(P7'\0QZ]:!M6L^Y_0BLD;\HZ.!UVL&Q^1-><+\7/
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MC_T^>&**)?\ E./X&_[$WQ1_Z?/#%%!4MU_AA_Z1$]F_X-R?^2::A_U_7_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD^'H8D$MG"!-,%'F2.0N2S8W=NF?K7HPSW%+10 4444 %%%% !1110 4444
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M-?V._ #_ )(G\+O^Q*T+_P!(HZ_CB_X+_?\ )Y?[/O\ V-6E_P#I?#7]COP
M_P"2)_"[_L2M"_\ 2*.@TG\$/G^43U^OYYO^#D;_ ),:'_8PC^5O7]#-?SS?
M\'(W_)C0_P"QA'\K>@5/XX^IW_\ P0+_ .3,_!O_ %XQ_P#H*U^[5?A+_P $
M"_\ DS/P;_UXQ_\ H*U^[5!+W?J_S"BBB@04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7\V]KIY\!_\%)-<\5SKY*7^IS*)"-H.Z4XPW?.ZOZ2
M*_!'_@H'X7;X5?%GPM\2T'DIK&MP(9P-N2\Z94L,'&#0!^\.GW:W]A:7L>"M
MS!',I[$.H-7!G'/6O/OA/J/]K_#7P5J>[=]M\/V%QN]?,CSFO06.!G'>@ "[
M>F>:6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ***"<<G@#DD]J *]W=065M/=W,BQ06\4DTKN0JJD:EV.3QT!QZFORR
M^/?Q9UGXL^+AX+\(RR'PK:R^3JLZD[#Y9P[$@XY /YUZY^U)\<)+94\#^#[K
MS]5N7:VO(X'RX5SM<':21@9&,?UKY'G:'X?^&V6TD#>+=:(9K+[\[R3#' Y;
MDGW]: %OH;R>YT_X<_#N%KEY9$AU6:)2Q4.P64L1[9[BOU#^"?PCTCX7^&K:
MWMX4;4KVWAFOYF12PF8!V52<D8)&>XQCUKPS]E3X-RZ-9)X^U^U\K5]5\QS!
M,F9$RHP<.,@9;/3G\Z^SM6U?3M"T^XU/5;J*SL;5#)-/*0J(H!/4X&2 <#CZ
MB@#@_BG\2=(^&_AR[U*_G5+N2VF&GQ9 :2XVXCX)SC<>,=Q7Y1V]WJ/C76]3
M^)'Q"D:)+::1]*21L!D!)BVY.#P%Y%=/\3O&6H?&WX@W&GQ7+?\ "(:/<NZ7
MP=A;E4?D[@=G\.?_ -=<W+I]]\1O%.D_#GPNK7NC12PPWE_ "8X\$!MSH"!T
M[G'K0!Z'\#OASJ/Q@\=OKGB&!U\-:9(9=.+)\CB(Y38<8.0!CFOU;L[2&QM+
M>SMU"0VT,<$:@8PD:A!T[D#)]ZX7X9> K+X>>%M/T"V2-I+:/;-.H&9&P!][
MN.,_C7H= !1110 44F<Y ///X4*"!R<\^] "T444 %%%%'R_K\P$R"<=Z6C'
MM^E0RW,$&/.E2/=TW'&?\^M)NVKLEUN&KV1*"#G';K2DXZURVO\ C/PSX8LY
M+[6=6M+*"-=Q,DBJ6]ANP,_4^]8O@_XH>#/'.]=!UBUO)4;:8DD5F/IC!.?7
MG%<L\PP%/$1PL\;A(8F=N7#SQ%&->5_Y:3FIN_1*-VCHCA<5.E*O##5YT(?%
M6C2G*G'UFERK[].IZ'136!.,'&/J/Y4ZNLYQ 0<X[=:",\&E_"B@ '''I111
M0 4449STH ***;@[LYX].?3T^M #J*"< GTIO+*,<<^I]Z '44#H** "BJ%_
MJFG:7&)M1O(+.,G >=P@/YT^RU"RU&+S[&YANH3_ ,M(6#K^8J/:4^?V?/#V
MB7,Z?,N?E[\E^:WG:Q7)/EY^67)>W/ROEOVYK6OY7+E%&:*LD**:K;L\=*=0
M 4444 %%%% !5/4/^/"]_P"O6?\ ]%-5RJ>H?\>%[_UZS_\ HIJ /Y Y?^4X
M_@;_ +$WQ1_Z?/#%%$O_ "G'\#?]B;XH_P#3YX8HH*ENO\,/_2(GLW_!N3_R
M334/^OZ__P#2R:OZHJ_E=_X-R?\ DFFH?]?U_P#^EDU?U14!/XG\OR04444$
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y\?\%#_ (D^
M/?A[\%_$#^"]/FOY-2TFZMYTAC,C*KJP) &>1M'OSZ5_G@_$'Q]\1_#/QDO_
M !A-;ZWI.I+XB^V2.T4T"@+<[V&X[>!@G_\ 4*_U(O$GA/0/%UC)IOB+3;?5
M+*0,K07"!T*MG(P0?4U^4G[8'_!)'X(_M!:'>CPIH6F^&-<N(YF,T4440:9@
M2I60(I&6/&3P>I/6@#FO^"0O[;VC_M%_"32?!M]JD4WB3PY8)#*LUPK7$ABC
M4,,%MQ.4/!ZYXYK]HZ_B9^%_['O[2/\ P3/^/&F77A"TU76O"][JJ_VC/;_:
M)(%MGN,ONVC:%V$^W'I7]BWPA\>I\1/ ^B>("GE74^GV9O83G='<M"OFA@>0
M=X/YT >H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM+Z/^T?\#O#GB1-4AN==^RQ&_M_-5I@6A4YV@EOE*L6SZT ?<]%%% !1110
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M%N\Z<))VY9V^%OHY674_HFT_4;+5+6.\T^YBNK:4926%U=3[94GD5=K\#_\
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M HHHH **** "BBB@ )QS2 Y&:6B@ HHHS0 4444 -.[(QTXST]?SIU%&<=:
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MZT#]HSP-=^"]?OKJP@FBE2.6V9E.Z12/F*D-CGW^E?0](<]CCF@#^&S]N/\
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MHH*ENO\ ##_TB)[-_P &Y/\ R334/^OZ_P#_ $LFK^J*OY7?^#<G_DFFH?\
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MZ]2G;F<9+5J^UMC[2-3$X#ZO@LZS+ER^GAFX8RA)4:=DDJ<)7MS=.N_D>_\
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MM_P13\-:IX>_9CB_M.*2(WDEI-"CAA\C([# /UH _9//'/IS_6OG3XV?M*^
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M-9NN9[NV5G/7HJBORI\07EOKWB'P[\-8[C-\HM8S"IR<KM&.,]P0*_5WX=Z
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M^#?^O&/_ -!6OW:H)>[]7^84444""BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***9)(D2/)(RI'&I=W8X5549+,3P !R: 'T5\X^-OVL_@!\/;
MF6S\5_$31=-N86VR0M/&SJP."""Z\@]:P?#/[;/[-'BZ\2PT/XG:)=74CB-(
MS/$I9F. !B5N_'2@#ZLHJAINIV&L6<-_IEU#>6<ZAHIX'#HX(R,$>W/-7Z "
MBBB@!,\@=S3-Q#'/3TX_#]*D]\<TF!Z#\J %I" >" 1[C/\ .EHH 8(HQTC0
M?1%_PI]%&:+A\A,\@=S2T>^.:* "BBB@ HHHH **** "D*[NN>*6B@ HHHH
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M9B_\*ZU::M;%0V^W<$[3WVYSCUH [$<<>E%%% !1110 4444 %%%% !1110
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MRDAUN1UGL8I%^ZA.]!AN@ Z]2*_0\]./3BHK>WAM(8[>WC6*&% D<:#"JJC
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M/W@?7-2D>:ZGL(D=W)+$)!!@'))[F@#ZEHHIH7!)SUSV]3F@!U%%% !1110
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MJWHJ&VG6YMX+E/N7$,4Z?[LJ+(OZ,*FH **** "BBB@ HHHH *#G!QU[444
M(,XYZ_Y]*6C..M,+A59W(1%!9F)X '))XX&* 'UX)\8OCOX:^%]FUO-<)<ZO
M<1$6T$,BN8W8$+O"DD-T(YXS@\UYY\?OVF=,\ ::=+\(O%KGB6Z,MJUK /,:
MV+@QA\ Y#*26SCC@CD5\)VV@S:E,_CGXE:HTHO2;A+2YD+"VR0RQJCD[<=,
M#TQ0!9UJ7Q%\6=<G\2^-K^6S\-6KO<PPR2E$DC!WJF&."",#'OVZ55M!KGQ5
MU&+P;\.[*6TT:S=+:XNH8RBS(I"LQ<#G(&:T_#/A+Q9\>/$47AK18IM)\%6<
MH4ZC&KQQ3Q1]06  8%5YYQC-?J#\+OA+X:^&&C6UAI5E!]M2-5N;Y4'F3.
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M@GSWCPV1G))89]/_ ->*Y*S_ &COB5X+\20)X+>ZATM[D(YA9PJQEAD_*<
M>W_U_GN$?&7*,MKT,-7P65Y_DN*E&GCN>C&CF."E*T55Q.+GIBYQO>2CJW=^
M1[F?^'>-QU">*PV.Q^5YI07/A'&LZF"KQBTW2HX>-W0C)*RYM$O4[_X*?\$\
M?&OP9UBYT76KR\O+.21UMA;,[1[2QV!@F!CGG_.?HC6/@O<?#"]34];L)/[(
MB/GRO)$1^Z3YFRQ4#. <Y[5ZKX#_ &QV\)3>&9O%,(UR75W@6[>=5D-KYA7<
M3NSC;N]OYFOTK\<:1X ^/OPHO1I4EB]Q>Z2T\*HT:2I*\!W0M_P(\8_$<C'[
MME?AOP%Q'7GFF"PF'Q-?GABJ-"O^\I155*I%4[2Y))I]%:.BD?E>8\9\691&
MG@<57JT*4HSP]6M1M"<W!J$G)6YHOM?=:H_'33M-\ _M)^,=!TKX7Z,/MNA7
M,"ZI.EN"/W3CS"6 QV)R?RK]WO GP[TO1? 5AX4U32[&=!IXM;M9;:*0N)(@
MC@ET+ KV.<@_2OQ(_9&@\?\ [.7QC\4:1<> 2-"O[RXC36C%E1$TC?.)2O'R
M\\$>I[5^HOQ)_;8^#'P[TU8]1\2VG_"02P?)IJR1LZ3E<;<!]Q._H-O'J:^\
MR')LDR;$X_/<3"E@L;B(+#574IK#T:5"C'E5*CS))IQ2ORZOSU/E,YQV:9C3
MPF5T)5<5AJ3^L4E"?MZLZM2TI3J.-VFFW9-:6[GX.?\ !07]GN;X5_M#>&?$
M_P )M12QAOM3AEU:V$@CMU!E5I R A0!R.F,=Z^F?B+^U?;:G\./"_PF\%)'
M<_$1K2SM[R:PVMEBJI(28R><Y(SS^6:^0OVH]?\ ''[1'Q/TJ;1;F[L]#U2[
M39?()56*-Y!\P8# P#^/I7W-^R%^PR/"'Q(TGQ5K4A\1P20P3OJ$Y:78VU&*
M[G# 8/&.OUQBOF,!Q-1XDS+%0X>PN*GE.(QJP6+Q->#I7]G)1G+#4I>]9-:5
ME[MM?7Z;%9/_ &1EV&J9Y7H?VEAL,\5A</2:G)MJ\8XFK'W6TG_"?O=M=_M?
M]DSX)6UUX4TCQ-XVCN9?%,*1S2K< DK(<'^+I@XZ=_2OT,6,+&D8X5 %7']U
M1M7],55L=-L=-B6&QMHK>-55 L:[1A0 ,XXSQS@"KU?LE"A3P\(TZ<;<L(0Y
MFO>DH+E3E+K*W7<_*Z^(JXB;G5DY-RE)+[,.=W:BNBOT*E]90:A9W%C<+N@N
M8FAD4C.488/!X-?S"?\ !4?]AJ?P)KMQ\>?!^GRW-O)=RM-#:1%I"0 YR$!Y
MP_/'7BOZAJY3QEX)\-^/M&FT#Q3IL.J:7.<O;3HKH3@KG#*PZ'TKP.)N%\MX
MGR_$8/&X>E.M4P]2C0Q,HWJ4'/K%]KZM:W/6R+/L;D6,HXC#5:D:4:T*E:C&
M5HUE%ZIIIJ]MF?RF?L+O\5/%EQ8Z+H6D:A9Z;J3HFI+/%(BE6(5]XQC&.H/7
MM7]+WA+X2Z-X2^&]_IYTFQ;5I=&O))9FMH_,^T_9'=?FV[MPD'7UZ'%=)X!^
M!_PW^&KL_A3P[9:<Y)*M%#&A3)SQM4'/3G/X<UV_C"]N['PUK5Q8PFXO$T^Z
M$$(&2\CPNJ@#N<D5\]P!P)_J7DJRZMC99A5INNJ-1Q]RC2J-R5.E&2TMUM:[
M\F>QQ?Q6N*,S^N4\*L)3G['VD6TYU*D$DYSDGKMIVZ6/Y[?AYX4UG5/B5\1_
M[8UR6QU6TO[PZ+"UPT4:[99/*"J6 & !QUXK9\?^*_&FI>';GP+\6KLZGH.)
M(;3Y_-4QG(7N>JX_SQ7SUXK\(_M#3?%CQAKUQI.HZ#I!OKF2&Z$<T2O'YK,"
M&"@8(Q^8]*R;OQYK;SMI7B RZBT!*M-,K'!7KR1_D^U?R_QMXC87(\SGP_FE
M#/<EQN!EB53S[$*HLHQ<*M5N-/%4G%+&4N5V4(=UV/W'A[A:6:86.:X&KE>.
MP^)CAN;*J?)]>P\Z=.,93P]7_F'FWO)];WOJ2_"/]DGX6>+/&\5KJ'DV^@W\
M_P RR *NUY.G/LV#]/I6]^W9_P $F_[/\+Z/XC_9YO=TF8[BZ33C\P&,L<19
MQQC'3KSWQ4TOQ.J6<]UIVHFQN[7F*.-]I!4[@!@@CD8XZ<>E?0'P=_;/O_")
MET;QEJKZE;7 -K!!</YBKN.U<!\XQCCCCCGU]#@_C[@BK4PN1\19/@ZU//*G
MLL)Q#@HPBJV(G&ROA+NIAX-ZQE4T3>YEQ%POQ1AXU<UR;,L12J9;34Z^2XF3
MG35%6;O77N5IVO=1?E>USYL^#/P;^*?@[X?67@_4CJ-]=RVRQ7^\R2-&P4(<
M]2#GG\/2O2?"/PN\+^%KZ6R^(EQ=6ME>-@_:G9$^?KPY ].O3\Z_33X&_%7X
M3R:XTGB6>R%QKK$V,4XC*J9ON#:2#U..",=<'H>2_P""BG[.NJ>/?AI!X@^%
M-DC:B"6<V0(Q"0'252F"5/S^N"I!'>OT;!>"V0VCF4,;F&>4,/7G6H9/C\6Z
M^'ITG/G4%34E:+T:B^C[7/BL3XDYIS_4JF%PF65:].-*KF.$H*E5G/E47+F:
MU:>CE]Y\;>"?V;? K_%O0=3\ 0PZAIMS<PR7$D2+*B@R G>5R/S/?FOUL^*G
M[(OPP^)'@.XT?6+$64L6B3 W%E&D;&9+-F!<KM8@,HSU/4X/ KXU_P"">6E:
M)\)?!5S'\5-6MX_$B(BH=0?+0,K_ # !\$,!TX_#O7Z%^-/VA?A1HOA?6;Z7
MQ9ITA&FWBQ0QRJ7D>2!XT51GU;/T%?H7"W"W#G#"SG.:BP^!J9Y6AB,50K5(
M4\/@HT:?LU0PZDTZ<+)2DM+O4^-S[/<XSBIE^ I/$8F.5PE2HU:49SJXF524
M9NI5<4^>=WRIM;'\Q_PHT/6?V:/VF;S2;>ZN7^',6IO'>K.[>2\(G^;?N^4_
M*#_^KK^@'Q?_ &G- \-^)+6[^$%O'<WNKP16\"6(4E+R157<0G.0_7\_<_FS
M\0_B9K7Q*^,6NZ'I>FRG1]3U*41:FL3@!))F"L' ]#GK].#7ZB?L5_L<QP^*
M+?Q!XLC.KZ;"4N[8W \Q8WP)!CS,X*D=NI[]Z\W+,\P>?XZ&'R7VF(RY8QNG
MCTK>RK0ERRBDU>I1T:4U[NS>Y[6/RNOE.$>,S5QIXUX6*E@I2356E)0:YWHH
MU?[K]ZVI]I?LH_#?XCZWIZ^._C-YLVJWT4-]HRS9+0QRN'48?E<(#GTX%?H
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M,[Q7-A!.-Z11-\ZEE<$# P,>X_#[W"[%5(E5%48"JJJJCL HP /8"G*@0(J
M*B *J@8 "C: /0 < 4Z@ I"V.N:,?,&].WY_XTN,]1G\* "BBB@ HHHH ***
M* "BBB@ HHHH **** "ORH_X*(_$SQ?X5N_"_ASP[?/86^LB%+F<2&)%\QRN
MYFR ./\ .:_5>OQB_P""H_AW4_%^H^#?#NE22VMS?"")+R(-NA9W(#!UY4C.
M<]*!JW7^F?(>I>/OC?\ LZOHOCG2?%*^(M)O9[>>\L+.]^TRK'(0[AHT9F&
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MOK7CF_CBNI[JX42W$<Y.\EG<,P(;L2#W'K7[.CC@# '  [4 %%%% !1323D
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M-*JV=RAL\$$9!_ \4X< #THH Y7Q%X,\.^)[";3]4TRTDBG!#,MO"LO/7#!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDC@8Z?Y% .1FEJCJ&HV6DVDM[?W$=K:P*6DED8(J@#)ZD?I0%[%ZBOEOQ?\
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M6)V%7*_'B.Z_:-_9>G&CZ'I]_P".+,/Y;3RQRW2F-#G)R'4C )YZ<=Q7T?\
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M%;V]K$L482-5;:H"C<P ). /:M:BB@ HHHH **** "BBB@ HHIK$C&!G\#0
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MFF)RO%RISJX>5N>E)2A-/:46@HHHKZ4\8*0D< ]^*6D..,]>W% " @': ?\
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M<+$I56+MC=N'/4CGCC-<W\.5M?&T7BCPI:SI_9ZM*D,^\8=<M@YR <X'^<T
M?0?[//P9M?BS>?\ "Q/%;-<VD5P3!#G*F0'*J,GC[OH>/RK],+&QLM)LH;.T
MBBMK6UB6-%55151!C+$ #W)-?E)\%?B_XB^"&JS>"]:M&_X1,3NT=ZZY08)
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MB@ HHHH **** "BBB@ HHHH 0 #H*6BN-\7>/?#'@>U-WXBU*.RCVE@"5+D
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MZ_GT\,7;!D+&+C@\]\C\Z\;_ &+XK_P?^U'XCU?5FD@M]4EFB DR@<2L1CG
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M%Y9=",@N;6S8D'D>8J;3]0O3 R.U?HYX:\+Z)X0TRVTC1+..UM;=0D85%WD
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M9D21\#.%0G<2>W%:]? O[6?PN\9:IJ%EXZ\/:S-;VFF*C7%E',R*PB +[D!
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M/[-Q<L.Y_5Y2="HHU'4?+*E3E;6;VO&]KG5:QXUL]<^"7B;Q+I]O%YUMX:U
MM9[5+1S0VX^4QXW#[P;I][-?P$_'K6;_ .)_[26J"1IK>>'Q:+<01L8R4%X5
M*[1CC!P.,?05_5QIW[37V7Q7X\\.6'[[PGK2WMK;19/DK'-N3"C[G(VY]A]!
M7Q[X(_87_9Z\0_$^[^)_BSQ!:Z?<RZDVJFT\R,*T@E\W:1GDGGL>G K\<XHX
MSX;XQJ8'A++N(,MJYY]8DZ^'CB:4J,J%"24ZKFFX\TDFXPWUL?JW"V39CPI#
M,<]Q^58V&7SHP^K5?85'452K&\:3A9NT9.TI;.WR/I;P)\+O%_PI_9V^'^I?
M".YGTOQ/K]I9+<3EF0EY47=DY!P2<9XSQ7ZJ_LUZ+\3]'\$0CXHZBVHZU<I%
M.LK.7(5U#'KGUKXF\:_%7PAJ<'A7X;_#^Y,T>A/;06DD:_*S0LJ+\P'.<8R#
MT[5]_>%?&<'A?P;IDOC6_CM)TM8MID=2[((Q@8)']>_:OT[A^&#PV+K*CB:D
MJ&%PF'H>[44<#3G"$83Y8_#S3D[IJQ^>9U/%8C"TG4H0=7$XJO6O[/FQ<HSF
MI4[R2YN5)VMTZGLW.3Z<8_K2 '&&Y_S^%>1Z=\<?AYJ=U%9P:S&)YV"0JVW$
MC$X !W#N17K22H\:2AAY;JKJQ( *NH93G..0<U]C1Q%#$)NA5IU4G9N$E*S\
M[;'RU2C6HM*K2G3<ME.+C?TON/Z#V _E0#GD4 AAD$$'H0<@_B*6MC(*JW-[
M9V:[[NZ@MEZ[II4C&/7YR*LG.#CK@X^N.*_+3]I7QQ\0K#QY%::_-/H/P_>Y
M$+:JK-"B@G&2P(7IC'/3\*XLPQ<L%A9UX4G6G&RC!/E3;VYI/2*[MZ(ZL'AE
MBJ\:4JBI1=VY-7=ETC'>4GT1^C.H>/\ PKIR-)+K%DZ1@F1TG0HH'7+9(XYS
MBL'Q)\6_"7A_PE>^+AJ%O=V%G!).WE2JP_=H6PQ!XSCZU\@Z=\/_ (::MX!E
MOE^(8N+/4+-I%NOMJLRLR$G!\S@@_3I7PSXHUY_#]GKW@.WUR?5O"$\5RGV_
MS&D"[@P SN/&#@\C]#7SV*S[&X>G1G5PM*G'$TI^_3K1K.A5M[CG&/Q0N[R>
MRZM=/;PV383$5*D*6*G4G0J1<H5*4J7M*5US\KEM+>R>K/L7X-?\%&/ 'Q3^
M(M_X)B,4+07+P))O "[9"H.<C^N<>_'Z40SQ74,=Q;2I+#*BNCH0RLK ,"",
M]01QVK^'?3D\4_#GXV7U]X"26X@NKYG$Z!@P!E+$Y'/K@DYYYYK^B3]D#]M7
M3M2NM-^&7CB\\G6_+B17N&PRN5V[=SXQSC(R.@STS7Y?P+XLRQG%N8\#\3XG
M!+-5.I7RFOAZD.3%8:,FG"I9^Y5CLHO5[=S[;BO@&CALAP?$F0TL4\$X0IX^
MC74G*E6:7OPD_BA*_0_6OG'OC]:_,SX@>'[6]_:!23QO'<MX?DN=BRL6\CD]
M!DA<G)XQW]\G] -8^(7@_08HIM2UNR@28 H1+&2=V",_,,=>]>;?%*W\ ^*_
M!=QK]S>V*16JF]AU&-XQ)E%S@LI)RV%P?J,]J_9\QE#$4YT:&(P\J^'M7J4)
MSA*]..K52/->,6KOF:LG8_.,OY\/4A4JT:T:.(O0C6C&<;3D[+D=K.2:V6I\
MZ?M9?"SX:>'_ -FOXA^(;6/R8[;P[/<V-P' #2F,E"O3!P&.><;>?6OXK/@3
MX_\ &_CGXFZAX<T:^D>TA\4RP0[9&+*JW15<D'/;U_E7];?C/XS^!OC5\)?&
MGP;O]9$,26ES8P3^9CS5V21+SG)'/')Z^M?EM^QG_P $Y= ^'/Q4O_&6I7R-
MX:DUA]1^TNR[0AE+@Y)ZXYSS[=>/QKC.CD7&F*R3*<NJ9-F#HUXUL?@HUJ4Z
MV&=*4>:M*BGS15)JRF^UUJ?K/!]?$\,Y9G>,S*GCL-4J)1P%:I2FJ==2@N6-
M.=K.<T]8[_B?IY\+/B?\0/@QX%\+^&]4%S>W>K6UO%:D;F,9=% ]<8SW.#CG
MUK]1?A;?ZWJ?A:UOM=WB\N DN'SN573=@Y^M?"7CCQ)X%OO&?@O0O!*0:[_9
MTMO#<$[9!%L<(<8SC '7(%?H@VL:9H&C65SJ,D5A$;6 ^6-HP3$I("Y'3/KQ
MR.U?J>00I8?ZS2ABW6PN"A2H4GSWH4X1IJ_++X7RVMOI\C\VSN3K+#U'AO98
MC&2J5JJY?WLI.?N^XM8\R:?G<Z7-%8FC:]I.NQ&?3+E)U&<X(#8]=N2<<?3W
MK;KZ>$XU(J4)1G%[2BTXOT:;7XGSLHR@W&47&2W4E9KY!1115$A1110 4444
M %%%% !1110 4444 %4]0_X\+W_KUG_]%-5RJ>H?\>%[_P!>L_\ Z*:@#^0.
M7_E./X&_[$WQ1_Z?/#%%$O\ RG'\#?\ 8F^*/_3YX8HH*ENO\,/_ $B)[-_P
M;D_\DTU#_K^O_P#TLFK^J*OY7?\ @W)_Y)IJ'_7]?_\ I9-7]45 3^)_+\D%
M%%%!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444C#<,=.: %HH'  ]*
M1AN&.G- "T5FZIJMAHMG)?:C<);VT*[G=V X YV@D9/L*^</&'[4_P .='M+
MF+1]42_U="R1VX5?]8O &-S;LGI_7/ !].LZQ(TDSJD:C+.Q"JH'4L3@ >YK
MR_QO\7O!_@K3)KZXU2SO9XL_Z';7,;S';P<A2<'/&.OTXK\]=5_:=^+?C*ZG
MT"+138:3>$QK?)'Y7[MR1DN%7) Y&3@5X[>^%;'PKK'_  D7B_Q3<7T-P_G/
M8O*TJ+O^8J5+$<<]ORH ^F/&_P"UOJ7CBTGT+X?Z?=Z?J)W*ER=X._IG=QT[
M=/YFO 4@\6>(!.GQ:\2!H<,Z6\MSABI'"@,V>A'&,U0N]<UC4[NUD^$?AD7Z
M$J)9XK<DC) 8Y"^G/M7O7AO]E/Q%\5+6VUSQQJ=UHERI5WM09!D]=NT<X[=,
M#OCN ?/^D>(]-T*YG\.>#M GNY+IO*COA$TJ?-\N_< 0.3GM7M7P[_9C^)/B
MO58M6\:WSCPU=G>MBS%<0MSC82.QQ]:^\O 'P8\&^!-*MK"+3+.^NH513>S6
MZO*VP  @L,@\9)//''>O6&:"SMV8[(+>",L>B)&BC)]  * /(_ OP+^'_P /
MI4N=#TI%NE W32JCY8?Q!2IQ^9KUB[O;/3X3/>W,%I O_+2>18HQCD\L0/PK
MYS^(7[3?@+PI::A9Z;J:7WB&$-'!9*JD&4=.C.'YP,8[^M?$FN_&#XH?&N*X
MT+4(9/#NFJ9!'=1C[.&0YPY(V@DC&.?Y9 !]??%C]JOPIX"N'TO38_[;O)4,
M<<UF_F11RL, G9GH3D9]*^'S>^*?B#XDN/%OQ!O&3PG&S7-C:7+$*B[BZ *V
M!GD8XKE[2/PG\/HKG2]4N3XD\17#LML9_P#2&$AR$()W<Y/\SS7H/@+X<?$K
MXP7"Z3K=A/H?ADMMAF$;1*T1Y'.%&-I[4 8/@ZTU+XC?%[2H=%@=_"E@RPNT
M:EH/+3:!G VXP#4G[0ND67PA^+'AS4--06RZA=VRNR*$)9W4$$CW)_ST_2WX
M1_!7P[\*-+:QT]8[JX?;ONW3Y^.N"P#<G'/'TK\W/^"DY.F^(?A]> [3-K%H
M ?8RJ<=,_AT_2@#]9O!MV;_PKX?O"=QN=*M)BWKOB4YKI:X#X6N9_AQX+D)Y
M?P[IK9Z_\L%KO@,#% "T444 %%%% !1110 4444 %%%% !1110 444@(.<=N
MM $-U<1VMO-<2N(XXHWD9V.  JEN3^%?A-\7_P!NKQ5#\<I/ACH&K1PV[7SV
MOF&4; #)Y?()QWZ?TX'[?^*M-DUGP]JVG02M%-<V5RD3KD$2&%P@'?EB!7\=
M7[6WP0^+OPC^-NM?$/6[6\@T!;Z:YMM06*3/E^<75@XXZ8/!_EQ^8>*.=<1Y
M%E&'QV19=6Q].C6Y\PAAI-5U05M*<8IMMZW?G]WW? >5Y/FV85\-FF+I82<J
M2CA'72=*563M[U]--[-ZVZ]+O[=?P+^*_@_XE:1\?-<OKW5?#%V8KJ9[.23R
M%23#-ED)7'7K_A7<?";QG#%I>D_$+PA<O]IA$<TUO(Y<J4P6# D]\YX]CWKW
M'X2?M$:/^T;\*KGX5^,XUO='M]/:WBU"^P9%F$910#)DY#$8P<_E7YZW3ZK^
MSYXWUS0]0W+X-NIIUTIVR(FB=CLVY^7&T\8__5_(_BA1AQIEV6\=<"YSC</G
MF35(/,LJ>(DL;EV)BXJ;E2OS6=M9VL[V/Z'X*<^'<5C.%^)<MPU7+<;&?U+'
M^RB\-C<.U[B4K<J=OL]-S]^[:3X>_MB_!2?2=?O=.L/&6E6+M&7\I)6DBC)
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M/.>E?;7[5>I>-[#X4:XG@6RDO=4NK2ZAE2-2S+ 8L,<+R,@FOX_/#OCGQ?\
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MX(:0-5N-0M?$_B 6R7"6-SLF8W&P-L*ON(^; Z'T]J^!_P!KS]OOXJ^%!?>
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M^5N-PQM&=O.>O'UKRRQTSPO\.=1N/^$LUZ;7I9V.(IW:=07)X^;<,9)&,>U
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M-0N9I1"L\EM.6D+, 221SDMW/-?37A[]E3]H;1=:TS5?$^@W=B\CPW1!MY$
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M]'BMH_MD-EEHD<)\Z_+E1SC'3\Z^:;+P/-XMUFW@359H+#PK*  KD).MN_\
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MIXK/<HIX53Q<6J%7$8>;2E.,E_O%H:V^R?SKZ?\ LZ^+?&L</B/3+]HM3MY
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M[<SV]K.Q;(<EE 5B?IT[TDT_CW6M2BG^&'A02:5.P"W,5L<[2<;MP7N,8^M
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M &[ (;/(R3G_ !KZ11$C4)&JHB@!550J@#H !@ ?2G44 %%%-=U12S' '4T
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M5XX\,QZMI-\D<EPYM@Z?,OS DH1ZGK7I/@?]L3X#>#9--NII[>'4K!HC)L9
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M@.IW%MQ#YR>WXYKZFT?1M.T&QBT[2[9+:UA 5(T ' X&X@#<0/6M2DR,X[T
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MNN,G_?20#^M?T+5_//\ \'(Q(_89]AXAR3Z?);@_I0*'QQ]5^!\D_P#!&_\
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M#VM5_=1JN  JCT& M2 8&/S^M"\*H] /Y4M !1110 4444 %(21CC.?TI:*
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M%(5RYY.3L/4^]9/A/]M[XV_8[/5]3T('PG#'#!+>"$%U55"EB^W.0 <<@C
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M.T\87_&OF$I!X!\)VQT*WCU+QEJL:.Q*AYUEE )[%OO'B@#3U36/C+ NV_\
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M/ 'IVH _;*BBD(SP: %HI 0>E+0 4444 %%%% !1110 4444 %%%% !1110
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MM:2M':I*C2%VC8!&4'KN(&.XZ^E?EWK&N^#K.Q-IK&G'2M1 VN\$&Q@PZD8
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MO%-X DK0XN!W'E0J23[G!)SU.: .Y\9>,M(\%Z+>:QJEQ%&EM&76)G >0XR
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M%4*KYDW!KV=10:LW3U=NMVMS^<S4?B!8^(YE:_A U=&S/<C@,W&XYX&">?\
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M;W?7<_,\9B)8G$U:SE*2G.3CS=(7]U)?926RZ;=!:*#GM2#..>M=9RBT444
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M"XU3RUY(5G#8'/J><=>*L0_\%!+=Y?)?P->9#!2VVXP<\$\''Y5X[>?#[X]
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M7Q]=VVA!CH[RN)&C_P!7D=<X^7KU_'TKQ+Q=>:1X4\-KX)TK=<ZSJ$7D0W<
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MX\_'R,@B+/&3\_J.G>LN\?QU\6;B&3Q[J!LK&T;SBGG;5<*<D$9P?IS],8H
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MEU9]A(*AY3G!QCK[_P#UO3M/#/C?X?1LL<4MY>R9!Q,C-N(!X.X'T'Z<T:]
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M (27IW$O7]:B?]C[XLSLJCQ08ER-Q,VW@E<\[AV![U^I>03CO1SGIQZ__6H
M^,_A/^RIIWAF>'4O&SQZ[J-L0]L[NLNV13E3D[L8//OC&.]?9,420QQPQ*$C
MB18XT48540!5  X  %244 ,R&W*0",$$'D$=""".AKP+XB_L[^ _'#3ZG_9<
M-MKY#-%?(%4[SZ\#&,GG/M7T!10!^>L?[(/B6&Y>2+7PL3$[4^T#@9) QN]\
M?X5UFF_LHRHX;4M06X&1N'F!@1W[GKS7V]10!\N6G[*?PX95.IZ<EPW&[A3N
M]><?SKI+3]F/X-6@7R_"=L6&/G8KDGU_U?\ GUZU[_03CK0!YCI_P>^'VF;?
ML6@6\.S[N #C'3^&NVLM!TK3BOV2SABV@  (O&.AZ=?I6Q10 444UB0,CUH
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M "O+O&_QI^%WPZBEE\8^,]$T4PY#PW5W&DV1U 0D<CW85\X_MU?M:Z%^R?\
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MRB>OU_/-_P '(W_)C0_[&$?RMZ_H9K^>;_@Y&_Y,:'_8PC^5O0*G\<?4[_\
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MO+&ZL=X#*2&7//'&,5^1?C?]HSXD^.;V>?4;S6HI;MRQ6U,Q4%CG'RG&._\
M(5^+\:>.G!G".*EE<:U7.,X4O9K!9=!UU"JMZ=6<+\LTVDU^9^Y<"^ /&_&>
M%AFTZ-'),DE%3>.S.:P[G3=K5:5.HUSP:U3OYV/ZJ#\6_AH&VGQMH ;T^W)G
M^5:=C\0?!.ILJ:?XGTB[9B JPW:,23T]*_D$W_$*XC-XNL>)@I&_'^D].O\
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M_P"/"]_Z]9__ $4U '\@<O\ RG'\#?\ 8F^*/_3YX8HHE_Y3C^!O^Q-\4?\
MI\\,44%2W7^&'_I$3V;_ (-R?^2::A_U_7__ *635_5%7\KO_!N3_P DTU#_
M *_K_P#]+)J_JBH"?Q/Y?D@HHHH)"BBB@ HHHH *0Y(XX-+10 @R!SR:6BB@
M HHHH **** "BBB@ HHHH ,>WZ4444 %%%% !1110 4444 %%%% !1110 4=
M>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI&94!9F"J.
MK,0 /J3@"OC+X^_MB^ /A%%=Z4FHPW.OH'5(TD1E5U&/X2>=W&2<>U<>/S#
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M!Y?AS\(?!'@^XB$-SHVCV]K<(%V_O8UVG/OA10![)35!&<G/YFG44 ?R&_\
M!<GQ]K7B/XM>$/AI<W$K:)/K]O:O;AV5&C>X"$$ XYR1]/U_;WX"0^ /V1/V
M)_"FM:);V-AJMUX.M-05-B"YN[V>,A%P/F=4\OS,'JY!(.*_*O\ X+H_ /6[
M.;P]\;-)L+B[ATG54OIS;PM(RBWF\UB=HR!CGZ5Z?^R?\;_!O[:_P2\%^ +G
M7K?2]?\ #&DPV36-Y=)"7>")8PCQNPZ,.A'KTH \:^ OCGQ]XY_:<?XN:]XD
M:VLKS72$TR:4JIC:?C$3$#!'MTY%?9G_  6<^"/A'XD_LTM\1KJR@;5M.LX[
MB&[CCCC<O'&KJP=0&SE>QKY,UC]DWXL^!_C+IVH6FLV%OX:L-1BNYS#<QI";
M6*7<S$AMO*@G\_6L/_@K1^VOH>J?"?P]^SUX"NUUCQ'=P6>GW\>GR"X8S.$A
MD!$98Y#9Z^_M0!]9_P#!##XB:IK/P+_X1:]E>6VTR>2*W#LS[!'E0,DG  7
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MHH **** &J",Y.?S-.HHH **** #&.@Q^%%%% !1110 4444 &,=!C\****
M"BBB@!I!)!!XXR.?6G444 %%%% !1110 4444 -()((/'&1SZTZBB@ HHHH
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M#_T&@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1/#GQ&S/PWS/%9KE>#P6+Q&(PL\/3>+IQD\-.6V(HS<92C4CY6O8_%;X!?\
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MGU_G7L8_Z362XJBZ/"?#F=YOFE1<M'#5\)4HP]I+2+<E%72;O:UG;Y'C9?\
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M  4D\7M_PC=]'XCCEFS9O>M'=C*'";MY'H<]:_0O]AS_ ((_^+;[QEIGQ?\
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MQC_]!6OW:H)>[]7^84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC(Q%O$& 88R&"9S7ROXE_8X^'GB/5)]7>^U*VNI69PL)"Q*S-NZ!^!GT!^E
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M;:22NV]$DMVV]DAI.348IN4FDDE=MMV22ZMO1(Z1F"J68A54$LQX  &22>P
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M96;6OW'IE%-&[)STYQT]?SI&WYXSCM^7?_Z_X5]J?#I7ZI>N@^BBB@04444
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M16MG:QK#!!$H2..-!A54#@ 591$C18XT6-$ 5$10J*HZ!54 *!V   I2,C%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9-$U_1H)=5M0(7BDW1QED1>-_#*,?7BO#O\ @E/I_B']H/P[XCB^*6FRB^\
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M_P#?Z/\ ^*H^UVO_ #\V_P#W^C_^*H L457^UVO_ #\V_P#W^C_^*H^UVO\
MS\V__?Z/_P"*H L457^UVO\ S\V__?Z/_P"*H^UVO_/S;_\ ?Z/_ .*H L45
M7^UVO_/S;_\ ?Z/_ .*H^UVO_/S;_P#?Z/\ ^*H L457^UVO_/S;_P#?Z/\
M^*H^UVO_ #\V_P#W^C_^*H L457^UVO_ #\V_P#W^C_^*H^UVO\ S\V__?Z/
M_P"*H L457^UVO\ S\V__?Z/_P"*H^UVO_/S;_\ ?Z/_ .*H L457^UVO_/S
M;_\ ?Z/_ .*H^UVO_/S;_P#?Z/\ ^*H L457^UVO_/S;_P#?Z/\ ^*H^UVO_
M #\V_P#W^C_^*H L457^UVO_ #\V_P#W^C_^*H^UVO\ S\V__?Z/_P"*H L4
M57^UVO\ S\V__?Z/_P"*H^UVO_/S;_\ ?Z/_ .*H L457^UVO_/S;_\ ?Z/_
M .*H^UVO_/S;_P#?Z/\ ^*H L457^UVO_/S;_P#?Z/\ ^*H^UVO_ #\V_P#W
M^C_^*H L457^UVO_ #\V_P#W^C_^*H^UVO\ S\V__?Z/_P"*H L457^UVO\
MS\V__?Z/_P"*H^UVO_/S;_\ ?Z/_ .*H L457^UVO_/S;_\ ?Z/_ .*H^UVO
M_/S;_P#?Z/\ ^*H L457^UVO_/S;_P#?Z/\ ^*H^UVO_ #\V_P#W^C_^*H L
M457^UVO_ #\V_P#W^C_^*H^UVO\ S\V__?Z/_P"*H L457^UVO\ S\V__?Z/
M_P"*H^UVO_/S;_\ ?Z/_ .*H L457^UVO_/S;_\ ?Z/_ .*H^UVO_/S;_P#?
MZ/\ ^*H L457^UVO_/S;_P#?Z/\ ^*H^UVO_ #\V_P#W^C_^*H L457^UVO_
M #\V_P#W^C_^*H^UVO\ S\V__?Z/_P"*H L457^UVO\ S\V__?Z/_P"*H^UV
MO_/S;_\ ?Z/_ .*H L457^UVO_/S;_\ ?Z/_ .*H^UVO_/S;_P#?Z/\ ^*H
ML457^UVO_/S;_P#?Z/\ ^*H^UVO_ #\V_P#W^C_^*H L457^UVO_ #\V_P#W
M^C_^*H^UVO\ S\V__?Z/_P"*H L457^UVO\ S\V__?Z/_P"*H^UVO_/S;_\
M?Z/_ .*H L457^UVO_/S;_\ ?Z/_ .*H^UVO_/S;_P#?Z/\ ^*H L457^UVO
M_/S;_P#?Z/\ ^*H^UVO_ #\V_P#W^C_^*H L457^UVO_ #\V_P#W^C_^*H^U
MVO\ S\V__?Z/_P"*H L457^UVO\ S\V__?Z/_P"*H^UVO_/S;_\ ?Z/_ .*H
M L457^UVO_/S;_\ ?Z/_ .*H^UVO_/S;_P#?Z/\ ^*H L457^UVO_/S;_P#?
MZ/\ ^*H^UVO_ #\V_P#W^C_^*H L457^UVO_ #\V_P#W^C_^*H^UVO\ S\V_
M_?Z/_P"*H L457^UVO\ S\V__?Z/_P"*H^UVO_/S;_\ ?Z/_ .*H L457^UV
MO_/S;_\ ?Z/_ .*H^UVO_/S;_P#?Z/\ ^*H L457^UVO_/S;_P#?Z/\ ^*H^
MUVO_ #\V_P#W^C_^*H L457^UVO_ #\V_P#W^C_^*H^UVO\ S\V__?Z/_P"*
MH L457^UVO\ S\V__?Z/_P"*H^UVO_/S;_\ ?Z/_ .*H L457^UVO_/S;_\
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M:[7_ )^;?_O]'_\ %4 6**K_ &NU_P"?FW_[_1__ !5'VNU_Y^;?_O\ 1_\
MQ5 %BBJ_VNU_Y^;?_O\ 1_\ Q5'VNU_Y^;?_ +_1_P#Q5 %BBJ_VNU_Y^;?_
M +_1_P#Q5'VNU_Y^;?\ [_1__%4 6**K_:[7_GYM_P#O]'_\51]KM?\ GYM_
M^_T?_P 50!8HJO\ :[7_ )^;?_O]'_\ %4?:[7_GYM_^_P!'_P#%4 6**K_:
M[7_GYM_^_P!'_P#%4?:[7_GYM_\ O]'_ /%4 6**K_:[7_GYM_\ O]'_ /%4
M?:[7_GYM_P#O]'_\50!8HJO]KM?^?FW_ ._T?_Q5'VNU_P"?FW_[_1__ !5
M%BBJ_P!KM?\ GYM_^_T?_P 51]KM?^?FW_[_ $?_ ,50!8HJO]KM?^?FW_[_
M $?_ ,51]KM?^?FW_P"_T?\ \50!8HJO]KM?^?FW_P"_T?\ \51]KM?^?FW_
M ._T?_Q5 %BBJ_VNU_Y^;?\ [_1__%4?:[7_ )^;?_O]'_\ %4 6**K_ &NU
M_P"?FW_[_1__ !5'VNU_Y^;?_O\ 1_\ Q5 %BBJ_VNU_Y^;?_O\ 1_\ Q5'V
MNU_Y^;?_ +_1_P#Q5 %BBJ_VNU_Y^;?_ +_1_P#Q5'VNU_Y^;?\ [_1__%4
M6**K_:[7_GYM_P#O]'_\51]KM?\ GYM_^_T?_P 50!8HJO\ :[7_ )^;?_O]
M'_\ %4?:[7_GYM_^_P!'_P#%4 6**K_:[7_GYM_^_P!'_P#%4?:[7_GYM_\
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MX+*_]$.G_P#!ZW_R)7]D-% 7\E^/^?E_5V?QO?\ "^O^"RO_ $0Z?_P>M_\
M(E'_  OK_@LK_P!$.G_\'K?_ ")7]D-% 7\E^/\ GY?U=G\;W_"^O^"RO_1#
MI_\ P>M_\B4?\+Z_X+*_]$.G_P#!ZW_R)7]D-% 7\E^/^?E_5V?QO?\ "^O^
M"RO_ $0Z?_P>M_\ (E'_  OK_@LK_P!$.G_\'K?_ ")7]D-% 7\E^/\ GY?U
M=G\;W_"^O^"RO_1#I_\ P>M_\B4?\+Z_X+*_]$.G_P#!ZW_R)7]D-% 7\E^/
M^?E_5V?QO?\ "^O^"RO_ $0Z?_P>M_\ (E'_  OK_@LK_P!$.G_\'K?_ ")7
M]D-% 7\E^/\ GY?U=G\;W_"^O^"RO_1#I_\ P>M_\B4?\+Z_X+*_]$.G_P#!
MZW_R)7]D-% 7\E^/^?E_5V?QO?\ "^O^"RO_ $0Z?_P>M_\ (E'_  OK_@LK
M_P!$.G_\'K?_ ")7]D-% 7\E^/\ GY?U=G\;W_"^O^"RO_1#I_\ P>M_\B4?
M\+Z_X+*_]$.G_P#!ZW_R)7]D-% 7\E^/^?E_5V?QO?\ "^O^"RO_ $0Z?_P>
MM_\ (E'_  OK_@LK_P!$.G_\'K?_ ")7]D-% 7\E^/\ GY?U=G\;W_"^O^"R
MO_1#I_\ P>M_\B4?\+Z_X+*_]$.G_P#!ZW_R)7]D-% 7\E^/^?E_5V?QO?\
M"^O^"RO_ $0Z?_P>M_\ (E'_  OK_@LK_P!$.G_\'K?_ ")7]D-% 7\E^/\
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M  OK_@LK_P!$.G_\'K?_ ")7]D-% 7\E^/\ GY?U=G\;W_"^O^"RO_1#I_\
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MX+*_]$.G_P#!ZW_R)7]D-% 7\E^/^?E_5V?QO?\ "^O^"RO_ $0Z?_P>M_\
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MO_1#I_\ P>M_\B4?\+Z_X+*_]$.G_P#!ZW_R)7]D-% 7\E^/^?E_5V?QO?\
M"^O^"RO_ $0Z?_P>M_\ (E'_  OK_@LK_P!$.G_\'K?_ ")7]D-% 7\E^/\
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M  OK_@LK_P!$.G_\'K?_ ")7]D-% 7\E^/\ GY?U=G\;W_"^O^"RO_1#I_\
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MX+*_]$.G_P#!ZW_R)7]D-% 7\E^/^?E_5V?QO?\ "^O^"RO_ $0Z?_P>M_\
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MO_1#I_\ P>M_\B4?\+Z_X+*_]$.G_P#!ZW_R)7]D-% 7\E^/^?E_5V?QO?\
M"^O^"RO_ $0Z?_P>M_\ (E'_  OK_@LK_P!$.G_\'K?_ ")7]D-% 7\E^/\
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M  OK_@LK_P!$.G_\'K?_ ")7]D-% 7\E^/\ GY?U=G\;W_"^O^"RO_1#I_\
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MX+*_]$.G_P#!ZW_R)7]D-% 7\E^/^?E_5V?QO?\ "^O^"RO_ $0Z?_P>M_\
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MO_1#I_\ P>M_\B4?\+Z_X+*_]$.G_P#!ZW_R)7]D-% 7\E^/^?E_5V?QO?\
M"^O^"RO_ $0Z?_P>M_\ (E'_  OK_@LK_P!$.G_\'K?_ ")7]D-% 7\E^/\
MGY?U=G\;W_"^O^"RO_1#I_\ P>M_\B4?\+Z_X+*_]$.G_P#!ZW_R)7]D-% 7
M\E^/^?E_5V?QO?\ "^O^"RO_ $0Z?_P>M_\ (E'_  OK_@LK_P!$.G_\'K?_
M ")7]D-% 7\E^/\ GY?U=G\;W_"^O^"RG_1#IQ_W'7_I9FDD^/'_  63>":
M_ Z<B9&0D:Z^!N!!_P"7//>O[(J* YO[L?N/XFOV'_V9?V]M?_X*.>!/V@_C
MM\-3X<\.V>@ZYIE_=_VA+>NLNH:CH=S"OEFUA10!8RDR-)E0-@4^8Q4K^V6B
-@'*]KI:)+33;[S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gu0gjnulhgsv000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +Z!X@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#D_P#@E%_P
M2Q\+?MA>#[C6/%&KZO=26MQ<0&>;4+QGD%O/)'YCXF"!G5=S!551GA0.!^T!
M_P"#<KX0,S$:G?H!T!U"[.?_ "/61_P;BRR#X9:F@8A6N]2!'J/M%QQ^/2OL
M[_@JG_P40\?_ +%WC?P!8^&+*>[TS6FLOM@B1F \]TWY"@YX;'/;CI0:.4E)
MV?;]'ZGR&/\ @W*^$9)!U&_ ['^T+LY_*>FO_P &Y?PCW B_O^/^HA>=O^V_
M\Q7Z._$']O'6K;]F+X=?&+1HEBU7Q3+IT=S:QX27?<%%.8P-P&3R,#GGKS7W
M=X#^.?A:_P#"/P^N?%.LV^G^(_%^CV=W%93$++-/..@!(.2-I/&<GG)YH%SR
M[_UI_E_6A_/G_P 0YOPD_P"?_4/_  87G_QZC_B',^$O_/\ ZA_X,+O^7G9K
M^D\_$WP4NL3Z"VMVPU2VB\^:U++O2+&[<?FSC'/2O+-1_:P^"&F:Z_AZX\7V
MIOXF=)EC*,(I$W91AYF<Y7'.,']0.>7\S_K_ (9?<?@-_P 0YGP?Z?VM>A_^
M>?\ :%WNZ9'_ "W_ *4W_B',^$O:_P!0_'4+L?\ M:OTYC_:GU/7OCU-IGA_
M4Y9_"J3[FE#'R4A##GCY5&WD=L?E7V+K_P"U3\%O"PMTUKQAI]O(VQ+@&>#,
M$A"@A_W@R=Q/'R_AT '/+O\ UI_DOZL?@!_Q#F_"3_G_ -0_\&%Y_P#'J:O_
M  ;F?";G-_J/;'_$QNS_ .UJ_HOO/CO\++#0=,\377BNPBT;6'CCT^[,B;+A
MY<!%7Y\9.>F36U>?%?P'87NDZ?=:_:Q7>MQ)/ID3,NZYCD&49,L#R".QH#GE
M_,_Z_P"&7W'\W/\ Q#F?"7_G_P!0_P#!C=C^<U-'_!N;\)>]_J'_ (,+O_X^
M:_H)\4?M0_!GPCK\7AC5_%EG#KDKA%L=\?F9/L7W?AM_&O:]"U[3?$>GP:GI
M4XN+2=%>.0=PPR/4?K0'/+O_ ,#^K+[C^8S_ (AS?A)_S_ZA_P"#"\_^/4?\
M0YOPD_Y_]0_\&%Y_\>K^HRB@.>7\S_K_ (9?<?RY_P#$.;\)/^?_ %#_ ,&%
MY_\ 'J/^(<WX2?\ /_J'_@PO/_CU?U&44!SR_F?]?\,ON/Y<_P#B'-^$G_/_
M *A_X,+S_P"/4?\ $.;\)/\ G_U#_P &%Y_\>K^HRB@.>7\S_K_AE]Q_+G_Q
M#F_"3_G_ -0_\&%Y_P#'J/\ B'-^$G_/_J'_ (,+S_X]7]1E% <\OYG_ %_P
MR^X_ES_XAS?A)_S_ .H?^#"\_P#CU'_$.;\)/^?_ %#_ ,&%Y_\ 'J_J,HH#
MGE_,_P"O^&7W'\N?_$.;\)/^?_4/_!A>?_'J/^(<WX2?\_\ J'_@PO/_ (]7
M]1E% <\OYG_7_#+[C^7/_B'-^$G_ #_ZA_X,+S_X]1_Q#F_"3_G_ -0_\&%Y
M_P#'J_J,HH#GE_,_Z_X9?<?RY_\ $.;\)/\ G_U#_P &%Y_\>H_XAS?A)_S_
M .H?^#"\_P#CU?U&44!SR_F?]?\ #+[C^7/_ (AS?A)_S_ZA_P"#"\_^/4?\
M0YOPD_Y_]0_\&%Y_\>K^HRB@.>7\S_K_ (9?<?RY_P#$.;\)/^?_ %#_ ,&%
MY_\ 'J4?\&YOPE'(O]0_\&%W_P#':_J+HH#GEW_+^NB/Y<7_ .#<WX3'&+_4
M>^?^)C=C_P!K4X?\&YOPD_Y_]0_\&%Y_\>'\Z_J,HH#GE_,_Z_X9?<?R#?&C
M_@@3\,?!=C"=.U'4DN+E/W+"_O!ELE>")^<'L*\BTC_@W9U+7](.K66LZOY4
M@+1 :C?Y(.2,#S\^F?SK^G#]KG6+C3[OPS'YS16S21[ST4 R?-_/O_2O5/!'
MQA^'WASP?I,.K>(H87$:#YRK'<RJ,#!!ZCWH%S2[G\A6J_\ !O[K6@%ENKS7
MIR>!MOM1/&/^N_H/SZYKYO\ C-_P22M?A?I5I)=?\)#"\EPBR3O>:BL>"PS\
MQGQT_P \U_<_XK^.7@/3+"WN8[B/4S=+FU_=AE;(XQG<><@_Y-?D/^V_\?[3
MQUIVG>!+3PU%;W-SJ*!+Q(%#[9'5%Y"Y_7OF@.:7?\O\C\O?V</^"&OPP^+/
MPXB\375[J9N4M?-F9K^].2$!/)GYYXKYT^)G_!&WPWH/B>33]$FUN>V@N"A6
M"]U \!CG[L_H /\ ]1K^MC]F#PG<_#[]G*"[D=HI;C26G(Q@[#& #R,]3C\3
MBN)^!=E8>,/'&IMJ]C'>P?:Y<-*JL.6/<@]OTH#FEW?]?U_6I_+_ *#_ ,$C
M_A>+:)-6BUM+D@;R]W?Y!QR3F;^=>B6/_!&OX*ZQIFJF+4-0M;FVL9IHF>_O
M%_>(A91S/US[\=:_KGUKX#>#-5DEDCLH+8R XVQ+\N1VPO\ GKUKPSQ]^RQH
MJ>'M:N[37?[-,=A=2;E8Q;MD3.%R=H/0#KF@%.2:=]C^/?\ 9I_X)$>$OB+\
M5=>\(Z[K&IRV=K>2PVF=3O65E$C*NW,_/ '3V]37ZP'_ (-S?A(0A%_J&2HS
M_I]V,''(/[X_K7I7[(^AZAI?[1>J6EK>R30V.J.K3C+"4+.1G=R#TZ^E?T?1
MDF.,MR2BDGU)49_6@?/+O_7?UT/Y=S_P;G?"4]=0U _]Q"[_ /CM)_Q#F_"3
M_G_U#_P87G_QZOZC** YY=[>EO+_ "/Y<_\ B'-^$G_/_J'_ (,+S_X]1_Q#
MF_"3_G_U#_P87G_QZOZC** YY?S/^O\ AE]Q_+G_ ,0YOPD_Y_\ 4/\ P87G
M_P >H_XAS?A)_P _^H?^#"\_^/5_4910'/+^9_U_PR^X_ES_ .(<WX2?\_\
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M ,>K^HRB@.>7\S_K_AE]Q_+G_P 0YOPD_P"?_4/_  87G_QZC_B'-^$G_/\
MZA_X,+S_ ./5_4910'/+^9_U_P ,ON/Y<_\ B'-^$G_/_J'_ (,+S_X]1_Q#
MF_"3_G_U#_P87G_QZOZC** YY?S/^O\ AE]Q_+G_ ,0YOPD_Y_\ 4/\ P87G
M_P >H_XAS?A)_P _^H?^#"\_^/5_4910'/+^9_U_PR^X_ES_ .(<WX2?\_\
MJ'_@PO/_ (]1_P 0YOPD_P"?_4/_  87G_QZOZC** YY?S/^O^&7W'\N?_$.
M;\)/^?\ U#_P87G_ ,>H_P"(<WX2?\_^H?\ @PO/_CU?U&44!SR_F?\ 7_#+
M[C^7/_B'-^$G_/\ ZA_X,+S_ ./4?\0YOPD_Y_\ 4/\ P87G_P >K^HRB@.>
M7\S_ *_X9?<?RY_\0YOPD_Y_]0_\&%Y_\>I#_P &YOPEP<7^H9Q_T$+S_P"/
M5_4;10'/+^9_U_PR^X_ER3_@W,^$V.;_ %#KWU&[_P#CU _X-S/A(,_Z?J'/
M_40O/_CQ_I7]!GQ&_:>^#?PIUZW\-^./%=KHVJW,BQ0P3-&&9W.%&&D0\GCI
M7K=EXP\/ZAX93Q?:7\<OA][,WZWX(\LVJ]9,ABN/^!4!SR_F?]?\,ON/YFO^
M(<SX2_\ /_?_ /@QN_Y>=FD_XAS?A)_S_P"H?^#"\_\ CU?T#^#_ -J/X+^/
M?%TG@CPMXMM-3\0Q3&![*-HMPE!VE?EE8YSQT_*OH6@.>7\S_K_AE]Q_+G_Q
M#F_"3_G_ -0_\&%Y_P#'J/\ B'-^$G_/_J'_ (,+S_X]7].6N^(='\-67]H:
MW?P:?9[UC\ZX=43>W098@?Y'K6A8WUKJ5I;WUC/'<VEU&LL$\3!XY$;HRL"0
M><@\]010'/+^9_U_PR^X_E]_XAS?A)_S_P"H?^#"\_\ CU!_X-S/A)_S_P"H
M?^#"\_\ CU?U&44!SR_F?]?\,ON/Y<!_P;E_"8-_Q_ZAC_L(7F.GIYQI_P#Q
M#F_"3_G_ -0_\&%Y_P#'J_IQUWQ%HWAJT6^UN_@T^U:01+-<.J(7;HN6(]16
MG:7=M?6T%Y9S1W%K<QK+!/$P>.2-QE65E)!'\CD'D4"YY=_R/Y>Q_P &YOPD
M_P"?_4/_  87G_QX?SKQ7XV?\&^'@?PEH4VO:'J&J"WM(]]QY>H7F  "3DK/
M^&2*_KU8D#@9Y]#7DWQQ1I/A;XL4':?[-<Y';C_/O0/GEWO_ %_P+'\3-U_P
M1V\''1+/5+?4M6Q)=K;R8U"^'.X#M/WZ'-?H/X _X-Y/A7X@\(:-K%U?ZB9[
M^V2X;=?WF2&'7)G!/.?_ -=?;%C;7<W@5561F\G5]^<=-LI/\OSS7ZZ? 37A
MJWP^T2W>3?-8VD<3>H4!< CM@DG\: YY;W[=NA_*9^T9_P $%?A_\+_#EOKV
MGZCJ:Q2W'D$KJ%Z.0%."1/[C^5?-\'_!%KP[)J/AF4ZEJQL=4,!G_P")A?[=
MLC ')\\]O3U-?UQ?MNVUU=_"^VBMBPVZ@TC;1G.U8QSQTY/TKX\L9I$\!Z-J
M!<^;IT,.6[KM /7.1TXH%S2[_P!?U_5C\[O#_P#P;O?"+5M)LKX7^H?OX(W)
M-_>#+%03UN!T/M6L?^#<WX2?\_\ J'_@PO/_ (\?YU_0Y^S_ .(Y/$GP^L;J
M24RM$WE GD@!?Y<<?_7KW#GO_+']30/GEW_K3_)?U8_ES_XAS?A)_P _^H?^
M#"\_^/4?\0YOPD_Y_P#4/_!A>?\ QZOZC** YY?S/^O^&7W'\N?_ !#F_"3_
M )_]0_\ !A>?_'J/^(<WX2?\_P#J'_@PO/\ X]7]1E% <\OYG_7_  R^X_ES
M_P"(<WX2?\_^H?\ @PO/_CU'_$.;\)/^?_4/_!A>?_'J_J,HH#GE_,_Z_P"&
M7W'\N?\ Q#F_"3_G_P!0_P#!A>?_ !ZC_B'-^$G_ #_ZA_X,+S_X]7]1E% <
M\OYG_7_#+[C^7/\ XAS?A)_S_P"H?^#"\_\ CU'_ !#F_"3_ )_]0_\ !A>?
M_'J_J,HH#GE_,_Z_X9?<?RY_\0YOPD_Y_P#4/_!A>?\ QZC_ (AS?A)_S_ZA
M_P"#"\_^/5_4910'/+^9_P!?\,ON/Y<_^(<WX2?\_P#J'_@PO/\ X]1_Q#F_
M"3_G_P!0_P#!A>?_ !ZOZC** YY?S/\ K_AE]Q_+G_Q#F_"3_G_U#_P87G_Q
MZC_B'-^$G_/_ *A_X,+S_P"/5_4910'/+^9_U_PR^X_ES_XAS?A)_P _^H?^
M#"\_^/4?\0YOPD_Y_P#4/_!A>?\ QZOZC** YY?S/^O^&7W'\N?_ !#F_"3_
M )_]0_\ !A>?_'J/^(<WX2?\_P#J'_@PO/\ X]7]1E% <\OYG_7_  R^X_ES
M_P"(<WX2?\_^H?\ @PO/_CU'_$.;\)/^?_4/_!A>?_'J_J,HH#GE_,_Z_P"&
M7W'\N?\ Q#F_"3_G_P!0_P#!A>?_ !ZC_B'-^$G_ #_ZA_X,+S_X]7]1E% <
M\OYG_7_#+[C^7/\ XAS?A)_S_P"H?^#"\_\ CU/3_@W-^$?S;K_4.AQ_Q,+O
MK_W_ !_GN*_J)HH#GE_,_P"O^&7W'^;U^WM^P[I?["W[87P'L_#&I:HUE>>*
M=*$]E+J%ZUK/MOH?]9 9S&_/]Y3]?7_0T^"5VFH?"'X;7BV\-L)_!F@-Y,*!
M8U(T^!&*CU=E,C>KLQ[U_&Q_P< SO+^V9^SX&?<1XJTL ?\ ;_"?QK^QGX ?
M\D3^%W_8E:%_Z11T%3;<8-^?Y1['KHVDD8Z>PK\ /^#C75Y--_8-U*VMXPD]
M_K1A6[1FBN+<&&-/W$L95T),F20PY5>F*_H!Q[?I7\\__!R,?^,&L8_YF'.?
MJMN/\#03#XXZ7U_K_@_J?C!_P2[_ .",7@C]I_\ 9\\._$+Q/JNKW%YJ$/G3
M2SZE?R,2^#@N]P21DX'/!QWK],?^(<GX1%2PU._SDX3[?=^OKY^.G^%?67_!
M J21OV+_  >A;Y%L(VV^^8@/IC/:O&_VP?\ @JQ\1/V9OV^- ^"4^FSR^ ]3
MU&WL&N/++0;)9%C^;*E#@-GG\J <Y)O6UNWD[_I_P#RX?\&Y?PC_ (M1U >P
MU"[.>GI/36_X-S/A)GB_U#_P87?_ ,>/]/I7ZF_M'?MDZSX"U+X,2>%U\RP^
M(,NG>8(3NP+ORF;<!DX ?'/3&.E?=^F?%GP7=7VFZ!-K=LOB*[TNUOY-.W+Y
MJB6V260D;L@ LPZ=O2@.>7?^M/\ )?U8_G"_XAS?A)_S_P"H?^#"\_\ CU+_
M ,0YGPE_Y_\ 4/\ P87?\O._G7](-G\7?A_?G6EM?$-I*?#_ )G]K .N;3R@
M2^_#'IM/7'2O*K+]KGX(Z[)KUCH?B^WN[S2+2[>3R]I'GPQ.?+4J[88.!C/U
MP.E <\OYG_7_  R^X_!4_P#!N;\'B/W6K7LK#AU74;LE#Z']_P ?Y[<TW_B'
M,^$O_/\ ZA_X,;O^7G9K]*OV+_VGM;^)?Q/^+=OX@U-SX8\/W-]]GN+A_P!U
M''!*^ULL<#"H.F./:OM";]K+X&0:F-,?QKIOFF;[-Y@GAV>?NV^7CS<_>XSQ
M].* YY=_Z_JWW(_ 3_B'-^$G_/\ ZA_X,+S_ ./4H_X-SOA*.FH:A_X,+O\
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M1_Q#F_"3_G_U#_P87G_QZOZC** YY?S/^O\ AE]Q_+G_ ,0YOPD_Y_\ 4/\
MP87G_P >H_XAS?A)_P _^H?^#"\_^/5_4910'/+^9_U_PR^X_ES_ .(<WX2?
M\_\ J'_@PO/_ (]1_P 0YOPD_P"?_4/_  87G_QZOZC** YY?S/^O^&7W'\N
M?_$.;\)/^?\ U#_P87G_ ,>H_P"(<WX2?\_^H?\ @PO/_CU?U&44!SR_F?\
M7_#+[C^7/_B'-^$G_/\ ZA_X,+S_ ./4?\0YOPD_Y_\ 4/\ P87G_P >K^HR
MB@.>7\S_ *_X9?<?RY_\0YOPD_Y_]0_\&%Y_\>H_XAS?A)_S_P"H?^#"\_\
MCU?U&44!SR_F?]?\,ON/Y<_^(<WX2?\ /_J'_@PO/_CU'_$.;\)/^?\ U#_P
M87G_ ,>K^HRB@.>7\S_K_AE]Q_+G_P 0YOPD_P"?_4/_  87G_QZC_B'-^$G
M_/\ ZA_X,+S_ ./5_4910'/+^9_U_P ,ON/Y<_\ B'-^$G_/_J'_ (,+S_X]
M1_Q#F_"3_G_U#_P87G_QZOZC** YY?S/^O\ AE]Q_+G_ ,0YOPD_Y_\ 4/\
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MAU&SO;>Z>.TFD4;(G#$E4(XP/3W^GWSX%_:J\'Z%^SJ/@!?:B/\ A8">'I=
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MVIV]N(FWR!9FF7 QGG QQ]*^]OV"_&GQ6U'X=:7X*^)/AZ72)?"&FIIEK/-
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MN8CYQX *D$<YZGC]#2>)?VKI+[P=?0>'P&MUL3#'?# ?"K@$,!D].Q[8[8H
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M:B@<I& 2<8[Y_"M:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OF7]K&W-S\)M2C R?.0^_ _SFOIJO%OCUI#:S\/M2M$7<?OXQZ*?QH
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MI_G2T %(&STS2T4 %%%-.#\I.": %#9)'/%+2 8&*6@ HHHH **** "BBB@
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MF_X.1O\ DQH?]C"/Y6]?T,U_/-_P<C?\F-#_ +&$?RMZ!4_CCZG?_P#! O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY  ;;C:3CC'ZT ?GW\+?VJ_BQ\5_ .M?#?Q'K$]M96.MMIEKJ,L[B,6JW'E
M!V( &W'?%<[^V3\'-(^&FI? CQ'HWB:WU36;Z]TZ6?;<+*Y9Y(F.,.3]XG]:
M_8'6O^"8?A+1_A7=^&O"M]Y&O7$BW<U]"I67[0PWR%7&"V)>,@\]L]:\:TG_
M ()::OXWUGP5?^/?%-Y<6W@JYAF@CN9)'5Q"ZLH 8G.0H& #^% %GX!_&36)
M?BUHN@>(_$<5A9Q^$D:*&YN @+"S!7"LPY[#VKYBT;]JCQMIGQ=^/'A:QUA]
M1TW=?Q65S#.7BMU+2*#E20N /7CUK[5^,O\ P3JU/5OB/I7C+P?KES8I9:>F
MGLMLSH&C$:QY(7!&5]>E;WP5_P""8?A_P-IOCR^UO5/M^O>-K>X5KB?,DL#S
MA^0Q)*D%ACD4 <9^QA\#?#'C+X<^,OB%KOB5+WQ9J*ZC&K_:@_D;XIG&XF3*
M_=V\#()Y]:_,S]GS]EGP%XK_ &@OC#>:UJTC7]O?Z@8]]P2K%'DQM!?'51T]
M,>U?J_\ L]_L?_$3X,>(-=\(QZW?3^%]8N+ATF+R&.%;AV^Z=Q "JQ';'M6?
MJ'[!.M?#SXES>*O!VI3W,'B*X,FI/&7X\UOWF[N,%CG.,]>!S0!^9?Q0L_BE
MIU_!\/\ X37LJ+I.IK-=-:NPE^RP2[G+%"3C8#G/!KV#X@_MA>+_ !&?A9\*
MO!VJ->>*/#PL[7Q1#:SEYQ+&$CG$P0ELY5L@^G;%?KG\-_V--$\*^+-0\7:A
M*M[<:MI<MM+%+AO+EGC*E\'/()ST_P#K_/\ \"_^"7'A+X5?'[Q?\:-2U0:O
M_P )%>W-Y;Z=,?,6U,LC.JHI)"@9Z #'2@#\C_B7\8]0U;X[P>#_ !J][<0_
MV>#;VBRR;UN_*PK;,\8>OU6_X)A7OQ1FU#QQ;>++NZD\*P-(/#]M<.[&&+S/
MD #GC"XZ5!^T#_P3ZM;CXO6WQG\+6B7UYYFTV B#*B[@?N#., ^GXU]Z?LW?
M#*Y\"Z))=WMI]BO-01?.@"A AP#C''?VH ^GJ*** /RH^/VFBR^-?]JLH DG
M^\/4G_ZW^>37-OJ)M?BAX.124^U3P$#^_EUX[9_R*]Z_;,\/)HFF6GC2W5GF
M^U*'V*2V58-SCV(YZ8KY3U$:MK6G>%_'^CQ^9J.C+#,D"\LYBVM@J,D=.F*
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MF_X.1O\ DQH?]C"/Y6]?T,U_/-_P<C?\F-#_ +&$?RMZ!4_CCZG?_P#! O\
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MK_\ ]+)J_JBH"?Q/Y?D@HHHH)"BBB@ HHHH ***"<=: "B@'/2FJ2<Y&/P-
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MS_PHP&55:68\18Q8C,<SC4:C6@FFJ<H_:VZ^9]8QQ+#'%%$ D<2JBH. $4
M #T J6BBON#^;5IHMEH?)G[:GQ U+X;_  &\3>(M&E,>JP-"MJ$;#G*RAL8Y
M[KT'/X5SO["OB#Q%XV^"ND>,O$TDDE]JLDP'FL2RB,H>_/.[FO"/VS/&1\2_
M$[PS\$9SNLO$#69EB/*,9-N-R]#][)S7W_\ "'X?67PQ\!Z-X1L$6."QBW%$
M&%6214W@#C^[Z4!_7Y?\'\"U\5?!MCX^\!>(_#&HQ+-;7^GW&Y'4,"R0R%<
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MO_7C'_Z"M?NU02]WZO\ ,****!!1110 4444 %%(2!C/?I2T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114-Q,L$$LS\+%&\C
M'T"@D_RH ^/?VKOB)<Z-X?D\+Z0[#5;Y/E1"?,;<O  !SR&["OESX"?%:Z^%
M'F/XD\.W<EQJ#N);EHY 0KL>?,QGOGO[UT'COQ18>,?VCM'MKR5'TZUN88I(
MRP,1"R!<'G';OCMZ5^AVI> /!>OZ;]D;2--:)HE6&:**,N@VX4AEZ\=>^1]:
M .5_M7P5\:/!USI]W);"+4(&0P2O'Y\$DB,%9-V&SGJ!@\#VK\+?%?PE\7?
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M2$$DE\\XZ=><5_0W^PO_ ,$QO"WPH@TWQEX^TZ"[U^,12K97, ;9*-K$$,"
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MXNM1PE)4:$)59.7+"$;)65DW97M>P444@(/2NT^?%HHHH **** "BB@G'6@
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MV2(B65NL;,J@;G  )) R>@Z]\UUJ@@<G//O2T4 %%%% !1110 4444 %%%%
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M!\7/#FHZ!X[B^P:_X<=-.A69=DURL#-&6.<,QV@'N0 !] #]":*** "BBB@
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MM=3UNXC\J0B%9'#N"IZ+GJ?K5#]D#]FW[5X@?XN>([06EU-/]HBLVCV#+,)
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MEX;:\F)N(OFB(5BQ_>+E>V>O?Z4 ?MA2$XY-(,+A<\X ^O:ER,X[T +1110
M51U._BTO3[W49SB&RMI;F4^B0H7;]!5ZO'_CGXIL?#7PV\5/=2F.>]T2_M;0
M+U::6%HQCW&[/'?% 'YK3V\?[0?[4^D>.-";SK+PE>Q03&+YD06TF,,1GIM'
M7GZ&OV()QR:_*+_@FAX*UG1[7XB:YK\,C/JFJS3V$DZ$'RI;G=E=WJIK]7J
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _B#_X+_?\
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M7\,-/;4_&&K1:9:*A<O(5'RC_>9:_,#XV_\ !6#X6>%I5TOX?7L>MZI/(UO
MJ>7,S3!MH78N[&20,#)]_3BQF98#+XJ6-Q=##7:455FHRFVTE&$=Y-W6R/H,
MBX4XDXFJNED.29CFKA=UJF#PU2K1P\(IRE4KU8KDIPBDVW)Z+H?L)17R-^R1
M\7_'OQD\'2^)_&FE-IBW")+8!HC%YD;LI!P0/X#GI_2OKD?U/\ZZJ515:<:D
M5)1FE)<RL[-73MYK5'CXK#SPF(K8:HX2J4*DJ53V<E.*G!\LX\RT;C)-/S05
M3U#_ (\+W_KUG_\ 135:X8Y!/&/\]*JZA_QX7O\ UZS_ /HIJLYS^0.7_E./
MX&_[$WQ1_P"GSPQ11+_RG'\#?]B;XH_]/GABB@J6Z_PP_P#2(GLW_!N3_P D
MTU#_ *_K_P#]+)J_JBK^5W_@W)_Y)IJ'_7]?_P#I9-7]45 3^)_+\D%%%%!(
M4444 %%%% !112%<D'GB@!:_+S_@H1JMSK&F6?P_NBZ:)J[VQNGR0G.WKT'?
M/^<U^H=?"O[>OPRU?QG\&M;U;PG;&;Q5I8CELO+3=*5168[<?,<;!G'M0!Z?
M^RCX-TCPI\"/#GA;3@DFFK;W"'R\#>MS#$DH)'<KP#R?K7XL?M'_ +/?@OP-
M_P %$_ASXAT:RN8K_5;S3KUMKL%9II%F!P#@_>]/I@5^CG[!7QMT_6OA%9_#
MC6+];?XFZ!'J,5U8WSK&TDT4*+ /WC*PQ(G QSGH.<_F1^TOX%_;6\9?M9Z%
M\1]$\-FXT7PSJ-K%;3QQEHS:VTH12& QCRU'?CZ#@ _I0:UCN].-E=1AXKBS
M^SSQL 05DA\MU(.0>"?QK\===5?A=^V%HGASPH/L^F:Q?HUY'%\D;&67YMRK
MQW_R:^_;KXQ3_#GX*1^+_BG<VUCXA&D7$C6:2QB9KI;4")-F[<&\WGIDGCKD
MU\&?LI6%]^T?\3M4^+^KP2I;Z+J#'3Y)XR"\:RGRRI8=",<CKQCCF@#]C:**
M* "BBB@ HHHH **** "BBB@ HHHH **0[NPS_GZTM  3@$^E>)_'Z\ELOAYJ
MDL606CE0D<8!C->V5\(?MO?M#?#_ .%GPTUG3]:U*$ZM/"X@MTD0LC&-AR 2
M<Y(!X&,'K6.(Q-#"TI5L15A1I1WG-\J]/-OHCTLJR?-<]QE/+\GP&)S'&U6E
M3P^%I2JU&FTG)J*TC&]Y-[(^</V<M%^#%I+XG\0_$C6=-@N&,\@@O9HT9B68
ML &R2^,[1C!/!(&33_'OQ2^$WB"&Y\._#314O6EE>U%S9J'!W$H&!C![X.:_
M'3X+?#CXD_M>^.[E_"^M:G8^'6NI&F\AY1%Y/F,W.T@8VC&,]#TK^BK]G#]C
MGPK\&M'L_P"T"NL:IY43327*>81*%!)+-DYW9]ZXLMS.GF<:U6A3FL/"2C2J
MS7+[7:[BNW9]NA]-QKP+C>!I97A,TQN$K9KCL/+$8W+\+45666;>SI8AK:K)
M:N+MRNZ/$?V=?V.-/M]07QOXAMW!O'$XM[C+8R0V KYZ9'']*_3&WT^PT'1Y
M;:PACMK6UM9F54 4#RXFY. !GY?2M2&&*"-888DBB0!41%"J ..%7IVKCOB%
MJHTCPGJ]T6V@V<Z9SC&Z,]#_ /7'6O3/AS\UM*T+_A>/QCU;3;Y#=Z9IMY*L
MR_>4*DC9)ST  SG/K7U!XH_9-\*W45NOAM38-$%)&\1CS% PPY Z@'VZ'-?G
MW\*_BYK'@;Q]XMU#P[:O?/<7%QYNU"XP6;/0'U]/ZU]9:;^TY\1+^PDNUT@Q
MB(%G\R#;\J]>J>W;UH K>+O@O\;/#=M%+X>\2RPZ78)N<1W/"1IW;:_ ^OZU
M^?WB?XD_$3XI_$O3_@]K-Q/K%K::E$LTBLTJ[ED4-TR/X?IT[5]%_$O]M'QY
MKZ7'@?P]ISOJ&H 6LSV\0+)O.QN47.-Q)QD#CVKWG]DK]FQ=#N1\2O%UHLGB
M&^?[4OGQYD5Y/G'WANX)!R>U 'VU\,?#4/A+P-X>T.&(1?8]/A610NWY\<Y'
MKC%=[2    # '  Z 4M !1110 4444 %<'\1? &B?$;PSJ/A_6K9)TNK.YBM
MV< B&>6(JD@R.S;<G(P.>U=Y10!^ EY?_$;]ASQCJ_AKQ'HNH^,_A_XLN6,4
M%NLMQ#;6UT[#&%#HH5&'3T[5[1HOA_\ 8N^(4%KXQ\1>$8[#4[=EOTLKI%#B
MZ.)#^[?!SO[8[>M?KCK_ (1\,^*8O)\0Z'INK(%*K]MM8IF0<_<=U+*03D8/
M6OE3Q)^Q;\/M>U?^TH9WTV+S3)]DMHML6"P.W:K*,<8[4 ?#OQC_ &S]:UC2
MD^ _P)\&7^G75VD6E:7KEG#,D-M;']T"K1CRTX8EB.O&>E?7/[&O[+UU\*-!
MB\8>/V_M'XD:Q_I5YJ$I#S1K.N\J['+YPV IP>I]*[#Q7J_[-7[)GAI-<\:2
M>'].DM$8_;[FWLI=1)49'RS29AR1PW+YYQC%>9?L^_MN:9^TI\0KS3_AY"US
MX,M962*_"*RND?&?-50K''/IZ 9Q0!^B6 3G'(HP,Y[THXX]*Q_$&JQZ'H>K
M:Q+_ *O3-/NKU_\ =MXFE/Z+0!L45^<7P _X*)_"WXS_ !/USX50WT,7B'2K
MN:V6,.@8M#(4(*]3R/7->Y6'[3/AZ_\ B+XK^'\4L;:AX:LYKN901D)$I<D]
M^@_SUH ^JZ\[^(?@"Q\?6$&GW_,$3[F4]&!(R#R,\=J^*OA'_P %#OAC\1_B
MMJ?PE%Y GB&QU%[%8A(@<N)?*QC.>OK7T#^TU^TGX5_9L\)VWBGQ3,D5M<RM
M'&&*Y)0J"<-VYQTH ]I\'>"]'\%::FFZ1;I#&% ?8@7<1CDXZ].M=?7YVQ_M
MY>#]5^!VJ_%W1Y8Y;2QA>1<%"I(3<O8]<_X"O"OA9_P4CFU&"P\3>/;![/PE
MJ]X+>RO$AVQE6<JK&3: .,<_CWH _8900.3GGWI3SP>AXKDO!?C;P_X^T.S\
M0>'+R.\L+R&.:-D96*B10P#;2>1GGI6CK?B/1_#L44VKWL-HDSA(_-D12Q/&
M0&(./?IU]* /A_\ :]_84\ ?M)Z+<W":?:6/BS:WV>_\N*/+E3ABV%P03GOW
M-?S!?M!?\$Z?BW\%];N7AT[5=;CM)9)+=[(3;2H8L@!CR,8 QCMGMS7]M%MJ
M^F7D*7%M?VDL,BAD=9XR"",_WNOM5#5=,\,ZDJ_VS9:1>+-\BF]AMI@X/  :
M0'(YX.<>]?*<0<'9-Q"G4Q5#V6,BOW6+HODJ1ET<[?';I?MZG[CX4?2!\0O"
M-RPF1Y@L;D&(?+C,AS)/$X&I2=N:%&$^94.;6_*K>\]+)(_@IB\7_M3^#;+[
M#HV@^([18!Y: B[7"KQCI].?U%/G\9_M4^+; 6.JZ'XCNUN!LE11=MD'Y3VS
MT[>GUX_MN\2_#3X!2ZA!8ZUH7A:VO;LYC7R[:)B2>_.T$GIP.O/J-?2O@5\'
M=!7[=!X6\/B$#>LTUO;& +U#!SA#[')S7Q__ !#+&^S5+_6W,O9*HI>SO)7A
MI[F]K+9'[U_Q.7D'UMYA_P 0+X->/>'5+ZQ[.BE'$7N\7\-^9O6RBWTLM3^.
MCX"_\$\_B_\ &W6K99=,U;1!=31R7+W@G"E6<,^?, &,9Z].>:_IO_9%_P""
M?_P\_9WT>TN=0TVTU+Q0B(TEZ4B<K* ,MNPQSGH!C\"*^XM F\"03&V\/+H-
MM/'\@CL([2&3 ^7"^6 Q&./>NTKZWAW@S)^'7[;#4G6QLM:F+K>_4<GO*-[\
MC?D?A/BM](7Q"\68QP&<8]9=P]0]W"Y!E:>&P,*2^&G6C3Y574=+<RMI>PBJ
M$544 *H"J , *HP  .  !@ 4N/;]*3(SCO2U]<?A04444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'P_\ MO0Q3>!]-65<@7*D?7?7P?I^\>.OA:,_
M(DEGM7J/]8G4>O2ONW]MEL^$-/0=1.I]_O U\)6"8\>?#'=D'S;7_P!#7':@
M#]R+0YM;8X S;PG Z#,:G ]J_*[]NWYOB3X !'W6MON\$\YY/U./I7ZH6?\
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M+0!^8W[5D$4WC+1W89>.Y0@GGD,".OOR/\BO._A2SO\ M":!)(02D=N%R,C
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MY$"1G_@*@4 :.!G/>EI,<@]Q_G^M-._L!_G\: 'T444 %%%% !13#+&&V&1
M_P#=++N_[YSG]*>3@9/ '4G@4 %%,62-CA71CZ*RD_H:?0 4444 %%%% !11
M2$@8SWZ4 +1110!\(?MD7*76D65@""ZSKQGT8#_'BOC.UM_+\??#=2,E);0>
MO\:<=/4$U])_M/:D;[QC%I ;(2?[O/\ >QTZ_7_"O$'MD@^)'@*)ARD]KCV
M="?\,=: /V/M/^/2U_Z]X?\ T6M?F!^VD@O_ (E>#T49-J\ /U7:>?QSQG-?
MI];';9VY]+:(_E$IK\P_VCRVK?$G39 -WD3#IST;'8?UH X?X#.=0^/\5@<$
M1QQ'UZ*OMZCG^M?KX %  Z 8'X5^./[-4TA_:>N8V'"Q@#VP"#_G-?L?0 44
M44 %%%% !12$@=:6@ HHHH ***3(!QWH 6BBB@ HHHH **** "BBB@ HHHH
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M8C<.J^N>>_-?LE0!^:7_  4BTC4[3X<:3XIT.RDN[NTU6,7(B5F,<,;([2,
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MC]A:\?\ @E\'/#WP1\&6W@_PZ UM$5DEEV;3)+L 8^I&XL1GDYYKU\]#]#0
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M;M0_6\G_ ,:_JCK^5S_@W)(_X5IJ [_;M0_]+)_\*_JCH"?Q/Y?DCY[\?_M
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M5A\PXQ0!^GOQ&_:I\#>!?!.C^-XIX-2T[5VC2,I)E4+X&,HPY&?6OF'XG_\
M!230O!-AI]QH/A&;Q+<WZ1.EM:BXD<+)@YQ$^> >>M?DS^QOXAU7X^/K_P"S
M=XKN;N?5O!ES=NCSEFP+=W* %B?3'&/PKVWP1\7/@I^SY\:W\._%VSAU2#2F
MET^".XA2>,2 -&AV.I7AL8&,'\J /UG^#_[:WP]^)'@R_P#$&KRVWAG6]-M7
MN;CP_=2F.YPD1?:$E?S =W!&.GN.?E#0_P#@KG\,]4^*%U\/[G14L[6UU#[
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MW'EU5T[7/WA_80\//X>_9Q\#V\IWS26,>YSU9410#G\?TK[&)"*S,0%&6)/
M 'J?8"O%_P!GWP_)X0^#G@O1;L>5)I^CPB??\NT[06+9Z?I]*\=^.G[02:5Y
MGA'P;)]LUZY)MF$!\Q@S@KCY">AQCO7K9AGF X9R7#XC,9\DH8>C2HX:+3KX
MG$>SC&-"A#>=24M-/-^1_/N,R[%\8<8YW++%[2EB\WQ^*>)G[M"AA)XJI)5Z
MT]H0C3:?RL;_ ,:OVF?"W@"WN=&L+R"[\0S(T-O;1R!I/-8$ *H.<Y(QQG(/
M2OQ-_P""@&G?$_QM\*]+\8:S<W6F6ESJL3)%*[HKP.X8+@_WE8?_ *L8]5^)
MW[.OQNE\3Z/\6;A;VYM;>>*\N;202-'M602$,I&,<'->N?M*^(=&^-7P)\->
M%M2%M8:C87-G%)!$521I(Q'&<H.<YC[CU-?SUQ#F&=<11SO,N*Y8O)*65X=5
M\DX>@G&&-I2E!K%597_?32?OTGMMW/W;AC+,GX7Q7#V%X8>&SV68XCV>>9^I
M*57 5%!J6&I17\!2=^6K'=).W?ZQ_P""=_@71_#W[/WA#4X;2/\ M&\L8FFN
MB@W.3$A+!BN3D\@@]LU]]_-NSV]/PKP']E_PW%X4^"7@C1H1^[MM,C )ZGY5
M&3Q[<5] 5_27#\*4,DRKV%*G1ISR_"5/9TZ:IQ4JE"$I/D6B;;;EYG\U\15:
MM;/LXG5K5:\O[2QL54JU'5FXPQ%2,%SO5I122\@HHHKV#Q@HHHH **** "BB
MB@ K)UO6;#0-+O=6U*XBMK6QM9[F1Y6"*5@B:4J">I(7 'J:UCSQZU^6O[>W
MQ=UG5]-L/A+\+[J2?Q9?WYMM4BM6S+';2,L<BE4;=M"C/(_B(QZ@'R3\7]5\
M>_MZ_&^Q\)>#[NYM?A=X:O8K;Q#:V\DJP7:03*DQ;:=K;\-U]<U^SOPY^!OP
M_P#AOX%T_P !Z+H5HNE6MM%',KQ1LTTP0"20MM/5LXZ_TKR/]C_]GS2_@K\/
MK"ZD@4^)_$-E#=ZW,\8\Q9Y#O=2Q&0VX9/L>O)%?7] &+HOA[1_#T!M]'L8+
M*)L;EA14!QZ[0,UM444 %%%% "9R#@_CZ4O^<_Y_QJ/:WW>Q/7O_ $IX&T8H
M\_E_2_4/ZV_46BBD+ =2!]2!_.@!"V"!CK2L<#..]0F:WR,S1 CMYB>OIFI!
M(C?<="?9@W\C0']?U]X'&X<<_P \\?ICC^E*S;<<=:=11W_K[@"BBB@ SGI3
M0V21CIG^=*!C@4M !30&R23QV%*,XYX_PIAFB7[TL8^KJ/YF@"3/;O14(E@8
MY$T9XQ@2(?Y'WJ4$8XY'MS0 M%%% !1110!_+_\ \%$/VI/CQ\$?VTO#L7AS
MQ)=6_@6YU>VMY]*2>01M&\H5AL4[>A]/_K_LE\1?V@(]+_9!N/'J:I%9^*=9
M\)!=*5I0MPVISH9$=!G<<(I&1SE@!ZU^4_[7OP>/QO\ VYX/#EU9S/::8S:B
M)3$6AS;EI =V-O;_ #FOE?XC_$#XJ?&'XS0?L^>$K35D\-?#>ZCMK]%AF^RR
MPVK!&SP4(VJ?;!H ^B/^">7[7_QG'C?Q"?C1K%U<:6^K3?8$O)I"IM6F;8%$
MC 8V>GU'K7[]Z+\</"VM:#J?B"VGB-EID+33N'^4!5+')W>@]C[5_.AXA\$:
MA!X@L-'\/:9<6EU8VJ_;GMX&7<\2?O&)51SD?_J[>L^!_P!JOP!X,^%GQ+^'
M6N2ZC_PE1L+JWC!23>)=CJ-N>?O'MZ 4 >[_ +8__!4BY^%WAF+4_ FA2ZC;
M)JBV4UW;*\BEM_ED%UW=^V<<\>_T5\/?V\-9U3X$>'/B;>^![V^EO=/BFF18
MIP68H&SA2IZ>F>U?C[JMA8/^QW=>)=?T%]0CN?$WVJ*2ZM3)/Y+76X$;E+8Q
MC''H:]N^*/[9=K\+?@!\%_"_@;PC'>VNIVMI#J*+9;_+5D16W@+\O!/7']:
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M?!B8KO\ H1[^G/B_QIL+#2/V*/@_J/B+P\U_<P^([1YI9K0R7*QK<IG=E2P
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MP?FX.<#J3W /,/A9\+_&_P"WG\<9OBSXZ>ZC^$VCZJS6VAS.X@E$4I*$1O\
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MUG>Y72M.6XDSYDXL[<2OGKOD$>YL^Y-7HH88%V00QPIG.V*-8USZX0 9]^M
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M8V]<\8[@<U_5'<6UO=PM;W4$5Q XP\4R+)&P]&5@5/XBJ=CH^DZ4"-.TVQL
MQY^R6L,&2?7RD7->1F644LTG06)JU?JU*7/+#PDX1JR3NO:-?%"VCB]&C[7A
M3C;&<'X?,I95@L&\TQ]/V%/-,32C7K8&BU:7U6$U:E6O=QK1:E%['Y\^)OV<
MOAE^S/\ LW>)I_#6A6RZSI&A2%]0$:-+-<F-B2&V9[$YSR1[BOYAO@5IMQ^T
M#^TJDMW'YT^G^)WP@4Y5([LXXQV _'BO[8O'?@W3/B!X7U/PKJXW:?JL)AG&
M,Y0JRG@\'ACUKXD^#O\ P3G^#?P9\=W/CSPZC-J-Q=/=LCP*JB1W+GH>F37@
M\0<+3S;&9#[&=.AEV58N.(J82,8QA/EM:T5;566N_74_2_#/Q@PW!.1>)$<?
M0Q>8\4<99-4RO"9S4K3J5Z"JVYU4JR;ERR;;M>RZ))*WVU\/]+&A^"?#.DJF
MP6&DVEOMZ8*K@_J<UV-,1%C18U&%0*J@=@N,#]*?7VJ2226B6B79+8_ '*4F
MY3=YR;E-]Y2=Y/YMMA12'...M SCGK0(6BBB@ JGJ'_'A>_]>L__ **:KE4]
M0_X\+W_KUG_]%-0!_('+_P IQ_ W_8F^*/\ T^>&**)?^4X_@;_L3?%'_I\\
M,44%2W7^&'_I$3V3_@W)/_%M=0&/^7[4.?\ M\N/;V_6OZHB"2"#QQD<^M?R
MO_\ !N3_ ,DTU#_K^O\ _P!+)J_JBH"?Q/Y?DCE_%?@WP[XVTYM)\2Z=#J5@
MV[=!,JLIW8!R&5AV]*\T7]F_X.+H5YX;7P;IZZ/?Y^U6@CC"R9ZY_=_TKW.B
M@D\PT?X.?#S0O"T'@S3/#]M;>';9_,AT]53RT?.<CY .OM_6LZ;X#_"ZXUO3
M_$,WABSDU;2P!8W3(A>$+TV_N\\>Q%>P44 ?+WCS]CWX%?$76W\0^(_"-M/J
MTJ^7-=!8]TL> NP_(#@@8Y8_2O1_A5\#_AM\%M/N=-^'?AZWT&VO"#=+ %S,
MP(;<Q5$ZL-W3K7K5% &/KVA:9XDTJ\T;5[9+JPOH7AGA< AD=2IZ@C.#7S-<
M_LY^!?AOX-\41^ -&2SO]86<RF-%S(USNW<*.Q/Z]J^L:1E5QM90P/4, 1^1
MR* /RD_9+_8EC^$WC[QG\6Y83#KOB1;SEAM8M/O.<<'O_P#KKF[C_@G]X9^(
MWQ6U7Q9X_P!,;4$NM2:Z1G4X ,I?/(_/U]:_7Y551M555?[J@ ?D.* J@Y"J
M#ZA0#^E 'D_@SX)?#KP+X;;POH6@6L.FS6WV6X4QQEID*>6V3LXR,]<_EQ7F
M.C?L=?!'0/$]WXHTSPS;P7E\)3<!4C&^67=E]P3U8MC')KZHHH _/'X,_L:W
M'PP_:&\3?%87HET;5&G:QL&<.L!DW;"$).TKG/ ]/Q^S_$/PQ\%>*=6M];UO
M1H+W4K7;Y-RX7<FW&,$J3V]:[^B@#S.X^$'P_NKV#4)M MFN[9E>&7:F49,;
M2,H>F!T-2ZA\)O 6JZU:^(;_ $&VN-6LHQ%;73JI>-!T RF1QQP1T%>CT4 ?
M*GB/]C#X ^*O$=SXIUGP=;7.JW>?M$V(QYF>H/[LYSQU!KOQ^SW\*XO ]Q\/
M+;PW:V_A>Z&)K!$C*OGKN^15.>IXKVRB@#YC3]D7X)_V'#X=F\+V\^EVQ)MK
M=TCV0D\Y4%&''X9]:T? W[*_P7^'VLCQ#X>\*6EOK*#:E]LC$B)_=7"9'_?7
MX5]%T4 ><V/PG\"Z;J>KZO9Z)!%?ZXCQZG. FZY5QA@WR9Y!(.2>M9LWP2^&
M\_AW4/"S^'K;^Q=3=Y+RT"ILE=R2S$;,9))/2O6** /(/AI\$O WPF,Z>#-.
M33;:?=F%  !OSD * ,<UZ_110 T'.1CIQ7XZ?\%&/B/?:_=V_P (M&ADO;II
MDG>UAW,[LN"1M3)(^7TP>E?KMK^H'2M%U+400IL[26?)Z#8,Y-?A;H7Q<\$>
M)OVP%U'Q=Y<Z0:A]GS<8-L,.5PS-E1T]OTKYOB6M%X:A@77C0^OUX49SGLJ3
MDE/YNZL?O/@/ELJ.=9MQG/+:N:4^$,KQ&887#44W.>9QC%X1.VJC\5VN^W;V
MW]D7]J"+P#H&D?"WQCX??0QIY6(WES&\!&X[2[.=H;.T'Y@V,$C&3G[?^*WP
MF\&_';PO<77AJ[L?[8F0/;:M:2*I5I(\KYCKRK X]LYYZ&H/'W[/_P *?BG:
M/JEG/IFGSW-N&@O=/:V6-6*Y5G,<@:,]V&"1Z5^5?Q._:4\7_L5^(;GPWI^H
M_P!NZ4\C10>3,+DG!_=K@,^>@X/?%<M:K/*<(L/FW)BLKC!4XXF,5[2$4DJ<
M7"/E:TEK;;1J_P!%E^ P7B/Q)/._#?V_#?'?MI9ABLAQE2;PN-Q$JJJXN5+$
M5(J,G*HWS8>:Y97U5S.\>_$3XH_\$_IKS4/%FJ7&JZ;+O:T229IHY(W8F/80
MQ##IR.!6;^R3X5\0_MC_ !\M_P!I/7;62+1+2X25(Y$81MAMRX# #D#CJ?Q-
M<19Z?\8?^"C'B;2)?%6BW%KX*MY8R[SV[*I@C;)^\H&-O..X]CBOV2TWPOX(
M_8]^"K:3X9BM[<VUJ@"JL<<LUREN58HJG<RB0G:>-V3Z<>'25.E3Q.;X^O.'
M"V5KZ_AXXFZJ>TI1YE4O+5PB](KK?N[GUG'7$ZRG!X?(,)EV7TO&3B##U,BX
MFS#)G#ZE3R_$RC3GA53I)4Z>(K12=62U4D[D_P"T)\7SX-TQ/"GA5%N-4NHA
M L=M\S1;EP%&SD$;L$ #GIVK\Y/AQ?\ B'P5\7(/%7Q*TJX.FW=TDL4]VCF)
M=S CEP5&.>*]M_9B\36OQ+^(>K:_X\8>4]Q*^EK??*A^<F-4\S@]L8[=,\Y_
M0KXD_"+PI\2]"33KJUM8&B7-K=6T4:D#;\@WQCD#J&Y//)Z8^&I9?F_B'"GQ
MWE>9X>=; 8ISR#**G+4P;I4)VE'$\WP5:Z]Z-1J\7:W<_-99CE/A_*IP3F>6
M5?98_"QIYYF]/FCBHU*\$[X9KXZ=!^Y."E9J[]>IMKG1O'_A!OL+PS:=JMCY
M:!0K+'N48  R%QVQT!QGK7\]WQ\^&/C[P;^TA9:-;SSS^&9M727[.K.T0!E!
MX4$K@@]AW%?I#<^*?B!^SSKEEHTD5S<^#HI DDS*[*D.?O$G. %_STKYTN_B
M[HWQN_:=TW3-)@2XM4EB::3:&VR;AN&><$8__7S4\:9ME7$]#)\%BJ%3"<2T
M<WP66XK SYJ=3EK-2Q'LM5[;"N>T_AMZW.O@3*,VX;Q&=XW!UJ.,X;GDN/S.
MCC(.,X?N$HX=U-O98I1=G3WND?K=\+(/LOP_\,P[-ACTR$%<8P<?Y_G7H"G(
MSCO6?I%BFFZ;9V48PMO"B >F!^GTK1K]^PU)8?#X?#Q5HT:%*DDMDJ<(PM?Y
M:'\_8FL\1B*^(=VZ]:I5;>[=23FW]["BBBMS **** "BBB@ HHHH \]^*?CJ
MV^&W@77O&-TH:'1[5IB&Z;BK!3[X(SCO7Y;?LG^!=2^,OQPU?]H/4=TVASW=
MRMM;R;GA#AF*@*V5'*CICK^->X?ML_$V5+_1O@PA_=^-OLL,F.N)N.1WX;/0
MU]1_LZ_"JU^$/PWTSPQ;H%8[;N5@ "S2QJW/?/)- 'NZJJ*%50JJ %4#  '0
M "EHHH **** "BBB@ SV[TC,J*S,0JJ"S$\  #))^@I&&>1U&,?G7/\ BR/4
M)O#&N1:7G^T9-+NTL\9S]H:%A'C'?<10-*[2NE=I7>ROU?DCY9_:-_;0^&'[
M/NES3ZEJECJ&IQHS?84G&\,%R%(#JV[/!&#SP,\U^%'QE_X+.ZEXDNKJR\,J
M=%C#21PE-Z# ) (9>3VR<GD]:^)?VO?A/^T;X@^.^K:!XC77)YM3U=ETB(1S
MO;F*6?"#&-N-I'X?3%?H)^R__P $@9/&.E6.K?%^U-D)DCFPT.QRI"MTVY)Q
MQSC!ZXY-?D^99OQMG>:8K+,@P:RS#82?LZN,Q:Y?:+=\LG9)VUTWT^?]R\'^
M'WT</#C@W)>,O%CB&?&6;Y]0CC,!PYD-3VDL"[1M"O&E=RAS.TY35TT[GPU<
M?\%(_CK>7#7-MXIN_LY;<N)IL!0>.AXX_(]NM>M_#K_@K?X]\&W\$OB'59-4
M6-U+P-)(Y(!!*X)Q^'],5^T-A_P2)_9PLK-;7RKAL+M+?9XSVP<9;J?_ *W2
MOGOXS_\ !&?X8G1;[4/AVCR:N(F:"&6%0QDP2,!<Y&[C@Y_G7/\ ZO\ B-A%
M[?"YU0KUTN9TJLER-I)M*_H['L0\5OHA9VUE6>^&N:9;ELK488[!<WMZ:DU&
M-2HXKF7+O)O;6Y[O^S!_P50^&GQNNK/1]<%KH-[*$0SSR>5N=L ?*[A>2>R\
M^HK]7[#4++5+2"_TZYBO+.Y0207$#!XI4/1E8=17\$WQX^ ?Q<_99\4O_:L&
MJ:8]O=A[.6SBDBCQ$X(RR  #@8_#MBOUD_X)X?\ !4S4='BT_P !_&2\==&A
M9;:RN[F3$H^Z@;<Y/( !]#CGC&/8X=XTKSKRRGB>C'+,RIS]G"K4?)2Q+TUB
MWHKO9]3\\\6?H[99A\KI\=^"^:5>-.#<51^M5\%A5]8S#):;5W#$0C^\DJ:=
MI<RTL[:K7^H&BO./ ?Q7\$?$;28-7\-:Y8W-O.BNJ&Z@$N& (^7>">".@KOC
M>V:C<UW; >IGB _,MBOT=232::::333333V::T>Z/Y&<9QE*$H3C.$G"<90E
M&491=G&49)--=FBS7(>-?'7AGX?Z)=:]XHU2UTRQMH9)=US*L9E,8SL3<1DY
M(^E>2?&;]ISX7?!72+O4?$VO6?FPP2.D$-S"Y:14)56*N>I R!D\COT_E _;
MO_X**>/OCSXDN?"_AJ\O+?PA'-+#9FPD<&1/,('"-W'.,=?QKP,_XDR_(,-*
MKB*D*F(DK4,'"2=:M/2T5%:I.ZU/U#PO\).*?%+.*6"RC"5\/E%.I'^U<_K4
M90R_+<.I6J5:E::4'**NU&]M-]C]7_VB?^"R'A'P;>ZCX<\*645Q)&\ENM_"
M6DR1E0ZN&8#U.,>U?EQXJ_X*E?%?Q+?2SZ'XBGMXW=F$22RC:&/'1NO(_+N*
M\^_92_8+^*G[1-[:Z]=Z?>2^&IGB:YN+RW?>49L,VYQSUSW_ ,/W:\"?\$;?
M@)I6GVTVN"634FC0S"*!&57VC<N25Y!';/\ ,5^=4O\ B(O%"^MTZE+)LMJN
M]&C-)8A1>SUULTK^MS^ML;#Z(O@S4CD>-P>8^(W%^#C&./S##2<\K=91C[2"
MLG!.$W:RTTV/Q2T7_@IG\9=%NDNM6\3W+0HX)22:7Y@N"PY/<=N/I7Z$_ 3_
M (+1:7<7EEH'BZQ%TDKQQM>R;@$Y"LV_<I''/)QQGGM]C>*/^"/7[.VMV4L=
MNLT,_EOY1:! N_!VYVECC. <#\*_&W]KG_@F#X^^#T%]K?@'3YIM!M!)*9[:
M M*(U).047.1CK[]J*N%\2.'H/%TL72S?!T??K8:RE7G%--J*WV7W+?L8+.?
MH?>*]>&0XW(<P\/\^QK='+<X4Y0R[#U96C3G7DER+WFKQ?=J^I_5'\(_CEX$
M^,6@V>L^&-8LKA[F-'>TCG5I$+KG 4,3CKU.>#Z9KV3('4BOY9/^"2_@S]H*
MV^(,=[.VLGP58RQQWJ7BS+&-C8; ?@8Y&><=N*_J98#&YC@ <]AQR:_3<AS2
MKG&68?'5L'4P-6K'W\/433A))7:OJXMZIG\:>)?!N$X"XQS;AG 9[A.(\'@*
MW+A\UP<HRIUZ<O>AS<FD:D8M<R\UU'T@!!.3U/'7BFQRQRC,;JX!P2I!P??'
M2GU[!\$>6R_![P1-XSD\>2Z9$_B*6-HGO#&A<HX(8;B">0?\YKF/#/[-GPD\
M*>*];\::3X8M(O$'B!G?4;TQQ;Y6<DL<^7GG)[U[S10!X[#\"OAQ%J=SJW]A
MV[7=TLBR.8XQQ(,-CY3S^5> 77[ GP'O_$VI^);[P]!+<:G*\DP$:<[R3C&
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MLQR<_NR.IZD&OH[P/X"\*_#G1(O#WA#2H=(TF$[DM8  H8#&3A5!./:NQHH
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M');S6\=NSJ"X59HY><G 7CGUZ5^6OB#]OOX@?L[ZO=_#* 2ZXUO))!ITT/\
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MG##&>!WYXK^2']IO]L?XJ_M0_$.ZL[BZU-=/EO632[:R:5HY(VE(CRJ$@C&
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M5?[0DOP&\.0:I;VAN[FXC=HHE!9F.2  !SR1_A7T[H&OZ3XFTFQUK1+ZWO\
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MQ0!^=/\ P3G^('Q0^#WQ'^*7BWQOK%W%\-)+O5X[>>ZEE-J"3,$P7.P=0?\
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M4(?<#M7Z0?\ !.[2/B7X"T?6/A?XNBN5T/PHK6FBR3JP#0POLC"ENVT=OZT
M?IYCOCGUQ7FOQ>NFL_AWXFN5)!BL';(_*O2J\9^/M[#:?"[Q0)'57FL72-2<
M%C@]!WZ4 ?F#X6UJ$^']5OYV >XN9X@QZG>Q7KG_ #TK[3_9)\*'1;+5]5$6
MQ=3_ 'BMC&\%L@]/UK\W;>6XA\#0#YD:76%'3&X>;S^!S_\ JK]F/@A8I9_#
M?PXX0*\]C'([8Y((&,GOSGK0!D_'[Q4GA7P-=7+R",7(D@R3C.4&,<CGD_TK
M\N3IK2>$O$&JD;AJ.^4?[09B>._(/^/>OMO]N>XFA^&-DL#,KOJ.#MSRI">G
MT-?'-C?Q?\(IX9T!BOVC4XH05)^9MX52,'DDY]/:ANWWK\78#[]_9$@^S_"B
MS0IL)NF)&,?PU]2YKR+X)^'V\-^!M/L6386"RXQC.Y1["O7"N2#SQ0 M%%%
M!7F7Q(^)6E_#W36N[MEDN2,QVQ/S/D9&!D'_ /77IM?G=^VF-6:YTL:1%<37
M12()'$K,A^4?> ]_T]\5S8NM*AAZE2$92E&.BBFW?NEU]#W.',NH9KG>7X'%
M5J6'P];$4U7J5I^SIJGS+G4I_936G-T/?O!VJ^ OC*J7^L:9;2W\4FZ&VF49
M5LY#8()STX('O7T39V=M86T-I:1+#;VZ".*-1PB#@ ?A7YW_ +)6C>(5U)KK
M78KBVD^\L;JR)TST.!]. <^]?HU48*\J$*TX<M6I%.<G!1G+1?%;7?HWT/1X
MSI4,#G.*RG 8R>*RO!5+82"KRK8:G=>\Z%WRV?\ ,DF]GL%%%!S@XZ]J[#Y(
M*\B^,/PWL_B'X2U/3TBC75C;M]CNPH\Q'"L -W4]>.<\8Z5ZVN[/S=/P_I0H
M'..0>N?_ -7O0!_,WXU\!_&CX<_%S0]+TWQ==);)K*&:U2>10T(FSM*AL8QP
M1^%?T;^ )+J3P5X8>^8O=MH]G]H=LEGE$8#,2>[$9K\+O^"EWBZ+X>_$#PIJ
M_@DM=:P^J0MJ44)+&-/-0N64<CC))/)_6OU__9F^($?Q"^$?A+56=6ODTFTC
MO4# LDHB7(8#D')/7]*B-6G-N,9QE)-II/56M=6\CKJX#'4*4:];"5Z5&HE*
MG5G3<83C+9QD][]/(^@:***LY HHHH **0D*"3T'6O!O$W[1OPW\*>*8/"&K
M:FL6L7$@CCB#H,LQP!@\\FIE.,$G*2BFTDY-*[;V5]V]M-3>AAL1BI2AAZ-6
MO*$)59QI0E-QIP5YSDHIVC%:MO1=3WJD4$#DYY]ZIZ??P:E:0WMJV^"=0\;=
M<J0"#QQWJ[5& 4444 %%%% !1110!_$'_P %_O\ D\O]GW_L:M+_ /2^&O['
M?@!_R1/X7?\ 8E:%_P"D4=?QQ?\ !?[_ )/+_9]_[&K2_P#TOAK^QWX ?\D3
M^%W_ &)6A?\ I%'0:3^"'S_*)Z_7\\W_  <C?\F-#_L81_*WK^AFOYYO^#D;
M_DQH?]C"/Y6] J?QQ]3O_P#@@7_R9GX-_P"O&/\ ]!6OW:K\)?\ @@7_ ,F9
M^#?^O&/_ -!6OW:H)>[]7^84444""BBB@ HHHH **** "BBB@ HHHH ****
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M8KWE;N?WICV[\_G02%!)(  R2>  .Y-?S!^!O^"R'CPV$2^)=B7"HJMO8 Y
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M#<$8 QVKRSX3?\%*?VR/V1/$EKX7_:AT'6[OPW;7*6S3M;SLHAC(5G9B" ,
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M7'3I^% 'ZWZ5"MOIMA"H $=I;KP._E)D_B:NJV[/'2F0+M@A7^[%&OY(!4M
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M *]9_P#T4U6CC<,DYXQ^?TJKJ'_'A>_]>L__ **:C7KUVT _D#E_Y3C^!O\
ML3?%'_I\\,442_\ *<?P-_V)OBC_ -/GABB@J6Z_PP_](B>S?\&Y/_)--0_Z
M_K__ -+)J_JBK^5W_@W)_P"2::A_U_7_ /Z635_5%0$_B?R_)!11102%%%%
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M>A_R[C4;;;5[)MW1]0?$_P#X*$>&?"=ZNCP)''->L8K2;!S(S':NTDX^8D#
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M+4W5U$Z+,T*>:K.N,AL9&#SGUK\_=9_95^(1\6S^+)+Z^,YO!/% KOY87?O
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M\&_]>,?_ *"M?NU7X2_\$"_^3,_!O_7C'_Z"M?NU02]WZO\ ,****!!1110
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M\0V=T3.NEZI)L#98)Y<YZ ]. /I7[4:A_P >%]_UYW/_ *)>OP__ &07%_\
MM;_$E).?)U2\QG_9GDY_ST]^E '[C6R>7;P1@8$<,2 >R(J_TJ:BB@ HHHH
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MN"1CC\Z^T_V'M/NX/AS>76HVS174U\2C.I!:-MYR,X/I[?3BOCCP;X5\<?M
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MZ7LUA/(_S$MO=-G7G)'3CU]/W0TGPGX<T.%(=-T?3[=4  9+2#S..GS[-P_
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MS_\ @I'F\^'FBZ=<MLLFU6"0DG"EBZC!['@ XZT ?-/P=_9U\5?&3^VOCO\
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MO%.@12RB/48PTT;(K''SJ2,8]^:\!TO_ (.=;K[1#9R^#!<7,I"K&;(N6+=
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M&8)RQRF-HZ=1^HY\3F/$N$?U7$1PKK8C3#3IR;C.[2<%9?$D[]/74]#(N#?
MOB&&(S[*ZW$.'RW)W?,\/BJ2C/"JFN?ZQ6;T]DVE&R=[NUNA]8?L!_M+^)YO
M''C#XO\ Q-TN>XGFN[JYT:.[A=\(SR-&L8D!_O#@=N<=:Z7XE_&/XB^/?C?<
M?$[P9X9NK:Y65C');V\B&15;Y<;%'4 =\U^[7A3]A?X-Z%X;T;23I"136=E;
MQW1@AC599P@\S=]TGYL@Y'49KUSP[^S9\+?#1C-CH5LQC(.9+>')QZ_*>O\
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M&C.49RZ66J7FU_P-=OT/PM_U8_UWR"/%>'KXO+*F/H4WAJ,5)5*DIKD=:_\
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M04>3"3ES<RB^6HM[EE0% 50%50  !@ #@  = *7.>E%(!C@#%?9?\ _FP"0
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MXZ>OYT .)P.F?:@'(Z8]J%.>W>EH *3(]12'=D8Z<9Z>OYT;5]/YT .HHHH
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M,;./16Z[(GHHHKZ4_(PQ[?I1110!_$'_ ,%_O^3R_P!GW_L:M+_]+X:_L=^
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M/Z4 .HHHH 3(/0BEI H'0?SI: $)(Z#-+12'...O^?6@!:*09QSU_P ^E+0
M4444 %%%% !C/49_"BBB@ JI?74-G:SW$\@CCCB=BS''12>O'/%6Z^;?VJ?%
M5[X1^$^K:GI[E;H.L:A3ARK*0V,<]Q^?>@#\X-7EG\1?&#Q9J_B?.IZ/I,]Q
M-8"4EHXQ&Y*[<Y7H!TX_*NCT/X:>*OVB+V2/1-2FT;1;-S;B>(M&B(G'5<=
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MWX<_LJ>"_&_@S4_#UM%#IVLPI*J7"D)(K?, <CYACCZ=^.:^0W^!WQB_9_\
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M48;,<F&)W\9R,>^*Z,%G=#%5?JU>C7P.)>D*.*CR.MT<J3V<;[7LSR\^\/\
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M /M$KR ,)92H&XD?=4\=>/;-?T*4 ("3U&*6BB@ HHHH **** "OE?\ :?\
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MT3\3?VF/B0W@;PP;O2M&FN/LPN(!)&AA=M@/RX'0CUKBOA1^SE^TG\6->O\
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MJNYMX0]A[G'3IVS7Y._\-!?M.)\:KWQ?X'\(ZG>Z7J=RZJD-K<%$CD. V%3
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MUVT/TS#^'*P6$I8[BK/LLR)R]YY+5K*6=RINSC55!7A&$HOW;N]]T?K%>_\
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M3Z4L#1C&%8Q-M4\8ZMCZU^=M]^U;I&O?%OQ-\%_%-N-+L?#L#Q6$UTOEPR-
M-J^7NPN25XQU)XK[B_9FUR/5]!U002>9;P7 6W.<AHE8J&7G[I&,8_I6&2<-
M9+PIQ9FF0X>C".%XERJE'V-VY55A*7)B:E:35YSJ7E=NY><\0YOQ1PSEV?XF
MK.6+X?S6I4C522A16+JQEAZ=."TIQIV2M%+Y'R9\-=-A_9^^*=W!=7Q6TU.Z
MD2.W+$(/-D(VX)XSGL/\:_0OQCX/TCXF>$WL[A(LZC:(]O=XRT9=#MPX!('S
M'IT-?&/[:GA71]-LK+QA;ZC!9ZE9N9C"9520LASNP#W(Z$#^M?)6B_MK>/\
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M  7^_P"3R_V??^QJTO\ ]+X:_L=^ '_)$_A=_P!B5H7_ *11U_'%_P %_O\
MD\O]GW_L:M+_ /2^&O['?@!_R1/X7?\ 8E:%_P"D4=!I/X(?/\HGK]?ST_\
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MH4-]JD<UY+I\.IJDC^4CNT0*R 'H,8YX^E?L-^S#\ [CP!I4/B/Q/*;SQ%J
M,\IG >2-I1N(.X$C#$\9'L*S_P!GW]DWPQX CM/%7B/3H+OQA.L<]S/)$CNL
MY^=BS$$YR3]:^UP,<  *!@ ?YXKZW@3@K,,!2PF:\58IYCG%"E4HX"C4?M*6
M68.4^:E1IJ3:=:$.6,JFLDUNM#YCC[CC+<QGBLIX3P4<LRBO6C6S&O37+5S7
M&0@H5:\FK-4*DU*<:=^5IIVU%HHHK]4/R8,YZ<T4@ '04M !1110 PJ,@Y Z
M<>O-/I, G..15>]N5L[2XNGX2WA>5CTPJ*2>?H*$M?5_\ 3=DWV5]/(_-+_@
MH_\ M36/P1^&.J^'M/U$6GB?5K5A:B.0+,JO$V, $-SO!Q[?3'\H/PM\!>./
MVK?B8EI!%<ZIJ.J:D\=]<D22/%%+.06+D'& <]>GZ?:W_!7SXI2^-OC19+;W
MS"SL;R.S:)9?DPKK& 5''8=N,U^F'_!(/]F>R\,:._Q2N[2*7^U;<O;221A]
MLDB%E9"1@,&((QG&,\]:_&,TA/CCC661SFXY1D-JF-I1D[8B5XZZ:-O9H_T1
MX%K8/Z.'T<(>)V'P].KQ_P")LIX/AS'U:495<KP\HN+IJ\;TTD^=2BT[]3[*
M_9 _X)\?#3X"^$[$Z[H^G^(-=N;:&:9[R$2_9Y74,RY/\2G& &XZ'D$5^@^F
M^&/#^D*B:9I%C9+& $$$*H% Z8ZXQBMT<<#H.**_7\+A,-@:-/#X2C"A1I04
M(0IQ4;16B3:2;>BNWJS^ LYSK-N(L=B<SSS,,5FF.QE:6(Q%?%U9UG*K-WDX
MQJ2DJ<;_  QBDEZZA7BGQB^ GP[^-/AK5=!\6^'M.O9=0M9(([Z:!6G@=E*J
M^[!R 3D\9SSUKVNBMI1C4BX3C&<)*THR2E&2>EFGIU.&C7K8:M3Q&'JU*%>E
M)2I5J,Y4ZM.2::<)Q:DM4KV=G:S31_*[J>@>/O\ @FY^TI:'3+Z[D^&6KZI&
MQB4R_9(H99MP'4H %Q_*OZ7?A7\0--^*'@?1/&FEM'):ZO;+,NPA@I*JQ7C.
M,;AQ7PW_ ,%,_@OIWQ(^!&JZE;V:G7M+E6:"Y1%\X*B%AA\9&"O7WKRG_@EQ
M\4=0D^%L_@?69WGF\*1SKY;L6DQ$,8&<_P!P=L=AWKYK J>5YK6RY7_L^O2^
ML864FW[*JVN?#Q_NI7:_ _5.(ZF'XMX+P7%D^5<195B7EF=1IQ26+P5.DI4L
MUK\J_C2E:G/T?J?07[:/C#7]4\/2_#CP1?/9^)[EA.KP2;)MB@' P=WJ?K^O
M,_LK_$[Q?<?"GQ/X)UB26^\:>%[&Y,?F.7GDE6,@8R2Q)*=.M?./Q7\/?&+X
MP?M%R^(?AS%=6EAI\DMJ0X<1,JY3D$8YP/:K/PATOXG?LS_%/7_%'Q)MKK4+
M36V?S$C5F39(3NP -H/S<<<<'K7*\96EFD\0J6(CA_:3PLL19N@J-O=J);\R
MEK?3HO(_F-YG7EG,L7[+&PPCJU<%/%*-\*L/RIPJI7^)2^UR_,Y+P-I&I_&#
MQSK$7Q!^(][X/\16&LLUEI$ES);^=%'.,*$++D,!T_EU'T5\=_'7B".R\*?"
M#PGK,TKS&WM+C5HI6+,"0A<NIR<@\\]/7J?+OVG[SX9>)]%_X6;X'TJ\LO'D
METK)#:*\3,7VX9DC"Y)8DG '48Z8KS.$^-?!&G_#_P =>)]-O;Y]0N+9YO,2
M21X4+J1N)!(P.O3I[URSE]657#\SJNKR3K8RG*<G+#SFK<RNU"3V?*E^ARQJ
M/"O$82FW557V<\1F%&I4G*KAJE1?&I.U.>J3Y5HEK<]0^('P \?_ +.V@P?%
MN#Q_J&M2)<V+7&FO<3%5-Q&)63:YVMA@XXR.#D\C/Z)>#OB["GP%M/BCXB=;
M=;;17OKKS2%R\0&!R1DL23] :^1OVC_C7IWQ*^&.G>#/#NF74VK:A+ICD!2X
MC*1!&&T#(PS'KGH/0UXA^V1XRUGX7_LH>%_A\'DLK[Q'806LB E'/GHJ[0.#
M_&?Q],$5ZE.OALOGC*F'E+ZM2PD9-2E*4/K#:Y%S2;M)W2:7W:JWW? V2+-N
M,,-D64NI/!XNG1E52G4J1@U5B\35C*=VIQH<TN6]KKIT^$?'$?Q%_P""CO[2
M']D:3?7</PVTG5_+N5C:1;1XHI=K*=I"$$+],<5_0Y\#OV<OAO\  [PGHN@>
M&O#NFPWNFVR)-JB0 7,TP50S;\#C*C&1N)R2><#XR_X);?!BS^'OP>GUN[M5
M;6-9NHKDW4J S;9EDD8AVRW)P.OT]OU,.[L<?Y^E=628-1H_VAB(\V.QK]M5
ME-7=%/X:5)OX8I:Z6OZ'ZSX@Y]*>.EPME=3V/#F0/ZCA*%%\D<;.$$JN,QBC
M;VU:<G*/[SF44GU>BTUB1C S^!IU%>Z?G!Y]X^^%_@GXE:1>:1XNT"PU:&[M
MI;<274"R21>8I 9">ZG!&<],#%?S6_M"_ /QK^P/\=-)^)WP[O[N+P)JVHK<
MW]E:M)]FA@>XW2*RKA5"@D'<.@-?U)U\G_MF?"O1OB?\"O&]C?V<<]]::-<3
M6$I0-)'(O VDC(.6R"*\C-\OIXO#RK)>SQ>&BZV'KP5JL94US<G,M91FH\G*
M]-;JS/N.!N)<1DN:4\!5MB<DSBI# 9IEV(?-A9TL3-4OK*A*\:5;#RG[95(I
M-\MI/MW'[.WQHT;XY?#C2/&.D3QS>9;6T=V$8,5N/)'F;@.A+*V<]_K7O'X5
M^ W_  2;\=ZOX2U+7OA!J5S+(D6K3+#%(Q+*JRLJX4GI@XQ7[\UME6->/P.'
MQ,H\E2<$JL/Y*JTE%^=]?F>?QED,.&^(\SRJC4=?"4*[>"Q+M;$86HE.G4BU
MI;WG'K\.X4445Z)\N%%%% &=J^IV^CZ9?ZI=R+%;V%I<74K.< +!$TAY/KMQ
M^-?S&_M1?%CXB?MY?'FU^"GP_N[NR\)Z/J"6&KR6AD6"2.*;RYFD,9"X8*Q/
M)Y/TS^TW[>_Q,NOAK\#]4O;.<P3ZJMUIX8,5)$D*@<CW<_\ UQFOAK_@DW\$
MH]*3Q7\3M:MA/J'B"22[MKB= [@S3YW([ G(#$@]?I7SF;.KC\9A<II-JA*]
M;,91=I1HJSIQB_\ IX])7[GZIP7##<-Y!F_&^+IPJ9A2M@>%J5:,9X>MCIOD
MQ=6K&2?O86F^>E9?$C] ?V8?V//AG^SMX+TS1[#0M.O=>CC@EO=8DA#SFY$2
M[]CG!SOSN;Y@<#!]?L     8 X '0"EHKWJ-&EAZ<:-&$:=."2C""LDDK)Z;
MOS>KZL_-<;C<7F.*JXS'5ZN*Q5>4IU*U:<ISDY.[2<F^6-]HJT4M$C+O]'TG
M5 4U&PMKP,-K">(/D8Z'(YX]Z^4_C_\ L:_"?XV^%;_19/#FE:3J5Q#(L6H6
MUN$D#LK#YB QSG&"".^?4?7VT[MW;_ZV*=16HT<13E2KTX5J<HN$H5(J<7&6
MC5I)VOY68L%C<;EF(I8O+<7B<!BJ-6%:EB,'6GAZL*E.2G&2G3<6[22;4KI[
M-,_A4_:P_96\6?LG_$6Y@CAG&DV5Y)=6>IA7"G8V^,+(,#MC@_A7[B_\$FOV
MQO\ A./#@\">,M6+:A%$EOI8N),LRH5"!0Y!.>1QT#5]3?\ !3KX 67Q:^#5
MW=V=C$=6L%GEDN%B7S3'''O4LXPW7()]![FOYA_V/_%=W\+_ -J+PUH"WS0P
MZ=J,%O=1K+M!*W"J0ZCK^/7IG'%?C%7#_P"H/&.$EA93CDF?3]E]7;?+'$2:
MNHIOEBHM_$EU/]$<!F*^E']'G/:.>4J-?Q+\*\/]=AG$::]O7R>E&]ZT[<]2
M=6FDG&;:B]C^[<8ZCOW]?2ORI_:@_9CU?XM_M*^!?%,NG&]\.Z9Y/VO='NC!
M0#[V<KP?_P!7:OTX\,ZQ#KV@Z9JENP>.[LK>0,#D;FB4MT]_\]SN[0<$J"P[
MX&<^QQ7[:NEU=;_>KH_SEO\ FU\T[/\ %'\ZE_\ \$U?&OC?]KO6/$6NW%PW
MPTM[<-INF2%OLD<B $;4)V#&/2O;=2_8?\0:GJE[X7CM9(-#@9TM7"D1B./(
M4*1QS@=,BOV_V@'.T9/4X&3^/6C SG SZX&?SZT@/YL=2\(?M(?#;Q%J7PH\
M-^#;V[\+3QRVPU-+:1D9&RH^<# X/KZ'KTZ?3/V0OBEX,^%'B7QE8:7<7'BF
M\E>XBTP1,79F^8#9C/4D#BOZ(7@MRV][>%F/\1BC+>O4KG]:D,<9788T*_W2
MBE?RQC]* /YOOB7X _::\=? GP>B:'J,.HZ->0RWNC"&0>=#"XRC1@#(8#'W
M>]0>"_V>?B'\2?'_ ((\17WPY;PI)X=M((;VY2T,!N9(U"L['8N26!/.3^-?
MTBBWMP-H@A"_W1$F/RVXI5@A3[D$2_[L:+_): /RC^%/[/'C'PSXO^(^IS02
MQPZ[HMS:VYVG#O)$4 Z?Y/M7A&A?LH_$'PG\%/BW;VEA.^LZYJUY>65J$8M*
M'D:1<+U/_P!?%?NL%4=%4?10/Z4;$QMV+M/4;1@_AC% 'Y__ + ]]\2M,^&&
MG^"_'N@S:5)HTEPL,DT)B9D8+CDJ"0=@Q[Y[FOT"S3$BCC_U<:)_N(J_^@@4
M[ )SCD4 +12$XP,'GTI: "BBB@ HHHH \=^-_BFR\.^!-;@N)1%/JEA/:6V2
M =TBE<C)ZY&*_(O2+K4/AMX3UW7+M6D?4[^3R6(RQCF?(QD$XPU?7?[:/BH:
MC<>&]"T2X,US!<J+N&!LNN923O4>@//_ -:OGMH8_&_B3PY\-[B+"3I;-*NW
M^/CJ.N<^M 'VY^R;X-MX?#$/CK8$N==C9B-N&(<?-G\6KUOX\^+YO!7P^U+6
M(6*NO[H,#@C>I!QWZ$_YQ7<> _"UOX+\+:5X<ME"Q:?"(P!TSQG^5?%/[77Q
M(M[NXA^%T38NKZ1&;!Y^; ''?% 'S";:QU#PCKOB:(K'K&MPS>6PX=Y) <#U
M)R<>_O7V%^PYX;U#1OA[?RZU ?MT^H>9'+*IWF(^9T)[<C_/)^(=:TG5-&O_
M  /X?M-\T+W-O]KC3)&UY%SN _$&OV7\&Z/9Z+X=TJULX5A5K"TDD"J%S(T"
M,Q( ZY)SF@#J:*** "BBB@!F6SC'&?0],U\P?M,?M.^$/V=_!]]KNL743:C"
MCF"S?JS*F1P<YW' 'T-?45?!'[<?[(T'[2GP_OM.TR66'Q!MD^SLK8#$H-N
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M#TQ[8I!@?+G)'^?ZTZDP,Y[UH<@M<_XJO7TSPSK^H1+O>STF_N40#.6BM9&
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M:4F\+EL)>QP&&A:RA&A!J$U'[+DM$EI=7928'3 Q]*6BO>/RX*"<=C^%%%
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M8/UQ7YO:)XPTWX??&KPO\=[#PGJ.D1W-U9W=_>R6\D4!>:19-S/M PV202:
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M:6UAI7)!STQV]#FE8;ACIS2T5[)^?@. !Z4444 %%%% !1110 4444 %%%%
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MSU_P3Z^&7P]@@\=_%#6+7QS=^2;Z2'595NA%)L\S[LK'D-U4$'C&5SD>L_\
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M1\'?$_P_IFO^%M:T^_CU&SCNC:P744MS;%U!:.:)3O5D[_+T]P<>A\Y/IV%
M"DXZUS?B_6F\.^%O$&O(-S:3I-[?HO\ >:W@>11^) %=(1G@UYW\6E9OAIXW
M5 21X<U(X'4A8&) ^H% 'XU_ 'PU>?MP_&_Q%\0O'DKG0/ 6J-%'H\^XP7/D
MW C13&?E;) &,$8Y.!DU]3_M"O\ $+PO;:Z?AEX9.@:#X-TJYOH&LH?*CG6S
MC>4GY0 <A.E>6?\ !*[4[*Z;XO6T:I!=1:U+OA.%D<"\PS8X)P1SC/'/8FO1
M?V_/VR/"GP>T'_A7,&HV U[Q<LVC7 DD0O;QW8-NQ(/W1AR2>_KB@#G/^">'
M[4-[^V7X5\;Z)\3?#D%Y-X+O#8[-1M]Z3B*?[,WW@"20V<@^OM7BGQC^&4O[
M%/QRTSXM>#[^2+P[XTU7R?[#A9A;0&68*5\H$*"N>F.G08-?5?\ P3L^!.@?
M"3P1J?B#3-;T_5KOQZD.LW LI8Y/*^TN+AE<(200<#!KS'_@J3-'/IGPOLX'
M6:[&OQ.UO&P:55-TF"5&2.AX(!XSZ4 ?J9X/UL^)/"V@:\5VG5]+M+XJ.QN(
ME<C\S725YU\(D:/X8>!4<$,OAK2P0<Y!^SKP:]%H ,>WZ4444 %%%% !36)&
M,#/X&G44 %?A;_P4Z_9+UN^N-*^.'PWM7.L^&I/[4U 6J-YC>1-YC;@@!;@#
MVY]<BOW2K-UC2;#7M,O='U2W2ZL-0MY+:Z@D4,DD4@PP(8$9[CCJ*XLPP-',
M<+4PM=/EG9J2TE"<7>,HRW332O;='O<-<08[AC.<)G& DE5P\I1G3DN:G6P]
M5<E>E4@[QDITW)+F3LW<_*O]@;]OWPA\7O#=C\/O&>HII7CC0(;?26M[S$+S
M26P6 JPDVG.0,$GC&,>GZQH4<"1&#*X#*P(*E6Y!!'!![$$U^$W[47_!,C5M
M+\2W?Q0_9PN+C0=>\]]0G@M9/*)EW&4J$0C(![@<]P,X'SEX'_;0_:H_9WU%
M-!^*^B:YX@ATYC$TBQ3S*Z1<<84YR!]._6O(IYIB,LC[#.*4U3I)*.94HN6'
MG35E#VB2<E52LI65G;75Z_>8K@[*^,:T\RX#QN']OBY<\^%<;5C1S2CBIOFJ
M_5F^6C+!N?,Z;E/F3=EHK+];?^"ASW\'P3O9;*?R6D:2$ /L+,RKC@D9SGMG
MWQQ7X VOP]M/#OAO3-?^(]Y#I6DZLY_TUI0I*.<Y))!Y![GIZ5Y_^W=_P4W^
M(WQ:MT\/Z+IE]H=@K FTG22(F0# ^5@O0X[X_6OR<\9?M"_M$_%30;/P=JNG
M:KJ6C6AV6B6:RLP4$* #&,].>_\ A\WFG"67<79Q2SNK*&+P=#!TJ.$A)S4/
M;JHG.4Z<O=^"Z3Y=^NFGX#QCX<9G3XIDN(,*\'B<)@:5&&"JU8SC[2-9.;G[
M.4J;O#126M_.Q]E?M;_M)^'/#.B-\*? %TNM:'?1L)+^-O.VLX( W+GKDX&<
M\8SBK'_!+']CS6?VA/BQI?BS4M/F&D^';]+LR2Q,J-''('/+C';U]N]4OV*/
M^"97Q8_:)\0Z=K6OZ;JNFZ"MQ%/.FI)*#Y((9LF49QCW_+O_ &<_LR?LN_#_
M /9K\'6.A>$]+@M]0-G''J-VD:*TDN%W@%1D\CDD\Y(QW/WN"P.'P&'AAL-"
M-.E2BHQBEJE9:)[VTOKW]$>[AL-1PE&%"A!0ITTHP5M8I))KFW:NNOYGT%X:
MT*R\-:%I>B6$"06^G6-M:JB  9AA5&/ &26!-;M%!..:ZS<**0'/(I: $R,X
M[^E0W,$-U#);7"+)%,I1XW&5=3U!'3I4V!G..?\ (I<=#Z=/QH$U=--735GZ
M/<_E9_X*S_L@WOASQA/\7M"L'311/-*P@B8J).7R HX(R#TZGVKP3_@GI^WE
MK'[/>MP:#XAN9;CPUJLBP7'VG=LMHV=1G:_"A>".FW'J*_K8^*GPL\)_%_PG
M?>$?%]A'?:==Q2JH=%8Q221E Z[@>AVD@$9QUK^5S]MC_@F-XV^&&IZKXG\#
MVMU=^&I))9K:VL59F6,DOM C'! '3MWZ&OR?B;A_-\FS=\6<,P]K5EKF.7QO
M_M*NG*:25GI?=.W;1,_N?P<\5N N/O#^/@7XT8B6#P5*2CPCQ7.S>3U6[4,/
M*<KN$5-KE=U?2[WM_4/\*/CO\.OC#I%KJ?@_7K2_,\$<LENDJ>9&S@;D W$L
M5)QP,^U>RU_ ]\/OCU^T?\!&.G>$[?7=)6UE,;&Y:X0?*3SAL<8!_7IQC[J^
M$'_!5SX^>']4M#XUDO-9B5U$ULCO*[ 8X"C/K_.N_*_$W)L;.%#&T,7EV*OR
M5HUJ,_9QJ+XN1VYG&^Q\QQM]#;Q!X=PV*SCAW,\BXOR&WML#6R['T'BZF%EK
M3=>#J<D:KCJU>.O0_KWKX=_;!_;(^'W[.O@C6OM&LPR>+9+62+3=/@=7E\]U
MPO"EB6R=I&.#D9!Q7Y%^-O\ @I!\>_B]#;Z3\,/"FNZ3=W:?9UG^SSQJ'D&W
MS,[1_>'OD?2NG^"/_!._XQ?'7Q3IGQ$_:5U2]OM.>:.\2QNIW8;2ZR!3$QYX
M]CS7T]3.:F-3I9+1GB)U%:&-G%QPM"Z5Y3O:7,K^YIRMK7H?BN'\/\/P[..-
M\0<;0RNCAOWM3AZC6A5SC,>5WA1HJ#E25*;7+6?,I>SDVC%_82^ _C#]I#XU
MWG[2GQ"M+@Z7-J#W%BEW&X4QLYD0@/ZH,\>U?T@VMM%:6\5K BI!!&L<:*,*
MJKG  ]JY#X??#WPQ\,O#5EX5\)Z?%I^E64:(D<:*I<H@0,^T#)P.,YQD\UV]
M>EEN AE^'=.+YJM6;K8FKUJUY_'-]NR2T2/D>+>)<1Q1FOUR</88/"4(8#*L
M%'2G@<MH:4,/%+1N*5Y3M=MA1117H'S 4444 (2!UI:0@'K28.1C@#''^?:@
M!U?S=_\ !3+]F'X@?'#]KWX9ZEX6U&^TJTL[BQ2:ZM3(@50ZJV60@= >O6OZ
M1*Y/4?!/AS5=6M];OM/BGU&U(,-PRJ60J<@@E2<CZT ?GY^SO_P3XT;X/:SK
M7BW4O$,FMZ[XET06%Z\YDD>)Y8 CY=P0<$GD$_6O7?@U^QSX5^%6E_$/1Q<)
M?V/CZXO9[N)E)6/[9NW<$=MQZ<>E?:5% 'XMS_\ !*6WTKXC-XQ\,>+)K"PD
MOGNS80S-&BEY!(1LR!UR.GXXZ_I_X)^#GA[0/#EEI&O6=KX@N;:.-3<7T?GD
M;% PI;OGKR1P,5[+10!\7?&S]CGPI\6M8T/4EEBTJ'1KR*[CM(5*Q[HV#8 4
M<#(X&?J:KZM^QSX?U3XB>#/'SZAMNO"-I%:P1X;YUC4(.V.@'XU]LT4 ?">D
M?L2>&=*^*?CCXFIJ(:]\::?<6%S%A_W:SQF,GI@\'H#]*M_"W]B[PS\._ GC
MSP(;X7NF>.+NYN[M&!*(UPS,005[;NV>?PK[? (//3G'K3J /S'\4?\ !.;P
MUX@M?"^FKK9@TSPQJ,>H6EJID$?F1R"4 +C Y'IWY]_9OVH?V,O!/[3/P8T[
MX4^(?(MY-*MK2"RU<QDS1&VA2/(=5,G)C4C'3FOM*D!SR* /RXT#_@FCX,LO
MAMX-^&VMZN-8TGPC<PSP_:!(ZRB)@P3# GL!S^=?1_Q;_8Y^$OQ,^%#_  SB
M\-:/I"I:V$%KJ=O:A+B-K&'R0QD4%CYGWFP =P&,#(/US2%L$#GF@#Q7X _"
M*T^!OPTT7X=V=V;RUT?>(IB6.58(,<\\!!Z5[7[XYI" >HI: (IIH[>*2:5@
MD<2EW8]%4<DGZ5^4'[1&K7OC'XQV::7<-=:%8X^TQJQ:+]U@-D X[<YZ5^BG
MQ<\6Z?X5\%ZU-=W*6\]S87$-IN8*6E92!MSWK\D=!U^[T+2/$/B?6XWE^U7<
MJ6TDH+$I(Y"E2P/'(_+IVH ZKP[IL/QB^(NG:#I<&R/PS<1O*J+\H$#*6Z>@
M!YZU^PFE6HL-+L+/&T6EG;P'V\J)5)]N037Q/^R-\+X-+BN/B0B\^)(YF7<.
M1O R1^#=:^M_'?B_3_!'AR]U[4W"6UNC+N8@#>R.4SGCJ* /SS_:UUE/B7XC
MT3PQH%QOFT2Y_P!+C1L_<F+MNP>W.<_RKQ>&]G\3>/?#GPPDMC]E46R3,%)3
M<N 2Q QUSSFH[26^G\3>,/B/;2M+879N9;7+;D&YBR[,_P Z^C?V3/!5GXTO
M+KXC:I #?6EX8XF91G@G&"1['_.: /O?PAX>A\+>'M-T.W_U=C D8^NT _J*
MZ7IT%%)NYQSG_P"MF@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BD)
MQ@>M+0 4444 %%%% !1110 4444 %%%% !1110 53U#_ (\+W_KUG_\ 135<
MJGJ'_'A>_P#7K/\ ^BFH _D#E_Y3C^!O^Q-\4?\ I\\,442_\IQ_ W_8F^*/
M_3YX8HH*ENO\,/\ TB)[1_P;CE5^&>I$##&]U $CN#=S#G\*_J@K^5W_ (-R
M?^2::A_U_7__ *635_5%0$_B?R_)!11102%,>-)!AT5AZ,,T^B@"M]CM?^?>
M+_O@5*L4:?<C1?\ =4"I** "BBB@ HHHH **** "BBB@ HHHH *Y?Q;X+\,>
M.=*N-%\5:-9:SI]Q%)$T%["LJJ)%*EDW?=89R#TSU!&17444 ?A+\<OV)/B-
M^S]XDN/B]^S_ *O?W:">6[_X16S,HMX6#F3RUMP0-N-H^4%2.,\$#W?]G;_@
MH?8S0IX5_:(5_!OBV+RK6%9[;RS/*N$)<-LW%SU8MG/(]_UA95=2CJKHPPRL
M RD>A4@@CV-?%7Q^_8@^$OQH74-<DT@6'C 1M-I]_:LD*+=*"8\J@39\W.=Q
MZ 8[@ ^O= U_2/$^EVFMZ'>0WVGWL0E@GA96#*V&&[:S;6QS@\X(K98;@5/1
M@0?H1@U_/UI?@#]L;]D'7)_$6JZY?^)/AI83/+::7!.]SBVB<[(]J%N1%MXZ
MCI@<5]@_!O\ X*;> ?B%JT>@^)M!NO"%W&R07-WJ1DMX#+G:S@2@  D9P#U)
MP .  <!^V+\$O&7PV\::)\8_@]8RM=B\%YXB%I&VXQ+,3)YFP9P5()SD8^E>
M5?%2Y_9]_;3T#2/#_P 6?&DN@Z_IT$-M=Z9+*T*_:50+(2C$9(<<]Z_9RP\9
M_#[QW826>G>(="UVSU&!HGMX+RWF\R.1<%3&22& .1E>#R,U\H^-/V ?@CXA
MOKO7M,TJ;3=>N)#/YT<VV-I&;<>%"!><$9&..M 'Q]\!OAO^SI^Q])!=M\7[
MK4-&MB9;32_MC20( ,JJIN(YPHP!^F*YKXD_$3XA?MI_%K3/A]X.TVYG^#4-
MW$UQK B<0NJN/G,F-N< <Y[\XKZHTW_@G_\ "MWQ\1;TSP,^VTMY+Z.,3?,,
M*)))-HX'0;CR!MQS7VW\+OA'X%^$6A)H7@?2X["P(5M_R232+CC,P4,RG@XR
M0>#SC- &C\,_ EA\-?!>B^#=-;?::/;B&-P"-W R>0/3TKO:3/.,'UI: "F[
M?FW9_#'MBG4UW5%9W94102S,0JJ!U))X 'J: %!!SCMUI:^<_BU^TU\-_A/;
M,^I:M9WMRF[?:V]PK.A&>#MSSGKC]2:^%_$O_!6/X7Z9*;6TTJ5I%?:TC,[#
M'? ''\Z^>SKBSAOAU1>=YU@,NYK:8BO!25VEK"+E).[V:3/I<CX.XIXEYO[!
MR',LSY;ZX;#S<797TG)1@U;6Z;5MKGZZ4C#<,=.:_/#X4?\ !13X1?$1(TN;
MRUTN?A7\VX"88^H<\?Y^I^UO#'Q*\#^+X(IM \2:7?F0#$4-W$T@)[;=V2?I
MFO4P>8X#,*-.O@L9AL32K0C4IRI5H2<X32<9*-^>S333Y>IY..RO,LMK5*&/
MP.*PM6C*4*L:U&I%0G%VE%S<>2Z>C]X[H< #TICY(X'?_&G'D<=QQ0H(')SS
M[UVG  Z#Z"N5USP+X.\3$G7_  WI.K%A@F]M(YB?KD5U*DDM['_&G4FE).,D
MG%[IJZ?JGHRH3G3G&I3E*G4@[QG"3A.+[QE%J2?HSX(^/7_!/3X%?&ZV6*3P
MWI7A^48#R6-H$#>IP@)!/I^1'0>._#/_ ()._ ?X?7L=VUK:ZH$E60QS6V5(
M!SCYT[]\]:_5=01G)S^9IU*,(4U:G"%-=H1C%>K44M?,NK7Q&(ESXC$8C$3Z
M3Q%:I7DEV4JDI-+R3L>>^#/A5\/_ (?VT%OX3\+:3I!MT5%GM;6..=MH W%U
M P>/X0/ZUZ#@Y!ST[8]12T51D)D X[TTL0< ?H?2G8!.<<BJ.H:EIVE0M=:E
M>6UE"H+-+<RK$@ ')RQ'0>@H\WT3N^B76X*[T2NWHDNI>/0_0TB_='X_SKYK
M\:?M6?"+P;)+#/XGTR[FB)#)#=QGD9R!C)[>G>O.-._;L^#U]=K;-J=M "^W
MS'N%"CH,\_YQ7'/,<!3FJ=3&X6,VTDG7I[NV[4FEOU.ZEEF95H.I3P&,E!?:
M6'JI/TO!-[]$S[=I&) X&>?0UYCX0^,/P\\;01RZ'XGTFY>0#$"W<7F9/8#=
MS_GBO3E8,H92&5@"K Y!!Y!!'!!'0UU1G":YJ<X5([<U.49QVO\ %%M;.^YQ
MRA.F^6I"=.7\M2$H27K&23_ 4=!4%S;6]Y"]O=0QSP2 K)%*@='4]0RG((J>
MDP=Q.>/3GVJKDM7T:NNS5SYA^*'[)?P@^)L$HO?"^E6-W+N+W-O:HK,6SEC@
M'G)SQQUXKXT?_@DK\&9->MM9>XC=8+E9S;-"Q1P&#;"-F"#@#!Q]:_6JBN&O
MEF7XJ<:E?!X>K.#YHRE2@W?35NVKTZGTF6<8<4Y-0K87+.(,WP>&KQ<*E"CC
M\1&DXO1QC#VG+!-:6BDNQX?X3_9S^#GA#3-/T_3O 7AW=80QQK<O81M,[HJ@
MR,Q Y)&1QQQU/->QV&G6.EVZ6NG6D%G;(,)#;QK'&H]E4 5=HKKA3ITE:G3A
M37:$(P7W121X5?%8K%24L5B<1BIIMJ>)K5*\TY;M2JRDTW=WLQ#R.>!0.!QR
M*4C/!II!QA>.?>K, #?WN#G@8-.JM=75I91-<7D\-M"@RTLTBQH .>K$#CK7
M@_CG]ICX3^!HYOMWBG2IYX0Q>"&[C+ @<CKVYS].,UG4JTJ*<JM6G26]ZDXP
M3Z:<[5]MEV]32G1K5GRT:-6L[V:I4YU&O7D3LO-V/H&BOR/\;?\ !5OX8>&M
M<%A:6BWUNC[6DC=F##.,Y4_7IC^E>C_#_P#X*6?";QQ>6UG]F:P:<JIDDE(1
M<X!)+< #GN?I7S-+C?A*OF53)Z7$&62S*C-4ZN$^L1C4IS>T9<UHW=]$I,^J
MJ\ \:4<KIYU5X:S6&55H>THXWZM*5*I3ZRBHWFDGO>)^E-(2!UXKE?"WC;PU
MXRL8;_P_JUGJ$<T8?9!.CR)D9(90<\>HXQZ5U1 /45]2FFDTTT]4XM.+7=-.
MS3Z--IGR33BW&2<9)V<9)QDGV:=FGW328M%%%,04444 %%%% !1110 444U@
M3C!Q^8H =12$X&:0Y."#C\QU^E #J**0'.1Z4 )M^;=G\,>V*=163KNKP:%I
M-]J]S_J+&!IY.WRKC_&@#Y"_;!\9/%X._P"$8T"_:+Q!<7!#11.5D\M@$VD*
M=V#@YKX.O9IM&\+Z1X6EM_\ B>>(E2*XD"YD=YMH^8]<DG//>NW\::_>?$[X
MO7GBW36<Z)ISR;H<DQ9B+'[N<9XYS76?!SPLGQA^(LE_-%MB\+W&]01A<0OC
MZ<XQ[]*6MU\_Z\_T] /MS]FOP%/X ^'UMIUU%LN;IH[IR1@D.A(_F#1^T9XS
ML= \!ZMI#77V?4M8M&@M,-A\OD#;WR<?X5[XH6SM%& $M;<# & %ABZ #V7B
MORK_ &A?&B?&'Q_IVA>'9'C7PU<".^"M]XQN2^X#KSG&?H.G+ \)M+G5OAUX
M(GO+N)KN^UF\>-9&&Z3RYVZ\C.,-^OY?HQ^R=\-H_"OA8^*&3R[GQ/"MS*F,
M'YRK\CZBOC#P[9/\1OB5IGP]G@+6EBT.YMOR;X\9S[\?GZFOUP\.Z/#H&B:;
MH\"JL6GVT=N@48&$'M0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?Q!_\ !?[_ )/+
M_9]_[&K2_P#TOAK^QWX ?\D3^%W_ &)6A?\ I%'7\<7_  7^_P"3R_V??^QJ
MTO\ ]+X:_L=^ '_)$_A=_P!B5H7_ *11T&D_@A\_RB>OU_/-_P '(W_)C7_<
MP_\ LMO7]#-?SS?\'(W_ "8T/^QA'\K>@5/XX^IZ!_P0*VK^QCX."+MW6,>[
MWX0_SY_I7[LU^$O_  0+_P"3,_!O_7C'_P"@K7[M4$O=^K_,****!!4;PQ2_
MZR-'_P!Y0:DHH K_ &2UX_<1<?[ _P ]ZF5$3A$5?]U0/Y4ZB@ HHHH ****
M "BBB@ HHHH **** "O'_BY\$? ?QC\/7^B^*]#L+N>ZMY(K?498%:YM9&38
MLBO@M\O7UR 0>N?7B"2"#QQD<^M.H _GO\:? []H?]AGQB_B7X.7>J^-/"MW
M.MQ)9#SYX+*V9RSQB-@0H09&"!C'3IG]"?@#^WU\-?B):V'AWQOJ:>'?B&\B
MP76DRPK"AF;@K@F,1[6!SPV01TQS]_7EG:ZA;36EY!%<VTZ-'+%-&LB,KJ5.
M5<,,X/!QD'D<U^:?[0O_  3Q\$^+X[_QA\+()/#OQ$=Y9K>[BG$433N2RN-O
MEA=KGI],&@#],()X;J&*XMY$F@F19(I8V#HZ,,JRLI(((]/I5/5]-AUC2]0T
MJX&8-0M)[.7_ *YSQM&WZ-7X,>$OB-^U7^Q-<N_QG_M3QUX?C^2RB@:6Z M\
MG;@INXV=P<=QVK[V^!'_  4'^%GQA=8=3"^"KACL":S*8!O]_.P0,\=^.>:
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MOTT?D^S[/R"DR <=Z,\D=Q1@$YQR* %HHI#DCC@T +135/\ ">2.I_S]:=0
M4444 %%(&R2.>*0@D@@\<9'/K0 ZBBB@ I,@''>EI, G..10 C$C&!G\#3J*
M\]^)_CNT^'7A#4O$UXF^*TC( Y^^RG:?P- 'P9^UMXF?XA:WI/@WP]?,D^EW
M(^VQ1,<.!(2P< \^G/\ *O KZ.Y\2>)?#_PHCL\P2_9A<2JF06!7<20,9.><
MT:6VH:QK'B;XJ)(QM[X7$UI$[9 ))8;0>_3I^'-?2_[(W@Q/%UW?>/M=M?\
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M/"M]X$U:6Q\1Z9Y,U[86[^26D#[Y%>-<=^#QQTZ<5YM^R1_P<$ZKJATGP_\
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M_P#$+X:?M!_##2_ GBEM>\(:EI-CJ.M)9W1GBR85DF#A69<]0<X_45]7ZO\
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M+<!XX9K@,&9>< %L9R!Q_P#7K)L8M6^(_CW0M#\)6DH\)6%Q%'</&I\B2))
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MFW]MYWC,Q3;C6=.%-NW\*E3C3IJR22M&*5K+6[ZC=QR-O(XSP:#D'<.2>/\
M/Y4X #H*6O;/GQJC'XXS6'XHTRVUCP[K6FW<230W6F7L3(X!&6MY #STP<<U
MO5SWBR6:#PQK\T!(FBTF^>,CLRV[D?\ U_:IE;EES?#ROF]+._X7*A?GAR_%
MS1Y;[7NK?B?SU?"AF^#7[7=QX>L[H6UMKVL<P1/MC*RW!&T@''0__6[C^C.,
MY1#D'**<CD'('(/<&OY!/%_C/Q'!^TAK'BJ^O"DVC:T1;R%R FVZ.WG/08'/
M?UYY_J(_9Q\9W/COX6:!XANY_M$]S"BO*#G<5C7//MGKWK\J\-N)LKS;%\49
M1ELYJEDV:3I4Z51:QC)MU.5=$YW?9]#]B\4^%LVRC!<)9WFD*;JYUE%.I4KT
M_P#EY**BJ7,]=522ZZ?<>[4445^KGXV%%%(QP,X[T >._'OQ'-X5^%WB;68'
M,<MO:LJN#@@O'+W_  K\>_\ @G]X ;Q9\=?$WQ(UR 7AEN;N6WEF7?AP[%2"
MV>A S7Z=_MI7XT[]G[QC<L^P+''S_P  F_7TKY"_X)GQ/>>&[O5?+'ER37 \
MTCEOO8Y]<YKXW,8_7>+,IPE2*E3P.&GF=+O"O&;I\]O\.GRZ]/O,JG]0X+SK
M&T9.G6S#&0RFL];5*$J<*KIWZ-O7?;IU/UHVC:% P   !Q@#H!],4UE^4 <X
M/^-/HK[(^#&DG( ''&>#ZT,2,8&?P-.HH \>^.OP_M/B3\-]?\-7,*2&YMG>
M,LN2K)%)T[]P<>PK^3[QMX:3P%\:K?PW'\O]AZJTB#!&W9/N&/R]OQK^QUU6
M:-T8 JZLA!Y!#+@_H:_&SXQ?\$V-<^('Q<O?B#8:M%;VUW<-*8?.1" 9-V,;
MLCCVK\7\:. \SXWRO(7DBI0S7)\ZP^-CB)>[46&IRA*=.,U:5FT]+V[H_=_
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M4?Q]U/6?"%M-/>Q:H-(O)[5=ROB3RVC=EZ@X((/YFOWBAMXK>WCM8DVP11+
MB=EC5=BK^"C%<OI'@3POH6KW>N:7ID-KJ=[O%S<H%#R;_O;B%!.?<FNDY#^4
M#XC?L@_#J[_:'UF;]HB^GTZUN=:E?3FD1ML<3S9C6,D8  /&/\*_4WX(_L%_
M"9M&NV^$?C2[33;R #?#,Z[59<'E3Z'L.:_2?XG?LU?"'XO:A%JOCCPU'J5_
M"5*7".L3[EQAF/EL2?4D\Y/2NX\ _"[P=\-+ :;X1TXZ?:!=@C,GF87Z[5H
M_(']N+]F?4? ?[)D_A.QO+KQ9-<:O&9H[@27!(9T)R&R2,'&1Q7S?\1/@7IK
M_!W]E*WT[P'90W=GJ&D'6/*L5#.HDA,GF@)GUSNX^M?T6^)O"VA>+[ Z5X@L
MH[^R+"3R9 "I8=\,K#C [5C3_#3P;<6FF6,VCP/;:.R-I\95,6Y3&TK\F!C
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MV/Z!XZ\1,CS#PEX(X#X>G6HU\IJ>USK[,<2^6_+.UO:1YU]IM]6CV8C(QVH
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M$H1(?M#L2@(#%0QXSS^E?SO_ /!1#]O7Q9\6/&QLH1/IYT>XS:6;ED:+;*"
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M<QB2"9#'(AZ,I&"/RK!T#P?X>\,+=)HNGPV:WK%KE45<2ECEMP"@$$GD'(-
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MENO\,/\ TB)[-_P;D_\ )--0_P"OZ_\ _2R:OZHJ_E=_X-R?^2::A_U_7_\
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M^%;:(=!RA(^A\L5Z9H/@_0/#4?E:-9+:1CC:IXQZ< 4 =/2;>=W.?_K8I:*
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M)"J_> '.3MZ_AWK\#?A_X[\7_!WQ7%K.ERSZ-K-C?G[7:LS12210O\P*''!
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M?-MQ_G&:=0 A( ))P "23T '))^E?G+^UE\3;O7+_3O _A&X,ZR-]GU?RB2
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M!?Z5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '\0?_!?[_D\O]GW_L:M+_\
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M]T0@/&[$F!U'.03P.>* /T<HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>H?\
M'A>_]>L__HIJN53U#_CPO?\ KUG_ /134 ?R!R_\IQ_ W_8F^*/_ $^>&**)
M?^4X_@;_ +$WQ1_Z?/#%%!4MU_AA_P"D1/9O^#<G_DFFH?\ 7]?_ /I9-7]4
M5?RN_P#!N3_R334/^OZ__P#2R:OZHJ G\3^7Y(****"0HHHH **** "BBB@
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ML_$'PGH.B-XAU#5K:/2E4L;H2QE" ">&W8/3CGFOP8_X*C?&+Q_\1KG1M*^
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M !1110 4444 %%%% !1110 4444 %4]0_P"/"]_Z]9__ $4U7*IZA_QX7O\
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M03X:TM?M&K^(86M4DB)+6YD8K_">#P#G'KS0@/F?]I'XD:C\1O' ^'NGS/\
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MF?@W_KQC_P#05K]VJ"7N_5_F%%%% @HHHH **** "BBB@ HHHH **** "D)
MZTM'7J* "N3\<^*].\$^%-<\2ZG<16]OI6FWEX&E=4#200/(BC<>26 SBNLK
M\7/^"P_QJUWP9\+_  YX-\&7DG]K>)=4^Q7\-M(1)]FN72$JP0[NF<Y'?&*
M/C3P3HVN?\%*_P!J*Z\6ZO/=KX,^&>L)$UB^XV-S#8W2QKE#^[96"KVP1@#W
M_I0\,^&](\(Z)I_A_0K*"PTW3K>*W@M[>,1Q@1HJ%MJ\;FV@FO@S_@G#^S_I
MGP<^"&A:]%:K!K7CC2K75-5<IB5Y)BDS%F/S',BD\]Q[5^B- !1110 4444
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M_P F9^#?^O&/_P!!6OW:H)>[]7^84444""BBB@ HHHH **** "BBB@ HHHH
M**** "OYJ_C)K$O[0/[?3?".]8WFGZ%J@=+>4^9&ACFR"%;('3CC\?7^D/5+
M]-*TV[OYC\EI!),Q_P!Q2W4U_-=^RY;_ /"4?\%2_&/B7[\*WETPS\RY1V;C
M/'^>* /Z/_"&A1>&?#&A^'X$$<.D:=;V4:*,*JPKC '85T=%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@<?_ *NE% !1110 4449STH *0D#K1D>HH..^/Q_^O0 M%%(W3KMYZ_YQ0
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M@EMX>^'G[3G[-FF_%$#65T^'2$O=5F8R(VWRE+,[9!Y'<UWO@W2=-\4_M/\
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M%% !1110 4444 ?P^?\ !?EMW[9_[/J^GBO20>O_ #_1"O[)/@!_R1/X7?\
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M<*6!.<C\ZT?AY^T1\,OB1%=)H/B&SGU"PB,M[9+*ADB4#<6P&) QUW8]B>E
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ME'P!_P"2*?"__L2]#_\ 2..OXU_^"^W_ ">E^S__ -C9I/\ Z7Q5_91\ ?\
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M\.>#;,[?#\#P1W2=F4.H/R@>@ZXJQX]\KPY^T)J]]K2?9;&]N9$BFD&%?<Y
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M"6,E&U%QFHIPA.$K-^?5VZ]?V%^'_P#P4)\.>)=(U:QUJ,C4Q%*D*R# 8E2
M.3C^G/3@5\4:[^TQ\3K;QSJ-_I9C@\.W$LJ" L$A>%MW520O*_7W]:^+]6^(
MG@S3IC!X-MDU+6),+%#!\[RR'Y0 %SGD].O?I7N?PV_9\^,_QPM%DUK3KWPC
MI3*K_:Y5DA00N,ARS!>"#G\>^:^IP/B7](#Q8P^'RSA3+(9=3P?*\1FG+R8N
MG.5OWDJCC:*TYHIV]V]DSPZ_ _A9P.ZN89[C'7==^Y@I/FH2C&WN0I<SE+71
MVTOUV/6?AMJ'PGU7QI>>.O%.CV,WB42M/;2P0QOB?=N!+*I_BP:^C?&/Q=\8
M?$J&R\-O;?V=X6M[F!8KR%3'M@B"HH+ #^%<]?<\<UYU9?#7X"_LK>"==?QE
MXXT[Q%XGEMI#;PRW,<LL,V,@ ,Y8$-Q^7;-?(L_[:'AN?P5K?AW3TCAE$TQM
M-07:-L>YBF'],'_ZU?O5#-\?X=\,9;E_B%Q)2QN:XFA7KXFO@X^UQ&,Q"DO9
MX;&2I]]8WT[^OYK4RVCQEGF+QO"&45:>7T*M&CAXXIN%'#4FES5<+"IT6C:7
M;KH?O-IOQD\(?#WX?^'=#@U>"ZU1;.&WAS.KN7*_>/S9SGY>O]*?HW[1EGI]
MY%!XHS%!=N@@N"=L6'/RD.W'?_/;^5/0_P!J:\U?QK8V,WBE[M[6Y588/M#M
M@^8 %"ENW/ Z"OZ XF\%?$K]FNPOM5U.#1O$D=M&UO>O(L<KR!05PVX,<D#'
M?\.:^HX+\5:?&&:U,IP=&K@J^!P/UG#TZJ<,/B:%&,>:+E)6Y[:1N^RZG@<3
M\ 2X;P5'&XRI#$T\5B_88B=)WK4*M1^ZU!7?(K^\TOT/TDU7XA^&=*TFUUF6
M^BEL[M5:)HI$8D,,C."<>AK:\/\ B32_$EDE]IEPDL3'&W>I<9Z9 /?I^%?D
MW\,--\6OIVG:3XHOY[OPS'\L6I22,T1B'"L')QT&>N/T->X_"[Q#_8_Q:A\/
M:%KG]I:*6&^*.7>BG/0C=@=_\>U?H^"XHJXJM2E4P_L,/4KPPGLIW5=5I.WM
M%?XJ5]G&^A\3B<BHT:=6,,1[2K3I2KJI%<U*5-6?([?#4L[6=M=S]$0,9/K4
M-TGF6T\6\1^;#+&'8X"&1&4,3[$YJ>OB']N7X]'X'_"FYUK3[L1:JTKJD:MA
MPH52#USUSV[5]1F&/PV68/$8_&5%2PV&INI5J2T48KU\SPL'A*^.Q5'"8:#G
M7KU(PIQ763?Z;GQQ\:_"VI_!CQ[?>/\ Q9XC)\*S7#7,D0N_W:1"0L1@O@<?
MI7I=O^W=^RUXF\ 2Z+;/;SSRV36*2Q1PLPO&38)/- \P'?U&_!Z\8K\]ETWQ
M9^W1\&/$I_X31WUK['<&QT@7)$LC*KD(HW;LDC&,?T%?E]\&?#T?P:\5ZI\(
MOB1921:^NH3+:FY9M[$2,(W!DP<'@U^ >('B)F'!^08GBK(,A_M;"X^<7*3J
MQQ-)4G;FG>%^1.#?N.S;M=7W_7N%.#L+Q%FM'),WS.6"Q."3:A&#HU)-6MR\
MZ3FXM?%%O;?8_7#4O#7Q;U7PIXS'AK_B9^ /$<=VRJ3YKI;RJ[<#G&%88]!Z
MU^1GPJ\ 7_ACXPZKH]O<7.GQV]]/=B-28F-P&+8VC!^]QP*_7+]GCX\S?#;Q
M'9^$?%UT)_".ID0!)BK110S *.7^484X[<9KE?VL_@WX4\)^,K?XU_#6^M]0
ML]05;B:PM'1_GF&XC9&2 ><=/SK\8XJX@J^)GAA6SOA'$T,(LEP\ZV88''5H
M4LPP68<T:G/@*\FOW/-]B+O]Q^BY#E4>$.-895Q!"K4693C#!8O"TY3PF*PR
M7)&&+IJ]JO+O-V6I]3_LG?MQ+X-EN? OQ6FN8[*T_P!'TV\F8X CX0[G.W&!
MS[$X]OM7Q+^WS\%/#]Q90#4A="\D1%=)HV +D ?=R!C/<GWQTK\$YPGQ \-.
MCZ0]CK-]'^ZO-IC>)L$ [AA@0>?Q]ZY?2/@\/#^FJ_BS5FO)()?M$4LMP6\M
M0=P&6;^$>W..!7CY5]*3'<.\"<-X2OBL'F/%%*4,/C\)4ISKUEA:/+"[JP;C
M*K)?#+7?78ZL;X)X#..),UQ,:6*PF5S<IX>I2G"G2E5GJVHM7C"+W77HC]Z_
MCW^T_P#"<^!(M3M3'<:[?P))I4@$;31LRDJ-R@,2"5QGITYXK\[?B]X@\+_M
M3?"6/X?_ !0G5+*-RL1N&&?*PP&-YZX(QV_7'R7J/CG3=1LH=-TG/B*]TY?*
MM;6-C,5*@!5 &[O@8Z5T_P .?A9\8?BUK&GVVK>';WPMH*7,7F7TD<EO&;<.
M,L6*A<;3Z_GVZ'XQ^-7B7FM.' ?!<,NRZK3IX?$5\SH22JTY2C[6<JC2@XM7
M<=?ATV*H^''A_P %8/ZQQ'Q'*MBJ-2=>BL+6BYTZL4_9QA33YDT[<UE9M-J[
MW^I?V3/#W[(_[&>EM>64"WE]'&P18XP[%R.-@QCACZ'/0#M7VW\!_$;_ !1^
M*MY\3_#Q:P\-KN807&8SY)S_  G QM!SQR*^+_BAX9^"7P0UOPC9:W<V7B9]
MD']H6YDCER^%+!AEA][(Y&?>O+OB-^V+:?#_ %"6/X;VXT70+FT\K[) 51!E
M<9(0C^G?V-?T'5XPP/"&&P&$XHQ>78&OELJ$JF7Y=&U:KBY4HRJ54XR_AJ=T
MTUK>Y^51X=QW$^(QV*R2CCL9]=A5C]?QSO3CAU4]VFE+[;C9IWT5_(_;?Q=^
MU/\ #/P?J,VEWUS<7-S!)Y<@M=C@-G'7!KTKP!\5O"GQ&MOM&@W))QN,$I42
MJ,9Y4<C\NU?@E^Q]\;/"_P 3OB?'IGC+3DUR36)LDRXEV&1C@Y;.",^WUY-?
M;'B[4[G]GOXORZAHQ,7AW5XPL5@C$Q6XE'#;02!C<.<#^=?3<(^(U#BK#9CG
M6#QF%KY/EN+C@L;1A0J0Q6#JU%S4W5E)\LDTTG;;1^OS_$'!4\AKX3*\50KT
M<RQF'^M86I.K"5#$TXM1FH12NG>]M>Q^K!N[4/Y9N;</_<,T8?\ [Y+9_2IP
M<@$$-[CH?RXK\S]2M=<U&PG^(VF>/GDEE*W*:*ETP(!))3R]WX$;3UK[*^"/
MC&[\5^#[6?5"5U&(^7(C'YF &-WOT_GD]*^^R_.8XVLJ,J#HN=/VU&7M85(5
M:=]&G"Z4FG?E;ND?)8W*GA*'MXUXUE&HJ56/)*$H3LFU:6K2=US+0]F+ $#N
M:6FA<=3GZCI2!OFQCN?TKVSR!]%%% !5/4/^/"]_Z]9__135<JGJ'_'A>_\
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MT45[W;R22]$K)?))(^<[^;;?FVVV_5MML**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BD)(Z#- 8''(Y[9H 6BD)(Z#-** "H9KB
MWMQF>>& 'O-*D8_-V45QWCSQ]X=^'NAW6M^(+^&SBB@E>!)6"M/*B_+&@)YR
MQ /XU^5OCCXO_$KX]ZM<Q^&Y;GPWHEB[);W4;/"D\2Y&\,",[A\V>_?K0!^M
M\WB/0H"!+JU@I)P/])B(Z@=0Q'>KMOJ>G7>/LU]:3ENBQ7$3L?\ @*N6[=Q7
MXBFR\20L=*N/B'-)J3914-T^0Y)&/O\ J/YU'%<_&;X/7T/C1M=O=;L(9%<6
M FDE62,$$_+N(Z>V.: /OK]JOX!3_$?18M6\-QF'6K!GN'>)<2.$P_51DYY_
M'\Z^"/\ A:D_@;2SX4\9:)=7EU9)]F$S0,YX^3.2.HP3_P#7K]3_ (&?&K3/
MB_X6M=1D$5GK#*%O--/$BG8-Q\OL,[LC '(KKM:^$'PY\03/<:MX6TVZGD.Y
MY7B&\G).<^N3F@#\>M%^)W@>&2.]CT:]EN"VX0O;L8U))/ *X[?R_#T+2/ G
MQ"^/?BC3DM;.;3O *2Q-=@(T8,2NNX$8 /RY_6OTOM_@/\*;;!B\(:8".A,2
MD_H *]'T70-'\.VOV+1K""PMLY\J!-JY'3/?CM0!C>!?!.C> ?#UEX>T:%$M
M[1 IDV*'E<A0S,PY()' )]^]=7<3I;037$IQ'!&\KGT5%+']!4U8WB&TEOM$
MU.UA)66:RN%3'4L8GPOXGB@#\4]'T^\_:U_:PU[PCXYGG;PEX-O+FYL;8,6B
ME2T=G";"0AW*G3U]!7Z _M&_$?1OV<_@[?CP18Z?;^(=,TR.WT:PM(((KIA#
M"2'VQJ)'=V"L2<C+'VQ\0?L87T%M^UO\2M)G.V\A_M1#N^4L2DZ\9Y/..G7M
MUKPW_@H9K7Q\T;]I32]<\,^$=0\4> -/B"7=C%!//;2)%'AF9%5D.53)XYSZ
M4 >R_P#!-K]KGXO?M(^-_%V@_%?2P;"S6^-K#?P"0J(0YCS',K##!0""I&#7
M:?MF?!+2OA+XOLOVD_#!_LC^RKNV-U9V(^SV[RY0MN2/"D$ACR#Q^(KX#_X)
MF?'[Q;XI_:P\::6? L_AVQD^TP26IM&A6$$%)#C8H&,L?PSQ7ZV_\%);FVO?
MV=]:\.PW"?VQ?WEH;:T5AYK !B3M^]SE<8ZT ?47[/WQ'D^*_P +/#OC>0YD
MU:-V<]?F18\\_5C77_$7P%I7Q)\+:AX5UAY$LK^-T=H_O E&49Y'&3S[=J^=
MOV$-*O=%_9G\!Z??Q-#<PQ3[D8$, RP$$YYKZ_DRT4@0_,4<*?1BIQT]\5,H
MQG&4)KFA-.,D]G%Z-/U14)2C*,H-QE%IQ:W4D]&O-,_D8_;4_8B^)7P<\77_
M (P\/2K-X/M)YKM7MCFZ6(2%^H&[("_7/ZZ'P*^,T'Q/^'U]\-O%&^;P[;VD
MEM<'4"6E$P0K\HDY'.> #7V-^U9\4_$/A_Q[XKT/QOJ#WGAZX-S%9:?/EHV5
MF8*BASMZ' Q[].E?F%HQM!XCN[S1H!H]E-*T_P!D3]V)@6+=%QG<.O/?GBOX
M;\8,5E/!^;O..!JU?(^)Z6+_ '^3TW*I@\THM_OG4PL+N2J+XDUKI;8_J7@&
MGC\_RVEEW$]&GF>45:,?99@[4Z^"G9>S<*K22G3=K-;/\?!_%M[?? [QMKEC
M#YX\(7TLO]G;=PB"RL2,#[O?I[^M?+,WQ%\1>%?B3;^+],N-6-D]T)C!"TOD
ME"P)RJG;C!)(_P#UU^V7P\_9VMOVNM(\4V=Y:+;77A>UFDLV8 -<20(Q4#N2
M=HS_ "ZU\:>'O W@_P *>,-6^&WCO18HM1L[V6SM3<0@-(L;LB$&0<YP.F<_
MK7PF/G6APW'Q!Q_#<U2XAIXBAFN#P$HP4?9VC6J+D]ZDI-M\C:E'9M-'U>'C
M3JYS/A+#YM%U\G="KA*N)BVYQE:5-7>E1I*W-:W7:QT,O[7%GK6@:?I^GPFW
M\1W\<<432_([2E O4X))8^OXUS&M:)\;=7MDN?$L\\6D7Q$D3AF"F)^00>GW
M3QU]O;D/CE\%M/T'6='\2:) -/M-)EBN 8_E5E5@_88.5'^>E>SGXZOXQ\#6
M&@VP9Y]-AB@:;80<1@*<G&>B]N.O-?EV7X? 8"IDF;\)</4<SR^MC'4SR.)H
M2Q6(P-'FNDJBYE"-K7<K)/<^TQ-;$UJ>.P.<9B\'B:=*%+ NG45*&)J.*5U"
MZ;>ETMV[]CZ"_9<_9'UO7=0LO&6E72W-SIKI<^1<MO$K(1)M"L#D;EQT]O:O
MU<TCX@_&3Q!>2_#2+2+?28;2Q-L\T,(@9HX49"RE5!S@<'\*_)#X0?M+^(/!
M&H>&]/\ "UY)/+;31C4+*(Y,@#+O5E'7//7\,#FOU?\ A!\2O%OQ;^+&G36V
MAOI'G6,<<\GEB+S6= &8G SN/-?V%X2\691FV75:>4Y3CN',9_:T</BL.K2E
MFE.;:C4C."_=P4':-_L['\^\?Y+C<!C57Q^,PV;X;ZA.IAZTG;ZA4ARMP<)/
MWY2EO9.W3L?D/^T-^S;XH^*_C_7=)TS7]7.K:=+*;B!IYFC+*Q) 7<1UX''T
M]*^6_A;^Q9\=-<^+-KX$O&N(M FN(X)9Y1(%,3,%9BQ SP>?IQP17Z7_ /!1
M'5OCW^RQXWN/&?PO\ 7OBI=3<37L]I;/< K(0S'**PY'4]\9/K7PA\&O^"AO
M[0WBWXBZ7:ZK\,K_ ,.327-O#/?/9/"8RS .VXQK@KDYY[>_'VV9\*Y#A\RJ
M8_,*'URI3JNH\#CHRJJHG*]H.6EU>UUIOZ'CY=G^?5<KIPR^K3H4:M-0CB,/
M.$*E*2BE9Q2YDFV]'=OIY?3?Q^_X)U>"?V<KCPQKR:B+G7[XPR2)&^?WI8%L
MX[;\\?6I_$WQ$U1/#6E> DO+N.=%A^S0VLK!B<*%+(IY' XQCFO9?VRO',UM
MX:\%>+/$>O?VA=2QVTTUJ\N\P,ZJQ4H6R"K$\'WKQC]G?PO<>+_B#<_%+Q)9
MF3P3;:6[6]S,,P"40DIC<-F=P'O7S>?8>CB,WIQX>PV'R2L\3@Z>(A024XY9
M4@IUZGN[)6M>^G4]'*<56663J9Y5J9E'V&*G2G6;M/&PGRTH)2]=NMG9.Q]Q
M_!;X_1^"/AVOA#XMP23V]S;^3I=Q$I>>$.NU#(_WE/3OQ[=_<?V3O!EW>?$^
M7Q9I4L]SX=N)S/&\S%PJ,P*+N/3@],^U?!O[-GB'3_B+\8O'W@WQ=HXU71+R
MZG@\,3RQ;HK<%V6)HF8;!CC!4]OJ*_>WX#_">#X6>%_[-"H9)Y!-'C!,43 L
MJ9Z@@$#'M7Z;P]/^WZV7UH1A/"Y9*K3J59+][&M0GRT^>2LI^V2YT^GR9\'G
M:CE%'&T9-QKX]4ZD*<?X4J=6*E-Q3UC*DWRN^[1[M7Y3_P#!3+]G3XA?&KX>
M78\"M*T]M!)++$NX@JJDG  (!QGMW'O7ZL5X9^T%X^F^'?@*[UR-/,BR\=PN
MP/F(*I8$$'@Y.?7I7WF>8/ X_*L;A<QINI@ZM"<:\8_%R/=Q\UO\CX_*<3B\
M)F.$Q&"DHXJG6@Z+E\/-=64K]'M_2/X_/@'\4/'/[+OC1?#=_%J4.O6=R87B
MF$J6LC;RK J<(02#GU![\U[[^U5X3C^+&D6'QCT1(K7XDQ+'<SI; +F-0&);
M9UX'.?SKU+]K#7OAQ\4HU\3>#-$MD\4VI:6ZD@BC65I5.6SM&[.[/Y^O7P/P
M+XVN)-"_L;7)&AU*\(L(X9/O ./+& ?KGN>F:_@_B_B*GX:9D\HR3'T^*N#\
MZ4J>9Y#6J1KXC*JE27)%47)ODDN97>G+L[/0_J[(,L?&6$I9CFF$GD/$.6RC
M/!YE"/LH8Z,+2E[1)+GINS]W=WNGV^3?'/QUO&\%Q:4\KKXLTR(+.\+_ +X2
MQ#'&#NSE?6NK_9B_:GUK6TG\,>/;R>XM;9CL34)2PV)C "R$X&*Z[XJ_L;:K
MX!O+?XDW2/?:-K;"YG.&>.))B'.1@@8![\=_KQD?[,FG>(+"X\:^#[]83' Q
MF@A?:=X7)!53G/Z>W-?#<19=DG#N25<BS&CCLFP'$2CB\/BHN2C"6(:G3H57
M'3X79.5T_P #Z++<5C<XS&GFN$J8?,*^52]A7I>[=JE[LZD5*[W6R29](ZY^
MT7HE_/<Z'X.M=][#NCC:W7.& QP5'K^?->+6,_QJ\>^)3HMY<36^G7;F- [L
MI$;_ "+P?8Y_#K7GOP%U3PWX!\:W=MXW@1429A)=SC.T@D [F''0<$@?T^F)
M?'OAC4O'RWOAK7(8M*M\2B:-D"#:0< @X].>Y'O7Q&48+ACA7/*^ Q.05\?D
ML<L6*JYE&+JXFK?EO]4KVE&E6>\4];V>Q])C<1F^:X&E6PF8T<-CIXKV=/"S
MM&G2[.M#3F@GI+INNI][?LK_ +.>@?!>1/&_Q#C?5XGVW!$B&>('[PSN!';\
M?;/'U%^T'\6_'FI^";B\^&&D6.F>&S:-#;SVT*0R[PI52&0!MWO^/I7B'PI_
M:.TO7/ASK/A=[%?$TL4311W&P2&,A=H(;!Z=1SD5['HGAKQ#XY^#FII8PO8P
MZ3%-?BWP1O"!GV8')'&,#C^1_O;@',,JQ'"N1X'AG$X^AE6+P-2K0CC:7_"G
M0G?58JJH)SC%_#9[+S/Y;XHPN.HYWF.-SZ&&K8_"8NG3FZ,[X*K!I6E0IW:C
M)Z7\W]W\]OQ0\(_M*:GJ&J^,M;.MW\<$K26B8GE7&XE=GW@ .G'YU'\.?V1O
MVU/VBM*N=;T&TOH-+LXV:19XI0PB3)/WE]!R>O\ .OI_7O\ @IMH/PU\1ZO\
M-?&G@-+J/0[A[,R36087'EN8P=S)@_=S[\DFOT._8T_X*#6_CNSU_3? OA>.
MQM6LI62UCM514D6-MCC:@ *GH>G4#UKACP)PF\QCF>?NIF>)KUY0<JO-.<9)
M-KW;_#IHG'1>A[E;B[BG#Y=]4RS#8? T84823ARJ$H/E5UR_;:>[>]_,_-K]
MG?X:?&#X!^)+C4-9\S^V]#<K*S X62(G<2<#'.?<<^]?6/A;]H#QCXZ^*-L_
MQ.WS:"LT<!D)WJL8;'&<XX'Y^_7@OBQ\<9(K?XE2ZG^X\2W%]<K:6Q $I>21
M\!5'S>W%0Z%I;>#?@-H/Q0\509N]:O44)*,.J2OPV#\P^]Q_6O%P^#P^59O#
M#Y)3AA<BKTZF;9W0PLHPI8QT:KHTZ>)7\_*T[2M[J?3?HKUYYGEL\1FK=?-X
M3IY=EE2M>52BJM-593H-KX+]4K:[7/T9^,_C7P%HW@:VG^%UU=7&MR)'BV1V
M:/<VW(* X'.?RZ5]X?L<1ZWJ/PKTW7?$D;0ZK=/S&5VX0+D$C\5K\^_@=\/;
M7QG;^%=0T[3AJ6G:M!;SSRA#(D(;!.<Y Z_X&OV7\(>&K7PKH-GHUFJQQ6\:
MX51@*=HR,#Z8/]>:_:.',/'%9E/'T:,*.!HX>-/#T:-U2C.24E-W;YZEK>]%
MM)KR/RS/*RH9?2P4YRJ8J5:4ZM6I9U>6+LXNRO&/-JDUT.IHIJ\#&<_T]J7!
MR3GCTK[\^-%HHHH *IZA_P >%[_UZS_^BFJY5/4/^/"]_P"O6?\ ]%-0!_('
M+_RG'\#?]B;XH_\ 3YX8HHE_Y3C^!O\ L3?%'_I\\,44%2W7^&'_ *1$]F_X
M-R?^2::A_P!?U_\ ^EDU?U15_*[_ ,&Y/_)--0_Z_K__ -+)J_JBH"?Q/Y?D
M@HHHH)"BBB@ HHHH **** "BBB@ HHHH **** $#9)'/%<YXL\*Z1XST6[T'
M6[=+FPO(WBFC=%<%74JV W'(-=$3CHN<^G_ZJ=0!_/\ _ME_\$1/A%\6;+5/
M$GPXT]+3Q9=B9_+\B-"TTF6W#8"&7=WZ@]J_GN\,_LU_M0_\$M_V@--^(.MV
MFN7/A"VU:WC%M8QSF P>>O+(@"D;.H(_.O\ 01KS;XC?"+X=_%C3?[*\?>%]
M-\0V@^X+R%'>/&<%&8$ C/!(..U '"?LQ?&VS^/OPB\,?$*W1K>?5;2-[FUE
M^6:*4QHS;T/(.2P_"N5_;+^+.L?!KX)ZYXPT,L+^)UM(RF0VV>-U;'X5W?PJ
M^"FD_"2>XL_#+):>'?G%GI40VQ6X;.,( %&,XX]*^<_^"D\AB_9IUY_),^V_
MM24"EC]U^<#_ #W[4 >,_L'_  &L-0\.:A^T7K$0UCQ?XT2ZN;6'44%PD4K+
MYA*B0, -TB@$9_2O!/VU/BA^U!\"/#][\1]-OM,L;"SUB."+38)8XI&MGD^5
M1$"#C9QP,&OT/_84UK3YOV7?!-UYR0PV-G<+=X(!M]J1DEQU7C)&>X/I7Y7_
M /!3KP1X<^(&A7/BFU^-)&GZ=JL33>&%O/EFD1]WEF$/R00%^[0!^J?[/6IV
MW[4/[+?A[6?'ND637WC'1+BTU&1[6%IEE,: 3K(4+AP7ZAAP*^"_@Y%J?[*?
M[4Q^"6@7MQ<>%_$=\)Y$ED8I&LTF[:BDX &1C'M7V3_P3L\0R:E^SSX/TJ&T
M,6GZ59M%;7&TJ)QB,9![YP#^9KY-^+4L>H_\%!?#$-JXD>*6W5G3#!2-@.67
MCC^77F@#]JSG!QU[4B[L?-US_GI0!@ >@ _*EH *3=SCG/\ ];- ))(P1[_Y
M%+COCGUQ0 F1S[=:R=:T73?$6FW.EZK:Q7=G=1O%+%-&K@JRD$@,#@X-:H&-
MQ]?_ *]*,=L?A_\ 6H_K^D]'Z!_7]>9^,7[2O_!-F'5[V^\1_":!8]2U O++
M (P DCDL< #'/8CVS7Y:^-OV5?C%\-Q/%XDCU5"I;;]C64<#_<'MQ[_I_717
M-:YX/\,^)!C7-&LM2XQ_I,0<XK\?XO\  _@;C#%O,:^%Q&59DWSO%Y35>%E4
MJ75YU8T^52;U;:Z]#]MX*\?N/^"\)'+*.*P^<96DH+!YQ26+5*EHN6C*:?*D
ME:S7SV/XKI_"?CX:BL*'Q5Y0?;P;K&"<<9'\NM?0/@K]F;XL_$/R8M 35WN)
M-O%XLK+DX&3O!_7ZCBOZG/\ A1?PF+^8? ^B;LYS]F'7.?7UKKM$\#^$O#C!
MM$T'3].8# :WA"$?0\XKY-?1PX:Q<J*S?/,^QM##V]G16-J1C))JT:EW:2LM
M>FA]@_I0<48.G7>2Y#P_@<3B?XE>6"I3<;I:T[0O%IZI[[:Z'XT?LW?\$UKZ
MWU&SUWXN0 RVC)+%$4^\5P0"I7!YX]/7CFOV?\,^&-&\'Z1:Z-HMG#:6=K&L
M:+%&J$A1@%L>PZ9P/SKHZ3AAZBOVSASA?(^$\OAEN0Y?1P.&BES^S@O:UI)6
MYZU2UYR\WI?6Q^#<4<6\0<99G+->(LQKYCBFW[/VLW[*A!N_LZ-.[C"/:VP
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M^@K7[M5^$O\ P0+_ .3,_!O_ %XQ_P#H*U^[5!+W?J_S"BBB@04444 %%%%
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M$1B0I!(#*0 !W/YTRRU75O$M[:>!_AII[);6I2V>[ABP)%!\LLSJ,'/7)/\
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MOW:K\)?^"!?_ "9GX-_Z\8__ $%:_=J@E[OU?YA1110(**** "BBB@ HHHH
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M+9?$+X):E9VMFK+<_9K1U1MF0V J=SCTKP&_\6:/86"-I=DEGJD(+1E!M<N
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M4_;,+XUY/F4:>&SS*+1J4U'$8J=JT:56W\6A3C\"\DKIZK:[^+/@]\1OB_\
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M#//OY?\ 6KQ7)!STQV]#FEP/0?E0!&D4,"D111Q+_=BC5!Z=% %2 Y&:0MR
M!D=^_6EX [ #GT H 6BO#/'G[1GPF^'33P>)/%%E:WD.X&V\R,N7&?ESOP.1
MCH:^0O$G_!1+P78W<B:.UM>6P9@DF5;(!./4\@>_4=*\O,,\R7*I..9YMEV
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MCJ/["OP/U1W>ZTZ\9I"2Q$BYY)-<?>_\$X/V>KX$2V&IC/\ <G _KZU]_44
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MH **** "BBB@ HHHH *IZA_QX7O_ %ZS_P#HIJN53U#_ (\+W_KUG_\ 134
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MYQA+H[??^?\ +G\0/C/\3?C/?R-K]SJ.KQSR.JQV4LDA4,Q !"$D>_' KJ/
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M%)?+$(_,V-OSM Z$=<X_3UK^DOP/\$_AYX&TBQTS3/#>EF2TB1&O&MD\Z1U
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M*$K3E".J32UG%M)2BMTS^:OQ)X@\?_%W65EUM=8U:\NG4F:SDEDCWNPY^3/
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MP_.78]\FOEC]IO2?VB;#XA:+XVCN=2T_2]+^S72S@SQBX$>U@"<@,&"].>M
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M'!I,G=C''K@^G^->H>2* !G'?K2T4C#<,=.: %.>U(,XYZTHX 'I10 4444
M(&STS2T4C$@<#//H: %HQW_Q_E0.@HH ***\W\:_%?P5X"1SX@U6*VE5&980
M5+,P_@^]\ISP<CCF@#T<D $D@ #))X  ZDD] *\W\;_%/PGX'TV>_P!0U.SE
MEA5F%I%<1M,VWJ-JDD'/&,9Z^E?"WC;]KGQAK.HW&D^"-*^T:5<'RA?I%RD;
M%ESY@7/(P>O;/O7SSK?AN9KW_A+?&OB:X,,SB9]/>9F3#<LFS=CN>W_U@#Z
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M+8VGCKV_#I@U^_\ XI_:'U#XD?#Y/AUXOT6&72Q&UOYTZJ?+C(*AAN'& ?\
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M/<G^S[B>3RXC<2!1(<X&T$9.>PKY&_;&_;RTOX$7-EH=E&PN+F12;O)"LA(
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MFX=8DWA0$.XG /0=OI7O/_!5WX/_ !@\>Q3ZCX8M+J\T*P$D[(B2.BA,L2
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MFE  Z4,2!P,\^AI@)W#(QD8Z'_/6@#Y*_;&^-*_!;X6ZIKZ7\5E>&UG^S!Y
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MC',:\*"2A#EA+E5HNHE^\:71.5W;H?E]^VU^V!+\(-?T#PSX;U2!+V]GC@G
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M8I+%Y-E&$S+,7^X2@X/'4E&RYIQ7O0IQZWTML?''P-^%GQ+^,WC+1[V2._\
M"7A^VF1KHWWFVT?E@@MR^T8P#U]?S^O_ (@:%\ O"7C2#0/$EVFL7^GVR/\
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M[7PEHWAV\UFY:98F2TC>5B2^#P@;M_\ 7KZ"_9E_;D\&_'>Y70+Z >'O$<,
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M1F$,J1N=HY(4Y [<8QTK2M;CQEKFJI'\,/#2SZ1'B"2[@@R#M^5FW*I&3UH
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M( 6;..6SM.>OZUX;X&\26&MWDFI7LJV\=F?*NE#8RR\2;AGUSUY-?K5^PO\
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MBBB@ HHHH **** "BBB@ HHI"0.M "T444 %%("#TI: "BD)(' YH!)'(YH
M6BBF@G)!''..#ZT .HHIKND:L\C*B*,LS$*H [DG@4 .HKS34OBYX%TJ]^P7
M>L1)<[_+V#81NSC&=X[UV^EZSIVM6ZW6FW45Q$XR"C*6&1D94,3T_P#UT :E
M,^[N9F 4 DDG@#KDYX&!3QGO^E>._&GXA6/@3PAJ4TDXCU"[M98[%<@$R$$
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M3VL6L?#.M-/<VQ:;!BC65#(VZ1#D*&R>,YP#0!^DM%-R2W ^7UP?3UZ=:=0
M4444 %?,'[65YYOPD\0:%:N?[1U)(T@13AR!NSM ^;)W#I7T_7QC\=KHWGQ(
M\+Z#*2UM=M:^9$>58$KG(Z<]\B@#H?V./#]]X<^#FFV.HHR71NII'+YW,I^[
MDD<XR<?6OJVL;0=(M=$TNUL+2-8XHHT^51@;MBYZ>]; 7;TSS0 M%(1G@TM
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MV_M1Z3IVF?#ZP\8O%X!L]:%Y+:?:BL+6OG!]@7?L^X,8_2OZ$Z* /Q\^.?\
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M_P!]UV=E\1/"E^RK;ZG"Q8@#+H.O_ C0!W%%5;>]M+I0]O<PS*W(V2(QZ9Z
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M1?LC>%?%/P4L-(URRCTW4[JPB1-2CA NH]\0!(8!7!'K]/2ON>$<!Q;BO$3
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MC0-+?>""WV2(-SU(8*#GW_IQ0(_';P[X+\#7UC)/ILC:#K"@M;13R&*0R 9
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M7(_T9A:,^WCT)R>.X[Y]:_2/X!:AH#?"_P +P:7>6K+'8+YR(Z!DD[[P#G.
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MS?*7!8_=(QSGWKZNN]-^$'BDMH#3I)XT;]U##PTS3@XPR\G.[_.37[(?L6?
M6R\.?#R2/QMX7L+J6Z"&S%_:+)FW?^(*ZY#%<<]L_+@U]%DO#W%V:\9\,XG&
MUHX? 1P53%UL/@8I4,IJ8;E>'PM:4/=K.LM.:6KMON>)FF=Y#@.',ZI8:E*M
MB)XF&'IU<7_'S"%>WMJ\$U>FJ36EMM/0^'?B=^T+\)1J7PUO/#&EV_A6XFNK
M7[9;3(D$R(9@Q#956X&!SZXQP*]Q_:?^+&M^.?#?A/0?"T;RZ+<6=FLVIP9,
M:LT:@DR*,=O7WZ<5\I_\%8_V7M+L#X;\1> )AI6NZG,/[.T^V_<QI,MPRH%5
M=HQE1@\_H33OAK\8HOA=^S=;_#GXNQP?\)^]G&VE7#LAN2 @,6"<MD\=#P<?
M2OW7,\7B:<LPI8A0PTZ]*"HR:C*GBII)*E?I*?1'YE@<+0J1R^M0YL0H5)NI
M2YFIX>%TW4M=WC#OMU>Y]D>%? 6D>%_ASI>H>+]=1M4DACDTA)9QO,K#*!,M
MDD,0.E?=GP!GUN?P?G6F=B)%%H7+'-L0VPC/JN.GM7Y._LW^'_$/[46H:/'K
M-_?6.D^$IEEC5O,2.XC@8$ \X;*J/S_"OW$T?2K;1=,LM,M458K.VAMU(&-W
ME1A-QQW.,_C7=D67.C['$4X.A2^KVE!ZU*U6:3FZCWM3=U#R>AYV<8M3=2C.
M:K5?;-\R^"E"+]V,.EYK6;770N7,,$]O-!<(LEO)$R2HPW*T94[@0<YXK^,K
M_@I)>:=H'[7S6VB0)::?)=-Y@C38A9G.20 !VP<\_AQ7]G,B>9&\9X#JRY^H
MQ7\XG_!6S]CJ_P#LTOQF\+VKW5W;2-+,88B\B]6/W1G@'_)Q7S/BSE&:9YPM
M6P&68.GC)3J*5:,W:5*$5?VM-?:E&S]U;Z>1[GAWF6!RK/Z>+QF(GA^6#C3E
M&]IR;7N2V5I;*[T/RMT;1?$.HW9N=$EF=Y-C(T3-\ISD8P>._KQ]:_9SX6_'
M:ZT3]G>?X;:UX<NM:U:XM6@,S1-,T:LF"QRIQCW[#O7XX_LT>,=9O=1T/PS!
MI=Y<:Q<SQV\J26[Y5O,"$'(X.3WZ>U?U8_L\? O1]%\!KJ7BC0+.;5[_ $W=
MY=Q I9%EMRX.".&Y&..#S7Y%X*8"MB<LS+!8>MBL/C:4ZN#S&O74JN'A"+Y?
M9T*<KJ$I15FUUNS]&\4,52P^.R_%XBA1K8:K"GB,%2IM4Z\IN,?WE6:NY13=
M_P .NGY,_LX?LB^'?B)X['B^34[?1X8;G[1J&ERNL;$>:&9&0D'GD8Q[=Z_8
M;X[6^@?#;X":U9Z!%;06,&FO CPA/GV6S*7)3IN."0.F>I.#7XY>);7QYX*^
M.'BN+0[^XTR"\O9AI]E#(T4+9D.U0H(7&<9P.GY5W7C+XP_$_P#X1>X\%?$P
M21:/>0-''<,S'<KJ0#G/<<<_7WK[C#9IPWPGAL96HY'4HUZWUC"XW.J6&4Z\
M*NL(U,7.W/2P[3OS7LD];GRU?+L[S[$8.-;-85:-/V.)PN65*UJ<J?N3<,/%
MOEJUEM;JU9;GY,Z)\7](TSQ/X[?4)(S)/->^6[D$@EV[GIR1Z8]LUP.B:OX3
M^(>I&RU/5$CAN;TQ!A/M"J\A4G[PZ#\"*^B-+_9*T?QUXWDBLKT)INM7'SR;
ML8663DDYQW(/ZX!KL?VH_P#@E3XX^'/PTL?%GP@O);^^D5+F46A,CID!B<(2
M0<^OTK^=,I\*,]S/,L[XOX9KTJRQ6.^LSJ4*RK4JT(OF=-TD_P![3FM)PZMV
MZ'[+B^.,IP&&RW(,Z]KAZD,+[.$:E/V<J4U%1B_:/^'.*V;Z%'7?V+M(B\.:
M?J?@CQ*SC4(E>=[>Z.(O,4-R4DX(+'.??L*\B\,_L/:9)XF-_P")O$IN;>U<
M7%QYET6W1J=SH<N1DC(.>_Z^A? '0OC3X2\&1>'O%$FJ7.H3QF*99%E9H#C:
M<!LE<=N!V/'?W7P3\.S+J4UIXMUN\L1>D@M.[QJ/,XQEB,#)[_SKZ:6>T<5B
M\+A,'P5F3SR%6G2QF$J1J9?EKKT;04HU/X<J=5WJ.-[+9NVIXJRZM2HXFOB.
M)LOEELJ<Y4,3%PQ6/]E4][X?B4Z::@G\SX _:*\._"R^U;3?!WPLL2NIV$D,
M-_+$<^>Z%5<_+G.<-P/_ -7Z^?L5^$/V9]>^&J>!?C%X>ATK4["U,[ZM?*(%
MEQ#R?-<'//('?&. <CY]/[*&@:'\6_#^H:!,FLQ:E=PM+)'B?(>12=[#=^/;
M\Z_9KQG^Q#X1^('PN@TN*;_A&]9?1BQO;)3'(S_9MR!WCP1N88/8 ^E?H7AU
M@.*:_&^?8O.,#2AA\OPL,+/"*,98*I.O!3IK"5?@E[*+Y9N.[3OOK\7QAF&1
MQX;RK"X#%5?:8JNZT,1=K%1C3DH3EB*?Q+G=W&+O9-6/,OV:==^%O@;7/%,?
MPPOK!O#>@R7*/% T9%S&@8#[IYR!GC)Q7D&H?$[Q-XO^.]QJO@>*>T@EN&MF
M2$LJ!B^TMA< =^2/>OS*^'NF^,?V8OVAY? -[JM[>^#;O46@U"\F=RC1-,5<
MNS$CE2:^^_B/\<_AY\'/$=CJ_@CR=3N-5MXQ&L&V5OMLJC .S)SO(]_>OU3&
M5^?#+!TJ:H1ABHQE"FE[;#2E9NM3@O>C%?#=);W6]SXG"X=PQ4ZSJ/$.6%YH
M3GI2KQ2_A5)/24G>^O8^MQX@^*7@CXE^&[74]8FNK36YX//MS*QVB1E!!4YQ
MP3[U^G$#%X86/5HHV/U* G^=?FM^S%X6\>?%NZB^(OQ+M)K6W*I>Z&DRL"8B
M_P"ZVAL<9&>/KUK]*E!7:@'RJH4<=@H _E7TN287$X6.(56=2=&<X2PSJS<Y
M\B@N9R;U7-)W_P""CYS-L12KU*7)"G&I"$E6]G%0ASW325M^5+E;ZOS'X!.<
M<BEHHKW3R HHHH **** "BBB@ HHHH *IZA_QX7O_7K/_P"BFJY5/4/^/"]_
MZ]9__134 ?R!R_\ *<?P-_V)OBC_ -/GABBB7_E./X&_[$WQ1_Z?/#%%!4MU
M_AA_Z1$^1/\ @CCK,:^%K^QO?#UQJ%K_ &MJ"O-'&Q 7[=/SN"^F><_K7]!P
MT7P<JR7^@WBZ'JX^=%DE,;HX (SDJ001CFOSV_X-XO"GA[Q!\+-4CU/2[6Y>
M2]U#]])&C/Q=S\@D=>/7/]?WS\6_L;>#?$NHW.HQ:C<:?).Q<10AEC4DY'"G
MI]!0$OB?]=#XY\-:U\9K"1+N+Q9)?:=;G<L27#/F-3P -W< C] *]WTG]LNZ
M\,Q)I>O^'[J_GB^0SA9,EAP3N7D_B2/QKFO$_P  _B+X&+VG@X3ZG;KN"D[G
MW 9QSSU'_P!:O$[[3/B=H=XLOBGPFAMPP,DAM<G&03R5//7_ #U"3Z=\2?MN
M6;Z5/9VGA*[,^J6LUI"X65A&US$T62.1QN/7_P#5\Y?#:UN_ "^(/&7BB;R;
M;Q TUQ"DW'E";<X4YZ8W?YZ58'Q#\.B(VB>'(Y-0B7$8-J#MF& ,?+G.>?6N
M8L? 'QC^-NL0Z)>:;<:?X1DF0-,L3HB0AL#' ['\NM&H'>?L@>'M4U/X[ZWX
MU@B=]#NFN&BN0"8F+!\ -C:>.F*](_;=\;ZF/$^@_#J.61--UQ+47*JQ4'S5
M3/3K][G-?;WP@^%.B_"?PG8^'=-2.26%%:>Z*#S'D* ,-Y&[ YSZD^@%?G_^
MW#I-ZGQ)\*>(!"YL[,69DF53A-@CSEL8&,>O% 'FOB*[M/@=X4TG1],A6>XU
MXQQP,%W/'-<8 ;/)X+9))]:]A\$_LR?$S7=%BUW4_$'&LVR7UI"TXW0I.-R*
M5+9'!!'3CGIS7AOQ<M[OQ-HGA/7='07UOIDUI+=C'F>6D11F/&<8Q_C7Z(?"
MG]H7X>:MX:T'2!J)AU*QTVUM;J!P (YH4$;#)(P,C(&.!1_G_E_7_#@?,][^
MR/\ %N4NMKXH1$);&ZX7I[9;CVKG9?V:OB]X1;[9=:L=1B4Y(C;S<XY(RI/.
M/<U^I.G:UIFJQ"6QO()E(!PLB;L'_9W9_P \XJ^_DR*4D\MU/57VL#^!XH _
M(C4-<\3Z)OLKSPU=73H-C2+;L=W!S_#ZCK7F.J:S]LE?[5X'U!R2W*P2 =#_
M +/T^G2OVSDT'1)B6DTK3Y">I:UA8_F5/K5<^%?#39SH6EG/7_0H._7^"@#\
M-X4\-"4F]\)WMODG)='&#^(XX-=9I^D?#>[C/G6YLY#CB1MIR<COCG\,U^MV
MM_"3P5K2L)-'LX&8'F*! !D8R.,CZ9Q7C.M?LD^"=6E,BW$EKG/$:8ZGG&#C
MT_R*/^ !\%IX>\*P#=IVL);GG;^_QCZ<_P!:J36FK0$MIOC&.+;DK_I6,8Z<
M[O08[?6OMJ7]BKP<Z[5UB\0<] PZ\=F[50'[#O@\;O\ B?ZASG^]QG/^USUH
M ^,(=>^)]J=MEX_1%7./]+('!Q_>]*<WB[XQ[21X_P _]O7O[-7V'-^PYX:
M)M_$%YGGAFD'7OU('/O66W[$=D"0NN7..V)&_P : /E:+Q3\9&7)\?9S_P!/
M?3KZMFGOXC^-5S&88?'N)#@ _:F^F/O8_P :^H1^Q<D?RKK%R1Z[V]_<T/\
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M(+9)SWK^>O\ 8U_X(^?'+]H_5X?&/Q0TJ[LM(\03)?7=Q<V\B/\ OI!(Q)8
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M^T5\0? Q2/7;>ZU+RB-Y.]MV,YZYSG!KT>']NZV4+'/X.N6D ^9@LPR>_ (
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M=:/X?@MYT(*N=C'(Y!_U8Y_I^->KGGCUIH4 YY_S^% "@!0%4!5    P !T
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MW?J_S"N6U[P7X;\2J5UC3(+K(P244$_4[3D^]=310(\IL?@K\.=.N%NK7P_
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M4^$&D2J0/&-^,^MRY[9[O_GVJ5/@GHF#)/XQOS%'\Q7[2_S*.<8W\Y[?_KH
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M(')SS[TM%% !1110 4444 %%%!SVH **09[BEH 0@'K0 !T%+10 TD$[2/\
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MNMTWP/X8TD@V&EP0XZ84'^E=910 Q(XXEVQHL:CLJA1^E/SGI0>>/6D QP*
M%HHHH 9ALYSQG.,GIFGT44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ5>0C8QA1@>E?VF_L@>$(?!7[._PQT58P)XO#EF]Q(5 DDE9 K%SC<3\@ZT
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M!_R1/X7?]B5H7_I%'0:3^"'S_*)Z_7\\W_!R-_R8T/\ L81_*WK^AFOYYO\
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M[\P#^<S1/VAY[/XA?!NUU/X<76B>,+W5+)-6OY;26.261IU5V=B@)RQ)Y/\
M6O[$[34[27X;6.HZH8H+>X\)V\LPGQM!?2U.W#]6/4#U]*^3_BQ^QW\%?&?B
MO1/'SV_AO2W\.31WRI&+:-?W+"0%&0E3G&1D@^F>M?+W[7?[64/BK2[/X!?
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M>+G _!^23X9\&\JK8'$RG*.*XGQ*<<8YN"C4]E/XJE.:O:+;2;3TL>*?!?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I ".I)I:* "D)P0,=306
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M,6[YX'8YX^QQNR<],\4M #6;;CCK3J** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *IZA_P >%[_UZS_^BFJY5/4/^/"]
M_P"O6?\ ]%-0!_('+_RG'\#?]B;XH_\ 3YX8HHE_Y3C^!O\ L3?%'_I\\,44
M%2W7^&'_ *1$]F_X-R?^2::A_P!?U_\ ^EDU?U15_*[_ ,&Y/_)--0_Z_K__
M -+)J_JBH"?Q/Y?D@HHHH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP !P . *&W8^7KG_ #UI1G SU[T &<=:*0C/!I%W=_;'3^E #J*** "BBB@
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M$O=^K_,****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !30",_,3G]/UIU!S@XZ]J $ (ZG-+G/3FF_-M'KG
MGI[_ (>E"C:._3G_ .M0 N!Z#\J6BB@!,'.<G'I^'^32T4@8'..U "T444 %
M%%% !4>".0Q;&./\DU)30H&1SS0 H.1FD+8(&.N/YTH&!BEH **** "BBB@
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M%P<@YX]*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A3+HUUK\?C31VTFS8K<W@N!Y<3 X(;/OQ7X%_$;XC>*_B]XWO/"_A+69O\
MA$S']G1[>Y)7[/C:O*MC(7_$=J\9\.?#OQM/\0HO@\NNZB?"6M;I=2?[2Y8-
MG+8.[C^OXT ?U'^%?%_ASQMI46M^%]5M=8TR8XCN[5P\9/ID?C^1KI:_%7]@
MOQKK_A#XX>)_@*E_->>&="AN'MC-,9'#(K,.I/<?6OVJH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** (IX(KF)H9T62)QAD89!'O7Q]XU^!5YIVOZMXRT6X9XI4FDBTY
M.D;D,P(7V/<<_P!/L:FOM*E7 96X((R"#U!!ZBL,1AJ&*INEB*<:D'?22O:Z
MM=>?8Z<+B\1@ZGM<-5E2GHFXNS:34DGY71^;OPR^&/Q"UCQ)?:OK^L7>GZ=;
M3,\:22.BA8VS@ M@\#M7J]]^TA:^%?$,?@HH+WR_]'2]P6^;H/FS@\DXP<9Y
M KZYNM(LKJVFMO*6*.=2',2A"0PP>0 >0>_Y5\[^,?V=/#VIW$&IZ6C#4(YQ
M*SNJ[C\P)PWX8.>W>O@L5PMFV4T:='A#%+#SJ8A5L56Q]>I5<Z;G>5"$)RE&
M,;7Y6MM$DK(_0<'Q;D^<5ZU?C?"RQ4*>#]A@J.7T(45"LHJ,*]6=-1E*6R=[
MK=NX:S;:YXOT,RVFIR61NP)$E#E=@8ANN1P1QQ^==5X:\.)IWA1-*\2YU\$D
M[I<RY##!^]DY_H>OIT%IX/O;?3[#3P=L=O&BN1P3M&/P]Q^5=S9:3!:VL<#_
M #;>N?7K^?']*^NI8/%RY98FNG/V483<;.-VE[1\NJ=W=+LM/,^)J8K"*4EA
MZ#C2]K*I!-N,TD_W:4E>2:BE?S_#P6Y^ WA'Q+()9M+AM=/9PSVOEJ!(,[N5
MP01[^WY^X>&/"FA^#],BTG0;*.RLX@ (XP "0,9. *Z$*%4*HV@<#;QT^E*!
M@8KJPN7X'!.I+"86A0E5=ZDJ5.,'-]6W%+=ZV6ES'%YEC\<H1Q>+Q&(A3_AP
MJU9SC!+164FU=*RYGKYVT%S12%<D'GBEKLTZ==]/^#_D<(4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!_$'_P7^_Y/+_9]_P"QJTO_ -+X:_L=^ '_
M "1/X7?]B5H7_I%'7\<7_!?[_D\O]GW_ +&K2_\ TOAK^QWX ?\ )$_A=_V)
M6A?^D4=!I/X(?/\ *)Z_7\\__!R,/^,&0<_\S%T_X!;_ /ZJ_H8K^>;_ (.1
M\_\ ##/'7_A(>/\ OFWH%3^./J>@?\$"\G]C+P;[6,?X?*@K])?VI/VG]'^
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M&2TE%J49+249+5.+6J:[H_/'3_\ @GU\.;/XHR^.6AMGTT7!N(-,V K&Q8,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"JHFB "J  !\W0  "E%U:#I<6PSUQ+$,_P#CU 'X3>'_ /@G/\1==DT/X?\
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M]:^[*K_:[7_GYM_^_P!'_P#%4?:[7_GYM_\ O]'_ /%4 6**K_:[7_GYM_\
MO]'_ /%4?:[7_GYM_P#O]'_\50!8HJO]KM?^?FW_ ._T?_Q5'VNU_P"?FW_[
M_1__ !5 %BBJ_P!KM?\ GYM_^_T?_P 51]KM?^?FW_[_ $?_ ,50!8HJO]KM
M?^?FW_[_ $?_ ,51]KM?^?FW_P"_T?\ \50!8HJO]KM?^?FW_P"_T?\ \51]
MKM?^?FW_ ._T?_Q5 %BBJ_VNU_Y^;?\ [_1__%4?:[7_ )^;?_O]'_\ %4 6
M**K_ &NU_P"?FW_[_1__ !5'VNU_Y^;?_O\ 1_\ Q5 %BBJ_VNU_Y^;?_O\
M1_\ Q5'VNU_Y^;?_ +_1_P#Q5 %BBJ_VNU_Y^;?_ +_1_P#Q5'VNU_Y^;?\
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M:_\ /S;_ /?Z/_XJC[7:_P#/S;_]_H__ (J@"Q1UZBJ_VNU_Y^;?_O\ 1_\
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M1]KM?^?FW_[_ $?_ ,50!8HJO]KM?^?FW_[_ $?_ ,51]KM?^?FW_P"_T?\
M\50!8HJO]KM?^?FW_P"_T?\ \51]KM?^?FW_ ._T?_Q5 %BBJ_VNU_Y^;?\
M[_1__%4?:[7_ )^;?_O]'_\ %4 6**K_ &NU_P"?FW_[_1__ !5'VNU_Y^;?
M_O\ 1_\ Q5 %BBJ_VNU_Y^;?_O\ 1_\ Q5'VNU_Y^;?_ +_1_P#Q5 %BBJ_V
MNU_Y^;?_ +_1_P#Q5'VNU_Y^;?\ [_1__%4 6**K_:[7_GYM_P#O]'_\51]K
MM?\ GYM_^_T?_P 50!8HJO\ :[7_ )^;?_O]'_\ %4?:[7_GYM_^_P!'_P#%
M4 6**K_:[7_GYM_^_P!'_P#%4?:[7_GYM_\ O]'_ /%4 6**K_:[7_GYM_\
MO]'_ /%4?:[7_GYM_P#O]'_\50!8HJO]KM?^?FW_ ._T?_Q5'VNU_P"?FW_[
M_1__ !5 %BBJ_P!KM?\ GYM_^_T?_P 51]KM?^?FW_[_ $?_ ,50!8HJO]KM
M?^?FW_[_ $?_ ,51]KM?^?FW_P"_T?\ \50!8HJO]KM?^?FW_P"_T?\ \51]
MKM?^?FW_ ._T?_Q5 %BBJ_VNU_Y^;?\ [_1__%4?:[7_ )^;?_O]'_\ %4 6
M**K_ &NU_P"?FW_[_1__ !5'VNU_Y^;?_O\ 1_\ Q5 %BBJ_VNU_Y^;?_O\
M1_\ Q5'VNU_Y^;?_ +_1_P#Q5 %BBJ_VNU_Y^;?_ +_1_P#Q5'VNU_Y^;?\
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M2QJWAZ==!\<6KB6'6(2(KAR@+ "10'R2 ,;LD]/2OA?_ (('R62?L7^#";R
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M'_\ %4?:[7_GYM_^_P!'_P#%4 6**K_:[7_GYM_^_P!'_P#%4?:[7_GYM_\
MO]'_ /%4 6**K_:[7_GYM_\ O]'_ /%4?:[7_GYM_P#O]'_\50!8HJO]KM?^
M?FW_ ._T?_Q5'VNU_P"?FW_[_1__ !5 %BBJ_P!KM?\ GYM_^_T?_P 51]KM
M?^?FW_[_ $?_ ,50!8HJO]KM?^?FW_[_ $?_ ,51]KM?^?FW_P"_T?\ \50!
M8HJO]KM?^?FW_P"_T?\ \51]KM?^?FW_ ._T?_Q5 %BBJ_VNU_Y^;?\ [_1_
M_%4?:[7_ )^;?_O]'_\ %4 6**K_ &NU_P"?FW_[_1__ !5'VNU_Y^;?_O\
M1_\ Q5 %BBJ_VNU_Y^;?_O\ 1_\ Q5'VNU_Y^;?_ +_1_P#Q5 %BBJ_VNU_Y
M^;?_ +_1_P#Q5'VNU_Y^;?\ [_1__%4 6**K_:[7_GYM_P#O]'_\51]KM?\
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M_M=K_P _-O\ ]_H__BJ/M=K_ ,_-O_W^C_\ BJ +%%5_M=K_ ,_-O_W^C_\
MBJ/M=K_S\V__ '^C_P#BJ +%%5_M=K_S\V__ '^C_P#BJ/M=K_S\V_\ W^C_
M /BJ +%%5_M=K_S\V_\ W^C_ /BJ/M=K_P _-O\ ]_H__BJ +%%5_M=K_P _
M-O\ ]_H__BJ/M=K_ ,_-O_W^C_\ BJ +%%5_M=K_ ,_-O_W^C_\ BJ/M=K_S
M\V__ '^C_P#BJ +%%5_M=K_S\V__ '^C_P#BJ/M=K_S\V_\ W^C_ /BJ +%%
M5_M=K_S\V_\ W^C_ /BJ/M=K_P _-O\ ]_H__BJ +%%5_M=K_P _-O\ ]_H_
M_BJ/M=K_ ,_-O_W^C_\ BJ +%%5_M=K_ ,_-O_W^C_\ BJ/M=K_S\V__ '^C
M_P#BJ +%%5_M=K_S\V__ '^C_P#BJ/M=K_S\V_\ W^C_ /BJ +%%5_M=K_S\
MV_\ W^C_ /BJ/M=K_P _-O\ ]_H__BJ +%%5_M=K_P _-O\ ]_H__BJ/M=K_
M ,_-O_W^C_\ BJ +%%5_M=K_ ,_-O_W^C_\ BJ/M=K_S\V__ '^C_P#BJ +%
M%5_M=K_S\V__ '^C_P#BJ/M=K_S\V_\ W^C_ /BJ +%%5_M=K_S\V_\ W^C_
M /BJ/M=K_P _-O\ ]_H__BJ +%%5_M=K_P _-O\ ]_H__BJ/M=K_ ,_-O_W^
MC_\ BJ +%%5_M=K_ ,_-O_W^C_\ BJ/M=K_S\V__ '^C_P#BJ +%%5_M=K_S
M\V__ '^C_P#BJ/M=K_S\V_\ W^C_ /BJ +%4M2&=/O1_TZS_ /HMJE^UVO\
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M+[_X+*XQ_P *.N/_  ?,!^7V.O[(** OY+\?\_+^KL_C>_X7U_P65_Z(=/\
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M_!97_HAT_P#X/6_^1*_LAHH"_DOQ_P _+^KL_C>_X7U_P65_Z(=/_P"#UO\
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M_!97_HAT_P#X/6_^1*_LAHH"_DOQ_P _+^KL_C>_X7U_P65_Z(=/_P"#UO\
MY$H_X7U_P65_Z(=/_P"#UO\ Y$K^R&B@+^2_'_/R_J[/XWO^%]?\%E?^B'3_
M /@];_Y$H_X7U_P65_Z(=/\ ^#UO_D2O[(:* OY+\?\ /R_J[/XWO^%]?\%E
M?^B'3_\ @];_ .1*/^%]?\%E?^B'3_\ @];_ .1*_LAHH"_DOQ_S\OZNS^-[
M_A?7_!97_HAT_P#X/6_^1*/^%]?\%E?^B'3_ /@];_Y$K^R&B@+^2_'_ #\O
MZNS^-[_A?7_!97_HAT__ (/6_P#D2C_A?7_!97_HAT__ (/6_P#D2O[(:* O
MY+\?\_+^KL_C>_X7U_P65_Z(=/\ ^#UO_D2C_A?7_!97_HAT_P#X/6_^1*_L
MAHH"_DOQ_P _+^KL_C>_X7U_P65_Z(=/_P"#UO\ Y$H_X7U_P65_Z(=/_P"#
MUO\ Y$K^R&B@+^2_'_/R_J[/XWO^%]?\%E?^B'3_ /@];_Y$H_X7U_P65_Z(
M=/\ ^#UO_D2O[(:* OY+\?\ /R_J[/XWO^%]?\%E?^B'3_\ @];_ .1*/^%]
M?\%E?^B'3_\ @];_ .1*_LAHH"_DOQ_S\OZNS^-[_A?7_!97_HAT_P#X/6_^
M1*/^%]?\%E?^B'3_ /@];_Y$K^R&B@+^2_'_ #\OZNS^-[_A?7_!97_HAT__
M (/6_P#D2C_A?7_!97_HAT__ (/6_P#D2O[(:* OY+\?\_+^KL_C>_X7U_P6
M5_Z(=/\ ^#UO_D2C_A?7_!97_HAT_P#X/6_^1*_LAHH"_DOQ_P _+^KL_C>_
MX7U_P65_Z(=/_P"#UO\ Y$H_X7U_P65_Z(=/_P"#UO\ Y$K^R&B@+^2_'_/R
M_J[/XWO^%]?\%E?^B'3_ /@];_Y$H_X7U_P65_Z(=/\ ^#UO_D2O[(:* OY+
M\?\ /R_J[/XWO^%]?\%E?^B'3_\ @];_ .1*/^%]?\%E?^B'3_\ @];_ .1*
M_LAHH"_DOQ_S\OZNS^-[_A?7_!97_HAT_P#X/6_^1*/^%]?\%E?^B'3_ /@]
M;_Y$K^R&B@+^2_'_ #\OZNS^-[_A?7_!97_HAT__ (/6_P#D2C_A?7_!97_H
MAT__ (/6_P#D2O[(:* OY+\?\_+^KL_C>_X7U_P65_Z(=/\ ^#UO_D2C_A?7
M_!97_HAT_P#X/6_^1*_LAHH"_DOQ_P _+^KL_C>_X7U_P65_Z(=/_P"#UO\
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M_DOQ_P _+^KL_C>_X7U_P65_Z(=/_P"#UO\ Y$H_X7U_P65_Z(=/_P"#UO\
MY$K^R&B@+^2_'_/R_J[/XWO^%]?\%E?^B'3_ /@];_Y$H_X7U_P65_Z(=/\
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MXWO^%]?\%E?^B'3_ /@];_Y$H_X7U_P65_Z(=/\ ^#UO_D2O[(:* OY+\?\
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M_DOQ_P _+^KL_C>_X7U_P65_Z(=/_P"#UO\ Y$H_X7U_P65_Z(=/_P"#UO\
MY$K^R&B@+^2_'_/R_J[/XWO^%]?\%E?^B'3_ /@];_Y$H_X7U_P65_Z(=/\
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MXWO^%]?\%E?^B'3_ /@];_Y$H_X7U_P65_Z(=/\ ^#UO_D2O[(:* OY+\?\
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M_DOQ_P _+^KL_C>_X7U_P65_Z(=/_P"#UO\ Y$H_X7U_P65_Z(=/_P"#UO\
MY$K^R&B@+^2_'_/R_J[/XWO^%]?\%E?^B'3_ /@];_Y$H_X7U_P65_Z(=/\
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MXWO^%]?\%E?^B'3_ /@];_Y$H_X7U_P65_Z(=/\ ^#UO_D2O[(:* OY+\?\
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@:PHH L929&DRH&P*?,8J5_;+10#E>UTM$EIIM]Y__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gu0gjnulhgsv000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $; 2D# 2(  A$! Q$!_\0
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MXZ#\<GJ32FSC+%O,GR<_\MWQU!Z9]ORXZ58HH @^R1[@=\_!!_US=B3Z^_\
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MG-O::E;O<CK;LVR4?5&PP_*DZ<DKV"YJT445 RG%_P ABY_ZX1?S>KE4XO\
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MO_D3M<_[!\__ *+:@D3PI_R*&C_]>47_ * *V*Q_"G_(H:/_ ->47_H K8H
M**** "BBB@ KQK6[F"'7YKV7P_I2J]VZJTK2F:1T=5/ XW$-N ]!7KFH7;6.
MGS720-.8EW>6K*I;\6( _$UYG&-6N+N34]6MM?6"6Z$EO)%J=ND*QDC8,;L=
M\<$Y_&A?$@?PGJHZ5B7GA'0;_47U"YTV.2[?&Z7<P)QTZ&MNB@#(B\+Z+#JO
M]II8)]L#%UD9B=K'J0"< _2J"_\ )3Y?^P,G_HYJZ:N97_DI\O\ V!D_]'-0
M!TU%%% !1110 4444 %%%% !1110 4444 %%%% !69JFA6>J,LS;X+R,8BNX
M&VRQ_0]Q['(K3HI-)[E1DXN\3G!J^HZ&WEZ['YUIG"ZC;IP!_P!-4'*_49'T
MJ>?1++4&74=,N?LMPXW+<VI!63_>'1A6X>1@US\WA^6PF:Z\/3K9R')>T<9M
MI3[J/N'W7\0:B4$U9JZ-HSBW=>Z_P_X'Y"+K=[I)$>O6V(^@O;<%HS_O#JO\
MJW89XKB)989%DC89#(<@UDV/B"&YN/[.U&W:PU C'V>8@K+_ -<WZ./U]0*B
MF\.&UE:YT.Y-A,>6AQF"0^Z]O3(J%SQ^'WE^/]>OWBE%7M-6?X?UZ?<;]%8$
M'B,VTRVNN6QL)V.%ESNAD^C]OH:WE8,H92"IY!!ZUI"I&>QG*$H[G$V/BO0;
M[Q_FUU6VE%Q8I;Q;6^_()&)4>^"#^-=O52/_ )"UQ_UPB_\ 0GJW5\R:T7?\
MQ3W^[\@K(\5_\B=KG_8/G_\ 1;5KUD>*_P#D3M<_[!\__HMJ"1/"G_(H:/\
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M.:[&O&M;E@BU^6]G\-:.%>\=%>6.5YY&1U!Z$#<0VX#T%"^*P/8]EHH'2B@
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MER>#D?K6]2BK(J3NPHHHIDA1110 4444 %%%% !1110 4444 %%%% !1110
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MH **** "BBB@ HHHH *I:Q_R!+__ *]I/_035VD(# @@$$8(--.SN!\+*/\
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D0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gu0gjnulhgsv000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )"!7T# 2(  A$! Q$!_\0
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MM?$-K8P::TMK+MWSA6.,GGD<#'O4>TC9/N;K#5'-P:LTKZZ&]1115F 4444
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M"9(&(9L= <8(/ID=_>NFOHXR>R9Y&5N\YP3M*46EZG>75O%=VDMO,H:.1"K
MUP/P_D=1JUOG*",-^/(JW>_$*WFL6BL;2X^U2+M7>!A2>XP235OP=H<^EZ/=
M3W2%)[E<[#U50#C/OR:B4E.IS1V29M"E/#82I&LK<S5EZ/5F#X)UO3]'CO\
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MCKQSS3KM>TBI/34C+82=*JX13DK6O\^YL^&K_4M-\42Z%?W+W"G(4NQ;! W
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M=HL7B'Q-ISJ-6>&"%B-Y8[I&ZX)'.*G\' _\(KK?!Y5O_0#6C\.0?[$N>/\
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MQ0P,0&+G=(W7!(YQ6WI6O0:MX9N[2&&59+6QVN6 P3M(XY]J9\.@?[#N>/\
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MP7/7  Z#IS4O@K[0/&&HB[(-P(W\TC^]O7/ZU5\.>(AX8CN]/OK28R>9N54
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M\^9_Z *YTW;_ +=/8Q$8N=5M?;B0Z5;^(O$NDEQJKPPP$JIWG=*W7DCGN/\
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MM)^D7_HPUE[1RI1UUO9G>L-3AC7[ONN+:37E_F6+O4O&&B1?:KQ+:ZME/SE
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MYPOA6W\1Z3=+ITMBJV1E+R2MSCCL0?8=JN:/HFH6GC/4-0G@"VLN_8^]3G+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC(/(S0M?G_E?\@>G]>=CT*BJ]]?6VFV,U[>3+#;0(7DD;HJCJ:YC_A:?@?\
MZ&.S_P#'O\* .OHJAI&M:;K]B+W2KV*[MBQ7S(CD CJ#Z&K] !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %,E9TA=HT\QPI*IG&X]AFGT4,#R[0E\70:[<:[K7@RZN]5G)
MCC==0MA':0YX2,%\^Y/4UJ30:WX6\::QJECH<^K6&L)$Y6VE17AF1=N"&(^4
MCG(Z5WM%'I_7]?F'?^OZ_P CRP>#->L]$L=9CMHIM>AUF35Y[)90 PDR&B5S
MQD+CGID&MS3+35O$'CBW\1:CI,NE6>GVCP6T%Q(C2R2.1N8A20  ,=:[>BA:
M?UY6_('K_7G?\Q&4,I5@"#U!%1?9+;_GWB_[X%344 <3\/E"ZAXQ50 HUZ7
M _Z9QUVU<5X _P"0CXR_[#\W_HN.NUH **** "BBB@ HJ&WO+:[\S[-<PS>6
MQ1_+<-M8=CCH?:G3W$-K \]Q+'#"@RTDC!54>Y- $E%-CD2:-9(G5XW 964Y
M!![@TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'O5FKD[LB*L@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#"U3Q=I6DWFGVLLCS27]W]CC^S@.$EXR'Y^7K6LE[:R
M6K727,+6Z;MTJR HNW[V3TXP<^F*^<?&GA/5U\60O#9P:%'J6J-!;1K=R/\
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M%:91C))Z^WK27P-]?^&_K_AAOXDNG_#_ -?\.'_"S]"_MLVWG1?V9_9_V_\
MM/S1Y>W=MV[<9W9XQUSQBNRM[B&[MHKFWD62&5 \;J<AE(R"*^<_^%6Z[_PF
MAA\JS^W"S^VX^P?\2_S=V/)Z;<;>^.OYU]#:;%-!IEK#<+ LZ0JLBVZ[8PP
MR%'9<]*I?#?^NI+^*W]="U1112&%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!Q7@#_D(^,O^P_-_P"BXZ[6N*\ ?\A'
MQE_V'YO_ $7'7:T %(3A2?04M-?_ %;?0T >0?\ #1/AO_H$ZM_WS'_\71_P
MT3X;_P"@3JW_ 'S'_P#%U2_9XM+:?P_K+36\4C"Z0 N@)QL]Z]D_LVQ_Y\K;
M_OTO^% 'E'_#1/AO_H$ZM_WS'_\ %T?\-$^&_P#H$ZM_WS'_ /%UZO\ V;8_
M\^5M_P!^E_PH_LVQ_P"?*V_[]+_A0!Y1_P -$^&_^@3JW_?,?_Q='_#1/AO_
M *!.K?\ ?,?_ ,77J_\ 9MC_ ,^5M_WZ7_"N>\>V%DGP^\0NEI K+I\Y!$8!
M!V'VH O^$?%%IXQ\/Q:Q9030P2.R!)@-P*G!Z$BMRO-_@9_R2^S_ .N\W_H9
MKTB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBN.\5>/?^$<UVST:VT._P!5O;J!IUCM #A02/Z&@#KV1'*ED5BIRI(S@TZO
M//\ A8^M_P#1._$/_? H_P"%CZW_ -$[\0_]\"@#T'8@D,@1=Y&"V.<4ZO//
M^%CZW_T3OQ#_ -\"C_A8^M_]$[\0_P#? H ]!1$C!"(J@G)"C'-#HLB%74,I
MZAAD&O/O^%CZW_T3OQ#_ -\"C_A8^M_]$[\0_P#? H ]#  & , 45YY_PL?6
M_P#HG?B'_O@5<\/_ !#?5_$Z:!?>'-2TF[DMVN(_M8 #*#C_ !_*@#MZ***
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M7.>/_P#DGGB+_L'3_P#H!KHZYSQ__P D\\1?]@Z?_P! - '-? S_ ))?9_\
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MGEAM=6:*-IY"[8 [GUKTJD,**** "O/=3_Y+SH?_ &!YO_0S7H5<'J-G=/\
M&S1KQ;:9K5-)E1YQ&=BL6. 6Z ^U '>4444 %%%% !1110 5YYJ/_)>M&_[
MLO\ Z&:]#KSS4?\ DO6C?]@67_T,T >AT444 %%%% !1110 4444 %177_'I
M-_US;^52U%=?\>DW_7-OY4 </\%_^23:+_VW_P#1\E=[7!?!?_DDVB_]M_\
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M .2>>(O^P=/_ .@&NCKG/'__ "3SQ%_V#I__ $ T <U\#/\ DE]G_P!=YO\
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M"YW],GZ5K5V8;&4,4G*C*Z7K^IG4I3INTD%%%%=)F%9?B3_D5M7_ .O*;_T
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MJ@=C]HCPJDQDYVA2$!R<'!K8\'1:=<:UKNL:1<Z=+IUV8(HEL7!"F-6R7
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M('BD4HZGHP(P13Z* *]C8VNF6,5E90)!;0KMCB0851Z"K%%% !1110 4444
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M!"\JC)"\_-Q0!NT444 %%%% !1110 4444 9^HZWINDW%E;W]VD$M[+Y-LK
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M@=!16$WC#05\-)XA^WH=-? 20*268G&T+C=NSQC&:30O%VE^(+N>SMOM4%[
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M?P=H[7-NUO,;2/=$Q.5^4==V3^?-;5:3^)F<?A05Q_CSP;J7C.Q73X=>33[
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M@_\ Z":\TKTO5/\ D$WO_7!__037FE?/<0_Q8>AZ^4?!+U"BBBOGCU@HHHH
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MUI[:5X2\.I9ZG+-'9-=L=[",$EFVKA<A3@<TNH^AWWA.:*?08WAUXZXF]O\
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MC&?N5YK16_LX]C+GD=WX:^(__".^&M/T?^ROM'V.%8O-^T;-^.^-IQ^=:O\
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MKR/[C3HHHK<R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU?H6"_W:G_A7Y'R6)_C3]7^94U3_ )!-[_UP?_T$UYI7I>J?\@F]_P"N#_\
MH)KS2OGN(?XL/0]?*/@EZA1117SQZP4444 >@>&O^1?M?^!_^AFM:LGPU_R+
M]K_P/_T,UK5^A8+_ ':G_A7Y'R6)_C3]7^84445TF 5C:]_R[_\  OZ5LUC:
M]_R[_P# OZ5Y6=_[A4^7YHZ,)_&7]=#&HHHK\_/:"BBB@":T_P"/V#_KHO\
M.NLKD[3_ (_8/^NB_P ZZROL.&OX4_7]#S,?\2"L#7/^/U/^N8_F:WZP-<_X
M_4_ZYC^9KJX@_P!R?JC/!_Q3,HHHKX4]<**** +FE?\ (2A_'^1KIJYG2O\
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M!1110!-:?\?L'_71?YUUE<G:?\?L'_71?YUUE?8<-?PI^OZ'F8_XD%8&N?\
M'ZG_ %S'\S6_6!KG_'ZG_7,?S-=7$'^Y/U1G@_XIF4445\*>N%%%% %S2O\
MD)0_C_(UTU<SI7_(2A_'^1KIJ^UX;_W67^)_DCRL=_$7H%%%%?0'$%%%% !1
M110!7OKR.PLY+F56*)C(0<\D#^M8_P#PF&G_ //&Z_[Y7_XJK7B7_D7[K_@'
M_H8KS^OG\US&OAJRA3M:U_Q9Z^ P=*O3<I[W_P CMO\ A,-/_P">-U_WRO\
M\55S3=>M=4N&@@CF5E3>2Z@#&0.Q/K7GM=!X/_Y"TO\ UP/_ *$M<N"S;$UL
M1&G-JS?8VQ.7T:=*4X[H[:BBN:\:^(;[PYIMC/IUI#=7%U?16BQ2L5!WY'7L
M<XYYKZH\(Z6BN+T_7O$5AXPL]"\1)ILJZC;R2VLUBKIL=,%D8,3G@Y!X^E9>
MH^--:T+5;-=0U/PU<K->1VTVFVCM]HB5VP&!+Y8CC.5%"U:7?_A@Z-]CTBF1
MS12EQ'(C[&VMM8':?0^AKSJTE\3M\8-5ACN=.^SK:0,T;K*0(2[8VC=@28SD
M].G%+#XLMO#^A^+]573;2%[76)(%6(E!/(=@#2$DX)+<GT%)/2_];V!K6W];
M7/1Z*\]TCQQ=_P#"3Z;I5]J_A_54U(.%;29/FMY%7=AAO;<I (!XYJE_PF?C
M&Z\.:EXAM;31X[+3)IU>*02%[E8W()4@X3Y1WSD@]!3>@+4]/HKS'Q!?^(KS
MQYX2FTBXL8H;NUGEMX[A9".8U+>8%89ZC&.E>E 2FW 9D$VWDJ/EW8[#TS19
MI FF)]I@%T+4S1_:"AD$6X;RH."V.N,D#/O4M>;Z%I%QI/Q?E-YJ<^HWEQH;
M2S3R@*,^>H 11PJ@#I7I%"V3_K<;T=@HHHH$%%%% !1110 4444 %><:-X*\
M->([276;*[U^ 7<\C2J=1=&WABIW!6.#Q]<8KT>O%+JV\,/J^H3:7IOC?45-
MPWVJ\TR:0Q-(#\P!W#<1TXI=1]#UO1M(@T/35L;::YEC5BP>YF:5^3_>;FM"
ML#P8VE/X9MWT:[NKFS9F(>[E9Y5;/S*V[D$'C%;5S;Q7=K+;3*6BE0HX#$$@
MC!Y'(_"JE<E6//M6\*?\)'K&JC0?$<^F/%>0R7UN]HLT37"!'1U!((.-N<'!
MQS6UX2L(--U;6K>?5;C5-<)ADO[F6(1@@JWEA5' 4 -P/>N!O?#/@G1_$&HZ
M?;:#K^NW(=9)(=/DF*V@*C"L_F#).,\Y/.*[GX?1^&$L;T>'=/N-/F$H6]M[
MP.+A' X#[R3T/'..M*.VG];?U^ WOJ=C1110 4444 %%%% !1110!Q7@#_D(
M^,O^P_-_Z+CKM:XKP!_R$?&7_8?F_P#1<==K0!\Y^)?^1JUC_K]F_P#0S676
MIXE_Y&K6/^OV;_T,UEUV+8YWN%%%% CV3X3?\BK=?]?K_P#H"5WE<'\)O^15
MNO\ K]?_ - 2N\KEG\3-X['R_111748!1110![Q\._\ D1--_P"VO_HUZZBN
M7^'?_(B:;_VU_P#1KUU%<LOB9T1V"BHYYH[:WDGE)$<2%V(!. !D\#DUQC?%
MOP8B%WU*Y50,DG3[@ ?^.5(SMZ*XD?%GP:P!&HW)!Z$:?<?_ !%=M0 4444
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MWJ<DJW U26*3RGB&(C&FWKDYSUZ"MRBO6. :\:2H4D170]589!I0 H    X
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M "BBB@#BO '_ "$?&7_8?F_]%QUVM<5X _Y"/C+_ +#\W_HN.NUH ^<_$O\
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M5]1VT/3=Z;-^Y=F,[L\8ID%S;W4?F6\\4R XW1N&&?PKS/6;O1M<T?P=HVB
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MCUKJJ "BBHKB=;:!IG!*KC('7KBIG.,(N4M$AI-NR):XKXF?\@G1/^P[9?\
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M_P#Z":\TKTO5/^03>_\ 7!__ $$UYI7RO$/\6'H>]E'P2]0HHHKYX]8****
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M\1>@4445] <04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!Q7@#_D(^,O\ L/S?^BXZ[6N*\ ?\A'QE_P!A^;_T7'7:T ?.?B7_ )&K
M6/\ K]F_]#-9=:GB7_D:M8_Z_9O_ $,UEUV+8YWN%%%% CV3X3?\BK=?]?K_
M /H"5WE<'\)O^15NO^OU_P#T!*[RN6?Q,WCL?+]%%%=1@%%%% 'O'P[_ .1$
MTW_MK_Z->MW5/^03>_\ 7!__ $$UA?#O_D1--_[:_P#HUZW=4_Y!-[_UP?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#D_$NM:7INLQ+>^+X]);[+(OV5F0;B_"R<]U(..U<=_:>G?]%E
MD_*W_P#B:]4N-/LKMP]S9V\S@8#21*QQ^(J+^Q=*_P"@99_]^%_PI(;':2ZO
MI%FZ7OVY6A0BZX_?#'W^..>O%7*:B)&BI&JJBC"JHP *=5/<E;!1112&%%%%
M !1110!Y[\-O^1@\=?\ 8;D_E7H5>>_#;_D8/'7_ &&Y/Y5Z%0!4U3_D$WO_
M %P?_P!!->:5Z7JG_()O?^N#_P#H)KS2OE>(?XL/0][*/@EZA1117SQZP444
M4 >@>&O^1?M?^!_^AFM:LGPU_P B_:_\#_\ 0S6M7Z%@O]VI_P"%?D?)8G^-
M/U?YE35/^03>_P#7!_\ T$UYI7I>J?\ ()O?^N#_ /H)KS2OGN(?XL/0]?*/
M@EZA1117SQZP4444 >@>&O\ D7[7_@?_ *&:UJR?#7_(OVO_  /_ -#-:U?H
M6"_W:G_A7Y'R6)_C3]7^84445TF 5C:]_P N_P#P+^E;-8VO?\N__ OZ5Y6=
M_P"X5/E^:.C"?QE_70QJ***_/SV@HHHH FM/^/V#_KHO\ZZRN3M/^/V#_KHO
M\ZZROL.&OX4_7]#S,?\ $@K US_C]3_KF/YFM^L#7/\ C]3_ *YC^9KJX@_W
M)^J,\'_%,RBBBOA3UPHHHH N:5_R$H?Q_D:Z:N9TK_D)0_C_ "-=-7VO#?\
MNLO\3_)'E8[^(O0****^@.(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_B7YHSK?PY>C.FHHHK]+/!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'3D]J^;_ -6JO_/Q?B=WU^/8ZRKFE?\ (2A_'^1K)_X5;9_]#1XJ_P#!F?\
MXFG)\,+:-@R>*O%:L.A&J$'_ -!K;#\/5:5:%1S6C3^YDSQL91<;;G=45Q7_
M  KA?^AP\7_^#9O\*UM \+#0;F6<:YKFH>8FS9J-Z9E7G.0".#[U]4><;]%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*[WRH_\ GFOY4>5'_P \U_*O8I4U3@H+9*WW'G3FYR<GU."_X77X!_Z#3_\
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M9"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWMDCC)  ')KBM"TBZD\,V7BKPGJEQ?ZL8Q_:EE>7#/'>OC][&RM_JY <[<
M<=CFMW7=$O?#/B.;QEH%N]V)4VZIIP.6E3C]Y%Z.,#Y>C8]:V])T+3O[:/BC
M3'N;8:E;AI[8#9',3@K(Z$9#@9';KS0!BZ'X"\/W=O:ZDEIJMK9RD70T6YG=
M;>*3.<F$\9!YQT]J[RBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** .2^(.MZUX?T:TOM'%D!]LCBN9+Q6*1QL=H8[
M>0-Q4$]@:Q=0\3Z+>^3H_P 1O#Z:9*SYADNU$UI(P[I,/NG'KC /-=YJFG6V
ML:5=:;>)OM[J)HI![$8X]Z\_\!:*FI/J2^*&_M36-*<Z84NHP8XH0HVLBG@^
M8N&+'D].E $FOZ/::U':^&/#WAY+>T$\%R^JQP+';PHK!]T3#[[G&WCU.37H
M]4M*TC3]$L%L=,M(K6U5F98HQ@ DY/ZU=H **** "FRQ1S1/%*BR1NI5T89#
M ]01W%.HH R?#_AZT\-6$EC823_9&F:6*&63<( W\">BYR0.>IK6HHH ****
M .9\?:OJ^@^$[C4]'6W,T#HTK3HS*D6X;VP.3@<GVS7.WWBVPEM(M,^(N@1V
MMO.R^5>8^T6,S8R"K@90GDC(Z9YKT2X@BNK:6WGC62&5"DB,.&4C!!_"O,_!
M'A^-M>U+2=?F?4)_#^+?3H+A08DM9 2D@'1G(RI)Z!<4 3>(M*TS4]!_X1;P
MKX<MWAU"-6_M&&!!:0)GF3S!]]QC@#)SBO1XH_*ACCW,VQ0NYCDG'<U3TG1-
M,T*VDMM*L8+."20RM'"NU2QZG'X#\JOT %%%% !00""",@]0:** ,?0?#5CX
M;^VIIIFCMKF;SA:E\Q0L1R(Q_""><=,],5L444 %%%% &%XSO]5TKPAJ5_HT
M44E];Q>:BR*6& 06.!U(7) ]17(R>-8GT6*'QYH47]DWJ(R:E;*;BQF#8*DC
M&Z,GC&1^->E$!@00"#P0:\O\->'(H/&]YX=U:62XL=(7[9HME(H\H12,V7/]
MYD8[!GIVZ\ %K5K31&\-/HO@_P ,VM\-6@:..YM84^RQYXWR2CNO7'+<#%=W
MI%@=+T6PT\RF8VMO' 9&ZOM4+D_7%1:5H.DZ&;G^R]/M[/[2_F2B! H9L8S@
M?TK1H **** "BBB@#&TCPS8:'J>HWFG^;"E^PDEM0W[E9!G+JO\ "6XSZX%;
M-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_P"/7\06
MOB/P_/INNOIME<NUHV85DB$[<Q^8IZJV"N<\'!'6O0*R?$VAQ>(_#E[I4K;/
M/C_=R#K'(.4<>X8 _A0!Q\7Q*DT?5)M)\8:<L$]J$:74-.S/;)NSM+\;HB<<
M!L^O2M2VL=3\4>(]/UN_6T@T?3RTVGQV\WG-=,ZE1*S8 "[3D*.<GFI_A[8F
MV\%VR76G26M]*7^WBX!+S3!BKR,3RVXC(/H1VKJ@     !P * %KRG2XK^/Q
M/)X76YCT;5(S<WCZE]ECDFOU>7*%"X(QM.&')^3 P!7JU9^K:'I6NP)#JNGV
M]Y&C;D$R!MI]0>H_"@#A_#GAB/7-/U!Y[^[M-]W/:ZC%ITHCM;\JQ5I I!*%
MAPVPKSFO1HXTAB2*-0D:*%50,  =!4=K:6]C:QVMI!%!;Q+MCBB0*JCT ' J
M:@ HHHH **** &M%&[(SHK-&=R$C)4XQD>G!(_&G444 %%%% !1110 4444
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M IH15+%5 +'+$#J<8Y_ "G44 %%%% !1110 4444 %%%% !1110 4T(H<N%
M9@ 3CDXZ?SIU% !1110 4444 %%%% !1110 4444 %-V+OW[1NQC=CG'I3J*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gu0gjnulhgsv000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000007.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *6!XP# 2(  A$! Q$!_\0
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M_P"ND.T$#'7V%.HQ[?I0 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C
M]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\
MJ,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'
MH/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4
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M<LDYF@CD,<<H>1FY(PV??\:_LUH \Z\2_%?X=>#[\:9XG\5:1HEX1D17]S%
M<$9_C8'I[5PMQ^U'^S];:A!I<GQ2\(&^N7"0PKJEL69B< 8W@YR?2OXPO^#B
M[XD?&O1OVJO#'A?X;>,]3T"'5;VTL7ALKF>)<7++'G$3+R,Y^M?'7[0__!+G
M]JWX7_LP^'?VQK?X\>))[NST^#69M,_M.\*D^4MQLV"7\/Y4 ?Z$?B+X\_!O
MPK91ZAKWQ$\*Z?:S*&BDFU2U'F*W(*@N./KBM[P/\4?A_P#$FT>]\#>*-'\2
M01YW-IMU%<%<#OY;-P?49QWK_/7_ &*/V5?VJ?\ @J?\#O%'B#4?C)XA\-1^
M!=.NOWJ:A=1>:UC$W4^8,Y\O\:]]_P""&WQY^,_[,W[7/CO]F?Q[XTU+QKIN
MDZC>Z?!<WUS-<@B.9H5(,C/V';C\,T ?0O\ P5[_ ."P_P"VC\&/VK+?X#?L
M[Z;90FYO?L,$<*N9"WF>4A;:<LQSECU)/KFOE75O^"IO_!73]ER#P]\2_CWX
M=EG\ 7C6]U=O-;S&$6LI5R68\8\LG_'FO#?^"OWQ,M/A/_P4O\+_ !"NK474
M1U>'4&A*[_E$XD/RX]!Z5WW_  45_P""M7A;]I[X(^"?V;O#W@2"XUKQ#8V.
MDQSFR57261$@!5M@.03G/4\T ?UM_L;?\%*O#_[6'[)6K_&[0=.LD\0:%X:N
M;BYLXW_T5]0BM&92\752)!N90P5B!D#G/\D_AK_@XS_;%T;_ (*!:I\)/$ND
M6%S\-;7Q/)I_EB.5EALTN@@D<8\H1[#M'S[]RGY !N/[A?\ !++]C[Q#^S1_
MP3G\:7GB-&M)O$'A6^U6&V).%2:S>51@],9P!^F37\[W[$_[(.@_M,?&?]JS
MQC_9D5WXF\*7>MW&DL8PTJRV\LTB%.-V0R#I0!_=!\6?VO5T_P#8_NOV@/!%
MI97E_<>%UU-(6/F6]G=&R,TH0=21+Q'O)\M<@[FPP_,3_@BW_P %,?C'^VS\
M1/BAX8^).GV"V&@2ZB-.FA!\V$6DLC)L.>C+'L8$$$-P,@$?G%\)OVNGTS]D
M/XC?LT>/+DP^)M-CU;3;*SN24D$4"S1H DAW8P,=/\3I?\&SUD++XS?&I2-H
M5]9Y/3),W<].O^<4 ?O/_P %>/VW==_8C_9DUSQYX,M;.[\7S07/]FI<?,\3
M1QMY9B4$8=Y>I(SA0 0"0?YP/^"1G_!?;]I3XT?&FS\(_M'Z38V^A^)[]K;2
M&N@\;&.69DB:)F.0P!4@COZC-=1_P6G_ &J-*^-W[5VE?LH7U_'_ &(NMQV4
MT9F'E>7YXC<-DE<8ZY]:_.+]NSX4?#/]BWQ#^SIXV^&]_:6\FG7&C3ZJUG+%
MD'S(7??Y1'<]SF@#_2&T^\@U*PLM0M]K07UK!=PD88>7<1+*G( S@,!GO7(_
M$S6)/#_@+Q3J\-M#=366CWDD4,RYB:0Q,JEACG83N7_: /2OES_@GW\?M/\
MVB/V;? _C2PN4N_*TC3;*:5'#DNMJ."03TV$<\\5]&?&HX^%OC0_]02[_P#1
M9H _BM_9@_X*+?$@?\%7-7\">/;G1=,\"VVOS1_\3"41VHA$Y'(D8+@!>?7%
M?V;^&_VC/@AXMU--'\/?$?PMJ>IN5"V=MJ5O+,689"A$9CGG'3K7^97K?[/G
MCO\ :<_X*I>(OA[X+U^[\,WEWKUQ;?VC:2R0R)YMPR;MZ$$;2V<]<]Z^GOVI
M/V8_VF?^"0_[3?PS\97?QHU_Q5H^L7^G7%[I\^HW,T02:6-F!4RE<;2<\=Z
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M<DM^.<UZ3_P2&TW4M7_X)J^-M/TO5GT"XFL)T;5$F\AX%,;9DWY4C:"3U[4
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M[0/^"1O[0&N?M!_LJ>&O$WB&:2XU.RM["UGFE+,\C&V.YF+$GDIGKWH _4O
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MS8":W3S)2^]#D9[DGB@#]BK#]K;]G+4]670['XK^$+C4G?RU@CU6T8L^=NT
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ML_I7,)^T[\ I=8CT*'XH>$9M4E8)';1ZI:L[L3@ +OW$D_[-?P!?\%@_B?\
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M^-/&/CCX<> (/$:_"Z[;48;1KY[F2);1PZJ$\PE0"F!Q^8Z#XD^-'[/GP_\
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MM7R-\%/^">OPC^!]EXDLO"]E:11>)HKF*]$< 3<MR&$F?W:_WO?Z4 ?R$?\
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M8C<,C()Y%?Y\'[,'[>?@[P?_ ,%0/&/QRU3PK?+X3UKQ+=W-L[0/Y?ER7TC
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M'TCXC^$-:\&Z[$D^E:W:M:W<4BAT>-NH92",?A0!_*#_ ,&Q/[2'B(_""[^
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M6#*HR, '/?UQ7E?PC_X+ ^ ] _X)EZM^SE_PA&IR>,Y/#LFF&-;:7S4G^S&
M[AMR#NZU_=3\6/@I\/\ XR^"KCP'XVT*SU/09+8VL5K/#&\<*>7Y2A5=6& @
M P,'C-?F'X8_X(H?LH^'=8U34O\ A%M)N8-1EDD^RFS7;%YCEL &(+QF@#^<
M3_@W"L/$NJ7GQ<N=1T6_TN;6X-9GM([F-XV;[2LIC"A@"2<@>O/XU\HZO\>K
MG]A7_@IQXE\5_$?PSJDNC7WBTRQ7#12B)DDOS@J^,8P>.<=^E?W5_ 7]AWX1
M_L\ZU+JO@'2;/3$F&V2WMX%B5EZ8.U%!!'6O%_VLO^"6'[//[5OB.V\5>*-
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M^SCIWV"PGOG6_@8QP(SM@%#T45_2[X*\*6/@GPUI?AG30!9:7 (( HP B@
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M7#_@O3_P4>^ /[5/P0T3P=\&OA4K^+98X(["XT/28HKR)Y -@W6=O&0(V.Q
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M $37Y5?\%H?^1%^$_P#V-<'_ *50U^JO[/7_ "1#X7_]B?I/_HF@#V2BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "@#' HHH **** "BBB@!NU?3^=.HHH **** "BBB@ HHHH **** "BBB@
MI" >HI:* "BBB@ HHHH **** $P,Y[TM%% !1110 4444 %%%% !1110 444
M4 !&>#1110 4444 %%%% !1110 4444 %%%% !2$ XSVZ4M% !1110 4F 3G
M'(I:* "BBB@ HHHH **** "BBB@!,#.>]+110 4F 3G'(I:* "BBB@ HHHH
M**** "BBB@ I  .E+10 4$9X-%%  !C@4444 %%%% !1110 4444 %%%% "$
M ]12T44 %%%% !1110 A /44  =*6B@ HHHH **** "BBB@!  ,X[]:6BB@
MI,#.>]+10 FT9SCG.>]+110 4F!G..?\BEHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^#OCY\OBMB2.22/
M;%>'[AZC\Z^M?BS\-M6\2^(FO;2)GBSD$#/''TY_2O,S\%=>(!^SOD#/W>]
M'BVX>H_.@E3P2/SKVA/@MK^_)MGQ[I[=Z63X+:]C MVYS_#].E '2_ $C^W#
MCLW]*^TR<<U\T?"3P%JGAK5#/>0LB>I7'3&/;G-?2] &/K\+76@:W;Q@[[G2
M-2A0=R\ME-&OXY(K\2OV-?V=_&/@+]H[Q[XKUS2EFT[4M6N9X'O+99%*-,S
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M5\3[?^$@T'3=7VXV_;K9)L8Z8W>F*O:/X?T3P];?8]$TNSTRU_YX6<*Q1_\
M?(XH _E0G^#W[3?[-O[8?B+XY6<&IWG@NYN;B9+6'S67:6S@!<CD#I]*]U\(
M?"/XL?MK?M0^%/C3K-A>Z9H'@^6'SHKQ'172WVJ -^.R8'\J_HUU/PSX?UJ(
MP:KH]A?PMD-'<VZ2*<]>HHT/PQX>\-1/!H&CV&DPRG,D=C L*N<Y^8+UYH _
MGI_:H_9&^(/P*_:$L?VG/A[;SW-G%Y+WMO9*2["#:9%/EC.6"DX///3O7%?%
MSQ+\=/V_=6\+^ ]+TC5=(\,0R6J:^D\<J1R[659BP; (/S=1CD_A_2OJFD:7
MK=J]CJ]C;:A9R??M[J)98FXQRK<5B:%X$\'>&96F\/\ AO2=(E;EI+*U2%R3
MZD<T >1_LP?!"Q^ 'PGT3X?62(OV%%>?8  9C&JL>./O;J^@PX&X<_>-2TU?
MXO\ >- "CH/H/Y4M(.@^@_E2T %%%% !1110 4444 %%%% 'XC?\%H?^1%^$
M_P#V-<'_ *50U^JO[/7_ "1#X7_]B?I/_HFORJ_X+0_\B+\)_P#L:X/_ $JA
MK]5?V>O^2(?"_P#[$_2?_1- 'LE%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %'X4W;\V[/X8]L
M4Z@ I#GC'XTM% !2$XP/6DR=V,<>N#Z?XTZ@!,#.<<_Y%+110 GS9Z\>GX?3
MUI:*:J[<\YS[4 .HI&&X8Z<THX 'I0 4$XYHHH 0'(S2T44 %%%!..M !35_
MB_WC3@<]*:O\7^\: %'0?0?RI:0=!]!_*EH **** "BBB@ HHHH **** /Q&
M_P""T/\ R(OPG_[&N#_TJAK]5?V>O^2(?"__ +$_2?\ T37Y5?\ !:'_ )$7
MX3_]C7!_Z50U^JO[/7_)$/A?_P!B?I/_ *)H ]DHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /YU/^"C
MG_!2[Q=^S'\:W\#Z1<R1VRRL@1791A21T!&/:O@U_P#@ME\02JR?;IA@$[?-
M;)QSTKP__@NI%&W[5TI:-7/G2=1_MGW'Y9K\<A!:^2&>-!@<+TSCGU[_ *4
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MNH4OW=KZ:65D=;>?Y?WA;[K#BOZ1E_B_WC0 HZ#Z#^5+2#H/H/Y4M !1110
M4444 %%%% !1110!^(W_  6A_P"1%^$__8UP?^E4-?JK^SU_R1#X7_\ 8GZ3
M_P"B:_*K_@M#_P B+\)_^QK@_P#2J&OU5_9Z_P"2(?"__L3])_\ 1- 'LE%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M('/)H)P,URWBWQMX8\#:7-J_BC6++2;*%2S/=7$,3N "3Y:2.A? !R1P/7)
M/@?AW]LO]GWQ/KB^'],\=Z8VHLXC6.2XMD4L6V@;C/W- 'U*#D9I:K6EU:WT
M,=W97$-U;S(K1S6\B2Q.K $%70D'(QWX[C-6: /Q&_X+0_\ (B_"?_L:X/\
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M HI N"3SS01D8H 6O-_&?Q:\!^ )4A\4Z_9:5,^"L=S*D9(.,8W'OGTKT<#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEK?BF,KXMUF/[3=>:!YN^X0LY;/S<,V,GOZ5_0Y341(T6.-%C1 %5$4*B@=
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M@/\ X*Q?$7P/HW@OQN+V+1=!MX[>VM]2DE2,)#@* LK!>@' '^% 'L/[(/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML!LU.^R,]1YS=/\ ]=>-?$N_\0V^H);:,DI3> 63=@ 'D\?_ %J]>^/2Q?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+Y=W(N[: ,\-R>/ZT ?E?I?[.7_!*@ZYHSV_BCPR+E+N%K4"XM\^9N 7'/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU5_9Z_Y(A\+_ /L3])_]$U^57_!:'_D1?A/_ -C7!_Z50U^JO[/7_)$/A?\
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M!V3R;VTXSV$@Y]?\^XR ?Z,M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOK/_ ()3(S?\%'/!I&,"\M?TD3_ T ?Z,5%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "(OPG_[&N#_ -*H:_57]GK_ )(A\+_^Q/TG_P!$T >R4444 %%%% !1110
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MJMG8C#J!GJ>WT_I7UA_P2CE0?\%'/!J(, 7MH,_20<_3- '^C-1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%_\ V)^D_P#HF@#V2BBB@ HHHH **** "BBB@ KQKX_Y_P"%3>+_ /L&7/\
MZ(FKV6O&_C]S\)O&/_8+N?T@E- '^:W\?0#^UAXV$*_-_:5_O(Y_Y;-U/X?A
M[U6<!92@X9CR>_KT_P XXZXJ/XV71;]KOQW$ ?\ D)ZAR1Q_Q\..WM_]:G7,
M4IO,H<<G/IW_ ,]J (Y-SRK$ORA2-S>OK_/\*ED8)CRUW=-W'0]\C'K1(#N
M089>9#V/K^'>F/D O"-RC&[C/?'8_P"'% "VS!I/[K;L[?7G^N/\YKZL_P""
M4'S?\%'?!^4VG[9:<XQ_RU Z?K_(^GRS9>3.XQQ*#T/')''Y=3GTKZI_X)1K
M)'_P4>\'B4<&]M ,=_WJ_3M0!_HRT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P %H?\ D1?A/_V-<'_I5#7ZJ_L]?\D0^%__ &)^D_\ HF@#V2BBB@ HHHH
M**** "BBB@ KQOX_?\DF\8?]@NX_]$2U[)7C?Q^_Y)-XP_[!=Q_Z)EH _P U
M3XYI&G[6GCQT W_VCJ'_ *.DYZ<\_P J5&8K*['^-N?H3_2H?CBX3]KGQT&'
M#:E?>P_X^)._^?YU-,5CD9<?NG)XY^A[^WX^IH B:82*0?EW'&[U'(Y^ON3Z
MTZ.7[,#$HWASZ=.GZ\Y_QJ&0*I.?]5@[<=NGU_I4L)&3*OW5SC\/\30 U=D-
MS'(F S,,KQW'/3_/OVKZS_X)42[O^"CG@S(!/VRSS]1(O^-?)\:(UP)3R,G\
M./3'7BOJG_@D^PD_X*.^#^X%]:X[=)5_^M0!_HT4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!'\S.Q##K@$X_+G_ #SCZO\ ^"4(\C_@HWX.7&2UY:$_]_5XS_GFOE.SC57
MA'[TD_A_DX_#]/J__@E CC_@HUX/\[EC>VF.O>1>/SH _P!&*BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#&,?\M5H _T9:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP5X$O+74+/3]-MX)[NUD1TD9$0=4)[KG/?/'3) /J?'S%O7M^7^% (/3FEI
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !35_B_WC3J:O\ %_O&@"K?6B:AI]W8R'$=Y:3VKGT6
MXA:)C^ ;-?Q(_P#!5K]FS]JO]D/]I2P_:-_9@\-7OBAH-035)8[.&24'$PG!
M(4$]#GGD8Z=J_=#_ (*I_MK>+?V6-2^&EIX:OC91^()[.*\;S"@Q/=!23@C^
M C_#%<[^UC^VCHGA7]G'X>>+M2N]%U.]\2Z597%Y]I2"X;=<11LV2^3U)Z_A
M0!_+C\9/^"BG_!4K_@HNO@[X%^+/@9J7ASP]#J=G;ZO=V^AO:1W#JT<4UW<O
M%#&)965<M*^YSW;FO[3O^";G[.%W^SQ^SWX3TC5T,.NW^D6S:E P*M')MB=@
MP/0[PPQUXYK+_8.O_@Y\1?A#I'Q%M=.\)C6;V8M-(T&GQ20L4#(5W@,Q8EO7
M&T9'(K]&();>6-#:20O"H 40%&C"]@NS*@8Z <?2@"Q67K6BZ;XATRZTC5[6
M.\T^]C,5Q;RJ&21&&"K @@CFM2O(OCI\4X/@S\,/%'Q#N+*34$T"PFN5M(@6
M>618970 #D\IT[T ?-7B_P"&G[&'[)(U;XS^)?#7A#PIJ%O'=:BVISPV:7KO
M&C2EH$/EL79@561RR@DD E37\,?_  6C_P""JGB;_@I#XWG_ &6?V=O"%SXG
M\/-J4>E+J%K8O/$L33^2SB6.,KT!8G)[U\,_\%:/^"IW[8O[7OQ]U+P+X6\.
M^,=*^&NGZNU@]A9V>J-'J-J+LI*AEBVPP(L(W%Y"=V["J>:_4#_@FY^TY^QG
M^R#X/\.^)O&GP$O]8^)8@MWU&^U'27NI6O<*2^^2)FSYA)R3^5 '[V_\&^O_
M  3=UO\ 8Q^ .F>(?&$;V'B#6K9+V:QD5T>/[3#YDF4;D; W?&,5^VOCW]K/
MX'?#343I?C#Q8NF7H8J8C!OP0<=?-7O[5\[?L3_M]>#_ -L'35'A?PA=>&+*
M.V"1P2Q20QQQ;"!''&0$10. JC KVKXE_L7_  0^*^J'5_%^BW5W>%B^^.X$
M8R23TV'N: /Q_P#^"J?[3OP9^+WA?X5>'O GB)=9UA?%EO(55/+Q&]Q;[5V[
MGYR&.21G=C''/[H?L^HT7P3^&,;C#+X0TD-]?(K\%/\ @J%^R3\'/@EX=^%?
MB;P+IUQ8:N_BRWB(EE\T&-+B JV0%ZEB,?[.<U^]?[/TC2_!/X8R/]Y_"&DE
MOKY- 'L-%%% !1110 4444 %%%% !7CGQ^_Y)-XQ_P"P7<_^B):]CKQOX_''
MPF\8>^EW(_\ ($M '^:E\="?^&M/'P!\S_B8Z@,9Z?OF]NOIUI]L5E$T1^4E
MCTXZ\=A^/2G_ !W6.V_:S\=2DYWZE??*/3SS_D\&HRT;3&5/DR<G/?J<?Y_*
M@"+R!(7B#;3'R2._^>/_ -9I(T/V=UQN89Y[\D4KR;RYB&&V_,W8^OYGD4EN
MY6-V8@CH0.>_Y]J '0;<Q#:-P(SZ@'U'X5]7?\$I1G_@H[X-V\XO;3/XRK]/
M2OE*-"'656&&[>G3^7TX_'%?4_\ P2=#G_@HYX/(/6]L^O\ UU'M0!_HU]_S
M_I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKVLAEMK:5@0TL,3L/1FC#']<U8H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:O\7^\:=35_
MB_WC0!_,E_P<0?LW?&WXT>!/!>K?!;0[G6-9T6V$JK;0O*ZW%M,[*/D&0<>6
M1]:_E<\?_#+_ (*M_%'P#X>\"ZUX#\1&R\/V\5O;K):794)#@+C(]%&,5_J#
M75A8ZA$L=_9VUY&H^5+J".= 6 !PLBL!G S@<X'I69_PBGA@=/#VC#_N&V?_
M ,9H _SA?@)XF_X*\?!33O#O@?2? WB:/18[V!9]EI>JBQ!U#'@ #C(^F:_N
M9_X)Z>(/B]XA^#FF7?QBL[JR\2FQMS/%=*ZR"0B/?D/SG.:^X?\ A%/#&=W_
M  CVBY!R#_9EGD'V/D\5KV]I:VB[+6WAMT' 2"-(E ] J  =/2@"Q7,^+_">
MC>-]!O?#FOVD=[I>H(8[FVF4/'(I5E(96!!X8C\:Z:B@#\_YO^"9W[),]Y-J
M+_"WPX;Z>5YI+C^S+4NTCG)8DQYZ_C5:Z_X)E_LJ78 F^'&@, P89TZW."""
M/X.Q -?H310!X+\(/V<OAC\$8?(\!^'K#1TQC%I;QP\8Q_ !_GCM7O5%-()(
M(/'&1SZT ?B1_P %H?\ D1?A/_V-<'_I5#7ZJ_L]<_!#X7_]BAI'Z19K\JO^
M"T/_ "(OPG_[&N#_ -*H:_53]GLX^"'PO/\ U)^D_P#HF@#V6BD!R,TM !11
M10 4444 %%%% !7C?Q^S_P *F\8?]@NYS]!!,?Z5[)7C?Q^./A-XP]]+N1_Y
M EH _P TKX_;3^UMXV ;<?[2O@5ZY_?/V]\U)>H%P!\JDYX[^O\ GZ5)\>8$
MA_:R\=S'YV.HW^T?]O#_ *>G;GZ"GADF20RC)Y"#ZD8]/Z=: &6Y"Q;,<, -
MW?MCG],__7IJ1K$YWG]VV2/3/7OQFH)!*NT*#LSQ@<@<'FI)F7RPI.[I[X/?
ML2?\]* )H419068F,D^6/?H/RX'H.]?5/_!)^(#_ (*.>$"Q()O;0CCMYBG_
M #FOE*$A7B,@^0-D#TY]>O'OC%?6'_!*EE/_  4<\&%!N'VRTQCI]]<#C/<4
M ?Z,E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110!^(W_!:'_D1?A/_P!C7!_Z50U^JO[/7_)$/A?_ -B?I/\ Z)K\JO\
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M027%QR1MCC4L23V'% '78YS[8K\_?VR?'/[1OA*WMI/@GH-UJTIQY@@B=\9
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MR/\ U=W;0W*?[D\:R+_XZPJU0 4444 %%%% !1110 4444 %%%-4$9R<_F:
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MHV9ADGH)\]O\BH?@'9?M#?&?P@?%3_M*Z;II6X\@V\FM(C<JQS@S C[G7T-
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M;)(Z'ZU^-7Q _9 _;7USQ=J.J:#\3GM-(GGE>VMQJ878C.2HV^:,84@=/R%
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MU-LH5A%<Q@87H=ROU(_6@#J5_:I^"C$EO%5NF/XG$:C\S(*1_P!JOX*H,_\
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MGCG Y]:\=^/QQ\)O&'OI=R/_ "7FH _S4/C?,J_M<^/%D)(_M*_('7_EN_\
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MQMX&BOK\LS^9)#&QW')ZLI[G_)KCX_\ @BY_P3CB#$_#BU;(P ;6(X[#JO\
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M^H!_1+<_\%Q?V&-6M3;:GX@MK^QN%Q);SO;S1."/XHY8W5N#CIGJ*\L\=_\
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MYKL[86-1R22: /WJ);L,C_/O2@DCD<TAR6X. ",C)Y[_ -:=0 4444 %%%%
M!7R?^U+^V%\*/V2M%TC6OBAJ2Z?;:W*8;'<X7S'WF/'/7YAC _"OK"OYQO\
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M7/0=O;C_ .OB@#G/C7X=U"U\%[YO$<EP?.7$9N2P^\.@+'_.:Z;X9>&-1N?
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M&4$B>,C(& >>O'0T ?UN03+<00SH<I-%'*A]5D0.I_$$5(%V],\UG:/QI&E
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M!@1CHN>V>/>OYA?@SX2/@3XK>)O&>K_#?5YM.U:XFEMXS;S_ "B23(_A.?\
M/K7Z$_#GQAX)\6>*+?1K_P"&6JVUO-,J&:2WF50"ZC))7'K_ #]Z /W>OO\
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M3/ 7B7XH>(KK1[?4('$,]_<O&X61?E(:3&#T].M?+>C^&](\/RJVD)L+;BX
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MV!?212*<AA]G<JP(]J^9?^"#G@G0?!7Q7_:&L=!69+3[=?!4DD9PH%\N H/
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M3QU]AT %%%% !1110 4444 %-7^+_>-.IJ_Q?[QH 4=!]!_*EI!T'T'\J6@
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M9'_UZ^G_ /@DYO?_ (*-^#3G'^G6F1[F1?RS[9H _P!&ZBC/./K^F/\ &B@
MHHHH **** "J6I?\@Z__ .O*Z_\ 1$E7:I:E_P @Z_\ ^O*Z_P#1$E '\JW[
M)_\ R?+\</\ L+:G_P"E,E?J_<.RW,^UBO[U^AQ_$:_)W]E$,?VY?CC@X_XF
MNJ?^E,OX?G7ZP3?+<3[N?WLGO_%[T 'VB;C]X_R]/F/^/M2_:I_^>K?3)_QS
M4!ZGZTE $DDLDHP[%ASU)/7ZYKX>_P""AOR_![00.VK6QY]I5_QK[=KXB_X*
M'?\ )'M!_P"PK;?^C$H _9?]BPY_9H^%O_8 A_D#_6OJ:OEC]BO_ )-H^%O_
M & (/Y"OJ>@#\4/^"T^3\ K\#OI\W\GK^&/X="(+K>3\XU"<<>\A_P /R]Z_
MN:_X+5 GX :B%X;^SYB#]!)_];_.*_A;^' \N/7&E)+'4+C!^LC <_4_2@#T
M*[<JZDL<\<9XYQQ^7KGVI6,T@#*Q!&/E]01DGZ\?TYJ-U 8-,<[B-OH.OZX
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MY-?M&+M_X*"?!O&>=3T[_P!*(Z_JUM?^/:W_ .N$7_HM:_E+_:-_Y2"?!O\
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MOOQ_TB3W'I7("*1(@=Q&X@$'OD8Z>G/T_E0!-+=W.X".1Q"#@D'' )[].O\
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MM8/?U2GQ>%/ <$BR6?A#2;6<?=ECM858,,G.0N>M:0^7@9%&: /(/VF52/\
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M?\B@#\WKUE_X;_\ "2M]_P"V6P'_ ']7_ 9_2OZ<H?\ 51?]<T_]!%?S$:H
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MQU]AT %%%% !1110 4444 %-7^+_ 'C3J:O\7^\: %'0?0?RI:0=!]!_*EH
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MT9J*** "BBB@ HHHH *I:E_R#K__ *\KK_T1)5VJ6I?\@Z__ .O*Z_\ 1$E
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M8O\ T 5_#S\9_E\"E.K&[@(;TS(O&>W'KZ^M?W"_\$&,C]E+0@QW-]E@.?\
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M"#R:A()((/'&1SZT *2!UK5TS_E]_P"O&Y_]%M68VUE QR,?R]N:T]+ZWO\
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MGI7]<_\ P0=</X2U@]_LLAP,_P!W_"OY$[Y5VP1[QM\U.?0<_ETZX%?UU_\
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M7Y3_ +)T9?\ ;H^.4:'+#5=4R.,@_:9/R_6OUCELW%U.64G]Y)U(_O>_X]J
M,X$$XSWP?:I?EQMS_GKZ8IWV:0LP"$=3VZ_GV)_"E%K*!R#^)!_7(H B&,\D
MX!^7\_I7Q'_P4.<_\*>T'./^0M;?D9$S_(5]P"VE.?E/'TY_6OB#_@HE"\7P
M=T%G& =6M@,X _UJ>] '[)?L6D']FCX6GM_8$5?4H(/2OEO]BY"G[,_PKR.'
M\/0./<'C(Y]0:^I  .E 'XH_\%IUW_ +4$_O:=<#]'K^%KP&L@AUN#&0-0F.
M?^!G_/>O[J/^"U*.O[/M_-T4Z=<8/T\P'IS_ )Z]*_A3^'DRSIK8690PU"<=
M>@#D=/P/7WH ]#E7:(PPX7'3IU__ %^E/C9)' 0DG P.V<>G^&>/K4)O(8<1
MRD,>.>#TS_7C\>M-,]JO^K<"3KCO^GT_D>* 'KF-W6<85C@?T_0C\>M17(=;
M*\$0^4V\HSC_ &3P?I_D4UKN,C$Y!8@$$\'IC^8ZU/=SPQZ1>N'4?Z/+USQ\
MIX)^G;^E '[!?\$%41?BQJ)#98WO(]_,.?ZU_<E'_JX_]Q?_ $$5_#3_ ,$"
M&2[^+&I")Q(PO,D*>?\ 6GU(]??]*_N70;54>B@?D * '4444 %%%% !112$
M9[D?2@#Y$_;K_P"37_B=_P!@D_R>OR1_X)^MGX(7^>O]ISC'/:1Z_7']N=2W
M[+_Q/XR$T<LV?0;ADY]R*_)3_@G]&S_ ^^9%R/[4N.1CC]Z] 'V)2@$]*L"U
ME(!VGGZ?XTX6LH&0#GI_#_+/]: *E6[ @7<&?^>B_P#H0IOV:0Y./<]/_BJL
MV=K)]JM^#_K4]/7_ 'J /R1_:-_Y2"_!S_L):=_Z4I7]6MK_ ,>UO_UPB_\
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M+@H)_P!)GYX[.WN* /NG)#$CU/\ .FU8>UER1@@Y/<#^IIZVT@&"A/N<?XT
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M8]_7'\J_KU_X(.(&\):U)%S&MHY)'3YN/7U(Z?D* /Z-J*** "BBB@ HHHH
M*_!W_@K1_P E'^#?_7Y:?^E2U^\5?A)_P5GCQ\0_@RQ'W[NUVY Y(O"I/X;?
MKQZ4 >[:;_R+OAS_ +!%G_Z)2I@2,CUJ?3+63_A&O#;;,_\ $HLST'/[I1ZT
M_P"S2<_(>>G3C]: *E(!C)]:L_9I/3^7_P 52_99/0\].G/_ (]0!GZQ_P B
MAXQ_[ %__P"B)*^$/^"(/_)8?VB/^PA??^EPK[XUFUE_X0_QD<' T"_)Z<?Z
M/)[U\$?\$/P'^+_[1;*=WEZA>[L8XSJ"J,\^IQQ^= ']*M>=_%@D?#SQ41_T
M"KG_ - ->B5Y]\58VE^'OBM4&2-(NF_ (<]2/6@#_-U_;3*#]K;Q"T9R_P#:
MEUD'_KJV?7^5>>S1*K^8Q]"WY\_K_D5VG[;C10_M=:_^_57_ +4N04)YYE;/
M3ZG/]*X:2ZB( D< -QG/&!S[=3_^LT 31*KEG4Y4#IVS@CI]1WJI*X8,#\NW
MCC@=S[?X^_<1K,L<WRR#RCZ=."21^6:==75JA0*ZDMC./<8Z?YS0!/:<QY]^
MIZ]Q6+X5CEC^-'A7NIO[/&2#C]\A'^>/J*THKF(2A-^Q"PZ\9S_G^0YS5#PW
M/''\9?" \T9>_L\=\YF4#\>?3^5 '^C/^PP"/V>?!N?^?*W_ /2>.OL(9[U\
M@_L-HZ_L[^"G<'#V4&T\8.VWASC'INY^M?7U !1110 4444 %%%% !35_B_W
MC3J:O\7^\: %'0?0?RI:0=!]!_*EH ***#T- !7PE_P4JT#5O$W[&7QHT;1$
MEDU*Z\.SBW2)2SDB&?. O/>ONP< 9/X__KK"\3^'M.\6:#J?A_584N+#5+26
MUGC<!E9949<D'(.,]Z /\PS_ (-R]6L?@_\ \%-_%^@_$B6/2M2N?&5\D,FI
MNMON9KUPK RE3U(''7K[5_4G_P '.7Q.\):'^QEJ.BW&J:;=WVKVDBV=M#=P
M32YD,@4JJ.V=PPRXX(8'N,_G;_P4%_X(-?%_PC^T3<_M,?LT:G=:1?2:C)JA
MCTIWB)D,QFY^SX.?J0>QKYY\4_\ !+7]O#]O/7_"7ACXT>(M=?PYH\MFEW'>
M371BDC@= V1*=K JO(H ^GO^#2[P/K>G?#C6/$-Y;W4-I=75W);>;&RQD.2P
MVD@9!!_''O7] W[5GC;]NO2?&<T'P3T2YO/#XN-L<D4;%3$" #\O'3GIWSS7
MNW_!/C]A_P '_L2?!30?ASHEK;G4;6UMQ>W4:H&:580L@9D'S,6.3DY!'/-?
M?1;! QUQ_.@#^13]NOX?_P#!4C]H[1/!NG)X4O0N@ZC;W;!;=\%XY5=F( QD
MG&3WQ[8KZV^'GC#_ (*D^%/AOX2\*?\ "*W@?1-*M;%F$#;ML$84*2><9)./
MZ\U_1O10!_/K#\3O^"I<1CD7PM>L4;.UH6(8<Y!'/![U\=_&O]F+_@H!\?/B
M?H7Q=\3>'KF+7?#KQ-:1>2W'DD; .. ,<8Z<>M?UG9[=Z* /YA7\$_\ !2.3
MR@WAV]_<Q)"G[ES\L:[1Z]A47_"!_P#!2#<&_P"$=O,]?]1)_G]*_I_HH _F
M#_X07_@I W!\.WGK_J7_ ,141\ _\%(#_P R]>?]^)/Z8K^H&B@#^5/QG\#?
M^"A_C[3)-(U3P]>+;RIY3$POP",>G?'^<5VWP)\$_P#!2#]G?2+S1/"WAN[F
MM;S<SCR6(#=CCU!Y!]>>M?T[<]O\_H:* /Y,/C3^W9_P4X^%/BC2?#UUX=O%
MDU.Z2W0%'!)9]OKZG_#W^E=0\<?\%//B1X%MM.O?#-Z+37M,#2MY3\QW<((S
MCJ K'_\ 77Z&?M5?L]^*?BI\0?#/B#3PJP:7?PS-MB&-D<H/)P2>%ZDG/ODU
M^B7AFVFLO#NB6=P )K/2[&UDVC:-UO;QP\ 8Q]SGCK0!_#7XD_X(K_M6>+/'
M6J?$6_TBX&K:O+-/.AB.0TS%F]^K'T'>FK_P13_:JBE,PTFY)/)!A;Z'_/\
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M#?[<?_!3OXI>);G0[3P[>-):W1AP$<_<;!_$X^G'XU_4IX^TVXUGP;XBTJT
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MN[>_%?I@WQ-_X*FLD:?\(Q? 1*$&(7Y  &>A[ 5_0710!_/C_P +*_X*F?\
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MC*86ZL3GM[_RK^L3]G/P5JG@#X=Z7X;U,+YMG!&N0@5MR*$.2 ,_CG]37OM
M'\)T?_!%/]JJ"%;=-(N"@X_U1'IT]>GH?84__ARM^U2J!?['G'/),)]SZ5_=
M=10!_"<?^"*O[5C\_P!DW&.X\ICZ\<#'?W_I0/\ @BK^U2!@:1,,_P#3)N_'
MI7]V-% '\&.O_P#!#;]J#Q'IQTJ\TFX\EG20DPG[R-N&>/;\J_2C]F#X)_\
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M,A_EC^=?U 44 ?S KX$_X*0HDJ+X=O,31/"W[F0?*ZE3U^M<C\%/@1_P4+^
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MV1Q"^YTAC$:;CW("@ D].!Q2GXE_\%3#_P RS?8'3]S(?\?TK^@VB@#^>_\
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MU]!@U3O/^")/[4U] T,FCS[7(/\ J3C*_A_6O[NZ* /Y)_V7_P!E;]OW]D*
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M_P#6I] '\)C_ /!%3]JHX8:1<?+V$+8SGV%*O_!%;]JL#)TB<[N,&%OZ]?\
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MCD#\*^A?BO\ M%?\%1/ASX2O/$-QX9O4BTZU)W>4XRL*#G\<=>_TYK^E?/S
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M=10!_/C_ ,+*_P""IG_0LWW_ 'X?_"C_ (65_P %3/\ H6;[_OP_^%?T'44
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MFAV=U<[9(8Y=^P1H_.44KC'0\4 ?Z BNC@%&5@>A4A@>_49'2G5\"?\ !/\
M^(/Q+\4_ F#4?C/97&B^(=),4%[)J6^)ML,;B65VEYQP"3[UZ%XG_;O_ &2O
M!WB1?"/B/XW^"M-\1-+Y(TN?4D%SYN[;LV''.[B@#ZYHKQ;4/VB?@MI7A^#Q
M5J'Q"\/VN@7*+)#J<MVJVSHX!5@YP,$$$5Y1JG[?/[(>C7EE8:C\=/!%M=:@
MRK:1/J: S,Q"J%]<D@#&>M 'U\R(WWD5O]Y0?YBF//!%A9)8HCV#NB?D&(KR
M?7OBOH[_  ^O/'7@:ZM/%MHEF;FSDTQ_M$4^8_,CV[>N[TP<U_%9_P %%_\
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M8DDGDG\?7-?HI7YA_P#!(/PAXJ\#?L-_"CPWXSTR?2->L; "[L;A&CEA)AA
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M;_\ !*/X>^$?!OA6]UKQ9;Z)I<5SH]K;R27$;K!$&4HB%QM((Z#GC'6O)O\
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M9;#]EO75O=;63PW=>*TT.^_TBV8^4)"_EF+EE5VD50[D LQR20#Z$_X(I?\
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M;?P_=7*K%<.]NLJRM PX#AMV[\>: /T)_8._X+3K\?OV??BC'X\T:QT3XO\
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M,>@BN$VL3[#O72$X&:\_^*D^K6WP^\57.A!SJT&DW,MB$SO,Z(2@7'.<^G-
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MF6"2/[6[AA(4V<J>Q]Z /Z(O^"N6D>'[[]B7QUJEWX=TN[OI;*&6*\>RA-Q
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MC7<)M^<HO?.?J*^+/^#D_0=!LOB1\$);#0=-L+F1]-\V[M+.&W>=C>=6\J-
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MO+'X0_#^SU"%H+VW\.645Q"X(:.50VY2#R"* /6**** "BBB@ HHHH ****
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M *R=5T'0]<B\C6M'TS5H>GE:E86U['_WQ<Q2+^E:U% '#V/PR^'&F7'VO3O
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M+TV1M 47'; JV='T>2Q.F-IFGOIV-IL6M(#9[>F/LYC\G&.VW%:=&,=!C\*
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M?53%;*5([8(Q74A BJL:A @"HJ@*JJ,  #&  .@&,4^B@!!G'/7_ #Z4M%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .=\6/JT?AS5WT,$ZLMG(;''7S_X:\_^#5SX_N=!
MNW^( 8:F+MA!NZ^1EL?IM[U[%2$X'3/M0 M% HH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "FK_%_O&G4U?XO]XT *.@^@_E2T@Z#Z#^5+0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4F[G'.?\ ZV:1EW8YQCVIV.^.?7% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMPL^O>,8[.6QMX'WR2"Z"%<*AW$9;M_]>@#]^$D1QE'5QZHP8?F":4L%&6(
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MM]^V7\#/'_@CQS\0_ .L:'X*\7ZC:%&N+6ZB@6WNIEY^=0HPCU_3['_P4O\
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M<E52&=H\\D]EY]NM?TJI+%)GRY(Y,==CJV/KM)Q7^5]^S!^T=\7_ -GK]O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !35_B_WC3J:O\7^\: %'0?0?
MRI:0=!]!_*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'SX@_!H?#'QUIVC7_A"_U-](N48:+_9DCI,8S@M/9CYV";NCL ".<CC^?O\
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M?ASXT:]XX^ /Q2U+P/I/B*\N9KNVTR[D@CDCN9&9U(B8 C:Q!_IBOH7]C/\
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MC3^S5-)KGQ=^)]_XUU2XL9+=S?7+SR%Y8RK,=[,PY.<GB@#^6'XGZ;H>J_\
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M8L<9WQ;N=F"?YU_5;_P51_8*^,/[7VCZ;+\(/B#J'@;6M/AB N;"YD@??$N
MW[ME/8?G7Y3_ +&7_!OIX\\%?'?2?CA^T5X[NOB%K6CW,$UM-JEPT[@V[ C:
M92Q_A''YT ?U>^ O$=OXM\(:#X@M8S##J6GV]PL9&"F^-6(QVZ]ZZXG S65H
MFCV7A_2;'1].A6&ST^VBMX(T& %B0*,  =<>E:H.1R,>QH 4'/-%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U?XO\ >-.IJ_Q?
M[QH 0;L#&W&/>E^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@
M^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?
MUH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\
MV?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@
M^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?
MUH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\
MV?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@
M^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?
MUH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\
MV?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@
M^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?
MUH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\
MV?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@
M^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?
MUH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\
MV?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@
M^?\ V?UK\\?V[_V /@_^V9X3=?'^BZ)+JVE6S&RU*[T^::5=F3&7DBN$9BAV
M@8C&5'+9')10!^%OA[_@B%X EU(>';[Q-HMSX=%WL_LW[!JWE&$OM$90W6S
M4XQC%?T"?L9?L,_!S]C/PDVB_#'PYH6G76I6\7]H:A8Z:UM<2[@'(65YY&PY
M.7^16(RNXJ6R44 ?;GS_ .S^M'S_ .S^M%% !\_^S^M'S_[/ZT44 'S_ .S^
MM'S_ .S^M%% !\_^S^M'S_[/ZT44 'S_ .S^M'S_ .S^M%% !\_^S^M-+."!
MA><>OK110 N7W$87CZ^W^-+\_P#L_K110 ?/_L_K1\_^S^M%% !\_P#L_K1\
M_P#L_K110!\#_M__ +/EC^TK\*C\.-7ETJWTV[,QGEOK6ZG=EF"QO&#!-'^[
MVKD*5.&+-GG%<C_P3?\ V)O 7[&'PZU7PSX)LM"C_MB6.:\O=-L9[6:5E<N4
M=II7+1LV&8;<EE0[@ 02B@#])OG_ -G]:/G_ -G]:** #Y_]G]:/G_V?UHHH
M /G_ -G]:/G_ -G]:** #Y_]G]:/G_V?UHHH /G_ -G]:/G_ -G]:** #Y_]
MG]:/G_V?UHHH /G_ -G]:/G_ -G]:** #Y_]G]:/G_V?UHHH /G_ -G]:/G_
M -G]:** #Y_]G]:3+[@,+S]??_"BB@!?G_V?UH^?_9_6BB@ ^?\ V?UH^?\
MV?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@
M^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?
MUH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\
MV?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@
M^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?
MUH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\
MV?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@
M^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?
MUH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\
MV?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@
M^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?
MUH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\
MV?UHHH /G_V?UH^?_9_6BB@ ^?\ V?UH^?\ V?UHHH /G_V?UH^?_9_6BB@
3^?\ V?UHVDY))!_V3Q110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gu0gjnulhgsv000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gu0gjnulhgsv000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )(!<4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>.+Y=+2&[?;B1;F-61<8!'/H<4G'EA#34T]M[7%5/>]U+371;;,DT*PT^_\
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M64M(8W&(_E*A<9R>WK6+96U]J&M:H^E06U["92S/=Q*1R3C&?QJ4I1Y5;O\
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MPC8W8W>>NWZX/],UCQZ+XB\+ZA-)I$:W5K)V.#D=LC(.1ZBG3:3XD\4W4/\
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M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ(# D=0#TI:J,5%61-2I.I+FF[L****9F%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !6?K6EC6=*EL3*8O,(.\+NQ@@]/PK0HI2BI*S*A.4)*4=T4M(TX:3I4%B)
M3*(@1O*XSDD]/QJ[113V"4G*3D]V%%%(K*PRI!'L:"1:**165AE6!'L: %HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!KG@Q;#1YM1DU&6:YCPSEQPV2!]>]>B$A5+,0 !DD]JX#6=1N?%^I+I&E?\
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M0>^1^=+XMO8;/PY=B5U#S(8XU)Y8GT_G7/>'KB#2/ D]W?6XFAEG)2)@"'Z
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M3N>K'N3[U<HHK0YI2<FY2W84444""BBB@ HHHH **** "BBB@ HHHH ****
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MW_PD*VX^V&W\DL?]7O#9Q[CTK>HK24%-6D<E*K.E-3@[-'$+X!ND4*OB"95
MP (C@?\ C];-YH=])I5E:VFKS03VPP90#^]XQSS_ (UO45*HP2LC>>-KS:<G
M>WDO\CD;?P;/<7T=UK>IO>^7]V/!Q^.>WL!7744548**LC*M7J5FN=[!1115
M&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/^+/$Y\,Z
M=YT.FW6HW3H[QP0+@8099G<\(H'<_@#705B>+;NVM?"VJ"XN(H3)9S*@D<+N
M.P\#/6IFVHMHJ"O))E>#Q=;CX?Q>++V(P0-9+=O$K;B,KG:#QDY.*Q(?&OB"
MQNM(F\0Z#:V>F:O,L$,D%T9);=W&4$H*@<].#Q6!>E=1_9O6"RE2>:#2[=Y8
MXV#,H4JQ! Z<*?RK3\<ZG8Z[H?A6TTVYBN)[_5+26!8W#'8IW,V!V '/I6C2
M51KS2^3?]?<9IMP3\F_N1H7?C'Q!>WVK#PUH=I>V6D2&&XEN;HQM/(HRZ1 *
M>1TR3C-.F^()OM-T ^'K!;S4=<1I((9Y?+2%4'SM(P!.%/' Y-9W@35;'1;'
MQ=;:E=16\UEJ]U/,LKA3Y;896P>Q'2N6\#QMH>J^ KK4O]'@O-.O(HFE.T*[
MR^8HR>A*D8J8ZV3[+\4W^)4M+OS?YVO\CNK3Q])9PZ_#XEL8[*_T2%;B9;:4
MR1SQL/E:,D \D8P1UQ4,/C7Q!8W6D3>(=!M;/3-7F6"&2"Z,DMN[C*"4%0.>
MG!XKC?'<;:YJOCJZTT_:(;/1[:"5HCN!=9?-9<CJ0H.:Z;QSJ=CKNA^%;33;
MF*XGO]4M)8%C<,=BG<S8'8 <^E$=;-]TOQM?YK4):72\_P D_P S0N_&/B"]
MOM6'AK0[2]LM(D,-Q+<W1C:>11ETB 4\CIDG&:Z?P]K=MXD\/V6L6@98;N(.
M%;JIZ%3[@@C\*XGP)JMCHMCXNMM2NHK>:RU>ZGF65PI\ML,K8/8CI6M\*+6:
MT^&FCK,A1I$>8*PY"N[,OZ$41UC\D_O02W^;7W?U^)V=%<9<?";P-=7,MQ/X
M>@>:5R[L99/F8G)/WO6L?P]X?TOPK\8I]-T.U^QV4^@">6!)&*O(+C:&()/(
M''XGUH ]+HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** .,\8>/3X8N(H+?1KJ^;S84N)O]7#")&"K
M\Y'S-S]T9]\5I^+_ !#<^'-*MKBSLH[RYN;R*TBBDF\M=TAP"6P?Y5SWQ<O;
M1/"<=N]U"L_V^T?RS( VWSEYQUQ70>(;/0O$FE6UO?:DL<#7"R6\MO=B-C*F
M2-C ]1ST]*2UC\_PT&]'\OQU)]"O/$5U),-<TFRL44#RC;WAG+'OD%%Q6U7G
M7AJYN=.^)=YX>L];O-7TH:>+F7[7/Y[VLV_ 7S.O(YVDUZ#/#'<V\D$R[XI4
M*.I[@C!%5T3)ZM$E%</_ ,*?\ _]"Y!_W]D_^*JIX!TRTT'QSXTT;3(C;Z;;
M&R>&V#LR(SQ,6(R3R2!GZ#TI#/0Z*** "BBB@ HJE>:OIFGRQQ7NHVEM)+_J
MTGG5"_T!/-7>HR* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Q==N_$,+P0Z#I=I=/(&,D]Y<
MF*.+&,#"JS,3[#''6MJN7\9^,(?#%I!!"(Y]7OF,=E;.X4%N[N3]U%ZDTF-#
M_!GBF7Q-9WRWEC]BU#3KM[2ZA63>H=<<JV!D'-1^(?$VH6NO6GA[0=/@O-5G
M@:Y<W,QCA@B!QN8@$G)X  J'PA::7X6\,7,L^LVMU,9'O-3OA*NTRORS'T'&
M!["LM+ZUM_C0EU+<1"VU/0E%G,7&R0K)N(4]#P0:IKWDOZV;_-"^RW_6_P#D
MS?\ "?B:?7CJ-EJ%DMCJVF3B&Z@23>G(RKJV!E6'J*Z2N"\%NE_X_P#&VJVK
MB2RDGMK9)5.5=XX\/@]\$@5V.JZ58ZYID^FZE;K<6<X DB8D!@"".G/4"ET3
M\D'5HN45P_\ PI_P#_T+D'_?V3_XJF_"=!!X3NK6,MY%MJEW#"A8G8BRD*HS
MV% '=4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 5=0U*STJT-U?7"P0A@N]O4]*QE\3C_
M (2B;3W%NMA'9"[^U^9P02!UZ8YJWXF,@T241:0FJL2%%L^,'/&?PKRQ?"NH
M?\)))9"&T>XCMA='3R[^5C=_JP=V>,YZXS7/4J3C))+^K/\ X?0]? 82A6IR
ME5=GKV\M=]+>>FI[%8:A:ZI9I=V4RS0/G:Z]\'!ZU9K+\/,[:);F32UTQL$?
M95QA.?8#KUK4KH6QYE6*C-Q71^OY:!11109A1110 4444 %%%% !1110 444
M4 %%%% !5#4]$TG6EC75=+LK]8B3&+JW24(3UQN!Q5^B@#/T[0='T=)4TS2;
M&Q6;'FBVMDB#XZ9V@9ZGKZU7TWPGX>T:]DO=-T6PM+F3(:6&!5;!Z@$#@?2M
MBB@#'U'PGX>UB_COM2T6PN[I,!99H%9N.F21S^-6]2T?3=9L?L6I6%O=VN0?
M*FC#*".A /0U=HHZ6#S*6FZ/INCV/V+3;"WM+7D^5#&%4YZD@=3533?"?A[1
MKV2]TW1;"TN9,AI88%5L'J 0.!]*V**.MP\C'U'PGX>UB_COM2T6PN[I,!99
MH%9N.F21S^-:X 4    #  [4M% !7#_\UU/_ &+7_MS7<5P__-=3_P!BU_[<
MT =Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445
M!->6UO/;P33QQRW#%(49@#(P4L0!WX!/X4 3T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E:AX
M7\/ZM=?:M2T+3+VXVA?-N;2.1\#H,L"<4V;PMX?N-)72I=$TYM/1MZ6WV9!&
MK>H4# /)Y'K6O10!0TG0]*T*V-OI.G6ME"QRRV\00,?4XZGZU?HHH *X?PQ_
MR53QY]-._P#1+5W%</X8_P"2J>//IIW_ *):@#N**** "HYW>.WEDC3>ZH2J
M#^(@<"I** /@W5]4OM:U:YU'4IGFO)Y"TC.><^GL!T [ 5]*?L]:OJ.H^"KR
MUO'DEM[&Y\JVD<DX4J"4!]!^F[Z5I^(?@9X1\0:S)J9^VV,DS[YH[2151V/4
MX93@GVQ7<:!H&F>&='ATO2;9;>UBZ*#DL3U9CU)/K0!IT444 %%%% !1110
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M8NV389MOS%?3-6:*+#4FMF%%%% @HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KA_^:ZG_ +%K_P!N:[BN'_YKJ?\
ML6O_ &YH [BBBB@ HHHH **** "BBB@ HHHH **** ,?Q'XIT;PEIT=_KEY]
MDM9)1"K^4\F7() P@)Z*?RKE_P#A=OP\_P"AA_\ )*X_^-US_P"T=_R3S3_^
MPK'_ .BI:^8* /N_1-;T[Q'H\&K:3<?:+&?=Y<NQDW;6*GA@".01R*T*\_\
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M,IZ$'(I:IZ3I=IHFD6NF6,8CM;6(11K[#U]2>I/K5R@ HHHH **** "BBB@
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M'7/_ (%R?XT =1X'\5VWC/PG9ZQ!M621=EQ$#_JI1]Y?ZCV(K)U/_DL_A_\
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M'XLOHO\ 9DG]G#0UNQ#]LF_UIG*;L[\_=&,9Q7L=<.O_ "763_L6E_\ 2EJ
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M25TDS''X>E3HN4(V;:.EHHHKZL\$**** "BBB@ HHHH **** "BBB@ HHHH
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M  M_Y%W4_P#L,WO_ *--(9W%%%% !1110 4444 %%%% !1110 4444 %%%%
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MB.78ZOL;V;;C\:\VUSP_XNU6[NI[7P1;:>MW;16S0PW\.T^7,LF]\8SD J,
MGGFN_P#B/<75KX#U.>TO39LBH7G201NL>]=^UCT8KD#W(KAK>S^$,D<4G_"2
MLS, V9=9F#'ZC>,'\*4?BT&]CLO"$>IWGB#7-=U#2)M)2\6WACMIG5G;RPVY
MSM)'5L#V%=C2+C8NTY7''-+5,E!1112&%%%% !1110 4444 %%%% !7#_P#-
M=3_V+7_MS7<5P_\ S74_]BU_[<T =Q1110 4444 %%%% !1110 4444 %%<U
MXW_Y L/_ %\+_P"@M7 UXN.S?ZK6]ER7^=OT/2PN7^WI\_-;Y?\ !'_M'?\
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M*] U'4;32=/GO[^X2WM8$+R2N>%%8.G>/M!U+2=1U..6YBM-.(^T-/:NA4$
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M4 %%%% !1110 4444 %%%% !1110 4444 %,EABGB:*:-)(VX9'4$'\#3Z*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ3N8V"BBBF(QO%7_ "+5W_P#_P!#6O-:]*\5?\BU=_\  /\ T-:\UKY#/_\
M>8_X5^;/H<I_@OU_1!1117AGIA1110!['1117Z6?%A1110 4444 %%%% !11
M10!SOCBP74?"EQ ;RUM)!)%+%)=L%B,BR*R*Y]&8 ?C7"2:?X]U6?Q'92>%[
M:PCUXQQRWDFHQR1P((Q&Q55^9B0"1P,9YKO_ !GI@UCPI>V7VBVMF<*R3W)(
M2)@P(;(((((XYZXKD;>[\9Q11QOXZ\)S%0 7>#YF]SAP,_04DM6G_7]6'>UF
MCT>V@6VM8;=22L2*@)ZD 8J6D7.T9()QR12U3=W=DK1:!1112&8WBW66\/>$
M=5U=%#26EL\B ]"V/ES[9Q7G_A.[\)/?Z1->ZQK%QK]R59;VY>ZBAN)2,E$S
MB(KV"@8^M>@>+-%;Q%X3U32$<))=V[1HS= V.,^V<5Q$EIXH\4VOA[1;_P .
MRZ8NFW<%Q>WLL\;(WE=H@I))8]R!BB/Q?=^MPE\/W_I832]$'C^7Q%JNI:AJ
M"207\UEIRV]W)$MJL6 '"J0"Q/)SFLO1]:U#QS#X/T/4+VYCBGM+BXU)K>4Q
M/<^2_EJI9<$ D9..M;=I%XG\&W6O:?I_AV;5;?4+R6\L+F&>-$C:0#*R!B"H
M![C.:JV_@[6?!T7A34M.L_[5N-,MIK;4+:&15>02G>60M@':^>#C(I1V5]M/
MOL_UW'+=VWU^Z_\ EL4-4UB]^'T_B_2=.NKB2UATV&]T];B5I3;/(_E$!F))
M&2" 35W6=#/@2'P_KMAJ6HR7CW\%MJ+7%W)*MVDIPQ96) (/(P!BI+OP?K'C
M*+Q3J6HV?]ESZE91V>GVTTBLZ+&=X:0KD#<^. 3@5/<P^)_&7]AZ7J7AV;2X
M+&[BNM0N9IXV20Q<A8PI)(9NYQ@54=U??3[K_P"6XI;.VVOWV7Z[$.EZ(/'\
MOB+5=2U#4$D@OYK+3EM[N2);58L .%4@%B>3G-=1\.=9N]>\!:7?WS^9=E&C
ME<_QLC%,_4[<USUI%XG\&W6O:?I_AV;5;?4+R6\L+F&>-$C:0#*R!B"H![C.
M:ZOP5H#^&/!^G:1-(LD\$9,SKT+L2S8]LDTH_#\E]]M?^"$OB^;^XRKCX@RV
M]S+"/!/BZ7RW*>9'8(5;!QD'S.0:Q?#^N-KWQHEN6TC4],*>'O+\K481$[?Z
M0#N #'CG&?4&O3JX?_FNI_[%K_VYH [BBBB@ HHHH **** "BBB@ HHHH Y/
MXA65I?Z!!%>6L-S&+I6"31AP#M?G![\FO-/^$;T+_H"Z=_X"I_A7J7C?_D"P
M_P#7PO\ Z"U<#7Q^=5)QQ346UHCZ++81="[75D5O;06D"P6T$<$*YVQQ(%49
M.3@#CK6%X6_X^O$'_84D_P#04KHJYWPM_P ?7B#_ +"DG_H*5YM-MTJC?E^9
MV35IP2\_R.3^+W_,&_[;_P#M.O,:^G*N:1_R&K'_ *^(_P#T(5ZV S?V-.%#
MDOYW[OT.#%Y?[6<JO-;Y=EZG;^!/^2>>&?\ L%6O_HI:Z"BBOK#P"GJ__(%O
MO^O>3_T$UY17J^K_ /(%OO\ KWD_]!->45\KQ#_%AZ'O91\$O4YTZ?XJSQKU
MG_X _P#V55)/#WB*34X=0;7;7[1#&T:'['QM;&>-WM76T5Y"Q=2.R7_@*_R/
M0>'@]V_O?^9SO]G^*O\ H/6?_@#_ /95O6ZRI;1+/())@@$CJNT,V.2!VYJ2
MBLJE5S5FE\DE^1<*:CM?[VSU?2/^0+8_]>\?_H(JY5/2/^0+8_\ 7O'_ .@B
MKE?H-'^%'T1\C4^-^H4445J0%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %-=UC1G=@J*,LS'  ]:=4%Y9V^H64]G=Q++;SH8Y8VZ,I&"*
M'Y CB=:TK78_%L^LZ!K^BV$=U;1I+%=1%S-MSM<_,!D X!&..N>*V?#)\1&:
MX_MO6-(OTVCRUL(2A4]]V6/%)>_#[PEJ+Q/>:#9SM%$L*%U)*HHPJ_0"KFB>
M$M \-RS2:-I5M9/,H61HEP6 Z T+0'J;-%%% !1110 4444 %</X8_Y*IX\^
MFG?^B6KN*X?PQ_R53QY]-._]$M0!W%%%% 'E&K_\AJ^_Z^)/_0C5.KFK_P#(
M:OO^OB3_ -"-4Z_.:W\67JS[&E\"] HHHK(L*[[P1_R!9O\ KX;_ -!6N!KO
MO!'_ "!9O^OAO_05KV,C_P![7HSS\S_W=^J.EHHHK[,^;"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9=VEZ?F"UP>'.?GD_$CCV K*M1C6ING+9ETJCIS4UNCN/%GAV7Q1IT%M#?\
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M:U\AG_\ O,?\*_-GT.4_P7Z_H@HHHKPSTPHHHH ]CHHHK]+/BPHHHH ****
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M[>PKY[US5Y]<UBXU"?(,C?(N?N*.@_ 5]$NB2(4D564]0PR#4/V&T_Y]8/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0> X$T;QAXP\/68\O3;2>"XMH ?EA\V/+*H[#(SBNSU6YO;33)Y].L/[0NT
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M* "BBB@ KA_#'_)5/'GTT[_T2U=Q7#^&/^2J>//IIW_HEJ .XHHHH \HU?\
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MBB@ HHHH **** "BBB@ HHHH **** "JFI:98ZQ8R6.HVD-U:RC#Q3(&4_\
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M:IDH****0PHHHH **** "N'^%O\ R+NI_P#89O?_ $::[BN'^%O_ "+NI_\
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M*^@/("N:\;_\@6'_ *^%_P#06KI:YKQO_P @6'_KX7_T%JX<R_W2IZ'5@O\
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M $(U3K\YK?Q9>K/L:7P+T"BBBLBPKOO!'_(%F_Z^&_\ 05K@:[[P1_R!9O\
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M#"BBB@ HHHH **** "BBB@ KA_\ FNI_[%K_ -N:[BN'_P":ZG_L6O\ VYH
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M -BU_P"W- '<4444 <;X\_YA_P#VT_\ 9:XN*:*=2T4J2 '!*,#65^TCJMY
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M]AK<\<E^*,7C"5HE\2VGA71<X+F0/?3CVQE8A^9KN? 4G@B.*YM?"5W;7,P
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MJC\J .HHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N>\06OBR>ZB;P_J6F6MN$Q
M(MW;-(Q;/4$,.,8KH:IZLEW)HU\E@VV\:W<0-G&'VG:?SQ2D[*XUJ[''+!\1
M'G>!?$OAIID&6C%DY91[C?Q79Z<MZFG6ZZC-#->!!YTD*%49O4 DX%>'^'?$
M?@_PIXFA+V]S:73:,T%];RVLK7$UV9%)5N#N8X//3WKU;P!9W>G^!-'M;Z)X
M;A(.8G^]&"254^X4@?A5=/Z\_P#(GK_7D=)7G]QX1U#3M'LK73]1T]-2L]6F
MO--^U9"2J^\F-\<D[7?E<] :['6-9T[P_I<VI:K=);6<.-\C G&3@# Y)R>U
M>=^(?B#X7U"Z\-ZGI][<ZA+;7[E+&RM6>XD)B9<;&*D#YP<]^W?"Z_UW'T_K
MLSLO"&CZGI-A>OK$UK)?WUX]W,MH&$49957:N[DC"YR>Y-=#6+X>\3V?B..<
M0P7EI=6S 3V=["8IHL\J2OH1T(-;5 !116/K_B?3/#<=N;YYFFN7*6]M;PM+
M+,PY(5%!)Q0!L45D>'_$NF>)K66?3I9"8)#%/#-$T<L+C^%D8 @U!K_C#1_#
M=U;6VHR7'GW*L\4=O:R3,57&3A%..HH>@+4WJ*S]&UFTUVP^VV0N!#N*?O[=
MX6R/]EP#CWK0H *X?X6_\B[J?_89O?\ T::[BN'^%O\ R+NI_P#89O?_ $::
M .XHHHH QO%7_(M7?_ /_0UKS6O2O%7_ "+5W_P#_P!#6O-:^0S_ /WF/^%?
MFSZ'*?X+]?T04445X9Z84444 >QT445^EGQ84444 >4:O_R&K[_KXD_]"-4Z
MN:O_ ,AJ^_Z^)/\ T(U3K\YK?Q9>K/L:7P+T"BBBLBPKOO!'_(%F_P"OAO\
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MZ"M>QD?^]KT9Y^9_[N_5'2T445]F?-A7->-_^0+#_P!?"_\ H+5TM<UXW_Y
ML/\ U\+_ .@M7#F7^Z5/0ZL%_O$/4X&BBBO@CZH**** +FD?\AJQ_P"OB/\
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M "!;'_KWC_\ 015ROT:C_"CZ(^.J?&_4****U("BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X?PQ_R
M53QY]-._]$M7<5P_AC_DJGCSZ:=_Z):@#N**** /*-7_ .0U??\ 7Q)_Z$:I
MU<U?_D-7W_7Q)_Z$:IU^<UOXLO5GV-+X%Z!1116185WW@C_D"S?]?#?^@K7
MUWW@C_D"S?\ 7PW_ *"M>QD?^]KT9Y^9_P"[OU1TM%%%?9GS9\0>._\ DH?B
M;_L*W7_HUJN_#*[GLOB'I=Q;OLE3S=K8!QF)QW^M>Q^+OA_X8E\6:E.^F9DG
ME\Z1OM$OS.X#,?O=R2:SM.\&Z!I5]'>V5AY5Q%G8_G2-C((/!8CH37A8O.:,
M54HI-25U?3?;N>IA\MJ-PJ-JVC^7W%_XB>(=5O/ 6K6\]UOB>-0R^6HS\Z^@
MKIAXJUK:/]-[?\\D_P *X7QU_P B5J?_ %S7_P!"6NA'W1]*\*6,Q'L(OVCO
M=]7VB>JL/1]JUR+9=%YGS)7L'[./_)0]0_[!4G_HV*M7_A7GA;_H%_\ DQ+_
M /%5WOPO\(:%HNHZA?Z?8^3=>4L._P YV^1CDC!8CJB_E7TN&S>AB*JI03N^
M]O7N>+6R^K1@ZDFK+^NQZ;1117JG %%%(QVJ6P3@9P.IH 6BO.-;\<M/!:11
MM<Z/>QWJ"XAF7!\HYR<D<CI75:%XEC\07-R+:RN4LX@/*NI$PDWKC_/Y5G&K
M&3LCMJX"O2I^TDM/Z^^_2QNT445H<04444 %%%% !16)K_B-?#[VS3V-S-:R
M$^;<1+E81V)KD])\=?9VU-6EN-6N)+UELK>%<DQ]CTX'-9NK%2LSMI8"O5I^
MTBM/Z^ZWG8]'HID3F2)'*,A90=K#D>Q]Z?6AQ!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5P_PM_P"1=U/_ +#-[_Z--=Q7#_"W_D7=3_[#-[_Z-- '<4444 8WBK_D
M6KO_ (!_Z&M>:UZ5XJ_Y%J[_ . ?^AK7FM?(9_\ [S'_  K\V?0Y3_!?K^B"
MBBBO#/3"BBB@#V.BBBOTL^+"BBB@#RC5_P#D-7W_ %\2?^A&J=7-7_Y#5]_U
M\2?^A&J=?G-;^++U9]C2^!>@4445D6%=]X(_Y LW_7PW_H*UP-=]X(_Y LW_
M %\-_P"@K7L9'_O:]&>?F?\ N[]4=+1117V9\V%<UXW_ .0+#_U\+_Z"U=+7
M->-_^0+#_P!?"_\ H+5PYE_NE3T.K!?[Q#U.!HHHKX(^J"BBB@"YI'_(:L?^
MOB/_ -"%>KUY1I'_ "&K'_KXC_\ 0A7J]?5</?PI^IX6;_''T"BBBOH3R#&\
M5?\ (M7?_ /_ $-:\UKTKQ5_R+5W_P  _P#0UKS6OD,__P!YC_A7YL^ARG^"
M_7]$%%%%>&>F%%%% 'L=%%%?I9\6%%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYFY&Z'$;$?J!7BXS*L-RU*SO?5_J>EA\?7YH4U:VB/6?'+H?!>I@,I.Q>_\
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M1I.G&UO1=^O?YC(@ZQ(LC[W"@,V,9/<XI]%%:G"%%%% !1110 4444 %%%%
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M\+_Z"U<#7QF>?[V_1'TF6?[O\V%%%%>.>@%7-(_Y#5C_ -?$?_H0JG5S2/\
MD-6/_7Q'_P"A"M:/\6/JB*GP/T/5Z***_1CXXIZO_P @6^_Z]Y/_ $$UY17J
M^K_\@6^_Z]Y/_037E%?*\0_Q8>A[V4?!+U"BBBOGCU@HHHH ]7TC_D"V/_7O
M'_Z"*N53TC_D"V/_ %[Q_P#H(JY7Z-1_A1]$?'5/C?J%%%%:D!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %</X8_Y*IX\^FG?^B6KN*X?PQ_R53QY]-._]$M0!W%%%% 'E&K_\AJ^_
MZ^)/_0C5.KFK_P#(:OO^OB3_ -"-4Z_.:W\67JS[&E\"] HHHK(L*[[P1_R!
M9O\ KX;_ -!6N!KOO!'_ "!9O^OAO_05KV,C_P![7HSS\S_W=^J.EHHHK[,^
M;/$/%WP_\,2^+-2G?3,R3R^=(WVB7YG<!F/WNY)-9VG>#= TJ^CO;*P\JXBS
ML?SI&QD$'@L1T)KMO%7_ ",MW_P#_P! 6L:OA<;BJ_MZD.=VNU:[M:Y]3AJ%
M+V4)<JO9= HHHKSCK"NR\!_\Q#_MG_[-7&UV7@/_ )B'_;/_ -FKT\G_ -]A
M\_R9Q9C_ +M+Y?FCL:***^X/F HHJ"TO;6_C>2TN(YD21XF:-LA74E64^X((
MH GJ"YO;6S:!;FXCB-Q*(8@[8WN02%'J< _E4]?*?QD^($VO^-8[;2[EELM&
MDQ!)&WWIP?FD!]B  ?;/>@#ZLHKE/AWXQA\;>$+74P5%VO[F[C'\$H'/X'AA
M[&NKH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA_A;_R
M+NI_]AF]_P#1IKN*X?X6_P#(NZG_ -AF]_\ 1IH [BBBB@#&\5?\BU=_\ _]
M#6O-:]*\5?\ (M7?_ /_ $-:\UKY#/\ _>8_X5^;/H<I_@OU_1!1117AGIA1
M110!['1117Z6?%A1110!Y1J__(:OO^OB3_T(U3JYJ_\ R&K[_KXD_P#0C5.O
MSFM_%EZL^QI? O0****R+"N^\$?\@6;_ *^&_P#05K@:[[P1_P @6;_KX;_T
M%:]C(_\ >UZ,\_,_]W?JCI:***^S/FPKFO&__(%A_P"OA?\ T%JZ6N:\;_\
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M &-XJ_Y%J[_X!_Z&M>:UZ5XJ_P"1:N_^ ?\ H:UYK7R&?_[S'_"OS9]#E/\
M!?K^B"BBBO#/3"BBB@#V.BBBOTL^+"BBB@#RC5_^0U??]?$G_H1JG5S5_P#D
M-7W_ %\2?^A&J=?G-;^++U9]C2^!>@4445D6%=]X(_Y LW_7PW_H*UP-=]X(
M_P"0+-_U\-_Z"M>QD?\ O:]&>?F?^[OU1TM%%%?9GS85S7C?_D"P_P#7PO\
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MY\^'YC\0U\2>?'Y THV'DX.[<90^[TQ@8HY5V"[,/_A3?@7_ *!$W_@?<?\
MQRC_ (4WX%_Z!$W_ ('W'_QRN\HHY5V"[.&'PA\$@8&F7( Z#^T;G_XY2_\
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M3R__ !=1[.%V[;E<\K6N>/WW[/.HZ;I]Q?7?B/3X[>WC:61S$_"@9->.[97
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M\&-S_P#'*W_#WA;2/"T$T.D6\D*3L&D#W$DN2!@<NQQ^%;-% !1110 4444
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MK_H&W/\ X,;G_P".4U/@]X'C!":5<*"<D+J%P.?^_E=U10!P_P#PJ+P5_P!
MVY_\&-S_ /'*/^%1>"O^@;<_^#&Y_P#CE=Q10!PQ^$'@EAAM+N2#V.HW/_QR
MF?\ "F_ O_0(F_\  ^X_^.5WE%)I/<=V<'_PIOP+_P! B;_P/N/_ (Y7+>'O
MAGX3OO&WB[3KG3YGM=/FM5M4^VSC8'A#-R'R<GGG->RUS^C>'YM,\4^)-6DG
MC>/5I('C10<IY<00Y^I&:.5=@NS#_P"%-^!?^@1-_P"!]Q_\<H_X4WX%_P"@
M1-_X'W'_ ,<KO**.5=@NSA_^%1>"O^@;<_\ @QN?_CE'_"HO!7_0-N?_  8W
M/_QRNXHIB.'_ .%1>"O^@;<_^#&Y_P#CE'_"HO!7_0-N?_!C<_\ QRNXHH X
M0_!SP*3DZ1.2>I_M"X_^.4G_  IOP+_T")O_  /N/_CE=Y12Y5V'=GC7B3X9
M^$]/\7>$K&UT^9+;4+F>.Y3[;.=ZK"6 R7R.1VQ74_\ "F_ O_0(F_\  ^X_
M^.5N:YX?FU7Q'X=U..>-(]*GEED1@<N'C* #\3704<J[!=G!_P#"F_ O_0(F
M_P# ^X_^.4]?@_X(0872[A1Z#4;D?^U*[FBBR079P_\ PJ+P5_T#;G_P8W/_
M ,<H_P"%1>"O^@;<_P#@QN?_ (Y7<44Q'#_\*B\%?] VY_\ !C<__'*1O@_X
M(<8;2[AAZ'4;D_\ M2NYHH X/_A3?@7_ *!$W_@?<?\ QRC_ (4WX%_Z!$W_
M ('W'_QRN\HI<J[#NSQKP'\,_">M:7J4VH:?--)#JMU;QG[;.N(TD(4<..@[
M]:ZG_A3?@7_H$3?^!]Q_\<K<\(^'YO#FGWUO-/',UQJ%Q=J4! "R/N Y[BN@
MHY5V"[.$'P<\"@Y&D3@CH?[0N/\ XY3_ /A47@K_ *!MS_X,;G_XY7<44));
M"N</_P *B\%?] VY_P#!C<__ !RC_A47@K_H&W/_ (,;G_XY7<44P.&/P@\$
ML,-I=R0>QU&Y_P#CE,_X4WX%_P"@1-_X'W'_ ,<KO**32>X[LX/_ (4WX%_Z
M!$W_ ('W'_QRN6\!?#/PGK>CW\^H:?--+%J=U;HWVV=<(DA"CAQT'?K7LM<_
MX0\/S>'--N[6>>.9I[^XN@R @ 2.6 Y[C-'*NP79A_\ "F_ O_0(F_\  ^X_
M^.4?\*;\"_\ 0(F_\#[C_P".5WE%'*NP79P__"HO!7_0-N?_  8W/_QRC_A4
M7@K_ *!MS_X,;G_XY7<44Q'#_P#"HO!7_0-N?_!C<_\ QRC_ (5%X*_Z!MS_
M .#&Y_\ CE=Q10!E:!X;TOPQ8R6>DP20P22&5E>=Y26( SER3T XK5HHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKE
MO'VN7NB:!"NF,B:C?WD-C;2.NX1M(V-V.^!DUBJVL>#_ !IH-A<:]>ZOIVL^
M;#(+T)NBF5=P9"JC /(V\T+7\@>GYGH=%<MX^UR]T30(5TQD34;^\AL;:1UW
M"-I&QNQWP,FL56UCP?XTT&PN->O=7T[6?-AD%Z$W13*NX,A51@'D;>:%K^0/
M3\ST.BO+O&OB_6EUV"/0;O[/INGZA;6E]*(U;SY97 ,0)!P%7DD=V KU&A:J
M_P#7]:@]'8**** "BL[7M471/#^H:HZ[Q9V[S;?[VU2<5YM>7/BG0/!]AXXN
M/$=U=3,8)[W3GCC%MY,C*"B +N4J&'.3TH6KMZ?B'3^NAZU13=Q,>Y!N)&0,
MXS7 :!JWBD_$Z?2]=NK802:5]L2RM4RD!\W:!O(W.<#D\#G@4+>P=+GH-%<K
MXET/5+XW5['XLO=*MH8"T45K'&JHP!):1F!+#VXJ3X>ZS?\ B#P)I6J:F!]L
MGB)D8+M#X8@-CMD '\:%K?\ K^M@>ATU%%% !117 3R:MXN\:ZSI5KKEYI.F
MZ.D2$V002332+NR693\H&!@=:.M@Z7._HKDOA]K6H:OHMY!JLJS:AIE]-833
MJH7S2AX? X!((I_B70]4OC=7L?BR]TJVA@+116L<:JC $EI&8$L/;BE)I*_0
M:5W8ZJBN$\.7^M>+/AEI-_<ZP=)NYQNN;N*)-SH&9<KN^5"V <X/L*B\#ZCJ
M!\7:_HW]LS:WI%FD30WLVQF25L[HRZ !L=?:JM:3B3?2YZ!1112&%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 45R'Q+U74-&\%3W6F736MT;B")9E56*AI%4X#
M CH:S;>\U[PWX^T;0[S77UJRU6*9L3P1I+;F-<[LH!E3TY%"U_KRN#T1Z#17
MBS>(/$'_  C_ (A\0#QJUO<V%_<Q6^GRP0-'(J/A4QMW9/3@YK>\4^(K\ZIX
M7L-0U6;PWI^I6IEN;J(*K"?"D0[W!"=3R1STH6J7G;\5<'HW\_PT/2Z*S=#L
MKG3]-6"YU:;5#N+)<S*@<H>@)4 ''KCFM*@ HHHH **XWQEJ>I2:[H/AG2KU
MK"75'E>>[C4,\<,:Y(3<" Q) SCBH/#MWJFC^/+WPIJ&J7&IVS6*W]G<707S
ME&_8R,5 #<\@XH6O]=OZ_ 'H=S17&^,M3U*37=!\,Z5>M82ZH\KSW<:AGCAC
M7)";@0&)(&<<57\.WFIZ-X[OO"NHZI/J=J;%;^TN;H+YJ#?L=&*@!N>0<4+7
M^NW]?@#T.ZHKRZV\7:WJOQ'T62VNO*\-7TMS;V\/EK_I AC),VXC."QP,'HN
M>]>HT=+AUL%%%% !16=KVJ+HGA_4-4==XL[=YMO][:I.*\VO+GQ3H'@^P\<7
M'B.ZNIF,$][ISQQBV\F1E!1 %W*5##G)Z4+5V]/Q#I_70]:HINXF/<@W$C(&
M<9K@- U;Q2?B=/I>NW5L()-*^V)96J92 ^;M WD;G.!R>!SP*%O8.EST&BN.
M\6Z/J\EOJ6JQ>+KW38;:W,MO#;QQK&A5<DR%@2X)'3(P*TO!&K7NN>"=(U34
M4"7=S;*\F%P"?7';(Y_&A:I_U_6P/3^OZ[F_1110 445Y?:MXC\8V&M>(++Q
M)>::MM<SPZ;:6Z1^41$<9EW*2VX@]QBDW;\QI7/4**P_!VN/XD\'Z7K$B*DM
MU 'D5>@?HV/;(-<IX]MM?T+0M4\3P^+[R*:U;S;>T$,2V^W< (V7:68G.-V[
MKVIR]UV8H^\M#T>BN7U2WOM7TO3;B?Q#/H$#0![E+<1J[.5!QYC@[0.> .?6
MJ7PTU;4M5T;4/M]Z=0AM=0EM[._9 IN85QA^.#SD9'7%.VK785]$^YVM%%%(
M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !117%?$*_U2VD\.V6EZE+I[:CJB6T
MLT2(S!"K'C<".H%'8#M:*\_TC5=<TKQIJ7AF_P!6_M>*/3/M\-T\*1RPG=MV
M/L !SU!Q7)6/B3Q):^#=%\2+XN:_U"\GC1]'E@A(FW2;2J[5#@XYS[4+5Z?U
M=M?H#T_KRO\ J>VT5YMXAU6ZN_B/_P (]>^([GP_8_8TELVMS&C7<I)##>ZD
M<<#:.M=_IMO<VFG06]W>O>SQKM>X= C2>Y"\ _2A:JX/1V+5%%% !1110 45
MRGCW6K_2]-T^STJ58-0U6^BL89V4-Y.[)9\'@D '&:RK635_"GCW2=&N=;O-
M6T[6(9MIO0ADAFC 8D,JCY2#T[4+5_UVN#T/0**Y3Q[K5_I>FZ?9Z5*L&H:K
M?16,,[*&\G=DL^#P2 #C-95K)J_A3Q[I.C7.MWFK:=K$,VTWH0R0S1@,2&51
M\I!Z=J%J_P"NUP>AZ!17EWB;Q?K4GBS3UT6[\C1;;5H--NF$:M]JE<Y=02#@
M(!@D=V/I7J-"U5_Z_K4'H[!1110 445SGCK7Y_#/@Z^U.U56NE"QP!QD>8[!
M5)]@3G\*38TKG1T5YM=C7_!6J^'KJZ\1WFK6VI7B6-]#=)'M5Y =KQ;5!4 C
MISQ7H5Z]S'8SO90I-=*A,4;OL5FQP"<' SWIO:XEO8GHKA/ ^I^(;CQ5XHTW
MQ!?P7,EDUL8UMX@D<6]"Q5?XB.@R3DX[53\>VVOZ%H6J>)X?%]Y%-:MYMO:"
M&);?;N $;+M+,3G&[=U[4F[:L:5W9'H]%5M.GENM,M+B>/RII84>2/\ NL0"
M1^!JS5-6=B4[JX4444AA117FUM_PD'C:YU^_L_$=YI4%A>2V>GP6J1[&:,#+
MR[E)8%NV1@4F[?F.QZ317.^!=?F\3>"]-U:Y55N9HRLP48&]6*L1]2,U@^.;
M'7--T;6/$</C"]M7LXS-:VL<42P*!T1P5)<D\9R.O2G+W6[]!1][8] HKDYU
MU'7O#6CWD^NRZ"LUNDMX+=45V9D!VAW!" '/8FJ?PWU74M1M]:@N]0;5+.RO
MV@LM1=5!N(P!GE0 V#QN'6G;5KL*]TGW.XHHHI#"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#COB3IM]?>'[
M.[TZV>ZN=+U""_%O&,M*L;?,JCN<$\>U9+7S^.?&WAVXL-.U"#3M(:6YN9[R
MU> &1DVK&H8 DC))QQ7H]%"T_/Y@]?R///%[ZCXE\+QZA9:)J$5UHVL1W"VD
M\6V2X6)N2@[@@DCUQ4%Q=S>//%^@RZ99:A:66E":XFN[RT:$"5DV(BA\;B"<
MG'''6O2J*$NG]7M;] ?]>AXQKW@/Q9I/A?3].M-<CU&%-3AE*1:2?,WF3<9G
M82$G!.3G\Q7L%G'<164,=W.L]PJ 2RI'L#MCDA<G&?3)J>BG?2P=;A1112 R
M?$^EOK?A75=+B($EW:21(3TW%2!^M>:7NHWWB?P'I_@J/1-4@U=Q;VUZ9[1T
MBMTC9=[F0C:00O&"<YKV&BA:._I^ =/ZZF7'JKC7I=(_LV^6*&V687IC_<.<
MXV!N[=\5Y]%XBD?XK_VU_P (YXE6Q?2EL@[:1,,2>=NYXX7'>O5:*%NG_77_
M ##I9'F7C_5K_4-;3PW)I&NC0 @DO[JPL)9C==Q"C*,!?[QSGM7=>'[VVOM'
MA>TT^[L+>/\ =1V]W;- Z!>!\C<@>E:=%"T5@>KN%%%% !7G'VZ3P3X_\0W5
M_IVH3Z=K AGMY[.U><"1$V-&P4$@G@C/%>CT4=;ATL>>>%'U'PWX<NM5O=$U
M"6ZUK6'N39P1[I;=)6 4N.P"@$^F:J_$#5K_ %#6T\-R:1KHT ()+^ZL+"68
MW7<0HRC 7^\<Y[5Z;11V\O\ +0%U\SCKO6](;PE ;CPOJDND,XMGLI-+8M$B
MCAFA(SLX'(![5A^![4'QY?WOA[3+W3/"S601H9X&@CEN=V=\<;8P O!( KTV
MBG?6XK:6"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#BOBKIMSJW@6:SM+
M6>YD>YM\QP(S-M$JY/R\\#)SVK7T/P9H'AVZDN].L2EU(NQKB:9YI"OIN=B0
M/85O44+0'J>%VFF:7#8^(+/5O 6K7VK3ZC=/;W,>DMDAF/EE9\#:.^<\5U\>
MH+HO@_2="\;Z/?ZDSV2_:)ULC=Q;^1L8KD[P,<XY]:]%HI)6CR^GX#;N[^OX
MG"_"[3KS3M%U%7MKNSTR6^DDTRTN\^;#;G& 0>5&<D UW5%%4V2@HHHI#.%\
M;176F>*O#?BF*RN;NTL#/!>);1F21(Y% #A1R0".<56TB>XUGQQJ?C"/3+^/
M3;32_L=JDT#1RW3;C(Q1&P<< #.,FO0Z*%I^-OG_ ,.P>O\ 78\X\075X=4\
M(^-UT;41;VZ31WMGY!:X@250 Q0<\$<X]:J-I=_X_P#$.M:K9->:/92:4-+M
M;NYM61Y"S[Y&$;%6VX^7/'7CI7J5%%E^?X_\.PN_R_ \CO?"7B^R\5>#X8=9
MMYK>S$Z1S0:.5CM$$8&' D(.X<#)'/K7KE%%.[%8****0S)\3Z6^M^%=5TN(
M@27=I)$A/3<5('ZUYI>ZC?>)_ >G^"H]$U2#5W%O;7IGM'2*W2-EWN9"-I!"
M\8)SFO8:*%H[^GX!T_KJ9=MJKOK=YI1TV^CCM(4D6\>/]S-G^%&[D=Q7GT7B
M*1_BO_;7_".>)5L7TI;(.VD3#$GG;N>.%QWKU6BA;I_UU_S#I9'EWCG5;S5?
M$8\/WFBZ]_PCD&V2[EL=/EF^W-P1&&48$8_B.<DC%>@Z+?0ZCI4,]O975G#C
M8D%U;M Z!>,;#R!QQ[5H44+16!ZNX4444 %>3Z3JUWX*TG6_#=QHNJW%\;JX
MDTXVUH\D=RDI+)\X&%P3SDC%>L44FK_/0:=OS..\*QW/A'0O"_AJ?3KRXED@
M99[F!-T-LX&\[V[9)('KBN6UK6;C6_&;1ZYX>\1'0M*GS:VUOI4LJWDRG_6N
MP&"@_A4=>I]*]:HJFVY<W]?TB4K1L<9XDUG0KBRL5U_PSJ%[87$?GHTNEM.(
M'Z;73!9'P?3UYJG\,;.\MEUN1;2\L="FNPVE6=X&5XX]OS$*W*J3T!KOZ*2T
MN-ZV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N$^).B2:]/X7M?LES/;
M#5D:Y-OO!CCV,"Q9>5'OD5W=%'5!W,'3O"FC^'=/ODT>P$4EPA\R0NTDDIP<
M9=B6/YUXY8Z-;2?#RUTJU\":O%XM6/;'?C3&MC'-NX<SD#@#WKZ!HHZ_=^ [
MGG_B/5-':R&@^+?#VI:BR0)B:+3GGCG<J,F-T!VMG(YVFM7X;V.JZ=X%T^VU
M@3+<KO*1SMNDCC+$HK'U"X^G2NKHIWW\R;:)=@HHHI#"BBB@#B_B-87LMCI&
MJV%I+=RZ1J45Z]O"N7DC&0X4=S@YQ[5GP7<GC3X@Z)J=E87\&EZ-#.[W%W;/
M!YDLBA0BA@"<#))Z5Z)10M/Z\K ]?R/.?%4^HZ_H&DZ_::%J44^CZNMR]C-%
MB>2)"58JO?(.1ZU%++<^//&>F7NEV]_86.E6MR?MUW:-%^_E38H57P6V]3V]
MZ]+HI66S_K2P-_U\[GC6M>!?%NDZ/X=TVSUN*]M[;58'40Z0=T398F:0^8=P
M!))SC.>HKV&W65+:))Y5EF5 ))%3:';') R<9/;-2455] MK<****0!7*?$?
M1KS7? U_::?'YEXACGACS]]HW#[?J<$5U=%)C3/,M0U67Q]J?ANQL=)U.VCL
MK^._OY;RT>%8/+!Q'E@-S%CCC/2NTM]?:5=7:72=2A73I&0;K<DW0 SNB Y<
M'H,5LT4^FG];?Y"Z_P!?UU/,/">M2_\ "Q?$5U+H'B""WU>2V%O+/I<J(-D>
MUBY(PHSW-5-:UFXUOQFT>N>'O$1T+2I\VMM;Z5+*MY,I_P!:[ 8*#^%1UZGT
MKUJBA:6\@[^9!972WME#=+%-"LJ!Q'/&8W7/9E/(/M4]%% !1110 5Y;I.KW
M'@2;Q%I%YHVJ7,D^H37FG-:6CRI<++@A=RC"D'@YQ7J5%)J_Y?U]P[G#^#XK
MWP=X6\-:'=:9>7%S=%_M$ENF^.U9B7/F'L,MC/J*P/$VKW&M^+VT_6- \0'P
M[ILH98K73)91?S#HS,!CRU/0=SR:]7HJF[RO_7](2VM_7],X[Q!K>B7&E6!U
MOPSJ-YIMT#)METMIOL[#@"2/!9"<G!Q6=\-+.Y@U#7Y[6RO=/\-S31G3+2[5
MD9<+^\94;E$)Q@5Z%126C;!ZJP4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%5[Z]M]-T^YO[N3R[:VB::9]
MI.U%!+' Y. #TKB/^%V?#S_H8?\ R3N/_C= '?T5P'_"[/AY_P!##_Y)W'_Q
MNC_A=GP\_P"AA_\ ).X_^-T =_17 ?\ "[/AY_T,/_DG<?\ QNC_ (79\//^
MAA_\D[C_ .-T =_17 ?\+L^'G_0P_P#DG<?_ !NC_A=GP\_Z&'_R3N/_ (W0
M!W]%<!_PNSX>?]##_P"2=Q_\;H_X79\//^AA_P#).X_^-T =_17 ?\+L^'G_
M $,/_DG<?_&Z/^%V?#S_ *&'_P D[C_XW0!W]%<!_P +L^'G_0P_^2=Q_P#&
MZ/\ A=GP\_Z&'_R3N/\ XW0!W]%<!_PNSX>?]##_ .2=Q_\ &Z/^%V?#S_H8
M?_).X_\ C= '?T5P'_"[/AY_T,/_ ))W'_QNC_A=GP\_Z&'_ ,D[C_XW0!W]
M%<!_PNSX>?\ 0P_^2=Q_\;H_X79\//\ H8?_ "3N/_C= '?T5P'_  NSX>?]
M##_Y)W'_ ,;H_P"%V?#S_H8?_).X_P#C= '?T5P'_"[/AY_T,/\ Y)W'_P ;
MH_X79\//^AA_\D[C_P"-T =_17 ?\+L^'G_0P_\ DG<?_&ZZ;PWXJT7Q=827
MVAWOVNVBE,+OY3IAP <88 ]&% &S1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !16?KFL6^@:%>ZO=)*]O9Q--(L0!8@>F2!G\:\N_X:/\ "/\ T#-;_P"_
M,7_QR@#V&BO'O^&C_"/_ $#-;_[\Q?\ QRC_ (:/\(_] S6_^_,7_P <H ]A
MHKQ[_AH_PC_T#-;_ ._,7_QRC_AH_P (_P#0,UO_ +\Q?_'* /8:*\>_X:/\
M(_\ 0,UO_OS%_P#'*/\ AH_PC_T#-;_[\Q?_ !R@#V&BO'O^&C_"/_0,UO\
M[\Q?_'*/^&C_  C_ - S6_\ OS%_\<H ]AHKQ[_AH_PC_P! S6_^_,7_ ,<H
M_P"&C_"/_0,UO_OS%_\ '* /8:*\>_X:/\(_] S6_P#OS%_\<H_X:/\ "/\
MT#-;_P"_,7_QR@#V&BO'O^&C_"/_ $#-;_[\Q?\ QRC_ (:/\(_] S6_^_,7
M_P <H ]AHKQ[_AH_PC_T#-;_ ._,7_QRC_AH_P (_P#0,UO_ +\Q?_'* /8:
M*\>_X:/\(_\ 0,UO_OS%_P#'*/\ AH_PC_T#-;_[\Q?_ !R@#V&BO'O^&C_"
M/_0,UO\ [\Q?_'*/^&C_  C_ - S6_\ OS%_\<H ]AHKQ[_AH_PC_P! S6_^
M_,7_ ,<H_P"&C_"/_0,UO_OS%_\ '* /8:*\>_X:/\(_] S6_P#OS%_\<KT#
MP9XQT_QQH;:MIL-S# LS0E;E55L@ G[K$8Y'>@#H:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **YCQOXYTWP%I5OJ&J07<T4\_D*M
MJBLP;:6YW,.,*:X7_AH_PC_T#-;_ ._,7_QR@#V&BO'O^&C_  C_ - S6_\
MOS%_\<H_X:/\(_\ 0,UO_OS%_P#'* /8:*\>_P"&C_"/_0,UO_OS%_\ '*/^
M&C_"/_0,UO\ [\Q?_'* /8:*\>_X:/\ "/\ T#-;_P"_,7_QRC_AH_PC_P!
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M_P#OS%_\<H ]AHKQ[_AH_P (_P#0,UO_ +\Q?_'*/^&C_"/_ $#-;_[\Q?\
MQR@#V&BO'O\ AH_PC_T#-;_[\Q?_ !RO5M+U"+5M)LM2@5UANX$GC5P P5U#
M '&><&@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% $-W:P7UG/9W42RV\\;12QMT=6&"#]0:Y
M3_A57@7_ *%FR_)O\:[&B@#CO^%5>!?^A9LOR;_&C_A57@7_ *%FR_)O\:[&
MB@#CO^%5>!?^A9LOR;_&C_A57@7_ *%FR_)O\:[&B@#CO^%5>!?^A9LOR;_&
MC_A57@7_ *%FR_)O\:[&B@#CO^%5>!?^A9LOR;_&C_A57@7_ *%FR_)O\:[&
MB@#CO^%5>!?^A9LOR;_&C_A57@7_ *%FR_)O\:[&B@#CO^%5>!?^A9LOR;_&
MC_A57@7_ *%FR_)O\:[&B@#CO^%5>!?^A9LOR;_&C_A57@7_ *%FR_)O\:[&
MB@#CO^%5>!?^A9LOR;_&C_A57@7_ *%FR_)O\:[&B@#CO^%5>!?^A9LOR;_&
MC_A57@7_ *%FR_)O\:[&B@#CO^%5>!?^A9LOR;_&C_A57@7_ *%FR_)O\:[&
MB@#CO^%5>!?^A9LOR;_&C_A57@7_ *%FR_)O\:[&B@#CO^%5>!?^A9LOR;_&
MM[1/#VD^&[22TT:PBL[>23S&2+."V ,_D!^5:=% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% #)(HYHFCE19(V&&5AD$>XJG_ &'I'_0*L?\ P'3_  J_
M10!0_L/2/^@58_\ @.G^%']AZ1_T"K'_ ,!T_P *OT4 4/[#TC_H%6/_ (#I
M_A1_8>D?] JQ_P# =/\ "K]% %#^P](_Z!5C_P" Z?X4?V'I'_0*L?\ P'3_
M  J_10!0_L/2/^@58_\ @.G^%']AZ1_T"K'_ ,!T_P *OT4 4/[#TC_H%6/_
M (#I_A1_8>D?] JQ_P# =/\ "K]% %#^P](_Z!5C_P" Z?X4?V'I'_0*L?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH AN;2VO$"75O%.@.0LJ!@#Z\U6_L/2/\ H%6/_@.G^%7Z
M* *']AZ1_P! JQ_\!T_PH_L/2/\ H%6/_@.G^%7Z* *']AZ1_P! JQ_\!T_P
MH_L/2/\ H%6/_@.G^%7Z* *']AZ1_P! JQ_\!T_PH_L/2/\ H%6/_@.G^%7Z
M* *']AZ1_P! JQ_\!T_PH_L/2/\ H%6/_@.G^%7Z* *']AZ1_P! JQ_\!T_P
MH_L/2/\ H%6/_@.G^%7Z* *']AZ1_P! JQ_\!T_PH_L/2/\ H%6/_@.G^%7Z
M* *']AZ1_P! JQ_\!T_PH_L/2/\ H%6/_@.G^%7Z* *']AZ1_P! JQ_\!T_P
MH_L/2/\ H%6/_@.G^%7Z* *']AZ1_P! JQ_\!T_PH_L/2/\ H%6/_@.G^%7Z
M* *']AZ1_P! JQ_\!T_PH_L/2/\ H%6/_@.G^%7Z* *']AZ1_P! JQ_\!T_P
MH_L/2/\ H%6/_@.G^%7Z* *']AZ1_P! JQ_\!T_PJZB+&BHBA44 *JC  '84
MZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **\PE^,/VK4;V'P]X4U;6[.Q?9<7=L/
ME!']T8.>GM4VO?%Z+0_(D_X1?6KBVFM([OSUAPJ*PSACT!'>E?2X[:V/2:*\
MS\+_ !AB\4ZM96=MX8UB."Z<H+MD!B7&>2PXQQBO3*JUE<FX45YY+\8_#C>,
M[/PU8":^FN)Q;M<PX\I')QC)^]COCBNI\3^*]'\(:4=0UBZ$,1.V-%&YY6_N
MJ.Y_R:F_N\W0=M>7J;5%<MX$\<6?CW1I]2LK2>VCAN# 4F(R2%!SQ_O5R>L?
M&ZSLM3O[?2O#VI:O::<VV\O;<8CBP<$YP>.#R<=*;T=F"U5T>JT5QES\2](C
M\%6?B:SM;V_BO9!#!;6\6Z9I3GY",\$;3GK[9K'\-?&*UUCQ4GAS5=!O]%U"
M7B)+KN<9 ((!4D=.*=G?EZBOI<]+HIDTT=O!)-*P6.-2[,>P R37$?#'Q9JO
MC33M3U>]C@CL3>-%8HB$-Y:]V.>>H_(TEJ[#>BN=U1110 4444 %%>=>+/%^
MKQ?$KPYX2T*6-'N#Y]^S1A\0CG'/3A6_,5Z+0M5<'H[!1110 445PWQ/\5ZM
MX,T>PUG3XX);1+Q([Z.1"6,;=U.>#QC\11<+7.YHJ.WGCNK:*XA8-%*@=&'<
M$9!J2AJP)WU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFR.L4;2.<*
MH+$^@%#=M0'45Y%IOQ-\9^*C>ZAX3\*6EUH]K,8LW%SMFEP,\<@ X(.,'KWJ
M[XL^(/C/P\LEY!X+$FEQ6T<\EQ+<8,9*@LI _NDD=.U%[*[';6R/4**\Q\#^
M/_&'BR]L)KCPC';:+=!B;]+C(4 '!P>?O#%>FNZQHSL<*HR3Z"FU;<E.^PM%
M>46?QH35O'NEZ'IVC2_V;?.4COKG*&4#/S(N/NY&.3^5==XV\;VO@RPA=[.Y
MOKZZ++:VENA+2%1DDGL!D9/Z4F[1YBK>]RG4T5QWPX\:R^./"LFLW-I'9E+A
MXBB.6&% .<GZUP]S\8O%&H)J>K>&O"L5WX=TV0K-=32X=@.I R.W/ ; ZT/1
MV8EJKH]IHK@W\?W^I^"-+USPMX>FU2ZU!_+%MY@58&&=Q=NF 1C/&<CI6)X7
M^*>N3^/5\(>+-!ATZ_E!\MH)-P!V[@#R000.H-.SYN7J*ZMS'J]%5-4U"'2=
M)O-1G.(;6%YG^B@G^E<1\*=<U;5_!EQXA\1:B&6[NI'A$FU$@B!V@ \<9SU]
MJ2U;\AO2WF>A451;6])6]BLFU.R%W, T<!N%WN#T(7.3^%*FL:9+J+:='J-F
M]\G+6RSJ9%^JYS0!=HJE?ZSI>E&,:CJ5G9F3[@N)UCW?3<1FI+34+*_#&SO+
M>Y"<,890^WZX- %FBO+M9U[5=8^-VD^&]*OYX+'38?M6HB)L"3N%;U'W!_P(
MUZ#=Z]H]A=K:7FK6%O<OC;#-<HCG/3"DYH6J3[@]'8T**@>\M8KB.WDN84FE
MYCC9P&?Z#J:62[MHKB.WDN(DFE_U<;. S_0=30!-16=<:_HUI>K97.K6$-VV
M L$ERBR'/3Y2<UQ?Q:U_6?"EAH^O:9=NEI;WJI>VX4%9HV]<C(Z$<?WJ+[!8
M]%HJ.">.YMXIXFW1RH'1AW!&14E#5@3OJ%%%% !1110 4444 %%%% !1110
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MU"U:7<'HF^QZ31110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]\,6&F6_C2:VOH"?M-^+)6-R#G@IN&WKV/:LVG[+EZW?X_Y%_P#+R_33\/\
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M&FE^"M2GOK'4M6NI)HO*9+R=74#(.0 HYXH3NW)[L35DHK9''_'PDKX2C?\
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>stok-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T14:37:56.1216466+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 8d9d5b43144d4c21a62f9c029c9e37fb -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:stok="http://www.stoketherapeutics.com/20211231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.stoketherapeutics.com/20211231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.stoketherapeutics.com/20211231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="stok-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="stok-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="stok-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="stok-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated balance sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated balance sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated statements of operations and comprehensive loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100040 - Statement - Consolidated statements of stockholders&apos; equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100050 - Statement - Consolidated statements of cash flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>100060 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements">
        <link:definition>100070 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100080 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecurities" id="Role_DisclosureMarketableSecurities">
        <link:definition>100090 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100100 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities" id="Role_DisclosureAccruedAndOtherCurrentLiabilities">
        <link:definition>100110 - Disclosure - Accrued and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100120 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>100130 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>100140 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100150 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefits" id="Role_DisclosureEmployeeBenefits">
        <link:definition>100160 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100170 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies">
        <link:definition>100180 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables">
        <link:definition>100190 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100200 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables" id="Role_DisclosureMarketableSecuritiesTables">
        <link:definition>100210 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100220 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables">
        <link:definition>100230 - Disclosure - Accrued and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100240 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables" id="Role_DisclosureShareBasedCompensationTables">
        <link:definition>100250 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>100260 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100270 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100280 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100290 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails">
        <link:definition>100300 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Estimated Useful Lives for Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails">
        <link:definition>100310 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails">
        <link:definition>100320 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" id="Role_DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
        <link:definition>100340 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" id="Role_DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>100360 - Disclosure - Property and Equipment, Net - Summary of Property, and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
        <link:definition>100380 - Disclosure - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails">
        <link:definition>100400 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails2" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails2">
        <link:definition>100410 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails">
        <link:definition>100420 - Disclosure - Commitments and Contingencies - Summary of Lease Balances (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesDetails">
        <link:definition>100430 - Disclosure - Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate of Operating Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" id="Role_DisclosureShareBasedCompensationAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails" id="Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails">
        <link:definition>100450 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity for Awards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100460 - Disclosure - Share-Based Compensation - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails" id="Role_DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails">
        <link:definition>100470 - Disclosure - Share-Based Compensation - Summary of Fair Values of Options Granted to Employees and Directors (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100480 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>100490 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" id="Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
        <link:definition>100510 - Disclosure - Income Taxes - Reconciliation of Expected Income Tax Expense (Benefit) using Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100520 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails" id="Role_DisclosureEmployeeBenefitsAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Employee Benefits - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="stok_AccruedAndOtherCurrentLiabilities" name="AccruedAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="stok_FollowOnOfferingMember" name="FollowOnOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_AmortizationAndAccretionOfMarketableSecurities" name="AmortizationAndAccretionOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets" name="ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="stok_DeferredOfferingCostsNotYetPaid" name="DeferredOfferingCostsNotYetPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="stok_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock" name="ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_SummaryOfLeaseBalancesTableTextBlock" name="SummaryOfLeaseBalancesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock" name="SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_NatureOfBusinessAndBasisOfPresentationLineItems" name="NatureOfBusinessAndBasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_NatureOfBusinessAndBasisOfPresentationTable" name="NatureOfBusinessAndBasisOfPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_BaseProspectusMember" name="BaseProspectusMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_SalesAgreementProspectusMember" name="SalesAgreementProspectusMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_MaximumAggregateOfferingPrice" name="MaximumAggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="stok_SecuritiesIssuedInConnectionWithShelfRegistration" name="SecuritiesIssuedInConnectionWithShelfRegistration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" name="ProceedsFromIssuanceUnderwrittenPublicOfferingNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="stok_ComputerAndOfficeEquipmentMember" name="ComputerAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_LaboratoryEquipmentAndFurnitureAndFixturesMember" name="LaboratoryEquipmentAndFurnitureAndFixturesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_AccountingPoliciesTable" name="AccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_DebtSecuritiesAvailableForSaleMaturityPeriod" name="DebtSecuritiesAvailableForSaleMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_AccruedResearchAndDevelopmentCostsCurrent" name="AccruedResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="stok_AreaOfSpaceSubjectToOperatingLease" name="AreaOfSpaceSubjectToOperatingLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_OperatingLeaseCostPerYear" name="OperatingLeaseCostPerYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="stok_AnnualBaseRentIncreasePercentageForOperatingLease" name="AnnualBaseRentIncreasePercentageForOperatingLease" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_OperatingLeaseCommencementDate" name="OperatingLeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_LeaseCommencementTwoThousandAndTwentyOneMember" name="LeaseCommencementTwoThousandAndTwentyOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_LeaseCommencementTwoThousandAndTwentyTwoMember" name="LeaseCommencementTwoThousandAndTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_LeaseExtensionEndDateMember" name="LeaseExtensionEndDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_ColdSpringHarborLaboratoryAgreementMember" name="ColdSpringHarborLaboratoryAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_SouthamptonAgreementMember" name="SouthamptonAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_OperatingLeaseCommencementMonthAndYear" name="OperatingLeaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms" name="NumberOfRenewalOptionToExtendOperatingLeaseTerms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease" name="AreaOfAdditionalRentableSpaceSubjectToOperatingLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_AdditionalOperatingLeaseCommencementDate" name="AdditionalOperatingLeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_AdditionalLeaseExpirationDate" name="AdditionalLeaseExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_AdditionalOperatingLeaseRightOfUseAsset" name="AdditionalOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="stok_AdditionalOperatingLeaseLiabilities" name="AdditionalOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted" name="OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="stok_ConsultingServicesExpenses" name="ConsultingServicesExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="stok_ConsultingServicesAgreementTerm" name="ConsultingServicesAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_ScientificAdvisoryServicesExpenses" name="ScientificAdvisoryServicesExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="stok_ScientificAdvisoryServicesAgreementTerm" name="ScientificAdvisoryServicesAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_AnnualLicenseMaintenanceFee" name="AnnualLicenseMaintenanceFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="stok_MaximumAggregatePotentialMilestonePaymentsPayable" name="MaximumAggregatePotentialMilestonePaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="stok_ExpensesRelatedToReimbursablePatentCosts" name="ExpensesRelatedToReimbursablePatentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue" name="PercentageOfMaximumRequiredPaymentOfSublicenseRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_PercentageOfIncreaseInReservedCommonShares" name="PercentageOfIncreaseInReservedCommonShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_TwoThousandAndNineteenEquityIncentivePlanMember" name="TwoThousandAndNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_TwoThousandAndFourteenEquityIncentivePlanMember" name="TwoThousandAndFourteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember" name="TwoThousandAndNineteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="stok_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="stok_OperatingLossCarryforwardsExpirationBeginningYear" name="OperatingLossCarryforwardsExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_TaxCreditCarryforwardsExpirationBeginningYear" name="TaxCreditCarryforwardsExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct" name="PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct" name="PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_FederalNOLCarryForwardsPeriodUnderCARESAct" name="FederalNOLCarryForwardsPeriodUnderCARESAct" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="stok_UpfrontPaymentReceived" name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="stok_MilestonePaymentsReceivable" name="MilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="stok_AcadiaPharmaceuticalsIncMember" name="AcadiaPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>24
<FILENAME>stok-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T14:37:56.1216466+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 8d9d5b43144d4c21a62f9c029c9e37fb -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="stok-20211231.xsd#TemplateLink" roleURI="http://www.stoketherapeutics.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="stok-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AccruedAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="stok_AccruedAndOtherCurrentLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="stok_AccruedAndOtherCurrentLiabilities" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="stok-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="stok-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AmortizationAndAccretionOfMarketableSecurities" xlink:type="locator" xlink:label="stok_AmortizationAndAccretionOfMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="stok_AmortizationAndAccretionOfMarketableSecurities" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10200.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="stok-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:href="stok-20211231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="stok-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:href="stok-20211231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="locator" xlink:label="stok_AccruedResearchAndDevelopmentCostsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AccruedAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="stok_AccruedAndOtherCurrentLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="stok_AccruedAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="stok_AccruedAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="stok_AccruedAndOtherCurrentLiabilities" xlink:to="stok_AccruedResearchAndDevelopmentCostsCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="stok_AccruedAndOtherCurrentLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="stok_AccruedAndOtherCurrentLiabilities" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" xlink:href="stok-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails2" xlink:href="stok-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails2">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails" xlink:href="stok-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted" xlink:type="locator" xlink:label="stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="stok-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="stok-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>25
<FILENAME>stok-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T14:37:56.1216466+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 8d9d5b43144d4c21a62f9c029c9e37fb -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="stok-20211231.xsd#TemplateLink" roleURI="http://www.stoketherapeutics.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="stok-20211231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="stok-20211231.xsd#stok_FollowOnOfferingMember" xlink:type="locator" xlink:label="stok_FollowOnOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="stok_FollowOnOfferingMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="stok-20211231.xsd#stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" xlink:type="locator" xlink:label="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="stok-20211231.xsd#stok_SecuritiesIssuedInConnectionWithShelfRegistration" xlink:type="locator" xlink:label="stok_SecuritiesIssuedInConnectionWithShelfRegistration" />
    <link:loc xlink:href="stok-20211231.xsd#stok_MaximumAggregateOfferingPrice" xlink:type="locator" xlink:label="stok_MaximumAggregateOfferingPrice" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="stok_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_SalesAgreementProspectusMember" xlink:type="locator" xlink:label="stok_SalesAgreementProspectusMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_BaseProspectusMember" xlink:type="locator" xlink:label="stok_BaseProspectusMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="stok-20211231.xsd#stok_NatureOfBusinessAndBasisOfPresentationTable" xlink:type="locator" xlink:label="stok_NatureOfBusinessAndBasisOfPresentationTable" />
    <link:loc xlink:href="stok-20211231.xsd#stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:type="locator" xlink:label="stok_NatureOfBusinessAndBasisOfPresentationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="stok_NatureOfBusinessAndBasisOfPresentationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="stok_BaseProspectusMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="stok_SalesAgreementProspectusMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="stok_UnderwrittenPublicOfferingMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="stok_MaximumAggregateOfferingPrice" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="stok_SecuritiesIssuedInConnectionWithShelfRegistration" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" order="10680.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" xlink:href="stok-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_LaboratoryEquipmentAndFurnitureAndFixturesMember" xlink:type="locator" xlink:label="stok_LaboratoryEquipmentAndFurnitureAndFixturesMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ComputerAndOfficeEquipmentMember" xlink:type="locator" xlink:label="stok_ComputerAndOfficeEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="stok_ComputerAndOfficeEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="stok_LaboratoryEquipmentAndFurnitureAndFixturesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201711Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AccountingPoliciesTable" xlink:type="locator" xlink:label="stok_AccountingPoliciesTable" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AccountingPoliciesLineItems" xlink:type="locator" xlink:label="stok_AccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="stok_AccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="stok_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="stok_AccountingPoliciesTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201711Member" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRentCredit" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquity" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10940.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails" xlink:href="stok-20211231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10860.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:href="stok-20211231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10610.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:loc xlink:href="stok-20211231.xsd#stok_DebtSecuritiesAvailableForSaleMaturityPeriod" xlink:type="locator" xlink:label="stok_DebtSecuritiesAvailableForSaleMaturityPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="stok_DebtSecuritiesAvailableForSaleMaturityPeriod" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="10260.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="stok-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ExpensesRelatedToReimbursablePatentCosts" xlink:type="locator" xlink:label="stok_ExpensesRelatedToReimbursablePatentCosts" />
    <link:loc xlink:href="stok-20211231.xsd#stok_MaximumAggregatePotentialMilestonePaymentsPayable" xlink:type="locator" xlink:label="stok_MaximumAggregatePotentialMilestonePaymentsPayable" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AnnualLicenseMaintenanceFee" xlink:type="locator" xlink:label="stok_AnnualLicenseMaintenanceFee" />
    <link:loc xlink:href="stok-20211231.xsd#stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue" xlink:type="locator" xlink:label="stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ScientificAdvisoryServicesAgreementTerm" xlink:type="locator" xlink:label="stok_ScientificAdvisoryServicesAgreementTerm" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ScientificAdvisoryServicesExpenses" xlink:type="locator" xlink:label="stok_ScientificAdvisoryServicesExpenses" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ConsultingServicesAgreementTerm" xlink:type="locator" xlink:label="stok_ConsultingServicesAgreementTerm" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ConsultingServicesExpenses" xlink:type="locator" xlink:label="stok_ConsultingServicesExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AdditionalOperatingLeaseLiabilities" xlink:type="locator" xlink:label="stok_AdditionalOperatingLeaseLiabilities" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AdditionalOperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="stok_AdditionalOperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AdditionalLeaseExpirationDate" xlink:type="locator" xlink:label="stok_AdditionalLeaseExpirationDate" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AdditionalOperatingLeaseCommencementDate" xlink:type="locator" xlink:label="stok_AdditionalOperatingLeaseCommencementDate" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease" xlink:type="locator" xlink:label="stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="stok-20211231.xsd#stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms" xlink:type="locator" xlink:label="stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms" />
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="stok_OperatingLeaseCommencementMonthAndYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLeaseCommencementDate" xlink:type="locator" xlink:label="stok_OperatingLeaseCommencementDate" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AnnualBaseRentIncreasePercentageForOperatingLease" xlink:type="locator" xlink:label="stok_AnnualBaseRentIncreasePercentageForOperatingLease" />
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLeaseCostPerYear" xlink:type="locator" xlink:label="stok_OperatingLeaseCostPerYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AreaOfSpaceSubjectToOperatingLease" xlink:type="locator" xlink:label="stok_AreaOfSpaceSubjectToOperatingLease" />
    <link:loc xlink:href="stok-20211231.xsd#stok_SouthamptonAgreementMember" xlink:type="locator" xlink:label="stok_SouthamptonAgreementMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ColdSpringHarborLaboratoryAgreementMember" xlink:type="locator" xlink:label="stok_ColdSpringHarborLaboratoryAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="stok-20211231.xsd#stok_LeaseExtensionEndDateMember" xlink:type="locator" xlink:label="stok_LeaseExtensionEndDateMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_LeaseCommencementTwoThousandAndTwentyTwoMember" xlink:type="locator" xlink:label="stok_LeaseCommencementTwoThousandAndTwentyTwoMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_LeaseCommencementTwoThousandAndTwentyOneMember" xlink:type="locator" xlink:label="stok_LeaseCommencementTwoThousandAndTwentyOneMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="stok-20211231.xsd#stok_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="stok_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="stok-20211231.xsd#stok_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="stok_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="stok_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="stok_LeaseCommencementTwoThousandAndTwentyOneMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="stok_LeaseCommencementTwoThousandAndTwentyTwoMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="stok_LeaseExtensionEndDateMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="stok_CommitmentsAndContingenciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="stok_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_DirectorMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="stok_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="stok_ColdSpringHarborLaboratoryAgreementMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="stok_SouthamptonAgreementMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AreaOfSpaceSubjectToOperatingLease" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_OperatingLeaseCostPerYear" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AnnualBaseRentIncreasePercentageForOperatingLease" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_OperatingLeaseCommencementDate" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_OperatingLeaseCommencementMonthAndYear" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AdditionalOperatingLeaseCommencementDate" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AdditionalLeaseExpirationDate" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AdditionalOperatingLeaseRightOfUseAsset" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AdditionalOperatingLeaseLiabilities" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_ConsultingServicesExpenses" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_ConsultingServicesAgreementTerm" order="11810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_ScientificAdvisoryServicesExpenses" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_ScientificAdvisoryServicesAgreementTerm" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AnnualLicenseMaintenanceFee" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_MaximumAggregatePotentialMilestonePaymentsPayable" order="12050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_ExpensesRelatedToReimbursablePatentCosts" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_Liabilities" order="12240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="10230.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:type="locator" xlink:label="stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="stok-20211231.xsd#stok_PercentageOfIncreaseInReservedCommonShares" xlink:type="locator" xlink:label="stok_PercentageOfIncreaseInReservedCommonShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="stok-20211231.xsd#stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="stok-20211231.xsd#stok_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="stok_TwoThousandAndFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="stok_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="stok_TwoThousandAndNineteenEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="stok_TwoThousandAndFourteenEquityIncentivePlanMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="stok_PercentageOfIncreaseInReservedCommonShares" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="11160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="stok-20211231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails" xlink:href="stok-20211231.xsd#Role_DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="stok-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="stok-20211231.xsd#stok_FederalNOLCarryForwardsPeriodUnderCARESAct" xlink:type="locator" xlink:label="stok_FederalNOLCarryForwardsPeriodUnderCARESAct" />
    <link:loc xlink:href="stok-20211231.xsd#stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct" xlink:type="locator" xlink:label="stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct" />
    <link:loc xlink:href="stok-20211231.xsd#stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct" xlink:type="locator" xlink:label="stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="stok-20211231.xsd#stok_TaxCreditCarryforwardsExpirationBeginningYear" xlink:type="locator" xlink:label="stok_TaxCreditCarryforwardsExpirationBeginningYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLossCarryforwardsExpirationBeginningYear" xlink:type="locator" xlink:label="stok_OperatingLossCarryforwardsExpirationBeginningYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="stok-20211231.xsd#stok_IncomeTaxesTable" xlink:type="locator" xlink:label="stok_IncomeTaxesTable" />
    <link:loc xlink:href="stok-20211231.xsd#stok_IncomeTaxesLineItems" xlink:type="locator" xlink:label="stok_IncomeTaxesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="stok_IncomeTaxesLineItems" xlink:to="stok_IncomeTaxesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="stok_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="stok_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_IncomeTaxesLineItems" xlink:to="stok_OperatingLossCarryforwardsExpirationBeginningYear" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_IncomeTaxesLineItems" xlink:to="stok_TaxCreditCarryforwardsExpirationBeginningYear" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_IncomeTaxesLineItems" xlink:to="stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_IncomeTaxesLineItems" xlink:to="stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="stok_IncomeTaxesLineItems" xlink:to="stok_FederalNOLCarryForwardsPeriodUnderCARESAct" order="10920.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="stok-20211231.xsd#stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" xlink:type="locator" xlink:label="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="stok-20211231.xsd#stok_MilestonePaymentsReceivable" xlink:type="locator" xlink:label="stok_MilestonePaymentsReceivable" />
    <link:loc xlink:href="stok-20211231.xsd#stok_UpfrontPaymentReceived" xlink:type="locator" xlink:label="stok_UpfrontPaymentReceived" />
    <link:loc xlink:href="stok-20211231.xsd#stok_SalesAgreementProspectusMember" xlink:type="locator" xlink:label="stok_SalesAgreementProspectusMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AcadiaPharmaceuticalsIncMember" xlink:type="locator" xlink:label="stok_AcadiaPharmaceuticalsIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="stok_AcadiaPharmaceuticalsIncMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="stok_SalesAgreementProspectusMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="stok_UpfrontPaymentReceived" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="stok_MilestonePaymentsReceivable" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" order="10390.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>stok-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T14:37:56.1216466+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 8d9d5b43144d4c21a62f9c029c9e37fb -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well Known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address City Or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address State Or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm Id</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_AccruedAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="stok_AccruedAndOtherCurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="stok_AccruedAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_AccruedAndOtherCurrentLiabilities" xlink:to="stok_AccruedAndOtherCurrentLiabilities_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Finance Costs Current Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AccruedAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AccruedAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued And Other Current Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 36,902,499 and 36,577,149 shares issued and outstanding as of December 31, 2021 and 2020, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Nonoperating Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share&#8212;basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding&#8212;basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_FollowOnOfferingMember" xlink:type="locator" xlink:label="stok_FollowOnOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="stok_FollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on Offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_FollowOnOfferingMember" xlink:to="stok_FollowOnOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_FollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_FollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Offering [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock related to employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock related to employee stock purchase plan, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_AmortizationAndAccretionOfMarketableSecurities" xlink:type="locator" xlink:label="stok_AmortizationAndAccretionOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="stok_AmortizationAndAccretionOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization and accretion of marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_AmortizationAndAccretionOfMarketableSecurities" xlink:to="stok_AmortizationAndAccretionOfMarketableSecurities_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction in carrying amount of operating lease right of use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets" xlink:to="stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_DeferredOfferingCostsNotYetPaid" xlink:type="locator" xlink:label="stok_DeferredOfferingCostsNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="stok_DeferredOfferingCostsNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs not yet paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_DeferredOfferingCostsNotYetPaid" xlink:to="stok_DeferredOfferingCostsNotYetPaid_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AmortizationAndAccretionOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization and accretion of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AmortizationAndAccretionOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization And Accretion Of Marketable Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Property Plant Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in the carrying amount of right of use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reduction In Carrying Amount Of Operating Lease Right Of Use Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon public offerings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Employee Stock Purchase Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Plans</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Financing Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Payments For Other Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash&#8212;beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash&#8212;end of year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of Non-Cash Investing and Financing Activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets recognized in exchange for operating leases under Topic 842</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment included in accrued expense and accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_DeferredOfferingCostsNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs not yet paid</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_DeferredOfferingCostsNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Not Yet Paid</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the business and basis of presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of significant accounting policies and recent accounting pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_DeferredOfferingCostsPolicyTextBlock" xlink:type="locator" xlink:label="stok_DeferredOfferingCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="stok_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_DeferredOfferingCostsPolicyTextBlock" xlink:to="stok_DeferredOfferingCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="stok_PatentCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="stok_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_PatentCostsPolicyTextBlock" xlink:to="stok_PatentCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and Geographic Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" xlink:type="locator" xlink:label="stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company and smaller reporting company status.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" xlink:to="stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company and Smaller Reporting Company Status</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company And Smaller Reporting Company Status Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock" xlink:type="locator" xlink:label="stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of cash, cash equivalents and restricted cash and equivalents.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock" xlink:to="stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Cash Equivalents And Restricted Cash And Equivalents Table [Text Block]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of estimated useful lives of property and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Lives for Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Estimated Useful Lives Of Property And Equipment Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property, and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued And Other Current Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_SummaryOfLeaseBalancesTableTextBlock" xlink:type="locator" xlink:label="stok_SummaryOfLeaseBalancesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="stok_SummaryOfLeaseBalancesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of lease balances.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_SummaryOfLeaseBalancesTableTextBlock" xlink:to="stok_SummaryOfLeaseBalancesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_SummaryOfLeaseBalancesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Balances</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_SummaryOfLeaseBalancesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Lease Balances Table [Text Block]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of weighted average remaining lease term and weighted average discount rate of operating leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock" xlink:to="stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate of Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Weighted Average Remaining Lease Term And Weighted Average Discount Rate Of Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity for Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Values of Options Granted to Employees and Directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Expected Income Tax Expense (Benefit) using Federal Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:type="locator" xlink:label="stok_NatureOfBusinessAndBasisOfPresentationLineItems" />
    <link:label xml:lang="en-US" xlink:label="stok_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of the business and basis of presentation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="stok_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_NatureOfBusinessAndBasisOfPresentationTable" xlink:type="locator" xlink:label="stok_NatureOfBusinessAndBasisOfPresentationTable" />
    <link:label xml:lang="en-US" xlink:label="stok_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of the business and basis of presentation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="stok_NatureOfBusinessAndBasisOfPresentationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business And Basis Of Presentation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business And Basis Of Presentation [Table]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_BaseProspectusMember" xlink:type="locator" xlink:label="stok_BaseProspectusMember" />
    <link:label xml:lang="en-US" xlink:label="stok_BaseProspectusMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Base prospectus.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_BaseProspectusMember" xlink:to="stok_BaseProspectusMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_BaseProspectusMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base Prospectus</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_BaseProspectusMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Base Prospectus [Member]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_SalesAgreementProspectusMember" xlink:type="locator" xlink:label="stok_SalesAgreementProspectusMember" />
    <link:label xml:lang="en-US" xlink:label="stok_SalesAgreementProspectusMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement prospectus.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_SalesAgreementProspectusMember" xlink:to="stok_SalesAgreementProspectusMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_SalesAgreementProspectusMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement Prospectus</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_SalesAgreementProspectusMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement Prospectus [Member]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="stok_UnderwrittenPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="stok_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_UnderwrittenPublicOfferingMember" xlink:to="stok_UnderwrittenPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters&apos; Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business And Basis Of Presentation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business And Basis Of Presentation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity incorporation state name</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_MaximumAggregateOfferingPrice" xlink:type="locator" xlink:label="stok_MaximumAggregateOfferingPrice" />
    <link:label xml:lang="en-US" xlink:label="stok_MaximumAggregateOfferingPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate offering price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_MaximumAggregateOfferingPrice" xlink:to="stok_MaximumAggregateOfferingPrice_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_SecuritiesIssuedInConnectionWithShelfRegistration" xlink:type="locator" xlink:label="stok_SecuritiesIssuedInConnectionWithShelfRegistration" />
    <link:label xml:lang="en-US" xlink:label="stok_SecuritiesIssuedInConnectionWithShelfRegistration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities issued in connection with shelf registration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_SecuritiesIssuedInConnectionWithShelfRegistration" xlink:to="stok_SecuritiesIssuedInConnectionWithShelfRegistration_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_MaximumAggregateOfferingPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate offering price</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_MaximumAggregateOfferingPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Offering Price</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_SecuritiesIssuedInConnectionWithShelfRegistration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities issued in connection with shelf registration</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_SecuritiesIssuedInConnectionWithShelfRegistration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Securities Issued In Connection With Shelf Registration</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" xlink:type="locator" xlink:label="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" />
    <link:label xml:lang="en-US" xlink:label="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance underwritten public offering net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" xlink:to="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during period, shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued, price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from underwritten public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Underwritten Public Offering Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_ComputerAndOfficeEquipmentMember" xlink:type="locator" xlink:label="stok_ComputerAndOfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="stok_ComputerAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer and office equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_ComputerAndOfficeEquipmentMember" xlink:to="stok_ComputerAndOfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_ComputerAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer and Office Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ComputerAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer And Office Equipment [Member]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_LaboratoryEquipmentAndFurnitureAndFixturesMember" xlink:type="locator" xlink:label="stok_LaboratoryEquipmentAndFurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="stok_LaboratoryEquipmentAndFurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment and furniture and fixtures.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_LaboratoryEquipmentAndFurnitureAndFixturesMember" xlink:to="stok_LaboratoryEquipmentAndFurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_LaboratoryEquipmentAndFurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment and Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_LaboratoryEquipmentAndFurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment And Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_AccountingPoliciesLineItems" xlink:type="locator" xlink:label="stok_AccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="stok_AccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="stok_AccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AccountingPoliciesTable" xlink:type="locator" xlink:label="stok_AccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="stok_AccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_AccountingPoliciesTable" xlink:to="stok_AccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_AccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect Period Of Adoption [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect Period Of Adoption [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect Period Of Adoption Adjustment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201711Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201711Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2017-11</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201711Member" xlink:to="us-gaap_AccountingStandardsUpdate201711Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201711Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201711 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-13</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201813Member" xlink:to="us-gaap_AccountingStandardsUpdate201813Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201813 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-12</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201912 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative effect adjustment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized income tax benefits, interest or penalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal corporate tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Government Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total Marketable Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets, transfers to level 3, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketable Securities, Unrealized Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Marketable Securities, Fair Value</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_DebtSecuritiesAvailableForSaleMaturityPeriod" xlink:type="locator" xlink:label="stok_DebtSecuritiesAvailableForSaleMaturityPeriod" />
    <link:label xml:lang="en-US" xlink:label="stok_DebtSecuritiesAvailableForSaleMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities available-for-sale maturity period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_DebtSecuritiesAvailableForSaleMaturityPeriod" xlink:to="stok_DebtSecuritiesAvailableForSaleMaturityPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_DebtSecuritiesAvailableForSaleMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average maturity marketable securities period</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_DebtSecuritiesAvailableForSaleMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Maturity Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Allowance For Credit Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, and equipment, net</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="locator" xlink:label="stok_AccruedResearchAndDevelopmentCostsCurrent" />
    <link:label xml:lang="en-US" xlink:label="stok_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="stok_AccruedResearchAndDevelopmentCostsCurrent_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued employee compensation costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AccruedAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued and other current liabilities</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_AreaOfSpaceSubjectToOperatingLease" xlink:type="locator" xlink:label="stok_AreaOfSpaceSubjectToOperatingLease" />
    <link:label xml:lang="en-US" xlink:label="stok_AreaOfSpaceSubjectToOperatingLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of space subject to operating lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_AreaOfSpaceSubjectToOperatingLease" xlink:to="stok_AreaOfSpaceSubjectToOperatingLease_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLeaseCostPerYear" xlink:type="locator" xlink:label="stok_OperatingLeaseCostPerYear" />
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLeaseCostPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease cost per year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_OperatingLeaseCostPerYear" xlink:to="stok_OperatingLeaseCostPerYear_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AnnualBaseRentIncreasePercentageForOperatingLease" xlink:type="locator" xlink:label="stok_AnnualBaseRentIncreasePercentageForOperatingLease" />
    <link:label xml:lang="en-US" xlink:label="stok_AnnualBaseRentIncreasePercentageForOperatingLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual base rent increase percentage for operating lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_AnnualBaseRentIncreasePercentageForOperatingLease" xlink:to="stok_AnnualBaseRentIncreasePercentageForOperatingLease_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLeaseCommencementDate" xlink:type="locator" xlink:label="stok_OperatingLeaseCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_OperatingLeaseCommencementDate" xlink:to="stok_OperatingLeaseCommencementDate_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="stok_CommitmentsAndContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="stok_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_CommitmentsAndContingenciesLineItems_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="stok_CommitmentsAndContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="stok_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_CommitmentsAndContingenciesTable" xlink:to="stok_CommitmentsAndContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_LeaseCommencementTwoThousandAndTwentyOneMember" xlink:type="locator" xlink:label="stok_LeaseCommencementTwoThousandAndTwentyOneMember" />
    <link:label xml:lang="en-US" xlink:label="stok_LeaseCommencementTwoThousandAndTwentyOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement, two thousand and twenty one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_LeaseCommencementTwoThousandAndTwentyOneMember" xlink:to="stok_LeaseCommencementTwoThousandAndTwentyOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_LeaseCommencementTwoThousandAndTwentyOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Commencement on December 15, 2021</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_LeaseCommencementTwoThousandAndTwentyOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Two Thousand And Twenty One [Member]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_LeaseCommencementTwoThousandAndTwentyTwoMember" xlink:type="locator" xlink:label="stok_LeaseCommencementTwoThousandAndTwentyTwoMember" />
    <link:label xml:lang="en-US" xlink:label="stok_LeaseCommencementTwoThousandAndTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement, two thousand and twenty two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_LeaseCommencementTwoThousandAndTwentyTwoMember" xlink:to="stok_LeaseCommencementTwoThousandAndTwentyTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_LeaseCommencementTwoThousandAndTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Commencement on April 2022</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_LeaseCommencementTwoThousandAndTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Two Thousand And Twenty Two [Member]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_LeaseExtensionEndDateMember" xlink:type="locator" xlink:label="stok_LeaseExtensionEndDateMember" />
    <link:label xml:lang="en-US" xlink:label="stok_LeaseExtensionEndDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease extension end date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_LeaseExtensionEndDateMember" xlink:to="stok_LeaseExtensionEndDateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_LeaseExtensionEndDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Extension End Date April 30, 2025</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_LeaseExtensionEndDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Extension End Date [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:label xml:lang="en-US" xlink:label="srt_DirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Member of Board of Directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_DirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_ColdSpringHarborLaboratoryAgreementMember" xlink:type="locator" xlink:label="stok_ColdSpringHarborLaboratoryAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="stok_ColdSpringHarborLaboratoryAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cold Spring Harbor Laboratory Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_ColdSpringHarborLaboratoryAgreementMember" xlink:to="stok_ColdSpringHarborLaboratoryAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_ColdSpringHarborLaboratoryAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CSHL Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ColdSpringHarborLaboratoryAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cold Spring Harbor Laboratory Agreement [Member]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_SouthamptonAgreementMember" xlink:type="locator" xlink:label="stok_SouthamptonAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="stok_SouthamptonAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Southampton Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_SouthamptonAgreementMember" xlink:to="stok_SouthamptonAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_SouthamptonAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Southampton Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_SouthamptonAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Southampton Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AreaOfSpaceSubjectToOperatingLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of space subject to operating lease</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AreaOfSpaceSubjectToOperatingLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Space Subject To Operating Lease</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLeaseCostPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost per year</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLeaseCostPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost Per Year</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AnnualBaseRentIncreasePercentageForOperatingLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual base rent increase percentage for operating lease</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AnnualBaseRentIncreasePercentageForOperatingLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Base Rent Increase Percentage For Operating Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Date</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="stok_OperatingLeaseCommencementMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease, commencement month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_OperatingLeaseCommencementMonthAndYear" xlink:to="stok_OperatingLeaseCommencementMonthAndYear_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease commencement month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Month And Year</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms" xlink:type="locator" xlink:label="stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms" />
    <link:label xml:lang="en-US" xlink:label="stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of renewal option to extend operating lease terms.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms" xlink:to="stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options to renewal operating lease term</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Renewal Option To Extend Operating Lease Terms</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease" xlink:type="locator" xlink:label="stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease" />
    <link:label xml:lang="en-US" xlink:label="stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of additional rentable space subject to operating lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease" xlink:to="stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AdditionalOperatingLeaseCommencementDate" xlink:type="locator" xlink:label="stok_AdditionalOperatingLeaseCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="stok_AdditionalOperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional operating lease commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_AdditionalOperatingLeaseCommencementDate" xlink:to="stok_AdditionalOperatingLeaseCommencementDate_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AdditionalLeaseExpirationDate" xlink:type="locator" xlink:label="stok_AdditionalLeaseExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="stok_AdditionalLeaseExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional lease expiration date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_AdditionalLeaseExpirationDate" xlink:to="stok_AdditionalLeaseExpirationDate_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AdditionalOperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="stok_AdditionalOperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="stok_AdditionalOperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional operating lease, right-of-use asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_AdditionalOperatingLeaseRightOfUseAsset" xlink:to="stok_AdditionalOperatingLeaseRightOfUseAsset_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AdditionalOperatingLeaseLiabilities" xlink:type="locator" xlink:label="stok_AdditionalOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="stok_AdditionalOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional operating lease, liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_AdditionalOperatingLeaseLiabilities" xlink:to="stok_AdditionalOperatingLeaseLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of additional space subject to operating lease</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Additional Rentable Space Subject To Operating Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AdditionalOperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional operating lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AdditionalOperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Operating Lease Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AdditionalLeaseExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional operating lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AdditionalLeaseExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Lease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AdditionalOperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional operating lease, right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AdditionalOperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Operating Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AdditionalOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional operating lease, liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AdditionalOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Operating Lease Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to extend [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease payments under non-cancellable leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease liabilities</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted" xlink:type="locator" xlink:label="stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted" />
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liability excluding leases entered access yet to be granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted" xlink:to="stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current Statement Of Financial Position Extensible List</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current portion of operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Excluding Leases Entered Access Yet To Be Granted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term in years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_ConsultingServicesExpenses" xlink:type="locator" xlink:label="stok_ConsultingServicesExpenses" />
    <link:label xml:lang="en-US" xlink:label="stok_ConsultingServicesExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting services expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_ConsultingServicesExpenses" xlink:to="stok_ConsultingServicesExpenses_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ConsultingServicesAgreementTerm" xlink:type="locator" xlink:label="stok_ConsultingServicesAgreementTerm" />
    <link:label xml:lang="en-US" xlink:label="stok_ConsultingServicesAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting services agreement term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_ConsultingServicesAgreementTerm" xlink:to="stok_ConsultingServicesAgreementTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_ConsultingServicesExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting services expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ConsultingServicesExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Services Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ConsultingServicesAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting services agreement term</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ConsultingServicesAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Services Agreement Term</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_ScientificAdvisoryServicesExpenses" xlink:type="locator" xlink:label="stok_ScientificAdvisoryServicesExpenses" />
    <link:label xml:lang="en-US" xlink:label="stok_ScientificAdvisoryServicesExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Scientific advisory services expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_ScientificAdvisoryServicesExpenses" xlink:to="stok_ScientificAdvisoryServicesExpenses_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ScientificAdvisoryServicesAgreementTerm" xlink:type="locator" xlink:label="stok_ScientificAdvisoryServicesAgreementTerm" />
    <link:label xml:lang="en-US" xlink:label="stok_ScientificAdvisoryServicesAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Scientific advisory services agreement term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_ScientificAdvisoryServicesAgreementTerm" xlink:to="stok_ScientificAdvisoryServicesAgreementTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_ScientificAdvisoryServicesExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scientific advisory services expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ScientificAdvisoryServicesExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scientific Advisory Services Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ScientificAdvisoryServicesAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scientific advisory services agreement term</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ScientificAdvisoryServicesAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scientific Advisory Services Agreement Term</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_AnnualLicenseMaintenanceFee" xlink:type="locator" xlink:label="stok_AnnualLicenseMaintenanceFee" />
    <link:label xml:lang="en-US" xlink:label="stok_AnnualLicenseMaintenanceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual license maintenance fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_AnnualLicenseMaintenanceFee" xlink:to="stok_AnnualLicenseMaintenanceFee_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_MaximumAggregatePotentialMilestonePaymentsPayable" xlink:type="locator" xlink:label="stok_MaximumAggregatePotentialMilestonePaymentsPayable" />
    <link:label xml:lang="en-US" xlink:label="stok_MaximumAggregatePotentialMilestonePaymentsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate potential milestone payments payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_MaximumAggregatePotentialMilestonePaymentsPayable" xlink:to="stok_MaximumAggregatePotentialMilestonePaymentsPayable_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ExpensesRelatedToReimbursablePatentCosts" xlink:type="locator" xlink:label="stok_ExpensesRelatedToReimbursablePatentCosts" />
    <link:label xml:lang="en-US" xlink:label="stok_ExpensesRelatedToReimbursablePatentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expenses related to reimbursable patent costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_ExpensesRelatedToReimbursablePatentCosts" xlink:to="stok_ExpensesRelatedToReimbursablePatentCosts_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue" xlink:type="locator" xlink:label="stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue" />
    <link:label xml:lang="en-US" xlink:label="stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of maximum required payment of sublicense revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue" xlink:to="stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of maximum required payment of sublicense revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Maximum Required Payment Of Sublicense Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AnnualLicenseMaintenanceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fee</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AnnualLicenseMaintenanceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Maintenance Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_MaximumAggregatePotentialMilestonePaymentsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate potential milestone payments payable</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_MaximumAggregatePotentialMilestonePaymentsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Potential Milestone Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ExpensesRelatedToReimbursablePatentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses related to reimbursable patent costs</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ExpensesRelatedToReimbursablePatentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expenses Related To Reimbursable Patent Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities recorded under agreement</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_PercentageOfIncreaseInReservedCommonShares" xlink:type="locator" xlink:label="stok_PercentageOfIncreaseInReservedCommonShares" />
    <link:label xml:lang="en-US" xlink:label="stok_PercentageOfIncreaseInReservedCommonShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of increase in reserved common shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_PercentageOfIncreaseInReservedCommonShares" xlink:to="stok_PercentageOfIncreaseInReservedCommonShares_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="stok_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="stok_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2019 equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:to="stok_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nineteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="stok_TwoThousandAndFourteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="stok_TwoThousandAndFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2014 Equity Incentive Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:to="stok_TwoThousandAndFourteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_TwoThousandAndFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_TwoThousandAndFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2019 Employee Stock Purchase Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember" xlink:to="stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nineteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_PercentageOfIncreaseInReservedCommonShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase in reserved common shares</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_PercentageOfIncreaseInReservedCommonShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Increase In Reserved Common Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common shares available for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Option granted to purchase shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options vest period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Outstanding balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Number of shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Outstanding balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Exercisable as of December 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Outstanding balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Outstanding balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercisable as of December 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual life, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual life, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Outstanding value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Exercisable as of December 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:type="locator" xlink:label="stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />
    <link:label xml:lang="en-US" xlink:label="stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, grants in period, fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value per share of stock options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate grant date fair value of stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected weighted average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of common shares, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share, basic and diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options to Purchase Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_IncomeTaxesLineItems" xlink:type="locator" xlink:label="stok_IncomeTaxesLineItems" />
    <link:label xml:lang="en-US" xlink:label="stok_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_IncomeTaxesLineItems" xlink:to="stok_IncomeTaxesLineItems_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_IncomeTaxesTable" xlink:type="locator" xlink:label="stok_IncomeTaxesTable" />
    <link:label xml:lang="en-US" xlink:label="stok_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_IncomeTaxesTable" xlink:to="stok_IncomeTaxesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Tax Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected income tax benefit at the federal statutory rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLossCarryforwardsExpirationBeginningYear" xlink:type="locator" xlink:label="stok_OperatingLossCarryforwardsExpirationBeginningYear" />
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration beginning year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_OperatingLossCarryforwardsExpirationBeginningYear" xlink:to="stok_OperatingLossCarryforwardsExpirationBeginningYear_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_TaxCreditCarryforwardsExpirationBeginningYear" xlink:type="locator" xlink:label="stok_TaxCreditCarryforwardsExpirationBeginningYear" />
    <link:label xml:lang="en-US" xlink:label="stok_TaxCreditCarryforwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforwards expiration beginning year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_TaxCreditCarryforwardsExpirationBeginningYear" xlink:to="stok_TaxCreditCarryforwardsExpirationBeginningYear_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, expiration beginning year</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Beginning Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_TaxCreditCarryforwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards, expiration beginning year</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_TaxCreditCarryforwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforwards Expiration Beginning Year</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct" xlink:type="locator" xlink:label="stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct" />
    <link:label xml:lang="en-US" xlink:label="stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of taxable income, limitation repealed under CARES act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct" xlink:to="stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct" xlink:type="locator" xlink:label="stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct" />
    <link:label xml:lang="en-US" xlink:label="stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of federal NOL carry forwards subject to limitation under CARES act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct" xlink:to="stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_FederalNOLCarryForwardsPeriodUnderCARESAct" xlink:type="locator" xlink:label="stok_FederalNOLCarryForwardsPeriodUnderCARESAct" />
    <link:label xml:lang="en-US" xlink:label="stok_FederalNOLCarryForwardsPeriodUnderCARESAct_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal NOL carry forwards period under CARES act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_FederalNOLCarryForwardsPeriodUnderCARESAct" xlink:to="stok_FederalNOLCarryForwardsPeriodUnderCARESAct_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of taxable income, limitation repealed under CARES act</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Taxable Income Limitation Repealed Under C A R E S Act</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of federal NOL carry forwards subject to limitation under CARES act</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Federal N O L Carry Forwards Subject To Limitation Under C A R E S Act</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_FederalNOLCarryForwardsPeriodUnderCARESAct_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal NOL carry back period under CARES act</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_FederalNOLCarryForwardsPeriodUnderCARESAct_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal N O L Carry Forwards Period Under C A R E S Act</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum matching contribution percentage of employees salary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributions to 401(k) Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Cost Recognized</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_UpfrontPaymentReceived" xlink:type="locator" xlink:label="stok_UpfrontPaymentReceived" />
    <link:label xml:lang="en-US" xlink:label="stok_UpfrontPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_UpfrontPaymentReceived" xlink:to="stok_UpfrontPaymentReceived_lbl" />
    <link:loc xlink:href="stok-20211231.xsd#stok_MilestonePaymentsReceivable" xlink:type="locator" xlink:label="stok_MilestonePaymentsReceivable" />
    <link:label xml:lang="en-US" xlink:label="stok_MilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_MilestonePaymentsReceivable" xlink:to="stok_MilestonePaymentsReceivable_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="stok-20211231.xsd#stok_AcadiaPharmaceuticalsIncMember" xlink:type="locator" xlink:label="stok_AcadiaPharmaceuticalsIncMember" />
    <link:label xml:lang="en-US" xlink:label="stok_AcadiaPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Acadia pharmaceuticals Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stok_AcadiaPharmaceuticalsIncMember" xlink:to="stok_AcadiaPharmaceuticalsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="stok_AcadiaPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acadia Pharmaceuticals Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_AcadiaPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acadia Pharmaceuticals Inc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_UpfrontPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront Payment received</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_UpfrontPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_MilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestone payments receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="stok_MilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Receivable</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>27
<FILENAME>stok-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T14:37:56.1216466+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 8d9d5b43144d4c21a62f9c029c9e37fb -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/role/TemplateLink" xlink:href="stok-20211231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="stok-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="stok-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AccruedAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="stok_AccruedAndOtherCurrentLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="stok_AccruedAndOtherCurrentLiabilities" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="stok-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="stok-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="stok-20211231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="stok-20211231.xsd#stok_FollowOnOfferingMember" xlink:type="locator" xlink:label="stok_FollowOnOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="stok_FollowOnOfferingMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="stok-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="stok-20211231.xsd#stok_DeferredOfferingCostsNotYetPaid" xlink:type="locator" xlink:label="stok_DeferredOfferingCostsNotYetPaid" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets" xlink:type="locator" xlink:label="stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AmortizationAndAccretionOfMarketableSecurities" xlink:type="locator" xlink:label="stok_AmortizationAndAccretionOfMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="stok_AmortizationAndAccretionOfMarketableSecurities" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="stok_DeferredOfferingCostsNotYetPaid" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:href="stok-20211231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:href="stok-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="stok-20211231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecurities" xlink:href="stok-20211231.xsd#Role_DisclosureMarketableSecurities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecurities">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="stok-20211231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities" xlink:href="stok-20211231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="stok-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensation" xlink:href="stok-20211231.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:href="stok-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="stok-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefits" xlink:href="stok-20211231.xsd#Role_DisclosureEmployeeBenefits" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefits">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="stok-20211231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:href="stok-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="stok-20211231.xsd#stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" xlink:type="locator" xlink:label="stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="stok-20211231.xsd#stok_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="stok_PatentCostsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="stok-20211231.xsd#stok_DeferredOfferingCostsPolicyTextBlock" xlink:type="locator" xlink:label="stok_DeferredOfferingCostsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="stok_DeferredOfferingCostsPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="stok_PatentCostsPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" xlink:href="stok-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables">
    <link:loc xlink:href="stok-20211231.xsd#stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock" xlink:type="locator" xlink:label="stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="stok-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="stok-20211231.xsd#Role_DisclosureMarketableSecuritiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="stok-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:href="stok-20211231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables">
    <link:loc xlink:href="stok-20211231.xsd#stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="stok-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="stok-20211231.xsd#stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="stok-20211231.xsd#stok_SummaryOfLeaseBalancesTableTextBlock" xlink:type="locator" xlink:label="stok_SummaryOfLeaseBalancesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="stok_SummaryOfLeaseBalancesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables" xlink:href="stok-20211231.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:href="stok-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="stok-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="stok-20211231.xsd#stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" xlink:type="locator" xlink:label="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="stok-20211231.xsd#stok_SecuritiesIssuedInConnectionWithShelfRegistration" xlink:type="locator" xlink:label="stok_SecuritiesIssuedInConnectionWithShelfRegistration" />
    <link:loc xlink:href="stok-20211231.xsd#stok_MaximumAggregateOfferingPrice" xlink:type="locator" xlink:label="stok_MaximumAggregateOfferingPrice" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="stok-20211231.xsd#stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:type="locator" xlink:label="stok_NatureOfBusinessAndBasisOfPresentationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="stok_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_SalesAgreementProspectusMember" xlink:type="locator" xlink:label="stok_SalesAgreementProspectusMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_BaseProspectusMember" xlink:type="locator" xlink:label="stok_BaseProspectusMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="stok-20211231.xsd#stok_NatureOfBusinessAndBasisOfPresentationTable" xlink:type="locator" xlink:label="stok_NatureOfBusinessAndBasisOfPresentationTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="stok_NatureOfBusinessAndBasisOfPresentationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="stok_BaseProspectusMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="stok_SalesAgreementProspectusMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="stok_UnderwrittenPublicOfferingMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="stok_NatureOfBusinessAndBasisOfPresentationLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="stok_MaximumAggregateOfferingPrice" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="stok_SecuritiesIssuedInConnectionWithShelfRegistration" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="stok-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" xlink:href="stok-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_LaboratoryEquipmentAndFurnitureAndFixturesMember" xlink:type="locator" xlink:label="stok_LaboratoryEquipmentAndFurnitureAndFixturesMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ComputerAndOfficeEquipmentMember" xlink:type="locator" xlink:label="stok_ComputerAndOfficeEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="stok_ComputerAndOfficeEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="stok_LaboratoryEquipmentAndFurnitureAndFixturesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AccountingPoliciesLineItems" xlink:type="locator" xlink:label="stok_AccountingPoliciesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201711Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201711Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AccountingPoliciesTable" xlink:type="locator" xlink:label="stok_AccountingPoliciesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="stok_AccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_AccountingPoliciesTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201711Member" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_AccountingPoliciesTable" xlink:to="stok_AccountingPoliciesLineItems" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRentCredit" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquity" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails" xlink:href="stok-20211231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:href="stok-20211231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:loc xlink:href="stok-20211231.xsd#stok_DebtSecuritiesAvailableForSaleMaturityPeriod" xlink:type="locator" xlink:label="stok_DebtSecuritiesAvailableForSaleMaturityPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="stok_DebtSecuritiesAvailableForSaleMaturityPeriod" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="stok-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:href="stok-20211231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="stok-20211231.xsd#stok_AccruedAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="stok_AccruedAndOtherCurrentLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="locator" xlink:label="stok_AccruedResearchAndDevelopmentCostsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="stok_AccruedResearchAndDevelopmentCostsCurrent" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="stok_AccruedAndOtherCurrentLiabilities" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ExpensesRelatedToReimbursablePatentCosts" xlink:type="locator" xlink:label="stok_ExpensesRelatedToReimbursablePatentCosts" />
    <link:loc xlink:href="stok-20211231.xsd#stok_MaximumAggregatePotentialMilestonePaymentsPayable" xlink:type="locator" xlink:label="stok_MaximumAggregatePotentialMilestonePaymentsPayable" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AnnualLicenseMaintenanceFee" xlink:type="locator" xlink:label="stok_AnnualLicenseMaintenanceFee" />
    <link:loc xlink:href="stok-20211231.xsd#stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue" xlink:type="locator" xlink:label="stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ScientificAdvisoryServicesAgreementTerm" xlink:type="locator" xlink:label="stok_ScientificAdvisoryServicesAgreementTerm" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ScientificAdvisoryServicesExpenses" xlink:type="locator" xlink:label="stok_ScientificAdvisoryServicesExpenses" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ConsultingServicesAgreementTerm" xlink:type="locator" xlink:label="stok_ConsultingServicesAgreementTerm" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ConsultingServicesExpenses" xlink:type="locator" xlink:label="stok_ConsultingServicesExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AdditionalOperatingLeaseLiabilities" xlink:type="locator" xlink:label="stok_AdditionalOperatingLeaseLiabilities" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AdditionalOperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="stok_AdditionalOperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AdditionalLeaseExpirationDate" xlink:type="locator" xlink:label="stok_AdditionalLeaseExpirationDate" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AdditionalOperatingLeaseCommencementDate" xlink:type="locator" xlink:label="stok_AdditionalOperatingLeaseCommencementDate" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease" xlink:type="locator" xlink:label="stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="stok-20211231.xsd#stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms" xlink:type="locator" xlink:label="stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms" />
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="stok_OperatingLeaseCommencementMonthAndYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLeaseCommencementDate" xlink:type="locator" xlink:label="stok_OperatingLeaseCommencementDate" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AnnualBaseRentIncreasePercentageForOperatingLease" xlink:type="locator" xlink:label="stok_AnnualBaseRentIncreasePercentageForOperatingLease" />
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLeaseCostPerYear" xlink:type="locator" xlink:label="stok_OperatingLeaseCostPerYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AreaOfSpaceSubjectToOperatingLease" xlink:type="locator" xlink:label="stok_AreaOfSpaceSubjectToOperatingLease" />
    <link:loc xlink:href="stok-20211231.xsd#stok_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="stok_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:href="stok-20211231.xsd#stok_SouthamptonAgreementMember" xlink:type="locator" xlink:label="stok_SouthamptonAgreementMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ColdSpringHarborLaboratoryAgreementMember" xlink:type="locator" xlink:label="stok_ColdSpringHarborLaboratoryAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="stok-20211231.xsd#stok_LeaseExtensionEndDateMember" xlink:type="locator" xlink:label="stok_LeaseExtensionEndDateMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_LeaseCommencementTwoThousandAndTwentyTwoMember" xlink:type="locator" xlink:label="stok_LeaseCommencementTwoThousandAndTwentyTwoMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_LeaseCommencementTwoThousandAndTwentyOneMember" xlink:type="locator" xlink:label="stok_LeaseCommencementTwoThousandAndTwentyOneMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="stok-20211231.xsd#stok_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="stok_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="stok_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="stok_LeaseCommencementTwoThousandAndTwentyOneMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="stok_LeaseCommencementTwoThousandAndTwentyTwoMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="stok_LeaseExtensionEndDateMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_DirectorMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="stok_ColdSpringHarborLaboratoryAgreementMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="stok_SouthamptonAgreementMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesTable" xlink:to="stok_CommitmentsAndContingenciesLineItems" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AreaOfSpaceSubjectToOperatingLease" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_OperatingLeaseCostPerYear" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AnnualBaseRentIncreasePercentageForOperatingLease" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_OperatingLeaseCommencementDate" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_OperatingLeaseCommencementMonthAndYear" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AdditionalOperatingLeaseCommencementDate" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AdditionalLeaseExpirationDate" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AdditionalOperatingLeaseRightOfUseAsset" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AdditionalOperatingLeaseLiabilities" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_ConsultingServicesExpenses" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_ConsultingServicesAgreementTerm" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_ScientificAdvisoryServicesExpenses" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_ScientificAdvisoryServicesAgreementTerm" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_AnnualLicenseMaintenanceFee" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_MaximumAggregatePotentialMilestonePaymentsPayable" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="stok_ExpensesRelatedToReimbursablePatentCosts" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_Liabilities" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" xlink:href="stok-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails" xlink:href="stok-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails">
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted" xlink:type="locator" xlink:label="stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesDetails" xlink:href="stok-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="stok-20211231.xsd#stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:type="locator" xlink:label="stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="stok-20211231.xsd#stok_PercentageOfIncreaseInReservedCommonShares" xlink:type="locator" xlink:label="stok_PercentageOfIncreaseInReservedCommonShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="stok-20211231.xsd#stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:type="locator" xlink:label="srt_DirectorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="stok-20211231.xsd#stok_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="stok_TwoThousandAndFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="stok-20211231.xsd#stok_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="stok_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="stok_TwoThousandAndNineteenEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="stok_TwoThousandAndFourteenEquityIncentivePlanMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="stok_PercentageOfIncreaseInReservedCommonShares" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails" xlink:href="stok-20211231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="stok-20211231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails" xlink:href="stok-20211231.xsd#Role_DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="stok-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="stok-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="stok-20211231.xsd#stok_FederalNOLCarryForwardsPeriodUnderCARESAct" xlink:type="locator" xlink:label="stok_FederalNOLCarryForwardsPeriodUnderCARESAct" />
    <link:loc xlink:href="stok-20211231.xsd#stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct" xlink:type="locator" xlink:label="stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct" />
    <link:loc xlink:href="stok-20211231.xsd#stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct" xlink:type="locator" xlink:label="stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="stok-20211231.xsd#stok_TaxCreditCarryforwardsExpirationBeginningYear" xlink:type="locator" xlink:label="stok_TaxCreditCarryforwardsExpirationBeginningYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="stok-20211231.xsd#stok_OperatingLossCarryforwardsExpirationBeginningYear" xlink:type="locator" xlink:label="stok_OperatingLossCarryforwardsExpirationBeginningYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="stok-20211231.xsd#stok_IncomeTaxesLineItems" xlink:type="locator" xlink:label="stok_IncomeTaxesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="stok-20211231.xsd#stok_IncomeTaxesTable" xlink:type="locator" xlink:label="stok_IncomeTaxesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="stok_IncomeTaxesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_IncomeTaxesTable" xlink:to="stok_IncomeTaxesLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_IncomeTaxesLineItems" xlink:to="stok_OperatingLossCarryforwardsExpirationBeginningYear" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_IncomeTaxesLineItems" xlink:to="stok_TaxCreditCarryforwardsExpirationBeginningYear" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_IncomeTaxesLineItems" xlink:to="stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_IncomeTaxesLineItems" xlink:to="stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="stok_IncomeTaxesLineItems" xlink:to="stok_FederalNOLCarryForwardsPeriodUnderCARESAct" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:href="stok-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="stok-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="stok-20211231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="stok-20211231.xsd#stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" xlink:type="locator" xlink:label="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="stok-20211231.xsd#stok_MilestonePaymentsReceivable" xlink:type="locator" xlink:label="stok_MilestonePaymentsReceivable" />
    <link:loc xlink:href="stok-20211231.xsd#stok_UpfrontPaymentReceived" xlink:type="locator" xlink:label="stok_UpfrontPaymentReceived" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="stok-20211231.xsd#stok_SalesAgreementProspectusMember" xlink:type="locator" xlink:label="stok_SalesAgreementProspectusMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="stok-20211231.xsd#stok_AcadiaPharmaceuticalsIncMember" xlink:type="locator" xlink:label="stok_AcadiaPharmaceuticalsIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="stok_AcadiaPharmaceuticalsIncMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="stok_SalesAgreementProspectusMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="stok_UpfrontPaymentReceived" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="stok_MilestonePaymentsReceivable" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113061052824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Stoke Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001623526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,359,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1144582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">45 Wiggins Ave<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Bedford<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">01730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">430-8200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, MA USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">STOK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K to the extent stated herein. The Definitive Proxy Statement will be filed within 120 days of the Registrant&#8217;s fiscal year ended December 31, 2021.&#160;Except with respect to information specifically incorporated by reference in this Form 10-K, the Definitive Proxy Statement is not deemed to be filed as part of this Form 10-K.</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Auditor Firm Id:</span><span style="Background-color:#FFFFFF;margin-left:36pt;"/><span style="Background-color:#FFFFFF;">185</span><span style="Background-color:#FFFFFF;margin-left:36pt;"/><span style="Background-color:#FFFFFF;">Auditor Name:</span><span style="Background-color:#FFFFFF;margin-left:36pt;"/><span style="Background-color:#FFFFFF;">KPMG LLP</span><span style="Background-color:#FFFFFF;margin-left:36pt;"/><span style="Background-color:#FFFFFF;">Auditor Location:</span><span style="Background-color:#FFFFFF;margin-left:36pt;"/><span style="Background-color:#FFFFFF;">Boston, MA USA</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113064622344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated balance sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 144,895<span></span>
</td>
<td class="nump">$ 287,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">74,915<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,159<span></span>
</td>
<td class="nump">6,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Deferred financing costs</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">229,218<span></span>
</td>
<td class="nump">293,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">4,939<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,139<span></span>
</td>
<td class="nump">2,675<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">238,865<span></span>
</td>
<td class="nump">297,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,385<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AccruedAndOtherCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">14,754<span></span>
</td>
<td class="nump">9,930<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,139<span></span>
</td>
<td class="nump">11,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Long term liabilities</a></td>
<td class="nump">3,949<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">21,088<span></span>
</td>
<td class="nump">11,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 36,902,499 and 36,577,149 shares issued and outstanding as of December 31, 2021 and 2020, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">414,024<span></span>
</td>
<td class="nump">396,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(196,083)<span></span>
</td>
<td class="num">(110,278)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">217,777<span></span>
</td>
<td class="nump">286,078<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 238,865<span></span>
</td>
<td class="nump">$ 297,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_AccruedAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_AccruedAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113064524984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated balance sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">36,902,499<span></span>
</td>
<td class="nump">36,577,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">36,902,499<span></span>
</td>
<td class="nump">36,577,149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113064636216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of operations and comprehensive loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 54,168<span></span>
</td>
<td class="nump">$ 32,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">31,897<span></span>
</td>
<td class="nump">20,847<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">86,065<span></span>
</td>
<td class="nump">53,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(86,065)<span></span>
</td>
<td class="num">(53,044)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">801<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (85,805)<span></span>
</td>
<td class="num">$ (52,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share&#8212;basic and diluted</a></td>
<td class="num">$ (2.34)<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding&#8212;basic and diluted</a></td>
<td class="nump">36,739,269<span></span>
</td>
<td class="nump">33,488,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (85,805)<span></span>
</td>
<td class="num">$ (52,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (85,973)<span></span>
</td>
<td class="num">$ (52,243)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113059978744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated statements of stockholders' equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Follow-on Offering</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Follow-on Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Follow-on Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 224,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 282,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (58,035)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,861,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">2,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">822,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock related to employee stock purchase plan</a></td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock related to employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(52,243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,243)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">286,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(110,278)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,577,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, Shares</a></td>
<td class="nump">287,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock related to employee stock purchase plan</a></td>
<td class="nump">$ 509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock related to employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(85,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,805)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 217,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (168)<span></span>
</td>
<td class="num">$ (196,083)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,902,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113059012136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of cash flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (85,805)<span></span>
</td>
<td class="num">$ (52,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">974<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AmortizationAndAccretionOfMarketableSecurities', window );">Amortization and accretion of marketable securities</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">16,450<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets', window );">Reduction in the carrying amount of right of use assets</a></td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,851)<span></span>
</td>
<td class="num">(2,878)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">2,897<span></span>
</td>
<td class="nump">5,203<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(66,907)<span></span>
</td>
<td class="num">(42,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,200)<span></span>
</td>
<td class="num">(1,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(87,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales of marketable securities</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(76,426)<span></span>
</td>
<td class="num">(1,050)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock upon public offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">2,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from Employee Stock Purchase Plan</a></td>
<td class="nump">509<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">108,108<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(142,049)<span></span>
</td>
<td class="nump">64,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash&#8212;beginning of year</a></td>
<td class="nump">287,513<span></span>
</td>
<td class="nump">222,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash&#8212;end of year</a></td>
<td class="nump">145,464<span></span>
</td>
<td class="nump">287,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets recognized in exchange for operating leases under Topic 842</a></td>
<td class="nump">5,081<span></span>
</td>
<td class="nump">2,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in accrued expense and accounts payable</a></td>
<td class="nump">$ 1,267<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_DeferredOfferingCostsNotYetPaid', window );">Deferred offering costs not yet paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_AmortizationAndAccretionOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and accretion of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_AmortizationAndAccretionOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_DeferredOfferingCostsNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_DeferredOfferingCostsNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in carrying amount of operating lease right of use assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063370328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the business and basis of presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the business and basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Organization </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stoke Therapeutics, Inc. (the Company) was founded in June 2014 and was incorporated under the laws of the State of Delaware. The Company is an early-stage biopharmaceutical company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Shelf Registration</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company filed a universal Shelf Registration statement on Form S-3 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission (the &#8220;SEC&#8221;). The Registration Statement was declared effective by the SEC on July 20, 2020,&#160;&#160;and contains two prospectuses: a base prospectus, which covers the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $400,000,000 of our common stock, preferred stock, debt securities, warrants to purchase our common stock, preferred stock or debt securities, subscription rights to purchase our common stock, preferred stock or debt securities and/or units consisting of some or all of these securities; and a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $150,000,000 of our common stock that may be issued and sold under a Controlled Equity Offering Sales Agreement (&#8220;Sales Agreement&#8221;). The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The $150,000,000 of common stock that may be offered, issued and sold under the sales agreement prospectus is included in the $400,000,000 of securities that may be offered, issued and sold by the Company under the base prospectus. As of December 31, 2021, the Company had not issued any securities in connection with the Sales Agreement. (see note 12 for sales of common stock subsequent to year end)</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Follow-on public offering</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 24, 2020, pursuant to a prospectus supplement to the Registration Statement, we completed an underwritten public offering, of our common stock and issued and sold 2,875,000 shares of common stock at a public offering price of $39.00 per share, which included 375,000 shares sold upon full exercise of the underwriters&#8217; option to purchase additional shares of common stock resulting in net proceeds of $104.9 million after deducting underwriting discounts and commissions and estimated offering expenses.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Uncertainties </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects that its operating losses and negative cash flows will continue for the foreseeable future. As of the issuance date of its consolidated financial statements for the year ended December 31, 2021, the Company expects that its cash and cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into 2024. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company plans to seek additional funding through public or private equity offerings, debt financings, other collaborations, strategic </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alliances</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and licensing arrangements</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (see note 12 for license and collaboration agreement entered</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> January 2022)</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063164440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies and recent accounting pronouncements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of significant accounting policies and recent accounting pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of presentation and consolidation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP), and include the accounts of Stoke Therapeutics, Inc. and its wholly-owned subsidiary. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). All intercompany transactions between and among the Company and its&#8217; consolidated subsidiary have been eliminated. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, expenses and disclosure of contingent assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and cash equivalents </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash in checking, sweep and money market accounts. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted cash </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2021, restricted cash consisted of money market accounts collateralizing letters of credit issued as security deposits in connection with the Company&#8217;s leases of its corporate facilities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reconciles cash and cash equivalents and restricted cash per the consolidated balance sheets to the statement of cash flows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,895</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,308</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">569</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,464</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,513</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities consist of government securities and obligations, corporate bonds and commercial paper with original maturities of more than 90 days. Investments are classified as available-for-sale and are recorded on the balance sheet at fair value with unrealized gains or losses reported as a separate component of other comprehensive income/(loss). Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at an accredited financial institution in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair value of financial instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC Topic 820, <span style="font-style:italic;">Fair Value Measurement</span> (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC&#160;820 establishes a three-tier value hierarchy that distinguishes between the following: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;Quoted market prices in active markets for identical assets or liabilities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred offering costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with&#160;in-process&#160;equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in the consolidated statement of stockholders&#8217; equity as a reduction of additional&#160;paid-in&#160;capital. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying consolidated statements of operations and comprehensive loss. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful lives for property and equipment are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="width:45%; border-bottom:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="width:1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td style="width:45%; border-bottom:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;width:45%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer and office equipment</p></td>
<td style="background-color:#CFF0FC;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:45%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-5 years</p></td>
</tr>
<tr>
<td style="width:45%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment and Furniture and fixtures</p></td>
<td style="width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td style="width:45%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-7 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;width:45%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:45%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesser of estimated useful life or remaining lease term</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of long-lived assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the assets may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the assets from the expected future cash flows (undiscounted and without interest expense) of the related operations. If these cash flows are less than the carrying value of such assets, an impairment loss for the difference between the estimated fair value and carrying value is recorded. There were no impairment losses recognized during the years ended December 31, 2021 and 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, depreciation, third-party license fees, and costs related to third parties engaged to conduct preclinical research development activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions and other companies to conduct research on its behalf. These agreements are generally cancellable. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock options </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its stock-based awards granted based on the estimated fair values of the awards and recognizes the compensation for employees and nonemployees over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock-based awards. The Company has elected the practical expedient to use the midpoint between vesting date and the contractual term as the expected term for certain awards with service or performance conditions. Stock-based compensation is recognized using the straight-line method. Forfeitures of unvested stock-based awards are accounted for when they occur. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent costs </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements. The Company adopted Topic 842 on January 1, 2020 using the modified retrospective approach and elected to apply the transition method that allows companies to continue applying guidance under the lease standard in effect at that time in the comparative period financial statements and recognize a cumulative-effect adjustment to the balance sheet on the date of adoption. The Company has also elected the package of practical expedients to not reassess its prior conclusions about lease identification, lease classification and indirect costs and to not separate lease and non-lease components.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon adoption of Topic 842 on January 1, 2020, the Company recorded right-of-use assets of $2.2 million, operating lease liabilities of $2.2 million and the elimination of deferred rent of $0.03 million. Adoption of the standard did not result in the Company recording a cumulative effect adjustment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines whether an arrangement is a lease at inception. The Company accounts for a lease when it has the right to control the leased asset for a period of time while obtaining substantially all of the assets&#8217; economic benefits. The Company determined that it held operating leases for office and laboratory space as of January 1, 2020. Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. The discount rate used to determine the present value of the lease payments is the Company&#8217;s incremental borrowing rate based on the information available at lease inception, as the Company does not have information to determine the rate implicit in the leases. Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments (which include initial direct costs and lease incentives). The expense is included in operating expenses in the consolidated statements of operations and comprehensive loss. The Company&#8217;s lease agreements also contain variable payments, primarily maintenance-related costs, which are expensed as incurred and not included in the measurement of the right-of-use assets and lease liabilities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be settled or recovered. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December 31, 2021 and 2020, the Company has recorded a full valuation allowance. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Tax Cuts and Jobs Act (the TCJA) was enacted on December&#160;22, 2017. The TCJA reduced the U.S. federal corporate tax rate from a top rate of 35% to a flat rate of 21%. The Company continues to monitor for legislative developments, issuance of regulations and technical memorandum to provide further clarification and/or interpretations of the TCJA and will adjust its consolidated financial statements as needed. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment and geographic information </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in one segment in the United States. The Company&#8217;s chief executive officer, as the chief operating decision-maker, manages and allocates resources to the operations of the Company on a total company basis using consolidated financial information. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging growth company and smaller reporting company status </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&#160;Act). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act, until such time as those standards apply to private companies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS&#160;Act. As a result, the Company&#8217;s consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will remain an emerging growth company until the earliest of (i)&#160;the last day of its first fiscal year (a)&#160;&#160;in which the Company has total annual gross revenues of at least $1.07&#160;billion or (b)&#160;in which the Company is deemed to be a large accelerated filer, which means the market value of the Company&#8217;s common stock that is held by non-affiliates exceeds $700.0&#160;million as of the prior June 30<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>, (ii)&#160;the date on which the Company has issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period, and (iii) December 31, 2024</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also a &#8220;smaller reporting company,&#8221; meaning that in the event of an initial public offering the market value of its stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to the Company as a result of such offering is less than $700&#160;million and its annual revenue is less than $100&#160;million during the most recently completed fiscal year. The Company may continue to be a smaller reporting company as long as either (i)&#160;the market value of its stock held by non-affiliates is less than $250&#160;million or (ii)&#160;its annual revenue is less than $100 million during the most recently </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">completed fiscal year and the market value of its stock held by non-affiliates is less than $700&#160;million. If the Company is a smaller reporting company at the time it ceases to be an emerging growth company, the Company may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, the Company may choose to present only the two most recent fiscal years of audited financial statements in its Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently issued accounting pronouncements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.46%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, the FASB issued ASU 2017-11, <span style="font-style:italic;">Earnings Per Share</span> (Topic 260), <span style="font-style:italic;">Distinguishing Liabilities from Equity</span> (Topic 480) and <span style="font-style:italic;">Derivatives and Hedging</span> (Topic 815): <span style="font-style:italic;">I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</span>. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, <span style="font-style:italic;">Distinguishing Liabilities from Equity</span>, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this update do not have an accounting effect. For public business entities, the amendments in Part I of ASU-2017-11 are effective for fiscal years and interim periods within those years beginning after December&#160;15, 2018. For all other entities, the amendments in Part I of this update are effective for fiscal years beginning after December&#160;15, 2019, and interim periods within fiscal years beginning after December&#160;15, 2020. We adopted this update on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.46%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13,<span style="font-style:italic;">&#160;&#8220;Fair Value Measurement (Topic 820), Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement&#8221;.</span>&#160;This ASU removed the following disclosure requirements: (1)&#160;the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy; (2)&#160;the policy for timing of transfers between levels; and (3)&#160;the valuation processes for Level&#160;3 fair value measurements. Additionally, this update added the following disclosure requirements: (1)&#160;the changes in unrealized gains and losses for the period included in other comprehensive income and loss for recurring Level&#160;3 fair value measurements held at the end of the reporting period; (2)&#160;the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level&#160;3 fair value measurements. ASU&#160;2018-13 is effective for all entities, for fiscal years beginning after December&#160;15, 2019 with early adoption permitted. We adopted this update on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.36%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.36%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12,&#160;<span style="font-style:italic;">Income Taxes</span>&#160;<span style="font-style:italic;">(Topic 740): Simplifying the Accounting for Income Taxes.</span>&#160;This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for interim and annual periods beginning after December 15, 2020, and early adoption is permitted. <span style="Background-color:#FFFFFF;">The Company adopted this standard on January 1, 2021 and the adoption of this update did not have a material impact on its consolidated financial statements.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063308968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Fair value measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,897</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,897</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,524</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,524</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US Government debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,904</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,904</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,915</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,915</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,308</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,308</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,308</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,308</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US Government debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above and in Note 2. The carrying value of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s assets with fair value categorized as Level 1 within the fair value hierarchy include money market funds. Money market funds are publicly traded mutual funds and are presented as cash equivalents on the consolidated balance sheets as of December 30, 2021 and December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its marketable securities at fair value on a recurring basis and classifies those instruments within Level 2 of the fair value hierarchy.<span style="font-size:12pt;"> </span>Marketable securities are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no transfers to Level&#160;3 in the periods presented. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063321320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Marketable Securities</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s marketable securities as of December 31, 2021 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,598</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,524</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US Government debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,998</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,904</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,083</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(168</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,915</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no marketable securities as of December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average maturity of the Company&#8217;s marketable securities as of December 31, 2021 ranges from approximately 0.2 years to 1.1 years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not record an allowance for credit losses as of December&#160;31, 2021 related to our marketable securities. Further, given the lack of significant change in the credit risk of these investments, the Company did&#160;not recognize any other-than-temporary impairment losses. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063323000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Property and equipment, net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,670</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,936</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,606</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,367</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,661</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,692</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,139</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,675</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $1.0 million and $0.9 million&#160;for the years ended December 31, 2021 and 2020, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063326024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued and other current liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Accrued and other current liabilities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued employee compensation costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,383</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,123</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">593</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,801</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,689</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,507</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,066</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,754</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,930</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063383272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.<span style="font-weight:normal;"> </span>Commitments and contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Company entered into an agreement to lease approximately 23,000 square feet of space for a term of three years. Lease terms are triple net lease commencing at $0.9 million per year, then with 3% annual base rent increases plus operating expenses, real estate taxes, utilities and janitorial fees. The lease commencement date was December&#160;10, 2018. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, the Company entered into an agreement to extend the initial term of the 23,000 square foot lease for a period of three years commencing on December 15, 2021 and ending December 31, 2024.&#160;&#160;In addition, this lease provides for the lease of an additional 15,000 square feet of rentable space beginning in April 2022 and ending on December 31, 2024. The Company recognized a right-of-use asset and operating lease liability of <span>$3.5</span> million for the 23,000 square feet.&#160;&#160;As the Company did not have access to the additional 15,000 square feet of space, a right of use asset was not recognized as of December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, the Company entered into an agreement to lease 2,485 square feet of space for an initial term of three years. The lease includes one renewal option for an additional two years, however, any time after the initial term the landlord may relocate the Company from the premises to a space reasonably comparable in size and utility. As the Company does not have the right to control the use of the identified asset after the initial term, the renewal option was excluded from the lease liability calculation. Lease terms commence at $0.2 million per annum, with 2.5% annual base rent increases plus operating expenses, real estate taxes, utilities and janitorial fees. The lease commencement date was May 1, 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-size:10pt;">In June 2021, the Company amended the agreement to extend the initial term of the 2,485 square foot lease for a period of three years commencing May 1, 2022 and ending April 30, 2025. In addition, the amendment provided for the lease of an additional 2,357 square feet of rentable space beginning on July 6, 2021 and ending on April 30, 2025. The amended lease provides the Company with the option to extend the term of the lease for an additional two years. The Company recognized a right-of-use asset and operating lease liabilities of $0.7 million for the extension of the lease to April 30, 2025 and a right-of-use asset and operating lease liabilities of $0.8 million for the additional 2,357 square feet of rentable space. </span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments under non-cancellable leases as of December 31, 2021, including leases entered into where access has yet to be granted, are as follows (in thousands): <span style="font-family:Calibri;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,124</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,532</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,608</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,437</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(462</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,975</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease balances as of December 31, 2021 and December 31, 2020 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,939</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,115</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Portion of operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,507</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,066</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current portion of operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,532</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,039</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,146</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average remaining lease term and weighted average discount rate of our operating leases as of December 31, 2021 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease term in years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000411">3.1</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.14</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Topic 842, lease expense incurred under operating leases was approximately $1.4 million for the year ended December 31, 2021, and $1.1 million for the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Consulting Agreement </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2014, the Company entered into a consulting agreement with a member of the Company&#8217;s board of directors, who is also an employee of Cold Spring Harbor Laboratory (&#8220;CSHL&#8221;), to provide consulting services related to scientific research related to the development of antisense-based drugs, therapies, diagnostic and research tools, products, services and intellectual property. The Company recognized expenses of $0.02 million for the year ended December 31, 2020. The initial term of this agreement was five years and the parties mutually agreed not to extend the consulting agreement in April 2020. &#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Scientific Advisory Board Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, the Company entered into a scientific advisory board agreement with a member of the Company&#8217;s board of directors, who is also an employee of CSHL, to provide scientific advisory services related to the Company&#8217;s Targeted Augmentation of Nuclear Gene Output (&#8220;TANGO&#8221;) antisense oligonucleotide technology and other antisense oligonucleotide technologies, as well as current and future therapeutic targets and programs. Following the expiration of the initial scientific agreement in June 2021, the parties entered into a subsequent scientific board agreement. The Company recognized expense of $0.05 million each for the years ended December 31, 2021 and 2020 for such scientific advisory services. The term of this agreement is 12 months.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License and research agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, the Company entered into a worldwide license agreement, or the CSHL Agreement, with CSHL, with respect to TANGO patents. Under the CSHL Agreement, the Company receives an exclusive (except with respect to certain government rights and non-exclusive licenses), worldwide license under certain patents and applications relating to TANGO. The CSHL Agreement obligates the Company to make payments that are contingent upon certain milestones being achieved. The Company is also required to pay royalties, tiered based on the scope of patent coverage for each licensed product, ranging from a low-single digit percentage to a mid-single digit percentage on annual net sales. These royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until the latest of (i)&#160;the expiration of the last valid claim of a CSHL patent covering the applicable licensed product or (ii)&#160;the expiration of any regulatory exclusivity for the applicable licensed product. In addition, if the Company sublicenses the rights under the CSHL Agreement, the Company is required to pay a maximum of twenty percent of the sublicense revenue to CSHL, which may be reduced to a mid-teens or a mid-single digit percentage upon achievement of certain clinical milestones for the applicable licensed product. Finally, the Company is required to pay an annual license maintenance fee of $0.01 million, which amount is creditable against any owed royalty or milestone payments. The maximum aggregate potential milestone payments payable total approximately $0.9 million. Additionally, certain licenses under the CSHL Agreement require the Company to reimburse CSHL for certain past and ongoing patent related expenses, however there were no expenses related to these reimbursable patent costs during the years ended December 31, 2021 and 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, the Company entered into an exclusive, worldwide license agreement with the University of Southampton, or the Southampton Agreement, whereby the Company acquired rights to foundational technologies related to the Company&#8217;s TANGO technology. Under the Southampton Agreement, the Company receives an exclusive, worldwide license under certain licensed patents and applications relating to TANGO. Under the Southampton Agreement, the Company may be obligated to make additional payments that are contingent upon certain milestones being achieved, as well as royalties on future product sales. These royalty obligations survive until the latest of (i)&#160;the expiration of the last valid claim of a licensed patent covering a subject product or (ii)&#160;the expiration of any regulatory exclusivity for the subject product in a country. In addition, if the Company sublicenses its rights under the Southampton Agreement, the Company is required to pay a mid-single digit percentage of the sublicense revenue to the University of Southampton. The maximum aggregate potential milestone payments payable by the Company total approximately 0.4 million pounds sterling (approximately $0.5 million as of December 31, 2021). As of December 31, 2021, and 2020, the Company has recorded no liabilities under the Southampton Agreement. For the year ended December 31, 2021 these expenses were $0.12 million compared to $0.09 million for the year ended December 31, 2020. Additionally, certain licenses under the Southampton Agreement require the Company to reimburse the University of Southampton for certain past and ongoing patent related expenses. (see note 12 for payments to University of Southampton)</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Litigation </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which it is focused. As of December 31, 2021, the Company had no legal proceedings to which it was a party or to which its property was subject. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063326024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Share-Based Compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company&#8217;s board of directors and stockholders approved the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which became effective on June 17, 2019 and replaced the Company&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;). In addition to the shares of common stock reserved for future issuance under the 2014 Plan that were added to the 2019 Plan upon its effective date, the Company initially reserved 2,200,000 shares of common stock for issuance under the 2019 Plan. The number of shares reserved for issuance under the Company&#8217;s 2019 Plan will increase automatically on January 1 of each of 2020 through 2029 by the number of shares equal to 4% of the aggregate number of outstanding shares of the Company&#8217;s common stock as of the immediately preceding December 31, or a lesser number as may be determined by the Company&#8217;s board of directors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 there were no shares available for future issuance under the 2014 Plan and 2,372,006 shares were available under the 2019 Plan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2021 and December 31, 2020, the Company granted options to purchase 1,311,897 and 1,231,532 shares of common stock to certain of its employees, and directors, respectively. The options vest up to four years except for certain options granted to members of our board of directors which vest over one or three years and are exercisable at a per share price equal to the fair value of the common stock on the grant date. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of stock option activity for awards is presented below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:94.36%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">life (years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,454,422</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.80</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000454">8.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,685</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,311,897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53.93</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(287,566</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.70</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,973</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40.12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,476</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.73</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,435,304</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.77</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000455">8.0</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,981</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,103,635</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000456">6.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,003</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at December 31, 2021 and 2020. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value per share of stock options granted during the years ended December 31, 2021 and 2020 was $34.07 and $14.75, respectively. The aggregate grant date fair value of stock options granted during the years ended December 31, 2021 and 2020 was approximately $44.7 million and $18.2 million, respectively. The aggregate intrinsic value of stock options exercised during the year ended December 31, 2021 and 2020 was approximately $9.9 million and $27.3 million, respectively.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based compensation and stock options </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense of $16.5 million and $5.8 million during the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, there was $45.0 million of unrecognized compensation cost related to unvested stock-based compensation arrangements granted under the 2014 and the 2019 Plans. The compensation is expected to be recognized over a weighted average period of 2.8 years as of December 31, 2021. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense recorded as research and development and general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,215</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,875</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,235</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,893</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,450</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,768</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option pricing model to calculate the grant-date fair value of an award. The fair values of the options granted to employees and directors were calculated using the following assumptions for the years ended December 31, 2021 and 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000478">0.78-1.51%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000479">0.38-1.48%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000482">5.5-6.25 years</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000484">5.5-6.25 years</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70-73%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2019 Employee stock purchase plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company adopted the 2019 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), which became effective on June 18, 2019. The Company initially reserved 315,000 shares of common stock for sale under the ESPP. At December 31, 2021, the Company had 634,580 shares available for issuance under the plan. The average grant date fair value per share under the plan was $46.08 for 2021. The total ESPP stock-based compensation expense for the year ended December 31, 2021 was $0.3 million and for the year ended December 31, 2020 was $0.3 million. The number of shares reserved for issuance under the ESPP will increase automatically on January 1st of each of the first ten calendar years following the first offering date by the number of shares equal to the lesser of 1% of the total outstanding shares of the Company&#8217;s common stock as of the immediately preceding December 31 or a lower amount determined by the Company&#8217;s board of directors. The aggregate number of shares issued over the term of the ESPP will not exceed 3,150,000 shares of the Company&#8217;s common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113064620520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per share attributable to common stockholders</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">9. <span style="font-family:Times New Roman;">Net loss per share attributable to common stockholders </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,805</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,243</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of common shares, basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and diluted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,739,269</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,488,456</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.34</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.56</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potential dilutive securities, which include common stock options and ESPP purchase rights, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,435,304</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,454,424</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063370328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Income taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the expected income tax expense (benefit) computed using the federal statutory income tax rate the Company&#8217;s effective income tax rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected income tax benefit at the federal statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible items</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The principal components of the Company&#8217;s deferred tax assets and liabilities consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,231</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,097</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,726</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,816</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,075</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,293</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,206</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,032</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> As of December 31, 2021 and 2020, the Company had federal net operating loss carryforwards of $191.1 million and $116.9 million, respectively, which may be available to reduce future taxable income, and expire at various dates beginning in 2034, for those net operating loss carryforwards generated prior to 2018. Net operating losses generated in 2018 and beyond have no expiration. As of December 31, 2021 and 2020, the Company had state net operating loss carry forwards of $191.4 million and $118.8 million, respectively, which may be available to reduce future taxable income and expire at various dates beginning in 2034. In addition, at December 31, 2021 and 2020, the Company had federal research and development tax credit carryforwards of $5.4 million and $2.0 million, respectively, and state research and development tax credit carry forwards of $3.0 million and $1.0 million, respectively.&#160;&#160;Both federal and state research and development tax credit carry forwards may be available to reduce future tax liabilities and expire at various dates beginning in 2030. In accordance with ASC 740, <span style="font-style:italic;">Accounting for Income Taxes</span>, management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards. Management has determined that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets and, as a result, a full valuation allowance of $66.0 million and $37.2 million was established at December 31, 2021 and 2020, respectively. The change in the valuation allowance was an increase of $28.8 million and $19.3 million in 2021 and 2020, respectively.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CARES Act temporarily repealed the 80% taxable income limitation for tax years beginning before January 1, 2021. Federal NOL carry forwards generated from 2018 or later and Federal NOL carryforwards to taxable years beginning after December 31, 2021 will be subject to the 80% limitation. Also, under the CARES Act, federal NOLs arising in 2018, 2019 and 2020 can be carried back 5 years. New legislation or regulation which could affect our tax burden could be enacted by any governmental authority. The Company cannot predict the timing or extent of such&#160;tax-related&#160;developments which could have a negative impact on our financial results. Additionally, the Company uses its best judgment in attempting to quantify and reserve for these tax obligations. </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended (the Code) due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. The Company has not conducted a formal study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined for purposes of Section&#160;382 and 383 of the Code, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards may be subject to an annual limitation under Section&#160;382 and 383 of the Code, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term&#160;tax-exempt&#160;rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies ASC 740 related to accounting for uncertainty in income taxes. The Company&#8217;s reserves related to income taxes are based on a determination of whether, and how much of, a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. At December 31, 2021, and 2020 the Company had no unrecognized tax benefits. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as income tax expense in the accompanying consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063176760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee benefits</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Employee benefits </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-size:10pt;">In 2016, the Company established a defined-contribution savings plan under Section&#160;401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. On January 1, 2020, the Company began to make matching contributions up to 4% of annual salary for those employees who are participating in the 401(k) Plan. For the year ended December 31, 2021, the Company made matching contributions of $0.5 million and for the year ended December 31, 2020, the Company made matching contributions of $0.2 million. </span>&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113064694952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. Subsequent events </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, the Company entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. (&#8220;Acadia&#8221;) for the discovery, development and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (the &#8220;CNS&#8221;). The agreement focuses on the targets SYNGAP1, MECP2 (Rett syndrome), and an undisclosed neurodevelopmental target of mutual interest. In connection with each target, the Company will collaborate with Acadia to identify potential treatments for further development and commercialization as licensed products. With respect to SYNGAP1, the Company has agreed with Acadia to co-develop and co-commercialize licensed products for such target globally, and in connection therewith the Company granted to Acadia worldwide, co-exclusive (with the Company) licenses for such licensed products. With respect to MECP2 and the neurodevelopmental target, the Company granted to Acadia worldwide, exclusive licenses to develop and commercialize licensed products for such targets. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the agreement, the Company received an upfront payment of $60 million from Acadia. Acadia agreed to fund the research to identify potential licensed products for MECP2 and the neurodevelopmental target, and the Company will equally fund with Acadia the research to identify potential licensed products for SYNGAP1. The Company is eligible to receive up to $907.5 million in potential total milestone payments based upon the achievement of certain development, regulatory, first commercial sales and sales milestone events across the programs for the three targets, assuming each milestone were achieved at least once. With respect to licensed products for MECP2 and the neurodevelopmental target, the Company is also eligible to receive tiered royalties at percentages ranging from the mid-single digits to the mid-teens on future net sales by Acadia of licensed products worldwide. Royalties payable under the agreement are subject to standard royalty reductions. For SYNGAP1 licensed products that the Company is co-developing and co-commercializing, the Company will be responsible for 50% of the development and commercialization costs and will receive 50% of the profits from global commercialization.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of and related to the out-license of SYNGAP1, the Company is obligated to make payments to the University of Southampton under certain licensed patents and applications relating to TANGO.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since December 31, 2021, the Company sold approximately 403,000 shares of our common stock and received $7.5 million after deducting commissions related to the Sales Agreement. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated subsequent events through the issuance date of these consolidated financial statements.&#160;&#160;The Company has concluded that no events or transactions other than those described above have occurred that require disclosure in the accompanying consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063461672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of presentation and consolidation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP), and include the accounts of Stoke Therapeutics, Inc. and its wholly-owned subsidiary. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). All intercompany transactions between and among the Company and its&#8217; consolidated subsidiary have been eliminated. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, expenses and disclosure of contingent assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and cash equivalents </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash in checking, sweep and money market accounts. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted cash </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2021, restricted cash consisted of money market accounts collateralizing letters of credit issued as security deposits in connection with the Company&#8217;s leases of its corporate facilities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reconciles cash and cash equivalents and restricted cash per the consolidated balance sheets to the statement of cash flows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,895</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,308</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">569</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,464</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,513</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities consist of government securities and obligations, corporate bonds and commercial paper with original maturities of more than 90 days. Investments are classified as available-for-sale and are recorded on the balance sheet at fair value with unrealized gains or losses reported as a separate component of other comprehensive income/(loss). Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at an accredited financial institution in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair value of financial instruments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC Topic 820, <span style="font-style:italic;">Fair Value Measurement</span> (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC&#160;820 establishes a three-tier value hierarchy that distinguishes between the following: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;Quoted market prices in active markets for identical assets or liabilities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred offering costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with&#160;in-process&#160;equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in the consolidated statement of stockholders&#8217; equity as a reduction of additional&#160;paid-in&#160;capital. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying consolidated statements of operations and comprehensive loss. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful lives for property and equipment are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="width:45%; border-bottom:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="width:1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td style="width:45%; border-bottom:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;width:45%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer and office equipment</p></td>
<td style="background-color:#CFF0FC;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:45%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-5 years</p></td>
</tr>
<tr>
<td style="width:45%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment and Furniture and fixtures</p></td>
<td style="width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td style="width:45%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-7 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;width:45%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:45%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesser of estimated useful life or remaining lease term</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of long-lived assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the assets may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the assets from the expected future cash flows (undiscounted and without interest expense) of the related operations. If these cash flows are less than the carrying value of such assets, an impairment loss for the difference between the estimated fair value and carrying value is recorded. There were no impairment losses recognized during the years ended December 31, 2021 and 2020. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, depreciation, third-party license fees, and costs related to third parties engaged to conduct preclinical research development activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions and other companies to conduct research on its behalf. These agreements are generally cancellable. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Options</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock options </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its stock-based awards granted based on the estimated fair values of the awards and recognizes the compensation for employees and nonemployees over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock-based awards. The Company has elected the practical expedient to use the midpoint between vesting date and the contractual term as the expected term for certain awards with service or performance conditions. Stock-based compensation is recognized using the straight-line method. Forfeitures of unvested stock-based awards are accounted for when they occur. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent costs </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements. The Company adopted Topic 842 on January 1, 2020 using the modified retrospective approach and elected to apply the transition method that allows companies to continue applying guidance under the lease standard in effect at that time in the comparative period financial statements and recognize a cumulative-effect adjustment to the balance sheet on the date of adoption. The Company has also elected the package of practical expedients to not reassess its prior conclusions about lease identification, lease classification and indirect costs and to not separate lease and non-lease components.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon adoption of Topic 842 on January 1, 2020, the Company recorded right-of-use assets of $2.2 million, operating lease liabilities of $2.2 million and the elimination of deferred rent of $0.03 million. Adoption of the standard did not result in the Company recording a cumulative effect adjustment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines whether an arrangement is a lease at inception. The Company accounts for a lease when it has the right to control the leased asset for a period of time while obtaining substantially all of the assets&#8217; economic benefits. The Company determined that it held operating leases for office and laboratory space as of January 1, 2020. Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. The discount rate used to determine the present value of the lease payments is the Company&#8217;s incremental borrowing rate based on the information available at lease inception, as the Company does not have information to determine the rate implicit in the leases. Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments (which include initial direct costs and lease incentives). The expense is included in operating expenses in the consolidated statements of operations and comprehensive loss. The Company&#8217;s lease agreements also contain variable payments, primarily maintenance-related costs, which are expensed as incurred and not included in the measurement of the right-of-use assets and lease liabilities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be settled or recovered. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December 31, 2021 and 2020, the Company has recorded a full valuation allowance. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Tax Cuts and Jobs Act (the TCJA) was enacted on December&#160;22, 2017. The TCJA reduced the U.S. federal corporate tax rate from a top rate of 35% to a flat rate of 21%. The Company continues to monitor for legislative developments, issuance of regulations and technical memorandum to provide further clarification and/or interpretations of the TCJA and will adjust its consolidated financial statements as needed. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment and geographic information </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in one segment in the United States. The Company&#8217;s chief executive officer, as the chief operating decision-maker, manages and allocates resources to the operations of the Company on a total company basis using consolidated financial information. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock', window );">Emerging Growth Company and Smaller Reporting Company Status</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging growth company and smaller reporting company status </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&#160;Act). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act, until such time as those standards apply to private companies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS&#160;Act. As a result, the Company&#8217;s consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will remain an emerging growth company until the earliest of (i)&#160;the last day of its first fiscal year (a)&#160;&#160;in which the Company has total annual gross revenues of at least $1.07&#160;billion or (b)&#160;in which the Company is deemed to be a large accelerated filer, which means the market value of the Company&#8217;s common stock that is held by non-affiliates exceeds $700.0&#160;million as of the prior June 30<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>, (ii)&#160;the date on which the Company has issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period, and (iii) December 31, 2024</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also a &#8220;smaller reporting company,&#8221; meaning that in the event of an initial public offering the market value of its stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to the Company as a result of such offering is less than $700&#160;million and its annual revenue is less than $100&#160;million during the most recently completed fiscal year. The Company may continue to be a smaller reporting company as long as either (i)&#160;the market value of its stock held by non-affiliates is less than $250&#160;million or (ii)&#160;its annual revenue is less than $100 million during the most recently </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">completed fiscal year and the market value of its stock held by non-affiliates is less than $700&#160;million. If the Company is a smaller reporting company at the time it ceases to be an emerging growth company, the Company may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, the Company may choose to present only the two most recent fiscal years of audited financial statements in its Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently issued accounting pronouncements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.46%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, the FASB issued ASU 2017-11, <span style="font-style:italic;">Earnings Per Share</span> (Topic 260), <span style="font-style:italic;">Distinguishing Liabilities from Equity</span> (Topic 480) and <span style="font-style:italic;">Derivatives and Hedging</span> (Topic 815): <span style="font-style:italic;">I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</span>. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, <span style="font-style:italic;">Distinguishing Liabilities from Equity</span>, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this update do not have an accounting effect. For public business entities, the amendments in Part I of ASU-2017-11 are effective for fiscal years and interim periods within those years beginning after December&#160;15, 2018. For all other entities, the amendments in Part I of this update are effective for fiscal years beginning after December&#160;15, 2019, and interim periods within fiscal years beginning after December&#160;15, 2020. We adopted this update on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.46%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13,<span style="font-style:italic;">&#160;&#8220;Fair Value Measurement (Topic 820), Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement&#8221;.</span>&#160;This ASU removed the following disclosure requirements: (1)&#160;the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy; (2)&#160;the policy for timing of transfers between levels; and (3)&#160;the valuation processes for Level&#160;3 fair value measurements. Additionally, this update added the following disclosure requirements: (1)&#160;the changes in unrealized gains and losses for the period included in other comprehensive income and loss for recurring Level&#160;3 fair value measurements held at the end of the reporting period; (2)&#160;the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level&#160;3 fair value measurements. ASU&#160;2018-13 is effective for all entities, for fiscal years beginning after December&#160;15, 2019 with early adoption permitted. We adopted this update on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.36%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.36%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12,&#160;<span style="font-style:italic;">Income Taxes</span>&#160;<span style="font-style:italic;">(Topic 740): Simplifying the Accounting for Income Taxes.</span>&#160;This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for interim and annual periods beginning after December 15, 2020, and early adoption is permitted. <span style="Background-color:#FFFFFF;">The Company adopted this standard on January 1, 2021 and the adoption of this update did not have a material impact on its consolidated financial statements.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company and smaller reporting company status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063183656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reconciles cash and cash equivalents and restricted cash per the consolidated balance sheets to the statement of cash flows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,895</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,308</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">569</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,464</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,513</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">Schedule of Estimated Useful Lives for Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful lives for property and equipment are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="width:45%; border-bottom:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="width:1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td style="width:45%; border-bottom:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful life</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;width:45%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer and office equipment</p></td>
<td style="background-color:#CFF0FC;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:45%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-5 years</p></td>
</tr>
<tr>
<td style="width:45%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment and Furniture and fixtures</p></td>
<td style="width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td style="width:45%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-7 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;width:45%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:45%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesser of estimated useful life or remaining lease term</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash, cash equivalents and restricted cash and equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063211064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,897</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,897</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,524</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,524</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US Government debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,904</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,904</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,915</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,915</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,308</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,308</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,308</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287,308</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US Government debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063353736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s marketable securities as of December 31, 2021 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,598</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,524</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US Government debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,998</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,904</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,083</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(168</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,915</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113064686680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property, and Equipment, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,670</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,936</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,606</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,367</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,661</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,692</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,139</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,675</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063357256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued and Other Current Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued employee compensation costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,383</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,123</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">593</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,801</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,689</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,507</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,066</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,754</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,930</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113144515656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments under non-cancellable leases as of December 31, 2021, including leases entered into where access has yet to be granted, are as follows (in thousands): <span style="font-family:Calibri;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,124</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,532</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,608</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,437</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(462</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,975</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_SummaryOfLeaseBalancesTableTextBlock', window );">Summary of Lease Balances</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease balances as of December 31, 2021 and December 31, 2020 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,939</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,115</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Portion of operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,507</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,066</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current portion of operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,532</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,039</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,146</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock', window );">Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate of Operating Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average remaining lease term and weighted average discount rate of our operating leases as of December 31, 2021 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease term in years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000411">3.1</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.14</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_SummaryOfLeaseBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of lease balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_SummaryOfLeaseBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of weighted average remaining lease term and weighted average discount rate of operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113144584312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity for Awards</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of stock option activity for awards is presented below: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:94.36%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">life (years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,454,422</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.80</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000454">8.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,685</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,311,897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53.93</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(287,566</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.70</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,973</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40.12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,476</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.73</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,435,304</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.77</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000455">8.0</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,981</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,103,635</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000456">6.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,003</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense recorded as research and development and general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,215</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,875</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,235</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,893</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,450</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,768</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Fair Values of Options Granted to Employees and Directors</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option pricing model to calculate the grant-date fair value of an award. The fair values of the options granted to employees and directors were calculated using the following assumptions for the years ended December 31, 2021 and 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000478">0.78-1.51%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000479">0.38-1.48%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000482">5.5-6.25 years</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000484">5.5-6.25 years</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70-73%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063220648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,805</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,243</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of common shares, basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and diluted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,739,269</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,488,456</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.34</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.56</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,435,304</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,454,424</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063157928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Expected Income Tax Expense (Benefit) using Federal Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the expected income tax expense (benefit) computed using the federal statutory income tax rate the Company&#8217;s effective income tax rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected income tax benefit at the federal statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible items</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The principal components of the Company&#8217;s deferred tax assets and liabilities consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,231</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,097</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,726</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,816</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,075</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,293</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,206</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,032</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113059840216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 24, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity incorporation state name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_SecuritiesIssuedInConnectionWithShelfRegistration', window );">Securities issued in connection with shelf registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet', window );">Net proceeds from underwritten public offering</a></td>
<td class="nump">$ 104,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=stok_BaseProspectusMember', window );">Base Prospectus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=stok_SalesAgreementProspectusMember', window );">Sales Agreement Prospectus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet', window );">Net proceeds from underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=stok_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="nump">2,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued, price per share</a></td>
<td class="nump">$ 39.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_NatureOfBusinessAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature of the business and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_NatureOfBusinessAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance underwritten public offering net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_SecuritiesIssuedInConnectionWithShelfRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities issued in connection with shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_SecuritiesIssuedInConnectionWithShelfRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=stok_BaseProspectusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=stok_BaseProspectusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=stok_SalesAgreementProspectusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=stok_SalesAgreementProspectusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=stok_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=stok_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113061026264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 144,895<span></span>
</td>
<td class="nump">$ 287,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 145,464<span></span>
</td>
<td class="nump">$ 287,513<span></span>
</td>
<td class="nump">$ 222,676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063461960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Estimated Useful Lives for Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=stok_ComputerAndOfficeEquipmentMember', window );">Computer and Office Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=stok_ComputerAndOfficeEquipmentMember', window );">Computer and Office Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=stok_LaboratoryEquipmentAndFurnitureAndFixturesMember', window );">Laboratory Equipment and Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=stok_LaboratoryEquipmentAndFurnitureAndFixturesMember', window );">Laboratory Equipment and Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful life</a></td>
<td class="text">Lesser of estimated useful life or remaining lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=stok_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=stok_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=stok_LaboratoryEquipmentAndFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=stok_LaboratoryEquipmentAndFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113056048136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">4,939,000<span></span>
</td>
<td class="nump">1,115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">6,975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Cumulative effect adjustment</a></td>
<td class="nump">217,777,000<span></span>
</td>
<td class="nump">$ 286,078,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,428,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized income tax benefits, interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02 | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Cumulative effect adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member', window );">ASU 2017-11</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member', window );">ASU 2018-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">ASU 2019-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201711Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113056174968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total Marketable Securities</a></td>
<td class="nump">$ 74,915<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total Marketable Securities</a></td>
<td class="nump">17,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total Marketable Securities</a></td>
<td class="nump">27,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total Marketable Securities</a></td>
<td class="nump">29,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">144,897<span></span>
</td>
<td class="nump">287,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total Marketable Securities</a></td>
<td class="nump">74,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">144,897<span></span>
</td>
<td class="nump">287,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">144,897<span></span>
</td>
<td class="nump">287,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">144,897<span></span>
</td>
<td class="nump">$ 287,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total Marketable Securities</a></td>
<td class="nump">74,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total Marketable Securities</a></td>
<td class="nump">17,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Corporate Bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total Marketable Securities</a></td>
<td class="nump">17,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total Marketable Securities</a></td>
<td class="nump">27,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total Marketable Securities</a></td>
<td class="nump">27,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | US Government Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total Marketable Securities</a></td>
<td class="nump">29,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | US Government Debt Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total Marketable Securities</a></td>
<td class="nump">$ 29,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063363752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Fair value assets, transfers to level 3, amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113056027656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable Securities, Amortized Cost</a></td>
<td class="nump">$ 75,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable Securities, Unrealized Loss</a></td>
<td class="num">(168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable Securities, Fair Value</a></td>
<td class="nump">74,915<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable Securities, Amortized Cost</a></td>
<td class="nump">17,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable Securities, Unrealized Loss</a></td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable Securities, Fair Value</a></td>
<td class="nump">17,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable Securities, Amortized Cost</a></td>
<td class="nump">27,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable Securities, Fair Value</a></td>
<td class="nump">27,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable Securities, Amortized Cost</a></td>
<td class="nump">29,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable Securities, Unrealized Loss</a></td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable Securities, Fair Value</a></td>
<td class="nump">$ 29,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113064607352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 74,915<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_DebtSecuritiesAvailableForSaleMaturityPeriod', window );">Weighted average maturity marketable securities period</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_DebtSecuritiesAvailableForSaleMaturityPeriod', window );">Weighted average maturity marketable securities period</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_DebtSecuritiesAvailableForSaleMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities available-for-sale maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_DebtSecuritiesAvailableForSaleMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113060051592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property, and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, and equipment, gross</a></td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="nump">$ 4,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(2,661)<span></span>
</td>
<td class="num">(1,692)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, and equipment, net</a></td>
<td class="nump">4,139<span></span>
</td>
<td class="nump">2,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, and equipment, gross</a></td>
<td class="nump">4,670<span></span>
</td>
<td class="nump">3,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, and equipment, gross</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, and equipment, gross</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, and equipment, gross</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, and equipment, gross</a></td>
<td class="nump">$ 1,606<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113064701384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 974<span></span>
</td>
<td class="nump">$ 888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113059003704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee compensation costs</a></td>
<td class="nump">$ 5,383<span></span>
</td>
<td class="nump">$ 4,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development costs</a></td>
<td class="nump">6,801<span></span>
</td>
<td class="nump">3,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">1,507<span></span>
</td>
<td class="nump">1,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AccruedAndOtherCurrentLiabilities', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 14,754<span></span>
</td>
<td class="nump">$ 9,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_AccruedAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_AccruedAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113053730456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Option</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AreaOfSpaceSubjectToOperatingLease', window );">Area of space subject to operating lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,485<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_OperatingLeaseCostPerYear', window );">Operating lease cost per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AnnualBaseRentIncreasePercentageForOperatingLease', window );">Annual base rent increase percentage for operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_OperatingLeaseCommencementDate', window );">Operating lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  01,  2019<span></span>
</td>
<td class="text">Dec. 10,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,939,000<span></span>
</td>
<td class="nump">$ 1,115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms', window );">Number of options to renewal operating lease term | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities recorded under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,088,000<span></span>
</td>
<td class="nump">11,847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=stok_ColdSpringHarborLaboratoryAgreementMember', window );">CSHL Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue', window );">Percentage of maximum required payment of sublicense revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_MaximumAggregatePotentialMilestonePaymentsPayable', window );">Maximum aggregate potential milestone payments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_ExpensesRelatedToReimbursablePatentCosts', window );">Expenses related to reimbursable patent costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=stok_SouthamptonAgreementMember', window );">Southampton Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_MaximumAggregatePotentialMilestonePaymentsPayable', window );">Maximum aggregate potential milestone payments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_ExpensesRelatedToReimbursablePatentCosts', window );">Expenses related to reimbursable patent costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">90,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities recorded under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Member of Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_ConsultingServicesExpenses', window );">Consulting services expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_ConsultingServicesAgreementTerm', window );">Consulting services agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_ScientificAdvisoryServicesExpenses', window );">Scientific advisory services expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000.00<span></span>
</td>
<td class="nump">50,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_ScientificAdvisoryServicesAgreementTerm', window );">Scientific advisory services agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating leases expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=stok_LeaseCommencementTwoThousandAndTwentyOneMember', window );">Lease Commencement on December 15, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AreaOfSpaceSubjectToOperatingLease', window );">Area of space subject to operating lease | ft&#178;</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_OperatingLeaseCommencementDate', window );">Operating lease commencement date</a></td>
<td class="text">Dec. 15,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease expiration date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=stok_LeaseCommencementTwoThousandAndTwentyTwoMember', window );">Lease Commencement on April 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AreaOfSpaceSubjectToOperatingLease', window );">Area of space subject to operating lease | ft&#178;</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease expiration date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_OperatingLeaseCommencementMonthAndYear', window );">Operating lease commencement month and year</a></td>
<td class="text">2022-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=stok_LeaseExtensionEndDateMember', window );">Lease Extension End Date April 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AreaOfSpaceSubjectToOperatingLease', window );">Area of space subject to operating lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_OperatingLeaseCommencementDate', window );">Operating lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease', window );">Area of additional space subject to operating lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AdditionalOperatingLeaseCommencementDate', window );">Additional operating lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  06,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AdditionalLeaseExpirationDate', window );">Additional operating lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AdditionalOperatingLeaseRightOfUseAsset', window );">Additional operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_AdditionalOperatingLeaseLiabilities', window );">Additional operating lease, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The amended lease provides the Company with the option to extend the term of the lease for an additional two years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, existence of option to extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_AdditionalLeaseExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional lease expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_AdditionalLeaseExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_AdditionalOperatingLeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional operating lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_AdditionalOperatingLeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_AdditionalOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional operating lease, liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_AdditionalOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_AdditionalOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional operating lease, right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_AdditionalOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_AnnualBaseRentIncreasePercentageForOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual base rent increase percentage for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_AnnualBaseRentIncreasePercentageForOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_AnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_AnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of additional rentable space subject to operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_AreaOfSpaceSubjectToOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of space subject to operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_AreaOfSpaceSubjectToOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_ConsultingServicesAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consulting services agreement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_ConsultingServicesAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_ConsultingServicesExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consulting services expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_ConsultingServicesExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_ExpensesRelatedToReimbursablePatentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses related to reimbursable patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_ExpensesRelatedToReimbursablePatentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_MaximumAggregatePotentialMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate potential milestone payments payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_MaximumAggregatePotentialMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of renewal option to extend operating lease terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_OperatingLeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_OperatingLeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_OperatingLeaseCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease, commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_OperatingLeaseCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_OperatingLeaseCostPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease cost per year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_OperatingLeaseCostPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum required payment of sublicense revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_ScientificAdvisoryServicesAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Scientific advisory services agreement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_ScientificAdvisoryServicesAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_ScientificAdvisoryServicesExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Scientific advisory services expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_ScientificAdvisoryServicesExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=stok_ColdSpringHarborLaboratoryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=stok_ColdSpringHarborLaboratoryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=stok_SouthamptonAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=stok_SouthamptonAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=stok_LeaseCommencementTwoThousandAndTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=stok_LeaseCommencementTwoThousandAndTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=stok_LeaseCommencementTwoThousandAndTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=stok_LeaseCommencementTwoThousandAndTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=stok_LeaseExtensionEndDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=stok_LeaseExtensionEndDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113059849576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future minimum lease payments under non-cancellable leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 2,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">2,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">2,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">7,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 6,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113064094840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Lease Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 4,939<span></span>
</td>
<td class="nump">$ 1,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">$ 1,507<span></span>
</td>
<td class="nump">$ 1,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent<span></span>
</td>
<td class="text">us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of operating lease liabilities</a></td>
<td class="nump">$ 3,532<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Long term liabilities<span></span>
</td>
<td class="text">Long term liabilities<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 5,039<span></span>
</td>
<td class="nump">$ 1,146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability excluding leases entered access yet to be granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063167464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate of Operating Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term in years</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.14%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113059316200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option granted to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,311,897<span></span>
</td>
<td class="nump">1,231,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.07<span></span>
</td>
<td class="nump">$ 14.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Aggregate grant date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,700<span></span>
</td>
<td class="nump">$ 18,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
<td class="nump">27,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,450<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Expected weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Member of Board of Directors | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Member of Board of Directors | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=stok_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for issuance</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_PercentageOfIncreaseInReservedCommonShares', window );">Percentage of increase in reserved common shares</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,372,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=stok_TwoThousandAndFourteenEquityIncentivePlanMember', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for issuance</a></td>
<td class="nump">315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">634,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember', window );">2019 ESPP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for issuance</a></td>
<td class="nump">3,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_PercentageOfIncreaseInReservedCommonShares', window );">Percentage of increase in reserved common shares</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_PercentageOfIncreaseInReservedCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in reserved common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_PercentageOfIncreaseInReservedCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, grants in period, fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=stok_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=stok_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=stok_TwoThousandAndFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=stok_TwoThousandAndFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113063475608">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Stock Option Activity for Awards (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,454,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,311,897<span></span>
</td>
<td class="nump">1,231,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(287,566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(41,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares, Expired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,435,304<span></span>
</td>
<td class="nump">4,454,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Exercisable as of December 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,103,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19.77<span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable as of December 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">8 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 64,981<span></span>
</td>
<td class="nump">$ 236,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable as of December 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 52,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at December 31, 2021 and 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113053659016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">$ 16,450<span></span>
</td>
<td class="nump">$ 5,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">6,215<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">$ 10,235<span></span>
</td>
<td class="nump">$ 3,893<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113060013256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Fair Values of Options Granted to Employees and Directors (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.78%<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.51%<span></span>
</td>
<td class="nump">1.48%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113064222872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (85,805)<span></span>
</td>
<td class="num">$ (52,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares, basic and diluted</a></td>
<td class="nump">36,739,269<span></span>
</td>
<td class="nump">33,488,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (2.34)<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113056199640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">5,435,304<span></span>
</td>
<td class="nump">4,454,424<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113055951208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">66,032,000<span></span>
</td>
<td class="nump">37,206,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">$ 28,800,000<span></span>
</td>
<td class="nump">19,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct', window );">Percentage of taxable income, limitation repealed under CARES act</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct', window );">Percentage of federal NOL carry forwards subject to limitation under CARES act</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_FederalNOLCarryForwardsPeriodUnderCARESAct', window );">Federal NOL carry back period under CARES act</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 191,100,000<span></span>
</td>
<td class="nump">$ 116,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_OperatingLossCarryforwardsExpirationBeginningYear', window );">Operating loss carryforwards, expiration beginning year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">2034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development Tax Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_TaxCreditCarryforwardsExpirationBeginningYear', window );">Tax credit carryforwards, expiration beginning year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 191,400,000<span></span>
</td>
<td class="nump">$ 118,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_OperatingLossCarryforwardsExpirationBeginningYear', window );">Operating loss carryforwards, expiration beginning year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">2034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development Tax Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_TaxCreditCarryforwardsExpirationBeginningYear', window );">Tax credit carryforwards, expiration beginning year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">2030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_FederalNOLCarryForwardsPeriodUnderCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal NOL carry forwards period under CARES act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_FederalNOLCarryForwardsPeriodUnderCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_OperatingLossCarryforwardsExpirationBeginningYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration beginning year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_OperatingLossCarryforwardsExpirationBeginningYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of federal NOL carry forwards subject to limitation under CARES act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of taxable income, limitation repealed under CARES act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_TaxCreditCarryforwardsExpirationBeginningYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforwards expiration beginning year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_TaxCreditCarryforwardsExpirationBeginningYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113059959336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Expected Income Tax Expense (Benefit) using Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Expected income tax benefit at the federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible items</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit, net</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(33.40%)<span></span>
</td>
<td class="num">(36.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113059921320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state net operating loss carryforwards</a></td>
<td class="nump">$ 52,231<span></span>
</td>
<td class="nump">$ 32,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">7,726<span></span>
</td>
<td class="nump">2,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">6,075<span></span>
</td>
<td class="nump">2,293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">66,032<span></span>
</td>
<td class="nump">37,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">$ (66,032)<span></span>
</td>
<td class="num">$ (37,206)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113060000568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contributions to 401(k) Plan</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Maximum matching contribution percentage of employees salary</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113059752104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=stok_SalesAgreementProspectusMember', window );">Sales Agreement Prospectus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, Shares</a></td>
<td class="nump">403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet', window );">Net proceeds from underwritten public offering</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Acadia Pharmaceuticals Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_UpfrontPaymentReceived', window );">Upfront Payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_stok_MilestonePaymentsReceivable', window );">Potential milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 907.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_MilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_MilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance underwritten public offering net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_stok_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">stok_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>stok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=stok_SalesAgreementProspectusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=stok_SalesAgreementProspectusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=stok_AcadiaPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=stok_AcadiaPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>stok-10k_20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stok="http://www.stoketherapeutics.com/20211231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="stok-20211231.xsd" xlink:type="simple"/>
    <context id="C_0001623526_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001623526_20220301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="C_0001623526_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokBaseProspectusMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:BaseProspectusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokSalesAgreementProspectusMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:SalesAgreementProspectusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_stokUnderwrittenPublicOfferingMember_20201123_20201124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-23</startDate>
            <endDate>2020-11-24</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_stokUnderwrittenPublicOfferingMember_20201124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-24</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20201123_20201124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-23</startDate>
            <endDate>2020-11-24</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201123_20201124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-23</startDate>
            <endDate>2020-11-24</endDate>
        </period>
    </context>
    <context id="C_0001623526_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokComputerAndOfficeEquipmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">stok:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokComputerAndOfficeEquipmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">stok:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokLaboratoryEquipmentAndFurnitureAndFixturesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">stok:LaboratoryEquipmentAndFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokLaboratoryEquipmentAndFurnitureAndFixturesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">stok:LaboratoryEquipmentAndFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="C_0001623526_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="C_0001623526_20170101_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201711Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201711Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201813Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_srtRangeAxis_srtMinimumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_srtRangeAxis_srtMaximumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_20180801_20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210901_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">stok:LeaseCommencementTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">stok:LeaseCommencementTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyTwoMember_20210901_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">stok:LeaseCommencementTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyTwoMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">stok:LeaseCommencementTwoThousandAndTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0001623526_20181201_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">stok:LeaseExtensionEndDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">stok:LeaseExtensionEndDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20150701_20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:ColdSpringHarborLaboratoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-01</startDate>
            <endDate>2015-07-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:ColdSpringHarborLaboratoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:ColdSpringHarborLaboratoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:ColdSpringHarborLaboratoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:SouthamptonAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:SouthamptonAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:SouthamptonAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">stok:SouthamptonAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEquityIncentivePlanMember_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEquityIncentivePlanMember_20190601_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndFourteenEquityIncentivePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEquityIncentivePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_srtRangeAxis_srtMinimumMember_srtTitleOfIndividualAxis_srtDirectorMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_srtRangeAxis_srtMaximumMember_srtTitleOfIndividualAxis_srtDirectorMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_srtRangeAxis_srtMinimumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_srtRangeAxis_srtMaximumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20190601_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">stok:TwoThousandAndNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001623526_srtCounterpartyNameAxis_stokAcadiaPharmaceuticalsIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">stok:AcadiaPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokSalesAgreementProspectusMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001623526</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">stok:SalesAgreementProspectusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_stokSegment">
        <measure>stok:Segment</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_stokOption">
        <measure>stok:Option</measure>
    </unit>
    <unit id="U_iso4217GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001623526_20210101_20211231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001623526_20210101_20211231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001623526_20210101_20211231" id="F_000006">0001623526</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001623526_20210101_20211231" id="F_000010">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231"
      id="F_000271">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201711Member_20211231"
      id="F_000281">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201711Member_20211231"
      id="F_000283">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20211231"
      id="F_000284">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20211231"
      id="F_000286">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231"
      id="F_000287">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231"
      id="F_000289">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630"
      id="F_000391">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001623526_20211231"
      id="F_000066"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001623526_20201231"
      id="F_000067"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001623526_20211231" id="F_000403">http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001623526_20201231" id="F_000404">http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndOtherAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001623526_20211231" id="F_000407">http://fasb.org/us-gaap/2021-01-31#LiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001623526_20201231" id="F_000408">http://fasb.org/us-gaap/2021-01-31#LiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001623526_20211231" id="F_000411">P3Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001623526_20200101_20201231" id="F_000454">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001623526_20210101_20211231" id="F_000455">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001623526_20210101_20211231" id="F_000456">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001623526_20210101_20211231"
      decimals="INF"
      id="F_000478"
      unitRef="U_xbrlipure">0.0151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001623526_20200101_20201231"
      decimals="INF"
      id="F_000479"
      unitRef="U_xbrlipure">0.0148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001623526_srtRangeAxis_srtMinimumMember_20210101_20211231"
      id="F_000482">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_20210101_20211231"
      id="F_000483">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001623526_srtRangeAxis_srtMinimumMember_20200101_20201231"
      id="F_000484">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_20200101_20201231"
      id="F_000485">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001623526_20210101_20211231"
      decimals="INF"
      id="F_000476"
      unitRef="U_xbrlipure">0.0078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001623526_20200101_20201231"
      decimals="INF"
      id="F_000477"
      unitRef="U_xbrlipure">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001623526_20210101_20211231"
      decimals="2"
      id="F_000486"
      unitRef="U_xbrlipure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001623526_20210101_20211231"
      decimals="2"
      id="F_000488"
      unitRef="U_xbrlipure">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <dei:DocumentType contextRef="C_0001623526_20210101_20211231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001623526_20210101_20211231" id="F_000028">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001623526_20210101_20211231" id="F_000002">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001623526_20210101_20211231" id="F_000003">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001623526_20210101_20211231" id="F_000029">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001623526_20210101_20211231" id="F_000019">001-38938</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001623526_20210101_20211231" id="F_000005">Stoke Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001623526_20210101_20211231" id="F_000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001623526_20210101_20211231" id="F_000021">47-1144582</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001623526_20210101_20211231" id="F_000022">45 Wiggins Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001623526_20210101_20211231" id="F_000023">Bedford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001623526_20210101_20211231" id="F_000024">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001623526_20210101_20211231" id="F_000025">01730</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001623526_20210101_20211231" id="F_000026">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001623526_20210101_20211231" id="F_000027">430-8200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001623526_20210101_20211231" id="F_000034">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001623526_20210101_20211231" id="F_000035">STOK</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001623526_20210101_20211231" id="F_000036">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001623526_20210101_20211231" id="F_000012">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001623526_20210101_20211231" id="F_000008">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001623526_20210101_20211231" id="F_000007">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001623526_20210101_20211231" id="F_000009">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001623526_20210101_20211231" id="F_000011">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001623526_20210101_20211231" id="F_000016">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001623526_20210101_20211231" id="F_000017">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="C_0001623526_20210101_20211231" id="F_000018">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001623526_20210101_20211231" id="F_000030">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001623526_20210101_20211231" id="F_000015">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001623526_20210630"
      decimals="-6"
      id="F_000013"
      unitRef="U_iso4217USD">665000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001623526_20220301"
      decimals="INF"
      id="F_000014"
      unitRef="U_xbrlishares">37359218</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000201">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Portions of the registrant&#x2019;s Definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K to the extent stated herein. The Definitive Proxy Statement will be filed within 120 days of the Registrant&#x2019;s fiscal year ended December 31, 2021.&#160;Except with respect to information specifically incorporated by reference in this Form 10-K, the Definitive Proxy Statement is not deemed to be filed as part of this Form 10-K.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Auditor Firm Id:&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;margin-left:36pt;"/&gt;&lt;span style="Background-color:#FFFFFF;"&gt;185&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;margin-left:36pt;"/&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Auditor Name:&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;margin-left:36pt;"/&gt;&lt;span style="Background-color:#FFFFFF;"&gt;KPMG LLP&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;margin-left:36pt;"/&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Auditor Location:&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;margin-left:36pt;"/&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Boston, MA USA&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="C_0001623526_20210101_20211231" id="F_000031">185</dei:AuditorFirmId>
    <dei:AuditorName contextRef="C_0001623526_20210101_20211231" id="F_000032">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="C_0001623526_20210101_20211231" id="F_000033">Boston, MA USA</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">144895000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">287308000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">74915000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">9159000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">6435000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">117000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">181000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">132000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">6000</us-gaap:InterestReceivableCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">229218000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">293930000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">569000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">205000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">4939000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">1115000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">4139000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">2675000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">238865000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">297925000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">2385000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">1495000</us-gaap:AccountsPayableCurrent>
    <stok:AccruedAndOtherCurrentLiabilities
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">14754000</stok:AccruedAndOtherCurrentLiabilities>
    <stok:AccruedAndOtherCurrentLiabilities
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">9930000</stok:AccruedAndOtherCurrentLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">17139000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">11425000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">3949000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">422000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">21088000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">11847000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001623526_20211231"
      decimals="INF"
      id="F_000079"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001623526_20201231"
      decimals="INF"
      id="F_000080"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001623526_20211231"
      decimals="INF"
      id="F_000081"
      unitRef="U_xbrlishares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001623526_20201231"
      decimals="INF"
      id="F_000082"
      unitRef="U_xbrlishares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001623526_20211231"
      decimals="INF"
      id="F_000083"
      unitRef="U_xbrlishares">36902499</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001623526_20211231"
      decimals="INF"
      id="F_000085"
      unitRef="U_xbrlishares">36902499</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001623526_20201231"
      decimals="INF"
      id="F_000084"
      unitRef="U_xbrlishares">36577149</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001623526_20201231"
      decimals="INF"
      id="F_000086"
      unitRef="U_xbrlishares">36577149</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">414024000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">396352000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">-168000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">-196083000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">-110278000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">217777000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">286078000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">238865000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">297925000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">54168000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">32197000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">31897000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">20847000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">86065000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">53044000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">-86065000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">-53044000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">120000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">700000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">140000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">101000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">260000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">801000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">-85805000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">-52243000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001623526_20210101_20211231"
      decimals="2"
      id="F_000103"
      unitRef="U_iso4217USD_xbrlishares">-2.34</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001623526_20200101_20201231"
      decimals="2"
      id="F_000104"
      unitRef="U_iso4217USD_xbrlishares">-1.56</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001623526_20210101_20211231"
      decimals="0"
      id="F_000105"
      unitRef="U_xbrlishares">36739269</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001623526_20200101_20201231"
      decimals="0"
      id="F_000106"
      unitRef="U_xbrlishares">33488456</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">-85805000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">-52243000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">-168000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">-168000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">-85973000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">-52243000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000113"
      unitRef="U_xbrlishares">32861842</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">282460000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">-58035000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_20191231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">224428000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">5768000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">5768000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000120"
      unitRef="U_xbrlishares">822916</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">2843000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">2843000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000123"
      unitRef="U_xbrlishares">17391</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">352000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">352000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20200101_20201231"
      decimals="INF"
      id="F_000126"
      unitRef="U_xbrlishares">2875000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">104929000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">104930000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">-52243000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">-52243000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000132"
      unitRef="U_xbrlishares">36577149</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">396352000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">-110278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">286078000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">-168000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">-168000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">16450000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">16450000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000141"
      unitRef="U_xbrlishares">304857</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">777000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">777000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000144"
      unitRef="U_xbrlishares">20493</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">509000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">509000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20210101_20211231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">-64000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokFollowOnOfferingMember_20210101_20211231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-64000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">-85805000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">-85805000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000151"
      unitRef="U_xbrlishares">36902499</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">414024000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">-168000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">-196083000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">217777000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">-85805000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">-52243000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">974000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">888000</us-gaap:Depreciation>
    <stok:AmortizationAndAccretionOfMarketableSecurities
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">143000</stok:AmortizationAndAccretionOfMarketableSecurities>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">16450000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">5768000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">-29000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">-3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <stok:ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">1256000</stok:ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets>
    <stok:ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">1038000</stok:ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">2851000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">2878000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">2897000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">5203000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-66907000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">-42221000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">1200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">1050000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">87226000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">12000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">-76426000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">-1050000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">105398000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">306000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">777000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">2843000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">509000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">352000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">179000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">-2000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">1284000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">108108000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">-142049000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">64837000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">287513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001623526_20191231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">222676000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">145464000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">287513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">5081000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">2153000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">1267000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">6000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <stok:DeferredOfferingCostsNotYetPaid
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">162000</stok:DeferredOfferingCostsNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000202">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Nature of the business and basis of presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Organization &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stoke Therapeutics, Inc. (the Company) was founded in June 2014 and was incorporated under the laws of the State of Delaware. The Company is an early-stage biopharmaceutical company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Shelf Registration&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2020, the Company filed a universal Shelf Registration statement on Form S-3 (the &#x201c;Registration Statement&#x201d;) with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). The Registration Statement was declared effective by the SEC on July 20, 2020,&#160;&#160;and contains two prospectuses: a base prospectus, which covers the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $400,000,000 of our common stock, preferred stock, debt securities, warrants to purchase our common stock, preferred stock or debt securities, subscription rights to purchase our common stock, preferred stock or debt securities and/or units consisting of some or all of these securities; and a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $150,000,000 of our common stock that may be issued and sold under a Controlled Equity Offering Sales Agreement (&#x201c;Sales Agreement&#x201d;). The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The $150,000,000 of common stock that may be offered, issued and sold under the sales agreement prospectus is included in the $400,000,000 of securities that may be offered, issued and sold by the Company under the base prospectus. As of December 31, 2021, the Company had not issued any securities in connection with the Sales Agreement. (see note 12 for sales of common stock subsequent to year end)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Follow-on public offering&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 24, 2020, pursuant to a prospectus supplement to the Registration Statement, we completed an underwritten public offering, of our common stock and issued and sold 2,875,000 shares of common stock at a public offering price of $39.00 per share, which included 375,000 shares sold upon full exercise of the underwriters&#x2019; option to purchase additional shares of common stock resulting in net proceeds of $104.9 million after deducting underwriting discounts and commissions and estimated offering expenses.&#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Uncertainties &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Liquidity &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expects that its operating losses and negative cash flows will continue for the foreseeable future. As of the issuance date of its consolidated financial statements for the year ended December 31, 2021, the Company expects that its cash and cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into 2024. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company plans to seek additional funding through public or private equity offerings, debt financings, other collaborations, strategic &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;alliances&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and licensing arrangements&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; (see note 12 for license and collaboration agreement entered&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;in&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;to&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; January 2022)&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. &lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001623526_20210101_20211231" id="F_000248">DE</dei:EntityIncorporationStateCountryCode>
    <stok:MaximumAggregateOfferingPrice
      contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokBaseProspectusMember_20200701_20200731"
      decimals="INF"
      id="F_000249"
      unitRef="U_iso4217USD">400000000</stok:MaximumAggregateOfferingPrice>
    <stok:MaximumAggregateOfferingPrice
      contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokSalesAgreementProspectusMember_20200701_20200731"
      decimals="INF"
      id="F_000251"
      unitRef="U_iso4217USD">150000000</stok:MaximumAggregateOfferingPrice>
    <stok:MaximumAggregateOfferingPrice
      contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokSalesAgreementProspectusMember_20200701_20200731"
      decimals="INF"
      id="F_000252"
      unitRef="U_iso4217USD">150000000</stok:MaximumAggregateOfferingPrice>
    <stok:MaximumAggregateOfferingPrice
      contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokBaseProspectusMember_20200701_20200731"
      decimals="INF"
      id="F_000250"
      unitRef="U_iso4217USD">400000000</stok:MaximumAggregateOfferingPrice>
    <stok:SecuritiesIssuedInConnectionWithShelfRegistration
      contextRef="C_0001623526_20211231"
      decimals="INF"
      id="F_000253"
      unitRef="U_iso4217USD">0</stok:SecuritiesIssuedInConnectionWithShelfRegistration>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_stokUnderwrittenPublicOfferingMember_20201123_20201124"
      decimals="INF"
      id="F_000254"
      unitRef="U_xbrlishares">2875000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_stokUnderwrittenPublicOfferingMember_20201124"
      decimals="INF"
      id="F_000255"
      unitRef="U_iso4217USD_xbrlishares">39.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20201123_20201124"
      decimals="INF"
      id="F_000256"
      unitRef="U_xbrlishares">375000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <stok:ProceedsFromIssuanceUnderwrittenPublicOfferingNet
      contextRef="C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201123_20201124"
      decimals="-5"
      id="F_000257"
      unitRef="U_iso4217USD">104900000</stok:ProceedsFromIssuanceUnderwrittenPublicOfferingNet>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000203">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Summary of significant accounting policies and recent accounting pronouncements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of presentation and consolidation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP), and include the accounts of Stoke Therapeutics, Inc. and its wholly-owned subsidiary. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). All intercompany transactions between and among the Company and its&#x2019; consolidated subsidiary have been eliminated. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of estimates &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, expenses and disclosure of contingent assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash in checking, sweep and money market accounts. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted cash &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December 31, 2021, restricted cash consisted of money market accounts collateralizing letters of credit issued as security deposits in connection with the Company&#x2019;s leases of its corporate facilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table reconciles cash and cash equivalents and restricted cash per the consolidated balance sheets to the statement of cash flows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,895&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287,308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;569&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;145,464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Marketable Securities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities consist of government securities and obligations, corporate bonds and commercial paper with original maturities of more than 90 days. Investments are classified as available-for-sale and are recorded on the balance sheet at fair value with unrealized gains or losses reported as a separate component of other comprehensive income/(loss). Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentration of credit risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at an accredited financial institution in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair value of financial instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC Topic 820, &lt;span style="font-style:italic;"&gt;Fair Value Measurement&lt;/span&gt; (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC&#160;820 establishes a three-tier value hierarchy that distinguishes between the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;1&#x2014;Quoted market prices in active markets for identical assets or liabilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;2&#x2014;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;3&#x2014;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Deferred offering costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with&#160;in-process&#160;equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in the consolidated statement of stockholders&#x2019; equity as a reduction of additional&#160;paid-in&#160;capital. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying consolidated statements of operations and comprehensive loss. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful lives for property and equipment are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="width:45%; border-bottom:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:45%; border-bottom:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;width:45%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:45%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:45%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment and Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:45%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5-7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;width:45%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:45%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of long-lived assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the assets may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the assets from the expected future cash flows (undiscounted and without interest expense) of the related operations. If these cash flows are less than the carrying value of such assets, an impairment loss for the difference between the estimated fair value and carrying value is recorded. There were no impairment losses recognized during the years ended December 31, 2021 and 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and development costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, depreciation, third-party license fees, and costs related to third parties engaged to conduct preclinical research development activities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development contracts with research institutions and other companies to conduct research on its behalf. These agreements are generally cancellable. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock options &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures its stock-based awards granted based on the estimated fair values of the awards and recognizes the compensation for employees and nonemployees over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock-based awards. The Company has elected the practical expedient to use the midpoint between vesting date and the contractual term as the expected term for certain awards with service or performance conditions. Stock-based compensation is recognized using the straight-line method. Forfeitures of unvested stock-based awards are accounted for when they occur. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Patent costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements. The Company adopted Topic 842 on January 1, 2020 using the modified retrospective approach and elected to apply the transition method that allows companies to continue applying guidance under the lease standard in effect at that time in the comparative period financial statements and recognize a cumulative-effect adjustment to the balance sheet on the date of adoption. The Company has also elected the package of practical expedients to not reassess its prior conclusions about lease identification, lease classification and indirect costs and to not separate lease and non-lease components.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon adoption of Topic 842 on January 1, 2020, the Company recorded right-of-use assets of $2.2 million, operating lease liabilities of $2.2 million and the elimination of deferred rent of $0.03 million. Adoption of the standard did not result in the Company recording a cumulative effect adjustment.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines whether an arrangement is a lease at inception. The Company accounts for a lease when it has the right to control the leased asset for a period of time while obtaining substantially all of the assets&#x2019; economic benefits. The Company determined that it held operating leases for office and laboratory space as of January 1, 2020. Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. The discount rate used to determine the present value of the lease payments is the Company&#x2019;s incremental borrowing rate based on the information available at lease inception, as the Company does not have information to determine the rate implicit in the leases. Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments (which include initial direct costs and lease incentives). The expense is included in operating expenses in the consolidated statements of operations and comprehensive loss. The Company&#x2019;s lease agreements also contain variable payments, primarily maintenance-related costs, which are expensed as incurred and not included in the measurement of the right-of-use assets and lease liabilities.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income taxes &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be settled or recovered. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December 31, 2021 and 2020, the Company has recorded a full valuation allowance. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Tax Cuts and Jobs Act (the TCJA) was enacted on December&#160;22, 2017. The TCJA reduced the U.S. federal corporate tax rate from a top rate of 35% to a flat rate of 21%. The Company continues to monitor for legislative developments, issuance of regulations and technical memorandum to provide further clarification and/or interpretations of the TCJA and will adjust its consolidated financial statements as needed. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment and geographic information &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in one segment in the United States. The Company&#x2019;s chief executive officer, as the chief operating decision-maker, manages and allocates resources to the operations of the Company on a total company basis using consolidated financial information. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Emerging growth company and smaller reporting company status &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&#160;Act). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act, until such time as those standards apply to private companies. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS&#160;Act. As a result, the Company&#x2019;s consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will remain an emerging growth company until the earliest of (i)&#160;the last day of its first fiscal year (a)&#160;&#160;in which the Company has total annual gross revenues of at least $1.07&#160;billion or (b)&#160;in which the Company is deemed to be a large accelerated filer, which means the market value of the Company&#x2019;s common stock that is held by non-affiliates exceeds $700.0&#160;million as of the prior June 30&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;th&lt;/sup&gt;, (ii)&#160;the date on which the Company has issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period, and (iii) December 31, 2024&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is also a &#x201c;smaller reporting company,&#x201d; meaning that in the event of an initial public offering the market value of its stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to the Company as a result of such offering is less than $700&#160;million and its annual revenue is less than $100&#160;million during the most recently completed fiscal year. The Company may continue to be a smaller reporting company as long as either (i)&#160;the market value of its stock held by non-affiliates is less than $250&#160;million or (ii)&#160;its annual revenue is less than $100 million during the most recently &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;completed fiscal year and the market value of its stock held by non-affiliates is less than $700&#160;million. If the Company is a smaller reporting company at the time it ceases to be an emerging growth company, the Company may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, the Company may choose to present only the two most recent fiscal years of audited financial statements in its Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently issued accounting pronouncements &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.46%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2017, the FASB issued ASU 2017-11, &lt;span style="font-style:italic;"&gt;Earnings Per Share&lt;/span&gt; (Topic 260), &lt;span style="font-style:italic;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt; (Topic 480) and &lt;span style="font-style:italic;"&gt;Derivatives and Hedging&lt;/span&gt; (Topic 815): &lt;span style="font-style:italic;"&gt;I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception&lt;/span&gt;. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, &lt;span style="font-style:italic;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this update do not have an accounting effect. For public business entities, the amendments in Part I of ASU-2017-11 are effective for fiscal years and interim periods within those years beginning after December&#160;15, 2018. For all other entities, the amendments in Part I of this update are effective for fiscal years beginning after December&#160;15, 2019, and interim periods within fiscal years beginning after December&#160;15, 2020. We adopted this update on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.46%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU 2018-13,&lt;span style="font-style:italic;"&gt;&#160;&#x201c;Fair Value Measurement (Topic 820), Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&#x201d;.&lt;/span&gt;&#160;This ASU removed the following disclosure requirements: (1)&#160;the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy; (2)&#160;the policy for timing of transfers between levels; and (3)&#160;the valuation processes for Level&#160;3 fair value measurements. Additionally, this update added the following disclosure requirements: (1)&#160;the changes in unrealized gains and losses for the period included in other comprehensive income and loss for recurring Level&#160;3 fair value measurements held at the end of the reporting period; (2)&#160;the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level&#160;3 fair value measurements. ASU&#160;2018-13 is effective for all entities, for fiscal years beginning after December&#160;15, 2019 with early adoption permitted. We adopted this update on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.36%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.36%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU 2019-12,&#160;&lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt;&#160;&lt;span style="font-style:italic;"&gt;(Topic 740): Simplifying the Accounting for Income Taxes.&lt;/span&gt;&#160;This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for interim and annual periods beginning after December 15, 2020, and early adoption is permitted. &lt;span style="Background-color:#FFFFFF;"&gt;The Company adopted this standard on January 1, 2021 and the adoption of this update did not have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000214">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of presentation and consolidation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP), and include the accounts of Stoke Therapeutics, Inc. and its wholly-owned subsidiary. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). All intercompany transactions between and among the Company and its&#x2019; consolidated subsidiary have been eliminated. &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001623526_20210101_20211231" id="F_000215">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of estimates &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, expenses and disclosure of contingent assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates. &lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000216">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash in checking, sweep and money market accounts. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_0001623526_20210101_20211231" id="F_000217">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted cash &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December 31, 2021, restricted cash consisted of money market accounts collateralizing letters of credit issued as security deposits in connection with the Company&#x2019;s leases of its corporate facilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table reconciles cash and cash equivalents and restricted cash per the consolidated balance sheets to the statement of cash flows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,895&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287,308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;569&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;145,464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <stok:ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000232">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table reconciles cash and cash equivalents and restricted cash per the consolidated balance sheets to the statement of cash flows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,895&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287,308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;569&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.14%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;145,464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</stok:ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">144895000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">287308000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">569000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">205000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">145464000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">287513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:MarketableSecuritiesPolicy contextRef="C_0001623526_20210101_20211231" id="F_000218">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Marketable Securities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.36%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities consist of government securities and obligations, corporate bonds and commercial paper with original maturities of more than 90 days. Investments are classified as available-for-sale and are recorded on the balance sheet at fair value with unrealized gains or losses reported as a separate component of other comprehensive income/(loss). Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001623526_20210101_20211231" id="F_000219">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentration of credit risk &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at an accredited financial institution in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_0001623526_20210101_20211231" id="F_000220">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair value of financial instruments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC Topic 820, &lt;span style="font-style:italic;"&gt;Fair Value Measurement&lt;/span&gt; (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC&#160;820 establishes a three-tier value hierarchy that distinguishes between the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;1&#x2014;Quoted market prices in active markets for identical assets or liabilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;2&#x2014;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;3&#x2014;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <stok:DeferredOfferingCostsPolicyTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000221">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Deferred offering costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with&#160;in-process&#160;equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in the consolidated statement of stockholders&#x2019; equity as a reduction of additional&#160;paid-in&#160;capital. &lt;/p&gt;</stok:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000222">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying consolidated statements of operations and comprehensive loss. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful lives for property and equipment are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="width:45%; border-bottom:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:45%; border-bottom:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;width:45%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:45%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:45%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment and Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:45%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5-7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;width:45%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:45%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <stok:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000233">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful lives for property and equipment are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="width:45%; border-bottom:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:45%; border-bottom:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;width:45%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:45%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width:45%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment and Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:45%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5-7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;width:45%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:45%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</stok:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001623526_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokComputerAndOfficeEquipmentMember_20210101_20211231"
      id="F_000264">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokComputerAndOfficeEquipmentMember_20210101_20211231"
      id="F_000265">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001623526_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokLaboratoryEquipmentAndFurnitureAndFixturesMember_20210101_20211231"
      id="F_000266">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokLaboratoryEquipmentAndFurnitureAndFixturesMember_20210101_20211231"
      id="F_000267">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231"
      id="F_000268">Lesser of estimated useful life or remaining lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000223">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of long-lived assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the assets may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the assets from the expected future cash flows (undiscounted and without interest expense) of the related operations. If these cash flows are less than the carrying value of such assets, an impairment loss for the difference between the estimated fair value and carrying value is recorded. There were no impairment losses recognized during the years ended December 31, 2021 and 2020. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0001623526_20200101_20201231"
      decimals="INF"
      id="F_000270"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0001623526_20210101_20211231"
      decimals="INF"
      id="F_000269"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001623526_20210101_20211231" id="F_000224">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and development costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, depreciation, third-party license fees, and costs related to third parties engaged to conduct preclinical research development activities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development contracts with research institutions and other companies to conduct research on its behalf. These agreements are generally cancellable. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001623526_20210101_20211231" id="F_000225">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock options &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures its stock-based awards granted based on the estimated fair values of the awards and recognizes the compensation for employees and nonemployees over the requisite service period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock-based awards. The Company has elected the practical expedient to use the midpoint between vesting date and the contractual term as the expected term for certain awards with service or performance conditions. Stock-based compensation is recognized using the straight-line method. Forfeitures of unvested stock-based awards are accounted for when they occur. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <stok:PatentCostsPolicyTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000226">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Patent costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. &lt;/p&gt;</stok:PatentCostsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000227">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements. The Company adopted Topic 842 on January 1, 2020 using the modified retrospective approach and elected to apply the transition method that allows companies to continue applying guidance under the lease standard in effect at that time in the comparative period financial statements and recognize a cumulative-effect adjustment to the balance sheet on the date of adoption. The Company has also elected the package of practical expedients to not reassess its prior conclusions about lease identification, lease classification and indirect costs and to not separate lease and non-lease components.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon adoption of Topic 842 on January 1, 2020, the Company recorded right-of-use assets of $2.2 million, operating lease liabilities of $2.2 million and the elimination of deferred rent of $0.03 million. Adoption of the standard did not result in the Company recording a cumulative effect adjustment.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines whether an arrangement is a lease at inception. The Company accounts for a lease when it has the right to control the leased asset for a period of time while obtaining substantially all of the assets&#x2019; economic benefits. The Company determined that it held operating leases for office and laboratory space as of January 1, 2020. Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. The discount rate used to determine the present value of the lease payments is the Company&#x2019;s incremental borrowing rate based on the information available at lease inception, as the Company does not have information to determine the rate implicit in the leases. Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments (which include initial direct costs and lease incentives). The expense is included in operating expenses in the consolidated statements of operations and comprehensive loss. The Company&#x2019;s lease agreements also contain variable payments, primarily maintenance-related costs, which are expensed as incurred and not included in the measurement of the right-of-use assets and lease liabilities.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231"
      id="F_000272">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101"
      decimals="-5"
      id="F_000273"
      unitRef="U_iso4217USD">2200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101"
      decimals="-5"
      id="F_000274"
      unitRef="U_iso4217USD">2200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DeferredRentCredit
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101"
      decimals="-4"
      id="F_000275"
      unitRef="U_iso4217USD">30000.00</us-gaap:DeferredRentCredit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001623526_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101"
      decimals="INF"
      id="F_000276"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquity>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000228">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income taxes &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be settled or recovered. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. At December 31, 2021 and 2020, the Company has recorded a full valuation allowance. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Tax Cuts and Jobs Act (the TCJA) was enacted on December&#160;22, 2017. The TCJA reduced the U.S. federal corporate tax rate from a top rate of 35% to a flat rate of 21%. The Company continues to monitor for legislative developments, issuance of regulations and technical memorandum to provide further clarification and/or interpretations of the TCJA and will adjust its consolidated financial statements as needed. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_0001623526_20210101_20211231"
      decimals="INF"
      id="F_000277"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001623526_20170101_20171231"
      decimals="2"
      id="F_000278"
      unitRef="U_xbrlipure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001623526_20210101_20211231"
      decimals="2"
      id="F_000279"
      unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000229">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment and geographic information &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in one segment in the United States. The Company&#x2019;s chief executive officer, as the chief operating decision-maker, manages and allocates resources to the operations of the Company on a total company basis using consolidated financial information. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001623526_20210101_20211231"
      decimals="INF"
      id="F_000280"
      unitRef="U_stokSegment">1</us-gaap:NumberOfOperatingSegments>
    <stok:EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000230">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Emerging growth company and smaller reporting company status &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&#160;Act). Under the JOBS&#160;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&#160;Act, until such time as those standards apply to private companies. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS&#160;Act. As a result, the Company&#x2019;s consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will remain an emerging growth company until the earliest of (i)&#160;the last day of its first fiscal year (a)&#160;&#160;in which the Company has total annual gross revenues of at least $1.07&#160;billion or (b)&#160;in which the Company is deemed to be a large accelerated filer, which means the market value of the Company&#x2019;s common stock that is held by non-affiliates exceeds $700.0&#160;million as of the prior June 30&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;th&lt;/sup&gt;, (ii)&#160;the date on which the Company has issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period, and (iii) December 31, 2024&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is also a &#x201c;smaller reporting company,&#x201d; meaning that in the event of an initial public offering the market value of its stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to the Company as a result of such offering is less than $700&#160;million and its annual revenue is less than $100&#160;million during the most recently completed fiscal year. The Company may continue to be a smaller reporting company as long as either (i)&#160;the market value of its stock held by non-affiliates is less than $250&#160;million or (ii)&#160;its annual revenue is less than $100 million during the most recently &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;completed fiscal year and the market value of its stock held by non-affiliates is less than $700&#160;million. If the Company is a smaller reporting company at the time it ceases to be an emerging growth company, the Company may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, the Company may choose to present only the two most recent fiscal years of audited financial statements in its Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. &lt;/span&gt;&lt;/p&gt;</stok:EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently issued accounting pronouncements &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.46%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2017, the FASB issued ASU 2017-11, &lt;span style="font-style:italic;"&gt;Earnings Per Share&lt;/span&gt; (Topic 260), &lt;span style="font-style:italic;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt; (Topic 480) and &lt;span style="font-style:italic;"&gt;Derivatives and Hedging&lt;/span&gt; (Topic 815): &lt;span style="font-style:italic;"&gt;I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception&lt;/span&gt;. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, &lt;span style="font-style:italic;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this update do not have an accounting effect. For public business entities, the amendments in Part I of ASU-2017-11 are effective for fiscal years and interim periods within those years beginning after December&#160;15, 2018. For all other entities, the amendments in Part I of this update are effective for fiscal years beginning after December&#160;15, 2019, and interim periods within fiscal years beginning after December&#160;15, 2020. We adopted this update on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.46%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU 2018-13,&lt;span style="font-style:italic;"&gt;&#160;&#x201c;Fair Value Measurement (Topic 820), Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&#x201d;.&lt;/span&gt;&#160;This ASU removed the following disclosure requirements: (1)&#160;the amount of and reasons for transfers between Level&#160;1 and Level&#160;2 of the fair value hierarchy; (2)&#160;the policy for timing of transfers between levels; and (3)&#160;the valuation processes for Level&#160;3 fair value measurements. Additionally, this update added the following disclosure requirements: (1)&#160;the changes in unrealized gains and losses for the period included in other comprehensive income and loss for recurring Level&#160;3 fair value measurements held at the end of the reporting period; (2)&#160;the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level&#160;3 fair value measurements. ASU&#160;2018-13 is effective for all entities, for fiscal years beginning after December&#160;15, 2019 with early adoption permitted. We adopted this update on January 1, 2020, and the adoption did not have a material impact on our consolidated financial statements.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.36%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.36%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU 2019-12,&#160;&lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt;&#160;&lt;span style="font-style:italic;"&gt;(Topic 740): Simplifying the Accounting for Income Taxes.&lt;/span&gt;&#160;This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU is effective for interim and annual periods beginning after December 15, 2020, and early adoption is permitted. &lt;span style="Background-color:#FFFFFF;"&gt;The Company adopted this standard on January 1, 2021 and the adoption of this update did not have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201711Member_20211231"
      id="F_000282">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20211231"
      id="F_000285">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20211231"
      id="F_000288">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000204">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Fair value measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable Securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US Government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287,308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287,308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287,308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287,308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable Securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US Government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above and in Note 2. The carrying value of the Company&#x2019;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s assets with fair value categorized as Level 1 within the fair value hierarchy include money market funds. Money market funds are publicly traded mutual funds and are presented as cash equivalents on the consolidated balance sheets as of December 30, 2021 and December 31, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures its marketable securities at fair value on a recurring basis and classifies those instruments within Level 2 of the fair value hierarchy.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;Marketable securities are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no transfers to Level&#160;3 in the periods presented. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000234">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable Securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US Government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287,308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287,308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287,308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;287,308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable Securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US Government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">144897000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">144897000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">144897000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">144897000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">17524000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217USD">17524000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217USD">27487000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000297"
      unitRef="U_iso4217USD">27487000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000298"
      unitRef="U_iso4217USD">29904000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000299"
      unitRef="U_iso4217USD">29904000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000300"
      unitRef="U_iso4217USD">74915000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231"
      decimals="-3"
      id="F_000301"
      unitRef="U_iso4217USD">74915000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000302"
      unitRef="U_iso4217USD">287308000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001623526_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000303"
      unitRef="U_iso4217USD">287308000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001623526_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000304"
      unitRef="U_iso4217USD">287308000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000305"
      unitRef="U_iso4217USD">287308000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_0001623526_20210101_20211231"
      decimals="INF"
      id="F_000306"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_0001623526_20200101_20201231"
      decimals="INF"
      id="F_000307"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000205">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Marketable Securities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s marketable securities as of December 31, 2021 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,598&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US Government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,998&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,083&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no marketable securities as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average maturity of the Company&#x2019;s marketable securities as of December 31, 2021 ranges from approximately 0.2 years to 1.1 years.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company did not record an allowance for credit losses as of December&#160;31, 2021 related to our marketable securities. Further, given the lack of significant change in the credit risk of these investments, the Company did&#160;not recognize any other-than-temporary impairment losses. &lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000235">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s marketable securities as of December 31, 2021 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,598&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US Government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,998&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,083&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000308"
      unitRef="U_iso4217USD">17598000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000312"
      unitRef="U_iso4217USD">74000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">17524000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000309"
      unitRef="U_iso4217USD">27487000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000316"
      unitRef="U_iso4217USD">27487000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000310"
      unitRef="U_iso4217USD">29998000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000313"
      unitRef="U_iso4217USD">94000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001623526_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000317"
      unitRef="U_iso4217USD">29904000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000311"
      unitRef="U_iso4217USD">75083000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000314"
      unitRef="U_iso4217USD">168000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000318"
      unitRef="U_iso4217USD">74915000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000319"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <stok:DebtSecuritiesAvailableForSaleMaturityPeriod
      contextRef="C_0001623526_srtRangeAxis_srtMinimumMember_20210101_20211231"
      id="F_000320">P0Y2M12D</stok:DebtSecuritiesAvailableForSaleMaturityPeriod>
    <stok:DebtSecuritiesAvailableForSaleMaturityPeriod
      contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_20210101_20211231"
      id="F_000321">P1Y1M6D</stok:DebtSecuritiesAvailableForSaleMaturityPeriod>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000206">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Property and equipment, net &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,670&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,936&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;153&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;263&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;210&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,661&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,692&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense was $1.0 million and $0.9 million&#160;for the years ended December 31, 2021 and 2020, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000236">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,670&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,936&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;153&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;263&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;210&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,661&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,692&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231"
      decimals="-3"
      id="F_000323"
      unitRef="U_iso4217USD">4670000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231"
      decimals="-3"
      id="F_000324"
      unitRef="U_iso4217USD">3936000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">153000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">108000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">263000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">210000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20211231"
      decimals="-3"
      id="F_000329"
      unitRef="U_iso4217USD">108000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231"
      decimals="-3"
      id="F_000330"
      unitRef="U_iso4217USD">108000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">1606000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001623526_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231"
      decimals="-3"
      id="F_000332"
      unitRef="U_iso4217USD">5000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000333"
      unitRef="U_iso4217USD">6800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">4367000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">2661000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">1692000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000337"
      unitRef="U_iso4217USD">4139000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000338"
      unitRef="U_iso4217USD">2675000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_0001623526_20210101_20211231"
      decimals="-5"
      id="F_000339"
      unitRef="U_iso4217USD">1000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001623526_20200101_20201231"
      decimals="-5"
      id="F_000340"
      unitRef="U_iso4217USD">900000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000207">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Accrued and other current liabilities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued and other current liabilities consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued employee compensation costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,383&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,123&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;523&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;593&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,801&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,689&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,507&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,066&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;540&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;459&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,754&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <stok:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000237">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued and other current liabilities consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued employee compensation costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,383&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,123&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;523&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;593&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,801&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,689&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,507&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,066&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;540&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;459&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,754&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</stok:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">5383000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000342"
      unitRef="U_iso4217USD">4123000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000343"
      unitRef="U_iso4217USD">523000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000344"
      unitRef="U_iso4217USD">593000</us-gaap:AccruedProfessionalFeesCurrent>
    <stok:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000345"
      unitRef="U_iso4217USD">6801000</stok:AccruedResearchAndDevelopmentCostsCurrent>
    <stok:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000346"
      unitRef="U_iso4217USD">3689000</stok:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000347"
      unitRef="U_iso4217USD">1507000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000348"
      unitRef="U_iso4217USD">1066000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000349"
      unitRef="U_iso4217USD">540000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000350"
      unitRef="U_iso4217USD">459000</us-gaap:OtherLiabilitiesCurrent>
    <stok:AccruedAndOtherCurrentLiabilities
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000351"
      unitRef="U_iso4217USD">14754000</stok:AccruedAndOtherCurrentLiabilities>
    <stok:AccruedAndOtherCurrentLiabilities
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000352"
      unitRef="U_iso4217USD">9930000</stok:AccruedAndOtherCurrentLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000208">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;Commitments and contingencies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the Company entered into an agreement to lease approximately 23,000 square feet of space for a term of three years. Lease terms are triple net lease commencing at $0.9 million per year, then with 3% annual base rent increases plus operating expenses, real estate taxes, utilities and janitorial fees. The lease commencement date was December&#160;10, 2018. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2021, the Company entered into an agreement to extend the initial term of the 23,000 square foot lease for a period of three years commencing on December 15, 2021 and ending December 31, 2024.&#160;&#160;In addition, this lease provides for the lease of an additional 15,000 square feet of rentable space beginning in April 2022 and ending on December 31, 2024. The Company recognized a right-of-use asset and operating lease liability of &lt;span&gt;$3.5&lt;/span&gt; million for the 23,000 square feet.&#160;&#160;As the Company did not have access to the additional 15,000 square feet of space, a right of use asset was not recognized as of December 31, 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2018, the Company entered into an agreement to lease 2,485 square feet of space for an initial term of three years. The lease includes one renewal option for an additional two years, however, any time after the initial term the landlord may relocate the Company from the premises to a space reasonably comparable in size and utility. As the Company does not have the right to control the use of the identified asset after the initial term, the renewal option was excluded from the lease liability calculation. Lease terms commence at $0.2 million per annum, with 2.5% annual base rent increases plus operating expenses, real estate taxes, utilities and janitorial fees. The lease commencement date was May 1, 2019. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;span style="font-size:10pt;"&gt;In June 2021, the Company amended the agreement to extend the initial term of the 2,485 square foot lease for a period of three years commencing May 1, 2022 and ending April 30, 2025. In addition, the amendment provided for the lease of an additional 2,357 square feet of rentable space beginning on July 6, 2021 and ending on April 30, 2025. The amended lease provides the Company with the option to extend the term of the lease for an additional two years. The Company recognized a right-of-use asset and operating lease liabilities of $0.7 million for the extension of the lease to April 30, 2025 and a right-of-use asset and operating lease liabilities of $0.8 million for the additional 2,357 square feet of rentable space. &lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum lease payments under non-cancellable leases as of December 31, 2021, including leases entered into where access has yet to be granted, are as follows (in thousands): &lt;span style="font-family:Calibri;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,124&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,532&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,608&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,437&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(462&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,975&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease balances as of December 31, 2021 and December 31, 2020 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,939&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current Portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,507&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,066&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,532&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,039&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,146&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average remaining lease term and weighted average discount rate of our operating leases as of December 31, 2021 are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average remaining lease term in years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000411"&gt;3.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with Topic 842, lease expense incurred under operating leases was approximately $1.4 million for the year ended December 31, 2021, and $1.1 million for the year ended December 31, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Consulting Agreement &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2014, the Company entered into a consulting agreement with a member of the Company&#x2019;s board of directors, who is also an employee of Cold Spring Harbor Laboratory (&#x201c;CSHL&#x201d;), to provide consulting services related to scientific research related to the development of antisense-based drugs, therapies, diagnostic and research tools, products, services and intellectual property. The Company recognized expenses of $0.02 million for the year ended December 31, 2020. The initial term of this agreement was five years and the parties mutually agreed not to extend the consulting agreement in April 2020. &#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Scientific Advisory Board Agreement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2020, the Company entered into a scientific advisory board agreement with a member of the Company&#x2019;s board of directors, who is also an employee of CSHL, to provide scientific advisory services related to the Company&#x2019;s Targeted Augmentation of Nuclear Gene Output (&#x201c;TANGO&#x201d;) antisense oligonucleotide technology and other antisense oligonucleotide technologies, as well as current and future therapeutic targets and programs. Following the expiration of the initial scientific agreement in June 2021, the parties entered into a subsequent scientific board agreement. The Company recognized expense of $0.05 million each for the years ended December 31, 2021 and 2020 for such scientific advisory services. The term of this agreement is 12 months.&#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;License and research agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2015, the Company entered into a worldwide license agreement, or the CSHL Agreement, with CSHL, with respect to TANGO patents. Under the CSHL Agreement, the Company receives an exclusive (except with respect to certain government rights and non-exclusive licenses), worldwide license under certain patents and applications relating to TANGO. The CSHL Agreement obligates the Company to make payments that are contingent upon certain milestones being achieved. The Company is also required to pay royalties, tiered based on the scope of patent coverage for each licensed product, ranging from a low-single digit percentage to a mid-single digit percentage on annual net sales. These royalty obligations apply on a licensed product-by-licensed product and country-by-country basis until the latest of (i)&#160;the expiration of the last valid claim of a CSHL patent covering the applicable licensed product or (ii)&#160;the expiration of any regulatory exclusivity for the applicable licensed product. In addition, if the Company sublicenses the rights under the CSHL Agreement, the Company is required to pay a maximum of twenty percent of the sublicense revenue to CSHL, which may be reduced to a mid-teens or a mid-single digit percentage upon achievement of certain clinical milestones for the applicable licensed product. Finally, the Company is required to pay an annual license maintenance fee of $0.01 million, which amount is creditable against any owed royalty or milestone payments. The maximum aggregate potential milestone payments payable total approximately $0.9 million. Additionally, certain licenses under the CSHL Agreement require the Company to reimburse CSHL for certain past and ongoing patent related expenses, however there were no expenses related to these reimbursable patent costs during the years ended December 31, 2021 and 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2016, the Company entered into an exclusive, worldwide license agreement with the University of Southampton, or the Southampton Agreement, whereby the Company acquired rights to foundational technologies related to the Company&#x2019;s TANGO technology. Under the Southampton Agreement, the Company receives an exclusive, worldwide license under certain licensed patents and applications relating to TANGO. Under the Southampton Agreement, the Company may be obligated to make additional payments that are contingent upon certain milestones being achieved, as well as royalties on future product sales. These royalty obligations survive until the latest of (i)&#160;the expiration of the last valid claim of a licensed patent covering a subject product or (ii)&#160;the expiration of any regulatory exclusivity for the subject product in a country. In addition, if the Company sublicenses its rights under the Southampton Agreement, the Company is required to pay a mid-single digit percentage of the sublicense revenue to the University of Southampton. The maximum aggregate potential milestone payments payable by the Company total approximately 0.4 million pounds sterling (approximately $0.5 million as of December 31, 2021). As of December 31, 2021, and 2020, the Company has recorded no liabilities under the Southampton Agreement. For the year ended December 31, 2021 these expenses were $0.12 million compared to $0.09 million for the year ended December 31, 2020. Additionally, certain licenses under the Southampton Agreement require the Company to reimburse the University of Southampton for certain past and ongoing patent related expenses. (see note 12 for payments to University of Southampton)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Litigation &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which it is focused. As of December 31, 2021, the Company had no legal proceedings to which it was a party or to which its property was subject. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <stok:AreaOfSpaceSubjectToOperatingLease
      contextRef="C_0001623526_20180801_20180831"
      decimals="INF"
      id="F_000353"
      unitRef="U_utrsqft">23000</stok:AreaOfSpaceSubjectToOperatingLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="C_0001623526_20180831" id="F_000354">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <stok:OperatingLeaseCostPerYear
      contextRef="C_0001623526_20180801_20180831"
      decimals="-5"
      id="F_000355"
      unitRef="U_iso4217USD">900000</stok:OperatingLeaseCostPerYear>
    <stok:AnnualBaseRentIncreasePercentageForOperatingLease
      contextRef="C_0001623526_20180801_20180831"
      decimals="2"
      id="F_000356"
      unitRef="U_xbrlipure">0.03</stok:AnnualBaseRentIncreasePercentageForOperatingLease>
    <stok:OperatingLeaseCommencementDate contextRef="C_0001623526_20180801_20180831" id="F_000357">2018-12-10</stok:OperatingLeaseCommencementDate>
    <stok:AreaOfSpaceSubjectToOperatingLease
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210901_20210930"
      decimals="INF"
      id="F_000358"
      unitRef="U_utrsqft">23000</stok:AreaOfSpaceSubjectToOperatingLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210930"
      id="F_000359">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <stok:OperatingLeaseCommencementDate
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210901_20210930"
      id="F_000362">2021-12-15</stok:OperatingLeaseCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210901_20210930"
      id="F_000363">2024-12-31</us-gaap:LeaseExpirationDate1>
    <stok:AreaOfSpaceSubjectToOperatingLease
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyTwoMember_20210901_20210930"
      decimals="INF"
      id="F_000364"
      unitRef="U_utrsqft">15000</stok:AreaOfSpaceSubjectToOperatingLease>
    <stok:OperatingLeaseCommencementMonthAndYear
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyTwoMember_20210901_20210930"
      id="F_000365">2022-04</stok:OperatingLeaseCommencementMonthAndYear>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyTwoMember_20210901_20210930"
      id="F_000366">2024-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210930"
      decimals="-5"
      id="F_000360"
      unitRef="U_iso4217USD">3500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyOneMember_20210930"
      decimals="-5"
      id="F_000361"
      unitRef="U_iso4217USD">3500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyTwoMember_20210930"
      decimals="INF"
      id="F_000367"
      unitRef="U_iso4217USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseCommencementTwoThousandAndTwentyTwoMember_20210930"
      decimals="INF"
      id="F_000368"
      unitRef="U_iso4217USD">0</us-gaap:OperatingLeaseLiability>
    <stok:AreaOfSpaceSubjectToOperatingLease
      contextRef="C_0001623526_20181201_20181231"
      decimals="INF"
      id="F_000369"
      unitRef="U_utrsqft">2485</stok:AreaOfSpaceSubjectToOperatingLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="C_0001623526_20181231" id="F_000370">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <stok:NumberOfRenewalOptionToExtendOperatingLeaseTerms
      contextRef="C_0001623526_20181201_20181231"
      decimals="INF"
      id="F_000371"
      unitRef="U_stokOption">1</stok:NumberOfRenewalOptionToExtendOperatingLeaseTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="C_0001623526_20181231" id="F_000372">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <stok:OperatingLeaseCostPerYear
      contextRef="C_0001623526_20181201_20181231"
      decimals="-5"
      id="F_000373"
      unitRef="U_iso4217USD">200000</stok:OperatingLeaseCostPerYear>
    <stok:AnnualBaseRentIncreasePercentageForOperatingLease
      contextRef="C_0001623526_20181201_20181231"
      decimals="3"
      id="F_000374"
      unitRef="U_xbrlipure">0.025</stok:AnnualBaseRentIncreasePercentageForOperatingLease>
    <stok:OperatingLeaseCommencementDate contextRef="C_0001623526_20181201_20181231" id="F_000375">2019-05-01</stok:OperatingLeaseCommencementDate>
    <stok:AreaOfSpaceSubjectToOperatingLease
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630"
      decimals="INF"
      id="F_000376"
      unitRef="U_utrsqft">2485</stok:AreaOfSpaceSubjectToOperatingLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210630"
      id="F_000377">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <stok:OperatingLeaseCommencementDate
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630"
      id="F_000378">2022-05-01</stok:OperatingLeaseCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630"
      id="F_000379">2025-04-30</us-gaap:LeaseExpirationDate1>
    <stok:AreaOfAdditionalRentableSpaceSubjectToOperatingLease
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630"
      decimals="INF"
      id="F_000380"
      unitRef="U_utrsqft">2357</stok:AreaOfAdditionalRentableSpaceSubjectToOperatingLease>
    <stok:AdditionalOperatingLeaseCommencementDate
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630"
      id="F_000381">2021-07-06</stok:AdditionalOperatingLeaseCommencementDate>
    <stok:AdditionalLeaseExpirationDate
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630"
      id="F_000382">2025-04-30</stok:AdditionalLeaseExpirationDate>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630"
      id="F_000390">The amended lease provides the Company with the option to extend the term of the lease for an additional two years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210630"
      id="F_000383">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210630"
      decimals="-5"
      id="F_000384"
      unitRef="U_iso4217USD">700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210630"
      decimals="-5"
      id="F_000385"
      unitRef="U_iso4217USD">700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630"
      id="F_000386">2025-04-30</us-gaap:LeaseExpirationDate1>
    <stok:AdditionalOperatingLeaseRightOfUseAsset
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210630"
      decimals="-5"
      id="F_000388"
      unitRef="U_iso4217USD">800000</stok:AdditionalOperatingLeaseRightOfUseAsset>
    <stok:AdditionalOperatingLeaseLiabilities
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210630"
      decimals="-5"
      id="F_000389"
      unitRef="U_iso4217USD">800000</stok:AdditionalOperatingLeaseLiabilities>
    <stok:AreaOfAdditionalRentableSpaceSubjectToOperatingLease
      contextRef="C_0001623526_us-gaapLeaseContractualTermAxis_stokLeaseExtensionEndDateMember_20210601_20210630"
      decimals="INF"
      id="F_000387"
      unitRef="U_utrsqft">2357</stok:AreaOfAdditionalRentableSpaceSubjectToOperatingLease>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000238">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum lease payments under non-cancellable leases as of December 31, 2021, including leases entered into where access has yet to be granted, are as follows (in thousands): &lt;span style="font-family:Calibri;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,124&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,532&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,608&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,437&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(462&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,975&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000392"
      unitRef="U_iso4217USD">2124000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000393"
      unitRef="U_iso4217USD">2532000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000394"
      unitRef="U_iso4217USD">2608000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000395"
      unitRef="U_iso4217USD">173000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000396"
      unitRef="U_iso4217USD">7437000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000397"
      unitRef="U_iso4217USD">462000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000398"
      unitRef="U_iso4217USD">6975000</us-gaap:OperatingLeaseLiability>
    <stok:SummaryOfLeaseBalancesTableTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000239">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease balances as of December 31, 2021 and December 31, 2020 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,939&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current Portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,507&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,066&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,532&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,039&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,146&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</stok:SummaryOfLeaseBalancesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000399"
      unitRef="U_iso4217USD">4939000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000400"
      unitRef="U_iso4217USD">1115000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">1507000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000402"
      unitRef="U_iso4217USD">1066000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000405"
      unitRef="U_iso4217USD">3532000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000406"
      unitRef="U_iso4217USD">80000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <stok:OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000409"
      unitRef="U_iso4217USD">5039000</stok:OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted>
    <stok:OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000410"
      unitRef="U_iso4217USD">1146000</stok:OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted>
    <stok:SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000240">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average remaining lease term and weighted average discount rate of our operating leases as of December 31, 2021 are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average remaining lease term in years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000411"&gt;3.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;</stok:SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001623526_20211231"
      decimals="4"
      id="F_000412"
      unitRef="U_xbrlipure">0.0414</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20210101_20211231"
      decimals="-5"
      id="F_000413"
      unitRef="U_iso4217USD">1400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001623526_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101_20201231"
      decimals="-5"
      id="F_000414"
      unitRef="U_iso4217USD">1100000</us-gaap:OperatingLeaseExpense>
    <stok:ConsultingServicesExpenses
      contextRef="C_0001623526_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20200101_20201231"
      decimals="-4"
      id="F_000415"
      unitRef="U_iso4217USD">20000.00</stok:ConsultingServicesExpenses>
    <stok:ConsultingServicesAgreementTerm
      contextRef="C_0001623526_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20210101_20211231"
      id="F_000416">P5Y</stok:ConsultingServicesAgreementTerm>
    <stok:ScientificAdvisoryServicesExpenses
      contextRef="C_0001623526_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20200101_20201231"
      decimals="-4"
      id="F_000418"
      unitRef="U_iso4217USD">50000.00</stok:ScientificAdvisoryServicesExpenses>
    <stok:ScientificAdvisoryServicesExpenses
      contextRef="C_0001623526_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20210101_20211231"
      decimals="-4"
      id="F_000417"
      unitRef="U_iso4217USD">50000.00</stok:ScientificAdvisoryServicesExpenses>
    <stok:ScientificAdvisoryServicesAgreementTerm
      contextRef="C_0001623526_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20210101_20211231"
      id="F_000419">P12M</stok:ScientificAdvisoryServicesAgreementTerm>
    <stok:PercentageOfMaximumRequiredPaymentOfSublicenseRevenue
      contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20150701_20150731"
      decimals="INF"
      id="F_000420"
      unitRef="U_xbrlipure">0.20</stok:PercentageOfMaximumRequiredPaymentOfSublicenseRevenue>
    <stok:AnnualLicenseMaintenanceFee
      contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20210101_20211231"
      decimals="-4"
      id="F_000421"
      unitRef="U_iso4217USD">10000.00</stok:AnnualLicenseMaintenanceFee>
    <stok:MaximumAggregatePotentialMilestonePaymentsPayable
      contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20211231"
      decimals="INF"
      id="F_000422"
      unitRef="U_iso4217USD">900000</stok:MaximumAggregatePotentialMilestonePaymentsPayable>
    <stok:ExpensesRelatedToReimbursablePatentCosts
      contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20210101_20211231"
      decimals="INF"
      id="F_000423"
      unitRef="U_iso4217USD">0</stok:ExpensesRelatedToReimbursablePatentCosts>
    <stok:ExpensesRelatedToReimbursablePatentCosts
      contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokColdSpringHarborLaboratoryAgreementMember_20200101_20201231"
      decimals="INF"
      id="F_000424"
      unitRef="U_iso4217USD">0</stok:ExpensesRelatedToReimbursablePatentCosts>
    <stok:MaximumAggregatePotentialMilestonePaymentsPayable
      contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20211231"
      decimals="INF"
      id="F_000425"
      unitRef="U_iso4217GBP">400000</stok:MaximumAggregatePotentialMilestonePaymentsPayable>
    <stok:MaximumAggregatePotentialMilestonePaymentsPayable
      contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20211231"
      decimals="INF"
      id="F_000426"
      unitRef="U_iso4217USD">500000</stok:MaximumAggregatePotentialMilestonePaymentsPayable>
    <us-gaap:Liabilities
      contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20211231"
      decimals="INF"
      id="F_000427"
      unitRef="U_iso4217USD">0</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20201231"
      decimals="INF"
      id="F_000428"
      unitRef="U_iso4217USD">0</us-gaap:Liabilities>
    <stok:ExpensesRelatedToReimbursablePatentCosts
      contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20210101_20211231"
      decimals="-4"
      id="F_000429"
      unitRef="U_iso4217USD">120000</stok:ExpensesRelatedToReimbursablePatentCosts>
    <stok:ExpensesRelatedToReimbursablePatentCosts
      contextRef="C_0001623526_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_stokSouthamptonAgreementMember_20200101_20201231"
      decimals="-4"
      id="F_000430"
      unitRef="U_iso4217USD">90000.00</stok:ExpensesRelatedToReimbursablePatentCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000209">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Share-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2019, the Company&#x2019;s board of directors and stockholders approved the 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) which became effective on June 17, 2019 and replaced the Company&#x2019;s 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;). In addition to the shares of common stock reserved for future issuance under the 2014 Plan that were added to the 2019 Plan upon its effective date, the Company initially reserved 2,200,000 shares of common stock for issuance under the 2019 Plan. The number of shares reserved for issuance under the Company&#x2019;s 2019 Plan will increase automatically on January 1 of each of 2020 through 2029 by the number of shares equal to 4% of the aggregate number of outstanding shares of the Company&#x2019;s common stock as of the immediately preceding December 31, or a lesser number as may be determined by the Company&#x2019;s board of directors. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021 there were no shares available for future issuance under the 2014 Plan and 2,372,006 shares were available under the 2019 Plan. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December 31, 2021 and December 31, 2020, the Company granted options to purchase 1,311,897 and 1,231,532 shares of common stock to certain of its employees, and directors, respectively. The options vest up to four years except for certain options granted to members of our board of directors which vest over one or three years and are exercisable at a per share price equal to the fair value of the common stock on the grant date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of stock option activity for awards is presented below: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:94.36%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;life (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,454,422&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000454"&gt;8.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;236,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,311,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53.93&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(287,566&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,973&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.73&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,435,304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000455"&gt;8.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,981&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,103,635&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000456"&gt;6.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,003&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at December 31, 2021 and 2020. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average grant date fair value per share of stock options granted during the years ended December 31, 2021 and 2020 was $34.07 and $14.75, respectively. The aggregate grant date fair value of stock options granted during the years ended December 31, 2021 and 2020 was approximately $44.7 million and $18.2 million, respectively. The aggregate intrinsic value of stock options exercised during the year ended December 31, 2021 and 2020 was approximately $9.9 million and $27.3 million, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-based compensation and stock options &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded stock-based compensation expense of $16.5 million and $5.8 million during the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, there was $45.0 million of unrecognized compensation cost related to unvested stock-based compensation arrangements granted under the 2014 and the 2019 Plans. The compensation is expected to be recognized over a weighted average period of 2.8 years as of December 31, 2021. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense recorded as research and development and general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,215&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,893&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,450&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,768&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the Black-Scholes option pricing model to calculate the grant-date fair value of an award. The fair values of the options granted to employees and directors were calculated using the following assumptions for the years ended December 31, 2021 and 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000478"&gt;0.78-1.51%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000479"&gt;0.38-1.48%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000482"&gt;5.5-6.25 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000484"&gt;5.5-6.25 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70-73%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;2019 Employee stock purchase plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2019, the Company adopted the 2019 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), which became effective on June 18, 2019. The Company initially reserved 315,000 shares of common stock for sale under the ESPP. At December 31, 2021, the Company had 634,580 shares available for issuance under the plan. The average grant date fair value per share under the plan was $46.08 for 2021. The total ESPP stock-based compensation expense for the year ended December 31, 2021 was $0.3 million and for the year ended December 31, 2020 was $0.3 million. The number of shares reserved for issuance under the ESPP will increase automatically on January 1st of each of the first ten calendar years following the first offering date by the number of shares equal to the lesser of 1% of the total outstanding shares of the Company&#x2019;s common stock as of the immediately preceding December 31 or a lower amount determined by the Company&#x2019;s board of directors. The aggregate number of shares issued over the term of the ESPP will not exceed 3,150,000 shares of the Company&#x2019;s common stock.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEquityIncentivePlanMember_20190630"
      decimals="INF"
      id="F_000431"
      unitRef="U_xbrlishares">2200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <stok:PercentageOfIncreaseInReservedCommonShares
      contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEquityIncentivePlanMember_20190601_20190630"
      decimals="2"
      id="F_000432"
      unitRef="U_xbrlipure">0.04</stok:PercentageOfIncreaseInReservedCommonShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndFourteenEquityIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000433"
      unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEquityIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000434"
      unitRef="U_xbrlishares">2372006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001623526_20210101_20211231"
      decimals="INF"
      id="F_000435"
      unitRef="U_xbrlishares">1311897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001623526_20200101_20201231"
      decimals="INF"
      id="F_000436"
      unitRef="U_xbrlishares">1231532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_20210101_20211231"
      id="F_000437">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001623526_srtRangeAxis_srtMinimumMember_srtTitleOfIndividualAxis_srtDirectorMember_20210101_20211231"
      id="F_000438">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_srtTitleOfIndividualAxis_srtDirectorMember_20210101_20211231"
      id="F_000439">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000241">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of stock option activity for awards is presented below: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:94.36%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;life (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,454,422&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000454"&gt;8.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;236,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,311,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53.93&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(287,566&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,973&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.73&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,435,304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000455"&gt;8.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,981&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,103,635&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000456"&gt;6.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,003&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001623526_20201231"
      decimals="INF"
      id="F_000440"
      unitRef="U_xbrlishares">4454422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001623526_20201231"
      decimals="2"
      id="F_000447"
      unitRef="U_iso4217USD_xbrlishares">8.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000457"
      unitRef="U_iso4217USD">236685000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001623526_20210101_20211231"
      decimals="INF"
      id="F_000441"
      unitRef="U_xbrlishares">1311897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001623526_20210101_20211231"
      decimals="2"
      id="F_000448"
      unitRef="U_iso4217USD_xbrlishares">53.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001623526_20210101_20211231"
      decimals="INF"
      id="F_000442"
      unitRef="U_xbrlishares">287566</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001623526_20210101_20211231"
      decimals="2"
      id="F_000449"
      unitRef="U_iso4217USD_xbrlishares">2.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001623526_20210101_20211231"
      decimals="INF"
      id="F_000443"
      unitRef="U_xbrlishares">41973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001623526_20210101_20211231"
      decimals="2"
      id="F_000450"
      unitRef="U_iso4217USD_xbrlishares">40.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_0001623526_20210101_20211231"
      decimals="INF"
      id="F_000444"
      unitRef="U_xbrlishares">1476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001623526_20210101_20211231"
      decimals="2"
      id="F_000451"
      unitRef="U_iso4217USD_xbrlishares">28.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001623526_20211231"
      decimals="INF"
      id="F_000445"
      unitRef="U_xbrlishares">5435304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001623526_20211231"
      decimals="2"
      id="F_000452"
      unitRef="U_iso4217USD_xbrlishares">19.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000458"
      unitRef="U_iso4217USD">64981000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001623526_20211231"
      decimals="INF"
      id="F_000446"
      unitRef="U_xbrlishares">3103635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001623526_20211231"
      decimals="2"
      id="F_000453"
      unitRef="U_iso4217USD_xbrlishares">9.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000459"
      unitRef="U_iso4217USD">52003000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001623526_20210101_20211231"
      decimals="2"
      id="F_000460"
      unitRef="U_iso4217USD_xbrlishares">34.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001623526_20200101_20201231"
      decimals="2"
      id="F_000461"
      unitRef="U_iso4217USD_xbrlishares">14.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <stok:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="C_0001623526_20210101_20211231"
      decimals="-5"
      id="F_000462"
      unitRef="U_iso4217USD">44700000</stok:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <stok:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="C_0001623526_20200101_20201231"
      decimals="-5"
      id="F_000463"
      unitRef="U_iso4217USD">18200000</stok:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001623526_20210101_20211231"
      decimals="-5"
      id="F_000464"
      unitRef="U_iso4217USD">9900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001623526_20200101_20201231"
      decimals="-5"
      id="F_000465"
      unitRef="U_iso4217USD">27300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001623526_20210101_20211231"
      decimals="-5"
      id="F_000466"
      unitRef="U_iso4217USD">16500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001623526_20200101_20201231"
      decimals="-5"
      id="F_000467"
      unitRef="U_iso4217USD">5800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_0001623526_20211231"
      decimals="-5"
      id="F_000468"
      unitRef="U_iso4217USD">45000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="C_0001623526_20210101_20211231" id="F_000469">P2Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000242">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense recorded as research and development and general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,215&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,893&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,450&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,768&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000470"
      unitRef="U_iso4217USD">6215000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000471"
      unitRef="U_iso4217USD">1875000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000472"
      unitRef="U_iso4217USD">10235000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000473"
      unitRef="U_iso4217USD">3893000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000474"
      unitRef="U_iso4217USD">16450000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000475"
      unitRef="U_iso4217USD">5768000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000243">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the Black-Scholes option pricing model to calculate the grant-date fair value of an award. The fair values of the options granted to employees and directors were calculated using the following assumptions for the years ended December 31, 2021 and 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000478"&gt;0.78-1.51%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000479"&gt;0.38-1.48%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000482"&gt;5.5-6.25 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000484"&gt;5.5-6.25 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.46%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70-73%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001623526_20210101_20211231"
      decimals="2"
      id="F_000480"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001623526_20200101_20201231"
      decimals="2"
      id="F_000481"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001623526_20200101_20201231"
      decimals="2"
      id="F_000487"
      unitRef="U_xbrlipure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20190630"
      decimals="INF"
      id="F_000489"
      unitRef="U_xbrlishares">315000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20211231"
      decimals="INF"
      id="F_000490"
      unitRef="U_xbrlishares">634580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="2"
      id="F_000491"
      unitRef="U_iso4217USD_xbrlishares">46.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="-5"
      id="F_000492"
      unitRef="U_iso4217USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001623526_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="-5"
      id="F_000493"
      unitRef="U_iso4217USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <stok:PercentageOfIncreaseInReservedCommonShares
      contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20190601_20190630"
      decimals="2"
      id="F_000494"
      unitRef="U_xbrlipure">0.01</stok:PercentageOfIncreaseInReservedCommonShares>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_stokTwoThousandAndNineteenEmployeeStockPurchasePlanMember_20190630"
      decimals="INF"
      id="F_000495"
      unitRef="U_xbrlishares">3150000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000210">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. &lt;span style="font-family:Times New Roman;"&gt;Net loss per share attributable to common stockholders &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(85,805&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(52,243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average number of common shares, basic&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,739,269&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,488,456&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.56&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s potential dilutive securities, which include common stock options and ESPP purchase rights, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,435,304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,454,424&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000244">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(85,805&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(52,243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average number of common shares, basic&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,739,269&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,488,456&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.56&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001623526_20210101_20211231"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">-85805000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001623526_20200101_20201231"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">-52243000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001623526_20210101_20211231"
      decimals="0"
      id="F_000498"
      unitRef="U_xbrlishares">36739269</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001623526_20200101_20201231"
      decimals="0"
      id="F_000499"
      unitRef="U_xbrlishares">33488456</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001623526_20210101_20211231"
      decimals="2"
      id="F_000500"
      unitRef="U_iso4217USD_xbrlishares">-2.34</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001623526_20200101_20201231"
      decimals="2"
      id="F_000501"
      unitRef="U_iso4217USD_xbrlishares">-1.56</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000245">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,435,304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,454,424&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001623526_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="0"
      id="F_000502"
      unitRef="U_xbrlishares">5435304</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001623526_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="0"
      id="F_000503"
      unitRef="U_xbrlishares">4454424</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000211">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Income taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the expected income tax expense (benefit) computed using the federal statutory income tax rate the Company&#x2019;s effective income tax rate is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected income tax benefit at the federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible items&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(33.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal and state net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,231&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,097&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,726&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,816&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,075&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,293&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(66,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; As of December 31, 2021 and 2020, the Company had federal net operating loss carryforwards of $191.1 million and $116.9 million, respectively, which may be available to reduce future taxable income, and expire at various dates beginning in 2034, for those net operating loss carryforwards generated prior to 2018. Net operating losses generated in 2018 and beyond have no expiration. As of December 31, 2021 and 2020, the Company had state net operating loss carry forwards of $191.4 million and $118.8 million, respectively, which may be available to reduce future taxable income and expire at various dates beginning in 2034. In addition, at December 31, 2021 and 2020, the Company had federal research and development tax credit carryforwards of $5.4 million and $2.0 million, respectively, and state research and development tax credit carry forwards of $3.0 million and $1.0 million, respectively.&#160;&#160;Both federal and state research and development tax credit carry forwards may be available to reduce future tax liabilities and expire at various dates beginning in 2030. In accordance with ASC 740, &lt;span style="font-style:italic;"&gt;Accounting for Income Taxes&lt;/span&gt;, management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards. Management has determined that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets and, as a result, a full valuation allowance of $66.0 million and $37.2 million was established at December 31, 2021 and 2020, respectively. The change in the valuation allowance was an increase of $28.8 million and $19.3 million in 2021 and 2020, respectively.&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The CARES Act temporarily repealed the 80% taxable income limitation for tax years beginning before January 1, 2021. Federal NOL carry forwards generated from 2018 or later and Federal NOL carryforwards to taxable years beginning after December 31, 2021 will be subject to the 80% limitation. Also, under the CARES Act, federal NOLs arising in 2018, 2019 and 2020 can be carried back 5 years. New legislation or regulation which could affect our tax burden could be enacted by any governmental authority. The Company cannot predict the timing or extent of such&#160;tax-related&#160;developments which could have a negative impact on our financial results. Additionally, the Company uses its best judgment in attempting to quantify and reserve for these tax obligations. &lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended (the Code) due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. The Company has not conducted a formal study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined for purposes of Section&#160;382 and 383 of the Code, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards may be subject to an annual limitation under Section&#160;382 and 383 of the Code, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term&#160;tax-exempt&#160;rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies ASC 740 related to accounting for uncertainty in income taxes. The Company&#x2019;s reserves related to income taxes are based on a determination of whether, and how much of, a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. At December 31, 2021, and 2020 the Company had no unrecognized tax benefits. Interest and penalty charges, if any, related to unrecognized tax benefits would be classified as income tax expense in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000246">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the expected income tax expense (benefit) computed using the federal statutory income tax rate the Company&#x2019;s effective income tax rate is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected income tax benefit at the federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible items&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(33.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001623526_20210101_20211231"
      decimals="INF"
      id="F_000506"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001623526_20200101_20201231"
      decimals="INF"
      id="F_000507"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001623526_20210101_20211231"
      decimals="3"
      id="F_000508"
      unitRef="U_xbrlipure">0.079</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001623526_20200101_20201231"
      decimals="3"
      id="F_000509"
      unitRef="U_xbrlipure">0.083</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_0001623526_20210101_20211231"
      decimals="3"
      id="F_000510"
      unitRef="U_xbrlipure">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_0001623526_20200101_20201231"
      decimals="3"
      id="F_000511"
      unitRef="U_xbrlipure">0.062</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001623526_20210101_20211231"
      decimals="3"
      id="F_000512"
      unitRef="U_xbrlipure">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001623526_20200101_20201231"
      decimals="3"
      id="F_000513"
      unitRef="U_xbrlipure">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001623526_20210101_20211231"
      decimals="3"
      id="F_000514"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001623526_20200101_20201231"
      decimals="3"
      id="F_000515"
      unitRef="U_xbrlipure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001623526_20210101_20211231"
      decimals="3"
      id="F_000516"
      unitRef="U_xbrlipure">-0.334</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001623526_20200101_20201231"
      decimals="3"
      id="F_000517"
      unitRef="U_xbrlipure">-0.369</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001623526_20210101_20211231"
      decimals="3"
      id="F_000518"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001623526_20200101_20201231"
      decimals="3"
      id="F_000519"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000247">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal and state net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,231&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,097&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,726&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,816&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,075&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,293&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(66,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000520"
      unitRef="U_iso4217USD">52231000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000521"
      unitRef="U_iso4217USD">32097000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000522"
      unitRef="U_iso4217USD">7726000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000523"
      unitRef="U_iso4217USD">2816000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000524"
      unitRef="U_iso4217USD">6075000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000525"
      unitRef="U_iso4217USD">2293000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000526"
      unitRef="U_iso4217USD">66032000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000527"
      unitRef="U_iso4217USD">37206000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001623526_20211231"
      decimals="-3"
      id="F_000528"
      unitRef="U_iso4217USD">66032000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001623526_20201231"
      decimals="-3"
      id="F_000529"
      unitRef="U_iso4217USD">37206000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-5"
      id="F_000530"
      unitRef="U_iso4217USD">191100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000531"
      unitRef="U_iso4217USD">116900000</us-gaap:OperatingLossCarryforwards>
    <stok:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231"
      id="F_000532">2034</stok:OperatingLossCarryforwardsExpirationBeginningYear>
    <stok:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_000533">2034</stok:OperatingLossCarryforwardsExpirationBeginningYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231"
      decimals="-5"
      id="F_000534"
      unitRef="U_iso4217USD">191400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-5"
      id="F_000535"
      unitRef="U_iso4217USD">118800000</us-gaap:OperatingLossCarryforwards>
    <stok:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231"
      id="F_000536">2034</stok:OperatingLossCarryforwardsExpirationBeginningYear>
    <stok:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231"
      id="F_000537">2034</stok:OperatingLossCarryforwardsExpirationBeginningYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231"
      decimals="-5"
      id="F_000538"
      unitRef="U_iso4217USD">5400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231"
      decimals="-5"
      id="F_000539"
      unitRef="U_iso4217USD">2000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231"
      decimals="-5"
      id="F_000540"
      unitRef="U_iso4217USD">3000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231"
      decimals="-5"
      id="F_000541"
      unitRef="U_iso4217USD">1000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <stok:TaxCreditCarryforwardsExpirationBeginningYear
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231"
      id="F_000542">2030</stok:TaxCreditCarryforwardsExpirationBeginningYear>
    <stok:TaxCreditCarryforwardsExpirationBeginningYear
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231"
      id="F_000543">2030</stok:TaxCreditCarryforwardsExpirationBeginningYear>
    <stok:TaxCreditCarryforwardsExpirationBeginningYear
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231"
      id="F_000544">2030</stok:TaxCreditCarryforwardsExpirationBeginningYear>
    <stok:TaxCreditCarryforwardsExpirationBeginningYear
      contextRef="C_0001623526_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231"
      id="F_000545">2030</stok:TaxCreditCarryforwardsExpirationBeginningYear>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001623526_20211231"
      decimals="-5"
      id="F_000546"
      unitRef="U_iso4217USD">66000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001623526_20201231"
      decimals="-5"
      id="F_000547"
      unitRef="U_iso4217USD">37200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001623526_20210101_20211231"
      decimals="-5"
      id="F_000548"
      unitRef="U_iso4217USD">28800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001623526_20200101_20201231"
      decimals="-5"
      id="F_000549"
      unitRef="U_iso4217USD">19300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <stok:PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct
      contextRef="C_0001623526_20210101_20211231"
      decimals="2"
      id="F_000550"
      unitRef="U_xbrlipure">0.80</stok:PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct>
    <stok:PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct
      contextRef="C_0001623526_20210101_20211231"
      decimals="2"
      id="F_000551"
      unitRef="U_xbrlipure">0.80</stok:PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct>
    <stok:FederalNOLCarryForwardsPeriodUnderCARESAct contextRef="C_0001623526_20210101_20211231" id="F_000552">P5Y</stok:FederalNOLCarryForwardsPeriodUnderCARESAct>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001623526_20211231"
      decimals="INF"
      id="F_000504"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001623526_20201231"
      decimals="INF"
      id="F_000505"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000212">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. Employee benefits &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;span style="font-size:10pt;"&gt;In 2016, the Company established a defined-contribution savings plan under Section&#160;401(k) of the Internal Revenue Code (the &#x201c;401(k) Plan&#x201d;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. On January 1, 2020, the Company began to make matching contributions up to 4% of annual salary for those employees who are participating in the 401(k) Plan. For the year ended December 31, 2021, the Company made matching contributions of $0.5 million and for the year ended December 31, 2020, the Company made matching contributions of $0.2 million. &lt;/span&gt;&#160;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_0001623526_srtRangeAxis_srtMaximumMember_20210101_20211231"
      decimals="INF"
      id="F_000553"
      unitRef="U_xbrlipure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0001623526_20210101_20211231"
      decimals="-5"
      id="F_000554"
      unitRef="U_iso4217USD">500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0001623526_20200101_20201231"
      decimals="-5"
      id="F_000555"
      unitRef="U_iso4217USD">200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001623526_20210101_20211231" id="F_000213">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. Subsequent events &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2022, the Company entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. (&#x201c;Acadia&#x201d;) for the discovery, development and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (the &#x201c;CNS&#x201d;). The agreement focuses on the targets SYNGAP1, MECP2 (Rett syndrome), and an undisclosed neurodevelopmental target of mutual interest. In connection with each target, the Company will collaborate with Acadia to identify potential treatments for further development and commercialization as licensed products. With respect to SYNGAP1, the Company has agreed with Acadia to co-develop and co-commercialize licensed products for such target globally, and in connection therewith the Company granted to Acadia worldwide, co-exclusive (with the Company) licenses for such licensed products. With respect to MECP2 and the neurodevelopmental target, the Company granted to Acadia worldwide, exclusive licenses to develop and commercialize licensed products for such targets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the terms of the agreement, the Company received an upfront payment of $60 million from Acadia. Acadia agreed to fund the research to identify potential licensed products for MECP2 and the neurodevelopmental target, and the Company will equally fund with Acadia the research to identify potential licensed products for SYNGAP1. The Company is eligible to receive up to $907.5 million in potential total milestone payments based upon the achievement of certain development, regulatory, first commercial sales and sales milestone events across the programs for the three targets, assuming each milestone were achieved at least once. With respect to licensed products for MECP2 and the neurodevelopmental target, the Company is also eligible to receive tiered royalties at percentages ranging from the mid-single digits to the mid-teens on future net sales by Acadia of licensed products worldwide. Royalties payable under the agreement are subject to standard royalty reductions. For SYNGAP1 licensed products that the Company is co-developing and co-commercializing, the Company will be responsible for 50% of the development and commercialization costs and will receive 50% of the profits from global commercialization.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of and related to the out-license of SYNGAP1, the Company is obligated to make payments to the University of Southampton under certain licensed patents and applications relating to TANGO.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since December 31, 2021, the Company sold approximately 403,000 shares of our common stock and received $7.5 million after deducting commissions related to the Sales Agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated subsequent events through the issuance date of these consolidated financial statements.&#160;&#160;The Company has concluded that no events or transactions other than those described above have occurred that require disclosure in the accompanying consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <stok:UpfrontPaymentReceived
      contextRef="C_0001623526_srtCounterpartyNameAxis_stokAcadiaPharmaceuticalsIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220131"
      decimals="-6"
      id="F_000556"
      unitRef="U_iso4217USD">60000000</stok:UpfrontPaymentReceived>
    <stok:MilestonePaymentsReceivable
      contextRef="C_0001623526_srtCounterpartyNameAxis_stokAcadiaPharmaceuticalsIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220131"
      decimals="-5"
      id="F_000557"
      unitRef="U_iso4217USD">907500000</stok:MilestonePaymentsReceivable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokSalesAgreementProspectusMember_20210101_20211231"
      decimals="0"
      id="F_000558"
      unitRef="U_xbrlishares">403000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <stok:ProceedsFromIssuanceUnderwrittenPublicOfferingNet
      contextRef="C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokSalesAgreementProspectusMember_20210101_20211231"
      decimals="-5"
      id="F_000559"
      unitRef="U_iso4217USD">7500000</stok:ProceedsFromIssuanceUnderwrittenPublicOfferingNet>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_000458"
          xlink:label="F_000458"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000459"
          xlink:label="F_000459"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000457"
          xlink:label="F_000457"
          xlink:type="locator"/>
        <link:footnote id="FNT_000000" xlink:label="FNT_000000" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at December 31, 2021 and 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000458"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000459"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000457"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M.4$@(4?'P.FQAQ5(Z8A(QH^.,^A3.N#Q^)']UGLG+QMN8:7E5U%@N0S>!:R
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MQD<E\-\,QZGEBI>2YUD2*TB(5'C!-5*2\ W!4!&QGFM)XC(A:UY@H*1Z!0]
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M80W&\,)@--C9@K&K$W1V00X>GMRLKG<)GD96UY]*;!SR[#O&2Q7Q&"C8"KR
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MH*[,UDS1Z6:*-";IR[<FIV<JA^.ZXG;>)T\R4Z@5JWD1A-Y@B"PU<7TSU85
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MK*_"ZP<M2GN;O!):B]PV-XQ"I!D#^+X60N\?S 3-'R0N_P=02P,$%     @
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M/K/>*5[\S\TB=)Y4ZG_OV>!)VN );_#DRS((F0S,L.\VEX$7&>1??U$&]Q(
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M!9E_B,]621(I)VTA@Q*X#S:F9\^V6SMR >1H]R/NXB:*Z*!!'H;@F6SBM3J
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MG!P>@1&RF=[*TUPBB!,4!/[5$8M DOR)5U:Z[D9EP%V<5+W:R%# +OKKT[,
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M316>A(GQ], ,PX)>]&A9@/9S0_W43MC ]C_"XA]02P,$%     @ PX!J5&2
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M43L'LJ^5L@\3EZ#[7[#X!U!+ P04    " ##@&I4#R\HB?,"  !&!@  &0
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MD]"B V<6YCNR14>6?$ 6)_1.25L9>B,+*-X2A!A9'UZR#V^1'&6\AGQ(TWA
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M#]H9X'FIE-TOG(/^KV/V%U!+ P04    " ##@&I4&<@> J,"  #E!0  &0
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MTV.5()4L%8$FB;(^I$C]:2&2!@)__]O5>'3YM15S(PM.E+%&-$>&1^9?KXQ
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MA%6.$R5(&A&0U?*@)RGQ@\ZH>'E< 35V*R&ICP 4N/Y?J#I3U 5X);5,N7D
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M<R;ERY62@#TMP'-Z:UG]H /JK]ZN_PM02P,$%     @ PX!J5# %*^NL"
MUA@  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULM5E=C]NX%7W7KR#<
MI$@ C:Q/VY-,!L@DV78+;'>02;LHBC[0$FT+D42%E,9Q?WW/)279\M@SL\'V
M(6.)(N\]]_+<#S)76ZF^ZHT0#?M>%I5^-]DT3?UF.M7I1I1<>[(6%;ZLI"IY
M@U>UGNI:"9Z9164Q#7U_-BUY7DVNK\S8K;J^DFU3Y)6X54RW9<G5[D84<OMN
M$DSZ@<_Y>M/0P/3ZJN9K<2>:?]2W"F_304J6EZ+2N:R8$JMWD_?!FYN8YIL)
M_\S%5A\\,[)D*>57>ODY>S?Q"9 H1-J0!(Z?>_%!% 4) HQOG<S)H)(6'C[W
MTG\RML.6)=?B@RQ^R[-F\VZRF+!,K'A;-)_E]J^BLR<A>:DLM/G+MG;N/)RP
MM-6-++O%0%#FE?WEWSL_'"Q8^&<6A-V"T."VB@S*C[SAUU=*;IFBV9!&#\94
MLQK@\HHVY:Y1^)IC77-]M^%*7-S KHQ]D"7V6G-RU]6T@72:,TT[23=64GA&
M4A"R7V35;#3[5&4B&PN8 M: +>RQW82/2OPH4H]%@<M"/PP>D1<-MD9&7G1.
M7J[30NI6"?;K:F0M^RP*WA@7Z$8SXY2E\<DMWX&"&/OW^Z5N%$CTGT>0Q .2
MV"")_P"O/RYIX;%SPMC/%?M;6PFX+[AT6;,1YC.O=G_^TR(,YF\U6TJN,B97
M+,L5PD0JS7B5,; N_;J1129HH*Z5O(=L$D"BV*=O;=[L(#Z%9Q!3[+;@%7M%
MWTERZ+\UTVC4O =O7[/M)D\W;"E27@HF5BMAHI')#F(P=ZUL4J]$7?"TTW@,
M&;/BYR&(1P@\<@?/LMRXII%&N";7:7) *LL2X\9R -!"D<E(>FS5-L287.N6
M0Q]KP6[5.\/JP!MOV%9@&C00<+GWEIG0UA">@T9[TS,0;K0K+*\ CA?%;@\@
M=)%=7=_WST$EA*>A6<T>^X+7JBV7^(+%G9B1A2?6G_!Z9\DV+PH@35$!-,QM
MD:# MM3 IMWD58ODS@)2)CCV'+^(7Q]BE6S7&WJY9,N=4?, E_C6\H+<%[^D
M49K#UVLEUG#6P6Q4%]V *GFU/G#,*> C9_%A6EZ6(LLA%*A1S$ V$H6$(XP*
M2CIP#&>%T'!4KQGK2[X#BY'W&Z&0CN'!SI2G0\MC[XW^D19*;;0>U#'\J61O
M$+_G><&7A7@V"REV0C>:AR#,K!=C63G(.DF1CZTB\VET)SAB7E &/P&4-!R/
M^F,2KQ6O*)/*F@)-TU[6K4HWQ); C8+ 75S.C:# #2$BB<)SW,;25*@&G05]
M,M%3UH7<":%=(V%PK4N$KFU@%3O+^1[ O= -XH^DK62K>@N_IZ)NC&L''=V"
MW@(L*(VEVE).G4J7-J\9'4B2(">2F20'*]$[DY#"/J@4*LVUV0:D"\YJS#>F
M@X(Y]G0@/_ESQ7/%[GG1BIZS(]]0#L.8P6I2"=C5=U8FGNRL>M_Z4,(D<_D6
M1F@PB8BOA3%U2<W9&^?O1^'H_&::&DS@L T]6F]#A_CA=R6H$20RI>@%J%R2
M246^$NR5\<9KY_T0SSEFY&COTL[.5RQX[?QZ$-K\9+SX3NS&"?Z%H?/"67@+
M'W]\/(;1S)TM$N<O=@.=@6Y.$GF7D?.I Y\YK\+%W$UF,^>U$WISWT&#MQ(Y
MK7D5!^[E/,*'V/>"$&MJ[#7& S>>F_D+#Y^?1ADXB1M'B1OY,: %E]Y\WL&<
MQ>[E(NC16#J<$1&Y@1^YLRC!,DB(G9EWB<>$(CP"IM?.EU&&//8H-AF9.6UM
M<P,MQ)DL1PU2@K+(4C1;(2R5QEO;D\[DBV)'=O;Q07PV"W23ET;P$UQ=29MQ
MAI0P5,O<JL94L:.8.)UQ:,]M3&^/^;;G_R&(?6 =1<(^N+/?D_),_=K"?2^B
MV/-M]GH1Q-X\.95X]MMQ&MT?C,GT9]_-3J"8O8@!"P>%HC"!;X NO+ ?>1SO
M,7T>(.TY\@#K#T&]]"['2,.Y%YU#>D= +FQ3GAYVN4/#.J#\<E".D*>E(FCZ
MW'KQG9Z-L2^"F9>,(27>8ACXW?MS;,.9^N_V#0 Q+$X\?]"(V6U%)JRK_+_'
MP%.<5:# QC:J1EM1&7K,5*[ M+6P!YJ>=4>=1!_=0WN@+4M&@G)MW)9VFI>"
M'8 T=9 _C%5$92Y-^0SAU*XVGO;((]O=;]>PL=QVLQP]AFT*!)PM:S+2O*]%
M!?V%+<,9>K:<SG&F!>]DZ3X/\32UM.D*F)9%GG'K4OQ8OU$O %/X/AG2(B4V
M=%,!H3AAFNH*7"M9H*[J-\Z_3H>(8Y*\*6F?SYA ]<(- RH *&5S%+>SYCB!
MCXXJ0=%8H-AA_@QED@I.XLYG"^<P*EHRFBR^P4'KZ\5=BL,>-6"V7: "0!XH
M929,/S+4D'W/<7$BJU$+2LV%)<S^V]!UG^BPAHYNW-#9\G!0NUK=AYYUJBV\
M:'@ZD7V->5Y@/FM'<OWU8D5M'-(BT%"P 8KC>_/%1> EP4L\1O08+UY2GV##
M(4.GE4$PV^6BR!P?LYR#S]0*.8F77,R\,+%HCU^'N?<2MN<%&C=G[E_,HY?X
M>>G8(WCGMB[S#1UV3>> L^=^$ 9;,#K*]W),O+';7HX]3W=GZ4]WM[?],=I]
M\B2_L"=Y;Y2&3QQMHR!YZF"K^>C$0CB01$^T"6,K-SQCLRAVDX5_^C!UXA15
M#V?EY[86X[5=\IYY_L*HL%F,Y#6R0;@2]J=KT"&+SY+8:/+WE=*P^ADK_0<K
M?_!RP-CRW'L .ACM;P), .<*@PW:3LP&5-Z?R?:1O9\FJ5>E(;,13UX;T-?N
MS(ZOP7")8#?A_W]MT-T:R"V5P%*VQ* ?NBH8-V8/#*9=Z4NML0\J>I#[[:ED
M8PZZ%&UND!Q?)#UEN'?JIG-Z<-=<"K4V-^JT#K;::^=A=+BT?V_OJO?3[8W_
M+URMT6YBPU98BKR:3)BRM^CVI9&UN;E>R@;T,H\;P4%#FH#O*RF;_H44#/^5
M<?T_4$L#!!0    ( ,. :E2O:'>DP ,  /4(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;)U6;6_;-A#^KE]Q4(=A!53+EN3$\6P#>2LV8.V,NEM1
M#/M 2R>+"$6J)%6G^_4[4K)CMXE;Y(-E4N0]]]QS1YYF6Z7O3(5HX;X6TLS#
MRMIF&L<FK[!F9J :E+12*ETS2U.]B4VCD17>J!9Q,AR>Q37C,ES,_+NE7LQ4
M:P67N-1@VKIF^LL5"K6=AZ-P]^(=WU36O8@7LX9M<(7VKV:I:1;O40I>HS1<
M2=!8SL/+T?0J<_O]AK\Y;LW!&%PD:Z7NW.3W8AX.'2$4F%N'P.CO,UZC$ Z(
M:'SJ,<.]2V=X.-ZAO_:Q4RQK9O!:B0^\L-4\G(108,E:8=^I[6_8QS-V>+D2
MQC]AV^T=CT/(6V-5W1L3@YK+[I_=]SH<&$R&3Q@DO4'B>7>./,L;9MEBIM46
MM-M-:&[@0_761(Y+EY25U;3*R<XNWE+>_U#&P!(UK"JF$2ZMU7S=6K86"%;!
MM:IKTF]E57Y7*5&@-K/8DF^'$.>]GZO.3_*$GU$";Y2TE8%;66!Q#! 3Z3WS
M9,?\*CF)>(/Y -)1!,DP&9W 2_=*I!XO?0+OEFG)Y>90B7\NU\9J*IQ_3^!G
M>_S,XV<GE!9.Z8;PC<=G7RF==TJ;[RA]VL_% )[G"MY7"*42=$Y)!^BV=H>5
M_X<&+"V364,@_D"ITIT'G@.3!11<M!8+D,]S35@.GDJM8?++-/B(3 .Z2@'*
M,]9K0J-<!R[7[C$,WK8U:F:5G@:[<(.?@E\FXV@R' <OW7B<1$F6TO@&I:*S
MT^W^X \J%J_89P+8(,C6PQ.%'3-'VT3?1A>D9]%Y>A$E9Q=!FD;99!)EX[/@
M6[D?LR5"R2#-.FJC =F]](KW,?_\8I*,SG\E$&516LY$9TEW%AC,6\TM=Z2V
M%<\KX#(7;8%'6H)J7%Z,]WJ[6BZA:75>T94%VH5,QA7%#&M$"7CO 0HHM:H?
M2^VIA':U@&5)5RO=NJTH")3<6OYJQWG@8J,+5CDQW.YM+SM\1W:@SF$LA>!J
ML#5DX$J&B;P5S!)Y9:L?*SO>L32L[LCLA'X(W1[5^X/N7Y4!-3M#*V3@KO\"
M7"^I52OM,5=FG7.N"E>WT7-T);&\10=C*,D%SYEWC#DC+?JT^]-)S;F7WB>U
M8J2L/,Y!GZ%I\,01^O. _:YV2.Q]U1P65S".LG0<I<,LR*CHZ9=DCUV*\4$K
MH@.Z\0W7$!3IU76E_=M]3[_L6MG#]NZ#X W3&TZ4!)9D.AR<4PO579/M)E8U
MOK%135";],.*ODM0NPVT7BI*:3]Q#O9?.HO_ 5!+ P04    " ##@&I4RLT6
M$,T(  !;%P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6RU6&USV[@1
M_LY?@5&33C*C2"+E%]GG>,9Q<FTZ=[E,G&NGT^D'B 0E)"3! *!EW:_OLPN*
MIF3)OK37#[;X BQVGWWVP1(7*V._NJ527MR51>5>#Y;>U^?CL4N7JI1N9&I5
MX4UN;"D];NUB[&JK9,:3RF*<3"8GXU+J:G!YP<\^VLL+T_A"5^JC%:XI2VG7
M;U1A5J\'\6#SX)->+#T]&%]>U'*A;I3_M?YH<3?NK&2Z5)73IA)6Y:\'5_'Y
MFR,:SP/^KM7*]:X%13(WYBO=O,]>#R;DD"I4ZLF"Q,^MNE9%08;@QK?6YJ!;
MDB;VKS?6?^38$<M<.G5MBG_HS"]?#V8#D:E<-H7_9%9_56T\QV0O-87C_V(5
MQDZG Y$VSINRG0P/2EV%7WG7XM";,)L<F)"T$Q+V.RS$7KZ57EY>6+,2ED;#
M&EUPJ#P;SNF*DG+C+=YJS/.7[ZO4E$I\EG?*78P]+-+S<=K.?A-F)P=FQXGX
MV51^Z<2[*E/9MH$Q7.G\23;^O$D>M?A6I2,QC8<BF23Q(_:F77Q3MC=],C[Q
M5KNT,*ZQ2OSK:NZ\!2/^_<@21]T21[S$T>-+^$,0/CX[GHQ$WX*X M=34Z6Z
MT)*):W+AETJHNQI,5IG0W6A^5CDE7LQ5I7+M7PJ\JAL:U3A=+7ABKC)E92&<
ME[[QQJ[[%JSTBD==8Z*LUG_^TRR)3W]P0N6YXHIY,%H[(9W(38&"=N?1/Y6T
M0E'Z!9*GRKFRE,"($DC_)M&[/9ZW#@OI#_A(2T5)/)I$SS<_-YZ7[X$U%!5T
M"P!MYK=FH]/1630;3:,/IGH%SQI$,B\PUZO219/1470R2J)/RL'W="EDE:&2
M;Z%0-?3&B]2J3'LV'AV-XBC&X%_@IL74"?Z2Z'HIJP7Y(FYET80\20)$5JF*
M7DRG6.(E?D_@Q\OHL_&RX+G/PW_Q&3'7%J'H&EY3TDR%E=TFV;O9@,XH"Z\8
M.^F<PE#R&AR9@RA>@S@@C=/.;TR$!($$Y]$5VSV0G;</39]'/[9XTAJ.86>@
M:SSTQ"O4$1:4UJZQ+ZRDS5ST+#I.ALDTQL4T&4[.3@_C2RL%C%UT.CQ-3J)D
M.(M/6HQ/AI/38SQ)SJ;17RPMM"?ZZ 3#IDDT/1TFDY/H)^7<^?Y<M ,I&V'L
MR^@#8MEG\UG$@"<_]*X>8L?2Q#$1?L-^OL129AT7GT*,[#Z+S^)1#&$O"G8;
M1I_%,5BS>32$&K@Z5&*Q'HK54@/04JY!=2%OI2XD$=L;C /-D?;&D\(A*GX1
MJF7(EJ$6&J]0<K?2:M, 6&36P=)"5Q4Y"3XGD^G1$.2QB,NXI_,N%B@Y*M:,
M"$W3#&S$LY'X\&"FZH_FM>(9>S97:X.?I83<5"8XRHD<B>_'_W&^B@?P'^W"
M/QO-_ECXOP]]V@^$S% =[  F_#?LLT\7WQXZ'N^BD8PFA["XUX;?O=8V^--[
MVRWTAQ8;B3?&+[O8_J>5?U?RMH3U>[(W"=E+4V,STA^T<W#\ZN9:G!XA6U=X
MT51,22JQ?O?%>\+UU:=W-QB% !3V!(NU"NR%JE:R(*W"D-GD^2Z]"EUJ'X2/
M"Q?^KP%+W[NYPALE_B:K!KVW:'DT$ANA__#+3[M W9=J;DT9BA76"SRRC,F#
MN=U40+IQ<=<1F=/TAXQ>(>^4%]?,ORB*WW31WH<'.2B<&8H&[88-U-\ -NS8
M 7>0,ZM=EY5X1HO$9UW9P-V*%B.O-0*<R_2K. Z^DG"M1 &'7=$V8!896#3M
M79  I+'($ PU2<(T ?1Y8S-5M>]@7E62^Y[Y6E!Y+LRMLA71DSC<0%^M]N#V
MYUX)P['*>$@IJ)N&WL@C?$0"+]2=)VZC=EP#'[#D*ZL*3E&/^V[+1=94"3E<
MR-#-81URN6*O<UV!I3KH!3YD$/U5JSS80M?;\M*0@&//1FAH,[XTV8)+#1!+
M3W1E6B-OWQH)BN=KAILJU-ZJ=D?!#2-EYH5>,)Y8\5>/2OMMJ]E]<M?9F/X^
MB6MKO\<Q23?0$CC,PH+R*/KU%)AV$[XAG9C.$EYM.IMN7'U?@=! 2WR"!U5#
M<&6*7L9GLY,AM<JR#.WQBP!FIEZ*K&'=,2N4F%OJ6J3<4*)REI 8SIE)TX8;
M%'#AEA0'0L 88D!(+8\@^+G=8^UB,@'CAX8I=(Z+1\N29(B\W"E<MAZ*H^&T
MP(& "I8GC_,<K=+^;6Z;R4M$3E1&6TK]-]D1?(A 77Z3L37JNQSQ55'GAP'!
M6_8+WY46G\-DIH,"\6_&TC\5D)HK%%T)]NH:OFP"[MF $J3LI*HYJ2WZ!(33
MBTKG&B%[;L,+=8>:Y!RG!BR'AP;U0>ZSDG/AR1 !I#[?V7\=?Y)!4[!6MB\>
M)@1Z3WP%9EP3=6-KXX*_+<WVL8QHP[T K0-%4+M!#=M\?5\9L;3] 554/54Z
MAV,*8J4)%112R<! ,'-M 7^;U?7F6Y8Z?'7H(\EY QF7G6IV W>K@>QS%=1U
M@=03@PM3+5[1^JRJZH[DC+]!0Y^#T3U=[T?>J24NOS3.LP)SEJWZUJ!GR""I
MU;H/#.$7Y):*][[9)7>EP*[__T]AVP[T*+-=O(P,'4:$QD5LMAF*>+N%:4!
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MG*'Q"B1?:.VV&^]@>"!G/P%02P,$%     @ PX!J5(>T.V17!@  -A   !D
M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULI5AK;]LV%/TKA-<-*>#8CI/T
MF01PTL<ZH%F0M"N&81]HZ4KF0HDJ2<7Q?OW.)259;IPTV[XX$D6>>^ZY#Y(Y
M6AI[[19$7MP6NG3'@X7WU:OQV"4+*J0;F8I*?,F,+:3'J\W'KK(DT["HT./I
M9/)L7$A5#DZ.PMB%/3DRM=>JI LK7%T4TJY.29OE\6!OT Y<JGSA>6!\<E3)
MG*[(?ZXN+-[&'4JJ"BJ=,J6PE!T/9GNO3@]X?ICPFZ*EZST+]F1NS#6_?$B/
M!Q,F1)H2SP@2?V[HC+1F(-#XVF ..I.\L/_<HK\+OL.7N71T9O07E?K%\>#%
M0*24R5K[2[/\F1I_#ADO,=J%7[&,<Z<O!R*IG3=%LQ@,"E7&O_*VT:&WX,7D
MG@739L$T\(Z& LLWTLN3(VN6PO)LH/%#<#6L!CE5<E"NO,57A77^Y*J>._I:
M4^G%VQO\NJ.Q!RQ_'"<-Q&F$F-X#L3<5'TWI%TZ\+5-*-P'&X-.1FK:D3J</
M(KZA9"3V]X9B.IGN/8"WWSFY'_#V'^ND^&,V=]XB)?Y\ /Z@@S\(\ ??AZ=[
M-7P0@DOOE:MD0L<#U)8C>T,#"#L2=[#%AU+\(LL:%<3R3(?"+TB<F:*2Y4I@
M!EE*A2J]$5)HE:!^2,@R%<@4+>?&RE@-N24J&':I_$+,$IDJ*2X6$IF>4.U5
M(C7;0B!V?OKAQ70Z>1WGA)>]UT\%&D(PG2J7F!NRJR&JX0957@78:+(HR"9*
M:O5W-&LR46*R%I?GLUVNIE04E*H$<K@.T:.[^ ""Z0Z8-GI@)1YR*@GL1$FU
M-3V#4C,3 J3C98P#WQ%CC:GVQM1.N)7S5(@=_M;X='9^U3HT$I\POM8E,R@_
M!BLC*6ES@OQ7OY^_GUT@-S^^/;N8BIU+\A[(96I-04^'@:@L15VR+MJPAUNH
M1C0F6M2^QH *@7-^Q/%-3%DV72M$AV2R:)9LAGNIM.X%EC:"B0Q0*<RI;"4J
MX_F)+;?B1KVSV@+0/B)TTK7IE(H*_M0)=@/QA0V"> 6^;+&3IT]S@;5!V/1;
M@HG9;2PW5G?[ANFNQ4#:U9T>(M=F+K5>1>75AGCL&06+?3:YE1 [9?,-$6P<
M.D7?I2$SH-M$UPY[A=CY=NW3EE"/QR-$B:G"_!CKWG08/I[FFF-'"/,VI?Q7
M.H+U16U=#9N,%#*>;-'54E<7FR0M)006,>6KS&(?$)5<M<7[Y-D$FY;6' Q\
M+!I/1JU'35+ 8%8WZG#WDY9Y;4W?[8X\6N!VRD8!H;]R!D4.&PGZ7_DT51!;
M2FM+.4%:Y6JNB<$:Z2 ;OSUY.7D^.NS$0A[W2M:P"_B$_F!*:@5V(C;0NFI:
M%+J$@M>M^ E9CU-9O[2'L)K76GK#[3I3UOE>H@@G82)H%)_6)IN]1R;6.!>,
MP5]D:-'KV@O$LLTF*.UPSE-E'IO7&FD9NGEDBK3Q0J-G@V^9T-W"^9_1]IOJ
M8T<S6T/@5=@TK5E)C6?'M"IHPF@Y7E&).;L24IA!"Y7N.HQHWOYRY5U;,_S!
M$SCSMI&AM5LFZ!L]YZLVLQ">N[YU]3T2EQT5!%LR7>0FV<U2%+P?NGK^5Z.6
M\]!$VM81KDX&1CZANM^MTW*+:;^ R]_(M>[-[/N6]HSA+=O1/-0,<M(%F3E@
MAY,?VS[R_7TF,<[') QP;8QZ&&"=L>8A'+'_W\5!CP$*4\'YG%>&$P0A]V/#
M82!<4G;;(Q)F;-V[((29(V?:=86\[E5@ _2Y!$7K%#1G'. N9%$AWYNPM:6X
M%E[Z6%!\6J@JC ?2+C)DO8'\:7;^_E<< 15J0^!,3,4<6.VY>).F,SH@67.K
M<%<AM+.#R?YP,ID(AT-=/!29V@:AP O%F%PWFC0M_$F_ <G,AU-!2"#0X67*
MN37'M8I7(;=G;59N-CW>^NE&ZCJL<'=.L^@:IL[C)@M\[#_P->6C3 PV(H,-
M'=ZI-"!DJL24T*P\!D(4[EK$$NR/*7/DQ"Y-:XY[%:K9R5@6PH3##R9Q!\5A
M#1Z[Q*HYMZ8Y#JI PX])DMK:%LW" V7CP1<'/"YQU3;@))*(BGV7]K:[Q[AW
MET-&Y^'&RA[5I8_7NFZTNQ3/XEUP/3W>J#^B#2HXJ2G#TLGH^>% V'A+C2_>
M5.%F.#<>]\SPN,#%GBQ/P/?,8 ]J7MA ]Z^"DW\ 4$L#!!0    ( ,. :E3H
MCIG)01L  ')3   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;+5<6Y/;
M-I9^]Z]@]69V[2JU6E*[8SNWJO9MIK/)Q.N.9QZV]@$B(0DQ12H J;;FU^_Y
MS@% 4*)H3V;WP6Z)(@\.SOT&?O=0VX]NHW63?=J6E?O^8M,TNV^NKER^T5OE
MIO5.5_3+JK9;U=!7N[YR.ZM5P0]MRZO%;/;UU5:9ZN*'[_C:._O#=W7;E*;2
M[VSFVNU6V<-+7=8/WU_,+\*%]V:]:7#AZH?O=FJM[W7S8??.TK>K"*4P6UTY
M4U>9U:OO+V[GW[Q<\ -\Q]^,?G#)YPQ;6=;U1WRY*[Z_F $C7>J\ 0A%?_;Z
ME2Y+0"(\?O= +^*:>##]'*"_Y<W39I;*Z5=U^7=3-)OO+YY?9(5>J;9LWM</
M?]%^0S> E]>EX_^S!W_O["++6]?46_\P8; UE?Q5GSPAON2!A7]@P7C+0HSE
M:]6H'[ZS]4-F<3=!PP?>*C]-R)D*7+EO+/UJZ+GFAWOA1E:OLGNSKLS*Y*IJ
MLML\K]NJ,=4Z>U>7)C?:9:HJLO<ZUT<_V[JBS[DF5C4N>QQN?_+=54/X896K
MW./R4G!9G,%EOLA^KJMFX[(W5:&+/H KVEC<W2+L[N5B%.)KG4^SZ_DD6\P6
M\Q%XUY%:UPSO^@R\(;+\]^W2-9:DZW]&%G@:%WC*"SP]L\!+Y8P#,]Y9[8B@
M2D27*/^JKAPM6?"5(=J. H9R?^-V*M??7^P VN[U1;?:[GBU/%TM^W6C27WR
M>KM3U0&;[W[61;8RE:IRH\K,$00O!QNUU]E2ZPJP=\K2?:9B(+:@NS6)>;/)
M/DSOI]E:5]JJLCS@9[T#2-71>6<- =^51.G'?[Z]??=DP@C2Q;(M=-9XU%HL
M"B%NZH\:"%NUTVUC<C?)[BJ2 GZ([GG8U+349?U0T3JN73I3&%* :79;'6!F
MM-5 CY ET$YG5=W0TDV=J=V..*Z6I<[6K9%-$/6V&OI"O_.S^  L,^6R%2%5
M>$"IQMPWA(NRA2.>%JQP3.3'__YOSQ>+V;>W]Z_XT_S;)XSTX),?=J!]\LR'
M^ P1 0N^C5P9!/"RIC_Q^;>W]R\# *)$61+:C;:>XQF)=^44FU%'3&T>P%?@
MIK8U0<5RK_RMGLP -G_V;5]0.FHGXJ%+0V8-OT^S$06ZB0IT,ZI 'XAE1($W
MKC%DLK4;TI11",.:XL'J )950B1;N$<_?EXI2!;H)KA2TQQ$ UA8K/Z]-;06
M&?:*7"%NAB!M%8ERMR03W)'[W DCFHUJ,K5:D7]C%A VM67MV49UH/MU0RI0
M&K4TI6G(8$TRK-8<Z.\G\NW.0RZ,R\O:M5;[O4!@@(B X'L2*-..Q!EI=[;3
MUI TYZS'5N_)>XK*EW"+#'*C"* 0P=B\W1)A2(<(GQ6)EBP C*R! I(4YDU+
MY".RD(-UA%%; LL5M&QEZRWMN78)?4;%Y^LH/E^/BL\KY39B;O'A#1%JKTKP
M;DB.1D$-RU&$G^.#[N"S0 4E@B290ELB"JGBABA(1"T-W0V2[FG+(D\L08J$
MSYHUR5M)$M.T%K+%1L!JG6W%H=8V(PM*\$14V'C [K>6V$)4)&E;ZA.DICVL
M"I(O!Q.*?WPK6+G1^4>2E$GFR"KL>&^TICX0+O8C197!.(^RYUEDS[-1]KRG
MK5N30\A!R2&F?#$ WL%MDU&,H+=+$JH0)TP@<[V[F!\.7XEF@[NC6\J2B$I^
MS/P#EK;430,&0O#)^9F&?(5KH9PN<SH7+G449<-0^4B5V9H856],'0%54%>"
MR2RH+2D\.$D*%-42'%L1,O4#T&C87UE-T.D6[?DV*("X>+SQ'3P: >R9MJ4J
MV?EQT,FN$;=$,\=;QL,KPL%]\^B6$4ZI_ A4QG^S1V?UX=%7C^9/GTZ>O[BA
M3XOGSR;7L^>/CKCWZ.;K%P3FAN^]F3S]^JF_]V9^/2)LSZ.P/1^5E9^9Q4S
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M%>30A(@[98I+)$-"]'$I6G12M!B5HG<4YVFP (Q!3K\#GH-"- IH6(AZT'6
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M4?>\6M%&?\H:F8E3/"DC\YHH<HY',5UG>#[>&GY/I$3<SG!?2Q[&*)X/B?]
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M0>T4:#]7RG83YZ#_"5K^!5!+ P04    " ##@&I4^U')5-8"   =!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q]5=]OVC 0?L]?8673U$JH(2$T
M0 $)Z(]56J6JM-W#M >3'&#5L5/;*>W^^IT="'0#7L#GN_N^[X[ST5])]:*7
M (:\YUSH@;\TIN@%@4Z7D%-])@L0Z)E+E5.#IEH$NE! ,Y>4\R!J-L^#G#+A
M#_ON[EX-^[(TG FX5T27>4[5QQBX7 W\T-]</+#%TMB+8-@OZ *F8)Z*>X56
M4*-D+ >AF11$P7S@C\+>.+;Q+N"9P4KOG(FM9";EBS5NLX'?M(* 0VHL L6O
M-Y@ YQ8(9;RN,?V:TB;NGC?HUZYVK&5&-4PD_\DRLQSX'9]D,*<E-P]R]1W6
M];0M7BJY=I]D5<6VFSY)2VUDODY&!3D3U3=]7_=A)Z%S*"%:)T1.=T7D5%Y2
M0X=])5=$V6A$LP=7JLM&<4S8'V5J%'H9YIGA'54O8.B, YE"6BIF&&AR\FAO
M]&D_,,AA(X-TC3>N\*(#>&%$[J0P2TVN1 ;99X  Q=4*HXW"<704\1+2,](*
M&R1J1N$1O%9=<<OAM0[@W8HWT ;GRFAR"3-#1B(C5Z\E,Q^[+?@UFFFC<&A^
M'^&,:\[8<<8'.*?5R!,Y)WL;OJ_/QQ$?ET#FDN.;8F)!*KSJ8;$_J-Z@>R+S
M@HJ/;U\Z49A<:)R:FEEOZZ3:JL(F0SX#53>:G#"!*++45&3ZM.?]%^&-<JD,
MLF7(I(WW)' I<&??X#+0NQ<_I-;>-66*/%->@G>W3TK/FTA52$4-D)E$5N^K
M%R:-=K>#!U=%=(&GDR3V3M>N*,:</ >5,LI)00M0Z(F21MQ)/B5M3VOGTY3<
MR#=0P@X"/F.<@ZT2&]9M=/\E[E;$UM6,O4=I*$<S:3>:G=;GR/"\XT*3N-$-
MV_L&*-AYLJA_X1:3)JDLA:E>;WU;[[Y1]>2WX=7BQ&8NL-^$PQQ3FV=)VR>J
M6D:5863A%L!,&EPG[KC$_0W*!J!_+J79&):@_D<8_@502P,$%     @ PX!J
M5.+4#OVX @  L04  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULA53)
M;MLP$+WS*PBAAP00HLV6G< V8&=!"R2MD70Y%#U0TL@B0I$J2<7)WW<HV8H#
M).Y!XC;OO9DA9V9;I1]-!6#I<RVDF7N5M<U%$)B\@IJ9,]6 Q)-2Z9I97.I-
M8!H-K.A M0CB,$R#FG'I+6;=WEHO9JJU@DM8:VK:NF;Z905";>=>Y.TW[OFF
MLFXC6,P:MH$'L#^:M<95,+ 4O 9IN))40SGWEM'%:N3L.X.?'+;F8$Y=))E2
MCV[QI9A[H7,(!.36,3 <GN 2A'!$Z,;?':<W2#K@X7S/?M/%CK%DS,"E$K]X
M8:NY-_5H 25KA;U7V\^PBV?L^'(E3/>GV]YV%'HT;XU5]0Z,'M1<]B-[WN7A
M ##]"!#O ''G=R_4>7G%+%O,M-I2[:R1S4VZ4#LT.L>ENY0'J_&4(\XNUAKO
M5]L7RF1!K_^VO,&,6Y]^Q?=P\IUE LSI++"HY.R#?,>ZZEGC#UBCF-XI:2M#
MKV4!Q5N" %T<_(SW?J[BHXQ7D)_1)/)I',;1$;YDB#OI^)+_Q;T63%JZ/(R>
M_EYFQFI\,'^.*(T&I5&G-/I Z:%_[E25="_JOY/M]Y)\G/C-U<$KF<2KRQ66
MC;%0.%E; 2V5P/KC<G-!EL9M8D*ASD"[I!*75/<+R2W+E&96H<,#)?E$1GXZ
M"7%,_/,D)3>MEMRV&CKIDC^[N2'1."%1."6W@&52*5%07C=:/8$C,21.$Q)'
M(?E6ECR' WJ'<=\E.FUUVY<KEQ2Q&^1%8C\-4S(FJ3\-0_0E22<H8@S6=-[6
MK6 NT *P*^6<.30YB?TTC<@I.4'L>8P3%T.4G..(1Y/Q>Q<;')11#7K3-0N#
MN6RE[2MJV!WZT;(OPU?SOIG=,;WATE !)4+#L\G8H[IO$/W"JJ8KRDQ9+/%N
M6F%/!>T,\+Q4RNX73F#HTHM_4$L#!!0    ( ,. :E3B%^-RL0(  -$%   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;(U4RV[;,!"\ZRL(H8<6$**W
M8P>V 3MIT0(-8B1]'(H>:&EE$:%(E:3BY.^[I&Q%!6*C%XF/G=G9D7;G>ZD>
M=0U@R'/#A5[XM3'M51CJHH:&Z@O9@L";2JJ&&MRJ7:A;!;1TH(:'211-PH8R
MX2_G[FRCEG/9&<X$;!317=-0];(&+O<+/_:/!_=L5QM[$"[G+=W! YCO[4;A
M+AQ82M: T$P*HJ!:^*OX:IW9>!?P@\%>C];$5K*5\M%NOI0+/[*"@$-A+ /%
MUQ-< ^>6"&7\.7#Z0TH+'*^/[)]<[5C+EFJXEOPG*TV]\*<^*:&B'3?W<O\9
M#O7DEJ^07+LGV?>Q>>23HM-&-@<P*FB8Z-_T^>##"# ]!4@.@,3I[A,YE3?4
MT.5<R3U1-AK9[,*5ZM HC@G[41Z,PEN&.+-<%87JH"14E.3.U*#(=:<4"$.^
M,KIEG!D&FKS_1K<<](=Y:#"G18;%@7_=\R<G^..$W$IA:DT^BA+*?PE"%#LH
M3HZ*U\E9QALH+D@:!R2)DO@,7SHXD#J^] 3?AKZXXL@*+7!V4*[)K]56&X7_
MS.\S*;(A1>929"=2/& KE1T'(BOR7X:_Y?/Y%&-:Z6B+ RT??<="8C=I@W&H
M!*-()3FV)1.[*V^E[2&Z"\T6X>BP9QVVC\@[TD/3<OD"@$P-S@5-76L54AOM
MO?/R()VF^,Z".$D'3*MD!=IV,>5>CA?Y[/52@0:JBMH)+^$)IT3;6-D]YR28
M1K&7!I/IS#OZU$KELJ):G$T*)8@=X8"M.:[5BX,\NL1G-)EX=Z<<\?(L\K)\
MAJ+C++C,,US,@ED:O?75PU&;-:!V;IA84SMA^HX;3H=YM>K;]#6\'W:W5.V8
MT"B[0FAT<9G[1/4#I-\8V;JFW4J#(\ M:YRYH&P WE=2FN/&)ABF^/(O4$L#
M!!0    ( ,. :E0T#S79S ,  )P)   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;(U6VV[C-A!]UU<00@ML ,6Z6)83PS9@.UUL@4UK)-GFH>@#+8TM
M8BE1):EX\_<=4I=-XD3UBWC1S#F',\/+_"CD=Y4#:/*CX*5:N+G6U<SW59I#
M0=5(5%#BG[V0!=4XE =?51)H9IT*[D=!D/@%9:6[G-NYK5S.1:TY*V$KB:J+
M@LKG-7!Q7+BAVTW<L4.NS82_G%?T />@OU5;B2._1\E8 :5BHB02]@MW%<[6
MB;&W!G\Q.*H7?6)6LA/BNQG\GBW<P @"#JDV"!2;)]@ YP8(9?S;8KH]I7%\
MV>_0/]NUXUIV5,%&\$>6Z7SA7KDD@SVMN;X3QR_0KF=B\%+!E?V28VL;N"2M
ME19%ZXP*"E8V+?W1QN$<AZAUB*SNALBJO*&:+N=2'(DTUHAF.G:IUAO%L=(D
MY5Y+_,O03R\WHBB8QBAK16B9D8TH-2L/4*8,%/GT0'<<U,7<U\AE//RTQ5TW
MN-$'N&%$;A$J5^2W,H/L-8"/(GNE4:=T'0TBWD Z(N/0(U$0A0-XXW[E8XLW
M/F/EJY.5WS"5<J%J">3OU4YIB>7SSP!KW+/&EC7^@/4>=U56<R!B3S[7VN#?
MLI(5=4&^ E87V=+G1M,WC)LD?XCR<D/+%,O6I*(Q4N_E8YBWY2I:+FZYJHZK
MMEPE<J4ON*P1EH4R8C'\4.S0JDN!1UB9\CK#F'66B 42,ORA!3GFV,==EX)2
M)$>09SQB<'X'Y" I6F8>H<9"D;W@>#A@N;&2Z%S4"BM17<P<I(F<R NCV'3'
MV)V,(]/%L9<$5Z8[<<+IV'D0FO(WJW)^<:9>/)XZ7XT"5E2U;K2A+J6=3W$2
M.1?.%@=H39XHKVU6&A#.Z(YQIK$6$"?QKJ>3@>Q/^NQ/AK/?''V&ILGVFG(3
M\'<3.@S5^.]:_X^29/?TV]G@_^*^.@$SD0[-)W#^K$!2LU.(-"?>I=A?ULK
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MF6G3"(>/9CZR2P.B]DZ-&B515(P:(=O!]:5_=V>N+_7**=G"G>%VU33";&Y
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ME U"RGY92$MAF/.&=QQ90]XJ9A@6[N8QYZU-9:ED_5)NIT5V3$#GR=P_E9#
MWJEYIJI&&D":E+],-K83C2MH8"_8@MC;NI:M,"B.UFB#J;3VU-@L,UE8=01=
M1$>$>4:.V,2<10>C"4/@G#K'D--6 [ZQU-T9P/:'+:7E!:E0+O@HL*;X,>S-
MD&DH2VPO4^^$4#\>L)>-):CM*6A:E5<8Z;/CX&5!FF1!$J5>BM+";YP>$TEX
M<-GC,=BZEJ81"O/5W?O#VZ%K+KMF\;2]:[D?J-HRI,2A1--H]!9+K+HVUDV,
M;%SKV$B#C<@-*^S\H.P&7"\EEK2?6 ?#?XG%3U!+ P04    " ##@&I4<J07
M;MH#  #D"   &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6R-5MMNXS80
M?>=7$.YN$0.N)5&^)%[;@!-GVP5VMX&3MBB*/M#2R"96(E62BI._[Y"ZQ$T=
MMP^6>)DY<V9XQ/'\H/0WLP>P]*G(I5GT]M:6LR PR1X*;H:J!(D[F=(%MSC5
MN\"4&GCJG8H\8&$X"0HN9&\Y]VMW>CE7E<V%A#M-35447#]?0ZX.BU[4:Q<V
M8K>W;B%8SDN^@WNPOY1W&F=!AY** J012E(-V:*WBF;78V?O#7X5<#!'8^HR
MV2KUS4T^I8M>Z A!#HEU"!Q?CW #>>Z D,9?#6:O"^D<C\<M^D>?.^:RY09N
M5/Z;2.U^T;OLT10R7N5VHPX_09./)YBHW/@G/32V88\FE;&J:)R102%D_>9/
M31W^CP-K')CG70?R+-?<\N5<JP/5SAK1W,"GZKV1G)#N4.ZMQEV!?G;Y22:J
M /K G\#0BP>^S<'TYX%%:&<0) W,=0W#WH")&/VBI-T;>BM32/\)$""GCAAK
MB5VSLXAK2(8TC@:4A2PZ@Q=WB<8>+_[/1.E:F"17IM) _UAMC=4HC3_/A!AU
M(48^Q.B-$!M(E$Q$+K@7G,KH[5.)ZH.4'D5W:]( O;@&"9FP?5H9(7?T(Z2@
M>4[O+;>55?KYV&G#+5"KZ&V6@=?QZ\U31W:>[0J_J==\[1XHM)Q%'<%B!&@Y
M;UO.N%56SJHF[QRS)@'3)7"$H'T":'6#CEP^?__=)8NF'PR%+J/7UL)0;FBF
M<KPXS(S\#EQ3<.JBJ THMJ"=/HC3AWN$Y/8$\X8PY?8-CBX48=$P)._;ESN!
M8SI@!E3B_8@%:OT;6#(=7I'+84R^*OD#,JLP$_R"J+!0&!(.1V0R9&0#!KDG
M>\IEBC?&(]Z$)=YKEB8:4F$].!D-(Q*A\<](4Z-KB#]&;O9<[AP7^LCSJCXG
M[@K"90+D(HXQ1!_?$^31)P_*\MS[OJ^?9T0][D0]/BN3>VP#:84Y8?9KR$ C
M9Z^ZE3%@C<_IL^!;E)$58$[I\'R !SR64F.U18F%=;I2$HMC6CV^%DS:DG#'
MRU](Y"\D$ 6[AK$M1*TAU.F,K$R=R$D!K?\-/2/M=^EB&*\,KX42%ZV3/MXD
M&)!K_8PM\L!U:L@[,F8#%D<XB-D@O)J^+0$7J9:!(=/!E$T(&UQ&DT8&DT$X
M'>,*NXK)C]H%.I$]F:!9S$@\';!P0CZ#,;/3<FD,G6!JVS[YBKF<PGQ'?,'9
MAY?1*3$%1YVG +WS_=75OY*V;D+=:M?"5W7G>C&O^_\7KG="&II#AJ[A<(JR
MT75/K2=6E;Z/;97%KNB'>_P; MH9X'ZFE&TG+D#WQV;Y-U!+ P04    " ##
M@&I4@SA6*;X#  !^#@  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6R]
M5VUOVS80_BN$,* MD$:B_!87MH'8[K ,:V/4R/9AV =&.ME$)%(CJ3@%]N-W
ME&1)763.Z##K@TV)O+OGGCL^$F<'J9[T'L"0ERP5>N[MC<D_^+Z.]I Q?2US
M$#B32)4Q@[=JY^M< 8M+HRSUPR 8^QGCPEO,RF<;M9C)PJ1<P$8176094U^7
MD,K#W*/>\<$7OML;^\!?S'*V@RV8AWRC\,YOO,0\ Z&Y%$1!,O=NZ8=U&%J#
M<L6O' ZZ,R8VE4<IG^S-73SW HL(4HB,=<'P[QE6D*;6$^+XLW;J-3&M87=\
M]/YCF3PF\\@TK&3Z&X_-?N[=>"2&A!6I^2(//T&=T,CZBV2JRU]RJ-<&'HD*
M;616&R."C(OJG[W41'0,Z/"$05@;A.<:#&J#P;D&P]I@6#)3I5+RL&:&+69*
M'HBRJ]&;'91DEM:8/A>V[ENC<):CG5E\9J900&1"S![(LM XKS5A(B9+IKFV
M,QL%&H1A9:'>D]LXYG;(4G(GJLZS$V_78!A/]3M<\K!=D[<_O)OY!B':0'Y4
MPUE6<,)3<.3S-0F'5R0,PJ#'?.4V_[E(K\F GC1?N\W7$#7F]%MS'WEMR T;
M<L/2W\!-[GW2$GO;$'O_#V)__P57D#L#F?[#$7O0Q!Z4L8<G8G\4AINOA(M(
MJERJ*H;&6$ $RZ"/'+?#]4<'JF&#:NATLH6H4-@]H G7NH 8 9)("E'+P(&;
M/<%N3A,4E1W7I@+>A[8*-"H#675[7F#%GWNPC1IL(R>VE<PRA+ U,GIRI#IN
MW(TO7OQ)$WOB3.4SOC!R)2. 6)-$R8P4(@9U0.H-")(7CRF/<&LGH+C8]6W3
MR2MV:3"<!O;J9_FF@7;CA(;Y ^8N=8XE+[0CV6GC<7IQHFG0ZF?@S.<3>^%9
MD1&VVV''VNUUI!4KP*.^C;:J77;9'0;UU<\N[>@Y=>\PEN+FND4P@*]G<Q[5
MM%4T>GE)HZVF4;<&?1?9@]>M/'*3W:H9_1<YLUIQ5+*XJ( @'AE?H8HQY*+W
M)50Y'7]3_L%I.*V 4;>"_>=MOZX#=,F:C%Q4M6I(QTYL#UTDFPK)_;%X?Y$S
MQ9>V"D@GEV_45N2H6^6^JS&6M=-N8X0W)?\GV&\EDD[/QG-5[16+I\+2"V7Z
MJA$&TWX48:N5H5LKFQX I=^0^[SD_NS:AZT&AO3BM0\['WWA_U#[VFFW]H.^
MTON=;WU[,OO$U(X+35)(T#"XGF#)5'78J6Z,S,O/_T=I\#!1#O=X0 1E%^!\
M(J4YWM@317/D7/P-4$L#!!0    ( ,. :E30*WWOD@(  -@&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;(U574_;,!3]*U;$ TB,?)>"TDC0;-H>
M)E44MH=I#VYRTU@X=K&=EOW[V4[(0INROC37]CG'Y]Z;WB0[+IYE!:#0:TV9
MG#F54IM;UY5Y!3665WP#3)^47-18Z:58NW(C !>65%,W\+R)6V/"G#2Q>PN1
M)KQ1E#!8""2;NL;BSSU0OILYOO.V\4#6E3(;;IIL\!J6H)XV"Z%7;J]2D!J8
M))PA >7,N?-OL]C@+> '@9T<Q,ADLN+\V2R^%3/',X: 0JZ, M:/+<R!4B.D
M;;QTFDY_I2$.XS?U+S9WG<L*2YAS^I,4JIHY4P<54.*&J@>^^PI=/M9@SJFT
MOVC783T'Y8U4O.[(VD%-6/O$KUT=!@0_.D((.D)P*B'L".&IA*@C1+8R;2JV
M#AE6.$T$WR%AT%K-!+:8EJW3)\RT?:F$/B6:I])EVV[$2[0D:T9*DF.FT%V>
M\X8IPM9HP2G)"4B$68$>((>]8\&9CG/0[X*2Z!-:ZC>S:"@8R3F6E>79X/-+
M0[:86EPK)I4@N8+N_#P#A0F5%UKE:9FA\[,+=(8(0X\5;Z1FR,15.F?CW,V[
M_.[;_((C^6607Z'0OT2!%_@C]/GI=&^$GIU,]V_>TUW=J+Y;0=^MP.J%1_3&
MVO+K;J7+J/\_OS^X(.PO".T%T9$+^H;E)H!_#1NK?"L56RDS7K:I'T73FSAQ
MM\,*'\*"Z77H37O8.Z=1[S3ZT.G@Y3%>Q_RU I/!Q?'D9L_<(2;PXG%G<>\L
M_M#9(U>86E.7!V6TM17_MQZ/E#:.)M&>^T.8+FWLA^]AV0@L"";7D[T\W<$8
M,3/_.Q9KPB2B4&JB=W6M%40[1]N%XAL[659<Z3EEPTI_>D 8@#XO.5=O"S.L
M^H]9^A=02P,$%     @ PX!J5(\#?L43 P  /0L  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&ULM5;);MLP$/T50J<6:*/%6Q+8!N(L:  '-6*D/10]
MT-+((D*1"DG5#M"/[Y"R):>(Y0*U+Q*W>3/SAAB^X4JJ9YT!&++.N= C+S.F
MN/1]'6>04WTF"Q"XDTJ54X-3M?1UH8 FSBCG?A0$?3^G3'CCH5N;J?%0EH8S
M 3-%=)GG5+U.@,O5R N][<(C6V;&+OCC84&7, ?S5,P4SOP:)6$Y",VD( K2
MD7<57D["@35P)[XQ6.F=,;&I+*1\MI/[9.0%-B+@$!L+0?'W"ZZ!<XN$<;QL
M0+W:IS7<'6_1[USRF,R":KB6_#M+3#;RSCV20$I+;A[EZ@ML$NI9O%AR[;YD
MM3D;>"0NM9'YQA@CR)FH_G2](6+'H-??8Q!M#"(7=^7(17E##1T/E5P194\C
MFAVX5)TU!L>$K<K<*-QE:&?&\ZH:1*9DSI:"I2RFPI"K.):E,$PLR4QR%C/0
MA(J$/$(,?VTK*7 < Y;*:/*9S/'B)"4'"WFK#4/F("%/&M*2DRF60!.\3-:N
M &5>'>SM2\D*"T ^W("AC.N/0]]@>C9(/]ZD,JE2B?:D$D;D00J3:7(K$DC>
M OC(2TU.M"5G$K4BWD!\1CKA)Q(%4=B"UZG)[CB\[AZ\:YD7I0'E<OZ:(M>P
MD_IO\L $R\N\Q5.W]M1UGCI[/-7LSK@KYQN.?TSQ-+DWD.N?+;YZM:]>:U9-
MD<NJR)RE\%[YVF$ZY!6HTBT!]>N ^O]',UT?H'E0>QJ<G.;SVM?Y<6ANA^D=
MI/FB#NBB%6E*%U)1([%[-$E;RN]*)9@I%50SMK9C_4_W.PR:OA6<G/IPITN&
MQR'_ ,YA]L.HB2DZ-O\'+W[8M+*P<WK^FW86=H_$?SO.X##_3=L+VQO6%% -
M9)(GY#XOE/Q5O8!MT$T#"_NG)[=I8N'@2.2VXTQ!:^RZ^.[#>X@$7WT%5BE:
MW< M>P2[]+O7T=]1-#FHI=-MFCC548F;>K76AE>5(FJ.5\+R@:HE$QH=IF@:
MG VPJJK2:M7$R,+IHX4TJ+;<,$-]"\H>P/U42K.=6 >U8A[_ 5!+ P04
M" ##@&I4[.3P$R4%  !X&0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6S%64UOXS80/6]_!6&TP"X0QR+ES\ QX,0.FJ+;!FND/10]T-+89E<259*.
MTZ(_OJ2DB'8L4=YNC>204!)GY@TY\QXCC7=<?)8; (6>XRB1UZV-4NE5IR.#
M#<147O(4$OUDQ45,E;X4ZXY,!= P,XJC#O&\?B>F+&E-QMF]!S$9\ZV*6 (/
M LEM'%/QUPU$?'?=PJV7&Y_8>J/,C<YDG-(U+$ ]I@]"7W5*+R&+(9&,)TC
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M4 G]K*R=*^ _<"M2]ERD!VXR_ZT+.HS"-G(4.I#")B1M-($.*5H_@6IHZYE
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MDP;.!_#^REK:3[Q ]TAFOP%02P,$%     @ PX!J5/$SPG@4 P  9@P  !D
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M]?$V^TU6/!0S)Y*.>?2'!6HY-'H&"FA(TDC=\\TW6A34U?E\'LGL%VV*6,M
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M,&0^_9"KX,JML'M\O2L3P]ZA]?9:&[C0NSWH-=G*!7&[#8YY(I5(\R,KG(>
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M G!_K93=3]Q!V?[FIO\ 4$L#!!0    ( ,. :E3\.BT&%@,  ',)   9
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MZ)J9:VM(#>UUE%P19:,QFQTX;1P:NV'"GN+$*-QEB#.]@<PR9O!8C"94S,A
M"L/$ D3*0),ZF:Q/E\@Y&0'*1<XIIR+%O:,A&,JX/L:HV\F0''TZ)I\($^1F
M*0N-N73'-\C0UO'3DLWYFDWT"ILAI"<D#FLD"J)P#WSP=GCP$NZC+I4X425.
MY/+%;Q"GOR/.D.F42UTH('?]J38*+?GS0-6XJAJ[JHU7JE[EH*BM0[A37%DG
MUN6\7N"$:@UFK[+KI(E+:I_=AU[C-#[M^ ^;^NT&A6&85$$O^#8JOHV#? >%
M4B@1R:5R3R9:16ZUP!F=,LX,RK:/>F.751*TMJCO"0J:S?W4DXIZ\D:IG;EK
M9%02?:J1LJT:F1AJP)K =G;)!-J?44[&4C/7[]W%H[&OM2D'Q.MM#ZQ;/,RC
MT/4%I?E9/TUE@6X;TR>*Z=!S5V8)"I=5 ;/1'Q5+<OL>D?]1Z878S4KLYL'2
MWZ2HIQ_V2G/'!G$21UM>V0UJ!_N=TJK(M][M%&PL?8]9+D21N:Q2[/7,848C
MB60,J.POB@T^G.:%8.U*L/;!O#?28-__>+CMG7-+@IUWV&Y0&#:V7P3^QI5H
M/T>^4K5@0B.-.<*"DQ;BU?J*7T^,S-TM.94&[UPW7.)7$2@;@/MS*<WSQ%Z\
MU7=6[S=02P,$%     @ PX!J5/B9X.XV @  %04  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#,N>&ULE53;CMHP$/V54:1*K=02".RV6@$2%U6MU&H1M-V'
MJ@\F&8BUOJ3VL"Q_W[$3(JH%U+XDOLR<.>>,[>'>ND=?(A(\:V7\*"F)JKLT
M]7F)6OB.K=#PSL8Z+8BG;IOZRJ$H8I)6:=;MWJ9:2).,AW%MX<9#NR,E#2X<
M^)W6PAVFJ.Q^E/22X\)2;DL*"^EX6(DMKI"^5PO'L[1%*:1&XZ4UX' S2B:]
MN^D@Q,> 'Q+W_F0,0<G:VL<P^5R,DFX@A IS"@B"?T\X0Z4"$-/XW6 F;<F0
M>#H^HG^,VEG+6GB<6?4@"RI'R8<$"MR(G:*EW7_"1L]-P,NM\O$+^R:VFT"^
M\V1UD\P,M#3U7SPW/IPD9/T+"5F3D$7>=:'(<BY(C(?.[L&%:$8+@R@U9C,Y
M:4)35N1X5W(>C6=6:TGL,GD0IH"9-23-%DTNT<,[6-7- KN!AZ@0"Y@\H>.&
MP1)#USD:OB ; ]_0Z0CR(G(N?6YWAF I" /6?<4;U*9Z>#U'$E+Y-\.46%8@
ME^:-A&DM(;L@88YY!_J]MY!UL][?Z2F[T5J2M99D$:__#Y9,7E@2I"CK=P[A
MYV3MR?&Y^G6E:K^MVH]5!Q>JMIZ)QC/7NJNBNQ3<E08.*)P_Y])U_'Z="#W0
MK*>$6RC$P5\A/FB)#_Z/>'%L-G<8SQ&]CC?H] :OSO%*3TYY>#"^"K>5QK,]
M&P;J=M[?).#J2UA/R%;QX*\M\36*PY+?+70A@/<WUM)Q$NY2^Q*._P!02P,$
M%     @ PX!J5$.Y9DI>!0  (!D  !D   !X;"]W;W)K<VAE971S+W-H965T
M-#0N>&ULS5EM;]LV$/XKA-$!+=!&(BF_%8Z!..ZP#LMF-,OZ8=@'1J)MH9+H
MD92=#/OQ.TJRJ-@2[0T9X"\))?'NGKLCGSO2DYV0W]2:<XV>TB13U[VUUIN/
MGJ?"-4^9NA(;GL&7I9 IT_ H5Y[:2,ZB0BA-/.+[ R]E<=:;3HIW"SF=B%PG
M<<87$JD\39E\GO%$[*Y[N+=_\25>K;5YX4TG&[;B]UP_;!82GKQ:2Q2G/%.Q
MR)#DR^O>#?XXIT,C4,SX+>8[U1@CX\JC$-_,P^?HNN<;1#SAH38J&/S;\EN>
M)$83X/BS4MJK;1K!YGBO_?O">7#FD2E^*Y*O<:37U[U1#T5\R?)$?Q&['WCE
M4-_H"T6BBK]H5\WU>RC,E19I)0P(TC@K_[.G*A - =#3+D J 7(@0+H$:"5
M#RT$'0)!)1 4D2E=*>(P9YI-)U+LD#2S09L9%,$LI,'].#-YO]<2OL8@IZ?W
M:R;YAQE$+D*W(H7EI%B1D _H)HIB,V0)^IR5*\Q\>#OGFL6)>@=3'N[GZ.V;
M=^@-\I RFA2*,_20Q5J]AY<P_G4M<L6R2$T\#7"-42^LH,U*:*0#&D9W(M-K
MA3YE$8]:Y&]/R!.' @_B5 >+[(,U(TZ-/^;9%:+^>T1\/&X#Y!:?\Q#$L1$G
MN$5\?KZX[_"&UJFGA3[J2CUJ2?V-E"Q;<=C=&LV>47/>@CT7KV]V3$;H]Y]
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M"]R\?F+_ZLRCF3NJ82SY;Y:9^2 X"D@&4[K@YEHNOT-ER F<2*[=+UE6>Z.
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M\1L E-V ZU,IS=/ WJ#^JAC^!U!+ P04    " ##@&I4[: _IML"  !?!P
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M&>V =3D-]UJ;^ZW\9GK%I2$"EDB,+E)4T%6KKB96K7VW6RB+O=,/"_R[@78
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MS@"_YPKCK3?.07-W3_X 4$L#!!0    ( ,. :E2FULT+- ,  "P3   -
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M',$4@ 8,21*W#^[L1_%ZGXHW_Q\;_0902P,$%     @ PX!J5)>*NQS
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M4$L! A0#%     @ PX!J5 =!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " ##@&I4:6ASX^X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" ##@&I4F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,. :E3' %I6- <  &,=   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" ##@&I44XO]RU@%  #5$P  &               @(%W#P  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ PX!J5%UJ8:9H @  E08  !@
M             ("!!14  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( ,. :E1&--@')@0  +T.   8              " @:,7  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " ##@&I4/QY%K <%  !P
M%@  &               @('_&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ PX!J5.1VS09K!@  G!@  !@              ("!/"$
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ,. :E1D #N6
MX @  +D6   8              " @=TG  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " ##@&I4)= Q:Y@9   M20  &
M@('S,   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ PX!J
M5-;AJA9M!   +PP  !@              ("!P4H  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( ,. :E1D@&IFF@,  ",(   9
M      " @61/  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ PX!J5 \O*(GS @  1@8  !D              ("!-5,  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " ##@&I4&<@> J,"  #E!0
M&0              @(%?5@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( ,. :E1?2GO&;@P   $G   9              " @3E9  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ PX!J5# %*^NL
M"   UA@  !D              ("!WF4  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " ##@&I4KVAWI, #  #U"   &0
M@('!;@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ,.
M:E3*S180S0@  %L7   9              " @;AR  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ PX!J5 :L@'0U P  + <  !D
M         ("!O'L  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " ##@&I4A[0[9%<&   V$   &0              @($H?P  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,. :E3HCIG)01L  ')3
M   9              " @;:%  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ PX!J5$L<K,1+ P  GP<  !D              ("!+J$
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " ##@&I4B*%?
M76(#   0"0  &0              @(&PI   >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( ,. :E3[4<E4U@(  !T&   9
M  " @4FH  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
MPX!J5.+4#OVX @  L04  !D              ("!5JL  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " ##@&I4XA?C<K$"  #1!0  &0
M            @(%%K@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( ,. :E0T#S79S ,  )P)   9              " @2VQ  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ PX!J5(2IQDK-!
M]@H  !D              ("!,+4  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " ##@&I4AW#;=(D#  !7"   &0              @($T
MN@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ,. :E1R
MI!=NV@,  .0(   9              " @?2]  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ PX!J5(,X5BF^ P  ?@X  !D
M     ("!!<(  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,. :E281>7_1 (  # %   9              "
M@2;6  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ PX!J
M5/$SPG@4 P  9@P  !D              ("!H=@  'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " ##@&I4OJTU8[P"  !O"   &0
M        @('LVP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( ,. :E0EN;>940,  $$-   9              " @=_>  !X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ PX!J5(P+(/!& @  *@4
M !D              ("!9^(  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " ##@&I41 0N0-H"   F"   &0              @('DY
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( ,. :E05*G#J
MIP@  "8N   9              " @?7G  !X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ PX!J5-%0P)ZG @  \@8  !D
M ("!T_   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " ##
M@&I4_#HM!A8#  !S"0  &0              @(&Q\P  >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( ,. :E3XF>#N-@(  !4%   9
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M970T-RYX;6Q02P$"% ,4    " ##@&I4[: _IML"  !?!P  &0
M    @(&\"@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M ,. :E0ET@/9K (  &(&   9              " @<X- 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ PX!J5+UH74X_!   [!$  !D
M             ("!L1 ! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    " ##@&I4K7TS;DL#   8"P  &0              @($G%0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( ,. :E2V?[FTM@(
M #L'   9              " @:D8 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ PX!J5'JN,FJ3 @  KP8  !D              ("!
MEAL! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " ##@&I4
M!IE*7?L"  #'!P  &0              @(%@'@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( ,. :E2FULT+- ,  "P3   -
M      "  9(A 0!X;"]S='EL97,N>&UL4$L! A0#%     @ PX!J5)>*NQS
M    $P(   L              ( !\20! %]R96QS+RYR96QS4$L! A0#%
M  @ PX!J5"KCUZEN!   8B0   \              ( !VB4! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( ,. :E0/E%1(V@$  %D@   :
M  "  74J 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M ,. :E0A7:<FS0$  "0@   3              "  8<L 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     ^ #X Z1   (4N 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>137</ContextCount>
  <ElementCount>363</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated balance sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated balance sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated balance sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated balance sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated statements of operations and comprehensive loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated statements of operations and comprehensive loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated statements of stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated statements of stockholders' equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated statements of cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated statements of cash flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Accrued and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecurities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Accrued and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Estimated Useful Lives for Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Estimated Useful Lives for Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Property and Equipment, Net - Summary of Property, and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property, and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Commitments and Contingencies - Summary of Lease Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Lease Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity for Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Stock Option Activity for Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Share-Based Compensation - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Share-Based Compensation - Summary of Fair Values of Options Granted to Employees and Directors (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Fair Values of Options Granted to Employees and Directors (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Income Taxes - Reconciliation of Expected Income Tax Expense (Benefit) using Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Expected Income Tax Expense (Benefit) using Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Employee Benefits - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails</Role>
      <ShortName>Employee Benefits - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="stok-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="stok-10k_20211231.htm">stok-10k_20211231.htm</File>
    <File>stok-20211231.xsd</File>
    <File>stok-20211231_cal.xml</File>
    <File>stok-20211231_def.xml</File>
    <File>stok-20211231_lab.xml</File>
    <File>stok-20211231_pre.xml</File>
    <File>stok-ex1013_176.htm</File>
    <File>stok-ex231_6.htm</File>
    <File>stok-ex311_13.htm</File>
    <File>stok-ex312_10.htm</File>
    <File>stok-ex321_9.htm</File>
    <File>stok-ex322_8.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gu0gjnulhgsv000001.jpg</File>
    <File>gu0gjnulhgsv000002.jpg</File>
    <File>gu0gjnulhgsv000003.jpg</File>
    <File>gu0gjnulhgsv000004.jpg</File>
    <File>gu0gjnulhgsv000005.jpg</File>
    <File>gu0gjnulhgsv000006.jpg</File>
    <File>gu0gjnulhgsv000007.jpg</File>
    <File>gu0gjnulhgsv000008.jpg</File>
    <File>gu0gjnulhgsv000009.jpg</File>
    <File>gu0gjnulhgsv000010.jpg</File>
    <File>gu0gjnulhgsv000011.jpg</File>
    <File>gu0gjnulhgsv000012.jpg</File>
    <File>gu0gjnulhgsv000013.jpg</File>
    <File>gu0gjnulhgsv000014.jpg</File>
    <File>gu0gjnulhgsv000015.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="440">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "stok-10k_20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "contextCount": 137,
   "dts": {
    "calculationLink": {
     "local": [
      "stok-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "stok-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "stok-10k_20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "stok-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "stok-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "stok-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 433,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 28,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 32
   },
   "keyCustom": 46,
   "keyStandard": 317,
   "memberCustom": 15,
   "memberStandard": 32,
   "nsprefix": "stok",
   "nsuri": "http://www.stoketherapeutics.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Marketable Securities",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Property and Equipment, Net",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Accrued and Other Current Liabilities",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities",
     "shortName": "Accrued and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Commitments and Contingencies",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Share-Based Compensation",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Income Taxes",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Employee Benefits",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefits",
     "shortName": "Employee Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Subsequent Events",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated balance sheets",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated balance sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "stok:ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "stok:ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "stok:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Accrued and Other Current Liabilities (Tables)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "stok:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationStateCountryCode",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "stok:SecuritiesIssuedInConnectionWithShelfRegistration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated balance sheets (Parenthetical)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated balance sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "stok:ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "stok:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokComputerAndOfficeEquipmentMember_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Estimated Useful Lives for Property and Equipment (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Estimated Useful Lives for Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "stok:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_stokComputerAndOfficeEquipmentMember_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails",
     "shortName": "Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
     "shortName": "Marketable Securities - Summary of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Marketable Securities - Additional Information (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Property and Equipment, Net - Summary of Property, and Equipment, Net (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Summary of Property, and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "stok:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "stok:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated statements of operations and comprehensive loss",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated statements of operations and comprehensive loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20181201_20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "stok:AreaOfSpaceSubjectToOperatingLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_utrsqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20181201_20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "stok:AreaOfSpaceSubjectToOperatingLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_utrsqft",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Commitments and Contingencies - Summary of Lease Balances (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails",
     "shortName": "Commitments and Contingencies - Summary of Lease Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "stok:SummaryOfLeaseBalancesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "stok:SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate of Operating Leases (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate of Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "stok:SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity for Awards (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails",
     "shortName": "Share-Based Compensation - Summary of Stock Option Activity for Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Share-Based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Share-Based Compensation - Summary of Fair Values of Options Granted to Employees and Directors (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails",
     "shortName": "Share-Based Compensation - Summary of Fair Values of Options Granted to Employees and Directors (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated statements of stockholders' equity",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated statements of stockholders' equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Income Taxes - Reconciliation of Expected Income Tax Expense (Benefit) using Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Expected Income Tax Expense (Benefit) using Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Employee Benefits - Additional Information (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails",
     "shortName": "Employee Benefits - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_us-gaapSubsidiarySaleOfStockAxis_stokSalesAgreementProspectusMember_20210101_20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_srtCounterpartyNameAxis_stokAcadiaPharmaceuticalsIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220131",
      "decimals": "-6",
      "lang": null,
      "name": "stok:UpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated statements of cash flows",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated statements of cash flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - Nature of the Business and Basis of Presentation",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements",
     "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Fair Value Measurements",
     "role": "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "stok-10k_20211231.htm",
      "contextRef": "C_0001623526_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 48,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "verboseLabel": "Entity incorporation state name"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r46",
      "r48",
      "r93",
      "r94",
      "r226",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r99",
      "r107",
      "r113",
      "r179",
      "r283",
      "r284",
      "r285",
      "r317",
      "r318",
      "r341",
      "r344",
      "r346",
      "r347",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect Period Of Adoption Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r99",
      "r107",
      "r113",
      "r179",
      "r283",
      "r284",
      "r285",
      "r317",
      "r318",
      "r341",
      "r344",
      "r346",
      "r347",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect Period Of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r99",
      "r107",
      "r113",
      "r179",
      "r283",
      "r284",
      "r285",
      "r317",
      "r318",
      "r341",
      "r344",
      "r346",
      "r347",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect Period Of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Member of Board of Directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r225",
      "r231",
      "r249",
      "r250",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r438",
      "r480",
      "r481",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r225",
      "r231",
      "r249",
      "r250",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r438",
      "r480",
      "r481",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r225",
      "r231",
      "r238",
      "r249",
      "r250",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r438",
      "r480",
      "r481",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r225",
      "r231",
      "r238",
      "r249",
      "r250",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r438",
      "r480",
      "r481",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r47",
      "r48",
      "r93",
      "r94",
      "r226",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r155",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_AcadiaPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acadia pharmaceuticals Inc.",
        "label": "Acadia Pharmaceuticals Inc [Member]",
        "terseLabel": "Acadia Pharmaceuticals Inc."
       }
      }
     },
     "localname": "AcadiaPharmaceuticalsIncMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_AccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Line Items]",
        "terseLabel": "Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "AccountingPoliciesLineItems",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stok_AccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Table]",
        "terseLabel": "Accounting Policies [Table]"
       }
      }
     },
     "localname": "AccountingPoliciesTable",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stok_AccruedAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued and other current liabilities.",
        "label": "Accrued And Other Current Liabilities",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilities",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "stok_AccruedAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development costs current.",
        "label": "Accrued Research And Development Costs Current",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_AdditionalLeaseExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional lease expiration date.",
        "label": "Additional Lease Expiration Date",
        "terseLabel": "Additional operating lease expiration date"
       }
      }
     },
     "localname": "AdditionalLeaseExpirationDate",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "stok_AdditionalOperatingLeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional operating lease commencement date.",
        "label": "Additional Operating Lease Commencement Date",
        "terseLabel": "Additional operating lease commencement date"
       }
      }
     },
     "localname": "AdditionalOperatingLeaseCommencementDate",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "stok_AdditionalOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional operating lease, liabilities.",
        "label": "Additional Operating Lease Liabilities",
        "terseLabel": "Additional operating lease, liabilities"
       }
      }
     },
     "localname": "AdditionalOperatingLeaseLiabilities",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_AdditionalOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional operating lease, right-of-use asset.",
        "label": "Additional Operating Lease Right Of Use Asset",
        "terseLabel": "Additional operating lease, right-of-use asset"
       }
      }
     },
     "localname": "AdditionalOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_AmortizationAndAccretionOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and accretion of marketable securities.",
        "label": "Amortization And Accretion Of Marketable Securities",
        "terseLabel": "Amortization and accretion of marketable securities"
       }
      }
     },
     "localname": "AmortizationAndAccretionOfMarketableSecurities",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_AnnualBaseRentIncreasePercentageForOperatingLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual base rent increase percentage for operating lease.",
        "label": "Annual Base Rent Increase Percentage For Operating Lease",
        "terseLabel": "Annual base rent increase percentage for operating lease"
       }
      }
     },
     "localname": "AnnualBaseRentIncreasePercentageForOperatingLease",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "stok_AnnualLicenseMaintenanceFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license maintenance fee.",
        "label": "Annual License Maintenance Fee",
        "terseLabel": "Annual license maintenance fee"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFee",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_AreaOfAdditionalRentableSpaceSubjectToOperatingLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of additional rentable space subject to operating lease.",
        "label": "Area Of Additional Rentable Space Subject To Operating Lease",
        "terseLabel": "Area of additional space subject to operating lease"
       }
      }
     },
     "localname": "AreaOfAdditionalRentableSpaceSubjectToOperatingLease",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "stok_AreaOfSpaceSubjectToOperatingLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of space subject to operating lease.",
        "label": "Area Of Space Subject To Operating Lease",
        "terseLabel": "Area of space subject to operating lease"
       }
      }
     },
     "localname": "AreaOfSpaceSubjectToOperatingLease",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "stok_BaseProspectusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base prospectus.",
        "label": "Base Prospectus [Member]",
        "terseLabel": "Base Prospectus"
       }
      }
     },
     "localname": "BaseProspectusMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_ColdSpringHarborLaboratoryAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cold Spring Harbor Laboratory Agreement.",
        "label": "Cold Spring Harbor Laboratory Agreement [Member]",
        "terseLabel": "CSHL Agreement"
       }
      }
     },
     "localname": "ColdSpringHarborLaboratoryAgreementMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stok_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stok_ComputerAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer and office equipment.",
        "label": "Computer And Office Equipment [Member]",
        "terseLabel": "Computer and Office Equipment"
       }
      }
     },
     "localname": "ComputerAndOfficeEquipmentMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_ConsultingServicesAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting services agreement term.",
        "label": "Consulting Services Agreement Term",
        "terseLabel": "Consulting services agreement term"
       }
      }
     },
     "localname": "ConsultingServicesAgreementTerm",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "stok_ConsultingServicesExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting services expenses.",
        "label": "Consulting Services Expenses",
        "terseLabel": "Consulting services expenses"
       }
      }
     },
     "localname": "ConsultingServicesExpenses",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_DebtSecuritiesAvailableForSaleMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities available-for-sale maturity period.",
        "label": "Debt Securities Available For Sale Maturity Period",
        "terseLabel": "Weighted average maturity marketable securities period"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleMaturityPeriod",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "stok_DeferredOfferingCostsNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs not yet paid.",
        "label": "Deferred Offering Costs Not Yet Paid",
        "terseLabel": "Deferred offering costs not yet paid"
       }
      }
     },
     "localname": "DeferredOfferingCostsNotYetPaid",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_DeferredOfferingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs.",
        "label": "Deferred Offering Costs Policy [Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "stok_EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company and smaller reporting company status.",
        "label": "Emerging Growth Company And Smaller Reporting Company Status Policy [Text Block]",
        "terseLabel": "Emerging Growth Company and Smaller Reporting Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyAndSmallerReportingCompanyStatusPolicyTextBlock",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "stok_ExpensesRelatedToReimbursablePatentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses related to reimbursable patent costs.",
        "label": "Expenses Related To Reimbursable Patent Costs",
        "terseLabel": "Expenses related to reimbursable patent costs"
       }
      }
     },
     "localname": "ExpensesRelatedToReimbursablePatentCosts",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_FederalNOLCarryForwardsPeriodUnderCARESAct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal NOL carry forwards period under CARES act.",
        "label": "Federal N O L Carry Forwards Period Under C A R E S Act",
        "terseLabel": "Federal NOL carry back period under CARES act"
       }
      }
     },
     "localname": "FederalNOLCarryForwardsPeriodUnderCARESAct",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "stok_FollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-on Offering.",
        "label": "Follow On Offering [Member]",
        "terseLabel": "Follow-on Offering"
       }
      }
     },
     "localname": "FollowOnOfferingMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stok_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stok_LaboratoryEquipmentAndFurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment and furniture and fixtures.",
        "label": "Laboratory Equipment And Furniture And Fixtures [Member]",
        "terseLabel": "Laboratory Equipment and Furniture and Fixtures"
       }
      }
     },
     "localname": "LaboratoryEquipmentAndFurnitureAndFixturesMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_LeaseCommencementTwoThousandAndTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement, two thousand and twenty one.",
        "label": "Lease Commencement Two Thousand And Twenty One [Member]",
        "terseLabel": "Lease Commencement on December 15, 2021"
       }
      }
     },
     "localname": "LeaseCommencementTwoThousandAndTwentyOneMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_LeaseCommencementTwoThousandAndTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement, two thousand and twenty two.",
        "label": "Lease Commencement Two Thousand And Twenty Two [Member]",
        "terseLabel": "Lease Commencement on April 2022"
       }
      }
     },
     "localname": "LeaseCommencementTwoThousandAndTwentyTwoMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_LeaseExtensionEndDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease extension end date.",
        "label": "Lease Extension End Date [Member]",
        "terseLabel": "Lease Extension End Date April 30, 2025"
       }
      }
     },
     "localname": "LeaseExtensionEndDateMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_MaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate offering price.",
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPrice",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_MaximumAggregatePotentialMilestonePaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate potential milestone payments payable.",
        "label": "Maximum Aggregate Potential Milestone Payments Payable",
        "terseLabel": "Maximum aggregate potential milestone payments payable"
       }
      }
     },
     "localname": "MaximumAggregatePotentialMilestonePaymentsPayable",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_MilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments receivable.",
        "label": "Milestone Payments Receivable",
        "terseLabel": "Potential milestone payments receivable"
       }
      }
     },
     "localname": "MilestonePaymentsReceivable",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_NatureOfBusinessAndBasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the business and basis of presentation.",
        "label": "Nature Of Business And Basis Of Presentation [Line Items]",
        "terseLabel": "Nature Of Business And Basis Of Presentation [Line Items]"
       }
      }
     },
     "localname": "NatureOfBusinessAndBasisOfPresentationLineItems",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stok_NatureOfBusinessAndBasisOfPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the business and basis of presentation.",
        "label": "Nature Of Business And Basis Of Presentation [Table]",
        "terseLabel": "Nature Of Business And Basis Of Presentation [Table]"
       }
      }
     },
     "localname": "NatureOfBusinessAndBasisOfPresentationTable",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stok_NumberOfRenewalOptionToExtendOperatingLeaseTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of renewal option to extend operating lease terms.",
        "label": "Number Of Renewal Option To Extend Operating Lease Terms",
        "terseLabel": "Number of options to renewal operating lease term"
       }
      }
     },
     "localname": "NumberOfRenewalOptionToExtendOperatingLeaseTerms",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "stok_OperatingLeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease commencement date.",
        "label": "Operating Lease Commencement Date",
        "terseLabel": "Operating lease commencement date"
       }
      }
     },
     "localname": "OperatingLeaseCommencementDate",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "stok_OperatingLeaseCommencementMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease, commencement month and year.",
        "label": "Operating Lease Commencement Month And Year",
        "terseLabel": "Operating lease commencement month and year"
       }
      }
     },
     "localname": "OperatingLeaseCommencementMonthAndYear",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "stok_OperatingLeaseCostPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease cost per year.",
        "label": "Operating Lease Cost Per Year",
        "terseLabel": "Operating lease cost per year"
       }
      }
     },
     "localname": "OperatingLeaseCostPerYear",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted": {
     "auth_ref": [],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liability excluding leases entered access yet to be granted.",
        "label": "Operating Lease Liability Excluding Leases Entered Access Yet To Be Granted",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_OperatingLossCarryforwardsExpirationBeginningYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration beginning year.",
        "label": "Operating Loss Carryforwards Expiration Beginning Year",
        "terseLabel": "Operating loss carryforwards, expiration beginning year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationBeginningYear",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "stok_PatentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent costs.",
        "label": "Patent Costs Policy [Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyTextBlock",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "stok_PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of federal NOL carry forwards subject to limitation under CARES act.",
        "label": "Percentage Of Federal N O L Carry Forwards Subject To Limitation Under C A R E S Act",
        "terseLabel": "Percentage of federal NOL carry forwards subject to limitation under CARES act"
       }
      }
     },
     "localname": "PercentageOfFederalNOLCarryForwardsSubjectToLimitationUnderCARESAct",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "stok_PercentageOfIncreaseInReservedCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in reserved common shares.",
        "label": "Percentage Of Increase In Reserved Common Shares",
        "terseLabel": "Percentage of increase in reserved common shares"
       }
      }
     },
     "localname": "PercentageOfIncreaseInReservedCommonShares",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "stok_PercentageOfMaximumRequiredPaymentOfSublicenseRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of maximum required payment of sublicense revenue.",
        "label": "Percentage Of Maximum Required Payment Of Sublicense Revenue",
        "terseLabel": "Percentage of maximum required payment of sublicense revenue"
       }
      }
     },
     "localname": "PercentageOfMaximumRequiredPaymentOfSublicenseRevenue",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "stok_PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of taxable income, limitation repealed under CARES act.",
        "label": "Percentage Of Taxable Income Limitation Repealed Under C A R E S Act",
        "terseLabel": "Percentage of taxable income, limitation repealed under CARES act"
       }
      }
     },
     "localname": "PercentageOfTaxableIncomeLimitationRepealedUnderCARESAct",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "stok_ProceedsFromIssuanceUnderwrittenPublicOfferingNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance underwritten public offering net.",
        "label": "Proceeds From Issuance Underwritten Public Offering Net",
        "terseLabel": "Net proceeds from underwritten public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceUnderwrittenPublicOfferingNet",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in carrying amount of operating lease right of use assets",
        "label": "Reduction In Carrying Amount Of Operating Lease Right Of Use Assets",
        "terseLabel": "Reduction in the carrying amount of right of use assets"
       }
      }
     },
     "localname": "ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_SalesAgreementProspectusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agreement prospectus.",
        "label": "Sales Agreement Prospectus [Member]",
        "terseLabel": "Sales Agreement Prospectus"
       }
      }
     },
     "localname": "SalesAgreementProspectusMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued and other current liabilities.",
        "label": "Schedule Of Accrued And Other Current Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "stok_ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash, cash equivalents and restricted cash and equivalents.",
        "label": "Schedule Of Cash Cash Equivalents And Restricted Cash And Equivalents Table [Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashAndEquivalentsTableTextBlock",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "stok_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of estimated useful lives of property and equipment.",
        "label": "Schedule Of Estimated Useful Lives Of Property And Equipment Table [Text Block]",
        "terseLabel": "Schedule of Estimated Useful Lives for Property and Equipment"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "stok_ScientificAdvisoryServicesAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scientific advisory services agreement term.",
        "label": "Scientific Advisory Services Agreement Term",
        "terseLabel": "Scientific advisory services agreement term"
       }
      }
     },
     "localname": "ScientificAdvisoryServicesAgreementTerm",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "stok_ScientificAdvisoryServicesExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scientific advisory services expenses.",
        "label": "Scientific Advisory Services Expenses",
        "terseLabel": "Scientific advisory services expenses"
       }
      }
     },
     "localname": "ScientificAdvisoryServicesExpenses",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_SecuritiesIssuedInConnectionWithShelfRegistration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities issued in connection with shelf registration.",
        "label": "Securities Issued In Connection With Shelf Registration",
        "terseLabel": "Securities issued in connection with shelf registration"
       }
      }
     },
     "localname": "SecuritiesIssuedInConnectionWithShelfRegistration",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options, grants in period, fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value",
        "terseLabel": "Aggregate grant date fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "stok_SouthamptonAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Southampton Agreement.",
        "label": "Southampton Agreement [Member]",
        "terseLabel": "Southampton Agreement"
       }
      }
     },
     "localname": "SouthamptonAgreementMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_SummaryOfLeaseBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of lease balances.",
        "label": "Summary Of Lease Balances Table [Text Block]",
        "terseLabel": "Summary of Lease Balances"
       }
      }
     },
     "localname": "SummaryOfLeaseBalancesTableTextBlock",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "stok_SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of weighted average remaining lease term and weighted average discount rate of operating leases.",
        "label": "Summary Of Weighted Average Remaining Lease Term And Weighted Average Discount Rate Of Operating Leases Table [Text Block]",
        "terseLabel": "Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate of Operating Leases"
       }
      }
     },
     "localname": "SummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesTableTextBlock",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "stok_TaxCreditCarryforwardsExpirationBeginningYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforwards expiration beginning year.",
        "label": "Tax Credit Carryforwards Expiration Beginning Year",
        "terseLabel": "Tax credit carryforwards, expiration beginning year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardsExpirationBeginningYear",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "stok_TwoThousandAndFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2014 Equity Incentive Plan.",
        "label": "Two Thousand And Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "TwoThousandAndFourteenEquityIncentivePlanMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_TwoThousandAndNineteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Employee Stock Purchase Plan.",
        "label": "Two Thousand And Nineteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2019 ESPP"
       }
      }
     },
     "localname": "TwoThousandAndNineteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_TwoThousandAndNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 equity incentive plan.",
        "label": "Two Thousand And Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "localname": "TwoThousandAndNineteenEquityIncentivePlanMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten public offering.",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stok_UpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received.",
        "label": "Upfront Payment Received",
        "terseLabel": "Upfront Payment received"
       }
      }
     },
     "localname": "UpfrontPaymentReceived",
     "nsuri": "http://www.stoketherapeutics.com/20211231",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201711Member": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2017-11 Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.",
        "label": "Accounting Standards Update201711 [Member]",
        "terseLabel": "ASU 2017-11"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201711Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201813Member": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.",
        "label": "Accounting Standards Update201813 [Member]",
        "terseLabel": "ASU 2018-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201813Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update201912 [Member]",
        "terseLabel": "ASU 2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37",
      "r404"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r39"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "stok_AccruedAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits Current",
        "terseLabel": "Accrued employee compensation costs"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r39"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "stok_AccruedAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued professional"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36",
      "r200"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r51",
      "r52",
      "r53",
      "r472",
      "r489",
      "r493"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r50",
      "r53",
      "r61",
      "r62",
      "r63",
      "r96",
      "r97",
      "r98",
      "r331",
      "r484",
      "r485",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r25",
      "r286",
      "r404"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r283",
      "r284",
      "r285",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r101",
      "r102",
      "r103",
      "r104",
      "r113",
      "r157",
      "r158",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r213",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r315",
      "r316",
      "r317",
      "r318",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r397",
      "r441",
      "r442",
      "r443",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r252",
      "r253",
      "r289",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r253",
      "r275",
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r90",
      "r135",
      "r144",
      "r150",
      "r172",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r327",
      "r332",
      "r361",
      "r402",
      "r404",
      "r458",
      "r470"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r45",
      "r90",
      "r172",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r327",
      "r332",
      "r361",
      "r402",
      "r404"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Marketable Securities, Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Marketable Securities, Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r162",
      "r188"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Marketable Securities, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r161",
      "r188"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "positiveLabel": "Marketable Securities, Fair Value",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Total Marketable Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r6",
      "r95",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description And Basis Of Presentation [Text Block]",
        "terseLabel": "Nature of the business and basis of presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Property and equipment included in accrued expense and accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r33",
      "r83"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      },
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "terseLabel": "Total cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r17",
      "r84",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r78",
      "r83",
      "r88"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r371"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r96",
      "r97",
      "r100",
      "r157",
      "r158",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r213",
      "r279",
      "r280",
      "r281",
      "r315",
      "r336",
      "r338",
      "r339",
      "r362",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r383",
      "r397",
      "r441",
      "r442",
      "r482",
      "r483",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r96",
      "r97",
      "r107",
      "r157",
      "r158",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r213",
      "r279",
      "r280",
      "r281",
      "r315",
      "r336",
      "r338",
      "r339",
      "r340",
      "r343",
      "r362",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r383",
      "r397",
      "r441",
      "r442",
      "r482",
      "r483",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r101",
      "r112",
      "r159",
      "r180",
      "r286",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r210",
      "r460",
      "r476"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r211",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Number of shares of common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r96",
      "r97",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24",
      "r404"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 36,902,499 and 36,577,149 shares issued and outstanding as of December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r236",
      "r237",
      "r251",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation And Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r59",
      "r68",
      "r463",
      "r479"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income Net Of Tax [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r125",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r239",
      "r247",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r163",
      "r188",
      "r191",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Allowance For Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "auth_ref": [
      "r44",
      "r380"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Deferred Finance Costs Current Net",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsCurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCredit": {
     "auth_ref": [
      "r381",
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized.",
        "label": "Deferred Rent Credit",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r307"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r312",
      "r313"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Federal and state net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r312",
      "r313"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r310",
      "r312",
      "r313"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan Cost Recognized",
        "terseLabel": "Contributions to 401(k) Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent",
        "terseLabel": "Maximum matching contribution percentage of employees salary"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r81",
      "r198"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share\u2014basic and diluted",
        "verboseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net loss per share attributable to common stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r91",
      "r298",
      "r321"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal corporate tax rate",
        "verboseLabel": "Expected income tax benefit at the federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r298",
      "r321"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r298",
      "r321"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense",
        "terseLabel": "Non-deductible items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r298",
      "r321"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r298",
      "r321"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r298",
      "r321"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits Research",
        "terseLabel": "Research and development credit, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfExpectedIncomeTaxExpenseBenefitUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Outstanding Options to Purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r61",
      "r62",
      "r63",
      "r96",
      "r97",
      "r98",
      "r102",
      "r109",
      "r111",
      "r122",
      "r179",
      "r234",
      "r235",
      "r283",
      "r284",
      "r285",
      "r317",
      "r318",
      "r346",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r484",
      "r485",
      "r486",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value Assets Measured On Recurring Basis [Text Block]",
        "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis and Level of Fair Value Hierarchy Utilized"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r227",
      "r229",
      "r230",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r350",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r349",
      "r350",
      "r352",
      "r353",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r227",
      "r239",
      "r240",
      "r245",
      "r247",
      "r350",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r227",
      "r229",
      "r230",
      "r239",
      "r240",
      "r245",
      "r247",
      "r350",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r227",
      "r229",
      "r230",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r350",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3",
        "terseLabel": "Fair value assets, transfers to level 3, amount"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r227",
      "r229",
      "r230",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r355",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r358",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r193",
      "r194",
      "r228",
      "r233",
      "r337",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain Loss On Sale Of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r81",
      "r197",
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment Of Long Lived Assets Held For Use",
        "terseLabel": "Impairment losses recognized"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r195",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r203",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r299",
      "r303",
      "r309",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r296",
      "r297",
      "r303",
      "r304",
      "r308",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10060.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income Expense Nonoperating Net",
        "terseLabel": "Interest income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Debt And Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r456",
      "r467",
      "r495",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Operating lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee Operating Lease Existence Of Option To Extend",
        "terseLabel": "Operating lease, existence of option to extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r90",
      "r145",
      "r172",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r328",
      "r332",
      "r333",
      "r361",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities recorded under agreement",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r30",
      "r90",
      "r172",
      "r361",
      "r404",
      "r459",
      "r474"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r90",
      "r172",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r328",
      "r332",
      "r333",
      "r361",
      "r402",
      "r403",
      "r404"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r21",
      "r22",
      "r90",
      "r172",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r328",
      "r332",
      "r333",
      "r361",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities Noncurrent",
        "terseLabel": "Long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Text Block]",
        "terseLabel": "Summary of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r54",
      "r57",
      "r63",
      "r66",
      "r82",
      "r90",
      "r101",
      "r105",
      "r106",
      "r107",
      "r108",
      "r110",
      "r111",
      "r114",
      "r135",
      "r143",
      "r146",
      "r149",
      "r151",
      "r172",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r348",
      "r361",
      "r461",
      "r477"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing And Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-Cash Investing and Financing Activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10090.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r135",
      "r143",
      "r146",
      "r149",
      "r151"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Operating leases expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]",
        "terseLabel": "Future minimum lease payments under non-cancellable leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "stok_AccruedAndOtherCurrentLiabilities",
       "weight": 1.0
      },
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails": {
       "order": 10010.0,
       "parentTag": "stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease Liability Current Statement Of Financial Position Extensible List",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails": {
       "order": 10020.0,
       "parentTag": "stok_OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Non-current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfLeaseBalancesDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r393",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r392",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted average remaining lease term in years"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateOfOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r55",
      "r58",
      "r61",
      "r62",
      "r64",
      "r67",
      "r234",
      "r372",
      "r377",
      "r378",
      "r462",
      "r478"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income Loss Net Of Tax",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r49",
      "r51"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r39",
      "r404"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "stok_AccruedAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10070.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Underwriters' Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments Of Financing Costs",
        "negatedLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "negatedLabel": "Payment of offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments To Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r254",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r31",
      "r32"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of common stock upon public offerings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r75",
      "r76"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds From Payments For Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds From Sale And Maturity Of Marketable Securities",
        "terseLabel": "Sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r74",
      "r278"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds From Stock Plans",
        "terseLabel": "Proceeds from Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r54",
      "r57",
      "r63",
      "r77",
      "r90",
      "r101",
      "r110",
      "r111",
      "r135",
      "r143",
      "r146",
      "r149",
      "r151",
      "r172",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r326",
      "r329",
      "r330",
      "r334",
      "r335",
      "r348",
      "r361",
      "r464"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r36",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r205",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property Plant And Equipment Estimated Useful Lives",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r35",
      "r199"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property, and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r201",
      "r404",
      "r468",
      "r475"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r201",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r18",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Summary of Property, and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r18",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r246",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r246",
      "r398",
      "r401",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r292",
      "r439",
      "r503"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research [Member]",
        "terseLabel": "Research and Development Tax Credit"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r17",
      "r83",
      "r88",
      "r457",
      "r471"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r10",
      "r20",
      "r88",
      "r496"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r235",
      "r286",
      "r404",
      "r473",
      "r488",
      "r493"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r96",
      "r97",
      "r98",
      "r102",
      "r109",
      "r111",
      "r179",
      "r283",
      "r284",
      "r285",
      "r317",
      "r318",
      "r346",
      "r484",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r65",
      "r90",
      "r133",
      "r134",
      "r142",
      "r147",
      "r148",
      "r152",
      "r153",
      "r154",
      "r172",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r361",
      "r464"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r391",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Right-of-use assets recognized in exchange for operating leases under Topic 842"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "verboseLabel": "Stock issued, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Reconciliation of Expected Income Tax Expense (Benefit) using Federal Statutory Income Tax Rate to Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r253",
      "r274",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r253",
      "r274",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r36",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r254",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r257",
      "r264",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity for Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Fair Values of Options Granted to Employees and Directors"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment and Geographic Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "verboseLabel": "Options vest period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Number of common shares available for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of shares, Exercisable as of December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercisable as of December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period",
        "negatedLabel": "Number of shares, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "positiveLabel": "Number of shares, Granted",
        "verboseLabel": "Option granted to purchase shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Outstanding value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r259",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of shares, Outstanding balance",
        "periodStartLabel": "Number of shares, Outstanding balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Outstanding balance",
        "periodStartLabel": "Weighted average exercise price, Outstanding balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r254",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r270",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfFairValuesOfOptionsGrantedToEmployeesAndDirectorsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate intrinsic value, Exercisable as of December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted average remaining contractual life, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted average remaining contractual life, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Expected weighted average period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r89",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies and recent accounting pronouncements"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r43",
      "r61",
      "r62",
      "r63",
      "r96",
      "r97",
      "r98",
      "r102",
      "r109",
      "r111",
      "r122",
      "r179",
      "r234",
      "r235",
      "r283",
      "r284",
      "r285",
      "r317",
      "r318",
      "r346",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r484",
      "r485",
      "r486",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r122",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r23",
      "r24",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock related to employee stock purchase plan, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r23",
      "r24",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock, Shares",
        "verboseLabel": "Stock issued during period, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r24",
      "r234",
      "r235",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of shares, Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfStockOptionActivityForAwardsDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r23",
      "r24",
      "r234",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock related to employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r23",
      "r24",
      "r234",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r234",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r28",
      "r29",
      "r90",
      "r156",
      "r172",
      "r361",
      "r404"
     ],
     "calculation": {
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Cumulative effect adjustment",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r379",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r379",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r379",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r379",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r405",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r228",
      "r233",
      "r337",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r101",
      "r102",
      "r103",
      "r104",
      "r113",
      "r157",
      "r158",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r213",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r315",
      "r316",
      "r317",
      "r318",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r397",
      "r441",
      "r442",
      "r443",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r92",
      "r239",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "U S Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government Debt Securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyUtilizedDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r295",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Expense",
        "terseLabel": "Unrecognized income tax benefits, interest or penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r123",
      "r124",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted average common shares outstanding\u2014basic and diluted",
        "verboseLabel": "Weighted-average number of common shares, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.stoketherapeutics.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=123465656&loc=SL109261606-128450"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117817908&loc=SL117819236-161440"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r504": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r505": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r506": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r507": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r508": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r509": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r510": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r511": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r512": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r513": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r514": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r515": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r516": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r517": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r518": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r519": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r520": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r521": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r522": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001564590-22-009634-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-009634-xbrl.zip
M4$L#!!0    ( ,. :E0KP)3)XM($ )0[!0 6    9W4P9VIN=6QH9W-V,# P
M,# Q+FIP9^R[!U13;[HOO!$$! 1ITHD*"@B(2),:;!01:2I2)$H1 0$1Z9"
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MT'H%@A#17$JSLT8(4MCNA;Q;VK6EEED'3QKKO>(_M_8I^<(+YS[F7JG*O+_
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M?>G@4-^1P%$;#B,!HZC86TS9)\,R_:10%"&9UG>I,T0#4M$,S6E:F&%+6HT
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MQN@]6CT2 X\+1S %OG/2'/1B!3-!4G.Y/Y"M8RB7"S1-)F*8)9/-O'(X *H
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M;&+B5G&XICI9_#Q7Z\%;Y]<.0\-"3S3#HA $J\K96'Q+3R&UKN^:4J88DRR
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M1*G-9AUM+B4-W1P)=<+)^[@57ASL<U5 G%GX+/]T?)G-NSO\-+1_-TD&?R%
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MV^> \;7HVX60$T/P&^2V 5Z'7* F_>"*OA^9$[[!HIY#9ABX(!.7+_#IPW,
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M/<X!F?NMTXK!\5]#/ -$JD_YZX]@$6=6%J[>K<<*?4K,:=NCD3R:RFO.ZU<
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M^<?TW"56&X,_'%TWV.S(;9!.\RV8'D-6"5P*^_B< C5J1W3#+/YV.H*,(9W
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M?1 (\CZ.WJ&E%JD'A-;C4-V/"?H="_RCF-@'1^H@]M1[V!/\L$ZEM U6
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M?,HY0-.2-(OH@A $(,0/!1'PK3XPZ8K;L>N_[(;RXF+(!/XM*B)ZF69%_2\
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ME'RU_)F^YJBU(V'"^J:9*KRKW[<CU&SQ#$#_EZ(PZ$D&E5MJ!SJ$>DI(5.;
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MOZXA0GULA5?"@*)M0</E!Y(,[8KLS(6M>V#+O+\C5M^+?<PO>/WD21?(K%E
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M3A1^IV-:V5]/OB##Y(U:S!-(>YC\ZP#5-&Q%>#RP)PQD06&F3,TSPP0ALF>
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M=X_!,@8VMM2D<AY)4DF&;<"KGE"6?(A_3?5P^4.NVJ_4#]?L68CU!G:A<?'
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MX<0*;3,\*MCZ#,#6="L4U=;C-D[9Z'UC=7?I!R-IZC(.Q8$Y0'*3^A;@UUV
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MX'XR-NW;:"6D9Q$E]4=/>+<;GMV\QK#W[B+)]'LX"[/]S3XJ1T7;6#O+<S2
M]?0*TB.A&#U$&)0)0@5VPR(^XG5H]_'W36"N\;H9!OQ?YIZ4<79J#/M=("9-
M]^CAR'.J$HZP&*/621.?ROG^TXVG][5@R _1N3/99_S2;O_]W&.XUT44(??+
M)6 UEL@D,>(,]YQS=3/#7.N0NOWWNPS/)4 !@#?[V6:*6UT-$R$6KFQ@NA!0
M>$$0!4:TW1JO8_7T]2<O^J]>,2IG^_CM=4]:6 \B2N';+6XS,0Z+'-+ !$(0
MU/Q"\T2IFC@?^APY\OOG@D(9)S0J@N(AR4E1_!MQ/]EN(SJE5DF?D0E7B*F?
MWLX6 RX..^PS^"$GZ>]+7P+%)> E;-(FJL@]N,50WY5O^1(@B(_'^!1P%$6T
MJ N\4AK<CNP8.<V,MQRE0!![3&S%6'!MR_3'B+<;'!"[4>(_BV%3&UKBKT6V
MQ';G@ ZUJC/[>Y5(C^-]&T^#];E'_[=NZ#<!"E26J^5<7$=_0J0Z<N@Y<=@5
M9<=.%6HEHPJ<#\JBW'J\?RA9/-R)TS"1"<7,<T"A373%<UPH02: =?'=)?M$
M;ITR)PACJ$ER;<'@O.9M\RBM7AXN.W=+;-RRE\T41T]MZ[R(NS>9Z4VYKAY)
MX82?1PZO7A#OE\S\/==+OC%1,\<&Z(-5F7>1:QT?)'A9:S@D&P[QJ]HZ3YW7
M"G@-TE/*:?Q(:CJ)!3^OBQ/3B*]%Z\GTOH< )5.-0SI:)H#Z,T9#$@_SK.O(
M/YND3;V6=C:&^]X=<S8(!,) ?(3,-M9_.%SM&U6$F0Y[US2<D/O4YCE#GHYT
M?VS4O3K'2OD1GL!HXNNVZT[UP!KZ7<'$A;X-_2)<%N:CGC%WL]PJ1S#>#[[[
MN0]".P'B\K,QPE14R#J=_^!C[95*%ASP4^)D.89'@>@N 1WR1%H\*W9A)%Y)
M(085VS.Q4*5$5<KC*QK F2Z]C*6@UI?IM0?U?OCK,&LB*A?]]6FOQ*<S5Q=U
MBW]=9;U5=# CO32R9&O6/)I ->:O6$U6^RG)%CXOPYHMTYS2N:P797SK@WQS
MM3M-/(GU<S;T1Y6Y./XN!>W"CM?Y*(O=S9"RT/-,I-VS)R_'[ S"'I7F^%#'
MT(_#;)P3M7B_F_/.BL2WLQ?PK<OZ]S?JGB9GK1%=ZQ@-V5?C:FA6LVMNF/];
M"T7%T+ZP?4+ R"7@>T:%L;(:44D,NCT-)3!.DN _#EX"!/HPLH2HM@>7@(F-
M\ ??;<[T5#XB=G2QFD28DH3Z=1UO(@MTDT$YB4C;KX)U]2:)/X-,7FF,^L%X
M=_=I1.E]2J[0/E;V<^0!XO_HQ! ,ZR;:),I#F7"R76TR$]^TL*)9= 6OYNI5
M)<L$%H(]65_Z',$?VLPBEE?^FF:SV9!O;N<M;>R:A,AU]F<W$I:.X%[?0_3%
MQXAT8*71%A&*T(<C]',6?CZS^%\?CE\<C!UFQG^A:UN:KB[$T6.:5BTF\&JR
MX<)K4S4_K\=.W&?^)*:+:![A[#;]:? (*.9W>**,8\(R6T!OXN([92:VQN%I
MTJ,O3W4XK^VH<,EQV:6J:!]!PVQ(B6S@.Q-['Y8B()SUHZ[P&[(Z ,O?[>'S
M/08*/Q<FR@.F&$GBX6_-':,>E@VQF=;IE%'_M69%O[]A[RT8$"(5:B-E21R&
M7,>Y+R\Q:B[3L@KO'X=E#MBI_X[U:O:E4KQ]?@+_X<1JW#O]O/V8A@28\"N'
M?D!_5NR$-QXM&]_BB'5[^4QA/^K.82K;RYJ+88^._4O =H7;*I&2@(9%+C'5
MVMSQNP0\<U45K>5KTO"6 PS8*,6/(*<1-BG&&E/&QL2M8(HUN1S!T"^E],7/
MZ3<?<>HOCX38T+50H^LP;6$YYEV%0ZXG%F$2O>;V NMU>L.24DB5-*8_"K([
MWAC-1UCEI>B'(S1S'?Y@7ED20XDV,U^'4[)CVYD^OK8K5E%1@M 0>^N!-"IO
MW6^#39B_6[&]<$+U=F0JM-LO_/S$LRN4B5%6 5;CU3!]'=8"4^7'K>X:(:>&
MM7-K\PU6_?4L'8+Z[N;[?W/HI1IPJACBU@GM8]=KLQ6[Z=:L/H4&26Q/!SB_
M<M#J%(/Y,'?*RLUQX9< U;J&J1]Y#!96"B5^HQ](!1+ZV!E&3?/&'@$%_>)/
MQ'&D*W"&^7^[6-ZUPV6^L!K=R+[T[!SBSH:2-WDS]D(9+_2Y_11(+](BZ^*.
M#LR-^L' +7BVW;QF++_E!W_W/1ADIS_+O P[80=Q?.L\.=STZ?[FXOOTY+&^
M_'.#"&!XD(MF^U(5H@,:@?J%I8]H$7!R_Y&#2IOCOG4?ZOT^'7B*1-NHCSWB
M]++#P-J;W(K*MDX">!ALMB.Q6U[!WRJ,>UED^[-5N=:R:[_)=HB%'^)\GV.J
M<0%S%\Q&OHD'HX+O4N83?VO\MD_4USZ.?D#Z"W07? LCVVFGX">EIRN#"IH-
M P#<AQ]1 ?JDMX\,'M%2R+-L]D 4H!T:(.XEEU.?2\"-FK?VK4U.B;ZU$5Z*
M5<L)M9)/SX+$ TRWZQ#%'$+JD[4W'W]3U'+L_RM#LX9$NX5AO3HX^0@_F0VP
MOFD*JL5!,%D6F2XZ4YJA% YEA/99&V\Y<WCN1^]5M>UCM(97]D!2HM%9<QFP
M!4>?.A#G_<TC\P#56 "Z.8!E#6>F59>5_^,18\V@Z)R'M:JX\#E9FF4^R?G<
MKD">@*GO!0&#:)S6;673)%K(W!1UJK-RJVN 7V7$G_;J099PY9AO'0B.%C$/
M;W19,W WZHMR7;G3_1*31"7XU^V!GW(GP_Y_G>F!D)%_AEX"*%")(RB]:,3+
M[2[U@G)YJK1MHXD7^\<\Y9E7"9LV*=#;""=]9F(/Y%XC9A%6? EPV]3G5J=(
M$F_DISAU"1[)#@U=8AHT_W&0>;_KS_S7'Q7B+U:C8DQK/AEJ9UIRK[MHN;C6
M.%\"U-.6Q:VYL3R'"%H"@A:[5)?Z.OJ71PH?IF'^26EI0Z-A]XOHF,Q2V:&(
MC/648U.IED#L[95X_.USER&UGHR"WK+"P=;R6UH9;]=B9[Z>W.P6W_RU;.*^
MDX2VN4F\$A) D4N D[+/]-,:'9U/*=P)+!HSKH/![72/5DOPNAYW J"]0-R#
MOJB:*+#Q]WESG.#BR\&6DYW25[%5D(./L2VK#2=R\%D1V4[B#4(\A*HN"?VU
M?'>HMA106MDGC!1P,XX6S/K]_;%/MJS]N0=Z_,6F4?<?W/EA!+6#RS;.;\6M
M-%#;X(^QF(CE_:/H;<C>QK0'\O:/(HJ(7^+I/C8ZO7I<79._&KZ)]V>""O3%
MN@<>;H2]V.35R[Y?8^AM7VNH=Y7B:_A[#I<7))0$T"\L8@VW[EWK<SU\:)%&
MHC&LRO;S$6EV5MEA$KKG$A )9L)ZTC.!M<<KZ+[Y?DCL44;)1_F*<Z==UY!?
M::T_L<5*P[L1D0%UB-5>3J-Y[7/S)7 QQ-/NQ:&<<F7<@M0P]'$;#_X^IJB[
ME?+A=IG%R[N\0^53-08EI.Z_9'OE28O=])6RO^*<S2#N*^P"V$73=/2&!4FT
MUR_)Z,Q:<;<42I1!]R&8R04>('VWQ:I\'C]M%F>$QI>^UW-,-3YYB1=VVDAO
M!;U=R3-LN=W&"H_+HMC3HS)QWD>6U#6.M4#1Y!?473)9I3-G;QF%A .37P$D
MF3DJ1]D=RZ'*2T 0"^ZB U$3EAKKKG2(>^-JQ7NA4%WSB%45K2H40O]ZWG23
M=B0:P@4945A/C>4QE07113]*?#:P4T('P?++D4!'M,_&]U?V8K'-)UD3'X;X
MR!IJM6R=\E%L[[Z%H[/?:Z@0P)/80M<4#V4:V/7H7"/*[AHO\!V+Z/:1C"P]
M\R$=AIU:ZSFJC1HB6\#\]O*S/!ETBX9O;,=T7@RZ<:T!/QPG22<5L7<KCF-R
M;M8VV2I+>2_A? %315^%5\'\5I1A.?JE:FE' =PX0^8(_!I6G(8DV&:X?7-T
M8.F<ZXRD**38/"J_2[B@U7J-P8&5C/,TP@2U1!*+;G0BS]Y"56Q=E#3NM]U;
M:#HN-7;=6]"2KS_]^3U:R.N_&ON0CD $<%MSZ/J/WOLL"P_>?@@T^1J^V5!V
M'83CEMNW25VJ@G[T%HM!L$M#4?0&"S(1R@L#<Q;]C6@ZUNC@\A3VXLTX1&Q@
MQ&XU5N8%8JR-YAYA*;9MD.;K=E3#FB^Z>A0Y":V&=Y;9?%*A/1JAL<@Q471;
M?P40'N\M'P$?Z ("FTJ_AQE3E0*,20$DHP"!M_\)QS0G^T]_%__X_;@TY+<^
M ""I=4ZEP;KFS=*W87D)^,P]R8?I;;R3!MME?=A<4]WK=1(>]LFO+ZC[^<.*
M\293)ZL=^-09]SH,)7LRBGM] =KTTB]Q3E4(+[HK%13&S]9U_9<A:9G;"-FK
MP_81:9P!-HU(K5CBE[BU-=@E^.%EEQ8[KVQ..\\U5G_E*D]_99<5&]0I6F67
M;84^[KSNXXHTDO^;T=3LA\A/7JV-T6:84):YV'P(\)GI7_Z=*\(B^YC4JV <
M5XZ%3,Y2)LK_'-WQS!?Z,)?HT2?7L1VG"]%/?X-WS?KS]4<U5\>/:MI/L.JR
MF)X*F[?UX"H?K3DKV8D-PF '$1C$KB2W/)\6T_)RA16;Z@Y['B=%TI5.J^\D
M3%WC2H4M\'W@I:AG9*JK"*.UA'8\)2HL6DH/U4>[$8<M/%><?C)R*G#*X>/=
M:K>A=(CE<J(RQA5_"Q=AG/3BY8).^_C3M>"K&/# 09^9[M)&X&_QG[ROJK:P
M$43_;-8)RI::HV!U*[H$E(^W!?[S[B5SQ-E^L-A50Z.4,AJB,FXXA*FQBC]M
MMUQS6PV%_9N1K:M,,J.^BVF<HCH>__.AM-]3)M%5Z%R1LUO)Y/R>HZN#V7YX
M8Z%%ZL#DZ[@.K\  9UT-:4&Y"H?!EF]S%MG[%^+0CA=7%=6MJ7KLN,,E9W&
M@>:P?]W-IQTHU&"MM=-R'DVP^3DI7*OS5.QH^RM<>.^YUO5N&DZ!YT<.KR=-
M,;K8U65@S\BL8X\8H8R\I%"Y=290_MU*X@/L[1#)7P#2C_%==4+'241*]"7@
M^K/)#WXUEP 2O'V+]UBN0UU5<V/2K?BFC_7R2L$D1W(;,78SZ,6'<(6# ;_L
M&,_? YF$3,%)<'*EF*[M8O2^XR3^L >65V<6,;")70HY*[!^N#QO#"PW[7AM
M.BU%D_K-]'WW8Y66Q,*L@M\UU75E-EODT8?Q)'A3C&:W*Q^M39?Y>NQ0R]^*
M8K><6^A@[O5%RN6XD.;5P#=Y7E9S)%N.D?2_ZX2.O'G&G0HS=!].Z"IGN&@V
MJ21D.K)JW_JT*J?5Z9',RZIAX..1;)^DZ_.VVC(B%NR-AD6<\TZWKL0:(I]5
MUH5K^5H.5*8_LU.\[<$JS[UIK87]=I*)L\*8/FV>!.O"S<Y^=G#GWYSO7,]_
MP6L<W;CUZ!>K4AQ!)9E^#D&D$EC=CP?Q-&(0X7 Q$?P]]O&N-^]XWMOKBW_L
ME/48ED!BX:0J*\\07%W:%??S!6UYRM4H*/G-:XYJ7IB4*);K3RJ)89*BP8;#
M J^J8GC!( .]?&BMU_FD PU"I*O$O, \I3"9_7O%I+NK[ S!AO =NES%R8!Q
MW<M#CU"9J7OPN/,V+76:/TM(H:M@#3Z6ZZN%6/J5$:E2L#;=]>,CN;CH0+^%
MV4]:PGEO[?HTMG_AFZ,/]V=U3JAQ)1=/%E';R("@M;:[Z2LNWSX/^BX:?*.9
MR_1"*E\"NDY=VF$8C:7@#!.8JTP#;Y+AV]'?]S^R&I_$#B::?M%\=PF0L,DR
MO%K&GWNHMS]L&?97H2J.W@[Q1AH$*GM7:Q/K5<HK?Y[?QTD9RG/*4GS%Q?;@
MY'KE\%VT_$KETP;Q-2%5[_5N^U1-Z,;WB# 3J1RQ:>I-.N46W:<B5'*\/!DV
M7T6IZ?0]YN(+()_P9)> D#$G7^94<XK//]3'M;&]R"HW$GFJ(81G0I]2ID=V
M8%#L2CR.&[FS6SZKP]$T1$.T.%//>=2,\=EPLHM99J?O1+!!76 X/OKX-GK5
MH'(<A7Z&*_FHED VZMIXY&32%P.OA+@V0G%9&)8[(@?[H?)#-9@#"*F[.V"\
MP3CA+!24-E^_\ZH:EGL:?8S^LNK)WM6%O[B[P%XO9Y0LN:-L9OYPPUK+4\R_
MK.?4^1PV!>Q4B;,FP_7DS&Z#6*:%*SC_//2MB?-VNMFT0:)V.ZY5SP^4#K?_
MQ?$4OGX58V++(RBJN14:W^JZ*C"3G;#'8L'*[\K8V/!V"+D\ZP9' WS+(;CW
MCQS :\:C'S[AR3Y>X9'Z&COUTUM<VKEOJ6M25TZ+UP=>]CF@$'K7+ZVC0>_:
M*OM<^'O6O=N1&#^J^08PDN+!0%: YVGN4'^^LX:(EYCT9! 7V>VD22PR^IUG
MWX/?;A4D'8*J':=]VD&!%!V<%F(=^V2ZJ_)*_J+IMW'1+U'\+1*YGG$W7C>$
M^%/@_S3&TQ"'8)1* BNM[KT9^N$B][$4D:Q+!JT2/6TFGCKL9_X;_*V!0XPD
MJS_Q5#B/.T5>9=#7<[4+X[^JY.,DND-IXY,/STR#K2#M,))]O&X)+O6B:U3'
MHV3@X!F9T_"!GD2PXN%5V#3(TNS^&BG4@(K6D!L^);LEQW7SZ7G<4BP O%E&
M'$102=L Q+I21\M7,><W!]W7>TW?RY,5VV#A<E>:!R<?F#^[R=PDTC*->DO]
MJORN^"=1CV#3& \KYA[].;%E9"?P=A<:R.2<Q%?[\#M37;"0N.VC-<]'&Q.7
M /A.$W,/_#HNHB/);UMWZEZ:>EV]K"SM'\T_[=&D#/?#S_0FLCU&1RG2\7*$
MY+9;8!E$DME8B\J[C.Y*%G.L7>Q+C4=6C90-&.5 I'<AGAY#GMAVST+Y/DM?
M%'YI]]U]^AK_V:7F&/8-A'D]9G\5&$Q\8&YCA=,QKYUDUG.ZL\63P9>J(J38
M_\068NG5QP1'0R.)=["0HA*GN[QX7U.4CN3BXXH?8RFNL5_H-.B+<^CEIO_=
M? \[7_K(A_,'?09@CL9;=EW6[^E+#^NX]DK!G!=Q:ACW1SCE@KHH=$,JK82I
MO3B<ZO.71P [EKX"A8O5^JXLV3X[]-1>O;O[BNT%J/>@N[SYHEF'?-BO5P'Y
MLTRHM.GF0#N3@SP9IRJ9-WDPQ[.$[K=[\V2&W01RIUG6/JCV!MXXD #+<?9-
M[TMPV\_.(@\8I5B#][R-7>KC\#5D_Q2]7D^?=U/QPW+&$70&XE&&0_2,:\M^
MTRH0U+?]T<5!B+!9MV2Z$&V^DKQ;.UZ1%9.R;<@1N2MY=!0_P]>?BP0'2@FP
M%24YJ>SJS!WFT(^7OUC5F8Q_]M(:.+"HC;>HF5JKPS+'[T6I-#8W]JD<C?6=
M'1W!9_49YX.^=:&Z&SON, O2ZUGSV:SI0NXMID]![LW3Q)[*"M^X! 3%LSN6
M*%T"%-CJ%Q',KT";A,2CW&)A(J\$89.%4@)F$'-Z"5")6"2[I4H1)RE_#$^
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M_VX5$7"@3P/Y!;P!9G!=N8>.I1)2S'(;WJ+=BFRS3.I=%F_?;HC[2A#:&GA
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M-:(3P8(S&>G(Z(L0*< 00J-$WM5I&/)3W L6B-G(!OQIK31J7&7ITS9"*'W
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M_]WE7#_RZ")(7Z.MKJVF,=8AVL(_+]GU=4*SG<S$%CTZ(<3[D;#X0KQ[T27
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M',&?G$DPU3O&)6_]E_L()5M +#KP:M*J+P%_"\M2])]? N*IE\Z/89< =6D
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M/<E62F$$92MU%U]?KE%@LJZ #1!8W%PRVHIG@PPR![R)?RW[L8+8X5](YGC
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M5_0CA954E@D^*^?&D99.OB=C;JZY^1FS*Z2PTW,J +ZT+AWA#$=)TGJ.W8A
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M'N7K4G5/:U]V$SCL(P]]M=KV%:SCSDT[H<5*NI^<PRFBL)*=B\@R_EW&0)$
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MA'-E" DU\A(P]72NS6B>#GH/=B!P]6MY$F=Y[5MO"1HEKVW(:WLEM13PK0N
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MN:OG*R!K5F"T"YD8N]+QF4YHO"8-&Y3E_$U&VU,UH.YA]1G-V"V$EF9+87Y
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M7B&JW5G-"T^B.J_E[SJ^DOZSS&7?LN&^]?>'8O/)Q8BF@=9#@+C6"N!)(FB
M_0-BI8I-09I2),*/N_U[J8<MF?*6W-O+$^O4+G+,8V"7X+Q@N@A1S)Z"![.D
M2.J=*MFYQ7?B8H/!;W\IKSJ/^BXYW$_8//?4G0SD=22[G)]D_S1V*8!9-&=E
M:57@B/BT:*IE+Z"K2I@Y$9#I:A5O@YV:DM^&7N%NN6-M?0?LO1+EI%2,JM5X
MQ5G0"VY1EPCYFA]J9K\=>^1(8^\'D\(XEVN<#J;1KN?QZ,E+L+]%4[A6VJ&K
ML\\+QZ2 R*&^'/7P/#PDV^1:JQPF'AU^GH%6KF]4>M@P4?O@=^RB48#07\UU
M0-%"PTZ&)\835 NZQ;P8;J<9]S(E#JQYE6/PJ(VJJ^1##RX"0!X)E3Y\NA;B
M"]F21M^OJ=I/D2V#\T8WEFSZ^6Q8BL'N!EK4G.JHPY0=;=C?T8\:BQ1VLSV:
M[FV8[[1,NDXA_IAKEL)+GC)53+/Z.8->P8E!QT)/#_UF #N(X;\!X&,P</30
MYI-!'=5)2<3!W0KA3>H<3TXGOQ=W1K("6%M*#XEA& [RJ$,WLS5]NAIQ<<$+
M7?\P_/>:<]8L'Y!P#_@9:0[&2ADUE.WR8WO.-":Y-HF?Y!'Q"X?@HH;>=\U1
M;/DIN^#?Y2L:>N'C6/18:^*]U52BU9S6RD]9\LU:)IUFQ=P"L7W'KB_W_P(Y
MUO1_F,=<#(D;]57O*L@D/X7,*!0*MQN9O/NB*VL<W3+?S<_M&L#K@!G$#-[^
M\RQ,(BIMR/5 :>H&T$DU_['GH80VR(,C;&!+EF6K4$_PEFX (*;7.4IW,-,:
M8V7NM;J4*Q/?8TZ1KLD!5'* V9_K1;O :]/K ^N961N.V,.AN1W"-IW/C[YI
MGG9&=M"BCCH]9O!6"CL]6-O66S2TZ^L0'_]8?^:HBWYJK80+6<:B;:!/.IYS
M$YUZ6DM%=[Z:=)G\M*5'[54HF>8F.=<TNGV+W%/'43> <7JE@>/HCH?H\/#C
M84IQK!E1'3OYYTZ[XM%NNS=]+#4%>H:Z75U[@XP@C9(G\%F\M>D()4&LT*B4
M/K5+]8M=2A=40,) =+G7NQ#88._0FA:\S/N$,C;[V@-= 6O',8PI<'Q_X6PI
ME"^=(A_<9-7YL[-RP\#7+>=5%J*OB<)[#*%;P-B>+*MG?1+-P3@TM940:90Z
MN MC=G@S H_NFNHPN*QCJN.I?:[$JM5KD">?D"ROK6\1)%O+W-JF)N7OW8S:
MN>:?S.W[7[3F?]<T69<$AF/!-C> Z;(;P"5_$=X%WG\JFIXACC-@>+"9]+6X
M:R6P?211RA[V%MZ./0J2^3^)F7#FL)6%[ N>M/!K&.@&L/-J\MK0@!J3W7^L
MHD9CH/G_X0SQ_Q1=YBKO\0R?,^S>)GPN9+TN&_5D=;, ?EU"64HX8S'/2*/]
M(L^-PXM<*!H*/0OCI=1Y\+2"IWJC0)W,&VIH/MZ\WY15IY&PR:*6OG'!8ZJR
M)G:1PI-"3ZIE,U1@P5?(D[CQL66#][LZ[X'0E1E8XCP8=3!Y=K91/E3*HM?_
MFD4B3UB9) 1318[/[NYZW*%9CYF]"HXQMT A/E=@%5?SJ=@3 A[&=%#1*AU7
M6.4@C5RM5NC;^8%NI=G4X.HUO5P)"_WSL,I:I]?$*4^4GNK=UU04BT:_'.Y@
MI]O-KH1WY:(BU\9[4*'7<P(V\F_#^\0=O; D;IS8Z.F.-3'9C+$*9NJOWG;'
M+,\G^)Y&;Q =%_/D:?L6,&N+)4[-!^1=3O.M8K/?5PV<<*ULKYZ(T!\3$3.F
MVTO(TY3:HC#RGC'/'5E*DE_M3)>'ZRV<;SZ_D%BI;T^^3FF5K8M!IS]-[?0+
M3$;'SIO^,O\FP8E:_4/2<C)=7R=X5KK^=S\*U;\.Z@ =B!"X^,F[_TP+F#AM
MOK*-'*Q;/GC :!=3!7_:W*@ T"/6N5*S@0AA"E>N2M-=P4<*&AYOQIQ3Z]"E
M?>ZB;&(M-"D=;,U5X(-QM+_A=1/,^6CVH);]'CAV[M3%W*BW<*=<OBF[6AM.
M\F+QPU\6,L7*R/TP9N*$]CIR1D+8:WM.?CMT)+\>F=EFJ&4V56(J:O'P[! R
M)/*Y^HA&<,/:M'VFS%1)KE? [F<C@DR'UJB Q:' N<R/^([A%;>*1OJ>25*
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MY3< )U*B:5V,Q6KP4[[VA3=SKV2,&P#T(EE:W?JW39)AWK)5'W@,_X"6!#Z
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M/!EN)/E,M]KQQ>*GW.*E?2L]$%FF[O2QGY<HL7_RC2>RCYVHU+!0G3KA2N2
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M9_6K[Q'1Q5XIV(O3GV*N.?\8Z@L4WM^*SO9X;KX%#[L!N 0A*%WI8%6;Y?G
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MZY[XS%=!ZD,LCC^)*QTT'&_&>#U8_S(#3X=YD&-XS#O@<\;/?J'#/Y;GH6X
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M<ZW?G@^?:A#XB=]A^V-^[_;%T6B/STJD$,,))0+,2FU^PY<\Z]>B0[M^J+9
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M)DT*55*3Y>@>RB?-F&IP7; DPP'P:IXUZCDGS7; #'QO"ZN;E</39_8VR3'
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MPM"$EI_JIK<#I3X>@H>UW=[-SV4G325:ZRW=YN^$L(TC--XM<>HUO "(M#5
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M!6R\YA5#$LN>G(Q5^!WL"Z+.E&=@PLJ(*^#CF?Z02'X SRRCKN=$Z"'!O2M
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M3/VQIJN>1604*!!!19;!@F^S*:Z^[V,>G68"//24F/MU8;S)O^]RC;.4DT&
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M8*Z08M4>&H"W@:\6YI%< 0[LODCZ@ZA60:5&2=G"9)/)GN+#_IL_VW4598&
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M=.V0C5\A3LP4\MRP[ <?4Z7&Z ODP:"X<;/+[W-X3QY%R34&.41@(J3L:Z=
MZJ7I&C)IB6^//(%^JX^GH^+6Q2'42IQ_P!QXQD+34,L=L]?&#&8Q^T<\V8]^
M6:ZR?VWQR'9!\I*A\A9;VN4Y8Y4XK@!7O7(S4Z> &]H>KA4>+)IWH_QC:UV7
MLE%$Q+8IUFDK%"%N5T#4;42\"H(X7$B*'$IK+N%H%KRGS1M=&^;Z@]VKES+@
M[&0SI2)\4-QDKX%:9X@T-@[-I/7,M4@K);G-0=6-60[LZZ)CF^PA&@V2Z%*Z
MN_ZYAX,'D:W&R3]6Y9TJEBKF)R19P$8D4IB3YB2Y"K7$X@;J>-TY4;_ M%>
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ML#S33/SYOI7"P\-S;O77_.+)1+_S;%>:RCD #!2K%>15FX'8^BA\HL!.(K@
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M^B^KWN1'[OXV/1 !Q[6#SJ,@C;G/$HYS9XP/N7C$P^V]#GTZQIRDME^"E:^
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MKM3GO,O;IV $7F.&4\0KPL>\+DS^!VOO&=1DVW:-QAN0#H(@'51Z[[U$4;J
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M%FE(Y4@>,CQ]>OJ*!G=@H\Q@-W_)W>E<8G9V96"%04/5.F(%]QT\GIT@+AX
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M^NWG5;Y"KF$-I8-5%R#4?U,ME?WCK.KR*]9RDDKRIQ$B!*R=#N>8I= >,-*
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M]O&$AW@3JYV7@.1##662U/14,,F0GY,?BDL"<8Q<WPD5>*JCPYK27L:9]\%
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M89:H+SA5)91ZC*N2:MAM=LK7M@T\I'6WAU[4A&YBDM&T-,3)99KGAE7+NP7
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M:!K;]_^U[X\+Z ,0-"@(FSX>OP*0\PJ!OB/@3[@[K2_(M%D+0B3!?QJARE<
MC(\T$&\;2/<N_97S_-8O#Q"LXV8,$FC2=?U$*:$*^$=HSYEX1"<3-C)K; <\
M.TPE)ESA 'W ,Y^:M_GG?!+&3!">:H#3N9*@EJ,+7S6WM6:BLN39'Y<?]#TT
MY>ZUYYZIS2;>!E\\A*A@/?<^HX!T;CK*S6*NG-_D%OMZB"1LH] GN^ _R,A0
M!KQ@MRN+SEC-$$"NL==[$,%%=%20810\!(&'U/^]P[+LW<.NHK>MXG/O7-ZZ
M/Z<K/'27W 3)^=K^"_?"]#*XKK#;,P9<+Y8A=P6@APBZ5;MAZ<Q-6YL9?M<)
MD:J>O>"). 2W\=Z^N4_WE.7B&_^=?^Y]@3%Q1)H P7Z&SXWNRM+IZ>M1-E")
MX].-<" YQ.JRM-IOM00/5K^/5$L?BG/\*,?;E^?;0$6FOAP^(KV\ [R^9"95
M9KQYC]P+]=X4S;UO+HB\_/5;0<#GRR7ZT(L'!)G69(?W"8D?2*0B$K#=;"HJ
MUVQ*HPF])J$>_D^H I2]8!C_:\!FF7*0]Q5@!X"1F .BSS[XP8!XFV.]=JL+
M/:$5ETVCG\_Y[AN2AMT:7T@P_W,&;TQ&O )I--:-RS*UPJW(X@=(WO/3D\XG
MUP9LU*,OD]I);BK 6RBN<U16>NM:"-L,P O4#JHQ;[[, 3DE4R[>N=2S_'&A
M)K>*2]3\ UC4/AK3 ?[<+]RY@2TH0A_&GB,3G+#D'TXX8M%9/A>H*.2G.]$C
MIC[:=L$%F0=S@MVC'PM9UY-V^^82-Y*=OSZ;.ACCK4L]OEE6^X0D/ \'JX.(
M51*X_MHEC:M/$E2.;,T2ODNNO+:-PP3LSIPQ[\BUCGST^3*[$_2V<@:9[N?A
M6Y G\M_HL"/#:/"-=D;,TJQ^Z6<7WPILYR7ZEAH"'\[#F3ZJ'/RFH]>[BY4D
MC-S53H\S#\E[K5=M,^$G#"XG@$C&)._DJ:RX364S= UM=XX #H[F4IO6']][
MG>4BV)IIIV:OULWT@^U-O_QV@?.- F'LBTR4V/U-LTEQAMM?/B[<XO$0EDZ"
M@GK@]SKE"7Y34&<@PSQ!$4--^%Z_=$<IN?XN\)Y[<7X!,BW(QPV$!#;L(_?Y
M5I4.2?'\^G*ICDKS>L'.?36SS F.[7TK";YY)^2I\YXKM%UNR=$VJEC:Q&+?
MH'/'O+FO6JJVR^R!+6Q;L^0_=D2P1!4$]KYO@<-+,B$$+<)BP5%^HS911XLC
M[FM1)LBOC%U_:^ZDOA->B^$6C*Z#%"J.NJG5\L5BY!73!R]KY(?(8WJW!TY;
M,_4]8.=T,Z$C4X6D[7XK;HO.8L2O%2KUB]8*QVQ<@Y(+5O(\>;[+6-@8,.$*
M0/N6^  BKZA+YI T/1H>!A0Z8OQZ!7!RAHW0WB9.+'%>?FTW0E^\TC?7FVBG
M#99MK%PH%%N8'QCHM-ECS"]BY3((A9>#R$]-:O%WQP(+?VLR/+8XHK*]Z7<B
MLCM7H(Y@$[=*7N6^8^J"E!CN*!#.8J 9E \83Q0Z;GLU:-+PLW'N_/-FGD[N
M&WEN^E6V%Q6B2!%?A%F?[NC94<6^W9<F'37L^O@O*Y-5\"S4I@%O5;T,49[P
MDV@P])6/7A+B1"OKRD7]6B59W_]G/@YL>-3C+H*F_7#ZLEFC;"<HI*1OP7PH
M=NU-XJ,P\#3/:FH+-N\4+X*KUP>N()/?*ON7N!K)]@PV,UAJ"/_+/?.<,[+(
M2UBM\7H$:J3M*YSC'9GNL;GY?4*T_2BK>5KIE=$JGSUDIIL4:'-)#3EXV?O9
MG8HF$(7S#,N2X,B<R"*7Z+*UKAJEURP._'X497I(89(>[[/1_G9L'ES6[S7B
M%/?[2%5Y4!+3_;I>UPMI7\_I*49IX=KPSSXVRO*]-:8\(RTQ)]?-:N9?<]=_
M=4;]7(*][)M[EU_50RJU9-=:(8HYQ<GK?&U/*0=N;$DF!9R;[SW:0V!H5KO8
M357YL,JEQ[V68=*#3C?6$DLX8I7"^:@,V;A[ZO^;/C#[",$-2!KOL^$;_]*&
MC=SE/)/^Q:!4O;EI]_N)PB^0Y84UE1> \A8 N!EWOD2Z4HVXH4>1@WTAM*'0
M1VGV8.7!1.A8ULN(C'\51J7%<WY?:2P&2^OT/1I4[9-;5L5^.\4-!AB2<=8_
M@%G*UK.?3(M93[/=?F &NU\]29ENG.>RG%F:WW@W[@%LDO97A,+V,%/8C3_&
M?_ZKJ"*A3(A(4?3>'59-!^2MIIH=>KP8&4-OX_4";%ZH/"PO+@C]$-EX"L60
M+J:'9)X<@63@*T775R.;W V,5H3%-%P^M0PH?-%HZ\J7(CH(8[0'T"T<DG,O
M/X,^ -V!D*TFSS6C[2R?,(]4E._DI"-#?)ZF*1OI*9#%IWB'^4Z7;>.:"<S'
MZ(Q..?Q?AZ:SWZ)[GGSUSEG@=,I=5C(MKA@/:7 I$*,-FBT80K K$8S;&N+
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M!;##/ILB?_3MWZO ,G;F0\S%L%6!H9E;E6QIY3(S.OEO;< ".>$IF%1H$ET
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M&[KT$9.,1D:J/L2K&V#](SW%2NL[XWVMM&0,9=L>6!?'Y6J3\)$[DY09V92
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MM;]=C3G*PZ65?%[9GF[NEDNK8/E;4?)[_Z]<:'B7JI#W<K3%(0SC26?O\]E
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MNW_T#!_E+EY 3!93:#)A]\F!?YKI()9/%1V6OA<264KL'F<:5K"U7_E+ZW-
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M37T7E8Z8HJ70TA/$0<!8=[H N#&>4L!E96N!3>/J8;KHU>(HF NB(<-)L6>
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M//9M5>C;AR6_YD/WL74<\$L4,T8(6[$#),7>PC$P%;._]/IMV#ULD=4.@MU
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M,F+OLO[=?L'1,H,0G8*($("C'H_&/(0@LRPGCEDJ'S^495SY&4F!D1^((:V
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MK#,E^]VT3/3*>'7@1"T>'UGM=*CC!GBPZSGFW7C(\UT"OQY&,ZU254#IL?&
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MD/9K.#H?+(:^76[:9E'2S/S4P41>^&MJDD\M@[_!Z\\<RK_! VC\/";G12L
M0,I(DLWQ1O<=Y"VI)!"CE=O2BW^:G_&%E-4F:/L5]=, 6.OXCVQ*=OPVECB^
MHM7A#^TP?)(?NCZS^&P@H31>=1SYV65'X%0>5QN:V IB+B-(< Q<A!57A3]1
M6DC<8R0T(YF)/68&M@N,U\M+@]D5R.N .8CND6@05B/&;86T:V I_#ESE<$)
MRNO>X[#AUYQ,$I8LE9(GB"Z"[;+L2,Q!4\AJ9)*H*4RZ V,9GMJH;5'43YTI
M.61LX"@GXO3G8JDU[OY!"\D0/L3EIEIBGUM&'$U "K/\D7RU#DTTOZM,3]K5
MT(;]BJO +8"?TF+R>_)[/3E*+B:SND9U^&4V";;[*2@-B'T'#,YZ@&^$^W&.
MBCVO#Y8OCW#Q^%1N?M-W?6#/7.GWB#:HZ$H;+31#V+@V+-[3._@@M[MTJZU2
M6\G[QL98LTAG"QEV*2IMJ/KBN<#)3Y='15])UB0=6\OU_FY$&V[C19Q^@E56
M=(S"T3]>5M><_"RXK;6?9((<7J#L/*0LD84\-Y)W+AYA""]ZE>ZA5O!.4Z#O
MD1##:S^6<U%(ASPC7B$;#^V4CD6XK,BY^ G9'2[N)^>D.,IQ\Y4]D)P=J<+4
M/6P1O4B1O]_C<JY-\)\XAMTVT9#;,<X>$^&M-NO')P[8+J3^D.0,.DV[6 E=
M%/ %[W[0^*E(W1HQ8ZD_78+GZW(]4PZ0%<FQ_^NSGEKXRJ%H<9]!@H]6-IUX
MLD)+ W-UR%\%)E&&+U52=I0@9SG>I9^$M\ TJ^NG"ORE\I7F6+6>6QKU,0)(
MNH'M2%W(;6(;E"Q=J=$Y&"+6J/'\ "#1(5H^:=6VII6S(X48@T8L_3)LYXB:
M#39&Q,J*LQ= R712;V_3[)E:?#O]I'K,?9@XUA@'( ACO3K4KQ7BE36E_;/-
M D5YOX><[1H#" $7=4AK?^56:.5'(DU%4P/N(XJYR=IV[T;JC5!WW@>5*FW=
MRG2'T$ZM !\' MM%4MG1_K695UXV/^Q(C0Y*]41_)-#PIEVW0<G4G:&.3%:<
M[]J:B_R4-@P7S$-6"G(?? 0462R1ETJV[AJ-$\2PCEV%WRV?QY',V>[$P+OU
MGSKILJ@1OC&V=@.R*;M +'Z\4>H7Y;)DI6#+]I0S_7SS^X$R$;M"+TE$9@".
M@U'1&Z@C1#*$GMB=MM$U$KM4I=E8HNYE^;#';]8XV=TD]?K+[,\D&]>1!:>$
MFVB33$VV#X["#!-"*_<5/^M[Y;]_SR?C%NTRE9[K!\3"PZKO+NBJCF57-T](
M^)?KZPW.->RU![KM:0"@\E]ML_BQRCOUY01^Y%BAF;['(>T=S@_C+VL9R97F
M,P>63J<N ;L2YYP.'#30#PA*/+Q]2L>N10 ;FE#;?==VAJ?!P?9WK]4+QH3I
M887M_9&];@0VO35MM<4S+Z=-]#3+CO%MP=EJ>4>60U%<A[&@,6L6JPDCLF(M
M8'?U%W\A3PBN_L[NK#))+2-[TC4"S(]]"B+N *TX*<H=*MAB]HH\FD/NU"6_
M3^9)MG3FEG_"N$H^&86<YEWI+L'ZH%8F+S+G\#"5*N)D1)J$!$<#9[1+X_XU
MT#@Q$ZN,+DQV%BJ("RWCK$USEE?1YYH>V_#<S7TBC5)>B8+=P^NV-<1/9-?$
MO:P8+U 5_$[3GP!X8DF%N9?@-HZ0LR5!(_ \M9%^EB60D48B9]5/>V;QE9E+
M0*&UA+HO>%VG4T7A[@'?V3*%PU8FZ"0"_R[7;,#&'Y&K<9?N<W'I-5+&8=PB
M\KFL J8,VFUH'()L^^M,";9RRH\]8($>@9<V'@PSW'&;/X<5O+)9IKRQ8!R*
M4PZW2#3@DOB$XGKXAGIFP"<62ED @ 3A0X'!EX JSR"O'*.EV0'/[0:!KECN
MAI<#53M6KGN:"CWFST2'_!171F9L5G@[3%+#6FN]?,KR8P[JGDG.;L!E@X)&
M#Z0VQYH&=+"&44U/^1V@=X]/J;N'NCK'%&4^V6(ZZ'J=&A4AP<2K-+GJ!@==
M%1Q[\7<(\>?^-V>XT. ^U1U5MCF9^OW6@F98\ACR^ +X1%X-"]]IPS&LT'4:
MF$LT-(U_LG3A>BJ<'9O/89Y)*G[&@:U=7@J59]BDLIMUK)*@Z<XQQF%N&>QI
M&MEP7\6E;81Y/F?"$Q]VG\,W-_]G3[/_F_)_G([]/]^>_ZM_J%Y78/P%\E3T
M7TL15#3T[ YJ;Q)"?0EHNWX)6!TDL%P"S)]> OX(@!KU_H-7_0JP!/P_^(;^
M*^%1D-PGTE9] VRP_F<?F_OW??39=+9WC#UVEPCG<^HB%]C\R67 IIZ'^BLH
MW'R&)*[:1/V6C^6@3C.4V6X&/C,OY,\>L0E! 5,0<QO=CAC*B)'B-VLQ5ZN8
M&:7IO:Z139[U1&XD&S$^@N=!MCD(D;QP#G>^TS3;7#\]6/\@_U5O[V[&R4:9
M"XCY$K"<EG8)Z$32S#L\3^M\JR"';WQ:]><)24KW74IGMU/49FTK*)04S=&1
MR=!6*:W^/)-1]='+VY\>BKS5]"9%^A!$@R1)I08(VACYY\.3_!-N1OSO7D&.
ML+CUF'EGB/( -!0U30S (*B>R7:TF]]>EF?/M!<_2,M"29\_[6PQ.1B>.HG?
M -G53N;-A/?VV -:NX3$ R3;>M8%_G*=XETDMU](;:IT<$9:/'I!0C@[_BMV
M#>>\NX!='%DA;;UPHO\5Z[ MNF'2_Y:)P5[TLTO6'0J"8?^_=_P1^BTL6,L<
MR_I+56@XLE; ^2Y-\D&0.^OREZ=X"#0?R%IFOH]&AEN^/F0T?C/GDO6U;P0-
M2ES":K(9J>)^K=!_&ZI1]YP(B"M\4DG9>(2(&<K]::J58&FGR%\?;6^5O/XW
M^;:( V/YKKH^4>6\M!". DN$NVY5)N:E#C,EWQ8J0A5C%">)V]7'8_OK_C(.
MYSR+A%?X*"@&R3CTJ*S3ZQF+Y_NY:*O8>9]5'ZCP2W#)B2T*PN#P#%R+CD_9
MT,EP_MI)<?+>M5_9W.?]!O 5*%_/<%2VA!S--U.<\&/+UXJ@*'&2N.](V9^B
M\.5M<O:DMYX'I!*VKV_8-#Y[,DJ(P\<BJRB[=NF7VN1YL88PNPVEL+=I<V[\
MUR6>GY@>]>WXNRSEX^)VDLO^9-W$IL#1C.]D%;)/&>[9 ;8? M8\XT["G&8(
M4%V!@18!@L[O%EJP$_3^-LL;;:[*O.>CY[=4EH-@.>5V:XQ6S),5^EN3]G'-
MYB61[G9C?T^3$D"40@MG(MR6@E'D>>%E45V&"!$KYU)]%YT<31@2W"=P7J-E
M6!8W(M,,/ G%KZ=Y=2#9P3YF$AT&O^8$4V$V3T]+KO?<M_F<YS+'KL KFWA\
M=6*=^Q+16FT(,C^1,42G 0K;9>O"TXYQB:A]S!6HE^43>,^="MJFW?3 U_O'
MYJQ-R%I+XR_J8!7(Z([:=1(Z<O (L  J\^]ZC7(.U06CE_WT*8=F<T.Y;J@@
M/44IZE/V%\,:2M;(T_ZZ:'JO%,L_JTP)@RZ3Z#OL<XO0>GTNYJJ)4\N[?&X"
M0EYR4(I#)Z:\3C%1IG41\>2;CW2J5N83X/1_VN05[RH51]4F+Z*@$\H$&@QZ
M(350GJ*#^W.K4S5OX-K>_<?6U%P5?3=@WS!7ZO1#K4D0J"5ZLKAP?W>6;(KP
MH08IMC&EVBG<:$^@5JOAUI!_K%D0/'7Y\S=^[35X:,X=[3@' 23A>XVO5*%T
MH<TWS-/CCVNZ=.8>5KR-C57.EP"G'XBO.G0+*%D=I_^$XEN[DM>;1$]BL;&9
M&)$@HMC8_FX.3/K-/HE:]JGKM1!^E=[SG@+?>&[+BV6!5JC=D-(EX U>',.2
M*9N<*3;S4YF1W>3X9!C87>^"@PM2B!L@*\X*'TS6$/MT8')-ITZ>5F-%K#V
M32C#]K2654NR^<.T0J*N"Y /N)R^^* 1F]KIZ(9N:QXJFK0FN^;7G3?X'F!Z
MW,/J11#XZX.,!\V8K/"&$Y[BVO]V>C&L/T_MO,>^LDHNML'I*J="*#GKQ#H5
MSRZ%BIGIIWLW5T2Z7G@YL69<*"!&9/E73)'A>!_DR:=U[(R!1?C IA*\.T?)
MQ_QL'YIJ#<G$4-Y9-Q7M_.;S/5-2F29C;?K3<&D1@;K(@*IQU[/TZ+!^7%N1
M[LSNE$];D?8:-HQ 2]-=RTZ)%Y*JJO/U/F:RJ>ZGOLL=G[M\=J !]B+0\*)=
MP5[ML[51^T(ZZD-^+"$-[C</!7/Z^IB&*22/AU0O 3??323,H;7"=J?>J L7
M9W,Z->8K1%.X?1781$R':26,+&L%%Z3(A6(T U*CJ1L-$6Z]B)C<O"C,IT\"
M71I6W@8L5,'./N(NS_2VU-C=C($B7'O;6EOF',LV84XT0X<9!BPL_55EZK>3
MU;0S:U<3?LNU&/N':'"O B0QLAS&GXGPT]\@*P1F O\B_VYMH7=!X4]>1DE"
M%\!/[MR3P%^#3\2F;(E5O_*VVAAVNG[OG([NB^ M\(-8MR4ZPA:!OND2$*R.
M6;^"JS^9A8Z>JESCNC!%0YH5H:9$$>P9&-:15AC!J7NRK?K>X-/]TNU:+[DN
MB+@=#*M^":"RNP30.?NYB_]HZ7&#. 5?1U/0##][+TRXPL04#MA]NCH2B173
MJ^ L2F35L[6L-!T6'=P>6"@RO%Y VC=8QI.DJR;AH!E._(+U[?1+#ZESBP,[
M1Q08E)/(]Z^I\^<V;^E5#+.6YP4U1*U/;?+.P"I:;J$,.\T9QCP4I0YWEN>A
MLU0BAXS &,BUJZBL#K5VIB+X7Y2WT)ELGL6<Q,.[7 H+NHX+CVX76Y*_B1B/
MWDB[.,7RAJ:W0YC&C_XO\MX[J.FOVQ<. M)!$*07 :4*TCM!_=&E]QH1E [2
M$2(!I/<B(#4B()U([X1>A4@-@M10I$DB+4 (E^<Y]]RY]SGG//?>.6?>>>=]
M_U@SF22S)_L[:ZW/Y[.S]EK2[PZ<R0?-V?Z45>8=[9R_3#=!,T8V5MLB;68:
MACVDK,2CEC=[#Y]"?6^2"\US6E#+\HZSXQCKQ9\:S\'MHZNJ!;UL 2U$6WOS
MFCTJG_7T.1K6 XWL$K"1FVB'-4>7-KEKK3'_?BAT^YN'9WZ=FM=R%^45%'][
M'((618U'Y:X)!7LR[3:S%-;!K?2;01U':IOO"B?(AKF@H">@C@#3K[:+8ZX^
M3&ED*4/<' G%+Y)'O_K2D&"#^RA\<T2@5#G+M:X9JM9:YIO-@$]W-#?8WJMP
MCHCV7 /FX:<!+1B"^JM/4B-5'?YM'5-/FPGZHH]B]<FV$S"(H*O\[_ 7>E2N
M!:S39CVV\O"&[Y^C1.O>RM!5?#"Y+1:IG.<#<@BL/WV*94#IW16-]T.0\2XL
MC&W'?_Q"2_.X:7WQ+W5XN=1A%QMZ+GU-1YR*1[7Y4BJQ35#U7H"[,9-!'G5X
M*/ VW!48*G-!= V@Z;CO\W)9L.GKK+OB^>\B&=8IN;O^ZSTMW4K!(:^O 7%=
MY+^ Z"D@T9<&]#WHO53/8LL'Q\XOP[E[^?L\>P\F?&8"I"X388&,?1P/6J+V
M+*;O=Q0L]:<J5*354#]A-EK^G-7-09^K7S_+.[7FND=$YBK-Z*O5>0O7>N5$
MB&94P]J4_X(T.@Y>5M_MZWL^"?.EF&FT<O5A4UU8"EUL .@!D]G_"&U!(H%?
MESM%^ZX!"1"&YJ4FN/LZ:V7E(_:,\(E*!7G\_M6J>B/$0!N]V#-68>M*J!%]
M^?2*1:$RL;S-V"Z\>!^A*\>GM/M.9NTLXCB>=4EZ2#.<5>E)]N]5\I('KR>T
MJ3[1^?QD >!N8V<=UZ$L> 0G80<PH$B'ZBJSWHZZY,77QQS/?;B;/WY<O2,V
MW(.W_5LK(>#5APY/5S1L+:N?,[+):/%9\?P.G<N"7\+S>T:;0SSGJ4,):1)Y
M2=O*UX!)OY5>SUN@1PT!\FPT[,7A5KX+N3QO FZ;_ CUV;&YU[Y&0Q.8]529
M=:[AEZBO#YO759JQFGXJ5=GM32X[%39J)\)S,#;C,]@,B[@4!'-\!PLYOW.&
MS5N;JY<M#M#'7 /:^)G:RIAV5I"8&L@0L%9]8"6*KWN%,V3(?^$LNFAJ >7F
M\>HG R<?H2**#T<,T5L@Z14%!+YF<C].O#6WS!JP0O^*QT&-1([B*P'6E&_P
MD#%0HM?VUFPIQDVZ.9.,O,(Y*69SQ96TZ2]U A)")R:26Z%RR3\.U]DG6M$2
MO7@Q3,3ZU,&^^N+S?8:9 3;M*%.N0Z#8D/7K!A&@,R0BLU[Q;F"DJ<;*F%VM
M+FLI[ACV34X*P8X=%)..A#R,1./?YH[6BM@EWA?VBA@&N..4A,!@::S'7(4G
M^(D'LH[_B/7@F7( (;+FG1+^ \$933\\ DX%<4XD%FE04EM ZK_WJ;ZJ*#8:
MUOOVV8!Y)?$')2[)6%H>.<@"W[_"Q/<8-L6O(1I7S O_3-EUANF_(56\]#FP
M5J3"L*Y)U[K#L,&6'[&ZRT\D*QZ^CEVE2KM-QB2T"+6\LL3R83QUL,UK@8WQ
ME&\S=RAE7ND^@;Z@?A?[0A-O3(!>"?W;V?Z=P+GU14-L6-F214F1<-1L_,&'
M!'#D;8EIDB:%BY D++ GB#/<-]Z&3ZT^:EDA,$TZE8?\3X9^^\>3@[V"#J35
M?Z[^][^Z/:8,CC7]&L [?;,B;.\:<"6< Z\0Q)M!5G]"SQ_F1%]!0-> '8?9
M*P/]NUCHV)\GJO3Z&O\Z'NG?,WU=^<DGS*O? =1!!L:P$PJJAU-62VJ[%$*R
MMW<\1-C4Z>W3,_U7 X"18#],T>D4FJ1/6XZUSWL!NZ(?[SWB7/)\>M]K$N(=
M0$=#DM3*]IUD@3=L)NQ$MD:O'R^#1D:X+9]9SAP<K*MH&@B[/Z1WP(75 5EP
M;EW8Q4O5D%G&1%?TF<XLF)95NM_YGNL+1EE;#=LX-1]DC>M4!_LE*_X[\FAP
MA1;W]F&Y_?W;KO[P9?_F%5.0A%SW(#_A+N@.?AE>OQVUE;9\V6^4_9E7? C@
MV?;FS3/.35MU&*1'*X2VPZ.+,6WKMUU^2>'KG\%>]<FCG7K:5^^[B#OK9&+!
M2E?5X%'%'<KVD)#BWT(/O=_)7JGZSG'6,NYO?I'>TR/\*WKYS7+!UTMR +8'
MN/JI0&36SYQ[\EANX^M;0,#E_34*/S['DI!4,"_V(_2.KU#P>9&31P&O,VVZ
M,W4(>HAIZ NP^O4.O#ZZE_V!_SS6=.'^=^^(Y,(_ T&OWZ]>$?89G%M*I2VH
MR2Z4)@2](0;X'N>^79J 7,R7? XE?RHNIJT*X'L2-N^E&=Y'-:0$'RG\NXP3
MF %0RQ[?"'H".3DB2O\SCA/<.7[!TK8$;76:,X5_--_#Z]_,DJ=UI%;\<"Z%
MLI:0';,#^OZ"Z&[Z# 89=RYTVG*5?\,HDFY(12.[-!./C<>40$W5-H",,G70
MXFGS\L3F+QHY!!,,NOZ\ILDQ2RK"12Z*NDHL&UR"%C9A#/0YT[&Q:E>?0M=X
MJO./T]>F>H_5SKB\D. ?0@4JJF;HZDFB&&LRU6MQS)AQ:#\PVI89\ZBQWZ?S
M-)\RBY5-0;C8!TZ4HL?N=<Q.4HX\:KP4"IGA$+W*[/ +1D>OSS;.6%(&J$T,
MGIY]H^5]:1@S>M@;%BE'<@Q;AI*!M=%ZB56/1'%*Z^S25Q[KFO?X/0R*#7>I
M>S^=, \Q5P[[M#$/TM%YGP;N@EH'[5R",PICPS<K9F6<M?*V\@IY<^HU][K
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M-CW!%>_-=^GPA,LX :SJNZIE2TD*F.6 )"7F@_ #AW3%I,!AV!+Y$2(22M,
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MK#1<(5KN-:V'O@_RTQY>ZMALWSU(D=FK(O"IC+BJE[_&88(<#P=T.\FUV_?
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M"3TU=C$5.I>%=T>(0AP0S?;Z-U\.T\FS>]81KPT>XAS9CZ ^H"HX:1>'\S6
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M'PL% 7R*;+XG#.?R;<N%J)4[NWA%C('H6J7%@UP]1K8UAN:'W<OS@\!\OVL
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M=^,\C?%A5U2#!MCML^=VS?=.F?,N2_AW#H&B-^[1+N1U+&<NS*\Z.368KL4
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M_E,%5 Y4WFX:!4^.U<6*DJ<PZ7'WOTI6KRI+=HUUO9_@,:[O41U)#*L$C:>
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M_7M304#XWW)PN^D (:H#QC?-6%=>E/_6/(Q[]P"DA&H5*?QQC2[S>UY^8C"
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M\3O@G*7ZG^7"-4)O.L]IU71P'0%"?T"&N3L[+"1AT&S/&=^MB+["T0(CR:X
MG>H-G<8BEB&=-Y-9_'6=!L-3/M.>AT]IK<\F%+37WNJSXOG2:"O"K8+"GMK0
MZE<H%6UA^>93ED<)?+C\==/QW2[3$IW-^)+W':$&#&9'*-?)(XXP(%WR.SP[
MT4;C.5U8_J9AD1BS90L414/Y"1';_:KC_8]UBY9G'>D@$X4S5Z@['M$QE]4>
MQXN&7 *Z,_D%.ZK,Y'['TR#_Y#Y^W/6NE9(OS]\<N?/G7 R2UL;TMQ;EIKH_
M*Q?YG/E#%4V/;K"^+(,DSX4FD;?9$JF6HHNWVQG%6745D&YI!3IM^U+T/F,3
M>,XOW' CQV<[02H:_@B<@J: JO&U(U@VLVZT"IAHL[8V?AIT=#6IJV"2C&E/
MI*0, 0=!/F+OOV\_I1",K*0-/W]+$Y=NEKO9>TO;P&<M P-[NH2NWYZOF3RY
M" A55*'I,BGC3E3XO1K<M93HR!B28Z!KNM"\H51?@]=HJ9NY^##1+(=W,\05
M1/>&(;%V2PR,O3X#N:?ER?LE=>3I[XVM1ORG5^PZ$  PP6J9OB1G?L%L S^/
MUO?A-["T^L!>*Q_-U]+[#](,:1<7)P.5Q_-D?8*:>PGB8O.?DMT7'M6@;7NP
M2GH5JKC3XY1T44JB([SN@$G7$:9Q4V?HEU43+*[W?U5[P3/?U\?$)Y"M\P"5
MB5:1]<&(B$QVHV&"UJTG-RK-5+=LV;F][0U^2YJ$RSIZ+HGT(Q8. C\W7?3^
M;: WY+VY;&QC]HBZAM5&L?-Z5,?X5]RW4FFS^##QU);B_3T%FZ(CX';&N;M$
MB$T#3J+;H=RJLOH2H#7N=M\JB!]#OZ[B_A%5H7A\#NI"UJ':]1D63![*W?&2
M$'@*TLYY1_.%\D\?.\HC$#^&O+9.A2?OU(O+58NM"N3;1<A_6[S?#MAE?_=H
M'7]2#GY&4%4%YI<0JHR<^F^G[# ^%VMW$WNT0&&"_!3@&7L=<@H:2^3I;*;J
MA.@02GFMNIGS:-6!5 ;I6U/&IJJ_FDHHEH4KP;0U://84K=@".URA(S9"P?+
M7]_-%@K"BW0^%.@8VI4XBEE(1OWQ_ANWB(R#7[U%A^?2LQJ5USP]3?!_M/.>
M77.1=1[0B1D@9Z(RLRO0@R"&T5&+MW'('5U<,O#*X3 +OJF,&>AR9;<;Z"2+
M62^_T>LVS7=O4UUIW)OK@=<?0?6[+>,I S4U,='=.D$L#[F:EJSRO"X!]#!6
MZ'M"3:G#\5Q=N!M4[$?>;PN;P_A^-XXZ>NGNR-">\:W3X[\P*<(DUL))CYNR
M_<-@Y6;U!@;/<J#,I%.FI*,^Y5$X%A(%<I_&C%L6$MPQEX#K[T@575 MX9EB
M.4&+R(ZIJ SE"OW9'N;Q-5T53Q.3ZKDF]"9X5J8370G<MLNK6?U*XQ?([<QH
M%:W"QA\3PHZ)RT8]5 '-P\F(FE?O!1->A.KC\$X,=.5K-\UL95;2+P%4;3TC
MGKUW6R4(V9BL8/ U.>2-62=?>8O[@5_@]F^_\Z=(A(JRVX0O]JW8+38W815V
MHARN(.]E,C#L>%EC1-Q%%5'YT/"FC7O"S;@-],ST(8^%9!LNC(OL$S;:POPC
M(GG@4['-J9>+:;GXFQSAI-?1R+ "KW'3Q?755Y@%WUM8J9G2A%@5CJ,9P[AI
M_/#A<KBAVIS#\YWZV8) %F+</)P--G$)H"7R%0[EH<T6S!;:!5-NU\PLR;M/
M4[2(M/&Q- OA.>=W..GZ!;FBF9*8"GO\7O41FT!+*=N!^*J.2\"M5L'>?,B@
MGJZ'KJ5SHOB]&6NKD.3A&ZBZZ42P,Z3I=<-%)DEBL-"^JQOSQT*RPIC_%DO]
MUP_SCVY;?5@G/YT>_Q#W>4*QA.[;NK&J+6NK?C)V.;AG-)3Z2_>[S0FSB3\F
MVOO]LF,^\UI;!\1'[:_[G##2S8;4AYZBMGQ;QJ:))50ON\:C7J5^,FCT;:G9
MAI5R-;TDF334,5QTRKZ_!.PES%X(?_ @NZ90_Q<N+G( -*B9EN.B(O$[9*K[
MW?M:-F!?Y-46I'U/M07]D4O?]%QD*2[:E0A:.C<Y>@QZ]?G4@Y_O>Q#[G[WQ
MTY5#1.O@P;=E)V'I'W\;QH\G;';>&[ XH#73Q;^F^JZZ;O#=BQG(9 JOBX%,
MO2HL,HP3R'Z@UU_CX#CF:S;X9#8*\'#7P2';?6)]4]F XK0B=OT0X;Q/.?J_
M:DT;N>9V^N$ZCQI<F1!.HF;$D<ZQ"MM_L&4,+SZN(QF8<:+V%H]J!,2J ?JX
MV,RDD^L0T XCGA'& 96=5GTNGG110=>2,9HP/GA [O)I:>?VH>#X_M9#OB2^
M"L1."F[K&'IE>VXA6;=J!"JF$G!S<UJR@\R%^PHI829*/4L-UQ\MO8N]!-3.
M\=850**T?TU5IWW;K;[0G!,I<?AIXVV_:MZ9)&#M!=2Y!,C$S8<<?\6S1<'M
M U]WGWFE* L[*.=U':<Z^HV4NG"??Q46'^VAN Y_B\8]C9O/[%W.ZE !DD-Z
M+5YCAY39Q;9=RFUYG7*?5]^FG^]_]T$26 X PO_^#';O7Z+75BL$%%>B31[/
MWV^N"6UT2<"RS^_[4!Y>@=G<Z^/U$,QPS27@!JAC2!2"[AX8HMO)2^4*KTJ\
MISWWL:)J(OI(U><TEH$&-L['M0)FZH<704S]WEB(I]HFDY_X.L_H'*!>P*K)
MSFT3M*3#(@WCX2U<)4+$UW=SR7E;/(=@]TU)$UF\<#LZV_E.F#0NB=2$^;NJ
M,5'S/3O5?B>;TN';P*/YH.?6C.A"N3,D+@Y[-<DD:8CI>%<KT\3.WC+$4N%7
MUR;*Z</@0<\2DR87?SKCR AE\;_++=37&\5,%GO]FET#G\X+;L;Z]6EB*@ '
MGGO25MLJ3S#!IOG=.7#=J6Z*<*$8Z?U-#I" )G1^W  /&):2[A! RVGS/P2J
MD773WVMK#5[_HSO#S20ULCP^A:QLV,$T!C]W^CQE;/N$NZ)^H#'S1^PIHEV?
M\,!N^V/I/"38+3+S1J6#Z)OF.M:;=X09%FV%@Q@L9GOE"*!8,[94NU.CMUW-
M:KRPNQC1%^X$Q7M^;SH[S(ZRKR5Z9"1'H<I[#R5&+P&Q^YD\0U5ZS%CM8JA"
M#\3/AC#;/R>+E[N;K>F96&W%M3O_%_83-@#F;E; O\4,A]"5$77+-N:\I!QO
MJI:L54>JVU*_=7?5\YP) $W6$*%0IHL?4!/<ZZ[CN;#OONY<CQ25PQ)*MT[8
M*8Q>Q#UF8#F?Q[TF45,M 7EGWM9%6M>-V.TO:W,:4:50DU?0M@5N)TBK+$<>
M0Q7Q3N'UXZ+9SUFB<Y+<Z5G3[6W];-\;*?J/=(U'6PEIS=4?!&C?GS JQ#7K
MX:PBZMGDN@S;ES;7514BTTM6E<I-=""I<I*3?+)W[FEK=U_A66M1W@9\M/@%
M[>X>20.B3!H'7TN](T$43%6\9N>0H>"%TIU!N;9 $)DP*=@BFAY*6:"O$"XA
M5K.5I#5SUQN>Y3#G4\(K$]*G=-@-2XP<KH2R4']+MW!(P?P="TDO>,WV** $
M-- PGUA;&VFW6O\B7+475!#6OLJ1?+?&I-@]5)7WSOE0B9#ZTY_E4Y5U2P'H
M'39\N";A%>[<?$*P-4S-U%S=>WSI@%E[+3[TCF?Z$<![#SS@&]MLB"":X+?]
MC["#OD7ZY=L:9OV""0<?1ZR7*<=_\91,PNWA<_!N-(_<Z?WZYOK:CZMNE1M-
M6?0<PR.,>C>.US^"P; V<*51&1;.,D>X!/2D6MV/1G#C'ZFZ5-33LHN4TP?
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MUS?& X[OC8Z_(N#QOMVP6Y-N*1T2F/."L XLB-=(+'WEJ7;[WH@OHEA=DC3
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M-]5*?Y$$7TI7E\X$?VY$Q<EIEV5/'SD5.>^4FS[^9T$EB;J<_I^0Q(\7(C-
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M\U@>N_+'\>I+@(/>8DR(W2(+VX+"P7(N$._10VUBU'[:-"S'7@-)BMFTNP3
M4B?>%87]$JP[WS"BHFH0CD/KN")J047@&[D@T*"+XX*>6J[31^-\'L=/BD;E
MH3D959X_QK7>+Y9,C^"PL-M+RQ!:7&V#/5VNTMT@$>3LO-_-T(&N>+JFY4)D
M*:1*MLN6'FR*UD'&'0XFF,TJCWYJI])>_2A",5 T'\^@<0DXFMG-Z!R9G9L_
M;AQ7,G+R=ZZ=L6&IR=26>4EJI7E-0E\QQ3?^$B!6@RN,:J99N010@CM-\.Z8
MEMN"-1R*LVZ[.EUW'L9Q5-Z]\7C84\$)5 JYK^+SI=,+1\[3Z?VB/C+W7J1K
M6)O6 X-CWX0W<:E+!07SD(0B]=<3ZE,HC&Z9MPI#Y_J8S[[?DS*&LONB#3TF
M:=)^"+64.NG2&5<N:F1-=VY-GLL9%$Y1A^,B>'4S:N\K:NF+&X5JVF_C9R1*
MG>$</H$.#3B1@^X"6WH^7;;03_ /CS=/]+B"6AKH$FVO5U^0FX\1-+\^>GBN
M<]^LC"1IS<3XY44D[0M8;MK.!J88W]LVS4[STPFN$RG([A[.J78M.]OIZS&F
M7/K4U_:*T@H[?$92>!YQCHB7QOM(]:&=M9FCV\;6&[6^KNLGE/H!^4Y4)A@M
M&2UR%4FS7XN3QQ1J,?T4RU'58LU,%+)^LEF'&%]L.E8)O<@ .01Y6$^*-#LB
MK$5_#6=N>J]:U>* =QG<*=M6WUJ]/SXNG_K%BZ;KT;MEHXT=%[VWK!DYWC6O
M--IQYW4BDX,(X@7GBB>,DO !__A<&Q_6SAX5>7BUQVPTE6HGU*2I!!.?!TON
MF1C,*!T1'LB73UT"PGD8FBUQ'NB>'.G:R#/U''M.[_ZUZ.;I]R2?LJG_*LT<
MLX0WFW]\/>MCX:]KE(@:<CJN]L27*%0C,HVRWDCSRHDOMC^>DSU7Y!EIAJ5@
M/%FG;'GB.U_C/;[K?N.NSFG]8LA9VMZAM_P1T9):I]N["MJE.9?!YZ.124>+
M L]GCKR+7<8'WMYQ67<>!#(\LN[R6?$Z/"Q/)]XF=L.YI$?B9%K)FEVCJRG*
M>$/-UQBN2TA=?RWR:(0<7LA);XNXTGP&7):8Y9T*3& 2&T$<>WTO-L/(2WKG
M.'W$D[+OJ<0 D%;=:)E-I08;U5Z.%_38I4$O1S=:EQ5C!RX!G:F:WA[4)R,.
MV$^##VCGXUU#&^0WZI \[I^Q94^CAG[8'U#R6!7I%G_'ROT9^/$]N]Q9WL4G
MT-H%^06S-DL,,@464K>6*C"]F=!/Y*63>X(0$D0X,36DN+=PS6^N'2[W[N$%
M3$-A3L D:M?^[W$Y4'PG7PS'Q@DBQ U32\ =%1%T<(PO]&A<;*YI#]9OJ$;M
MC,X-M,=T1(C$^G/22B2ZSL+<RCE_N:/*KX.KN@).CB,F*^9UI(L'F]N&?W1K
MW>X3[L(&70EE)QC5 AB)IAGI%F<P_ZS$Z(YHLEP8D@)\?*)E[SF;TQ8X\VOC
M=X!<_%(V.) FJA^HI$N;>X^)P2C1W)#29RNPB=_5YLQ'F;.0V=PQM2C7N.BS
M^F^[0BV?K&K<3[BH(+^X=>/LK"*/%^$V_H(G5(6K/%Q%M)WO^$2&J)OAQ9"1
M>VN[ACKIY./A7F\=S.LBM9G-SQ^G8GO;Q7#$&S4?,X1K'K(2EKH65W^X<CA2
M ^$XEP%'Z>'C<'&]2S0XWT1I:X;]+;"2A%+%V]@%%L>8KZ\Y;LBU&\UO 4_J
MK@ >K'(;;'O^4)A-X(,.]X/G!@]$BG+S@A_UUD"S.B>(RZ49T^&OE,3,A:NW
MC%,N=ESUX:(J_D"A<X>&B<U]I_:--_*JG.YLLNSX(]T"H5Z\8:&)L)&7GME
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MC(@C==?D$[*]FEO-W.A_OI0MG$' ?'Q0/,R@UY> <#@KMR*2%:_]?%+:TN_
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MMCW[8.;AEB )AW(+3.M@)(:'H5D9.]@Y$T!L\69'5+OUO^4S>%C"PDN1\UN
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MZG?G[5LS;T5QL@.D_O%YW)TIFEL*AX?EK;#7,!;H8.XU;$]JT+?^K\XJ?),
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M8N3I&J7O';+$0N[5*R&?2A3#B<>!G,69^]%!K_^Z<[0KO$#D5SF!O[341>?
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M5V1TP>HKJY:0% 2KWT%17Y9!M-L_-$-+5%_C DNNMHETF[SX^"P5#>]%CU\
M6& .'K$\-7O(XI!_""9^ 16; 49UXPL<#8^;#7U:EB4H$GT:K@:>W78;>@*>
MY5TYB5I/.5$E92Z@+&[BM$,R)>]H]<NPT00"TX''ZTJ?*,Z^MTJ/@AQYICLZ
M#B$#^N^VN&]C6Q*R)E/FU,3VQ/]Y8T+%_[Y<><O_0+U5>!D^];6#O:@3'K_
M3_K.6YN)_@?]L(EE6RB-3_/G(ZKC8;<A(#\V> 6^6[)L#C3!^8(AVAWU8\^E
MT='KC"I4FPPV59^OWVP3T[_5@@N_!>T+D2,$8RXU0XEYC/@(TR3G+B)B;S)[
M\RH=YEF&'&6E% J8"=C_S_<L3W[STNT9:<H#Z.10U)/_EY-SC!_Y+^?W4'=)
MLJ>2OD44(##T,RB !./1HK&O=''N#HHG,U%@; 4)%$MP%LBD..>6I\?D U:S
M*?HQOC/ZPX7B!>C0 J %?0^=7P=R;_#<F*6F\MTGH$?4D^-7%AKAC 2D"C;T
M W@;7>+R-@;LX^?>N.0SOOP.J&U,2B=S;)%%/G3?]8^L,_]V8$*LE;.VKU0'
M1=I>;B@R>D8I8WGHX<PX*:-;8NA:J8R8A0 MA_,P_8*B%[HB,+'BW"-$8+2.
M3>3O!"]#]]J+Z.WX=;D=6,4;"^@<3\UJ[ZW%^(KRKY1*CMULFZCA?&CCKC)K
M*SLI$DH',>NX"V4<$YES,<O8+1[@4,L[V3E'#?Q,:MFWC<;QX,T)ET:MS3*@
M \7BXA+X;?.C"$OI'[6=N++:ER#*I&?"[*!9>[Q[6J<+CD-'?#.)//QKGA>?
M2^"O[/^XF2,SML<7<E7?*^L"T%9,V=G*?0F"0=#KQ*>J=:,B[#;R#QE%/^%X
MG[%9>9*F'5_X\I!<SZ*[0#="Z)>1U*BE,A*UCLX#;8?ZV%?5#681KKOT'%2T
M'&RH(50KH+)''<>2@/CGX2ABJ4F-C=NJA"\H+"MS)I=>B*".S>A8I Z1%XAJ
MED7NT'OAWR&(?-< %,/76-&EH[0G/9A,Z_6B)P #52: @5IPP-&_2&;H\K-J
MH'HG[ .9GN#EY$6J*FEG*5J]6ULE4JB9S[MJ[908%.^4NZ_,'5GN9ODVTLZG
M>"M W\IJIH-OSR'M=O7WU$A:[\X52@#Z+[P+/A-L2P@KGKMT.MYS5K/35>%G
MZWPWE-\H7&.E\NM6H+!U68'%(F]#G[K53%'#5;#SM96V+VU9U^K 7N]4P(-F
MHF(E=GE"&SRW?-<FI&L?<#W[>YW8DZ*&^?)%12#K^ F%K=X.*/I^LT'E'AIH
M4;*J[@&O!0;<.>(/Y*55E]N.PX/>+UX!6N&<#".ZE&0L*HB*GMN*=>5A:8;
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MHG(5=J'!JU[4UIP\;*E[LY=@J\>ZWK "SEF'"F&1].O33O2.]%RTCFZ&V2+
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M/YZ&\L;5;#NNV02M(]@4A&RPD<7HL7O!4R.2O;]^9+1[M>0D#IG)[&',\[I
MR/*>/#K4=#MKL%IF4%Y4*772&TC:1BV%F5O/%7K[C\_H@;=%7E>\NPH^M022
M]>H-6HFK-0V\?QFZ][' ;BA71_9X[.0K7<DUP X8'@CL^7X-B"A=ISO.@M<E
M<;9834L+%=!\(@>^)XA?O.3P:PZIZ0N]9V;"0ZFT(:82\^0IU)!K.RXW,),0
MB0_ R?>#R A_P5EB64X30<G&5O#Y/N0G+^EXE=C%D06\!X%\N>X?>PK1>3:Q
M,CFL=S735\2H(DY?L[8Y3=KG/9=0P'F;?#J/'>&81Q,LVY"E,[7@JV6*XEI9
MKK2A%])O0B*\%2*Y[7,WO&/P[$0=%H)6IH79NF7%*5)XXNF\F:;8BP>;27[)
MH"A.1)'MHXROD.>%2@+3M&V5 PJ7$#MWA=BH\]1;F/[[ ZQ7@C58EBZ=:!BG
M+\=>DCG$OWMVK+DC I*$F<8E9-R$<-O/ZY*S.5R,Q8JNX9VQC3J92X6Q3*,E
M29]JN+GI'Y+F*M*$G&"=3RW&%;C23,\^YE_"/J*1A^J/./\)H]9DR,Y.W$.V
MY:'R_A4YEIRLQ$A<"CK6L_;_J1>_<[3Y5JS[TSV.[.UDYYG?)&5E[Q^7*+^.
M,"0QH T# &0X;ST1Z+$/TQ+^D#0F\7,GE^+BY.M-4@Y*ZX$D'G6>"H<"H8-.
M0]52.VZ2$XD+/!V1DN+RGT4",UYP7=Z"$@_K"BHSN^VC>3N;*GE*I?.-+N>V
MIV\?N?7<#_(M.@(C^K029]RGPVSRE]=(JJKX9D3@B%J"LN?W7[^(_]3<WEYZ
MM\^8M$]>"8V!=2K K%;)B<,@FN,KY0J>)APBNB*_;19>E?]&Q/IGCN'&%3H4
M=69?S",[ZN&,AN,?1NU'A/A+KF(4<7;S2_C^GG1I!B1RM6^$%^HI4F5D_HF1
MB7?-_BM\I4BWC.F9H2[3,U8 R7O ,>F'_Q115?XW!4*:[>7H\#WYWOO 2V E
M0"Y%X</2^*U; DR>!R&>SRCO\29 BKZ3O] HO^\Y\YP-J"M;/$ZB;-C<%-FW
M$C2<OD!VMZ[F)\<#4=X3#)B9H'GUK?5MYI0CC%H"AEF$@(=S(>M';.8>'B^2
MGZI6R?8YI[/$%8058QX?M=1]%N@=+<S",%6VM*673D5VS?1J=>4]KFGYO)%/
M5K>BH[GW;3G/-9F1O@=P2YT/\&_9ZXW:E#>3-E\6^TO?**RAA\R^9!QE6SNX
M;$N>\^'Z3QOQ>VNBI+N!D:4H=9]+Y?I/PT$;$G82M_TY+U]ZA@;BXK#>X/1_
M:_/<^V9;'46*0+%NCUHLU*VSM"]?*G79;OJY8::^HO\R7V-\ZYL.K)LX=[?!
M8*U"L'BK1G?S-/^0('D _]%,HE!./4)+D:X1U0[H\Z2]][1']5YD-\Q^TM?@
MX4.0VZ1.&KT6[X4O5/4DFE9%E?N8)TE+B)Q<$@V[311PL)3!2D54PAR>-;+X
M)658)RO3M9: ?+*/<G/;!.>MDV6G%6SD<J/@>^ R%$ZBVJ!TIN@A_W0QY<='
MV=^*F7@+&[4>I2#T4<ZZY2\*=Z;#OZ%DGS=D:O4B]P:/0]2?CTG\VS6%;OP:
MH.'K]HY1CY[<4L#AO^3*K?3ZQV%Y>\_HOJ5\O:#;?,9]_/4F'\<D:6Y/B+.@
MV6S=*MW.U"ZROFOQC:E @*V+E8IXKMKQ"3'UB.8/AN51>8@HX;X?#-GLHL>*
M1%D?W4+UZ[+:*T7!-;9ZWOVV,@BIR-G8+V#<Y-L>JF_,:..0-"6,9OLD' 8J
M*\T=C%4, FP^ 0X@C+>HGQ8^.2'G.6+"+U\:_0U*7\#;*:DL!(W#'1N;WU.Y
MM/YCD171T3'&EU<\V>(^7WNZ78^?JRH./S%[WUB+$0M(O"*X;K8$+U\#%#+Q
M%/BB;HFFYO1;!I!YN_J?AM)"0C,4VDXXC8*I]/.B&OOIEZ'>91DTVO?C^%MI
ME.P%#6/S>$VU2O[X$$>R['<W&5^#"X'<_Y'LBX\+7B;GS07T>SDZY7ZM48S8
M5<Z3Q(C0*_BN3,B5<JTE/6/3A]1V,\]I6H&B):+=62/,WDA2V6;G?KF;(;V-
MK92IUY(*:!^[>94]A59Z9?RDM6DO)V83H4'PP\=?<A'>S9W\N1ML-M5J6V:V
MNF/,L.28R>C]BWG3^MWN-VX\S]<^>=QLF_ZI)%:Z+QUG.Q<'?;0$[JA.#Y6G
M"GM<^L]-PU-$%<G.G[]^BP67&!\LNV;!OF>.>U3L7/S&]/NI\\?D!PNC-R*Y
MC\)&GP!..F3RZ*#\^+_;<ZI4+:K\M]L^MQ!OKJS>/[H_AYDM 1VCSFAW//]<
M%Z?FNG1''J.3G'MTE82Z3]!=J7E>"&%<?+J4M$IF5-MY$XSGN]E7C])9@/?/
M^F=F(R-FVK-*A:3UU$9_X[JYC:G5N<,2(M\KG>+++QT(8G\GU(31K@SX2@>D
M4665JT]W.FTVY$F&_K HKE+;L1P3[4/<Z%XCP=%KF<Y(&-=?OE(NCI.(,_;J
MB5*H'I7S14\BJ&%VJY%BP;98'0RY__H>'*-H-'D-,$S7:O_Y[O!-@-?0SF8+
MO;$;.2#F7+P/2!]L^RA]#?[!8\_?<^<TES\&&=!30Y:[X-9U_FKQ1T>5"HCV
M,\G570+_5361/5AO[D !Y"HP<8#VT_0.>?JUN?/\E5FJ_RU,(KBK+1,6UWZC
M#O<8;_G'O*9A^N%]JR,W'L.D+Z@7H5Y>GG&!QY)XG4NM8.F4#B5I/$/(FEE*
M@<5(L6._+G.<M?/.*S63]NZC=.O51^TF5]^/\Y"/NM>98]$.![["(,U)XHA/
M;9C"NS75^O=\W$_>MLGN/0-. V.)(A#-3F1$0GHI^(6[+V>>;83=L\GS<-=Y
MV>7LTSV\]V\YRP*N4EN:?8>!%/ZWE=.D4Y,($N@-@ADVKR^/'B_?"V(EZ"$Y
M_X0SS_)C1!Z)"1^9[>N:!9#$,K'MS2("6\4K?T.Y)X7K16F77GH7O0K;/^P,
M8].])1:Z7+U$]"$9_W]XSRK\PVQ:Z(O_KF3HO[7_:!@E,.;T/)<PR31 JBBV
M./XN564BH74<.+<A_.C <Q1VL5#T[;W"V3I+-]WM8.W)+#6<70;32:V@B ;?
M%Q+6RU^%G^0I":GXOWL&67^*P8Q='BJLW\I:["GK1X/[7W+%<E<63M<1SG0O
MU0J3!OJ5(EN%K@&17B)\79HW<VV_F'>EQ'_=FXPKFT28&@J/D/\>RT>M"*Z+
M,/2IWNL^;Q 7+BLLDD'M#DF4FR*-BK CCC,\YS%SB+4OJYP^Y[<M-%"?KE8?
MSM->265;GZ/S*\'4?_<\T789L)RF=ZD&-S45159HX;'\V-ZY\7'[0.+99^EI
MN\^  @! L?P0"5--I"I]QRQ@R_K3,.YGJBS:28?.9ZJQIK[R^^H6]">H<"ZV
MGE^31F&/?+^(G,Z1FD9FSEC=0DOQH2V.K[T!)$ $_)U,IE4091RKCT]T9RXM
M6;R#Y;^]^N1^I/H @"O0>P=<O +$GJ:@XI^NJDVX/JBM:7B6U,_^&-M*T_ML
ML+_>=0)<N2DKHI]D914Z>+@O8A$9IW<*,7W]O7 ]62]+XS!EN8&HBF8;#<G&
MT8J8[.\][=TRR=#0,N@U3#6^*6SN6%S(L_!PTT,6HR:^FDDB*\M)Q\'^*F>^
MGZM)*0]MF;\1 V#KA];5Z3U9$IO*!.CG3H?);%?RKY'L_)>\B<OQB#!CG!H'
M]=%O!Q*'?AB.:$ ;^F_RK76U#\%$8%KC]5ZG,1)T-&1+NV-0^X1(UW:8C?62
MV7JOR/&)A/<]8)#O/6!771$ E\8A>D$4>*#67V#4G=[?3&.R8TXR5YF26BEP
M2GX^QMH7>&'<M2)U515L5;$KS:X3*@&O<S0F'V+981&XQVQ^_L%[H'-O4>GD
M:+01]3/SC$B_RH[/7.L6_YBG$Y"10C/\:&3^( AV\E[I/3[Q\C4^??UAX=\!
M+YTKI78?Z"Y)X9JVJ1>Q/SEP_=JY]4>$=F!U\MBE_[I2A3M!B^$<X\8GL@\]
M'6_YR)M+?LXDV=Y6X=3(/(N@),BXY0\D!)6XCJKQ"KP;:E.UU"D*$5ZC6[B%
M[C%F5A+'?2]7,(8_T!1)?7083BTNH!V6*]L7Y/.5[C:6V!:"IK*OQJY&/:R/
M'+"R29XGXJQ9J2FTO1-[,B/I&'=R>=K2.[@$)Q-2'R1160[?B; !^F"\"D#;
M;= &A_9;V(8/SC156=_FS:*MU&(+*;FT"FYFHY/[>:^<C[J)E"0%OR\LHU!!
M<%K314<D(?,+"\/\MT(,1=(3WKN$A<%WWO-P1I)#XU@%43A$Q\B='.^U]2;X
M9AEO8JG*+TLVQKA&MGF5*<+>EGLH.R>B%Y8@=]:U&E7S*$\DSBXIDT-%8?IA
M]J<F3N\YKN*VD.T*M9$U3MJ['^O5C[]6;%\Y)JTO#ESV;$OB1/=342.J:XV8
MYS"TYA46YK;2+/VEB&GVC<?SI2?/R4+%1H-B )<JOKC5SJRS\6"SHJ4]SYXM
MF:W#3/?/'I0-K$%8+R<(5&#%?$3R>RQ*LP0N^CR2S7*AH>_/S^= /E:^:LP.
MN(KF&]Z_ESDM,*V@T 2<E06Q-V[ZP"OC0V:%X%)LGO; LW3^4..BHW44&XCR
M:C;]:LN]S7VQ]1XD0V2!#A.?XG*K,L]Z/FZZTJ^_]N0LIW\2'DG)F)0KTZ\8
MY N?!%%!-/_!^J7>2LI_T^OJ".AZ7\9Q#6CM]/)$-O,GRZ!-U@W5QF\:O([0
ME0/(4R:_OW?T]E \5Q&4RC\JNZ?YWTAH_4>_!E-^ !R$0_0@*"&4<Z-SDO(.
M?![!L2H9](Z)MLI\O"D= .]S^[9M3W18 C04(0=S70T;=PZ4Q7_+?9@\JT-^
MO]U51'; +/%^\$@\:S#'?N<8G*?-$[T[EQ]>:4QW4^Y'_'I1S=P;^3]_ SW]
M8G+M>'/EQ[X;*&T]]:9*LR#5X8P=:/K/?6-0O5LBY:\=5(Z>&MK(YQ-OA(TA
M&W6AR&VEK[/2D3!G89Y^+BZ<SZF<3[-=T;?%I2_WO\BU)K*+Z9;U^_F+NL\U
M=N>17@/6\O/(%311\B-\X/'C^1/,+?'O%5Z%FD(8-VK; <&F-,&4SKWILR,=
MO FR.#Y8JV0E6'KBP4<1]A>G'MR&V5('E"4D'_YT2IX3\+4+ZS_F30-.P;&]
MH_J^3V<T)*J]PE._H6^=YPG"%(6KK@'67,"XW[/E^@)]5K]?IKYDW=J.W&I;
ME:BT'0$2R,UR2>VO 3<9\'E6E\ICQ?@HO1!0]Z<]&A?A*EO^2LI?QO?-.*P;
MGU_,'6MAT]?A45 !O-.PR80[YJ PR"'7)U+9B[5D\%P'#@Z^8">"K@$.H'"Y
M603N^ZH^+I@>KV?WDVZS3(*"YV#S(^N@$G%;!E[33AL<@H/O5Z\#J78N;)?_
M1F(6&FKT1*\_0IXO+E_2:QL VBYI@^;6WTC'B:'<&1]C$X*RC7X]";@*T BM
M5#&X!M14NY9/GB;[>?AK+ART.UR)2F(O9,_()L:\*MK3&)A27[\NV3'0,[D0
M$ U*#6EO/3@#E=1(WZ![<1OTLA,>K21+D)J3<&<P"7X^3JII5?PJ72Z<S)VZ
M!#7/U-_H.;B=S]0+*292\F#S7DT<#];%J]QKT]N];;F[Z"46::2\TA+0=T]F
M+X&\\A7,%1RU(H[E*DF4X--MKDMBGD]E>U?XH3&!V(?(%^<206FD]&S.>.\S
M QDBOU6+%/1T93MZ54&\#=V&+KR5#Q('GP3+]T@H1HK9LI9]=C8X54CXG%VF
MHI-F%(GA_<,FG%MRC(B#,?-,@^S=&2%9JI.$A8T)OH:TU2%C_FN W0.PL!1-
M&8?5L]^WY.>P&5ATIS11[JK1/1]1TYI  [-,&0TGIR1=SBUY HI- .7 =-4O
MC?"A*V,F6&^'I#'4WNG/*'K^0\)/37ZWYZ21Q/94-)"\G9I /=5^?SG8I#U(
M34$W733 _EVHDNV*+25@;XP)OV6[KGK+D^CZ&=MNW ,)7!BE;*Z,+V;M196K
M?$[)JZGT9Y-*2XI?#-&9\=*^-]8D*#@J'NRG8\3*X4MG&U$^NNRD5Y)>:RBP
MPU_T*$]\2@?QFP<+6N<+IXL(%L0.;>T]IU\TU?3TV,?V# U%1'J1K*';O5<0
M5NUT>&]S[&KH<0N(WN(>QN9%Z.XV]&J?\<8"7W;V&2C1E+ -XO2%QQ ?3"D(
MVQ;G<!Z?6T7*'^O?A?#,EP5W%,1_]>69;-^=@0KA8:@_41(A4I?ZD7^,-1W>
M>=@9V:?<^ZBHSB>CX)D(!5D/B+&YL9OL?K:70;U=+S!MV^D=G8@KG2KFJPF2
MJ/]Y;NE)#7W JN&;3^>VM)2O+C!87%:J5]9^MH I&OM:2@OI1X-!>,'34&SB
MQWJFB2H1=,-TSOMXUK)RYC7: K@+U! CE]96Y$C% +;HIQPC5ASH-P4F?J$.
MBDNX$MS];>W1E*E=_W@\50(C8"&B[I=NOQN\;"X9*,GT^',QVR ?D]UYRD)_
MLQ1_V6FCKN6+=.9)H6JUIU6%=U37=.9V]).]GLCE0B0G,QTE#C*;G>U:,R++
M52HZJT/-WC]55P  -E+V!;.F"6^^.C(?:7F7O8F,4#\,QV50<%@[R (342/.
M3DEC4EDPINH;ZYKRX>&YY)D33[2#@N>9\$7K'PE6:XC8QKL$G;FM*07Y$LOT
M>OJEI_]8.:JSKG0&@%W\QTP/CX)#@A'4Y;K=S8>?9Q0Q[,&SYD?$?7=__.]
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M>O[IB'J[#^C<069A^]?L/Q"9'0X=+;DF,6^?%JA,%3ZNNALI50JX^P?3T>=
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MF@#R'NZ$[6UP.(J4(+P#KC[_@K?!='?4!U;6-5S9S90*VUY8X#>D:=V':VX
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MRN>:YBG/"YN)!$IW[AKN]VON.XO7&OLM^9#I+J\:)M+"N5E+7.2U[*UYZ U
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M27F%>.M]NZ&S>W4?3Q?<A]=T(^^]O?V,WOVNG *]L&YA2R:I_;#K\3*>[U<
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M49Y[XD3[JOA/3=A<HB!=7GZ_9@V^2<MA7'=QO@KU;%7GGRM)TTW\_4/>26C
MQCA&[@6?89*0CJA^(NC"ZWPC=?DS'*3,>YW1:(NIT:QM3#E:O=+YZ?T\3B'Q
M7DM< "DQ8(NS%J1;@/H0T<QICM,\O((=S'4;D\W?6<O\\(TXY&+88@MX[;N#
MIUOMQ':'\6)JPN.V)O:,5F;EX_=ZCP#$MSRZ "S(5Q@0G@[1 :3]W(!B7@);
MVLM39L:?6HEBBG[9!A X:TE .HUVQ^Q?PW#9G>PN-BTSA8V,/@%%@LX?_9GE
M)7.UR(LM,A,1DC8?2@^6_9N[Y0;%862M: ]<;GA?F5X(&;-/_]R05)&I']+S
MPSXL]?'I8]S3-2],?LQ08WUB&JMV8M??&GJC6B,H/IL]U* ;[N)TXM2%H(,!
M(5L:F.7(DQ(Y5,U:8U7$P5LVO?#/%#I+8KO30;[3J\N1RJQ@5,1R6[UTON@?
MS/J2X32-PCO/$(QI7P9N!_[*Y*]=V[_;I(UT*X,@=6S('NGCC'=><9$'(C2W
M,W0\$H=O %8H2PPBO&+&!A<<6O&*$"-"_27GSPW@=<=3M0Q+@UMK+][9#V[?
MD:+R,3T]]%C![?+V$9#?MY@%\ZH$M4V[8,M4\X51,?S*HV.%=XKCG;E3YPM/
MMO9G5^>1Y! 2=-A7U\\GJ>UG4]4)CCW6) /1^M)NW>SXIF'D%$JL4>_*G= '
M$Y[\K"34*)=O7HV0JHU[17/KG.\U$,W2'WSMT0E#.H(K1?8*KS1Q_-1AS8+3
M0D(G_>0>+N6#@F_O&))VK8(:NO^#$=-G;Z^C_R&3OP06;$B%F;K?6=+18U49
M@= YKVIJ5260&'BL%M_^)(,Q23Y)@NAK]$OK;<,2S6*E)OG*[2ZA1:?>@:K3
M$7RP8)NQD<!;[(]7,#H:LL3?JFE9LN.)3_K.JH<<%(0+><=ZKL\QR?MQ*ZC[
MA*%S>;L011E:<S/[:-N/O8 K/LO4+TNO5?(^<C1_^&1"S+(.D\15=%"N7N#3
M)3[6YY[]&=5P!;"\B']WCS\C(.T?6>9LVSK+PREA^M$4S<088")<KI)Q4(%O
MD5#TX9-*+R_W?5CBU@V@G.G?+]Y.60Y7],,*;]I6/]H\U D931&IM,X)%W[*
MLC@.3#;#+1Q+%'4P_)EE% >;Y9N3\DLYZ<?R""K*9<L:;IGIC,8T^YTJ#2!(
M*2)E&Z<I2?42%57363U</(H4/M5^.@3Z:O_S#W6G 9AB./DOC$ZR]R=C5SKU
MC\)ZP/[W$B$]']EO #2[0;[^RC> Z]0;@%T1I<PJ#RJ\N>]X7B?.DCQ"_4?#
M3R/<A]O>A"8J@57J0!C+U W 29<65]-1_15TIA[J8@NG]"EH_RRJP-SX1_U<
M=8T#;G:=>9WFN<NF30:ZMT,P5.89?]/6_\ HY7F$%]&Q==CB&LN@ORNE-:,(
M37"N6;HFBQ7GY]RDH8I-(W[K1P5]WUU_>;);C#47.1=#"7ZFZ()WN3HYCFL[
M:GK=70FCSV@GC:03G(_ 2;K9RW6GW/9EC[I90YZ__IV=J==RZZ<[2\H2).SN
M&]LHH+<:>%>3.U2-KSQ;GEV\J-#V[ &M^BJ_BJ@8N QN90;\";RM?<6W(PX%
M5^)";:M2[@E/K72*=S]\:"&CUKM_V+U] NX&AQK@#3!NF(V&')%-B0-9HF?\
M? !L=W\,2?XKD^KWQ#$GE428/D)?A0:&J1-$>N!"DS\ME!_!T[=/^4@\2,=]
M8FOW%#DH)$,@G;_2VY;W^HFY;.\280KX>)KE(Y0_%]DVU>SF'^B]=Q7,?"UP
M2?<K  14EKL!M,J?ZM['>;>Q(MH;>DZ6V7&^Y+8IIRQZZTD\K[LA#V,?I,5N
M=5K_;SP&'/\2>]XF1'5G,@[&YQ#$)9S/'>QWX?\E:A8O#^>_SOSW2CYE,L+
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MWP+49)S_=C.,;L/$<"&8U([73HPIE356E-49('$B <E/JMPL!T\O5(##);
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M\6]?#='?CV;UDY3"GU25*2GVRN_9=QQYA(K *<U8ALQ$!T\&W.SEW7OK'U2
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M-G[Z[Z5;"SV:Q&+6/UG2&W>LV 2O-+7U3;HU"+;',[M4);FFCP)U"-I3*H_
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M:#W)2YKH)OOI3U<.:;^R5M';<]HN[R05D8]NLMDBS?H)O@*#TH;2K]16J=(
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MXCZ\!Q=MGXJ,/J@0N\EL-N-0WCS2;5/QTE'_&6,F3WYWT_R<P[[39(KD97;
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M:\8<'4=<A^@ZQXV#K7QJJ*";K?"X<]ILEYEQYQ7 )3$C(O7OHS[@PV$M="4
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MY/<GAS%*FG<^R'-? 2JA!5#48JW+._*N7+)QR[J4COH9YWQ.FH9P*Z%/Z,R
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M3'&:,RF#W[=A!,ZBT2"E4-.+'][#]*'V7_[*FOKX"]:B2&[_U9+C8_=%I2_
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M%_( ]^UA+3V-28'<<LG3)$/M_/ME/&.6FV:Y(W/(G1/,KOTDK]DK$Z[;$G5
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M[GWA\@RG5-<C H<'<@1.P#&&%*>[1S3D_H+UT%IEY_*N'YH4BW3YJ\_H_))
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M%8LVKXW@7+V)_ZN]]PYK\MGVQ5]L"%*4WJ,"@A01$.E$1+J @(C4*%5$.DB
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M(MF3=Y4O6"G2JNPBAZ1&-'8YRTG)>4.K:VYMXW)S>4.[ .SY7'=8Z,C1[B8
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M#G+V-[XXU1A8(&_O&/7$I/N]>^=_PV! J2LGZ=OG:+7W&/,N"E EO^:'08;
M.0=/#DJN$V_@SC@>;\3WS']2[WHLK1P*^&%%5N[:>5VY# VL_6AV]U9[7UB&
M7I70VY.=[NMCJ'>#/]ON>RFL:DI<8 J_:7BA$DOO^Z#UF_>+C)0<MLFJH:8S
MV_DQ<"&"2$N?2K,(_GA$2M6I?7^6#Y]:&# 7NT6J#>#!1 NJ #PGR+<,)ZO/
M'%H%/^9Z]>$+*_?1$$_>.3LE'[(/)!+$CGJP$04"^5U$RHF3KHVC?9<\W.QE
M7U^5]=H\A[ZNT'T_>A7.0_X$YFX6&=?PFB'(G:A)5#^Q*>_4?H\X'N$S3N4P
MD*W';MC4X RGNXTY[6JG.[V.>0X)1W0X5<TH^8H.Q>B9YN8++4TN27K\1!C/
M30&>"YHIF"TDN\( 77M%9W^\R*GDF47ZE.6^0F>NH:'/<K?AHDO.KH+;D@@,
M\M;K#C N(I9CO.%+,E&; A15!:OC$LCTPA@/_HE6YBB3Z6OQ=ME?Q!^=2D<$
MAV!5YK;Y7;=.4U7IE6;P2>[P[*TCZZ"Z+D,9S\>+> I O[\U:[Y:B(^9\?NX
M)R 49JISWVVT(EY3O-)G[T008F<E%+\7#U-(E5? !"I^H^\9CF QV7UQT:57
M6<,JMSA!$^J&869%E#IDGC7K*=M\R!7XJMF<?L=W/J&YV*7I('AQQVW& P35
MZ"K=)W,-/_*#[D:"'5\HWKJF$CKAG.[40$_6(A^'#Z!8X*>@R1IEW^>&/"0W
MY$ZNK9]]/1]PAB$Z[H7(V<U@)<SPCB:NIC,9.M!"!N&/?_5@'R(]9;46?,*E
M]Y.[G%EQL0G>-[,196$>96%S$P[18'V*?)I5VHW!^\X;E@C4ER?IZ=KR?>O9
M&"2*=V0Q^B 8?1[>9?C<S,D=T:4][CBR*JPSF/\L>P@K\GE:HKAHJ>]A(#M;
M7 -(RIH"9%96[2TN_BNQ2_>;C;8_XI40F!_\82G-VNAJ;H'%W1O1-G.-]4]&
MS6X[5#OY8IB-VD*D?H"B&O7?0HUN9EG@.0I=WKM4+UNZ-O3<$7TA*A&@ZGG"
M4,E_67PK83>#*H]Y\&\4H"*WN=#1K[@5N;*+^UI=/>8V(9MC+59J_5XSHW2D
MY=,B-UJ#^!-F3BJF .Y2!%%TM#-.OK58N4-)/M1C0R6\5F?=#F27\MG]#I;
M3#N0"\ _P*=1.(N$4S#9ZD$R/QQ--HJ'V1=T7LAB&+.K&BRS!J^/WPNINZF(
MB?>\;$B';ITN0Q-9D['.:YW88Z1LQ$/]-2U&#OV??OI2S \3E'($=1>$7(^1
MO!OO25WSZ80_@;=FX;0\CA.%$PP)H7@D&B^5<.-9@(32NU,?K=6$[=H\QV\K
M=BN*#-22-OHK,^1OE-4,^,;PNJEU_1"*..6J8_]$%!OWN(".I^ 3/UIH+@V8
M;>:$2>#\VYCIEJ:8<7>2W7)= H,;;XFIL[Q]WA7J7W>K;LZ!>5.5D_;L8H*>
MY3^_*OS?Y]5%)003\7">A^ =4@'\I4\:.1$N2[S;UWR:(&B!M\V5,+B:]:A_
M?$P9&.AY<OOX)R$^^P1+LONOMQ#[%^H32/"'D -3+T@PHM50;H-U'(IJY;ER
M819,;TM*.+0TDZANM1A&I/E4 ,[*M0??_Q00J0EF1K3JJTE#B^Y6*XFT'A:A
MF P*Y(H>ZMI[]GT\=8''_JQ-[5VR>TX^%E(RS0SSN8_-8EJJ_\BB]7*8PZLW
MV(YY0]+)7>"JZ:<QK]8YIT;37<]^.+\ZSEZ]O,\H8BYBMDMG_@W'\;& M2'>
MH*L.$C)0@4,M'\A+"E!IOL8_"QFIF.7+6U^*3T!:+PQ&GA\UF2%#I)Z_#>#J
MOK_4>2RK9)H+]0 <00&.^?[<8>9=2:WWUADY)5'PE&EN_=[#X;;I! 1CL]1/
MCUGF$RN[+P]@QOO)>DDY0@]/W$TU@?(3D(N'N]FXC2@*\! 1R2/2P6]OTA36
M-I88\RAUL[RK2%Y1@FDJ<A.I37#-'B=_0U2$K[_!V'A;%:V9?+WA+C"'2KH0
M*\X1/&&ON+*3S3S!",)NM*DB.LH)&KKXZH2 65'K[@MO^#!?2YCZ:W?0[,.$
MAEG:,"*=G1^8P_6'DEQ:O%/#B_-8I"$%,(;T^G=,1PAB(.U2D9!*HW 5B.1&
MAP>KZV[QAW'MX,9':9[?PLT.CV@IF[L=WH"BNZ9YR1=AQP@!)2O]/\D<>-O7
M^0;(LKK+ 0D2+BBATAYA5 H )W;B?5H/-I[X40 N@K)EV?#JMMO5=4+3^R>:
MDAZL.FSQC2G=>OLO=^^22C^2E2V@%,#DQTSDC5*<S6IUO[7.NRNCQ[KDG<XR
M19_B.S!?R&K-T+A+ ..+9E&M!K26R>8X"0&N1FA/%OK6PDCR1/Q.W*$(M8@V
M 7I"P.'UWMFZ5/XS.ZKWK ,,"\\R]&^W'N-;3 -(8SCS;JEPQ.D=Q6T$+;1;
M[\>.N)-C6G__O?Z<"_X7(<9/I%<Z#6:-XB ,,,'94XA3T+#.>ML,I,WENU=&
M\X[,C,8?"=_IZ5(6$-]_2'#&V[?#&?!N&]'-1UW]RY?3R#DJE]_OW?R4_$5<
MM$4J1![4OHE\Y]OKVEYOU"D)ZD15,54]GA(;O%;?9W'IKI5@LX#D]%4%(6>5
M6[3;-H6P:SAXHH,?H[9M657EF?T\%T?Z=RK._JIEUI4(/C+;EQP;5SQA0-OM
M0F_TQ-2IT/F.%DP$&L5.X,3SSLI'DZ6@4UMM9)8?3E2^?[-[US<H*,E\E3#6
M6&1_#M'Q&,F-6VQ'\1KAZ:7"OI0LB[19_ECR$SG43V5,KV9:!R.QUT"#B' 8
M9 ;-ZV+L"N<<<O.+D[&/6E^S5G$X<("#$TM24>R(>RB>%?)IPLPL(J00(;<8
MX2OJ+C#2*YW8?KZ"Z?T>R)+TX9]VW3R9_T3\51IWG\.S+FXNAS,;$!!T&&.V
MD(%<GI+I<^>>3;F0)*FHI#4G>X1S9(^/ AB5%2(K"\UI4FK/QCYAOJ6^+,Z@
MQ1,A]B8W*I_GN7^_WFY]U7"6??ZIF(Y[RT'6<A8FF<]J&ZXFF^CNVX#>H!B:
MN8C7?ZCH!A>M''1.9>5;W43SZ J^"X^K"#EU#Z=L7C0-[^=H9L<SP.E%I6"H
M;=^F5H\WV?L583T*K5T!1YKKZOLE2HKSJC=311=-^#K>TC%<#@ $U#?VS;^1
MI4D9*JJ%$^J%2P_:;\5[B2M_6 =?%F$DW%NL"21(F)]R&C7@\85JL)5N%4:9
ME9F5[2R;^>0M!MQZ*G)12[IJWW+\1E(Y6+T5[VZ4;EX,B<.5=U[/9!ZY5S"_
M?4[S>GETK/A0AARWGI5(4/%XK>O5L<68;5G)O'SAQ(8C-UXHVH1&N=?QG>D&
M9?C9\N!F7:;8#,0[ZH9;A=9?RLQ=;CT<521'(O/573"'X\%J[4:TCQ[CW]7Q
ML5;:X_9 *?Y7+6]R5)>U4("K4W4[*_MXDOA*X3V\]WSJA7J?7>.G$X^PCU]6
MPNKS_7T;)%70SPJCVR[JWO^IT+];7GAL/+;?:,]%UU:W(!<!;F]UAQ^%:G>4
MTSGUSU0-C+:K(E.S=60;4EJ/!1W"X3,S"?0/X,P#Y_M]>457/\X")[' D6M=
MAD#)4U$S^IP'?(R-O@<FH:'1RVWS!#[60HD+'.%T9OZ%8K>QM/)#-6PU@:,N
M/GRVC@G=HMJ<,1UVYXP(GD5W?&)9^BQTJWP_UF4V/_YNW:=C+B0 S2WI5?*;
M-B* YSS#_T\O\OY?=MX $_EBP=@3ZFCB5QLPAH,"D#^0(\3_O$J^10$8J)8L
M08>J&9O=?K*#X]7RLQ&M1S81]E(G#N]V$V %XMLO=]^3\K<1(0*GZP8?V8=9
MX76>=[N^O;@EXGTBX)GA5NWS$S0_7;=<R2>9LPCV4G3.Y%#\&K6X=]N[.T@A
M4G95G(\QE=F]?C#%@[?J96Y'UW36;3RSD8C#<F^!_="!=$$H\_TL"^+Y7X8W
MS![?59$K%=7,8O.@&=2< EO3T^>-RGERPC/O^FHV36QZ62>\XB?\;#]1(U^S
MT.6EE_5XXX-U?.W],PY,QFB[QK L#5MG+)B) #$AN)4\4&.#,&M*?GLFP2-K
M&1R2>('][0-;J?2ZUE;3]$Q/&7'<0#>X6CL&[+#&8Q0Q-CE7#HVT^-&96]YS
M<0M6F$__AN9<-08?&VL7"BH#<R-<-\)0Q_SBQ#7Q"5&K']>K+B:=1<I<ZEV]
M92\AXQ-V8%ZQA&"#,1<1KH/Y+5U_.+<;N==H&[NPW4AD8TX]F]BRK482WW]!
MJB"?G(#9#:G10@<ZTSIW8M4D:@?RGS^;NG+$GG?3FQ;OCRQN=/,/F$E@(FCL
M^N&FZH0LF0H=\\<FE^.\KY]<O!%_W7$R=J9B8V69YE ;8Q2'8% 3GI@<@XIT
MCMDV^=A9N-M5OK; BC]O>1+02JNP720@0VC%86<..LB2^#NO<^C>G]'>??TD
MU=LK1*V*N$WTQ<U-EYK'D=FDVD LZ&(C[&@Q>.;\:,!B@>N[/-/PQ_S6B6O#
MM*$3U@21VZ2\9AF#')@ZWLH%SE_ZG:GBV(F]S_:^SP-&QJP1I[<W"+=HUQ"=
MD#A+H[!FMFGB31RIM[DJWVI<KK.Q>E4HWFSDKF_/XI)M $YCMQ#7G=#, >Y(
MX()80A]V2O%,OJ]7NWW_MO0$E/\JN=$<2P%:-I[9B@S#A/&',QR%T#TR&^[R
MX*-*B[R7O7<B)G2B-%C:UPLH@("X<CN"E<SM@BI'/8/)8\=_/.ES][C#7/Y5
M,-%:-AQ\D38:(#]58<9KM&2=65U X2!1VZ3 ?N#F@,5G?ONCA1[7E#.'GKGA
MO\S83#^;P[G5Q/H6$K59V9)OQML,%%UL/<;TZCSJ#6CTZ"PR2K)1$HM@@K']
M<,_+,K;ZM#U<6^?\8"@L](DU9FVVR6/7#F_41@&.0Q<[4;BJJJ+"9H6/_L.W
M>N3Z+M,]_K1\8N$L;*1+M>#H >-PLRCA5+LAJS7^TIM[^RVL>C2T!X@XNV40
M=2)?NG/G((X"Q&['!"G7W,5DY/,*/58PXUK712[:,NIW9_$O$HJ*EBV'9D<(
M@;.K2\6,7]SH6'M*8Z6Y6D#HJ3I())B1Z(H'MYFGCI&;"AAEVRN^^#Q:\=Z_
M,%)Q5L1?HS((KO*==D<Y[^$=I<[PDOR\"6U_^R 6M)O/F4F^,OE)1\$"N4#4
M52HESP*Q$C5FT4PK:J>'U@46AMOH=I4Y$[_4Q2O>.:O;LZR4!1G83OJOQ7?^
MW92=[G,-=(G<!ZY@?JJF_#/BQ^;8%-J<E?M$3LU>[$>U>[U/?)XK4P"Q?!QX
M]R;!#Q>F6U-C(X8V&9R]I38JH==Q)K946,-9,#X0GG7'G8LVG<=3<:'VA\U+
MDM<"R*2-%-RIL1(?+O_LEI6FF>MKX;EO>VE.1D?*T<A9JL&9HGO[KK#MNW;%
M'J'Q][D]DO5YVFS&[3R:]!)>76^-3[N9&;< 3"$F]4(%GY9+8B]_OG8V;"0A
M,/A/^R:/)Z?V_)LV?I V)K96B[\X?G&U'+.JJJY)W )U2XU&MH X&^4+1IKC
M')T_&K!UG2+,FCW__,DK=<Q0W_[8:1K5^H0%'RQD]0UV(Z19>G#C?;\[\LK(
M.G]QE9&8EKXOT^/GK9Y7,6?0#\DMXJ%X"M#N00_3[;OD*\7J4KWWN$;,[/T#
M09>7GH)B<\XH'T@&]8E(;BF0(YHYVOM+A1BBL76!H*#%-<;.\6&'/5]TZHLY
M='L5_GJF^]G^=*1%NM==G6[9+V+"1MQ)6.>+&-?^QR95%VU/I\7MS%<L(Z3
M1RG (P]^XKG!<[4O;>I^/"I^17-O0RCZC?2+$6\MZ5A[/!(E <:4"&.,P4^?
M?RJ*\+C8I<,W=T21*#X(%T6TRC0*6 8A([^_2'V<I,&;_;G! 0NZO!'/C'JX
M+WN'JNZ=B#:NL2,WCEE%$BNXQC.# A_S+>*179ZCX'[6IX(,-;2OYAMU7_09
M<O&DO,^-#F=W9':[L+^_FO12WFR$A&;-#.8A]'OW2N_?<6FWJ#Y7B)V)C(GG
M,<NH(\6>KPO@RTR5A!E047((D5UC;C_BWBTEO'TFZ,LIK?73+)JT-@GM6>[.
M'P:G\Z268;-BQYHZ?":GH-7D=8^)\:RK]@*[*L<5Y_B8#<5WK%K!N)MH#NZW
M1FP=[R8S;BS:A95BY!6XL> $2Q([0?J0B7B.H.'G6K1TX%D_].[D^D!''.>K
MRX@8H9#V[T'V81HX;.?TZ3(VP5E:EO[/T,!TK.FAO%ARQ/G<=(>EVW/P;1%7
M_3<.AS'D\_Y/R#PS>'85^9GH_6[6.^^7*(#+ I6:FR[HBE5.#,P7\O/,KPQK
M8(Q&(&2Z&=(S"=#I9J%QSOB9_@>5RE4*IB$CFQ,LM=ATIN8FA.LVZ!0!T7ZU
M;4"]?^W*"/OUJ+6<DY>5F-3"-MD;^+PZ8OAT$KMRZ*/>LFMGFP',+:9/UI8R
M70\TSGV2:>;Y4N#X6HLEE9/Y>OJ]204M.?$K22EZ ]&&[]\/3<LZ;^Z=\>)P
MZU3,%)3[YN57!HW>L='D27Y1>,O@L/*G>@V/9W2?Z'MN14&^P&'96:,3!.?.
MZG(+0J1.Y>#;1&YN=T$&SY8P= &:^YMX_GO%;GX$NCA(%5N?5/ENQR1F\LJV
MRXZ1%M15FUM2F".7^H=;TC3&,J\A9ZO;Z-?UL3#%"D*.5+PEK_. 9FMMV,T1
M^J[.,(#3_<3)7S&U*-^,\^TWRL(,!R3[Q_I'CWG="*,QTP)F*]DR(PM6R)I*
M=9=?PX_2K,%SGK3?5VV<U)LVSZ&W_>$V^1GVS$=Y;V2]:R$@WNYG8SM_=!?)
M-MWEUD&ORX_=V[,?<XY?W3=K>*@M5,CR,O%)P5SRS2<+IY[?9)$(-60:2+_M
MG]JV3&?W*.[S=>Q2]PKD+/$6#MTMKIB7/-/8'[(O_J2;W\@VC (4VSC3[1IP
M(S\9G7&!X&XY;X'++UVB6?28VB/G-R/:N^10](C66W)'^C3]?<\K\LDFO""K
M>AWL9C./@T]#]]H$..(6AJM6&)44NFSR7FM]5UKD7H+(0=&[NZ04&"U_.S1L
M%AV)29NT?F-6JR$K$Q9.\UI;)'8.^SU3?+-K9=> 5$,^K^76&/!A65H#_$56
M* GY68L9H3$N9Z5);5I^@E3WRZ(/,'/\I49')Q8#>NM/_M+*42?O'DW>/IH7
M#"@EQ&7AK"#'"(%619"PL2NVRK40:<G4'Q<OW8R7X3RBVC*'C86S[[O@F7>?
M48M[2IX8FRG%38>K:&(8Z0\\+EZZ5]U4&6OU=5R+_H,HC5H(PV/D]$;8-$[W
MUT&=D[U5"S'O)Q_ZC,O4NAF*.C(LJ_=,H%M5ZY!]Q:=:F]EQ0RE-$<]F2(*&
M-=6:.C_&C:KB2G. BH_JHPUS-?REHD?WWY)>HS 1@4.[17E4.KL;@8=-B=5E
MWFA\8S#H+ESK-&$VR>#->=8GM);F.8+YI_F,U.H:+@:3]\8YGPC&/4YY5_6>
M[F3#DV.<3&;7+EF+A>CV<%DG6&_93BA@+K$Q,-A77P;X:?=G4__[IKS_SC.N
M%0@N!4'3#X]NU6>BWB+'-#!,D?B]&7+QC%4K?UZ1#YT5HSE7ZFA;J;4:G7'2
M24&N5K0E.>#7PEM^I5&$4F+J.E>Z[;*"MJ/)71O#ZYN!R5VN!Z\.;9!$XCA)
MY2<%('SXD[N ]FQ"V_3("C:AO8BDW")-:#=.UBP=LJ_CS(1U\DSH\3KA1L0K
M0L?YH;^B&'"W(2&LQ-N-A" ,1$F_V$(K"S36XA1P<H3F$_=B?-7ARNX;E?6M
MM1I$4&\,.'-U.(V0,Y,02KP_RR_?4=^OX5.PY"3[L.LN?6$,;^!BHKI(US0#
MPN$E9%1>GZ!1^-5N,'M@Z]A7IIT4M_8;-"I/+$($*$!^ N'4+@]>;J_=@Y,(
MQI\HEO"QWL<O^??7F9X4BMJ55K$_BT,8NN[T7)+(,;M16WU;D_[#A2C@ P#
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M\YUSUYQO9LV]=V9]66NO0/+D??9^?GO_=LD+]%$Z#CAQT<S2#&!B/,XRG04
M^@1PX6^__<\\_ESD?_8:3/1F@(?MR 'K<V:F4\ 1'B9F'B9Z.P & *:C_]<"
MX+\^F(XPLQP]QLIVG)V#L:#J!'"$B9GY" OST:,L+(QW(QCO RP\1WFEU$R.
M\=G?9#T5P*\>]3*/3?K\YQ:!RS^),AJW J./LY\4%!(6.2TK)Z]PYIRFEK:.
MKMZ%OTS-S"TL+SI<N>KHY'S-Q>/VG;N>7M[W@H)#0L-@#Q\]>1KS+/9Y7'SJ
MJ]=IZ1EOWF:^SR_X4%A47%+ZY6ME575-[;>ZUK;VCLZN[I[O@T/#([^PHV/C
MLW/X^85%PM+R"FES:WMG=X^\?_#'+B: ^5],_P_MXF'8=82%A9F%]8]=3$?"
M_BS@83DJI7:,U\2>]68 WRGU*#;^\R_S/K<<E]:X3!2X%?B3_:3,N=G3I#^F
M_<VR_YQAT?]#EOV+8?_-KG& DYF) 1XS#P !]C5V3:DOC,"P>ES"##_MU,JC
MSCP_3Z7O@AEV#9YI2HNPO4_7HF/]\][(7^W1-^Y7W'ZU^X@.1-^&]\U40B/#
M;?%NQU9HWR&<'PN]<F@DEPM"M_PY\=(+D*)R?\AG3IX5Y)?0M#RW\%]U354!
M=T[M<FAN%P?1@0BG)=;V*587:KR1^)*@.^]6'C$Y87U]X==BC1G/J<FC6]II
M.#'=?HO<G]\M&^%N>I#53?.W%$'&QC+A+.027\V6D=_;\Y;S41)XNP;3ER_C
M(POZF61V-[91N7?HP)-0(_:)-(U5K)VIE(1#3XE;:?=Q7,4#51-QO5_H>".-
M:6\ZP-(D0D;.=M9H?G0IK"IZT?O"_&;CA[<&':'G]=(E"214'<(;%6^D-4#A
M(KJO8-KY)FQ+ET]J7*]TR-Y2BQ)^$:/;T],/?\V1XT8'RB'=E,-:QK8P^!%G
MLU<K$HJ/=80J9)!7:_^2S.G# J&H=(@WE'P*W()ZYBZ2<8V(>?Y;4S7&_.V=
M4C>+?)D]JR<)<,U=2)MM IH?XH-,<J!AZ  Q8\4(7#-T3-2>]\>),T_267C0
M"2F"07RMT3#4%R.=<.!7T]'P,_5#.\E"D^1/UXW7:OAZSC[E!T^]8P5.F%V,
M#.CB9S6HWZ5 4"W.E HJ$H)[ CU&DPI7JR0AG^\<ED/679^G;UVN-Q5U"MC/
M#,@!H1;<?_K1@6.D<.;&Q(JS#8Y[)WOW""^NUGIAF>LYHB'VU\V?(;R37T!.
MGO.&>-*!V+VP\4N9P9MMXL/'+&)##O$2.;7=*-=7SM0*VI%PU>'UD+)RET/;
MUZ5&'UT>7CK3_LQW_Y8JR" !7\Z$4:8#OY +5"^&)Y"X,2WJ38&K6"5?S('Q
M<$7#U^3=II_Q?I0+'42N6][(CDL\@1Q:98% LSAB4'$;U(86:+B!N%VOPF\]
M=[S__<#OU(4B(__ IRDF^F0#IRX7UC@ZX V.<Q?]I6P _GC/*31%_ZWGM3OZ
M)S0>2'WM!##NPXQCH0,NB(R=/,(OQCD_V&BFFEAY3TOFD+F;S(J"#_T#^B>B
M[V$I%[*(KVB('1!%R!U!6J%>HD8WV/(I86(;3/#70I*%F[\H[:9I=F7^5&6Q
M8 2T@"25[0<\UTYLD^9)1;2IU-*NTX$YL9FGR"TZ4(S M3*>DNWIP(E%B@P=
M0%(O,(Y:$$EYA"[^+L_]$*%!0\]F3"*4$21NOU;;?3HP#"'>?$@'NHKIP/,@
M."\"0\MC>!@'AF8(';[#@!;]E@Y B;V_(1D0<JSVK!R%#JR R:H-=  _C&C7
M11^'$.B '1UHB6$\2Z!6U..9<Z!]= !%OK,'[D7^G760O]?4:4?8E FCLHC
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M7,/CSG9)$*+;:G:ZEIPH_$5S6G$XE<A'C0M3K<KO/XR/JYJ_W6/JU\AIU,&
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M)(!4'JR%S._BP@@"%"O:2":H#0P*M\EP(6N7G:VV+A9=R)EJ;MG2CF0'TYI
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M:I,'XRJ_O#Y@+%6B3U>QVK%M),&/,- (<57#8@>_@=<!C'H"#B_YG=KE=?D
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MO'&!5I?K_-TWNHJ-'Y_H [TUJ#4IU. 6A_L<P488LP^W#_&&9?-_!)^QH\5
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M]='YI_-O<UV)Q8_WW@;_V3'W1K0&T*.66(I1)5@!?24] ZDXSR/.K#08V\6
M;N'NV]/')VL=+>#KPB;(X!.&CR9%PK939Z]9:PH<ZO+6G8$.#DT27Y$$=6Y9
MO;J$\5&:,T^M[QJ")2H:['AET_( >"A$#,>$8G3'U-6[%WM^(NTM6QK\_B=E
M@?9XDV5OHN3&KW@]XW@];[./*Y/?[R[)F#T)E%W_:9PM/)KV0B];1]V\T],S
MZVV3GKA [D_.9OX/2CPMT'CE3*H!,L]11?4:>BJR'/]VO%,_MP8".AYS1H?J
MVX5A#)$4T2B,>_1Q!S#JKVOEG] /Z[R!Z:!/QWD>ZBV%JM$<&4EI#%KFG\.-
MU'15;^ ,0#BAC)U-R5Q&_\3W:ZD0V]VJU)$F&O<W :JT'B8VRRR]Q#%@[6F$
MK_ML;/<R$Y%N"VWJ+*ACK:.SZ)[FF^85-RNBPWX&"8VOQW\@7 _K7N)I;)1_
M=SZ:+?=;41Z[V#T>MOE+WMMB?.$^U=-[8X\L]Z*YC>I_2[/C1<]@F$M S]7_
M@CN!=$3)'M37YA'['HNX!VA]YPS7-I</OPY.>;[TJBENF@/K3G<OL(@.&9P,
M\/J?I;8\?[%,G=>ZU/<,F()8GO9W@-:O""73PB'IH6K4ST6VJ@^02$50N)(5
MEYN6*7C_&B7^W Q5 ZH[/JG%L+9G7-OHPY*C.(W+7IPUY"@XS S?!-)0\J_S
MX46W8R\!">>YX2"[FP]1S]&7@.Z!>[/64CL/OW0_^L:N).C)<T1R^M+O7;7.
MF*8G3;+@\J,D\PQN+Q)^$YQ*"((GZV)FQ1#/E'=2@RO"TJ'J8]S410/JU-DF
MUUMB'Z2OQ?1>9&J&#2UIJ.XH&B-8+C:Y8L4<Q>R]=&(VNKZ;D:02>6, U"%]
M<FM@!O6;.%F4B2$!7I1?;TD9LR*R9SK_P9!=K<H[!S]39C8"Y08Y<',B([[Z
MOBX:S,@1$]&LR VW:9#0$!W@3Z:X'\<PZB\7Q*NNBBW:L<=*W-2R64$P7 +L
M-E4&HJ^W<YID?7@ YV*:8=E:IH;:. L]$UV.]HYW.Q PMW&]&-)IUE'BQWXR
M\-R..4/UG23CL%CR@&^M$T5CY0SS@])%LU,965PBQ0-LQUO"E9!I( ?^9NG\
MIH+RXZ:$9+NGXI-)[ ^TTY8ZOEARV7_RW]\A.=_^L3$'C3R:MQ+4K[=T%M7I
M]NC^0$.RL$*3$Z;^@7:J- XB*(>&4Q*E<'ZH]'BR\_?CW*9"I$ZWOAB-]0.6
MP\D80@-M*I6.3D3^8VK]OS?M-YH<T^$PK9< F/DEX,C8B.* XG_NV8^&KBD2
MK\"R4J$'>!Z,Z6%F$9_!O;X$Y#\Z<?_OS?K/\157$:<1=/!$CNZ<"+\$C ^4
MGO_X)H@%9:R&7M'HIW\'R%$0H@Y: /&!+(+KET- ;]VIK:B'O@;!F*PL968M
MJ.XGV291:A33[I[Q5?8IPMJ"C4LN 6]P[E93S9MSSX__[ [+[Z&/K\&C$V,D
MRXD+EX#ZXZ*0XZ&S LQH!JR/)KU*5O6N3=-\38E* '7"$8FS.0$&=3.<:^YF
M]2->;YYN$41^C5Z[929^MYM^@%/ZX*1^,)]A@@*8]F"9 [1R-:AJ-0(LVI>@
M;8U5B!1?U97(5'(KBNHN_T+%YX5V4)W95^B[!'QX&LR)L\G#@=MYF&LF=FHL
M*6DRL[.KM/FK.AC/PK.9&0VM#=<S3Y9G!;N(C+AEC/T+S$P"7NYUR0"77:]E
M; .C^;4!3JW1YLE/'3%9Y]>4LS[025V)3K^K23109;]XOHG!/;1.%@?V-OF\
MH8ZJ*& 8N#=60E,&JTE^24\K(XNX!@>SA G9WD[[(-+UZ3X[&<]*#)$;[I@;
MD9FQ(WSANM$$#Y'@'Z^YZ=T]5GK?_O,;8;FYU==2TI%\5TH!/'O: 6>"=K[&
M7&G!.Y*MQR"ZS5/&RM4O%M<7=/<,R0@.I!/_NVWD?"V0RQ=A8038U-<$\"KU
M'\$^70)<RKV>B")S4ZA9DE&;?O2>4:/,J^>^,)CS8=')ZK0;IU;=V)OK;1/*
M#SP'K%:#VX-H<7@'TC\@.\)#Y,E7S(RV8VTVYX46$>!NTY##(/1&?8_S[[KG
M^CS+ID51.)'>^<V+O;V:'Q/77A3L2&?]4HWORFEDP9QV@?X<6,+(-]3%OO;Z
MR>O+52T-.4ST)_6Q;U&_U2I2=;4CP\:MVB,@TOY>?5U)9^H<6-^UZ>*\?H8.
MC_TOD'U,O6H"\8@"VH7 QX/G,KIR;N "\I8D/]2:-$[+,;M76\Z_I$CB_T3/
M'."BV\63=\ MVD8(:V/8;K)+5.B69-?DG>*WX2=?99),-QEDD\4OD$S:EP=
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M/U.%SYX2>\LE+P'Z2-B.WPH%/@D4OGQRUP%\KLD-Y0+_OWY#GH*[?8C_$4B
MJBYCO!3PGW]?:8*/4-% 8H3SV=]+0%@2?+4WDA#'=V;Y6P3*]?YJ6$1*UDN
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M-65@K_^P@*!D#TKJ19-77DRG:<F#5F%'$5]'W5Y/B.,/X1=GLBQ;)0+JWY]
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M&+OJ]F1V/N2W[Q$!JD.D(@XJ5^2<OVO$DN_6<N9Q&8\P(UI;=LC?/(]6S:'
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M-/A[8VV\>,W)_2*L&YRMJ;&F6<;NM@@5[<.LA+=LZ,IO=!/_Q(\AH3ZN\]Q
MXV8^TH1_WHO]'PG62'[/CF__<I<971/B]?)&M(I?!9\7RC,1/H;TO95;Y\&L
MK^D&Q[7"^^I0^9]42-MW+2<C_5[G'A[GO9\B7.&8=.'TS\U3"[9STY!\A\JH
MHWDV\30-0+X#)^!5<,?]2P!(#Y=R\H/00@1"AHC"&'A$L)GCNC[*LK\,]7FP
M_U=-14D#.N[F[-^V(]BZ._%&"B9",C9S]0G3):#[5#=U($_H[T-/SC">CAF5
M#ZM0/==Z^'?ANS],MR"#N,.35 PX%'_]&PYG2/N]T+EN>D8JJ@"17B^MS4MC
M@C%I-,YI& DT#(/P;_"(8JR_H@,D7(]&))_&M7@M#/+%FY&T70 ?9LT<['X/
M-L=2A*M3:6)*46NKOW$QLS]B-2.PLU;?XL(CWS22Q7_SV06_=H"RM!ACC9'U
M78BP');6C"?FA?6UK<WF'/25ZO2?9JWSEHOJA&D(Q^-R!":KZ**Q6GUQ/6;%
M '%!\S1(/E/BVG,8WA*9+?&4_'N%8YVW='M"4#':*]"#"M:>CZO$,IV8$@J#
MU3#J-PW6+7\?$T1W6?TD1?7XOJ 'V(=L;NY;OT9"68)?$+ZKRP?;US1/RU'?
ME&U_-U-OH:?-'Y,PC5RDH"$W&-O4 ([OEB^6[^BKY6-?=K:S)+/2?N318O=2
M8LY0J$MW;MM#<?JJ<=B; +\R@#.6?\'[6LW;6/U_;*.>C_0NTVX],^^075M$
MU_L]#EY>8NLK%!V&N^W/=:+$@5WR()J*/<A829/66ZNQU<&N$K9-N+OU;)\3
M@.!3CX6&[^UK9;O"'%/ /.F5BUH3T&7 7]BB<Z!F+'/+9+GX@J^YW2,^C  \
M-]YM&67?X?[Q-W%<N2^J0D+N5IU^^(3FD%+'$WQ?RRDHWN,20 (!X=\02H/-
MOXW8>@==CR>@-/U_'MR,JB+Y@^V%#GRCV]A"=RMS%R1-NOE:"HEI6Y8(:GZ$
MMA_&6/%U<PBT<C[YL95ND:5[FC/J\\6L_JYA.>1VL#9V.=;7<(Y"AY#*:=I4
M70FO)K<\E!68_:(TQ B*72[W4)?%S6!)3ZB:L:X?SS\2>:NJ$[2K[9(J'KZ5
M%5IMZ#,<_P#R(/('FV/\NJSN'%P"K*;+Q-U<T9+<J=7?<K1(W\DS4K+A S87
M K3;<^?\NL <L%I]%5*6ZA>L#(SM5'7RM..&5BTA2W#&G;YNT+P9DJ<46V7E
MA3;,G-:]2T0$1<3)7'L1QOYZTG,B]_%,&IX/]Q4%_0ADPK,B+=FM@,_:(JC/
M^-XPA.G][-6BX+K(\AP!0$V2K<T[A_XN/.146%SF?;D>$I=9\!,7]N@W6K<V
M_MF000SXV,MJ-$ETO7"\+[<3+@-U<H]3Y\=H)?UP4K;[]O4*OF^W)MW.NB56
M244I4A; [T=P1D$C09RJ01>>6^B.]//RT3@?*M4O=V7OJ>"+.I0&UXL$#]'%
M%'N)<6WW@I4QZK$\\')<QN/()\FVX6[7AR'6EEQ[_#0TB>4!@@EPY^5PXJWZ
MWV[WLBV&NA]:.Q!'Q8H87<T]ZV]3J32N%^^"TT&8*ZR=18,Q13M]WS?C44/]
M>^!G]=69>Z+IHP>;*:W@L4AH]PSBW?*U?>)-?^"*0:-DE#V6VOFIXX%B0W:A
M:,O_0=U[AL/UQ7V_(R(27?0Z$H0H$='K$(D2?S5$"Q/1":+W&25(U""('D%T
MHQ-MH@MA=-&9T1EFU,',>/SO^YQSG?MYGE.N\^:<\V*_6]=>>Z^U]EJ?[_[]
MUG<]6]BWB3B"/OI"0GB( _7)^\76!UD:SHXS_XS3=)WM.Z;*#^N4XR4_EAJG
MO'QPEZDE]*.G74_L9;7\P69B'_SF]9PTM22  :%I!2+Q1N-.2Y26MPG)9J;=
M[QP.[ZA4_/UGGY=T_NCP4F^^N%^:6Q)7YQ \DX=)^*TTM^67 >7I,6MD7;LL
M=.U7BP$0/[W#6Z[&7DY/5#0L2N\0=*?KHW9DLNDG&<GEJCX>2^&G_2F1:4UV
MQ>;!VACH1UB#.XO5S@[_./XLZ=5#/C8./\XW02;'_!C8ZRF\%N8*T'6QT4X?
M_6K2>T"@/2Z<XL\"G8;-A"0)2Z]6,.S63F6RA*LL*O'<'HK8!,>7&&T3I3W;
MV![T ]'5N\>PF<3XIG!$)WL$0SAFI* )0VM#A%+@DS3YB)W8UY>> D^X<RLV
MYT)!&E";Q'.^-/C)Z?+O\HD.I49E1O]J5&4$E-?*[I*+5Z#+0E\#WRYSZ'R,
M2(35K6K$'$U5O$@LI8)R?R$Y)R\8( _+7UG;*>0,&@"!^N#F1("ZR:\6"YIX
M%_J+=75(V\R:I(RVTTJ0%(0JLV_)?Y?G!+WC<BJS8E<3O3H=<8]5PER]>\&5
MD61/\O^![_+_WV+/_\0Y-%7^AQ(#"A+GK=C;L Y[8U@9]>KX]9:\YQE(S:/V
MF.>"OTA3SG;/OUX!PH7Q!F,=7,2Q#B&< _(<?:RCVI"UM>HR;6JNX<1'\00G
MRQ>'^JRT>WESZKA5QUVG;1R&-*L4^Q84@/+X:<;Y)ISV%CP%@1/LQS,4(.%=
M5X"8)C 0[A 45![PO27%,$-RH)"J1^:KUSK *W%7!5BQC-%?_B3=\JZ%K"&.
M?L?@_CR#(D"S^(^U ,VW_5]O);(]ML':D!$HO3<'>'8?93$-$SUV<:$6.@PP
M/WS^T96(2 JU[''CZU/A+K0]X3V7F8"[)W[4*NY>A25<<)?--7X.!S[9&+>W
M]X<8KT]FKP4>7RMA1L@4O'X3S56LBHE8J4JMG-V209^RN8FB]WE?4L%;Y(18
M> JX";1% .>M=#]@/3F><:G;$O.!&EKDR,VOGG8XROPI60&5)A(:?DMB!@/;
M!^FJ,>=9,U!)^OK6)&T9WGQY$8.7NV[)E]?D)[]!R#N64PS"/OCSVG_FU;.6
M +?OPP.9K\Q8DZ\ CSL7$3#8"\+HINRO^2O ]!5 J>3_V 3EI:E#TJ0-=XXS
M95:)2&512VO2O7!&AS2--V5E;2<"P$H!?L;U!P6,6:ZM?&GHIN_:Y39:OTMZ
M91Y*)K] -^XE6UH$\ID-0Y@@4WF<WHC(/.8B#[I)=[Y6ZYM.1_5NK\-R?O)F
M>RI_A8WI?0+7_\A@A6/.PNS9$YJK$71T2??NNMIQ^-K& 2LAE \246(?X?7C
M HGHG-5T(T2J9V&D^E?Z4,)'-,'E\,]93Z8P&R&Z:W(U8Z-A\\3?YO6YYQZ_
M0X$NO-.P3>94.TAJ@> 0I2B1)D#]4@&9>>+9!B/7WC7L5*?>8!T4&I;2T)HH
M4&)I:'JYC18P(!3#'<58MH8+EG?D_<*KF&F?4!_QO>4DFX\+ZWKC+8O?/5%8
M6=[[;;U2^G82KVYB,&ELJ&)K?8_A27C/INR]NB2<25NP)$8F&L^V&L(]I%G=
M&.T:7Y=A$T]JMZJN8$HCOJ,P\_VQ !RBT;2.WST6^9YFHR':-3%<0]>[\8*E
M=Z:83#=[1_ES^)B@F.]NT&O\LDQY^O0?CY>#U4==ZTMC%?P4R5[9#T59%',K
M!Q?FT$$W[O?%<CK3TY$9&T0:DP( L@ *G-CI*);*W!%367ATNW+]9]QK\7="
M^>E\3;*<W"=G5:IL:' 2O&%J:KD'RNT$N=/D9[K6ILF7%"!^H_,.BK5/2TG)
M95QQ8O\*$ 6E4V9US*4;JT K&A2>(QRH4I[5]?$?*;9]-N)\+Q&7^[.J X4$
M=7.]DOO>,2.9_<#O_%"=-0Y*2962^U4*RQQ[28&#=ITRFQ/.$F"\S^JB@K[^
MR-5$WM+\$,GK\*9"Y>UMTB8V4H$-O3@@586;V(PN1B!&K,K=3IC.(B"G\[WO
M44-[(%8%781X1BC#VV .D"+EF(E?F8&+NR8F3\4:9P45Q3GW$YN4VW?W$F<9
M5IY!R?&TCFXV?:4A-.=#B4O4^.P4! \J#PM[2/@"MWN&^>)+%,>692V^^[@6
M@=8TZU=?T#Y40@02F*_U6$F^L?J-DE\ 7\![0;KZ__T/KJQR)VGV_1R_PIW&
M,2M3\#/,@L5@_KAF7LF],+9C661]R3?:;MJY(>+M"<PRBJ;5XYHJ:E17T:]V
M-)H_%VBXW=SWU*/*Z&88D>/$^,,B1:X *Q% 1IC[_:9IO&>MX]:*I'#)=_O'
M&C<#VK#G1!^"^;"B])CBV=U^*O&' ?RIX?>%XM+LWP( )IM-Z'M7 #(^0B[<
M84A)=_X5UCBU_Z.HX?.H,8'0XMS04!JN(<_'M\B;E01)$PDIU_7D0&^ ;%V%
MEL&3E?5]6$[5X$4+_>0%]=IOY/Z9.KWS/)_I-CL"22^D\OV+5;%W//*7Y\&=
MMP':[SJ___K%(8UAI (\EMV3-\$VH?1P0F+]L/EHE%UB)R)2WYGY@M3ESIW6
MB:EIL=JV7\Q_> 3/:9N8"*;$H>4[[D1FO!3F)*TA1&FC53J+<L=5SMZGV6[H
MH8C6 $%>GWR\6:$N5^E)"$@(__Q?OV3_?6W>50+[X&HJU+>)HDI%X>,"*VE<
M\-_^0$(K+T^BOL8F. G4)+8'0^7%R=>SY'(V)F_QE77?!CLNYZG- Y..80A%
MX\[-G]$DF\W<'#]V-EE;Q/.CPM-%409S51WO6ZX T2 M3"S7Y_6.>^]/09_*
MA.0>W6VK82U+$/+-X2O27H0N:?3 ,7IZD6.X<N0D>VXE^9QDC^,/DA1/%E;K
M&5Y%J*'+A7934]3X;==*E.FW<*D8P4EK [HW '(NX:/Y4V%"]DG>!W-;+US4
MS.]))D:NWPW-^@IQ&'4%'ZD+3J\^\NDZ3%XD:'*?_/=AV5>?J+[!]&DO=A>3
MD[EI'XN@=M^.N4P<O ^XV\3M8-8K?]CSQMB];#W%#[PG:6CDRI4Z8^WX/>O(
MX5L?5&\$K@$2YS*%\(V**!KD[YC3%%/HV97.#;E*>@K:W7_.P\F90!VPV0>+
M(S+@.%;9VAQ0'"65DB64T0&V]%> <OWA<$W$K6;@[,1I-<[R4L=TAP5.XT/;
MV/_# <TG/U! 5>*;2AK75/J-ME,ONE&".'0%P!CHO-1M\&O$3.>7:S?2]=[[
M4^>K_]0/-#-_$3!^@)R2O%12)_WJSJ.%XOULW*<AA9\E+KSO+X3,L.L6$7\X
M20U,#ETS!HR4;1=]!=B!;;FL/NM#K?9'V(LV_\Z?4][_.>#FI<(=\1^VJ9X:
MG.SF@J0C'4+^,4 J'$</RWCS*WF[!8\:V?,YYM<1N\-0?B)?K!&VJ1=&_U>/
M+YG0:FH#\!6+=(D()1]K#30YGKFT7%+*ZVK70:4,>5'_XD2!6F$;P%77$3CT
M4GVNVX-$VM YR2M<C;;>]P0!?;TY!_^J_'G29>-G<?2"$OMQ?M@?B:]M?9$O
MLN&FT8H!;_-/*QHMV3OBB%474C,%7^PZ>+$<^:_\\4V\+H]@NBGI4QLK"X4;
M'91-L-3&&H(<I'^9IB*8$I.H^KPQ7FPS\I_#\S?*B@TH7XF1_?=!)M-,77B9
M!FW0+<?/?:U&9MW]A#K=19<6V/8[9IHT<$37BN/SIPD,M!JT+QZ:J3/FLQ:F
M#Q M^FU<[&47K*P_IBOS<GRJ_%0IO;]N6+&0U1QWAY/3Z]^TT7'/I&%&KUZ1
MNR7^/^)12:QV9EPOJGE.;C* 1ZX >,;HE3]6;-CUJJ9O/8VG)FY-,@_9(ZDL
M[G*N>(7K*84(7_#!/H#>04/GX+W#?-*Q;@YM,5P?;[CQ[/7_W$7/<$F \W#Y
M76,H&HH13W=KSN>!7[C><?+;+@FEU7^QG9KPK+F0B52T?'0'59&BZ+,9W?VR
M1SU*VL-MZ([Y"REWQI/:0X<N$$;[X*/7$@YFA%F;H7H3R1=/GQ?ZB^ZQ/$U(
MS7$G;+'V;S\;HOA\ \X!M3Z8E>F'D[?Y!%7B$N:T_1_D+-A+ZQO!65=\B,UR
M?<*G_[P''#,-KSX@!0WB:!\,X9)3"C)6>0T_;,O)>1K\0)84+I]!><O[%/NC
MC]SIO"J&HH3*SG6EC6KHRM+%I (_#;;/X#(GS8_@,58RT.A<BBF\89JA\UVG
MZ7'-QK%PR\6WOH: W?"VZ8YR5!ZE8_)7']&W(]/&.\G#[,#?7X$3NS&;!\H\
MP;+3[S9KX=.26:W"'QQ_1 5\\U_D9.()Q]N*KWG*;8,+&P38/.MS<K*<?S<4
M^ 4]F%F#V-QYKDNC_P59S")8)/4GQ23Q26S3DW&"F-?YZOCU+%W._6B\ Y0C
MT!/E(D:[Z)SH?JJU^%D5F-.4^HXDL9OT$+95L)K7 Z7!ZV(:,Y!@6F?FF6HK
M<U7)\#M,?W2QI79O"E$;#^!98-Q#F;URS"FUX262MENX4A;\8GQ!BRL[B>&.
MB"W_,X<25MZ)A1G$<@T0O8M$S.[O@RG]PT^1EQHQ$I0<T?::"^]O'/ !;I\@
M.%>.P*EOF@ND5I=X8"D>=IJ*-$\J=M8S,F,B657;'QHYS>M4$0*!LP&;'Q0Y
MD,51 6!.G'!D)<W]@??^P4"6]Q%?=FQ<9C[PLJ$>CR9O3"T9:&N)M1%A$"&\
M&2:O"TSEK,R+?53LY-CH.Z[#R?"BE*^B[$6)H6HG+W9+?N;Z?M"5RNF.1[BU
M#J;QRKBY?P+#YP*<DI,?IKR1!833>.5"J6;6_=!AE_;!*H3"-KM'$87.,J\R
MN;K/7^TR5M5HLGT$1/+8 *T(+F@03N!L+Q]3K!JD]S&/L8%+GMKRIHE@^MT>
MV+W7TJCVNNR3W>4M,8+K<'/LQWOI[WNLJ6!D!HH0)S,!/7K6!O1#@]:F9!=\
M1C1>U8H" ^L.!C/X]\I/X?J5?X%.'#Y@)#)[UQN$.N5E*[S?_*S*:D,)>\Y6
M)F[;=&7B(8*CDFA/P6MU02>RS>$@5$'"%7!@28^PSAOO")Z @/ <XQ7HXWDQ
M>M-N5R>*7D8G205C&Q(5Q-<G[\E!H9PFO*CE>8$5>.CQCRDQ_'-7$>U<9G\-
M5>(1P\P<7*?4/)7"K<BY?O6V^HF G&#?0_/#M!91O;77CTBYOKYULJYF%7DE
M3/^I= ^#"V1T-BHW](2@99\_]]+^;JE70:+4!P)/Q^%_V<"N &"\,!)&2EP&
MULTDW'QHC2RYWYS16*$C(N*5[;.4-W0$JU($(2TY>D[%=]A%]TS2Q@7M_!<M
MUGEY\(58A'FVLC!M3'AI%.Q%NTS]MHZNV$9&HT.*_:RH7]1P[8*;Q<>$Y(+X
M[LE\ ^41J?OPRL1TN(N<M+_GJ$/44_$37]#HM7[>2<2IBLZXW6F)+;D".-*6
M[,YU+!-JW,=G-,=6O1)!ZZ2RB -3B \6]@EMILA6W%=P2VO%XPH0(OIN7L=L
M[EKH[1XI3IRPK*CT=RU3TFKS W$[,ZG$OWOD71EA7&YU5X"$RL#ESIN.1#9_
M:XZ26O"DJ#\,G>0#Q O#:R(N^[]**ZR@+L*&03A@X#6)D&^RO7^ \_ZZZ_-.
MJ=KV!0&.J45C-F(Z,GV:8/Z=Q 9<V/L-+HW5>O(#J<7B-5L]+&P!2IN?J#9.
MEZ">Y7 QWP>M!+C\GYLL_H^7L9(:45$,NCL-)3!.>9;N +&K05< J^MGW_KQ
MC7:-!GRN"PJ#[^E@-8AYBN+/[UX!!CWPU%> M^XQH./SU1A!(0L8IOL*H/EI
M;QGCIH=/T5$CPJ_[]KC6F5A2?FYYK>H]H6N9SJ 3 O0*4.1E<J+ -]J=*&V*
M1*CQEI'B:F[\Y\'7_-_+&Q;+!/U^-CUS8YISG-(;BP5 2<W,B64MD'0O+^K>
M6EU>43>^5/*OB^%>1PSS;-]2_'*7-X\E3;KR6*X[#\H:_'B\TL>BY)ZCF_W?
M5M^\S[FTZT1_6#Z$$J_E_G&)+J+'SU.-/(M=SL3[Z;>J#:_FN/NH- %27MEO
MM/:% )KP#C;<I\M7SU>A'YF)C!.;]2TQ%OENP:6\23]#X-TI1"C[)4A]LF/Y
MN^E.<O!WY.]'>8IO&!_I*<FR?:/VE67K<W+90% 2IZ"W\9;81U> 5=V4JDZ!
MF./-I$>N_V!6S>^KW7AR>\U/ZMAS064U1H?AP^6ZK3IE0NM' 7=4#" MXSY?
MR=A +)];D267FO##E?*' SP)WV(JYA)R,Y9#'+_NMFPPD6(=2'>WES)NE?Y8
M^)FPK%^7T=DWL&_MAZB-YDM\?UNYGN3(KP?Z=_,T$ ?S$EV.5R0K=C9YDB9V
MGT]<7'3R"E "R< +D_Z"5^?M#6%VB$K:75< FCV1@_MOQ@:1;!2?/64OY8^5
M3TYRE@ILWC N6:JZ-X=^-V.Z\[OO:4HRN><M,CW&ZI&;U8/)^9R*NE4?H&V%
M$>>CI**NKA6BR(;Z*&$71WJ;&,$DFW@F%0"9/@!]HGSR%B[[#NIT!:#'M9Z&
M3W8P.*+.V'7F-10V*9B -_.Z<Z<N^!G'GKNP-3>'ODL0%XD7$B*GD+&+!2B_
M0_'IDPT*2Y\2EY:Z@KZT-#XWS?F>NJ$GV$BSH+S'F?M5(/.<!0GL6V;#":M,
MMJE@?YWZCK?T#1CM/^<)%\]>#P3VA2K_^=[A2LB%/'D=;#%J.^7VY_W7SO/7
M91(Y?\]5^SQF2+_=:@LZ#2=4KN!>HK1IJ4SUG-Y/#%/=C4R3>7/H>A-PAV\M
M-S=;GWS)^S^WR+P&=R,80+%X_D)<V(R+,]TGCT3]XL21MB$+P@]E9D<@O2N$
MU9E]4MP_%STM6QDW1IN1L/1A?V64?-3(V!\F*L"GYN4N#A"GU^'X7)Q_S_0S
M;6FAR[SDS?:I6I+)>JP@\'5U+\#L>]W;:<F,M<?=I::_!67_INO7,>R1XI<Q
MG%-964,6LG$S)O2JK&R+(C&A5X#6YOC^O_:A O;]J$PFC]]K%T?Z%E;F2SS)
MTTB.#XK[4<\^0Q2T.B^FDCU^K]!H*97 ]29&04H=AW(_$FXO.>78Q$B)[/=3
ME,DGNR"!\?!ZI1X_"7^Q3G&EI2)/\[\+%G=[S55>\E5YQ)W^VJP*M")\5Q9Q
M^2=^!4'"TC+EUJTJ;+$^RU9;K" 17TA,Q6YVS8LQX^_CPMR1H)B+X)3MIJ8[
M0D,>;*Z1?SG#5T.OU];3$2@]RDJN%/RXJ/NGW3_JM$*ICJMU(_S%6@C*\$TG
M1?G*>@Z<@[%"9U[=>W>RL?QT8R3G(&NPO1V[(2P9L_ZB \$4]T4$93D6./)P
ME]U=J^#W"3PJC[X#B-?$S"0J@IGV2W_LI-<@WE?8^J/'S62X5C#2X?Z\W#G"
MHR!G+J 6+CUH]6&;@ C=5YTL/4Y54F'JPG*RSH&U-T?'L&EJW?YN(),BD_!L
MITN :Y#C1I]ZC!)&J^EA/4DJ.E0<05H$H;?R#T*F?[@".#NVT?MP]71PI1BI
M_W/PMX;-(Q+!2EHL=;B@UFVX2B5-2O997;:M^*/$/]0^7X?+FK\B<[)MA.8&
MV\1%C]31LT"G;D7-YCJF^#\2OA@Y.*V=Z8[$K^=!0DSO/YF__B*2RF9=_Z&B
M:O:R'*.ADZ6)LUY54E[9L'"5E_3:!\!>N6F\]IJN5A2V];X"T&Z_^O"FUXF.
M=S25K7*:K'E+"8HX/X-M4XD(Z%%'1^HE,#Y4#[18BI<M=5J; &75>,6_MKI?
M"*%(W1D1@_J^= W<(MI$6Z/Q-42I<]%+/_\-Q*] =$<YE&6>-]PG1]3_K6].
M-R7B-3L!B(O$*G3#:>O/[2:K4M!1+-*G@[]:E6D6XC;E-EEA&ZC33-P\$A0'
MYJ[ *YZ.2^<]*JRN>/)0T-I)>M,)Q6&Q'7:.-V'$GIIU-X#J,+N7VLIE/]_/
MNI(C!"=37HC=1>%96Q>]7(KSSSB!JZ=VO32F@R?,9LG6$^4Q?URJC(7TIUUH
MBO!F3@ZNL)W T_Q+0[P+[NC?3:X4P4(UDY*6RK-O&W)6[_95TMVSX%?A4@_,
M/;G@O01!!N>.1:V1T$\R[E#?+KDYMK5'2_9/=&?X"/MRP,^P]X0,R$V<S*]<
MLE$?06\7^C(K,PT/OCR'1*&1 M@@C1II)]$24JO/2*;/I/++F!40") EW0:K
M=4^,E*V;!LY>%A.*S()>U&_-SXY]0 MY[W<\5'\T'C+S<@,7;SLZ+#PV\' R
MP>+II--(Y>*+B7"#4K-EHV*^M8*Q)^TY.0V1]=)I22+2&![- I4;98D_Y,[*
M6=E&Y*X ]]-B3A&WGY+T!7D7_9>M^@69IBLQ9NMODM0XAGAS8Y)*'6SV&!E4
MN+VP7GJ34B 2E^D6^^H6:I2YUKJS.\\GUX1^DMCDU@!>^(H+_N@:\HM:3/IC
M]>+8]S.00#IG*V$,:LFRLJK W4>Q<4^FV8BJL!3=YP&>B48G7C[#%2--/HIV
MW,)S-/_,D=*ZUS#=P,'56[GXM>);_;/4V9^AO[?(2\NO":%3/)@->07X,$<3
MC]Q"3>)U$YG6T6CDG4=FV0=)9@O,BKGJ7@D>XZ$@,OA*U#)&[PP7AF15%L,A
M-'-9)<UXFT.7^T9JW[T?2I3T-$7W*VDR$:I,9RV<IM-._\U5F*[A>]S+'FFL
M.2D46@;@I)E"@4@@Y/XO5S3"WRD*K 91!DF&+PGNL]^>NAD7ZC-W2U==KST(
MHNZQ%-:XA!S3O*TD5_0_/4#E?PF]!Y-C_4[!TVU!6(%G6".3FZ:FX*(>3%*J
M?W>XZLO/ZB#YR],8 /XQH0FZ\I4HB#O'\G8N26+<"KV'+*G?39_.W1(7^0X4
M^_/'4=W/5:GN1$E!C(/8M:2(R0O#W_/#S!LD]_=DWFY(,4B3OJ]ESL]Q5+^6
MK J;G7M*>H/U!NU-^L^0;QA'4JS-]3B^ABL&)'FODACRK(=:*_=(L^:23CM*
M8>F93H;EVEU/K[ 4G$EU, ,AKDT;L]R?QQ*LH31RZ<YIOJ1J7XRCVMJ!I^V[
MG##Q:J;;.I;\%' 6-$B97'EC.Y$01$6\AIN/< >]V7 Q ,ZAUYP\#DD<B["8
M*FK3_#VG^)//ON^]1R?I\E('XS5^Y@0_F, K?<.QSZ\N?3Z=RSXCL?&/D(LD
MC@Y6IAK\)4W4;;A,L7+ DJZ"HSIXLTB1E-[9VR/<R][6I]EIQ$?91[T "#M>
MFI#^+TG'0:BJ,7H)#;$9;<)>=FRFM@[BWR6#;W"$A4+%OL%JKP"V[G\C3 E9
MP>9-'I8B<T9> 4G?N@%LK9X!%T"H,^')Z#$7J/N4^0*2=^,Y(WV%LS& 7_^-
M]W;_^79\)@"?1B@%V2RSNRQS5,(=:6^"Z]ES,M&'^>]D%=%OR_QHVOO=?C2+
MT1*[E4&X87>DPD%<8!;X40UCK&.ZB%[ZYZ<A1_,@Q#*P/JYLQV#*TB*\@O3A
MP8 B=\#%:%E)OH$QH[>Q?IERZ!L* )ZVD1#=(1\L6=V*L\1< 5[G3G0WS8C,
M?EIX]L9>EM1I3O5E)W"DI16*$Z"-%ZW'M6F5.-N[,VP+N?&D^]HZ&;$,KFTJ
MA&[CDL#-D3:/6,LRR$D:XW\%WN+E30R$&H3+*JD2U4-!)&\(G^".L$^!F':L
MQL>J++5&:\?&VJ$'RW6)Z:P"K/-Y[B,M"E> OT"D>Z=VLP_B0V!%FLG9G\K
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MXD*??!#4./()F6.SLM&B*(Q<Q\3C?5F>*O0U7X(R+SUKRMT,33&WE%SPVU<
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M%]</QIY>7[9N*>?@8$70E0QXT\EP_32<0C'((\#C/3>'MTN:O?_\/8CE[%P
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M',_[@=C5!G^?'SDQAUP"!OK+FN29(7M0TA/T'W&&]I<0= S.1(I!9#+^Q-1
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M^K:+?KJ0[N+->H&QE<XVU+6-$1V&+NSN".7NYHI;P1Y-!W?,#H=7SWG\O+#
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MZY< U"DLDC2X@-./:K:S=T,1=>L"10*_3ZXQ'D2^*E5[%JH(GBJ7LBW(IKA
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MOU=8I'C2=X2*!5V##67+$:;*\N.0;CY^KZKVFUJR^8-&DE+O_[D'Z5/Y.QQ
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M[N9H,%A+$)4%NT8:F:<A['[KAN?HU>Z[;[I]B5VT5Q1""[4KHKY]_W>70IX
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M)M>P%?(R#??K@%;B>H%RB@(-EP#P:##3MVR'NE#GA0_A0GSVI%].5J30/ $
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M4 8<:IL,LVU]5(UW1@;ZTQ;*CKSHF-TYDJUFO;\DP7+GS0K(S&>M* +O*_W
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M]MRW> 8'[&VOLL=EN$O-$_4(,DN+45"6Q$X+[IJ87+$370ON9],/1?[X1W^
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M/TT&'1G)#58/F%/=YQMDV[@]YQH1O#A-CH_+J' BWX-?J@S5+5K# U>BG96
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M57![J%363I0Y>P*=@U=.GAH3FI],MWCF&[_@2MBQ=]E)[(L+>VML]B:T;R@
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M*=7TSB3TUC\FJA> E0$BVP7 0NP"\%?0LEG_UC$4L7]);H/^U_W_H)IQR5J
MKI9(7AG_Z1<!Z6RRXZ+/T.J[I'>)"::U/\W#$C_RGM-+&37_B!V;6M[48U2
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M/\.<^>]R):'5*SG >QVK'_,E)S6Q:9BX4G3]?L=[(BZT+IGR8;EZ*D*1<+L
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M$=4#SM]4)-R%Q*G:LUGMSR]SKB3$>XW(%MQ:,K(P%-DDR=< ?IYWT[=T?I\
MM^+/ \.I(D)H!-W('*O_&]%7_^Y *]\PFP:AND^OVERN 1,&#X _V/Z#^XSW
M&O 6A6.]ZEVA@V\?]= 9FS>"UV*NTFCG._Z3W\SJ\/LUX,[O:\"@S#1H]_P:
M< W0YT/LQ(<7]%Z!TTD%/D4\C.^?4U$OAOCV>VA;MS=^:WC-//\YD^JK29[
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MOMCZLB5[=%5[P88;Z[R2^0HBVZLRZT;_3!(Z(U4S-D_W5E#Q>P!,6.& T>_
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MP NC_S8S)CRZHU"UCWIO/FJ\-R30'_1Z5+7B-4X#K8_-O4$V&5"/";P]*L'
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MY24F&L'BR@"WG+%FN2Z9Z&AOF,[=<GLP^?-I087LGI7L^J0YLKX;L6+\'&-
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MG0'-JBR+R#>9C, X(5Q?-54RA0%AVS'DN77B5I<ELNWN6[1ILN.7=4P"3W2
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ML%/[W9?Z%?P+0,)9><U'>%(-HEV=1IN/7+4L[C0OJ[L5P%3&7@OV2*6G'MT
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M0ZZ5.;]G%T(=Q7T_^:AE-HZ+_I5J/LV:-CSW"*EO8@=E/-O^3EC"R_:^]L#
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MUH;HO Z+#HT-'2]L.F@;-"E;9":B% 1R- H?"<6./N<LD$\^);AL$]G/DAX
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M?:83ZH&+KJG#>+%M+U).I*ZY--?K_GF2T-<J%GV?)"'@ MB>_F.\4XT=//;
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MDZ,;['CU&)%7I8]1!%P*/-]7GH2@[+E_>(?J=ZG2]\R4]\CU.OM)S7PWA\A
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M'@^]K:EE[;#;O]B*T/>J$J@9.%&WD=\0'^)BQJ_ 'CV)E#9VTAGS"0L'K-9
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M=UZD$I\7D7!08+04;?K37^T^FG\-V8.@<O6%/V.R]0XB<W$P>'4UC\J18[4
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M?U;"]VYK<B]95#D EC:#'P<10MTJUZ7C"HC&'$#UM]\]Z.-P25Y%_DKI&\$
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M(^8:EU@J@+4!V#)S2O3126\NV\;9,^WJUNOC/%%\%DKRVJJ9=D0$U7$A<S^
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M2'-9 X\UFQS[8X7HNT#D'1?%50>FC?N[A8U.8HF^$:8?4<E-]T1'&(X0!9\
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M@3-8/<'1GB"+^N+QS#[F_H9FBXI3Q+@DY73K.(G84W9K@F#'(Y+FQ\?!4[+
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M#AN9C<=?#\+(M)_%E2Q#PMSF'3*D^[G[$Y3'OGV+L1YYY.$C>U(!PM_0.S>
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M"];RBDIN] Z)=424'P7BT--O:Q#QK4+5:'PPUY42RA\HEYLAB1.(R'/-O?>
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M<%8OYZU+KPAL6?P> E[_O5\HA@-C6-?F4^RP9@.WO^M\;K&*YWL@^6_GLC5
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MK\P"Z5\!4JE6+D[@5X 7,@ 8C^__U#>?0S1*7?6Z9(1>BYSR"6J#)X9_8#'
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MZ(+8,(27QFS%JI(Y6_:OQ-;\D0YU<?IND76:T>1[LTH1>S!S,3^U4A?4=P4
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M*-IH3.K3J;ULG>;^"$CVB SUOMZ$O'9EX6]^X&#^_"Y9%S!JF1.;M"#01R,
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M4JO;7]T,O9-*1K7+9>=U3,]"3E7?3\)<$>0"4=)M';H,NY;-$5(!X@R:CHZ
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MA?S#AY2<(Q:%BC$L1N##G0*M^X;EL$ YMQ_X-$(Q41*7L];4=Q=[NIA1.AS
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MPB]CV>0'A,^$4:KE5:Z=E%-B,OV.,Z;+#YUHR3TF!RHSX*_,BB:\:'Z\^<]
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MGW1VBY)@C0OZI!8#!98X3YSMB6:9^_7:.H1EWEC\_W 1@AOX:S3NAB'7#Z\
M3BN7'/5(@G@,LG8E''CXG,@*^Y55!-MF"L#[P/YWQ_AS@%9C)P[C=T_^>^.W
MW0OV_W'-[L<5>)\3I2O _VA>C*2 _<^%O!2A2+/S_WA41OR_E=!E**<M&4X>
MI#C?K-Y;EV7)86VB:;SK7.AR]S,]4^TZ]J<95O?2#[(XN-*HL=?OA7FF.R,.
M0U'7S^M6K]_1WN3S;+IA+BG,S.>BDNI*G&A_;2];ABIP'5E1#>B/[O-94Q"9
M?$_&W8)8(T,U(LOQO-=<"M])@_3%T1S$O4E96J(I^EBCM\2Z"Z]Y2'(:",0)
MG#1UP6,[F1-1'BGQ=Q1?2KD%<40]$JY?5C^GDOJBL*2PA>B CEU*WX4O6*VE
MIB"=8(DVW)-;F,T\CU#2LI.&?(9[CTH.4[X^N6^\5EA2'=9%G-;'>0UV J;J
MAU7Y!U>?5;G\;*C:#OQV8&''UFUF4X2T<3LD(U),,U\!WL'<X<PXR2E3K"F<
M9G9A#+WY(P&K;4U%^(1Y0J;PA\ATX[P!VX;R;+L"W)HC-->38;((&X@HF8XW
M4\ZBZ*"$F<57>ND"(Y1%I/Q<K6:G1AB=P6VL' H1TVZ;W+R3_6CH'ZTOT=A]
M*340L>%'I(I%_V$<!#>0]8(I(*Z0$RZ[D2VMAA8K7W[GC<1_V&_GDDO,\A.O
MAQ#;K*?W?C;0T1+'"TFG&_@=6G78_J0=-=^.8)!73@7UA*LV%K__+Y8"#V\X
M%R< !$L"]4+\4@J1!8H)@!1GNT*Y&.<YS5+#E)2BK*P8<A[LD#QB:&)1_)2%
M6R3]8!!(6_T\I$0D8Z67 P#B_]9S,OZ6;!M<<_[Y>U7<T*JB8I:C<HPIF^W;
MN"$9%):.=H/3* LM"=VEH+:AHF=7U\_5,UZ?[2@35(LH#9$.Q<OT_9Z@>//+
M?9=WP*3;_EM=4HFBKZN,7<$?H4E+O?S6?GPK?+#ZAZHR[@E:M]*KRA+\:X0D
M6$?$.R<Y;GC@QKK39S7*"ZGGUTD2!WV+Z2R<^XQ^[>@0+IANU"R4$BN:OR:0
M4M#2'T: ZA!RB1SXYPW-EZ;ORA==&3W5W#2-)9R&1 9OK3OQY>+$^^$8'1 =
M)+HFB@,?F/;*ZR[K#S9:\[6-5]YTY]O@L72,5Y\-55\%Y.V 25F&XHC^<&U&
MAC'/>EYBYGZN]K;%[Q#@- ;;U*NGT-.,2^MF"R@,9:78@G#H)WT=>SJ9GN0^
MN]#6VC$1X:ZV6@[F.ME56!C82!S0IM]<S\=XR\'@KP(P0" >BBO#!J)@J'MO
M+5W>R NZ3WU?+8P2)T.\)$(0,^(TL&X^?S4Z)3:\?DK*Y>\@G8G:<Y]?9O,K
M%-<P#(Y5O9$E,%LM*M.4%%%L'DF=\G&Y0&H"[!52Y13++8D-$ZIA55VC^P=-
M]PBU9%-HFR]S*-?]XE;3V&3V-NG[ 2.48;6=1L3T63=X,?A87,@$^_-5<\C2
M\CIZL\6#>?2MHFKL.O#?]"439 L]&.=/\+)N;([LT>&7^B%&GQ5G:JH42;O&
M!5+&@B>=>N&Q84"<&ZH-2.O,\KZ;M%3PKJ+ZURG)+[?2 0+Y)_C*\DE_+K[>
M1JWROXTL%V_S;4DC_MP4("'A">#QL?SC*[4+;O$&QN:KH/8M,>RBMW?FZFL_
M[!S F1,J2C(*- Y\6UQ+@J8.BG!R<3;\6(%X=L1I2G"<09%6\^KW'=88.@H=
MYR^&-@>**2E:XORB3 FR20&;V9W_\/C_4SLYP9M[VX4NSI]N-J]P0G8?XV!%
M2[L+A*EG'NXMA_@^B[+39*N,?6\W.31=WP0U7GG*\^"D^BFY4\*RENC>QX'S
M4DIM,4DZ_M#"/[N'3?UA$EC0'A4Z^,3#TJ+>BW1;DJ%Q?(Q)SD=]"5H:;6NB
M@=A^S-+N@R7KAP';0<HYC$OF>,7Z0B//LH_,:>;OZ>2[@=%VKUQ95YP;,5Z]
M5A)BG_M%I_9OW<+WWFK[I+R^E3&7)2X.-?C2OPH&;._G^M%[2)]BWU?BJ2\S
M[56&3P[ 1> ;,">"."JE4/R$/]%@WC/*CU!LT+'W 8^C5G]&*S_,Y2O5#X"4
MQUX![-VX0GL&3;'M9V!,7KV4%OVM/:U3SR0YGN2)KB[EDQ-$?DE.OQHYU$C\
M7;M7J[GXZ(O2^'B>W@<;2:BZM";.R_G=.21BN_#NM*>,KNGFM9"#K+^=>F2]
MP=0X.ZX@CY<"9ZDQ!KAYI2 9JQHN&5A&>R$I<C;,V4MI^6?C% >Y@ U5%N=I
MO!3N!_'!][2T@/AX9]:-QQERMH\4Y<H/^\,&7>9O[P],K9\4DF^HF>F#=L'I
M<,IPW#ML6CWI^^_;>E(S22^2CH8&;H?,[P9D?:NK;VHPRHK@CP,ZL'VB,I[^
M;VQWC?KJSB1'<D1*T"73]K6&AO>T5;KI^'/S3XD*Y/8X/-GR2J8:, D7X F7
MWT[*);JK.<$7SDY3KG\R/KBI_W@/]:72["RLO/- 9"\(>GJ4Y3(WQ-B5D,Z$
MRWX9VL977L)($.JFX^J2"CLJ@W;"F_#$:Q0VZZ9+-@V2@/1VA^C^V>N"@F6J
MPIR#=JP>@FP@@VN/@1-7@!3D:@V\KFRO8"*Q76+U/K?RH?(N6!@$EO&2W3_W
MSFL*_G"&F%BA@8B?%EW?2AG>?5H&SKY],1;;NTNC3>'A45/R490XREE9[_ZZ
MZ:[?XG6[3N""!!$IV"^E_RX<A]0OLTV+\6HE(9TN%=^K[W5[3ZXM3B%?A''C
M>7 !F#I0K!Y&+?KX#R6Y/7U,PSL&=7V)(\EH=M4N?3*):YT,G.HDQ0MB)GKW
MQ,C1J9IU"0HO79GJBV6,\NW3ZHD!^S1G(!2^7PEAH$OU+J7]0I\L#@K!J7W"
MVV%D$44[F'@G#H^?M;Y%":^"W4>3#BGL!R;GF?'A>$=,9PG&#)U=CKD"F >9
MP UAWZM*8^Z<ES[4_[7&MC>3<4S\75/J%NH6GQ94[].>\.&RCY853S3!NUV3
ME(EX0!Y\(6&^SRP$FNN8W+&\<O(R;E7)5[/G*/($T=T>,N+[*HCF::< '7 O
M). 3AJUY*O.K1E:Y$'3W3_*_ZM"FQL'=,,8W%BFLBOY%)NVM^CESCPYS#7P#
MM5WI0@.:UJ8[<7[8G&[N.\U3K 8O.+)S)U7JHP[Y[VKR%.83U3XB?JEQ0)[U
MP!KD_G4'H%4"1'7WX>7*C4&2I%(/4Y0'F,<UE7TFCA ]J9%PJG8%;"!%@,[B
MT)YC4Y(T-?BVNKYFESQ_>B<.+WR2<PJKQ65]P3T]0JGFV?L7<CUWCBFM$,C&
M1LF?8^LCF([@4YW/>E[JNGMJI%8GCF)\+:+IOO32Q91FO3)QES:1-^Z_7^RS
MDJL5O&*TH_RLC%K5)2(&R!X7V35[,5,Y"V^)+3.YU.J)O-0."?U*H!N&W[!Q
M"^/ 1L_W'$\A#JH\/4OKZPI>!_.=ESK/K-]4.2I<B0X;@"I>YY@?7J86YQ:,
M%1C('FH]7H"V9DJ,L9VS#3B^\.B-3)M&V+SPP-]2N]%^?XU@UDM4FZZ?KG8V
MTES3;XV1'!5B''[3ZXV'Y\ES-YP>#" 3PRCF5&EP\5"Z*HL=R?M1M5:+%M]N
MT-N^=_]%JR[YZ';H?&TW-Q-FGMR'UF4@2^*74^X:YF1[<J3(---[9FOH?$\=
M=):UIL(8Y5E8GMS_*C0/RV*2@]E0YN9E4Q8-D:K^,)+_Q_6;;ZJP"6NWNLZR
MJZZU1PN^%U+2Q<&:I'I_]R)D+V6^]TSJ;9H^X,.[(8-P%0 ;HKC^8 'V'/=Z
ME4)9M-AE6RVARGC0W9!'RWEP-(+,YC8Y\_E!#?3U/!2(9>W'ZMC++8KOB\VR
MCK[M:T].N7ZU\F=5-'3HCY@]?!@_-B=VR4H+4G<W+XZ3!/B!+<+<%CL@!1X+
M#A1/P+DEXU+E>U"."2-?T96&Y3I:BDQ8Q@[7^O34%D.:1GAVO'/8?'S/>O \
MW0;[VY"TLH1H2F9K7?N]\M@H$WG0^7:;I:F:UC7]=QN'R6^S.JECER,A_@^E
M. VL'Z\X98OV/33Q:7C'MG<^GTR<6FFD.>A+7%0:H^O*]4U,C#(UK__5WK/_
M2^17:D8&'&&T?1(;B3>XE V;A-&*B'_Z-NV?;/3BF@$JJ UME)VE\DE%+&*1
M8.WS2^WOF _8W6%@# JN_BW/P>#\1MH/W? =B=0\P);,94,8WP#,#E6KDWRX
M\%M/M!=.]]&W?20A(0&A=R?#R+#L >JN>,APO]0AS@%W/W?^<S.8ZYE$KZ",
MT>TKP*\=K5UM/6VLSQ>X<JM&10]D98VL3SP625F_2#!EG9:V-IVE;LQ>[8&V
M,#EJBTV>@3XK^:U4$9+]S0\0 < $&Y;IK<[F]N33/CL7'S_>].KD\O>#"LIG
M$ZY'P 4OFSE5/DC&<\Q+1?YL(G>VLVW"/0KS63FA)%L/DL8;>RE+A#\8AJ,!
M^/?YZ']EDZIW=="BE.@YA3=I(@L.T=!OEJ#FWG?#_)=;"37LXY(V]]=^L)@]
MC1'KI$RY:;XD:V_*$)G\4M$@<^E^%5/AM\UE61=_@P+;.DYXC(3Y\%P1Z*X5
M*Z>*.Y,C^U/C7:4!(3<M+='[(_O56XXK81/(&_AG:&3B0G8M%BV;H3=7\[%>
M6"=:8)BZKX^9#=HNF4+&M7L,[UD6 D?!&:N)7(M+O5ZH.C9G=!#]YKV((C,>
M[U):,L\L#'?&I<U?&P&LZ.>VR[:W0: T&W$Z:*VR9 7;$_KNU7")%.&?[5J?
M(*/HP?AC>&*.E&[QH)>(TIZ.]%,=[]&,E!NDM_W ];TWWHW<B\N^:2*04!1W
ML=*(E($^YY\ITZZV;GE5,&-=5=]RWO!*3URR0'YMC1(2DFD*_/TGE,.$MUJO
M6M%2U2%=S_KWA0?='NEJ?/O3SKOBTD$(GA2Y0(.[Z8%)T,Y. K%AWZ=UE$,S
M5I!7N.*?23C?T6WD(U5>6 ]0M@FS!Q67]MVM.8TTA.AM'9'PO-WP&_9$PET)
MXI/VD/ID607:;9:17PH*:G*9I5< 9;,9!]S2FP?FN>83;W8,_-?+M,4>;532
M0GK'#2RUSC3&-S^\DN66=_W@/!OE.E#L6JG;8I2>F+['KE3?%K2$_\^TNF3B
MCT.H#N;^66J[JD.J#::_-"?A_4WJ&![R(9L6/O@ ,A=&@QOM*[S7"5?'+NG>
MRM6]M&+8>1XC'+3@MY1."G.',:Q9M%.@(0Y)+].WS<BQ[VE/NOAM"<*X*-S*
M&I6'W&G:/%Z&M.G7JL?3]6#7/!)&/K^N0;4<7F1AV/M7"FF*YB+$+$K@+C/[
M4?^PJFNSN?17W3^'#5RY#2M^IR ROZKAF3Y'DYW9;)"XCT6E0;5TBSV76$9K
M4&?LCL _+):DVY3[$09Q2M/?;N R0>E*P?>U;O5+!A]_QCQB-_<4N7AP&HPI
M[^-2'%RCZZWT\T(K66GNBWG>2_K:E-WVX>#Z$2/3_KD=P5<%NB;NX/IE8)Q_
M0Y*R:_]&E[LYI.6,'XX?-I-MCDL,VK@=JR^NP?I@;%"1*T"TA]-J7D'C%> O
MJV+3[Z7-^X1%):WZ_#M2^:G8WHB_J]AVTL1>>\FXR1ZG3,)G\-,DYA"92O6?
M7S SJX@8O;#CI6/?^0HDTP1]-'I)!LIB6P86A#^0K-8*%9PJ$Q3L-LNOWEM(
M>:\_*\QW5(G:PR.91(!=\Z>@ +0P^!@L^5Q2PGM1?F@+0VPX46^YUL\C&'@,
MD06>P"V=Z_;V!:]<(Z9@B,1VJ+(IY08)']LVV(DX? 6H.^N&T^S*$OFQW!6.
M7N@@_]Q0!6Z)>Q_S[EN8KW->;'%)@'6NP4&]'>2%0OP>W]G5DVBHT.K3N4T9
M?).\+_3F%8!\>&]QKFX5>-O[%44,.ND*P)Q0DG2QS-#(=R-;"72I("\C\+#M
M]Y'VO);PBF=&ORJ?G7P):YJC_/_%W'M'-?EUZZ)!4! ITCL!:=)!>HV(= 'I
M4@,B77IO"8)([P)*1SJ(2!>DMPA([QT2>DVH 4*X_+Z]S[CW?&/?L_>?YX\U
M1L;(&F_>D377G,^<SRSJ8FYM(Q1:\1*T5<#*^J?;A?7N3J;>FBY0R0"N;B:1
MWH#:W8G%(::2\**E=_F1*J8^EYZSR%^8H>"IU80%X%I"N&BF-HG3N?"0?/QK
ME2=]$BYA ,:S@Q&V7:<3_"YPW?VVKVNY9#W;A@[304R%2;_:W"<PB!W].X,Z
ML@:+K+=AYCT. UM\63H4^F(,Q-L880S&%T-SW4/)>W?-'9'I]>I^],A2MB^S
M+)\L.2A=1426#1UD/_WA,*Z7[!$=X#H.VUU42]KP/S=/5\\L1WD)E1<_R>9N
MUNL9^*P?G%[G,I89'51Y:0^YG,<N@6N-^J"D3/APIM2*'1/GWSU1 4D_%^B=
M ;PI'4S5X&00I??1;-<1O,(,':A:*TY]\<E^?)C@@H;T%TZ=-P)YE62Q@=">
M4UQK*UK;TX1VS+>06ON3#P98?E7O8;S7\5F2ME]R-9CW(U)P/QUIW>DQA BV
M-JR?LIB1(+4]Y@O_*M3KDZP&VEIN+ZYEO([B@3T,@\%K[")2"BS2O,KUNG7*
M/KG%IFQD:I;"M#26Y$C[A*1L-93?9*!I;>LVFW8T^-2+'*-K4G.J-3DW?/^>
MUMH 8Z -$:%U[8"JT!9@T:"5??4C>\R?H)IMY6$2'"GFI;VRFZ2@0.1)!S,E
MBC0>H[*V].+:<&K_,%,S9;]&C7YQX&M<:@,B5(4%FWIL!!->(XVU$*T>O?-_
MW_*R3[BPJ5S+RKQ<-@MAW-?)"L?FU%\+7G/Z':W"/K8Q@CY Q-'W!M4;1T_G
M;!JGJMZ/O=SG[S"OD?YARL;CRU1XV(T3MND&D>"%QXOWOBZ(]FZO%1+C^M2C
M_NR-Y+3%>I&FZ&?SHZ<K\)6_>W B>1'VM7*QD@BW' FJ^U'=?0[P++DY)<W*
M=QEJ,B8SM5*@.=S56T"D/ C(A/YM;HSXY=3_(TCJ_JSK,\G&M$AE!IGGYJUR
M<A5G%ZOX,>^]B(6"I&:XXA<LQI9?0L52'_45 (2X9 '"9W*>8'+LWUL (P;7
MWQOA[+G6<]Y?8J^[I&)=W&']R)W<A1#/T5]72-HRP<()OSNC,1;"C;',[4E3
M$T_GWYC[Y*<H"O[-']KC#H/^N:B:KL%0 R-*QWNLJJ+^"NI2G?WNT\O6<F9N
MR'#5ZI>/Z+1VE\PZK QX\_DGFO>%UVGCE..++,,*C4Y8H(-/PBP#*85]\^>3
M^?F5A3IDM7+"D'G/\;,"V6/)0R=_SW@H:1'$Q8D9B!(,P0JB=9=73#/@*SH9
MN(&$?__^_O)CM4."\>H<XW0:1_KGZZZ!]K8(V"K55LQ]K(H>[1O18U7.X^W0
MZ.VO\M7X0D,Y*,<J[!/9F%>%<BL]\OSS9FKVMTOSZ=TC@R7'"!TEJCUFM_][
M>?Y_C>>- R,-7&=IL1/8A[F].91AS*)C3ZXUOU=S'0TNL'JQ?J:^'A ^ZSB_
M22VFG4HJ<&-B?%;S<Z#F9S<W4R?>EGP=#D8PB/VF',(:1)4#^@"J)\F%:Z.5
M@T3<SAM\65VHB,3WK5_0(N*BI=\%SLQ6WZG7Y[> =]KA24":((E1P3-M9HY:
MCJR4EQ/#M0<WTX]<+!6M:3&\5R3H@^N'&#ST;LHB.JRS^55 W77C"O_WP*Q?
M+-6LCUSZ1\R CI>"72M(%<&Y&849ZZD?7L[BQY+%QB^)'R@0>M 0,S_%O;Q"
M@KI7YNVPA('7"MO+@BBY^"J[54V0?KQ!Z+E4>.,<VU?"D!_BUI;WVFN!H7?X
M4CL,BS,:Q/1M 887 ,FVNP]+^Z X0LEJADJ CR ,L?089K0_,ET]0@TI\>GT
MAIS@&UE=VBB[QY][(;[//G3"GDLSDCM-E *J>K713T&="4"_$YB0HSSS)[@3
M4_Z;E]\'8YVW\<OZH%^JYK,75V.]UR_*)0*T,N_.#-A@> $ZFQ9:&6[SC?YE
MA]L[)R#XY&_Y6^Y55)1RW<^)]7)X]G[1UN25!1D\JSO,<Q'XV,8+>2;\BUM*
M)YZ3>3QU.=W]L/$5IN .S;A@2% 277-B>[> QPNRFI#D2UM]GFX?1"?;* (E
M=C6MK,Q35)QK\_8WWX%5 _BPYX/*.L^&<W<0Z,/:^\S[21MM$[M^A.JI=W]O
MN6E+KN'U%Q2(;)/1.!M1BQF9N_$5*M^=.5<K=S3EH#Q7\_J''8U]1E#T'P5Q
MA\R < _ X7T;I[0=[V^[B:\^3.T+'!?>(V%)C(>->E5::K\@9;2;6:X "WZU
M\?LR?&WZ$?9CV\SZK/#<P<<)^7-Z]]H<0G)QZ0)E!C('*9)$72OX-8Q9>QM,
M%CT*<2L9D;V[-2 MIRO%F[ JS5M QXTXPMUYA$2D'_@;PGMY"[BI;&'T$HQI
M$YHZW/=IN:AI(?JCO#^@I:P"+CD1NW:]@PD+J$_991B:AG'F-0K=Z#=?3*D9
MSOE<2/ M"GUNG"Z-NNB_F-7VRLO^2;W[8&-2[YY<) 6E)L],KXL57%JI3+IQ
M1_#S63BLT41\O04TEL1VCA5HX]*/QFTHJY-9#.C-F//=\)V#5&", 7H:(>Y#
M OZR7C#Y.LL TH'V\I%U*X4145WF+SLY]PG_B3J&2.72HBNTD$81WD!RQ\(8
M8G$VT77&QWD4DZA1>G1!-Q2I0QJ*Y4+A(,]SV?NVS3.?O2I7R6"PE3^J] 8W
M;/4X<W6!"+V#Z:_6V)JF*YDEK?EPY765^AX>:I?(>E=MM9^#D;'R7.C*<R?>
MX OG[S<%&X-,Q;H=5SER<M6]$'XX311=Q"/WA =N#<8O/O&4D,VL]W +!'SF
M/IF3DZ?AJ!]9E)5 =@O"EQ\A7/B'W&ECF4AHNYN_^-+T$RDIX2VZ3!6F. ?D
M3A>GEBE4[$P'9#=HMNYSB[Z\!7A?&89[RI-4!XMTS3-]C%:<WT'V# 0<FN4$
M[Q7ALQ7+59R'!PJX1@]F3L]CN>#$Q0L)72N_H1L[:,;V*(QI$5I%*UUWJN@A
MD;IQB(UA!UY.*_H4X[05V?X>%/[,0BRI.5F*7)'.+D.H"8@DLZA$L:U]07]P
M//>TR/1CI+(9Q G+B@5X3K=)3M\"+(DI=).-*^NKG40_-FP\"_NUE15^"Y#;
MB;PZ>8%&(5<L%M;]0ON(9V'9WH_W]OY@S:6JE,-Z(;2_E)*!9/;);#?C8AHL
MVIC[Q40@,G#J50F&PM4BTW\<RV$V2TX %@@L@KG'%<0"N_?,_HDWB4,$YO]P
MUJ"GRH1B#U4A2SY-1PE?0Y@^B:!'\?<+Z=.R/1-JP7-F=B5)WGA-5_X>XHX'
M$#;'Y<<W16T 99OQ'V=@ZOK<)?,9&F:[]%M L)W\4H 1][>[!ZO< AR6N-Y$
MJ**T.P/_U&W;OK&97)^PP>MC</#D2A/ITX*KY9$NJ_.N02/NI#*B<\E:JU&;
M 1TZT36__D%B;@D0(A,B_E@]E37A0CO_ &R*5H0MDZ.6OK0C?]0[5)A2$;<M
M=<IH!S<-R]GC5O^7 TKE4;> GEP2C.QXT>191>D')8\TN %YM<[-LBH=HOH'
M$$$# Q%C^,<%VL?S?Z, \PW-KUG7DR*E!K9*68BL9XIY3^P,VE"@WB5U;6IT
MVY4S2.G$PIB/T^?E&U^7ZX\?XIH.GC.TD\D&PV\!"6VL@8&!7T^/<#I9'1:;
MXH@<^NFX\,A@)44>Y(YNZ4#2-L:YN@OKQVWYA"ZVB8F%7_49,7.[D#JTW52+
M9X4)1A)M;?=DV_6) O2[:<%]A:ZF9Z6(=O>S7D@LAO(F6U8&V=PG]0,>H3?]
M55'-_\F1MP^@<5A932_+$B%[\UP2-+=W[G,+^/B6MD438=\V ^=ZER&6K1B^
M=&+32)H';^MM::F;X.=H;D[C=7+RFU>QXXDLCU;#E63Z=2]OZBQ.XD7UG>RZ
M6-?6AMBJ%;$:^,D2(;)P>R%V0>_0US^"-*8.9:E6)]BE=37X^*$X-L;ZU;H:
M\:2#\:<X[:B3\_ I61UOP5 L<\MWX[\T$H^KV? .;!>S?+EV#L#B^!-8.N.'
MMCY304[?8Y\4^(\KB2YZ2%DJ JNHY(:6$KJ=0?O-[ZV-47T%D=/WF;T6-BY]
MW9L^] \'1Y0 7T-&H+5*O9CS=G)Y-MM#+#HSTJLBSW1_KKN4 /$H#*9M1@@
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MV?"G4 <KY(I)U]K.@(BO@R2,3%<\Q@$Z6'($49E?J;'KY#6M>K@CSXDJ-].
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MSF=%!4("RN//+9\%G,DB>1&N:*ZTU&]!G$CSOV J,5,_C&II=,3KH#JBJA,
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MSR1Q=H8IZ"9A_PF_Z81O!^EXU6M2]6N*^:?;+&,+RX952:Z&CQ?68+KG+"7
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M1,(@8W+E?_<<WVF9]<Q\:J1Z=G\7F37N_NN$3!^BS[JQ-KS=EK> AJ#*PUM
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MH8Q+= L8591+_@6V2->Y7L?O9>C/= GSY''8-+B'('R;4DG>9Y-!AX]?&AB
M8CTGZ4!)+<,L:%"SL)AG[Y]+F#IPQ *(C$A3'<]QR[L+22=SU/8)STX^N/"Y
M4%R?-Y./=^59>5.Y0YA9VVZ*0VQW!\%%NQ=8L7K2K89C*-_4YU\['$]G$N[Y
M[4+=@$J85S=-@6(H.6M48%E$XV@XM1A[S CS.['YMP=[FE)*%O:X1^YNPZ7X
MDG,L,1T*Q;Z5:A%&OXZ>0:;_R-J7)803/"%/3@V7P_,_KQH!J!/M,-X"DC52
MC."**<:/.7_9;B:'/P,;O'^"\T>#IVT0S)I7'C?>?ZY__S,60 ',*V@H@-Z
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M^P"EG:[B?KM9]J>2G<#3@.S/4,\&Y'* C]*P*Q 9N?Z^,)^]I2F?AD[%.ID
MJF^IR#W O-*FJSDF/2;3HF$NLB)R4<DR4H"A;'V.G!@T5=-XC<OHL4<P42L:
MD:7I2WOS&K;O@Z&(T,X_ZOZD))1B,!LL[]%\(7MZY8/51]X",%0T/;98KEV3
M.I.C>$]=H8,A+$I\%U:@&01:D%G/6J/D99]UZ1#R<OWT&>'[3M&UV+LWE*C
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MS#"YNU5SJ@E@XDE'&29*BJ\?BA[IP434))2KGOFINR\KIG1-YGV+JD]-:D%
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MILY<3/BC7:@]VA9V")"Y;LM<N@P#0I4:'1L/M0>][-YDN%7&13IO:3?ZJ5J
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M..9-&I&:3!R6,-/JSEHK8F^P'1(TSE7)V1)/6#;=1APF.GY ?$1H5W(62V2
MW_=.%QL4%0EJY-0G*(P6A!/?-H)D/$$K1;!:5%S5$9?0>.>4B7E$_52!%O>8
MK*A7D32),W=YH_G2+>YD$.\8ITHS_]HYF-$D^:[88]'/O04WS##*YGPS3*Q)
M[3UL BH_0&%(%2+]Q0/G9;:^[PGE,]_3G8,V*C)V.>R3!]"#T/=0VV:$.['I
M0HLDC(]ZS]&%O&D'J[&(@S@ J%)OU_&V;.X/X$JJW#3IVUMPVS9;^JM%NF:6
M+X% )NO EZ^U<V5_=P1EZN3J\7;AN.](%,?H^B:X&" $Q=3EN9T&/>;*Q0-#
M:871+"P\C- '5P#'/]^L+'.?L]DT;=@YZ/K$T@*X%X-73&?9/48C,\ET^,UL
M)7=\4YQE74QC"X.[*6V9IH! :I*'\/KRS% O#PU0P!D18D1(^#G-WK'*0F?O
M_I#Y>H"&Y.Z"9&ZO[69>P_'RSA!^V>RR0!86K0I":4&';+Q5T%&[:R9=B7(!
M\0_I_Y1W<BEL]H60=2+Z?('35.&YP&WEU,P6^:'C%\K&O$*5(:J_G7?@^3L.
MS17 E6JF\KZU+]JQ+A9#]-':=Y]>M+J37-61&\N@NOTN\.U-%+T[R1V3H/AU
MW..?Q"":TD\.;RH6@^W.'6N&H4G^N'&JL^FA*T =//J(" 1= 6XU%J[.;K>Z
MC=Y_MD:_]/B :NE!O#MN6O:HH>.R:'R(JYTPB&^<9>(R"U/Y\ CEB1EDK#YS
MX^<VF^@SRGO8SO!JK=>HJ3XL29.Y 2Q]X+97:3XS6RJH@,&PRZPNRVZJ/=?)
MKMPO9#[#) [NZ7Q\_4 G*,]IYJ9I@NW;K<[5>X.W'L22[EW6JS*3Z(D#-MB@
M=H[O%DY(I6KG&)39&,]ROY;#W8.<O7UX#],%YAW=G,C>5]#!W))3S?:ZQM"E
MZUG'95N(,FXTPEH8A:QMS!OOR6H?Y1_>N358H,C#E\EY+?Z4;+Q"3/AB--C\
MCCX^PZPNA$EA=/LS3WFH@[&SS^7GT+RF3/72;2\36M8=;"X= MA&+P8N?QO:
M5/.J]&=3YIR>^M"T1W$OBN)X.!!3ML5-/^5I?GZ\FD+5YBA^JVGHT>T!3G$>
M<E6(]$D$$835V1Y"L$-N\S<W.K.[O]SI<:-,&44-_5BYGW-TRK1 #-1OFO38
ML%+%[<)<3$S:'1:VA<,XU@5J!+8TW6(OC2[CD9Q.[(BHAM%KQ.*=N8]DOEB,
M^U* )B3+^)^GD0.X0*(ON+O]1JK#EU%675;%MU)+3%@AXJS!T*.BF!Y,C5&F
MK))/^/BMA7K=P=TY]+'\?0=6-T14H04].Z3B]'%QA&%?7QF3-VM0?9'" *S=
MG'U^!SZ"A%\H$9OZ:WJP*E*7!1.[JS2_\X6%?N0UGWV@J@J]ZV&Y&**)1\7)
MB-,0I_;6<<],(]G4?JP%,-\)QGL57@$FP?E@=O)]2,^)"W$ML+A"FN>6M57[
M[T_?GM8,/-*@6YR[AN/!62+ZQ %)T;]FER$!LV(-@F% J$$,IR*GHX<9-V1C
M>ZX]4:1W8T&RSQN#Y.NVV7Y3(UT:,4C(ZWI:=*=AF5]AO&QRXNM<G<GTKR,?
M!?L@Y//#BHR.Y\;QSEC)9IC3!LLM<U_?!/*8U;L]=U=N2J+K-Z*CVO31LP0Q
M#P:JT'E=.R]J.MCG4W+#N<"%**0.(Y;T*+D84CLUJ-S6G&[3FJ(P[>QU_1.:
MZP>N$03Z.6RX NH?I89PSYL2D'!?&\R\__U9/1&/#YU=23>BQL\(8Y4A;.Z!
M:&Z!VIJ)C=27XR*Y#!P_:T-BO6A)27KXJIU,.JSFQY9&]?>]."]94'V=N4+L
MIY\J>7*5+U 2I3PVVCG%E6PC=!DOE=&!I>NV:]TAH9GK,UE&WI;-;ESF1AL?
M??)9L=75IQNR+,XE*K9<1347I:Y_905E#X%YPT1^LVRS:3M!=4DPI#=A=0WP
M"EW,"85> ?B@8ZWH;G%*2!7/7SW0/'8TV_ %,&Z/NM=OJP71^T*(I]C>7NH
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MPZXE^DEF,.V?)O:?'TZ#DH5?M-7%QU^77$)^QJ-WBJI(:@U1A@1DD7_1Z,?
MCYZ&S?'I=R2"+R7C3Q'E2 [RJ"HU_FY-3*7H<8QW1,8!_2,5_,H&X2O=:"\Q
MB&"*8[<8QLBD]N"K>AZM2KP%^F;\$QHT< 0TG>2A1=FYWQ058B:FP.>56H7V
M8!)R9G89(H&T= H;JI,G]AG9Q9LEMM5U3?5J71:0#(E_3UX)IQ&2>CUO$QFN
M@:(;%'89PP+"*E8HDKX$7B^>^74S,X+TSU>BLMY+Z2<UB6.S , -JU5:@!@C
MY[4YQ);U@]\R_@Z3LLK*][ZFGL2D2*,O^#:.$!%D(>ATH,0'GNYYS]W,D7Y/
M\9^CG-6="MOGM*%0CVG$WT?NT7?LR;0U_D?]25"^5I84X"SQ)F:"+&-)5P-]
M2)Y19<(G',V9?+%]A%#>BZ3.#A!G_;1F3'Z12,>;XSCA3YSOA?(16W )%A>F
MKZ;YQ]OY@]?FIEYGR9J9;7C<9KVF5]R\:XE,*(4(:#5D:M6I(;9+6QYF.)'6
MI>.O'4H([-MR3N=#J#%)?4FQ34G?B8G]N*?XG6]QSNG<_ <QG0]6Z-K(P:^H
M\A9&5T9ON'@O.65(N<Y]FSG,XER@D\EIHFXK'=C<M?Y01.(E(@B)V&G3W]]2
MG_RF^*>E,61^_T6547C]_7C<]!AREFCQ5ULH8U;_3O2J-L6>:X$\G\N(5P W
MGVL;I'7DE[KJVO&" Q%WF_HHQ8.5!-L7B4J/*8H (?OX^1,7O'S8U)!AR_C4
M?N]CICTQN*M@VK4V0.0H+]\&R763\5G"4XVRZ*\WC%^5 ?X 6 &A@A/_V;0W
M[:\N@@;XRUP[^T_SG"?X3H)XE[N05'9"7K6' F="P4.Z)K4KP#3"^/)CB-9E
M$=[QR>^X/265^%<1(]J[MW*E=\GJFA<!P]^'\1&XC*WIX<,UP?LON0\_I]D]
MTEI9]>,ZP[9? <BW%]UEH-03BZN&W"QO;PYT);]S_'J,+JX$0)/_1U7H+Z/Z
M37P?@[(18T]N"HJ\JIJBHG0,#$G2/IX[6\9U$":.ZE8:^OUAHA;?O7H^;"^]
ME[@"V.\JC1QVZ1-3GD\><Y1_47L1!)6&?SX<"77=TCY A2_170$^\G29* F2
M;TIS2R9)T&T3SZ=+P^BT >;_O?S,?HTR!;)! 3?W9WQU$UH.<9.9WYZ\EE!9
M,0[0>"*9[Y%[_A?["2PG" )5UWY<,"A:E.3L^/;\,CZULE9$/R;KF8"'PF**
M)J;_"6*!8\BNO:&Y/O72JE><^@K0NF5T!5 B^X-6OH'K-F+(S"Z^)&/\O)YX
M%"7*"94H:\LJ0-M%Z 2NA"?FM4]W$S_$CGJQW13@2;8_\C4GFAL+&7>:IB0H
MU4_X^ZP3T_S;@^$671,^%2;NFM19MD(K_UA[18@8LPZ,W%\W2<!5!.5E_H%"
M(51@,(TKB[F=T#DTQAZ8X,GY)<%:!O2X:TNR<SMG*K!O>;:I%\6]^XT8@3FX
M MB-Q00];/QQR" BS7 _#%3,5?X%GQDGHQ>3$1-:4KM9S?MY+=DK?A[RUCOI
M!>=A7L,YX8+1A?M.6RZ)FFM"/LM_MT[M<<HSX(\(K;G@/-^S<W8R$WX_PKME
M@\WH9XU/QNNP41=;;F6AKLG+*1ZN1QW9I4]5]P7DQIJ:80;>#IZ<Q9&XIRF)
MXO3IW5&3A.;HJN!F8Z:10N/M83L$U^I1L"6)I>DRMWZ?C;4^5W!JJ/?<[O,7
M[T9W0HY<L/PF6GM--HD2'*)"B,RFBH?^#N*JK]&0EY8BQ5/Y-E%0"%P!$.!2
M6,-HY]!H&)S-$PA>8?YR=)$=F;?W>/*C=Z&DPP#G&]_-X:"/2Y2UQ/-&X6_S
MLJ/1'$.Q?O1G\;4MUUII"*,"U>?3\#XB]Z.5)8FBGL\MQC]]0L;J\4&A9ETC
M'4+$C(+2_EI3?21<7"X03Q9XC.7FSO"/\.[&5=?;1O?K^^@7"QD9^&07A]J[
MFP9N^ COLT#$0'><! N6S407RN]45CN1_LP#N'KV[3@#+H5W>6:'3L+@&'*^
MHST";+XX8]E=(E*;9RL<?X_1=YP4/ST"9@&MY+GC]3J5P+TO?2WR5+0A*1B9
MTP!C#7L:1D&0+A71-"9$%(]+@$[WGT\5B<\<326YUR<& +T;@V@"#LI@W65)
MM 3Y\ 7UGM<^V-A9/\FS7*")5+K,!ONR55:NB!A_://\8FJP6/%?$+%6&3@,
M,1@HQ3G_[AZ)N*T[:%3TQ&>R_,FF,]C8_0+>G$=-$/N I8MAGHL*.PJL:9[:
M,_:PPIW!@GN\.=_E^8X7A7RX\"=/Y+%=?E:5<0HV32!)<U=^ _/Y6"HVTD;Y
MA'6F?+1%0!=O!.M]@+F!WR_1IKYHR\/.W=7HRI>BM/_A=!(&V8=#%UW?X8I&
M=WPOP)ON6!3'5JOG7(7(JL00\%,F33(GK:Z&WA%BUQ+%]KY2AR4B"&DJTEWI
M8E:"22UF=[;(*G@UZ]O6M('R/5NFC^BU(9A9O@Q!2+[V5_*7&*G=.*G:U<@^
MB3,=K+2O.>#Y\%=]?8/5:<:VAV(P&![*F1D7:G_ 0%TTRR>I#9Y'2H1+X2,8
MCFX7A(&Q_#FQ<V9N-4+-ZO[6XQ-DY2\0D3"S$]JX=?-ZXDUA?"%&OH=N5J?G
M"L#BGZ!V83 ITJX2<+@9>3>^CA7^6*IEQ$O9=V$:?*%/'B??)VC W?,ALLB?
M4REB<(YY_.[-9^^JPP765F'GVX-H;XLN3$US&</'/Q,EI>VB=US<)_+WE/GQ
MPB3E8@]W/6U.4&0O%E^/8<=[)2F76NO*15B;MA'GP SOP*&:$ %-)+&'D-K+
M(JDQ?>Z0[B^3>5^#)IG/92VI!' MKQMY!2#Z/TKFB2G\_2B@ [_@>J(<IQSX
MP_0BGLWHF+6+Z_R=Z7OR:)XTT0*ON9)166)6WYJ9&&+_]@_9[L58GVROG9V=
M!ZO#]J7K-FS6=&6ISA,_;DHL+NL_#9QN#5_^FT(RY^\/K-M2,LB5[@BC,3NH
M^YG-1MTVQ7H2PRI5CEGFNGZ%&J+::8YC=:LN1^21N=G<%J1<HJBV0NP"\05U
MT?NA\7J[+:W'$][@@UU!8<%Y\)=S^@L)TL,Q('WIUM+#WR)S8STF"?'Z/SY[
MK]\$\J#/SJ?G."*]1X(NA0>0C) FC:GV?[[OI"Q-;2TMB"ZVV#V-[]!B^W'^
MSK$48=#0UM@>/^0N].)#;(8&S36NQ-LD%==3MZQ$GKN9F,U?:?:W^R9/W3E&
MBE'*FD7?YM8V:\[$G,T;>3G,_0LFODZ*^I\Z5YE96WDR9H6:%(OCYBL9QKOG
MZI$/ZQ-/GU_(A!VPV;Z^UU>_IVQ&_TDZO(N[(^E0[<*5Q$BTQ]*_(U"L3'C]
M"?RU.,#_.UKDM=>9FSLO_ H KH3IH.[)F!+HPALN'\HNRZ[#95[%.TI)=.((
MLJ1*\G@<]@H0:2TR2:+#&K>,'[6U#2P)/O=+2,^MEN>D_>BG2O(&YT ZLH'%
M4:XF?7;+\Z^MM/T%L=6_>Y0.XU+J';),OV?LA=+5X?<ICA?&)'O6Q4713[W2
MV?/F9_N=91:"/#H*#T@C,$Q2O!@.SX=DG!0#XMY1SV])_YS_E?!="OI6L_E\
MNAO%I$H#0?4$=TP58U:;5>]-" 1D[<ISO+%75.1=PP4$'ZTC,_'\%7.+Z2>I
MKA)&7[0M%NUN*@(E0N#6:-ES CYJQ3$"^9@\W(KJ$5YMA/<).\KV=6S\.+W^
MA,VN:ZWUP_(8*@DHB0DYE/M9,^M7XU^R^CJ#FNO+*D2HYGSRCEFL08?2JY*C
M'FUV<8?*87=EGM\ASKEOI"IH[W/_,<RPC^BS\7K]_6%.1X1VFE!)J7&:24.J
MQ2!YZQ?9308^6X=.UJ.+)<F6-C/0B]F\!9!Y!Z\ TE:F/?.7'E< ;'K31R0_
M\%3)I55M_?G(*Q]&>#9@Y1U\"MGV^VB9B<1&C*H(D2.$&*"++"R'/1V!*P6U
M^_9J+<3->-_C33-N52((J\<,*?A) HZ;G^HW?^'R$,5)28C!VL/#4R^%5^M$
M-.]5/>KU<J2W<:I \]Q>.Q-38C2^LS15N/8=8SVB^\I9E'2B&GY732117P<T
M2&#BOAX>*2Z1+]A:;31FD"DC8^*\?[87'!4=PK)"=\/E7)GH; -R<3+C28_Z
MV0/TS6NY#/8&EUT!ZD:CR;2NYGJDAZW=LV:0J!T /X:^?_[$2\U[^9A43IC&
M!G8C8L%WZKEX]0FD^W-;3^@KWGZ68E&P:I>C ]HJ#@?3[0S95$(V>O4"L2H:
M+^_B7JC_XWO;GB*\.7GBS3F4Z:2=WK07=!=2_F!E9YX^TY9+"$']Q880DEYC
M%@N9WGW<G?$(>@3F;\DRC4\^"%%7BV@>BCKD?M"EQJ8A72Q$U#[B?ZQ?!)1.
M4-3V,YZ8EMUE>0>O0]['PR*1/3B=6]_),RC[9G:W,K)/,5T8K047"V$3#(>*
MM1/I/4-+B>)8L;K\36N1%*R=1H>K7QHO0YON965GYP8KVN4"?N))N )T70$B
M@K]7?H<L]S&/+UHRQR[I9$>D>H<@",];?BA<]%!N_.+YB/*$$04$NI*2S'=/
M^Y?I0HQ#:5\;6.1[.I;<ZJ24#IU9Y:*Z IBCJJN)P:P+Q:=I$F99:<+&N2^H
MFC[6, I>:)Q9GJ9JR56.H5=BV_\X3"%B^FV<C KU9G"V42G%)K4?C2R=RQ]W
MO]RNJG3]M85R@--!AY#7"9?U)TK?8[#*VU_B@N1V/945W]XZ,_4"$N9)*N*X
MT/V(X]$8\P_C]?/N GIUXZMY3,R$KMSD# -5_0F*>+\1A=VSUQ</H"/0:T00
M+@AH(=Z;/<H@]D$D1>O&).[GM_[%6\ZL=&UYN;[6$1=:I% "51R2UPP5_I7^
MSZENJ]'8_!7 >^:9UOSN[A$B#TVXP<E]O2"GQ></UG8'GX8MF_0S"LW9&6M;
M*QE;6\:KQ"K*$-CB[;7KR]Y:<QUBRU#V3(99TB9ZZI!'^U4;QOCEYRW$)BP=
MFXM\*7]_!$8XYO2%JIWZAWDJ@?=>R'9;5@5$K2JS*P^#P-AJ/3Z@<1]SFW5&
MQWX]XQH4!VCA5=%4/5Z#LB'Q\)TK -Y"'S\HT4)(ZA-^T5=']W X&-[WWBQD
M)!@'?P+6)_?S4!][1JG>3WI%S#CH*=[*[#[X-?2IR!$F"5@F$['M52Q_W[B]
M$(3F8<66@WYY_$\"0ZI!3^ND8C5YJGPZ73_@U3M1VH6_V9BFWZ ?RZCHY5,8
M.51RX/L.,OZ]T&HLZO4[L^4OKA.7@,M4,J/X>[]*'>.,_\;;FT=#&;___R.*
MLI4ENU&($-EW4\D>BI!U" G9$L8V@[)D#:&$J6Q9)]D9)ON6?5_'S-B7S%C&
M8&9\>W]^YW=^O\_W<[[_?O]X_7>?<]_GOJ_E\;S.==T7N\#?!KKQ:NG+TIB9
M9'ISBN>.8>\(V"1=_V>6X<PKE_JDBEG9?N<H_2U/Z_>TD7GAS-"33,R-J#8G
M_ 1:P;W-!OQG=4]Y/7 /6HQKV'E$@)1.;DD:OIX,?')L!G679$P\ JZ,7%+A
MF!19%P9&%EOY]?Z/R;K_WEYD5QH22X8X_)-AY>> T]L_:$]H__?FHH>H_1P8
M+6SF"S:%H@5Y'G\E<YO\3R"-W0R&DZ\Q+NN]U[H9IC+A0Y8,F^+*?SSAZD[[
MD98BAWDO<A5P)%9< 3U&A[&2FO&[\Q:3"%N;NB<M^:;H2[]%?@BEYBW5GOB=
M R[AMJ\;X0_,?YX9ZOGZ!(C*UD0: 6M-KD0$BS8YM_K%4TN*Z^N;$KO\F/R[
M0PKB*HOQ0O$78.PG4'VR @&4Y%7+N/)S*HPKY),?W]!/_?B[OCTWZ%'G@+)B
M-R?,.8#V5EI]D]?IIEIZT<:4=9V<*C^3BS_\H M:[0ED">.KL!U@GHHLBLTP
M/.GSY&U*1PO13.=]1GP*>W+&!3'JM)*STRNWFXEY/L!OV/_#_\.E\9''!@2]
M&+(]H1CSMSR;?'HXAWB'R?IS36KX9C##+&-BZC'DU&ISN@V49 /J&N2IW/D=
MM35ZS=OY19O[)<XX^KR"-X)(J[6/^&U!.M);&+[>UJH)WYX9P]@8^2IQ=RO4
M\8RJ"(H*>W$.8*#*NFOQC8H(ZT]+/V?[GG-+-&#81&5X<_L>L%HA5L2O[4?%
MFO4N)M>T3\I 2/-G/Q_"Y.B@OEMF3K@=Q;P,-XK:E48:2_R:G>VI/0<$)],
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M,[G)-=R/1&>3\Z;. 9ZL<Q?XLJX[" #=AGN7[O'P55'0Q=L66%(5P0U[89=
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M=3%3UQ+UZ#QY?>^J/%9C^4BS#^M SVJW9>O"Z:C2U;R5=1=XQ)8*Z,T;ZK!
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M%6[^RVB$""=)P9._XWTZ0(PQOZ.>:U_$W#O(?<KD5R.]P'))LPG*@NK>8^W
M4Q627Z:Y?[60X&,^D+%C6;YVPAI"T:%\1^HI_XNG,QH\!".ED-:T5KO[!P-Z
M^XG>1QJ$:30/@H^2!UO.;F4B9?EI?:G8(K0!DC)'13Y(I-',)N89"#ESDH!
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M:X:8LI#D9FNV;<V<>;-[?G%=3H7?!:BQF)@:[GF#7J 2EH#G ,.FR=:%DK3
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M,,'4,,&2T'FL9I=%"]%NN5N<VD/?L#MLZG%(@CFEL%Q6'L!*(OU_N[/2PST
M)&J'84-CAJTMX;G=VRC<[L-UU6%"P#KGN#$&%8L5%MF1<9W36OE2S^^&;A *
M.4*4?:/$A=W@N^05>!)W#H )^"^V9LQMG -^P=X>%FD3^_Y>N.IW<X4_W!@
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MZ+AS1!88H\;>%$*[<[A4M81@RC3 ,I^+9Y79A$J$SG6KP? ;H!J^>&7VSQ=
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MOTSN;S?N_';#GZR%@D5WP*] [V$B B5:%5S*XWX,BK1\J:DO* THV5N5*"Z
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MB%M9L5(")#2Q?L1&Q.[O/CL&LP>;X3Y?&P[6]YN&9>TH]J99(<0X(KWD$RX
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M.:<&J#'0DQ]Y:2>WC,VEC@NTB/;)'*^EV"5GU:P:4Q"XKC$\@?X;#5Y,_[O
MT2)C&:R-ZRF-LVL_F&ON:HGSELE@>?"AX0J%W4Q"8\+VN6M<:Y0QSW"HQHJW
M/C&[F+2GA1%/B;/'F&K6_\:3+C5R<<_/,X5K,4D(A_-W/Q*\$=%,LMGM,C&H
M>:J_K*VN+E"N;$"!A/=LJM#F?7!H*,PE^T<LZK]I77C_"A7H*?'^%C\PP#ZD
MYW3M9Q>)W]'0?< [9Y+@,A1LCVELRY%GQY(GNON+LYF9WQ>F+>G+(MI,?/YM
M9OI9AU&]$D2OG?U:R5'6.-_DNL_60W-MJ?#DV+P)]<8,HS*C"$V3?+F1,CUM
M@Q(]O<L#/SR3JO6V/Y_"S]7@;7**[%B%1PT0BO*;RC\V^=+]'J@\8E: O4;*
M=<L3E&"\A)P+8#$53@?C"-:LF6C2+>\M=CI)OV-5OOH[G^$*T'LKK.B46^B,
M(Z^%D6L)3KK<4C:4:.LHS 5]P2_,:\(M4:+G[/DC;%Q02]FJ7AE)T1/\]$T<
M=&1 2'_[?I%Z6>6<DZR>8G)U\@\W>6\W%&E[)<I!+/PL:5JY9"G3(K,,>B?Z
MUV.;ZCM718@5WWD9Q\9?(K[UM)D5Q:/=*6=Z>64/>OFO+*[ ^T7AVF=W8LZF
M7DX]*2A2K+\JUSV>]76L4-K>Y5!V_L2D^634;GW<Z6/Q00]73"PX27J+_\RK
MQ+R;-@HOE0<U[U92>#2Z6%4;>_59C/334 #X:J#)MCE27R(I%4],0:U_1JI+
MQ/*P/12DB]&6N-QU7B;]OCO%*9E2,'OYF9O-=*T[J_O[XM(3481 <_Y2NG]P
M92PE)Z?WOLK1H.:VZI"M9CXH7DJ%YI\R CZSX2,4G9E6T=9XHM6T]C7HB@&4
MAX+L;6Q\+1;1!9G,;[66^5"78.?^I4>^?CK_BC1U3R4-ZZWC'77],4*7)KD2
M_":V>I"[MR'YZE.QP0.\LFU$EOD*4D_*9^;\6<&HS]H/;?G\X7YORP[^3@W&
M='29K7/7W _O%#NP0-?]+SGI^E7X"=@('*,KQHV[HC#$"KURH%-FP@">=+7\
MSD:V*T3_@D;>TPQ>I;&3NGP!L$)C$=$W75=;4AG1:(64#^[L;:V>0Z3(I5[D
M9E@05#3?T<TV!GWO_/? S9]Q,ZD>JMN;QJ]KLJ7TAB;OG^LH3?76A\F^Z^WM
M5>/:/M3'O0FFT)#L]Q:FN0+5_DA9,A:6B1@/N'GB[.7G)!34;^W^8\&;E@E7
MLHK[=37XB4L/(^MU;T]#'Z;4+\M,Y3,;1]63^(/Q2W_,1)&[(UL6'(JB[5]>
M>4+WW48._&YEW#KY B#[B;O-4DU>6.;D.<\KBEQM8' 3]"*GY9XK.^K!+^,/
MU4+6S]([J%B/5Y.7>-XUSVF.QKK/:=TM#7FJ_)3@,)3#96N?\:)058A?N[P@
MW>7!7L7(#"=K:,M-J,)293IWXA(7]\R3FL?/.@USO9AL[%-9*P,J#V_YWDG+
M>,:MY[+I-%JD3E^H35^D1Y5&%_[,CND';WF2HG:JH'%6Z;.L4CV]@ZS,E,R0
M&?)>3DXXPMGWMF6H'#JM//0_J3;Y_[7BY')<WR:1@B9?VRP3!>DO@-PVR/ J
M7'$!XR6#_SA\^8UPN%#@5?WEA)(-,$8EC>=$'..%\;9E4_1N?=1V%D/XW5 7
MML<7AN9-X[MJ9O6(FIO6.A)%!5Y\ S]X!;OD1DBV"^"(&3E7^J^6L3D*%7AR
MG!V:\B7""',DI7-/1U:01N^2TP@/502,70#?0.URE?@+8"?\^=^77;6!@:9C
M1P8\/YNX,#)+J#>O=)"T&W06ED7*+F2O/WAGO08--OMOCKP=XJYIO29+NGJ\
M/XH_R:7EPDUAZGK0\+?'7 )HR"[H=DN/!$A2EH(D:%U)Z*"H8S< T_$4A7-9
M#J*\$5ZM_6'+]'KWW=BJ;JX&-HCG0@ERY@=V* 9T5?$N]F%OQ;&.XV[E1_%S
M'PDQQ%!(!P7/Y)D!Q6IG6L9@0@!/L!PVQ2]M0B0]DB,[GRQ>O)SBZ6@1=^W&
MS0??L5$Z5 &^:*W]/!6VTE\##;X[>H$.6.3C<?B+7D7);Y90B&ECH_NG1!UE
MU94W8=!U4NQBHK6G/Z9HN27U!Y=R7]#'9,'&Q(_,I-PY4WBL"M<1N(Z\>;'X
MY@V[A]_'IN2S*SN728O7<W>"",[$['/XU+RX!D9M-B"D,+J!C=-[8KY)<KT5
MSI$7,ET4D>38UL]:1ZV)?T8$OSF;KW_U>VFJ$O?BFCW@+N1,0J&(:-S=S@#.
M=3H0M9 HZ>+EI*W6S:7VY#6IN._;V=W-R4]PJ$41=>;$)M6BZ6I?LR)C4NP*
M,?54J1(ZTUK"T>5/=O+$"^S+*"K;8SMS=.9M#?&N@%(8I!3<W"MS,R-NU93*
ML2^3T6*7IT/!WHQHL3<%[/I,&SM*:B-_\8*^V/6WD'#LO92>Z4U=F 0NJ'V:
MO(B-95Y@+'+I8#]#=7\.-;1MU5S?X<E&ZX[.K'O]DM1C_FV5NWMW*-CR:5?.
MS>0]E\"@$%&6RJZ*32F[OC%7B-*#OB^HVS-J6.D8Q#>74;DGNP-MO(F($]00
M*#((&H7.26J=VF+0IF_XU;E">GQR@M\@/;%RB.@V>3X9& 7!%@5$!\K#%Q[A
M7;#3H-@%SHK(GT3[IW'=>K,D"PWKM4I$N6 _XM4AT,*0'#<QA>2<[IK2-?"C
MC-/ZDX]1;1,MY!D+G=46E'EB=Y.^ZTL-M+:2'<AQTEIBDX?:2K#KRRLOZ5F@
MO:<$#;WC="A1'E?M29VC-'8C-2X_H$MQMW1)3Y-'%JP'^]@%>.O>3\+1FM;]
M@5F)\MG:C'A]N2O[A(5M@T)_]9(1]';O02("*PI;EIU=W5C&8C]8+?NRX6DY
MU]_@\&K+)1? DI@+;60+?:06FZ+!?<QG>]C#).WUK_^(GLB<!&.8>SH6HN2M
MWX9PB]%19'W##Z18DB;NP=.= ?S>R,K;#CB=]#F$4?.KE=7LH C#\OZ#-==&
M?^^A^B?+S5H8R+-J#$4WX9$5]MKSFL:_]F%H#\4:AI!QHUEJAU@[YFU$[=_6
M;&_(1'D3?"DBZ=Y(I_><AEM!0 3P:I:U1%;YSV%V^KM@$>R50=KK+O>L9*R_
M"9%-7'VB^Y'XT)^KJ%B)<&Y L;T"IL,S>E[7![WSR>>,YF3TR@U5#^"*W@@\
M',YXBJ5J(TU&A]RB/3LSQW])7W++=G=[YX3N_Q)GZM35SR"KZ-$Q"4OM=^:^
M_KM\V9LOIO;*,\[4[*'5P\#XA0H UJ2/!;>:;)@U&18^(%$P6I3BO!+HN1ES
M@& @CL 8?Y,MV%&6!*@DKBK[VU#3IOQ%]@J-8US#N_:"=<J4VU4-#K(6E[E"
M+H"S^>RBR&!WS-F#Y^BT@Y,G;]\E9GH"&'_2#;">XT0NR'(+59^=EGT_D>^M
M:.65:F!+5-QS]/,% .II40359_WH=;$0HY@S[[TU^8UM35;D#2)3N;FLEZ;"
MMJ2;41,S]K21,!ZDHG7$)W VKH*!=YY/?3K2O]8JXQ5;E\N=&QN<KPC7<R0=
M.89$PYF"'=8L-\UCSRR]W.R-]MYH0 QC'48K DP*R_ V]4F:>TW0X9ZWS>:;
M47T:<V#P6)"IL1UF^^3MI\=>C@<6ZI.0I#L-)J1%;JD;.5R$E&!]]">[S"[_
M] >9@_:KZ< Q$;Y^)5113'?T_JX+&),.31/Z:Y<^,+A3#RL/7 818"[@SIMB
M83Y,AS4A#%;V8_:/20KZ27KF*$K.3HZ1]16H%V)DK8;QU;!?XA:1;4K8PR-P
M1)#I6V42J%0[AV:]E<XK<=$\$[+SO2%2?*(** W&A$M #O&/E"M2A#A2'B29
MUGX@R2'IU9L+1#?'#)U <67+>&>_C$Q'C,Y0VGKO3"/OR^S\SYL;+L?D8M10
M+X:;(K3:<>EL]E7UU!+[J^O*IP.ONY@,BC7M-#_X/!^[D]"FPD1R.K&$FKP
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ML#H>!_CG!?")]K/U\X71P]**<U#PLV[P$C_9(A"\3^P_,]VZRV0^(Q0<BF\
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MD6DYISW%H1GP@LE@N>HCFJ1+M_Z*TKON[+%3RA+64]H\]]C>0OHH>FB9MB\
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M!,U0=YLD_4Z:4_$2CB@TTV3I]Z0;/M6IY2,)R8&0C]U"Y"P&@RMJVRZ Z0M
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MG_O\-5&MUS8U\3]>]H4V=2&3;,+"UM$+%,E9JE\\XB242#]^G O3 G@3?:F
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MC$?4PEP1L7KJ Z03.,=55!O/M/GGE5.J=RNLLG>4PP3C(K6ZN_NA;]ER'*A
M*;B+=%1#6]8?>NR.4<JJF%R0ID"9)/QVS17QG-YQX 4B#>P*(9X!-2.B'(72
M;7&H5YMJYR.-,QY^=C#)E]PWBXB'JA' K>;Q2%ZP&SS!BH*B KCT53U0]?!Q
M84ON/B[9B#2&D\CX-_P^/"WA_HCO>IK!P%@C8[!LW?!>HL OXM>[^NO5/-WR
M+WE!,UE, )?1U5"O3EXFG3H""8QHOD,J(\/!F C(<<KI8.4*//S5WE$I>,/^
M5=K.S3I#81NO@TRO'$[$HN.@)Q4XC@^F;WA=)E]OO7^J9W\Y[G;-XW'Z.K9P
ML.5=XRB8:V(<^-0%5[ +%8C>]YNZEOE\NU5TY+A)M.\15BRGI@MAGW*'7$8Y
M%GQ^9,.WI-3NR/SM9[TO=@'79-NBW \>G.?4B<>6TJ$4J< 8?)'\F.8)> Y4
MLTJC]]JX@COJ4'^DK+X\D= X&.M),FC'G7C@"F^_=M*;3;W$&V@2A0W)[7*V
M(OGJ[\&<ZY1XK\^S]'\8V$Q>+-1[YOWRS:6+1!V;3CNF&"K@"HIQ%!Y3U %]
M>6+SXLW%#!?;AQ>Y5#U.EW< *,<1FEJH@!TL?2]O>8RF9X^M)O(E,]=9\1PB
M1Z-1X?.C9U[]T^%/QDD&[W$I%-@>)TG $89?)5\CA]>;\RB@HNLO86U]$P6;
MOBL04M4Z,P?/,YC0 II/G,S<!\VU$-FFN)!AK4HUE+M48%X$_1*^0P6*8)@6
MVD>B)17@6B))4@$XV8"F:GXX*1!9]%.&(P"F2D'.I?^"*<+P')XMY@=48 2,
MNQ] !3J+J, K'R@W#$7)HWD8&XJB"QEY2#,M,H,*0' ]F^!T,#%:8TZ:1 56
M0<3S]50 .P)KTT*R@)>I@ 45:(ZD?8HA5E5BZ7,@O50 07RX#^J!_T4Z\%\Y
MM=D3-*1#*2W!QDDJ1XF+*,KI/J(I%0 ?1E/8E<#$/=!?^2PYC/\0NIR^ UZC
M"(9T;B__O:2)?^5SE&QDJ>_3<P#?HP+LC=@#G[\3U?@O;%+R97*U%DFH0RH0
M!?$B_: "?R=I_E\YA5F^_7_!*.JT[[TIW"*P0C05H*TS/80]9#6B?>G3R/UJ
M\3ZLZ!1SNS$A<M84>,.TU0F&[X)'W%4N6VL)^#*WA5Q.IJWN1ZF@ I(P@6HD
M[C(J6MD?KW.17%QLX*'(X%EGT6!9[6_5"4^T@E@7DH3+<1?7<>7^"0_?MI3]
M]KV8>TE66%IU8?PW%>B("39"\R+G375ZGGE\_:"SD'*Z0QD-IGPF;+$&*Q(1
M\\)%2KZB+PZ'M-R3KJIVQ=+=;EX(!<3>_GN,%""Y*\V)XI!U\H?H -^5S>#<
MZ63=&[^K@67P"L.RV@$9ST]AT<5]@KQ2SV''^2Y]=DG&W_.-MFCH9Z/KXG$9
MYR-;$J?GW*M;-C2L\)SQ.H&]^RP24W8]SXT(I[_RB8;IX)O$"2BU;9OU5ESB
M'3R\<U+'SX?ME[^W<*ND'\?+#@L-=H'XYQW,&QLC_U4E2FMF4'?_= HS"P[5
M"F/-PQO.+!759E28.I^ ^8NH2LW!T0L^<"K@ ,:DD[CXYV!MG,QFI;.0)XYN
M5_%&CI0=R6UCVX,5HDLB;,68D#5R]CM.9\P2KCAK GWH"  J=+NL /W7P_%W
M)&8B&C?=C.9T&JZ\[JV)R,N>*>UVZ.T%FA;<EP4QRQ)_#(Y(/X#JI9&D1V"8
M7^:,E0T#WT=]&=\M=X&G;$(3SBM3WC A"ZO5MI'M:*+&JF=4#L\(R4RQM,2<
M\:-5URG=RP>XDX(=+WZ)O-A7(]]=0U807HN($P/YD&G7#J[R-FZJ:#*1#FU:
MP96>&T[8.-#QU^I'K4OH&V-WID*_NJ.73X0E]J0U20M*-S))A?F8(1<IQCNI
M1QRP9C$=)?P69+P"S>6P)N;X7KZ+/7V<")&O,E?%W&,E&X!Q'BXM.EXPV!_G
M14(.B;H-KZ$(6+,.Y91&5+!< #9  =H[*Q7?'YIK=33TQ;])5V!\Q>%O:1NG
M/OU/I!RF?V60?Z7U?QGE?U>C?.JF+;<4+*6LUT,V"& "X<_7K26 %Y&[5("5
MDE]$>QQ].$Q*G(.WHW%&G Q$V'Q. <:GZ$FNW<=V_HW]UK>_C,5@CLKHWVYC
MR$=4@'@ZNA41HUV%="I]HITA]#SYB_T>V^RK.WXUV#=@(3*2V%/@H+&A5 PY
M=KEO6?&9UB^3M6$BLGME-IAS#-*$Y'*I4#V 38W3+TH"<Q/'F+>R)R206/T?
MB^AML+PG&#,#>OEF$G*M^C#,OW0I68GXSF%9.?]\$\]^)\VZPYAL,(4Y&S,]
MX],6^.")4-GSE4\FQM-;-<QM2J1Z6!)D>F90Q77_K-[.9*]%HG5D+!9_!GEN
MUE1'&<]O;U8HX[GY2%S]^$;[M_$R?\(*,>Q/KAS?.P!%@H\C,9%4@"/8:?Y<
MA8*-Y4COH"J[7EY0#F<])?00IGW8C,3\0K\,2E#:8_>B LIL2'/7DCTF#$>A
MET9G3\GC30&C]G>YX',GXL-U.T<>(&\^!NG431]"%F$K_SN[UK_B_?^#1BFD
M8<WWN,2E&5C1<TTJ$!.)AAQ1P"@OR,CU_ZBUOC4"@1S]'#EA3V@A<KK,O3:[
MY2:'XEVY''3.EVVL$NZ^"UX35WV'AF^=.Z2MEE?8+%<QHL=%4J^W]W=_26$?
M$.Z./-;QT14GP2=6]M/9T^:1[AIQ@L9VJ$L ["EJ$J>Z*=%N=X>>@IX#OX8Y
M@0'P0@R)%F_?Y"Y3@2&9W[+N-<U(\$_=1 =A4PE1W4@H':RY(_!+%>AK)+F@
MXK[TB"_JM.)@IES<LT%CL7MINF4O,U1,[O\LT[;9HN@BKU(":8@=2P4.5 02
MR==B#D/@I,=20OUZ110+/6%*'X2Q42A8F&@[CXX=SVP@=R8$1[F]?WWUT '^
MQ+=C10R#T_!*F4(ZU!M3 8;WY/>E4+K?<-'=F<O;(3S6"9.C9T84)V_]8I#5
MS,*\'L7O$+E1\ZCUHZ/SQ.-[&G?7W#]-V]\]N7/9-M_BI[%$%C3UT.KHFO_R
M+?);FGXND-_ME71O[O8]NBYDLI3B=<7VFOTMGJ0FO0KZ+(0DW!X*&2?QY!.M
M: N?)/+CA><(85C81DF= .G2DW3K9WU%,Q(F(J%\]#=4 OJ9B#:Y&B3A2IR1
M!E??/-NK,N'4L$JYO--,>:PN3)F'[^?YV^ \1*46\/<;B7,.CY8ZKX]&)?+B
M]=>3>I/9O&\3,%P^.2%R1>0\/17B<BNDXD9,P91_^-+%*[AZ#90;;V_79MJ'
MRR96\5G/P?TTUX6MV)/25P:(@TC,+'B2\'->IA+,3XZOD7;O*'WV$L/3L19&
MRY>(?N0K-,X8'0D5(^+=<5M&XTJ5)[3=7L;U58YL.<IK37=,=FUEDJW)&94T
M[T-70]J1KZ9.H!+50"?N$$_9CMKWU5RGW)KGFXK945\2#_[LE94%7']"C)C;
MS,>9$Q+K!VFMCN?)NRMI2YMR![:++[;?U"9#Y%E8.9C969H!/"U>D'N%!S [
ML7.%-)=O !][,/@4L0?GZ2E4Z[7\<61=Z,./MIBQ\YJM8"()(W&G\_A=YP/L
MNK]]__W$3TI*.I>3$"_4C[?I])RB)Y3A;6)(++BCVR,5^7-:'ZNCNP/N<Q*\
M;SDQ7NJ?11>\ '/IG:6,P([KL?O;M,Z>KQMU[YWJ*ZC/_.8:IP-]_L3/)(@K
MQ$M?-MD!UO,)&18.P\PDAGM][E9O\.%5@16G[LGE)N\SFL*9$LV'\N"4$XM$
MQB=Y93K6@YM'>7OV2?"\(WW4' 0&'8#PZ]R?0X>#&?>"/+E0)_I+"B<:1K[U
M!W?GF& E&\=F4NJRQKMGY6K)!:2;F2ZO+I!=K.):'M]/6R*:R7YNCI1?K'82
M8,C*I)\R0^Y]@H?K+'$2-2"8A@6H>UJYG]_)#LDXR]J'OX/B$I#+Q^%_2TQG
M4238J@ 5^!I):WU!E-2CN"-18HG16#U7E?JLK"?7*B')2$TR('@L_#8 QG,S
M/TT($K&9Y/VWEM.-*/&O O*_;0'YYXUB_8(6ZL?7@\]^'?25&VD<N58U]KTW
M%#*3LJWH3R:$!#YOAUE51LZ'M[;6C@T9P%P< ..G':V' XH!?N $>"0,=QD>
ME7,>STB.))3#>-6K%02XGVB\8RU-V#D2.HR%$35<,';%]^=-[1\L-HUL?J\1
M60C)/1D/2X$$_&;#1F!G'(=;J_E9EF9_@GUK3OYXQ90 ](4X8.#A5(![CW_$
M92SX>I!'^K?O89)E#/;EP\D^W;]5DP[H"<E;U7N'2C4D43P3B:N$\ +7WC#:
M=CC:/M3,_B6XX>IBJ#-3.&/S2E^P' 9)E-0(U9,BV;]O:12I&X5?#]_X ).E
M$#]_Z([(,I]@AX\A"[9>-S(-0WG](9:5H\%/QP_W#E+O56H(+_0VO71XN;75
M)2X6P+LUP8;I*)GK<[+&SWY[VJ%KX6#Z4*?(.[AW0_SK6C1J+(R6W783V\%Q
M,-PE6)38\6_#UVQJW_VHV6Z+V-B?_M[D@46)H@XT$==PGB3A'EQ=F][);Z/.
M#2.G5K<5UFHI.+%?.YJZ/A%]4 QT1'O'SK_P>G5]5F=A&X[;M*5(V ]THQ/?
M'S1>1'0BQ!'M/Q ]#88Z?HA4%[/:'P"($UE[3+_P"<I9.Z%,%RK'86LT'U$]
M&!ZC%=I?H!.F#/G71O=XWVQ.V%C5@<P/_+$-P>>.KM*<AM.\Z?H9A1L[-\<*
MS;[5GLE\O:,T*_O,L)EI\PU,9)SFF?-48,JKXNCW>K!&H6*^Y$\A'2-45J@Q
MHA3ZD#(&J0#%D8+*?HL='Z_@<3]!;GNFGW.#SZ^+7Y-M)$TR1=^GB]1*?@/#
MO*0"G-#S)&U/'F+XT2W5\B^/G4>4;K"%]_28CP#^:PF5>S17S\:]C8<]?B(
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MDX+1.Q,CW$21OK/34/$^56!M!^!<TD3TF$>-M1[)M:79W-7Z4?LL_KC_(RV
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MF>%IESQECBJFQ&J_*/GTA+#B5X">6CTU)..<.>:<P?JU2^NR5]):[ !BOI/
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MLV/P: 00IH=%X#PG4E\!;983P-]M\"%RWAAK0!)_XAX)0.? M)<,NT] YJS
M8[)6S?) <1+&H]V9J.^S='&3@M_L \"M2$$LH<T=!T,C^D",07\F9[9\M=R#
M;[\*$J:MX/?*&,MHP/CM3Y0"H<^ABY? II91BH<_PA=\'F)X+[OU_:=&+5F:
M(\,4$VBC!  ="Q(ZE9>B=3$?4TI3R:%QT*3FCV!Z*(</-3>QE3M7&YZ W,*8
MR'VDW906.M 1=H,K@ZQPAM(RZG3_$GQ"ZDK[NNJ4MVX]<.(7C= ! @ #@CB
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M5!#4L 6Q_OOT>%\>.F2(>";66OX]'6N@C&:G[&O1F/D;^3 9L.L6F S*29I
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M*%.4-3%LZ_4VC[;J2:Y 5$']^\*JU:&PFW-'(-ZB(V^L58.]B5BR7DRR4(I
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M,\K0@FHON71:"EX&DI#8M'^1;/1W]8ULJ[M71.*N#9J7)?6?10LA"A")?!1
M":P8;G9B#V)=NF"C7O)!2?(E0_I<]-$ELH ^1<C2J-(('*ZT^FXOET9+$NSX
MD@0;$[>J(^. U2WY"$4C=;X(,"/,<3_6',R!<&FQ'A':WS&[S_AEUDEW9S%5
M1B\<PZC>"Q(]@$>','Z^Y(W?+:LQT:[.K^W U[>D+3M!'W9K=QG+GBD$]<J\
MZ8%I605V(&@VF_O>'E>$^M^P%8S0EOJ@^:GF28L%RY) I:\9N&8#N<U'ZVY[
M/7Y<:F?!=TNWHN[@&;E@HD5>V]51V'@X*)^/GC1<P";1?@W"CT\(O;/0%_LJ
M0$5W+H>[1=PPSEB3L2V<_!>C^[B:D%L^+[[D_ %!=>(>D<WQ>_6$A[@DEL;?
M.D5"X$[,N"P7XA];R,^[BFBM&/_]6"SA/CMVJ+"'_!$MT/V\-9S\]BJYY_W0
MHR,,@H[4"V8@R*PX81]?_X:Z +BP?';1VNOWZ!!1RV6\2W[ZF?@=0GWYD$&7
ML&# /%*ZM*UV#3M%_/9:X=TW.&6V3?,N<3:BHC'P$[P:*@]QPQHDJ]T(,EF6
MBO5OJ9N$F#B[^GV85K<_?^QZ\-UH3I4)-8T()DF11D%,[?+6?[WQ0SKUDTRQ
MLXH3LT',8)%"_L\VR/5.GK:*K+$+@",HIMD\X:B @T%AUGWAIE)1K>:;UX5=
M (W-#@X>%<;W9 1T4!\2Q@ER'D)$GAF[HMH?;BE(E1FP^@KOS;H,G2:6R[UY
M=TE9\D0#@C26'BJ$X8L^=N!O/9/,%;;=%K7J3BGP[9B6ZF:*S*?&IWAYL#<5
MS>A(Y#@M>M7V6LDR:JK9*N1'A:S6!T"9,'D%D75E1SDW)#QH3)-\PLN+ &2_
M?#;5K^-/P"E(6Q:4O--'N[3Q+E<[<>^G\4KD2Y50%0LW=RQ+=S:BFX]%)?7+
MPLC:1XL/'S37PLF4!L@Y>.O/>,Y-;49N1(ZT&M>Y^]#'\9LD=61RJ-6?-L(\
M7[5SMY4@]C1Z#FZD*DERQBQK=RH/C%8"0GBS0E=&$VZDN[;33PA.>.PDCP5]
M?Z\3X9/QXA/WF]$-HYGMQOO";_G0)TEU,:Y_S*+<?)$'ZS5-C$.=IS\Z_[%P
M&.7E'3L:C>'ES!_OFE7YN(,T\*X6SA%;IF]9505]A(L2OP.5BV:#KK?J>=A[
M4553]INV)DO77H_N&Z;R!8W>(\."8@*&$&]@K'5S8:*N7/I8GGF7;A4.G,&M
MGU2OCSRGSN5+Y\/*NP8WE,\U2EI/CP_MM$ 5YNBI':1Y$SX@,/1\*+JI0<W^
M8$D\7J[ C5B-^2R,#!'2AZW8O)+;$0! WY/]^M^E ?Y[EZGJ(Q)0"K8]#2.R
M3OG^CW8GGYC6&,&G^J WB!T]K!:I "BCP?R_V)V(6L,QR N =MS.$L;3@)"N
M]XB$@%\ CFK<2&45IS;_CN>)NL$*3&J DM7HP2T]LX7\^R9EER#Z+U=S0-UE
MO/+E!=5D&6.TXG=N40P%?MHRU*0V/K#6+J=N#S''FF#<S5-PD M Q#N#&TG5
M);-;^4)+;",;_<6JJQY(-6H?\#R7:'.-$OTWVIK4=\\2KVE]9B/@+L6.V3_%
M3\V(GI8H/!*3O% )L2]F:A2I>1N7[>(G3*A=2QN$?OH3#M(%N<,3;/D:\ \D
M2*FJ[=6,12].I.LHG7AMNK7MN9T9(@_)EGA\;)4O"1&-K6^['%VKD="7A!+-
M&N(G'?_'VJ:.7.U.'1P,^:%,)3!9*!<1#G(QB,HD1Q?TC0A;Y1B,?Y@M1K&C
M&&]R2"<,B2Q'\XTW\QC@B/CJRDUC" A/_7GKUVC%FU>'5K,_HZ[6?!R\NXG"
M''UB>G(YX*\0G0FH'/0W+Q-&*L)6PM9#L?N[^(3ERL,K-G>5938XSE#'+9>R
MP%R-&W\'LZW30O'<&N]E<,A6VV31$>DZ^E !=7CY7B@&+KMZA3\WQZ+QV^</
MK0W4O@:HN"D@C>*&W_P^+:?.24^;\YE;1)3-<6G[GZNX<P5<I2R^WLE,%O[U
M9K0AH./OW2M3_VYQB;&#,P_Q+IGKU8X186'^9.6B=8V7^FP/G)R4 &1I.LL
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MU+D9Y=Z,\$L::6MSC$+?_]_;.B8VS,^"U@RQ_=^2$V6_)=+6? =>>\"?\B2
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MOY_ZZZ.#@#X#JU%B.,+^[07  79E!#V3Z+>E:$39U$1FF=?:,7*8F*\]:OL
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MEIP/GA)I/ISN/H)EP-X=EH(/^;]'*'):<1< T.?"=E8\XOP1'HF.R7 O7WA
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M!CT?UAAG-OT>4L<%MZ\%56Y3;UN7+7KNXBS&J&\7!_FL>^\W:[<.ZTPW(U6
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M9-M"\?2%1?4$2;C"H-U$\9D.2<6DD[,<&S6!=(?$JKI&9W2^79](L[Y]\<=
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M^=)'-/BXKT V?>Y*Z2VETBNORG)_99643IT"*EP.LUAOY&:1>#E*Q%D<ZW2
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M'K-,J@@%G@)4\O]?(@" (?II(G$Q,:!_3J> 2>@IH$R"!Y2L6?CE/Q4 S-)
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MNC4KH63^UHVT KF0*[,G.9J78,Z=+;P00<\1F5)_O/+L4LQ+$U%.B1=L39G
MG.13@"%9?NY&CZ^7>_+"$&NW#IL5BZ&1\M#8^Z,D M E%D5M^C%=Z1N4O#J\
M]%0C$O>(GB%1&7/Q"<?]9K=3@,OSG02(@V]5UB.=N2SE;L+--,6,37C/\?4P
MU.+ T78<[?I,Q ]MEO:N@ID6L9FV,<263F8B&1@-)QW+4^6@;.1)4OYX:1S*
M^,KK%9Z_@46[=A=\$SE&A6@6^TJ$<PNS2F3[<7'*.]Q!]K3>!P.QB=2^?E[K
MYS$/SL&<_X4(A6#5CL_#&H;Q\YTH3AA9S;[8GYQF]:KM!EUV7L B=<FJU:7N
MUO//IP &G[$[R=F^,<.>%D/EA&/;R0+@I&+Y1\F^[=3'(].R_7N)@3(J:%9?
M#%<H OX>^,[TZWM'3+215.>/\L?MC_.J5B+!YF7[H<#R2PRI"<GGBWH* /AL
M>F7NS"5'7R/(:,_.SO_J">5YWC<*-?"?^FK4[S^Z@'LNVC,AS]__NPOY *DY
M!?2P0.RPKW+.$)9->-\FX,!>[:GBC4_3>147W@>CQ*"S5(<L^:ZP_[K)XB?2
MB/XX<BX^R;B]F/$VH=NGV_V98[Z>WT.Q5V3T&^2S4T#4@>UV?/5V$D(\?-T2
M(9:*WWZ@U+L2+)@_+X""*;>ZJ(>8,HP#*X8W#_/@C,1[5^ ^/3=+BTKXL+6W
MZ?I2C"^E/#QX5\>^PSZS*C48IN<_#4QVUQ<Z%ZX,"/QO+7D"JZ)K6L#;'<?2
M%!E@<@K<C_=M#D??<3:TN+E>H+=[,?OPQ-@?PO_?B:77.?P("9@SOKL^UP[(
M#?/#2[WQHN:QCCS ?:R%#IDP(-<@+\RT@+<F$7USE\LI%1@>7%6XY_VV>Z>
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MA8GYIGUV17.J&V9FW3_TQ :D;BDR#JPC:WEHU@DT%=F@&$E3+?J.^:%E^X0
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M''YP%YD@)$1%!3BY]T,1%_%O_HVHS'64E6?JWT?3LP5A]'N Z"A_>@L,T0V
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M0NG$[P$8& @FX)Q0.R<B8(U89>"+4$KL71SE*^C UFGIOQ,296W%7B]-\QM
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M:SW?MS'5I;EDO*&EQ(K$2@8^;XRZGD\>U&KI;<IJ,DME.T5OO"W^&/-ZO9I
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M,NV<^0]%) +&^1E^C5=L3JI1H.E%8H*IH3*;N1D3*>LR;??U3D3OS <#AY'
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M OVZKBI^S&A6@*& N#*M;!!!W]_7F0?^"8I:IIEJ4:VGVG%BY_.535!%P-;
M[H@P_/"W=T9 $CF^A^9:'E;)&FH7OT*%@J^=EHO_,R,#>)B97930HC=N3A^C
M\-C?JS/6NRE^W6/1K//H2VRQ=8T=PTC@-;<+QP9G'D,1C[0X3?)2W;PI.>=\
MG#6/AM8+X3CS_ 5?=8Z,9KL@E1#;9?R2KTQ]C& +^]I/CJEDN\@59G5^9L=+
MO]-KE8"M?9XK?9P7EAU]2<EP_;6(WDZHARGM$Q]9R4.6<]:R=72+4]=%I/2J
M9POX+$O-2J'"HI DR%$J$/$KPJ'(WJ1HTGNTO >M<W^CX4G"L+L;7Y$<:,9>
MKP]D;4;]8J!DK'#22TML9M[-^G0FH54EA KWC\!"FC_R^$I@"ZF0 YH[E:]@
MRA7F98AS/6G?[0G)QDE<E[4Q_B5>;\>=:[E=Q$T,2>JS_<<B/=IG9RVOY?EV
M+1(6+ITAR7[JYU.7(7%3#AQ> G_RU6D26YG+XM@^T')XS6<3$?$ :OZG;.8_
M]3#_VO=C7AH8A?.WN $@_C+O2YYB@@N"_][U\QQ^E DE@,YF(!.O%?RM8NZE
M[>*$;@ 3CX,D_T.1^M5_*%+S?X.7\N*-H:N+.1><WZ*NH> ;P/:[Z6O=5]38
MG,$C)16:5VK_^R'F#Z777]U&Q.+>8+MR<6(3-G;9/+5?7U54?'QK(S!XE-4X
MJ@>Z?F<<A +1SOJ#E. S@@4&=&='+8Y#M_P,GRC>B<L\8TO%KB#!M#LK-"'<
ME$R.L;YMS),^A+K,D5>BO)H)41OLK,&!UR A## !/NTL07WK_?FQ^4R+$*8X
M74QD3VSEJ7FP$X0WYCRW(&_Q6K!KA,1<\V./-0:_:9BFFQ6@U&9BC1%2'V^?
M"*HWV>9BKJW7VXHYQ#_!+O1<&G^$J-7[XFE:F_70 YO\5D2??*48YB[N75VT
MW8)P8/K>_TA4GN0GQU1'I%VR1EKZ;=Q>MB4FW[2[0S7V+A/AXK?F1HE3P^JS
MUJ4XN29R?J'K5-.5['-/*B;P#/4,7-_*%D[(9D1KZLV$4.Y(MCW E$\&^$G*
MNMAD)4QK8<U%/=K9V5:R('6Z7;,AP*&ML%%IJ7!N9!RH/O&!-3OC(&5TB<Y+
M.<<!D"73@89!@+FOF6G?A&V+TL=1SQW_EO2<A\,-3O>K_EH[GD+O@_!K>VT0
M/)6[H73B>]Z@V5>)@T/?2:G#R&]G\"L0ME"'W+_M.D.I^>O:Y(35 M4[9\[%
M3T0*^AW[)BOU-X /+5P8V34R/0<JLU$DWT!>VLS18J*\=1(-8*C1RE.J5VH+
M1GL*[ -'9C-BH]9(8?='93J\"EYK!MOX%BC_>EZ0+IAT3!TJL\5:=A2U*K[2
M(Q@-9%SI;/J]N(3ETFP[8D^J5Z=,)]UG.6H5 MT;E<&/]1?? (H38H>$&O>F
M!5AZ!Z]+ZR@^?S-T1'C"'W>]">)9>3Z=72<KPF!S,85@[?W9CO*\V[2H$KYQ
M64MF\_K)7HFN[L^,;K/S*B?C$!?=<^@>*=KL%=8,#7N9HY^:WP2/CB7FJ)L@
M$LW6 1_'7!W]$@OFG7P^65$S2$.U8/I=;8H,0/R=5<;@G"DAQ[X<X3?C^[MQ
MT:XQ\J'P[J8,8I]1X@U+$6_[QG8ANL'1H%3+89^WE\2@&+<E.]!6D1-G9_+Y
M. [!^F58ZMJ-VJB<YW!O^[?+9!&06Z4XWV3 ^GU2W#'>PYRK&_9 , +'5>)(
MWB$T<(\%1?[XOI!.2)!Q,D3SNESA 4Y0?<5TYL$?LS#SU\,T.=Z>1))>\W F
MD,LAEF^T<Q!.K+XF&.7[+6NF^NE,NV]Z4K[4*X *X-84&?7 ^KKU +)E)QN<
M8DM*&IUW72 GKO:VF#?)A]?XV\8'/>USA NB9->]4 4L-B)R:D9I:(/IT<L6
MI>*6FBA0%M'++."L^WGU=>=LF1/3UP5EV0$_V/.^BJT0,8L6 -H+1,@-;\DW
M>?4ZK>"$;P"$O!.G@]%BDVNU]&/<+\#+1 X&;^-+5V\/R=SJ#9:"]<$H\&.@
M&FB/3L39&1L]>AB#GWB?:FIF(FGU',4!@Z0,G,#DT%Q[F"NPB>//W9]_SIWD
M?EU_?U0'\9PC.#C9FOR&XXK\N?*@BC>-,L)&3@(<[=EM_2CC5;R,O[-AD Z5
M/J6>>E/V];PI9\AI-V-4I'\_4MC<3"/+.81(N'/5<4/JZU19;)>NAM@CB\_\
MWQOUM$Y >I @4(_. G&/I_VE7:2@6+S88/V5DB[R&:/E\5>A/$*E$1WMKOH_
MH+V-JT=8I]6S5)IOBT:7O? Z$80(E7!\.S/<7XD\O+V#/6X3SE(#_ BJ[^MJ
M]G#Y[F^8JJM\L6W[_ - R(]PU/EX!$IFKWYEA5^99XZ:.7%1S]-O4JS2"#$_
MCJ/L#@H1OQRE\/<+'_0BP5#XF3(BJ*T>M[8I>%MKI\J+Q?/RHEL"#58V0U2[
MLQ\CC_E;W<]4E . I!,>WIY8PU2-5!:7@&D8U_Y36<[M;;9O>9>:KZ>IK./N
MC@,,#1D % " -2"D=4<#[[X'72T%T^.8Q53[\*S3R]PQUWDN-=W6?L,+5:/U
M&I=V[3EH4_C<@HG$I5LTOT^\H(&L5=)7N>+S$UM+#KOC.W;$,/%+D$[G4MT-
M0/38ZRP1G=MFA#6YLL918G]^RB+H"0S^-71+[1#FDN=<=8<@S9Q-U:TB6-:A
M>!;\/;GW;.)(@I'2R8N\,PGQ*->/5?[/[;D[J$SKT_RE8Y>^BUZ'J5>W5.Z@
MOBEZBBJ2_M.D!/YV ZA]7HU3Q[@FK8)/<RRGV%,&5Y-JCR>S&WI"/AMOQ!<<
MGMT ]A.#OO_V4R7LRHKZ?OOER;HW#EI,_.>P:Y_;/N0>>CF9WKYJ8K6^%]3<
M< ,PW7.4RGMMK?;)DDJY^(SV"8#FE5=X0FL)D<>H*<#TWVJM2?YX:+X(\COY
M?CLF?C-&-"I-C.N[GR$HZ7$^,3O[IT"J_N^4O:-87FABB.2\O[F_X)I$2K&Y
M0@63DOA2IA=KF,_LBI@BBC :M[OEAN74P5&KXJGFJ%'@/M(7TS@MJ'!+7>W4
M^]0)/S?)@R%20/D+CSB[J1A\F.")%M"P8ZIFD!F93RMI5#74GO#%3L]_?]BL
MOJZN.N)A;9BL/_6'&!H#E='<2L"V(JF#@YNU"V%6/@]A;8T3S?W>'WI28Y:&
M!NX /&3ZG^A-;C9#I67:\CN3QU^9I*U=G[&3E^<'WG=W5%E*S*B$CFK<7DT9
M%;N%_745@._]M2.JA2%MEPD8"CH0V'.QOCH,.TR->W><_7UK1?Q":34QADT6
M*X_D%J@X/*@QR^#+.6F5JZG^2B=QD6X'3&18]0(C3J<K:O<>F+WIH.U^4,:1
MI!'SYW=[V+TJ]A^[4[ZP4<&$&T 5L&OTH]Z*?Y1*[95 H[3?D9ZXVF CU\9"
M4ES2%.5O>#;N!=J+\9O=?93"[;X;@*6'#8_7M(;%(&EB\J]65S/.I6\>@1*7
M>U!5K!W*@H!GP-$=]#' :Q2K4&[.W09VB!V<JKGN$Y_7]'E26M<7BA/XB\&R
MMYLBLZP+=YN4:Z=;>&CJW1K<> &+:NS2O9Y>V[/&33 <C>;:^H_D6\[G=T7&
M22A4&;?A7),7QALYB:#5'""K]U,-Y)M[$RJ3[ST88SCO%%)*$TAW -.W5DV!
M>Z"K9[/8L+.#YU.OM=7B&=_Q2DH6"F,I R\RN8#^VY]U>]\>*Q#C9WO6[ M4
MF:-B#:H-4W0A+4U.&(OYT\7+.'!4R"T[PZK7>WF)T&JAU[]'YU>%/5O-GP@8
M/AD>JJR%I,VY6)_L(L]Q-,M+-;M+I%W?WM8U9EF(MR8&\"5%;'$QC(2 N[_A
MOF% L3@HIJA[Z-<;\]W)-T/+A@T.-L+T7&Z,4GT%P5[H73S)-J;>9 J9TUV7
MX+V5I-F2Q-HI 9+D"+3.P?2$U$'(KR-#F"$"$H'3P]^6=ITV!G@''OSD#[VM
MQ$\L^VN,Q6/1.$O@/B:\I[3!WJ.04TZX,Z;<+OKW'Y!=;$FY>8DVSW*N1Q,$
M47LX>[*-R0EGH]#MGEDU%VN Q;'RZ'5MSGXY7N,1SW?L&-3PC)T6FPQRFMP:
MG54]4T[L3//-EL/XYFPXKG:C560@N[UKH;LY??5M3J<-A(HT@%+ /1D ,8"R
M0.3NH[KH1_4Q4E;QROD>N;F\Q>VW#&Y-Y/,U5_K#=MC8^D7:&'X+F7#J1"4P
M$X05,!D@DS<SU'D,RIZ4;W'YKI_^@?)X<%%M+IIDHKSV=JGEC"P3RGA3N3@7
MWV9,I'+OW_/8IK6964J+X8;9H\-RO_VUFF02E(GE/U;CT?B&A=;F;6 8N:8*
M(.1UR"P4K1,LB,SZC.?'/N/UE^Q+*SA4V<^XSM:,MK[>G'XWV]VVZ+*H(W4.
MBPLAPB^!Z:"V3ZT65@_[ABG.=K4F#^BF6TR*512Z6%PV2$+&5LE<.JZN= +Q
M44Y;E(G@GX>=-X!Y2J4<%4Q(BAO9SUY,O,;(!&$+<R2]P.T'!L?-TCT /S"9
M@AA."MM:8.;81HB1R*K@G]D6^V0Z!!,C_"2:5\P!^9#4(>>IN$YI"-NB1@+W
M$J^T\7U,W9>(O=%BQ\N^2,N&J^>87YK<9MZR,>\7-EBE3J1@N2%WH!WZ)Q5"
M9OZ"J(.L4@>\",6C[.U<^[&7%+UD$SQO"GZMQ%&H/@P-F=.U\%MUB\F^BXW(
MF]]E8T6<#'YTM3:Y0W0Y:_[0XQ,32$@81VS1^NN/93C@]S.>]?N>E&,)Y "!
MOZ=I;HJ;;./H#<",I@;P@7H,^?D?FK(!9N:Z G4!:0<RJ8K4B)U3%HZ& RO\
M@?O,\MU@\MJ"."#/?J:&JF4X8@$8 0@Q]_?K(<_U%\!OKW>]6=:\.QI\T$6P
MFS,"5X2^&Z6HC8HZJ$VA4BI]^$F88:DQW*,/CC7>K&RK(U@;?E]OE*Q;QJ>Y
ML;Y__6=DSZY(_(H 372HD;(&C:3K1<YE.3^FOYO,]269D)&BL1^D>SE&Y+=/
MA3S$/H>0>/AL!MCN#M>/>&26KH84PD5',IBQ?&^FSFRU7HJ%HM)74K#7,H@Y
M4#WAHA^(TKEFE_G+.ESR:GZ9D;;P:*1=I%0=\"DHA"4&>[2,$TA<TR$=N&K.
M4I;U3I:\,$^_UP+3'P!%:7_]3@F_ ;R39;=!%TZ3!9&:5_<*N4M:_T7KNXBI
M659WT1.8"%9U[=<:E,AA/N!-09YZ=5SP"?$D[EK8(NL_(T?$%KG_-8#?IGZ=
M7U%;7V.2VY#\]-'MX#S&NXVG?2Q7I[A?I[5>(;SHW@SD/MO6LVF:#*?ODJFO
MS*U!WIF!EXB,#)NI8_-FVO?%&[06&3'N*;'Z5Y).9GZF2PI%!9]M#44R^T@3
M"QA^OPZL3HE;+<QT.^23%W3)_G,AN0K^^!W=EO7TK+'THYB=T97L;^P+3TIV
M#P*XW#5YL.$:G/%/"#>%=UE_T3WMI7**5=DXZAQ\=0]D#D.Z*C<?F5+D;Z>2
M9N]=S&%T;-T/\>Y@EUJ?%(\EU0E3N&<\8;JS:Q;#PLW\Y1<A[G+K$M%C,S'2
MH)WZDA;RE$65<@,+=3UF1&3T##[?T2U2=?!TN1.<;4F6$>NDWVM9;5B%>_8%
M:4B8IOR!/3Q^/EYFLKQNLW6K,KOY.H@?HWPK3471G[GYFN\!F.;/?0N!'($B
MY_3$\X>"5[UGNHM7(3Y'Q!V',<L<V P/,:8I8[ICQ:&[D+C2M#YSBG!6>':P
M,T3ZY[2<%OW'S:8&LUA.AL2 >0W?A1S=?M3_0]UW1379=>L&4>D@O1L0I!=I
MTHF(= &5$GI40)KT%B D(%6J@(!21:0(0A!!D!9Z%2)=.B$@TA-J@! .WW_&
M.&/O?Y^R;\_%NLJ;-ROKF>U9<\ZU<,@/;3Z"<K";W+P9F'*SHKB\M"[MT>Q7
M[MFVC1M-[I^7L 3/8 U%UO A'_EU<*?.[F\#A0^KTA&BK@%2FUZIR\!:2-<%
M@+<O2X,%1TKW\W*_DR:JP#'2)K(HM8PM'=#</-BU%SA3V,P'X7I3^'])7>LI
M+MXPK@SPUFKL&E[4T._CZ.?HZX9GV+I^U^#7K]T<TIC_Z#(CIZJ3_^+7W5=4
M@#5R/.@3G(T0C$%3R:>Y3J:^7_%8\$_]'+ ;K8;-CZV$'=K3]KS@L8I>?FGA
M$_]9]WIVQS/V'8?8V>P"06MS?O7<XJJ\ (V8%$Z,+(FIVWN!6:33%)GLDRG'
MLFVU+&^;P;(:9.Q_JJ,"^1.D:1XB KQ'L??I(3;W<#<[@/54\Z3A_]N6IO]3
MV@PP2G]=KB#$6H2L?%JI]X18L9J2 N2MA-UV\,'LT@XTQKXN!4?9W L:Y"YX
M2RME>2,,E1$BW9/R>A)!#Q,MLZ<RVT@AIU$BN^D@)]INOF'LDTA_>.*!LR=M
M/B)4+=X@AF31N2+@\"&ZO?HT\K[ <.#JCD8K$;P"Y_/I'-SGJ8C:FQGM7-XO
MOP!8_)2S[,W/-(PJ^V'G.HA)"D+XRM5EEFX0K[6G]B[Y28G\+#N#W7RL/]GF
ME.8F-RSC/Y-=R'*^IGU[UT!TL]"A+=OY=0 Z;C((Q08['$6NZ3#:95$RSJKZ
M\'&T@8PGCBFZT-/U;?G"N)60E/#:34,ZX]_RWX\#G_*NB#@]_TW7?!/U.%S&
M#MRS&YT*T\'!N%*BL,F+8+VT4%')5(>Y'-^F!T\=.-I[0!KBPDO"2<F1Q>U+
M0'9C/"%FU)33/;+^)^<T\:FS,/$(R7T;DTMO$M?CG7)C)$:5ZGWOIK(7\S*+
MA3BK]:<BZ8ISIP4S/".<*, IN%SKH9I?Y=?-\7,FF2%^3P4IW>.4P<9]!_,%
M)->!^6N:U-+4.:]33"7MZ_D8OM^D7^*-N@87L8,"S4QB2"KCL-DU<;K"W#U6
M^E_7MW@\^MHY^-:NMUX*QZMH(OMHJS"AM$-_B6-TUMYF,UB!)@'TMJ]$6[)
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MX4;JIT;/KR4073[:)/<P#XVE$!Y= <8#/J[)_V3\*3TYBIMW5#[)7@9NX47
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M8Z<S/VVY>6 ,M:\Z2.STE,8]U(QQMI-%!,#]/.F1SYCJO?YC!07WCN9KG<W
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M=\X$[9]UZJ_R%G&V*_?^"<W-7D6X#C%HX3)JB-JDD13]EF^!/P(7!-PC&1?
MY%=W>A9_!B@A8S54B=Z_FGFQK!,:S+.V0V6&(M)'"B^T!&343L)T]#=/_,QJ
M=^G@OPIJCW]+J84T1B.CM K39 6-)J?[^X9E:B\ QC&UG?C;GOR#/KD,-A1Q
M0PTI8ET2&@SR':;I;:/^,U!;6[S!7'*&?*$P][Y\Q@C:- J3^H)#2KXBH2C=
M>\'!<!9[AZ/QC>5IZF>:9>]:7-5&4<7=.=/5^KNQH L 3>ERZ;875EV\S1Y8
MW932$>C;[E4&^:C'_YZQ@_W%65)JFFSHU&;L*W\$.8P*%Y"<4+:1#<\]>A.<
MI<BL!$Z-)\YA4_?R]5<*M" 2\]T8K^FB-A*X\\Q0IES7Z_N&3M*UD53 <TV^
MNT'DFX>;$%Y+6YCE>46SOD;NU%3F9&MH<4>WP!7^JRN'V%7U$']D60>V>H[W
M20RW3*7I:^BN3#&E65&,0;'U'0,Q&;?=WQCLQ_0$8XL_82;DW%'=^"2N.MER
M%H)?^%[CMPRQWSFCI=8F5F:>4Y5Q.1[:!AMB_?:G80[X;R1J?@P#.<2P",JT
M &1S*TSTZ?2D_8D^UJ3A?';\M;UO^Y"@N%S:#9E!'L7\"K"9I]">:!9)M3$2
MO"6RPT=;%AUA5QCZ])!8,4YT.+LQA'M^VKDL^:9A\D5MFK(G)N_AAI6-GY.>
M0%7(X8;[I25>DDYJEL&BKEG9Y$D_K!X7J+];'WB?QC_XGE'BSV(M3X&4-H>K
M?IU1/7_F('E_;$%=T'@B",+ X!H]**)(B171E[+&==D9N*J*:MLM;/2\R[UI
MWF$E95/@?4[-N2WQX#Q36@;IEMX^E6 [?OO^L(QITIS3[0DWA,+BM_JVE-<(
MEF:MBO5%]E8^.RM;FT$)]V?!P1(OGE/9>F3TZ%^2/N9\C>GS]ZBE_$7:4D)[
MA6)"[3N%,YHG>T4_V1S#?GAKW<4/@R &EX'J4E'!504T];P- ;FT,KI.$FS\
M$>-58_GU]8JLRC?8U]0F95 $FG,H;/>,@J#;-0FDD ?=(.R)@GO8\=O-KI'!
MQ0_<\\Y>>QK",]8<K:2D&;N5) H8M2@H.BU_.,@H-7HJE&-%!]1J_RX+"Z[,
M9WO2M<#JU%^>W>W$$!S8\S R2J4FK^]\;7_<,>Z9UC%I6_/Y22)S37*:@8]-
MP.[&75 -P]9^:4=U.V[QP>^$6O8(0X<-%K,+ *X?\FWA'(MIC0+^N''J<P'8
M1!:M_U..K'!^I>5W6;>UN$OEK1:F7\1KF\+"0<+->7,%%2&HYI-&KVGN(V@N
M:PZFZE4;/I(!0PK;S!I'/#.9]C*;\VQE=7E0;Z&788+)<#M=^9\[]+;$/D+2
M!>#JC_/\9B./6U#G3HOLJSN5=<O431SG<[(?A&\V$*_!@XG:E]Y "J8/;D 1
MW/'&6!U_J:.C7Y A1IY5<YV5_IL):>ZG6B7Z$CY2)XYZ;P-<>1\C[O+!:\F(
M27,$]J.#\R1DTL8&G ^_4/!TZ5VDW;RXX$.&>Y8\X8@V/,0"]D\SV-3&+[=
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M<4"G_93@US4#3)#/,7*_-UZIH*YQ1+D6$ZJ/?1_85QCN)9D\R=E.<7/.XA#
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M%1HYKS9F5IB]Y/W(QGO:OQYV6R+#0<_0'(3=;HN;8AKRKN\K7SC5R:;Y?@P
M2B&FD:C-A_5WBK.?>A-.Y3=&BU_'JO%;J]7=JIIJ;GWP)SC,MH(WKLWBLT&E
MK=J)L(IT=FY>^O'M"7>O1Y>H-2S]ZX^5EB%ZHW?/0] 7EQRQREQ=BZ0FC=B<
M1)RSC),1(P8O **].,7SUZTB%X"QM1B1CY 38U $:LL(KTLJ4)/1OF880.)
MK#.JYY#H^B\ ::YEB*G#"P ITP@RP8H01^$\38CI1EHD%/*2P]:XD<K*J(@F
MJR=\'^-%!/_];(;[>G_E]-@+A041!6-EI<S))@!?_6V($.D7JE8AMK/RUIK)
MB)!-)5P;NAQ/0<?WYE4Y*U@X9I/X=6I@V"^77CNB(J5WPFQ=:SY*/L!] G&-
MZ\Y"P(N#1#!::WQ %A88E%CZJFTT0,RH5+FIW-^UY$>%15[!;24OX=]'*=PP
M2YQ)^%)&W;S;Z *&-=Z&D_VG,[!#![JVN0YA(^0<+3$M#A82#!]RQ10*R-I0
MCKQ?6;DVFTARF.()/*'!K,42K?"]O=YN$&9/K^U+:C3729O\M]5&?V]%L3R5
MX(_T)[3C$O0(S%@&.L)Q9Z97:(EUW8\,+O6_@S],AL)U2WRRB>QRV&2%99[L
M8)+%%.V*OYSE*N'U&<@CY\G'C3*S;HO.(>OL*(AL35W6Y[-,NW88>^J?-WW?
MA#4$T.ZKOKT8+&>CLI$U_M7;.[7NW0N?2L6[2Y&>L7F$_:-VPBQF=M.RSHL&
MXGH$9O:0JVL>8#7T$%8BCQ@O6(O_>[B84,"I9HIAF2#R>@0'"]B<5*Z\MJQ@
MZ3.M%U;& L_=SH;7.A>8SPLUV&8W9-?O/K9;L/KQ7?RJO2,[&0MV)P:0V3?L
M/=WC_@<=<U/Z^WD^\;$/[K@G\S&-ZEEX9GT68WDO"]QY0$LEHT?F=Z+/;'*N
MO5;^HQX,J ZZ*5.1_@+WH5IY2$6F]&PC-2%:;$/R?L%WU,Y"OH?LG> %?9MK
M<?G@=F68W-S'  N0<!Y8PTV^V"W#9=[/Y/?,H7G.MM_^MW9$O6(/B(S0&,:]
M/!]]%%O<*5?6TISL,O7\NZ)G.DU?.UIS?:8Y!SL.5SO_KN9>0D"T+8@VCJN)
M2N"' JXUC\JKW1'D3027 BOA1?#9?!8"-]Z]X_&Z3]5[Q3@%2VMNU3Q1?N:3
MFJ0R2!\GFH\Y6:]_+;WT,C@_.4_9AE\A6&/-)HI"*[8U)SV4J\;E4^^O5 M
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M!'Z/G1;;G=7X8U^CXJBT)I9-'O,1H90PZ2='F#[7[<JVA)IU6 [;OV[JO7'
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MK#CW&U_":41IOQG5-7G+$B>S3NI->,,+C^"CY,,1NO_+D]I_7WJ4\BL>&DH
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M%9@W$/<EK/802**G$2 YX@ '7/(E%UY?.P)&4<'/%P 2/9C9<^:K_])2ESQ
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M_]+6)]4<_<QV9E%F2[N:V6)+'C'%\()7V,,"C%@^E7V@[!DW[6,>**GD =A
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M9<Q.YWI:D)7*9V,";64L?"E0H\ ]Q\&0/])/2PZ&)4CVUX7,D#E9.N6M612
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MPVFD-E%5&O8;>IR!G\?<LG?K7Y2>:6>N>#",]'//7NAB30FRIDP@9=FY!,S
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MZP/:#V)A5W^L(\LU"I3/3GPUP7,"^(*3'14<&QBAZZ48>$X_5_KC;D[>B><
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M'T:J19I896E181CGS6H!ZY,-_@9)4=8_>%U?PMNGSEJ,V5IC*7A5^IC)JU%
M\PV]2<Q7ATT=:VK>%8 <1HG;AB4SE8I(7JPM^WP%-T] =P3T4=&\93DS_:EM
MRWG5\#E+6+.:.YN0A''/V[W6][_%U<>//3+/,CK=V\@\3-R6K)I?)"(=:!/D
MF<J;DJ;-*1[XUT5GSN\6;"*\N &0[FZ\6NV&^/SIB<F]DNL6(RX\ =%=ZX+B
MEX!-.!*"YX/T(;>-&+T@-Y74P;G^&U\7KKI>,<XUTSKWT:?>@%;5C4EIK%S5
M@!B.E#JY#^BB+CM\+]=QY;@ZK=1L3I=YUD'<R!(Z_N7-IJL#)]H7_.33]%!
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M(V-&%4[:I%0KZ^6 \$L #GD<@5T:8%$"DK=M4>(CC\1$OL2M8GPW54PVQ>U
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MVH!1H@_P7M@-(.H^KO8+6[> U)ID1^H^'9<V5%&F;O4UF7/SW5.^[_#? P-
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M=@3)"HJWT$O" AS6-2)3<GRGM;):]41&_J+6A2)Q!Q:5-=/2@JW#8F.B*I9
MB=$6F/(8YL9:2%KX$\<"8[L&CX8SW6*F&T-!9J9?3#28=KEN_-L<6_M[9M>
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M15=UQ[7-CW8A<[;T^"+B%\2D"<P 7\@W0804NB@JB!N^??/(.W3GEP+32@$
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M2[BO?_?0FRQ-,Q;C1([L&E$?WB6ZK>/,CPH"AX9Q_M)G@$+%Z2LJP@ED^5@
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M425FB2DP&A2\BVP1?5M.T"_V238Q?:3U-G%'E_SE8Q_08X'I,\!6)_A<G#/
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M:<"VVS2S]N(F9MI6:;Z.8GWU(>^Z,JV4(_?[9#CKLNG6JET<IT)-^VTLVRY
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M3/+\P71Z(E![ NUT(RBJ\-X$Q!%-=9$3G>"O*T/_J^^3&.M;0P,8] H0#5V
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MZV4-L68.YIXHEBD$Z-)8R;WT4)K1S:7@S0WSFMG()CRI]9WO089E]K4G7A\
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M/V.RON[T9=\O<4_ 0D;Y0^,<UP;X><J"B^KW_QUCQB@) #@67E':^[,J^W"
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M6 8GRR;FD:TY2/'#]A KL*[*^RO7@! ?#I*_]=NW R&9CD2(M&^JP[0/K'\
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MCV'#1AM/LMX[?1GOLO?A-:6+*,!7:SZ%+%7L3-06RL5+.Q4MIEA8-F%D;V@
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M+&;^F'!GSJ\*&F^F2[05; @.M%?&&>7(Q\,M?#G"Z6:\B1[(K(^-B2Z(C6<
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M#-$S-R\/ 2-Y;MG^XC+]@K?',.E(6[!_6"(UYA32*"BP5)&=(!=-FFWJ8$
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MOR3E'N:P8U'I2[+=3FR%>.$8+OFW\@'ACEV<*9+[NN?4&VH'Z</LV=H%#D+
M*!\1\D!F*A!H8:''@<P'^YM3Y&6[=:SD?'17+-'S9PP74E&E[Z5HYWV^.#WL
M[*S6I'G'H>]<>2OA)X!SE<)Q]C\,IV3WQUO:H_\!T./_;='+_RRQZ]%[Q=MU
MJ<Y:VQSMF5)2R5+B$E%/ 2.G* #S]*@&[^AKSD;H*;Q.)[Z,B[ZJ52(+=G(
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M?E CQA/[ J>#"3AM#';53ETPB*=KRI_ZH)::]$5=?Z'G@\UFTHO)K@INYGS
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M=/XI(H)$_\'E8"=<->X!Z@; A-M$NA0BQADO5!NB!L1ZR.?H?U0N/31+]ER
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MU<.=>&D0$ZSMA:"$NXTB-CZU0%YR]'=EB^G@G4\/8G6H#'LNLB>7[Z+V'N%
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M"'(:NNO*+H-W0/V]8*UXDBL1NT6JFMT[&'L[V_?."AKN\0 /6X'O#N#"C":
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M:7GN_LLVVMW1V@LANCC3\@L;V4E%@M?5"&M%W,=:Q>>AMKSN>0C%_7SGD/"
MJV8O@X03T;0I,P"5N5Z 2E_E^\Y#M:DZ0#.9[Z+Z![CIO_G&!8 XC?9F&<_V
M,"<,I'B9Y<6(=#,O"C[309[!/)T/UD*6VPH+EL4ND]!#!!S:<.#1[0-56!D4
M1Y%G "65T\83D17)N7SQR7[!*_EL)DO0<%<;!ICC062#<M,":TWT9F>@T]!L
M!*MX.;P9G?VQ0]YK$H<_ZN2H*8Q2X )?ZHYXG)# E:.WG[[B%S4ZK'W*=2ND
MS7+SXI00-WP <G:WT ]KJ[%F'Y,@R\A_\//00L?\1?\M[H1!37_@Y*@U^U4*
MR,F=P7Q4PH;FKY2?,%?'!Z7:!(!6!/<:S/_BT,<R(UZXF_)1NQUO\IM?T\:D
ML8;M?Z+U-]>]/CC8_%Q;J0D\E6=]8K&\H"P FL2E^)"[J_89YQ4-,1[!&*91
M%:C)@LAC 2#9-_!0&X(5!__(DSJQ^2J>K%E%V?L.PM0DN)-=B0L',C\XAD<M
M\.$CN$8^V%!W%% H\%2E()8XG6WU.0SFO4%I4'2J.7+/=D4X;.%NV/)U&DO?
M#ZO9TM*50J'PM#XWE-L;)(I]_,1Q=_(KWL,&[Q^\"J('%[A3[CM(K1O;L4:\
M((\%_'Y/U3>\=D%Z%1;A4[]19\[T^FT^8AVL)7PQ0"ZH6[R<%Z5GV51]T#OW
M<RYQXA*9X1B@V>?2QV%NW.<U%;WS.,<I^!VZ//G$(!\M\+[>JN9O</.2,#T>
ML]S2TN /K[8MFG;Q=BM/&I@K[)?6+N3V9VR3X0SFWW-RH&FC[3E[%RUC<C5-
M9PF-0#]28  CSE8C.Z6!\@660\%Y8)W5,_^A^M@>(FQ72TSF%;@R<O<T]1=L
MB S\Z : ]N*#[59?2%&^Y9N,>*8\:,KG2RLR6@1REE'G-X9776K0&&OA(1>?
MGHYU''D+6&[5O^7281\D%5KH.12.,(BHL&)J)^C@0PL(8EAHR4JS48K[\8YC
M^KXTDS(O[VR833R,7>'9-D<-K!WV8 MQJ^5S_@C%6 '9<XH_8".XZ> NH1@$
MPOQ=Q#_[ODC+B[>^, FMNHQIEMR?4!Y?_RCE0^O>)"HG:^NM)*V 1VU6GJKC
M=XJOAY T[ZNZ4C=.?.6&> U_U5/^*LR\?,<(!9S#EV<ESL^BK!]APBO=Z"TR
MWI3K<F&Z#+HW:+=ZQ7^5%SGL.9@Y7]:^6X5U7EQ3+FTY9KSGY_C897L#J!:I
M.$VWY-[(WNYE+H8.^0X09H4'X6T><2":#T@:ET42H,6/Q:U??T>'G&("O/C$
M0UF[)2-MIX)!J*W)W?,5-#&<&GZ?H!AEZ2R;\2"_<]-36+CWGG=P\#EF_7!R
MKQJ;IXSSV;H!L$+I[I7Z*I;;@#^2">;9<FH_A?&C9'802YN9YQ5#JYD+X.?R
M*A-*E.6Y7ZDXWU0R[6'Z9</.(M>W^<]]XHXHQ9=:9/JD\R*.,C-N .3O*O*9
MQ>4K2T,_\#EM'5JU/U^'GA8/0.!SX*#['7.:[5/]61)]SNMF&Y1BIR=VVB_I
MF/^H%]FH2]<_&:^U+OQ+M1=Y"1S"PKL:0/&0VS&@" EUNQQ(%?EGVD:+Q.?$
MM[A887RX@<?M[>Y>0-N\I@1\!(M(GX# Z_OCSTGZ%KW8FEW[6QY>+YJCNQOO
MMS""<5)*MED6_%D%3+=%],W,KD/66!T9NP(EAJ(A+-B)Z;5&=+22C+.A6S3&
M>8V<Z :P?3&Y<?UL,T/2<(52"8E];Y5^ _#0^R1JAKC_XENA!;4U\"B<^5(#
M*>>GJ;P1#+KK4)\J]0EWK@*SN8<E+<D-[ZQEX'F1D\>DDU5=V-=7,EY[=E2C
M(';U#6A6ND./X)SP&/CT7&34!YAE]/I+^B91",BZ6;5EBX.^R2</+_H/51>I
M12OY#-UJN45UZF3<LN%#-=*HV";;2[4Y*XV::Z+*H(Q\.<W'WNH7MQ87T?+\
MHR#'H<C, PR(T6*&H-/8^$>\-H&UMUUMU';GB)6</%XAQS6)B(,!OP@T2'5-
M7WL-3D27OP\WN]2@M5CW*M*'47YZN\>+M]SOPH1*^POZE'YLVZ!Z5E#\M#=9
MQE$ZW_D%ATO)@N2D\8FP#3A'?*<"^.S;MNQXUVS<X?1]!W*SA@WYUA#=&X"%
MQ 7%D@T%X578LCL\2@()>O5GO]^5I[G5*9^Z_E9E78DG)>QB_*#!\>/U/>@@
M@CYSM7W"6$%\XE'XC*BXUQQ2A*A6AB)L^,(1A\)XS-1>DY+@\CI-&*SO_L+F
M=X?GSO0]5A$4G']L&BIM6ZUXY^D2?-UFI(E_F8,"KU!NJ9KN.)WVP$M%3+@H
M$EZ1HVZ87&QN4"@S7R)5*(7 K#%-LKQ;>*Q)E;1>KT/#W^/T-L_<!]7#U$T]
MFIDC59QH_J/LQY7@I*_'70@]C J\JC:6VY+PR6>;^CR&ZWVKWRKW">.6Z1?H
MO+$-3<MCYPOQ?<-7 8^K3,>Q]0(,X8P<D4HVH<9H%N@S_'6W%8F:;&KI#\ZG
M-?V)O424(@P)DX2-VA82YT7F8X^H&4B+Z/#[#SNVP;1M"":N1_X1)'>$E687
M)S/[V#!0[A6GMZ),#&1]_*VCI2^\.HS.MMY:LMH]V1A/=F1W5O<_SSF6E@KS
M'$QAG90K3+=C8TZ^^FD>YP+IRY2,( RG?&N8_7V="GV"K\4@22'Z2Z6P=E=_
MWZ4KY=+UE@=I3JF\,P-H#Z)U7@5DJORH!7ZVA/ R>@!"QF\^X'Q;%Q*-\1&Q
M.A3FB%Z-'S\_6SF8)::BF@:_;&VHR6+/S9]7=?7P#W@<Z:JW'37WQ6]OJ%;C
MDE\%.YCV#0+R^ RB?&\[1A_TR-^?5.VGWO,TAQE*12;Y!I^3JX-;Z>/]O_[$
M$SULCNZP==E,-W]>;4G\Y+4M7S+VT$(5L=_W#<3<O61,0LVXZCF7XFA>#2QK
M5EM(Y8NL7B^4[2GQ\=Y"E16.W@!(6OB%8W.S5,:^!05;:!(S+=BD#7Z0YG9D
MXKUS<11[C I@P@ O)S?@N^.K%LC/UGQC0FZE+5V2.7(PIY^N56("Z6X)L81Y
M739E:)J07UG@DN-.]"4DDLF0*31VD]= Y#WM3G7O=KOLDU7T\^JL[3^'TQ/T
MC%IN6^U\6<X:'Y(V])+4&Q5&/#+\M,G^XYER:TCC=.A_TC;@0^3> -@9T"<[
MH.MHE_K7)U1X;/,- &5V S@VU",Y)!$F%'*T+IX^P>?= '01C-\^P]:EKXEO
M .5271P7$&P7+9W@)/Y?Q/_^Z@2$EU*U'A: LKJ(V&Q/I"9=-1J0T8Y\$Y-N
MR"X^5)%I54BY,K&8M[ JS' '&G9['74N3R*RBR0(HC> MH>$YQ<3X3_475?N
M'Y_GC9_0/_@^P)PH[+BT%'L!151?L5L3WN'KL6UQD9%[L^8?G]/XT$BNL]?/
M46D= X?_F_.,ZHX\'=:CPV9F=8^^%\HU"[/O]Z3:[W0(UA&1]0RX,!DV5]VC
MPC9:Y C^]!T/L.<$&*GR_L=Q !@XK+Y/:V0A-VN!YZJORI193GC)W]W;0?Y<
MK"J;P\[XQ_^[,M47<ON+D>'_T3DDWE#4YD R_(5JS7D,H*]M@)%A1$GC"W$D
MVGBO98L!?_TOJI?U=K4]1&)NYXI#D%^8W*_$^!O "C)"@</Y<'X[;6(/^":E
MTLQDP(TR2U6&-T2A&C?1?.G8M<(H=.Q![N3O=[9O_;1,S5O*N[AUM< 3C,%#
MRD9<D0^;U(-688PN-+-XZP7'S!E>/VK-!V]?VW$^4)&E],$;-=N8C$F8<=T
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MSZX9P7KJ^3JM@OW&&#GU[KVVH%B['<6'TQ@<B7Y#IG"T A^-J4;7I^>6V9]
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M,XY(&?8 +V<SPF5U9.U\I'ROVX>+G!)$8].[N"<-M,'V=66B0PD:M<S0%/\
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MM)#IY-KP#\_F]M%.BNOW=M/53IO%19L!DR(_,D5M&]YJ/7A$YE2'ON*(S%U
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M>YCG>E+2SR/041(&/!>(<YO>/@J"/*3K<.]ENKY(K^%C_+0@>F?X 1U?Z'W
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M3^L^F@P?ZTQ<VIQY8*,L\#CI)NW[.K]"\ @2:]49"5O_X'5E%/NN"-@YLRB
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M\&S=*3E I$Q]HMJV,-*AT>$?4P\H2OMOW8G_ZT)>0^*A>R=JZ)EC:D^9U#E
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M7-E_]C_(>\^H)KMN7?A&%*0C37IX*-*;@M*C(EUZE184$8&'+A!:0A%1JH"
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M[=)('TV7<]EC/NKJS7,MY1KL;T>J!'S"54I:A[<VH_+G0L"&&YS6',) 13'
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M:)JB,O34_^,*CX]KUYRVT:4/4GE2YD.*UB*R'O=WET\K!HO;UL5VG%?W-;5
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M2)Y#TA\X&$7VC<_,R9;S"+7TK2L2!%5'J/&$Q'Y+,M#E/ EBBA!A3%> OO5
MWQXDQHEFCKBHG]BN^VX>HZ13XY',3]IH3C2<A5A4W8[?2#32BLR1 ;EQJN/Y
MD@':9R0AK\/V*VDNS2U->?9B_0O>WV:#MU<+?7+ZPS)0[>7N*);DDV<M&-9J
MCY#MH0L]J-#'HJ=5)8W<(]Q]TE-@KYUHM14DXAZ4#'0SB!J7/%]M3IG7WZ,'
MOC?*6_A%5JZJR[,1'# 7\@0Y)N\V^[0]M*'[1/_ZC2+QZ;:ZJ5GXZ>%;EJFO
ML+\(5S <!6"V-5U55I4KR[> I%WU2S\.5HN42C&78VC%*>($=+!?=VPLWS6O
MMC#/-M:;;<S[:2PQ2]0/BH[_?":=-:[!67RO;\64T_-\F:JT>N'0RH$ TAXX
M@Q9BX%$??]1 BPW_/A=<TO%(Y?P^=HQS64OL[#U1_!U=>Q^[Q6ZTR&#$=@<W
M2'('DF[[$35+ESA'R+:)?!I3M*S:V:=V2@8.VM1-&0F+Z/V_JWMEES=S:-E%
MKF.H4-NT/V!Y/Q$WM9HFX+[JLFH>PJ8T3HX7'E&-.[I@2[5)X-0(*-A7-2A]
MLMZ9I;DN_5;U0\5O?@[4X.N1X;;I O;=EDE7TM!EI2&G58=1&;]-+ ^JHE%D
MX,51S;7?!9>B?)9YO&]JWN(^UH62\G[0EJPC64D2A)%O3:-U//N-2W.#)?/G
M4MJ+N4=*[7<_&MD2.GU%T^:A^*)4VK"Z,997J<TP>-GAIXI^]-06[=7G2S^7
MZI,_(T5U_*IH3>:E?VJHGTH0"GNO]M](V)'SOI$W-"1'M4$D \,7 *CSFP\>
M,Y-PM!Q>QG:[7_Y-_K3/F=U!'_B$. E_K@0Y_UMR]?&):/-0V>!S:H,LZM1F
M%LN#K0V(KP.LQYDNJEC@T=EKEP:FF'#LZF\X_2&")N(<SOWI]32?YJQO+DYW
MJNB.Y@MHCX6CP#)$23P(4F!>8@=E/OG!OBR*\!*BUJ!.SV\^Z WG+-S$XVW[
M">-;RM=_HK(+94<R&H+U!]3UM,=^3*TS.G/CED25[ 4S^>04AEQ]N%T7AX8C
M]W*G$R2*S%[VI0G]KB[3 <5$25#O(;KAU60@$?:3%XJ .-WNEE[I7HV?:_7A
MG@O#M-<3(G$WT)3I&]/ 2Y/*:-OSR"'+6NQU=&.<E/]PZ A*S;;:_.9%$YK'
M0%"_^,D>17WP;"V._EMW<(L?Y]BC<W5&1(^6@C#Y_^<A30X+_D..Z&B>PU4$
M![ N245;1'I2"[@+//Z0!WI5 #\9;Z.AO=\+R'+\;&D$K>)+S:CY7ZI0Z"2O
MWV^M&(KBD7BONBFI&_Z#2N>OD?N&UQ;^U_Z^9&DPE!JTNO!JE3_H[85W+RD,
MM.0?K;:H539Z.>)"@D8X_E<6T^MA;>#6UW['V+Z+(K0B"%]/_.+E" 9""-;H
MA7R0-]>,41-G])NAY&<.Y7V+&\[]^C0JG$/)':@]&5E'+C"3-L_3JH^V3,]+
M>6L]Y4:?CB6>)N,(>;IL55[H2NONR=A6J9]YY<-:Z8G&D:L8,K"E0V%HM36$
MEQGK(";Y!S\0OZY]%4ES\;#;BW,:- #/\PP0-Z0/Y2D$U&]CD3;"3'F$WUFK
MB)^1,_W!O8<SNCN9 [0J*A0F/;55QXD/BKB*:GY-1"JF&,47063**M"N\8:9
M$L.R*JJ6";5-LMNE7WZ<A&D$]NS[05OIOZV/%R5_6+,->E-NWF4@*3%L@@_X
MXCT]OP[U)@.;6%RB1:O7*8)^IF[L;(U#2)P,_ 5:G2ES@%'4$(ULD$3=8Z*8
M]^%O.XV ^BX.A$BJ!%SMA.9E4I+MI,8;R:#(EB$_D[J=+=A'HQFG[>-CU4\G
M&^5[%!T5FBK^Y>10>GIFKF"A5.RC;WSNK$>UR?#PV-VZ9\-]"^KACZUD_.]4
M) " ^S+ GA28NB3U(R+/]8]:L.SG#S-W3K<Q$'M8:R MFC4@$E=_$-90Z5OV
M&ECES_VC<TDZLAQ U%):RK.,D.\-H%4>BE*\P--O+WEQA":**^&FWJW9!'M@
M*<(2E<I(F/PU TV\&T,2HL?H6/A_[3/,2X)9XPI[37_1=A:H-+8:7Y4.E]6"
M+@[%+J4^3"KE9XP<-7TK,HK4+4/D8;38T"3IKC-+S2$_PF]IM2#QBQ7[]C-6
M7@X%;_;=$:_<FS[I.<PNOQYL]% :+^(!NYEK'J\M9D&4X)*06CTB.QG @CH%
M=+T*&8V#/CUNCEU98+B])ZK_?7"9@5GMTKHJ->=A]B;DE,M34!;7GX\W''2K
M3J/Q]N',;%K"=3>J'"'FO;ZK=9O?$CC+_(AA3@P\'TBUSR;MBJ/(B'N_^O[Z
M4A\S^=>HBHA=!NGXYH6(ZPR=)A>'KLW)!66[N,4?*O%+WP\]+L=X24M8ERVL
M*RXPV9M:;O@+BOMKR4LB,C'5AI7E%G)9?\G9OY+T^&["8%WIO)EA BY<V3HB
MLENB\$WY53*M;T)3OT5WB H6\S\!&X[C3(GL@2CW>.77!U[S;'QCC#%VV#3K
MW?7.9R$^':*!!-03Q,\$Z2T)/W=&--ZB[^>@PJN-@06+9)7=@89(5R_-(+UO
MUAC'P[8+\94YF%)#-1W#JC=&WF+AFP^@X=VY-^*>M$2";E<_ZS:MT]%_&\=Y
MTYK;<8LA'>C 'N?.ODLX@?;J2/1*]$EGZDB+9J8;R*;;BZ8R-5 $YZQW_<+'
MAA;?QK&Z /\1>^L__<;HEV(I:[WG7YT/_Y_<T+A!Y*,(1]$QRCLB-LC F4PN
MLD**9 M'S14>7\F-/X-#R,#:PXDS<S-V0N'0[BT=#C/]_Y@Y^93FO,)YP8LB
M0F>W4%.R%5#I;OL!<;/1K179J27S,^F*=U$:P:<H^:XM(_#?N(G6EIJ\K1TR
M "@/.I$&D30^)LNX'@7%[3<71\KX:/<0Q8_?LF0$R4\;=0XF*>E;_&R2@CH*
M+F:3 ?M&.C+@QA08_L;)XX%C?NPP/_-B#_@KHI5RPW#BR/3E_H 6)4%Q*]JW
MI_K8=#U\)!CBV>_[:P=C[C>$66*8X\LD@I]3O'WE?J//P%=LP_%W60#V8.14
MD&@QIX'DD@0=X-J;2$?[Q/5*6/\BIV(JP9!*!0"IDX$OI,R3%SI<]8.+0F Y
MELU8O"TW&7B:7>HO#YE\!_]UBOFV6:%A]L QN>=[0XRMQK9 ] ZD//0\MHU_
MM500>>8)$$;0X,WR4N@C:) \GT;8=O'?VK/JS4/U.JJ6&2W<&J=8[AW(PUXV
M;7Z_GB*1%UPJ/W4YS0%K@!D K%Z945_E"WAYL?.\X"V!BT(ISUH9,/*;.R@P
MO]))X:'C]9ECQI\0(6OU$00U]\"JUL3^!0ZJXPW09BS&SL=9OPY7K:ANN44=
MG7ZS;R<"'A>4Z[M9+*7B;63F$)W6&!H=+7!:T#HU.VY&.Y15^*6P^YFU6D%>
M-E/?-L?VP2IHN-G(=#H5-?$6(M\5W/M,*U@Z/1(^008*G>MV]ME3:JE6U."=
M._$SCQ:K'W/A-D\; :P ^%F+ERRMX5C"6?HP=WT4<+'5M6AM:LV!XT_9T4E1
MQE1[((@C:HEZR^A?JN/_2:,)#]E_E^&KWO2GTS+%9U)6UBHUD-Z# FA%#P'Z
MO4"\:5<#[X\?2OF&4U;C%MH"X]='JY[-Q<9P2WYU"<Q+62Q<'2%R!)+HF5 C
MTZ;HR9K2M9FZJ@65]MJ6VKJZ%.BWSZU9V[&>E=L+/$U'W()UN"/B)?G>=G7"
M?"2>%E.8*N?K8T/RD-O_O3T]SVKDI[][E-''QQ^\9$:[[U(JQ5)&N\?S)XPH
M/=3JBR]%AW27E63W:5W[J63)K-T=%,)KG#9^7C1 \Y?M,+C!=LNK"#;P)P4(
MQ+7HV-.<=W@D>9\JB(U'H]Y*JHFI)>0N(^[B5N'23I?6A3/$GTJ8(-8#>7:[
M=2WA48T+8G,9>J+&@1PTTR4J4AU;(N?A!V74)Y-C9, W=3J+#%B0OD->\+*I
MZ[O:>LU&-M'R@%O72*&(TE9Q[ X-8>6G;ZL81E;>N?X)L^C8MLW?D@?4:2F4
M66#B=<R.ER>R.:Y]^8YV F%T/Y !5MFWXIL#L!5(71Q(\N9I3<OL[G?H3I=\
M*K*6 LG:6*T,"@5.;%";V(F6VWG;<#F[+_CI+='.P';M!CY]3;C&#]K#4V,S
MW8# X]Q=TV@RP*VAC.]'+\3AJ;N.%.<\3NJJKM[(0G<9_A1I7GJRW&S[Z<<_
MJMG^-XT63TL&+I#(0,;062%\TW.4#.RW\Y+Z80!\@)W@1 8>V,21@??F4_C>
M_]9U/SS ,2#PH#AB:N\[&: 5@0\DLYQRZ^TV('X_0A;X$E3Y2'<?PW]U@3/;
MSI7B^\<IL(>*AN\^@C%1H):"(?N<B/D*HAB%-%T@ P,YA!ND5E<R\,,&&5SV
MC\P7"M*?^\,)6?G3%7^,CD-=3&@M2>%C?10' =A37N<1]1\L$=-),[4.8@3;
M8X/DX]O9)A*5#]/.]]:D6S&NDJB=/G)084(6:Z:ZO.]DA*##[S&XEYM/C2UM
M.$Y,;9;B GQS69AU_CZ[Q6?GGGK(008T;$>!V+%<>X!P9'?VJI;M_6,Q&63+
MWOG^Y0/B1OR;0Q.\A(SW 2KV\UX'=@Q1>OP]\D '@/G-P[XZ@].FB_"&;\63
M',O^E/5D6;LG?JA&>,V=AID0^7Q9>HLTM8<8,Z0P=GI3"B@_%W%/F!(P/;D=
MK"K ITQUEDJ2$C=EW]94>8,_0(PKW%K[@\Y.#9LO\+9_Q;]@!OHT%OU_*5]G
M^76$^?A],!'!R5DW+*KMWQ"0]S 275#PFG*3IP3URLY32,U(/$RP5V"+>,F3
M%[,%]O+^9!TOUN"R6I W-:ID?I-S^^/;UH:LR77E++J7_3(^5#8VJ-@\4F3E
M,O(YZ,M4;,3-W75GOII$@\DK,@_SZ<L>:6Q_91@_H$4J'[A1H/7@_JD(M.!7
M8S:$F<+Y:JG[PB)W3*3K*#/$35H?IZS^OHF6;Q==,Z;Y/;)(!XCH]CB5B)#Y
M&JFMG[+6^+7CN-E=-):8',0%KW'OW*!A\D:K6]TGWN,Y.>O\'EXVXF]T4S"\
ME"B+TWIM-?T["\_1M\"!!>%X-ZOV6P0T'DPNJ#P#^,QO<7.OTWC=3@!4]\D
M./._BXA*;K=$5_&:Y>,4CV+GWZ]5.K9FA:C35#>,'Q[WV=I\UW_5!,V*G3M
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MAL[%:!(CX09ZUHFE>R82F4,OE(7KY,[)L:*.[]MT1YX_L:V9VM2@0\LSX5)
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M_.VS[KF_O<_=]YR[[[[GK'7\8];*FI5OGBGOO/,\\\T[G\E!)Q>][OFO'ZE
M0S-FBU B>^Z!S -QG8RXBA<6\Y]OPIV;H<J><*;A@S+)"Z5O?_J_,44Y[6<V
M51?HN.GD1A3# K2Z\P[6H.S0=EB-W],&%IP_!%71#2LP[.:[:*<JW\(C*"LU
MX<;]DVUY%=( /458Q*([AI5&;&!QE3D*N%S%8CO9C/AF]MHSGT%F<!L*#/9
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M=#K_91=SF(F^"%RK#XI805;N-?>=,E/1*, =NU8]%+Q904Y?W">MK8_N=G?
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M_?LG6KKL9 "*[/4#%?1LVM-2L%OCF7;?SQP?E_I=AO5&GIV2>FBJ</P8P,3
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M/?9T]_A>+!#T\>_-)5@MRW#0[Y].[E"GC@DOD,^;O^\8,:+E$Z"6?O9]M$Z
MM_* 4)4U+@02,7PC/DB#\X,5 MCL>>%[4X!N0M538E%.^\3PEKG=QE!7^O15
MRNN;E!8W<J76J+FD]0[-"(8FMAJM#MCSTJ[B32=(Z-;V^K_4NSAVD%W$I:6Y
M-HL8MI(*FD[$D8WJ0PIPOI"BT!K=YNP07:N>MF('8QN>U6U0Z \U05TUNHQ"
M5N96;9T3Y5[&,R8R$^\W5"^6)ENPN%X$:G73\89K^YFE18F:,LM:*X(A@./
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M@T[72C^K.)&Z$^>7[]YNC%QH##EK!@E/*:]9\+P:JHA1&*^5;YC2WBJ?'$
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MB9.*B)%IWNGJXS=*&LH95-ZA+84ZLT3-KU>[3VQTK<BRQIK?Y]57)G[W BI
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MO7FFTP!)^15827%AKEV(<<#LQ'H2BQAQ-2U!;Q?:7[>Z_T:YJ#!:8^/)<B=
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MI>TX7;5>FRS>8--<P/QD]KJ793JJ7IVL[U(C]H=U0[6U:7__>GTS>'ZS:K@
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MK"AQ:FE#\"8@!L;KN6+/+[11B##?GWJ61[G9\&RL+?E!5V=RY5:).#H22$K
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MZ,MY%2O6L^XSO ESCEB G$]!I[XHR]H,(Z:P?V=<X_03:W[ZU"?K$+7WK+!
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M2\#RWNUCQWUK#TNHQA8E1"2P-:VAB(72B?NW.DJHWW!0C3&:>DE,ZT+XZ$M
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M90=$I%<-P3S!W$V#3LNO3.X<?$("DTU(8(9NGX ?<S\;#^%.Z950WGFH6'8
M/UV"'FPA@4-?\$_8_SU8@T.MK,+5HH05F4E2DSM"^C <5;PI)/#T:V[B<P./
MO#;E*:*_!@ETUEO9J3C_'W;Q$_J?&%I>9#-4C>5B\0!69>O]/'B1KZ"W=*US
M]A5(6[WSJ<M!G0R6>,J#D89=$19:K=Q$7#E!F8_@MA5U<O)#ZV3CGN3V-I*5
MY+DGOA?H][!7]FC*^98_OK9^T2. ,\CK[\3'P>4*W49-[>5X4?\-T4\24V(&
M7H<'H2_?[C\>!$$;3?IZ#Y  FK@_L+:+[P!/145 6?!%-+Q'ASTG[OBO4V;
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M^=HR?E;]?H-]P>HK@=&!<8^,5W\T6-2E'6R ?/KM_YL 4$L#!!0    ( ,.
M:E0ISTS,CL@  *%B 0 6    9W4P9VIN=6QH9W-V,# P,# U+FIP9^RZ9U13
M7[LONBA2I/<.2I$.4J4'1)I(5T&JB A(";UWI$I'0'H3 6FB](YTD-X[2>@]
MU  AN?GO<^[9[SECGSONN9_NAW=F/!\RULK*>N9\YJ_,.='SZ'6 _+FJABJ
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M5VP\'&>]UOXB=:+VS5OEUF"N^@39PP95>I(SRL?RD6>]@*^C3WP)&N":T\3
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M#: :R>XH4VW6USFZZ3HOZ"KS;B%\=7G(=,Q\OED'G3_7Q7>!YEU32U3?G&"
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MA)8L%9V_M347LC'4*>W091ZNIGMA2*?K:KB>+(-C?^)-.93E)U(L-23G/0P
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M.NYAK^&.Y):D\2/6\GCV;%T5](+,Y9J;Q27*34&+'!KB;%XG8$X"F>EEY96
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M;JMD@9)]S%_Q$7@+GYNB0']2.JG.P #U'1@@4P9]%P,<D'[^RQ\*))-((!C
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M5\#.FXOQ#O+&))=L,U")!92<0K()Y],]K6:8M1/\>+K:<O&)S&P!$>*>^?2
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M?%Q]BX9+2)Q':LZIA9Q/'PU6CVB@, K4OA)R22VR9[<TLG 0CU</*<:Y"5F
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M':"H>H6H[< );2G')2!.N.-#OJ4%\:UT)_W%2I)_WC&">J\]B1[?&]!1!0%
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M)RXM/\ST+!OIH1U--AF(>8*_G,Q<%(@H+H.4!8.*]TVMI$3A$\EU;^?K?(.
M>=QEI^F59"2B\6Z6U:Z'\U'RJCW3V)#S:M3:P9#J7S&!O_]@LA_B Z;J0S^N
M\O](,(A2I->=E__=472'/NOLP,R@J06RJ<0[+_U:]O=;U+]J\YM2(Y/'=O@Y
M<.Q\V&C-T3P8W/X61I0):B_QWUT<OPT1S"._7^ ><>2'7QJ(\%;$+:X"K5>T
MV$E<)_6U^Y._!V__D_Y<1,"0(3E[9+S3*Z/=1O33_1HKP2$[SD<FMW.9)A8L
MN\#?NJV!WT7/OT+XWZ;HK0RL_#:ONQI!=PE!,4<$4(YO?C\&<P(]A%?%QQ*9
MA]BV&>I&?I_!9S" 5<^J&B!JVJXGO^J\GS7B_[.UY']W2<H/'G9];%&\M!;1
M-;,M)0"F1&"\V%I@96MQU^Q2$&_!%]_?':6@Z'7>,JJU0L'0BZB1\S5^O?JO
MW7$E/C.EJE_$0*/W)@QNJ,7&:=%9VU[L,+0P-O$";-B77Z?+)N'$0;5>R'HY
MK<X"*0<>;-]U>YTS<QC*Y7Q81I+SY\8VT<*DX^\C=B<(@-50WM!WIM01SWT;
M?_8ST>5=NOK[08SO#&51LLVBD'_#)F2[X9!H4M--2O/0L1"'7TH!W@[_K*?^
M'Z>?\?"_/1[^?D>WQ%A9@<F*2W,HG__SMH%W][6+54MS@>3>*K^T'; M6-OA
MH+Y<H&LE*&3(RTX .I@8MR3L"  1<&$Y?OJS_UNQZE^-:7]"RK\'4OZ%8O0R
M&["6ESR\+.)QU;/"89.WU!<VS;F*CD1H'1>2;_>0_2XF^X5^&T<V*?JMR1OH
MPT8(8R&7B5*?\>%W_=?O35J]UY^4O!4U&LMT%0;Q%CK<3_M9[_:'T,^H[=\:
MM>WNAVT\KN]]A$QX=-6X+-:F,ORZT"6=TQM;91:@U06DY9]O^.PCLOCG0CZ_
M==MVW#?#0T%;1(M33@ .-0N3FP.3&]V(R,'XTN]K0GG/&P0@$I%)7+6F1ZP[
M6VO?^W6#3MYT2^M.CEJ*#@F_LNAG=]'_8?IO=$;_$\>M*'-E/IP>\6DDGP ,
M;1. @VMYAM"X_N%VHB@[G/O=8?)LYJX<E)<4] PFWR'>>?97?_K?H96Z21[5
MV^HP_ST]*OJO)J6H%-#*HT/IS_<P1ZT1-5ZH_C][.MS/>L?_E?6.?XFHN:81
M07!/B:E#5Y'(=-T!0=VN_N*NQC$H>M)+I=#! $W^4D2(:M3&F5-L*&MP=4J,
MCJ)075[T8U7L@[6/'[C#AG-D^2.3KF-=N! YQOJVN[*/Q,%==5S01\;D6E8J
MM,$&ZF>7RN9]A&O/3@MAU7 <[U;X<R.-E \'3'P5+T(YOY%S#C28.*%EC+T9
ME^:J1?H8#MQ>(*[:?+7\(:"S&8IHEK1X(2L,76'=:?JVM(5U*KCPMG&]B+=J
M_![L^.QE<@PGLHCH<E1,+1Q1@O<O$AVGUD72'MY?#UT<06_A_4&XR$H",..(
M:%S#NA$7'@U>U0B!J0:V3_%U$X I9QS1?4P-(#I!A6#L& A=X\V)Z"%BV4@]
M$,[61^98T!8!P!HWT( 7B0N_G2\<+Z:,$YP(2-Z^2@!FH]L( %L*C5S:+X>R
M,<&;N@^8$9MJ,P0@].L?/J<_58MZ/[S>:0JU%RRB/D%K[:*[5S.5M&[ !;_<
M.F?!S4Z;Y(_,Z'6/$$%QIQ'%?8JK%[&P0<2)#;^>3< 910# B'TJ M!8/A_N
M(*AKK66 0$<L@;?VB&ML L?[R[FDJ@0@N0'G3WQ86<0C@.\&;WX#5F4[>?^0
MJ/+@O_3\5\X@ -T3> 4$.CU>IBDZ_K6N*8[;'8([(GZ#& $X!?[M6SLYISYW
MJO$)X>ED>/#>!&"3C?@MH-^^<S[\Z=SC3(;8[^<7_MMW.BA7VI=J!W7\,+WO
MWBJ1/BIAD$/T>=HF?C,ZWR+H>W[K#UBA6E_W*:=HF2!^_-,_<CDB=9%>CXC]
MOO_7X!_^,N#^723#.N"'/UIHT]+ *'TVYRA\U7TH;FYC#!]\M=5Y)M>#=6M+
M7\U5M?74AD:=UI#/:[.7P5'OAS;-L@O-\(P@OX;%RT3!V20 OZ30-J$KCDZ
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M,55=$38]?B^>Y9ZTO=+'Z/[-DUR^- 4/"4 CS930 4,9!,?40@":!_O/*-C
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MU':77__MHYFH%3G* <>E[6[*Y:^NMAU.1U\C[T'$6.+O;LGJ3]Y/'-[]4"
MT@A0^II?-@P>,/SP*F<'=2TY9T7/\A]H<5)S;1C=):%U,^_SM_AYY;J_.(0<
M4/.QFH(6KQDQ?RDMDR_WRGQPB?_( W^/I%]+(^Q6/'<,CU[H!W-S"4J:FU2/
M;&1Y>\O D<M>>^3K(\UB*N-OG7%V<FPB8XM&*4[CDH5NA>!FSHL-SS\&N\9$
M#D^8J,\JL&TN1;KM7E2>BC?#2?0IO?[(ZI"[.BHD/=@>Q6'WU@P<7@<XE^E)
M38::P"R:SG3;MZQS/?97EM$/"]B\4.@:>P_&UE11L81_+]+LQK(?> JLS4MZ
MIYK\I+$"9W"2AF0EC.]#O'-Z>HM''LOZ#;[*YB*)Z&<WF[@ =KND_1QIG@(C
MPT7#EOIT+HA@R'IFMZXB.2D!X !G LY/%E^0.6F/D<A8#7QP]6C<K;_4IU0Q
M32HP-O#M\9U'YOK]=   >C+0<!(B&U>XC&=+<HEGNZW^I)<].F0KA !\B-U)
MH6X?XV)QUN&XKGEY8*&:,9H\C*=V$!G%OSOM'-0[X:9SBP/;EHT+-?BJA;LQ
M$RAR<BZB;*52^M!UK,+MB:2/EZSN$2]I588N9>IK7R)S[>LO]^X8J['U'OB4
M]TY56.BG$  #X1,\U!Z"'M1(H::-?=JRC5];8W+Z2%K_0W:D_U8J O<5UJH6
MKK .)L.S@Z'J'M_H1U]3+M>\O">/=2( W*0]O(7"&@T#VZ9,RJG6%0WPBIJ7
M[;"GGQB>L7"#/AWL'NCD=3/5[D4NC8.*H[1J0\O;S[,]>+F]_V;G2+:,I'](
M*A^;,6RMGKDT2&=M&&B\00DK4ZK/?VHWF-[G*9/3D=V4LU*=WFU'.\90!N*_
M]M8LR[L!7YTZF;Z;? :;ANE:HEJ(H5C-A9)NMLW)L1HJ!X6NYSHF*D-B-?I/
MP54R8(WR$\=IS/99%U<",2F;TEI3T(Q/46O>6EPYVNUMRPC)M6S2TZ88?G?^
M8D,%FXOKJ79?=$O8Z614/WZ8SOGF6O\@%[J$&HP2C+O1?498A8.C[CJY8=8[
M4!E.9Y#;H69U,(?]/E'%GZ<X<MCO]=1DDP;;.-9JG)B^?G59'(X&10..K 3@
MI4#9:?W9:$ZK>=@K:-M>)EQ^/ZC5E-78H!L8<KR\/>(V\7"4Y5905ODJ25#
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M&FQ5J'!<[]ENT]4X9U'9!\E]\5__!6((/^DG_:2?]*].A&__!U!+ P04
M" ##@&I4OP8%.,B@ 0"%0P( %@   &=U,&=J;G5L:&=S=C P,# P-BYJ<&?L
MNW=0$V_8+ARD@]*+U*@@B+0?(B(U(@H" H)*%:("T@14$ ($0E%Z$1 0%&*A
MBA"5$GJ 4$4,"%*"0$@$I 02@;"2PI??^W[SGG^^/[XYY\R<<V;.SFPRF7UF
M][GN^WKNZ[IW-P?3!P20B+6%E06(@[UI<&B 0 >S(//_^/4_LOU[DO_1<W <
M=(%$^3@+>;"<'"= AT0Y.$4Y#GI!8!"(@_L_!X#^WXWC$"<7-P\O'[^ ('M
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M1$HM?SN7N9WQ*D''PQ-9[=_:V.JQ6M@4]?1#G$1S?:EZBHOB4^_4HBLF68'
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M-&H1@\7PQ)K$CH,_EF#((:%42*^;:>5BNK^V*>X(^0O_2.XF1QQ<GCRP@L=
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M4&GR(H8A@K.>U,,\A30N?OY<X(1A^PW-UR[3D5^^WR*?UAF\GU6TSBX"7"4
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M1V1CKCM0.NMO[S]>G4C)C=2<UQ7G++H%?GX @D7LCPJY;?TP<IOK@*ZL>J.
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M;8H(PBC2[C!'PWD9V4R^H$("+ YN7/)3]E2/XT^3\]\]CZV>O5)QRMKIRO/
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MW50[3-Q^'.F\83WVYFN]C^:=IY**1Z'.1#+R(P+W$MQP.IHFS_QNI T<H/S
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M#E+]^R5- -'IQ!2AGQ]NM2D+ZAJS>6/QH'VB*+C*)84XD'G^M]G]*F'C5K:
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MK38QGX^7%>9M*CU6G(GXW#.F'?W%4OS17)[?.PSEY#Z(BQS$W8L2A[@)2JU
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M?5#X+X3JM<<?O\XXL<C"/N@#\PN$G OH,F/"6#?)COLKF'W0BXU.U);6$@H
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M>?6FV>OQ/B7V*YH_K$DXA8'O#N]2H'YY_*&E=!%QG,]:>160V-=^F@+M54-
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M18?((&G(L"+D'&HV>F?3C:S^+?QAS@E7+<Y^4GC\P8#8N- ($_GLH;?03["
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M\6_>34.W",RN'?K=T08=DK8<)494[F.\FDYJSA9AZV TS<O-U/-6)!\6?OB
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M-8N*&""BT5.X!.1?*D<.SW,!Z@4UYE;O0 BR 6F>S-3?-(8<_HHLZF930[C
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MG^A(2M+Y+@-1&&'O882=04X0GH*4;,K:3AQ?'%LX$/+S#H&8E; U9<\3&;?
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M)?+^O).44/2F_X/_X\-XC=IG/J2+V)NNS7[=HZC9G2/X*)B"]6;0_)[X8&8
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MF8BQ8\"D0>"JV;$___Y1N-B^/7 2&:\"")N=_F^/165A%+-YO!F]['6P7%7
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M(>)P8K_H AN9USC/#S=B.=K"%C:G"Q Y'SS]=%G[KCMGG-YXB?KET<D'6K_
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MT>2LBQY]UII;M(K+4PMWKAG\&B82PK*)R!E(W+_AYM] Y+_[F"I[[73VVRO
M7_&R80TDNV!QYNOP/RNK^AOLK/MWTGA-:6%R@6#T@[_B-> <W .S-;&5XK^
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MPI"A/Q79/ULW/+]TL/_D@\ST!].Z>%FJ/A>(-SVV4>3R/+VK 7ETWGLH6FM
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M6IG)'*NRC0.,-&V]"QN__>^Z<H6'U@WQP9&S(H7QF0M<,^<"QGG9:VNX1[C
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M(GWH9T<;)DPP,FZ8B<V\*K2P5;@LMNU,[ZN?W<RU$\&.[!7UJ+23&O#00/,
M(+K37!(-9E#5Q5Y&&8QZ>RU.![ZW'ZSDF(0+6;4/E.K< 0O'/F3$G4;*DT"V
M.X!X9@$V!U>(C0RM!#.NSV/B# /];?-$WEZ1?/4^24S9^G)XF!$?Y839AR!E
M@.+$8,YOHU5 $CL0)H$768C)__ZC?G#SPKURO_1 =D=T\T)L>+O,<+T1D2YO
MP3UBY\0LZ$X*JD5%XJZE%FSP=#SXJMB0=>H-)=>F79W3.K+1IS??%GTQ&"G
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ME-"OU;ZLE$S>)=)]P4(U"/DYA )U.>"K2UH\\#.^VZ)<S*YIMC0)7[:K1P9
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M2U/M P6? (35F!!0[<2HB#+I8Z-YH/'8[-GUM[)!W]&QP9X:(]4W"'=B3I0
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MI%J<H:&UH>V72ZMW!IFR8K<$3^-.#JW2YF6 (3U]<8=L(/6/='?PM\7*'->
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M"EO")+D B4%7H)L@P>XZ+''R(0ZJ[8]=<]H75-P:S)34$$V%)%YR*?P8R64
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M(XL=S67N=KN_J'3=^#;WX2D=?^;;170QO5;>YWW\.AGQ,NN DW21' WG#&3
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M#>)D2=+355\4D;$%,;V")*4D'/RQ?7]LW_^H[<N7CBB_*E*28I,;RGA"7'/
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MCBY&8O6EHP5I?ZA*%@4JX@P67LZ@.98ZL5]3TYJ=?-QQG4=#^YRMD\P45UH
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MN6:E@PN)A9?R/V8-$9DH0"0#D7Y]KI@"$#;%* "'$V*V&7$0^M-Y"+H^A,3
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MS!J*W]]:/3- S]^I&:W6K\N:=_Q U\UT_X74K25Q=M>U9NJR:_VK=YP ?]J
M ?'QLZ.I5N(T6!<RXUVJ^[E#:WO;9>B"K"([-D#S:]B0:L))/87^1->'*QW)
MFACW>0G86#&9P1R7/Y,25_4FT ;<+@*36NKN)]AKI^[-ZPM-JYV.['*0T+KV
M*"%.U7S]$ ?S^H]O1 52-6(F0988 ";E!=T![>=VL'JQ"LL^4992Z89.^0\R
M>-4^XP^[CD&#TL%EFXZ56.I4/)"SD:U/R))$#UPKBK7!P.5!K94[_OF 79<C
MKJXJD"GO2OC#[T=;A-)1C3>,-1Q<8!?.W[8X&<73SL8S($+S3C>3 PXP)D:)
MB_R*WXWU:#+-D(:PG^0-;$]*B4'FM-U$MX 23CZ[=4/7U$(NJ.7H(U@/JBT>
M/-F[RHZSVK3"MG_ 40!+9%/=ZL:4S41GP625T 5]ZZZ[<L\>Q'VA,TFS5R2I
M]6L.NMAOZLT@B.S6L^;-L+&(37QP.K^ZW8+QH&CEZU;/YFXU+X-C6A*599N;
M;C)-8F$L5L27*&I88"&:#KHI&M&#)ABW_'R0Q7I$9&A-:@;U(6[*-?WV^OW%
MAIN<7U8D/ZN=_ER^9+:_LXH"C'X%=_ JI&<-W 01HNH[;'QD(G^IQ42'4&G)
MR=O6_ZN])PUJ<MDR+!(V9=]DB5=4E%7$#<7$C?TB( (*2%1$! 1$!,*6L.^"
MXA6NJ 3ERB)"4):H+"%L$0&#@" !3$+8(20!#3%\22;JJYHWMUY-U<RKFC<U
M<W^<[J_[5'5U?WWJ+'WZ]!D%G>Y=/G,X/S3/$U85EV*IK/CGR L56I$!#]VR
M$?%YF>;$<FPG;UK<G#)@$08_/YIA;'/'[H6BJFZDN7C%;,-!C,^3>-C&:A@E
M0RB[?7C5>V$D>_O,KG=$FY9,)@=YL(V@5V#,:Q1-G@J=_^;>#\'. DHN>%3#
M@=2F X%_C),X![R9&:LWL\8L$9Y]MK_63)Z<ME.*/S<$JAP/X]ZU%&M<)LX(
M]QI0 !,B^4<^A#-R8"J,)E]JR*9QSP9T\8)[V$2KXL??3JJJ17J)6X+HA&:4
M)5^*F7^/XB@]AU3HI]@'&1RKR6Q[ISZDO\W93^0,"-1]I++B27P0;A%(O&/U
M(:=): __O7(LVC0[24S$M/S" 7= Y0?#_??:]UWIHQ</31IC I8D%7<Y/E1
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MOMLI;D-%'U514LKO71=6&IG?A;GDRAO1_C(PVPGP="B@YM"S#Y%&70;$&3<
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M;#\-FVHIN-B<H59X1;?8I3%4R<[OC;D_UU812:9?46:1+\D J_";7RTVI%;
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M[/LQR[<\I6!5P3C%96,B%.?8<H7EV22W#HLZAS;DC9\QROX]<=G1HTD]*QI
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M]*VD"'G>%&2W9K=>W 'YQM@M5RGX((^MLUOUD.Q]&!AK>B =.>?S*HFUB)*
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M@A9.SS4YQNB"5+G"JQ3C"$AMU?U7[+O\;H@_.F9.;-;L!<7N7&L<)HJVP9/
MU7<30PL;7\!?A</FQK(NQ1/<CSR6O[7_,88C'S%8BQQQ\S;MKS_C<TM[2J/W
M<H5\5N#]_=W\BBF$  U3\<UW$:"'1NK8*]-J/+\C[J9*Y1M<<?G E@!ZT8B+
MAN0R <KE:6-Z,DS_9MC7A(0 [1EVJ+7*8S/A\CQU.75YS%&I K@!79]R\#YN
M)GGGQGOD%9^CKWP%6V_W3WR[>>CQWE.5'H7Z&^AAE)7VS%Z*8QL5CI7M"YF"
M!NC0OXXI=!AXAKT^1D['T@5;AV<\^[7JC#5&&.%.+>4L'S>2I;[;]@C,%D&7
MJL,8A1VF_/+>6WH/4_?\>6+F,%@[Q_<69D_G+ _B[!9T'XO8RZE^L"$3(<K@
MAU'WA3Q0[*^$GB22M/# S,UH7?QG#_@Q1FHHA)L"=W[4_.XW6918?<HB."#S
M:*_[JU3>5AD9XI#=W@=%H[XGO@?+WSVA<FQ>?SMF<RX:4H 8+R*;4V*)RN2'
MY?12$YF)WF!OT<RM:O)9ZT^QOAEVV9K9^VUYC39671W;>P5H(714:. !"J_U
M@+:;7"O?MYMY.W92;Z7JG!RN-7_:!]$]GV:'I2LOYIGGE(TWI"$]_=\X?=LB
MK+QRNA:@_KU&./%EN&#SM/C3UT0F$+_QXK##K^+/59:N68L66FRS\ I0\P%P
M-)AKPRYAV#*9+.2(\ #$4VY^",>O!B +6Q]\"=Y*M;;Y]R3G[P'"_<>^,O([
MDJ+*2WN$XF("RWZQ3.#L2^1/Z-@2PS*AA0E0!3<0=$%3F6__A,7_PK\8++!_
MY]H7Z^/!J2P-O""8PNM\[L4H6N:+"0)O6\C9U!/4NRW$4D^N=6^D#")AD*5O
M-S].KN=3[3G>%%_]XEFJ5?1'C% PS>=5-)]4RL ?*FFFMV2ZYX_#M[8@XZ/O
M:=!5">!\7Q1HK:3X;P\;^4<1INW6BNUC IW)1 2CXPMDXYT$_3*] #7[*%*-
M"91#K)A O_;V92:PAV5:9HAB(?34V_"%2]H[[ZG&\&]\%"@3N ;+8@*O?#C&
M_BL<UK_PGP=&* 13A"!>6!6%_8!+S#3MG/F1,:'RX8'PF+E01A_+1J9H,P%,
M-93O[ =$P#,/P9KN6_G! _40QH&W0OY4Q[/.VL'S5D/PZBCTKSS:'3[G[4,%
M6F)2:N?P"'<6:P$P!I(F,H'>/CY2X<'M^2,P$$Y\K;O[R2++<0MX$HQ>!0]M
MSJ?]I'"17>XT7HT#?A=)F_/"D6_>;>E4E[<%2[R8GTB[ R]=7S4%CXW0!(,9
M^_EQZ>/W<5S$%>2=M=:,YCM-7AEIC?DX5,1]!G1XMQ8CY9#P9S2IY(60QQ/]
MYM61;2:0!1W; PAW^<GH$>$)L_Q^,(7^D%JN)FO"R>FIQ(44P]CAUR18B4X&
MUD[@YC"F<CP@[AVT#9#/J?J<%]JTE%\J3"N$];H;_D1A7H$K9]K!"8T&),9[
M3#!6^MK.S+FXE>N?K1_X&R4EBWF;+E-/O$.%9Z0-L='=QB@C+8XD\>5ZBZ*I
MDWO//8::'69+F;]3*X;6_Y",2$(<7)[U":@/PCZ_9X\=\'?OT;E@$"-A;X9,
M8DC VB)*6Y><0AQ(!,;;US8!_0=*"^#:&E] ?MBM* W]I31$*IAX$3HZWP[G
M(J"3C31)@6XU_DYMTZ?#:OBWK\]Z='W2D^48+)0K >"V.A"!1O#BZ=<(O!JO
M^Z=%U2H7WT<[RX_SIJI(,@_NG:BI'-9:RIU8:16>O& )2Y)"#*#849B"F7*'
MNC>1?.DX]UJ2A=-0E7*7']KRQM<">XGQ'^<TPD[8(7RVRV?Z1GKR= FZ'R/Y
M*;\^]N*0(JXFB87NW0+M02'-KO(I[]?JUK?,]0IY%SGL20H/2LY5[V17E%[I
MF>6,GUL1\[H6%,T_JKYHZ%"I>29(P(8S445#R6<V-5;N[>_+"9R.ZU>)J#:P
M-,H?-7YAILT@X.4[7P37!T4KN?J'/[('WFED)(BEQ(#PT'Y4?&4@Q:)25?>,
M8%7G("%STG9;3:$7=VL]RU3R@L8KS4Z<EJE3_N-W[T#R64U :'>0(U2  ;[R
M?7BK0(-(J.RO1J?Y._R4=GDMII4+,@J>;I1F,6 &8] Y87F*&#]Q8>!9"1-X
M]/'(X.'K>J'KHM<R8GBGC8*'[CO.U3R 7YU)A%<J-A$L\,;HMM1 VQ'M):?-
M5(WOAG5QD_PF_56FM]CBW34T]*1Y $B1C>[EP=!DKX8!9%GH 0MJCDBP/+&F
M'W\#.OPI-%V&HM:ZMFTPGQ1B?,P5W]4XY%\V8_+<ZW8PM!>Z[$WU"4_'S+IK
M4_CQ4[;^I]R)/\N8P.A'M6)5S6_^4HGB%P^I9HUN;LQ]:MP7*4MYP*)G'E)I
MFUM8N[OAL-'1(DKPA5P5D>'[<4Y";F*X_>59^?'B^%)%U@2QE( D&>GC]LR\
M7(JX\>Y+SRVU0[7XD:U;/X,O_=PH$_F)U$X]V6M3:8<*NA\D76^]>4_<E+:T
M?9^B2(+B=)>#J5Y=1)>VZ<-#VC/[I"U'F\/N:V7*O<GY+M79)J//!"1V9AC[
ML1\9_2:*%*M;J+W#C!&SQL])<UN7/ZU?:N7\#;Y+*4_3N .WK62CQKZB(%H+
M#IW<X:EY?9/T\<YXU*SN6?7\=<$:V^ %E^1=[6($P#&/3.0I"5+CB+CZ4)SQ
M*;>O<6I3XSN^U[U":Q"_Z-C KZU)C(R<?[*=] ^>)!LE]3_6,+^U]_^QW]\'
M^OR?70/A+_RG@HW&FHK-=[:ZJ4[?Q.2O>7_#@XZDE]ZDW:X=+W NGW1$XE.\
MB8SP+>08E'(\V1Q5Y55G*[^.4)0-O;%SE^$Z@@_+V=N>4>R012U)D,>G,&3H
MP:8\_NU"R'.W4=# -G#KTGEK,9>H01E4Z/V4K$V3IQJ=;-/[9E((G00TJK3!
M_FO8,V_98QD9B-U]A"7:#@ W11%/AF0Q1%U.P*?B[;*,*P;!YW@9#7#/G[3;
MK*YR74-W?)Y8TT IR144S!NCV*"CF\#EANJ:AHJOG^OLAVONKCM/RO%QM!KY
M"R59=6YG/)HWV:3P4KWAS4<CW>Z_NXD0A'BF7@I70T<49T*A5MYATOD5DX$:
M)\Q3<9HB'D$UF;8FY#.PC? DPUPM-TNGV:EDJ^XOKK/?^98!GEIMRGG2*7+\
M;C)7I#[I1ETQA1=+Z$$52KYUZ/ -(==>2IU\('_C].W4&M =3 I/>"'O[J&H
M/"90O8KNW0/K$P5_MB HOIWR8ZA7?#4(K__Z="YKRW\VMK9+*H9M">H";[X&
MR/ //,OG/3X9:AS9.@HNW>Z^#2^'++N1>-N80"4WJLJBH^%@9:"XFZODV*$\
M0:D8\\ 3Q,GYL$6_113EJ&Z3FG3D;>(<PA-3)ZYVY,'A:?X#'N^]-I@ SQ#;
M^&Z9MU'>,86?SU8N5PQ9[1S4RAH91V4&4I1V$^\A?(U&X:7VQ",_)WY71[0:
MDQ$W5F1\\%\5S,KW]0*DP2JX)ZH<WC(C0%.GY[\B.CXBY,U<$<DA/<L]6[UP
MRUD(LU,-.DM;I@13I6FG$LB9PT96.'^NCY%'WBP*=G89'7D9/OOTDRWF$M&'
M8Q".R6!1H(EX.]';DG)VT,D7S*?U:)!J8?>\*_W\BX$CC@(![-ZMLRFDI8*B
M,29P$T)16GE.U:8DAAQ QH_/)[I]%.&MO-)^9V%=SVWFZP7U'C\,.!7^R:)]
M-09>I9!#6L> QZ=;S]<]7'06SNOTOZ!PVVNO'C&:)P)9!?L5[MGD+DZ:?VAD
M^#[2G'@\#H[3KZ2 +[K9V<3@+M5QS.L_/< S"GHYWP# #1%$1W#*> )Z=0R/
MA:2%="NLM^9%?OV9/^ TE2@7JN&J_.DVY9JI!T_4^RT.LEQ]!;B<";3>C\]3
MJ(EM)I!S85 5H<\'%58FV341-^<@_O!1?"NX$M+<071/?SVVH.E3$+J2X^_)
M;L:?R^\L;]G'UEH*1) &4,*T0Q]8HV7.X UW=*" L$B.14=WGF18;NG-F.$[
M%[H?/?QL:2@$Y'M(<9B"#T1Z#4:>*H--@OE#[?9O#_B6Z[P*..YO?>!V+(PP
M8>+*-J*'G$)2Y*H(#;WQ)H?;I7\XBNIL/0BH%E9!DHM!]Z0V04B*P^KR"RK;
M&7_,P;!VJ"!!G<317AWF>]O[T;U^JV#NN,]71%PM%_?:(5_[K2_.8.<)==2]
MD1:D3!H;,70FN5X71S_KI&!>D;DHE.:"U)+^XK5]>W]!&[O!C6@])C#Q[O00
M)"!*S6Y@U/IM.^[(.C9VM_YF"1#FOUT77."W-8,7<&VG2KEWD%M\1YK(RBIW
M.N35,P)_//.XW80)6%HON(?\P03&=,E*E"R2"UX%59E X+JJ\P*GG,L8'[_^
MX]8K?>M[S[AD%0U)@TP Z;ZP6Y.(E$!P*J*8!": *^9C?HV$I+K8);7<>UGI
MFW+^P]6S 6<ZSS=/Y'OQW@2VTQE<XH&&D1=)7M-6EYQ"[XS:OROZ]F4#_T6F
MH4%Y1^&/T,3(FCH3X"025VE"BIB<]L[C]8[$Q96#(->AV?2+>=;B)]%^=[NE
M4L*. Y?OW.M1SQA'E=D(W*][H3%^?W9MI9CGQCE//RYI"_!*'"05N,GS;\,<
MG!@O(NA"N%!;MK[FK\[TM#IQ%[!;,9Y4".K_2Y?__P@VVBB\^1P<\V1&D GX
M@=-X2;PM-6L38T9IS9?3]%73& GI1&2O/$N(0)&AXV,_/W(!&>LU[D&][LI4
MUU?1D"1/UF3EH1!^K4I44M<1C5/JOWUSP$0S<-K 896(#ZQY ?[1"DF#\S(!
M-[C?$WO0.HME.7=+B_M$GJ-GF2CH)D5>AJNV9RBO&0KHS3(!Q *T[\7?XC)6
M+6D@CCQG);;=# [6^UXL(PI5)G3>=(]0BJ44]_IO7PNS/VJ8_8$_8RROD21X
MO0]'5^,QVFZ&H&=K+TX-3(E!G_QD66 YON:5T+V&[JZLE>+)G2\P1J\3J*XL
M^NN [X%QI%K;$77C9M"ZMQ/E8IB G6_ *PO)Z*AR3?/;YC /BZH0"/%VZ?($
M]1RL'[*W'E(,Z\V1**D?UA'X^"9DQO#>5)!60MB38(1*6OW(VA@1A*UI18U!
ML71Z.B&L>'(I@N:P?F1YO.%Y[['N>,XY+\_'K1N]YSPXQB.OLQ9;![T2'IC^
M:%R7]9W7@RS78N-KRZGP;-3-!YF@)^R2-WC8\QCC$$R!B0!E"HM\,,Z)DM;V
M>W&Q?60\M&+*> BI\E[]RM16X)&*S%;%:51*.N5P+X&+*GL%-B5175KBL^.6
MD/ Q\$:"7<'*P+Y7\=XW^+X6OWO#<+D:(Q70P=6,W! DCCRJ! LL..RD)QPO
M^UBYX.GPH*R^G.\DF_U[?J4BSMMZA3SQCV?3]+2X\065E4"L;/"WPGSN$57<
MC"1+Y<9=QU%)VLFJ"M^%57I#@[AM,>QVV9D&HDT@^=O&=TQ-0-B9"35R%,GD
M2R-XT"CLM<ZK'KDKLU^JSZBX^$BFT+N!J+,\YKXWJTI^EFVH3XVYG@H-U%"V
MT*Y/5+']P+;'C0LD)TU9T73P^:_?!/1ALZ@" #XKQ;3;^INE]CP1%X(ST-*_
MV7R*Y7GJ_\] \5_X%\6?8?[!MW_&6_'U4#R<,]P _8-4C2KZG2W*SV=;KG&&
MLW_#X_2#ISFRL1DIZ3=I_91?+)%KUD3Y/%/#4^+>1YHTY-C/S-OX?7!J73>Y
M,R$QUCP[+YE@O,@$:$)+Y N49*H]1=2RKU%F:>2K]*^RXKYN[>)>+I5U2TSV
M24,]J0(]Y)P++HPFR(L7;;(1\(?C1#NDKZM\P&5;.4B[.^3,7A@=/:)HY"E6
MR/O61 W>+("Z?E"PO;I1E9[-4*/ 6P;1D35^PMFE_H%R.L2)4V>.9=Y#-\!/
M0S_IMB*$:!H4*&AW9QU..7NDLBI&;+6QG_QX8O_!YBW=RZ!\'*HG'7=]E:",
M@SYJE"(BEQOP"+#?U[C&&N&&#5^%ERI'!#R0F?7^33N..P?AS2J1AT@Y+="*
MG'A_AO;S0=S;RO<Z7W2GO?.]N&3HT][=^;'Y?:"%AGOS[=!'!MXM,VSAR6CG
MNF-7?$0$W<_UW$;5I4YZT1T;(J0CP2PV4TVX^(6>8J)UIBC1MG!:^LL:)UM*
M+M48/76@&X#O8P)5CC1A47PIH8SJOP390Q,DF=B!: :#F\G)7*\9_??]KG('
M5P;F6[Z-;D39E7ZBK)(M22&Z,I+UE*M4)]_WN%;5YY-G_'%F<[FGE T>']>P
MTI=*JZ*1&"U@=B,S$I5,'&9(^TET]R8$:D/$IYW=9K3*_.Z46[\YF]*<#,("
M^HL1(QMEK&[:L%3HB!NC%0[XHWRA<0@I(^MW?A'76N_=NVI2&E*>6Q1C6$2^
MW2/B\TR/K>]Q4!][233DHQI% 1+'4 YWQ)BDED9>(+D6G!C"5CZX>/E^UAUY
M22%V>96QR;T1&_/".X[0SC":I!FK(0%*(O4L#5)'\<5WU'UM(&[[B06L)-<^
M=HIY4%,NGRD*28^@1]+?P[09$XW<I/QA\-YZJ9WJF!KN\AZ5'X7M7_SU]]VY
MBQC48FN"-_L<>DSAP)ZF\CXQ<MLORN!KP>V5,RD\ 7F$_,G[;S>?H%T00A4I
MC-Q)*J*I#,",*<XV@JV*;<-WT$>K?83J)D]+;7#HGP-[@,XY;IH1^>72,>C6
MTP_GCA#3,OF80,4LMSWHXQ\)<R7_-JDQR?2+_'HWI]>U:)'ZF0ZX2#T(PW4!
MS%H0SI=Z8\HGOV=D\JBGHANCE/N;FMHC[U%/,3IE).F%FV+:![W;)-(RB4KV
MV==C\@']5MZSP J4_)'"SRLJ ^GWD,>>FCJS#@LXR@2(/R$<^RX8A15]NL.>
M$2RJ_QO&!")H<O1:E@9&@%JM SFG?D/XJK[L+7USX'Z<KD:'Y?I3S4H32]D'
M(^*@0>W-FE8PY4CZ@RHFP![N[5!/8M3*;]W5&5'I[U:)#3JC=V/ZQ-AL6KCL
M5B'OR,Q^RFK+M$Z-J(G43]5-O?TKO!SO4R)BBLES=1+;6QAHD[0<!I;YU>'I
MNZG%\Q]@[M1,:\^ Z=DL=%G4GO_'^/@+_]KX-\8A"<HXH,9:E^)#3, #&EL=
MT9AP$^I VO.TRRSX4TW6NA;_X]MW"2%W\4C83]H3VA%Z#4P)-MAX2$:7,D:Z
M,0YE6]24S(TT#HH((M^XTRT>-P&^C0^8@:*I0;O9<+#.F8IY@AEQ40GE(]EU
M$-*:IUI<GOQ\*TF+?R4S;'1-QBDLTU0JJ+,3V0*.@Q.M BE'5MMM;L+WT'0I
M*-] N,\J?T6L8TVJM3+?>:'OB9F7HKD 4J9!'\B1JLMRO8GG$ ]&QD_OF,=A
MB_"2N5?3K!?\R[R\ZSVK$,&']-6R\A'("$:.R3Z:-Q'1,0,:"T>V"+0JY 1Q
M7C@I*]=E.6;>]S)\/QO UL2.>K::C"!:]%(4D,OS\.*;"'[8<1>SD!S^2><)
MG?=^Y/C;36_4T9IKEIB J3Y2'IU,C]M Q#HKMBS9&&(:/^R@XOT)5RV/.VW%
M)][E/!1OUK,'B&IU34^C29>$,X&6B)F'H5]$\+;#'[PK"G3MOY\N-V WP^!#
M0X?L0=O=C!D$T1(^KDP^32__"+\)&<.?'5JIO#Q</.PUN/&EI!4YSOWKI*E^
M)R$:5H6@VC#ZH36[LJN+[8FCZB,23)3[/M#>^T/.UQ<,D/4F(Q];MN<"1FK!
MT-\-[WX;*-3RQSH-:$TY")SP1'VN^7K2P%/0G'8_Y.,=-#:]]84&O')A>B_Q
MQ=,.LW5"B+2.^!T#Z85;98B.: @(@HECT8^U<OJH"]8FNP;W[#NEQBF=H.ON
M(Q- ?:CRJV+]=G=* >,IG>?B>0&M*_@SJ7Q[+IW9GP0R?5<(@#P H46 MEN_
MO\^*"0CQMCPB*YJHQM409+QU3QQ\2?JB)LZAQYDU-+*8ODR&XSK_W-"U!&^#
MA/_?;>B.$O^6P?6_)_;A&)"B$75@@)U%ILY*'[H]'3_W54XT.-IG?:NH2'Q=
M8&MRR?1*@:4TVZJI1(CCKYS4/Q^W6FX7;>06A4'RA]-<_+Y&I@MW?^&33A<_
MUIIKMF@,,9B;8!SPI'*]!6BG;LV#[\XP@73[O2B:4)_RE4A]!R90F.1)JH-@
MH6&PWD)DR\P!'O2Y*CD&78E&]]M>H3? ,64SY35IMR*Y1&)Q)4,%K1><5JZ'
MI>X_[>W ]?"NF*L(2+^+?T*;#&F!4%1%E]6O$JFM!I&-.BY<RQMU/MYQW,>-
M?IK5?G9SD2?%YGLB;P+TZB+M[<-P3!7JTYM9VBD])G"7EV'L7D&T8.Q/IAYA
M])GH5%/@Q*6.KG?A:83^0Q6!\B+>>NXB#L91*-:HG@D^(RLF]H\Z]A?^)?'W
MYY'8:'WPYC:X:'T@E@G$NX,HOIB&&U$\@2*?JK]^C0^+9@*E-K.S7X4[!*5M
M]0C0'VKM@:-%Y!CZHT8)BB$YF0CM4)Y(M6L;OGWSXGCKAW/=C;].%_L[I=]%
M(S<8[^"8!D1Y:<?J>$*S#/\7BJ*G\5S=RPG0J4!)H^0@SAX2WJ=33RE\M1NN
M+J-#9S6%^0#EC^0M"E?KP)%51<UJTJ;'9RYD7DJ1U]O/_KTY@JT)C#65::7*
M,H%F X@OBG+4OS>A497F3NF/ B544D?E_77FKSP5L2P*U1M=/SAV( V1X,R8
M9P)>@6,SK="*L)8RT::(/0,SD@>45%>.#]OI=JL?2\GYUG/%NPS.!=]KP@%O
M=C#9Y^)CPD=,*]2B"QSH=%CP5^.V]'20_&*U]P[D!=P?3+2CPI/)3 "TT4]*
MPGXTLB(K!QG6QYMK8'5?M&4MS30 44M_YR?]%R4Z60+21WT*V>N#\0NA%!L\
M>\HE)G#==8V'QZ17-X)L0$*E,X$UJ_JK+/FM2Z?SJP+P7#L"&*O* :67T>Z,
M+(2J,(%QQU^/OCSFWEX=S(<!^W_ 'S(.9&7YA^ROL3.Q>[M:,%,6P8L63@./
M3Z#M%,V'5HEVI07S$Q,3T[E!<L8=0J_:4;7HBS6H;7P9$/F"5('=>DAPM$R:
M/O!P1OZFT^O'\W-; 9 7$="X1K%P0RI/F^3](N5F01'!3OT.2$/2=WIA]9Z^
M^EHYO>SCIWB6#==7\T?**$>O1G'8992DWYE0W)-P'3R?!,S?H+A@FC+>Q"SD
MYY^@GL[%_XXR5EY&4>1UXRN9 "]K(IRA28H\V5)O&<F.*_)+%-><0Q(S+=P[
M&D-2/5U>]"Q.//\%S'(,-'Y@*8:]^=O= _Q$&,[,;^)D41HHKQ9=NKFUPL9(
MJ?SWDG[_PK\6?C+4ME+_/%%9N+]FY.3WEA523GAE5=[L1Y.M#$&K=/>[^"0&
MR\'!O$41[<'C.6A$Y65DTTPT(?AEET*Q%J6]6%70.O?AL3!N$<6?B2JV=F\9
M/U?SA >1$OB]DTX]@]XO'Y[L.,<$FC2A\[L^[%/ZR]"9.$1U34)HX%A%Z_L/
ME)XNIX>5?"[W?FQQA>SK/"/_JZF0-W0 <AU,4:[/*TW0%@_MY:O*7YMPFTSI
ML<A20,_.OYZ&GV74HJXBN".O$)$M4;JVE%KC-H:<M9Z(]Q=YU#/VP,7@ M9D
M?B],@U'N,_;W[Y:*TRT0^9R#^3DZ^/%,BH85/5UGSYO3*3IW@]:X8YOF4,C>
M46M<3OONXU&X0GKY(Z']$^:D(^WY KVW2%KR9R?"4E/8Q+[U#D2;8(OUY=(.
MJ@K]$5(L^6_(@%/N8$#6B<\[9,;=OK%:$!CY[)A*@_72C@6*>3(>A.GO1!7<
M!)B -CSM>PZD"IG:]TE2VW Y95,F.(0);(ZD1EJC2 <;"[/'-<Y>#-^3=1<
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MO\Y=]^ &>&3GTHQT8CKY,ZG_^;.>(CC+1E&=&"QL(C->B4\)NS;W9?<BY9E
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M^_SQ007,? *B=YY8LZ.I_QV?7(KPWL >XKQF)OQ(XE:R0>K5C[ZWH>-&9.Z
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M GHFDDORR>9A9J="YL.\_$J>_$B<*YY<2+QM+ (YJ0>N14QHPND?>(/NHJ^
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MVCMU.&&/7 UY*7&^\J=_:%4>CIR-Q=(GY2R\0WV6TZ+KJ<W']L.CXLE=[VF
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M@9AS?PG&G[F*U1_!S]9KVF0F*>^H5O4(A7SK?';&R#4\V<'=J@.)6;$EN<U
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M/2?PLVP<K-XZ'A#2&%0*CK^=,2-%Q^E,6J^K^O%7HI]?\_.[2U055E>?/@T
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M.GVGYM#&\\9V.W\G^!?N3XS;F+[*43/$Z;IU-H9A!OE(M\([WUK+WPL"RVV
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MH$HS#/>K JPQK2OKM-I<]\:GY,@,#!7;Y;*P&#H_R\ MIF%FF*N?&'U?*Y!
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M('KSCW)AZ4&(0V"1&C#\S>LIC=H[&>CJ>%HWV=^ O1Q6D)/B/WGA#4?:0HU
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M'=G'N&G/ ]K:]N(CET)4 X[Y?5,JKTO[$MJJ_1+J.*'KHVYR<26.- MOAP^
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M$+3+7G%UPP8'Z+!HS^X_T-&<]@U%>#[B I /3O\IP@4FMW2<S*]59N4G/=W
M2</ZJQO'@V[ IMCSY_6@X+_@Y[5HU&E+CAK:<R38=I65SK5KZ&ANU?%IZ;_K
M$.'8-<LY8D_^%L3^98 H('"V+'QLZ"=^I8/H/8K_( !^'DE/:R$R#^,P>@I%
M 4I7:6OC<W63,*]'G9+-U\6*_#;75DO@ _EC7FPQ%X8E+64F0D]DK+XH_C0P
M.6(Z:KX[Z33*>_;;)TH"EKB)R=6> V< E*K+0J%;+-"N2WL#]K6N.\O6&]/C
M^ZH:]B6VW$U'*L=M0:K268=ZQO/9XONNT1:$P!A4-?2^/O=-2OJ.@PKX*M:?
M2P\?6V;2 F;R0I^S@H'OHT>9<W1E"O'9R4LJ(9(?'!R)U7I3+HV:0@V4F8+Y
MKAN/QO&6C\P#54XZR?<[!E8/.CUM>"4E=_MTHC&3)V<X/V'D, _3FXYAB^0R
M<'12.W8WV[9WU8WD1-=O)]E^N'GK[,]I8VIBDG?/T*?B%=#)V7(*![[C!S2E
MM3="<D?Q]4>U5R?8# +(ZF-Z7$Y&WW\+8U_P-$#;65K/$?3O(9GR>.K5&-#@
MN?ST\4T6(2X3@X"%(U(45]E9'J:U)5.>1+7=M_UD(-'E688!UA'P&V*#_!-A
M@?H-K]#LN =H!&@8UZ:UBWQ.*G;?Y>I3'0K50^MY(X?*M"&;OT!<%H58<*.\
M^#5P4&^QPG(Y%[&MVU?9NK&8_U],V7_-B]PZYG/NXD-#S]+J%SV5@%N]'GE5
MB=]A+\U>='8$?/Y:SIN0LX+L2@&?!1. 9)ASFAH4QAM=.JOW"@WT5GV+\?2T
M_?H@*O'Y"_1>Q@[N:D'X9Z4V$O9P,^<[EN/5_<]R&/CD3WA !0Q*VB=!*]F(
M7C/@Y"H-RA9#J1% ]L5N3,Z0:J:0/1RNSH5OX_*Y,!KT=3/ *SRZM6%B'+,P
M\G?-H3'??DZ'$?XXE7'E6&+RKC5G[C%0AWY\\9G?^UU*$5DZ88AT[).]2+98
M$:4S$A;U2%7863^^4NX*_,C&[S>V0WKH[/QI2SZNN$=0\N6.<O+\,&%?QN;;
M@O/,#B>=P+R05_*'&WJW=*"=3VWHTMH83G2O*+SGDF3(HSH%%MR>=>_R%"3#
MDP?WU3OLX;#(Y_$PA.X6Y!Z.[^]JGALYJH[4"I=D>BZKPN;+O_!]CY*<NFUS
MR4R&HAE"FIQY@J \)5?.A%=NK)9HFF:-98^;IW%Z0C?LZH6SW^,;[4%L7T(S
MY0E4FS]DNM*G&>S:N34$!I=GC*>=5QTL_@ ?D)3ZZ3U9<Y<(^B^C94."-4A:
M_?D@*;\"B>*\Y>"'L:A$[V7&[FH-[,T+X)>\!HL%L^1]Z^.D'#:YQ\]MU^^
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MQKV8I,W>A'30'B[[Z9H53X,O(/.E''^6FR-E>@M2H;KP WQ-""=9SWP<*QX
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MM\K%*@QS:8?63+(3X7]D81J"^[M#[<6 6RSI#;P/1WL3A2=A>[$#NQR8K)(
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M'.\&3T@G1*,4YVMJ=I<63<D:C+ME+%"^?W7Y/4E5;M:S@C(2+8["E$[-($6
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M7KDL(0@Z1[[LAK3IC2#Q_9&K"K'VS!Z&-IT8OP8+WSQ%[OA\L/M4R:$.X9+
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M R="3C'+\TL+:"L=FXC8XNO^Q9M.7W_F>6?2AV0XRMW_51#@;_MPYU/$MKK
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MFZTV[YP[CADTH6 B53R60BSIHFV#^B6_A;Q.38UW)D7M>UF@[\/?>9AG*/:
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MS])BW\4#WYAN=)?6IF.]FGRL0Z_1,CV>6LV#^CZ(4N6YO?^E H_\333O][?
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MP-XC*/C1G71R*XPG9"?SVAA&\C[#PETNPY6O(VOXUS<M8SN- R:\,YZ!Q/%
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M-];GS-^9\BTM$V?=X76)$?6_%(?%?"#1TIU@D2. ,W)6&9<;A3A+&[1=Z;D
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M*5 %=HNQFYN:ZS"B_MZ%W>G[A/J&&8FP*K N=Q6H;]-D%=["G[>MH_RB1:/
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M M>?^%L9"3WQ9R_ENOU=_R3PFLJMOH:UZX!G?Y.[E&-T6HX [A-ZS%B.:[B
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MCJ0WS%L[5[$TI45,]<:2^4.^OB!WF8IL@X+IJ&'!X6MZ@47STCX?.G./82L
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MUCKJ8GS.9Q)TF$1O:/^H!?\-E2]KS#A;MU>!)A-K?3%J>8F&[QK33EU\OR-
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MZQ;*8KX'RP"Q<<V\OV0==#1[$A355__3UUS^9]=B#C6+JUTF_PY2!)2Q]%W
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M]Q9J@)0;OWWV.?O;X]YS]S[GGCWNRGC_L-9XUWQF?>8[0_!3^$7 [:=J&FH
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M/WV+SEYBK-JYU=!DR4BYROE:&;:F]M8C>/$ZJ>VBFS)K-!V@L=H16%W2-5$
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M@>Y!:.9+?T8B1>%KHR'.F6Q.CG5UG7.=JD/CQLT<FR],.CUSKGK]F5P[G%F
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MT.8G*09?WYS+5>Z9GNWIT'H6^(]N]81&OD_,&+8,>1'LX7\D'YOI-I5'68
M#K7]9Q'OT<>,6V!P9PTX!!U;+JW<#BASYTWI=]&:83D?L%>@<TN:J?G E[KT
MQ24)ZE<*CP[R[9]\LDUW'_?,44GZ?3G2BL+>L].9=EOE7G0L40@UBUV:K'@5
M'WOM "0_YK2OS\N?AG^<R5B0],@YDD3+KINJPWI"0BN"<PV]/"R<+_A\O>_0
M%L=2T;/RGJF7L;Y!T"4;W;.J%CW'80GMPBIYM_,*--?M4:7@"+YI-B1!;SN?
M(80:P%A"RSHHE<6=B\-.D1-+^M^O':D-?[%$JD!-CSKVQB^LSRM_4._L;-%2
M\,;'2?7RUWT33!-/)$_YFO#2)R,:]1=DQ5R4[_=7K>2K67G>#HSPIR1TC^!(
MNS>?KM%.2$YG)AY6'9)B;?L!J+QK#1QC1?ZC^63%<X'GU=M@YI:/04,-2,\T
MCQ"SNJ1VBA%*C/3MQ[ R0X+?\\2ZII>[YKR#;4:TL$LT?3K68\?H>P F'$;4
MR#/74A$/:AZMU4A^H^47A2*6_;YL-=S-5,PXG2=)KP0QWX9*$'I'&"F%"+D'
M[*5K*(IGVC'7(=T^!:*(1HJB9:(Z83QMBN@\"H'9EWF9JB1@J=4C7WF=^_7W
MHW[I,<E#VJT;:+=<BLZ-/4]C:0PF5=?XS]7)_U>&AM/U@<J49-O9L' -\<)C
MO'"H<$Z)XBO[[W=TF&N!XKO954<?6MPK;<^S.8]?&R3H*6[.Z'?8?>%00$&9
MQ7A&N6W8RO.#6FZ,L<78:E'9,O71"^"&1>K2W5[9S=QI_PF/B6/RV<P](')/
M3*9<Y0S%E9_@T:!.YPIE&B;*VX;E7%PY;)&@!'D?QF/;Q:O+NR>@NCU?E3_Y
M&-U_2&O\8R3@^W__]3__ 9#GZ70I)9)I[F80IOR"0H#S;[/>FUWI/W&!=+#<
M \B]&8 ,YU38 =O=8A0?=4+77AJ>F,G= XAF;K?<;J4PO*9ABR>B 3==#NJ:
MO8TVX!IE!US3"X75H&@9\ 2G\X\"_]Z<\SE??WHC[6N0)G@BQ3UIOZ6=UJ\4
MS7PW)LFQQ&2KT21O]I 3M!'G%I]/W3/:&#L<J>@=7-2X>'772"DR-]JU2H\;
M3JL+<GH,=O$G&(SC**S,%I,J,3+:/?>D\FK1 \WK# QZ,[TAJTD")4YE>@SY
MYH0*.,.W@.D!,C0)+,S2/'4]N!)I-+YO&YQ^?-I1\;X+QQ9*TDR6,+UVE2LD
M53<N"O@_$]&G>I5<_)&];MN3.-,,[H$Z-(QQ'HF_!5PB5(SU;*?G?E4^T(>K
M?:Z"8]WT<39PE<KM9ZM&) /M8$T9(^LS"A-YNM-%_?9)A--LRS<D'M4COM=2
MGCT>[6B2P5X+32LGK3Q3G*?@L),MU,DE>8@MY"V3Z7.[.&4'24'%7LG^EB#E
M>,LQS@+E?(]*5.YZCMI^[-@<VIHINE/%A1<D.AZ@OVA+G3)X\0-OR1BY6KH'
M7&$58(C_I0[=)><O>>'_\KE UP5^,?[VMCZ8668Z!$H/4[]F/HT5U+S-([H'
M<)US*M(?M)E>[TJJ&[AI*65:'$XU%-CUL\_"NZC?ZV!9 7]QS!IEQPUR&]Z.
MC[:AVIW*.CL\FF/A"$O0&]%VCM?ZT.-K/A3=DT5X#TCQ37[V,);ZQ>91:?-J
M:_GQ==O  4=RYATM??8B]&_B4!I/ASS-X8!HWQ&L4$0Q?[>]M1A0?NJ<:0&/
MVL22FE%X )H\Z?\(:N75(P(/@"$;%!OAC05AE. E.P-6]+TW.5BVW[-FWJ7X
M&$+'H]9)[FXSB^]$32#'HIU7WV<KP)R>DV=5G!#7]3*56J0<3@<@^S-!L]=*
M2WJUGP::E[P!NL7[$.@MT)YJ(E^(7V0L24](95[\^G8SQX_A.P3TNG'NS#G2
MMU=0AN_%(0"OM^?<D'+DFG&RQ:2F%G/R.;ZM<UZP;&T8*VU(AP'_UKA:8,13
M0C6CJI;DJ0>,J6/]5^C_P)0;!\AG6 ABXM6<)O:S")F5F\ "B"HO17=2N*+J
M^MZLLA3)5/?=+<NG4W=QO8>P\9>)O!73B2)G5[CPJ<#H3CGU-GDYFSKUR^6!
M! "UJHL\@Z[_!48W>=7.%3 B_7$ $XZ8SLH)2,(RQ9:2H+F$&G$S+31BP%C1
M\![50&YSE/]_>SDTA0'R)EJ"[A[@LWH/D)W<-[-;/.&_\+W=C;TE-ZQ+DHSX
MT);W G:D^?M!)Q>0JLO:O?E[XX-67>2SB5KE75)6NI7Y%8W+V60-X0X,FC/A
M@M\&>(Y>(]'%QVXB9^7>+/DK.,H4!R84&IV++H]XT'!P<;]P4>J=,>E6;<FY
M+N]SSW/V.3D\Y:T82L'[8L%S,+U[:"IL>J&T8EMW"3^\$4JTQ5OK332:^W:R
M%PWN;X6\?H,V%W%^^URS=KR9I'!1U4+9S!*E7_K@)6O]I=S&X>&!;7<_O>?I
M+U+X^GG&C[^T8*4975P;Q6I.,/SZ',Y23[@]"XL?-;^6EK:PUE?L/URGU$W<
MLP??$3\LK487TJ)A?GPL92<=(BJN$&<:GA!YM^$IX0Z<IJC3W#^-6.;6?V5D
MZQ)_(6S_K=Y'S$UDR XPPBM!;[:L<8TJ]XQZ@,OM.OHX]M*CX>W7.]1;W>->
MF @[LRJOYXXM=D($4K4+T]W&0#MPFVYLN9YHJ-W\;L -TKXY4SGA*D7V387T
MN" >J>W>*R"S1ZYCM#U%&04=J.O@;#L"7@]<Q=IE#(ONM-'O7E7I%(O70D,7
M_\;.K+O*93<JR.-;,O><@*:-F[?)6Q^RWI=+P_FB$$^=/M'_:9XM8_CC#1S4
M79IRV6231&NR5E4Y@"_H-]&& J$K[SE46T8A!UP5(.ML#D6_!N9@_41LA0Y&
MQO2T&T[:B@.#[U81*CA@K7C*X I][/;5=;)"?1^6I&(]?1E0<HZ] U-<T7D(
MF?0<?@&^O4;8W@O'!RS0_I<:JGJ.6<JMBVS+D)-3NL!SR)F.H=<Y(05-\IJ9
M$X'$Z>H5B9?/;A<5J6"5UQAIA*'[R<&[3[(<WQ2""]X=D=(X_\0^HR>^\.GY
MULB/>#$99^2/TUF#JFW1@=U#EU8)/"H.W1]N^FQ[]H&HKFJ2/Z-W46U"-9<F
M-S"H#9LBP9 2C?[Y\BL)<;^VRCCEY?&1J\N<EVZ4 D:F^M48AB780$P*!6Z]
MW_2F=OF54N5&T[4&YK./O.8M]64@;W0!C&C!$FM$^R;2"RC'@%'B24F" X24
MF,[92896^@LO=1U;7%]U1".".J7C<?"$Q\_#NW_(.3P(]*/:9 \/JH+TNSI1
MJ-VT8TW"%O6[-"VG#!_\_ =]3K=6[/;@K&C_;F,(=QWDDLI/_.ZTYRX2-M/Y
MHVW-]NC\>HK^B@MISPXEO86^@A@N%6_? Y!_8&&B_>\WI617G?,*F(MC<AML
M@8Q7F=SSIM3\M<E(L3OA5C"?U)TT'XM]O%%N^2Q6 .N4?D]9?V]^.63A4)58
MD5M/N8>C:CU(D!1EWV0_?V[(.T_/V$CJS+L($:/XI%L,P8YEVGYLRM?R:71G
MM,N^S,Y$P&86587]8)LY=JY*%]Q7OIW%RKMUQGX\1(WCU:&XZ!;A$4-Q#M'<
MU2:S@9I.YB6>AU%_3:=NV6V-?3/DQ^/6/<TG= ^ Q&8<%\\;S$[;D ,GO\@_
M:M89KNHB#M9" 0/P 3#L_YR*MOUOI9[_V];W-L8KG2U?G]$L1)<2XZCB@6CO
M1DJXS48Q/,"U;9_%/< _I[FMY.Q_K ,_#HS8E=@''.=QMTYM)F5#KEAJTF(
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M#RR+9RJ']7-I?&DQ(/]E::%JF<BC"2X _<6MQQEB5']&QAXU*81BDO]1>&=
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M DLNI'G!)WH,JDR/B*51^$H]E=E90'/.^#C#86GQRW0!$/GS!+Y_8&[[9#Z
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MT$Y/Y[1$1^_Y4OV,>97.E"R(1UUB:?8]Z/ND^%V:F,LN^5GQ<'USC;+74C?
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MQ SG=G6WP)!EPYQ]>P?5:XT(WU2+Z#9W^_7<5S%:ZH'[06FIB=GM;[2%Q'!
M+5]J5=15"D(>-V@Z_&IZ-6T<W;:&@<80LMW-IV'LU7H,>0=[,GI ?*#\41]4
MX#7 #R&%5U10VVPP9F9S^QQK=*UF**[$K'#@(.I0Z6M53E#0E%YJ,WJH8E%V
MOQSQH:VK;^M%%G@Y_T[[/:7<%0_B7Z]RYU[JJPVDH%U\+M--8%+WRHM)GM/S
MR$Z3!9X2Z^%HU#O*XQ?8JGK[^=T3%^%+697<BZ)=@Q\.>53FAOI&MBO'=/JD
M;:" ]F=1'P1T""C#;UPE(A*G*21\O30'Z2 S1#)97X5GI,S&R^@-BGT? "N[
M+<SS\H/IFNV%ITS+&$.#\O6U[S8<_Y*+^$=>@MR6<B*C==2?;6S].5AF.Z^^
M)?N($4#MR5I3*,(,C SX2SER.X>2DEQ/_%\R+&6>=O/7XIFJUT_4B4MJ<Z?!
M@"\(:/ PW\S6U/*(QI&U._*-T.A8+H8+I-;BT'KP.)P)GRF-IM+VRG]XP<T@
M5T[99Y[M:UZV>PYMQX^*;R;@K*H@WE%P@'UESH.U#4:,,Q4(S_^BCV-MIW$=
M>J%_9#]B[<S$UUP=?L"5P!0M9157BI/\1HA=9%5<J$2SVW,R'&]_CV?$UINT
M6NI1LZ]EK$4?A<;@S[>O_.\!^)CEUCUQ7S?>5RJV!)DK$P[(S:Y'^:N9-1U0
M/$/;EIY57:R\##5->Q[BX-YKW=38JF!^[;"KPEXK1?TFF,B)["?;7!:6HSB>
M?+D7%4A'M.9L(W##_K".J0^HQ*:E$Q5UT]\IZ>CDJX-(@@V4JCCC;*< QPS!
M:Z^9W$0)DN$$&'&>*#VK$1N5-_90,U_8[ @N9MP<9NWE%Z<U3LO1ANN?+E\G
M'F8Q;XA<+KX!;-]Z9Y$MAO8IE];N2Y^-W6F;T8S-JX@Y\WD2UF;@B^*^T7&3
MH&U&5(V[;20L6,3<.A9F4QA(D&P,.,8/B$KPNG[/48KW,Z:]*W;-WQ[M%$#_
M!11,/Y@?=]E,"&=+I'&;(8"SMV:M&)Z]>A% D%+V/M!LC9]+>^*=R\>$8M?G
MKG&N73CND.<CX&]TB]#U.WG3?R/+^3=3-PJUUT=W#:.W_58H-7T8U*6LXAKV
M,PGDK_J=%UR'8I\C;"_!.@&_,1#PJF1*VC=UJ%W0,\I+C$TIPE?L:?&="N6:
M5?N^?QA].#.Y[-<%Y609G5>@L2"4=>Y960Q,BJ@V>HR!3JTJZTDED>M0;@N<
M.G/NHVW>;15($ ^EW(W]T!;M8K9]TM=J/]=/Z<B(/;>S,-*XXR(2W?+)I[OA
MMB9WWDZ7_#EEE0W,1&7THQH1DWI8F%,/$YRO22"GDIYP8=8.&"$@GRY?'V/H
M;)]*#"!(&&U=3*NIR2<9L'#N*6@>E=N*?<K1T,G!_:@UNW:E0XKS)5JIP"1"
ML*%C7KG2P&3$5F"AVFVK*$[>'6+'G#:21,)P:2ZL,O1<J%L+U:[)</<\<.%0
M.U%#-U2]!@1!-WU:F4@9[Z_-%,N32I+PF*#0!T0*HOJ0XY\]>7JC2MT-%%FH
M+"\=YXR?4OIHU/Y+:?1Q/2B^!K/CJ$0K*O;THU4:<>%F-/^0W(A2,R(M*WW?
MNMKM+8P WTK,@9[]TL_UY]NFY'2F>'-;(N-&MC=8-VS3E-UR8#N@_ZF0_=8^
MW-#P;K0VV5NR5IHQ4L;E"VN '\(FE+.-SX/1U3HFGZI'I5EOS[QQG*NMMG-[
MI=\*Z7&2'WT/\$[I9KR4 6K(+Z"E_YY''(.9?D8S6ZHS'F&I9UK/)EY--'WB
MUOCZ[/.( 3 G=(E <]B,CE-9X8#J7,=6MD S-7W>R?(7XE/WX*JU^E2+I.ID
M);0NR9T6K!5N,+QA6'C]XF#%,IF[B+%F T#,^P+7Q7O(AUD#,?I[@&TC>PI<
M%V([;.FUHOU\V)O!Y]=IKMMET)^=WHY94DKF+JJ_JH_K2+F:F_-]ZWDJ3.WG
M'1X+3O,D,!^Q*\S3N\C]#0+!J.PI;JHMD>ENP1-I%''JL +A#OIODOAU\Y=5
M^U8+35K+,5[T!A[K<W++<;QROFJU.G>-03_F?F7XOA=<V35HO!ML' >MU#1$
M$O\<HE;%<;2U2)I =>$-<F8@]EWR]%&>4\S7:UEZN@U;Y4.;/HM>A-OI *>^
MUSJL@XFN!^+:SS>*.%$ <5A;?)/!>7_VT^K8.;QUNP<\L2G I19B6%I:B>N-
M4+!6>SDG)8X! XA$B$3]]VOK_Q5#(^DR5TZ13I[2_2%9 ^/2D[,BKK",-?[\
MA3&.@"X-CCK0:0)0OO:H/GZ78T]<F;B^T&GXX8,17HMKQ/Z-]6<3KQ29%&6D
M+W^$I>A0)X_E&RF-0C!-K,\)08@$WH_UXT>3!56SLBQ)/*'D-H.MG@Q1;#25
M)BT*<(,J5;OCAFEEKLZWK/UUNH?R5Z;AO\G,NI;QB-F0MTGS *<X9;%87-\.
MO&K!M^5Q"DOX6+2[,EJ^];_MIZK5IB(=-P@Q] 6SVN <P<@?O[-$50SG233K
M6WX\BO<-FUG>?.F26Y"%Q:R4H"JA^15_SNW\K@T6H]IC:ON@6OKU"D,69#@U
ML(@5'9GB S![A:V>H1C[TSX&DU%=R+^2#TX>^O2*$)VDKPI! U^?#V7(#&Q?
M:1"<$HB\-2&K_@%C5G9V7U_HPK)QU'X;WKKE1TP9L48L<EY4&5.GZ*#2WV=1
M4RU\-TQ$PFG#P(L5/I]5Z+\?Q4TY]&)SAREF94IF?*^P-GGF<30,=#> S^R'
M67^I,$S]>6UMW/#KC.;V\<^6S_8V&]?2N1[/!CGU$*Z)":HNWGT8$=U'^POY
MS\(A3R;<^;,RP(@L!KTSUCE35_:U3'P42:5U,<KW_#/=J?%VSHK,WSS91*1*
M%)V??NG326<15<-]8]Z ELL_,SER=9?ZS-W]%JKPV_BYU/AOUR>U,<9C3[L-
M]+,UB%SKI%R<\I\!G(>LOR[MO]B+DW*KY&W/5GJ7M$J ^;:/.OB=D$GF9EMI
MV0SST'S.1W?]]!7[V0S#R/E8G@%A17H;H?8](0"!4GM#:XWR+4OGK(ESA;?@
M.!\8NMY=?AY&M.8=R];;38 A]@:U<FK\N-ZPN'+) ZW3ASO!6A"^8#L\F2U=
MFD),&^1!2 Z(JQ]F:TP)KKW>%5Z)(8VQQ8572VQBG[Q?T74:=A(ABOD)YW@]
M"3$#FBM-I'L[YM8H;S;$P]%?\"IHWVDL<IA[]O-$YT<@Q SALQTD1G,_][.,
M*.^&M1T"C2I C'XWT15Z)P#&L4BW4ZFI8Q%CC*^@ F"R\K9%NG)R?1QC7UUX
M% .&;PTWBM1E^.9XH5'ST4(\U,$9XFY1W>7LA-1X;+6A/1N"(8RQ;I)ZJ^)R
MG@Y;J#G:U?FT@WF"4X2(.1C@.9#B5NN7$EJM%TCP Y?(E\WLO"#@N<;+/ ._
MHPC.WD=]O)H[4,TJ:2!VTU8Y?H3>Z'T/,"W=3D%X7 5_0GBJAS,D>32N1<66
MK+V7M:P,@3VUMPPN())W/VMHGJ;237]9KS'\+5M(\HC(B*BM8;SB\ZB8K+.W
M#?!NP2/]9%\]FQR7:2 _CE2!.GKNL?JVL6[(<Z+*PR<U/X .S_9%WT55IT4M
M-CZ:%*:L[H<EYF34K]+P-]X#C"4KXUZ,7^VX3^BF>J6H_7!K\#-^3S8TF(P[
M8#=:3C/3@(PJ"(_QKR'\>8I1!4^WWW=^#@\^LE<A8_Q4MS+[K8@?4\'I'F!C
M'C_%\KS=(V/;>=:05H5L8T8U'Q<AKS7F+IB^>"T]RH"P7W5FT(6 !M/>:M6_
MG250^7SD&JM8ACP]AZ;"'T0(P[]4PAJQ :Q')#!EZU%VHU>9NUQ'!?*=/B[,
M\U?M"?4*6C;ZY2=;$TAY8#E^BC=%3LY)[D(FG"BJQ?J,D<8=8F[25[B]^;K:
MT+1NSJ@L)[X8$QL.P!9DC\+UT9[A$-*,,K39_6;./A5E+A&*43([+5]AGS,K
M0CM9Z.QRG &,^+$V3R&+0BQ+$1:*ZZ*T*EJC?W5\C+>/R+7)U_(N\ U;1P(;
M A@ ER#J_<L,41$>,80\C8\E69ZPHY.NQNYD2LV,BF=%E@A; =&\X4RXE>OZ
MJUX)O6%-5^5AGB1 .GSRZG8)V?3#8B)I>>+=@&$'>6_Y6K?%&S)%QD$K]+6
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MN+N[!H?@#HT%=W=HZ.&]^KWWSMRY,VO^S>FU?]2JZE.US_.<??9SJF#SL#_
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MY']ZEE5#I;GT.M,PH.*:[U0F653T<N$1N+I^\LV/KNIOS.#P503/B=XT>,*
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MF*;FM@F"=OHM]'$>Q$WZT3TG#!R1!(,F4$1(>5,N,F00PVIK76N'\644/2%
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M4J+UYZ^O/=1(<%R3J@PD076C^6(V<R\[P^<:NI:P\[Z3&%SC N, X]]*^0]
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M:AYW@41JIO2H#Y<($Z*\2D/ZY_'F>VY=!!NL<NQ82:2;V@?KP<ZGC-;'\*J
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M6,+/?S\IR/*-N3CN@I@7:;.;C' *82R-Z5DNAAUZ4 7K%1S=.:6^-AT)'PV
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M9%F6#_BKF7L&S H&5=_(\7$AJ_0)(I:AHL_(NS>H$+[&T75(!E2JHRH(2,H
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MI_\[84:]+$:XQJ$O[=WRMU2XY:A;WI<,F,XUH6%8C'KW"L\V9CE(70;0W\]
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M3)Q4_M'LRZU>?<TN5\7VU=82"HL\'[J!JP[%HX)9N(\US.0[<3^,,#ZI(P]
MW*I+U!PV]^MP&5H6E>OMYJ\E97:AZEX,"E4;I^/ JLBH/>5CF)CIVQ6N->9Z
M_BP[@CMN.81?Y-O+]TE/G&R9RYF+>6M";;?L-VR]6W:]RIDC!(5@5*YAR=E8
MI,U8V+Y=?;>4 =<#;95@J'#[6+Z%T]1R>?U>ZP)-IH7>M5P'!OLS7,EUB ]I
ME$#T(X)P/[QOXZ+/YPL+BZ5NJV\R/<M.>*#<$,EWXY&GP[TD;[9Z" =FE+8R
M1;'PUXGW\E<%??UT!:^"49"_^=>$7\(Y\N?94V:Y=Y5HR(!%5C;H-NG&C8"@
MH,440?CHLT;)%^R5^^S&O-2<;":"$>W7WP>1[IOYUH9_7+P6 %O]ZZK(>[Z#
MV+J4/?DQOCG]# X>S6UM'GQ&QZD43Y=B3PXL@AZ9^J"[1_%:2& H8<VDL5K?
M[LH3K-NW)7$9'VG_SHS,9DFZ8T%;"XT>C^GD/,1-5H#DNTG9"NTC<^?^' ZH
MF37EK7B^C<JIQ$BN!NZ^91$,71P&QDE*=RJBI)2S<6490'MX<[%RN+AX*:J'
M1:U ,/4[H^MRT>"_]G]M_.\F\OB;OF8BJ?EZ8LV1^8)-'TD^\Z2KD-@!Q6(<
M6'P(TE,28=;)TX@?<Z&I"$@4!W@8>U>+YM.D'DO;N(/@.PIMO_FP[E!F^>XV
MM^G-D 5VW(2Y#!]!866>F>S *0$YR>"6+\0;FQ]QJ,"C5&_*&<=<9G$'2^@:
M1^N>*?86VMG1]-SE8)(N3!'\?WJYKJ@F@"@;C(I(41 P5&D"$HKTWJ5+!RD!
M% .$%HH@2),F"$A'JA"4*ET@E% $I-=00T@ 17I)Z"#5Q?W9K_W8LWOVXWW.
MF7ONN_/FSIDWDW) B%GG_4RE8[RCUG+J\ 7NNJ<C4<AL8#7\VJ.KW+&KC!>X
M+;@8\EBT_WB\>:?^DY^(7)@GS<D3?$'7DTN+&R+?L2S"V10K]6N?*>; N@&/
MW(D.]BX?\"FBJ6L $FJ-,5.O[:SQ_\$=V/]'Q&LM1H40POP]GY[!V\X/+BAA
M+KZ),QD('W9(: 3/R3/%(\+[\X/@LZ.?"Q;:>7J]]OQ<I<I:W*^3T,P%[UR3
MIF.2JP]T^MPIJH T91T#2>?K3?,5086#P$Y[BOKRW9ZM?8(OS*,9:D"ER9R]
M>/+[-['2:ZIX:W4 ;F@QW315F/VMG7S6"IW+=^OF2B!4H9WBD.OVX%B@":XA
M2@C9Z4[#S^HVGDS3:?=)X84)E7]<P:_7':6B,I;@S*9=3)P3Q2O9IT]CWK$9
M4)E+XUXI45R34'^SB*)-_G.F$AG,/_C(V-7-\(<GQZV6GQ]AGB?2(\)XZ=\A
M,O[Q3OFAD@-X,ZD140O&X&B".(OI 99 S$?% 35K\A*$^$#72+CL[GK%>L6N
MQGSJDC2T<%+_[0-FE.H'(%J\:0NV*M6T]I0'JUW.M"<N_?\"%HO/'^W:X(?9
M-)<&6<.=*N]=TL2!+P.T_@+>?CH'0SIQK8C\DBA"3F:JEK2*5&\KE+&_V6JA
M..'=2EY!G0P.#.Q^R^%.9=XAHT:.'/\X-#)0]@YV20<=F?7>-N.:+J\XP <,
MON>%D=4_/)FMI8@@\4JYI$.M97D_$W4Q4\1+' %U,J]C7EF!!SDHFCY>S)/(
MG9\C$)F$FSF_C05S2JU^=C+#=#_V*LYD]S7>+M><I=U-P5=SA,C<!F<W[O9\
M@'_5L.<:X?(+K,$RF1U'/O9?"EMXS["FU;Z2K\^R+H*6;S&<T_*DB'Z07!VW
M99UI%GO>4G*&Y2P!?:9"Y*>]^<*FB47K4<(<Y]EJIW5[L1CK;](JQ)N@,.4>
M,N(=4E)<_K0[>PVUW)8IA,U6:W6GXI$JPJI@Q*H:E7^$#SZY,C3Q6<F/%C.2
MF& L;RI5SX*O#!+BZ@CU%G\.=E%N#3L><01]LP*F<IY@#CUJWEEE.1B4%X*Y
M7<<LLBK+!'.\BKO2W$6LK?B%!'_1LP4%) < Y/U8-BU<:K6JYIU\O^';;6.U
M8U/H977N2MHK]8/D:&YZ!, 29V?S:IBZ?"#$EJ]$6/PD(<O<EK_T!.A([$6T
MAX9GFQB]B<I$?G&W]1A]KF?K9/]<:.!'];+^D!:^%]3CMYY(.0#.W#F.P4,F
MQ<FA<$;R%Q:!*'()8)-M* "VA![07*TJ<VL)^H+K8$9SE==P-/Z(CP B"E[1
M?4R:7@' Q$@F#:V&+N7&!(A$@9D5 0I*!5.2?5J WEA.;R1(JF-+UWHB4,NI
M9,-K?5?9BZ6[D=4QR<35%8C\E4P%"F#UT 6XCOT//Y_[/PH250,-IWO.U8O?
M2M^:M.T/_P5LIT"\3:3F/JG7QM3%,/K+])VEOF?I5@[^(G!4 2\)^KY'!I\L
MY5(7R4;H,>B1K6EV]-)5J!D]>R::C<H94,3BGL]83CIARH"*&5!S$\'M[1=4
MWR^<6]^_KQ C*%=QI"V,<)GG)^TE1H-D(T!H?I*E;"CP6MW7(JU!R!^).4*1
MI.#HW&"0P':F\\G>3,_XYYH]B<.^S;Y>VO46LD)=<*VN7W6G@Z(LIP#9NWK-
M?MD[K_Q646A]-8"=Y'O7G\\_F/OQ^"WT1S.$/GDH02/5UT?(0:TRK)1O1*&=
MO]!6STL!Y>-L\E+,G@S(#?2*'OFUK<;F'O>767J+5&S9YWM(+Y4<5 SPF? /
M0=]KS:_XE!6HE98_+&YL2*/GEJZ8!5/$/EZB#KM3/)$%L2;7KJUS<10[LX]>
M-,_V4SJ)R0<(7_+?L1S-*U\371HK7W*DZE&+G->QT\0[WCI[);44U!'K_95]
MC+Y7_[NF7?+1ROKC[0!NWP6?TFKR'Z%K\OI<F%9:DJ&9-X(]&$HQO^-K+IJ<
MD1IQNT=Q[QK0B?KS_&_8<KJ8P_6K=YYE%L^JB1G-5;]_$6VC7$='QM<(\)[U
MDT,L36M<$;&.8$6.'S*5_2E 0#XDTF4Y4*B$:3*T\R3[O=1WG<3%R,H%F":0
M?JZXS9<O:.8I_AI*WI]^Z==VL>=\E!U?P;W,R?::[FW,N*E5:KEV1,[ M(^A
MS0FKV_;L4"WW1$*F/PQ7F_+CU!=GE[6F%5C. (W9B39ZZ$#1H<Q"!JST#+E)
M2E>G]M)".XA3MRFIH/%;?6JF7+W(DPK4JUNDG$F)5'<*V<>VGO@D=;JE[5H.
MKW8SWZ96M7VOI(@3]X\!]$_(R;L4S(J-ZGBR4Y\8%-38VR;(U@NQB&ZFM*_&
M#-3MZ#9@Z=RXW@@.=^TCTZJ. S']L?0/O $Q5"0G)*#*RAC 2F[[J54ZC;9]
M,VY%=?DDWSD=Y#8CO=DO18CY_IT5^?QNL"LRI;6=@MHZU*0/L!B'E5K/]KW2
MWW^YN/]U@*-B<*?[W9)H.%V?H[C4L353MGKUK5%D@*174NY"KS2:5F"+1=#G
MP(PR;^-^DZM$I,M7A4Y/^36<K?0'J.99-'KX6!]$6_8;_DS66O.\<E?97;X9
M#4C@T  /E#U(!W)**2 %E-=\:<W8RYRSYA'')2S+M1=AW8*S=:B+??K *LJ]
M6"%4\??:K[C^ )B7+Y,56'E)3@+E(.)V<BVMYZUQF+X>D@1C:.634[F!*[.<
MB5Y 9E<,ZH@E1LXM:]ZE_/)-9NE7KG.RO)>1$[1%%%]7NZ'>N55V?SBNVY>(
MMI&$@GI7-0Y/@:.;CI5,ZFUM<)E._=JFL G[C^FZ_-7N<]&WR&-C229S/9^P
M\DS5Z929$R0ZN:)="7?K!1L]FU2>2UE1A1P>HZ]-GUXV T>)CI4RO4;?&YL9
M@PI&+8AI>\]2%T7L-"1& 0+;*>@)NL*JC71,\GI]&B]: "\EHA[3=</J_$L&
M1:[7**.,E0QVGNL:"1NLN!40R7#]0:%'NK!SPVEKP70/><!7)&IY;QYP"7D/
M?'7>>WWGC9QWZ:G:4;5],6[]5#=/>Q2K_.J)@7K>LT164&VL1^.LB-8J+J+J
M</-2Z2^@JO,<_20/E=#@G+Z[4:L10%GNLRW0I+Q$#"R%^1 ZL_<GBE<-K,4'
MSX62(66Y2-V'8:@4-[*!<#0/S\]6\O.VNS(;X!",N(6K^^4T76-219W6)$DV
M=*MSQ:T8*"VU)447]+KU59">)G\>I)%@><,G[B[7ERF+7.ZG7SL]0_Q]OSC?
M4?V6UZ@I/G,@ZS279$-&=$^CCM=MSXP1# +!]BI:W8?-Q121(ID1YPJVAB$0
M%QCKS!?OD[=LIR?/=ZYL0$S#+E7U:[E="SAJOQRW,K84^I)"M?0\WX_K[JQ;
M+YM)O67$Q7&4&%K(*!B\=7SMC5T#5J<@ZI9M,TFD9Q+BSZ;&X450^X'L;?"=
MSM.(Y8E9_ :\_E2@?,=/V10(NV%.PZ!'=<=&NM)79ZKJH SL%[CF)N" :M&O
MY7_S&FL?2$3S@,-[/?_$87UD-\ ?&J;E5,10X@P5JA"!)NO[CJ-V=O=-;F]I
M8K6N[_>VZE UESCCHAIJ40UU]9_0:60X@>7%V%+//N9J:.[3($=_1R'1JKQ&
MZ&^XPZ9^VAYI70AD/3IP[:7 BH3==2""]MWIOD94'1,>*\X%B6*K0R(PHN0:
M:8G5ZB-;N]/ ^-X=&2S52DS[E,V?-V7J,?/'_6%/,OKIA][CD?M]6V\.RM^\
MAC_%]5+&IF$6X-N"YDCUIQDK?(!!7[1B(1CK9$58J^1^?L\9XY,\*)0D.PR[
M,<27!*=FX"(+3SL)Z9-+&CT@V-99OWU8UY!C-$,4BFCQFE7/M!.NA3E+,X4+
MDLKM=INV5;6;77XWNU)$ A)S:*VR(B\N6/$YDW+DK(K'X^.3A9M3(S>]4OK7
MNTWU:6SZG3R_]E*0>7MO.I&PQZ0Y6>LSG+78^:Y6"!P"F_(:<U3.+/=9^S:$
M"^I/4Y%O SU2YY-?_*HDAJ3\3++\SH$A(MGAW)S)TOG)[*D],'Q&K\U["N&#
M_,*_@(KPDM$QJQOS#<$5CC65['&$ F0,%)DHV')((7,Q%MK;:IUK,T58ADMR
M_-XD_ 4XW.N^'6;<3[-3WN'K%8\,?IY^$CIC:/7!&<&>V.&Z0@[.K49[\F3>
M>J4M1=X>2!%&MO2[\N?#^=8%%P;XO-1*CFVCHZ6ZVL<7PK'?EH!__A-!U::2
M#"/X76-DI\'$069>?6.][=>*[#&F=%F/(8973-=A;7OK*GV[?[XOZF8Y?1E7
M&](NYX)F7M<TXO!*->[_"W",]5VR_ NPR5VA(*Y5PB!-:7N;>M\0F W<N,L"
M;3FQE-L@7ND&*)O>=#/VH#S@%F;?+$&S*<UL@C-KO]]8U+8>]*-R:REB]L]J
M0QVY@7^P3=N2[Z09I>.TR/H\74ORT7K&7)1/)M7,/1K;3V==(2W9F(;HZX0R
M1S*X)TM+A1<;C8P;\%@?S\DS'B(C TZNP=19JUB+S,'JH_H$6T[>J86?B/!=
MRY=S0[=9#J-V698P#1M=5I;]Q:V35%<+YUN[!S -I[P=WDUN('L*_IAB,77?
M*$U9O W[>XJS>B\P'Y7ZXQQ?.TE_0# C;KL7[@+-(=;*+K3T_1X$+LC0I\Q(
MF5B2AA0BKR7^=-WC"KV/)&^E-J6OD5^%$*,Y(V[C5$?8D:-3G;:1LEDN-X4+
M"A+74[RW<82SDSS6A4NA)KA:-,<YPB1T,_K[^V1/3@WJ+K_;8GY.0U%Y*&M5
M0PP_8T^_H-'>;Z*Z@AW]&@,M]]8-&"!E0__ICO_D?<;>J,!Z]3/YG"Y&+^N!
M!/J]H?)V*B; 79(-SRS6D#I91G!4NMG4BQ3K26BS>CP3B"=F9C3UF3UT6F%V
M%[U@O)F%*<YO5[&N&!YNN?;;6\?@GM/+FRN"CZ78H#RQ$W4YX:^]KJI=9J7[
MV&$Q8MV-/<&X/E[*0A,+ZAR-7 .RROL=E3UV:4H9=GHSWHZ9-ANW^*!,S_BX
ML!T^LW2>R0GJ*/F>?MD4G,$"YU8GH!AZ/*WJ0\N=T\UD;+]GS6L>,M&CR)C5
MY(J,LF$\TG=.31D0+HHTFV8.*XKRA6&XG_#/R?J9RK<+OO6^;?$5NY+I*-7O
MF/W-'/55XQHD8HU$1K5$!0N O4SM!R3>88FFJR[<D/SV$VLY)YD*$Z.NJ,2&
M\Q</S+;7ORI_K'>K XB)N'C+]A> WI') L=,5;DC+WQM6FM18<(N]M>':9.(
M(K_Z]U8Y 0?H$CKG:4M,55W)C=9/3%+N"FB.5"4Z ,/+[F.W_A&)Q0<Y5QIE
ML:;K<&),^RR64>%*A!.>83HJ9XH^!&<\C1>>M%6?U[=1T_):E#T+YF=ZTQ7/
MWLRK/(#[.,=^6D(A2N0EO0A^+GJ5W-WR.<5W[H>IU$3SU2PL_%?>JJT""O"@
MIZ:R+LX?3=B:]HGGKUAH9H-0MTA+Z[>V,^G+^]&2X,:L$H[BCH^RTWSTKU-Z
MEFJ1:^ZF_XBBVX^;\_H38*JQ2[F'"VHLN+DG+['\@0 OS,\T+O)GAIV.7:G3
M$W]Z@KW:V"56S:9=B]IHK''::2*06A)7DX&:Q-L71.&1._)M3/G/4?N<*K84
MI\T64.:3%_<VIT-5IJY&7[Y<#]Y$C8]9P>LK*N?U[>CWQL5:TU8>/G#@ZN*
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ML=_%JX(B;JO5/)9XU*-TP$PE7]IBR9U"FKGLE.:T$E;S\L9)Z%)XK[YSFQI
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MXH%C-V@5[NE)2\EY,&SC0\F#+[1@// A!P]HLT3 D)IX8'(0#U!JXC*%.?#
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M4K,<$_K&\0"X&IUTN^3&.)83]?JPE>U#7^S2N:R]@N'D[E=(,%$XQ0+=3>Z
M/=NPHRV!%D)H)\40HOFCMD@<22<>:+?! [^S+&M>T#*#,5<)X?W:%UJG?+;&
MBNR-^Q#/_#EEVS=#=\W>Y%RY5OOJ^"Q-H /QI_:03YC@1<U@(\</1C &:,R\
M]G /*F?R:]QL8N>I$Y4EH@'P$V$L[;^B3A7,HR$ID'&)U?N=S/#V>LGO:5<P
MT=F]3 ,(/Q95RYHB1[K.M4@;57;7[3BPT1GSVRL"/W&\YML92XZ_HU-!QK7#
M^J<\$8_8&5)2F.^</ ](>>5D5YGH4XB17%;/^0 W'ZD(%].N.'3.55_KO&H1
MH=C!\77AQ8M!6N\Y3RQX\0,?(1B"8^7C0Y"@2\\Q'>TR:P6RT/%G%<-N#7J1
MT0TKMDZ3$QJ+OT^)A$7O&BFPL*VW07I]=*I1^B691E,F%0UQQ0G@F()V15^7
M6829$L]>[ &B6_,09+#MF(98\>'*RIVR9;/ORX!)QMK:7XLQO!\_E9'W@P3>
MG#$DX4/M\[1J!-V)/9?],,N8?,V3:CD#4.:N+J%Y;S!:;X4T;QV$R*2N3Z%5
M7YF7&W>N7N3I:3 H1B9Z27-BL@:*]["42#X<@P^UIE;:WAYOH(!/XLGT5.P-
M]HS??!L;#FSL!:I6'=.:C<H;8,3S!4F$Y4S0(7P<XN@)N?7)/JRL/E+RW)RO
M<S9L][SZ^'SRN(2I;*S>TF;J24X&7RO[^23/DT;UI[U)7;H.FO&7/2(?;<X8
MN$RU$Y([-1--XO%Y:4YEXAJ[IG1]T;1J7\^R B:_(@D!7RA6BX^8,P\MW1HQ
M> O5'F_U%_R&\AW&#)M4!&G4)>\,3L_0/0J+3I"V_PR\(;F"%GX_=W/$5QUY
M-G6BF]+OSC'T<*C*X J4;_[R)[_5 \V5+H?^M?$9SW(M)>*_S\G_@PAP8@F.
M[30_EI@@H)"C?TG*1SF&59X8^(.1=YDE8:]JO5;H-<L\XZ=CR3AQ<;L2&MM/
MATN*B_:*T>?&H:&6M119'TR7%/)5NM"<=XSGPNKNP2A-!]?/--_Z*ONA+D^W
M-0J/N$U:E89VE5<-#S:[2;V>'<"V+J?YQV4L($CMS#A0\)"*T,Y=KGF#%-5+
MS3NF3]; ]_@!\+T-=4\W/3[[^O'Y@JL&&CCSP(X$Q-MZO44$\];4^+L2="2?
MOOT)<VVZ:@6(9_6I^TILG\Q)CBV<?%".=XD:K#>BU)=7C$AU=>> ZCIY"@W.
M7);>A=NAM_B]#(2%XQH?(1IZUV&)2[7P%N&/;!WO+)!M:W7IE+*<Z1-/8@)3
M[ISZCG&O_MA@Y'*&&VW*62/Q@-[8+E;2+V-^:GI;AGD8-$7,^NJ'R4I 6L'F
MJ4&&EL;>R;8/MJVK\J"J,\T\"T/69KUDGQ F,:OS6XW FT%UTN\RY-\S2</H
M/(6EN^F\Y'2-/-_Z6BU<&.MRT8V*6V39Z9SV<GUE#%1S@56S!+;[I#A)E>BE
MAWK@*JJ-S] #AW!V**7IN$.]9*%M4EPLQ$B$-'Q+M$W6-[-T@H*CY('L<?86
MC@S%7+5,2PXY23!Z$?N49/ZNTHC85?CLNQSN+25O)49!-K]4W$MG=<,C_5.N
M1RC)Q?LE2_L,V45?S2>GO(Z;YXZLHT>JR;C9==?#W#L43<E"<6P=)5!CY6'Q
MZ;;2NL%$MKZ7R0G\0!,7AFQ+H#$]1C^2?Q\VDE-0AY;JI1E>XM[2/X &Z0R\
M_!ZTWY;=PBW?0>+;RS>[3K;*6>#:9J1[MO[[D2G_Y++JWNZKP/N?HKXFJES[
MP0?Z !E\'!.S:@%RG^4R]4-./Z_%"-@OM-:4LGU2HOA4=\K'X+!=)0^>S*NW
M1.[KHVB#Y 1RC$PF>6H?1XOO"E3K7_G"6:V3EHHR2U#2.W*LTUP+7M&OBC6_
MY62@0#Z2C>FT729-&[!%3EZD9@C-V;ZY]Y/=.?*S9ZY;)-&6/PA3D L-^JVZ
MS/2J3MA%_FCB[^\T:IZQ@'S2,O;9T#)W! 4=$K">[ :(5 1U!.V/.=):)-;L
MUGL#B%JHG]FQ:MR-UQ:KE= WN>MDE9 DI&:S.J2I4:)Q-'WDS7HI\U#3R[#]
M-:&E*Y?9G8#]=_YQ.Q*)N9@@E:& <RNLR#<\$/]B#W:^XJJ3/MXU+_ \L8\N
M?&VGQ,_/P0OQH?'R1F=VKW!8D<6H1/"ZUZLT]KPX0#[PRGK-BF>1, E6J@&I
M'.'NTZ!@K(1<W7FA](8W.BL\D+QO01'DD]IZ:,S7GN =^V9 7#:Y<<ZMY94E
M]CQ:]2)TJ<@\5<?0F%P3^^T[QP4E[*CWBH=G9$YT%\HYM^BID+^?PLD9Y]OK
M:.FL8A$Y>J^L\"F:!O<WD]W*"IRL9U&7P8\T<%,HL^CVO Q>+'?AL3(\SQSW
M+:O7?@!7=1O&1J, T<- ,)SA3'VV.*F!DHCVVOMEUI=EXR84S] 7D*_*AG0R
M]ZPLHKI<J+5M=QPU*F3RT2N?MYXHV==]XLSAYOYZE)6>F*NEQ$BTA& J7QOU
MOXOA;W-8+_/2:YXQCN(2I5&\=L(TAG%<K*^U#N5%/:DKZ2VV6P/SWS&;??%\
MG'51-SK%>CAOJ6[JCJ)+^QSB8V9-EN<JAB,RH)X6#Y";'W=@?_.?O,B .B!&
MO/S-7 \NEM,:H(62&$-8]E9MW/@'7U/W=.,MC5>UE><W-2BYZBCIJ_).UHN\
M]1@-;3<=HP@8H>^1,L8UPV:.HAY9+R@[/9<1FAQDL:;2<\]87@'^].>0/U.G
MXZ+Q/.4VU\UDG<&L2*O"2Z,W(([)'@L_8CJDMCLJO"48YXJJ1A@JB@8.>P46
M3X+%CRJ^)RS1?+T5:=>]:M1FRZ%MK].<^/UYF#..*7N.9!:E*&=[D7%B[]][
M#.:>")\^\4&W>3 ^._+$U5'&&<V/!3$M@H/P #)T O-N8@MFAQM/79M=>7-0
M=4GD)&+'>JK8%XQTQ%YO9#5EW\4#]JW]PJDKIS ?#DMG]%%Q=@ASLH?:2N7E
MV//ITV_I(;=9"<H'_A,B^L><4@+&$'*AJ,%%N ?X7-Z;%/#" Z&PE1)?&3Q0
MG8#[:(2^0JABF?% IQG&'0\X"U_056S\IYW_YZ1XG2KVK0"E%BKB0_:*JF_,
M3_!J"J@>K"$%"LZ<,DX<*;AB=VCKG5QNP(D'*/@^NCN(FY(NAJ&K&V2?R#]8
M1M^*Q#P^\M/=&Z_8-*4U]M&,!LNYGNH>SK]RO;#OQ]QS.9STVT?_-CGBJY.^
M^:JH%VOV8IO#VL?_4<[R\WED_-94"1M-@/A'_]VVP0EX JRO4GS^RD;2\\MS
MS=S7"7X;$[Y[F@;_\&;05G["1TY=,^*I0#>L 0]$=\":)9<$C5.MS6Q>.E0>
M/[+IR(9>*!;)RS;5,B<]4G[Y2XQ,/% /-H."WA9MW<F]^?5]!DO/Z+QG ?8!
M<!GXP:BEI#5"^ "T$(-NLUHJ#=\#7T)GN@]I,VB47/L7'$M%$AZ.[HN?\"D8
MVJ/@;V 1D)+TK#:QM&SF<&4O9;-S<(.=\_R4@L@@'E@^5W^O^]8]9F01#]R%
M\19XF,D..F0>./#$MSLWJ65.OS_:/%VJM<OSR7Z^I;734![H/-WS0.6,*SWA
M;GQ/_X1!#E9ZOLL()P/N*:4:-'G,$Z@;+S88'4"&8CQ;R4)REC,DHDT?[O_V
MZ3B\FV\U!5<!@B^K@X+M=RL^DJ&>>*A&#I^R22?-DHW9/<*4S^>/PN +'N(&
M I#EV3NK!Q+D>^+; 4UJ'W\2HT C5S8%BXOV;S),:W(,IH6S!X(^YVMK6MH]
M#]'SI[BEKL2H<_^_ C__3X$A :[SMC3V86&>,@3J<IRM.Y=DB_R.<^W*)=',
ME5=T,+82@M'-O\<#&Y !@O-9$N(+TP-.4J9^/-#LN8 'SMC08"PKH:IHT_K_
M >,'4'@]GW@HAQG?X"N/C0(8/1]R5J^DWC/="!'G>#=A.#: \[M#YQD:'&@K
MS5L39X3>%!B)4597V2O]ZODB_[(J'V  NLA:IK8,Y13E%+HZ9)P]0_ Q\+&1
M"Y2SQ$2MQ.[$^STQ_.[]GQV+.-:\-<=7%D=Y!!]V[-U <,(N[7U=]KO25$E9
M4MX])6M1#^_(V=8%5\GI%*"R-@JL*-W2CK[YUT%Q3VH%P8^'Q;/:PC_=@^^3
M=H,P].M'!6@C30^N#GH=3&S5)U@O'O@AM;C0/:NR-WXTG?S%Z]Y#CR>T!Q>D
M#IMSG$/BA>RRY);.0P\EP1=HKZ*G=W(S;34IGB2O:8W7C5[LW,Y=3V,W]G(0
MXHU@O?GP0)6;5/>9J"K?6V#_.0R9B@'C AL(^KI\#P^@])05![1,\ "6SY_P
MKZ\EC_! 4Q@8JP?Z$Y\NT?^N;";#OFI?MB6I';.VO>W16\E3LL:9<>]6J*(R
M4UY%^+4!IK7?*QI#N^HJ0]QP.Q]9_2MZ9S!D&H2 4Q=:)+I<IGCCNC\9_&?(
MUD;F4MJ:A!,Z'^N,6#])\9AGV\ #[D7NH<X3V!A+-*[B+I=\J>KO;!6I<XDB
MN^*O2M8NPYYN\]_9_5+[L<V9RO6)=^9'5M"/D8.*,I&SAN>P*QEH[Y)#K,K.
M$:7\0V'1OJUKPS7A31WC0X7CPEX+\C=M?<^Y%>!.,O+EOU-=@%N8C'?\Q7Y%
MVJF#>8, ;]X?TWSK\+7VB-=5BKO;A*BWO\X)HP:M$<(>-RABJ<*9IBK;S/:[
M-7LBY8TS+D241"%. (G6#_6\7Y.C2'Q/D6?\#NN,XG7?5M>WT./LS+3V\E)Q
MN[J'1L?;)PYO_CO:UGNRKJCD2G#-/RT"[$]^_(SL?PLVZ\VDO<BB4\2D3%$X
M'HB-%-M)H!#J6;\VI2'V?GQ@[,,O2-(&/HU![$!*\<#D]H! /^X.'NB)PP.6
MII&X?K. !UQ_#OWUA":( X-&3MB,&AYX+$@ -M =[_L)!;YFJ/'C^&1KGU68
M]2G,-N#5Y&?I]@7G%-JN*M@B#1)Q0>D-Q@%M>*!US#\!#_#Z$++-"0TAP5RN
MK5TLG)>5OT+A(_X2ULRY"#MC1L.P1*%X(#@#1[=/B0<&JC+PP *5.5;=?LQJ
M_2-:4&:UJ*2B2&;,'2C7F;UYKU^#HM?*BVV*%X9Y5"^,!Q[.1>*!MR(PE/B?
M^BNX;W9C4$(VLFP"PN8W@Q%<;7*)F.#4(.JU?383O_14V/+JGP<$(8.@YK@/
M#2 \ +PD)$^(0X@TW/F@N)T/>V..A6!LCLJ$J,B*P"2!_R3E+*.KPF)7'2O\
M3SW\VCF3;<8#:$&"+V*("7U<-1;:9A.K(U6Z]MKR+5F1WK=1MUU]R5B-$4%'
M>AK.HC7#2_!'Y2E:7E<&;_]3_0PJB^TIZ$T<(CZ><46F0VFU1LH;0!IE#6^;
M7Z91JHP.)#[CH)-]I[QLUF&9-6%;NO.]/) HC/,C$5AG9#P.:XP'8BP*8=.@
M"TY.[POWQ:/PR:;@'%J;+/LW!,SEQOJ!4>L!*8$X\$ $'EA)@R;CF@S,S^X4
MO$?F?)"3=E[89?!"4_,;9@XO>$;O++]^+9+'$R/-<U)\V $[T)13QP,O"DHN
M&$=[H;*XQW[$N*9*@LT*0N!T4T\[-*[=FFWYY^I/O%O:<K5;H- Y/=[3]>T7
M=YYCILZ>\]24@E+"FI-[?B!D7V-"R$%>%L81,.X_F(,E07W7Q&%8&H+Z0HID
M!<[EGTZ83,PVN1/Q4+R(DHF1.9#*V:><?6W]SY>WYE]O!^X:X_K#C@[9%>4C
M@D)"UZ7B;V<;0$\[>HA^KH^%_I1^^>P?VRC_>7P$<U%V;ZYJ3ENND:H/:_<T
M3]<KK;V:GUM@F1JE%>;@X'_0TG>L6/:$K3G'RGN-[Y5E'^K%33H<&=JS&H<N
M.WUQ?2M]7-Q84\2-4QN&37R#H7/U1]A=[[7R?/'V8]0RS2'_]WJD\V:$38]+
M>JVDGD44[,H!+&3NVF!10O/AHYSF0!C=E"(_T8',/=\\C<_+0PT.]=M+^UAO
MZ"-<NP]XE?>WF&\-*;P\*\4#_]RZS3S%]KQG"DK_48H_K[5$C@_,.GN:/7F[
M6O %"?'= Y)GFAJ:3(D$B!;YJ^&K7PUEA''\22X^%+E%_]SR7MZQ3.*)YS/D
M=J>*"+H1L*&X=P==DZGP_/-_9V'=M'K.@_AW_GE\&Q+CYY;]IJ<5H_KC4H3U
MC+2!)<L_F]FO\3I^C2=*^(;A)(S'9(34I.ZY(\Z062K5)??FVO-?>^?U43&A
M$S__&P8TG9[P1PQ94V";G-K$ _2^?A K>^J*6ICU3@AK\\TU/C[ 29H')[$E
ML=8($"(&'$6,6YP_XRT8*A@,:HZ\G]/>_Z?B]\^)AO^CW#_DD7^LCX&#(F'<
MTQ/"@NX1BMAT:G?W+EO8@4$]# \X[5_000J*KQ <S#KC$<9&X(>OH_OBMF;H
MV>]IM[Y5-WP[%W^AY-!Z_R+T?8LPI\\XPB!V^TPRO%#AUAPTLB5)HF'%9;J0
M?_SJ=>W[Q=!#QO6;<;<^'>UTY9>0'6 [?&7JD4QXX*,5%\N@<*$[>5%B_73"
M:],:(,RK:"9B/ISWI/7"\7&L[N"1^OW)>D6.W"1?)R6^.*=")W;VX),ML10/
MB:K%"^,EN;/:6XC%685YS8G5N3DEX2B: ;"W=PI-7+<YAKV=ZWH] J4W+1%1
M0Y(_9173$\;$N$X:P'VTG8*$:+IWSTW-[H^TN=[VJ9NOJ.5TJ%GFU&DY\PBW
MDH^K& ^6$*6__O'[P_!VU4X^XNONZ[%M2M;+U)Y/47KQ 4O= B1^#ZY"/'/*
M3JT0M8\.4TY.0$8E)1C/5H7K[UMP-T*&9-5A:O9#ANK\GV*CHZZI$DLM3QQG
M1BJB0"%8JZQM_^O#Z4-WT87E]PM<RE2Y4SCBS42BY#$GO;=SCZJ,<?$<*;M[
M\U:.8ZL^('8,P@A%]M$ME4]CB/W\OO[SM6I;.E*J!U1$LI^7*P=$3$$M^RQJ
MRR#:AMW>[\8S+2+OK,)2/[PEXY9;3HM+7(#1V$V!0WT-_6"V*]/F,XZ5,!%V
M[SW7E$LJ"Q'5>?XL&)@N<B\R3S%_ZB+-L"3-9KS'H(OI&6V7YM?,4VFC W.8
M]L4>Y!11;1XR-6W+15'][O+-[6<6$#I.C?V&2 R-\K))SOM"7HP/BH::QNL:
M ?;R6/%]257F/J0"+SRLK(<LS&JVSXD/[^XMQM/23#6W[;U,)!:K>L:X<JP5
MTU@17(QEQW5458WX\DKL]N4Y.L7<-1!3?D?4I]C\5K%#9UM/M5VDS&?_5/CP
M9OZG+&@10I[@H%R=2DIV!YVVE/TLL6+7196C/.Y+7^-PLC-:M^O9T-A:9T(Y
MXE1_O1#U!H9V<]\^6@$Q$Q+I9PCHF("'E)7-$*:?'=\NMF(ME!@-%/M^;73\
M(E><+,'/O)8<STE-81O9Q9"F^0/N#= Q=14!0$%,A?\^&2<A/;$?S\@NWML3
M'-UH_#[?*W<+S]>S5I@$G)*].:X^FQ!-J.WTJ%VFC'N)M2H#)'LERJ/;:XCO
MZKX5A6Z;:$_L1;9&IM1+Y/O*5 S>#&V5H<GPS+OL*&K#<T.E'W0PZN-C4&2T
M16V![!(T^,'VDK>VK.ONOMYL2. -5+!82MB1G('D8JX_/\;X<>C34F1?*@^]
MF&CYX5?'SRL'MX@166XG"0@Z1[FKXNKIBC0US@*/%?KE[*+: @Y7?KK,/F@Z
M.3O6\T0(8&&/0D(J:A(6SZ)L0'1'(!9,1%?_P_(J-F_CPMJPP_:5]H[\6^37
M=BCZ7:<*-9<Y84:H6QD9T*?=&A;944(.%61^83/A^5=35KC\PJV@EDV--Y L
M'^UA97I'\K>.>=G>'M)3:4<N/VM]177<V>XZ5:3\!9/0-,<_)B%(]EO0\])1
M\QX;ZJXF'LT8U_B%L-C3R*>)_)XG'F7G^Q?/JVL.MAO&9R\<U,A:?9+AY)#Q
MP'8!>\B3+DW[&\)<.POT[VBDY,_U33M:S5DF,08:*/GVZ,QPT=<4=R$"IT4Q
M_E:<C!QNLN'JM&^/<NM!2XD.CUVWIQ;G7@0^H%=X\X%JXMK*N5O>$>(*Q!-V
M><>-]6[5EO/=&PN'SRPAK["MNQ>V/L'8<2S]^7YC/XYHX_A0L*U<)_?&JP<+
MH(=B9DJH)Q2^G$N4PJP;5?2*/DZ_76UN"?8W;XC 6BHL0L;><$/=MI]GFL@\
M#&F1)R>66+=?N#!H0]#=&O75?'%C<)>NP\KN(#/-9N75!SZN'(66BL=O<C*&
MS3&.B=IU.?FCT_N$Y&J*T5G$%,K)7E2);[OG;LTCDGSW?O#)NFZGK,]OFEYX
M[0>(@^@PCXQ&Q&WMIY9;BM?4U$HDQ*ZA!5)GT'+NU_;-/BCIIQ17<O*,O#G!
M55Q9*X\\%28@PY=->&#HJZF@JY$R-H%@HJ4O\,#FL_P6[*N7"L3#&^DA>U*7
M0FY_^8/^'D!X"WJ-M\UCT,B@B[!C6-=3[<D(V0R'D-LE]XXTP9A>/,"SM8ZK
M(X"QKP9)1A P17P?22VRO?#DD@1#;=?$ZPX>?XSG<8DQ)C'=3N$&TN3,/\'Q
M.#0[_C[]ONY/ZMAN.H'$\A&<T.1D$P3TH3PFJKTTS]: AR@ /C^&-M+R;]@=
M6"],3O(W+1F91O$%.V)9I^XB#:>K/B1J7YNV+!];9N786['DC'PH&P+[X&N5
MN_W-;FIVA7FLD;-2^-C@8$*-OX0WF(_U!WK+>:JL7C,36M>N97,F,1KU;7CE
M<8)>=<0K;G]1+0-G*;(ML8B61%^!Q09/S6%W&+G=0'TM=V;TI'GA1Y4G_5T&
MLG7K.2;';;<2N!O/\(!90WV(P9JJ?<[1YDP!2T2]>>Z&*P:N,>C6]+6EICXX
M"U;^,T1CC<0WXV#'>Z21&Y/H"EF<)7X^4'2]VE3#DOV1$\V",JDBR8MU;KF0
M#.MTS/X39":.MG*H<,]^A4&).>_X6RB'@X;KM=.RSLUA^<VI\9;=I],M.(:A
M\MS&R8MDSW63SC5^2QXQ^NH(L30R"8^<GCI3OUD'I2V7TTD"T"@MH VK5\[!
M;&L.N%_(:JBX\P@ZC+G(BOM!7TYT+G\CI&Q(/NSGK4-<-1CW#A*#D@PZ4G^T
MQ!<H86QL+MK5#9OB/61\0ZC[.K%$Q<TXR62-FA"1!&BBKG7>]:6:+<,FB<9L
M]%Z^^/' *;R%#=YR;LK2A>+ZD&MF)SMQ^DWEX>Z.5#0LSAO19',,-3I6V6,J
MRJI__8[HMD> D]0;-[YB,-=1/]1L> G^.]HB:P)JK1E#Q*U:ZS50J6D62W1F
M8(J<;TXJ?B=AJFQT8-DPLL9044]VAT5G.FPU\C?TMJD>3U(\(G+#92A40\8?
ME#>GI<3TTX-0,[T%K^1@'Q#PC2<NV Z=?V@.P#HU,0%_P!F&T4V]C6$,_9HN
M9O*?GR88DL$Q?_<.;<F?-VT?<.EE_3I<0.&!BQ8$6K&XN"95IYE+J@HUARB&
M>CO2LIL:[)RJ*V;/->HJRMQ<<*VKV1U*..=>0IQ@64YG81]<=#/NJ):[#Q6Q
M-MUR*S>0N(A&F9_C*+%[B.;(G<@0/#"/-%]WQS&!#!)SQJ[_GW P^IE9''WD
M%&3JA;WR-<#A@7=X0+8$F?$W8X$,/ON])%-3<C6?!!&0%V(!T;>-O8W[B2FY
MP .D.$_S1>71-=#S@*%!D_%CY3;8/D;XL!8/7 %_5Q#  [ F6.HX1NO(*^B_
M,8]K?QRZ_&W&-9-> EWV52.8AVN6'0-4UTBSO//X235#:B$'J=#]E3CBI'U?
MOJ6-HZ/XOCU0Z=;QO&!; 1*Z\'V]Z@ ;/)6P=]'IT)EZ;>Q]B;J9R'SM8>7Q
MH8S=[?1:FNOI(;<! A'#4?/8V/ZKL G^;3R@).%J1H,'HD$$._AFC\"%&A4L
M3?=J+E$EX%B0/9V<F4ZULW,U-R5=R"FB**;3JON\=J0+LC'62_%Q68:; VH+
M:X%#) '7IC9*]9YE2!&G7%F#[QO4#:!Y%1>E_8H/#*KTIG!U$]L;Q9"_T>\C
M5TO4P[[9/:'B>EJ2VZ(':KQ=^9$N4*;8K^)7ZMF_R]0*)(2J8W+D[HB+86ZJ
MI#[BSIAE>N%-]V!%!P_\3ZKXY5DK37S(&N)OF_TM=T&/0BEQ5GI-R=\V^WO#
MV#JD+7RP:?-W$H#^UC#.ZENVZ62,_CYS*/^M8?2I\W7X7T/QS(F/%I4;SPO]
M>%[/!NF."^UE8&F)R"!Q\GD?06UR?;/1]@UHGUH[I\[/#=O_(KVLW-2APWS8
MLG%XC>'Q<AR.1WXTR-)(8B3);F,YA5=#XZJ^S>WTD%>_=D!(_S[E[.\5?_E>
M$;^UIA="_JFNSNV90*>$CR8C5K4F2&]0OVM><WB?08WUB-E=U9!=P8*<@N\Z
MS03)6^]UF=BJVHHW.RT65OH,^?-W+4=/-A*2"8KP0/_7#M=]Y)7POXX__4OF
M(?RGR+B )5YTI+>I/?E8$4FOEM707G1L7Y C_H&E2]_LT5ME4I^T"X'ZXI\%
M2MPA#@?V7#"4)NY5R3G;#NS8^X]CU1#8(2]L8MP2#Y2-?]%C^+]_]&IP9ZF?
M+-PB5G>8]YRKQK%'DMP9 6J>[P;W.)N:,HF]2RJ3;%GBM]CB_S0+7U\YS_B$
MA!/J^XI9=)'V5:MBXS!UAV5V%%8-B\)V2(R.BRTAR-M*"@WBR]CES:;7JFHU
M:)25'-_@S#]+$"+-J; #^Z/Q9T:0RG4(MQ,?X+>ZF^(:<,3AUB7FY!M[JH '
MD!I3&&]HB./5#_I5;:#50]/E4W?9*[?3J^2^%5.V&:VN5>7#FKD7Q_& BG/H
M^=<3^^6-ENU^<().&X(5FK9&^1$K^R52UKB.M0M=I8-5'EB&6_1GNQ.01:@C
ME2W,^N-IE6CJB239/B$!+6Z \R1^G\X]Y:XR...JY$JYYS;&_[T>W@2ZJ#D5
M"BTX$-R0X80'E7\N/^=IM>T6V>;VM-R#/ T1>!6CKYRHG;FEWN>PN\>T8G[5
MW;C.Y^))U["N3U9:CV![O/WG0G+IPT<11.O@>!^#XK'7I5\-(49^JUG-GW'C
M=(&&7P$578Z ZO<=?"5YA07#GQ9M4J4X'M_6UTDB6.H[1-%=;!_?8GN!NU]N
M)^E>+JJ7-+^]%CR9R$P^3F0BLAC,NM[H)V(6J[LCWFTO,T5N8=I+10DD_A 5
MO;UP-0*R^ARVR 019O(K-)4,C<@@ +%)WWVQ?>=PA+#)T?I0D4_CWCG"%+80
M'5+ 5L&Q5(A8\#?R/K$>&S'X'=/?Y#'LR\'%C:(.BUS*O7M#N2;>5K*8 [CF
M:<]GV_2S5SEOTG:>!D=KA'G?$A]N560W5GE\,%LX),(^[GJ/JO7. IKX6H&W
MJY>LWSE'Z<DGH^V260C.ND'+S'-Q__<YT'#&L+M2PC/<E*:0;<D8ZJ1GAH&5
M03=OXXF,9\GC[-%R1JN>XDK"8D<K*C$^(R(0&1QBQH5 %N?Q?<0*TMD\?WVB
M;L:L=/0,'+4Y'1:R+0=>H@0QV-KZ6=Y27%+IGPNOR\,#<F-%3F;7D;U[P7EP
M!HR6B'/*[$3)3+79"JVYQ1''T;JS&US<8POQ\VAS-%"&/\[3+E2E\^@@8>/,
M?6#?IM"1&I/4TGKF.578J4JWFT1VCI+\>HPFE+\BQA+UKS*+(T6+[@PFYV@9
M%@>H[)5F_+&?U;I I&;F6;QEX"\Y9MXBPY,E/J&"&VS44 3-Z,P/SYP3?\[3
MB?9"2S8M<MUTV!LTZD2K8<^%"D.6C".#C2;+*JTC6YBU:66TFFJ=)WQ@0@TJ
M)4I558%#<[(^T#&IE\\^AMQCI'FKR^:0#,FT14Y,/KY9]<$C/W+-3_6HP"UO
MV/DDJT[X6JB>O49,A=0.PF"-4*H3PKA1RHU_4^)_1F1P+"'_)0K@VNM %VE_
MG'W\W>$Y(]$Z3I!0ES<@MW%+YF<W( ,"_;^VT'E]%L<O6A'HA^-?_LN^_X-,
M]D.P?(Y+QH^M8&5V^NON%5-./UM2.%PC5T<,E)1^2\\LXC9BVGJ6FZ_C8;,L
M)[S4G3W"WM+(HU0U9K$(2C<I>6T.6S\-<&WG$L U544,M8/+MUE@@D6UX1U\
MX:W>,#',*)P1JM_=>LQE,E];%YGL$P<25[]0KCHJ["?'R"RKU288C#LHX<J$
MNWCO/G_R]H4]#XW*%HS69-&N8,8<=C1R].G;53Q@%Q_NJ)GAKYGI4S36[6:$
MA'T ?[-?J6N,W95IFYQU=^K@2_-XOXGM7XQ("Q& *BJZ9'2UON1_R2]3P3F-
M:UQ(#^$/>_BK<*N&!RG0C,C=H*FL_7UL*/E"<2_]7%9D*NB+M%;_L,2TUL/!
M^=53\ !7CN3R/.TL)J=))C[4DD=D9O9FOOC.0ZI[<E$4NYNZ$B BY6)?T7)D
M=I94A(W]RS!-VAX&76(JL;"P2 =:NYV-+*O7==-(SB/-*@+BHO+:"\[ JI>=
MTZ3Z%-F0J5>\HG9E%)48&<P#W:&Z?\D@+$)YFU"3,JE7U=SA_4:(]H'_ONWR
MBYQPO,BBU;0O<[S(.B^9I$/Y;R#>KB,Y;_CXMK$9"THO(7CGMZ@U@>KJZ@I8
MPU68UOX%Q+L:P8BYO[:%@:1QU##+=(47*S;WY+R'PWQACYX_%4I>"^J%16]K
MEVBRD#YBW.5%]E=]JJ^3'_]*%G*T/6OPZRU<S99(7.)U//!;K;;'=(YS],#9
MA?,(:GB#C3HA2/PS^IRGN41H?5]E=N)\5/,*U&R^A<TZIFC=[#?/F1E0 _>%
M'YD4'M@>NY!Q\EQ/(V#->+&KZHH6W_# I>TQS;H+%J4U@F1OO)K^B6W^:^W?
M%P^@C$U05@FM!TF7\WP8]65<S!H*7;^%CS[?ZZ)ACZCA)+6'KK<GL,4G+W :
M*XTXV+\8<1SN4[GU:K8K4+EIA3CZ_6._E?I9!+LY\F7LJN,0'G"IV1DQ$%R"
M@S;F&.LJ2VO4NF>?KKQFIR3WG9SQWOUYLN75U";9 J8K=V14]7&TY]S-NHB)
MKRYM#.I*!?:K>/P;VFU-#1M;O!W<W0P2E5#]+9)LEN;3F[5H9.M$S4%A%:7%
M9*;]] .%5K@=FII;OVQ</-E>4S.AM[SF :J1_.<95V!^<VU#* $B+>$!#EL%
MBI!F4U,'N>1.;%P,(Q6W5-]:)QGH-[A=]Y __X9,R<<7@T;#>M^J:]F+N' #
MK0G<I8]2%HY_,L87_[2?-$WM95IGVV^?IX3Z&(R(UTVX<WM:W0Z.D6(,IMC+
M\;@GN\XU620(6?(/SK33LHV:LDLJSD11&/7_5GF8&4[^\ZXHL,QA+1>BFEU<
M&V3,6<34"W7L2*(-1B<7/>E;7%2[>U$LD'FP4O6C<T[63>Z=\N7ZX250FR!M
M*YS6/5E60-W0(OF-_LG09%Q58DL>?TEL']%"P%/'3\Y/U;D6E;PJ@Y9-)9O3
M*) 2J6@6%]7\Z19'H@#&#V]N=UL%DO7(O*ZU?]1>ZY"\K"[9/*SH,3[U^VN5
MS,<Z# %U^PR3_5W>Q$9/[R?P[XW//#9=[CDWV=@H%C;"I*9OG,TDB3,;%1?!
M@%EGY@0;ZWNT!BN6R%YG+EE,6>[DMADKP17\!=7%SW,,7]]JTIRFB[N8\0E4
MBU DYHCN?6A;X9#E>2!?''(0R;&E<&W408XE=_O8G_M[==+^??V-X*OMYY_\
M3Y^O4"WO'8;LE MSV";A@8]'?E?(A18:AZ:O"C;S!UUK7VEA4-;XXLXX5K"/
M%<2]="Q1![,37(: C-4CV\#4<[9)?9F]KO:6F?TKZG*H\.\**I?D,^/[Y,FT
MM#9!3.7J.@;EP];#1^%"QO.8PUCM\@/M]6&+SC[H=D3ZAX+OEW<+9//YB[/\
MF!.R3<W[B@>-'QY*/:"D^Q(;=K)4C_1U1=;9(K<H+(L:DK^I%C-WGWCT:%)R
M.[3[+*IIUS8$#:UG#YKYS[-B[]7&9=5$ZC![NG@]L[.WT1^=EOKAH@A^)F)R
MTIIW)( (26,:L*_H-5#_WAC^^_SDB3V%7!IT6<[S<EJ56MVWXAC'[S4[X@81
M&&NM42P8%:])UK%$N>OZU$='+'FS?M-^_EH3K#M" ;E4O0UCAR8\PB3D0UB\
MLX[Z@^PK@DIKJKQFEX.O)=N20Y]=0BIGRPXD.0@@3J</+T^I'^,! 9SRD)M!
MO&J1.6*7TBJG+7<F552=K_=<M&=.C4.$NDJ*+T<B&66NBZ(I6>H&4T+-=6J_
MITVU&Y_'5R9F"+[UR.-77&?M.'^8U=6I<((5AOUT'JV8F@]']!P;"81A#)<,
MY?06J!6.EW1X9QY,SXAQQ&RV:]:P@L-?8?:7:> +YG1"T:Y9)K,J W?G7FG?
M9GWY1/I,/R92H%0D0;1F4]P@" ^T/+7! VCA>=C\2@:.34<9#WSU/R<4++RJ
MRM5:9B \0'TG P\,(/P(M4],WA8>*#<-WPN&0:PRS:=F^^UYG#1NF<]*:S-5
MHWE S6_E#T)..YK@Y5Q9;Y 3F*2>+?H8)H<BW;OS(6Z.+63;YH\F9WF//DEJ
M\>3&7G<WS+"9(=XJ)"*;&"!!ZUM_='?< ='8R2"BUR\B9M</JG;GRZVO-76L
M0'H)6-MMKBKH!HK1GZ+1GI$N0?+U)A >W#11W?T6.GL0-E3;@"AZ<%1;D+MU
MOU8#+G&Q$RAK8^ 609]L<]3\#O(.Y=@V#:)2_F+2DJU.<!ZZ\M)ZT0_N@!!@
MPMD:3YS;T:#L@U)@K;_*M/]13L+/UBNWYSC*YN"2%?Q+?T_!0<I1Q_I3DYF2
M!-BX8X^3\YK)-+@;]G-/7)/>UHR[PB?U%LKA97BE-'F7[GD@,.H':3MC"7*P
MJ!P5;KW:(_GD'9_+$V?L]654"0,RO@B&W&Y;E:BC*#\WKCZ4J)/ZE,[QZ4T)
ME;*&/&;WF6U29<92?W!P?D=&JOX+G,LD>]9'9;8HHADL70T9X.)?\3NDINM>
MR.C^JGV_BY?>;>FQ3_!2K5H_TV.SJH/=F3,INB[RC2=V[-W3IC)#:@73G^V+
M,JYYY43=%!Y)(W660;1"RE&"XT%8L<6:H^US'FK/RDW!Y5#N[#4ROAS0HJ%1
M501:F,F7?^Q(8)=&[7-A)KW9IFO/2XOK[LL]6FGU*][Z>V;[HG+B#:O,WNX-
MK2P>J!EC=8X!E:\Q*A.BW^3)N=_Q/SWHQ/%,8,#-"C0Q_2TQ%?$%="I%]GN2
M<@!I<['R/FWO3-A8?#1*: W&UK(8[M-BP"8X._+:^(G/I\\J]=%U-J<:1,M\
M:0)/&M82/!J7KI[HPB%I[Y48=3_]+>SX=_K7O*+S'[WQ]MA*[O)'JWR-1C\L
MS'12G(TV@RRI<^&!9G^Y(=\[JW6;EH81YQK^&O23BHKHZ[0M<XU9Z1]]OH?N
M8K9A_6<CB0)Y0G@@,%[.N-63NPG&J=,F,Z-3'.QNM9*UU-P750DT35%L@5%;
MFM1[*.NV7NMV&:OZ[:]":2_4\F[:M+7L$J^27/(&_32HT-+IWIO^;NN[C[.2
MW]_$&&,CB3'^7W!]<[>;#Y3FH-OGI:8L+?W4( ;?ZTBT8-&VD4&,U8LSJ_&H
M_@2+0"EIIFU=O2J/>1]_%EX!WJWY.:AF.[4PCAY!@]$?WTU**UFU:WQ]OEE_
MNKHLZQH ?R#R&XJFS!$EL&3]NP5RAT7](D$XU4]@NOSU_)JVUG<I;@N03CMD
M".NZ ,.H@[^#ERR/P3O;I>ZXC)Y#$2P8:KG=ZS[RU>T4K@QKNA[3,+15A"GK
MP%*0B/JZHWKZ&>WO&LM5\5/><D[AFBR<!1M48IQ1GFV2:7>N3AO:??91V[\Q
MRVHMJ_C,:Q</$)6XI'_2"0FO%: N.#0O0,Q ^8+*J75:*Q'T%77L=W:+W*M3
MQ=%Q5\2QL5&TEMNX44NUI5YI'(G:(BOZO*S(*'LZ&?;]&QUIK%?<1!A1I.]:
MXZ?TV) J_JE.OVEJ4S5XT?0Y(9!$PGT-&8_G+F$LB_W2#.^ZS=\RSN,VG3-:
MI-&LZK*;[0@6E--!G30G!28S=0ZWTG)(BCT8+,08\&0O4! [,>VA]5/F\(!D
M,LR[5*YQ73@ND@*Y5V6-'%Y2#C5H,_/[ON5Z.N;Y<';%,,&5,\,&/ ?ZF-<H
M..]7;'X)4[!3Y;3I9'I:5CX0A<QSXW8)BX[*8=ICU'V"6MUG]R>5-X$?FJ/D
M9)>*2ZQ+9K'R(^AU6WLA"89!V1O:+=Y4"V^].KSS4*_7#G^ Z991&JF@[OS-
M@ZGN"++/+ #<^0"$H2CQ)0A<D>!Y(@&AEG<X%VZ:.=TW07)E.9Z#-^DFIM4%
MIV:$,CP9U1)>+!QSQ'PI6=6VJ6PD0W%5I/-#X>U38UF.,C)&)K(JE<7D?%XV
M/_185]X/& PPZLW/NQPBCD[HN_=R3XWW17S-\<!-LQH\8$8H?S8NUVN3]N]D
M"+'@C!B@>" GP/SAX+-EMW$??YJU$'WG T\%;TS@%2P=\A81%4]5N\QZE]T(
M)C'+$ )GJ6?*WGIV>IQ QQ@OOU,7J.FD" HH<4XOUDSR[3]-Q@I:*AAT=\'5
M_"5KEA08WX$#S5F%Y(1N:F5"5'A*XZ)8]-<I$'G72%[ '\U%DFPP-_+585(S
MYFAG3;;N?BWMNK\^U3+#P7:\Q6_O;@O), ^![)4:RQ9O7G3BK'OA-+=&;V"Z
M(59%[=K;RL-99=%]7H^I*VIVW]WS$S&:(W=DPR2TSMU$E01Q#]073/;F<S[O
MC69;)KKOT3ZSWN"SRSAVXC.)$]K%MG7%#4U68 3I%^<I7HWXWD&!6KEH1MMJ
MU9P4)MF,'0X\W64E >>*.CS@T?!=S=@KV>W;X]TPJZBKVH,:9SQGI!6.->8[
MS+##3;*+<T:_=_TX/T)M@WA9J*5B!?MFB ?Z,T$G.WJ"UBW'1HU!N;:!M[^R
MQ \9)VI??^JH71=4W0?1#P%6ZKF1TRT*5$KV]W^H0B^S'2S3BIQQA:*?"12E
MAP!KC3?P0*<TBN7B/:&T'U"'5J860$-U,'R015D0A9WG53.A;I^)#%J'0:_?
M8WKAT=7<9%P5Z,ME68K%-E6U>MT_HTR;!WX.TK$*4'&\HH<W?T'.!4 68;13
M-F/:ZKP5^7%/4@-<8S1Y -DSW8/LV6,/K! UPKTXX8+V]BB6N\"VMK]Y6ZK0
MP2%6[=1A_1TS=$GZH=H]5F+I[4UC.#-6LF!^#N/9:B2?/-^987+Z?4KY)%6T
M*(ZSOSO,9SQ7W_SC;H7L[*6#<94D5L?7ZL$\/7JZ7!0_2=:O=7#:]FFK)3HD
MQQQ9YF@(/16<%,\XD%-^WEB'J5AFA_C)#!E+6;Q]*_2,+(SF>2,MQP(1?-O0
M#&B$46*.LI)_:ZRK.\@L.Y?(O^S7%L3#(,6NH6G1Z\/2@B &OR\4HEZ)ZLTU
MD>Q#QN@]<P.B://D8/R=*.N65(WS-B0TM*7*([X**(P)GDPX"1T(SW>-;N+P
MK^B\XIHE-6+J"$M$Q[9;Y#=#V:>25)7P@!<$EHRKD KW_('<A#-(I*JUFE&/
M^BIEV FO3:MF.WK==.VDRNWR4^;C%#'V;&0/]J>%QE 3-WD'1HQ'7@OI4_;:
MXR.*7;L3S^^-;9PLL8J$Q3>^GA<C]IA+W ]Q=W<Y3X%SK^WO'Y[.(,.M6\Y&
MDEB:JY>'A.?4[EA*/JWL4Z_N@<$B$[YN1\0-8,J41_;\9:&:6N\U:^/;*5UX
M:U0,,\*P6#&B@!'WHQ+]]/*UDT_UT^>C'U=/I'T+"7E15?%?4_WV8CUAUMF^
MVA@?+Y@G:58A;,IX+4V13>C%,]&.@)@'6$@NH:#9;R)@48D-&$:$@$Q#OM"\
M"UDG1&Q9).R"VAN$H[(@#/,7VU]L?[']Q?:_-AOL[V^2K<+H_KBTPD55-734
M</_,':446NY1I2I VAWV;_=6O+, ZRUOYLBB4_.I*;U?=Q+@PKL>FT(]RU(S
M-&(!PP/Z,.SUM%]7.'1^7>%P V/5";$8#Y#S_;I4I?OK4I4I[1^OK/[%]1?7
M7UQ_<?V_RD42!15KKJRB-S'&6#\)A*;(N2A;,'R_)TU"5T/"=52CQ$B$G_P_
M %!+ P04    " ##@&I46/6;3%DI  #J-   %@   &=U,&=J;G5L:&=S=C P
M,# Q,BYJ<&?5>@=4%-FV=C5!@B(B.38("A*5C(0F#%ERS@HB200E(] @(MH*
M2! 4E9RA0:')H04$%"0GR5&BY-0T3?=?S-QW[XSW_7?FOO7>'XIU6'6Z]@G?
MV6?O_>U31?A&F ;.::EIJ@$0" 2X ?X!A#% !2 _=8KL%"DY&1D9!04YY1DZ
MJC.G3Y]A/D]+3<?. N5@9V%CX^01YN6\(,C-QL8G=5GPRE5Q<7$HKXR\M*B<
ML)BXZ$DG$ H*BC.GSS!143&)<K%QB?[;%^$C0$,.88#\((9< (AH(,0T$,(G
M  H $%+(KQ?PMPM"1$Q">HJ,G(+R-"A0?@X@@A 3$Y$0DY*2D(!/@\'G  D-
MZ7FNJTJG: UNDEVX1R<:%IM.SJW\H9'>L'>31\S^_D,*2@9&)F:6BY=X^2[S
MBTM(2DG+7%/Y155-74-3R\C8Q-3,W,+2X9;C;2=G%U<O;Q]?/_^ P/!'$8\C
MGSQ%Q,4GO$Q,>O4Z.2,S*SLG-R^_H+0,55Y1655=T]3\J:6U[?.7]K[^@<&A
MX6\CHS.S<_/?%Q:7EE>VMG=V]_8/,(?8$UP0@!CR']=_BHL&Q$5$0D),0G:"
M"T+D=R) 0T+*=?74>24#LIOW:"^(AI'3*<>F?VBDX!8SW*2WO]]+R< C/G-Q
MZP3:K\C^&K"'_R5D?P?V#URCP!EB"*@\8AH !AQ@^3)"*?]5R<U;&?6-!5*-
M!H3NI/,2:;].E.@>?%+X<B&%N1<UQ8)Y]LERO=[Q;-K0\$;NJ)+W0_/I:#GB
M"#G'ISS)EI6.JX?P5_+T>+OA\<"+[_9R,N]42DKI6X^A)Q(IB/.Q-"UZUK9%
MB:G4[D+%*'G^KF&=Z@$'&TWNYZ%/","E/2"T2M:K]:J9!)RVTV&V,%B2B^S;
M](=$ F"8J*BMSK(9YJE(\G:O&^B9K\2CS."A;I5[A:77$)DWB\Q=XR<;G6!O
M+CZ?5&WZX?@-0\86[<\=&VM]-V*6FL/-P['H4DPF;^0&NY:BTSW_%Q]FE?6^
M]+^K=RV.0%IA?$*X7 ^T.JF*"_KH=(N"4!\YYJ>-1AKN/D579V,1!^4UZ%X"
M$+MLHB2!5-#QM:&_*Y;7 E3Y^TK1Q(?Z.;"K7U^H$HAAQ*PJET7:;IV*R<B)
MX%:[^'C(A6JPM!H08SAD99ZG1.9/N-W#W6ZP.SLR.CZIDZ',H/V%LO'<#M.Z
M._HJEE*BQA;]L.HMJF8;UR=OBIA&E3QAI/%WL*O?8G][Q97E#))^W+?X^GTV
MHFRI^\2W?(IDJ1&6;Z]E/W,=#CF?JM?PCNN<BV72.Y\[=J'63F<@'V6=+6M%
M1-H\ZMQ'; [QK"EE^O)K17ZQ%E^\*&VN%_4V]0'K9(:,^<3<TL50@ZWCR8B\
ME1JU7)?3*V\&EGJ;*)';GWWSYE-?6SUNN^O)/]A5&. ^AZ9<KAP*O%7I9VI&
M)=^GZ/>IG2Z6EN&B<4K:HC1=?#UR&/<&=^W1NY)CG^- =B3]][G6%)F!,5O\
MISYOWTCU^F3>Q!5U.PG:#$X2'&;^ U< F[$H3F/+8/-[R7/N'M12D-1VP):.
M9^ORRR>&RV$H/IYIMC@RUPN'R$6/MIOU[/5PJFX]MS&3>NU+U8]L:IC/$W-.
MMDL+@A#D736S-;CB7*SNW,N_+=T%S _S^A1!MJ0T^OO:O_0M7D^&EZ,LWBDZ
M'IKL-*5DV;^'MJ2(;)$FYN<[CZHE\4;>%+.*2/:SJMYWM.B9N\'N29UK^5HS
MS\;#"2/Y4-)C'6?2K=Q7;B7DH5TY@%JN6Y6-F*)[H[4.50-B/IFT;^M0MT(W
M$3CNS625?9%*N[;YC\/#1.3<K=IRT8& [%E-3M/A<+D' 87^8;M4MHN*M;57
M6)_<]1;(%!=,FRXDCBL2I99W,TV212S#/S[I&#<,=L<0@$;Y4PB^?$&^# 3P
MWUL*5O0"&%X&7'IWQLN.Y^S0EH9G":<1BK85(DT'<:W;#I9JL:4>WM.>HEIF
MP$Z^+M#9?RTXNN:>_=#^RE?FQWVYS&V6V<?56\_P$4+4!("( !PY0L=2F=!+
MACT$8%.$ %085E0J]7U=-NRWW%)_M&<%HUW>3W8:XW:>?<B,6WBJM>>W9 [5
ME2YVFQF*#Y@5H5@93:Q8&;Y6![MIX2!S_$G#X0QUK8=':T;UH(*(S6BGN]0C
M;Q6Z/(.FR9<\-.$/>4B"5=5S)X/,^U!'#TY#3SE?&1U+B^8;VN R]F;[DBR8
M*H$M/%43($L [(9_<?5WQ,$SK98GV=XT^U*[W#*D+0RNN^-O'!9[CK72?6].
M'$IBYYJL%RT^AF)H-FT0LVBWOB+]R^BGRY]9D](7"N!W@^P)0+JV"@'XB,:/
MJ.\OMHI@Z5 PW&D"L)8P,3$VL7>8BZ40L)R 31. 5TG[(?);=^-2F ;K8$XY
M%E>C/"3$T1:_Y&71?F\]I22-YU\JVA58A2/,DM$C%<M16:IN;+7#268\Q>.+
MN4'VU1MKW<_M=B\[PS&,!&",G[@(YS[NBW%H#G4*=>0E &X&0P1@J*#INVFE
MWK;?\>F-:;=C4Q&HA:U:Q9:;%/F^EYC X]'P,XHRP)4E3]?$IVFNJWD65N,X
MD<WRIY6Q9VKRG*VO&(KV9N1L3KZ68W':[V[=P#($R1  .*A&COQ^(\S 9Z:E
M$ 9E>$3*]9AV2^[U\KN)N%.#@_7P\UWE,^Q>G\RPC]&<DH'(\+"T)D?#<UQ?
M;C>V;>B1<(339RJ\+EH)D=G,J95,=L^H**VR:A'C#CA_K9CQL6PU66QR*[X7
MTT\ %#TH"<#4??A6.PP5(DX >EB;T ?CJ;C["2;([W@=&+KDE01\M6MU75).
M9.;82+=TR]O/M\%JA27JZW[F5Z,%[CQ*?SFGGME2X3JN8IU-!I$SR%?X82OG
MGK'71AL4Q#2ULH$/^N#..!<"D"85 =^HAF&^0T=A+/ EJAF[HW4]O(RRI14X
MCXO?7$:M)TLV_*2@B@-ZGVRHC8\4[KA[OW;/20K$E9ZO8NK24_G,5$0EJ[G5
M'2DH@A/*<:Y@O'8G[OI^359EF"G?O+TORGS\JVC@.?EE O"' =3W8UI3L<3^
M9OBC> (0K3\XF)HZNX%%""1YB#1:;0O 0B4LY" SXL'\3:NFO:*W^CT0<D:%
MMT09OGOUA'_^C-PXY9+4NU(2X#7-3MU,0ZY%?&=+T_.'!IYO 'A%QEU\S\+N
M7PUG8K,C-;5W'J$IW)9G8&MWG+F5BP^=I"< #?,$8"[ABTB#1,V,=\GI5J]!
MBQUL=9;!BK=9_''FG!_NT-\+CX7A3'Q3J. ,#>\\@^SHG_NE^*VKOCZ\[L\>
M(+<H#NDS4*4#_LO%UF=V3:'#!%,R(R"OUC6Y/8@486J^=RZ6 N+I^_Y"[BO>
M1PT7G"U]$Q]2B9A'.W\OU;T0K3$@6B.B.L<9%NJ?S?@@8&H3?4A1:_=Y(Z^$
M9;.H.\-_RF"(>>Q'<G2M5XZ-4T:#BG+;UCAZD\M4X=)G[.!\"W-#6UJWJX+I
M3''V2]@N$P'8O7;A,"%H;;L>W1F\Q/-COM9NL7]';UW>%['CP=":J""&']@2
MCA$NF<E!&3]"HD>Y2Q/.6TP*!SX/FF;SSL=IYC=*1$9X!U/N)5T?*B'1\?*0
M9;@"V+RTDV%NE7^L3L?K7>^.&<.32]W>Z+7;;(A,!S'/(4_K;%9&" <IS1Q)
MBW>JZ]UZJ^/Z4.S*&6*>5VVOR'DWG$J0@:2H*>?RQS?(=\XI4-]YWF^9MFIO
MR5=PK?QE:_J-H8KA[6]E[Z?$^4__Z.;2/,J*%AN-9PY$;!. R$J[;_ S/D=Y
M?E=+Z]#>DRU/O^F*ZO'F!J8_R&YTV@R!,C2%X\_S5#S3=]>#HOUXQ(B.M<YI
MC/73V7CTZWW2VM"M=%OWE0]!+'A/T4S8^;?L)B+HRUF,I=H_LA]-/.%\.\?$
MD1KER!M= O^P]ZRRO-(%69Z9/9K7GM]1("#S97U$NBU;H0)?6;G UCZ,+S?#
M1:\7V+GZ!GJ,1(Q/6E2_<Y]AU6:,K0$ A<AO]M5(7K,M1AROW[6SA3[9G222
MEWU+W!QY[AR]*CZ[;"Y,OBNSGYUTMWJ+G^F^[9A2Q8ZY[]'U.I'9/%!K'Y<L
MRQ>Q'H=6 ZRE(79(Y.&[8/I%ESD1&FM_N.U0QC-M#7&WPE>C4M%J;H^>I$#.
M2+)7+5+%?S.-P5V\AJSOCES?X"YE\:WD;V8C1RY\M#B=+FSEMLC$[3HGK\.S
MX9$T5SE)-8HWPTD=17<AIG?AAT(*%PG >_>2'=>-RTC#F\&6:WC-"#HS^KGZ
M\\%FAIN[!. ;?$Q2TD]4T\?M*/Z% W_NG:*"  74JZXAQ$XA^IPS5B0L2 ?V
M>/?5KKN*[I/7/_#M+^H,Z0\M'@8A&Z<?JK.[P3Y9FJ1&R+%F8IYI1]@/WJA"
MN6R08<?2?A3,FJY,K\M=G7ONG5/NNXO3O%^*+ID.1-)W.]?L#6668*);G6?.
M+<>KLEV$G&G,..MW:^_+&J*Y'W<O;PHC^PN:83\_W_7@<9]@8<!5]NZ=*Q/Q
M$;JOF>5;!*8\1-KL2X:'-V5'\WWR1T9L0/*I7?&@[>K'L-.,7-H<X:& W%O*
MQ2"9PM5A!?XA5)3MG,Y+\;TGF9:6FC3W.#_SH)#/;T15[<KD?)NSP#S-<R5;
MJ.Q-8]#GN+<(Z[X,5?H OR92.;6-+VJP]U _AMMT-2!V-'!^L[337K,CG/VD
M[U!%\99/YG<N&5QJ,CFX2;[+51:=*<VZM8HM3WJR^X;=V)Q)PG_^RL4::7]V
M.LDA^T\:Y-U<1KE:;EA<8RW<#C[NDV!&-DU]R%SG10!NWB, &4.U[0SY"LNP
M>FN1PFWWX*Y&53K]*QD(/N#?+VT-6TZ/=SN^"&[@E+(M;=2C-KL?L-VM!I[G
MRS"30%M#1>54T]P8%41[P,?J#K#](+$6'D8SZK,;5P!RQRCLC?U"TT"JO:FG
M-[=.50QUW',G5G%Q<?VZ3![D8?^#KHP-<F!&E$T 'FTT@AY(8@F.N1I) !"9
M>%HT&1@!A],)P'0K%,__"+F-GB, 9R\5.ZA/6T5N+C[U[GCVY)?DQ'2AM:P/
M\4>)/.*WYCU5^.1N9R9]Q#Y/I7[\?-BTSW5GHBT@P+/EH:9(<JD,D_4<,7%T
M<_9= M#D!S(2+,LN#,?43 !:# @ Q50X 5AR.R%I#F#$I]<$:8L0!MXL@.5T
M/3K$P_J/ONR=VF*QUJ@);HCWNHN[7)6B82E\ZCZ1=/S;E/SE#6L<C%JA8T9>
M0+<236S8+]PP0=JOGK#S['SS7:_WZ]S,70)./V.*P>CBH 1 Q19$',X$QQ0(
M'0?>D2K^3F6D.HPS<4Z^7<[QQB'GM<&ZZKNO\?5-^1-E"U%$1(K=DW/<DS73
M1'GZ5X"/1.]A,[*;\&.J0"C^S$T",%MXGV*FIA(Q.VF^\-"8FBWVO:,/-^=#
M:<[HW:;1\;B"J?I=W^>C/N7U+:UJW%7OTI5E<>W1\*W1<NN29W@N9PZRN"%Y
M5XO>]7"F1P:,GZV=8*_2*#FH-KLJLUQ8'L<4C;D@G1Y(?.H4*I^/;NZ4&?F0
M81!*L>@W8](6+C%2QTL67OR]ORN*X7/R'@]<P9P^C.+[G=$BQ4;WQ6%Z%3SC
M01AZL?X 3Y2ZE?G'"ME,Y;A "#IZT2 @;44R12#&IC>QRV;?OOW!@WS+*P7(
M:AL+DU(UC5'%[KQB%=/-M?5G,]7>JZNKZE5#02IL'2*)DTKC)D]>W#HGF@M(
M':@]& "UB*ZC(@#R&^A-.@(0I>JSU3VSMH9*'(:[5#U4*I]-[ A\O\NYZ6*%
M/<P]C$"7O$R:=G,113\*TL#:K%I.LCZ3$>%M>**S\$OL')&1>.D'H_C*!78,
MT@-B]=6;6<(M:\RO2'=XFTC&!+[G&O*$SHPQ!W<+XY"IUKOL&V4??;_#+9<\
M'.I958C^XSPDCH,/"(!([5=3 @!KQD,WMB6%ZECS5*;1M$L+#QR\"JUM.DZ?
M<D=<[)IH8\9.0UN+7#GHZFO[<=QWXZT*G8?U=3RU)9EX'#5T963DMZS;<.)2
M#\OPA29@'/ !E;_BB-F;4=?O<$"6QKY0?<4)LIJ!N/(&NT/A9M<#="I>I[KV
M4N3L:6JH:PAGO_MN1^V#,8T;V^L>M\)ZTF5@@KKD,OO%#8/%'*.2M0B^8DK\
MUH47GPN"B>D-U1M( W)Q(O#3\!Z8-3@8UV]&<WJJ:6J7>ABV20[?,AY"-*]Z
M#0C(&@6[2D7M%@8KS'C^$FNCN_EVGVL0NCV&&:)^U,"]A!<;X"WM1Y8S93T6
MD8@:()+@YO2\'[!0@P7F[#>UIQIG97SRYZ0"=[7/%+K'L]$4O#0Q]#1_'E\5
MEJJD#XLHG[#2Z4/IN.S.Y'S3IHO3\^!&)=F:C;-20J"<M(_OOF1 ;SUKLF4=
M6O>.4G[PP>^.\F?N2D$()P=:64#J]ULNW7EW&R>);]B2\"E)G4/O';!S]92_
M R-/_?J+?:I3Q339;KF>0]O\=\8+"GX)?>YI<<VGV/"@V>^:7F00]XQFR;1V
MSH"CX\MPE# 0^]@7Y5Z[0 (T+[!Q\,,Q=I.G"$#*P12&$MY:.(GSP/CD6Y8C
ML7H^H-L)O/S#+QT;WB+@<A#"2K6*P5\J?E=(36;C%A@\:CE^'-UVI/9@[!Z?
MTUUCGH9;<5?MZ6XDR9U]6"-"NNRUG$)?H?U>8>*^Y?I2S.'J9>&IQ'L8L].Y
M.!<,N!N/4W4JX]K9%CLJ^C^YI69,&_>%](10J$'@J*RY@K&S,$FZ TLPY1M*
M]426[!W['77J890DN#935ILR9GNFKG<UZ71^I^IG7*V4EZ\96BB<&2LD #08
M)X-H<U/VR]DN+Y^.CV6.2FZMKB+F,S&',S)&0;Z6_?E+ICTT8 )HA)YY@+'"
MAV$7\1!J/']TY:D2#%[VS373I[,>U*N3G#5E97TB0N7:4ZCT-_IQ9$JH,^<X
M[XT-U=X2-- .+8EY=?DSV;>MY!UJC"V> 4Q-0JH)0"B84R)*]-.=X]:PU,@F
M!%\:T;]=%C9$)%9+Z&U< FT6WKB0EK^L;Y88C._JZJOK"*LP!B#G?@0FQ_](
MN0(.N0!ZX(<NZ$/^T&N4<WOHB :J+8X/"LA"YRGGAE2/UR*C.3ICQGPSUI"/
MQ&&6T%M;D<=DXC <K0X!^&(<'-\*W64[B1LZ4F#NI$\&(P"4VC.+QZ>G#F7!
M6-S&1P B+F[NX",V<.^J0(M\V?-3$X-]/29XCQ<(N5%\"O=2D8T X"Z+1*;N
MBL#GU]H( %LFGBZIN1O+B-[V!6-@M)G2'QNHC\B!GE^I$PQ;)/WP;1, 9 &;
M60T<\)YZ A!?"<7=C\$8VE'#EFS!^8[%X&5LR'YJ\1,D2#<8(>,P 01 ^0"O
M.PXFI.N"@NZ[G==&F[I@PD-#%Q_3C>L.Z!,]3]$%V-V@/ZUA3*E_,SX\&8JG
MR"$ \P7 $K^,^\RK<,&K7Z+?#+"90O]D[$IV9)U>@_0%M3UC8*"\^_A?KQ4[
M*?W_3R*L>B[NW$D/_"UB##]32/!?: VC4<Y; C[2A_V)2KWIS&#_#XD('X3P
M]$L@&4X?JVC5EJ-K'SB9BQ]R^7PZW\YT]5V;>6BK[+"!(BG=OU?8CG-Q"?).
M^$93*%9RO7*5J!^OQ5%& &X44A^S^EGM_BU;O@@(_=K 4!^BK:GZ]PI1[W]4
MF+,R0AD06I:_'>C]HQ)W<L,'<<[*3CL+_P3;9MM,/8ZX10#Z! J6W%*VJ'&1
M<KP@?[: [2)6:E@ OF+7(\M!(_/:LC)MF##5VZ^LO/?#OQV[BJP%PX^2G;[S
M8H8%6AHEBW:WKR6>S=2<<%OP,383."XI(0!>UW%9!( %5KY' -9=4A-2Y]2'
M9D:.F[%OCTKJ5O**S8[L[/ +KP\U\>)PMU4",-X/NPQKC4$VEQV%KWBM-^P4
M9%0=E9QS2TSLEHM=;C%CIBQ)T95W(\8S!&_@L&,$8 I<EI:A^U_Y6D;-CJ*X
MDTR3Z]P/4E)5 R)Q@D=3AWN5! #M1 ">9?ZQ11^^+WWQ@/XXZ<GV4;=>1EWS
M'Q_W@A%=X0 ?[$X -D9 .K'TJSC9OBUWQX:\ @+TT!8'Z)U5#P(0 GH(1LM
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MT2Z")[N>H: @HZ#]91?2,^^_.A"@/'_)BTHHHXEFX4I$SQ>*3BR;4E#7C<'
MKW5$8NDV@?F"46"9Z?@OT_[!LG^;86'_+LO^'\/^9A<"@(V,]'3QD D TH#+
M&];"$,S_P?\_P,'2EU5E=\,XK?F)>9E^:/QG\+!TI/L#\;%0D7]51U3YC_K!
M3IY/;+_X9V%4<*=JG6NQ7)VC=!8YN#%#8V'+(^#%[HF=40#0J=*)V;+<P)J5
M6OVD>M0GP"[EC1\/UP%RR)B3;'CX%=(U!;7NV$CZGIB/DG)6^1K(W[SBSX1!
M$/,QYM8+]ITPE2]*!"^W![4"(]V/>9*<@?TK)HP646LQ$2C)I=)?2M@KQ!GG
MPS)PM:,;TM*T$8?N[84MZIA7A:M:+9EJ,"L,7S+&5V3S25^3^O3U]<G9N*VM
MS"*VQD'^D21:A[K0/0.F^37\NJV:)=J1$I4V>V#G!'6?*BK_!D=8\PVTE0&D
MU]' 7%@8M8'U^><G=:IR7"SYY>AM595=)2M?AM;0U>3#[T/HYA7[<K_=1NLD
M2=0"C=4:(YFR;N894@]X/UETYD$^D!<VQ]J$O04)K9M2TCT(F+YR >G;!9(H
M;QI /ZZ?U#B#5U);!4((KG0_V\:M,&5@:!G,%C$\PUMA594,[5$R!6.P5NI3
M#&3;"Z>Z!CL3YTX5 Y)K2U29UJLUJB=->E*DY[U<B.]QJ(:"?OG9MTB24(X3
MNUR/LW.^MO5_A94,%M[W6OQPJXZ@/Y'>K#EN.MV6FY"HK1,DT=GQXI#0H!R2
M^!-EI?[*)G0[3J5#;>!'J+<O-J<?F@O&'>N&'+N[$YQK0M-XKML;/V/!;CWA
MS&[FU3T[E]('(-\Z<-. F3<75/?C35+Q14$;1ZQ<BUL'EHX>2U3_',6;QJ+R
M7J\W&:=:ICM5H=W.OVI'*[>/7M>/!CK5B?:T_#4Q#6GI-:.YS*6KU(%8:3HN
MZC@_.00(B^N:%.11: ?R#NJ*Q+_I:H+ZEI!T;&W]L>2T4_6@A09_#L%3-B()
MU^$X9Q7<A_N<&I+S/S78MJQ=^,]*?L9=N'> 6RSC:AT#[?T),N ;;)\\K5U<
MS\]J/"7,P"NET'BC>'R1YE/I/^,FJ[4DW*ZJ++!6'[]TT32]D;V=\AKGOIZ;
M#4I1@3&SA4D^)<[3CX0> WA!CX!<I^P8,)RXN3G6V@7P-!?Y%JK*^S4]Z<P%
MY"S^BVIPEL(*:G,UXZ[OV;NNKCF^0>]_!4IU3CDH644)@?1UY-;JJ9"NH*US
MT1A<\-6M2GQ'/].?/62>6/:,+$AZFJEGYU5GS'G=K,K<DWI/J^[+2SEB#:2_
M"ZY^8^/Q>^OM+9$%QF3Q?#DO7Z)-9Q64.N3Q3>TG]N=\:K>((]3C'5\]KY9L
M[:C^=;5^DB9ZO>IL?H56,&%XXB@6F#=3R[-?E(/4\2Z<[IY]C;_7%3^#7$MQ
MMJCHR0TY'&NBB2(*:^ 1:;JB@D Q5HG+SD8"I]FN,;+Q,GB^:_D?(]E4$]->
M8B>^A . <QF8:K3Y/N?VA5VEJP/BXUX\SGU5?0Y[]8B2]#MHS3D'!W9@S0&9
ML >A",H#L3N'B63.X2A014<'?P$Q9YP=XV0)PN>SUG^N )L6+;OJ< IXXVDE
M;M1O_^*0VYF?\MMKJM3PK$R1TM0=DU?GS,4KG=2_*N/DWH^0*[++RZ"%:\Z9
M=#L29*S8K21XVI.QWCO,UH%4V^B-V)\"DT608D-[U >S BI":<S/\\;5#V_4
M\3\G+ABZMM$TEW@(8[!\B+6K]+IIS/5T>=_4V92A>8=!QUS6W!(&)^+JF^@G
MV_G5K; K-U6#2Z@VYJ BIY%L,FEC.EQA1/ (,$T+-LK:U?S^76-:7Z.'\N Z
M"34HK\&=PVSUR26K#PP+JXS,_RQ6.*J4VR+79BRM[JJVP?8^8L:W-5M\V*+^
MP7)4N#--RMC2 JQPBJO"+;%PITO"FO4U;<$$51%=(2MY5VY?<!(>G* ;G.F[
MX*TK\$$&]S:#C!V,"XO"?)PL";O952@]/-[+W,G)(M+C9$\%UYMC<:GONB.E
MHA?BBYG(A1U?E%=.. AI(R _]5TDL"Z+<85J81>%4,WO73@73X.:O6QO0B,V
M18X  <'Q CJD^HV-O+'<-?2AZF\8(L>82NY+;D@;6N(\J0.:T&B-N&O?KV7R
M"#9P:FI0CFJ<O&R)D'C#Q_.9+QQVH^.5E9MXRX<PD^'G62!H9M3T_.:F/%WG
M%+<.D7YQ']^7@0B0_[.?;Y>A]0AP <ELBI -^FU;Y''$]'U2!@WX\;UZ'TR@
MS)]0:Z6<QJX=EY:1 (ICK>3]SPMJQ1\P2SZ'?+5.182\B%O*[S,ZC/$D!S:0
M& !7=SF00))*DOQ;HN6;\';UY:K/:I5:.X@W"2&O EU>H]""+?97.W+;\L)&
M*P,D1K,AYY*H<1OMZC5C-LLS@CAB<JC>IM4ZM&EA?A0#0/U^>.L[O_IAH& 5
MJUL;ZFNIKT@WVNEV_1!@3$EHA1:FOO(!XE)\AX-6>7H9)B&%**K-8- [U9?$
M3'(UB<I<E=0]=]0.&+[@B!5:'45&%EFZI=+VM,PR[5='-@JXN)6&1Q=-:,R;
M#-K:"_YL.5F1W0]-#>$W(1E,@/AZ.LI0T5HWY$Y;MMKDJEB)2D_F[,ASL< 2
MI A+_)L_)K\IC+.NET/YH%2LN$IM. .0)C*B&C9_*Q57XEJU#2_DESQOMY1)
MFZ>[CBZ_N*R2M4N@\4G'-O;VS8Z:\]N<3)]0(U3>QRNL&*ZRG^#\> G?^9XC
M'] ==:.3J0_/8*4YV& E/N,3(;_1_!D]+/D7%X/MR_^8AP&Y"_*?? <E&>Q^
M,QZ/FUV#,.B]L'_Y*90_<T.B$>_-@.2.C<C ](ZIA*0R:"T.MF-77M 2ML(C
M1%X$DCXL>B;-JZMM/%F</Z0J/U7"@O2V*'5;UT,V8GZOD>=)*+ FW:A*\7S;
MX35\E;KARW32BTW#;X2OUI@%K.MLBP[JU_N2\]QK4$,=S,1EM*==<L#&XG_&
MK:FS.=6P:P@G/P2OIIWI?4+61T*Q=L,1@,Y$DS-YA<6QEBIJRA$#_DX@_?#9
M.!$'?^A5\7WK4H#'3]2S=GF#_>"IT&<4F=@5R^FIRK<B*OM\H2XOV^=>/[FG
MD5."USUX167WWFDB()IEY W=Q]/!-S.8D)HKL1$@LV:IH0+US,M4G,2Y$U&1
M;1,U$BJ3??B#;8=:)TU:@5+;'T,$_+*)9_>&TXQILI!@A&" ,>J=M9OX+<5:
MX52[S#)&82.,Z%?]5D&2#/(M>'8KF!T>M]CO9803AAB(EVQ< Z':./.*(/Q6
MDQ1,IK!&:8E]2A7I.AOB)A>$AC\"D1=10*JZ*J?N,@+#O4QDK9XVY-K3-550
M6/P M 1>5_P3%U@<:>J^97S':Y8\&[<AH;"L6;$M] WQRG#O-Z/Q#=\2-M$5
MYDC<[<#%Q<I/^YV](KLO:2_N+JU.*[4\UCG /VW15^QD9)5$Y@W; D8N9AX!
MD64LZ="?P*=W-0$/D,4YE35C%2'^]8*/@:B.64>U4;90EDQ-F(GDWH\$Y-R6
M)Z68:OJF<)B2 ;OJ&?I%90F&?&[K9ZO*'D_+PH-"4)<_C6;1O'TFT?S\KE>F
M=[WRG*^R(DW'H&#]4@F+#JRZCS_XP\\$7683UQQ X%&PLF=Z=$P F[<K=2)H
MT4CY#PJM6NX)CO/V=!Y]UL*)_Y@4ZXS"0R+FM^?9><7Y929Z D4?LHW-"[8L
M=]GD31)%VHP7[C+?1+2TMAYU;%05SXY0L$7]_K,NLT9;@\M1^3":K'SEZTZ1
M;L\4/I8RG=NW>O:LXL\5W\:N,HP)!L-17FZ25T%N2/)+$I4N426F*,D/%:24
M5,/C["4G$#K_6+'?+<EN12Y/N&$J\ AX":]2*V./2(<5!1\"*]E\S'O@1@,Q
MT_K)'$/]10FH/Q+PU/NFG+$=O"F<4FKDD]13:*[N2;[K2X^>E-KQ767,OF51
MB;6%?/F,RS<A+*O <!.W>'08R=0XX5P DU(ZU'<$N&FX)P^R"*R^V!\"EVWI
MT1=&-^@69[GIF5:?0PM4>J2HH.>FS"KSL@RN M]?C8J2(6_Y;60OP3,&^[+R
M0" BS.C9O'YCP(-\HA /L8\#V\?W4- .L]O0TAKR[G19'5@=R\?O5!UTJ-EE
M0SI-M^R>VR(J.NCFJHN^2Z/KR/6NCB004>.NJCQ7>7DG9K!6G=&K N,&WJF6
MJ3*"A(FLCW?\$L)W.!P'L.SR"*!ZW9>(6(6,/[_DH2H5M"0.0GBEIEM'(S]=
MN%$E_9)<<(PZCDJ@/MR+:HGI!TO!PDX^C)OL>*LW.FY22G(\/?.J3$8TD[G*
MH/K.X7E@5XJCV2, Y/\(<#IZ! A61S\=J'69WU>]$Z+AG/)PWOOS59%KZ36J
M"X5IEZ??O>B27I&=7^Q50*M!2. WJFO_Z0<_I]T<C\NJW(VU2;\BUA/-!+J-
M[(O8K1N2.Y;E6>')?4A\*F,3W75*[B Z:0CO8HE[J^E!KG>YF=FN5Y-^[<L1
M3I5/+>-F"M](MO*HON?U]L(;,S7WTHFC3<(30'[)8#?XS8>N95/YM>U&1W];
MWB7;'*_#3_)!:6I4-6+VVZZ3?16_*MVF2QLG;UF@YY1+C3X!2KXDU?H$VR<%
M-H8Z">\3;!=!'#7':'?QK<GW_ETG@L9O6Z>=#I@"M48XC .[VG2E>44/AQ_2
M_?6;0(?R'4V1WBJ<G#'\"2 1L Y0KN1/CD%<^TP)FR$0_@B(';SR?E!:J#C+
M?@2\)M'O"2*OAS?$.CF;Z;./$2M3/I.ZIHT%@TG?PK@DR(/+Q@$J%1'91'XY
MZZ^IPN-:EN[Y#I4G*!8N>-BU^87FNYOI_&@=QK3;,_EN64P_*D>PM[I-C19M
M606(IO3L"/7'OK5^+XDQ)#VDK[F"=TWJ27MS&;SF2-2=Q5U0/%XNN/?L)9MI
MOEBCB_'OVVF9JMEA[R*SV9ZVDHP7;\D'E*AT^Z4M;#N23$R6CMLG_$R#HO&6
M#G$0#G <WP#K5.L\$T6RD.9-Z2^5_.9&9E>M%X%F6-E5/E] (@7D [BHOE2>
M=X[U1UY?O$OLP,[^I.EL7[*=EN;>/XUWL&U2,!>OSWVG5:YU_HV+DL_IT/ P
MBNWT)SE;=J\$@7/QHECM/ETU\V7XHONVN_!;7IX$Z"T??(=::EE9PJV"C%+-
M/X__4'.P8'M_]5J@"..6# VC_1'@+NF>!X%O"R_0=\"(%^TGC PCQ5NN8_<7
M;_2$FDIV]<RXQ'YE?N1&#@V%(3?9HUA3J&&PMIF:?WN#/V^H\$6NV7BELX/[
M]M/5#8*# X<9\7R66&Y*7_3'CZ+!V_8Q6BL2(#B*6N;:MRJ/^6GXSBJ30Q"]
MUM?OMFHJB3])JJJL[.-I3#%"<7*>R:#3J^?*+[;M!":*=C=QB16ZG!>0*F2I
MJ/D_!2LKG]J>"S&A>&?WCY/D?:'4?^J[Z')6FY078;C9WLNJ0H%.*V^3K=WP
MH[]0.JMKPZM]!M^U3WGH-'V/'TM[5ZWO8O8J4+W#9O>!"L83(%JB@&)1P[F*
MQ2@>+8&]6C? -L(M<5>EBKT-URU00?SZ=6B\TS6TX;G=(,JU%$@SLH&0"[)V
MD?TV:*FTT:'6(Y^IUICRRW!%CP7VB2-JJKI=?85+2F0=:ADF@LZ!_[YZDVR<
M)03M6G!NIN]H^V)"\=4V817V&1UF*T89-\*7(#G'1IF@ ^$,7EPP*(SC^'HB
M&\?Z]=G? >PNPN"AIO)'P#3J@V[BT>6#W+#T[G(7"'X! 7)MQ/H"GQUD*'[1
M=$_(T5./]/ ?Q<,=M_'+>_>];0D5)T0'^\@1-1_B-"^MW9FS?"XJT^&;,CX4
M0.UT^IKKX'"#\2"=;U!JD"Y(I(H6C\G*L?)-\[6#;AI-7]3X"0E-LLT*$&7.
MP&B[3FE32*Z7H,'KESMT!EX6(2#Y1E$L:Z&/=(R=X?V/Z($#GVV89[4%Z<_<
M5JD,\6/^L *1TT5'_^G.CE:JQ7 /+""P1G577 95J*]:WK#M(=U;0X72F5H!
M%YR\=_55-T1I)(0463K)T;9;C.LAF7JK,WR$CV_O>JH^X89HUX#T:&[19^7:
MHR%J_V)%KB71D)0,Q7W+56DP Q^JK0[<=]65//3D$IP UC/^KA:X?010FHS9
MHMY++5ZF?!O"["4;7,WC$!JYZ;DU[NB @VMJA6GGBU4^M5^N>5!S?)T\'U-0
MAB]-0"BQ%/4LA>Z_/%N5Q*,BR$KT +OWBO6/#60Z-&6DYK?EO?[UFD%TZ+QD
MM!CXO>-L=TO:#E9<?.YJTGFQ6]/Q1[N7M^@*= )?6%@7J"K/-1+52<#VOE<P
M.T=-+MB^#.+K@FY$0!K$+YA/>*, [CG35H4+CI>923?I"7H9!5)R:!M<*8?;
M^<J;S@)C_HK'NO"B4B.N'I,7='GRE"#T(0;4BFZF%U/P#NS5F+1*G62^>%=S
MQ]I:]_8XQBCB.-X(.<RBW[CIFV:<[4FK P1&"]63AL:1/S42,H:&?]Q%3W80
MSHT "_E#F%F%0W\+B=X[IA[31%;@N%&[*^J"K)$#K)_X=UQ2ADIO)@*A=^!B
M<QK!(>4-SLW/K]UQ]R9$*-3,F-H)D6;,FF 0_%XZG4V%65-TK*B8-_D\8*D+
MKAJF$'P16PK/GVSZ>"Y-O&#V&F3/:RS3[OMK,[=EDUSZ-\S[AKE .@GLR;J$
M.O'L(-7O.,3?5C"SOE6E3-BJQ5+4P7^,N?!AZE[PE81*L;&/MSZ4"=HTV+SY
MO'XD97S7*$B871#,L%_\"+!U^AGBL2,<]+DJCW?"$T?O4-V?%26> +CI5\.G
M4'%1O4B&P2UA6-9K_7;: G!BK:'AIBZZ6NI^5L*XDM6D^;N\LE4KK68R_;;6
M;*&$HXV+0><X,KTQ'5/)843B^(6N_]JM:]S,M'[/16NO4GGUI?Z[RL)YC)<
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ME:F\J_?M.XRSFMNI*&GG^@NPT.IGI/S&X&\---8%)%B+]%&^3QINUZ[EZB.
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MI1O]>MYU?P$,@-6<#0/XEI=U003ZI%.CE1MHD38I8=<B!.Q>00M!?C"BIS&
M'=DCA@M7J!WK(4,Y!@"+Q ".[YI7XTF=BB^J)*&]=J_)2,PM=FQY&\?//<T+
MG19TS[DSZ;%7-8"AHXTW>'*:O^T3^?Y1*2S9P@ .;_SN2?H C^^8ZUGPM0,[
M(K[L6;/B-SUVWT3S#C*<9*&Q\>G40%^7W#M:YS&S$GS:HDJ%42WBE[_#&]NX
MN;'QG^;*':/Q/9 %OJL$I<6%,Z<]R)H;8A+-BP%D_\>[FQPK\JNTY4,T0W X
MBG=()E:"I].3HGOS01(V'WJXSFF)[.4L]MZ<!/R53/^]/[TA#@EC?>@?IQOW
MCV[$NW]I:@#I$4<_&Y(36RGR'6\\XXFYT?06S=/)V?:*Z8%P&4O'V+P7T:SO
M.*+&J\H\@32#I1L,Z)B7S&-5=OP@/5HQAP$D4)@>L$ 9+[L>/;G?<T"9OGSI
M]'Q8:.3UX7CK[3#=@$G+#JZ]MCU">Z$[<Z\EW:KT^'G,-'FCA4N.<:&O,V\/
MR4OQ#[^>,H G__AB]?K#C: -4N('OI_$_ZV9$9Q5!L15. RQO:1[?6M,MNZ/
MRM]3V  80F->>LE@@7N,I1D5_'S-_\O:FB4'!N!G'GMT!#SSVHI/C>:!52J^
M^:\_8+(6 XAD(6$1^E8Q@3=H[<SUW-PVZIY*T,:/S['Q;]W9_(8(3'<YU#PO
MBPDEGJJ/.7CTLR.?5? [0"UOJYDY.P>HNI+O^[6HW2/,?\14U"(;-H"# 2!2
MAKSEU&OW,8#0XZ9[.[EV.VR4=;%)>0G*#\0%$4AG*;X.*!1>LEHY[D%.;R_K
MD#]>J1#VPW"'2<^(/0T75RM3TZ#':0]4A?RHA $0.L4ZG'!76I!.VCGXB)/:
M>EF--+QWR.L5O;D<Y!+_,1]YL1LQ<O$+ UA$JV$ ;24]@NX.RO02/AZ0"GO1
MZ?SC)(([/$1*^C>%I2P1;,B7SS.I1X2. RCYX7B%/I'KKS;'YQYJ900].AD
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MQL;/$!W"4)H2\Q>D]D 4%0:P;++P[6.LCI =?5[6&>B<_I4+U>MG*RY.:QC
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M#ZL()E=K3)205SUT5B= E33O8P A_)!%JF@D:.1N_'62:NH#ZCS3RA?A]/2
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MMI&W>CNW7%A;&W5!]MRBQMW!D9M-(-4QCO$J$X7'//="Y+ZFJD9[3&V1OU(
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M!3B9OP"<_WQ;4?\'E\$P]*<.%2M&.[%2)$54IQU2:G@8#.8KG7>1C5#W8S*
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M#DR37*0_@5+JMQ,KJ%&RO6A22W05/[R933 CL ;!D#&U&(/]WYX#3G@*2M]
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M#CPBBSE<UN-#$6SG^SH4;^L#9S%?7I#F6J\UT:[]5B.@5W63I^55**&H=,+
M?EXSB:5(8GQ'_TW0JTW*HAQ+,^PWZ<I3J=X?CDN51QJ%LBSY6"9T@_H*R_>V
M8($YU(D;J!M7'KL&]-\(8[D/698'>'4=E"1??YF6'A#2G&]DVU2-ZN,7Q>>U
M&G8>:K!#KG]G3,)PY4C*C?Z?$(?+[&]3#+"-:%+ 39 '7K=TT;L7(2)@N#O6
M#[&^ J<?(X%C$0B3C:!\N(S<14CGC!JY\">:O&%X?C5"YP*X_CL5E-]^J:!T
M^C,5E)2XV]/"UZFHXG&";!8M39E-_35BN@>?'H(>)WIXB;L5VQ O?7Z;_>E5
M@-S9H#HV(NN(=AK1X\W1N4BHQX;@R?5WU)^OBY0Z6)RBT0E<L:Z#4Z00A',G
M&1$:3.GW :(WM!Q8A\F'/@ZP)X]ZJ70F:B*U]S6&BVU8FFJB14N8FVLGQ^23
M.2TC/5N?7G.=]VG=?>+*8A#S>%3H,C8XTRJJE>+UN[-;/,%QMR5KOG^PI1[
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M/F:?A"XB;QC]$.S]0C1U?F (K9B-H<<)X=[_JN2)WU__0WSYJW/4GIJ#\XB
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M=IW^7G6)Z]GQUG[>>KU7Y^%<T %R>WO1TM2!')YF"@W?CFV1,'@S_TK5ZZ"
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MRP*RVLM:(.9+WIMDX8KN@#6+OZ"5V^^N$I,NM-B()VXV:(,VB\I!7A(M6US
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M?)4N%I)^92F$L__(_'_^G_]+L%Y._0M02P,$%     @ PX!J5&HE+;B(M0
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MX3E]N6=X;P>10\R15HYZKZ(7PCU_?I"W";L[#1_]>J4[=@PY0V/VNT#"LUW
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M^4QR[X\Z*8E0I4!9I5':\JI:%<HN,)Y84%W(H PV[Z$.%\=(IGXO(<QJ4:I
M^J7PLM;DNCD#"[Y"'#95$^@>T;)JX9G>U<X?DS:%%6417ALN[?YUDDM?0#9#
M63HQ_<DUD6=>6%M0[$TYTQ)GQT%-B9B]1+W.)-C)*JQSM$W<^:B*GV?A@:S4
M6%JU3W9-1,OB(SJ]U?-(<NK;CMB%$>*CM2C0XQ:R^CC[[Y+VN<\FU&6_@2WY
M?\Q#=4]]!16G:&#7$8STS0X[X#RG=$#2N!K55;N[SW(O1W]^.RZ^AT%?&]Z$
M*7<6VY[G)@19=[E^+"_QKV6(&+\GXO^6F;\IE$"X-OTXBY&P6 EKWL#L>/S9
MV-S2IGV7!ZI6A-%Z(TS]D'5C (:8'1RZ1.3XKGF72I--V%'Q3I=,9#OM^0J2
M/GBB$BH'JU.?)?T6P4YIG"TIU%D[20<-:]8W6Z3M4YY)$1$+HFN+P6P/6)PE
MJ2+'^AJAIJ47/D89FJ6]3^.3M2%(5^F*1?C!<98HW)G*P";E'513\*;7Q/S9
M:U(Y3#T38YXE*@YT>)@$*>EO2)87IBR[*#^6U_5PBPM>A)X3%*% \Q07Q&/Q
M8UF_>/L#(@!!NR&-<$YW;,6K)UL7-ZJU2>#5;]X=EEZG*P$@'&/HM6L;\(,!
M%^3D2(9K'"JN,ZI-+:#)9NC=W[GIIBI@#RFYY@_?QK='@=+C/W,R[Q4>]?"N
M(@]DF49':>*-)V6&Y:1(L65  O042#Q&9J2[?=_5PUD4"!'/_WMBX,_)#7&F
MD,.M(LB\[RD*%#2  MV+B46!!&O6D'>M(&<]_YBX\.M.BE\;_>LTB5]VCO30
M-Q-[E-K86)F>E"?//%H)V>PT=\!<\0I[+DJ-&]S>)Z(1W0=H_@Z14<@VOAX*
ME&&YCI[Z'TTH)5$;N^+0[]$KW)R4KI7PC)\]665GR*D?Y0\1>M=56GWFG*O=
M9FXDY+-K:<@MH>?JZ"#X\Y-97Y!"9Y]([8BF^(]ZF+\R%9=<P?T83"Y20SK&
MR)WXQ2/S8)6VEE<B$*N%QX_,GG6*E@QU.Q*95!9DZZ:U$[6]CZ<J^"$E:CNB
MYTOOI$#X3")=V.>M7'Y&/]I@RDT.7\?*E?&D4&_Q^H.9X^C0!IXTOI=F+Z*-
M(IK0 O9A)]+6F*^!<"-@W5X65]9H?]3J43KSY!/I)^\R;6"I5/L=&5G70F1^
M5BZS<-\U65$;09):KRF-BC*XMH> S.9$TO-ARTH1QTJ2"2IU(BHJ[^!<:Q?[
MHD"%$2L&2P)Z",ZFAM?C::/RB!DETI2H\XBT/J*-$'$!TW)]Q6J9WX<1;/;-
MN%11H(='\++UL4G+GI>75I.S=P[9&+-M5B2N6>;(Q-AZ^3!%_O]._AFY#5#5
M7W>EUZM^A03BB,QV"MYS"3K(0(&2@6=S"_B4#YV1$_2*"3B_+!W%/()BHD#M
MY< 1=$!#3L)&Z^C_XJ2A5I0WQ'&FNQK*QHG$/+XFNN',L11^9S'HS</N79Q%
M @_+(5/TBYM6VCJ,GVN)+1!LC?U9!WC2[X%\S/^QS0WZA\UE^>_9W (S@A[G
M[!F-C',P.S,A9#?B;H]Z_NF86&>C:QI8H,,?ZRMXF#W"H,3K-2TBBSK>-)@S
MV0\KVZG[S%&\?&#OBAXJ[FJ$V;"B/LX^\$[)@*7F*I/4L:W.THE$%O:CW\A\
M2[>XR]%98+R\7?!-^XH7J4WB)YOI^$Y=_\[3$O4<;WZUL4>4SE0$-D9*:[>0
MIT'S2.4A)T<=O^9X?I<H@DJ5W-V.Y9F7WP.4HGDP)4B]6\UV9Y9/:3J>XQ?3
MU-DSAOH=DU0Q^G3_F)+80"/"?9BY0VG?X[QIKI(&#O4K*R20Q9J<G1)_&O"L
MWKT[),..^]SC3:>,\!I5D&K:5NRAJ<N=-(@51@I'>6UGN.UAM,+KQ2H2(;PY
MC2EITIH5WT)K>Y+GY0<?@I4'%6I'.;0B/ZOM4H>'F(HO7L)9X'Y[5Z$RZ0$O
M0/+J\:-)!J[F:[K3.L(/2LI\=J"K%3_;G@=95I,Z;FAQ1NL5:#O1S)XP[W3E
M[AT_<CQ1&J%6'^Q??L80\>X[-V:SU:8TQ=CQM1W.U@6R)CE.U+8>#S:4[7LR
MV&//;<GX$<L>G*<MR=]?+/=Z>O?JD1=G,9G[INGQC!B)O[[LO2VV=![E&!Z+
MQBJ,O0=#WMYC83BYCU]1[9]>^?&KHT!Z2BC0(+W&.GWLOD]SI8M?@'%\I^L+
M$N7W#3QO-@+Y]#K$C-:@MXZ/%VL"0/2>"$"<I0&A!W!"?WSMYKR;%1";N9"M
M&<@1#92*'P6R\\@]8NT[#8WDR:=+KV>X>%V8<A/U7?^(>N+B F,@Z%DG_PSZ
M.T7?GUSV""&8N]OPKH@NA-J/@$9P8<&WK;^8LD&8\HT<G;L"KB"B<:AQ?A]
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M 5[87QORT0*$$0<@C'0? <+H3=Y(#Q521$7H&$&!_$*O(=02FO\LY^<UCBJ
MBD<&2UZP3W4AL$_UYE_A*W-]1P+?4W:NX'+ L559$_KZ7P=+B?=@P"4IU>%;
M"_ C?*@!%0KDJA-T>"ATZK@9$A- !RT5M,@!B+*=X!)9MPPTD;Y)(4!O4@A[
M%Z< L MSK. #P7*EYD)^(K\O-0Q8Z?.E_Y(S;/_G<@:PX7 BGN_,QBWIQV,7
M\#_A]6YXL%F1<)+@I'557"IX-"[QLU7&B1M_V(ESEA[\;/%Y7<S!LH[T2?5*
MD)B&^YS@8^N,?A?]ZKF'IAWY3A7F#YZTJ%00ISDQ[3(P,<)F=L@Q)>"LR9__
M0*,"V17%-JJ,CL8K(43<3H<"J^O'K#=^P"[K(;$_,#YC?.!A%U] PN /4"!0
M# KD"+Q]* Q>*&)OFS;78'CP?#AF]T>9!;YW-#=E,EJ/=3+Y4'F2D&)Y5>1"
M=J"Y7?/SU@PKR,,P]"9N<AW;X25'P?*ILP#-7'Z.?"DCUB:[F!)VA5?M8IC6
M$-Z#1XNR]TW#3<<NQ&H71?+/]Q-2R@.KY<-^'+JU&+WTT!Z?Y%UZ?,,,T,-[
M@)4Y1HI7#2B5)6ET:0[I#[.?$TN9VA;'TP0EDE)$?Z8*GU:>Y$2G;:YA._-[
MD_).L]2<K$$YKM&2D5SLF#3(DHAH)SF:XSAIH]27\=D)"=$S*JLX\)J8TGWP
M2R(9P2!>#_PT49#^N@:6*=O<[/3,-51^F%J=Z>.C<_.#7&4EK:1\T+HD?[*Y
MV9]E2[\SP=_VT(%^LTI[!;\R 2SH\'K@(J._2VA6\/UJ+B#:2C?^J'"C1X&H
M&/_,(KPV:_V-"&I^Z.ZQHT#-<#92V7WC=>#,0:#=]:USO/\Y"3KR_V)"W,U4
M!.<4?WY99^-%BH>:;8NV1C9&5O?C'>*I/)&CVU^BQ^7:SREQPGW9=.+457BY
MQJ^$\S?A)G,GQU^<-5E6SLW$M0X3+S!!X-ZJFH\)V=.;<I(DVAWW<6^!OAI&
M>M;29F\S$RT'Z"&HF3G3'F3Y7"]7*#+6,CPJH@[+/L"/\PKZ@U4MMZ/55L5^
MYYF ZYNZP15;XNEF.8D[[\%7# (-#5?TB1 T-B?]+BG>>%F;!UW:6EWVX%41
M5RK+N=5&4DL%34K+GY0NBH!E&SL&0T#O.B"Z(^U[, E[J;G[4H9C#I[E_HR6
M.S,5/PQ]M=LO)55 GYVHK1^ -<]*&M>D2^ 216]5';,[7W76>OL9=JSMKN#
M9>CII?;_,+79&&ASQ<U*SF-*QR61)R9;[UK)]VWTK*7:"%)HF@^L(AZ<L(]"
M=I4-2Q^IH$ &UPM=;(]-N0Y8UV[14=6;K-?K9J% \GQ;5D*C<VDN8ZTQ7(XJ
MG16.>4:.+)7EPV2*[<G"*='64ZT.%??DL+GY@TI5ZN#U"'NXW_=R(O9C F9G
M]GUQDG8/ZX",;A4Y002_L6>0BH??_N[0Z^'4F-&Y-ZXFU,;!RP,-,*WET*//
M2V&RVG%MY,>E!>M<CAH]]<59FX\F=)O0IUB2I_M(PXL?>*7U+S\*LYW>-W5
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M?()1@891^'#"#07B?&&/K"'/ >Z'K3N>CNF* T&C.:*:L,-%MW+^TA_S6YL
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MNBI<N[56;FO*$O*B*16M5EJ*?.I.WN/E^=,XFST4CTKW<<_B*^M6N_(*2-;
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MBZ,)X?O6[P=N/F8D7EEP55>=ZK-"'\:$)YU*A<$N4\1JK2']^9-,2A/&QF7
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M40%MNU==TBUE%8&C,K*D6> '>;*K<SE%SVD_SII\F2DB]2S)+7DX:/QPD&Z
M:Z[4_ '$ C&\1:,GW7I<UTMG(?#$;(Z-F!%M/5>HN@\[:7CIF3! ].* ,I )
M);T(N]!MJ>V?+:.N&YFI5UGV-&O]\5D@FWI[0'"N$*6-?D:.^J Q<J+"G\BK
MGD\*(^+NAC+Z?/ZLH2"VZVLMEX! .3TV([&]LQEK1Y.4./10)7",K<_FYK7@
MCPTLQEF^62^&D<?%M;=>^QA6[$:--76S"NH:\P&6;TNMU;@:'P;@ /UWDAJ3
MG% /0BE?:FG][]U#]X_;#>(WJC+(EO0J2D1"'3QX]=2E5JH7M9]0.A$%RC>;
MH>Y4&)1;O]SGBR_9E&I-<S][P*2]8?+SYX*(*R";4F*9@<#X+,>6^SRP]+A>
M5A<.S=IR1HM^SUKR-^5.[[8<$YF>O&=\7!>^3+X KCV2QY V&LCHEBM;Y6SK
M5QHP\>MGTB8B'LZH.W+@ 'J=3U?-ZA[K;H\M9P9YFVG09X1NA=/LB&E:4K+&
M\/\$-5RWE#PG !M!S!=*&6BJ-&%V=R<-Y%.L+$4B+&"O"6G;PARNN;2D,94D
M)"0Y_=P[L&OS\KJR4T_@B[<AI=M&ITA507/J+XX/WH&FQ(]^YE4Y'>&#5BIF
M)W& :^7 1:46CR);/5_%+\X%Y>G1XU4:D#Y/'\;<S@9&+SY7:=(53T\YZA#U
M%A]>4::GW&(INW+?RH/)V2@,+F=1[/$PSSG?5_1FP2+]3,<]/(6-T2:R;Z+>
MS#6DBEMT2LH9"^U*,A%VF3:HH;'PBB&GW]MSIA U1<J>/.$G[$^58WP3YI)G
M&IB4O/LYOS*+S7&,=,58'CQ&E/7WVGU0L1=T;7U=?1%T[C.(WLN2V C@SAE'
M6@[+J('+O3^H2"7&/HK*&6-K?UX0E&, 6DQX?OXI9U FFKLDOBW5/9/T2N89
MG[>U[[3-")BO >0_273N'*5[%%5@.)CS*VX@*DN>FW.%9G;WT$4X$#/&I7V3
M;:L*V>PIK*E"7H*_GX<@]N G5V1AQ<)6*C!K:8_<.P[D.$6BQ"#]H[8&UO"$
MW84U'.A:O.Q&(R\F'*G3+ A]$$/=8.7JM OB\;#EA;X0JS9IS%$,@/3J.3RR
MP).5H(,V5=QN0T>.HSWS O)G!B+B:V-C''*4:+CO2ZV0"@$D]HRD-.)M<R<N
MX_II[WG&3DY4=^^X]O7YL*?2;#KUF@WN$?RVGLJR#-B<JK\KK#:F9NZ@U#!?
M;[>?T8XXA<?RFW0,_MIF-& M[8 !.,KY=K]E#6IO3IP(=?-^VV!@I-+Y]%D#
M:]R.9)<56WWYIQ^_=X/>1]N_33(:@]Z')4HNATT\J5']P'7NG5*-3'<9J2/)
M2BD4_7)&T=_*=K=O4:%5B8@IFR\PB,PNL>)F\_P*_)4(DAV3M&:!NKD[=?1-
MZNZTL:)40:1@];/%X*IL8@C3]X6(C:W")$A[OJV8+ZA)6L'V]M.H>S<BB@#6
M .*#3;UMU2A5]5Q6*&6, "K>VDW^4XUT+]/:Q8NJQE;8*P<GFSD*G8W>!C!]
M+^I3L?)2DYK/SEM>B&WPR'ZC.(G(2';D&U\EXUCLR'BQL0UB7 I96,'V?'WZ
M"0]A4%3H&RX@&]U@M^ @U'S:7VIH!R/JD3W-4 3E<^R8_NILYNQAI:72.5S[
MBMB=N7FL8VI\LV(9JW>>6U"Q>ADH[VV\[;MZ"BE[DALE1^L>7,PY?=^'?NUI
M\-,2W?%>P!WQ.S.9Z6Y S0-'R)+MSN(P6TWU?&%[T8NSRIJ\L_>A44^K%C#0
MQ![D=RAPCW#:Y#=_L9,*?=>B"YQ ,EV;"1(0=]1^M1R9HQ.-N<VY'YHUQ5LN
MLEW:P@7TLZHA>:.S'NK+1J!'R_3Q.W--XORX-7H:/1-HAI@OP &@]=,9@4=J
MJ()B Z "WJ\3:;6'YD*)%S(.U\LZTH*=A4-I>9$]S+EIP0]=B9;7N 1NG5+U
MSWG3/(<GHH'A?%-J]:SO&Y)XR=]71C^S$&*D'G@N*]>PL:3 ^(A!Y5"HZ,8\
M0]K, EY6-B0 ;\_E9)F^(MS]Q\$H*GW;T]X%LF5; ,V:^J*"R'+565V7WV;P
M=!F1.K76[OY)6\S&\.&E024*J*%)" ]+ZX_K6+!AFOV0?%'=$-XI3O%\0&K$
M2/KWI?.:R8[0>30.$'(H:79WDB]E2:T?;#P\4)$K(KA3'QF6]&**=.W50JB\
M=R-3.Y-$J>>0 0K6B?YAE/[2;!-!C6@;07B0W3JB;$BR70Q?N*9,>^4Q9X%W
MU*;-*ONA6VL_51(9/CF)"547:4%<'C6X$DC?#HG?UC'UUINRW]@KX^<[3OOQ
M'ICBT S/O'?V,O&9%:NG1/>.[48-B=G)QNL-^O=RS A_]4*+776^3F^2&K'3
MPYEDF>[#X9+<ZAO7WP $Q#U+YN]"S7_),)&6<<*?1?AY1L_"VO)KNL5E'/#?
M7/-VS$PI'U0>!KD;/%!SXXD;O)>ZM&0]RSZ@)"Z(!@@  ,2 &]H'\F$T'=2?
M;.6@149&JX9+M7<6)PV$XDS%9.Y(W9%U4RLYA"TP]?&S;*>Z>/L+^Y0:;0[/
M/1LU59/]V?8"/RKB.6/#N?<*R=PO\&+&+'2\/8-L!T;^XGY-]",9&$EE6V1Q
MUU/9*Q)2ZUUVH^;,;;9N!"KS';_5+R.B]!SOI<W4*WKF3]8%0)F8&_EJQ*!'
M-S[BXTL K/<+:]3!)D^V+4XH7ZK\;Z\4_#<H9/RHF'TPEIK@(^C$"3G_U4?L
M$V@U(+Y_@&G:TZOB["#2LUP!2Y>$+=S#%.( IU-GZ(?XW^074\!;CCC 3R<<
M )3W7[:ZPNPJ&%AC>=<Q][,<<(!D_5.GJ>8*M-7JWF16%]WIOZ2*"@*W"^$
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M?.'_DJ+X_S83^N]2\'"3_P-02P,$%     @ PX!J5!@B>\[&UP  .PP! !8
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M<,H_:8_MK@NBW:$-2N2*S,[Z>Y+S"/!LN[DN\5,/84Y4KO]1JYQNDXP631J
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M3]"P[Z:E)"]]/UAO3# :^*L0L2X.>5,NK3Y9/ >=CTE)*S!A.RU_"_1WE3I
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M*-LR!A[_HA0NR<& YD$P9OW_Z78*^?<&,=1:-RG"/\X>?;5T^\\]]3<X:EX
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MS\^C^F]M]7L9_9!4GC@FW2WW/Y#<E4/"1;MZKSK#CW2VGMR/ %:+F/F@L*H
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MN\9ZT>E[0C<FT=0)]\D:+P]^8P!N+LLRC;?Q'%%&/&YOP449Q ?A\;OCIQE
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M[;?*/8_K/5B])UUZ^66J%__&ZT5$<(?@T#@RM6;#^XY 30NJ_J("DN8ZXHA
M.DEW4I[5/;R,U1[+0&53+1O(0-W?U0>77+5*TGL&\\V M9K[]RB>'_!(O]<
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MA)*)FYW7JN6K)Y\X*'OLMW=T4/4BY$!5WQ-^1,1HO"IHS!9"J^DK3-(H2F5
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M1%"D(Z" HB @'6D1E2X"TFM4I)?0.X0BH$@1$%"J]!(@TCN1WJ43I??>0C-
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M&,VYLUA>6>1OQ1&V821DKG?'YG8X7_BWW-7,FINGW$;^N<Q+MXCF6&;:06+
MYXMOF-=)"Z*:8A\0D='<5#91GAO3IR ?MV(HC\Y;@5/!*?7'&^NMNZ><KI%)
M]PXY"1J0%X<LUO+.Z?-2&4Q^STPZ2,G1M1$8A<@LM*=6"_.[%<;^;V[J_RVY
M*7JITP"_SQK^%$%"=H_VZA2[CN548E'=.]ANKS''TXWRJ7N!.:4] :E18(&)
M_*[]U11#)LM:G71K0F^L<*M&,A%)+1O&P1#^%>\C=]N0!/C//#<OS@Y\1#F,
MQ#PX :U>!V8==LS9UX\%XZ)==G'PG@EZY7JCR>FEW+U" W+=MYFO7RU=8#]&
M[(JT&.<\"4VGM\1^K#!@:9&I\F9YI'2/DBNZ0.]U$LH!_G(Z<MRTIC-H=F!T
M79;'9O:#[.PCRFLVA6)W>Q](6JUY(#0/4\#]V*]B@_?1-(C9#T*(2]Y!W3IZ
M7<096OREKVH#+EZ_<U;T*NE2@0^+U5KJRA&7GKD==^"\*X5/80_W-UV1EV$I
MM]L,8CM =O<0.FF!Z=7X,N0BA29TK:C=T'QT(;N9K7"E2%?%S-V*NF"@EXNM
M^7+'>*5ZC;_;7'RJX_0%^ 1A\Z@72I6].C9G-# CY,*Y]F\:HM=<C>[WGJU9
MO56>@O+$/Q\Y 8V,8,/5'Y2CSZQ>2I*3[KN3%B8?Y:GP<=XQG)3BC@W]/D=(
MKMGTQH.IF8.RF8/X;Q,0R3'9F81GN[HA\W.2K784<X9E5$+.T'<<QL'#M2*%
M#WD#G2_>L"[D%31G/O\L62N,G8(A];I_<J#C0(TYMHF2_L$;X;"&)_<ET1M/
MTA)<*;7N@C]OPF:>781Y@4T8=$N^1R-A\2RBK7Q^:Q@M'-53/:Z+-36_)_8)
MYE_4;BD!]+2MH5SN4<EVK5Y/XE-Y&]M99#A9.M\S=NTE-HG(^'4A')^0(5]J
MM$;]H!ICM]7;>\T\H%[BUQ(>J/<&^N-KM"K/IQ&7,!5:'QFMXU]59W7=4JE9
M[THQP:XXLSP<D*!-AY@?"9Z 1DTO>WNZ<J^C&QTB2X/%-7Y\(4PQ0,GIU%,/
M\.Z!*<:^K7J4CF;.1@T8=#]1X!"E9Y]V6BS/2WFIN.F^4U\WLW5Y+6I93[/B
M]9TMVU>#["+]+4+Y8U14=N.7[A.YTA= SUN,M@_MA[GJE_FW+CV]FZ?;<BNN
M0SZ H*J-.'QNL$_K; 5Y[@SRRBKMB _W]F:$54YQNXTS0=A7JML^!@[VX7=%
MKYK%KV*Y>(KL36ZTYL(M/-X[7'H6]^3!E:M+'/8D%8IJ&-D?(LN_%?'/U@)*
M=IV%'O;-!XJC97(I^[WDT9QP"?SK$HRA7U=H%+84??T!.$E^S!W;"7@9?<01
M#H8CX*HMI/BMWK$$\['610H"(%/.E]-'_XCX.1'FM/[7,E-MOI]C=P43/\&P
M@69F9R8/2BRWT/0=S/+4E<$!J B+PUHEHR<FRI9\R\:L]%]G)^O?UA)-L^N>
MS_T"<E!V*-7N@N4+P2*9MT[7C"8=A.7HRJ2NH#O<;<-C^^%<BI_\J5Y>CJ_!
MY6:?@'KW$3@\!(T03(O8#T+L7,.W!^\*#&O&]!O2\7]N?^9P+C,O'H+UMT:N
M^<.660M0@X-Q@E0UR5=1=^))6]"VKR9O;A>FIG-_J;"J;#RO:#O6+LDO,%">
M V=OV#8+UF],IOS<SSQO4)9C9WK^L_"2Z4IT1%UX6=V?%ESO!*1:,K">48>L
M"AD=N0.-UR*%1X$ZI.9)FTY @8'36T?T>P@L*01=&.1VO2HP-9D]]N9Q!VN0
M^O[92I;71[(?S\:ETSFMR7=9N5BV7%-[]W+>3DR51,YB#G8!,M%B83%[4<SS
MC<X=>SF[S ]'!/%3>7SFHP:4^9]7RNW;LSE7SOA3%+48_;G_*+?K%^WXBA9N
MEI;(R?NQ(Y?RH1<(ZU[SN&U@C7<*#WX5(Z[H8Y->+!:@G-[Q:UQAB+A9Q>C@
MX@47#/)AWY>,0\3"4;1W\1+>Y^8)J+Y'V<K9#F4'5[E]5H:(5F)78]5*!8,+
MP%?S[B(24XW@<!;WS>JDP5?N1L&Z,M1+L[ KF.!69K:!#2%TEL[*P -6\X*G
M"DH2SXMBZ<824]037Y+B> LBB/9(94UD[G0#$A1E!T*(EJ U)U.GQ3U[U)O5
MS"O4C!3,'!VIB]L'B_D,9#,NG?\B<7O+3^..<X^285^M6>;-.LENETM<#=Y"
M[T*TP])?M+=WIF/D)WS=>VZ+WT1)9[I$2W(>:P_N38"/'^SLT%GO?'K<LY/4
M1ICB%5)CI$PT6AZPK0=XQL>JAG%!7>OH'BOF;Y>*S]1)V5*H]U*GST)I 8PZ
MGWA$>] S&6%A9AW5(93D5Q5KP<).43FC0; 2'9_+)>X^MEW%YZHMR1JRTS3'
M0JDP/48__9%6U=M><*&ZLI2OH/OENV*Z=F)I(C.Z9?L05$E*LQ@T##;#7(N:
M/!+'"2N]MF4>$?2TT/1/)*;C^FKG.!"WCX'LL.QCQG;%/V2%F'!3O6'UUWC_
M[#Y;3OZ&67,\;W"ZW/"^N/YUCO$K\@303ZM6H1AEXYR6K"D5J2+V@REH=<1Z
M*Y%:K:+CS6F!Z%ZF>X6#.BGR S:F(_N"%6$VJ=<+F0B>I4R0(#@J'!66HW<8
M)M(FPG#)V29,"X'=VL(#H1E%HB;09LV0V7HZ"VTQ:!!'\N+X*,Q\LLN3.I5N
MA\U!N%#<3B#"8\,RONAVX!\,\#^VX\D9?G@Z6X[)<_]S[:RYL!<KD#VRDA,0
M\@*>N@>SUEC.D)S@G2]!&STU^AT9327BT%JH07EVZ'DRC&&Z8$\EN'<ZL#JZ
M9>?MH%5=MAC\/(V!&;/6EI'P'/AKS!ZT GMY3*,F>?1U9%J&95[(W;QT$*GS
M"S<Q"UL)^G0EH1K]]A'[Z"LT-WS4)MZ /_;8#"OHECXV' !&\I1^$4+W_%D]
M?5WLXNQ(XYBZNJ,SR:3O95\<.5^O:.$5M7ID]: M0EL-.>(EDKYV$"WM:?^1
M/IV@MJF&T$Z]U$=H3YRS.N89O7P#D9W%&=:VA;Q;]_E*R?D>#&XA%_"0UY/(
MN"6\V4>,\,%4<PHU]N$L]^UXFUNZ#RTK&$GSH^R>\)^U#QD:DKJ$$=$8*BR[
M4"=E5ED=DQ43..1+8QQE1W$U?I-2\,T9V9 0,<Y0@B?I:?*&MNYQC<IB8PIU
MZ/ DTT#N@C*7D!MW= ()":,[$,J_A_<^D?[K-+83?4IC/;__8S3VWXPA[H[_
M$4.L_X>6ZJ2%K-PE_2=^;/I7J&^G!/F#-(6WAXE.98YW+35,ADI[::GTU.]5
M!BP/RV<82@;O/*+-\?.7;W:H[>RU(V93\*ST7S&]$=Q?I-G00!H_CU-+IL!D
MF0"\E]3CM':%N(<+_T 5#VY'*1M\_2O;B2B;0?[0A;W!R^\4334;^0$]Z+LJ
M_:?<$WM^'QW]JO#N3%<HX6 .=22NRA'7#F/#"_VQ3D 8VG08LFBU(#!NRQIT
MDR]3.(YWM5?NO.*5  =#9?!&5\KFPT,6--S#)5UHH4F.]1.!B->GHPB/A@))
M"CP8@J]*6>1ZR]-MK\FG^FIQU'JDCM0^:U061Z7-,;<!T1P0[!$JM4@-65U[
MZH]RZJBZ.Q\N9^"TTN/=,)]D0MVH9[AV1!)>.L&H/A)>8)$WUKV\HY^A3%;D
MV\8(.I27)/<IZX6X-2X]'LHW+44GQC='Y,C9V%M6.Q04R=IDL(?47D[9BJ<I
MX#D!+3WSN'D,:THNOOFZN^_-I<Y/?/>;[$A26[2+A^\XWZS2%\]9LM(-O?+J
MWLX\D\8Q*D5WI;H$:S;\76C%6+.D(F9(7]:U^:6U3/LTQ9;S8M1<:]RH7% M
M).<%33)*UTH<,NY+Z_+E C&]M2U'E6@+^QYRORYHI!Q?7K52JOUQV>AF/83&
MPN7NFD=0E85',3=JU*F\XE@\<+RP8"%G5)Z-1$C&&48WY2:NC>9T"^0^ 95P
M5.W81 WPE]QY,BXOWROM5\$DT)&U-Z2D/CQJ'J7Q)D,F<K?H EFYV+1K-BK6
MJM\ROBW"B][=*K_C!=1Z*>I2.1KYO?=]9E&EUUC)5)8H0KYVL&"?FV]=B/CX
M$?\G!>D;7KT&&VT011M!9.&L,K^;[?5*HB9!AT#1&W1769YP*NXBR%?BO6!4
M^^=K[UE<S(HQ>\$-]>GV8XU:<GG@*WH'/G3PE:O?PNFQM]X_VZU:XOF,/HQN
MV4RQNJ:R_'5G,8UO:+GX)6DB3T^M&Q5-8\?B;AL;7E:%TD3&EG*7 C7E/A'<
MY:I."_/M[2]=V:N[9V,KQ%4@*_-"N65D8DFR7I6$.A5@,_,EDVY0.?36:^0,
M:__BD&FRSKS_1NE2Y;D$T$Z0QAQ)(H)$TH%/#2/7XD$>.2MIO^&$4VQ2KHN_
M;F4>[Y3J2A 436#G]^8JK.0K%RHG34R'.?54\M5J^V7MV7.R^S^01M4VM3 H
MIZ)QBYGY +LU&!Q3"1)-GOQN>KFZ)';ZL^2YE7CM(9>^O8F5$I^%[Z&;O719
MTHY09Y:/4 GU:Z(3C$'T6*[N_80Z1H-^+%.ZN:_<)TO7A1O^0GP!5Y]_3'L^
MY-44N:$=_;AX&]D2QCDE6Q;2.:CY.<F6>UHU,C:"&&(^!S@7<"LHI,' $%QX
M($D>4I #&5OQ\/J!LNZ GJ&-C+EPB>0S44IC%1BCSTQ^ DHY1F!I#6!H*E^)
MWVCW%^Q=9,4P1<A6 5/RI+>#=MA'TB@R^X-KES$H[_^^4*'K3R ^0MN$/+PL
M.'4,P'6Z487SSZD5NQ<^YX\$"B-:6"(7 6??Q];[W2E[7?'XB1@/*_/BI84A
M^PW@O<M::WN6X,:(-"FQ[%;<@Y#4_(FI;RL(J8^9Y=E.&<3ENB.L7Y*?+$X;
M%]A[1$1@53(2^+RGZ=-$XK@L2+#*SVQV/M_0#IT3E4CF>DKQ,*W*D!>"5I[,
M)*/%GX]M'.Z@-$A2/$]D3)*4Y^ ^%Z&W>GI80<BL<[E?EIUB(3^)465NXMRY
M*J5'0=&V[;&5B#<I.^?[P>OB)L"PN-+PX^7X^:EW)R"&I5JC[&8:,2>:%#9]
M2ZT?MB;35&$[]UO=VQ1G\,,-L-YFJWT/9*?+>RVS@X6*'S>QP9A^7)4-K@-Y
M'2\(LYQ&+LU2P(?QZD]";B'N-_^^5IHKK+ S9*=$HF1M//D$Q,M]!/%T+VR3
M9;F\#LW<M"_[.? BX_X> XVR-$)!-T] #6+,8JOCR @L",%;,NB\AGCMPY_P
M:,3X\W/N8OGH,??^RKNA=^F)[F+#W:E7J;0'Q_23W1M3@B-,,LSM+<2BLE(S
M#"0[#0P?+K)OW?1J7#TGL13*S'D0,[WVUC/)8TU]V&=,JHQ4!AQGRZIS .?M
MY'=KLD]VFT\$>B%2L#5$DX+JGF'=YLD5\6=L8@BO(/K\Z)F^;EH)9WOD7>N[
M4[M7?,6-)TN=(626D.TH8>0G2SO=2>4S8^,MSK8F(2;J,1+\[YHXWEGEI05M
M;N%<B-.*NJ;<C%5'!.N$+ZIKA^O#)66Y%F.Y#$,:R!\03WS9B%(VJMP&E&2.
M$7S).QOZO8"]?$<"65?G-U$C8<S$IZ^AAO.AP08<86T=\'3;7S-GNHXQK=ED
M1X]VNQRIJRI8-=P9[8E_///KM=V'M$R2#WDIY:V@7([F7=[II/#9W"S>G7/W
MO,>(8B?W7:+^IB8'O;:U:+(<Z]&2R%]8!&_*E>\F@U)_J/@FR5=5HO?^']N/
MFTJH3MG)AO0$I.[6_=;"=I>*)';T?(O[0;")!/YFG0U4<7MP4NI#?"BE=#9B
M4_>C+W%O][<V#M8ZQJ?T YMMWWU0'R XEHC);9\G;DO9<T9"PBG398/I0]=&
M:A\/&""^1=\/VC[,R.THOQTV(\UQK?S>C]R1K:.MHV_>8 3OP%*^&T0KVG"[
M_&.>,D,;]W"U_&J*$]_5N3%)+J.<Y?X/I4IT/2'?WOM1C7*=O81-GV]?"_\(
M'\XHZ%X_70I.I1%Z*^VS8"^#N5A=>:ZCF0_")NN>4F[(N[>^"M>2T\/3WOHA
M91R2&3!A,TCJ54H=BS@'QIB'K!E]I3XO*&8-]ED*G)T(EI 7D?//T"A<T#Q>
M<UGSUZ\:!/]6[9K1'[5KGO] [9K&;T1QQ>,7NEKO^1KVEN(AJE/JO ?@>D D
M/!I.X?"3VT^YX&*O7P*[D-1GR F C@;ZR'6\@(6!M0^!&PUO$OQ5%&<](@P,
M F MV[PK1EJN^!GUA</T]/-8$YP37TY:"!9[<)I]/E\ GCN@.%I&?JWNG-_X
MZ_,Q.0.>"@=[V-V&E><B-#@!10P!,V)\&#_U4ZD<_#5X/"5/ , *JFZ 5L^H
MG)9$@*K^R@=_'$#.WZ"8PX8Y#1_4BN#7>-'@#F8M<<S;/N"/1X2O_PY(/U-$
M1"Q[,MO5MU44:HF:T'4X[^$<\/ *#*K7]+NREXGSTP2%&S;0B4.I)5O&*Z2J
M"Y'=(\G! .-% +/;NTN=C8L!H%0"ACX 0#3J I>G&2^9IT[HE<IDKCCBR!?F
M+ZYK/0V+W@6<!\7*RB?DM_E;[%*H-N:K^_=TKB?+LT?KE6G&\^W**H@^3YXK
M<'72'MZ'L'U=_@I6V0[*Y*D5BKAL=7GU2H/U07DNU&;^CN4)R+VWVZ'9?IF+
MAR)8[W-_ON"]VH<D!UH)CE</NJC#V:.--\_(\@:,>WUR[.A5W%.\I0>#W/5(
MK%L*<KX^9X(FC\MMLBV19BJ;OZ+_422-[YE&$*,*NV,\@M?79E,0>LD"15O8
M!8<([;1';EBY'BK.12=2DTB8UI#>6H&N_2U.BH*V+SF]I:"6=K\\7-9U(4'G
MO?\[';I)X] SW09^:[Z<917^+17^^Q!R'-)U;'2A]@3$P2@QH#(Q\55@56##
MT)!*TI4XJ^TZW.T!'HJ1*W1*>LIE\U F+%6!HX)?CK.8R#KGF=Q]CY'%HN>P
M'(S/;..@NK!(B<QG(W;]$.9Y'CDC3W3\8%KP*3S'5CQ\OUT1))1RL<W&='3X
M_:@UI]SWV4&OK!>PU\CX\:4H^7N%A2&W*^QO/$L+N4WVKYVKQ94P7"AA0HWM
MR%@Y$FI)]YOOL'=DA]*WB0_=)A-8EJ,> /3/^01$NH/O:JPVT*(MWRJT0"VI
M479F/H_58J^V;W]*#B8='A!4=CAN>3,+OI295!H[4F!C86'%I4AK3SSQP:_C
M"XA@ )C'G\XU^G=N87C8^TN-8)G$;R6$1=:.=8V 9LD5>_U6[A^  9@-:P$*
MYX/$^\9,:M_!WX0R1<0MIX6LWOW#49S[.3.J7_T31GRN_Z6>L.:G0I. *]LJ
M_4E./K>P$8*GA:^.ZW]4E2@-G(#FKP"Z8' %P!QJVSP+V,[YTW*[\Z>%?E_1
M&KOZ*_82E!U7Z'WOA&K,67EH+U/FYSRO2]<NENO(LRWPD1E.B&GQ>G0"T@?<
MW6-Z;M@>/1?'L;KJZ0YZB&/LU)RJ@8K0S*L))7;\(W_SVA'NA<JO]([]02IL
MR58=)R ="Q@;P.:*.;#M^YQ</> R(8I#/$#^D#UX(;,G0] 4C5*YNDH3BW?4
M_$5$MLS[JKTKG8H2$6I*G(GJ7NU[G']!0I7&/N3P; \&QF>4!<:-(#"0^5[A
M"#3;:K@IP&YZ5-Q.)68=@#2<QN$@"P1EVC<;.-/OS*W:V4S].<P@2[Q<Q]Z@
M.^5*M]XK84HW\6:XJYA@Y .;N?'5R@Y"F'7(%CQD&#F/<(/B&U"PGEN$ZM)H
MR=8*SQNU]5='G%KDN]X@4C5DYR]^"I+83?F">OB/9T;_7=G3KU9'Y+FYAF_A
M*M1&*W?9W<Q3P_EK7\;>"(+A-!=)\)>M#%UL'GNI<^56'SH89.;?^$ ^YN^#
M5%'</P%=UH698ZPTBIO;>LNB)!X0.,:P+700@E\7LCU"T^1FFY>[J'N)#HW(
ML^J,M8=?"B:DI[<50&$M )<1P5<7_D,N\F9_?D;XWA3;ET#;#R!3.A;P5<>1
MPF%/^OC9QDFS\JCO&6$Z#3=%9.6/LZ^^=)K-UY3LT#_-F9HE8?70U"/1Z:,6
M+KE. >J.3"W#I;*R_I?#CN_C6<E)YHS4,BQIE*:AK_6THJ&N5-:-LY?97]KX
M&5(%229<'%R#*(_(9 <)6K%L2!.'$ ^S6_!J3B0^[GGG0/=.(/K+E]SRL--
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MK2,7P#ZDX"R;:R!E;DAEU&[%NM:@]+SSU*+-DJNUS4K 2)*,%^Q@$HSW\;F
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M8:T^C;O%-?&OQ!:W7$4(\I]]GU2I0-U[W_-V@4"^Q5H!3SC*/DPZ=7=D/%%
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M\JWI 9?BCB)=P;H6D0XS]7S6B$B&JDJ%2LTX,$(H6O8BE[#Q&3G@H=9R<?*
MNO"4Y[-H>+"2XX031(IW )Y_*-H_/=?E'G>-3&ZMYO,K@E<-I!*7VP2WBO[A
M?_<_'YYU\"B,.Q)&G#EV8;!;JI:3$_U0Q[PTVJL[!]SNWHR/ZHPP6QY1.SS.
M&[KI4_N8_AY*"RNG+=>/+U4NC:PWSF?>Z#^[?1HB8C\5%5F,6W8*8>NC<A,A
M?L]>6IP"<&3@!H[(KG]MER!LAT$]8M6*WXD@PKYX32-D4/#L"V+@LADVYS'%
M]1*86@TYBZP(0V&^LM'P1_AC06F&!H#6#8.M;1WJPO=E&8+%3YS2KLVM](G/
M_8#:,9[WCG@)'63#TZX69S/=D/O&<0A!++3@R7XJ$B8HL+F>(RM3=?>7)U83
M(_2TS!H]UR\O=U=L:&U.F1F3TFJ=.0BQ\Y_Y.3@J/O1P*A#D2N.:DI&9].FI
MO;@S1E^B4SSA!(3M)3GX#K5?JE^-O[_793;V?UO03&=Y5&T,J.YE5LR$9K72
M^OWS#B^CV\+>L^KV +8X \50Q7^U"2;^^TAS#0I3Z"I0_&L?4OX;_\9_Q^G$
MWP!02P,$%     @ PX!J5)>B?D3+E , DOLJ !4   !S=&]K+3$P:U\R,#(Q
M,3(S,2YH=&WLO7ESVTBV)_KWFXCW'?#4TW?L&)(FJ5VN\@2MQ:4N:[FBW'5K
M7KQP)(&DB#8(L+!(8O\QG_V=)1-(D"!%RI2X"#5SVR*))9>39S^_\\O_>NQ[
MEG4OP\@-_%^W&K7ZEB5].W!<_^[7K23N5@^V_M>G__N__?+_5*O6R=GYI=6R
M8_=>GKB1[051$LIW[8OWUKGON;ZT_NOSS5?K)+"3OO1CJVKUXGAP].'#P\-#
MS>FZ?A1X20SOB6IVT/]@5:OZP<>A%/B#=2)B:=%_1U:SWFQ6Z]O51OVVL7>T
MLWVTNU\[V&G6&]N-_UFO']7KQ@/^R1.PC/^.K-U:O=:H[3</C NOA?U#W$GK
M_,2X\, Y='8[.]N-G1UGQVXVQ%ZS>VC7FX?VH=S>[W;,D0:#8>C>]6+KG?V>
MA@CS]7WI>7)HG;F^\&U7>%9;S[0"2V/7K);G63=X6V3=R$B&]]*IJ:?V8M@!
MV 4_.GKLA)[[ZY:Q:OA-+0CO/C3K]>T/L((QO$!N&=<[V0WFQ7L?^$=]:10'
M/W)/QB]DW).A&$@8JLU[ A-J-)K;#7U;$E7CX4!&Z:U=$77H'?H7NJ5:;U1S
M-]T),2B\!W\HN"6*!V%^'I&T:W?!_0?\A6Y(+PWC26-*?RIZ0Q@7WE!TJ6M/
M&(MKYX;B"UBWXDOII]S%\M'N%5^+O^0N=>)P9(HY6H"?/^#/>$\=AV[<*=WB
M=\ /](J_=O2E=A*&<-*'Q=?K7W/CLH/$C\-)=_"/^3G[2;]91)_-.LPZEG[D
M=CQ9Q<N $.G 5)O(@A1] U/)4^W#-CV@<7AX^(%^36DN#B<>G,,/\*N^<.R1
M^2.&/W=$E!XQ-PIVFHW]:8>2KTC''+E%(X9+&Q_^Z^)KV^[)OJB.GF3W<=(;
M&GCLD;DB;TT)#UA.TG^".N"B*BVL:Z?W/7U3_@;W,2Z^(1O3AS@4?M0-PCYM
M( YYMUIO5IM[QD.J0"5Y]J.HYJGG'&3G<C(A( O=(EXJA8/_]F4L2/A4Y5^)
M>__KUG'@ [7%U5N8XY9E\Z=?MV(@P@]TM_4![XO=V)/P!S)'D#L_OFM^6(.+
MX/</^H)?/NA7H5"X_ )RP0<A&LO0ND>QTZSM-Q1_[P3.\-,OCGMO1?'0D[]N
M.6XT\,00-U'BJ/^O7]S'(WR<#/$3?W0=1_KTD3[#M9>\,Y;K_+IU]KV._\'*
M^**/CY3N40MDKH-R]\P3=VJ.C_&-[,+L\?+&7G-[M[E'4ZK#_TOGMO6I*[Q(
M_O(A]YZGWKUCOEN+_#/0"H1W#=<&SAE\%\TWCK,_YQS$GCF(4Q]V9W@,PPB%
M=^X[\O%W.9QO -FO\PVD43<'<DR\4RW&GU*$I[Z#BLU\8ZE6&TT@_KD&TMQ/
M24+)VJ/CGO#OY+G?LHE!@UIW';J@I P\F7W5!F;DB-")O@T<&&C+"0:Q=*:,
M5SV]Y?PKB6+<^>@L""_E@_F6P(<_;4F_MA[=*+UITFOAQ._5FQ>RWY&AL1!Q
MF,Q'G,V#-5^%_49C$:NPO8A5..\#/X8G"^^TVY5VO+[+L;/>1''0V%[$*NQM
M"%$L:#GVUYLH#AL+X9>'&T(4"UF.[<,Q\?%51I&45P,R4OR[KQ(LA%,8$VB1
MMKSJ7@U08[T-3M&DF8$,Z'Y424-AQXGP;F78IRFBWJD>3L91X"O5P9A5?4^I
M"?6][?K3TSO#=Z!K)/%='M&W[\ID^=8^V3*4F+UQUA#T^R[O3\MW<, P>9BR
M*Y]2[)0/(7*/?-<#/1L&N?5)#U,/Z;GC'#^SSQUG??YQCI'+3GU,SN8)Y:LK
M.JZ'JBGKA4"V,9'U53=U&%T'D8NO.DV-XJ] 7;,L\J>GG2Q_4T<FNA9# 8^&
M-;I"SP]\#?-U]/A@M=0(YSHN._4QP?HZ\Z^OROS'Z''"_"\#WUX6"1B3S(8Q
MYSP/EC;/V;=Z ?-LC+'__#S_D.C(E4X+#'YQ)V]D7[B^_A%9>6.F3;O>_K-Q
ML7<RW]AVQ\Y:NR="B1XKX'O] :PH>4]:88@"')?^\S"[! X ?M5Z *G)0BNZ
M2F)T1:&_?]+$1B15\XF]TG:LVK3K@_FL^IW=W96?XZBM/O\<QV3MS\[Q]%&&
MMALA?YMQCD^1Z>@<]_YLU"^:.U,IMDB*4U1CD(32$.([^V/,A&;W^>D%^#RZ
M &?"#?\IO$2VHBCI\VK<N-&/LU""!@L:J8SB&]2AQ*/;3_ISS=IRI.WVA1?]
MNG5^>;;UJ5ZK-W8;<RLRQ4LPIG6OQA*,'."B)=@YF%-'.F@NC-Z+YGKZ. "#
M0SI/D744PC+ \UG9#N,+.!>P'J9V/4+TNW_N7<QWM,?=+JLQ5=[Z*5/=^W-[
MWJDN3AJ]Z*Z.B:1G[.KBA-*+[NK85)_:U=G95;'(>E%VQ1OYLQR[OC^=7<V^
M!&.:_FHLP=,<N[Z]H"48]Q\N= GT.?AGX,%CT)A8 !TT<0GVZPM:@)=57"8L
MP,^I+KP VX4+0%\:X49<CU!V)4;_9:36"*/B1Q&%KN'5%D7>CS!>_.M6Y/8'
M'L:QZ;M>B".C\&D:.GV,'/VS".TPP!CHS/'W.5( 9HWL?_KE0WX^V3J,3)S7
M(@J2,%L*(HHCM0]$%T\ISG2?OE%2D%)]I[]T'?RZZ\K0HD')PE#Y\?GO^0CE
MZ,WZ31\*7J7>-*#0[,CKP38*8_0R?M*&=+VA'Y+]EK]'LE^2[U"!ROPO^<&8
M+];?J47,+2P>/UK5G/<O/XD^&-IP*C^I"X[@"OU(_5/N/?C,.7:/W*HKOVF<
M01*K+=NK;M?39ZM??GH#Z(L(65<T80<4C= EB]N"9GV[O@[GQM@"2E3,3LW/
M;<%4\EP3GI(CSQQ_>+FUJ:_?VM07N3:%O'/**7;<>YC,R.#P(9><CA?H&<[-
M>?,'?^QQQJM.I!_T77_:RYYD,OFWC3]1_VK.]UF,:=2X6GE*RTGV^MR2O;Y(
MR3YQ894>G<8*3O]*,%@$NG3@CP9_,=(7^.TXL'^D-B]&?9>Q&^DBRSL<=IY\
M'1C"X\!S;3?F@5J.V^>0KF$Y3)ORUB<SO)F;]"\?"E\Q>AKR _L)-M4X?!46
M/@\AM!R'HDC"NQ:N<^X?BX$;"^_M$,74!2@)9' C8^'ZTCD5(<8^HK=#&<4S
MWU"26-Y^KO[:+)*?+EWW>4N,]4VH;6^'HI:DO[T!*M)W)YW(=5P1#MO"DU==
MNB1-J#P+/"]XN/*ONET8K7^W410X:>9;GW#J1\5S?X+^RA.PJB=@NI0N3\-Z
MG(92PYCO9)3TO$AZ?HL4]%,.@TT@I-7W'&P</17;/!M.04MW52\VHO9*KI4-
M)XH5T'=6FD"F2)X-IXS5<%6O($FT;#OI)QY<R:5J>%4H>[C,]_+<MX-^KB1T
MN0EGK\=(9EV5):@L2\Z;>QU)]78H;?DB:^.HJU A?C,4M0HNT$V@HA=U@6X
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M,Q?IO-DD@#+2_GRBV+BH61F:FI<(WH8#N?323B65Z6"":PT$]9-@?PO:T;4
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M.1Y)A?*2Q #4IT<7#I*$Q_YW=73/*&L(II[X+A_&;]_=*-B!H7QKGVR91[H
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M<*TO-Z>*R_UQ?OO;]];Q\1P<[IAZ7&##%N)KH,2)NU J3O<'0B2WN(F*P"_
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M>]!F.F.ST%XI]8RUXI:EGE'J&:6>L:EZQFD!%%K<"RE;([4KT]"D\DIY*BM
MV9;L  &!".(Y'E%+5)S"5"72@,@[DM3O:U-DX<1Q_R%5J#5QO1B#NF0,&R-5
M@6#EEU$9?.D8.FZ0)I!C+-F[0U.]UU<=U--8--!9+T#LN%PD^J$7>*CK  G9
MH3N(T;%"D4IV1R@Q&6J?8)JS(BB,@^%!C5^:H96JC'[M)+%A)3JF8F-$F]3Z
MY?.,V/-(GB*'.]'#ZNO.">2#C#B[A]U,_<2+W0'.@A8N%RR>K&@]E?7S#G_3
M21R7[32AD!85E:QSW_J'\!/<@F:]V>1D1=^'8V%CXMP(;9%+I64+QQ76=4_
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M6SE-T2*#&ULP<B]"1#UPPTFB1 7Z"< !!@@<QWR@>2D;322JM #-1<O9*'=
MGMK*$M04T!=V#WM/##GW ;,3%!O,K8 *>--MLAJ!LHNWW:6",7I2%D;C\H^7
MOL"UD,N]&0VE3I4?+C6=8<^OVJL5L]93-_4V+<_.JHV/_.65K.$HFD!PNGS0
M85(7R 170;JC.N][_!CI-$DJ0BMZ;&#2L:$<%9*R]BN,4_-B#7O3#GB1K(EU
M-*NWC\8%PG2CNH!4B^QLM7/Z/3L3WF,:VV_#RFZN@I5]\,KKT0:.8,LCE0Z!
M*3QSS67E%$541!00Y<]J:(4I;J0TI*WDIED\%&J^O#BI3#)]6KG"58'7\G@8
MUI,^/@:^(<A391"QLZSF;J$.6+.^NC^*="S]P&A.#3$:4Q&+GS1)-[R<092Q
M7I@^M\+PGICH*%/P>7L(%.>)J)_3"SO#Z78G*4G1-+5Q0=J=]H;0G+2!CI?K
M67$I-\./C^Y-O ;JW[E/>GPH$*@U2(NS<6I6],,=#)2^@(!J2"4\ *7T"NWO
MH,NS*!;[6N(P\;D-;*K*9T ]6?P>WX)U*8@DARNB'JD7F!X[Y$Y5#!8 D@_K
M^ JSRJ_FK,372.Z8X9Q[8^9<\LQ< T-/EEHIW:4;]JPI6B#>9.+3CNYZ5[B>
M4MPZ<A))%RJ"^LD+U %+Y>]EE+_=HXS$GA])V1MYRIN-GVR7FEV19K?>KL^=
MY[H^%T[E"V53&Q1K(W#\F-K^@"K$PGR]@VQ&>QREFVCD/L*/P1IPJ;I+T;R-
M;/:RY=\,6U'BNI2X+B6NR]J<G'7 =6EU7.X)%VB4;K)GJ "?JQ$TN@A5#6JC
M795G+ #0164(*(%!U0Q&+?_,-6Y9TI^:AK;,C)D4S8 ,;(7\H2V]:-A'-/1H
M=+(E,MEZGL-2@I42K)1@&RO!5+4[RS%=CS:2F?:S@BIU@1M"*)]K5N04KEA]
M*?P\W$WF DT3WT))U77*@4KP$1GZEYY-S?I"277H"L]AI1..JG8K4\2!NK1&
MB1NK/JYI+64!HKE^O,KJ0[&I<,XS0',"&2LN%U1EL]A]-+V[2NCO69VZSB,Q
M]0OT/M,<XS"A@(471!&V$$X!@]*!E6)W39E'*79+L5N*W4T5N]]B%KC"#H%U
M6Q',F[,0"?DZ#P\"TH)#D1C0%<AL$:E&-ZDRODF!@UY 7!=$<^$W$3H>"B6=
M*9 BD.AD2IN+IA5$$L]3YN%/<GW!1\0QPN^EO4NZGGQTQPUNQL.8M$@9\NB$
MM2KEXWJ>\E(^EO*QE(^;*A\O@PR)*/$?8/J2DN^K*DV&JY<6)^D45A[F+L4(
M]A'#TXFMH[F),48%/'>2@Z_KBQ]4J6Q<[X:8J15&+G[H@TCJ9L!D6!FGZMW2
M%F @O8*^*I]22$ZJ="HP:^YTGPPP=6,WBA)D8FSBJOJR+#UM%)ZZ0'(S( T6
MU>G&*SK-"#T '4DYXFF)N4[_ZR!*C>?VW31OQW-_@-SN!0'!$AHOP'9F@5]5
M^8T\XE+4KBO#*$5M*6I+4;NIHM:(85(&;H H9Y$TQ)R3J.9"BY*VVN=)%=GJ
M]>1JQ??&;LRO,X*2V'1"0WH[>5Q#SB=-1:Z> CI%QR90+ Z5\,V6@4> T.V1
MN)-ZM& .JPSK"8:H($QA&7,Y,LD\0O/4CEX-0H=]LJD@@)Y(,5O/Q9S[+*<6
MYUC1.@=_Y06V6I4461$S;.VR[=,Z,XA2M):BM12MFRI:1[R\#Q3G"T,&K$CC
MBE1.88B+!:0%F?T)%S*362J=QQ2+K!3@U=^M1.I0)R4=7[8KEAR"4/WA.K[D
MRBV6NJJ[8A6[7RFT\8J2^803'8TWSLXD/C<Z#=%'0!TPN-&CWMI2+*\I<RG%
M<BF62[&\J6+YS'W$CA)D8\$0J&L+-EGA!:UVJ'P5?H8%>(;HR8EOW7,Q@]6G
MYH*$2X5BY:\$%M^-B\K(J5H2,W^H,X12(4P]@:')5;:1&RN8FXACKH3_RO>@
MF0C"+!$(T-F*&+TF\6*V)+'!,(62AVE$EKN8D3%N^J&C'L%S<L[57XF+;1&=
M?R41PY=V9/P@I9\"NJD:4G;4PWQR85Y& K6ZZ4;HL5(8_$X:[0YT%!R+83#6
M+#'P[/8[21A12T>KEU 0&KL>!C:[P!6HKMI/'J1^T2!4I::(SUT*Z#5E,Z6
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M*"BFIB2'ZO^BM97?W#$QC-R/D5UC:?=\L*;N"#'!Q'<6BF7Z2;\CJ3E$!A'
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MRRL4 Z+@)6X5$%(09G40Z<3)*+KS@DX^&8T^>6+(^@961*:H6[C7A#%"(HX
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M1#-E),$:>\*HA<"@&%[J24R13;#0!(BQ)P=D0&<8='A+ZCV$2=)E&581E=O
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MN5[I4\IG,(L K#TFP]"M/\ZU=\MYXK+E0-VD6(KFP^D.OP^/+)\**K$YO^Z
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MIUF[5 Z;I4\:'L/@Z^UY7!MC()*AHI@ D_''_!8S)<^*W\T[*/-\& V>)M;
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M+;-)H>UVL.MMKCJUX5_<"1!9V+<WYA=5XA7X(P$$>9,9B<#\ F+A6?5V H)
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MZ%=667W\>2JK-RD;=3%5YA^UBB?!_ 9[1"G[/<B>OKBN1B'IN&H<Q!_+#EN
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M=RT==.HN^.]>H."<T%X@JE<0HL_D )UK_@!9XMP#*B[S@?"1"\_5^&,W.DM
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MM2%NI;MW.I.B-*3Z]=5I59\DW-<A>G/%*^KSG*\: 3*5/.7[LESR0PG7>%Z
M2PB_"[]9-!$"($)FC3..]#' C59[48C"(H']E)"2%.80%.M Z-;?"_RA3"5^
MX#\QJC'\DO9'SXMJ3K@YQ?G>2".O:WHG0+[?-71\VHLM#%50VO$)+2LYQV)*
M*,H56K+."(T3H2^[HC:\#IFUQ?!P;,$_#:=TK #CLS5F: 0%&K@T$530V-5[
M8+WA+K\\/<*T;Z&S^"U;]SB.-R_!&>7X2L.+*N9S]XNNK/Z%,<FQ=K\3@;==
M">%EMS1<WIE]0<&^\I=6U;^MX_/-,)@.H+6S:H[%:R<B9TQ:@'7*RS!H]%L_
ML/MZ&/+;#^)SEI0OT+7RQ4$,Q5:5UG-]ZU/?HK<R.I/59HE[S#>&2 O$@3**
MT=S1PG%.NUJP5UR@Q@1^249*@RPO*F'JT@X@"!]["$<O?GEJTR?K#E/80=PY
M5(Y93XZ%$W LWM6NCS-B:!3[HZ?%JM#1)QNME;G;^7S/48:FJX1MG7=; R73
M,J@ GB@=."UFI2$7VXH$!T$;O0V&GD-9&"&6@\+?R5-E5JKJ1ATFD5?[H[?A
M@]TL48O@<V%W]T15I:]D' #IC0 7IA.L YFB,,1+!7') >&P66<8T,X!5&3H
M++(S $IZ;*C#-O5=!_&8.ZCF)%'*XW;[3Y23Z6RWE4K3"WJ)L<38 AOQNDXQ
MM4[L;MQM;5#$:A/20/RJ^1 4=-C-;K6.X-EZ;D0B!1^"D#2G!)7$B'?9 F-U
MHE/QL1<NE\ZP_DG_-8G=#P= WIG]K<Q.4R<GSQLGL_#>*(E%3-OC883^]O-K
MN94,>G>R.>76H56/)9$^\'2D^0S5!\4<WH(@$"EPJ1L*]U3<#NGG&%RY V\D
MN1!FOU4A*%@I(=J7Q&K)U0.A>YKP]O9'/X?U[!$J<VOSG(5-"K 3:'4S8B2P
MUS?/!10 )FY.RIJ_&ZLR(RMU.,&8?^";PEY47=JQ6W_4CD;W[^U-P\.>%Y6
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M&IVZ9M%GCDF>+&AULXW:W;E%U*'>M%J=Z';9%6P@\M;;]B,#\CY3="2A)DV
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MK4*Z:U^.)-S4$U<@2NT'E@);036II\(LMFZ1^(6$3J-57P[NH[CT$ZW+%N"
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M3@%''U'OK/3?4^]^#!>*/U?=2=/*%HZ_LNKX_7N?6!V_X"F_X&-M5\>_S#I
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M#<M/] 0?KUE1]/$]\- [16XE2K%@2!U4]$P/Q/^5QSN=T\$#]/G)HPDYB(P
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M&5\WV(D$^&--Q.+0" RAPG"7X+%Q4UA5- TU3YFJ<BKLN.+RF=G,^]@2-ZO
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MY:I7FA>O(P? <=X6V9/Z+2[K4MK0"72WK-9.K/DX0625D/3P!].G= 6A#&R
M(4ZN D"]U;;0T='K5>/[JWE#Q(\W&U^A=UAF&,\'M3*Z] 56@?Y*BP]T/WO
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MO!@^N&3CBBT(:F"=7_IM9 !=,6-8;"*59HJ$+25@O ?3*F4IE^+P_G#$HM#
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MTD$U5M=F^%X Y).BC8Q!4CEG@/B@>O,(I8@@:!DT. >PV@ (Z!TR\K^O#[X
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MC?%$QRS]JD;0CXT"%#]0L1MOY-<*HJ$H8Y@.P>'*69,S\D? =BL1.[H 36_
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MQX?31=;?\P?-.Z0XR=\5_!+>%Y4=WKE;;H6C'!K9>!=Q1A7!IX47AL6HI+\
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M/M[(Z:.2^<<RA/ICV4?,#6+/'0WS('967UO4)=_N@@<A;J?@)$!/.)5Q8&O
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M8GL_Q+;7I!$G"2RFX8EI69%DBSP,2=AI=@N".@CJ(*CW0U##YU1EE=4(@HK
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M?EM;Y\L(=\#;*OF$@=S)2)!2<F]&JD*T#"V/%@3WQ':N'?8<%$M==CPI82?
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MP9:M*=NR]7Q+_)3'=1.EL75RIJ %0"8N@;#1@_A;E.YV;!]Y6DW)L_T*=%&
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M)H%%JJZ_!5[_DHV[\D3L';._^XJNJ;?EP';S-C\C>GE\NV>;>P)\"G9#S<%
MFF2ZQ$ <,":I>O4'+S(</Y;H(%GXL6HKY'2=C\KNE*O)==M<SV*>P-<CF.2,
M:+Q-JO5=_'M\PEI94/?'UJZ1"0,8A+?J?[/XQ;FH" ^+5Z_SO&_1Y?9CIQ*[
M&7RR<U/LHW<8GU0GT;!W#G]6B#6<6N?<@KUZ/C1C.\?=,5I+%_)R.(YV1*0_
M&RLU.+#)'U+,0,?P*\1:]T1,!E9Z1G$.&6EH824Y($P7+0B9-C$WG>%VYV"C
M)^OVU)F5B(*/:<9!6/W+8*$]&OOCGG-SAK.J/;1VC[L_(T"Q9DTN$"XV)04A
M@1Q:;0>+GK%)!^:5\>#;%V6:'KRJL+/L-Y1;ITV% R<_X'R".;WX.4@2C'>C
MI&G$&K.WY^#)K8QY$T/M;5RG\;^CG_)R MQTROBF;PAYF$0!_]X_NU[XRA.H
MPW8"QS6\B7/^ HJ5:7*^$-VS.6%/_Y0Y8;9(Y'X/!;.U'W.=5(O#P1I3:'.F
M-Q?" 8VO!#,Q5K>9N'S7E=7N<+#M4IA<K$+3$=QQ1W3'<Q0==!!%B#/6^+ 8
M'T=ORHJPL$DL\:!9N6.-D5[VQMFKCB)50P)L90_LFT6+%;1\PD8F3 ."*)?1
M]31^)Z,1SBA\5 ;BG3CH;Q69'2TZD$1SVS(E&U#A8R32L!+E[L3 "4"[7I2\
M+/EX3ZBP& 6I$R<::>E=,03YW(/T1HNII>T3\';968K,_KL%&430GDQJWF8<
M.F[SU -3R?UNWSD%Q7@>*PYZL,#V:BCYE+Z,OC$%;[$/ <C\AZ0[X' L<2O)
M!%[@HBV*-'+LDL(K-?B"RG!@*^9Q\HE:T60, 5B;(T;Y[T/69U4G,$/HW'PH
MB$C Y3E^" V3EID_:)B<M5G*_%QW1LS(UY05CZCALT:I_S*EP0B<NB**B2TE
M4?6L:#GRYU*3;E: Q\9:M$7Q;Y WA+"-;%48.,AUIM%0(-Y9R3K2@HV7?6&Q
MSG2Z?NW(5AFR/%C#CK+&W13<]87A41Y.?-KR@<[@<"=!W* 'G2?=-K!]? (\
M3P8>CH,?T'YJ&>T<CS1\ XBIP;$4B<8-\7"C/;PF@^4,;<E@C=R<!G&IHO/,
M7-0R.WN0S=?/@=MU2QF$\B6%E_Y*G@/'@;])!? ZO96SI"C2?:\$OVUAZ -U
M((R G/7G\N)PQ+6C><?7N]SKMN(R2U\?UR#CZHZ=:UF8LF="V8VY>131@&=D
M*QN\ >,7]9 =H4.#4M3BQR&,[M+3E\])']+V^5NG<^,[4]'DY*";S>D.(  X
M,J0@VVK-1*Q:8Q93"=S1'!Y. _6'V1T-.IS^>"L>5"&37VZ^?3Q* 5,:=CH0
M;ULN<];( !Y')U;Y8VBSI%C9M:>@V?%1O$3+FZ@@P!$R^'TZ%,QY;S@N;=7G
M]DO -,B-C#FYC#'9<,#PD^3%;KAY)=<$,)]-XCH3,X>M J<TB2DM%Q$G:G!V
M[LV1\4C>E')4KKDBI @/?OHL5HF@8GD.LHYET8I#4_-!(K>\!-6+#B0:96G&
MHWQNHP;SSN7K1]C19):9\XX9/RP,@8FDDHUG4IHZJ;()6Y99F;KH V7+SH!H
MFBS#&LF:+13995;3J+8HK7@]V<:*%,X_;/),['<VY3%*"J^&JRA!0N,5V<YR
MJU,?QY^=E:+!CRNQJ\#\;ELEZ.,O2DP/LTO"WX7#"&M,0I,GD:/'PB:;9EU3
M-+YS+'0IJT^$@N/Q+EYH]X'\BA3X,4Z67(*S\3;8#P AL:@%C0<'F-M[9>,-
MA_<0O7-180'.B%.R[-=0'D3Y74?6J&^):5PP6I$1)!BH*Y=TO0\ ) OBR(D]
M>WP1KHLN4V; X[WQQXY!)]2+3%@%Y!-.G]>A5!E90UG]R6HS/\.A \VP5")O
M4_CV829&8VY:Q7,J<HIIU,'(01]=PXZL/?,S]G14?T0E'"D=$I>A,,BFRTZ)
M*+J=%3[[PL2?"B+C"+V_OGN!LC:%U9#CZ(JHR)BUZ^/97-:/BD$[L6B'[YGB
MZ\EYER2.2[A9B_**"9>]=&0V=7JP\2E@#YQG2/C>KBTAZQ%/IJ=C8!#34X6$
M^6Y:QW7GXO>$X@5H#W2")"7X?NC#N=B"B]/H "_PP7/$]<+B%>),G.-55EA"
M;F57!Z%KU!6^<W!9@>,60-=$YW_2V4S;BN^TGM5Z=PH(_P\M?<[()+.J4L\B
M!4.4OU,:568*^T;'VUJ;./ *."0#AX$K.;SGK7L ;!'PC7C$5(;2\* 2JF94
ME8X>VF;37/D ZK@ON[)Y5GL7X>>CIC(\>!'%A:OL5B=3GD1E0AS!L5XMG@^R
MGNE2W[KRQ@UR\48K8V!YJM[@,'#4<$E.5?.[Z_?_Z 8>IB5+%N"J)%N@'EO$
M2UN,%=<SV'2,VF!1KX2YDGB!JY,=44*4.(N22UDM4>1"U)<(?V1%&F=8Q,!9
M4H*VQ*0"G37<=TPK[H'#S8EE/-3$-7'%1V419^DF>\N15*Y*S#FW78B'1@<&
M$T+"I,+<X&.A=5&[7>;"9BD!,^HPD>$$Z\K+!8DQG4 D-:;@C_EQD<OI.'1,
MKJ*M]557V6:7S]5O=A2G%Y?U2SS@?V>R?=;TYIPAV3B%8D("7YBJZ00V&C*=
MKUUQO77'XJ,;#KQ>S,HNZBQ3CM6II1G7R)/=X>L\,/XS^D]H@:5Z*YI><E__
MI1S4EIG$,8V![0;4/<+17"\M/G54M).>I;RU@7TWC1U'WRP7]"9W0U=MC?T:
M0^\BKZJB;Z+Z6227J!%VZ?KXKHQ$68>G&'.ZRBLGQTAZOR^@-I4$_E8Z!"XM
MZ]K%!.VS.^Y0OL9G?^$W@MGXMV]>?WSYYO>C'W__]>V'EZ?O?OF?ER]^/_UX
M\NK5[\_?O7GS\NW'TXT:F?_\Q?[]-5A^T=&/X^C7@FO#S5I0@+M8'E7 3Z?1
M<Q!8[+%='K]2*7PY=WAR^6Z.P5OXW;J:K%WB\./?WW]X]_[EAX^O7YX*+QV/
ML3AF@=T$UZYXVCY/MV,3EDG2+I8<D?I,^77XX?'#T>'A853_NZ6HDV&5Q$EF
MTA=Y/,$:!\R^$IH-:I8?30JO!C7[!E1=G,S /V@PC,"UOCBG/*[%%P4]2^F7
M?G;A42]X04J0[[/MY&KX\8\I<^%[YT>/AY:.'\ME1[3:B0'J%))JM TPQQP)
M+5*)G ^L#K:.TO^R:X]&SQX=K]DFNR_/X_FDRE+L^.KLS&4;4^JR'A[2JQ_3
MJR<FI_"P#85A6T<N5:DMO]9W6+4?"3^K ,O^ 'LM*.BJ=<+2]T!;XVTBKUUM
M\/@</&&^1"(%Z$KC8TQZO2+,C6Q)'UMIQT7)H]]_>?G3R2\H4)Z_?/GB]=N?
M5*(\'$>_4!7->PM:L/.EE*_0.+3U2/!_&T*DWE4J\*"X"]</.;@&AYL@UBWU
M*&#XS"4RNP;D;RZDB7%C%F7<"D0U AA[6'T+!X+T'8NLD XA9_*.I!^=S/G8
M!90TJLOA-UNN8]?S@1(;N<W1->!=P.=[)CFV5/%378Q8BXVHS3+5],<4"T"Y
M51#$A$3TR50?L9U>KRS;3Y$4YHR!,3A1B?X+Y]D6+2?4R"#WJS)!BF")PUKV
MVZ43]_CW-Z_?OOS]].35RX__^OW%Z]/GO[P[_?6#U>0@P]]@M]EI/#6P,R]L
ME<[:<O*=L;X:4!E:7KMW+M9W7^IBK?WN8:&Z;4S]_N3#Q]]?O_[F[_B7Z/7K
MRX[HYD2\TR/ZY/<W)Q]^?OGQ]U?O/OS^X>5/KT\_?C@![Y'<R'=O?W_Y?WZ5
MPPI6#Y>3D]'W@6HPX%TN,/&<0SXO_]U2W>$'D\?<8.Q0T]YX57ROZ[K%.G?N
M"3(DJ_E>+XZRPV+P[^COVD*5TSA?\XFT&;^R7A7[XYK=-'W;0S_Z2T.D _+B
M]C_[=K[P3DRKRWSK:X:U[XA$76[;;5W[KHC>8@T%^H;'CT8./($+F[@>@]T[
MA7N7JC'P#4U%%2-#06NJST 9Q?4<-8B.Z'CT[*FXM&"W&2D4\&]J7 .3/M[%
MJ/_R\+LQW(O5N'2_31MP!48:/>P^G=Y)H)2(R( 5YE62U18DRWZ3<26QY4(A
M:J39LNM*#J^: ])B\A>F43N=KOS+T>&C\7<1D#:G:#8U7\%BVZ2QF VX"/P'
M-Q5JT0^5R->US<AJST#JMD8[K,;L9?*?EU6V?O/W?X[?4V']&5SB2=%??GD^
M A5T80KIHY+.+_@Y_P![%YKHM(45==  'OQZ>O(M7T;);W"K_R@1L6)2EI\.
MJI9#$VS>5[8,U7X!0XZA1<^NC_3J#9!H'+VE,A:I8]7>LC[Z#_[R]?MW7&-*
MN44J8!]HP]3&A?*"EGATV,&"H8PO)3JP;X;%K\N!4$^8;1RP:[ _IS)O>%-.
M/[VBIF\S27&7NO@?#C+G P+9IKLM\TYJ1AQ9*0?FPB]BG>]\G*"*/GJX$!Y3
M>,#Z6)1:M/2\WC0C@A\DA $,]L52/NBNE8=;P%P4G"S1ZEZ#_:RD2,'$%%2?
M@M@E%P7^9M(V^%LLGV8114 J)D\9<8.Z) NL09LL$:#@D[Z'?68" C:VS\2M
M;'4'*&!H$1!EF2NK=.N0@(DNI:FH$'>I#:+8UY[=U%V]RX/Q0DL6=OM V.H,
M(.I*;<8EM2^^%JPS:C+D'G"SL!EAJ:G18M4%-<_K@];6RVQ2[>%BN=.VD# P
M+G9M^0=WM!D7-1- MX&*#_<81?6QX'6R0?T]T0CS/(83(? _J-!AP?XK!KKB
MO"R[UU2,L (<V:(G<_V^[OP ^-P:K#I7L-(MB#P3\%8_]<T/JE?#:5%O5J>_
M?H9#,.#B5B8WYW$AT)7>5W'YIP?EUD$.E'V63R(K"BYM)9V('=VP<&*#T1#@
MB)1=UR;W#;2A6C60P53:B+4\\,I"FCJR2EJC.&C*S+*S(LF/37QX>?KRP_^\
M?"$AB"?CZ/_[8*A),_W_OZ[ 6I<'V>U(WK/#/Z6;_68?>47*:3="A<3 3W]_
M<_+VY*>75(]!\>]?3T]?OWO[._STEW^=OC[]_95P]E,,KJV4^F! O*TMLO$)
MN'#+.B/Q\,K*S^<J]NB:#TZ$OK,B]-(HVK4.RY<"W]\L7O&OLE7 .6#,5#0N
MXMNIT^GM4NSMTAI-8S&!;#WS,$IJ4YXQ/C(Y9IL507-ZAT.?8#88ZB\QW/5G
M\MI<<&N&&-$GW SVP?;HO8)O!D_NX.=Q=(I]^N(M9@C_-9?DE:][Z"EK=P"A
MDBA>"\N_SLM]_ [_U7U,7MP2M(MJ =/$#N"SI>U0LZK9WQ2K)D?.2X ;+D M
M'^3@<A/N;;=>7/.5U,S"3W,-XQ0E]C@D 0V*X9*EXY7:B-HF>QW;CZ3S\ ,V
MQ[QB$T&[#?'I\NM3&?/Z%C$?/MBV]%>RVE]DM:=VM?H,V!JJB]7 $W7S>1",
M"*=28>%?US[QR][%(U/&I!@ QAQL&A0;K*D L*TNV;]=#J"_.P=-G\&C=SL3
M+^EQ;:5+&84TK1"V0+H]B4ER*M0GZO- 8:PT)Q/<4'X$O$X$[&3<" HK EMB
M%\KG!3U+S^>'MR<'$T*PP@:.!$_@.+IBSL\K^H]"P]J>S$UQX*Q4R^CCR=N?
MWD4//E)!+#SXI#VS+:&XU+=MDF-#, Y4B-ZUS:)MON4JICB9C;3G24K4.6K6
MP&=A:AVDZ5E9X/UE0R5%#^3PG9R^T_/TK=C'W&Q#)QMQ (S=@AR?+' NTPR.
M&P5_\0-'T>G'GP\.#X]&&,5 T(D\*X .N6WLTQ*F!B,<6C[_H@)OLHGJ99%6
M5#P0*SFD'>B,MAQ$$KHA399$9I'E9E$OQ_U[(P)MCQ%G L[M?[CA;5JQ2T"3
M.:@A6D%^IQ5)!(S59?^ACB-7'^4UZ/%74A<VE21/#0=RA%OHI1C\8X@3PD7P
M.@0$,(;73*M'CW<6PZ_C9K;T4$5Z=Q%*MD9WSQ#4YER1'+1AOQ/,S)I;"1W>
M>7QAT^,S0'N)^1)FBSW+=,J)$^)H%B_R$EQ&JAG#>O<EE<5P:L U)':+ A]C
ML'<J"^R= ZQA2Q7W!-]G2W0H^D6]\"1Y+,?C&8@5"*&_GD8? Z>@;<JZQ#>F
M-'L+#POQ3]R M #&L8?WQ;L3-S6%ZO5+/I5S*IL'.X30I_GN@F!WX"TT!)&/
M,2,F(1PBF#:XCRO;I+E3NZDZ.P26C($!?"JVW-;+&DULQ>(T2_R0O)E1>R_L
M'%4)<N'\ EL/:FX=2 TLE4V:U('O4]X!.VPI-23Q#7X#!4(6MAV-)MWDF9EJ
MM&8"TC!U3=/62O(%K<K,_3@UK#:P'YW4D4!0+$!I&$Z>4!<X,EV;2/\JJ+*#
M.6BPJ,8XDB984!?H-GK5KDBYPFLY.9B6;&Z-HI,4%Q-]&$<_5V@L5Z/H_6S\
M8DRYON>85SM=T!+^$5?PO.@7]U3EX>>G_["3?_#EN&W_@@5C66R]T-9EXCC5
M*76;)%)V=OK^]=L/)__O2?2@("NX G7W+;(+?HS5S,/:!YZ.V;IY6S.2MIXN
M;AV-,?QT@!&?0C"/WE?E%%X+C[(?ZXTIH#MX9Q3##"4Z''@-H3EMK/R'UUEC
MPPR8&K?G4MY9P/B"?2$+$4>G_)\M$.7X\(B+G__98OWUX=%CYD*I33YZPDW)
M12.]JSA)IZSR] *A#X!M>2O!1! ?AE3A]9EN9&76KP67&G+G^6G9 B?,%XW$
M3!=J%XU69_3(' I9% )I-M9-]1# :G;/2"N4;.Z-Q>H#FH/<1:2MLCA@N"?2
M^O: TK@,!JGF@LQ&S413T&PQ9>LA+CI=#;I;Z 6F!>6VCKX;^:A0N.!9G+*@
MEH9(-,M .P*)Q#$BSR_.C4AW[*FB!FSVRA?QDJNH"X5U=E? \L#30MI>CA6U
M([S^KNAO9;\Z0I5MOW)!N?+U^W?>#+0-BR6^&QT^?31Z^O3)%Q9+'#V[O%CB
M:'3T[.'HR9,G6U8N\?CHYN42F ^=("JL\>ZU>\2M@BLVX5^.QX_UQ;V"BIWF
M7R>(L;*GH>&%K-FFA"43PZZ2?$3@VYG)I[8ZD8AK@R$VQ'5Z\+ SXZ]SN8WF
M6-WOX+^Z17L69O^YI5SGL:<OG[LY).B<#;^']+--6CI,"1U<\?(Y+EQV0.J;
M?.I*,!/E/$CA"\+D(P6 @83O<9JBM.S(#UUKZ#F/P775+",ZQ-1>3L<8I:<L
M0[<<T?86#)4RCX'U6IQ6>(980HT9.L6/#@^QI(G*F@8DQZ@O;'$2TZ3I5*I<
MQ%45BXJQQ_3*!S$,1N]1V'";5!F?^@HY].9/Q:WZ*T%F9 2"4=0"TXR67"FX
M.=S;+PAQ]E8W>#ZFS:Z=U> 1C"FEL:(K:-76UR;1T>-+220(9-(YTA/RVC;U
MO"1,$3R.4NKY3E_$-: G]L-4J?1^WCTJ"F$:8>ZZUGHF;]-Y"!M]30_?C7RM
M+LO;W+8\U@/@TBO0=<LMFMK ,WA=_<U:NU&RLM&:'5/C9 W%*58E>D[\GOY)
M\O=BD_?VSK%;QLIW7E9=9.]'\XM*:/0U'>HPNFLA2'M.@'9);AONM4#!<&(B
M!LTP S]06_S+LRJ>\R#NI?0R^03'8T=L<LVBW*WK!0VEK/M7RKI?]0)'MP"N
ML ,6YRHTP5W6>:[%2[B;1744PY:M#?74EBV)Y$5/F6[9$K=N0:,M6P_J8#1X
M_K)EZP(S>OQHR]:T;2+!:OMB"^GW[.GX\9:M2<VC?F@9[*DM6RG6+X^XBADK
M@\_!N:#*8/8;>H.-1I$.T<4B7L.(??N19N,8NHV?CUA:G;/(<G,4,)%L:LG&
MQG^4E:03)-&,Z>$&-F?2-@Y=MC9QE:P"#+KI,9RL14.;'\]9E;\\>SQ^%G5.
MWN/C\;']B8]M7Z\#MZ?[V 7R.?$2_U2D- U>3]IYRP5GC(7:L /PW9/Q46=A
M\>###C=ZV-'A^*$-N.XV#[VC1#3F3Y:1#&>F@Y4Q^FI;^)RDKHZ+)%+,RTO
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MMBZ:BT]ZZUV_3FH-1P!>*GH3DA'_2F\B[\MDJ?==6MFT"P+G(^%-D3&+")A
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M*_]>Q(V6,,!WIB:J35(9RL(W4CD#O^.#72#<"%W/_S:?D[RML2AC>1VQ??7
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M8?^)H%IXH^,4SF56-RA7SXW;NDN^[LGVB[--OA!QF^#'0-L,O@86280V58T
M9CF++D6)\="OJ)+3%)3G)/&4Y0(>,VCYC]P+&9JFJ;.4L*FFIJ[YN A^7 <W
M*S=G<3Z*9BWLECM%HPY<76.260':[@S>$L-M+"_C!$YL01%[]V!:*>AGKT.
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M'0(#@'K80B@2T7VS?3N/G2^@'%HM]?#)J/V\U=H2CO1]-%M@ ///VB#2Y\I
MW]II$K[3)A',D6^/8ODV^^.=4&9SOZ6WQTUA:R\$@N[N-0_W'KIT5'*K#OPJ
MHZ?PJ[4-E9Z&(>WF$KCT2[&C;/!GN%;BR$'&D#MY]Y2<@9$ (8 U>UL&K YU
M#IN'BY52;@S7_H.NY&3*(ZU\V><E(E S.+#X6L[J%$>[H(W1"D.+%,CQ;#83
M<H?2-L&A6 ?-G04 DHUA&>8QQFG-AGL3(WA0"9E93]BTU8YE"*L8IU8;;MI6
MTXU\N2AYG9#R[N4?VZW6@SW\LQ%^1ER\3F0W=7EPP\[G,?!,XGWTT9N]M&H=
M-/;W5W8(!2N'V3:*/0,+/WN&#?4,5J.URSU,5LV&ITK;7G9Q8YTXH-*VMG'H
M!3OG-<:,F WLH>]C3:>QT]DSCS.L(":P@;T#"__FLH&]PR\[UHYY?-EX]> U
MMY?EP+F,XC (I+\=2=].I)O7WQN';+#'9CQI<]G 'ON7=KNQU^+NH*MF@Z$:
MPNZ!A7]SV<#NX1>KT[!V'EQ$R1IB6$['"W(/Y<#EP(O<[9$=)6,1R^C&<QZ>
MS3'^NE[ W\8;(S/8P.[Z%ZNQM__@\AE6D/56$/8.+/R;RP;V#N =V@\_H9,5
MQ+!<CM?G'EQ<Z7@P**_O.<()@SCU$Z"#<1@'NVM&EC:7#>RN?]GM')K'%U8/
M$]C OH&%?W/9P+[AEX/#!Q=:LGH8EL@9<.3L.K'EH^UXOI=X\$X\!EGU2"Z?
MC+ST$<@UFKR22?7OS!.@:WL,[_IQR40DCOMEUH15^\U[6M-R%P]DWW[#ZNRO
M_&1D;HAIG&:Q/S*&%>R/UH!5[(\6PW0;.ZL[;IG]4:T:-,_.Z)^C;^)>\V#7
M;.9<AHGMW]_?:(YFO1##9D43W.;2('B2VUPNRTM3C\GC!I>/#T5V&M;>RDYA
MY?Z6YII0]F;&L(*]&7LS]F:+G$O7;EB'#T9Z-\6;*?IGY+^+4R^16*^B8_/S
M36[&!'"XBS9)]F62@.#H3KAOMUO-A?CTG#M>9=Z/.(:_[L^^52_E4>3!?&'
MPDZ2R.NEJN-O$E(?Y$J'8\MJMD76*1G>,)I[<%(#*!LZWZC;,GQA)WB'_I'&
MTR]6_9TP3F(<K2KL+@VH'X7#? 2N !MPFPSPQ7<V3\Y'U2ROKI_FI*&9M)H'
MY9G@ W7K%7J>/L\7QA)>1_90DPIG$WDXE&*,\+0$]QJ+ZEYC>DH\JW!=]*6,
M*T.[0QHML]N1_RH#&=D^3=9VAU[@Q7!CXMW()VU(;IRN+3)OU:B\8S4/GZ!1
M>1OD]<D:E8,:6Q.-RB>95(H]JEW&2"C;"POEBJKM]O1\!E$VH9%]+;=[0(-O
MVW8?YO/6]F_M<;PEWLQ5O?MG::AT_A-[W&4S,FYT4W[J>E%EFN^I)B3\GV^0
M H;3X<=:C/*@N5^+<5:-8SDVT?%%+691!$$4^I3%&J8TD+;K0!J4U&,RJ,^U
M&.C,('62%6( [Y.1CFO!%#D0R";D@A,8+ORA/]E!D((UJ\7,PQ'.N2;*03X
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M1-]'AV[S0H&&J  :U5+ZK5^2\%H2*RD>0_/XXUXKAXK3$03!,!<*A8\<&^)
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M,W9\JL7 ,_=4YPV)!4K)PGL;.38PS,)Q;,"Q <<&ZQ<;+)D6S\A;M7^IE*J
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M</'OTVSGE+73!,IGX79I3]1'J=.O+FZ^<!Z]FZ:>DKM3)\F]TW0WY]GNFD.
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MH94>'-VG*]%>^GP!N)$Y4]Z=(7[/A!>*\+5^A?/D<9PO!KKV*]B ?BINK/3
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MV1YZ[I4L$T-S0))XAC$3@1'>P^/^YW\,VZWVF[$9.I9A>K9A.VX<"9N/@W3
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M'*4+RXJGL4N!#-G ,A>Z9[NE'6+:V"UV)MF^:8]2QKZQ+=,.';9EC ,KB.;
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M:I4U>:Q:3$C5@X()J?Q0,2$Q(94?'"8DAH()Z2R@8D)B0BH_.$Q(# 43TEE
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MHO)U"9$40IK7*[O;9T3?V7IZK,Z+TU:+<RU-@]PDTPX_NX(YRX%:+QQZH^V
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M[#H:2MC?")$Q$BFU+41XI#;!PL#%<72]_%W-_IW/^D7MLU>L/=Z%*VDR^X%
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M)3M..H>=^O"HH'K(!BYP:J@BTYD,=^IO&<;D4,!:!>(N=C/1F$A8][).8"K
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M>_^7!WC&.)Y#F-3!1>:P7%]C>[R9:UJY//9KCP*OV'M'IDJJQ+%/&###1E8
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MZT5\A]EKJ$LK/=AAO=6I/4D!R1D+Q98_('_]#_'7IPQ_)>YA&UW9]_.MX(<
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M?]PISNX'UVP1EK9/:KA]>LMA!KQ?<$V]=]?%L*5P! ;C/1BAX[,3$;,_KIK
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MAC9'7J,"1-?""A!6FS5NU;*ZL&RS/ZQS[XMY<\*:2[-3 ]O^P&:^N"@7X;^
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M;TWP/\,4J_?N6LD&X4)JW6F6.7+-Q#F+0D''8F>X8%@\,89G_#A9Q)F[/ZY
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M6,T+.L<3;&.VXP:@I:;$[Y8_(G0%OBX>\)E)*V1%G.CUR9Y(1+0IKY@"!NA
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M\S7&)B?")JS-:4!V4=VK#FLK0Z'9:EQN8<#MTW]-@ G,#4\T/C-1_(U#*9_
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MZA4RU2;@DVE[IEZA-?/,^>]>$*\U\=SNF_>6:;/Z1$Q2;37?O =/C==>A^3
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ME1QT;.Y*QX,U#"^/CAMZ:.6FHQ!>F]M:A(_00,48O,8^<3E_@2$ MW67H4.
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MNS7^'7@^AGE+.JO2I&/+\@F4I,I.\0R2_@JS@:!N!ZCK'A[J\D8SFE2^(9]
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M]A].ZQ]P(;>V\<4!A?Z?P#4]P^33+&3X.J4;OLQ1S).28*L)'#0&!S:!95C
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M,Q%)A;]_@<R%,ALM#*<(W@Q^;PRLLY\X_T7T&8!K?1C70;D546=NC#!*A#2
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M3 2J. XZ-8TZUJU8Z/<]F2+$$GW@,V9S?RG,R&)J2-!S-(\T#]B375L,; T
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MX.-V:#1$Q^\5/O;AT@7[NE>!,/BX,WXZFI_  @IZ'L(7Q18HZQZ18#7%(2X
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M/\*DFP'=X[/W./=\25U,[SX^PZ/5O<LV8L.:M5H:&592 YXU4#Y1J\W*7[[
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M).\L@ \53;KWO77<%_A96P[9XDM^.9ZO=OAKY*E:VK&*O:IZ@IE\&ZW-/I.
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M"!HC%S\F2IK3IL*C^G$QPM(;9F8P[ B:,K/R"26Z]UL(9_S _P_R?@'+ 9;
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MFFR49NL%(WM[A!R*6%W%<#8G^"D1O^J!VT(P6D&:D?/ SHN8+-;R 63%94Q
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M3:I TUF1S;-()U7 WF95V@I-_4QF3>9$ ^R0/:JW*>)@C$=;OA[1!K-I$\
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M&[Y^%W0BL87% 1_C57S)X(,;3A8(/GD)"+/7?TL]@/B@%' U9G8Z SGOF=J
MT\&ZGAVXF?>FW!&P%XD ,&%F$CB3I2:_*["S@1UG1S/"65/3CM4-]]6 6&NC
M.MX&==J-J2,N>AF$7NC;.FOJI&X<XPYN]L^:UAGSV9PUR4#?[\*]2I\?S#(N
MG0OAR%E3:9F2E0V[@A8+'KG=/9+ SZHGZ*ZB>XB:66!U,C'OPOGJ2AP6=Y8W
MWW)9\MH:CDS*ZK"WK*4E-#\;B!O7SGDMO90Q$IPEFAK:/7I*FY1FXO'B)CHG
M3LUTAI]4--&U<KXD^/$"2I7Z-8XXF@Q<#:=)[>IS$IJ6LZ.\LVWN16?=T(QP
M9#2T?X<$,4.G!N-TYU"9S!QORB./<]O)D(T.'"-AVGSRXT9SC0,5*-?+;Z-@
M$!9+U>ZK_J77YF!2)VHM5]^E03=QZ?"12<K(%S-ROBT<L)"KTS"Q4JC2M+&
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MDZ5;:BQNJ3V)9 ,[+OHY+,YB'KS74QSB=<![FM -9A_<XM C$, 7X>HJ9*/
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M.@P#(T%MPU#P>26K<R^1-] ^,H;"6Y7L2#&N8(I6C*L+-B:)6ENP:U*CEO4
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M/V("J#][&A)XV&<V D^)K$W#S-E,'GC8Y[,)/(>8*P6>FM)GA&]_X%ELHX!
MQ.EI$^_J"-4C#GQN-.)<O"8XA.3!BW %)[<ZX:6-QA!;:Z9I,7#@C"'"D&GH
MR*F\#$945F^NXG'HZ#DW= &)D8Q?ZNO?O><KC#\8\G>;HR(] YKJO?0=YL_&
M;KV(Q3/H#>/QM]SQZ;[\&]63+Q6J0UH=RW(Q;YDI!\19N+'UUX"2ZBMS/K"1
M!L10F3$ZW:/J;Z?J25\,7_U<K>G;9D"R=8[FN ^U'YNU*<<]=3?:OO+I6+-]
MQU%2LFWVK[I=LX]^.0\B[#.C55A)-GQ+8ZUR0,5",P1QSD'7Z)1ZT0I^R%A.
MG,G<H7G:KAMWM)R:;49ZPM51TT.@1<0FCR<LW@2)D^<'>HNC-8TVD#H%B<=L
M-GM@PU=?.!EA."00&1# QE11>OA5?AI5DNPHOP> ?.-4.I[$)^0[0B"?*_.,
M2<.B5O![$T9$:O93?UI7$JHPGX?"?"YS\X%5(L@VV>)06Z<@M<YZT@C#2:RH
M$.#?H<AB*&HP+#.AJ([?FS B@Z%(Q"%#E]QGE*SNM] I^&]>]$BCZ[SP].(I
MPEP>Q7-@!8K:F7>2'"RE29(5$NR1X(\* 5 N@0M'QNK@4CT5SP/(2B[E_=^N
M"[!,)$V..I0TG$C:HK%[HGNZ2YZ]S3:AH6YXZ"*A:4;M)*T$@!([M]Q= ATJ
MJ3)'D2A[<",,PQW9]A!(A_02?BH?C\9ZD:*0H7XMV[';K1&2\0<WU@/N2IT=
MR=?;\QD=*0ULN4:<(4HYPN*Z5AID_)3J.,:X.G#(8%VNLQV RI9=AMJ0E-X^
MZA8JA=0>2R8.)5I+(T?5=>@^2GE" ["KNY'(PF;^EO$<'C L%R+H,KI*%0+G
M1T+J@\@2RM@@&"/T#R.#F.@9?V6RTGS#/]O!D\JX@3T"_B@3 !42B,,BV;E-
MUW)MO);O=L3:4_EY#*G5(TNC.>\<S=!2"Y]8&(8CT$'%9-K(&2^]4"8_1@F&
MHZIA;8 ]/]UWM>I,#[#]51D.-3Q*6>HTRW(;1*)H/K/Y$[7U;=/W!SY2J]&S
M'\5PSE BAHWZ;K -FOJ+P4:5N0A#OD@56;>YWCD+FY.'^1 F/2]6P]>\!BDS
M4W*N_/2E>R4K-V?>[."T;;EF"RG\Q2/++=C' ^49VJO#791\L1EUPIKSJ"HC
M*S.J$ *.CB(A!EMT<T]+J'A+L3HHD M;>2=JBFB; !V$P*S@+D>? FN!<0P@
M%["K'MBX.VA2&>]RC5+V2/"'XT,A0>/QQ^A=NYI.?E*)09ZA!XD54F;/ITJD
MK4^61[FINGV6V(1<ST'B@1H=1ZG["#%SMN[:&BHE>Q>K59#PS@AP; )EA0P6
M\54E/JBLKQHSJX5^O5P4?@@'LLRH^*^F2=#!:.C5?\T9&:JJ*4]0UUPE&=@Q
MT<(TZ\L2)XMN*L-+M;0\T/0:=NL:]M9(9;"1-5"U;5F-9SIN65,78H<FU*I#
MHR'K+GAZ3I;KSS%>L-E?H7.B+#W# :M&?^1XQ1:MP/^8KH]WS-H\$,$M&Y-#
MMR]@-6K9J-V5FE ,MKD*+</V9KQ9AH*ME7IEN&QD35#V&=B!6F>W#&]*URJM
MP<?*W)IBZ+5<KI()9S(,R.]R<T5;05MA.3NW<9*#(0ZX+7=HW2B)G]*5H"-#
M.X2L\9K-GB5:69+) =:T'IO90/L]CK.%0,L8HX7=(9KO#2:)HW3S.:=&UP_>
MM4:_,XOW$-4;FZ%7$75J9L^YJ]1'N)"H7Y6Z>RG1 F//O4230MV'K/MVHGX%
MZ(*37;P&<0)KI.7:K+]U$#:+8RNC$;P09[R+F^U2]L+/2;3#:.V1N*^_QI3^
MV6\!/:[: \"LT.YVX)PYK'"F]N;6Y<*MM^>OS<YW>/$8*S\(4J-KNI=S,Q_S
MKGRY2W811IL@##:[3;JEVJ:<T2Y<X0B%-#SV/08W(?R@@/^1*_V&==#O[=/=
MI?TY(4V:<P++C8LSWH@Q1S]G["?HCW(8X_)6XR7]W+ YY>$+)B^8YS(J]A32
MY6$V=LOP-._I_<6]IYQ]E;#NF8CE]3M77+NGYUR.JG.#*$C((A*!G=C=-BD-
MDI,?OE ;OIV3M@]]RLJ*)W\W+T^N ZKAP!5MS@P\+7<%":!+@=-.RCA+9; ,
M(#X2UL#,BJM^/T-7K<"JZZR%1F<'X0"'!2%<=ME+I@Q;'BMHCX,V\++BKST=
M,5STUPJFFNY:Z'-N^.D[*\C@JJ_:\-$QL#7DDS3Q2.J3#_!S[61J7CXZQ#?'
M\LGI?-$I#_P<KH+8I[LPP:N+5Y_]Z6(#_S+FCNT,+&'<QG @X!\%X"%^@NX8
MUP7N*-AL=] P(V <&<F>S <G?+47=5G'[5;VO!!6=.FR%$B(@80<@Y)#N@_/
M]V;&^(*C1YHO F\9"<B4>_'(CM]HBKE'*MU%I]I,/ABF-;);91_'%]R!5@L?
M=/D/G#S04_QCY(&"9<*1*4Y&:M1H<!ZC?$T.ZA[A3+#T?@MA(1KRN&QHCWE.
M\"-&3T(^%_*[S1E2<^$;;=A&J8G3(NO9+H+GE/<,<Y[RNEQ?!J$7^H%';FG,
ML[[2+H*/A'TK-G MK,/3]$6BN@PV,T.N169(+MP12L4[0KF $%MS$5$F(_JY
MD!*!F(XDC1BWMMYK:%U$WXIE]5Q?[S.3*EG4LM&B:@;E1HK*_H;9G!B @0!4
M)F8<_X*XA9(HD%V2XKBE$<>+9Y$U3]2]R<83AX,&4/O]O*Y?YP'L]<R"H7/.
M-NJZ0(^M1?Q=71T4$JHM$"Y"MKP7;V;<7B<,,D"5$#+Y:F$Z8U,(2^;6##/;
M$!\>K6M/M3,:=:]EY *)W\0H%0D)F1 3"G*<3S%*Y9IV7OL[AA=F3&,O[-,G
M?(>AG5GV2RC[I%0<5IVVJ:#1S\O\-)3Q1)Y@BJ*,:ZGP'@I"7@34R=6F OJM
M,X>LYN>&=(NGYZ"G_%$N0*GN8$==VPF<^CP]3[]C$]6M*$]OS*D;:5N"NH'7
M"$Z=W4:@R)E"T=IHRSIQJZ;GAJRL$V<"() @Z^$PK1-?O&[9NE$I?Z.%@"G0
M4H+6WP'&4(L!.+GH;7586EVJHBTG(6AQCHL^Y<NVM WC'0&Z]SAZ"=CB-R4L
M7_2IBX1VK],VDI:ZU&;L4)SRRXS;B;I.$B!12<UIE0@[))IW892MERQ'QYBY
M5.B.9C->WIL2]A1N6DXS<NWFTZ!)1YVZVENSW:--=-.T.Q)R,(B,3Q;VK0S"
M@M/T85+UF)D,J@.>HCNMB6+<]W[ 2 7KP%^L7H*81GOM25J&E&X?XU[2=CI+
MYVR1E_)U<_960)$JJE1K-F\GKC>K2],S;E_V9_E.(W-ONE>%MM_>S$W_8X6)
M2MMSF1AAH WZ2$,C!Z/*^-E8((SJ=]*HF5XQC#I*&0#-+B%$"]1K1ID9Q2</
MLO3A[A-?RKWD[:>A6Q:XG::=*LZB%2P1#-&FX(C6V(TJ]!)(45GM:2T,/GFO
M4!9H\<0L$-YYW-($S-0CGP*"V5^$.'O(P_X+M8&D+4B#LJ9=*7.R8FVI%"Q8
MI6*@;28'VF2"%(67MD(4%ZQ0WP;H, 2T+#:;[.XP@7=)#_0.!YO'710#W5L/
M&$,W;_EMDCQ!3?N496#%+#/F*!+<13NZ@C\S1!" MW%W8NNDC"_54K.6[=WF
M+<27Z]3F[_!ONR#"J]3 E^O[W6,ZX]SA%QS*O?,=0EW3*K6X63'10A+(!MRD
M<31*A<E")OPNSN5AO^8"N6"QPZR"#L=C?A907OH/@7_X7F!")9"#\2_7*%M&
M9$)D#ZGA=X4<Z,[4^*TORBNUQCM7Y#,8#*F,(V6$2IS0I8EQ3+2B+4.EMYR=
M[=!)==0Y>Y3S1[D 16V#6U.C'G>)6,99:7TXMX&2VAA3KI#F6^:+!&-T-GB,
M^6M^FQT;RL5=(^S3:,6&) KYYB=E0\^0RM/B5>A'D']R%=YA.)/#*V@W0\/[
M9R]2N(Y2(6E@1=/-8H2%;) * 'G&42H"[T5$0Q1S(5Q;O$H"W;1BE='V*"_&
M[_UGO-H1)A)G?<ID E$@ '"4%E'$;(C[2'RZ+_XFC>F++UZT>I ]Z++ 5#\?
MS9@0-D[WA6A\$0N,$>>,RN*ALGSH=%_YPVP1S(5$/W,Q'7D,9M[@J#5,WXQQ
MD6GLRD[(NF7JO_$V>/$:*%4[KWY/']LR'0O;>T8= 7DWW+51V;1+&2XIEM1T
MBGX&VI-9[#F%+;R.S6;?'*Y<0>FKL=N:RALLMZP0M]1[:+V"NKS]MNQ6'K[0
MAV>ZB[UPM0A7-T&($XS#B]]V0;)G*U/8P+]@8/L);QZQ5'5</;J:^Q9%/E8V
M+Q_>GWQ$F+.$K8O@B;:,J0O;%%V$Z1 -SPG-:HUC!B4P&'Y>,\E8TCC!>*.,
M.6+<4<8>"?XH%X /%OTL9# <3:"$L(UH(D'7B/WU\K$53;YOALF]:"*/<',T
MD=3PG-"L19/OK423D<;2%DTR]J:B2?/:.HZ2TKJ:_:N^IF8?_?(0)(0?HJV"
MEV"U\XCL5K#CRQKFUD;,O$UQ-G!(6C":."STHD![%>2<QDE9V<NRLLWL&_5L
M^^]!\LPO8MA$$3\'VP=ZP=PNV<MO)K7(&D*GF\W7ZBF2F+;YD(Q29X1?A]\!
M>U3FS]NJ<@EL[X8W6T+W&-\GU/_UE@WIV8L-[HG[J)O=2W5SL[<_SA@CSAEE
MK!U=V*I"W[-9EE'Z_& ^V#A?W-_>6MLXCS&B_NUSAQ6;6O>J7]SVW2NU72M=
MLV%=)7BC='=B@MN V[3!W"W<T4K<G_5<GX%TB(OGRMVL.9NBYM&;O_V0<4W'
M3N!)$U4@%)YYVR#QB$A:R1)9+FDD>JA?Q?$.<CQ5XHP&<7VS4&9FH=;W#B8/
MGJS-6<-/6<X3GVSR3*@UC5"0RN%&M- W!#H8@]F!GKJ^X)XN)%+^PL\AVS*%
MFHF A SH2@IQ%W/]VI\L]"?ZS6^TY&"@?!^;#O0J+,#-+*!GH(XM&D6<2K.9
MXL6+%Q#(_6&6RHO_CK*4[)5A@@5"CTPV)XR*QR O8\TGBK6('F[-%]:-S\2:
M4PK0MVIHQM:GJ95F:88QR@7FDQL7>3:Q;[GEAX]<Z/@J9#$^H*L?(QJ/LX/N
M8C^!(;:+8Z/SH."6-9B#QS;;[/1%9JG@?&B3L"T34:T/M#=H1\9B62JH"%HQ
MK.6$K(@+.YLHQO_G)QQ#,3XQ *6&"&;Y3F!O#7+8"U@Q>F&<T);SF7F(ZC(<
M$[&I%9BW9"3&HI'XWU3$-!*-WJ1A:-!?[I(X\4)H+B-6BF,NI!J83S?]'0AC
MQMQ$X+E/O"AI.6@\0B76Z-$C;V"?V&M=!I=2+<"].4LROHPJFYT0U,@+<F?7
MH5O>/NVE[<#_J+][EHH6X%P9SHSQZGP7Y9.8V(3S7Z;#O7C%D1_$@YN)?12#
M#'GQAU7K&'-V<YNI+FFTQ@$<IN6V,>9<U<A^NAC3(,XX]I,R[O.2N<Q0759E
M<(YJA>LM69"M>:HD:;'GGUOXNGC=!J(5["3AJY']=,;7(,Y8T]\6:I.]C>#5
M95,&@U<K6&_)?FP%KY*D,L%K_ML4L>&]"-M]4&F[ZVHTYZMHN$8;_]BD@?F4
MGE@3QGYF5KZ)X;>8'L_4.L<^3_Y%WYT<(0#]K43X-CLS&M\;(7QS-F4AMA=F
MV'> XF8<*X7B6OO4[)S@-@K4\D9'$\F) [XN$6T=(!^T$\8I5[0%ME_'>;*4
MN=HY9>['_"LQ3:LGT@?]E+,!(#X"YR)M:_&XQF/MT:*M2;$LFK4Y,4=HWUZ/
MMU+W!L[$6 N&JA)G32/]%1FE0KSMJ1?9FDGUUJ)N)KY[@5=1L@G-7$G2"<*O
MQ)7FK *PGLV:C,$:B']=]FD^$N>#>,/!N.'*T9EPK"S;A :O*.L$(7EN60*V
M+-=D4-9"_6NS4O.!N3'[X,V%YH8+56="L[)LDZY%E&2=9+4\IPP(6W9K=K6L
M@?G79J,V5LP-F17Z@?FM'M+7\S',WAZY>:U9NIAUY5I36B0GKMV=F[.^OGR/
ML2\XE=#_2HS4:L:(BUN(QWY@'I4GM3L,Q6'9YV<T3"+/3W8>><#1YH-R_!U;
MO(%F/JZX(\3E*..-_((Y(L&ZNFQP*!9/9-#UN#R%)7R%QEN.UX]RX?I1-QTE
M'PHJC07QP<PM=+?/J6UXJ1>L&%N\Z:Q?0]R)0W=)XK<1NH<8M,'0K6T)7Z'Q
M&@[=G0OM]M ]Y_H=5VPH01@'_D\>V4V5LET7PHE,V*I0YH/MXNDIXN\.49!Q
M0B_ JGJ8QC]R*,!:-3L[J==-2+Y9$[.:7IT+C'[J-DOGEZQ5U4^U,CV0PHDY
MO";5J*%O7H>V=FW1SJ*R$=VW:W<6EXBU:"B_#&QI9#5T9JEFEE]Z022]J+/+
M7[-+DB5YK+3+XH(<"\OQRP;FE0SL<2\>(Z=_MTTMS .9CQ 54A^):KDQE-<7
MU[!':,UD%Q'2A:Y;MNV4CH'_NSELU#K?BO!?GK-95,G3)Q/-E1K%O:*.<*[&
M/1RM8 54N#9XNX@/O&H!;S&2QH2L@+9#2Y\)K-I:)6U)D_C*+-CX3K+_W1C_
M"P1C03"8OEWFFUA(-&^,FB.$7ER8O8KL6Z*,M;FY1#AXQ_1 $X],=ZPK)\_D
MJ4"=\HUXXG'HTED:VQN9[)7LTWQFF@3.7X,MVLI)JSQOX=)/?4:\(#R^X54S
M.!>O\*-21)2EJ&]'<APL],#E@:?AT (+CFY$($5$J9Y>YX%>ZL<Y2]3JT1=]
M$-IQO[SC-XY> A\WJ^2&AM!?!8M^'3&/&^7?G]$XN:')/W!RAWWZ% ;_PDIU
M;RT*H6\FUH0R'Q<^AU%.O1H8?,;?C:A@W]#H:-B]6:-*PU4F)4K%;(]:N:AB
MN1&G:XK*WX"X[ \3Q 1&A<1SNXS^24 2KB!2^^S'!PH?J:?!CGIY;5+JZ2X=
MS8W"?/#-1$)?ZJ?&SK4C<P(!&]?EINWCWY9NZ3K^IW2R"%<H]YL'RC_63<0?
M/YO3?\:K'<'+M=1LGJ[]V4_+=3'[B2TX3(WQ R0G*,T)=@088/0V!+*P?4[%
MA#[)\DN<0EKX7B%O=HK")48_<YG_MR/!WJJ%TE& ?Y/62!PP1#M!\2ID^TY\
MGW@)GPRN4TD7KX%2U^Y.,OHFT4'6?)@1S%#.#67LW @.,DA1!=4YC KI 03]
M#+Q<\95S"DL< ]Z2$3*.C"#\;X]IQ*O?9\KJ<QJ;?K\1W$;WG#L<8P;<,]L_
MG.,73.@6Y$J/SC]AU1X]4N3TD9(@;]Z7,J:([:10B:T;KJ0"(-70Y S (C6<
M%E6<LHL@]+-@.KJ/_8A#MN4F3*S%:L.VW'$"];=>L+:721+4ATZ*@7E/2]ER
M1ZLR=L/7U("D6OJ<!6BDBM?B *_)?<[,1O4Z"/$5FZJ5=ES&65N^'),7Q<)1
MO^F].LB*N+".G!S9,D35NUE5E-^8T2G?PYJT-\?R9O/<Y$4<[S;B'N$NB'^]
MC#"\0,1,O\D=VZ%\8@%]L]N,DCNK+-,$.8N*,EK8B3!FQVO&#7)H.3O$IEM\
MA#:"HQL1;W2[-)$SJX7MUV*#QG)GBT<&J"0_@@$@& '*AH!@#.A3GUG/-;!Z
MK^X%UDPFEXU:R#AF8!4<OY; 6K/+40-K&=NOQ08G"ZQ]9CV#P)IENYP'+\$*
MARL8V&01M5D81\RX23B+67NKE W:!YBXE*PWBN79BIGM(+YY*[,=)7/+S43G
M07(VV=1=8(R7'2TAQ00YH+U268R#4"36H>AGU[1,I!Y+@O5VS<A0:G!?F)M7
MQ=8NW?]$"2-#@F3OPGEECU2.S=.-4EH,AR\YO[=\7BEGF;87B1W8?CU6.-JR
ML1C#VSFV;,;'L=#JN#6/$DR_FA@Z4?"<0=2<=[A\@V%RZON='JF<-F9K=SS-
M"]$W>[\C9YDC+T0=O.,9P0JG6XA.<\US@Q/QT.&:QO'B,>:/BU6"80L!?8MI
M)&@^Q-SL-CB"<?W@1D#I!H)*Z<=)I:<>Q3B@]$D-\$ _9UQ&S\6KE1!@AO"(
MH^6:NW*YWXF.-ZC3UL=,E9=Y'SK'(=T$H4->I(TM':K7N>&8NN5!J0G!'O)H
MA0"5PA0R3FMHY"6V;'H-?'B9%)!=8JK8$V/Y2 ]JGA]GU6M"H0:ZAHIB&S;Q
MQUP;1U!_,/#YJY>5$,>()BZ\",I[Q+<XRI9#MH<, 9E ),X+N2L-SG9UD468
M!%R(X 7?8W\7!4F V0K0)[L57ETRKX=UV2Y)\]+K"AQ05L0,9Q,5'$Q(8K>0
M2%E"5(B(,AD1"(E*4O*B#ZF<D)Z?KJ =+2!BU @;*X>8@_AM&1R9T-8LE?H=
MIMO3?3,!U1HC5L484);6GE@6ZJ,W6Z(;T6L,.Z,C O>&;8ITFI-R8#O=M\;(
M:4J]-.OOQMM@]6HO_;1,&TI!>[0(<H2 J<MQI &\WF!05Z3K0/6X);";K 9,
M_F 7BN&+NI+J-2DZB!AX2EPG:MY[RD<266W-A*);1O/9BS&$2MBR<TG<<*9^
MV)K>B#=KTEF(4K\IWFWSA@V"SV3%)08N JYUJDJ8XSG9XN?:7AT)8_NX:]?J
M1QBW-7/K[&M3%2/<LBO#*^@I2T0,5.QB0W>ATEV5(8:3F9(0P$Y\.LZM*2ZL
M"6?6!%[/.XUDUD37"&?65#I.][B$;R(VU<S+7& JH_@F3,EP2%KTV)!<LW9Q
M\_[@O6*U.ED=7]9LD]Y$S$J/\S39( %.+O0A[X2 ]FJGNP-X/^S2%V(M7QP.
MM\';@?E ?7 %U*$5IU3<4*&8LY"[JIM.;J(CLLU*UTR$Q2YYIBS^[_4*PA]2
M&%H_N4[1ILF@G),;"Z$>5 X*63?KRDT$#HR_4/ZDU=[+H]4M]-Y$PR0*ELN[
MS\(3^HJZM^G+51PZ_6&B$WS&%L=)X)_!NC[:JY_>MQ#0QZ"1H'E'N,0KJ$#L
MANUWHT"EE..DQE.3SSB@E,5DY^^\?\(B7$'W!/+_LEUPO I\O6NK7E(#4J"Z
M2=MH9MWYG&[4=#=)A*BBNAQ'@Y2 X%71.3=49C>9T["9ZBS"JR Y\Z)HOZ81
M/"E2W3QT$-&'II6H>1>!Z5KP0F5F;CA-/T)46FG.HD$Z@9AH1]$X9KV<HEY2
MAI&QF5'4 I)+&46RR/5YCKE\HE%0ZO&B2=.)LCX\^MVCS#6*&KLG%"H0<<,_
M6L!HZ 1EMNF3S?Y._2NHZ2^.VH^ZKV4S3*8=0..9MY3L=J+*YS#*>W P:4YQ
MB-=!HK1X;26A;^XM),W;4)D17$JAQY25&V&F#QTJJ3)'D2 -($"D/Y4"03:3
M<KW&/ESMYTX-11R@\TSH!R0012Z2],0+MI@[9NK[RA_;>-.95Y<(\AO1S/B0
MEZ#D&:.UD G%F5"\>O[H:<P2^JN< I2"ITH8&<9G0*;M +Z6#IM*-@$/#4*<
M0-I29@ZIE;@1H8Q8!S6)QIPM(0V(N2"H=!W"2\]4A4'U$['RLL+%.'%#PQ5>
M[=B?/9*L@:+I&-',PZY5-/&T4 >'AL<%&Q3 @G$^4: 3>\4(T*[ON>*LZOD5
M2;*VH"ZZ?'YN$V<;3=,.W\3!KAD<<K1\%+(J'87XG#-?%<S'^3NL0-'UVW0_
M3\15W;XX!XM1)HF+7K]D^Y=HL?KG+D[ :(UO! [IV\6_SL_"0TG@,!^';@58
MT9V;%3M',%5=F4N!2F*XZ,=GSU!"\RH\QVL<1?P(:!''.(FA7*8X.B&$?O%"
MW_@Z7HFU78-1$,5\8!#,41"BEXP;\C)V\PD8.I:D&$N487IC5J,:@5++N@I1
M)J+(N^1"HEQ*M.BWMC$CU!D-DR#<!>'3<@MU8:&FP/#@TTS5M(4T<3$4,FCB
MD2S! 'YV.31T0MCK]>U*G ]<O;Y:L$8%[]$3H.NAZ\=(L_9T'Z4!";J=E&U4
MTDUC)=S8>)RC(Q5U)=&B:KIS&QE2 Z4T@7%N$Q:O/AA^ZL?A$U35+B<6*4U?
M2F0-@M?.QMK[ W[V%?,[#GX'EDD@BN'Z91D<]4 )R+O<L4_G,X*WPU%SUJ+<
M_)D<KB,Y;6/>H=99MC)I@^AVLQKQ]!HF37&"[:K+2@+>Y;8RVIX9N!WNVY(M
M.]T!]6%L@Z.V87.LH& RW@+%-WV,W -#Y[Q7*,=-E7?-9MT(C+E1&[Y!,[_\
M-W_:(=;YJ\-MF:-N4(6F=S=F9Q<VSNYK<C<8=DUA^>K!_L'P1P%3B)_8'FJ5
M^LLUCN,?W+U,T+P@&.'0?^R#?$=/Y0_4<(.''07R[QN$A=$S/\M #Y[YS#%E
M2+J<)%>5B^KO<(.;KN0GN8)K[0<>%Z_;0!RXG^*G((0R?_]@&QD9&]>EK%E/
M3)F3E9INRXYS.81S0=!C)@G:,U%<J/ZF;P-T& ):)0*;]_E#K561JJ:E*G&Q
M8J4/^<G3G"Q4#W.JK_5NRS2TA#!S$V+GXF/,>XZNR.G&RD+M L/>?<5(UQ-Z
M5Q&.3]>R%G?4'@IG.W8)7%$A ,HE0/_H'/68M824J\5WDC%=P<929?>VV=J-
MJ"@#5&]1(2/5U*V#0@H\FDJB]-4\=WA]*&-N5D/B!&/N1E,K%+IX@%:&]B>5
M@TX[<?UPF'5-9+G"ZL%>G;9^L%'E]54FPVN#38<J>F[ DKJ#YMP;$M)+V>IF
M^FS<8B9NF'A/>+EF7*#LO,C!O0XV@3@TN,-;[!&\^ARN<'2VN+NX7\AEO0YD
MH'G&HLO0RG%+(0S4KDB$.&EABR-$<HE0E(J$=B 3XD(AST]<.'T9;"/4"#1:
MIX5EEFD^Y<WRFD_WE^ET?[][_"?VDP=:2#'<U+5Y&;!Z3=XC.$!6O(6))E:8
M*%]SQ4(Z:(M9<@O'O6&H134YQB#TM'RDA2,3*J":45^%I*;%R[.P8MB7[::\
MY2*X:+L:2%--=<]R]BXOL@=/W<.WQM,J@QSH8;E&J1C90ZU"$)1)@CX+-: %
MND,7Z!XM3*MBTOFMW42&3FYO2$F-II-'3+1$U^+$!65BH50N]$#+-F7%E,:>
M.)J>]!0V\NCYO[;,&/,;*JF-L@EIP5P-6FLI7$&(5_#&- H>=V!QMTRATHT'
MY>@,RBEJI6OE12=P0V5V"/C)-= ;,<FK'S2JHD27 2*#L1G5=<Z#V"<TWFFV
MH5>A:ARU!BYC.EG!WL$^\1IP][M@J\+G VVO>RJC.JJ[7FRVA.YQ],E+_.<@
M?*K\7JS=#+BO%!?CF$MP->_>G[S78+/;H$W*%/EEB]A6M@M8"(C9[L C7N1(
MBT4#EM+O^=+8S-<J>B-#)@G*1*G]C1#&D4!Q1N/D+J].;R FU D:![K*P,(5
M;(E?#/OZ[]^?_.[7WW-LG?;D%BC[G;9)H[. K=<5@2DJN Z]4OV\94"$R:VW
MA^-B1A<'+W).T_EUS0/59G)6CL135F@K>*$H9>;"R7</*%1"6UIW*Y\"@MD/
M(4Y)QH*F[!%#/PU-L^B@:<4V<GZ9=<2I>0!'%PQ$!B@JJ[Q1G@_<[QYC_-N.
M\;]X8?^C?&S5_/T!35 ;Z%EH#9)S09R-6Z=3G9A0&5VYJ'^BJ_IQ#)^-2[75
M;"L)<^I/28[@ <#*3?.O(]/A 15U.8I"FQ\ EXF:RS:,5[VM; <1HTC8:B4[
M+X]H;Q[;HS)GL>CVBXDZQ=;&K-XPMH6 ,11LM8^MP^"D([2WC.W0DI.J;UT<
M]3:2E;+[.$I*-L_^5;=W]M$O9Y *CJ.M%R5[:,\LNQQJ_Z[&MK*%EHVSMX*+
M ]W">P&@?<IQ3=FD1<]FUCA2%GV'MTSJ9R_&BZ<(8]AEU\<KO\Y1)*@'AS2#
MK\(AU/&C6FJ<!5:I/Q5<4<X6-3B9ZH*IY>AQX7NKP+M]]J*-Y^-=$O@>B:]"
M7WXE)$5&\P"RFZR5,TC!$FVK/"&5U84#2$FXJ(+^'(:F'+Y27&Z5<7%E,*1O
M'*86@T,W0=<Z65GM-(RMQZ_M95P=KLNO7<NNZ@6I?7=T;2ISRBX@K7LD:2RF
MONHLFU1VSWE;N^=T>P2D6?@[8\);OU*L/+V@"6,1> 1MNFX69S"J%)?B@C1C
MA.[:AU'^@/G0K^S#["/V/X]LB?G7_Q]02P,$%     @ PX!J5*M!>]T9/P
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M3>V@*_A,>-XK"+3,+),U#5C--6^-T10.I$ M::S>GP>=. D>"&_93J/V'&3
M!]HIEK11KR#ID@239[8-;6$UL]-HFZG\G<\DL+=(6H&](0<_[EWX;%_KK;_Q
M<6$QJ?O>?G&][!0T#>B\D)=U;[0(/!HX)/CEW<GQ\<GQA^/C=T<+6(/, __+
MN]-W1W$(S- %8]ORV-_8G4M G)MTW*5L)CR"P@U)\LT^P[&SOCD>GU3C 4P\
MTP- I$0<<61^&.9**=4F')D?1V1V3 *.S==A8E-LUF6PG Q4[)98Y!P7Y>+W
MH' I.55Q> 8J@TL.R!R7@4K@:B<'AV>@0KC<995!<SIH0;SC<^2H#%H,ESJ-
M.3Z#EL-;WG^.R:!E</7]#0=IH)*XZ$XN ^73H&7PSD4J1V70,KCD'IRC,V@)
M7!33P*$9M"#.1Z1P2 8M=FM"BC*4/@]:#I?&C'%\!BV1"X, .3:#EL<%L9P<
MF4&+X[*87 [/H$5S<8QU!LX/ Y7(VQ'R'(Z!"N#]/ 8.R4#E;G'F"8=EH$*W
M/&^(0S-0@5N5_Y6!\V6@ G<G?8_C,5")NY5AR=$8J+#=2X+EB Q4SNXG+'-(
M!BI?=W++,SQ^'*@(*:X#P&$9Z,Y!E'7(L/I)@U;^]X][4-W !VU4)DD.PPR#
M<\I*]KA. H'EL8HPCR^$1%FD<V5=$G$RO:A*(L"N>$3OU J?DRF-P_<SRUHD
MG7XD7A1N/DD >W]\LBY^\R_KCW^_<:UGUP/3F(03WTDN[%ZH!PLMO/PKAK4E
M$O@K3@L1I"P_I&:#Z(SM!Q)9KD^<2ROP07&$$QLD0\PJ!3D79.K:KE 0-H::
MEF'E.KYC>X/=707DA<!Y;$F8T)N3&QJ&MR2ZFSY9;Y@QHDGK&;#CN*D4OK=<
MY]H_MQ9N9 G5I*DEH64 N;O[OUM>+)2/4-ZVHRV/25P0H:(->3=*S $0H* 8
M6-0C6 $@4+&34$I&RT!RFD!2@>AG]);ZMGA.90T!W<PCLD&K6E>SO6]XL4^8
M& YBXL!22Z5P2@RY!$0IZ=)9[$8XO+=6UK-'), MH]#1NI"1AE54= ^CT)QL
M.*@:FGH66ACNG4MJ%M:ZA1;V[@.Z($&TNH=325(V$3!:,+T")A6&Z6HZ6H9R
M!PQ83 _>$"LD26W4N^GWD"1X8L920TC340%6J6N#W7MNA2]RBJN<AL:5+R-9
MMQMJ83;)* "\'HA-W*6D2J@@HF40%VN'4%HUF)S3,(,1N9WK*&F2360!AZ/+
MMP6<]\C&9)!>5D+D].R,I>5Z;'E<T>#1\LC:<0H:ZX(\1_PWF;V#):WGU /R
MAYU3X!^F&); &#NY1.=6$*Q T.(/H6($]<LY&8NEA(!&YN6YULQNYE*]FV:E
MT>]I>N\OYP\0H=?9W8+4L&GY')F>!%:SJO>0V=MSIJ>MB,DLBA:TIH?BHW%#
MZV'38]+1" J9:Z9'8Z-1JS/<38]"1@-6<68S/0H7+]1*-E\+L:<TLKQ^X5,%
M3+FGQ?0X2W&,:KQJIH<<B@-5[4HU/>H.:\*W&W?7)S$D>P@4OQ Q/51/^MJI
M&,WRT^-/9LLP@=O'_#XMN2C-T/IJMGDEAI;H[3A';3![5&"-%44Z;) Z::'B
M9Y_T@B)I5F2UGAA: E,Q='G U%MEIJRURIBU#$!#ZR&J %#$=#LQM# @(@QT
M9\EMQZIF.!E:T$P.I])H9 Z7V:=-)%S8J/0,1D-+7,G!*)+ P)$;Y5IU!DN&
M5 L72*:8(/7I2QQ%]?IA#\5>9>#=)\B_$*#$4UD:IN,5TCR0W+QMWC5GY4B]
MK29&1W>"4<I"4E!6Z!W#6A+=#& 21R\@"/[9<!!Y,KH' BOZ+D@6OI-8P_<D
M2)B2'% YN3$4K'^W $(39_HC.0I!W-_.IK\;HQR\C4 W_>D4Y< 55]K6X3GK
MVF+-/@SOINN  OAKXD[,'<'9X5O>@L7WT5^+%C$63<;(KJ-$IBI )1D]N6:*
MZQSTJ+A!&2O?_8!8'E-U?X,C,RM4;KD^X^_.Y^&LD\ -X4\7\*L_2^MTJX2C
M.0^]61TI8_!YP,*A+DCZKXSAJJ(W74>1LFTK,VXA<EH&]AMAT6S$F2Q!PL[6
M)4OOIHFRSNGJ,RMT;9"]%ZX71[ASI&P/6H:_\=]NSA$-QEE+2LN 8!GQ+81A
M?Z>A'F;!!MB$5J:=KT/F48R7$]$G,96,I(Z2UFSBK;[S3"'3<<7H=;O<9$2X
M #&]I0/DMGUA<[V,KW&38YLWUL+TK\2'CCT0ZQ-G[OK)>Z'L*3^)W5Y+2E>Q
M!F(%-DN4NR!+XM$D7%MB.#6$NEE24C9I.1%-,[(D?HS;#KR-)AW!9$5V0)=!
MN91$YZZNNL'1(MBY)^O4:#\@ IR*?<31^F(T6O7RB H+4)[>_7G$3%B'<M1^
M&E&K,)YX$KQZ^=6G"!P9^96WC#E.ZB77@>(D<!#BF=O'1N]"\0-F019W]0&9
M0VBV()."L,YQPK.]S;;.I, 3PFV4=L5N4I[2K%ZR'2A"M7YPCIG9EBP",]D[
M$@ZEV5H! :70U1K/%C=;(6"N+06$W$]FFV^2:*FXQ.80FRT3%887",Q \Y@+
MGK)NMJ#0.R_%&6;'7\VV,B7%2V7$&$_>UF!_]BF"LOP9I691DW7/,_4]4K*
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M^M?^DH2,B8GOK%^0\&>)()4LOBI*5-."#E_8_YB"7%H>V_$/P%G@VB %V!^
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MK:;R&,4QX0UE((ZNKDH@Q2S)B#,!8IU+,?$!4]F),U\@K;.E-@EIY^P2B+V
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M<=X$"<FI'XL%LX/,368/S))P 1HB#I'<U9&1XHU=<$ES5-Q8MQ%U:\WAQZ?
M\D,K4;QX^2!"3=N[GJ[C6L$JQQ):4)03:5%#)F=/Q=IQ37,L@Z.]3@MJ?KB;
MX=1(MXWT+J!"FW(HT1KUPHWB1#('[HO9P(DK.UJIFCE@/XV ;0-69UWQ.M_'
M(W3;T-6;S1R\<:/NB[J*\Q"O(FSFJE.B6:O/Q=O:]=0X"'%^!EKK%.%+[K.1
M2T[,J40KO5X<(S/E69-M*>?\Y 65S5QUC5S-%.$#;[$R-:BI9WKX4(I<A60H
M?AZ\WBW'4.+R*\/UA\%["@IQQ5Z'9GA^41XP8\ANK[\QYQ@J=[\8@J%L. 5'
M5L.;,8?\2L)VT?']-SWWZH[+Q2[UA-N>!3YUC8J6:__]6O9[A>RW/\A]$RQ.
M+W9@P)M7\7X-:+Q(<AE".RDB 6IJ7=.!^JBK*KU\:;E'JGN?%P-//2T]02/%
M"SHZMX)@!?@G1;*QTRY <+SWTWGOAYR<H=Q:H1^^K-FQX[O<98M.GR)H\]EJ
M&EF>@89IT7,M5S0HJD/=$^-4GF/3#50)9#HMO5W$+T8Y(PEW6V=\P\H495$)
MD>MV8/NNA2;CNFD6.!T&46Y(\-ON<."CC9,8$16YWZ@]YEQ?@KGM1JTQ]V#Y
M,X)C;:M)NXR)!E3N--!43]8*":O]<3U?!'29BFY\C'4E&:DH4+!IV*43#5;\
MA0#?N8H#WV6.1?:S^\9^PD81XPE+\9]6"" !*Q ^!25*LMZ0_-83ZE;./L$
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M>A&7(7C"4OR7K]9O<-QC'KU_$$NLY!>&G+X4P6UQ<8);,47MN[SV4W#?U\D
M)-23("'%BQXE\]N1],E!]2P53M&U;P>,.#\.7M% 5LSC*2M!-XR@CT92)$>A
M,ZW#A.S=E/G L)>+(M0:& 4*38 F"K_TK%GJ0KS!U % $)/S*M X>K'FBXCZ
MV1$;4>ZRCH0D=I[SN&#OR/[-"IYI<&,]L\=#:+"291%!4<M&*[XXG 0!*WV6
MWB&F.^2)@@1@?F8FI)@C.Y3+TE;48=_!D<OT5M1A:Z5>+]P !!-%/%)8U$K3
MW"6^_'LKB%8RJW2_M7:VDU=DK"1A":8W_Q?\NA*GJBL(BL:)\GB,+-^Q B?\
MOG" DU.6O7:*KV A2%#/.Y+ +SO-I_>U^+$4M]<S+\X?\;K$+DB66_+*<;T/
MJ \_IN9UB%V!2,)2VGI]6H3C.0L>N@09"O./U,^5-.2YRA]-GE[ITPN-0UBF
M(.>?7N&C%7PFPRB";'N\W_E2("/(ZO-5;/1KG+JD\(JCBDIGP\!NUG(:JD\@
MPM5B! EI>[&YA(U<1H%$$"R2<.<A4') 4.'9-+TN.VYW[%9/*-R@II=K%Q9S
M-6CM5X0Q.Q1;0+M12>T\E*(ZJB',&6=#J9J A;#,$.?/'IH9RBZM&)#'K&UM
M<6H<CLV.M;3N2,Z7H=F2K]*A0=%.&%X_PDQI)[U[,6ZZ[:W[V3@0&SA$2Q#=
M,_D4ONG:=^0*E&R!8YXC8Z8\:[ QE=S+;._9+\;AV\Z]F9IY*"P#^H.9Z[R=
MRUV*O\)N\<GG 0!=%<Z0(?OCZ!H3<BG>%-0H_,G,58D/^Z&(("2.GIDU"J70
MPT2:<0#-=-'*+[^*J$,.FIG5SQOL67Q0*0?SQQ',RA6X&U#,D5-?^O)@D1,,
M%,^P^VJFU:T0NURNP 8U.#2.J!7>[.WEAW#(AGD[("/>MI.#.(+C5MU&$)\4
MEF%Y.II[0O;R5DH@1V^T^XK.:MB<T0S/SZ-LW,%3.'^88VCF!8(*# L3Q3EP
MHUH16WRE1O2)H1Y5]1 65ED[^3),MRE:&>]6]N  COI#","*XB\<RU&/U!R(
ML^I &68_CM[GW;N/\H)0'+51\=:AME/?*X-NO"S:O9X4J-W&T1N/;Z+HE2[
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MV[ZZ/>19<+)JW_*C?>!E%_&M&\I_$[]3O]6G5*#H\P@." 8$HBN>E),,W"
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MN#S+6H6K-2-"!50Q(E-.I$S<?&PNUR5+5:"!X'%]%:IL?864-$L%U1F >F'
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MY *V>Y8RJH]".R^J%&C0Y[N88]-LU<]\GV=V;TT172#NT#<])SLUT$!#T'M
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M6 [Q5PHY3H8E\]GT@QE&O@@V\N\YWN"-_-O(OXW\>T'R3WE*(\]S$9?,#0P
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M]X'P;[%G ]H<);->8JH4AA,,5";C4"98G?<G<'$T2?![K9LUK9=$@?0(&=.
M?3KZ,S0</#")\;/<AFA1HB,\D2;-ZS)2=5!@GP;^%02P29B-!1H5 JZ-ZWGC
M%I_"6=-\T/6 =GV"("*3C:B#SF#<*I-/,24N*GJ(X/_MS#9-?NNEIRT^T'V4
M-1X<9684-!U0[,="-#Z(II/G'JVB!.*&QU 0Q1MEI&:4NB^]QLT!59!08YR]
M]M'BW+<.VUIF@  ['36=EW(_$)1FWQL[HZP'HH-$0(O^1I,G5.BHV(Y"8+$$
M IDR$($2&8&3'RV)F"PASWO3XO77Z!Z]M*V52BIV'Q=SL(O"=$*04I%'0EI'
M+$7JQF.MJ9E"#/R^KJV_1)A"A%A64DM\+.7,=>]<&6 -3>,"9 5GS[=")]8W
M[1L#*^5VX/"]:G@LTZ.M:7)@(ZZF)%YX/52!X6?Q)H8PI[U[L$)[5S:M*)DX
M7^,QZZ8-"I EC9O(1E(]=Y<CK$+ +0F:)B\/(_V-I_&!/B8H&;IIW:_Y&%VO
M<;."G5_/W51U:YT$I@DM/,)HA-I]\UI97J3<\$#B!Q:#/GM&+X<K6 ;6V#[[
MG<J;#S=N7-XT;U<P''S3AX+ZT'-GC@0=T+0VM KR5>"/8]4\@/P&"N4 J&'<
M<K)1%.K^,IRIZ:;Z.\K1PHV0NG,:)J_E;-U9,>/5;=#PG\A>5%.;_(H2H(<B
M<SN^9>(+8XI*L#.E"KQB)<O YG([^I\^G$HL>UE*G4^UX4H!DMQ>;A5\//"<
MT3ZYH=X845@S3KEM7(D/E;_.0AO OJYABA L.G<1;&.JYQ.^0R *N$A"3E"M
M*:C=.+\)?G\3NP@N0K@0\3!QKLR9-KR6K;.;XZOM>A[/Q=._FT\P[]953!9V
M=AS[V$Z8&AS6/9;%EY.??ZU"F85/O_LB#O\"[T[3@]2*!RU\$E^B6,C;ILGJ
M.$E$6D__67R0DP@;L]7T"RP^S-;%E^.36L2[C FG*AR0<1,R5.*<"I2O>1-6
M^-"DYC)4U35H%$D4DVBZ$7$<Q3(9ME1?;Y15K'\47OM2#$1$F_0:=V^C*A9E
M3:^E+^/F4YU["HZH\8A X]85 9V/0"F#*P#Z,<*3;\("<X4%#E<6%KC.\]<(
MSTJ@T@GL"E@;F*_N:. <M9R>"*+[RJPFM*5NPZJ<)H*J:3J #HIV($R2&>K6
M59,<N'>,@T<1XCO4SU%KQR R<D.T*?*&TJT<_<Y.7&O:(:'2XA0"1VD16SI1
MP V /G""9(+2+)-MW78[T9"&&AF-H>?RE@6->PH,#,O4RA2&&2D6&II /##R
M!*LDB_-/*XM?FF9A7@H674T?T<Y2(TVDEFYXY5R\\NA)4H8I%8482Q@QKTM0
MJ6,WDR9;JYB6N4\ARR=G10T3<\[HFO>F&S;ZW*.:J\A?? (!TW14<^"F242I
M88V/)%9P0HV36;W,LV4R&8GG) /T4C=])MB&,$SKC[3XHFJ>R\(($EXT&A-7
M7\5B2.>K-<;B.!4UDW^.%I8QK(/63,]8?!TUL:*6&*#A]X.1 IILPX/43%EO
M>I<6IB:05F!\UD.)>;>^NS17V>KBP_1EB'5(?CT^M00/J>>57GR ^T%4*T-F
M*F)/3=E!G?Q<C#F"RMX'.R/)L45Z% ?-[53$"8\C:D*+5MH*<A]R-PJ! =FU
MB2O(?$23I1Z/71PJ"T.C#0\A:[+8QM/W%E^""/^,ZNGKB[/ L%[ZR!)FAXSB
M>N5 L(R&M<'%M\GU[UQ0;&_K><X77D=-Y6;Q]S>\37/H-HU+[<4'J!L@6?@8
M/.W-K!4?VVWO+>Z2C0689/5DQN(;UFMZ&8V?R#R5"\L$D6MJ4(OOU&WM&.+N
MXIBGKN>)I!:TXFY[?Q7^G?VF27>)W%^.?S9\[#4%X!(#X%G<RZ2F+Z3I=-;%
M2;=F3N RE7"FTG3>&I^%5]7X\<_MJ%Y\*!,)K6DD=-H?%B:&& BZ'O[T^R5
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MRGY894G#:@1GXQPTSY)J>JAURL%:QE2KF8.UE%8Y:%X1J!E37V>C=E7 B2O
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MA0*C.2@V-HQ%7(:J#%6I4"=HI,ARLU_#^X%T( @"VP]\K^4U_DQW@^8V4)'
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M1DD^@!HQL.0/THY(G,1B#"PHN*!C(6VHM,VP'H4<1JO<C5.C0Q!8;-D!>JT
MQ$#NFMW;<,23(; .WLU[F4()OW1R? "'OJI?.Z&C0_;)-()D):TA)3E;J'-&
M\< 2<G($D*);:Q'=T2)"+:)BCJ M5GF$@I3+M/:,V84Y_V,RL.G)_:Z\)^P_
MKQ5_MH0]!XM#0)SX3.9A$)8IR0IY9K>O0MG. )!;14]Y_J0S@PU@W#.6UD=3
M* 6);X<62!=QV'(L9T!Q#\(B@5I0K%S$>7128DR&NEBMI.#.*SJP4DBT$PU
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M=[D760H<;G:%I\361DK<9/C'GR/-!ZE+>=3V-"C/]/X/4$L#!!0    ( ,.
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M,# P,# Q+FIP9U!+ 0(4 Q0    ( ,. :E32VRQ\&AD$ #"(!  6
M      "  1;3! !G=3!G:FYU;&AG<W8P,# P,#(N:G!G4$L! A0#%     @
MPX!J5*0=WGV-! 0 P'4$ !8              ( !9.P( &=U,&=J;G5L:&=S
M=C P,# P,RYJ<&=02P$"% ,4    " ##@&I46Z6G@7J+  #)"P$ %@
M        @ $E\0P 9W4P9VIN=6QH9W-V,# P,# T+FIP9U!+ 0(4 Q0    (
M ,. :E0ISTS,CL@  *%B 0 6              "  =-\#0!G=3!G:FYU;&AG
M<W8P,# P,#4N:G!G4$L! A0#%     @ PX!J5+\&!3C(H $ A4," !8
M         ( !E44. &=U,&=J;G5L:&=S=C P,# P-BYJ<&=02P$"% ,4
M" ##@&I4.R#!8A.; 0!4Z@$ %@              @ &1Y@\ 9W4P9VIN=6QH
M9W-V,# P,# W+FIP9U!+ 0(4 Q0    ( ,. :E1'&7=DP'<  %.(   6
M          "  =B!$0!G=3!G:FYU;&AG<W8P,# P,#@N:G!G4$L! A0#%
M  @ PX!J5)(:4',8+   (3   !8              ( !S/D1 &=U,&=J;G5L
M:&=S=C P,# P.2YJ<&=02P$"% ,4    " ##@&I4-6[X!7%<  #I<   %@
M            @ $8)A( 9W4P9VIN=6QH9W-V,# P,#$P+FIP9U!+ 0(4 Q0
M   ( ,. :E0'Z5&A$3P  (Y3   6              "  ;V"$@!G=3!G:FYU
M;&AG<W8P,# P,3$N:G!G4$L! A0#%     @ PX!J5%CUFTQ9*0  ZC0  !8
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M;G5L:&=S=C P,# Q-2YJ<&=02P$"% ,4    " ##@&I4EZ)^1,N4 P"2^RH
M%0              @ %Z5!4 <W1O:RTQ,&M?,C R,3$R,S$N:'1M4$L! A0#
M%     @ PX!J5 8#Z_!_$P  M],  !$              ( !>.D8 '-T;VLM
M,C R,3$R,S$N>'-D4$L! A0#%     @ PX!J5+6T@)K3#0  7,@  !4
M         ( !)OT8 '-T;VLM,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M ,. :E3L'#O$52(  ) V @ 5              "  2P+&0!S=&]K+3(P,C$Q
M,C,Q7V1E9BYX;6Q02P$"% ,4    " ##@&I4>CS@=B9H  !-4 8 %0
M        @ &T+1D <W1O:RTR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @
MPX!J5*M!>]T9/P  /K@$ !4              ( !#989 '-T;VLM,C R,3$R
M,S%?<')E+GAM;%!+ 0(4 Q0    ( ,. :E3$62(-U$,  &8_ @ 3
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M>#,R,5\Y+FAT;5!+ 0(4 Q0    ( ,. :E08OT7K(@4  $X>   0
M      "  =@R&@!S=&]K+65X,S(R7S@N:'1M4$L%!@     ; !L  P<  "@X
$&@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
